

1	FINDPATTERNS on geneseq: allowing 0 mismatches	February 22, 2005 10:3
1	1 CXXCXXCX{10,12}CXXCXXXC	
1	AAW62828 ck: 8155 len: 666 1 Aaw62828 Macadamia integrifolia antimicrobi	
1	7 # CXXCXXCX{10,12}CXXCXXXC - pattern searched	
82: DPQTE	CXXCXXCX{12}CXXCXXXC - pattern matches	
	COQQRRCRQESDPQQYQRRCKEIC EEEEE	
AAW62830	ck: 7549 len: 625 1 Aaw62830 Macadamia integrifolia antimicrobi	
	matching portion of db sequence	
41: DPQTE	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{12}CXXCXXXC	
	COQQRRCRQESDPQQYQRRCKEIC EEEEE	
AAW62829	ck: 911 len: 666 1 Aaw62829 Macadamia integrifolia antimicrobi	
82: DPQTD	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{12}CXXCXXXC	
	COQQRRCRQESDPQQYQRRCKEIC EEEEE	
AAW60558	ck: 6048 len: 169 1 Aay60558 Human normal bladder tissue EST en	
89: WSGSN	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{10}CXXCXXXC	
	CCCNCCNCWSCNCCNCSGCCWSCC CCOWL	
92: SNCCC	CXXCXXCX{10}CXXCXXXC	
	CNCCNCSGCCNCSGCCWSCC WLNWV	
AAW74791	ck: 9481 len: 233 1 Aay74791 Neisseria meningitidis ORF 263 pro	
30: AAACT	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{10}CXXCXXXC	
	CGGGCGCTCGCGCTTACCCAAAGC CGTAA	
AAW64780	ck: 971 len: 66 1 Aay64780 Human 5' EST related polypeptide S	
27: VLCW	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{12}CXXCXXXC	
	CPVGMVCCVWVCICVWVCVCCMCCVLSC VVSHG	
AAW70731	ck: 9217 len: 31 1 Aay70731 Wnt antagonist protein consensus e	
3:	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{11}CXXCXXXC	
	CXCCCCCCCCXXXXXXCXXXCXXC X	
ABB66556	ck: 8119 len: 72 1 Abb66556 Drosophila melanogaster polypeptid	
10: PGGPC	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{10}CXXCXXXC	
	CGPGPCGPGCGPGCGPGCGPGCC GPCCG	
13: PCGPG	CXXCXXCX{11}CXXCXXXC	
	CGPGCGPGCGPGCGPGCGPGCC GPCCG	
21: CGGPC	CXXCXXCX{10}CXXCXXXC	
	CGPGCGPGCGPGCGPGCGPGCC GPCCG	
ABB60717	ck: 9817 len: 580 1 Abb60717 Drosophila melanogaster polypeptid	
	CXXCXXCX{10,12}CXXCXXXC	

11: NKPSS	CXXCXXCX{11}CXXCXXXC	
	CVDCCKDTILLPCGSASACDASCAAAC GLIPP	
ABB61256	ck: 9524 len: 43 1 Abb61256 Drosophila melanogaster polypepti	
3:	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{12}CXXCXXXC	
	CKGCGTNCQDTRKGDNCACNQDCKVC KNGPK	
ABB66555	ck: 915 len: 74 1 Abb66555 Drosophila melanogaster polypepti	
12: GFCGP	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{11}CXXCXXXC	
	CSPCGPCGPGCGPGCGSCPGSCC APCGP	
45: APCGP	CXXCXXCX{11}CXXCXXXC	
	CGPGPCGCGGCGPGCGPCGCPRCRYC GC	
ABB70243	ck: 3853 len: 47 1 Abb70243 Drosophila melanogaster polypepti	
3:	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{10}CXXCXXXC	
	CGPGPCGCGGCGPGCGPCGCPRCRYC TPAYI	
ABB60549	ck: 9665 len: 43 1 Abb60549 Drosophila melanogaster polypepti	
3:	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{12}CXXCXXXC	
	CKGGTNCQCSAQKCGDNCACNKDQCVC KNGPK	
ABB66384	ck: 6468 len: 271 1 Abb66384 Drosophila melanogaster polypepti	
119: PVNTC	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{11}CXXCXXXC	
	CMFCSNQCPSWYNYNPTGCVYCANCC NGCRN	
AAU07343	ck: 200 len: 1,679 1 Aau07343 1-aminocyclopropane carboxylate (A	
72: GCGGC	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{11}CXXCXXXC	
	CCCCCTACCCAGGCTTTACTCCACCC CGGCT	
73: CGGCC	CXXCXXCX{10}CXXCXXXC	
	CCCTACCCAGGCTTTACTCCACCC CGGCT	
79: CCCTA	CXXCXXCX{12}CXXCXXXC	
	CCCCAGGCTTTACTCCACCCCGGCTTC GCCA	
100: CACCC	CXXCXXCX{10}CXXCXXXC	
	CGGCTTCGCCCACTGTGTGCTTC CTCGG	
188: CAGGG	CXXCXXCX{12}CXXCXXXC	
	CTCCACCACTGTGTGGGCCCCACCTGC ATGCA	
516: CAGCG	CXXCXXCX{12}CXXCXXXC	
	CGACATGACAGGGTGGAGCATCCTGC TGCAG	
726: CTGAT	CXXCXXCX{12}CXXCXXXC	
	CCCCACCTTACTATGGCGCTATCACAC AGCAC	
AAO01712	ck: 8832 len: 55 1 Aao01712 Human polypeptide SEQ ID NO 15604	
13:	CXXCXXCX{10,12}CXXCXXXC	
	CXXCXXCX{11}CXXCXXXC	
	CMCCCAVMYICVCTRVCMKVCVCMC VRVCV	

use this  
to match  
alignments  
w/ citation  
printed in  
next bundle

1	AAO02062	ck: 6071	len: 73	! Aao02062 Human polypeptide SEQ ID NO 15954.	1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxx 36: AAAAT CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
	32: LILSV	CCVCVCVCVCAVCSVCVCVCVCVC VCLCV				CxxCxxxCx{10}CxxxCxxx 37: AAATC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
	AAO02284	ck: 6785	len: 155	! Aao02284 Human polypeptide SEQ ID NO 16176.		CxxCxxxCx{10}CxxxCxxx 38: AATCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
1		CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxx 115: VPNGM CPCMVCVCPCRDVYICVCVCVCVC MCLCP				CxxCxxxCx{10}CxxxCxxx 39: ATCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
	ABG27784	ck: 676	len: 90	! Abg27784 Novel human diagnostic protein #27		CxxCxxxCx{10}CxxxCxxx 40: TCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
1		CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxx 12: GGGGG CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCKWD				CxxCxxxCx{10}CxxxCxxx 41: CCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
		CxxCxxxCx{10}CxxxCxxx 13: GGGGC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCKDL				CxxCxxxCx{10}CxxxCxxx 42: CCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCGW	
		CxxCxxxCx{10}CxxxCxxx 14: GGGCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CKDLR				CxxCxxxCx{10}CxxxCxxx 43: CCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCKWL	
	ABG27785	ck: 8816	len: 130	! Abg27785 Novel human diagnostic protein #27		CxxCxxxCx{10}CxxxCxxx 44: CCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCKLR	
1		CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxx 92: AAGGG CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCGWF				CxxCxxxCx{10}CxxxCxxx 45: CCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCKLR	
		CxxCxxxCx{10}CxxxCxxx 93: AGGGC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CWGFS				CxxCxxxCx{10}CxxxCxxx 46: CCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CKLR	
		CxxCxxxCx{10}CxxxCxxx 94: GGGCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC WGFSD					ABG19008 ck: 1993 len: 398 ! Abg19008 Novel human diagnostic protein #189
	ABG08986	ck: 2423	len: 239	! Abg08986 Novel human diagnostic protein #89	1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxx 173: PRKGH CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
1		CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxx 116: CVCCV CVCVCICVICIXWVCVCVCVCVCIC CVCVC				CxxCxxxCx{11}CxxxCxxx 174: RKGHC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
		CxxCxxxCx{10}CxxxCxxx 118: CCVCV CVCVICVICIXWVCVCVCVCVCVCIC CVCVC				CxxCxxxCx{10}CxxxCxxx 175: KGHCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
	ABG23601	ck: 9127	len: 74	! Abg23601 Novel human diagnostic protein #23		CxxCxxxCx{10}CxxxCxxx 176: GHCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
1		CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxx 16: AAFWR CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CRDWW				CxxCxxxCx{10}CxxxCxxx 177: HCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
		CxxCxxxCx{10}CxxxCxxx 17: AFWR CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC RDWWS				CxxCxxxCx{10}CxxxCxxx 179: CCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
	ABG08984	ck: 5869	len: 166	! Abg08984 Novel human diagnostic protein #89		CxxCxxxCx{10}CxxxCxxx 180: CCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
1		CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxx 86: CVCCV CVCVCICVICIXWVCVCVCVCVCIC CVCVC				CxxCxxxCx{10}CxxxCxxx 181: CCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
		CxxCxxxCx{10}CxxxCxxx 88: CCVCV CVCVICVICIXWVCVCVCVCVCVCIC CVCVC				CxxCxxxCx{10}CxxxCxxx 183: CCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CCCCC	
	ABG27446	ck: 4889	len: 89	! Abg27446 Novel human diagnostic protein #27		CxxCxxxCx{10}CxxxCxxx 187: CCGSC CCYCHYCCYCCGCCGCCGCCGCCGCC CCCCC	
						CxxCxxxCx{10}CxxxCxxx 190: SCCCY CHYCCYCCGCCGCCGCCGCCGCCGCCGCC CCCCC	
						CxxCxxxCx{10}CxxxCxxx 194: YCHYC CCYCCGCCGCCGCCGCCGCCGCCGCCGCCGCC CCCCC	



195:	CHYCC	CxxCxxxCx{10}	CxxxCxxxxC	CYCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCCC
197:	YCCCY	CxxCxxxCx{10}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCYCC
198:	CCCYC	CxxCxxxCx{10}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CYCCC
199:	CCYCC	CxxCxxxCx{10}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	YCCCR
200:	CYCCC	CxxCxxxCx{11}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCRCY
201:	YCCCC	CxxCxxxCx{10}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCRCY
202:	CCCCC	CxxCxxxCx{10}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CRCYC
203:	CCCCC	CxxCxxxCx{10}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	RCYCC
204:	CCCCC	CxxCxxxCx{11}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	YCCCC
205:	CCCCC	CxxCxxxCx{10}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	YCCCC
206:	CCCCC	CxxCxxxCx{11}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCCCC
207:	CCCCC	CxxCxxxCx{10}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCCCC
208:	CCCCC	CxxCxxxCx{11}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCCYC
209:	CCCCC	CxxCxxxCx{10}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCCYC
210:	CCCCC	CxxCxxxCx{11}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CYCCC
211:	CCCCC	CxxCxxxCx{10}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CYCCC
213:	CCCCC	CxxCxxxCx{12}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCCCC
214:	CCCCC	CxxCxxxCx{11}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCCCC
215:	CCCCC	CxxCxxxCx{10}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCCCC
216:	CCCCC	CxxCxxxCx{11}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCCCC
217:	CCCCC	CxxCxxxCx{11}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCRCC
218:	CCCCC	CxxCxxxCx{10}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCRCC
220:	CCCCC	CxxCxxxCx{10}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	RCRCC
221:	CCCCC	CxxCxxxCx{11}	CxxxCxxxxC	CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	CCCCC

222:	CCCCC	CxxCxxxCx{10}	CxxxCxxxC	CCCYCCCRCCYCCCCCYCCCCCGRG	CCCCC
224:	CCCCC	CxxCxxxCx{10}	CxxxCxxxC	CYCCRCYCCGCCYCCGCCGRCC	CCCCR
228:	CCCYC	CxxCxxxCx{10}	CxxxCxxxC	CCRYCCGCCYCCGCCGRCCGCCCC	RCCCX
231:	YCCCR	CxxCxxxCx{10}	CxxxCxxxC	CYCCCCYCCGCCGCCGCCGCCGRCC	CXHYC
234:	CRVC	CxxCxxxCx{12}	CxxxCxxxC	CCCYCCGCCGCCGCCGCCGCCXHYC	CCGCC
235:	RCYCC	CxxCxxxCx{11}	CxxxCxxxC	CCCYCCGCCGCCGCCGCCGCCXHYC	CCGCC
238:	CCCCC	CxxCxxxCx{12}	CxxxCxxxC	CYCCGCCGCCGCCGCCGCCXHYCCCC	CGFGC
243:	CYCCC	CxxCxxxCx{12}	CxxxCxxxC	CCCRCCGCCGCCGCCXHYCCGCCCGC	CCGRY
245:	CCCCC	CxxCxxxCx{10}	CxxxCxxxC	CCRCGCCGCCGCCXHYCCGCCCGCG	CCCRY
246:	CCCCC	CxxCxxxCx{10}	CxxxCxxxC	CRCCGCCGCCGCCXHYCCGCCCGCGC	CCRYC
265:	HYCCC	CxxCxxxCx{12}	CxxxCxxxC	CCCGGCCCRCCCRRCYCFGCCCC	CCYCY
271:	CCGFG	CxxCxxxCx{10}	CxxxCxxxC	CCCRYCCCRRCYCFGCCGCCGVC	YCCCX

47: CCCCC CXXCXXXCX{10}CXXXCXXXC  
48: CCCCC CXXCXXXCX{10}CXXXCXXXC  
49: CCCCC CXXCXXXCX{10}CXXXCXXXC  
50: CCCCC CXXCXXXCX{10}CXXXCXXXC  
51: CCCCC CXXCXXXCX{10}CXXXCXXXC  
52: CCCCC CXXCXXXCX{10}CXXXCXXXC  
53: CCCCC CXXCXXXCX{10}CXXXCXXXC  
54: CCCCC CXXCXXXCX{10}CXXXCXXXC  
55: CCCCC CXXCXXXCX{11}CXXXCXXXC  
56: CCCCC CXXCXXXCX{10}CXXXCXXXC  
57: CCCCC CXXCXXXCX{10}CXXXCXXXC  
58: CCCCC CXXCXXXCX{10}CXXXCXXXC

ABG23598 ck: 8816 len: 130 ! Abg23598 Novel human diagnostic protein #23

92: AAGGG CXXCXXXCX{10,12}CXXXCXXXC  
93: AGGGC CXXCXXXCX{10}CXXXCXXXC  
94: GGGCC CXXCXXXCX{10}CXXXCXXXC

ABG23597 ck: 9127 len: 74 ! Abg23597 Novel human diagnostic protein #23

16: AAFWR CXXCXXXCX{10,12}CXXXCXXXC  
17: AFWR CXXCXXXCX{10}CXXXCXXXC

ABG23599 ck: 2373 len: 61 ! Abg23599 Novel human diagnostic protein #23

10: WWWWW CXXCXXXCX{10,12}CXXXCXXXC  
11: WWWWC CXXCXXXCX{10}CXXXCXXXC  
12: WWGCC CXXCXXXCX{10}CXXXCXXXC

13: WWGCC CXXCXXXCX{10}CXXXCXXXC  
14: WCCCC CXXCXXXCX{10}CXXXCXXXC  
15: CCCCC CXXCXXXCX{10}CXXXCXXXC  
16: CCCCC CXXCXXXCX{10}CXXXCXXXC  
17: CCCCC CXXCXXXCX{10}CXXXCXXXC  
18: CCCCC CXXCXXXCX{10}CXXXCXXXC  
19: CCCCC CXXCXXXCX{10}CXXXCXXXC  
20: CCCCC CXXCXXXCX{10}CXXXCXXXC  
21: CCCCC CXXCXXXCX{10}CXXXCXXXC  
22: CCCCC CXXCXXXCX{10}CXXXCXXXC  
23: CCCCC CXXCXXXCX{10}CXXXCXXXC  
24: CCCCC CXXCXXXCX{10}CXXXCXXXC  
25: CCCCC CXXCXXXCX{10}CXXXCXXXC  
26: CCCCC CXXCXXXCX{10}CXXXCXXXC  
27: CCCCC CXXCXXXCX{10}CXXXCXXXC  
28: CCCCC CXXCXXXCX{10}CXXXCXXXC  
29: CCCCC CXXCXXXCX{10}CXXXCXXXC  
30: CCCCC CXXCXXXCX{10}CXXXCXXXC  
31: CCCCC CXXCXXXCX{10}CXXXCXXXC  
32: CCCCC CXXCXXXCX{10}CXXXCXXXC  
33: CCCCC CXXCXXXCX{10}CXXXCXXXC  
34: CCCCC CXXCXXXCX{10}CXXXCXXXC

ABG27074 ck: 9200 len: 122 ! Abg27074 Novel human diagnostic protein #27

CXXCXXXCX{10,12}CXXXCXXXC  
84: AAGGG CXXCXXXCX{10}CXXXCXXXC  
CXXCXXXCX{10}CXXXCXXXC

1	85: AGGCG CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CMGFS CxxCxxxCx(10,12)CxxxCxxxC	ABG08983 ck: 1329 len: 87 ! Abg08983 Novel human diagnostic protein #89	1	ABG70822 ck: 8356 len: 3,907 ! Abg70822 Mouse myocardin associated protein
	86: GGGCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC WGFSD			
	14: GLXNG CCVCMVCVCVCVVRVWVWVCVVCVCVC VCVC	27: AEGED CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CLPPS		554: CTCCT CTGCTCCCCCAGCTCTGCTGCTTCCC AGCCT CxxCxxxCx(10,12)CxxxCxxxC CxxCxxxCx(12)CxxxCxxxC
	28: EGBDC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC LPPSA	27: AEGED CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CLPPS		557: CTCTG CTTCCCCCAGCTCTGCTGCTTCCCAGC CTCAC CxxCxxxCx(12)CxxxCxxxC
1	ABG27787 ck: 1603 len: 186 ! Abg27787 Novel human diagnostic protein #27	28: EGBDC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC LPPSA		560: TGCCT CCCCCACCTCTGCTGCTTCCCAGCTCAC CAATG CxxCxxxCx(11)CxxxCxxxC
	27: AEGED CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CLPPS			859: CACCA CAATACAGGCCATCTGCTGCCCGC CAAAG CxxCxxxCx(12)CxxxCxxxC
	28: EGBDC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC LPPSA			1,354: AGGG CTCACGCCCCCGTGTCTCCACCCCC TCGGA CxxCxxxCx(11)CxxxCxxxC
1	ABG23596 ck: 9127 len: 74 ! Abg23596 Novel human diagnostic protein #23	27: AEGED CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CLPPS		1,356: GGGCT CCAGCCCCCGTGTCTCCACCCCC CTCG
	16: AAFWR CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CRDWW	28: EGBDC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC LPPSA		1,694: GAGCC CAGAGCCCCCGTGTCTCCACCCCC CTCGG CxxCxxxCx(10)CxxxCxxxC
	17: AFWR CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC RDWWS			1,788: GGGCC CGCTCAGCCATTCAAGCCAGCTGGC GGCCC CxxCxxxCx(12)CxxxCxxxC
1	ABP02740 ck: 9587 len: 56 ! Abp02740 Human ORFX protein sequence SEQ ID	16: AAFWR CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC CRDWW		1,804: TTCAA CCCAGCTGGCGGCCCCAGCCACCAACC ACATA CxxCxxxCx(11)CxxxCxxxC
	1: CGDCVCVCAHMHMCACTCTCVCVCVCAC VHVSA	17: AFWR CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC RDWWS		2,065: GGGAG CCCCAGAGCCCTCTGCTCCAGCTGGC TCTCC CxxCxxxCx(11)CxxxCxxxC
1	ABP00320 ck: 5712 len: 75 ! Abp00320 Human ORFX protein sequence SEQ ID			2,069: GCCCC CAGAGCCCTGCTGCCAGCTGGCTCTC CAGCG CxxCxxxCx(11)CxxxCxxxC
	1: CGDCVCVCAHMHMCACTCTCVCVCVCAC VHVSA			2,072: CCCAG CAGCCTCTGCTCCAGCTGGCTCTCCAGC GCCTG CxxCxxxCx(10)CxxxCxxxC
1	ABP05967 ck: 9068 len: 100 ! Abp05967 Human ORFX protein sequence SEQ ID			2,402: AGTCC CCCCAGCTGCCCACTCTCTCCAGGC TCACC CxxCxxxCx(10)CxxxCxxxC
	5: HMYV CGGICVCMXACVCMVCVCMVCVCMVC PCMXA			2,414: CTGCC CCACCTCTCCAGGCTCACCTCCCTC COTGG CxxCxxxCx(10)CxxxCxxxC
1	AA014246 ck: 8867 len: 925 ! Aa014246 Human presenilin enhancer protein			2,562: CAGCA CTGCCATCTGGACCACTCCCTCCACCC ATGGA CxxCxxxCx(12)CxxxCxxxC
	562: TGGGG CATCTCTTATGTTCTCTGACCCAC CTGCT			2,718: CCTAG CCCCCCTCAGACCAACAGCCCCAGCC TCTTC CxxCxxxCx(10)CxxxCxxxC
	586: CTGAC CCACCTGCTGTGTGTCGCCAGACCTTC ATAAG			2,736: CACAG CCCCCAGCTCTTCTCCACAGACTTCC TCGAT CxxCxxxCx(10)CxxxCxxxC
1	ABG66758 ck: 95 len: 207 ! Abg66758 Human novel polypeptide #93. 8/200			3,000: GAGAG CAGCTCTCAAGAGAGAGCCCTGGCTCTC ACGCT CxxCxxxCx(11)CxxxCxxxC
	14: CAVCA CVCVFVCAVFMCAVHACVLCACVCCVLC SCVCC			3,252: GGCCT CTACCCCCCTATTCTCTGTGTGCCAAC CCAGG CxxCxxxCx(12)CxxxCxxxC
	146: CAVRL CAVCACVVCVLCVCAVGVSSVCCVCC AFVCV			3,499: GTGTG CCACAGCTGGTGCCCCAGTCTGGCATGC AGCTA CxxCxxxCx(11)CxxxCxxxC
1				3,575: CCCTG CCAGGCCCTATGCCCCACCTGCCCTGC TTCCT CxxCxxxCx(10)CxxxCxxxC
				3,648: CTGGC CTTCTGCGCAGGAGCTCTCCACCCACTC ACATT CxxCxxxCx(11)CxxxCxxxC
				3,664: GAGCT CTCACCCACTACATTCGGTCCCCGC GGCCT CxxCxxxCx(10)CxxxCxxxC

1 CxxCxxxCx{12}CxxxCxxx  
3,666: GCTCT CCACCATCATCATTCGGTCCCGCGGCGC TCACT  
CxxCxxxCx{12}CxxxCxxx  
3,670: TCCAC CCACTCATTCCGTCCTCCCGCGGCGCTCAC TGCAG  
AAU91279 ck: 387 len: 1,329 ! Aau91279 Human NOV3a protein.. 6/2002  
1 CXXCXXCXXC{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
30: TCTGC CAGCTACCTGGGCAACGACACCCGCATCC GCTGG  
CxxCxxxCx{10}CxxxCxxx  
51: GACAC CCGCATCCGCTGGTACCAACACCGAGC CCTTG  
CxxCxxxCx{11}CxxxCxxx  
916: TCCAG CTGCCCGCGAGTCTATTCTCATCCCTTC CGGCT  
CxxCxxxCx{10}CxxxCxxx  
1,017: CTCCT CCACAGCCACAGCAACGCTCTCCGCCC TGGAG  
ADI16594 ck: 6526 len: 202 ! Adi16594 Human NOVX protein to treat human  
1 CXXCXXCXXC{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
131: SSCQC CSCCKPYCSQSCKKPCCCSSGCGSSC CQSSC  
ADG34533 ck: 9646 len: 1,440 ! Adg34533 Glucocorticoid induced cell death  
1 CXXCXXCXXC{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
723: CTTTG CAGCATGTGAAGCTGTACGGCGACAAGC TAGAA  
ADG47243 ck: 4982 len: 162 ! Adg47243 Human TNF-Rdelta163 truncated protein  
1 CXXCXXCXXC{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
92: CATGG CGCCCGTCGCGTCTGGCGCGGCTGGC CGTGC  
ADN42248 ck: 6390 len: 202 ! Adn42248 Human novel proteinNOV 31. 6/2004  
1 CXXCXXCXXC{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
131: SSCQC CSCCKPYCSQSCKKPCCCSSGCGSSC CQSSC  
ADN89765 ck: 9819 len: 1,218 ! Adn89765 Human 202P5A5v.1 protein epitope #  
1 CXXCXXCXXC{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
364: CEECC CCCCCCGCCCEEEEEEEEECCCCCCCC CCHE  
CxxCxxxCx{11}CxxxCxxx  
365: BECCC CCCCCCGCCCEEEEEEEEECCCCCCCC CCHE  
CxxCxxxCx{10}CxxxCxxx  
366: ECCCC CCCCCCGCCCEEEEEEEEECCCCCCCC CCHE  
CxxCxxxCx{10}CxxxCxxx  
367: CCCCC CCCCCCGCCCEEEEEEEEECCCCCCCC CCHEC  
CxxCxxxCx{10}CxxxCxxx  
368: CCCCC CCCCCCGCCCEEEEEEEEECCCCCCCC CHECC  
CxxCxxxCx{10}CxxxCxxx  
384: EEEEE CCCCCCGCCCEEEEEEEEECCCCCCCC CHHHH  
CxxCxxxCx{10}CxxxCxxx

385: EEEEC CCCCCCGCCCEEEEEEEEECCCCCCCC HHHHH  
CxxCxxxCx{12}CxxxCxxx  
779: EEEEC CCCCCCGCCCEEEEEEEEECCCCCCCC HHHHH  
CxxCxxxCx{11}CxxxCxxx  
780: EEEEC CCCCCCGCCCEEEEEEEEECCCCCCCC HHHHH  
CxxCxxxCx{10}CxxxCxxx  
781: EEEEC CCCCCCGCCCEEEEEEEEECCCCCCCC HHHHH  
CxxCxxxCx{12}CxxxCxxx  
924: CCCCC CCCCCCGCCCEEEEEEEEECCCCCCCC HHECC  
ADN11593 ck: 9787 len: 2,688 ! Adn11593 Human CD91 protein fragment SEQ ID  
1 CXXCXXCXXC{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
357: CTGGG CTGCAGCACCATTGTGTCCCGCACACTC GATGG  
CxxCxxxCx{11}CxxxCxxx  
537: GGATA CTCTCTGCAGCGGATAACCGCTCTCTGC AAGGC  
CxxCxxxCx{12}CxxxCxxx  
2,657: TGAGG CCCAGCGCTCTGCATATCAGCACACTGC GCC  
ABO59388 ck: 7388 len: 47 ! Abo59388 Human genome derived single exon protein  
1 CXXCXXCXXC{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
8: KNWYY CCCCCCYCCYCCCCCCCCCCCCCCCC CCCCC  
CxxCxxxCx{10}CxxxCxxx  
9: NWYYC CCCCCCYCCYCCCCCCCCCCCCCCCC CCCCC  
CxxCxxxCx{10}CxxxCxxx  
10: WYYCC CCCCCYCCYCCCCCCCCCCCCCCCC CCCCC  
CxxCxxxCx{10}CxxxCxxx  
12: YCCCC CXYCCYCCCCCCCCCCCCCCCCCCCC CCCCC  
CxxCxxxCx{10}CxxxCxxx  
13: CCCCC CYCCYCCCCCCCCCCCCCCCCCCCC CCCCC  
CxxCxxxCx{10}CxxxCxxx  
16: CCCYC CYCCCCCCCCCCCCCCCCCCCCCCCC CCCCC  
CxxCxxxCx{10}CxxxCxxx  
17: CCYCC CYCCCCCCCCCYCCCCCCCCCCCCCCC CCCC  
CxxCxxxCx{10}CxxxCxxx  
19: YCCCY CCCCCCCCCCYCCCCCCCCCCCCCCC CC  
CxxCxxxCx{10}CxxxCxxx  
20: CCCYC CCCCCCCCCCYCCCCCCCCCCCCCCC C  
CxxCxxxCx{10}CxxxCxxx  
21: CCYCC CCCCCCCCCCYCCCCCCCCCCCCCCC CCCCC  
ADP30550 ck: 8986 len: 483 ! Adp30550 Human secreted protein SEQ ID #131  
1 CXXCXXCXXC{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
100: CTCCT CTCTACGCTCTCGCCCTGTGGGGCTC ACCTC  
CxxCxxxCx{10}CxxxCxxx  
107: TCACC CTCTCTGCCCTGTGTGGCGCTCACCTCC GCGGT  
ADP30551 ck: 2445 len: 207 ! Adp30551 Human secreted protein SEQ ID #131

[illegible]



1,037: TATGC CCTCATGCTCGGAGGGGCCAACAAGAC CTCCT  
CxxCxxxCx{10}CxxxCxxx  
1,215: GGCTT CACCTTCAGCTCTTGGCACCCCTC TGGCC  
CxxCxxxCx{11}CxxxCxxx  
1,218: CTCAC CTTCCAGCTCTTGGCACCCCTCTGGC CTCCC  
CxxCxxxCx{10}CxxxCxxx  
3,264: GTCAC CATCTGCTCTCAATGGCCAAACCCC GACCT  
CxxCxxxCx{12}CxxxCxxx  
3,286: GCCAA CCCCCAGCTCATACAAACTCAGGCCTGC AG  
CxxCxxxCx{11}CxxxCxxx  
3,287: CCAAC CCCGAGCTCATACAAACTCAGGCCTGC AG  
ADP31136 ck: 1875 len: 2,272 | Adp31136 Human secreted protein SEQ ID #190  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
274: AGCAG CCTCATCTGCTGTCTAGCGCCGCCAAC ATGGA  
CxxCxxxCx{12}CxxxCxxx  
628: ACCAA CCACATCGGGAGTGTGCGCGCCCTAC GTAGC  
CxxCxxxCx{12}CxxxCxxx  
1,742: TCCAT CCGGAGCTCATGCCAAGACCATATGC ACCTC  
CxxCxxxCx{11}CxxxCxxx  
1,796: AAGGC CTTTCATCCACGAGTGTGCGCTAC CTATA  
CxxCxxxCx{11}CxxxCxxx  
1,889: CGGGA CGATGCTGGGATGTACCATGCCCTC AAGGA  
CxxCxxxCx{10}CxxxCxxx  
2,048: GTGTC CAGCATACACCCCTGGCGGCCCC AGCAG  
CxxCxxxCx{12}CxxxCxxx  
2,128: GGGGG CAGCAGCTCTTCTCGGCGCCCAATC CCATC  
ADP31234 ck: 1398 len: 3,465 | Adp31234 Human secreted protein SEQ ID #200  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
359: GCCCG CAGCGCCAGCGAGGGCCCCCGCGGCC ATGCT  
CxxCxxxCx{12}CxxxCxxx  
473: GGCTT CCCCCTCGGGGAGGAGTGTGCCCTCC GCCGC  
CxxCxxxCx{11}CxxxCxxx  
573: CTGAG CTCGAGCGGTACTACTCCAGTCCCCC GGTC  
CxxCxxxCx{10}CxxxCxxx  
1,302: AACAA CAACACCCAGATAGTCTTACAATC CTTAC  
CxxCxxxCx{10}CxxxCxxx  
1,699: CCGTG CCACAGACCAACGGCTCTTTTACCC CAACA  
CxxCxxxCx{11}CxxxCxxx  
2,645: TAGCC CCGCTATCTGTGTCTCAGCGCTTCCCCAC ACCCC  
CxxCxxxCx{12}CxxxCxxx  
2,678: ACCCC CAACAGCCCCCTTACATCTGCATCCAAACC ACCGA  
CxxCxxxCx{12}CxxxCxxx  
2,681: CCAAA CAGCCCCCTTACATCTGCATCCAAACC GAATA  
CxxCxxxCx{12}CxxxCxxx  
2,907: AGAAA CGGCTTTCGGCGCGCGAACCACCTGCG GTGG

CxxCxxxCx{10}CxxxCxxx  
2,928: GAACC CGACCTGCGCTGGATTTCCTCGGGC GCAGG  
ADP31324 ck: 4933 len: 624 | Adp31324 Human secreted protein SEQ ID #201  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
336: GTGTA CTGCCCCAGCATGTGTCAGCTGCC TGTGA  
ADP31325 ck: 4933 len: 624 | Adp31325 Human secreted protein SEQ ID #202  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
336: GTGTA CTGCCCCAGCATGTGTCAGCTGCC TGTGA  
ADP31327 ck: 1885 len: 2,127 | Adp31327 Human secreted protein SEQ ID #209  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
652: ACAGC CTGCTTGCAGATACCTGTGCAGACAGTC AATAC  
ADP31364 ck: 5032 len: 687 | Adp31364 Human secreted protein SEQ ID #213  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
296: TGTCT CGACTGCCTACTCAGAGCTCTATCATCC AAGCT  
CxxCxxxCx{12}CxxxCxxx  
299: TCCGA CTGCTACTCAGAGCTCTATCATCCAAGC TTGT  
ADP31371 ck: 8173 len: 1,386 | Adp31371 Human secreted protein SEQ ID #213  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
8: GGAGA CAGCGGCTCTGTGTACTGGGCGCGGCC TCCT  
ADP31392 ck: 4716 len: 585 | Adp31392 Human secreted protein SEQ ID #215  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
37: GCCTC CTGCACACCTGAAGTAGACCCCTGC CTTTG  
ADP31419 ck: 3662 len: 1,662 | Adp31419 Human secreted protein SEQ ID #218  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
118: CTGAA CAACGCTTCAGCCCTAGACCTTCCCTC TGACA  
CxxCxxxCx{10}CxxxCxxx  
601: GCTTT CTTGATCAGATGGGAAGCCACAGTC CTCCT  
ADP31488 ck: 2208 len: 1,398 | Adp31488 Human secreted protein SEQ ID #225  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
756: GCCCA CGCCAGCCACAGAGGGCCCTCCCCAC CCTCT  
ADP31501 ck: 9247 len: 225 | Adp31501 Human secreted protein SEQ ID #226  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
152: GGAAG CAGCAGATCATCTCTCACCGCATTC CAGAC

1	ADP31543	ck: 1539	len: 651	! Adp31543 Human secreted protein SEQ ID #2311	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{10}CxxCxxxC 23: GCTGA CGCAGCGCTGCTGTTCACAGCC CTTCC 41: TGTTC CCACGAGCCTTCCTCTCCCTTCAGGC ATGAC
1	ADP31556	ck: 5715	len: 1,812	! Adp31556 Human secreted protein SEQ ID #232	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{10}CxxCxxxC 468: ATCAC CTCACGCTGCCCTATGTGCTCTGAC CATCT 1,029: GCGGC CTACGCGAGCTGGTGTTCAGACCTGC GACAT
1	ADP31589	ck: 1874	len: 1,358	! Adp31589 Human secreted protein SEQ ID #235	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{12}CxxCxxxC 289: CCAGA CATCGCCTGGATGCTTCGGCTCTGGC TGGTC 608: GTGTG CCGCGTGAGCTTGGGCCCTACACGCC CGGCC
1	ADP31651	ck: 9556	len: 555	! Adp31651 Human secreted protein SEQ ID #241	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{10}CxxCxxxC 23: ACCCT CTCGCTCAGGACCTCGGCCCTCATCC CAGGG 116: ACCCG GAACGTGTGGGCTTGCTACTGGGGGCC GCCTT 470: GTGGA CTTGGGGGCTGGAGCCACAGCGCGGCC CGCGT
1	ADP31684	ck: 4855	len: 3,046	! Adp31684 Human secreted protein SEQ ID #245	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{11}CxxCxxxC 193: GCCTT CCTCATCAGTACGAGCGCCATCGAGC CTCCC 205: CAGTA CGAGCCCATGGAGCCTCCCGTCTCCC TATGC 668: TGTGC CATCTCCACCTCGAGGACACGCTGSC CCAGC
1	ADP31686	ck: 6057	len: 690	! Adp31686 Human secreted protein SEQ ID #245	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{12}CxxCxxxC 340: GCGAG CTGCGCGCGCGCTGCGCGGCCACCC GGACC 345: CTGCG CxxCxxxC{11}CxxCxxxC 488: TCGAG CGGCGCCTGCGCTGTGCTCTCCAGC CCGGC 610: GCGTG CGCCACGGGCGAGCTGGCGAGGACCC CTGAG
1	ADP30472	ck: 4200	len: 1,740	! Adp30472 Human secreted protein SEQ ID #123	1	
1	ADP31543	ck: 1539	len: 651	! Adp31543 Human secreted protein SEQ ID #2311	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{10}CxxCxxxC 23: GCTGA CGCAGCGCTGCTGTTCACAGCC CTTCC 41: TGTTC CCACGAGCCTTCCTCTCCCTTCAGGC ATGAC
1	ADP31556	ck: 5715	len: 1,812	! Adp31556 Human secreted protein SEQ ID #232	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{10}CxxCxxxC 468: ATCAC CTCACGCTGCCCTATGTGCTCTGAC CATCT 1,029: GCGGC CTACGCGAGCTGGTGTTCAGACCTGC GACAT
1	ADP31589	ck: 1874	len: 1,358	! Adp31589 Human secreted protein SEQ ID #235	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{12}CxxCxxxC 289: CCAGA CATCGCCTGGATGCTTCGGCTCTGGC TGGTC 608: GTGTG CCGCGTGAGCTTGGGCCCTACACGCC CGGCC
1	ADP31651	ck: 9556	len: 555	! Adp31651 Human secreted protein SEQ ID #241	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{10}CxxCxxxC 23: ACCCT CTCGCTCAGGACCTCGGCCCTCATCC CAGGG 116: ACCCG GAACGTGTGGGCTTGCTACTGGGGGCC GCCTT 470: GTGGA CTTGGGGGCTGGAGCCACAGCGCGGCC CGCGT
1	ADP31684	ck: 4855	len: 3,046	! Adp31684 Human secreted protein SEQ ID #245	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{11}CxxCxxxC 193: GCCTT CCTCATCAGTACGAGCGCCATCGAGC CTCCC 205: CAGTA CGAGCCCATGGAGCCTCCCGTCTCCC TATGC 668: TGTGC CATCTCCACCTCGAGGACACGCTGSC CCAGC
1	ADP31686	ck: 6057	len: 690	! Adp31686 Human secreted protein SEQ ID #245	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{12}CxxCxxxC 340: GCGAG CTGCGCGCGCGCTGCGCGGCCACCC GGACC 345: CTGCG CxxCxxxC{11}CxxCxxxC 488: TCGAG CGGCGCCTGCGCTGTGCTCTCCAGC CCGGC 610: GCGTG CGCCACGGGCGAGCTGGCGAGGACCC CTGAG
1	ADP30472	ck: 4200	len: 1,740	! Adp30472 Human secreted protein SEQ ID #123	1	
1	ADP30484	ck: 4048	len: 234	! Adp30484 Human secreted protein SEQ ID #1251	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{10}CxxCxxxC 580: CAATA CCACCACCGGGGTACCTTGGCAGC GTTGG 962: ACCAG CCGCATCAATCCTGGAGCCCCCAGAC CAGGT
1	ADP30495	ck: 403	len: 1,176	! Adp30495 Human secreted protein SEQ ID #1261	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{12}CxxCxxxC 12: TCCTT CATCCAGCTCCAAACCTTTTCAAGCCTGC TGCAA
1	ADP30530	ck: 2445	len: 207	! Adp30530 Human secreted protein SEQ ID #1291	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{10}CxxCxxxC 44: CAATA CCACCACCGGGGTACCTTGGCAGC GTTGG 436: ACCAG CCGCATCAATCCTGGAGCCCCCAGAC CAGGT
1	ADP30536	ck: 7217	len: 1,183	! Adp30536 Human secreted protein SEQ ID #1301	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{10}CxxCxxxC 83: CTCTG CGAGCGCGCGCTGCGCGAGCCACC CGCGG 90: ACGGG CGCGCTCGCCGAGCCACC CGCGC 92: GCGGG CxxCxxxC{12}CxxCxxxC 113: CCGCG CGCGCGCGGTCTCGCCCGCGCGCTGC CCCCC 118: GCGGG CxxCxxxC{11}CxxCxxxC 799: AGTGC CTGCCACCTGAGAAAGGCTACCTGCCTGC TGGGC
1	ADP30585	ck: 2463	len: 4,752	! Adp30585 Human secreted protein SEQ ID #1351	1	CXXCXXC{10,12}CXXCXXXC CxxCxxxC{10}CxxCxxxC 87: GACAG CGGCGTTCGGGGAACTCGGGCAGCC CTCTG 109: TCGGG CxxCxxxC{12}CxxCxxxC 126: GTAGC CGCGAGCGCGATGCCCACTACCTGCC GCTGC 1,394: TGGTT CATCTACTCTGTCAAAGCAAGCTTAC AGTAA



3,647: CCAGG	CxxCxxxCx{11}CxxxCxxxC CATCAACCCAGAGCTTGAGCGAGCTCTC	ATACC	ADP30628	ck: 5910	len: 234	Adp30628	Human secreted protein SEQ ID #139	1,833: CATCC	CGACACCCATGTACCGTCTCGGCCAGCC	AACCC			
143: CCTAA	CACCTGTCACACTACTGTCTCCC	AGTGA	ADP30628	ck: 5910	len: 234	Adp30628	Human secreted protein SEQ ID #139	1,905: GAAGG	CGGCTAACACAGAGCCACAGCCCGC	CCTAC			
ADP30635	ck: 776	len: 189	Adp30635	Human secreted protein SEQ ID #140				ADP30710	ck: 6107	len: 3,070	Adp30710	Human secreted protein SEQ ID #147	
13: ACGGG	CTTCGAGCTGGGAGGAGCGCGCTC	TTGTG	ADP30635	ck: 776	len: 189	Adp30635	Human secreted protein SEQ ID #140	1	CXXCXXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC				
ADP30640	ck: 1800	len: 291	Adp30640	Human secreted protein SEQ ID #140				592: TCCAG	CGACAGGCTAGTGTGGCGCTCCACC	GCTGA			
5: ATGA	CACGCGCCCGCTTCAACCAAACTTCC	TACGC	ADP30640	ck: 1800	len: 291	Adp30640	Human secreted protein SEQ ID #140	637: CGCAT	CATCTACCCCGCAGAGGCCCAAAACCATC	ATCGT			
13: CGCCC	CGCCTTCAACCCAACTTCTTAGCGCC	TGTTT	ADP30640	ck: 1800	len: 291	Adp30640	Human secreted protein SEQ ID #140	1,036: CTCAT	CTCCAGCAGGCGCTCCGGCTCTCCCGC	AGGGC			
135: ACTCG	CTGCTGCGTCCAGGACCGCACCTGC	CCCTC	ADP30640	ck: 1800	len: 291	Adp30640	Human secreted protein SEQ ID #140	1,220: GCTCC	CATCATCTCAGCTCGCCCGCACCTCC	AAGAC			
ADP30648	ck: 1656	len: 1,365	Adp30648	Human secreted protein SEQ ID #141				1,571: AGCAG	CAGCCAGCAGACGACGCGCGCTCTC	CCCCC			
480: AGCTC	CCTCTTCCCTACGTGTGTGGCCTGC	TTCTT	ADP30648	ck: 1656	len: 1,365	Adp30648	Human secreted protein SEQ ID #141	1,592: GGCGG	CCTCTCCCCCGAGAGCTCCGACAGGC	CCACC			
875: CATCC	CACCCACGTCAACTTCTCCCACTGAC	CACAA	ADP30648	ck: 1656	len: 1,365	Adp30648	Human secreted protein SEQ ID #141	2,295: GGCTC	CATCGTTCTCATCATCGTCACCTTCATCC	CCTTC			
ADP30651	ck: 2463	len: 4,752	Adp30651	Human secreted protein SEQ ID #141				ADP30713	ck: 9426	len: 2,322	Adp30713	Human secreted protein SEQ ID #148	
87: GACAG	CGCGGTGCGGGGAACTCGGGCAGCC	CTCTG	ADP30651	ck: 2463	len: 4,752	Adp30651	Human secreted protein SEQ ID #141	1	CXXCXXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC				
109: TCGGG	CAGCCCTCTGGGGTAGCGCGGAGCGCC	ATGCC	ADP30651	ck: 2463	len: 4,752	Adp30651	Human secreted protein SEQ ID #141	1,942: GGAGC	CAACTGGCGGAGGAGCTCCAACCTGC	TGGTG			
126: GTAGC	CGCCGAGCGCCATGCCCACTACTGCC	GCTGC	ADP30651	ck: 2463	len: 4,752	Adp30651	Human secreted protein SEQ ID #141	ADP30838	ck: 9460	len: 321	Adp30838	Human secreted protein SEQ ID #160	
1,394: TGGTT	CATCTACTCTGTCAAGCAAGCTTAC	AGTAA	ADP30651	ck: 2463	len: 4,752	Adp30651	Human secreted protein SEQ ID #141	1	CXXCXXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC				
3,647: CCAGG	CATCAACCCAGACTTGAGCCAGCTCTC	ATACC	ADP30651	ck: 2463	len: 4,752	Adp30651	Human secreted protein SEQ ID #141	ADP30849	ck: 642	len: 534	Adp30849	Human secreted protein SEQ ID #161	
ADP30657	ck: 9708	len: 2,123	Adp30657	Human secreted protein SEQ ID #142				1	CXXCXXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxxC				
719: GGAGC	CCCCAACTACAGCGTGGGTGCCACC	TACCT	ADP30657	ck: 9708	len: 2,123	Adp30657	Human secreted protein SEQ ID #142	114: TGCCA	CTTCCTCCAGCGCTCCTCCTCTGGC	TGTCA			
723: GCCCC	CAACTCACCAGCGTGGGTGCCACCTACC	TTATC	ADP30657	ck: 9708	len: 2,123	Adp30657	Human secreted protein SEQ ID #142	416: CCATC	CTACACCCCTTCATGCTGCTCAGGC	CCTTC			
1,339: CCCCC	CACCCTCCCTTCCAGGCCACGCTCAC	AGATG	ADP30657	ck: 9708	len: 2,123	Adp30657	Human secreted protein SEQ ID #142	ADP30874	ck: 5112	len: 1,032	Adp30874	Human secreted protein SEQ ID #164	
			ADP30657	ck: 9708	len: 2,123	Adp30657	Human secreted protein SEQ ID #142	1	CXXCXXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC				
			719: GGAGC	CCCCAACTACAGCGTGGGTGCCACC	TACCT			58: GACTA	CCCCTGCTGTGAAGAACCGGGCATCC	TGATG			
			723: GCCCC	CAACTCACCAGCGTGGGTGCCACCTACC	TTATC			ADP30888	ck: 873	len: 1,341	Adp30888	Human secreted protein SEQ ID #165	
			1,339: CCCCC	CACCCTCCCTTCCAGGCCACGCTCAC	AGATG			1	CXXCXXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC				
									91: GACTA	CCCCTGCTGTGAAGAACCGGGCATCC	TGATG		
									1,138: AGTGG	CACGGCCTGGCGCTCATCATCCACC	GCTCC		
										CxxCxxxCx{10}CxxxCxxxC			
									ADP30919	ck: 9820	len: 1,170	Adp30919	Human secreted protein SEQ ID #168
										CxxCxxxCx{12}CxxxCxxxC			

1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxx 66: GGGAG CAGGAGCTCCAGGAGTTCTGCCCCAC CATCC 96: ACCAT CCTCAGCAGCTGGATTCCCGGCGTCG ACCTC 233: CCTGG CTTCTCTCTGGGAGTCCTGCTCTGCC CTGCA 877: GCATC CAACAAGCTCTCTTCTTCAACTTCTTTTC TGCCT ADP30947 ck: 631 len: 2,468 ! Adp30947 Human secreted protein SEQ ID #171	1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxx 284: CAGCT CGGCCACGACCGCTGGCTGGACC CCAAC ADP31105 ck: 3999 len: 2,418 ! Adp31105 Human secreted protein SEQ ID #187
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxx 96: ACCAT CCTCAGCAGCTGGATTCCCGGCGTCG ACCTC 233: CCTGG CTTCTCTCTGGGAGTCCTGCTCTGCC CTGCA 877: GCATC CAACAAGCTCTCTTCTTCAACTTCTTTTC TGCCT ADP30947 ck: 631 len: 2,468 ! Adp30947 Human secreted protein SEQ ID #171	1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxx 117: ACCCA CCACTTCCAGCCAGAAACCTGTCTGCC TCCTA 516: AGAGA CTCCAAGCTCAGTGATTTCAGCCACCTACC TCTGT 866: TGAAC CTCCTTTCCACCTGACGAAACCTTCAGCC CATAT 867: GAAAC CTCCTTCACCTGACGAAACCTTCAGCC CATAT 2,297: TGAAC CTCCTTTCCACCTGACGAAACCTTCAGCC CATAT 2,298: GAAAC CTCCTTCACCTGACGAAACCTTCAGCC CATAT ADP31218 ck: 6303 len: 390 ! Adp31218 Human secreted protein SEQ ID #198
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxx 318: CCTCA CTGGTGGTGGCTCTGAGTGCCATC GAGCT ADP30996 ck: 761 len: 268 ! Adp30996 Human secreted protein SEQ ID #176	1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxx 263: GGTCC CACCAATCACTGTCTTCTCAGGCTGCC CAGGA ADP31230 ck: 7422 len: 891 ! Adp31230 Human secreted protein SEQ ID #199
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxx 94: CGCCC CGCGGGGTGTGGCTGCGCCCCAGC CAGCC 219: TCGGG CGCCCCCTTCTTCTCCCTTCTTTC CTGG ADP31003 ck: 5508 len: 1,419 ! Adp31003 Human secreted protein SEQ ID #177	1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxx 354: ATCAC CGCTCTCTGCCCATAGGTCTCACTGC CCACC ADP31247 ck: 4640 len: 390 ! Adp31247 Human secreted protein SEQ ID #204
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxx 322: GCTGT CGCTTGCTCTCCAGCTACTCCATCCACC TGCTA 795: GCCTT GGTCTGCCACCGAGGTGTCGCCATC TATAC 1,223: ATCTG CCCATTCTCATCTTTCATCTTCCCTGC CATCT ADP31033 ck: 6023 len: 831 ! Adp31033 Human secreted protein SEQ ID #180	1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxx 66: ATCTC CACCCAGCCCAATCTCCCGTGCCAGC CCTGC 104: TCTGT CTTCTCGCCACCATCTGGGCTCCACGC GGGCT 109: CCTCT CGCCACCATCTGGGCTCCACGGGGC TCCTT 244: CAGCC CGGCTCAGGATGAGCAGCAACCGAAC TCAGG 260: TGAGG CAGCAACCGAACTCAGGTGCGGCATCC CCACC ADP31450 ck: 7076 len: 1,266 ! Adp31450 Human secreted protein SEQ ID #221
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxx 502: GGAGG CGGGCGGGCGGAGGTGGCGGGGGC TCCCG 555: CGCTG CCGGACCGACCGCAGCGCGCGGCC GACCG 558: TGCCG CGACGACCGAGCGCGCGCGCGGAC CGCG ADP31070 ck: 5595 len: 522 ! Adp31070 Human secreted protein SEQ ID #183	1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxx ADP31450 ck: 7076 len: 1,266 ! Adp31450 Human secreted protein SEQ ID #221

1  
367: AGCGC CAGCGCCGCGGGAGAGCCGCGCGC GTTTC  
CxxCxxxCx{10}CxxxCxxxC  
567: CAAA CAGCATAGTCTCTCAAGCCCTGGATC CGCA  
CxxCxxxCx{12}CxxxCxxxC  
649: AGCG CTGCTCAGACTCCCTCCACAACCTGC CGGAG  
CxxCxxxCx{10}CxxxCxxxC  
705: TGTAG CCTCATCTGGGCCCGCAGCCCGCGAC AAGCC  
CxxCxxxCx{11}CxxxCxxxC  
712: TCCAT CTGGCCCGCAGCCCGCGCACAGCCGCC TCCGT  
CxxCxxxCx{12}CxxxCxxxC  
719: GCGCC CCAGGCCCGGCACAAGCCCGCTCGTC GGGG  
CxxCxxxCx{11}CxxxCxxxC  
ADP31451 ck: 8464 len: 450 ! Adp31451 Human secreted protein SEQ ID #221  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{10}CxxxCxxxC  
98: ATTCT CCCGGACCGCCCTAACACAGTC ACTTC  
CxxCxxxCx{10}CxxxCxxxC  
142: ATGCT CTTCAATTCCATTCTGTGCCAGGAG GGGAG  
CxxCxxxCx{10}CxxxCxxxC  
ADP31526 ck: 683 len: 2,709 ! Adp31526 Human secreted protein SEQ ID #229  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{12}CxxxCxxxC  
1,080: TCCAG CGGTCCCACTGGCAATTCGCCAGCTCAC ATTAC  
CxxCxxxCx{10}CxxxCxxxC  
1,138: TGGCC CAGCAGGCTCTGTGAGGCTGTCCAGC GTGTC  
CxxCxxxCx{11}CxxxCxxxC  
1,400: AGCG CCCACTCTCCCTGGTCCCTGCTGC TGCTC  
CxxCxxxCx{11}CxxxCxxxC  
1,579: CCGC CTGCTCCTCGGCTCACTCTGTCCACC TTCCA  
CxxCxxxCx{12}CxxxCxxxC  
2,137: CCAAG CGTCCAGCTCACTGTGGCTCCCGAC CACCC  
CxxCxxxCx{10}CxxxCxxxC  
2,216: ACGGA CCCTTCCACCAAGCCTTCTGTCCGC GGGGA  
CxxCxxxCx{11}CxxxCxxxC  
ADP31536 ck: 401 len: 1,530 ! Adp31536 Human secreted protein SEQ ID #230  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{12}CxxxCxxxC  
881: CGGTG CGACTCCTACCGCGCGCCGACAGGAC TTGCT  
CxxCxxxCx{11}CxxxCxxxC  
1,095: TCCAT CTTCAAGCTCTACACGGCGCACCTAC TATGT  
CxxCxxxCx{10}CxxxCxxxC  
ADP31599 ck: 4778 len: 1,996 ! Adp31599 Human secreted protein SEQ ID #236  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{12}CxxxCxxxC  
333: ATCGA CTCCTCCAGGGGTGTGTAGCGCTACC AGCTA  
CxxCxxxCx{10}CxxxCxxxC  
1,741: CCACT CTCATACAGGTGATATTTTCAACCCCC TCTCG  
CxxCxxxCx{12}CxxxCxxxC  
ADP31608 ck: 5984 len: 1,321 ! Adp31608 Human secreted protein SEQ ID #237

1  
46: GCCT CAGTCCCTCCCTCCACCTACCCCC TCACA  
CxxCxxxCx{10}CxxxCxxxC  
51: CAGCT CCCCTCCCTCCACCTACCCCCCTCACAC CCACC  
CxxCxxxCx{11}CxxxCxxxC  
52: AGCTC CCCCTCCCTCCACCTACCCCCCTCACAC CCACC  
CxxCxxxCx{10}CxxxCxxxC  
54: CTCCC CTCCTCCCTCCACCTACCCCCCTCACACC ACCAC  
CxxCxxxCx{10}CxxxCxxxC  
55: TCCCC CTCCTCCACCTACCCCCCTCACACCAC CACTA  
CxxCxxxCx{11}CxxxCxxxC  
69: CTTAC CCCCTCACACCCACCTACGACCCAC GGGAT  
CxxCxxxCx{11}CxxxCxxxC  
1,138: AGCG CTCCCTGGCGCGAAGTAGGCGCTCC CCCCC  
CxxCxxxCx{10}CxxxCxxxC  
ADP31652 ck: 5638 len: 711 ! Adp31652 Human secreted protein SEQ ID #241  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
307: GAAGT CTCAGCGCGCGCTCTCACTCTCATTC CTACC  
CxxCxxxCx{12}CxxxCxxxC  
310: GTTC CAGCCCGCTCTCTCACTCTCATTTCTCTAC CAACT  
CxxCxxxCx{12}CxxxCxxxC  
314: CCAGC CGGCTCTCTCACTCTCTTCTTCTACCAAC TTGCG  
CxxCxxxCx{11}CxxxCxxxC  
315: CAGCC CGCCTCTCACTCTCATTTCTTCTAACAC TTGCG  
CxxCxxxCx{12}CxxxCxxxC  
449: TCCCA CCGCATCAGTCCAGGCTCGGACCTTC TGCCA  
CxxCxxxCx{12}CxxxCxxxC  
453: ACCCC CATCAGTCCAGGCTCGGACCTTTCTGCC AGAGC  
CxxCxxxCx{12}CxxxCxxxC  
ADP31653 ck: 88 len: 1,623 ! Adp31653 Human secreted protein SEQ ID #242  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{10}CxxxCxxxC  
140: AGGAG CAGCTGTACGCGCTCACTCTCAGGC ACCCA  
CxxCxxxCx{12}CxxxCxxxC  
225: CAAGC CTACCTTCTTTGGACCGGCTCACTCATTC CCATG  
CxxCxxxCx{11}CxxxCxxxC  
655: GGGTG CTCAGGCTCAGAGACCCGCACTCGGCC AGAGC  
CxxCxxxCx{10}CxxxCxxxC  
877: CCACT CAGCCTATCTGACCGGCGCTCATGC TCCTT  
CxxCxxxCx{10}CxxxCxxxC  
1,146: TGGTG CCACGCGCTAGGACCGTGTCTAC GGCTG  
CxxCxxxCx{10}CxxxCxxxC  
1,161: CTAGG CACCGTCTCAGGCTGCGGCTGTGCC CTCGG  
CxxCxxxCx{10}CxxxCxxxC  
ADP30499 ck: 4585 len: 1,578 ! Adp30499 Human secreted protein SEQ ID #126  
CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
930: GTGCG CTGCGCGCAGCGGCGCCCTCTCCAAC ATCTA  
CxxCxxxCx{10}CxxxCxxxC

1	984: TGCCT CACCAAGCTGGAGAGATTCTCTGGCGGAC CACCT	CxxCxxxCx{11}CxxxCxxxC	723: CTCCA CACCGTGCAGGGCCTGGCCTCGCTCTC TGGCC	CxxCxxxCx{10}CxxxCxxxC
1,223: CCCAA CAGCCAACAGAGCCTTGTGAGCCAGGC AGGCA	CxxCxxxCx{11}CxxxCxxxC	ADP30522 ck: 291 len: 576 ! Adp30522 Human secreted protein SEQ ID #128	ADP30695 ck: 31 len: 1,135 ! Adp30695 Human secreted protein SEQ ID #146:	
307: GGTGG CCACTCGCTGGACAATAGCCTTCCTCCATC TTACG	CXXCXXCXXC{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC	346: ACCTT CTACATGCTGGAGTGGCTACCTGAC GCTCA	23: TCCTG CTGCTGCCCTGGCCTCTGCGCACCCCTGAC ATCAA	CXXCXXCXXC{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxxC
346: ACCTT CTACATGCTGGAGTGGCTACCTGAC GCTCA	CxxCxxxCx{10}CxxxCxxxC	ADP30542 ck: 8168 len: 1,521 ! Adp30542 Human secreted protein SEQ ID #130	594: CTCCA CACCGTGCAGGGCCTGGCCTCGCTCTC TGGCC	CxxCxxxCx{10}CxxxCxxxC
ADP30542 ck: 8168 len: 1,521 ! Adp30542 Human secreted protein SEQ ID #130	CXXCXXCXXC{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC	358: ATGAC CAACGAGCTGGTAGAGCGCCCTCACCAAC TGGCA	ADP30731 ck: 406 len: 1,380 ! Adp30731 Human secreted protein SEQ ID #149:	
358: ATGAC CAACGAGCTGGTAGAGCGCCCTCACCAAC TGGCA	CxxCxxxCx{11}CxxxCxxxC	826: CTCAT CATCTGTCTACCGATGGCGACCCAC TGTGG	415: TGGCG CTGCGGGCGAGGCGGTGGCGCCGCAC TCGGC	CXXCXXCXXC{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxxC
826: CTCAT CATCTGTCTACCGATGGCGACCCAC TGTGG	CxxCxxxCx{10}CxxxCxxxC	1,372: TGTCT CCGCATCCGATGCTGATCAGCAGGCCCTC CGGAA	859: TGGCG CCGGAGCGCTCGGCCCTCAGCCGCTGGC CGTCC	CxxCxxxCx{12}CxxxCxxxC
1,372: TGTCT CCGCATCCGATGCTGATCAGCAGGCCCTC CGGAA	CxxCxxxCx{12}CxxxCxxxC	ADP30549 ck: 8184 len: 425 ! Adp30549 Human secreted protein SEQ ID #131	873: CTCGG CCTCAGCGCCTGGCGGCTCTGCTCAC TCTGC	CXXCXXCXXC{10}CxxxCxxxC CxxCxxxCx{10}CxxxCxxxC
ADP30549 ck: 8184 len: 425 ! Adp30549 Human secreted protein SEQ ID #131	CXXCXXCXXC{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxxC	221: AAGAT CAGCAGCCTGCCAATTCTTCTTAC CATCA	1,092: GCCAG CACCGTGTGGACTTGGCGTCTGGC CAGCA	CxxCxxxCx{10}CxxxCxxxC
221: AAGAT CAGCAGCCTGCCAATTCTTCTTAC CATCA	CxxCxxxCx{10}CxxxCxxxC	ADP30586 ck: 9580 len: 948 ! Adp30586 Human secreted protein SEQ ID #135	1,122: GCCAG CATCATGCAGAGCGGCCACACGCGCATCC CGGTG	CXXCXXCXXC{12}CxxxCxxxC CxxCxxxCx{11}CxxxCxxxC
ADP30586 ck: 9580 len: 948 ! Adp30586 Human secreted protein SEQ ID #135	CXXCXXCXXC{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxxC	87: GACAG CGCGGTGCGGGGAACCTGGGCGGCC CTCTG	1,245: AGCAC CATCACTCGTTTCTACAAACCATCGCTC CACTT	CxxCxxxCx{10}CxxxCxxxC
87: GACAG CGCGGTGCGGGGAACCTGGGCGGCC CTCTG	CxxCxxxCx{10}CxxxCxxxC	109: TCGGG CAGCCCTTGGGGTAGCGCGCGAGCGCCC ATGCC	ADP30774 ck: 6317 len: 468 ! Adp30774 Human secreted protein SEQ ID #154:	
109: TCGGG CAGCCCTTGGGGTAGCGCGCGAGCGCCC ATGCC	CxxCxxxCx{12}CxxxCxxxC	126: GTAGC CGCCGAGGGCCCATGCCCACTACCTGCG GCTGC	166: GTGGT CATCTTCTGGCCTGCTTCTTGCCTAC CACGT	CXXCXXCXXC{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC
126: GTAGC CGCCGAGGGCCCATGCCCACTACCTGCG GCTGC	CxxCxxxCx{12}CxxxCxxxC	ADP30627 ck: 9331 len: 156 ! Adp30627 Human secreted protein SEQ ID #139	259: TTCAA GGCCTACCACTTCTCCCTCTGCTCAC CAGCT	CxxCxxxCx{10}CxxxCxxxC
ADP30627 ck: 9331 len: 156 ! Adp30627 Human secreted protein SEQ ID #139	CXXCXXCXXC{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxxC	35: GAAGT CTCACGCGGGAACAACATTACCTC TCTTC	336: CGAGA CCACCCACGGGACCTGGCGCGCTCC GGGG	CxxCxxxCx{10}CxxxCxxxC
35: GAAGT CTCACGCGGGAACAACATTACCTC TCTTC	CxxCxxxCx{10}CxxxCxxxC	ADP30659 ck: 934 len: 363 ! Adp30659 Human secreted protein SEQ ID #142	355: CTGGC CCGCTCGCGGGGCTGCTGGCCTTC CTCAC	CxxCxxxCx{11}CxxxCxxxC
ADP30659 ck: 934 len: 363 ! Adp30659 Human secreted protein SEQ ID #142	CXXCXXCXXC{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxxC	110: ATCCG CTGCGGTCTCGCCGAGACCCCGCGC GGATT	ADP30808 ck: 9566 len: 156 ! Adp30808 Human secreted protein SEQ ID #157:	
110: ATCCG CTGCGGTCTCGCCGAGACCCCGCGC GGATT	CxxCxxxCx{12}CxxxCxxxC	129: GAGAC CCCCAGCGGATTCGCCGCTCTTCCCGC GGGCG	54: TTGTA CAGCAGACCTAGAACCTGTGCGCTTC CCTGT	CXXCXXCXXC{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC
129: GAGAC CCCCAGCGGATTCGCCGCTCTTCCCGC GGGCG	CxxCxxxCx{12}CxxxCxxxC	ADP30683 ck: 6811 len: 1,264 ! Adp30683 Human secreted protein SEQ ID #145	70: ACAAC CTGCTGCCCTTCCCTGTCCCTTTCCACC CCCCC	CxxCxxxCx{11}CxxxCxxxC
ADP30683 ck: 6811 len: 1,264 ! Adp30683 Human secreted protein SEQ ID #145	CXXCXXCXXC{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxxC	23: TCCTG CTGCTGCCCTGCGCTCTGCGCACCCCTGAC ATCAA	ADP30883 ck: 9154 len: 1,260 ! Adp30883 Human secreted protein SEQ ID #165:	
23: TCCTG CTGCTGCCCTGCGCTCTGCGCACCCCTGAC ATCAA	CxxCxxxCx{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxxC		930: GTGGG CTGCGGGCAGCGGGCCACCCTCCAAC ATCTA	CXXCXXCXXC{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC
			984: TGCCT CACCAAGCTGGAGCAGTCTCTGGCGGAC CACCT	CxxCxxxCx{11}CxxxCxxxC
			ADP30908 ck: 9801 len: 936 ! Adp30908 Human secreted protein SEQ ID #167:	

```
1 CXXCXXXCX{10,12}CXXCXXXC
42: GCCAA CAGCGCCAGGAGGATGTGGCTTCAACC TCATC
372: GCCGC CCTTTCAGCCTGGTACTCGTGCGGCC GCCCA
CXXCXXXCX{12}CXXCXXXC
409: CAGCG CACCTGACCACCTGTGTGCGCCCTCAC CTGGG
CXXCXXXCX{12}CXXCXXXC
669: GTCTT CCTTCTCTTCGCGCCTTGCCCTTC GGCAT
ADP30987 ck: 7290 len: 1,616 ! Adp30987 Human secreted protein SEQ ID #179
1 CXXCXXXCX{10,12}CXXCXXXC
CXXCXXXCX{12}CXXCXXXC
762: TTCAT CGTATGCTGGCATGATCAGCGGGC CTGTG
CXXCXXXCX{11}CXXCXXXC
1,172: GGCCC CACCATCAGCGCTCTCTCTGCTGCGC CATCT
ADP31031 ck: 4845 len: 2,469 ! Adp31031 Human secreted protein SEQ ID #179
1 CXXCXXXCX{10,12}CXXCXXXC
CXXCXXXCX{12}CXXCXXXC
2,365: CAGTT CTCGGAACCATTTGTATCATCTCATCAGC CATTG
ADP31036 ck: 6448 len: 807 ! Adp31036 Human secreted protein SEQ ID #180
1 CXXCXXXCX{10,12}CXXCXXXC
CXXCXXXCX{12}CXXCXXXC
460: CACCC CACATCTTTACTCTACGGCTTACTGTC TGAGG
CXXCXXXCX{10}CXXCXXXC
648: CAACT CAGATCCCAACAAAGCCACGGATTC TTCAG
CXXCXXXCX{12}CXXCXXXC
766: AGGTA CTGAGCCCCAGCTCTCTGCCAGCACAC TGCCC
CXXCXXXCX{10}CXXCXXXC
772: TGCAG CCCCAGTCTCTGSCCAGCACACTGCC CAAAT
ADP31124 ck: 2732 len: 645 ! Adp31124 Human secreted protein SEQ ID #189
1 CXXCXXXCX{10,12}CXXCXXXC
CXXCXXXCX{11}CXXCXXXC
305: CTACC CGCCCACTTCATCCGAGCGCGCTGTC GTCCG
CXXCXXXCX{11}CXXCXXXC
467: CTTG CTTCCGCGCGCGCGCGCGGCCCTC TCCTG
CXXCXXXCX{10}CXXCXXXC
539: GGNGG CCCCTGCCGGCTTTGTCGGGACTC CCGCG
CXXCXXXCX{11}CXXCXXXC
558: TGTCT CCGCACTCCCGCGTCTCACTCCAGC GCCCC
CXXCXXXCX{10}CXXCXXXC
572: CGGGT CCTTACCCTCAGGCGCCCACTCCGC CGCGC
CXXCXXXCX{12}CXXCXXXC
575: GTCTT CACCTCCAGCGCCCACTCCCGCGGC TCGCA
CXXCXXXCX{10}CXXCXXXC
585: TCCAG CGGCCCACTCCCGCGGGTTCGAGCC TCCCC
CXXCXXXCX{12}CXXCXXXC
```

---

```
587: CAGCG CCCACTCCCGCGCGCTCGAGCCTCCC CGGCG
CXXCXXXCX{10}CXXCXXXC
589: GCGCC CCACTCCCGCGCGCTCGAGCCTCCC CGGCG
CXXCXXXCX{11}CXXCXXXC
592: CCCCA CTCGCGCGCGCTCGAGCCTCCCGCGC GCACC
CXXCXXXCX{11}CXXCXXXC
596: ACTCC CGCGCGCTCGAGCCTCCCGCGGCAC CCGCG
ADP31137 ck: 7329 len: 1,719 ! Adp31137 Human secreted protein SEQ ID #190
1 CXXCXXXCX{10,12}CXXCXXXC
CXXCXXXCX{12}CXXCXXXC
645: TTGGA CAGGAGCGCTGTGAGGCCATCCACC AGCTG
CXXCXXXCX{11}CXXCXXXC
1,569: TTCAT CAAGGGCAGCAGGGCCCCACAGCC TTCAG
ADP31172 ck: 5721 len: 255 ! Adp31172 Human secreted protein SEQ ID #193
1 CXXCXXXCX{10,12}CXXCXXXC
CXXCXXXCX{10}CXXCXXXC
73: GCTTT CATCTTAGAACAAGTTCCTGACCTAC TTCCC
ADP31238 ck: 5429 len: 945 ! Adp31238 Human secreted protein SEQ ID #200
1 CXXCXXXCX{10,12}CXXCXXXC
CXXCXXXCX{10}CXXCXXXC
27: GTCAA CTTGGGCGCTGTGCCGCCAAGCTGCC TCACT
ADP31337 ck: 9791 len: 900 ! Adp31337 Human secreted protein SEQ ID #210
1 CXXCXXXCX{10,12}CXXCXXXC
CXXCXXXCX{11}CXXCXXXC
585: GCATC CCAGGCCAGCGCTTATGTCCACCACC ATCGT
ADP31344 ck: 9535 len: 906 ! Adp31344 Human secreted protein SEQ ID #211
1 CXXCXXXCX{10,12}CXXCXXXC
CXXCXXXCX{10}CXXCXXXC
135: TGCAG CAGCTTCCGTGAGGATGCCCGCGGCC CCCAG
ADP31356 ck: 7035 len: 1,001 ! Adp31356 Human secreted protein SEQ ID #212
1 CXXCXXXCX{10,12}CXXCXXXC
CXXCXXXCX{12}CXXCXXXC
115: GGCCT CATCGCGCTGGCGCGCTGTCCATCGCAC TGGGC
CXXCXXXCX{10}CXXCXXXC
676: ATGGC CAACATCCTGGTGATCCACTGCCAGAC AACAG
ADP31508 ck: 2076 len: 1,113 ! Adp31508 Human secreted protein SEQ ID #227
1 CXXCXXXCX{10,12}CXXCXXXC
CXXCXXXCX{11}CXXCXXXC
365: TGTGC CACCAGTCAGATTTGTGCCCTTTCGAGC CTTAG
ADP31565 ck: 6040 len: 567 ! Adp31565 Human secreted protein SEQ ID #233
1 CXXCXXXCX{10,12}CXXCXXXC
CXXCXXXCX{10}CXXCXXXC
118: GGAGA CCTCAGGCCAGACTCCACTCCCCAGC TGTGA
```



1 CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
162: GGGG CCCCTACCGTGCCTTGCGCTGACCGC CTGGA  
CxxCxxxCx{12}CxxxCxxx  
440: CACTG CTCGGGCTTGGCTGGCTCCACCCATC TGGG  
CxxCxxxCx{12}CxxxCxxx  
457: CTGGC CTCACCCATCTGGGCCCTTCCGGAC CCTGG  
CxxCxxxCx{11}CxxxCxxx  
536: GGAGG CAGGGGCCGAGGGGCTCTGGCTGCC CTGG  
CxxCxxxCx{11}CxxxCxxx  
806: GGCTG CGGACCCCTGCCCTGTCTCAGACGAAC GGGAT  
ADP30965 ck: 6768 len: 1,147 | Adp30965 Human secreted protein SEQ ID #173  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
387: TGCTG CCACGGTCACTACATTTGACAGACGCTC TGTGT  
ADP30974 ck: 9207 len: 2,148 | Adp30974 Human secreted protein SEQ ID #174  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
691: CCTCT CCAGTCTCTGTGTGATGCTCACAGGC CGTTT  
ADP30990 ck: 3599 len: 759 | Adp30990 Human secreted protein SEQ ID #175  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
55: AGTGG CTTCGCCAGCGAAGCCAGCCATC AGCTC  
CxxCxxxCx{10}CxxxCxxx  
426: CCTA CTCTACAGCGCGGCTCTCGGCTC CGGG  
CxxCxxxCx{12}CxxxCxxx  
564: TGCTT CATCCGGACGGGGACCGCTTACCTGC AGCTG  
ADP31056 ck: 8276 len: 2,020 | Adp31056 Human secreted protein SEQ ID #182  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
1,244: GAATT CTGCTCTGACCAAGACCTCCGAGC CTCCT  
CxxCxxxCx{11}CxxxCxxx  
1,248: TCTGC CTCTGACCAAGACCTCCGAGCCTCC TGNAC  
ADP31089 ck: 2900 len: 457 | Adp31089 Human secreted protein SEQ ID #185  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
161: ATGGG CGGCTGCCCTGGGCTGGCTTCCAGCC CAGCA  
CxxCxxxCx{10}CxxxCxxx  
178: GCTCG CTCTTCCAGCCAGCATCCAGTGGC CGCC  
CxxCxxxCx{11}CxxxCxxx  
181: CGCCT CTTCCAGCCAGCATCCAGTGGCCCGC CAGGG  
CxxCxxxCx{12}CxxxCxxx  
237: CTTGG CGGAGTCTCTGGAACACAGCGACCGTC ATCGA  
ADP31098 ck: 1031 len: 3,579 | Adp31098 Human secreted protein SEQ ID #186  
CXXCXXXCX{10,12}CXXCXXXC

1 CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
102: CTAA CGTCCGCGAGTCTTGCCAGCCAGCCGTC CCGCA  
CxxCxxxCx{12}CxxxCxxx  
106: AGTGC CCGAGTCTTGGCAGCCAGCCGTCGCCG ATGGG  
CxxCxxxCx{12}CxxxCxxx  
3,197: CAACA CCGGTCCGCGAGCGCAGCCCTACACTC GCCG  
ADP31195 ck: 5863 len: 599 | Adp31195 Human secreted protein SEQ ID #191  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
231: CGAG CAACCGTGGGCTTCCGAGCTGCTGCC CGGG  
CxxCxxxCx{12}CxxxCxxx  
235: GCAAC GTGCGGCTTCCGAGCTGCTGCCCGGC GTGAG  
CxxCxxxCx{12}CxxxCxxx  
403: CACCC CTGCGTCTGGGCTCTGTCTCCGCGCGCC GGGG  
CxxCxxxCx{11}CxxxCxxx  
427: TCGG CGCCGGCGGCCCGGTCCCCACACC CTGTC  
CxxCxxxCx{12}CxxxCxxx  
431: GCGC CGCGCGCGCGGTGCCACACCCCTGC TCCTC  
ADP31210 ck: 5265 len: 1,227 | Adp31210 Human secreted protein SEQ ID #197  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
355: CGGT CGGCCCTCCAGCGAGTGCCCGGCTC CCGC  
CxxCxxxCx{10}CxxxCxxx  
356: CGTC CGCCTCCAGCAGGTGCCCGGCTC CCGC  
CxxCxxxCx{11}CxxxCxxx  
382: GCGT CCGCGCTCAGCATGTCTCTGCAGCC GCGTG  
CxxCxxxCx{11}CxxxCxxx  
1,142: TGAGA CCGCTGTACTTGGCCTCTTGCTCTCC AGATG  
ADP31248 ck: 2414 len: 576 | Adp31248 Human secreted protein SEQ ID #201  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
18: CATTC CGTCCGCTCTCTCGGACCGCCCGGC CGGG  
CxxCxxxCx{11}CxxxCxxx  
22: CGTC CGCCTCTCGGACCGCCCGCGCCGC GGGC  
ADP31249 ck: 978 len: 816 | Adp31249 Human secreted protein SEQ ID #201  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
18: CATTC CGTCCGCTCTCTCGGACCGCCCGGC CGGG  
CxxCxxxCx{11}CxxxCxxx  
22: CGTC CGCCTCTCGGACCGCCCGCGCGGC GGGC  
ADP31322 ck: 1143 len: 237 | Adp31322 Human secreted protein SEQ ID #208  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
13: AGGAG CGCAGTCCATGTTGAGGCTTCTCTCC TCAAG  
ADP31370 ck: 1970 len: 1,050 | Adp31370 Human secreted protein SEQ ID #213

1	CXXCXXXC{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxxC 481: GTTAC CTACCTTCCCGTACACACCGCGCC GCCAT	ADP31421 ck: 267 len: 204 ! Adp31421 Human secreted protein SEQ ID #218	997: TTGGG CTGCTCCCAATGCCCTCTCTCAGCGCC ACCCC CxxCxxxCx{10}CxxxCxxxC 1,011: AATGC CTTCTTCAGCGCGCACCCAGCCCC TGAGC CxxCxxxCx{12}CxxxCxxxC 1,022: CCAGC CGCCACCCAGCCCCCTGAGCCACAGCC ACAGC CxxCxxxCx{12}CxxxCxxxC 1,347: CTAGC CTTCCACCTGGCTCTCTGGCCACAGGC GCAAG CxxCxxxCx{10}CxxxCxxxC 1,364: CTCCT CGGCCACAGCGCGAAGCAGCCCCAC CTCAA	ADP30518 ck: 9327 len: 279 ! Adp30518 Human secreted protein SEQ ID #128: CXXCXXXC{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC 6: ATGCG CTGCTCGCGGAGGCGTCTGGCTGGC GCTGG CTGCTCGCGGAGGCGTCTGGCTGGC GTGCT
1	CXXCXXXC{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxxC 110: AGCTA CTGACGCGAACCACAAAGCCCTCCAAC AGTGC CxxCxxxCx{12}CxxxCxxxC 131: AAAGC CTTCAACAGTGCCTACAGCTACAGCC GGTCT	ADP31484 ck: 184 len: 480 ! Adp31484 Human secreted protein SEQ ID #225	ADP30604 ck: 7553 len: 171 ! Adp30604 Human secreted protein SEQ ID #137: CXXCXXXC{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxxC 137: CTGGA CCGGAGCAACAGAATCACCATACGCTC GTGCT CXXCXXXC{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC 13: ACGGG CTTGAGCTGGGAAGGAGCGCGCTC TTGTG	
1	CXXCXXXC{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxxC 939: TTCTC CACCTACCACGAGCGCTGTGCAGACTATC AGCCT CxxCxxxCx{10}CxxxCxxxC 1,196: GGAAG CAGCAGACATCACTCTCACCGGCATTC CAGAC	ADP31500 ck: 3635 len: 1,269 ! Adp31500 Human secreted protein SEQ ID #226	ADP30634 ck: 776 len: 189 ! Adp30634 Human secreted protein SEQ ID #140: CXXCXXXC{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC 13: ACGGG CTTGAGCTGGGAAGGAGCGCGCTC TTGTG	
1	CXXCXXXC{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxxC 164: TGTGC CACCAGTCAGATTGTGCCCTTCGAGC CTTAG	ADP31507 ck: 3953 len: 912 ! Adp31507 Human secreted protein SEQ ID #227	ADP30639 ck: 2410 len: 291 ! Adp30639 Human secreted protein SEQ ID #140: CXXCXXXC{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxxC 5: ATGA CAAGCGCCCGCGCTTCACCCAAACCTCC TACAC CxxCxxxCx{10}CxxxCxxxC 13: CGCCC CGGCTTCACCCAAACCTCTACACCC TGTTT CxxCxxxCx{11}CxxxCxxxC 135: ACTCG CTGCTGGCGCCCGGAGCCCGCACCTGC CCCTC	
1	CXXCXXXC{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxxC 477: AATTT CCCCATTAGCAGGCGAGGCCACGTTT AGATT	ADP31550 ck: 7908 len: 1,044 ! Adp31550 Human secreted protein SEQ ID #231	ADP30644 ck: 8206 len: 2,142 ! Adp30644 Human secreted protein SEQ ID #141: CXXCXXXC{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC 78: TGGTG CCAGGAGCACCCTCAACGCGGTGCC GCCCA CxxCxxxCx{10}CxxxCxxxC 609: CGGGG CCGGCCCGGAGCCCGCGCGGTCC AGCGC CxxCxxxCx{11}CxxxCxxxC 1,966: TGGAT CAGCAGACCCCGACCATCTCTTAACCGGC TGGCT	
1	CXXCXXXC{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC 406: AGGCT CCCCCAGCTCTCAGGCCCCACCTGCC ACCAC CxxCxxxCx{11}CxxxCxxxC 424: AGGCC CCACCTGGCACGACACTGCTCCATGC CCCTC CxxCxxxCx{10}CxxxCxxxC 425: GGCCC CACCTGCCACCACACTGCTCTCCATGC CCCTC CxxCxxxCx{11}CxxxCxxxC 560: CCCGG CAGCTCTCTCAGGCTCTCTCGGCTCGC CACTT CxxCxxxCx{11}CxxxCxxxC 692: AGGCA CCACCTGACCTGTCCAGGCGCTCTCTAC TGAGC CxxCxxxCx{12}CxxxCxxxC	ADP31654 ck: 9373 len: 1,533 ! Adp31654 Human secreted protein SEQ ID #242	ADP30684 ck: 9525 len: 1,498 ! Adp30684 Human secreted protein SEQ ID #145: CXXCXXXC{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC 10: AGCCT CCGCGTCTGCTATTGCGCAACCGCC GGGAC CxxCxxxCx{10}CxxxCxxxC 552: GCTGA GCGCAGCTCAGCTTCATCCACCTGC CAACC CxxCxxxCx{10}CxxxCxxxC 687: ACCCG CTCATCTCATGCTGCAACAAGCGAC TGGGG	



1	1,413: CAATG	CXXCXXXCX{11}CxxxCxxxC CCTCCCTCGGGTGAGCCCAACGGCTGGC	CCTGG	ADP30694	ck: 3634	len: 537	! Adp30694	Human secreted protein	SEQ ID #146
1	174: CAGAG	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{10}CxxxCxxxC CGCGGGCCATCCGCACTTCAGTTCC	CAGGA	ADP30694	ck: 3634	len: 537	! Adp30694	Human secreted protein	SEQ ID #146
1	266: CAGCG	CXXCXXXCX{12}CxxxCxxxC CCAGCGGCTGGAGTCGGCTCCGACCAACC	ATGGC	ADP30694	ck: 3634	len: 537	! Adp30694	Human secreted protein	SEQ ID #146
1	506: CTGGT	CXXCXXXCX{12}CxxxCxxxC CTACAGCCAGGAGGAGCGAGCTCCCAACC	GCC	ADP30694	ck: 3634	len: 537	! Adp30694	Human secreted protein	SEQ ID #146
1	197: ATGCA	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{11}CxxxCxxxC CGACACCGGGGGGCGGTCCCGCATAC	CAGCT	ADP30698	ck: 5109	len: 967	! Adp30698	Human secreted protein	SEQ ID #146
1	434: ACCTG	CXXCXXXCX{11}CxxxCxxxC CAACAGCCGAGGAGGAAACCGGGCCGCC	AAGAT	ADP30698	ck: 5109	len: 967	! Adp30698	Human secreted protein	SEQ ID #146
1	613: GGCCG	CXXCXXXCX{11}CxxxCxxxC CGACGGCGCTGGACAGGCCACCTTC	CACCT	ADP30698	ck: 5109	len: 967	! Adp30698	Human secreted protein	SEQ ID #146
1	616: CGCCA	CXXCXXXCX{12}CxxxCxxxC CGGCGCGCTGGACAGGCCACCTTC	TCACC	ADP30698	ck: 5109	len: 967	! Adp30698	Human secreted protein	SEQ ID #146
1	637: CCCAC	CXXCXXXCX{10}CxxxCxxxC CTTCGACCTCAGCTGCACTATCCAC	GGAGC	ADP30704	ck: 7790	len: 3,477	! Adp30704	Human secreted protein	SEQ ID #147
1	24: CTGCT	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{10}CxxxCxxxC CGTCTGGCTGCTGCTGCTCGGGTGGC	CTGGC	ADP30704	ck: 7790	len: 3,477	! Adp30704	Human secreted protein	SEQ ID #147
1	43: TGCTC	CXXCXXXCX{11}CxxxCxxxC CGGCTGCGCTGGGGGTGCGGGCCAGC	TGGAC	ADP30704	ck: 7790	len: 3,477	! Adp30704	Human secreted protein	SEQ ID #147
1	1,739: TAGTG	CXXCXXXCX{12}CxxxCxxxC CACCACCTATGGAGATGACCAACCTAAC	GCATC	ADP30704	ck: 7790	len: 3,477	! Adp30704	Human secreted protein	SEQ ID #147
1	ADP30724	ck: 2492	len: 2,976	! Adp30724	Human secreted protein	SEQ ID #149			
1	1,861: CTGGC	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{12}CxxxCxxxC CGCTTCCTGCTGCTTACGCCATCTTCC	TGGCA	ADP30724	ck: 2492	len: 2,976	! Adp30724	Human secreted protein	SEQ ID #149
1	2,131: CATGG	CXXCXXXCX{10}CxxxCxxxC CCCAGTCTGGAGCGGCTGGGCCAC	CACCTC	ADP30724	ck: 2492	len: 2,976	! Adp30724	Human secreted protein	SEQ ID #149
1	2,646: CAGCG	CXXCXXXCX{12}CxxxCxxxC CTTCCACCTCAATAGAGGCTGACGTCC	TCCTC	ADP30725	ck: 1124	len: 113	! Adp30725	Human secreted protein	SEQ ID #149
1	23: CGCGG	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{10}CxxxCxxxC CGGCTTCCTCGGCTCTGCTGGGC	CCTCT	ADP30725	ck: 1124	len: 113	! Adp30725	Human secreted protein	SEQ ID #149
1	26: CGCGG	CXXCXXXCX{11}CxxxCxxxC CTTCCTCGGCTCTGCTGGGCCCTC	TCGCG	ADP30725	ck: 1124	len: 113	! Adp30725	Human secreted protein	SEQ ID #149
1	ADP30727	ck: 7537	len: 2,514	! Adp30727	Human secreted protein	SEQ ID #149			
1	125: GGCGC	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{10}CxxxCxxxC CGCCCTCGCTCTGGGTCTTGACCACC	AGTCA	ADP30727	ck: 7537	len: 2,514	! Adp30727	Human secreted protein	SEQ ID #149
1	129: CCGCG	CXXCXXXCX{10}CxxxCxxxC CTTCGCTCTGGGTCTTGACCACCAGTC	AGACC	ADP30727	ck: 7537	len: 2,514	! Adp30727	Human secreted protein	SEQ ID #149
1	515: CATTG	CXXCXXXCX{11}CxxxCxxxC CCCCGACAGCCGCTCAGCTGCCCGC	CATCG	ADP30727	ck: 7537	len: 2,514	! Adp30727	Human secreted protein	SEQ ID #149
1	ADP30768	ck: 1707	len: 1,041	! Adp30768	Human secreted protein	SEQ ID #153			
1	12: ACAGG	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{12}CxxxCxxxC CCCCGACAGTCTCTCTCGGCAATC	ACTGG	ADP30768	ck: 1707	len: 1,041	! Adp30768	Human secreted protein	SEQ ID #153
1	244: ACTGG	CXXCXXXCX{12}CxxxCxxxC CGCCTGCCCTTCATCTCTGCCCACTCTC	TGGAT	ADP30768	ck: 1707	len: 1,041	! Adp30768	Human secreted protein	SEQ ID #153
1	290: CTTCA	CXXCXXXCX{10}CxxxCxxxC CCACCATCTATCTCACCGCCTCTTCC	TGGCA	ADP30768	ck: 1707	len: 1,041	! Adp30768	Human secreted protein	SEQ ID #153
1	294: ACCAC	CXXCXXXCX{10}CxxxCxxxC CATCTATCTCACCGCCTCTTCTCTGGC	AGCTG	ADP30768	ck: 1707	len: 1,041	! Adp30768	Human secreted protein	SEQ ID #153
1	836: CTTCT	CXXCXXXCX{10}CxxxCxxxC CTCTCTCGGGTTCCAAGCGACTTTC	ATGAG	ADP30768	ck: 1707	len: 1,041	! Adp30768	Human secreted protein	SEQ ID #153
1	ADP30780	ck: 6161	len: 774	! Adp30780	Human secreted protein	SEQ ID #154			
1	94: TGGAG	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{12}CxxxCxxxC CGTCCGCCAGGAAACCGCTTACAGAC	CCTGA	ADP30780	ck: 6161	len: 774	! Adp30780	Human secreted protein	SEQ ID #154
1	543: TACAT	CXXCXXXCX{11}CxxxCxxxC CAACACCCACATCTACACCCACCTTC	AGCTA	ADP30780	ck: 6161	len: 774	! Adp30780	Human secreted protein	SEQ ID #154
1	ADP30790	ck: 9391	len: 306	! Adp30790	Human secreted protein	SEQ ID #155			
1	80: TCGCG	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{11}CxxxCxxxC CTCCAGCTCTTACCGTGTACGTAC	CTGGT	ADP30790	ck: 9391	len: 306	! Adp30790	Human secreted protein	SEQ ID #155
1	ADP30943	ck: 102	len: 951	! Adp30943	Human secreted protein	SEQ ID #171			
1	681: GTGGC	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{10}CxxxCxxxC CCTCTTGTGACACATCTTCGGGC	CCTGA	ADP30943	ck: 102	len: 951	! Adp30943	Human secreted protein	SEQ ID #171
1	ADP30959	ck: 2576	len: 2,349	! Adp30959	Human secreted protein	SEQ ID #172			
1	74: ACATT	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{10}CxxxCxxxC CTTCATCTTCTGTTCTCTCTCTTC	TGGGC	ADP30959	ck: 2576	len: 2,349	! Adp30959	Human secreted protein	SEQ ID #172
1	274: AGCAA	CXXCXXXCX{11}CxxxCxxxC CACCAGCCACAGTCTACCGGCTCTC	ACCGT	ADP30959	ck: 2576	len: 2,349	! Adp30959	Human secreted protein	SEQ ID #172
1	289: AAGTC	CXXCXXXCX{11}CxxxCxxxC CTACCGGCTCTCACCGTCTCTCTCTTC	AGGAT	ADP30959	ck: 2576	len: 2,349	! Adp30959	Human secreted protein	SEQ ID #172
1	325: ATTAA	CXXCXXXCX{10}CxxxCxxxC CTACTACCTCTCGGAGGCTTCACCC	CGTGG	ADP30959	ck: 2576	len: 2,349	! Adp30959	Human secreted protein	SEQ ID #172
1	467: GGCTG	CXXCXXXCX{12}CxxxCxxxC CACCTGCCCGGAGGCGTCTCTCTCTTC	CGCGC	ADP30959	ck: 2576	len: 2,349	! Adp30959	Human secreted protein	SEQ ID #172

1	CxxCxxxCx{10,12}CxxxCxxxC 469: CTGCA CTGCCCCCAGGGGCTCCCTGCTGGC CGCGC	ADP311001 ck: 6715 len: 670 ! Adp311001 Human secreted protein SEQ ID #176	ADP31121 ck: 3265 len: 2,832 ! Adp31121 Human secreted protein SEQ ID #188
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxxC 472: AGTGG CTGTGCTCCTGCTGCTGCTGCGCTCC TGCTT	ADP31040 ck: 5348 len: 1,464 ! Adp31040 Human secreted protein SEQ ID #180	116: TATGC CCTCATGCTGGGAGGGGCCAAGACAGAC CTCCT
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC 226: TTTCT CTTCCATCTGATTTTGAACACACCATC CATGT	ADP31085 ck: 5186 len: 939 ! Adp31086 Human secreted protein SEQ ID #185	294: GGCCT CACCTTCAGCTCCTTGGCACCCCTC TGSCC
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxxC 19: TAGAT CCAGTCTCTTGACAAGTTCCGTTCATGC CGGTG	ADP31101 ck: 6929 len: 296 ! Adp31101 Human secreted protein SEQ ID #186	297: CTCAC CTTCCAGCTCCTTGGCACCCCTCTGGC CTCCTC
1	CxxCxxxCx{10}CxxxCxxxC 272: TCTCA CTGGATCCATGTTCTTCCGACCTCC CAGAA	ADP31115 ck: 4215 len: 192 ! Adp31115 Human secreted protein SEQ ID #188	2,334: GTCAC CATCTGCTGTCAATGGCCACCC GACCT
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxxC 77: TGCAC CATCCCCATCTAGTGGCCCACTGGC CTCAG	ADP31115 ck: 4215 len: 192 ! Adp31115 Human secreted protein SEQ ID #188	2,356: GCCAA CCCCAGACCTCATACAAACTCAGGCTGC AGAGG
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10,12}CxxxCxxxC 123: TCCGC CAACCCCTCTCAGCACACGCGCCTC CTTCC	ADP31115 ck: 4215 len: 192 ! Adp31115 Human secreted protein SEQ ID #188	2,357: CCAAC CCCCAGCTCATACAAACTCAGGCTGC AGAGG
1	CxxCxxxCx{10}CxxxCxxxC 128: CAACC CCCCCTCAGCACACGCGCTCCTTCC TAATG	ADP31120 ck: 6379 len: 2,943 ! Adp31120 Human secreted protein SEQ ID #188	2,756: CAGGA CCACTGTCAACATGCCCAATGCCCGGCC GTGGA
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC 123: TCCGC CAACCCCTCTCAGCACACGCGCCTC CTTCC	ADP31120 ck: 6379 len: 2,943 ! Adp31120 Human secreted protein SEQ ID #188	2,845: GACTG CCCCCCAGGGCCCAAAATCCCCACCC GGGAT
1	CxxCxxxCx{10}CxxxCxxxC 128: CAACC CCCCCTCAGCACACGCGCTCCTTCC TAATG	ADP31120 ck: 6379 len: 2,943 ! Adp31120 Human secreted protein SEQ ID #188	35: CTCAG CTCCTTCTGCTCCTCATCTCAACCAAGC CACCA
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxxC 294: GGCCT CACCTTCAGCTCCTTGGCACCCCTC TGSCC	ADP31120 ck: 6379 len: 2,943 ! Adp31120 Human secreted protein SEQ ID #188	38: AGTC CTTCTGCTCCTCATCTCAACCAAGCCACC ATGCC
1	CxxCxxxCx{11}CxxxCxxxC 297: CTCAC CTTCCAGCTCCTTGGCACCCCTCTGGC CTCCTC	ADP31120 ck: 6379 len: 2,943 ! Adp31120 Human secreted protein SEQ ID #188	
1	CxxCxxxCx{10}CxxxCxxxC 2,334: GTCAC CATCTGCTGTCAATGGCCACCC GACCT	ADP31120 ck: 6379 len: 2,943 ! Adp31120 Human secreted protein SEQ ID #188	
1	CxxCxxxCx{12}CxxxCxxxC 2,356: GCCAA CCCCAGACCTCATACAAACTCAGGCTGC AGAGG	ADP31120 ck: 6379 len: 2,943 ! Adp31120 Human secreted protein SEQ ID #188	
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxxC 2,357: CCAAC CCCCAGCTCATACAAACTCAGGCTGC AGAGG	ADP31120 ck: 6379 len: 2,943 ! Adp31120 Human secreted protein SEQ ID #188	
1	CxxCxxxCx{12}CxxxCxxxC 2,756: CAGGA CCACTGTCAACATGCCCAATGCCCGGCC GTGGA	ADP31120 ck: 6379 len: 2,943 ! Adp31120 Human secreted protein SEQ ID #188	
1	CxxCxxxCx{11}CxxxCxxxC 2,845: GACTG CCCCCCAGGGCCCAAAATCCCCACCC GGGAT	ADP31120 ck: 6379 len: 2,943 ! Adp31120 Human secreted protein SEQ ID #188	

1	ADP31260	ck: 9825	len: 4,683	! Adp31260 Human secreted protein SEQ ID #202	
		CXXCXXXCX{10,12}	CXXXCXXXC		
	109:	CGAC	CCACTGCTGCTGCTACTCTCAACC	CGCT	
	113:	CCAC	CTGTGCTGCTACTCTCAACCCGC	TGCC	
	120:	GCTGG	CTGCTACTCTCAACCCGCTGCTTC	CGGG	
	1,254:	GGCC	CAGCTCCCGGTGAGCTGCCCCAGCC	TCCGG	
	1,401:	CTGG	CCACATGGGGAGCCACTTCGTCC	AGTAG	
	2,601:	TACCG	CACCTCCGAGGACTTCTTGCTGC	CCATG	
	2,616:	GAGGA	CTTCTGCTGCCATGTGCTCAAGC	ACACA	
	2,761:	GGAGG	CGCACCTGAGGAGCCCTCCGC	CGTCG	
	3,218:	AGGCC	CTCTGACTACGCAGATCACCTGGC	ACCTG	
	4,049:	CGGG	CCCTATCCAGACCCCAACCCAGCATC	ATCCT	
	4,493:	TGTGT	CCCGGCGAGAGCTGTACACAGGC	TCAAC	
	ADP31275	ck: 5171	len: 849	! Adp31275 Human secreted protein SEQ ID #204	
		CXXCXXXCX{10,12}	CXXXCXXXC		
	534:	ACCTT	CTCAACCCCTCCCAAGTGTGCCAC	TGGCA	
	540:	CTCAA	CCGCTCCCAAGTGTGCCACTGC	ATTAG	
	625:	AGGG	CAGGCACCTCCAGAGTGGCTCCCTCC	CGGCC	
	650:	CCTCC	CTCCCGCTGGGTTCCCGGACGGC	TGCAG	
	ADP31302	ck: 6514	len: 1,536	! Adp31302 Human secreted protein SEQ ID #206	
		CXXCXXXCX{10,12}	CXXXCXXXC		
	92:	GGATG	CACCATCCCAATGCACCCCTGCTGC	TGGCA	
	143:	GAAG	CAACGGCCCGGCCCTCACCATGC	GGGCC	
	158:	GGCCC	CCTCACCATGCGGGCGGCCAACCGATC	CCACA	
	ADP31437	ck: 4380	len: 1,464	! Adp31437 Human secreted protein SEQ ID #220	
		CXXCXXXCX{10,12}	CXXXCXXXC		
	561:	AACTT	CCCCAACCTAGCAAGACGCAACATTC	AAATT	
	ADP31449	ck: 9923	len: 546	! Adp31449 Human secreted protein SEQ ID #221	
		CXXCXXXCX{10,12}	CXXXCXXXC		
	353:	CGTGA	CTGCCCGCGGTGCTCGCTCGACC	CACCA	
	ADP31462	ck: 9571	len: 1,101	! Adp31462 Human secreted protein SEQ ID #222	
		CXXCXXXCX{10,12}	CXXXCXXXC		
	73:	AATGG	CAGCAACACAGCCAGCTGACAGCC	ATTAA	
	ADP31478	ck: 6367	len: 444	! Adp31478 Human secreted protein SEQ ID #224	
		CXXCXXXCX{10,12}	CXXXCXXXC		
	294:	CCTCT	CGTCGCTCTTCTGCATCCCACTCCC	ATGCC	
	297:	CTCGT	CGTCCTTCTGCATCCCACTCCCATGC	CAGTT	
	ADP31505	ck: 6823	len: 312	! Adp31505 Human secreted protein SEQ ID #227	
		CXXCXXXCX{10,12}	CXXXCXXXC		
	58:	AGCAG	CTGCACCTGATGCAGAGCCGTCATGC	AAATC	
	ADP31567	ck: 8022	len: 471	! Adp31567 Human secreted protein SEQ ID #233	
		CXXCXXXCX{10,12}	CXXXCXXXC		
	92:	CTTTC	CAGCTTCCAGACTAGAATCTCAAGCAATC	TCCAA	
	ADP31570	ck: 5154	len: 1,560	! Adp31570 Human secreted protein SEQ ID #235	
		CXXCXXXCX{10,12}	CXXXCXXXC		
	200:	TGTGC	CTGCCATCTGGCGCGCCGACACTCCC	GAGAA	
	ADP31590	ck: 1874	len: 1,358	! Adp31590 Human secreted protein SEQ ID #235	
		CXXCXXXCX{10,12}	CXXXCXXXC		
	289:	CCAGA	CATCGCCTGGATGTCTCGGCTCTGGC	TGGTC	
	608:	GTTGT	CGCGTGCAGTTGGCCCTTACAGCC	CGGCC	
	ADP31593	ck: 6893	len: 1,689	! Adp31593 Human secreted protein SEQ ID #236	
		CXXCXXXCX{10,12}	CXXXCXXXC		
	631:	GCCGG	CGCCGGCGGCTGGGGAGGCTTGTGAC	GCTGC	
	ADP30476	ck: 5106	len: 312	! Adp30476 Human secreted protein SEQ ID #124	
		CXXCXXXCX{10,12}	CXXXCXXXC		
	87:	GACAG	CGCGGTGCGGGAACTCGGCAGCC	CTCTG	
	109:	TCGGG	GAGCCTCTGGGGTAGCCCGGAGGCC	ATGCC	
	126:	GTAGC	CGCCGAGCCCATGCCCACTACCTGCC	GCTGC	

1	ADP30615	ck: 6416	len: 153	! Adp30615 Human secreted protein SEQ ID #138	1	249: AACTC	CTTCCTGCATCAGAGGATCCCCAGTC	CGTAC	1730
				CXXCXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxx		763: ACTCT	CAGCCCACCAATGAAGCCACTCTATC	AAAGC	
	64: TATCC	CAGCCCACTGCAAGTCAAGTCAAGC	TCATC			ADP30962	ck: 6075	len: 1,789	! Adp30962 Human secreted protein SEQ ID #1729
1	ADP30623	ck: 3925	len: 213	! Adp30623 Human secreted protein SEQ ID #139	1		CXXCXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxx		
		CXXCXXCX{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxx				192: AGCAA	CACCAGGCACAAGTCTACGGGCTCTC	ACCGT	
104: CTCAC	CGGCGACCTCTCGGAGGAGCACCCGGTC	GGGTG				207: AAGTC	CTACCGGCTCTCACCGTCTGACTTTC	AGGAT	
ADP30638	ck: 1379	len: 291	! Adp30638 Human secreted protein SEQ ID #140			243: ATTAA	CTACTACTCTCGGAGGCTTCCACCC	CGTGG	
		CXXCXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxx				385: GGCTG	CACCTCGCCCCCAGGGGTCCTCTGTGGC	CGCGC	
5: ATGA	CAAGCCCCCACCCTTCACCCAAACCTCC	TACAC				387: CTGCA	CCTCGCCCCCAGGGGCTCCCTGTGGC	CGCGC	
13: CGCCC	CCACCTTCACGCAACCTCTACACCC	TGTTT				ADP30963	ck: 9300	len: 417	! Adp30963 Human secreted protein SEQ ID #1730
ADP30647	ck: 3437	len: 1,134	! Adp30647 Human secreted protein SEQ ID #141	1			CXXCXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxx		
285: GAAAC	CCTCTATCTCTCGGCATCTCTGGCAATC	ACAGC				246: CGCGG	CGGCTCGTGGAGCGCTCGCAGTCGCGC	AAAGA	
1,031: TACAG	CTCCATACCCCATCAACCTGTCTCTAC	AACAA				297: AGCGG	CAGTGTCTGAGCGGCAGCGGAC	CCTGC	
ADP30668	ck: 7042	len: 351	! Adp30668 Human secreted protein SEQ ID #143			309: CTGAG	CGGAGCGCAGCGGACCTGCGCTCGGCC	TGCGC	
		CXXCXXCX{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxx				312: AGCGG	CAGCAGGGGACCTGCGCTCGGCTCGC	CGAGC	
66: ATGGG	CGGCTGCGCTGGGCTCGGCTCTTCCAGCC	CAGCA				329: CCTGC	CCTCGGCTCGCGGCGCGGCTACC	TGGGC	
		CxxCxxxCx{10}CxxxCxxx				ADP30970	ck: 2852	len: 1,070	! Adp30970 Human secreted protein SEQ ID #1731
83: GCTCG	CCTCTTCCAGCCCATCCAGCTGGC	CGGCC					CXXCXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxx		
86: CGCCT	CTTCAGGCCAGCATCCAGCTGGCCCGC	CAGGG				192: AGCAA	CACCAGGCACAAGTCTACCGGCTCTC	ACCGT	
142: CTTGG	CAGCAGCCCTGAAACACAGCGGACCGTC	ATCGA				207: AAGTC	CTACGGGCTCTCACCGTCTGACTTTC	AGGAT	
ADP30707	ck: 1208	len: 354	! Adp30707 Human secreted protein SEQ ID #147	1		243: ATTAA	CTACTACTCTCGGAGGCTTCCACCC	CGTGG	
		CXXCXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxx				385: GGCTG	CACCTCGCCCCCAGGGGTCCTCTGTGGC	CGCGC	
24: CTGCT	CGTCTGGCTGCTGCTGCTCGGCTGCC	CTGGC				387: CTGCA	CCTCGCCCCCAGGGGCTCCCTGTGGC	CGCGC	
43: TGCTC	CGGCTGCGCTGGCGGTGCGGGCCAGC	TGGAC				ADP30973	ck: 2928	len: 1,065	! Adp30973 Human secreted protein SEQ ID #1740
ADP30928	ck: 237	len: 1,133	! Adp30928 Human secreted protein SEQ ID #169	1			CXXCXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxx		
		CXXCXXCX{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxx				943: TACAT	CTGCTTAACATGCTATTCTTCACTTCTCC	TTTCA	
ADP30935	ck: 6813	len: 1,205	! Adp30935 Human secreted protein SEQ ID #170	1		ADP30989	ck: 5153	len: 2,934	! Adp30989 Human secreted protein SEQ ID #1750
		CXXCXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxx					CXXCXXCX{10,12}CXXXCXXXC		

CxxCxxxCx{10}CxxxCxxx  
444: GTGGG CCACCTCATCTCACTTTTCATCCAC AACTC  
CxxCxxxCx{12}CxxxCxxx  
914: AGGTC CCGGCCAAGAGGTGAGCTTCTTGAC GCTAA  
CxxCxxxCx{10}CxxxCxxx  
1,067: GGAGG CCGCAGGACCCCAAGTCTCTATCC CTGGT  
CxxCxxxCx{10}CxxxCxxx  
1,198: GCCAT CCGCAGCAGCCGAGTCCAGGCCCC TCGAC  
CxxCxxxCx{11}CxxxCxxx  
1,261: CCACG CAGCGAGCCTGGGCCAGCTCCCCCTC CGGAG  
CxxCxxxCx{10}CxxxCxxx  
1,276: TGGGC CAGCCTCCCTCGGAGCCACGGCC AGCTC  
CxxCxxxCx{11}CxxxCxxx  
1,313: CATGG CTTACGCCCAGGCTCCAGCCCCACG CAAGC  
CxxCxxxCx{11}CxxxCxxx  
1,333: CCAGC CCGCAGCAACGCCACTGACCCCGC TACGC  
CxxCxxxCx{10}CxxxCxxx  
1,334: CAGCC CCGCAGCAACGCCACTGACCCCGC TACGC  
CxxCxxxCx{11}CxxxCxxx  
1,469: GCTGG CAGCGCCGAGGAGGCCCGGCTGGC ATTGG  
CxxCxxxCx{10}CxxxCxxx  
1,534: CGGGC CTGCGATCGCCTACATGCTTACCGAC CTTTA  
CxxCxxxCx{11}CxxxCxxx  
1,623: CCCTT CCCTTGCTGTACGGCGTGGCAGCC CTGAC  
CxxCxxxCx{11}CxxxCxxx  
1,681: GGCTG CCGCCACCGCTGCAAAACCACTCTCTG TGGGA  
CxxCxxxCx{12}CxxxCxxx  
1,941: GCTAG CGGCTGACGTGGCGGCTGGCTCTGGC TGTAC  
CxxCxxxCx{12}CxxxCxxx  
2,487: CAGCG CTGCGGCTCCGGCGCTGGCTCCCGC CGCCT  
CxxCxxxCx{10}CxxxCxxx  
2,490: CGCTG CGGCTCCGGGCTGGCTCCCGC GCCTG  
CxxCxxxCx{12}CxxxCxxx  
2,616: CTCAG CGAGTGGCGTGGCGGCGGCTCCAC AGCAC  
CxxCxxxCx{10}CxxxCxxx  
2,822: CCGGA CCGCAGCCCTGATTTACCGCGCTC GGCAG

ADP31005 ck: 8133 len: 1,306 ! Adp31005 Human secreted protein SEQ ID #177  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
565: CTTGG CTCTCTGCTGCGGTGGCGTGGCTGGC TGTGG  
CxxCxxxCx{12}CxxxCxxx  
876: CATCA CGCCATCCTGGTCTACCTGACGTCATC TTGGA  
CxxCxxxCx{11}CxxxCxxx  
1,090: GGGCT CTGCGTGTGGCCAGTGGCTACGCC TTGCT  
CxxCxxxCx{10}CxxxCxxx  
1,102: CTGGC CAGCTGGCTCAGCGCTTGTCTCTAC CAAGT  
CxxCxxxCx{10}CxxxCxxx  
1,117: ACCGC CTTGCTCTCAACCAAGTCTTCTGCC AGTGG

CxxCxxxCx{12}CxxxCxxx  
1,135: AAGTC CTTCTGCGAGTGGTGAGCACTTCGCC TCCAG  
CxxCxxxCx{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
ADP31009 ck: 1806 len: 549 ! Adp31009 Human secreted protein SEQ ID #177  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
499: CTTTC CTCCTGAGTGGTCTCTCAACAAGC CAGGA  
CxxCxxxCx{12}CxxxCxxx  
ADP31023 ck: 2920 len: 2,415 ! Adp31023 Human secreted protein SEQ ID #179  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
969: CATGG CGCGTGGGTTTCAGCAACACCTGC CCTGT  
CxxCxxxCx{12}CxxxCxxx  
1,086: CTGGG CAGCTGCCAAGTGTGATCCAAGTGTG CCAAT  
CxxCxxxCx{12}CxxxCxxx  
1,304: CGAAG CCAGTGCAGGACCTGCCCCCACTC ATGCT  
CxxCxxxCx{10}CxxxCxxx  
1,323: ACCTG CCCCCACTCATCTCTACAACCCAC CACGT  
CxxCxxxCx{12}CxxxCxxx  
ADP31057 ck: 759 len: 992 ! Adp31057 Human secreted protein SEQ ID #182  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
37: GGGGC CTTAGCCAAACCAATGCCAGCCAC GGAAT  
CxxCxxxCx{12}CxxxCxxx  
40: GCCTT CAGCCAAACCAATGCCAGCCACGGAC TTCGA  
CxxCxxxCx{10,12}CXXCXXXC  
ADP31068 ck: 5232 len: 5,397 ! Adp31068 Human secreted protein SEQ ID #183  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
999: CTCTG CGTCTCCCTGGTAAGAGCTCTGTCTTC TCTTC  
CxxCxxxCx{12}CxxxCxxx  
1,707: GTGGC CACCTATCAGCAGAGTGGCGCCTATC AGCAC  
CxxCxxxCx{11}CxxxCxxx  
1,836: GCGGC CAGCCAGCAGAACCAAGCTAACGCC CAGCT  
CxxCxxxCx{11}CxxxCxxx  
4,282: AGGTG CTCTCACCTCCAATGCCGCTCCTCCC CAGGT  
CxxCxxxCx{11}CxxxCxxx  
4,460: TGTCC CAGCGTCCAACTATCAGGCTCACACTC CTCTT  
CxxCxxxCx{11}CxxxCxxx  
4,464: CCAGC CGTCCAATCAGGCTCACACTCTCTCC TCACC  
CxxCxxxCx{11}CxxxCxxx  
4,468: CGTC CAACTATCAGGCTCACACTCTCTCTAC CTGGT  
CxxCxxxCx{10}CxxxCxxx  
ADP31145 ck: 1395 len: 611 ! Adp31145 Human secreted protein SEQ ID #191  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
333: TTGCC CTGCTCTCCATCACCTCCAGCCCTCC CTGTG  
CxxCxxxCx{10}CxxxCxxx  
550: GGCCC CAGCGCAGTGGCGGACCTAGCCTGC AAGGC  
CxxCxxxCx{10}CxxxCxxx  
ADP31258 ck: 4592 len: 2,808 ! Adp31258 Human secreted protein SEQ ID #202

1

CXXCXXCXX{10,12}|CXXCXXCXX  
CXXCXXCXX{10}|CXXCXXCXX  
34: CGGAC CCACCTGTGCTGCTACTCTCAACC CCGCT

CXXCXXCXX{10}|CXXCXXCXX  
38: CCCAC CTGTGCTGCTGCTACTCTCAACCCGC TGCCC

CXXCXXCXX{11}|CXXCXXCXX  
45: GCTGG CTGCCTACTCTCAACCCGCTGCCCTTC CGGGG

CXXCXXCXX{11}|CXXCXXCXX  
1,179: GGGCC GAGCTCCCGGTGCTGAGTGCCTCCAGCC TCGGC

CXXCXXCXX{10}|CXXCXXCXX  
1,326: CTGGC CCACATCGGGAAACGCCATCTCCGTCC AGTAG

CXXCXXCXX{10}|CXXCXXCXX  
2,526: TACCG GACCTTCGAGAGGACTCTTGCTGTC CCATG

CXXCXXCXX{12}|CXXCXXCXX  
2,541: GAGGA CTTCTTGCTGTCCCATGTGGTGTCAAGC ACACA

CXXCXXCXX{10}|CXXCXXCXX  
2,686: GGAGG GCGCACCTGAGGAGCCCTCCCGC CGTCG

ADP31270 ck: 8870 len: 1,782 | Adp31270 Hum

CXXCXXCXX{10,12}|CXXCXXCXX  
1,087: GGGCC CGCCCGTGTCTCCGGAGCGGACCGCC AGACT

CXXCXXCXX{12}|CXXCXXCXX  
1,243: GCCAG CCCCTTCCTCTGTCGAGCAGCAGCAGAC AAGTATA

ADP31296 ck: 3575 len: 1,010 | Adp31296 Hum

CXXCXXCXX{10,12}|CXXCXXCXX  
321: TGAAC CGACCTCAACTCTCTCCCCCACCATAC AGTGC

CXXCXXCXX{11}|CXXCXXCXX  
333: CAACT CTCCTCCCCACCATAGTGCCTTCAGC TACAG

CXXCXXCXX{12}|CXXCXXCXX  
517: TGATC CCTCTGACTACCACTTACCGAGCAGCC ACCAA

CXXCXXCXX{11}|CXXCXXCXX  
921: ACCCG GACCTTGCCAGCGCCGCCGATGCTGC TGCTG

ADP31366 ck: 5977 len: 2,391 | Adp31366 Hum

CXXCXXCXX{10,12}|CXXCXXCXX  
785: TGTGC CTCCTGGGCTGTGACCTTACCCCATCC CTTGG

CXXCXXCXX{12}|CXXCXXCXX  
803: CACCT CACCCATCCCTTGGGGGGTCTGTCTGTC TTCCC

CXXCXXCXX{11}|CXXCXXCXX  
1,829: TGTGG GTGCCCCCATGATCTCTCCCTGGAAGC CTTCC

CXXCXXCXX{11}|CXXCXXCXX  
2,082: ATCCC CTCCTTGCAACCTCACTCCACCCCTC ACTCC

CXXCXXCXX{12}|CXXCXXCXX  
2,089: CTTTG CCACCTTCATCTGACCTTCACCTCCTAC CTACA

CXXCXXCXX{11}|CXXCXXCXX  
2,090: CTTGC CACCTCCCACTCCACTCTCACTCTCTAC CTACA

1	2,094:	CCACC	CxxCxxxCx{11}CxxxCxxxXC	CTCCACTCCACCCTCCACTCTCTACCTAC	AAGAA
	2,111:	CTCCA	CxxCxxxCx{10}CxxxCxxxXC	CTCTCACTCAAGAAGTCCCTCGCGCC	TCTCC
	2,114:	CACTC	CxxCxxxCx{11}CxxxCxxxXC	CTAGCTACAAGAAGTCCCTCGGCTCTC	CTCCG
	2,220:	CAGGG	CxxCxxxCx{12}CxxxCxxxXC	CACCTGGCGCTGCAGAGCCACCACTATCC	TGTGG
	ADP31407	ck: 8427	len: 1,566	! Adp31407	Hum
	681:	AACTA	CXXCXXXCX{10,12}CXXXCXXXC	CXXCXXXCX{11}CxxxCxxxXC	
	681:	AACTA	CCTCTTCAGTTTTGTCTGCTGTGAC	CAAGC	
	ADP31422	ck: 267	len: 204	! Adp31422	Hum
	110:	AGCTA	CXXCXXXCX{10,12}CXXXCXXXC	CXXCXXXCX{12}CxxxCxxxXC	
	131:	AAAGC	CXXCXXXCX{12}CxxxCxxxXC	CTGCAGCGGAACACAAAGCCCTCCAA	AGTGC
	ADP31452	ck: 2960	len: 1,119	! Adp31452	Hum
	98:	ATTCT	CXXCXXXCX{10,12}CXXXCXXXC	CXXCXXXCX{10}CxxxCxxxXC	
	142:	ATGCT	CXXCXXXCX{10}CxxxCxxxXC	CCTCATTCATTCCTGTGCAGCGAGC	GCGAG
	588:	GGGCC	CXXCXXXCX{11}CxxxCxxxXC	CGGCGCTCACCTTTTACCCACCCCTAC	TGACA
	835:	ATAAC	CXXCXXXCX{10}CxxxCxxxXC	CTCCATGGGACAAACACTGGGCTGC	TGTGT
	ADP31506	ck: 4906	len: 543	! Adp31506	Hum
	37:	TCAAA	CXXCXXXCX{10,12}CXXXCXXXC	CXXCXXXCX{11}CxxxCxxxXC	
	44:	CCTGA	CXXCXXXCX{12}CxxxCxxxXC	CCTCAGACAGCGCGCTGTGCACACTCCC	ACCCA
	51:	TCAGA	CXXCXXXCX{12}CxxxCxxxXC	CAGCGCGCTGTGCACACTTCCACCCAGC	CCTCT
	509:	AGTTT	CXXCXXXCX{12}CxxxCxxxXC	CAGCACTCAGTGCATCCACACCCGCCACC	CCCTG
	ADP31520	ck: 4274	len: 735	! Adp31520	Hum
	108:	TACTT	CXXCXXXCX{10,12}CXXXCXXXC	CXXCXXXCX{11}CxxxCxxxXC	
	ADP31531	ck: 1758	len: 225	! Adp31531	Hum
				CXXCXXXCX{10,12}CXXXCXXXC	

1	1	7: TGGCA	CxxCxxxCx{10}CxxxCxxxC CGGCTGGCACCATTGGAGCGCCTCACCC AGGCC	ADP31532	ck: 1764	len: 1,518	Adp31532 Human secreted protein	SEQ ID #259
1	1	153: CTTGG	CxxCxxxCx{10}CxxxCxxxC CCCAGCGAGGGCCAGCCCAACAGGC AGCAC	ADP31532	ck: 1764	len: 1,518	Adp31532 Human secreted protein	SEQ ID #259
1	1	1,139: CTATG	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC CTTCCTGCATCTTGGCTTCACACTCC TTCTG	ADP31566	ck: 9888	len: 1,380	Adp31566 Human secreted protein	SEQ ID #233
1	1	1,200: AGCAG	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxxC CGACTCTCTCTCCATCTACCCGCCAAAC TGTGC	ADP31566	ck: 9888	len: 1,380	Adp31566 Human secreted protein	SEQ ID #233
1	1	ADP30486	ck: 9155	len: 1,179	Adp30486 Human secreted protein	SEQ ID #129		
1	1	100: GCGGC	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxxC CGCGGCCCAAGTGTGGTGGCGCGC CAGAG	ADP30486	ck: 9155	len: 1,179	Adp30486 Human secreted protein	SEQ ID #129
1	1	388: TGGCG	CxxCxxxCx{11}CxxxCxxxC CTGGCGCTCGGCACACGCCCGCGGC ACCCC	ADP30494	ck: 2291	len: 786	Adp30494 Human secreted protein	SEQ ID #126
1	1	212: GGTCA	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxxC CGCCACAGGAGGAGGCTCGAGGCTGCC AGAGG	ADP30511	ck: 723	len: 2,020	Adp30511 Human secreted protein	SEQ ID #127
1	1	253: AGGGG	CxxCxxxCx{10}CxxxCxxxC CTGCTGCTGAGCAGAGTCTGTCAGGC CTGCT	ADP30511	ck: 723	len: 2,020	Adp30511 Human secreted protein	SEQ ID #127
1	1	740: AACAT	CxxCxxxCx{10}CxxxCxxxC CACCAGCCGAGGGGAACTGGGACC ATCAC	ADP30511	ck: 723	len: 2,020	Adp30511 Human secreted protein	SEQ ID #127
1	1	161: GCCCC	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC CAGCCCCACAGCTTCGGGTCTCTCTTC CAAGA	ADP30511	ck: 723	len: 2,020	Adp30511 Human secreted protein	SEQ ID #127
1	1	1,087: CGGAA	CxxCxxxCx{12}CxxxCxxxC CCACCCCTCATGTACAACTGTCTCTGC CCACT	ADP30511	ck: 723	len: 2,020	Adp30511 Human secreted protein	SEQ ID #127
1	1	1,531: AGCAG	CxxCxxxCx{12}CxxxCxxxC CGCCTTCTGGAGTGTGAGCCCGCTGCG TGCAG	ADP30511	ck: 723	len: 2,020	Adp30511 Human secreted protein	SEQ ID #127
1	1	1,586: CTTTC	CxxCxxxCx{11}CxxxCxxxC CAGCGCGCAGGGGTGACAGCCACACCC AGGTG	ADP30512	ck: 723	len: 2,020	Adp30512 Human secreted protein	SEQ ID #127
1	1	1,885: GCGAA	CxxCxxxCx{10}CxxxCxxxC CTCCCTGCGCATGTGCCGCCGAGCC TGGCG	ADP30512	ck: 723	len: 2,020	Adp30512 Human secreted protein	SEQ ID #127
1	1	1,087: CGGAA	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC CAGCCCCACAGCTTCGGGTCTCTCTTC CAAGA	ADP30734	ck: 1579	len: 1,464	Adp30734 Human secreted protein	SEQ ID #150
1	1	1,087: CGGAA	CxxCxxxCx{12}CxxxCxxxC CCACCCCTCATGTACAACTGTCTCTGC CCACT	ADP30737	ck: 5586	len: 240	Adp30737 Human secreted protein	SEQ ID #150

1	ADP30754	ck: 8386	len: 249	! Adp30754 Human secreted protein SEQ ID #152		312: ACCTG	CxxCxxxCx{10}CxxxCxxx	CTGCAGTCCAAGTCAGAGCTCTCCAC	TACAC
	94: CAATT	CTTCTTGGCGCAATTACAACAAGCAAGC	AAGTG			ADP30830	ck: 4939	len: 186	! Adp30830 Human secreted protein SEQ ID #159:
		CXXCXXCX{10,12}CXXXCXXXC					CXXCXXCX{10,12}CXXXCXXXC		
		CxxCxxxCx{11}CxxxCxxx				111: ATGGA	CCCCTACTGTCCACATGGCTGCTCTC	CTTCT	
1	ADP30760	ck: 2069	len: 195	! Adp30760 Human secreted protein SEQ ID #152		ADP30850	ck: 1058	len: 681	! Adp30850 Human secreted protein SEQ ID #161:
	45: CCTGT	CGTCAATCACTTACCTACCTGCAGCC	TTCTG				CXXCXXCX{10,12}CXXXCXXXC		
		CxxCxxxCx{10}CxxxCxxx				153: CTCTG	CCGTACCGCACCTTGTGGCAGCTCC	TCGCC	
	86: ACCTG	CTGCAGTCCAAAGTCAGAGCTCTCCAC	TACAC			302: TGTCT	CCACTGTCTCTACTACTCAATCTACC	TGTGC	
		CxxCxxxCx{10}CxxxCxxx				358: TGCAG	CACCAGCTGTGTAGTGCCTTCGGGC	TCTCC	
1	ADP30776	ck: 6346	len: 573	! Adp30776 Human secreted protein SEQ ID #154		ADP30851	ck: 674	len: 894	! Adp30851 Human secreted protein SEQ ID #161:
	58: CTGCC	CGACTACCACAAGCGCTGCCGCCCTGC	CGCTC				CXXCXXCX{10,12}CXXXCXXXC		
		CxxCxxxCx{10}CxxxCxxx				319: TGTAC	CCCAGGGCTCCGACGCTGGCCTCC	ATCTG	
	64: GACTA	CCACAAGCGGTGCCGCTGCCGCTC	GGTGT			529: TCTTC	CTACTGGCTCTGGGGCCTTGCCAAC	ATCAC	
		CxxCxxxCx{10}CxxxCxxx				ADP30860	ck: 792	len: 1,038	! Adp30860 Human secreted protein SEQ ID #162:
	78: GCTGC	CGCCCTGGCGTCTGGTGTGCGAGCGCG	CAAGG				CXXCXXCX{10,12}CXXXCXXXC		
		CxxCxxxCx{10}CxxxCxxx				888: TTCTC	GTCTCCTCCCTACGGGACCACTTCC	TACAC	
	243: CACGG	CGCCCCCAGGCTTTCCAGCCAAAG	CCACC			ADP30866	ck: 8260	len: 1,002	! Adp30866 Human secreted protein SEQ ID #163:
		CxxCxxxCx{10}CxxxCxxx					CXXCXXCX{10,12}CXXXCXXXC		
	247: GCGCC	CCCCAGGCTTTCCAGCAAGCCAC	CCTTC			63: GGGAG	CAGCAGCTCCAGGAGTTCTGCCCCAC	CATCC	
		CxxCxxxCx{12}CxxxCxxx				93: ACCAT	CCTCCAGCAGCTGGATTCCCGGGCTGC	ACCTC	
	436: CCCTG	CTACCAGCGTCCITCAGTCCGACGAGC	GCAAG			230: CCTGG	CCTCTCTCTGGGAGTCTCTGCTCTGCC	CTGCA	
		CxxCxxxCx{12}CxxxCxxx				872: GCATC	CAACAAGCTCTCTTCTTCAACTGCTTTC	TGCCT	
	440: GCTAC	CAGCGCTCTTCAGTCCGACGAGGCAC	GTTCG			ADP30944	ck: 6837	len: 1,420	! Adp30944 Human secreted protein SEQ ID #171:
		CxxCxxxCx{10}CxxxCxxx					CXXCXXCX{10,12}CXXXCXXXC		
	444: CCAGC	CGTCTTCACTGCCACGAGCGCAGCTTC	GCCAC			397: GAGGT	CATCACCTGAATGCCACCTGGCCTAC	GCTCT	
		CxxCxxxCx{10}CxxxCxxx				ADP30948	ck: 6814	len: 1,481	! Adp30948 Human secreted protein SEQ ID #171:
	516: CATCT	CCACGTCCACCACAGTGGCCACCTTCC	TCATC				CXXCXXCX{10,12}CXXXCXXXC		
		CxxCxxxCx{12}CxxxCxxx				49: TGCTG	CCGTGGCGTGGCTGGCGCAGCGGC	CTGGC	
1	ADP30781	ck: 6161	len: 774	! Adp30781 Human secreted protein SEQ ID #154		240: GTCAA	CGCGAGCCCCGAGCTGTGCCCGCGTGC	GCCTG	
		CxxCxxxCx{11}CxxxCxxx							
	94: TGGAG	CGTCCGCCCAAGAACCCAGCTTACAGAC	CCTGA						
		CxxCxxxCx{10}CxxxCxxx							
	543: TACAT	CAACACCCACATCTATACCCACACCTTC	AGCTA						
		CxxCxxxCx{11}CxxxCxxx							
1	ADP30787	ck: 246	len: 186	! Adp30787 Human secreted protein SEQ ID #159					
		CXXCXXCX{10,12}CXXXCXXXC							
		CxxCxxxCx{12}CxxxCxxx							
	140: GCGGA	CACCGCCGATGGAGATCTCCGCCCGC	AGCCC						
		CxxCxxxCx{10}CxxxCxxx							
1	ADP30809	ck: 4224	len: 372	! Adp30809 Human secreted protein SEQ ID #157					
		CXXCXXCX{10,12}CXXXCXXXC							
		CxxCxxxCx{12}CxxxCxxx							
	271: CCTGT	CGTCAATCACTTACCTACCTGCAGCC	TTCTG						
		CxxCxxxCx{10}CxxxCxxx							



CxxCxxxCx{10}CxxxCxxx  
399: GGAGG CGTCCCTCGCTGGGCCCGGCCCC CGAGC  
CxxCxxxCx{11}CxxxCxxx  
1,048: GAGGC CCAGCCCAACACACAGGGGTGGCGCCC CACAC  
CxxCxxxCx{11}CxxxCxxx  
1,051: GCCCA CGCCCAACACACAGGGGTGGCGGCCAC ACCTG  
CxxCxxxCx{11}CxxxCxxx  
1,339: GGGCA CGACCTCAGTACTCTGCTGTCTCAC CAAGA  
CxxCxxxCx{11}CxxxCxxx  
1,419: TCACA CCGCTCCCTTCATCAGCCCACTCAC AGCTG  
CxxCxxxCx{10}CxxxCxxx  
1,420: CACAC CCCCTCCCTTCATCAGCCCACTCAC AGCTG  
CxxCxxxCx{12}CxxxCxxx  
1,439: AGCCC CACCTCAGCTGGTTCATCAGCTTCAGCC TCACC  
ADP30980 ck: 3887 len: 1,171 ! Adp30980 Human secreted protein SEQ ID #174  
CXXCXXXCX{10,12}CXXCXXXC  
444: GTGGG CCACCTCATCTCACTTTCATCCCAAC AACTC  
CxxCxxxCx{12}CxxxCxxx  
914: AGTTC CCCGCCCAAGCAGGCTGACCTTCTCTGAC GCTAA  
CxxCxxxCx{10}CxxxCxxx  
1,079: GGAGG CCCAGGCACCCCAAGTCTCTCATCC CTGGT

1

ADP30981 ck: 4607 len: 3,638 ! Adp30981 Human secreted protein SEQ ID #174  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
1,096: GAGAG CAGCAAGGGTGCACCGCTAGTGCTGAC CGCGG  
CxxCxxxCx{11}CxxxCxxx  
1,207: AGCAG CAGCGCACCGGCACGGCCCTACTCTAC CATCC  
CxxCxxxCx{10}CxxxCxxx  
1,212: CAGCG CACGGGCACGGCCCTACTACCATC CGAGT  
CxxCxxxCx{12}CxxxCxxx  
1,414: TTTCG CCGCGGCGGGAGCTTTTCGGACTCTC GCOCG  
CxxCxxxCx{11}CxxxCxxx  
1,905: AACGA CAAGCGCGGGTTTCAGCCAGCGGTC TAGGA  
CxxCxxxCx{12}CxxxCxxx  
1,992: AGCGC CACGACCGGATGAGGGCCCAACGCC AGCTT  
CxxCxxxCx{11}CxxxCxxx  
2,524: ATGGG CAGCGGCCCTTCTCCACCGCACCC TGGTG  
CxxCxxxCx{10}CxxxCxxx  
2,715: TTTCAT CTTCTGCTGGCCATGATGTGTGTGC CGTGC

1

ADP30994 ck: 4739 len: 1,023 ! Adp30994 Human secreted protein SEQ ID #176  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
719: GAGAT CTTCTGCTGCTCTCGGCATCTGCC TTTCAT  
ADP31011 ck: 9367 len: 885 ! Adp31011 Human secreted protein SEQ ID #177  
CXXCXXXCX{10,12}CXXCXXXC

1

CxxCxxxCx{12}CxxxCxxx  
581: TAAGA CCGCTACCGGCCCTCGCGCTGACGGGC CCGCG  
CxxCxxxCx{12}CxxxCxxx  
777: GAGCG CGAGCCCATCCAGCTGACCCCAAGCCCC GACGG  
ADP31151 ck: 126 len: 1,546 ! Adp31151 Human secreted protein SEQ ID #191  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
262: ACCTG CTCCTTCAGACCGCCACCAAGCGGTAC ACCAC  
CxxCxxxCx{10}CxxxCxxx  
579: TCCTC CGACCATCAGGAGGTGACAGGGCCC GCACC  
CxxCxxxCx{12}CxxxCxxx  
607: GCCCG CACGCGCTGGCGGGCGCCCTCTCTGC GCTGC  
CxxCxxxCx{10}CxxxCxxx  
1,123: TTATG CATCTTTCTACAGCCATTCTGGCCACC CGTTC  
CxxCxxxCx{12}CxxxCxxx  
1,172: GTGAC CCACCTCCGCGCCCATACCTCTCTCTC TTAGC  
CxxCxxxCx{10}CxxxCxxx  
1,267: GAGAC CTTCCCACTTTTCTGTCTCTCCACAC CCTGG  
CxxCxxxCx{10}CxxxCxxx  
1,286: TGTCC CTCACACCCCTGATTTTCTGGCCCC TCCTG  
ADP31173 ck: 9167 len: 330 ! Adp31173 Human secreted protein SEQ ID #194  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
73: GCTTT CATCTTACGAACAAGTCTCTGACCTAC TTCCC  
ADP31186 ck: 1415 len: 5,514 ! Adp31186 Human secreted protein SEQ ID #195  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
1,784: CTCAT CTGCGTCCGGAAGGAAGTATCGGCC GTCCG  
CxxCxxxCx{10}CxxxCxxx  
1,820: CTCAT CTGCGTCCGGAAGGAAGTATCGGCC GTCCC  
CxxCxxxCx{10}CxxxCxxx  
1,856: CTCAT CTGCGTCCGGAAGGAAGTATCGGCC GTCCC  
CxxCxxxCx{10}CxxxCxxx  
1,892: CTCAT CTGCGTCCGGAAGGAAGTATCGGCC GTCCG  
CxxCxxxCx{10}CxxxCxxx  
1,928: CTCAT CTGCGTCCGGAAGGAAGTATCGGCC GTCCC  
CxxCxxxCx{10}CxxxCxxx  
1,964: CTCAT CTGCGTCCGGAAGGAAGTATCGGCC GTCCC  
CxxCxxxCx{12}CxxxCxxx  
2,000: CTCAT CTGCGTCCGGAAGGAAGTATCGGCCGTG CCTCA  
CxxCxxxCx{10}CxxxCxxx  
2,035: CTCAT CTGCGTCCGGAAGGAAGTATCGGCC GTCCC  
CxxCxxxCx{10}CxxxCxxx  
2,107: CTCAT CTGCGTCCGGAAGGAAGTATCGGCC GTCCC  
CxxCxxxCx{10}CxxxCxxx  
2,143: CTCAT CTGCGTCCGGAAGGAAGTATCGGCC GTCCC  
CxxCxxxCx{10}CxxxCxxx

1

1

1

2,251: CTCAT CTGCGTCCGGAGGAAGTATCATCCGCC ATCCC  
CxxCxxxCx{10}CxxxCxxxC  
2,323: CTCAT CTGCGTCCGGAGGAAGTATCATCCGCC GTCCC  
CxxCxxxCx{12}CxxxCxxxC  
2,359: CTCAT CTGCGTCCGGAGGAATCATCCGCCGTC CCTCA  
CxxCxxxCx{10}CxxxCxxxC  
2,430: CTCAT CTGCGTCTGGAAGGAAGTATCCGCC TTTC  
CxxCxxxCx{10}CxxxCxxxC  
2,537: CTCAT CGGCGTCCGGAGGAAGTATCCGCC GTCCC  
CxxCxxxCx{12}CxxxCxxxC  
2,573: CTCAT CTGCGTCCGGAGGAATCATCCGCCGTC CCTCA  
CxxCxxxCx{12}CxxxCxxxC  
2,680: CTCAT CTGCGTCTGGAAGGAATCATCCGCCGTC CCTCA  
CxxCxxxCx{12}CxxxCxxxC  
2,858: CTCAT CGGCGTCCGGAGGAAGTATCCACC GTTCC  
CxxCxxxCx{10}CxxxCxxxC  
2,896: CTCAT CGGCGTCCGGAGGAAGTATCCACC GTTCC  
CxxCxxxCx{12}CxxxCxxxC  
2,968: CTCAT CTGCGTCTGGAAGGAATCATCCGCCGTC CCTCA  
CxxCxxxCx{12}CxxxCxxxC  
3,057: GAAGT CATCCGCCGATCATCCGCCGTCCTC ATCTG  
CxxCxxxCx{12}CxxxCxxxC  
3,231: CTCAT CGGCGTCCGGAGGAAGTATCCGCC GTTCC  
CxxCxxxCx{10}CxxxCxxxC  
3,302: CTCAT CGGCGTCCGGAGGAAGTATCCACC GTTCC  
CxxCxxxCx{12}CxxxCxxxC  
3,340: CTCAT CGGCGTCCGGAGGAAGTATCCGCC GTTCC  
CxxCxxxCx{12}CxxxCxxxC  
3,412: CTCAT CTGCGTCTGGAAGGAATCATCCGCCGTC CCTCA  
CxxCxxxCx{10}CxxxCxxxC  
3,519: CTCAT CTGCGTCCGGAGGAAGTATCCACC GTCCC  
CxxCxxxCx{10}CxxxCxxxC  
3,555: CTCAT CTGCGTCCGGAGGAAGTATCCGCC GTTCC  
CxxCxxxCx{12}CxxxCxxxC  
3,626: CTCAT CTGCGTCCGGAGGAAGTATCCGCCGTC CCTCA  
CxxCxxxCx{10}CxxxCxxxC  
3,661: CTCAT CTGCGTCCGGAGGAAGTATCCGCC GTTCC  
CxxCxxxCx{10}CxxxCxxxC  
3,697: CTCAT CTGCGTCTGGAAGGAAGTATCCGCC GTTCC  
CxxCxxxCx{12}CxxxCxxxC  
3,769: CTCAT CTGCGTCCGGAGGAAGTATCCACC GTCCTCA  
CxxCxxxCx{10}CxxxCxxxC  
3,804: CTCAT CTGCGTCCGGAGGAAGTATCCGCC GTCCC  
CxxCxxxCx{10}CxxxCxxxC  
3,840: CTCAT CTGCGTCTGGAAGGAAGTATCCGCC GTTCC  
CxxCxxxCx{12}CxxxCxxxC  
3,912: CTCAT CTGCGTCTGGAAGGAATCATCCACC GTCCTCA  
CxxCxxxCx{12}CxxxCxxxC  
3,947: CTCAT CTGCGTCCGGAGGAATCATCCACCCTC CCTCA

3,982: CTCAT CTGCGTCCGGAGGAAGTATCCGCC GTTCC  
CxxCxxxCx{10}CxxxCxxxC  
4,018: CTCAT CTGCGTCCAGGAAGGAATCATCCGCCGTC CCTCA  
CxxCxxxCx{12}CxxxCxxxC  
4,053: CTCAT CTGCGTCCAGGAAGGAAGTATCCACC GTCCC  
CxxCxxxCx{10}CxxxCxxxC  
4,089: CTCAT CTGCGTCCGGAGGAAGTATCCACC GTCCC  
CxxCxxxCx{10}CxxxCxxxC  
4,125: CTCAT CTGCGTCTGGAAGGAAGTATCCGCC GTTCC  
CxxCxxxCx{12}CxxxCxxxC  
4,197: CTCAT CTGCGTCCGGAGGAATCATCCGCCGTC CCTCA  
CxxCxxxCx{10}CxxxCxxxC  
4,270: CTCAT CGGGTCCCGAAGGAAGTATCCGCC GTCCC  
CxxCxxxCx{10}CxxxCxxxC  
4,377: CTCAT CGGGTCCCGAAGGAAGTATCCGCC GTCCC  
CxxCxxxCx{10}CxxxCxxxC  
4,449: CTCAT CTGCGTCCGGAGGAAGTATCCGCC GTCCC  
CxxCxxxCx{12}CxxxCxxxC  
4,485: CTCAT CTGCGTCTGGAAGGAAGTATCCGCC GTCCC  
CxxCxxxCx{10}CxxxCxxxC  
4,666: CTCAT CTGCGTCCGGAGGAAGTATCCGCC GTCCC  
CxxCxxxCx{12}CxxxCxxxC  
4,737: CTCAT CGGGTCCCGAAGGAAGTATCCGCC GTCCC  
CxxCxxxCx{10}CxxxCxxxC  
4,809: CTCAT CTGCGTCTGGAAGGAATCATCCGCCGTC CCTCA  
CxxCxxxCx{12}CxxxCxxxC

ADP31201 ck: 5537 len: 1,539 | Adp31201 Human secreted protein SEQ ID #196f

1

CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxxC  
546: CCACT CCCCTACCGCTGCACCAACCAATCCATC ATCAC

ADP31203 ck: 5545 len: 1,116 | Adp31203 Human secreted protein SEQ ID #197f

1

CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxxC  
123: CCACT CCCCTACCGCTGCACCAACCAATCCATC ATCAC

ADP31233 ck: 3065 len: 2,724 | Adp31233 Human secreted protein SEQ ID #200f

1

CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
204: CAGCA CAGCTGCGATACCACCTGCTCTCAGCC CAGCT  
CxxCxxxCx{12}CxxxCxxxC  
527: CACCC CTCNAACAGCTATGCTCAGCATTCCTAC TTGG  
CxxCxxxCx{10,12}CxxxCxxxC  
614: AAGAT CTACTCTCTTTCACCTCTCTGGCCCTC CCGG  
CxxCxxxCx{11}CxxxCxxxC  
669: GGGCA CGTCTCACCAGCAGAGGATCAACCATC CAAGC

ADP31341 ck: 4037 len: 2,382 | Adp31341 Human secreted protein SEQ ID #210f

[illegible]

3,952:	CTCCT	CxxCxxxCx{10,CxxxCxxxC CCTCTCCACCACACACCCCTCTCTCC	CCACC
3,955:	CTCCT	CxxCxxxCx{11,CxxxCxxxC CTTCACACACACCCCTCTCTCCCCAC	CACCTT
4,206:	TTTAC	CxxCxxxCx{10,CxxxCxxxC CCACAGGCTGAGCGAAGAACCTCC	AATCG
4,373:	GCCTT	CxxCxxxCx{11,CxxxCxxxC CCCTACTCTCCCACTTCCCACTC	CAACA
4,376:	TTCCC	CxxCxxxCx{12,CxxxCxxxC CTACTCTCCCACTTCCCACTCCAAC	AAGTCG
ADP31433	ck: 8464	len: 450	! Adp31433 Hum
		CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10,CxxxCxxxC	
98:	ATTCT	CCCCGACCCGCCCTAACCACTC	ACTTC
142:	ATGCT	CxxCxxxCx{10,CxxxCxxxC CTCATTTCCATTCTGTCCACGAC	GCGAG
ADP31438	ck: 1387	len: 675	! Adp31438 Hum
		CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{12,CxxxCxxxC	
316:	GGGCG	GGGTCCCGGGCTGAGCGAAAC	AGCGA
370:	ACCGG	CxxCxxxCx{12,CxxxCxxxC CACCGCGCCAGCGGGCCCGTCTCC	GGGCG
ADP31475	ck: 1185	len: 240	! Adp31475 Hum
		CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10,CxxxCxxxC	
38:	GAAC	CAACGCACATGACACCGTGCTG	AGCCC
ADP31490	ck: 3147	len: 171	! Adp31490 Hum
		CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10,CxxxCxxxC	
35:	GATTC	CTACAGTCCCTCTGCCGGCCCTC	AGGCT
45:	GTCCC	CxxCxxxCx{12,CxxxCxxxC CCTCTGCGCGCCCTCAGGTC	CACGG
ADP31611	ck: 6702	len: 1,472	! Adp31611 Hum
		CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10,CxxxCxxxC	
120:	CACCA	CCTCTCTCTCTCTCTCTTTATCC	TCTCT
123:	CACCT	CxxCxxxCx{11,CxxxCxxxC CCTCTCTCTCTCTCTTCATCTCTC	TGTCA
126:	CTCCT	CxxCxxxCx{12,CxxxCxxxC CCTCTCTCTCTCTCTATCTCTCTGTC	AGGAC
ADP31643	ck: 3052	len: 300	! Adp31643 Hum
		CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{12,CxxxCxxxC	
139:	TTAAG	CTGTAACTTAGAGCTGGCTGCAGGC	TGGCG

ADP30473 ck: 6643 len: 1,083 ! Adp30473 Human secreted protein SEQ ID #124  
1 CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
331: AGCGG CTGCGTTCACTCAGCAACTCCACCGCGC GCAAC  
CxxCxxxCx{10}CxxxCxxx  
960: CGCAG CCCCAAGCTGTCTACTCGGACCACCC CTTC A

ADP30487 ck: 2343 len: 882 ! Adp30487 Human secreted protein SEQ ID #125  
1 CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
100: GCGGC CGCGCCCCAAGTGTGGTCCGTGCCGC CAGAG  
CxxCxxxCx{11}CxxxCxxx  
388: TCGCG CTGCGGCTGGGCACACGCCCGCGCGC ACCCC

ADP30527 ck: 323 len: 701 ! Adp30527 Human secreted protein SEQ ID #129  
1 CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
21: GACTA CTGCGTGTGGGCGCTGGGCGCGCGGC CTGCA  
CxxCxxxCx{10}CxxxCxxx  
41: TGGGC CGCGGGCGTCGAGATGGCTACTTCC TGCAG  
CxxCxxxCx{12}CxxxCxxx  
252: CTGCT CTTACAGACTACTCGCGTGCCTACTTCC CCGAC  
CxxCxxxCx{12}CxxxCxxx  
261: AGACA CTACTCGGTGGCTACTTCCCGACGCGC GCGAC  
CxxCxxxCx{10}CxxxCxxx  
366: GCCCA CGTCACCTGGACAAGGACCGACAGGC CTGGA

ADP30528 ck: 8255 len: 626 ! Adp30528 Human secreted protein SEQ ID #129  
1 CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
392: GCGGT CTTCAACGAGGGGCCCACTCGCCCATCC TCAGC

ADP30565 ck: 8339 len: 1,478 ! Adp30565 Human secreted protein SEQ ID #133  
1 CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
422: AATGA CAACGCCCGCGCTTCAACCAAACTCC TACAC  
CxxCxxxCx{10}CxxxCxxx  
430: CGCCC CGCGCTTCACCCAAACCTCTACACCC TGTTTC  
CxxCxxxCx{11}CxxxCxxx  
552: ACTCG CTGCTGCCGCCCCAGACCCACACCTGC CCCTC  
CxxCxxxCx{12}CxxxCxxx  
800: CCCTG CACCGAGTGTGCCCGCGCGCGAGC CGGGC  
CxxCxxxCx{10}CxxxCxxx  
1,114: GGCGG CCCCGGCCAGGCCCAAGCGCGACTTC TCACC

ADP30574 ck: 6607 len: 1,099 ! Adp30574 Human secreted protein SEQ ID #134  
1 CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
133: GCGGG CATCTGGCAGAGGGGTCAAGGTCTCCC TTGAT  
CxxCxxxCx{11}CxxxCxxx  
263: TATCT CGGTATCATTTGAAGTACGAGCGCTCTGTC TGTCC

ADP30601 ck: 8766 len: 879 ! Adp30601 Human secreted protein SEQ ID #136  
1 CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
418: AACAA CCTCTTGAGGCGCTCGCCCGGACAGC TGGCC  
CxxCxxxCx{12}CxxxCxxx  
640: CGGAT CCGCTTTCTGGGCAAGAACGCTTTCGCCC AGCTA  
CxxCxxxCx{10}CxxxCxxx  
699: CCTCT CTGCCAAGAGCTACAGCCCTCCCTGC GCCAC  
CxxCxxxCx{10}CxxxCxxx  
710: ACGAG CTACAGCCCTCCCTGCGCCACGCGGC ACCTT  
CxxCxxxCx{12}CxxxCxxx  
718: CAGCC CTCCCTGCGCACGCGGCACCTTTCGCAC CGCTG  
CxxCxxxCx{12}CxxxCxxx  
732: CCAGG GGGCACCTTCGCACCGCTGGCTCCCTC TCCTC  
CxxCxxxCx{11}CxxxCxxx  
735: CGCGG CCACCTTGCACCGCTGGCTCCCTC CTCCC  
CxxCxxxCx{11}CxxxCxxx  
739: GCCAC CTTGCACCGCTGGCTCCCTCTCTCTC CTCAT  
CxxCxxxCx{12}CxxxCxxx  
749: CACCG CTGCGTCCCTCTCTCTCTCTCTCTCTC GGCCA  
CxxCxxxCx{12}CxxxCxxx  
760: TCCCT CTCCTCCCTCATCTCTCTGCGCAACACC TGCAG  
CxxCxxxCx{10}CxxxCxxx  
762: CCTCT CTGCTCATCTCTCTGSGCAACAAACC TGCAG  
CxxCxxxCx{12}CxxxCxxx  
836: TCGGC CTGCTCTGCTCAGGGCAACAGCTCAC GCACC

ADP30616 ck: 613 len: 300 ! Adp30616 Human secreted protein SEQ ID #138  
1 CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
256: TTCGC CTCCTACAGGAGAGTCCACCACC CACTA

ADP30667 ck: 2439 len: 3,411 ! Adp30667 Human secreted protein SEQ ID #143  
1 CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
2,551: GCCTG CTGAGTCCAGGAATATTCTCTACTACC ATTAC

ADP30681 ck: 7952 len: 2,827 ! Adp30681 Human secreted protein SEQ ID #144  
1 CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
554: TGGGC GGCCTGACCGCGTGGCTCTACTCTGC TTTC  
CxxCxxxCx{12}CxxxCxxx  
728: GCTTG CCCACGCGCGGCCAGCCCCAGGCCCTC AGGTG  
CxxCxxxCx{10}CxxxCxxx  
730: TTGCC CCACGCGGGGCCAGCCCGCCCTC AGGTG  
CxxCxxxCx{12}CxxxCxxx  
745: GCCAG CCCAGGCCCTCAGGTGCACCCCGCATGC ACTGC  
CxxCxxxCx{11}CxxxCxxx  
2,432: GGTG CCCCCTCTGTGGACTGCGCTGCCCTC TGTAT

53: GTCTT	CAGCGTGTCTATACACTGTGCCAGCCACC	ATCGT																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																								
-----------	-------------------------------	-------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

1 CXXCXXXC{10,12}CXXCXXXC  
114: TCCTG CTGCTGTACTGCCCGCCGCGCGG CAAGT  
386: AACCT CACCACCCAGTATGCTGTGTCGGGTGTC AGGTG  
1,616: CAAGG CGGCGGACTCGGGCTGGAGCGGCCGAC GCGCG  
1,666: TCGTG CCCAGAGCGGAGCGCGCACACCGGC TTCAC  
ADP31012 ck: 8731 len: 762 ! Adp31012 Human secreted protein SEQ ID #177  
1 CXXCXXXC{10,12}CXXCXXXC  
CXXCXXXC{12}CXXCXXXC  
458: TAAGA CGGTACCGGCCCTCGGGCTGACGGGC CCGCG  
654: GACGC CGAGCGCCATCAGCTGACCCAGGCCCC GACGG  
ADP31014 ck: 5040 len: 486 ! Adp31014 Human secreted protein SEQ ID #178  
1 CXXCXXXC{10,12}CXXCXXXC  
CXXCXXXC{12}CXXCXXXC  
182: TAAGA CGGTACCGGCCCTCGGGCTGACGGGC CCGCG  
378: GACGC CGAGCGCCATCAGCTGACCCAGGCCCC GACGG  
ADP31028 ck: 9653 len: 1,789 ! Adp31028 Human secreted protein SEQ ID #179  
1 CXXCXXXC{10,12}CXXCXXXC  
CXXCXXXC{12}CXXCXXXC  
733: GGCAG CTCGGGCTGATGATGTCATCACCGAGC TCGGC  
1,037: ACAAG CTTAGACCCCTGAGCAGCAGCCCTTC GCCTA  
1,166: AACGG CAGCTGGGCTGGTGAAGGCTCTCTGGC GGGGA  
ADP31037 ck: 4097 len: 848 ! Adp31037 Human secreted protein SEQ ID #180  
1 CXXCXXXC{10,12}CXXCXXXC  
CXXCXXXC{12}CXXCXXXC  
1: CCGCGGCTCGGCTAGGCGCCAGCGCTC CCGGC  
538: CACAG CATCTGGCTCGGCGGAGGCCCGCGGC GCCCC  
ADP31060 ck: 5784 len: 3,407 ! Adp31060 Human secreted protein SEQ ID #182  
1 CXXCXXXC{10,12}CXXCXXXC  
CXXCXXXC{11}CXXCXXXC  
2,483: CTTGC CAGCTGCCCGGCTCCACCACTCTACC GTTGC  
2,932: CGCCA CCCAGGTGGATGAGCCCTGGCGAGC TACAT  
ADP31108 ck: 4537 len: 222 ! Adp31108 Human secreted protein SEQ ID #187  
1 CXXCXXXC{10,12}CXXCXXXC  
CXXCXXXC{11}CXXCXXXC  
80: GGCGC CGCGGACCGTAAGTTTGGCGGCAAC TCCCC

1 CXXCXXXC{10}CXXCXXXC  
81: GCCGC CGCGACCGTAAGTTTGGCGGCAAC TCCCC  
ADP31127 ck: 3950 len: 888 ! Adp31127 Human secreted protein SEQ ID #189  
1 CXXCXXXC{10,12}CXXCXXXC  
CXXCXXXC{12}CXXCXXXC  
100: AGCAA CATCCTTCCTCCCTATACCCACCCCTC ATCTG  
119: CTATA CCCACCCCTCATCTGTGAAGCATGCCGC CTTAT  
121: ATACC CCACCTCATCTGTGAAGCATGCCGC CTTAT  
363: CCCGT CTGTGGCGCACTGCCACACGACTGCC TGGAG  
454: TCTTC CTGTGGCGCCATGCTGACGGCC GTGCT  
599: TTTCA CCACCAACGATTCTACCGCTCTCCACC TCCAG  
858: CTGAG CTACAACCACAGTGAGCATCCTCTGTG TGA  
ADP31143 ck: 8931 len: 575 ! Adp31143 Human secreted protein SEQ ID #191  
1 CXXCXXXC{10,12}CXXCXXXC  
CXXCXXXC{12}CXXCXXXC  
54: GCAGC CGGACAGCGGAGCGTCTCTGGCCACC ATGAA  
394: TTTGA CTGCTTCATGTTAGCATCTGCCCTC TTCAG  
ADP31285 ck: 2882 len: 811 ! Adp31285 Human secreted protein SEQ ID #205  
1 CXXCXXXC{10,12}CXXCXXXC  
CXXCXXXC{12}CXXCXXXC  
43: CTGTA CCACCTCAGAGGCGCTGCCCCACCTGC GTGCC  
58: AGGCC CTGCCCCACCTGGGTGCCCTCAGCC CCGGC  
64: TGCCC CACCTGGTGGCGCTAGCGCCCGGCC CATGG  
128: GACGT CACCTGCCGCGAGGCGCCATCCACC TCCAG  
194: CACTT CTTCTGTGTTCAGTCCACAGGGC ACATC  
ADP31293 ck: 3462 len: 1,221 ! Adp31293 Human secreted protein SEQ ID #206  
1 CXXCXXXC{10,12}CXXCXXXC  
CXXCXXXC{10}CXXCXXXC  
432: GGTGC CACCATTCGGAACATCACCAACAGAC CCAGT  
835: AGGGC CCCCTTCAGGCATGACTCTCCCTCC CCGCA  
839: GCCCC CTTAGGCATGACTCTCCCTCCCGC AGTCT  
ADP31310 ck: 8623 len: 11,328 ! Adp31310 Human secreted protein SEQ ID #207

1	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{10}CXXXCXXXC 2,617: CAGAA CTACTTTTCACTTGAGAACCAACCAGCC AGCA CXXCXXXCX{11}CXXXCXXXC 3,179: GGTGC CGTCAGTCTGCTTCTCTATCCCCCAACC CAATA CXXCXXXCX{11}CXXXCXXXC 4,598: GAAAT CCCCTGGCAAGCGCGTGCATGCTTTC CTCTT CXXCXXXCX{12}CXXXCXXXC 5,476: AAGCT CACCTGGCAACTGGAGGTTTCAGTCTTTC CCCTA ADP31311 ck: 4390 len: 10,944   Adp31311 Human secreted protein SEQ ID #20				
1	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{10}CXXXCXXXC 2,617: CAGAA CTACTTTTCACTTGAGAACCAACCAGCC AAGCA CXXCXXXCX{11}CXXXCXXXC 3,179: GGTGC CGTCAGTCTGCTTCTCTATCCCCCAACC CAATA CXXCXXXCX{11}CXXXCXXXC 4,598: GAAAT CCCCTGGCAAGCGCGTGCATGCTTTC CTCTT CXXCXXXCX{12}CXXXCXXXC 5,476: AAGCT CACCTGGCAACTGGAGGTTTCAGTCTTTC CCCTA ADP31349 ck: 5618 len: 420   Adp31349 Human secreted protein SEQ ID #211	1			
1	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{11}CXXXCXXXC 333: AGGAT CAGCAACACAATAATCAGCAAGCACTC AGTCA ADP31369 ck: 8768 len: 1,062   Adp31369 Human secreted protein SEQ ID #213	1			
1	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{12}CXXXCXXXC 493: GTTAC CTACTTCCCGCTCACAACACCCGCGCC GCCAT ADP31446 ck: 7494 len: 1,755   Adp31446 Human secreted protein SEQ ID #221	1			
1	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{11}CXXXCXXXC 103: TAGAA CCACAGTCACAAGCGGAGCCACAGC ACAGA ADP31494 ck: 3228 len: 9,195   Adp31494 Human secreted protein SEQ ID #226	1			
1	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{11}CXXXCXXXC 3,227: TGCTA CATCTGTCCCAACCTCTGACACACCTTC TCTCA CXXCXXXCX{10}CXXXCXXXC 3,916: CAGCT CAACCTCTCCCGCTCTCTCCCTCCCTCC CTCC CXXCXXXCX{11}CXXXCXXXC 3,919: CTCAA CTTCTTCCCGCTCTCTCCCGTCCCGCTC CTCTT CXXCXXXCX{10}CXXXCXXXC 3,920: TCAAC CTCTTCCCGCTCTCTCCCGTCCCGCTC CTCTT CXXCXXXCX{12}CXXXCXXXC 3,922: AACCT CTTCCCGCTCTCTCCCGTCCCGCTCTCTCC TCCTC CXXCXXXCX{10}CXXXCXXXC 3,943: CTCCC CTCTCTCTCTCTCTCCACCAACACC CTCC				
	CXXCXXXCX{11}CXXXCXXXC 3,946: CCCTT CTTCTCTCTCTCTCCACCAACCCTCTC CTCCC CXXCXXXCX{12}CXXXCXXXC 3,949: CTCTT CTTCTCTCTCTCCACCAACCCTCTCTCTCC CCAC CXXCXXXCX{10}CXXXCXXXC 3,952: CTCTT CTTCTCTCTCTCCACCAACCCTCTCTCTCC CCACC CXXCXXXCX{11}CXXXCXXXC 3,955: CTCTT CTTCTCTCTCTCTCTCTCTCTCTCTCTCTCT CACTT 4,206: TTTCAC CCACAGGCTGAGCAAGCAAGCAAGCTCC AATCG CXXCXXXCX{11}CXXXCXXXC 4,373: GCCTT CCCTAGTCTCCCACTTTTCCCACTCTC CAACA CXXCXXXCX{12}CXXXCXXXC 4,376: TTCCC CTACTCTCCCACTTTTCCCACTCTCCAAC AAGTC ADP31514 ck: 7610 len: 240   Adp31514 Human secreted protein SEQ ID #228	1			
	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{10}CXXXCXXXC 145: GATTC CTACAGTCCCGCTCTGCGGCGCCCTC AGGCT CXXCXXXCX{12}CXXXCXXXC 155: GTCCC CTCTGCGCGCCCTCAGGCTCCCAAC CACGG ADP31537 ck: 6431 len: 1,134   Adp31537 Human secreted protein SEQ ID #230	1			
	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{12}CXXXCXXXC 881: CGGTG CGACTCTCTACCGCGCGCGAGACGGAC TTCTT ADP31568 ck: 2180 len: 936   Adp31568 Human secreted protein SEQ ID #233	1			
	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{11}CXXXCXXXC 415: TCATA CGCAAGCCTGTGTCTGACAGACGCC ACCAG CXXCXXXCX{12}CXXXCXXXC 493: CGTTT CTCCCGCAAGTAACCTGTCTTCCGAGC GGGCT ADP31588 ck: 2404 len: 1,389   Adp31588 Human secreted protein SEQ ID #235	1			
	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{12}CXXXCXXXC 320: CCAGA CATCGCCTGTGATGTCTCGGCTCTGGC TGGTC CXXCXXXCX{10}CXXXCXXXC 639: GTGTG CCGGTGACAGTTGGGCTTACCAACC CGGC ADP31618 ck: 7920 len: 471   Adp31618 Human secreted protein SEQ ID #238	1			
	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{11}CXXXCXXXC 337: GACTT CGCTGACCTGTCTCCGACCTTCACGC GTCAT ADP30513 ck: 545 len: 638   Adp30513 Human secreted protein SEQ ID #128	1			
	CXXCXXXCX{10,12}CXXXCXXXC CXXCXXXCX{11}CXXXCXXXC 221: GGCAC CGGCTTCCACCTGCAGATCTGCGCCGAC GGCAG				

1	ADP30545	ck: 9625	len: 204	! Adp30545 Human secreted protein SEQ ID #131	
		CXXCXXXCX{10,12}CXXXCXXXC			
	137:	CTTGA	CAGCCTTCGATTAGACGGTGTGGC	TCCCC	
1	ADP30598	ck: 695	len: 681	! Adp30598 Human secreted protein SEQ ID #136	
		CXXCXXXCX{10,12}CXXXCXXXC			
	359:	GTCGA	CGTCACATATTATGTACACAGAC	GCGGC	
1	ADP30611	ck: 9382	len: 279	! Adp30611 Human secreted protein SEQ ID #137	
		CXXCXXXCX{10,12}CXXXCXXXC			
	91:	GGCGG	CACCGGCCAGGCCCGCGACTTGC	TCACC	
1	ADP30624	ck: 2154	len: 642	! Adp30624 Human secreted protein SEQ ID #139	
		CXXCXXXCX{10,12}CXXXCXXXC			
	176:	CGCCG	CCTCTTCCGCTTGACCCGCGATCAGGC	CGCCT	
	343:	CAACG	CACCGGACATCGCATACCCGCTGGC	CGCCC	
	356:	ATCGC	CATCACCCGCTGGCGGCCAGGGCGC	CGGCA	
1	ADP30643	ck: 776	len: 189	! Adp30643 Human secreted protein SEQ ID #141	
		CXXCXXXCX{10,12}CXXXCXXXC			
	13:	ACGGG	CTTCGAGCTGGGGAAGGAGGGCGGCTC	TTGTG	
1	ADP30675	ck: 8906	len: 1,289	! Adp30675 Human secreted protein SEQ ID #144	
		CXXCXXXCX{10,12}CXXXCXXXC			
	822:	TCAAG	CCACTACCTTTGGAACACTCCACCTCAC	TATCA	
1	ADP30749	ck: 2904	len: 2,803	! Adp30749 Human secreted protein SEQ ID #151	
		CXXCXXXCX{10,12}CXXXCXXXC			
	528:	AAGTC	CACCAGCTGCGAGTGGACCACTCCATC	CTGAC	
	843:	ATCAA	CATCGGCNCTTGGCGGACCCGCGCCAC	GGTGG	
	932:	GGTGG	CXXCXXXCX{12}CXXXCXXXC		
	1,753:	GGTGG	CTGCTGCGATCACAGCTGTACACAGGC	GGGCA	
	1,760:	GCCTG	CATCACAGCTGCTACAGGGGGCATCC	CGGTG	
1	ADP30752	ck: 2971	len: 1,849	! Adp30752 Human secreted protein SEQ ID #151	
		CXXCXXXCX{10,12}CXXXCXXXC			
	311:	GGTGT	CAACTCTCAGACTGGAATCATCCTTAC	TCTCT	

ADP30782	ck: 4195	len: 1,209	! Adp30782 Human secreted protein SEQ ID #154	
		CXXCXXXCX{10,12}CXXXCXXXC		
	206:	TCTTC	CTGCTTCATCAGCACTTCTCTTCTCTGC	TGCCT
	978:	TACAT	CAACACCCACATCTACACCCACACCTTC	AGCTA
ADP30786	ck: 246	len: 186	! Adp30786 Human secreted protein SEQ ID #155	
		CXXCXXXCX{10,12}CXXXCXXXC		
	140:	GCGGA	CACCGCCATGGAGATCTCCGCCCGC	AGCCC
ADP30819	ck: 2567	len: 423	! Adp30819 Human secreted protein SEQ ID #158	
		CXXCXXXCX{10,12}CXXXCXXXC		
	13:	CTGGG	CCCCTGGCGCGCTGCGCTCTCGCGCGC	TCCTA
	26:	CGCGG	CTGCCCTCTCGCGCGCTCTACCCCTC	GGAGC
ADP30824	ck: 9825	len: 318	! Adp30824 Human secreted protein SEQ ID #159	
		CXXCXXXCX{10,12}CXXXCXXXC		
	259:	GAAGA	CCTCGCTCTGATTTAATCTCGCGGGC	TTAAA
ADP30857	ck: 6986	len: 750	! Adp30857 Human secreted protein SEQ ID #162	
		CXXCXXXCX{10,12}CXXXCXXXC		
	689:	ATCAT	CTTCTGCTCTATCCCTTTCCAGCTCCC	CTTGC
ADP30868	ck: 9084	len: 681	! Adp30868 Human secreted protein SEQ ID #163	
		CXXCXXXCX{10,12}CXXXCXXXC		
	536:	GCACT	CGACAAGCCTTGCTATTCACTTCTCTTC	TGCAT
ADP30933	ck: 237	len: 1,133	! Adp30933 Human secreted protein SEQ ID #170	
		CXXCXXXCX{10,12}CXXXCXXXC		
	943:	TACAT	CTGCTAACATGCTTATTTTCATTTCTTC	TTTAT
ADP30979	ck: 4705	len: 414	! Adp30979 Human secreted protein SEQ ID #174	
		CXXCXXXCX{10,12}CXXXCXXXC		
	64:	AGGAC	CTGCTGCCAGCCAGACCGCAGCTCCC	TGTGC
ADP30993	ck: 2924	len: 1,191	! Adp30993 Human secreted protein SEQ ID #176	
		CXXCXXXCX{10,12}CXXXCXXXC		
	860:	TGCTC	CCCCTGGCTATAACATTTCTGTCAAAC	CAGAT
ADP31058	ck: 6937	len: 2,027	! Adp31058 Human secreted protein SEQ ID #182	
		CXXCXXXCX{10,12}CXXXCXXXC		



884:	GCGGT	CTACAAC	CTGTCCCGGAGGACCTACCGGC	CCTCC	CxxCxxxCx{12}CxxxCxxxC	ADP31237	ck: 5429	len: 945	!	Adp31237	Human secreted protein	SEQ ID #200
1,121:	AAGCG	CTGCCAC	CAGGATCTGGCATCCAC	AAAG	CxxCxxxCx{11}CxxxCxxxC	27:	GTCAA	CTTCGGCCTGGTCCGCCAAGCTGCC	TCACT	CXXCXXCX{10,12}CXXCXXXC		
1,831:	AGTCG	CTTCTGC	ACACAGCTGAGTCGAGGC	CCACA	CxxCxxxCx{10}CxxxCxxxC	ADP31376	ck: 446	len: 1,050	!	Adp31376	Human secreted protein	SEQ ID #214
1,835:	GCTTC	CTGCAC	AGCTGGAGGCCAC	AGTGC	CxxCxxxCx{10}CxxxCxxxC	620:	TGGCA	CTGCCCTCCCTGGTAGCAGGCCACAGCC	AGTGC	CXXCXXCX{10,12}CXXCXXXC		
1,868:	GTGCT	CGCCCCC	ATCTCTGACGCGCACTTCC	TGCAC	CxxCxxxCx{11}CxxxCxxxC	814:	ATGAG	CCACCTGCAGTCAGACACTGSCCCAC	CCAAC	CxxCxxxCx{12}CxxxCxxxC		
ADP31123	ck: 1270	len: 831	!	Adp31123	Human secreted protein	SEQ ID #189						
153:	GTGCC	CACCGC	CTCGAGGACCGGCGACC	CACCG	CXXCXXCX{10,12}CXXCXXXC	ADP31394	ck: 8083	len: 2,307	!	Adp31394	Human secreted protein	SEQ ID #216
155:	GCCCA	CGCGCCT	CGAGGACCGGACCCACC	GGCCT	CxxCxxxCx{10}CxxxCxxxC	1,757:	TGCTG	CTGCTCCGGAGCCCCGTACTATCAGCC	GTGGT	CXXCXXCX{10,12}CXXCXXXC		
158:	CACCG	CGCCTCG	GAGGACCGGCGACCCACCGC	CTCTT	CxxCxxxCx{12}CxxxCxxxC	ADP31545	ck: 5669	len: 3,201	!	Adp31545	Human secreted protein	SEQ ID #231
212:	CTACC	CGCCAACTT	CATCCGAGCGCGTGTG	GTCCG	CxxCxxxCx{11}CxxxCxxxC	393:	AACTT	CCCCAATCAGCAAGGCGGCCAACGTTT	AGAAAT	CxxCxxxCx{12}CxxxCxxxC		
ADP31155	ck: 3659	len: 1,173	!	Adp31155	Human secreted protein	SEQ ID #192						
365:	ACCTG	CCACTACC	ACAGCTGGCATTCATCC	ACCAA	CXXCXXCX{10,12}CXXCXXXC	ADP31598	ck: 954	len: 669	!	Adp31598	Human secreted protein	SEQ ID #236
400:	CAAAG	CCACCTG	CAGGCCAGAACTAACCTGC	CCAGG	CxxCxxxCx{11}CxxxCxxxC	210:	AATTT	CCCCAATCAGCAAGGCGGCCAACGTTT	AGATT	CXXCXXCX{10,12}CXXCXXXC		
497:	CACCTG	CTACTGCC	ATTGTCATGTATGCCAC	TGCCC	CxxCxxxCx{11}CxxxCxxxC	ADP31650	ck: 77	len: 1,494	!	Adp31650	Human secreted protein	SEQ ID #241
ADP31184	ck: 4817	len: 849	!	Adp31184	Human secreted protein	SEQ ID #195						
62:	TGCAC	CCTCTT	CTCACTGAGTGGCCCTTTCAACC	CTTAC	CXXCXXCX{10,12}CXXCXXXC	651:	AACTA	CCTCTTCCAGTTTTTTGTCCCTGCTGAC	CAAGC	CxxCxxxCx{11}CxxxCxxxC		
170:	CAGCG	CGGGCACC	CTGGGATCGTCCAGC	TCCAG	CxxCxxxCx{10}CxxxCxxxC	ADP31690	ck: 1533	len: 2,358	!	Adp31690	Human secreted protein	SEQ ID #245
303:	CCACT	CAACTGCC	ATGTACGACCGCCTGCAGC	TCATC	CxxCxxxCx{11}CxxxCxxxC	451:	TGGTG	CGGCCCTCAAGGTATGCCCCAGTCAGTC	GCCTA	CXXCXXCX{10,12}CXXCXXXC		
ADP31211	ck: 9462	len: 1,344	!	Adp31211	Human secreted protein	SEQ ID #197						
355:	CGGGT	CGGCCCT	CCACGAGGTGCCCGCGTCC	CCCGC	CXXCXXCX{10,12}CXXCXXXC	1,126:	ACCGA	CAGCCACACTGCACAGCCCTCCATC	CAGGC	CxxCxxxCx{10}CxxxCxxxC		
356:	CGGTC	CGCCCTC	CCACGAGGTGCCCGCGTCC	CCCGC	CxxCxxxCx{10}CxxxCxxxC	1,146:	AGACC	CTCCATCCAGGCCACCGTCCCGCATCC	TGCTT	CxxCxxxCx{12}CxxxCxxxC		
382:	GCGCT	CCCCGCT	CAGCCATGTCTCTGCAGCC	GCGTG	CxxCxxxCx{11}CxxxCxxxC	ADP30468	ck: 8242	len: 357	!	Adp30468	Human secreted protein	SEQ ID #123
1,142:	TGAGA	CCCTGT	CTACTTGGCCCTCTGCCTCC	AGATG	CxxCxxxCx{11}CxxxCxxxC	188:	GCGTG	CGGCCGACCGGCGGAGCTGGGCC	GCCTT	CXXCXXCX{10,12}CXXCXXXC		
						192:	GCGGC	CGACCGCGGAGCTGCGCCGCTTCTTCTG		CxxCxxxCx{10}CxxxCxxxC		
						ADP30482	ck: 9461	len: 1,107	!	Adp30482	Human secreted protein	SEQ ID #124

561:	CTCAG	CTCCATCCCCCATCCAGGGTCACTCCCAC	TGGGA
ADP30510	ck: 7647	len: 2,044	! Adp30510 Human secreted protein SEQ ID #127
215:	GCCCC	CAGCCCCCAGCGCTTCGGCTCTCCTTC	CAAGA
1,141:	CGGAA	CAACCCCTCATGTACAACTCTGTCTGC	CCACT
1,555:	AGCAG	CGCCTTTCTGGAGTGAGCCCGCTGCC	TGCAG
1,610:	CTTTC	CAGGGCAGGGTGACAGCCACACC	AGGTG
1,909:	GCGAA	CTCCCTGCGCATGTGCCGCCGAGCC	TGCGC
ADP30516	ck: 5109	len: 195	! Adp30516 Human secreted protein SEQ ID #128
6:	ATGCG	CTGCTCGCGGAGCGTCTGGCTGC	GCTGG
ADP30532	ck: 1001	len: 1,401	! Adp30532 Human secreted protein SEQ ID #129
36:	CTGAT	CCTCGGNACAGTCTCTCTCCTGC	CGAGG
392:	TCTGT	CCAGGGCACCATGACTGGGTGGCCATC	CAGTA
1,114:	ATTTC	CACCCAGCTGTAATCTCCTCACCATC	GATCT
ADP30572	ck: 4349	len: 2,835	! Adp30572 Human secreted protein SEQ ID #133
429:	CCATT	CAGCATCAAAGGTGGGTGAGGCTCC	AGATT
1,163:	TTAAT	CTGCCTACCTTCAGACGGCTCTGTC	TCTAT
1,257:	CTGGT	CAGCGTCTGAAGGTTCCAGTCAGAC	CACAG
1,548:	GATAT	CACATTCTTCCAGAACAGCCATC	CCAGA
2,249:	TGCAG	CAGCAGTCCCACTGCAACCTTCCTGC	CCGAG
ADP30652	ck: 5170	len: 594	! Adp30652 Human secreted protein SEQ ID #141
528:	TATGA	CGTCTACCTGATGGGAACCTCCATTC	ACTAC
ADP30692	ck: 9178	len: 659	! Adp30692 Human secreted protein SEQ ID #145
188:	CCCTG	CACGAGCTGTGCCCGGCGCGAGC	CGGGC
502:	AGCGG	CCCGGCCCAAGCCAGCGCACTCGC	TCACT
ADP30753	ck: 3809	len: 183	! Adp30753 Human secreted protein SEQ ID #152
115:	GAGGC	CTCGCACAGCTCTGGGCTCTCTGCC	GCTGC
141:	CTCTG	CCGTGCTCTGCTGTGTGGGAGC	CTGTG
ADP30815	ck: 1520	len: 162	! Adp30815 Human secreted protein SEQ ID #158
109:	CCAGC	CTCAGCCCGAGTGGAAAGCTCTCC	CGGGG
111:	AGCCT	CAAGCCAGCTGGAGCGCTCTCC	CGGGG
ADP30878	ck: 8628	len: 828	! Adp30878 Human secreted protein SEQ ID #164
597:	GTCAT	CACCTTCTCTCTCTCATCGAACACC	AGAAG
ADP30891	ck: 607	len: 762	! Adp30891 Human secreted protein SEQ ID #165
130:	GGCAC	CCACGCTCTACAATGGTGACCTTTTC	AGATG
ADP30898	ck: 8357	len: 1,215	! Adp30898 Human secreted protein SEQ ID #166
103:	GCACG	CCCCCAACTCTCTGCACCATCTCC	ACGGG
ADP30900	ck: 8357	len: 1,215	! Adp30900 Human secreted protein SEQ ID #167
103:	GCACG	CCCCCAACTCTCTGCACCATCTCC	ACGGG
ADP30918	ck: 131	len: 525	! Adp30918 Human secreted protein SEQ ID #168
120:	CTGCC	CTTCTGCTGGAGAGCCACTGGCTACC	TGTCT
225:	GCTCT	CTGCTGCACCGTGCCTTCACCTGC	CCTGA
240:	CGTGC	CTTCCACCTGGCTGTATGGCACCCACC	TCACC
244:	CCTTC	CACCTGGCCTGATGGCACCCACCTCAC	CTTGC
ADP30920	ck: 6653	len: 1,125	! Adp30920 Human secreted protein SEQ ID #169
1			

821: AGCCC	CACCGTCGGAGAGCCAGACAGCGGCG	AGCCG			
ADP30924	ck: 7005 len: 1,134	Adp30924 Human secreted protein SEQ ID #169			
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC				
130: GACAC	CTTCCAACTTTGCTCCCTGGCAACC	CCTAA			
ADP30957	ck: 2327 len: 915	Adp30957 Human secreted protein SEQ ID #172			
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxxC				
321: CTCTG	CCGCTAGCGACCTTCGTGCGAGCTCC	TCGCC			
470: TGCCT	CCACTGTCATCCTACACTCAATCTACC	TGTGC			
526: TGCAG	CACCCAGCTGTGTGTCAGTGCTTCGGGCG	TCTCC			
ADP31114	ck: 658 len: 1,288	Adp31114 Human secreted protein SEQ ID #188			
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC				
7: CCAAG	CTCCTTACCATGAGCAGACAAGCCAGC	AAGAC			
ADP31228	ck: 7949 len: 582	Adp31228 Human secreted protein SEQ ID #199			
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxxC				
121: TTGCC	CTGCACACCGGTTGGACCCATCCGCG	CCATC			
ADP31250	ck: 2456 len: 453	Adp31250 Human secreted protein SEQ ID #201			
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{11}CxxxCxxxC				
81: CATTC	CGTCCCGCTCTCTGGACCCGCCCGCG	CGGCG			
85: CGCTC	CCGCTCTCTGGACCCGCCCGCGCG	GGCGC			
ADP31259	ck: 9146 len: 4,848	Adp31259 Human secreted protein SEQ ID #202			
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC				
274: CGGAC	CCACCTGTGCTGCTCTCTCAACC	CGGCT			
278: CCCAC	CTGCTGTGCTGCTCTCTCAACCCCGC	TCGCC			
285: GCTGG	CTGCTACTCTCAACCCGCTGCGCTTC	CGGGG			
1,419: GGGCC	CAGCTCCCGGTGAGTGCCCCAGCC	TCGGG			
1,566: CTGCG	CCACATGGGGAGGCACCTTCGTCC	AGTAG			
2,766: TACCG	CACCTTCCGAGGAGACTTCTTGCTGC	CCATG			
2,781: GAGGA	CTTCTTGCTGCTCCATGTGGCTCAAGC	ACACA			
2,926: GGAGG	CGCCACCTGAGGAGCCCCCTCCCGC	CGTGC			
3,383: AGSCC	CTCCTGACCTACCGCAGATCACCTGGC	ACCTG			
4,214: CGGGG	CCCTATCCGAGACCCCAACCCAGACCATC	ATCCT			
4,658: TGTGT	CCCAGGCCAGCAGCTTGTACACAGCGC	TCAAC			
ADP31276	ck: 5171 len: 849	Adp31276 Human secreted protein SEQ ID #204			
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxxC				
534: ACCTT	CCTCAACCCCTCCCAAGTCGTCCCCAC	TCGCA			
540: CTCAA	CCCCCTCCCAAGTCGTCCCACTCGC	ATTAG			
625: AGGGG	CAGCGCACCTCCAGAGTGGCTCCCTCC	CCGCC			
650: CCTCC	CTCCCGCTCGGGTTCCGGACCCGCG	TGCAG			
ADP31303	ck: 3085 len: 900	Adp31303 Human secreted protein SEQ ID #207			
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC				
520: TGATG	CCACACCTGGCCAACCGCACAAAC	AAATT			
580: CACTC	CTGCTGCACCACTGCACCTCCCCAC	TGGGG			
ADP31350	ck: 7643 len: 306	Adp31350 Human secreted protein SEQ ID #211			
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxxC				
266: CTGTG	CATCGAGCCGTTCCTCCAGCCGCCGAGC	TGCTC			
ADP31361	ck: 6006 len: 615	Adp31361 Human secreted protein SEQ ID #212			
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC				
296: GAAGC	CCTCTCTCGCTCCAGGACCCCTCTACC	AGCAG			
ADP31401	ck: 2174 len: 263	Adp31401 Human secreted protein SEQ ID #216			
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{10}CxxxCxxxC				
6: TGCGG	CGCGCAGCCGCCGAGCGTGTCCAGC	GTTGG			
70: TAAGA	CACCCGCCGTTTACCCAGCAGCGGGC	CCAGC			
ADP31420	ck: 267 len: 204	Adp31420 Human secreted protein SEQ ID #218			
1	CXXCXXXCX{10,12}CXXXCXXXC CxxCxxxCx{12}CxxxCxxxC				
110: AGCTA	CTGCAGCCGAAACCAAGCCCTCCAAC	AGTGC			
131: AAAGC	CCTCCAAACAGTGCCTTACAGCTACAGCC	GGTCT			
ADP31423	ck: 5997 len: 177	Adp31423 Human secreted protein SEQ ID #219			

1	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC 63: GTGCT CTTAGCCTGTGCTGCTGCTACCTCC TGCCT 75: CTGTG CTGCTGTACCTCTGCTCCCGGC TGGAC ADP31491 ck: 2598 len: 1,596 ! Adp31491 Human secreted protein SEQ ID #225	CxxCxxxCx{10}CxxxCxxxC CTGCTCTGAAGGAAGTATCCGCC TTCC CxxCxxxCx{10}CxxxCxxxC CTGCTCCGGAAGGAAGTATCCGCC GTCCC CxxCxxxCx{12}CxxxCxxxC CTGCTCCGGAAGGAATATCCGCCCGTC CCTCA CxxCxxxCx{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxxC 26: CTGCG CTACCCAGCGGGCTGCCCGGCTCG CCTGC ADP31533 ck: 3976 len: 1,260 ! Adp31533 Human secreted protein SEQ ID #230	CxxCxxxCx{10}CxxxCxxxC CxxCxxxCx{10}CxxxCxxxC 462: GATCC CTACTTACCACCTTCACTCTCTCCGAGC AGGCA ADP31587 ck: 1874 len: 1,358 ! Adp31587 Human secreted protein SEQ ID #235	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxxC 289: CCAGA CATCGCCTTGGATGCTTTCGGCTCTGGC TGGTC CxxCxxxCx{10}CxxxCxxxC 608: GTGTG CGCGTGCAGCTTGGGCTTACCAGCC CGGCC ADP31591 ck: 1415 len: 5,514 ! Adp31591 Human secreted protein SEQ ID #239	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxxC 1,784: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTCCG CxxCxxxCx{10}CxxxCxxxC 1,820: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTCCC CxxCxxxCx{10}CxxxCxxxC 1,856: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTCCC CxxCxxxCx{10}CxxxCxxxC 1,892: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTCCG CxxCxxxCx{10}CxxxCxxxC 1,928: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTCCC CxxCxxxCx{10}CxxxCxxxC 1,964: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTCCC CxxCxxxCx{12}CxxxCxxxC 2,000: CTCAT CTGCTCCGGAAGGAATATCCGCCCGTC CCTCA CxxCxxxCx{10}CxxxCxxxC 2,035: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTCCC CxxCxxxCx{10}CxxxCxxxC 2,107: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTCCC CxxCxxxCx{10}CxxxCxxxC 2,143: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTCCC CxxCxxxCx{10}CxxxCxxxC 2,251: CTCAT CTGCTCCGGAAGGAAGTATCCGCC ATCCC CxxCxxxCx{10}CxxxCxxxC 2,323: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTCCC CxxCxxxCx{12}CxxxCxxxC 2,359: CTCAT CTGCTCCGGAAGGAATATCCGCCCGTC CCTCA	CxxCxxxCx{10}CxxxCxxxC 2,430: CTCAT CTGCTCCGGAAGGAAGTATCCGCC TTCC CxxCxxxCx{10}CxxxCxxxC 2,537: CTCAT CGGGTCCGGAAGGAAGTATCCGCC GTCCC CxxCxxxCx{12}CxxxCxxxC 2,573: CTCAT CTGCTCCGGAAGGAATATCCGCCCGTC CCTCA CxxCxxxCx{12}CxxxCxxxC 2,680: CTCAT CTGCTCTGAAGGAATATCCGCCCGTC CCTCA CxxCxxxCx{12}CxxxCxxxC 2,858: CTCAT CGGGTCCGGAAGGAATATCCAGCC GTTCC CxxCxxxCx{10}CxxxCxxxC 2,896: CTCAT CGGGTCCGGAAGGAAGTATCCAGCC GTTCC CxxCxxxCx{12}CxxxCxxxC 2,968: CTCAT CTGCTCTGAAGGAATATCCGCCCGTC CCTCA CxxCxxxCx{12}CxxxCxxxC 3,057: GAAGT CATCGGCCGAATCATCGCCGTCCTC ATCTG CxxCxxxCx{10}CxxxCxxxC 3,231: CTCAT CGGGTCCGGAAGGAAGTATCCGCC GTTCC CxxCxxxCx{12}CxxxCxxxC 3,302: CTCAT CGGGTCCGGAAGGAAGTATCCAGCC GTTCC CxxCxxxCx{10}CxxxCxxxC 3,340: CTCAT CGGGTCCGGAAGGAAGTATCCGCC GTTCC CxxCxxxCx{12}CxxxCxxxC 3,412: CTCAT CTGCTCTGAAGGAATATCCGCCCGTC CCTCA CxxCxxxCx{10}CxxxCxxxC 3,519: CTCAT CTGCTCCGGAAGGAAGTATCCAGCC GTCCC CxxCxxxCx{10}CxxxCxxxC 3,555: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTTCC CxxCxxxCx{12}CxxxCxxxC 3,626: CTCAT CTGCTCCGGAAGGAAGTATCCGCCCGTC CCTCA CxxCxxxCx{10}CxxxCxxxC 3,661: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTTCC CxxCxxxCx{10}CxxxCxxxC 3,697: CTCAT CTGCTCTGAAGGAAGTATCCGCC GTTCC CxxCxxxCx{12}CxxxCxxxC 3,769: CTCAT CTGCTCCGGAAGGAAGTATCCAGCCGT CCTCA CxxCxxxCx{10}CxxxCxxxC 3,804: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTCCC CxxCxxxCx{10}CxxxCxxxC 3,840: CTCAT CTGCTCTGAAGGAAGTATCCGCC GTTCC CxxCxxxCx{12}CxxxCxxxC 3,912: CTCAT CTGCTCTGAAGGAATATCCGCCCGTC CCTCA CxxCxxxCx{12}CxxxCxxxC 3,947: CTCAT CTGCTCCGGAAGGAATATCCAGCCCTC CCTCA CxxCxxxCx{10}CxxxCxxxC 3,982: CTCAT CTGCTCCGGAAGGAAGTATCCGCC GTTCC CxxCxxxCx{12}CxxxCxxxC 4,018: CTCAT CTGCTCCGGAAGGAATATCCAGCCGT CCTCA
---	--	---	---	--	--	--

4,053: CTCAT CxxCxxxCx{10}CxxxCxxxC  
CTGGTCCAGAGGAAGTCATCCACCC GTCCC

4,089: CTCAT CxxCxxxCx{10}CxxxCxxxC  
CTGGTCCGAGGAAGTCATCCACCC GTCCC

4,125: CTCAT CxxCxxxCx{10}CxxxCxxxC  
CTGGTCCGAGGAAGTCATCCGCC GTTTC

4,197: CTCAT CxxCxxxCx{12}CxxxCxxxC  
CTGGTCCGAGGAATCATCCGCCGTC CCTCA

4,270: CTCAT CxxCxxxCx{10}CxxxCxxxC  
CGGCTCCGAGGAAGTCATCCGCC GTCCC

4,377: CTCAT CxxCxxxCx{10}CxxxCxxxC  
CGGCTCCGAGGAAGTCATCCGCC GTCCC

4,449: CTCAT CxxCxxxCx{10}CxxxCxxxC  
CTGGTCCGAGGAAGTCATCCGCC GTCCC

4,485: CTCAT CxxCxxxCx{10}CxxxCxxxC  
CTGGTCCGAGGAAGTCATCCGCC GTCCC

4,666: CTCAT CxxCxxxCx{10}CxxxCxxxC  
CTGGTCCGAGGAAGTCATCCGCC GTCCC

4,737: CTCAT CxxCxxxCx{10}CxxxCxxxC  
CGGCTCCGAGGAAGTCATCCGCC GTCCC

4,809: CTCAT CxxCxxxCx{12}CxxxCxxxC  
CTGGTCCGAGGAATCATCCGCCGTC CCTCA

ADP31606 ck: 9398 len: 660 ! Adp31606 Human secreted protein SEQ ID #237

349: AGAGA CAACTTACTTGTTCATCTTACTGGC AAAAG

ADP31675 ck: 4672 len: 2,419 ! Adp31675 Human secreted protein SEQ ID #244

132: AACAA CAATGCCAGCAGAGAACCGACTGCC CCATC

354: GTGTT CAGCCACCGGCGAGACCGGGCTCC TTCTAT

546: GGGGG CATCAAGCTCAGGCCGAGCGGGCCGC GAGGA

582: GAGGG CATCCGGCTCTGCGCGTGCCGCCCAACC AGAAG

1,701: GAGCC CGGCCCTTGAGAGACCCCGTCTCAC GGAGT

1,989: CTGGA CGAGAACGTATCGACTCCCTGTGAGC TTCAA

2,069: GACAC CCTCAGCCCTCAAGTTTGCTACGACC GCCTC

ADP30504 ck: 7471 len: 1,107 ! Adp30504 Human secreted protein SEQ ID #127

56: TATTG CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
CTTCTTCTGGCAGACAGTTCAGCACTC GCCCA

ADP30509 ck: 723 len: 2,020 ! Adp30509 Human secreted protein SEQ ID #127

161: GCCCC CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{10}CxxxCxxxC  
CAGCCCCAGCGCTTCGGTCTCTCTTC CAAGA

1,087: CGGAA CxxCxxxCx{12}CxxxCxxxC  
CAACCCCTCATGTACAACCTCTGCTCTGC CCATC

1,531: AGCAG CxxCxxxCx{12}CxxxCxxxC  
CGCTTCTGGAGTGTAGCCCCGCTGCG TGCAG

1,586: CTTTC CxxCxxxCx{11}CxxxCxxxC  
CAGCGCGCAGGGGTGACGCCACACCC AGGTG

1,885: GCGAA CxxCxxxCx{10}CxxxCxxxC  
CTCCTGCGCATGTGCGCCGCGAGCC TCGCG

ADP30520 ck: 9327 len: 279 ! Adp30520 Human secreted protein SEQ ID #128

6: ATGCG CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{10}CxxxCxxxC  
CTGCTCGCGGAGGCTCTGGCTGGC GCTGG

ADP30541 ck: 9574 len: 729 ! Adp30541 Human secreted protein SEQ ID #130

166: TCCAT CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
CTGCCAGCCAGTTGTTGCTATCAGTC CAACC

ADP30577 ck: 3242 len: 1,179 ! Adp30577 Human secreted protein SEQ ID #134

193: CTCCC CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{10}CxxxCxxxC  
CTGCCCTCAAGTAACAAGCAGTCTCTGC ATGCA

ADP30591 ck: 7859 len: 1,587 ! Adp30591 Human secreted protein SEQ ID #135

1,089: GGTGA CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
CGCTCTCCCTGCTCTGAACACACGCGGCC GTCCC

1,094: CGCCT CxxCxxxCx{10}CxxxCxxxC  
CCCCTGCTCTGAACACACGCGCGTCC CTTTG

1,175: CATCT CxxCxxxCx{10}CxxxCxxxC  
CCCCCTCCATGCTCTGCGGGGTACC TGACG

1,179: TCCCC CxxCxxxCx{10}CxxxCxxxC  
CTCCATGCTCTGCGGGGTACTCTGAC GGGTG

1,365: TGGAT CxxCxxxCx{10}CxxxCxxxC  
CCACGAGCAGATGGAGAGCTGGCAGCC CCAGG

ADP30630 ck: 1138 len: 291 ! Adp30630 Human secreted protein SEQ ID #139

5: ATGA CXXCXXXCX{10,12}CXXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
CAACGCCCGCGCTTCACCCAAACCTCC TACAC

13: CGCCC CxxCxxxCx{10}CxxxCxxxC  
CGGCTTACCCAAACCTCTACACCC TGTTC

135: ACTCG CxxCxxxCx{11}CxxxCxxxC  
CTGTGCGCCCGCAGGACCCGACCTGC CCCTC

ADP30672 ck: 3506 len: 2,042 ! Adp30672 Human secreted protein SEQ ID #143

1 CXXCXXCXXC{10,12}CXXCXXCXXC  
932: TGAAC CCCGAGCAGAGAGCCACCCAGCCTGAC GGGCC  
1,083: CTCTC CGGCGCCTCTCATCATCACTCTGTCTTCC ATGTG  
ADP30679 ck: 9429 len: 821 ! Adp30679 Human secreted protein SEQ ID #144  
1 CXXCXXCXXC{10,12}CXXCXXCXXC  
CXXCXXCXXC{11}CXXCXXCXXC  
224: CGAAG CCTCCATCATGGGCCAGTTCGACCATCC CAACG  
661: GGCTG CCACCGCCATGGACTGGCCGAGCGCCC TGCAC  
662: GCTGC CACCGCCCATGGACTGGCCGAGCGCCC TGCAC  
ADP30705 ck: 3137 len: 6,465 ! Adp30705 Human secreted protein SEQ ID #147  
1 CXXCXXCXXC{10,12}CXXCXXCXXC  
CXXCXXCXXC{10}CXXCXXCXXC  
24: CTGCT CGTCTGGCTGCTCGTCTCCGGCTGCC CTGGC  
43: TGTCT CGGTGCTGCTGGGGTGGCGGCAGC TGGAC  
1,739: TAGTG CACCACATGGGAGATGACCAACCTTAAC GCATC  
3,670: TTCCC CAGCTGCGGCCACAACTCTCTCCAGCC CTATT  
6,355: ACCCA CCACCACCTGCTGTAAAGAGACTTACTGCC GTCAG  
ADP30730 ck: 5510 len: 420 ! Adp30730 Human secreted protein SEQ ID #149  
1 CXXCXXCXXC{10,12}CXXCXXCXXC  
CXXCXXCXXC{12}CXXCXXCXXC  
153: GTGAG CAACATCCACAACTCAACTCTGTCCACC AGTCG  
159: AACAT CCACAACCTCAACTCTGTCCACCAGTC GCCAC  
ADP30732 ck: 881 len: 1,339 ! Adp30732 Human secreted protein SEQ ID #149  
1 CXXCXXCXXC{10,12}CXXCXXCXXC  
CXXCXXCXXC{11}CXXCXXCXXC  
89: GACTA CCCCTGCTGTGAAGACGGGGCATCC TGATG  
1,136: AGTGG CACCGCCTGGCCCTCATCATCCACC GCTCC  
ADP30802 ck: 5842 len: 243 ! Adp30802 Human secreted protein SEQ ID #156  
1 CXXCXXCXXC{10,12}CXXCXXCXXC  
CXXCXXCXXC{11}CXXCXXCXXC  
139: ACGCT CACCAACGGGACCTGGCCACGGCTC CTGGC  
ADP30880 ck: 9773 len: 730 ! Adp30880 Human secreted protein SEQ ID #164  
1 CXXCXXCXXC{10,12}CXXCXXCXXC  
CXXCXXCXXC{11}CXXCXXCXXC  
112: GAGAG CGACCTGCAGTTCAACGGCGACCCCTC TGCAT

CXXCXXCXXC{12}CXXCXXCXXC  
475: ACCAT CTTCTCTCTTTCCGTGGGACCGCCCTGC TGGGC  
577: CTGGC CAAGCTGTGGGCTGTGTGGCTGC TTGGG  
ADP30889 ck: 2807 len: 1,933 ! Adp30889 Human secreted protein SEQ ID #165  
1 CXXCXXCXXC{10,12}CXXCXXCXXC  
CXXCXXCXXC{11}CXXCXXCXXC  
192: AGCAA CACCAGCCACAAGTCTACGGGCTCTC ACCGT  
207: AAGTC CTACCGGCTCTACCGTCTGACTTTC AGGAT  
243: ATTAA CTACTACTCTCGGAGGCTTCCACCC CGTGG  
385: GGCTG CACCTCGCCCGAGGGCTCCTGCTGGC CGCGC  
387: CTGCA CCTCGCCCGAGGCGTCCCTGCTGGC CGCGC  
ADP30910 ck: 8814 len: 2,700 ! Adp30910 Human secreted protein SEQ ID #167  
1 CXXCXXCXXC{10,12}CXXCXXCXXC  
CXXCXXCXXC{12}CXXCXXCXXC  
77: GCCCA CCCCTCATCCAGGTGCCCTGCCACC ACTTT  
95: AGGTG CCCCTGCACCACTTTGACCCCGTAC CTCAA  
375: GCCTC CTCCTGCTTCGGAGTCCACATCCCGGC GCTCT  
379: CCTCC CTGCTTCGGAGTCCACATCCCGCGCTC TGGGC  
580: TTGGG CATCGAAGCTGCCCTGCTGCCAGC CTGGC  
595: TGCCC CTGCTGCCAGCTCGCGGCAGCTGGC AGAGA  
1,158: CTGGC CTTCTTGCCCTGGCGGTGCCCGCCGGC GCCCC  
1,334: CTTGG CXXCXXCXXC{10}CXXCXXCXXC  
CTGCGGCTGGGGCTGGCTGCTGC TGCTG  
1,353: CTGGC CXXCXXCXXC{12}CXXCXXCXXC  
CTGCTGCTGCTGGCGCCCGCGCGCCGC CGCGG  
1,372: CCCGG CXXCXXCXXC{10}CXXCXXCXXC  
CGCGCGCGCGCGGTGCCACCGGC CTGGC  
1,375: GGCCG CXXCXXCXXC{12}CXXCXXCXXC  
CGCCCGCGGGTGGCCACCGGCTGGC TGGCG  
1,490: GCTCG CXXCXXCXXC{11}CXXCXXCXXC  
CCTCGCGGGCTGCACGCTTTCTGCG CGCTT  
1,738: AGGTG CXXCXXCXXC{12}CXXCXXCXXC  
CTGCACGCCCTGGGTACGGCGGCAATC CGGGC  
1,865: CTACC CXXCXXCXXC{11}CXXCXXCXXC  
CGGCGCTCTGCAGTCTCGGTGCCGC GCGCT  
CXXCXXCXXC{12}CXXCXXCXXC

1  
2,102: CGCGG CGGCCAACCCGGCCCCCGTCCCGGGTTCC TCTCC  
CxxCxxxCx{12}CxxxCxxx  
2,228: GCTTG CGCTGGCTCTTCCAGGGCCCTGCTTC GAGGA  
CxxCxxxCx{11}CxxxCxxx  
2,367: GAGCT CCCCTCCCTGGGGCTTGGCCCGAGGC AGCAG  
CxxCxxxCx{11}CxxxCxxx  
2,512: CCGCG CGGCCCTCAGGAAGCAGCCCCAGCCTCC CGGCC  
ADP30942 ck: 5326 len: 1,655 ! Adp30942 Human secreted protein SEQ ID #170  
1  
CXXCXXXCX{10,12}CXXCXXXC  
78: GCCT CACCTGGCAGACTCACCTGTGGCCCTC ATCTG  
CxxCxxxCx{11}CxxxCxxx  
173: CGTGC CACGAGCACCTGGGCTTGTGCTTGC CACCA  
CxxCxxxCx{12}CxxxCxxx  
207: ACCAT CATCTTCTGCTCTGAGACAAACAC CAGCC  
CxxCxxxCx{11}CxxxCxxx  
217: TCCTG CTCCTGACGACAAACACCCAGCCATC TTGAG  
CxxCxxxCx{10}CxxxCxxx  
1,410: GTCAT CACTTGGCAGCAGCACTCTCGGCATC GCCTG  
CxxCxxxCx{11}CxxxCxxx  
1,454: GTTTG CTGCTACCTGGGTGCTGCTCGCTAAC ATGTT  
CxxCxxxCx{12}CxxxCxxx  
1,509: TCCTG CTCCTGAGGACCAATACCCGGCCATC TACAA  
CxxCxxxCx{10}CxxxCxxx  
1,615: AAGGG CATCAATCATAAACAAGTATCAGGCCTAC GATGT  
ADP31000 ck: 4287 len: 930 ! Adp31000 Human secreted protein SEQ ID #176  
1  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
30: GGCTC CAGCGACCTCCTGGCCCCCAGCGATC AAGCT  
CxxCxxxCx{12}CxxxCxxx  
201: GACCT CTGCTCTGTGACCTTGGCTTGGTGC TGCAC  
CxxCxxxCx{11}CxxxCxxx  
248: AGACA CCTCAGACACGCGCTGTGCGAGCTTC CCAGG  
CxxCxxxCx{10}CxxxCxxx  
364: ACCCG CTGGTGCCCGGGGTGCGGTCCCC AGGCA  
CxxCxxxCx{10}CxxxCxxx  
372: CGTGC CCGGGCTGGGTCCCCAGGAGGC TCGGG  
CxxCxxxCx{10}CxxxCxxx  
644: CAAGG CTGCCGCAATGGTGTGGGCCAACCTCC TGGTG  
CxxCxxxCx{11}CxxxCxxx  
763: CGATC CGTGGGCCCTGTACATAACCAAGC TCTCA  
ADP31042 ck: 1520 len: 1,059 ! Adp31042 Human secreted protein SEQ ID #180  
1  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
741: CAGGA CTCGAGCTGAACGAGGTGCTCCAAAC AAGAA  
ADP31067 ck: 2601 len: 645 ! Adp31067 Human secreted protein SEQ ID #183

1  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
286: CACCA CAGCTCAGCTGGTGTGGCCATCATGC TGCAG  
CxxCxxxCx{12}CxxxCxxx  
397: ATTAC CACGAGCCTTGACACACCTGCTCCCTC CAAGC  
ADP31118 ck: 7832 len: 5,820 ! Adp31118 Human secreted protein SEQ ID #188  
1  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
116: TATGC CTTATGCTCGGAGGGCCAAACAGAC CTCCT  
CxxCxxxCx{10}CxxxCxxx  
294: GGGCT CACTTCCAGCTCTTGGACCCCTC TGGCC  
CxxCxxxCx{11}CxxxCxxx  
297: CTCAC CTTCCAGCTCTTGGCACCCTCTGGC CTCCG  
CxxCxxxCx{10}CxxxCxxx  
2,334: GTCAC CATCTGCTGTCAATGGCAACCCG GACCT  
CxxCxxxCx{12}CxxxCxxx  
2,356: GCGAA CCCCAGCTCATACAACTCAGGCTGC AGAGG  
CxxCxxxCx{11}CxxxCxxx  
2,357: CCAAC CCCCAGCTCATACAACTCAGGCTGC AGAGG  
CxxCxxxCx{12}CxxxCxxx  
2,756: CAGGA CCACTGTCACTGCTTCTACACTCTCTC TCAAC  
CxxCxxxCx{11}CxxxCxxx  
2,964: GGTCT CCCCAGACAGACTCACCCCACTCTC TGGGG  
CxxCxxxCx{12}CxxxCxxx  
3,343: TCTCA CTTCTCCACTCTCTTCTACACTCTCTC TCAAC  
CxxCxxxCx{10}CxxxCxxx  
3,346: GACCT CTTCACCTCTCTTCTACACTCTCTC AACGA  
CxxCxxxCx{10}CxxxCxxx  
3,520: GGGGC CATCCGCGCGGGCGGCCCATC CGGAA  
CxxCxxxCx{10}CxxxCxxx  
3,645: CCAGC CACCCGCGACCGGCTACAGCCGCC CGGGG  
CxxCxxxCx{11}CxxxCxxx  
5,519: GACAG CGGCTCCGACGGGCTCAGCTTCGCGGC CCCTC  
CxxCxxxCx{10}CxxxCxxx  
5,526: GCTCC CGAGGGCTCACCCTCCGCGCCCTCC CGCCA  
ADP31152 ck: 2801 len: 771 ! Adp31152 Human secreted protein SEQ ID #191  
1  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
34: TCCGG CTTCTCGCGCGCGCTTGGCGGC TTGGC  
CxxCxxxCx{11}CxxxCxxx  
336: ACCTG CTCCTTCCAGACCGGCCACCGCGTAC ACCAC  
CxxCxxxCx{10}CxxxCxxx  
653: TCCTC CGACCATCAGGAGTGACCGGCC GCACC  
ADP31355 ck: 6338 len: 346 ! Adp31355 Human secreted protein SEQ ID #212  
1  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
138: CTCCA CAGCGGCTTGTGTGCTTGGCACGTGC TGGGT





197: ATGCA CGACACCGGGGGCGCAGTCCCCCATAC CAGCT  
CxxCxxxCx{11}CxxxCxxx  
434: ACCTG CAACAGCGGAACGGAAACCGGGCCCC RAGAT  
CxxCxxxCx{11}CxxxCxxx  
613: GGCGG CCACGGCGCTGACAGCCCACTTC CACCT  
CxxCxxxCx{12}CxxxCxxx  
616: CGCCA CGGCGCGCTGGACAGCCCACTTCACCC TCACC  
CxxCxxxCx{10}CxxxCxxx  
637: CCCAC CTTCACCTACCCCTGCATATCCAC GGAGC  
ADP30720 ck: 9178 len: 659 | Adp30720 Human secreted protein SEQ ID #148  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
188: CCCTG CACGAGCTGTGCCCCGGGCGCGAGC CGGGC  
CxxCxxxCx{10}CxxxCxxx  
502: AGCGG CCCGGCCCAAGCCAGGCGGACTCGC TCACT  
ADP30770 ck: 8882 len: 780 | Adp30770 Human secreted protein SEQ ID #153  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
532: GCTGG CTGCTGCTTCTCTCTACCTTCATGC CCGAG  
CxxCxxxCx{12}CxxxCxxx  
738: TCTTC CTGCTACGTTGGCAGCAGCATCTCTAC TGCAT  
ADP30795 ck: 6255 len: 198 | Adp30795 Human secreted protein SEQ ID #156  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
58: CGCGG CCAGGCGGTGGACCCCACTCGGCCC GGCTC  
CxxCxxxCx{12}CxxxCxxx  
129: CTTTC CCCTGGCGCGGGCCCTCGCAGTC GCCGG  
CxxCxxxCx{10}CxxxCxxx  
139: GGCGG CGGCGGCCCTCGCAGTCGCCGGC CTCCG  
ADP30803 ck: 6543 len: 615 | Adp30803 Human secreted protein SEQ ID #157  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
316: TGTGT CACCCTCCCTAGGTGGCTTCAGCAGTC TCAAG  
CxxCxxxCx{10}CxxxCxxx  
318: TGTCA CCACTCCCTAGGTGGCTTCAGCAGTC TCAAG  
CxxCxxxCx{10}CxxxCxxx  
333: GGTGG CTTCAGCAGTCTGAGGCTTCTCAC ACACC  
CxxCxxxCx{10}CxxxCxxx  
337: GCTTC CAGCAGTCTCAAGGCTTCTCACAC CAGCA  
CxxCxxxCx{12}CxxxCxxx  
523: GCCAT CCCTGTCTCCGAGGAGCCGCTCCC TGGCG  
CxxCxxxCx{10}CxxxCxxx  
543: GGAAG CGGCTCCCTCGGGTCTCTGCTTCC ACCCG  
ADP30812 ck: 4081 len: 243 | Adp30812 Human secreted protein SEQ ID #157  
CXXCXXXCX{10,12}CXXCXXXC

5: ATGG CTTCGGCTCCCTGTGGCCCAAGCC CCCGT  
CxxCxxxCx{10}CxxxCxxx  
CxxCxxxCx{12}CxxxCxxx  
176: CCCAC CAACTGCTGGCTCTGTGGGCGCCTACC GCCAG  
ADP30897 ck: 1091 len: 779 | Adp30897 Human secreted protein SEQ ID #166  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
534: AAAAT CGACGCCACACTGGGGCTCTTACAATC AGGGG  
CxxCxxxCx{10}CxxxCxxx  
710: TACTC CTACTTCCACTTCGTCTTCTCTAGC TTCCC  
ADP30899 ck: 8711 len: 1,434 | Adp30899 Human secreted protein SEQ ID #166  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
74: TGTGG CTGCCATCTGGCGCGCGGAGACTCCC GAGAA  
ADP30905 ck: 8711 len: 1,434 | Adp30905 Human secreted protein SEQ ID #167  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
74: TGTGG CTGCCATCTGGCGCGCGGAGACTCCC GAGAA  
ADP30949 ck: 7913 len: 930 | Adp30949 Human secreted protein SEQ ID #171  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
368: CACCA CCAGGCCATCTGTGGCTGCGCTGGCCAGC CCCAG  
865: AGGAG CTACCCCTGGCAGACCCCTCCCCCGTCTTGCA  
CxxCxxxCx{11}CxxxCxxx  
868: AGCTA CCCCCTGGCAGACCCCTCCCCCGTCTTGC ACTGC  
CxxCxxxCx{12}CxxxCxxx  
869: GCTAC CCGCTGCCACACCTCCCCCGTCTTGC ACTGC  
CxxCxxxCx{11}CxxxCxxx  
881: CACAC CTTCCCCCGTCTTGCACTGCGCTGCTCAC CACAA  
CxxCxxxCx{12}CxxxCxxx  
882: ACACC CTCGCCCGTCTTGCACTGCGTCTCAC CACAA  
CxxCxxxCx{11}CxxxCxxx  
898: TTGCA CTGCTGCTCACCACAATGCCACCCGCC TCTAG  
ADP30998 ck: 4521 len: 1,041 | Adp30998 Human secreted protein SEQ ID #176  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
752: GCTGG CTGCTGCTTCTCTCTACCTTCATGC CCGAG  
CxxCxxxCx{12}CxxxCxxx  
958: TCTTC CTGCTCAGGTGGGAGCAGCATCTCTAC TGCAT  
ADP31078 ck: 5263 len: 573 | Adp31078 Human secreted protein SEQ ID #184  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
196: TGTGT CATCCCCCTCTCTCTTCTCTCTCTC CTGAG  
CxxCxxxCx{10}CxxxCxxx

514: GATGG CGTCTGCAACCTGGGACGACCC ACCAC

CxxCxxxCx{12}CxxxCxxxC

518: GCGTC CTGCAACCTGGGACGACCCACCAC ACC CTTCC

CxxCxxxCx{11}CxxxCxxxC

533: GGGAC CGACCCCAACCACTCTCCCGGCTCC TGACC

CxxCxxxCx{12}CxxxCxxxC

536: ACCGA CCCCCACCACTCTCCCGGCTCTGAC CTTTC

ADP31087 ck: 3134 len: 621 ! Adp31087 Human secreted protein SEQ ID #189

CXXCXXXCX{10,12}CXXXCXXXC

CxxCxxxCx{10}CxxxCxxxC

267: TACAA CATCAACGAGGCGCTTCCAGCCACC GCATG

ADP31138 ck: 330 len: 1,350 ! Adp31138 Human secreted protein SEQ ID #190

CXXCXXXCX{10,12}CXXXCXXXC

CxxCxxxCx{12}CxxxCxxxC

342: TTGGA CAGCGAGCGCTGTGCAAGGCATCCACC AGCTG

CxxCxxxCx{11}CxxxCxxxC

1,266: TTCAT CACGGGAGAGAGAGGGCCCCACAGCC TTCAG

ADP31139 ck: 5154 len: 1,560 ! Adp31139 Human secreted protein SEQ ID #190

CXXCXXXCX{10,12}CXXXCXXXC

CxxCxxxCx{10}CxxxCxxxC

200: TGTGG CTGCCATCTGGGCGCGCGAGACTCCC GAGAA

ADP31277 ck: 430 len: 702 ! Adp31277 Human secreted protein SEQ ID #204

CXXCXXXCX{10,12}CXXXCXXXC

CxxCxxxCx{12}CxxxCxxxC

387: ACCTT CCTAACCCCTCTCCCAAGTCGTCCCCAC TGGCA

CxxCxxxCx{10}CxxxCxxxC

393: CTCGA CCCCCTCCCAAGTCGTCCCCACTGCG ATTAG

CxxCxxxCx{12}CxxxCxxxC

478: AGCGG CAGCGACCTCCAGAGCTGGCTTCCCTCC CGCGC

CxxCxxxCx{10}CxxxCxxxC

503: CCTCC CTCCCCGCTCGGTTCCCGGACCGGC TGCAG

ADP31299 ck: 3827 len: 2,833 ! Adp31299 Human secreted protein SEQ ID #206

CXXCXXXCX{10,12}CXXXCXXXC

CxxCxxxCx{11}CxxxCxxxC

822: AGCCA CAATCTCAGGTCCAGATCACCCCTC TACCA

CxxCxxxCx{12}CxxxCxxxC

966: AAGTT CTCAGGCGCTGTGCACTAGCCAGC GGGCA

CxxCxxxCx{11}CxxxCxxxC

1,300: GTGAA CATCTGCTGGCCCCCACACAGCGCTGC TACTG

ADP31408 ck: 8569 len: 1,749 ! Adp31408 Human secreted protein SEQ ID #217

CXXCXXXCX{10,12}CXXXCXXXC

CxxCxxxCx{10}CxxxCxxxC

23: CTCTC CTGCGGCGCTGGCGCTCCCTGCAACC TGCCC

CxxCxxxCx{10}CxxxCxxxC

27: CTGCG CGGCTGCGCTCCCTGCAACCTGCC CAGCC

34: GCCTG CxxCxxxCx{11}CxxxCxxxC  
CGCTCCCTGCACCTTGCAGGCCTC GGCAC

45: CCCTG CxxCxxxCx{11}CxxxCxxxC  
CACCTGCCAGCCTCGGCACCAAC TCAGC

732: AACTA CxxCxxxCx{11}CxxxCxxxC  
CTCTTCAGTTTTTTGTCCCTGCTGAC CAAGC

ADP31410 ck: 450 len: 717 ! Adp31410 Human secreted protein SEQ ID #217:

CXXCXXXCX{10,12}CXXXCXXXC

236: TTTAG CxxCxxxCx{10}CxxxCxxxC  
CTACTGCCCGTGTCCCCCGGCCAAC CGGCC

CxxCxxxCx{11}CxxxCxxxC

243: ACTGG CxxCxxxCx{11}CxxxCxxxC  
CCCCGTGCCCGGCCCAACCGGCGGCC CTTAC

CxxCxxxCx{11}CxxxCxxxC

295: CGACT CxxCxxxCx{11}CxxxCxxxC  
CCGCTTCGCTCGGCGCGGCCCTTCC GCTGC

CxxCxxxCx{10}CxxxCxxxC

309: CTCGG CxxCxxxCx{10}CxxxCxxxC  
CCGGCGCCTTCCGCTGCGACCCGC GCGCG

CxxCxxxCx{11}CxxxCxxxC

314: CCGCG CxxCxxxCx{11}CxxxCxxxC  
GGCCTTCGCTCGGACCGGCGGCC GCGCG

CxxCxxxCx{11}CxxxCxxxC

324: TCCCG CxxCxxxCx{11}CxxxCxxxC  
CTGCGCAGCGCGCGCGCGCGCTC TCGCA

CxxCxxxCx{11}CxxxCxxxC

328: GCTGC CxxCxxxCx{11}CxxxCxxxC  
CGACCGCGCGCGCGCGCTCTCGC AGCAC

CxxCxxxCx{12}CxxxCxxxC

340: CCGCG CxxCxxxCx{12}CxxxCxxxC  
CGCGCGCGCTCTCGACACCGACCGCC GCGCG

CxxCxxxCx{10}CxxxCxxxC

469: GCGGG CxxCxxxCx{10}CxxxCxxxC  
CTCTCTTAGCCAGACCCCGCCCCC CGGCA

CxxCxxxCx{10}CxxxCxxxC

473: GCCTC CxxCxxxCx{10}CxxxCxxxC  
CTTCTAGCCAGACCCCGCCCCCGGC ACGCG

CxxCxxxCx{12}CxxxCxxxC

485: CCAGA CxxCxxxCx{12}CxxxCxxxC  
CCCCGCCCGCGCACGCTTCTTAAC GGCTG

CxxCxxxCx{10}CxxxCxxxC

487: AGACC CxxCxxxCx{10}CxxxCxxxC  
CGGCGCGCGCACCGCTTCTTAAC GGCTG

CxxCxxxCx{10}CxxxCxxxC

533: GCACA CxxCxxxCx{10}CxxxCxxxC  
CGGCACGGGAGCGGGGCTTCCAGCC CCAAT

CxxCxxxCx{11}CxxxCxxxC

551: CGGGG CxxCxxxCx{11}CxxxCxxxC  
CTTCAGGCCCAATAGTGACGCGCTC TGCCCT

CxxCxxxCx{10}CxxxCxxxC

552: GGGGC CxxCxxxCx{10}CxxxCxxxC  
CTCCAGCCCCAATAGTGACGCGCTC TGCCCT

ADP31428 ck: 3911 len: 741 ! Adp31428 Human secreted protein SEQ ID #219:

CXXCXXXCX{10,12}CXXXCXXXC

CxxCxxxCx{10}CxxxCxxxC

356: ACAGG CxxCxxxCx{10}CxxxCxxxC  
CAGCTCTAGCTTGGACACCAACCCCTC AGGGA

CxxCxxxCx{10}CxxxCxxxC

372: TTGGA CxxCxxxCx{10}CxxxCxxxC  
CACCAACCCCTCAGGAGCCTTTCTGCTC CTTCC

CxxCxxxCx{11}CxxxCxxxC

375: GACAC CxxCxxxCx{11}CxxxCxxxC  
CACCCCTCAGGAGCCTTTCTGCTTCC CCCAC

CxxCxxxCx{11}CxxxCxxxC

681:	CCAGG	CCCAGCAGCATCCCTACCACACTGTGCCAC	CACAC	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx	449:	CATGA	CTCGTCCAGGGCTCTGGCGGCAGCC	CCAGG	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx
693:	CATCC	CTACCACCTGTCCACACACACCCGAGC	TGCC	CxxCxxxCx{12}CxxxCxxx	468:	CTGGC	CGGAGCCCCAGGCTGGGCTCTCCAGGC	CAACT	CxxCxxxCx{12}CxxxCxxx
697:	CCTAC	CACCTGTCCACACACACCCGAGCTGCC	CACAT	CxxCxxxCx{10}CxxxCxxx	474:	GGCAG	CCCCAGCTGGGCTCTCCAGGCGAAC	TTCAC	CxxCxxxCx{10}CxxxCxxx
ADP31482	ck: 8375	len: 1,065	! Adp31482 Human secreted protein SEQ ID #224	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxx	723:	CTTTC	CTTCTGACCAAGGAGGGGAGCCCATC	ACCCA	CxxCxxxCx{11}CxxxCxxx
514:	GTGAC	CTGCTGTCTTCAGGCCCAACATGCATC	CCTTA	CxxCxxxCx{10}CxxxCxxx	851:	TGCTA	CAGCTCAGCAGATTCTTCCCTACCTGC	TGTCT	CxxCxxxCx{12}CxxxCxxx
ADP31483	ck: 4020	len: 267	! Adp31483 Human secreted protein SEQ ID #225	CxxCxxxCx{10}CxxxCxxx	ADP30502	ck: 4227	len: 1,167	! Adp30502 Human secreted protein SEQ ID #126	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx
147:	GTGAC	CCTTCCCAACCCCTGGACTTCACAC	ATGGA	CxxCxxxCx{10}CxxxCxxx	81:	GGGGC	CTCCGGCTCTGGCGGCTTCTCTGGC	CTGGA	CxxCxxxCx{10}CxxxCxxx
ADP31555	ck: 3018	len: 1,911	! Adp31555 Human secreted protein SEQ ID #232	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx	426:	AGCGC	CCACCGTCGGATGCTGACGCCGCCTTC	CATTT	CxxCxxxCx{11}CxxxCxxx
468:	ATCAC	CTCCAGCGCTGCCATATGCTCTCTGAC	CATCT	CxxCxxxCx{10}CxxxCxxx	1,021:	GGTTG	CATCCCCCTGTTCCGTACACCTCCCGCC	ACCGC	CxxCxxxCx{11}CxxxCxxx
685:	CCCTG	CTCCACACCCACATGCTCCAGGCCAC	CCCTG	CxxCxxxCx{11}CxxxCxxx	ADP30562	ck: 8514	len: 1,803	! Adp30562 Human secreted protein SEQ ID #132	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx
687:	CTGCT	CCACACCCACATGCTCCAGCCACC	CCTGG	CxxCxxxCx{10}CxxxCxxx	1,485:	GGGCC	CAGCAGGAGTGACAGCCGCTTGC	GGGAG	CxxCxxxCx{10}CxxxCxxx
705:	GCTCC	CAGCCACCCCTGGGCATCCAGGCCCCC	AGACA	CxxCxxxCx{12}CxxxCxxx	1,742:	AGGAA	CCCCGCCATGCTGTGCTCCCTCCCCC	CATTC	CxxCxxxCx{10}CxxxCxxx
730:	CAGGC	CCCAGACATGTGGCGCCCGAGGCC	TCCAC	CxxCxxxCx{11}CxxxCxxx	1,746:	ACCCC	CGCATGTGTGTCTCCCTCCCCCATTC	CCCGA	CxxCxxxCx{11}CxxxCxxx
766:	ACGGT	CCCGACCAAGTGCTCAGCTCTCACTC	CTGGG	CxxCxxxCx{12}CxxxCxxx	ADP30568	ck: 4280	len: 276	! Adp30568 Human secreted protein SEQ ID #133	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxx
1,128:	GGGGC	CTAGCGCAGCTGGTGTCCAGACCTGC	GACAT	CxxCxxxCx{11}CxxxCxxx	103:	TTCCT	CCCCGGCAGAGAAATCACCGTTCCAGC	TGATG	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx
ADP31581	ck: 5133	len: 816	! Adp31581 Human secreted protein SEQ ID #234	CxxCxxxCx{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxx	ADP30583	ck: 5578	len: 171	! Adp30583 Human secreted protein SEQ ID #135	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx
558:	AACTT	CCCAATCTAGCAGGCGCCACATTC	AAATT	CxxCxxxCx{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx	84:	AAGCT	CAACATCCCCAAAGTGTGCTGCCCTTC	ACGGC	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx
ADP31627	ck: 2048	len: 1,404	! Adp31627 Human secreted protein SEQ ID #239	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx	ADP30602	ck: 7553	len: 171	! Adp30602 Human secreted protein SEQ ID #136	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx
792:	GAGGC	CGCGCGGCTCCAGCCCACTGTCAATCC	GGGGC	CxxCxxxCx{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx	137:	CTGGA	CGCGAGCAACAGAAATCACCATACGCTC	GTGCT	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx
1,161:	TCTGT	CAGCTTCTCTCAGGTACCGCCACC	ACTGT	CxxCxxxCx{10}CxxxCxxx	ADP30618	ck: 6416	len: 153	! Adp30618 Human secreted protein SEQ ID #138	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx
1,287:	CAGTG	CTCCCAACACAGTCAGAACAGACTCGC	TGGGG	CxxCxxxCx{11}CxxxCxxx	64:	TATCC	CAGCCACTGCAGAGTCAAGGTCAAGC	TCATC	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx
1,288:	AGTGC	CTCCCAACACAGTCAGAACAGACTCGC	TGGGG	CxxCxxxCx{10}CxxxCxxx	ADP30663	ck: 6011	len: 843	! Adp30663 Human secreted protein SEQ ID #143	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx

1	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx 78: GGGCC CAGCCACTAGCGAGGCTCGCCAGAC AGAT	ADP30689	ck: 5223	len: 1,968	! Adp30689 Human secreted protein SEQ ID #145	877: GCATC CAACAAGTCTCTTCTTCAACTCTTTC TGCCT	CxxCxxxCx{12}CxxxCxxx	ADP30926	ck: 4100	len: 922	! Adp30926 Human secreted protein SEQ ID #169:
1	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx 303: ACGCT CTCCCTGATGTCTATCCAGGCCACC TGTGA	ADP30735	ck: 8711	len: 1,434	! Adp30735 Human secreted protein SEQ ID #150	11: CCGCG CTCCGCCCCCGCGCTCTCTTCTGCGCCTCC	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx	ADP30926	ck: 4100	len: 922	! Adp30926 Human secreted protein SEQ ID #169:
1	CxxCxxxCx{12}CxxxCxxx 756: GGCCT CATCACTAGTTCCACTTTACGAGCTGGC CAGAC	ADP30735	ck: 8711	len: 1,434	! Adp30735 Human secreted protein SEQ ID #150	13: CCGCT CGGCCCGCGCGCTCTCTTCTGCGCCTC CGAGG	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxx	ADP30926	ck: 4100	len: 922	! Adp30926 Human secreted protein SEQ ID #169:
1	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx 74: TGTGG CTGCCATCTGGGGCGCGCAGACTCCC GAGAA	ADP30785	ck: 246	len: 186	! Adp30785 Human secreted protein SEQ ID #155	14: CGCTC CGCCCCCGCGCTCTCTTCTGCGCCTC CGAGG	CxxCxxxCx{11}CxxxCxxx	ADP30926	ck: 4100	len: 922	! Adp30926 Human secreted protein SEQ ID #169:
1	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxx 140: GCGGA CACCCGCCATGGAGCATCTCCGCCCGC AGCC	ADP30785	ck: 246	len: 186	! Adp30785 Human secreted protein SEQ ID #155	177: ATCAG CGCGAGCTGGAGCGCGCGCGCACAGGC ACTCG	CxxCxxxCx{12}CxxxCxxx	ADP30926	ck: 4100	len: 922	! Adp30926 Human secreted protein SEQ ID #169:
1	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxx 689: ATCAT CTCTGTCTATCCCTTTCCAGCTCCC CTGGC	ADP30856	ck: 6986	len: 750	! Adp30856 Human secreted protein SEQ ID #162	194: CGGGC CGCGCACAGGCACTCGGCCAACGGC GCCGC	CxxCxxxCx{10}CxxxCxxx	ADP30929	ck: 9283	len: 1,142	! Adp30929 Human secreted protein SEQ ID #169:
1	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx 192: AGCAA CACCAGCCACAGTCTTACCGGCTCTC ACGT	ADP30902	ck: 2807	len: 1,933	! Adp30902 Human secreted protein SEQ ID #168	400: GGGTT CACCAGCGGTGACGAGGCCCATCCGCC TCTTC	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx	ADP30953	ck: 7719	len: 2,141	! Adp30953 Human secreted protein SEQ ID #172:
1	CxxCxxxCx{12}CxxxCxxx 207: AAGTC CTACGGGCTCTACCGTCTGACTTTC AGGAT	ADP30902	ck: 2807	len: 1,933	! Adp30902 Human secreted protein SEQ ID #168	ADP30929	ck: 9283	len: 1,142	! Adp30929 Human secreted protein SEQ ID #169:		
1	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx 192: AGCAA CACCAGCCACAGTCTTACCGGCTCTC ACGT	ADP30902	ck: 2807	len: 1,933	! Adp30902 Human secreted protein SEQ ID #168	157: CTCAT CAACCCACTATTGGTCTCTACCCAGC AATGG	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx	ADP30953	ck: 7719	len: 2,141	! Adp30953 Human secreted protein SEQ ID #172:
1	CxxCxxxCx{12}CxxxCxxx 207: AAGTC CTACGGGCTCTACCGTCTGACTTTC AGGAT	ADP30902	ck: 2807	len: 1,933	! Adp30902 Human secreted protein SEQ ID #168	ADP30929	ck: 9283	len: 1,142	! Adp30929 Human secreted protein SEQ ID #169:		
1	CxxCxxxCx{11}CxxxCxxx 243: ATTAA CTACTACCTCTCGGAGGCTTCCACC CGTGG	ADP30902	ck: 2807	len: 1,933	! Adp30902 Human secreted protein SEQ ID #168	367: TCATG CAGCTTCGGCAGGCTTGGCTAGCCCC TCCTG	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx	ADP30953	ck: 7719	len: 2,141	! Adp30953 Human secreted protein SEQ ID #172:
1	CxxCxxxCx{12}CxxxCxxx 385: GGCTG CACCTGCCCCCAGGGCGTCTCTGCTGGC CGCGC	ADP30902	ck: 2807	len: 1,933	! Adp30902 Human secreted protein SEQ ID #168	2,106: CCCTC CAACCCGAGGCTGTCCCCGACAGCC CTGTT	CxxCxxxCx{11}CxxxCxxx	ADP30953	ck: 7719	len: 2,141	! Adp30953 Human secreted protein SEQ ID #172:
1	CxxCxxxCx{10}CxxxCxxx 387: CTGCA CCTGCCCCCAGGGCGTCTCTGCTGGC CGCGC	ADP30902	ck: 2807	len: 1,933	! Adp30902 Human secreted protein SEQ ID #168	ADP31088	ck: 8726	len: 2,091	! Adp31088 Human secreted protein SEQ ID #185:		
1	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx 74: TGTGG CTGCCATCTGGCGCGCGCAGACTCCC GAGAA	ADP30903	ck: 8711	len: 1,434	! Adp30903 Human secreted protein SEQ ID #167	1,061: TCATT CTTCCTCCCTGAGCACAACAGAGCCAC TGACC	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxx	ADP31088	ck: 8726	len: 2,091	! Adp31088 Human secreted protein SEQ ID #185:
1	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx 66: GGGAG CAGCGAGCTCAGGAGTTCTGCCCCAC CATCC	ADP30922	ck: 9820	len: 1,170	! Adp30922 Human secreted protein SEQ ID #168	1,077: GAGCA CAACAGACCCACTGACCATCAACCTCC ATCCT	CxxCxxxCx{11}CxxxCxxx	ADP31119	ck: 5185	len: 8,973	! Adp31119 Human secreted protein SEQ ID #188:
1	CxxCxxxCx{11}CxxxCxxx 96: ACCAT CCTCAGAGCTGGATTCGGGCGCTGC ACCTC	ADP30922	ck: 9820	len: 1,170	! Adp30922 Human secreted protein SEQ ID #168	1,632: AAAGA CTGCTTACAGAGAGGAGCTGCTCC TGTGA	CxxCxxxCx{11}CxxxCxxx	ADP31119	ck: 5185	len: 8,973	! Adp31119 Human secreted protein SEQ ID #188:
1	CxxCxxxCx{11}CxxxCxxx 233: CCTGG CTCTCTCTGGGAGTCTCTGCTCTGCC CTGCA	ADP30922	ck: 9820	len: 1,170	! Adp30922 Human secreted protein SEQ ID #168	ADP31119	ck: 5185	len: 8,973	! Adp31119 Human secreted protein SEQ ID #188:		
1	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx 66: GGGAG CAGCGAGCTCAGGAGTTCTGCCCCAC CATCC	ADP30922	ck: 9820	len: 1,170	! Adp30922 Human secreted protein SEQ ID #168	116: TATGC CCTCATGCTCGGAGGGCCCAACAGAC CTCCT	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxx	ADP31119	ck: 5185	len: 8,973	! Adp31119 Human secreted protein SEQ ID #188:
1	CxxCxxxCx{11}CxxxCxxx 96: ACCAT CCTCAGAGCTGGATTCGGGCGCTGC ACCTC	ADP30922	ck: 9820	len: 1,170	! Adp30922 Human secreted protein SEQ ID #168	294: GGCCT CACCTTCAGTCTCTTGGCACCCCTC TGCC	CxxCxxxCx{10}CxxxCxxx	ADP31119	ck: 5185	len: 8,973	! Adp31119 Human secreted protein SEQ ID #188:
1	CxxCxxxCx{11}CxxxCxxx 233: CCTGG CTCTCTCTGGGAGTCTCTGCTCTGCC CTGCA	ADP30922	ck: 9820	len: 1,170	! Adp30922 Human secreted protein SEQ ID #168	297: CTCAC CTTCAGCTCTTGCAACCCCTCTGGC CTCCC	CxxCxxxCx{11}CxxxCxxx	ADP31119	ck: 5185	len: 8,973	! Adp31119 Human secreted protein SEQ ID #188:
1	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxx 66: GGGAG CAGCGAGCTCAGGAGTTCTGCCCCAC CATCC	ADP30922	ck: 9820	len: 1,170	! Adp30922 Human secreted protein SEQ ID #168	2,334: GTCAC CATCTGCTGTCAATGGCAACCCCC GACCT	CxxCxxxCx{10}CxxxCxxx	ADP31119	ck: 5185	len: 8,973	! Adp31119 Human secreted protein SEQ ID #188:
1	CxxCxxxCx{11}CxxxCxxx 96: ACCAT CCTCAGAGCTGGATTCGGGCGCTGC ACCTC	ADP30922	ck: 9820	len: 1,170	! Adp30922 Human secreted protein SEQ ID #168		CxxCxxxCx{12}CxxxCxxx	ADP31119	ck: 5185	len: 8,973	! Adp31119 Human secreted protein SEQ ID #188:
1	CxxCxxxCx{11}CxxxCxxx 233: CCTGG CTCTCTCTGGGAGTCTCTGCTCTGCC CTGCA	ADP30922	ck: 9820	len: 1,170	! Adp30922 Human secreted protein SEQ ID #168			ADP31119	ck: 5185	len: 8,973	! Adp31119 Human secreted protein SEQ ID #188:

2,356: GCCAA CCCCGACCTCATATAAAACTCAGGCCTGC AGAGG  
CxxCxxxCx{11}CxxxCxxxC  
2,357: CCAAC CCCGACCTCATACAAACTCAGGCCTGC AGAGG  
CxxCxxxCx{12}CxxxCxxxC  
2,510: CCACT CAGCAGCAGAGCCTCAGAGCCAGGC ACCGA  
CxxCxxxCx{10}CxxxCxxxC  
2,577: CGGG CCTCCAGTGGCGGCTCTTCCAGC CCAGC  
CxxCxxxCx{11}CxxxCxxxC  
3,022: GGCT CCCAACAACAGACTCACCCCACTCTC TGGG  
CxxCxxxCx{11}CxxxCxxxC  
3,364: TCTCA CTTCTCCACCTCTTACACTCTCTC TCAAC  
CxxCxxxCx{10}CxxxCxxxC  
3,367: CACCT CTTCCAGCTCTTACACTCTCTC AACGA  
CxxCxxxCx{10}CxxxCxxxC  
3,541: GGGG CATCCGCGCGGGCGGCCCCCATC CGAA  
CxxCxxxCx{10}CxxxCxxxC  
3,666: CCAGC CACCCGCGCAGCGCTACAAGCGCC CGGG  
CxxCxxxCx{11}CxxxCxxxC  
5,759: CAGTT CGCCCTCTTCACTGCCCCCCCCAC TACCT  
CxxCxxxCx{11}CxxxCxxxC  
5,995: TCCTT CTCTGGCAGCGCCAGCTGACACC TCCTG  
CxxCxxxCx{11}CxxxCxxxC  
6,123: GACTC CGTCCCCCAGACACACTTCTGACTGTC TCAGA  
CxxCxxxCx{11}CxxxCxxxC  
6,333: AATGG CCGCAGACTCTCCAGCTCTGACCCCC AATA  
CxxCxxxCx{12}CxxxCxxxC  
7,088: CATGC CTTATGCTGGGAGGGGCCAAGAC CTCCT  
CxxCxxxCx{10}CxxxCxxxC  
7,266: GGCTT CGCTTCAGCTCTTGGACCCCTC TGCC  
CxxCxxxCx{11}CxxxCxxxC  
7,269: CTGCG CTTCCAGCTCTTGGCACCCTCTGGC CTCCC  
CxxCxxxCx{11}CxxxCxxxC  
8,673: CACTA CCACCTCAGCTCCGCAACCCCTGGC CTTCT  
CxxCxxxCx{12}CxxxCxxxC  
ADP31148 ck: 173 len: 3,390 | Adp31148 Human secreted protein SEQ ID #191  
1  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
909: ATCAC CACGATCCACAGAAATACAACTACC ATCAG  
CxxCxxxCx{12}CxxxCxxxC  
3,335: TGCTT CTATGCTCAAAACCACTCCAAGCCATC TCCAG  
CxxCxxxCx{10,12}CXXCXXXC  
ADP31202 ck: 5275 len: 1,116 | Adp31202 Human secreted protein SEQ ID #196  
1  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxxC  
123: CCACT CCCTACCGTGCACCAATATCATC ATCAC  
CxxCxxxCx{11}CxxxCxxxC  
ADP31204 ck: 5371 len: 345 | Adp31204 Human secreted protein SEQ ID #197  
1  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
52: GGAAC CTTACGCCACCTGGGCGCCCTCACCC TGACA  
CxxCxxxCx{12}CxxxCxxxC

1  
55: AACTT CAGCCACCTGGGCGCCCTCACCTGAC ACCTT  
CxxCxxxCx{12}CxxxCxxxC  
ADP31261 ck: 2841 len: 799 | Adp31261 Human secreted protein SEQ ID #202  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxxC  
149: CCGG CCGCCCCCGGGGACACTCTCTCGC CGCCA  
CxxCxxxCx{11}CxxxCxxxC  
196: AAACA CTTTACTCTCTCGAGGCTCCCGGC TCCGG  
CxxCxxxCx{10,12}CXXCXXXC  
ADP31290 ck: 1374 len: 1,470 | Adp31290 Human secreted protein SEQ ID #205  
1  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxxC  
430: AGGAG CAGCCGCGCGCGCGCGCACCGC CGCG  
CxxCxxxCx{11}CxxxCxxxC  
433: AGGAG CCGCGCGCGCGCGCACCGCGGCC GCTGG  
CxxCxxxCx{10}CxxxCxxxC  
518: CGCTT CGCGCGCGCGCGCGCGCGGCC CGGGC  
CxxCxxxCx{10}CxxxCxxxC  
527: GCCCC CGCGCGCGCGCGCGCGCGGCC CGGGC  
CxxCxxxCx{10}CxxxCxxxC  
536: CGCCC CGCGCGCGCGCGCGCGCGGCC CGCGC  
CxxCxxxCx{11}CxxxCxxxC  
542: GGCGG CCGCGCGCGCGCGCGCGCGGCC GCCGG  
CxxCxxxCx{10}CxxxCxxxC  
551: GGCGG CCGCGCGCGCGCGCGCGCGGCC GCCGG  
CxxCxxxCx{12}CxxxCxxxC  
555: CCCCC CGCGCGCGCGCGCGCGCGCGGCC CCTTG  
CxxCxxxCx{10}CxxxCxxxC  
558: CCGCG CGCGCGCGCGCGCGCGCGGCC CTTGA  
CxxCxxxCx{12}CxxxCxxxC  
606: CCGCG CCGCGTCCCGCGCGCGCGCGGCC GCCGG  
CxxCxxxCx{12}CxxxCxxxC  
613: CCGGT CCGCGCGCGCGCGCGCGCGGCC CGCGG  
CxxCxxxCx{10}CxxxCxxxC  
615: GTTCC CGCGCGCGCGCGCGCGCGGCC CGGG  
CxxCxxxCx{11}CxxxCxxxC  
618: CCGCG CCGCGCGCGCGCGCGCGCGGCC GGCGC  
CxxCxxxCx{10}CxxxCxxxC  
619: CCGCG CCGCGCGCGCGCGCGCGCGGCC GGCGC  
CxxCxxxCx{10}CxxxCxxxC  
630: CCGCG CGCGCGCGCGCGCGCGCGGCC GCCCT  
CxxCxxxCx{10}CxxxCxxxC  
634: GGCGC CGCGCGCGCGCGCGCGCGGCC TCGCC  
CxxCxxxCx{10}CxxxCxxxC  
638: CGGCC CGCGCGCGCGCGCGCGCGGCC CCGGA  
CxxCxxxCx{10}CxxxCxxxC  
659: CGCGC CTTGCGCGGACCGCGCGCGGCC CGGTC  
CxxCxxxCx{12}CxxxCxxxC

678: GGGCC CGGCGCGGCGTCCCGGTCGGGCGGC CCGCG  
CxxCxxxCx{11}CxxxCxxxC  
712: CCGCG CGGCGCGCGCGCGCGCGCGCGCC CCGCG  
CxxCxxxCx{10}CxxxCxxxC  
718: CGCGG CCGCGCGCGCGCGCGCGCGCGCGC GCGGT  
CxxCxxxCx{12}CxxxCxxxC  
722: GCGCC CGGCGCGCGCGCGCGCGCGCGCGG GTC CCGCG  
CxxCxxxCx{11}CxxxCxxxC  
1,088: CGAGG CGGCGGCGTGTCTACCGCAGCTCAC GCACA  
CxxCxxxCx{11}CxxxCxxxC  
1,323: CCGGG CGGCGGCTGCCCACTTGCCAGCCTGC CACAA  
CxxCxxxCx{11}CxxxCxxxC  
1,421: CCAAG CTTCCAGCTGCAACCGGACCCCGGAC CCAGG  
CxxCxxxCx{10}CxxxCxxxC  
1,422: CAAGC CTTCCAGCTGCAACCGGACCCCGGAC CCAGG  
CxxCxxxCx{11}CxxxCxxxC  
1,425: GCCTC CAGCTGCAACCGGACCCCGGACCCGAC GCCTC  
CxxCxxxCx{12}CxxxCxxxC  
1,434: CTGCA CCGCACCGCCCGACCCGCGCTCCAGCC TGCAC  
CxxCxxxCx{12}CxxxCxxxC  
1,437: CACCG CGACCCCGGACCCGCGCTCCAGCCTGC ACTGA  
ADP31294 ck: 2725 len: 903 ! Adp31294 Human secreted protein SEQ ID #206  
CXXCXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
45: GTCAG CGTCTACGGATTCCGCCCGGGCCTCC AACCG  
CxxCxxxCx{12}CxxxCxxxC  
609: GCCAT CAGCAATCATGTCAACCCACCAACCAATTC CGAAA  
ADP31316 ck: 9046 len: 453 ! Adp31316 Human secreted protein SEQ ID #208  
CXXCXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
10: TCCCT CAGCTGCCCAAGCTGTGGTCTCTC CGAGG  
ADP31321 ck: 9096 len: 270 ! Adp31321 Human secreted protein SEQ ID #208  
CXXCXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxxC  
10: CAGCC CGCTGCCAGCATCGTGGCCGCCACC TGGAA  
ADP31403 ck: 4344 len: 437 ! Adp31403 Human secreted protein SEQ ID #217  
CXXCXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxxC  
95: GCCTA CGACCATCTCTTGAGAGACCACTACC AGCTG  
ADP31448 ck: 5912 len: 432 ! Adp31448 Human secreted protein SEQ ID #221  
CXXCXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
8: GAGGG CCGCCTCCAGCATCCATGACGCCGCGC GGCAC  
ADP31470 ck: 6977 len: 960 ! Adp31470 Human secreted protein SEQ ID #223

1  
CXXCXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxxC  
351: GGAGG CATCACACTACCTGACCTCAACTATC CTACA  
ADP31559 ck: 9950 len: 755 ! Adp31559 Human secreted protein SEQ ID #2326  
CXXCXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
171: CAGCA CTTCTACCGTACTGCGTGTGCCACTC ACCTT  
ADP31569 ck: 8440 len: 828 ! Adp31569 Human secreted protein SEQ ID #2336  
CXXCXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxxC  
108: GTGGC CCTCTCACCGCATCCACTTGCAGCC GCCTG  
CxxCxxxCx{12}CxxxCxxxC  
704: AGCTC CTCAGTCCAGTCCAGCATCTTTCCTAC AACTA  
CxxCxxxCx{11}CxxxCxxxC  
721: TCCAG CATCTTCTACAACTATTCTGCCTTCC ACTTC  
CxxCxxxCx{11}CxxxCxxxC  
740: CTATT CTGCTTCCACTTCTCTTCTCTCTG CACAC  
ADP31595 ck: 9916 len: 3,036 ! Adp31595 Human secreted protein SEQ ID #2367  
CXXCXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxxC  
1,482: CACCT CCACCTCGTCTTCTCTCTGCCAAGC AAATC  
CxxCxxxCx{10}CxxxCxxxC  
1,543: TGGAT CTTCAGACAACAGTCTCTAGCCCTC AGCCG  
CxxCxxxCx{12}CxxxCxxxC  
2,074: TGATT CACCTTCACCTTAGCATCCCCCTCTC AATGA  
CxxCxxxCx{10}CxxxCxxxC  
2,119: ATCTG CAGCTTCTTACTGACGACACCAATC AGCAT  
CxxCxxxCx{10}CxxxCxxxC  
2,842: GCTGC CTCCTGGTACAGTTACACGAGCTGC CATAC  
ADP31600 ck: 1550 len: 6,729 ! Adp31600 Human secreted protein SEQ ID #2367  
CXXCXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxxC  
273: GCAAA CCGTGGCATGAAGGGGTGAGTCTCTAC AAGAT  
CxxCxxxCx{12}CxxxCxxxC  
549: GACCA CATCGAGGTTTACCAACCGCAGCCTCAC CCCCC  
CxxCxxxCx{10}CxxxCxxxC  
566: ACCAA CCGCAGCCTACCCCCAGCTCTCTCC TATGG  
CxxCxxxCx{12}CxxxCxxxC  
2,382: TGGCA CCCCAGCTCAGGTAAAGTGCCCTCTCC AGGGA  
CxxCxxxCx{11}CxxxCxxxC  
2,384: GCACC CCACGCTCAGGTAAAGTGCCCTCTCC AGGGA  
CxxCxxxCx{10}CxxxCxxxC  
2,642: GCAAG CCTCTGACTGCTCAACAGACAAACCAAC TGGAT  
CxxCxxxCx{10}CxxxCxxxC  
3,413: GATAC CATCATCCAGAGGTGCCCAACTCAC TGACC  
CxxCxxxCx{11}CxxxCxxxC  
3,768: CTCCA CCCCATCTGATTGATTTAAACCAACTTCC TGGTG

3,769: TCAC CxxCxxxCx{10}CxxxCxxx  
4,118: GGGTG CxxCxxxCx{12}CxxxCxxx  
4,120: GTGCC CxxCxxxCx{10}CxxxCxxx  
5,323: GTTGT CxxCxxxCx{10}CxxxCxxx  
5,598: CGCCT CxxCxxxCx{12}CxxxCxxx  
5,613: TGATG CxxCxxxCx{12}CxxxCxxx  
5,724: TGGGT CxxCxxxCx{11}CxxxCxxx  
6,681: GAGTG CxxCxxxCx{11}CxxxCxxx

ADP31619 ck: 5648 len: 588 Human secreted protein SEQ ID #238

442: GACTT CxxCxxxCx{10,12}CxxxCxxx  
CGCTGACCTGCTCCGACCTTCACGC GTCAT

ADP30475 ck: 9707 len: 669 Human secreted protein SEQ ID #124

597: GCGTC CxxCxxxCx{12}CxxxCxxx  
CCACCCGCTTGGGGAGCCCGGACTCTC TCNAG

ADP30525 ck: 7074 len: 4,360 Human secreted protein SEQ ID #129

157: TGGGC CxxCxxxCx{10,12}CxxxCxxx  
161: CGGAC CxxCxxxCx{12}CxxxCxxx  
CGGCTCCGCTGACCCGACCTGCGGC CCGGC

881: GGGCG CxxCxxxCx{12}CxxxCxxx  
CTGCCAGACGGGAGTGCAACACGC GCGGC

1,247: TCACT CxxCxxxCx{11}CxxxCxxx  
CAGCCAGCTCGTACCTGCGAGCCAC TCTCG

1,254: GGCAG CxxCxxxCx{12}CxxxCxxx  
CCTCGTACCTGCGAGCCACTCTCGGCC ATCTG

1,278: CCTCT CxxCxxxCx{12}CxxxCxxx  
CGGCCATCTGAGTGCCAGCATCCCTGC CTGGA

1,484: TGTG CxxCxxxCx{12}CxxxCxxx  
CCGGTGCCCCCGCCTGTGCTCCCGGC GCTGC

1,901: GCAGG CxxCxxxCx{11}CxxxCxxx  
CTCCTTCACTGTGCTGCGCTGTGCG TTCCG

1,931: GGCTT CxxCxxxCx{12}CxxxCxxx  
CCGCTCCGAGGCGCCGGGCCCTTGCC AAGAT

2,150: CCGG CxxCxxxCx{10}CxxxCxxx  
CTCCTTCCAGTGACGACCTGTCTTC TGGCC  
2,514: GAGTG CxxCxxxCx{11}CxxxCxxx  
CATCTGTCTCCGGACACCGCGTGGC CGGA  
2,530: CGGGA CxxCxxxCx{10}CxxxCxxx  
CAGCGCGTGGCCGGACCTCGCCTCC TGCCT  
2,756: GAACA CxxCxxxCx{11}CxxxCxxx  
CCCTGGCTCTACCGCTGCACACGAGC CTGTG  
2,772: TACCG CxxCxxxCx{12}CxxxCxxx  
CTGCACACGACCTGTACCTGGCTATC AGCCC  
2,777: CTGCA CxxCxxxCx{11}CxxxCxxx  
CAGCAGCTGTGACCTGTGCTATCAGCC CACGC  
3,017: GAAGG CxxCxxxCx{12}CxxxCxxx  
CTCCTTCTCTGTGTCTGCCAACAGCC CGGAA  
3,097: TGTCT CxxCxxxCx{11}CxxxCxxx  
CCCAGGACGTTCCAGGCTCGAGCC CCAGG  
3,123: CGCAG CxxCxxxCx{12}CxxxCxxx  
CCCAGGACCTGTAGCCCGTTCTGCC CGCCA  
3,133: GGCAC CxxCxxxCx{10}CxxxCxxx  
CTGTAGCCCGTTCTGCCGCCAGGC CACCT  
3,147: CGGTT CxxCxxxCx{10}CxxxCxxx  
CTGCCCGCAGGCGCACTCGCCACCC CTGCC  
3,159: CCAGG CxxCxxxCx{11}CxxxCxxx  
CACTTCGCGCACCTGTGCCGCCGAC CCAGC  
3,165: CACCT CxxCxxxCx{10}CxxxCxxx  
CGCCACCTGCGCCGCGACCCAGC ACACC  
3,726: GTGTG CxxCxxxCx{10}CxxxCxxx  
CAGCCACCTGTGCTGACCGTCAGGC CACCT  
3,729: TGCAG CxxCxxxCx{11}CxxxCxxx  
CCACCTCGCTGGACCGTCAGGCCACC TACAC  
3,859: TGCTA CxxCxxxCx{12}CxxxCxxx  
CGCCCCCGCATATAGCCCCCGCGACC AGGTG  
3,996: GACCC CxxCxxxCx{12}CxxxCxxx  
CTACCCACGCGACCTGGGCCCTTGCCCC GCGGG

ADP30558 ck: 3574 len: 1,299 Human secreted protein SEQ ID #132

37: CTGGC CxxCxxxCx{10,12}CxxxCxxx  
CCCCGGCCTTCAGCAGCCACTCTCTAC ACAAG

996: GGCAG CxxCxxxCx{10}CxxxCxxx  
CTGCGAGCTGTGAACGTCAGGCTGGC CCTGG

1,182: CTCAG CxxCxxxCx{12}CxxxCxxx  
CTACGGCCTGGGGCCAGCTCTCTCAGCC GCACC

ADP30567 ck: 7235 len: 1,550 Human secreted protein SEQ ID #133

1,232: TTGGA CxxCxxxCx{10,12}CxxxCxxx  
CACTACAGAGATGCGGCGTCTCTCC ACCGC

1,280: ATCCA CxxCxxxCx{11}CxxxCxxx  
CGACCACCACTGTGGTGCAGGCTCC AGGCT

1	ADP30575	ck: 1699	len: 192	! Adp30575 Human secreted protein SEQ ID #134	
				CXXCXXC{10,12}CXXCXXC	
				CxxCxxxCx{11}CxxxCxxx	
	66:	GCGGC		CGCCGTGCTCCGGAGCGGACGCC AGGCA	
1	ADP30603	ck: 8325	len: 279	! Adp30603 Human secreted protein SEQ ID #137	
				CXXCXXC{10,12}CXXCXXC	
				CxxCxxxCx{10}CxxxCxxx	
	91:	GGCG		CCCCGCCAGGCCCGAGCGACTCGC TCACT	
1	ADP30633	ck: 1138	len: 291	! Adp30633 Human secreted protein SEQ ID #140	
				CXXCXXC{10,12}CXXCXXC	
				CxxCxxxCx{11}CxxxCxxx	
	5:	ATGA		GAACGCCCGGCTTACCCAAACCTCC TACAC	
				CxxCxxxCx{10}CxxxCxxx	
	13:	CGCCC		CGCCTTACCCAAACCTCTACACCC TGTTC	
				CxxCxxxCx{11}CxxxCxxx	
	135:	ACTCG		CTGCTGCCGCCAGGACCGGACCTGC CCCTC	
1	ADP30653	ck: 1735	len: 798	! Adp30653 Human secreted protein SEQ ID #142	
				CXXCXXC{10,12}CXXCXXC	
				CxxCxxxCx{12}CxxxCxxx	
	4:	CTG		CTGCTGCCCTGGCCTCTCGCACCTGAC ATCAA	
				CxxCxxxCx{10}CxxxCxxx	
	696:	CTCCA		CACCGTGAGGCTGGCTGCTCTC TGGCC	
1	ADP30682	ck: 8061	len: 1,194	! Adp30682 Human secreted protein SEQ ID #144	
				CXXCXXC{10,12}CXXCXXC	
				CxxCxxxCx{11}CxxxCxxx	
	6:	ATGGG		CAGCTGCCTTTCGAACGSGCTGCTAGC CTACC	
				CxxCxxxCx{10}CxxxCxxx	
	15:	TGCCT		CTTCGAACGGCTGCGTAGCTACCCCC TATGG	
				CxxCxxxCx{12}CxxxCxxx	
	403:	GAGCC		CAGCGGCTGGCGCACTTGGCTCCATAC AGCTA	
				CxxCxxxCx{10}CxxxCxxx	
	837:	GACTG		CACCACTCAGCTCAAGCAACAGCTCCC TGACC	
				CxxCxxxCx{12}CxxxCxxx	
	1,090:	CGGCC		CCCCCTTCAGGCGCTGCGGCTGAC CCTGT	
				CxxCxxxCx{10}CxxxCxxx	
	1,162:	CCAAT		CCCCCTACCGGCTCTGCGGCTGAC CCGGT	
1	ADP30688	ck: 5287	len: 976	! Adp30688 Human secreted protein SEQ ID #145	
				CXXCXXC{10,12}CXXCXXC	
				CxxCxxxCx{12}CxxxCxxx	
	769:	GCCCT		CACCCCGGATGCTTTGGCTGGCTACC TGGAC	
				CxxCxxxCx{10}CxxxCxxx	
	771:	CCTCA		CCCCCGGATGCTTTGGCTGGCTACC TGGAC	
1	ADP30699	ck: 9178	len: 659	! Adp30699 Human secreted protein SEQ ID #146	

1	ADP30701	ck: 9178	len: 659	! Adp30701 Human secreted protein SEQ ID #146	
				CXXCXXC{10,12}CXXCXXC	
				CxxCxxxCx{12}CxxxCxxx	
	188:	CCCTG		CACCGAGTGTGCTCCCGGGCGCGAGC CGGCG	
				CxxCxxxCx{10}CxxxCxxx	
	502:	AGCGG		CCCCGGCCCAAGCCCGAGCGGACTCGC TCACT	
1	ADP30706	ck: 7333	len: 5,304	! Adp30706 Human secreted protein SEQ ID #147	
				CXXCXXC{10,12}CXXCXXC	
				CxxCxxxCx{12}CxxxCxxx	
	188:	CCCTG		CACCGAGTGTGCTCCCGGGCGCGAGC CGGCG	
				CxxCxxxCx{10}CxxxCxxx	
	502:	AGCGG		CCCCGGCCCAAGCCCGAGCGGACTCGC TCACT	
1	ADP30712	ck: 9178	len: 659	! Adp30712 Human secreted protein SEQ ID #147	
				CXXCXXC{10,12}CXXCXXC	
				CxxCxxxCx{12}CxxxCxxx	
	188:	CCCTG		CACCGAGTGTGCTCCCGGGCGCGAGC CGGCG	
				CxxCxxxCx{10}CxxxCxxx	
	502:	AGCGG		CCCCGGCCCAAGCCCGAGCGGACTCGC TCACT	
1	ADP30726	ck: 2752	len: 939	! Adp30726 Human secreted protein SEQ ID #149	
				CXXCXXC{10,12}CXXCXXC	
				CxxCxxxCx{11}CxxxCxxx	
	51:	GGAAT		CTTCAATCATAGCCGCCACACACCTTC CTCCT	
1	ADP30740	ck: 112	len: 1,878	! Adp30740 Human secreted protein SEQ ID #150	
				CXXCXXC{10,12}CXXCXXC	
				CxxCxxxCx{12}CxxxCxxx	
	273:	GTCAAT		CATCTTCTGCTCTCTGTGCCAGGATC AGGAC	
				CxxCxxxCx{10}CxxxCxxx	
	339:	CAGCC		CTAGCCCCCGCCAGTACCCCCCTCC GCCAC	
				CxxCxxxCx{12}CxxxCxxx	
	358:	AGTAC		CCCCCTCGGCACAGAGCGCATCCCTGC CGAGT	
				CxxCxxxCx{10}CxxxCxxx	
	375:	CAGAA		GGGATCCCTCCGAGTACGCCCGCC CCCAC	
				CxxCxxxCx{12}CxxxCxxx	
	409:	CACCG		CACCCACGAGGACTACTCCGGCCAGAC CCCGG	
				CxxCxxxCx{10}CxxxCxxx	
	411:	CCGCA		CCCCACGAGGACTACTCCGGCCAGAC CCCGG	
				CxxCxxxCx{12}CxxxCxxx	



553: CGCCC CCCCCCCCCCGCCGAGAGCCTGCTGCC CAGGT  
CxxCxxxCx{11}CxxxCxxx  
554: GCCCC CCCCCCCCCCGCCGAGAGCCTGCTGCC CAGGT  
CxxCxxxCx{10}CxxxCxxx  
555: CCCCC CCCCCCCCCCGAGAGCCTGCTGCC CAGGT  
CxxCxxxCx{11}CxxxCxxx  
777: CTCTT CTTCCCGAGGAGGTTTCCAGCCAGC AATTG  
CxxCxxxCx{11}CxxxCxxx  
887: GGCCA CTTGGACAGTACCCGTGATCAACC GGCCG  
CxxCxxxCx{12}CxxxCxxx  
1,101: AACAT CCGTTCCGGTTAGGACCCCGACTTGC GGCAA  
CxxCxxxCx{12}CxxxCxxx  
1,619: GGCTG CGCACCCCCACCCCATCCGACTTAC GGAGC  
CxxCxxxCx{10}CxxxCxxx  
1,621: CTGCG CCACCCACCCCATCCCGACTTAC GGAGC  
CxxCxxxCx{12}CxxxCxxx  
1,772: CTACG CAGTCCGACCCGTACCATCACCAATC GGGCC  
ADP30895 ck: 8205 len: 594 ! Adp30895 Human secreted protein SEQ ID #166  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
372: TTGGC CTTACGCCCTGACTCCACCTCCACAC CCACA  
CxxCxxxCx{12}CxxxCxxx  
391: CCCAC CTCACACCATGATGACTTCTTCTCTC CAACC  
CxxCxxxCx{10}CxxxCxxx  
393: CACCT CCACCCACATGACTTCTTCTCTC CAACC  
ADP30909 ck: 2591 len: 395 ! Adp30909 Human secreted protein SEQ ID #167  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
66: GGGAG CAGCAGCTCCAGGAGTGTGCCCCAC CATCC  
CxxCxxxCx{11}CxxxCxxx  
96: ACCAT CTCACAGCTGGATTCCCGGCCCTGC ACCTC  
CxxCxxxCx{11}CxxxCxxx  
233: CCTGG CTTCTCTCTGGAGTCTCTGCTCTGCC CTGCA  
ADP30939 ck: 237 len: 1,133 ! Adp30939 Human secreted protein SEQ ID #170  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
943: TACAT CTGCTAACATGCTTATTTTCATCTTCC TTCAAT  
ADP30950 ck: 5321 len: 367 ! Adp30950 Human secreted protein SEQ ID #171  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
132: TTCTC CATCTACCTGGAGTCGCTGCTATCTTCC CGCAG  
ADP30952 ck: 736 len: 1,132 ! Adp30952 Human secreted protein SEQ ID #171  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
75: ATCTA CGGACCCACCTTCAGGGCAACCTGTC CCTCC

CxxCxxxCx{11}CxxxCxxx  
78: TACGG CAGCCACCTTCAGGGCAACCTGCTCCTC CTGAG  
CxxCxxxCx{10}CxxxCxxx  
499: TGCCA CCCATCCGTGCTCGACGTCGGAC GTCCA  
ADP30997 ck: 5840 len: 1,654 ! Adp30997 Human secreted protein SEQ ID #176  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
860: TGCTG CTGCAGACCTAGCCACCCCATCTTCC TGCTG  
CxxCxxxCx{10}CxxxCxxx  
991: TCCTA CGCAACCTGCTCATGGGTGCTCTC CTTCC  
CxxCxxxCx{11}CxxxCxxx  
994: TACGC CAACCTGCTCATGGGTGCTCTCTCTC CTTTC  
ADP31017 ck: 1833 len: 363 ! Adp31017 Human secreted protein SEQ ID #178  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
10: CCTGG CAGCCGCCCTTTTCCACACCGCCTCC CGGCA  
CxxCxxxCx{10}CxxxCxxx  
147: CAGAC CTGCCGGCGATCTCTGGTGCCTCC CGGTC  
ADP31026 ck: 8557 len: 2,201 ! Adp31026 Human secreted protein SEQ ID #179  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
299: GGATC CACCTGCCCGCCACCAAGCCAGCCCTC CAGCC  
CxxCxxxCx{10}CxxxCxxx  
306: CCTGC CGGCCACAAAGCCAGCCCTCCAGCC CAGGG  
CxxCxxxCx{10}CxxxCxxx  
424: AGTGG CTCGGCCGCTCTCTGGACGAGGCTC CGGCC  
CxxCxxxCx{11}CxxxCxxx  
1,210: GTCTT CCACGTGCTGACACGCTGCACCCCGC CCGCG  
CxxCxxxCx{10}CxxxCxxx  
1,249: CAGAG CCAGCACGAGAGGCCACTGGCTGSC GGTGC  
CxxCxxxCx{11}CxxxCxxx  
1,682: GTCTT CTTTCATCCCGAGAGCGCGGCCCTC AAGGC  
CxxCxxxCx{10}CxxxCxxx  
1,748: CGCCG GAGCACCCTGCTCTTACGCACAAGC CCAGA  
CxxCxxxCx{12}CxxxCxxx  
1,793: AAACA CAGCAGCCACCTCTTACAGCCACCATCC CTCTG  
CxxCxxxCx{12}CxxxCxxx  
1,796: CACAG CAGCCACCTCTTACAGCCACCATCTCCTC TGAAT  
ADP31035 ck: 3732 len: 1,365 ! Adp31035 Human secreted protein SEQ ID #180  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
689: GAGCG CGGCCCTGCTCCACGGGCCCATC CCATC  
ADP31048 ck: 5063 len: 2,104 ! Adp31048 Human secreted protein SEQ ID #181  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
253: AGGGC CAGCTGCCATCTCTATCATCGCCAGGC TGAGT

CxxCxxxCx{12}CxxxCxxx  
551: AGCTG CACCATCCAGTGTGAGCTGCTTGCCGAC ACCTG  
CxxCxxxCx{12}CxxxCxxx  
1,389: GCGAG CTTCGGCTGTGAGGAGATCCACCTTC CTGGG  
CxxCxxxCx{10}CxxxCxxx  
1,410: AGATC CCACCTCTCTGGGCCCCCTCTCACAGCC CAGGC  
CxxCxxxCx{11}CxxxCxxx  
1,418: CCCTC CTGGCCCTCTCACAGCCAGGCCATC CAAGA  
CxxCxxxCx{12}CxxxCxxx  
1,637: AACCC CAGCTCACAGAGCGGAAGCAACCGTCC CGGAG

ADP31051 ck: 8408 len: 1,431 ! Adp31051 Human secreted protein SEQ ID #181

CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
218: GCCTT CCAGGACACCCCTCTCAGCAGCCAGCC TGCCC  
CxxCxxxCx{10}CxxxCxxx  
325: CAGCT CTTCGGCTCAGACTCCCCACGCC AGCTT  
CxxCxxxCx{12}CxxxCxxx  
347: CCCCC CCCCAGCTTCAGTAGGGCTCTCAGAC ACCTG  
CxxCxxxCx{10}CxxxCxxx  
388: TTCCC CTGCAGCCAGCGCGGCTGACCCCC CGTGC  
CxxCxxxCx{11}CxxxCxxx  
468: CGGCA CACCAAGCTGAAGCACCACCGAGCCCC CCCCC  
CxxCxxxCx{10}CxxxCxxx  
516: AAGGT CTTCAGCTGTGCCAGCTTCCCCAC ACTCA  
CxxCxxxCx{11}CxxxCxxx  
523: TCCAG CTGTGCCAGCTTCCCCACACTACCC GGAGC  
CxxCxxxCx{12}CxxxCxxx  
816: GACAT CAACAACCGGTGGACAGAGCGGAAC CCCAT  
CxxCxxxCx{11}CxxxCxxx  
926: CAACC CTTCCTCCACCACCTCTCCACACCTC CTCAC  
CxxCxxxCx{10}CxxxCxxx  
932: TTCCT CCACACCTCTCCACACCTCTCTCAG CGGG  
CxxCxxxCx{11}CxxxCxxx  
935: CTCCA CCACCTCTCCAGACCTCTCTCACCGGC GGCCT  
CxxCxxxCx{12}CxxxCxxx  
938: CACCA CTCTCTCCACACCTCTCACCGGGCC TTCCC  
CxxCxxxCx{12}CxxxCxxx  
942: ACCTC CTCACACCTCTCTCACCGGCGCTTCC CGACA  
CxxCxxxCx{10}CxxxCxxx  
944: CTCCT CCACACCTCTCACCGGCGCTTCC CGACA  
CxxCxxxCx{11}CxxxCxxx  
947: CTCCA CACCTCTCACCGGCGCTTCCCGAC ATCAT  
CxxCxxxCx{10}CxxxCxxx  
959: CTCAC CGGGCCCTTCCGACATATCCAACC CATCC  
CxxCxxxCx{11}CxxxCxxx  
962: ACOGG GCGCCTTCCGACATATCCAACCATC CAGCG  
CxxCxxxCx{10}CxxxCxxx  
977: GACAT CATCAACCATCCAGCGCCACCGC CCCCC

CxxCxxxCx{10}CxxxCxxx  
986: CAACC CATCCAGGCGACACGCCCCCAACC CCTCA  
CxxCxxxCx{10}CxxxCxxx  
1,001: CACCA CGCCCCAACCCTCACTGGCCAGC GGGAC  
CxxCxxxCx{11}CxxxCxxx  
1,124: GCTCT CGCGGCTTGGGGGGCCCATCTCTC GCAAG  
CxxCxxxCx{11}CxxxCxxx  
1,144: GGCCC CATCTCTGCAAGGCCAGCCAGACCAGC GTGTA

ADP31073 ck: 4797 len: 1,083 ! Adp31073 Human secreted protein SEQ ID #184

CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
296: CAGGC CTGCGGCTGAAGAAGTGCTGCAGGC AGGGA  
CxxCxxxCx{12}CxxxCxxx  
504: CTGGA CAGCATCCATGAGACCTCGGCTCGCTAC TCTTC  
CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
304: GGGCT CTTCGCGCACCGGCTTCCGACGCC CTCCG  
CxxCxxxCx{11}CxxxCxxx  
307: CTCCT CGGCCACCGGCTTCCGACGCCCTCC GGGGA  
CxxCxxxCx{10}CxxxCxxx  
308: TCCTC CGCCACGGCTTCCGACGCCCTCC GGGGA

ADP31146 ck: 2736 len: 2,535 ! Adp31146 Human secreted protein SEQ ID #191

CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{10}CxxxCxxx  
115: TAAAG CACGCGCCCTTCAGTCTTACCAAC TTGCG  
CxxCxxxCx{12}CxxxCxxx  
117: AAGCA CGGCGCCCTTCAGTCTTACCAACTTC GGCTG  
CxxCxxxCx{12}CxxxCxxx  
1,194: GAGGT CAGCGTCATGCCATTTATGCCATCAGC TGTCG  
CxxCxxxCx{12}CxxxCxxx  
1,637: GCAGC CCACCCGAGCATGCAACTGCCCTGCC CTGCG  
CxxCxxxCx{10}CxxxCxxx  
1,707: AGCAT CGCATCTGCTTGACTGCAACTTC TGAAG

ADP31167 ck: 8125 len: 950 ! Adp31167 Human secreted protein SEQ ID #193

CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{12}CxxxCxxx  
643: CATGG CTGCTGCCACTGGTGACATGCCAACTTAC CAGAT  
CxxCxxxCx{11}CxxxCxxx  
750: CCCAG CAGCTGGCAGAAGAACAACGCAAAC GAGAG

ADP31212 ck: 543 len: 474 ! Adp31212 Human secreted protein SEQ ID #197

CXXCXXXCX{10,12}CXXCXXXC  
CxxCxxxCx{11}CxxxCxxx  
310: CCGGC CAGCGAGCGCTGCCATCTCTACGTGC GGACC  
CxxCxxxCx{12}CxxxCxxx

317: GCGGA	CGCGTGCATCTCTAGTCGGGACCATC	ATCAA			
ADP31220	ck: 9473	len: 876	!	Adp31220	Human secreted protein SEQ ID #198
1	CXXCXXXCX{10,12}CXXXCXXXC				
267: AGTAG	CAGCAGCGCAGCATTCACACAGAC	GCCTG			
651: CTGGT	CAGCATCTCAAGCCACTCTTCCTAC	CCCGG			
667: AGCCA	CTCTTCTTACCCGGATCTTACACTC	AAGGG			
745: CTCTG	CTGCAGCCTATTGTGTGGCTCCCTGTC	TACAA			
ADP31278	ck: 430	len: 702	!	Adp31278	Human secreted protein SEQ ID #204
1	CXXCXXXCX{10,12}CXXXCXXXC				
387: ACCTT	CCTCAACCCCTCCCAAGTCGTCCAC	TCGCA			
393: CTCAA	CCCCCTCCCAAGTCGTCCCACTCGC	ATTAG			
478: AGCGG	CAGGCACCTCCAGAGCTGGCTCCCTCC	CGGCC			
503: CTCTC	CTCCCCGCTCGGGTTCCTCGGACCGGC	TGCAG			
ADP31304	ck: 3085	len: 900	!	Adp31304	Human secreted protein SEQ ID #207
1	CXXCXXXCX{10,12}CXXXCXXXC				
520: TGATG	CCACACCTTGCCCAACCGCACACAAC	AAATT			
580: CACTC	CTGCTGCCACCACTGCACCTCCCCAC	TGGGG			
ADP31406	ck: 2221	len: 1,194	!	Adp31406	Human secreted protein SEQ ID #217
1	CXXCXXXCX{10,12}CXXXCXXXC				
681: AACTA	CCTCTTCCAGTTTGTCTCCTGCTGAC	CAAGC			
ADP31427	ck: 3586	len: 264	!	Adp31427	Human secreted protein SEQ ID #219
1	CXXCXXXCX{10,12}CXXXCXXXC				
183: TCAGT	CGACTGCCAAGCATGAAGCACTCTC	GAAGC			
ADP31564	ck: 640	len: 270	!	Adp31564	Human secreted protein SEQ ID #233
1	CXXCXXXCX{10,12}CXXXCXXXC				
107: GCCCT	CCACATCCAAAGTTTCTCCCTGGCTGCC	CTAAT			
ADP31645	ck: 5851	len: 603	!	Adp31645	Human secreted protein SEQ ID #241
1	CXXCXXXCX{10,12}CXXXCXXXC				
564: CACAG	CGACAAGTGTTACTTCCCACTCTCTCC	TCTGC			
ADP30469	ck: 2550	len: 2,454	!	Adp30469	Human secreted protein SEQ ID #126
1	CXXCXXXCX{10,12}CXXXCXXXC				
276: AGAAT	CAGCCCCCTAGATGCAAGCTGGCTTGC	CTTAG			
1,585: AGCCC	CACCAGTCCACACTAGTTTGCAGCCCGC	AGCAC			
ADP30496	ck: 3796	len: 783	!	Adp30496	Human secreted protein SEQ ID #126
1	CXXCXXXCX{10,12}CXXXCXXXC				
209: GGTC	CCGCCACAGCAGCGCTCCAGGCTGCC	AGAGG			
250: AGGGG	CTGCTGCTGAGCAGAGTCTGCAGGC	CTGCT			
737: AACAT	CACCAGCGAAGGGAGACCATGCGACC	ATCAC			
ADP30519	ck: 2331	len: 339	!	Adp30519	Human secreted protein SEQ ID #128
1	CXXCXXXCX{10,12}CXXXCXXXC				
6: ATGCG	CTGCTCGCGGGAGGCGTCTGGCTGGC	GCTGG			
ADP30555	ck: 8722	len: 864	!	Adp30555	Human secreted protein SEQ ID #132
1	CXXCXXXCX{10,12}CXXXCXXXC				
8: CTGCT	CTGCGCGCTGTGCTGCGGCTCTCTGC	CGCGG			
27: GCGGC	CTCTTGCGCCCGGCTGCCCGCGCGGC	TACTC			
221: GGCAT	CGCCTGTCTGCGCGCGGTGCGGCTTC	GCGGG			
446: GGGCG	CCCGAGCTGCCCGCGAGGCCACGGTC	TCGGC			
ADP30600	ck: 8766	len: 879	!	Adp30600	Human secreted protein SEQ ID #136
1	CXXCXXXCX{10,12}CXXXCXXXC				
418: AACAA	CCTTTGAGGCGCTGCCCGGCGCAGC	TGGCC			
640: CGGAT	CCGCTTTCTGGCAAGAACGCTTCGGCC	AGCTA			
599: CCTCT	CTGCCAACGAGCTACAGCCCTCTCTGC	GCCAC			
710: ACGAG	CTACAGCCCTCCCTGGGCCACGGGCGC	ACCTT			
718: CAGCC	CTCGCTGGCCAGCGGCCACCTTCGCAC	CGCTG			
732: CCACG	CGGCACTTTCGACACGCTGCGTCCCTC	TCCTC			
735: CGGGG	CCACCTTCGACAGCGCTGCGTCTCTC	CTCCC			
739: GCCAC	CTTCGACCGCTGCGTCTCTCTCC	CTCAT			



1	CxxCxxxCx{11}CxxxCxxxC 2,367: GAGCT CCCCTCCCTGGGGCTTGGCCCGAGCG AGCAG 2,512: CCCC CGGCCCTCGGGAGCAGCGCCAGCCTCC CGGCC	1	CXXCXXXCX{10,12}CXXCXXXC 955: TATAG CACTACCTGTGGACAGGCCTTCTAGC AATTT
ADP30927	ck: 5725 len: 1,670 ! Adp30927 Human secreted protein SEQ ID #169	ADP31010	ck: 6262 len: 735 ! Adp31010 Human secreted protein SEQ ID #177
1	CXXCXXXCX{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxxC 523: TCGAT CACCAACCCATCAAACTGCAACCAAC ACCAG 663: CTTGA CCACCATCATCGGCACCTCCACCAGCC TCATC 1,284: GCAGC CTCACCGTGGGTGTACACCTGCTGGC ATGCA 1,354: CAACC CAGCAACCATCACCATCTCTGCCCCATC CTGTG 1,370: ACCAT CTTCTGCCCATCTCTGTGAGCCTGTC TGAAG	431: TAAGA CGCTACCGGCCCTCGGGCTGACGGGC CGCGG 627: GACGC CGAGCCCATCCAGCTGACCCAGCCCC GACGG	431: TAAGA CGCTACCGGCCCTCGGGCTGACGGGC CGCGG 627: GACGC CGAGCCCATCCAGCTGACCCAGCCCC GACGG
ADP30938	ck: 6333 len: 2,828 ! Adp30938 Human secreted protein SEQ ID #170	ADP31071	ck: 1610 len: 1,122 ! Adp31071 Human secreted protein SEQ ID #183
1	CXXCXXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC 424: AAAGC CTTAGGCGCTACAAGTGTCTCTAGGCG AGATG 444: TGGTG CTAGCGCAGATGCAGCCAGCCTTCC TCTGC 1,738: GACAG CATCATCCAGGTCAAGAAGCTACCCCTAC TTGCC 2,069: AGCG CGGCTGGCTGGGAGGGCTCCCGGC GGGCC 2,332: CCAGT CTCCTTCAGCTGGTGGAGCAGACAACC CTGCA 2,336: TCTCC CTTCCAGCTGTGGAGCAGACAACCCCTGC ACAAG 2,659: GGCAT CTCCTTCCCGAGAGCCCCCTCTCTCC TGGCC 2,765: GCGA CATCTTGAGGGCCCCCAGCTGGGATC CACAG	485: TGGAC CGCTGCCCTTCCGGGGCGCTTCCCTGC TGGGC 502: CCGGG CGCTTCCTGCTGGGCCCTGGCAGTC GCTGG	485: TGGAC CGCTGCCCTTCCGGGGCGCTTCCCTGC TGGGC 502: CCGGG CGCTTCCTGCTGGGCCCTGGCAGTC GCTGG
ADP30967	ck: 7290 len: 1,616 ! Adp30967 Human secreted protein SEQ ID #173	ADP31094	ck: 8752 len: 383 ! Adp31094 Human secreted protein SEQ ID #186
1	CXXCXXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxxC 762: TTCAT CGTCATGCTGGCATGATCAGCCGGG CCTGT 1,172: GGGC CACCATCACCGCTCTCTCTCTGCTGCG CATCT	19: GCTGG CTGCCATCGGCTCCCTTACCACCTGCC CCAGA	19: GCTGG CTGCCATCGGCTCCCTTACCACCTGCC CCAGA
ADP30988	ck: 5081 len: 753 ! Adp30988 Human secreted protein SEQ ID #175	ADP31110	ck: 5502 len: 806 ! Adp31110 Human secreted protein SEQ ID #187
1	CXXCXXXCX{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxxC 50: CACCA CCACCACCAATTACAGCGCCTCTCC AGGGT	451: GTGTG CAGCATGTGCACCTCTGCTGGCAGC GGCTG	451: GTGTG CAGCATGTGCACCTCTGCTGGCAGC GGCTG
ADP30995	ck: 2575 len: 1,358 ! Adp30995 Human secreted protein SEQ ID #176	ADP31112	ck: 1469 len: 3,447 ! Adp31112 Human secreted protein SEQ ID #187
		408: ATCAC CACCAATCCACAATAAATAAACAATACC ATCAG	408: ATCAC CACCAATCCACAATAAATAAACAATACC ATCAG
		2,622: AGTCT CGTCTGCAGAGCCTGCGCCTGCTGCC TCCTT	2,622: AGTCT CGTCTGCAGAGCCTGCGCCTGCTGCC TCCTT
		3,089: TCTAG CAGCTGACGGTATTATCATCTACCGAGC TGCGT	3,089: TCTAG CAGCTGACGGTATTATCATCTACCGAGC TGCGT
		ADP31117	ck: 9880 len: 3,585 ! Adp31117 Human secreted protein SEQ ID #188
		64: TCCTT CTCCTGGCAGAGGCCCGAGCTGACCACC TCCTG	64: TCCTT CTCCTGGCAGAGGCCCGAGCTGACCACC TCCTG
		192: GGCTC GTGCCCCACACCAAGTTCTGACTGTC TCAGA	192: GGCTC GTGCCCCACACCAAGTTCTGACTGTC TCAGA
		402: AATGG CCGCAGACTCTCCAGCCTCTGACCCCC AATAA	402: AATGG CCGCAGACTCTCCAGCCTCTGACCCCC AATAA





1	1	CXXCXXXC{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxxC 44: GCGG CCGCCACCCTGTGTACAGCTGGCGGCC TGGCC 48: GCGC CACCTGTGTGACGCTGGCGGCTGGC CCGCG 233: GTACG CCTCGCTAGCGCTTTGGCAACCTCAC GTACC 564: CTCTA CAGCAACCCCTTCTACTGTCTCTGGAGC TGCTG 617: GCTGG CCGCTTTCACCAAGCCACACAGAGTAC GACCG 648: TACGA CCGCATGAGTCGAGTGGCGCCGTC TACTC 720: CACCG CAGCATCTTCAGAAACTGCAGTCAGTC TGCAC 787: GGGCC CCACGTCCAGATCCGGGCGCTCACAGCC GGGCC 897: GACGG CACCACGCCACTGGTGGGCCCTGCCAC GCTGG 983: GAACT CCGCCACCATCACCGTCAGTCGCCAGC CGGTT 993: ACCAT CACCGTCCAGCTGCCCGCCAGCCGTTCCACC GGTAG 1,155: ACCAG CGCGGGGTGGCCACAACACACACTGC CTCAC 1,191: ACCAT CTGCTTGCCCGGCTGCCAGCCCGCC TGGTC 1,798: TGGTG CTGCTGTCCAGCCGCTGGCGCCAAAGC ACGGC 1,810: CCGAG CCGCTGGCGCCAGACAGCGCTTCTGGC GCCCG 2,034: GCCGA CGCCATCTCTACTGTGTACACCGCGGCC GCC ADP30637 ck: 776 len: 189 ! Adp30637 Human secreted protein SEQ ID #140	ADP30884 ck: 7420 len: 1,221 ! Adp30884 Human secreted protein SEQ ID #1651
	1	CXXCXXXC{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC 891: GTGG CTGGGCGAGCGGGCCACCCCTCCAA ATCTA 945: TGCCT CACCAAGCTGAGCAGTTCTTGGCGGAC CACCT ADP30975 ck: 7535 len: 1,087 ! Adp30975 Human secreted protein SEQ ID #1742	CXXCXXXC{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxxC 355: CTGCT CAGCTGCAGCGCTGCCTTCGAGTCACCC GCCCC 427: GCCG CCGCTGCTGTGGGGTCTTGGCTGGC CGCCC 524: TGTGC CACCGTGGCGGTCACGCGCGGCC ACCTG 709: GCCTT CGGCTTGTCTGGGCCCCCTACCACGC AGTCA ADP30991 ck: 373 len: 253 ! Adp30991 Human secreted protein SEQ ID #1751
	1	CXXCXXXC{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxxC 83: AGCCT CTTCTCCCTGTGGCTCTCCACCGCTCC AGCCA 89: TTCTC CTTCTGGCTCTCCACCGCTCCAGCCACC CGCAC ADP31008 ck: 1233 len: 1,626 ! Adp31008 Human secreted protein SEQ ID #1771	CXXCXXXC{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC 525: AACAC CATCTCGAGGAACTCACTGGGGTCC AAGTG 790: ATCTT CTTCTCCCTCGGAGGGGGGCCAAGC GCTTC 926: CGCG CACCACAGCAGACCCTCGGCAGCTGTC CAAGT 928: CCGCA CCACAGGAGACCCTCGGCAGCTGTC CAAGT 1,247: CTCTA CAGCATTCCTCATCGAACAATCTTGGC AGTGG 1,425: AGAAG CGCTCACCCTTACCACCCGTCGCC TACCT 1,505: CCGGG CTGCTGCGCTGCACCTGGCGGCTCCC AGCCA 1,510: CTGCT CGCCTGCACTGGCGGCTCCAGCCAAC ATCCA ADP31043 ck: 7714 len: 1,189 ! Adp31043 Human secreted protein SEQ ID #1810
	1	CXXCXXXC{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC 871: CAGGA CTCAGCCTGAACCAGGTGCTCCAAAC AAGAA ADP31062 ck: 5784 len: 3,407 ! Adp31062 Human secreted protein SEQ ID #1821	CXXCXXXC{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC 871: CAGGA CTCAGCCTGAACCAGGTGCTCCAAAC AAGAA ADP31062 ck: 5784 len: 3,407 ! Adp31062 Human secreted protein SEQ ID #1821



```
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{11}CxxCxxxC
2,483: CTTGC CAGCTCGCGGCTCCACCACTCTACC GCTGC
      CxxCxxxCx{11}CxxCxxxC
2,932: CGCCA CCCAGGCTGGATGAGCCCTGGCGAGC TACAT

ADP31065 ck: 5718 len: 345 | Adp31065 Human secreted protein SEQ ID #183
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{10}CxxCxxxC
237: CAGCT CGGCCACGACCGCTGGCTGGACC CCAAC

ADP31075 ck: 8413 len: 366 | Adp31075 Human secreted protein SEQ ID #184
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{10}CxxCxxxC
258: GACCT CCCCTGCAGTCCGGTCCGCGGCC CGCCC
      CxxCxxxCx{11}CxxCxxxC
280: TCCGG CCGCCCGCCCGCTGGCGCACCTCGC CGTTC
      CxxCxxxCx{10}CxxCxxxC
281: CCGCG CGCCGCCCGCTGGCGCACCTCGC CGTTC
      CxxCxxxCx{11}CxxCxxxC
293: CCGCG CTGGGGCACCTGGCCGCTTCGCGGCC CTCCA
      CxxCxxxCx{11}CxxCxxxC
296: CGCTG CGGCCACTCGCGGTCTCGCGCCCTC CAAGC
      CxxCxxxCx{12}CxxCxxxC
300: GGGGC CACTCGCCCGTCTCGCGCCCTCCAAGC CACAG
      CxxCxxxCx{10}CxxCxxxC
302: GGCCA CCTGGCCCGTCTCGCGCCCTCCAAGC CACAG

ADP31140 ck: 2605 len: 933 | Adp31140 Human secreted protein SEQ ID #190
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{10}CxxCxxxC
567: GCTAT CATCGGCAGATGATGCTTTTCATAC AGTCA

ADP31153 ck: 7545 len: 1,092 | Adp31153 Human secreted protein SEQ ID #192
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{10}CxxCxxxC
123: CTGGG CCACGGGCGCACTGGCCATGATGC TGCCA
      CxxCxxxCx{12}CxxCxxxC
628: GGGTG CAACACTCTCTGATGCACACAGGCTGCC CATGG
      CxxCxxxCx{11}CxxCxxxC
841: CCTCA CTTGAGCGGGGAGGTGGGCGCTCC TAGAT
      CxxCxxxCx{10}CxxCxxxC
923: CTGGG CTGCTACGTGGACTTCTCCACCTAC TGGGC
      CxxCxxxCx{10}CxxCxxxC
936: GTGGA CTTCTCCACCTACTGGGCTTTCTTCC ACTCA
      CxxCxxxCx{11}CxxCxxxC
939: GACTT CTCACCTACTGGGCTTTCTTCCACTC AACCT
      CxxCxxxCx{12}CxxCxxxC
942: TTCTC CCACCTACTGGGCTTTCTTCCACTCAAC TGCCC

ADP31156 ck: 6430 len: 1,104 | Adp31156 Human secreted protein SEQ ID #197
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{10}CxxCxxxC
144: GAGCC CTACTGCTGGACATGGCATCCAGCC CAATG

ADP31224 ck: 5149 len: 456 | Adp31224 Human secreted protein SEQ ID #198
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{11}CxxCxxxC
25: AGTCA CCACTACAGTCAAGATGCTCACCTGC CCCAA
      CxxCxxxCx{12}CxxCxxxC
147: GGGTC CAGCCAGTCTGTGCCACTGCAGCCCTCC AAGCT

ADP31246 ck: 5234 len: 176 | Adp31246 Human secreted protein SEQ ID #201
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{11}CxxCxxxC
18: AGCTT CGACNACCGCGCAGCGCAGACCGCC ATCCA
      CxxCxxxCx{11}CxxCxxxC
26: CAACC CGGCCAGCGCGCAGCGCCATCCAGGC CATGA

ADP31340 ck: 4250 len: 861 | Adp31340 Human secreted protein SEQ ID #210
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{12}CxxCxxxC
638: GACTA CCACAAACATCCAAATGGCTTGCGAGC GGTGG
      CxxCxxxCx{12}CxxCxxxC
776: CATGA CTACTTCCAAACAAAGAGCTGGCTGAC GAGAG

ADP31360 ck: 6006 len: 615 | Adp31360 Human secreted protein SEQ ID #212
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{12}CxxCxxxC
296: GAAGC CTTCTCGCTCCAGGCACCCCTCTACC AGCAG

ADP31363 ck: 5767 len: 768 | Adp31363 Human secreted protein SEQ ID #213
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{12}CxxCxxxC
449: GAAGC CTTCTCGCTCCAGGCACCCCTCTACC AGCAG

ADP31372 ck: 2021 len: 1,848 | Adp31372 Human secreted protein SEQ ID #213
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{12}CxxCxxxC
470: GGAGA CAGCGGCTCTGGTACTGGGCGCGGCC TCTCT

ADP31409 ck: 4479 len: 906 | Adp31409 Human secreted protein SEQ ID #217
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{10}CxxCxxxC
210: TCGCG CTTTCATCCACACAGCCACGACCTCAC CTACT

ADP31417 ck: 6553 len: 555 | Adp31417 Human secreted protein SEQ ID #218
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{11}CxxCxxxC
359: ACTGC CCCAGTCACTAGGAGGTCTCCTCTC ACTTG
      CxxCxxxCx{10}CxxCxxxC
456: GTTCT CATGTCCACACACCGCGCATGC AGCCC
```

1	459: CTCAT	CxxCxxxCx{11}CxxxCxxxC CGTCCACACACCCGCGAGTGCATGCAGCC CACCC	ADP31546	ck: 2853	len: 2,664	! Adp31546 Human secreted protein SEQ ID #231:
	463: TCGTC	CxxCxxxCx{11}CxxxCxxxC CCACACCCGCGAGTGCATGCAGCCACC CGAC	23: GCTGA	CGCCAGCCCTGCTGTTGCCACACGACC	CTTCC	
	464: CGTCC	CxxCxxxCx{10}CxxxCxxxC CACACCCGCGAGTGCATGCAGCCACC CGAC	41: TGTTC	CxxCxxxCx{10}CxxxCxxxC CCACAGCCCTTCCTCTCCCTTCAGGC ATGAC		
	467: CCCAC	CxxCxxxCx{12}CxxxCxxxC CACCCGGCAGTCATGCAGCCACCCCGAC CACAC	463: CAGAA	CTCCCTCTAGGAAGCATCTTGGCCCTC	AGACC	
	518: TGTCC	CxxCxxxCx{11}CxxxCxxxC CCACCTGCACAGCTGCCCCCACTTCC TTCCG	486: CTTGC	CxxCxxxCx{10}CxxxCxxxC CCTCAGACCACCTGAGCACCACATTCC	CACTG	
1	ADP31513	ck: 3662	len: 1,662	! Adp31513 Human secreted protein SEQ ID #228		
	118: CTGAA	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxxC CAACAGCCTTACGCCCTAGACCTTCCCTC TGACA	2,366: CTTAA	CxxCxxxCx{11}CxxxCxxxC CTTCTTTACAAGTACTTACTGCTGCC	TGCTG	
	601: GCTTT	CxxCxxxCx{10}CxxxCxxxC CTCGATCAGATGGAGCCACAGTC CTCTC	2,385: ACTTA	CxxCxxxCx{11}CxxxCxxxC CTGCTGCTGCTGTGTGCCAGACGCTC	TTCTC	
	ADP31524	ck: 7764	len: 552	! Adp31524 Human secreted protein SEQ ID #229		
1	140: GCTTA	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC CTCCCTGCTCTAAACTCCACTGGCTGC CTTAT	ADP31551	ck: 373	len: 1,476	! Adp31551 Human secreted protein SEQ ID #231f
	ADP31525	ck: 9909	len: 528	! Adp31525 Human secreted protein SEQ ID #229		
1	116: GCTTA	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC CTCCCTGCTCTAAACTCCACTGGCTGC CTTAT	564: CACAA	CXXCXXCX{10,12}CXXCXXXC CAACAAGCTGCAGACGCCGGGCTGCC	GGACA	
	ADP31544	ck: 2234	len: 3,144	! Adp31544 Human secreted protein SEQ ID #231		
1	23: GCTGA	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{10}CxxxCxxxC CGCCAGCCCTGCTGTTCCACACGCC	654: CTGGG	CxxCxxxCx{11}CxxxCxxxC CCAGTGCCAAGCACCTGCCGCTGCC	CTGTA	
	41: TGTTC	CxxCxxxCx{10}CxxxCxxxC CCACAGCCCTTCCTCTCCCTTCAGGC	1,258: GCCTG	CxxCxxxCx{11}CxxxCxxxC CTGCTGCTGCTGGACCTGTCGGCAACC	GGCTG	
	463: CAGAA	CxxCxxxCx{10}CxxxCxxxC CTCCCTCTAGGAAGCATCTTGCCTC	ADP31620	ck: 5648	len: 588	! Adp31620 Human secreted protein SEQ ID #238:
	486: CTTGC	CxxCxxxCx{10}CxxxCxxxC CCTCAGACACCTGAGACCCCACTTCC	442: GACTT	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{11}CxxxCxxxC CGCTGACCTGCTCCGACCTTCACGC	GTCAT	
	948: TACGA	CxxCxxxCx{12}CxxxCxxxC CAGCAAGATGAGCCCTTACCCCTCTCCC	ADP66690	ck: 9406	len: 2,484	! Adp66690 Human mismatch repair protein MLH1
	2,366: CTTAA	CxxCxxxCx{11}CxxxCxxxC CTTCTTTACAAGTACTTACTGCTGCC	650: CAATG	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxxC CCTCAACGCTGGACAATATTCGCTCCATC	TTTGG	
	2,385: ACTTA	CxxCxxxCx{11}CxxxCxxxC CTGCTGCTGCTGTGTGCCAGACGCTC	1,760: GCCAG	CxxCxxxCx{11}CxxxCxxxC CACCGCTCTTGACCTTGCCTTCCTG	CTTAG	
	2,434: TGCAG	CxxCxxxCx{11}CxxxCxxxC CAGCAGACAGGTGCGATGACAGCCACC	ADQ76348	ck: 1208	len: 1,036	! Adq76348 Bovine recessive oncogene bgl-1-relj
	2,641: AATCA	CxxCxxxCx{11}CxxxCxxxC CATCTTCTTGTGTACCACCAACCAAC	102: TTCCC	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxxC CAACAGCCAGCGCTTGGCTTCGACC	CGGAG	
	2,658: TCTAC	CxxCxxxCx{12}CxxxCxxxC CACCAACCAACAGATGTACCCATCATTC	ADQ10419	ck: 8145	len: 3,046	! Adq10419 Human polypeptide #233. 9/2004
			757: GGATG	CXXCXXCX{10,12}CXXCXXXC CxxCxxxCx{12}CxxxCxxxC CTCTCTTGTGGAGCCATTCCATCCACC	CAGGT	

CxxCxxxCx(11)CxxxCxxx  
941: TTGCT CTGGCTCAGCCAGGAGTGCATT C AACAT  
CxxCxxxCx(12)CxxxCxxx  
957: CAGGG CAGCTGCATTCAACATCATCCGCCAGC GGTCC  
CxxCxxxCx(10)CxxxCxxx  
971: TTCAA CATCATCCGACGCGTCTGTGTGC CGCCG  
CxxCxxxCx(11)CxxxCxxx  
974: AACAT CATCCGCCACGGGTCTGTGCCGCC GATT C  
CxxCxxxCx(12)CxxxCxxx  
1,072: GAGCT CAGCAGTCTGTGCTTCTCTCACGGAC ATTGA  
CxxCxxxCx(12)CxxxCxxx  
1,631: AGACT CTGCAGCTTCTGTCTGGCTTACCAAGC CTTGG  
CxxCxxxCx(10)CxxxCxxx  
1,870: CTCGT CTACCGTCTACAATGGCTCTCTTGC TGCTG  
CxxCxxxCx(11)CxxxCxxx  
2,138: CTGGC CATCGTCTCTGGAGTGTCACTCTC CTCCT

ADQ10186 ck: 2811 len: 678 ! Adq10186 Human polypeptide #55. 9/2004

CXXCXXXCX(10,12)CXXCXXXC  
CXXCXXXCX(12)CXXCXXXC  
204: TAGGA CTCCTGTGCTCTTAGTCCAGACTCC AGGCA  
CXXCXXXCX(12)CXXCXXXC  
208: ACTCC CTGCTGTCTTAGTCCAGACTCCAGGC ATCCC

1

ADQ35137 ck: 7705 len: 101 ! Adq35137 Mutant cyanovirin-N protein SEQ ID  
CXXCXXXCX(10,12)CXXCXXXC  
CXXCXXXCX(12)CXXCXXXC  
9: FSQTC CCCCCCCCCCCTGTTGGCCCCCCCC CCCE N  
CxxCxxxCx(11)CxxxCxxx  
10: SQTCC CCCCCCCCCCCTGTTGGCCCCCCCC CCCE N  
CxxCxxxCx(10)CxxxCxxx  
11: QTCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCCE N  
CxxCxxxCx(10)CxxxCxxx  
12: TCCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCENV  
CxxCxxxCx(10)CxxxCxxx  
13: CCCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCENV  
CxxCxxxCx(10)CxxxCxxx  
14: CCCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCENV  
CxxCxxxCx(12)CxxxCxxx  
59: FIECC CCCCCCCCCCCTGTTGGCCCCCCCC CCCCC  
CxxCxxxCx(11)CxxxCxxx  
60: IECCC CCCCCCCCCCCTGTTGGCCCCCCCC CCCCC  
CxxCxxxCx(10)CxxxCxxx  
61: ECCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCCCC  
CxxCxxxCx(11)CxxxCxxx  
62: CCCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCANI  
CxxCxxxCx(10)CxxxCxxx  
63: CCCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCANI  
CxxCxxxCx(10)CxxxCxxx  
64: CCCCC CCCCCCCCCCCTGTTGGCCCCCCCC CANID

1

CxxCxxxCx(10)CxxxCxxx  
65: CCCCC CCCCCCCCCCCTGTTGGCCCCCCCC ANIDC  
ADQ35148 ck: 9816 len: 101 ! Adq35148 Mutant cyanovirin-N protein SEQ ID  
CXXCXXXCX(10,12)CXXCXXXC  
CXXCXXXCX(12)CXXCXXXC  
11: QTCYC CCCCCCCCCCCTGTTGGCCCCCCCC IENV D  
CxxCxxxCx(11)CxxxCxxx  
12: TCYCC CCCCCCCCCCCTGTTGGCCCCCCCC IENV D  
CxxCxxxCx(10)CxxxCxxx  
13: CYCCC CCCCCCCCCCCTGTTGGCCCCCCCC IENV D  
CxxCxxxCx(12)CxxxCxxx  
60: IETCR CCCCCCCCCCCTGTTGGCCCCCCCC CCIAN  
CxxCxxxCx(11)CxxxCxxx  
61: ETCRC CCCCCCCCCCCTGTTGGCCCCCCCC CCIAN  
CxxCxxxCx(10)CxxxCxxx  
62: TCRCC CCCCCCCCCCCTGTTGGCCCCCCCC CCIAN  
CxxCxxxCx(10)CxxxCxxx  
63: CRCCC CCCCCCCCCCCTGTTGGCCCCCCCC CIANI  
CxxCxxxCx(10)CxxxCxxx  
64: RCCCC CCCCCCCCCCCTGTTGGCCCCCCCC IANID  
ADQ35147 ck: 5108 len: 101 ! Adq35147 Mutant cyanovirin-N protein SEQ ID  
CXXCXXXCX(10,12)CXXCXXXC  
CXXCXXXCX(12)CXXCXXXC  
9: FSQTC CCCCCCCCCCCTGTTGGCCCCCCCC CCCE N  
CxxCxxxCx(11)CxxxCxxx  
10: SQTCC CCCCCCCCCCCTGTTGGCCCCCCCC CCCE N  
CxxCxxxCx(10)CxxxCxxx  
11: QTCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCCE N  
CxxCxxxCx(10)CxxxCxxx  
12: TCCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCENV  
CxxCxxxCx(10)CxxxCxxx  
13: CCCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCENV  
CxxCxxxCx(10)CxxxCxxx  
14: CCCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCENV  
CxxCxxxCx(12)CxxxCxxx  
59: FIECC CCCCCCCCCCCTGTTGGCCCCCCCC CCCCC  
CxxCxxxCx(11)CxxxCxxx  
60: IECCC CCCCCCCCCCCTGTTGGCCCCCCCC CCCCC  
CxxCxxxCx(10)CxxxCxxx  
61: ECCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCCCC  
CxxCxxxCx(10)CxxxCxxx  
62: CCCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCAN  
CxxCxxxCx(10)CxxxCxxx  
63: CCCCC CCCCCCCCCCCTGTTGGCCCCCCCC CCANI  
CxxCxxxCx(10)CxxxCxxx  
64: CCCCC CCCCCCCCCCCTGTTGGCCCCCCCC CANID  
CxxCxxxCx(10)CxxxCxxx

1

09/331,431

Tue Feb 22 12:26:15 2005

```
65: CCCCC CCCCCCKTRACCCCCCCCCCCCCC ANIDC
ADR09287 ck: 571 len: 201 ! ADR09287 Human protein useful for treating
1      CXXCXXCX{10,12}CXXCXXXC
      CxxCxxCx{10}CxxCxxxC
8: RAQEG CEGCVVCVCVLCVSVVCVCLCVC VCVCV
ADS10978 ck: 7493 len: 105 ! ADS10978 Human therapeutic protein - SEQ ID
1      CXXCXXCX{10,12}CXXCXXXC
      CxxCxxCx{11}CxxCxxxC
9: CGCGS CGCGGRCGGGCGGCGGCGGCGGCG
ADS12210 ck: 6981 len: 102 ! ADS12210 Human therapeutic contig protein -
1      CXXCXXCX{10,12}CXXCXXXC
      CxxCxxCx{11}CxxCxxxC
6: CGCGS CGCGGRCGGGCGGCGGCGGCGGCGGCGGCG
```

Databases searched:  
EMBL, Release 26.0, Released on 16Dec2004, Formatted on 7Jan2005

Total finds:	2,131
Total length:	221,821,841
Total sequences:	1,377,707
CPU time:	06:16.89

```
! FINDPATTERNS on geneseq: *-allowing 0 mismatches
! 1- <CXXXCX{10,12}>CXXXC> - February 18, 2005 13:51 ..
1 AAE21104 ck: 8379 len: 22 ! Aae21104 Human T-139 (TANGO-139) consensus
    <CXXXCX{10,12}>CXXXC>
    CxxxCx{12}>CxxxC
    1: CCNGCCPGYTGRCGCCGCGYGC
1 AAE20060 ck: 5068 len: 20 ! Aae20060 Complement C1s catalytic site-dire
    <CXXXCX{10,12}>CXXXC>
    CxxxCx{10}>CxxxC
    1: CRLGCTYGFNTDKKGCEAFC
```

Databases searched:  
EMBL, Release 26.0, Released on 16Dec2004, Formatted on 7Jan2005

Total finds:	2
Total length:	221,821,841
Total sequences:	1,377,707
CPU time:	03:28.31

This Page Blank (uspdtj)

11AA SEQUENCE 1.0  
ID AAE21104 standard; peptide; 22 AA.  
XX AC CAAE21104A  
XX DT 01-JUL-2002 (first entry)  
XX DE Human T-139 (TANGO-139) consensus sequence #3.  
XX KW Human; haematopoiesis; clotting; kidney failure; wound healing; cancer;  
KW neoplasia; pancreatic disorder; pancreatitis; cerebrovascular disease;  
KW heart disorder; ischaemic heart disease; neuroprotective; vulnery;  
KW cardiovascular disorder; ischaemic heart disease; immunosuppressive;  
KW glomerular disease; glomerulonephritis; uterine disorder; hyperplasia;  
KW fetal spleen; prostate disorder; inflammatory disease; Crohn's disease;  
KW proliferative disorder; gynaecological; haemostatic; antibacterial;  
KW systemic lupus erythematosus; immunodeficiency disorder; antiasthmatic;  
KW cytostatic; nephrotropic; antidiabetic; cerebroprotective; tranquilliser;  
KW hypotensive; tumour; injury; trauma; antineoplastic; vasotropic; antiulcer;  
KW apoptotic disorder; rheumatoid arthritis; cardiac; renal disorder;  
KW hepatotropic; antipsoriatic; anti-allergic; dermatological; virucide.  
XX OS Homo sapiens.  
XX PN US2002028508-A1.  
XX PD 07-MAR-2002.  
XX PF 21-FEB-2001; 2001US-00790264.  
XX PR 23-APR-1998; 98US-00065363.  
PR 23-APR-1998; 98US-00065361.  
PR 22-JUN-1998; 98US-00102705.  
PR 29-JUL-1998; 98US-00124538.  
PR 23-APR-1999; 99US-00298531.  
PR 22-JUN-1999; 99US-00337930.  
PR 29-JUL-1999; 99US-00363630.  
XX (HOLT/) HOLTZMAN D A.  
PA (GOOD/) GOODEARL A D J.  
PA (MCCA/) MCCARTHY S A.  
XX Holtzman DA, Goodearl ADJ, McCarthy SA;  
PI WPI; 2002-303420/34.  
XX Novel TANGO polypeptides and nucleic acid molecules useful as modulating  
PT agents in regulating cellular processes and for diagnosing and treating  
PT heart, liver, lung, kidney, inflammatory and cellular proliferative  
PT disorders.  
XX Example 3; Fig 2C; 138pp; English.  
XX The invention relates to nucleic acids encoding a variety of proteins  
CC human T139 (TANGO-139), T125 (TANGO-125), T110 (TANGO-110), murine T175  
CC (TANGO-175), human T175 or murine WDNM-2, having diagnostic, preventive,  
CC therapeutic and other uses. Polypeptide of the invention has the ability  
CC to inhibit a proteinase activity, to modulate cell-cell interactions,  
CC haematopoiesis and the ability to modulate clotting. Polypeptide and  
CC polynucleotide of the invention are useful for diagnosing and treating  
CC disorder characterised by their aberrant expression or activity. The  
CC antibodies are useful as modulating agents in regulating a variety of  
CC cellular processes e.g. cell proliferation and/or cell differentiation.  
CC TANGO-139 is useful for treating kidney defects such as kidney failure,  
CC TANGO-125 is useful in wound healing and for treating cancer, TANGO-110  
CC is useful for treating neoplasia, TANGO-177 or WDNM-2 is useful for  
CC treating cancer, are useful to treat pancreatic disorders, such as  
CC pancreatitis, cerebrovascular disease, and tumours, and injury or trauma  
CC to the brain. TANGO-125, 110, 175 molecules treat heart disorders, e.g.,  
CC ischaemic heart disease, cardiovascular disorders, such as ischaemic  
CC heart disease. TANGO-139, 125, 110 and 175 molecules are useful to treat  
CC renal (kidney) disorders, such as glomerular disease (e.g., acute and  
CC chronic glomerulonephritis), TANGO-175 is useful to treat uterine

disorders, hyperplasia of the endometrium. TANGO-110 is useful to treat  
spleen, e.g., the fetal spleen, associated diseases and disorder. TANGO-  
125 treats prostate disorders, such as inflammatory diseases, Crohn's  
disease and tumours. TANGO-139, 125, 110, 175 or WDNM-2 are useful for  
treating proliferative disorders, inflammatory disorders. TANGO-175, or  
WDNM-2 activity also include apoptotic disorders, rheumatoid arthritis,  
systemic lupus erythematosus, insulin-dependent diabetes mellitus, immune  
-related disorders, e.g., immunodeficiency disorders, viral disorders,  
cell growth disorders, e.g., cancers and inflammatory disorders and  
apoptotic disorders. The nucleic acids of the invention are used in gene  
therapy. The present sequence is human T-139 protein consensus sequence  
XX Sequence 22 AA;  
SQ  
AAE21104 Length: 22 February 22, 2005 14:14 Type: P Check: 8379 ..  
1 CCNGCCPGYT GRCCCGCGY GC

27 days

This page Blank (uspio)



!!AA SEQUENCE 1.0  
ID AAE20060 standard; peptide; 20 AA.  
XX AC AAE20060  
XX DT 18-JUN-2002 (first entry)  
XX DE Complement C1s catalytic site-directed moiety, peptide #61.  
XX KW Complement C1s; therapeutic; adult respiratory distress syndrome; stroke;  
KW preservative; ischaemia-reperfusion injury; myocardial infarct; sepsis;  
KW hyperacute rejectin; rheumatoid arthritis; burn; wound healing; asthma;  
KW systemic lupus erythematosus; SLE; haemolytic anaemia; serum sickness;  
KW restenosis; myasthenia gravis.  
XX OS Unidentified.  
XX PN WO200198365-A2.  
XX PD 27-DEC-2001.  
XX PF 18-JUN-2001; 2001WO-US019405.  
XX PR 21-JUN-2000; 2000US-0212998P.  
XX PA (ZYMO ) ZYMOGENETICS INC.  
XX PI West RR, Sheppard PO, Fox BA;  
XX DR WPI; 2002-241177/29.  
XX PT New complement C1s inhibitor polypeptides for treating diseases in which  
PT complement activation has been shown to occur, e.g. adult respiratory  
PT distress syndrome, ischemia-reperfusion injury, asthma, or sepsis.  
XX PS Disclosure; Page 20; 99pp; English.  
XX CC The invention relates to a polypeptide that inhibits complement C1s. The  
CC inhibitory peptides are useful as therapeutic agents, as preservatives in  
CC blood samples, and in affinity purification procedures to isolate C1s.  
CC Molecules that inhibit complement may be used for treating diseases in  
CC which complement activation has been shown to occur, e.g., adult  
CC respiratory distress syndrome, ischaemia-reperfusion injury (myocardial  
CC infarct, stroke), hyperacute rejectin, sepsis, burns, wound healing,  
CC asthma, restenosis, rheumatoid arthritis, systemic lupus erythematosus,  
CC serum sickness, haemolytic anaemias, or myasthenia gravis. The present  
CC peptide sequence is complement C1s catalytic site-directed moiety  
XX SQ Sequence 20 AA;

AAE20060 Length: 20 February 22, 2005 14:14 Type: P Check: 5068 ..

1 CRLGCTYGPK TDKKGCEAPC

done

**This Page Blank (uspto)**

! FINDPATTERNS on pir:\* allowing 0 mismatches

! 1-1-CXXXCX{10,12}CXXC\$ February 18, 2005 13:49 ..

Databases searched:

NRPF, Release 79.1, Released on 16Aug2004, Formatted on 17Oct2004

Total finds: 0  
Total length: 96,216,763  
Total sequences: 283,416  
CPU time: 46.59

This Page Blank (just to)

! FINDPATTERNS on uniprot allowing 0 mismatches

! ~~1~~XXXXXXXXXX(10,12)XXXXX February 18, 2005 13:54 ..

Databases searched:

UNIPROT, Release 3.1, Released on 9Nov2004, Formatted on 5Nov2004

Total finds: 512,079,187

Total length: 1,612,378

Total sequences: 04:37.99

CPU time:

This Page Blank (Jspdtj)

! FINDPATTERNS on geneseq: allowing 0 mismatches

! 1<CXXCXXCX{10,12}CXXCXXC> - pattern searched February 18, 2005 13

Databases searched:

EMBL, Release 26.0, Released on 16Dec2004, Formatted on 7Jan2005

Total finds: 0  
Total length: 221,821,841  
Total sequences: 1,377,707  
CPU time: 03:41.96

A - Geneseg

This Page Blank (uspio)



! FINDPATTERNS on ~~pir~~ allowing 0 mismatches

! 1 <CXXCXXCXX{10,12}>CXXCXXC>

February 18, 2005 13

Databases searched:

NERF, Release 79.1, Released on 16Aug2004, Formatted on 17Oct2004

Total finds: 96,216,763

Total length: 283,416

Total sequences: 44.71

CPU time:

PIR

This Page Blank (uspio)

! FINDPATTERNS on uniprot:\* allowing 0 mismatches

! 1<CXXCXXCXX(10,12)CXXCXXC>\*

February 18, 2005 13

Databases searched:

UNIPROT, Release 3.1, Released on 9Nov2004, Formatted on 5Nov2004

Total finds: 0

Total length: 512,079,187

Total sequences: 1,612,378

CPU time: 05:12.54

This Page Blank (usps)

! FINDPATTERNS on geneseq:\* allowing 0 mismatches

! 2-5(M/F)XXCXXCX(10,12)CXXCXXC(0,2)F

February 18,

Databases searched:

EMBL, Release 26.0, Released on 16Dec2004, Formatted on 7Jan2005

Total length: 221,821,841

Total sequences: 1,377,707

CPU time: 03:52.94

**This Page Blank (uspto)**

! FINDPATTERNS on pir:\*, allowing 0 mismatches  
! 1-<(Y,F)XXCXXCX{10,12}CXXCXX(Y,F)>

February 18,

Databases searched:  
NERF, Release 79.1, Released on 16Aug2004, Formatted on 17Oct2004

Total finds: 0  
Total lengths: 96,216,763  
Total sequences: 283,416  
CPU time: 48.00

**This Page Blank (uspto)**



! FINDPATTERNS on uniprot:\* allowing 0 mismatches

! 1. <[U,E]XXCXXCXX(40,42)CXXCXXCXX(VWF)S

February 18,

Databases searched:

UNIPROT, Release 3.1, Released on 9Nov2004, Formatted on 5Nov2004

Total finds: 1

Total length: 512,079,187

Total sequences: 1,612,378

CPU time: 05:13.79

This Page Blank (uspto)



This Page Blank (uspio)

```

!!IAA_SEQUENCE 1.0
P1:SMFF2- metallothionein 2 - fruit fly (Drosophila melanogaster)
C:Species: Drosophila melanogaster
C>Date: 31-Dec-1991 #sequence_revision 31-Dec-1991 #text_change 09-Jul-2004
C:Accession: S14706; A38808; A29863; S10476
R:Kuhn, R.; Theodor, L.; Mokdad, R.; Erraiss, N.E.; Cadic, A.; Wegnez, M.
J. Mol. Biol. 215, 217-224, 1990
A>Title: Metallothionein Mto gene of Drosophila melanogaster: structure and
regulation.
A:Reference number: S14706; MUID:91012582; PMID:1976815
A:Accession: S14706
A:Molecule type: DNA
A:Residues: 1-43 <SIL>
A:Cross-references: UNIPROT:P11956; EMBL:X52098; NID:G8274; PIDN:CAA36318.1;
PID:G295751
A:Accession: A38808
A:Molecule type: protein
A:Residues: 'X', 3-24, 'X', 26-27 <SIL2>
A>Note: 15-Thr was also found
R:Mokdad, R.; Debec, A.; Wegnez, M.
Proc. Natl. Acad. Sci. U.S.A. 84, 2658-2662, 1987
A>Title: Metallothionein genes in Drosophila melanogaster constitute a dual
system.
A:Reference number: A29863; MUID:87204190; PMID:3106973
A:Accession: A29863
A:Molecule type: mRNA
A:Residues: 1-43 <MOK>
A:Cross-references: GB:M16250; NID:G157884; PIDN:AAA28663.1; PID:G157885
C:Genetics:
A:Gene: Mto
A:Cross-references: FlyBase:FBgn0002869
A:Map position: 3R 92E
A:Introns: 9/1
C:Superfamily: metallothionein
C:Keywords: blocked amino end; chelation; metal binding
P1/Modified site: blocked amino end (Met) #status experimental
SMFF2 Length: 43 February 22, 2005 12:24 Type: P Check: 9665 ..

1 MVCKGGTNC QCSAQKCGDN CACNKDCQCV CKNGPKDQCC SNK

!!IAA_SEQUENCE 1.0
P1:S25775 - testis-specific protein Mst84Dd - fruit fly (Drosophila
melanogaster)
C:Species: Drosophila melanogaster
C>Date: 26-Jul-1996 #sequence_revision 26-Jul-1996 #text_change 09-Jul-2004
C:Accession: S25775; D56565
R:Kuhn, R.; Kuhn, C.; Boersch, D.; Glaetzer, K.H.; Schaefer, U.; Schaefer, M.
Mech. Dev. 35, 143-151, 1991
A>Title: A cluster of four genes selectively expressed in the male germ line of
Drosophila melanogaster.
A:Reference number: A56565; MUID:92102953; PMID:1684716
A:Accession: S25775
A:Molecule type: DNA
A:Residues: 1-68 <KUH>
A:Cross-references: UNIPROT:Q01645; EMBL:X67703; NID:G11072; PIDN:CAA47940.1;
PID:G11076
A>Note: sequence extracted from NCBI backbone (NCBIN:74217, NCBIP:74223)
C:Genetics:
A:Gene: Mst84Dd
A:Cross-references: FlyBase:FBgn0004175
A:Map position: 3
C:Superfamily: fruit fly testis-specific protein
C:Keywords: spermatogenesis; tandem repeat

S25775 Length: 68 February 22, 2005 12:24 Type: P Check: 4823 ..

1 MGCAPGGPCC GPCGCGGPGC CGPCGCGPGC GPCGCGGPGC GPCGCGGPGC
51 PCCGTMEKRN GLQRCPP

!!IAA_SEQUENCE 1.0
P1:S25773 - testis-specific protein Mst84Db - fruit fly (Drosophila

```

```

melanogaster)
C:Species: Drosophila melanogaster
C>Date: 26-Jul-1996 #sequence_revision 26-Jul-1996 #text_change 09-Jul-2004
C:Accession: S25773; B56565
R:Kuhn, R.; Kuhn, C.; Boersch, D.; Glaetzer, K.H.; Schaefer, U.; Schaefer, M.
Mech. Dev. 35, 143-151, 1991
A>Title: A cluster of four genes selectively expressed in the male germ line of
Drosophila melanogaster.
A:Reference number: A56565; MUID:92102953; PMID:1684716
A:Accession: S25773
A:Molecule type: DNA
A:Residues: 1-74 <KUH>
A:Cross-references: UNIPROT:Q01643; EMBL:X67703; NID:G11072; PIDN:CAA47938.1;
PID:G11074
A>Note: sequence extracted from NCBI backbone (NCBIN:74217, NCBIP:74220)
C:Genetics:
A:Gene: Mst84Db
A:Cross-references: FlyBase:FBgn0004173
A:Map position: 3
C:Superfamily: fruit fly testis-specific protein
C:Keywords: spermatogenesis; tandem repeat

S25773 Length: 74 February 22, 2005 12:24 Type: P Check: 1743 ..

1 MCCGPLGFCG PCSPCGGPGC PCGPGCGPGS CCSPCGSCCA PMGPGCGPGC
51 CGCGCGPGCL CGPCGCGCRP YCGC

!!IAA_SEQUENCE 1.0
P1:B21761 - high cysteine chorion B 12 protein precursor - silkworm
C:Species: Bombyx mori (silkworm)
C>Date: 20-Jul-1990 #sequence_revision 20-Jul-1990 #text_change 11-Jan-2000
C:Accession: B21761
R:Latrou, K.; Tsirlou, S.G.; Kafatos, F.C.
Proc. Natl. Acad. Sci. U.S.A. 81, 4452-4456, 1984
A>Title: DNA sequence transfer between two high-cysteine chorion gene families
in the silkworm Bombyx mori.
A:Reference number: A21761; MUID:84272653; PMID:6589605
A:Accession: B21761
A>Status: preliminary
A:Molecule type: DNA
A:Residues: 1-143 <IAT>
C:Superfamily: chorion class A protein pc292

B21761 Length: 143 February 22, 2005 12:24 Type: P Check: 5481 ..

1 MAKLIVFVC AIALVAOSVL GTCCGCCCRG CGCGCGGCGC GCENFRVCS
51 NSAAPTGLSI CSENRKGDV CVCGEVFFLG TADVCGNMCS SGCGCIDYGC
101 GNGCVGITS CGCGCGCGG CGCGCGGCGC CGCSCGRSCC GVV

!!IAA_SEQUENCE 1.0
P1:T27686 - hypothetical protein ZK1067.7 - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C>Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jul-2004
C:Accession: T27686
R:Thomas, K.
submitted to the EMBL Data Library, March 1996
A:Reference number: Z20404
A:Accession: T27686
A>Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-314 <WIL>
A:Cross-references: UNIPROT:Q23390; EMBL:Z70038; PIDN:CAA93886.1;
GSPDB:GN00020; CESP:ZK1067.7
A:Experimental source: clone ZK1067
C:Genetics:
A:Gene: CESP:ZK1067.7
A:Map position: 2
A:Introns: 30/3; 296/2
C:Superfamily: gliadin

```

*Chlorophyll  
sp. aurea*



51 KXNGGCGGCG GCGGGGGGCG CCCCRPRCCC CCRPKKCCCTC CRTCCCTRC  
 101 TCRPRCCCGC GCGCGCGCGG GGGGRKRSLLQ KLQIDEANRA LGIKRPPSNG  
 151 KC

!!IAA\_SEQUENCE 1.0  
 P1:T15651 - hypothetical protein C27A2.5 - Caenorhabditis elegans  
 C:Species: Caenorhabditis elegans  
 C>Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 09-Jul-2004  
 C:Accession: T15651  
 R:Nhan, M.  
 submitted to the EMBL Data Library, May 1996  
 A:Description: The sequence of C. elegans cosmid C27A2.  
 A:Reference number: Z18382  
 A:Accession: T15651  
 A:Status: preliminary; translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-188 <NHA>  
 A:Cross-references: UNIPROT:Q18238; EMBL:U58760; NID:gl330384; PID:gl330389;  
 PIDN:AA80710.1; GSPDB:GN00020; CESP:C27A2.5  
 A:Experimental source: strain Bristol N2; clone C27A2  
 C:Genetics:  
 A:Gene: CESP:C27A2.5  
 A:Map position: 2  
 A:Introns: 19/3; 91/2

T15651 Length: 188 February 22, 2005 12:24 Type: P Check: 4240 ..

1 MNKLVCTFA ILAIIAISQV QSAVLPVSSK EVALITSSAS TTSSETSID  
 51 TLGSSRVKQK GCGCGCGCGC GCGCGCGGG GCGCGCCCRP KCCCCRRCC  
 101 TCRTCCCTC CTCCRPCCC CCGCGCGCGG CCGGGRKRS LQNLRIALAN  
 151 KIEGIAKVK GSAVEASVM ALAPVNDATV EKKOVIN

!!IAA\_SEQUENCE 1.0  
 P1:T16246 - hypothetical protein F35A5.4 - Caenorhabditis elegans  
 C:Species: Caenorhabditis elegans  
 C>Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 09-Jul-2004  
 C:Accession: T16246  
 R:Leimbach, D.  
 submitted to the EMBL Data Library, January 1996  
 A:Description: The sequence of C. elegans cosmid F35A5.  
 A:Reference number: Z18485  
 A:Accession: T16246  
 A:Status: preliminary; translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-273 <LEI>  
 A:Cross-references: UNIPROT:Q20000; EMBL:U46675; NID:gl166613; PID:gl166614;  
 PIDN:AB52645.1; GSPDB:GN00028; CESP:F35A5.4  
 A:Experimental source: strain Bristol N2; clone F35A5  
 C:Genetics:  
 A:Gene: CESP:F35A5.4  
 A:Map position: X  
 A:Introns: 18/3; 62/3; 81/3; 100/3; 140/3; 226/2

T16246 Length: 273 February 22, 2005 12:24 Type: P Check: 4997 ..

1 MOYLAAFAV FQLSIGDFRS TSALTSPYLK MNGSLITRVR SKRQCCAMCP  
 51 SGNCGGSGCS GFVTCPRQC PMCTQACVMA KTSVCVDQCM PKCDSACINL  
 101 GBSCDQQCMP LCLPACINAI QGTECAPQC MPSCSNCIQ QVFPSCPOQC  
 151 QVCTPQCICQ SIQVAIQRPCT CASSCMPSCS QSCIQKYEIT VEQETCVAPC  
 201 MPACSSACVQ AVTCTCTNN CPICSQANC IPQCHPRCLP TCIOIQIISV  
 251 PLFVSKNQS LKHVSILRNY WPS

!!IAA\_SEQUENCE 1.0  
 P1:T24272 - hypothetical protein T01B7.8 - Caenorhabditis elegans  
 C:Species: Caenorhabditis elegans  
 C>Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 09-Jul-2004  
 C:Accession: T24272  
 R:Sims, M.  
 submitted to the EMBL Data Library, October 1995  
 A:Reference number: Z19867  
 A:Accession: T24272  
 A:Status: preliminary; translated from GB/EMBL/DBJ  
 A:Molecule type: DNA  
 A:Residues: 1-164 <WIL>  
 A:Cross-references: UNIPROT:Q22048; EMBL:Z66499; PIDN:CAA91301.1;  
 GSPDB:GN00020; CESP:T01B7.8  
 A:Experimental source: clone T01B7  
 C:Genetics:  
 A:Gene: CESP:T01B7.8  
 A:Map position: 2  
 A:Introns: 20/3; 90/2

T24272 Length: 164 February 22, 2005 12:24 Type: P Check: 3285 ..

1 MTTSTLAILL AIGTFIAVSQ VQSAVLPVSS TELATVGTDV STASTAIDTL  
 51 GNSSSRVKRQ GCGCGCGCGC GCGCGCGGG GCGCCCCRPR CCCCCRRCT  
 101 CCRCCCTRC CTCCRPCCG CCGCGCGCGC GGGGRKRS LQNLRIIDANR  
 151 ALGIKRSK ADRC

!!IAA\_SEQUENCE 1.0  
 P1:H71271 - hypothetical protein TP0856 - syphilis spirochete  
 C:Species: Treponema pallidum subsp. pallidum (syphilis spirochete)  
 C>Date: 24-Jul-1998 #sequence\_revision 24-Jul-1998 #text\_change 09-Jul-2004  
 C:Accession: H71271  
 R:Fraser, C.M.; Norris, S.J.; Weinstock, G.M.; White, O.; Sutton, G.G.; Dodson, R.; Gwinn, M.; Hickey, E.K.; Clayton, R.; Ketchum, K.A.; Sodergren, E.; Hardham, J.M.; McLeod, M.P.; Salzberg, S.; Peterson, J.; Khalak, H.; Richardson, D.; Howell, J.K.; Chidambaram, M.; Utterback, T.; McDonald, L.; Artach, P.; Bowman, C.; Cotton, M.D.; Fujii, C.; Garland, S.; Hatch, B.; Horst, K.; Roberts, K.; Watthey, L.; Weidman, J.; Smith, H.O.; Venter, J.C. Science 281, 375-388, 1998  
 A:Title: Complete genome sequence of Treponema pallidum, the syphilis spirochete.  
 A:Reference number: A71250; MUID:98332770; PMID:9665876  
 A:Accession: H71271  
 A:Status: preliminary; nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-325 <COL>  
 A:Cross-references: UNIPROT:O83828; GB:AE001256; GB:AE000520; NID:g3323171;  
 PIDN:AA65828.1; PID:g3323176  
 A:Experimental source: strain Nichols  
 C:Genetics:  
 A:Gene: TP0856

H71271 Length: 325 February 22, 2005 12:24 Type: P Check: 1526 ..

1 MVHYKSVYK SAALVCGFVL AGASVAIASS EAAAKTRSKM SEPKERRAVSS  
 51 PSGGRSLVLD GSFTALANDA SFPEANPAGS ANMTHSELTFF AHTVGFNNSH  
 101 AETLSYVQGS GNMGYGASMR MFPPESGPNF SPSTGPVCTP ASNPIKILGG  
 151 LGIVNFSRRF GGUSIGANLK AGFRDAQGLT HLSLGTDVGL QWGVNAKFF  
 201 SSAEPNMYVG LSATNLGFTV KLPGPSFVLC RATGQCCCKT CSGRTGVGT  
 251 CCNGEKPCCK DDCNCPCQD EATPGSPHAT DTMLRAGFAY RPLSWFLFSV  
 301 GVATRVNVSN LQVDHSGSAL PMRLG

This Page Blank (uspto)



```
! FINDPATTERNS on_uniprot.* allowing 0 mismatches
! 1_CXXCXXCXXC{10,12}CXXCXXXC February 22, 2005 10:3
<M84B_DROME ck: 1743 len: 74 ! Q01643 drosophila melanogaster (fruit fly).
1 CXXCXXCXXC{10,12}CXXCXXXC
CXXCXXCXXC{11}CXXCXXXC
12: GPGPC CSPGCGPCGPGCGGSCGPGSCC APWGP
CXXCXXCXXC{11}CXXCXXXC
45: APWGP CGPGCGCGGPGCLGPGCCGPRPYC GC
M84B_DROME ck: 4823 len: 68 ! Q01645 drosophila melanogaster (fruit fly).
1 CXXCXXCXXC{10,12}CXXCXXXC
CXXCXXCXXC{10}CXXCXXXC
10: PGGPC CGPGCGPGCCGPGCCGPGCGPC GPGGP
CXXCXXCXXC{10}CXXCXXXC
17: PCGPC CGPGCGPGCGPGCGPGCGPC GPGGP
MT2_DROME ck: 9665 len: 43 ! P11956 drosophila melanogaster (fruit fly).
1 CXXCXXCXXC{10,12}CXXCXXXC
CXXCXXCXXC{12}CXXCXXXC
3: MV CKGGGTNCQSAKQGNACNKCQCVC KNGPK
MT3_DROME ck: 9524 len: 43 ! Q9vdn2 drosophila melanogaster (fruit fly).
1 CXXCXXCXXC{10,12}CXXCXXXC
CXXCXXCXXC{12}CXXCXXXC
3: MV CKGGGTNCKQDTRKCGDNACNODCKVC KNGPK
MT4_DROME ck: 3624 len: 44 ! Q819b4 drosophila melanogaster (fruit fly).
1 CXXCXXCXXC{10,12}CXXCXXXC
CXXCXXCXXC{12}CXXCXXXC
3: MG CKAGGTNCQSATKCGDNACSCQQCQSC KNGPK
Y856_TREPA ck: 1526 len: 325 ! O83828 treponema pallidum, hypothetical up
1 CXXCXXCXXC{10,12}CXXCXXXC
CXXCXXCXXC{12}CXXCXXXC
238: TGRQC CKTSGRGTGVTCCNGBKPCCKDCDCNC PCQDE
Q16861 ck: 7355 len: 46 ! Q16861 homo sapiens (human). super cysteine
1 CXXCXXCXXC{10,12}CXXCXXXC
CXXCXXCXXC{10}CXXCXXXC
11: PDRSR CCCCCCCCCCCCCCCCCCCCCC LKHSK
Q62092 ck: 571 len: 201 ! Q62q92 homo sapiens (human). hypothetical p
1 CXXCXXCXXC{10,12}CXXCXXXC
CXXCXXCXXC{10}CXXCXXXC
8: RAQEG CEGCVCVCVVCLVSVVCLVCLVC VCVCV
Q17641 ck: 8575 len: 197 ! Q17641 caenorhabditis elegans. hypothetical
1 CXXCXXCXXC{10,12}CXXCXXXC
CXXCXXCXXC{10}CXXCXXXC
86: GGCGC CCCCPRCCCCRRCTCCRTCCCTRC CTCCR
CXXCXXCXXC{11}CXXCXXXC
93: CCRPR CCCCRRCTCCRTCCCTCCRPCC CGCGC
CXXCXXCXXC{10}CXXCXXXC
94: CRPRC CCCCRRCTCCRTCCCTCCRPCC CGCGC
CXXCXXCXXC{10}CXXCXXXC
97: RCCCC CRRCTCCRTCCCTCCRPCCCGC GCGGC
CXXCXXCXXC{11}CXXCXXXC
100: CCRRR CTTCCRTCCCTCCRPCCCGGCGC GCGGC
CXXCXXCXXC{10}CXXCXXXC
101: CRRRC CTCRTCCCTCCRPCCCGGCGC GCGGC
Q18238 ck: 4240 len: 188 ! Q18238 caenorhabditis elegans. hypothetical
1 CXXCXXCXXC{10,12}CXXCXXXC
CXXCXXCXXC{10}CXXCXXXC
85: GGCGC CCCCRRKCCCCRRCTCCRTCCCTRC CTCCR
CXXCXXCXXC{11}CXXCXXXC
92: CCRPK CCCCRRCTCCRTCCCTCCRPCC CGCGC
CXXCXXCXXC{10}CXXCXXXC
93: CRPKC CCCCRRCTCCRTCCCTCCRPCC CGCGC
CXXCXXCXXC{10}CXXCXXXC
96: KCCCC CRRCTCCRTCCCTCCRPCCCGC GCGGC
CXXCXXCXXC{11}CXXCXXXC
99: CCRRR CTTCCRTCCCTCCRPCCCGGCGC GCGGC
CXXCXXCXXC{10}CXXCXXXC
100: CRRRC CTCRTCCCTCCRPCCCGGCGC GCGGC
Q20000 ck: 4997 len: 273 ! Q20000 caenorhabditis elegans. hypothetical
1 CXXCXXCXXC{10,12}CXXCXXXC
CXXCXXCXXC{12}CXXCXXXC
214: VQAVT CSTCTNNCPISQANCIPOCMRCLPTC IQQIQ
Q22048 ck: 3285 len: 164 ! Q22048 caenorhabditis elegans. hypothetical
1 CXXCXXCXXC{10,12}CXXCXXXC
CXXCXXCXXC{10}CXXCXXXC
84: GGCGC CCCCRRKCCCCRRCTCCRTCCCTRC CTCCR
CXXCXXCXXC{11}CXXCXXXC
91: CCRPR CCCCRRCTCCRTCCCTCCRPCC CGCGC
CXXCXXCXXC{10}CXXCXXXC
92: CRPRC CCCCRRCTCCRTCCCTCCRPCC CGCGC
CXXCXXCXXC{10}CXXCXXXC
95: RCCCC CRRCTCCRTCCCTCCRPCCCGC GCGGC
CXXCXXCXXC{11}CXXCXXXC
98: CCRRR CTTCCRTCCCTCCRPCCCGGCGC GCGGC
CXXCXXCXXC{10}CXXCXXXC
99: CRRRC CTCRTCCCTCCRPCCCGGCGC GCGGC
Q23390 ck: 8047 len: 314 ! Q23390 caenorhabditis elegans. hypothetical
1 CXXCXXCXXC{10,12}CXXCXXXC
CXXCXXCXXC{12}CXXCXXXC
105: POTNN CNGCQQCQISSCATPICAQSCNNQCSSC GNSAP
```



1	Q7PUH8	ck: 4529	len: 45	! Q7puh8 anopheles gambiae str. pest. ensangp
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{11}CxxxCxxx
3:	MP	CKCGNDCKTSGSGSQPCATDCKAC	ASGGC	
1	Q7RQ6	ck: 9997	len: 402	! Q7rq6 plasmodium yoelii yoelii. ring-finge
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{10}CxxxCxxx
124:	GCPEC	CEGPECEDCHDENCPCDQTECTDEC	REBCA	
				CxxCxxxCx{11}CxxxCxxx
127:	ECCEG	CPECCEDCHDENCPCDQTECTDEC	REBCA	
1	Q7YWV7	ck: 8091	len: 212	! Q7yvw7 caenorhabditis elegans. hypothetical
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{11}CxxxCxxx
77:	RQGGG	CGCGGCGCGCCGPRCCCCRCCTCC	RTCCG	
				CxxCxxxCx{10}CxxxCxxx
86:	GGCG	CCCRPRCCCCRCCTCCRTCCCTC	CTCCR	
				CxxCxxxCx{11}CxxxCxxx
93:	CCRPR	CCCCRCCTCCRTCCCTCCCTCC	CRPCC	CGCG
				CxxCxxxCx{10}CxxxCxxx
94:	CRPRC	CCCRRCCTCCCTCCCTCCCTCC	CRPCC	CGCG
				CxxCxxxCx{10}CxxxCxxx
97:	RCCCC	CRRCCTCCCTCCCTCCCTCC	CRPCCG	CGCG
				CxxCxxxCx{11}CxxxCxxx
100:	CCRR	CCTCCTCCCTCCCTCCCTCC	CGCGG	CGCG
				CxxCxxxCx{10}CxxxCxxx
101:	CCBRC	CTCCTCCCTCCCTCCCTCC	CGCGG	CGCG
1	Q9VI99	ck: 8119	len: 72	! Q9vi99 drosophila melanogaster (fruit fly)
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{10}CxxxCxxx
10:	PGGPC	CGPGCCGPGCGPGCGPGCG	GPCG	
				CxxCxxxCx{11}CxxxCxxx
13:	PCCGP	CGPGCGPGCGPGCGPGCG	GPCGP	
				CxxCxxxCx{10}CxxxCxxx
21:	CCGPC	CGPGCGPGCGPGCGPGCG	GPCGP	
1	Q9VIA1	ck: 915	len: 74	! Q9via1 drosophila melanogaster (fruit fly)
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{11}CxxxCxxx
12:	GFCGP	CSPCGPGCGPGCGPGCG	SPCGSC	APCGP
				CxxCxxxCx{11}CxxxCxxx
45:	APCGP	CGPGCGPGCGPGCGPGCG	GPCR	PYC GC
1	Q9VM37	ck: 9817	len: 580	! Q9vm37 drosophila melanogaster (fruit fly)
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{11}CxxxCxxx
11:	NKPSS	CVDCCDKDTLLPCCSASACDAS	CDAAAC	GLIPP

1	Q9VU12	ck: 6468	len: 271	! Q9vu12 drosophila melanogaster (fruit fly)
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{11}CxxxCxxx
119:	PVNTC	CMFCSNQCPWSWIYNPTGCIYCANCC	NGCRN	
1	Q9XVX3	ck: 2827	len: 152	! Q9xvx3 caenorhabditis elegans. hypothetical
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{12}CxxxCxxx
71:	GGGCG	CCCRPRCCCCGPRKCCCTCCCTCC	CTCCR	
				CxxCxxxCx{12}CxxxCxxx
79:	CRPRC	CCCRPKCCCTCCCTCCCTCC	CTCCR	CGCG
				CxxCxxxCx{11}CxxxCxxx
87:	CRPKC	CTCCTCCCTCCCTCCCTCC	CGCG	
				CxxCxxxCx{10}CxxxCxxx
88:	RPKCC	CTCCTCCCTCCCTCCCTCC	CGCG	
1	Q9C6G7	ck: 6340	len: 661	! Q9c6g7 arabidopsis thaliana (mouse-ear cress)
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{11}CxxxCxxx
609:	NSRPF	CYTCELRCGQTLVFKYIGGCKSFCTLRC	IGNYF	
1	Q9C8A8	ck: 2666	len: 599	! Q9c8a8 arabidopsis thaliana (mouse-ear cress)
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{11}CxxxCxxx
547:	NSRPF	CYTCELRCGQTLVFKYIGGCKSFCTLRC	IGNYF	
1	Q9SPL3	ck: 7549	len: 625	! Q9spl3 macadamia integrifolia (macadamia nut)
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{12}CxxxCxxx
41:	DPQTE	COQCRRCRQESGPRQOQYQRRCKEIC	EBEEE	
1	Q9SPL4	ck: 911	len: 666	! Q9spl4 macadamia integrifolia (macadamia nut)
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{12}CxxxCxxx
82:	DPQTD	COQCRRCRQESGPRQOQYQRRCKEIC	EBEEE	
1	Q9SPL5	ck: 8155	len: 666	! Q9spl5 macadamia integrifolia (macadamia nut)
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{12}CxxxCxxx
82:	DPQTE	COQCRRCRQESGPRQOQYQRRCKEIC	EBEEE	
1	Q7UIX3	ck: 6414	len: 110	! Q7uix3 rhodopirellula baltica. hypothetical
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{11}CxxxCxxx
78:	ACAEI	CKACABSCFKVGMCKVECCRTCEQSC	SSMAA	
1	Q62220	ck: 7182	len: 223	! Q62220 mus musculus (mouse). serine 2 ultra
				CXXCXXXCX{10,12}CXXXCXXXC
				CxxCxxxCx{10}CxxxCxxx
57:	GGCGS	CGGCKGGCGGCGGCGGCGG	CCQSS	
				CxxCxxxCx{10}CxxxCxxx
67:	GGCGS	CGGCKGGCGGCGGCGGCGG	CCQSS	

```
Q9D122 ck: 8227 len: 167 ! Q9d122 mus musculus (mouse). mus musculus 1
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{11}CxxxCxxx
99: CGSSC CRPCRPCSPCCSPCCRPCRPCRPC CRPCC
103: CCRPC CRPCSPCCSPCCRPCRPCRPCRPC CCLRP
  CxxCxxxCx{11}CxxxCxxx
Q9D228 ck: 986 len: 113 ! Q9d228 mus musculus (mouse). mus musculus 6
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{10}CxxxCxxx
57: CGCGG CGCGCGCGCKPTVCCRRSCCRSC GCGSC
Q9D230 ck: 7679 len: 122 ! Q9d230 m mus musculus 6 days neonate skin c
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{10}CxxxCxxx
63: GGCGC CGCGCGCGCKPTVCCRRSCCRSC GCGSC
Q9D929 ck: 1883 len: 199 ! Q9d929 m mus musculus adult male testis cdr
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{11}CxxxCxxx
47: GFKWC CSTCYPRCFQGCCCTCYGRSERCWCMC YSRCC
59: CFQGC CCTCYGRSERCWCMCYSRCCQRCSCIC RATIR
  CxxCxxxCx{11}CxxxCxxx
Q9DAE3 ck: 2990 len: 120 ! Q9dae3 mus musculus (mouse). mus musculus a
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{11}CxxxCxxx
61: PPCPP CPPCHLVQSQGSTPTPLCPPLCSPRC SGTLA
Q69566 ck: 8293 len: 413 ! Q69566 human herpesvirus 6. u88. 10/2002
1 CXXCXXCX{10,12}CXXCXXXC
  CxxCxxxCx{11}CxxxCxxx
298: VCVCV CLLCNSLCMCMCMCMCMCMSLC MSILCM
```

Databases searched:  
UNIPROT, Release 3.1, Released on 9Nov2004, Formatted on 5Nov2004

Total finds:	105
Total length:	512,079,187
Total sequences:	1,612,378
CPU time:	11:09.95

```

!!IAA_SEQUENCE 1.0
ID M84D_DROME STANDARD; PRT; 74 AA.
AC Q01643;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Male specific sperm protein Mst84Db.
GN Name=Mst84Db;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Oregon-R;
RX MEDLINE=92102953; PubMed=1684716; DOI=10.1016/0925-4773(91)90064-D;
RA Kuhn R., Kuhn C., Boersch D., Glaetzer K.H., Schaefer U., Schaefer M.;
RT "A cluster of four genes selectively expressed in the male germ line
of Drosophila melanogaster."
RL Mech. Dev. 35:143-151(1991).
CC -!- TISSUE SPECIFICITY: Testis.
CC -!- DEVELOPMENTAL STAGE: Primary spermatocytes.
CC -!- DOMAIN: This protein is mostly composed of repetitive C-G-P
motifs.
CC -!- SIMILARITY: Belongs to the MST(3)CGP family.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC
DR EMBL; X67703; CAA47938.1; -.
DR PIR; S25773; S25773.
DR HSP; Q9S7B3; 1EHH.
DR FLYBase; FBgn0004173; Mst84Db.
DR InterPro; IPR005634; MSSP.
DR Pfam; PF03940; MSSP; 1.
KW Multigene family; Repeat; Spermatogenesis.
SQ SEQUENCE 74 AA; 6824 MW; D0793137A7E7D1D0 CRC64;

M84B_DROME Length: 74 February 22, 2005 12:25 Type: P Check: 1743 ..

1 MCGPLGFGC PCSPGCGFCG PCGPGCGQS CCSPGSCCA PNGPGCGPG
51 CCGGCGPCGL CGPCGCPRP YCGC

!!IAA_SEQUENCE 1.0
ID M84D_DROME STANDARD; PRT; 68 AA.
AC Q01645;
DT 01-JUL-1993 (Rel. 26, Created)
DT 01-JUL-1993 (Rel. 26, Last sequence update)
DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Male specific sperm protein Mst84Db.
GN Name=Mst84Db;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Oregon-R;
RX MEDLINE=92102953; PubMed=1684716; DOI=10.1016/0925-4773(91)90064-D;
RA Kuhn R., Kuhn C., Boersch D., Glaetzer K.H., Schaefer U., Schaefer M.;
RT "A cluster of four genes selectively expressed in the male germ line
of Drosophila melanogaster."
RL Mech. Dev. 35:143-151(1991).
CC -!- TISSUE SPECIFICITY: Testis.
CC -!- DEVELOPMENTAL STAGE: Primary spermatocytes.
CC -!- DOMAIN: This protein is mostly composed of repetitive C-G-P
motifs.
CC -!- SIMILARITY: Belongs to the MST(3)CGP family.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC
DR EMBL; X67703; CAA47938.1; -.
DR PIR; S25773; S25773.
DR HSP; Q9S7B3; 1EHH.
DR FLYBase; FBgn0004173; Mst84Db.
DR InterPro; IPR005634; MSSP.
DR Pfam; PF03940; MSSP; 1.
KW Multigene family; Repeat; Spermatogenesis.
SQ SEQUENCE 74 AA; 6824 MW; D0793137A7E7D1D0 CRC64;

M84B_DROME Length: 74 February 22, 2005 12:25 Type: P Check: 1743 ..

1 MCGPLGFGC PCSPGCGFCG PCGPGCGQS CCSPGSCCA PNGPGCGPG
51 CCGGCGPCGL CGPCGCPRP YCGC

```

```

CC -!- DOMAIN: This protein is mostly composed of repetitive C-G-P
motifs.
CC -!- SIMILARITY: Belongs to the MST(3)CGP family.
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
CC
DR EMBL; X67703; CAA47940.1; -.
DR PIR; S25775; S25775.
DR FLYBase; FBgn0004175; Mst84Dd.
DR InterPro; IPR005634; MSSP.
DR Pfam; PF03940; MSSP; 1.
KW Multigene family; Repeat; Spermatogenesis.
SQ SEQUENCE 68 AA; 6480 MW; 2F2BD26128DE3DEF CRC64;

M84D_DROME Length: 68 February 22, 2005 12:25 Type: P Check: 4823 ..

1 MGCAPGPGCC GPCGCGCGPC CGPCCGPGCG PCGPGCGPGC PRGPGCGPGC
51 PCCGTMEKRN GLQRCPPF

!!IAA_SEQUENCE 1.0
ID MT2_DROME STANDARD; PRT; 43 AA.
AC P11956; Q9VDM2;
DT 01-OCT-1989 (Rel. 12, Created)
DT 01-OCT-1989 (Rel. 12, Last sequence update)
DT 25-JAN-2005 (Rel. 46, Last annotation update)
DE Metallothionein 2 (MT-2) (Metallothionein B).
GN Name=MtnB; Synonym=Mto; ORFNames=CG4312;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Oregon-R;
RX MEDLINE=87204190; PubMed=3106973;
RA Mokdad R., Debec A., Wegnez M.;
RT "Metallothionein genes in Drosophila melanogaster constitute a dual
system."
RL Proc. Natl. Acad. Sci. U.S.A. 84:2658-2662(1987).
RN [2]
RP SEQUENCE FROM N.A., AND SEQUENCE OF 3-27.
RC STRAIN=Oregon-R;
RX MEDLINE=91012582; PubMed=1976815;
RA Silar P., Theodore L., Mokdad R., Errais N.-E., Cadic A., Wegnez M.;
RT "Metallothionein Mto gene of Drosophila melanogaster: structure and
regulation."
RL J. Mol. Biol. 215:217-224 (1990).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=Berkely;
RX MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scher S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Wortman J.R., Vandal M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,
RA Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkuch C., Baldwin D.,
RA Balow R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA Beeson K.Y., Benos P.V., Bernan B.P., Bhandari D., Bolshakov S.,
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,
RA Burtis K.C., Busam D.A., Butler H., Cadiou E., Center A., Chandra I.,
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,

```

RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,  
RA Foeller C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glaeser K.,  
RA Glödek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,  
RA Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,  
RA Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwach C.,  
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,  
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,  
RA Laeko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,  
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,  
RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,  
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,  
RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,  
RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,  
RA Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,  
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,  
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,  
RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,  
RA Wang Z.-Y., Wassarman D.A., Weinstein G.M., Weissbach J.,  
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,  
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,  
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;  
RA "The genome sequence of *Drosophila melanogaster*.";  
RL Science 287:2185-2195(2000).  
RN [4]  
RP GENOME REANNOTATION.  
RX MEDLINE=22426069; PubMed=12537572;  
RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,  
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,  
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,  
RA Bettencourt B.R., Celisner S.E., de Grey A.D.N.J., Drysdale R.A.,  
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,  
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,  
RA Lewis S.E.;  
RT "Annotation of the *Drosophila melanogaster* euchromatic genome: a  
RT systematic review.";  
RL Genome Biol. 3:RESEARCH0083.22(2002).  
RN [2]  
RP GENOME REANNOTATION.  
RX MEDLINE=22426069; PubMed=12537572;  
RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,  
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,  
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,  
RA Bettencourt B.R., Celisner S.E., de Grey A.D.N.J., Drysdale R.A.,  
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,  
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,  
RA Lewis S.E.;  
RT "Annotation of the *Drosophila melanogaster* euchromatic genome: a  
RT systematic review.";  
RL Genome Biol. 3:RESEARCH0083.22(2002).  
RN [3]  
RP IDENTIFICATION  
RX MEDLINE=22393008; PubMed=12505988; DOI=10.1093/emboj/cdg012;  
RA Egli D., Selvaraj A., Yepiskoposyan H., Zhang B., Hafen E.,  
RA Georgiev O., Schaffner W.;  
RT "Knockout of 'metal-responsive transcription factor' MTF-1 in  
RT *Drosophila* by homologous recombination reveals its central role in

Q9VDN2;  
05-JUL-2004 (Rel. 44, Created)  
05-JUL-2004 (Rel. 44, Last sequence update)  
25-JAN-2005 (Rel. 46, Last annotation update)  
DE Metallothionein 3 (MT-3) [Metallothionein C].  
GN Name=Mtnc; ORFNames=CG5097;  
OS *Drosophila melanogaster* (Fruit fly).  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
OC Ephydroidea; Drosophilidae; Drosophila.  
OX NCBI\_TaxID=7227;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Berkley;  
RX MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;  
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,  
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,  
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,  
RA Sutton G.G., Wortman J.R., Vandell M.D., Zhang Q., Chen L.X.,  
RA Brandon R.C., Rogers J.-H.C., Blazej R.G., Champe M., Pfeiffer B.D.,  
RA Abril J.F., Agayani A., An H.-J., Andrews-Fianknoch C., Baldwin D.,  
RA Balow R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,  
RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,  
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P.,  
RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,  
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,  
RA de Rubeis B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,  
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,  
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,  
RA Föster C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glaeser K.,  
RA Glödek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,  
RA Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,  
RA Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwach C.,  
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,  
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,  
RA Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,  
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,  
RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,  
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,  
RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacleb J.M.,  
RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,  
RA Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,  
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,  
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,  
RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,  
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,  
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,  
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;  
RT "The genome sequence of *Drosophila melanogaster*.";  
RL Science 287:2185-2195(2000).  
RN [2]  
RP GENOME REANNOTATION.  
RX MEDLINE=22426069; PubMed=12537572;  
RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,  
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,  
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,  
RA Bettencourt B.R., Celisner S.E., de Grey A.D.N.J., Drysdale R.A.,  
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,  
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,  
RA Lewis S.E.;  
RT "Annotation of the *Drosophila melanogaster* euchromatic genome: a  
RT systematic review.";  
RL Genome Biol. 3:RESEARCH0083.22(2002).  
RN [3]  
RP IDENTIFICATION  
RX MEDLINE=22393008; PubMed=12505988; DOI=10.1093/emboj/cdg012;  
RA Egli D., Selvaraj A., Yepiskoposyan H., Zhang B., Hafen E.,  
RA Georgiev O., Schaffner W.;  
RT "Knockout of 'metal-responsive transcription factor' MTF-1 in  
RT *Drosophila* by homologous recombination reveals its central role in

RT heavy metal homeostasis";  
 RA EMBO J. 22:100-108(2003).  
 CC -!- FUNCTION: This protein binds cations of several transition  
 CC elements. Thought to be involved in metal ion homeostasis (By  
 CC similarity).  
 CC -!- DOMAIN: All cysteine residues are arranged in C-X-C groups. These  
 CC are thought to be the metal-binding sites in other  
 CC metallothioneins.  
 CC -!- SIMILARITY: Belongs to the metallothionein superfamily. Family 5.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC -----  
 CC EMBL; AB003730; AAF55758.1; -;  
 DR FlyBase; FBgn0038790; MtnC.  
 DR InterPro; IPR000966; Metallothion\_5.  
 DR Pfam; PF02067; Metallothio\_5; 1.  
 DR PRINTS; PR00872; MTDIPTERA\_1.  
 KW Cadmium; Copper; Metal-binding; Zinc.  
 SQ SEQUENCE 43 AA; 4597 MW; E54E722B14E89DFE CRC64;  
 MT3\_DROME Length: 43 February 22, 2005 12:25 Type: P Check: 9524 ..  
 1 MVCKGGTGTC KCQDTRKCGDN CACNQDCKCV CKNGPKDQCC KSK  
 !!AA\_SEQUENCE 1.0  
 ID MT4\_DROME STANDARD; PRT; 44 AA.  
 AC Q81984; Q86B88;  
 DT 05-JUL-2004 (Rel. 44, Created)  
 DT 05-JUL-2004 (Rel. 44, Last sequence update)  
 DT 25-JAN-2005 (Rel. 46, Last annotation update)  
 DE Metallothionein 4 (MT-4) (Metallothionein D).  
 GN Name=MtnD; ORFNames=CG33192;  
 OS Drosophila melanogaster (Fruit fly).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
 OC Ephydroidea; Drosophilidae; Drosophila.  
 OX NCBI\_TaxID=7227;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Canton-S.  
 EX MEDLINE=2393008; PubMed=12505988; DOI=10.1093/emboj/cdg012;  
 RA Egli D., Selvaraj A., Yeliskoposyan H., Zhang B., Hafen E.,  
 RA Georgiev O., Schaffner W.;  
 RT "Knockout of 'metal-responsive transcription factor' MTF-1 in  
 RT Drosophila by homologous recombination reveals its central role in  
 RT heavy metal homeostasis";  
 RL EMBO J. 22:100-108(2003).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Berkley;  
 RX MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;  
 RA Adams M.D., Celisner S.E., Holt R.A., Evans C.A., Gocayne J.D.,  
 RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,  
 RA Sutton G.G., Wortman J.R., Richards S., Ashburner M., Henderson S.N.,  
 RA Brandon R.C., Rogers Y.-H.C., Yandell M.D., Zhang Q., Chen L.X.,  
 RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Pfeiffer B.D.,  
 RA Abril J.F., Agbayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,  
 RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,  
 RA Beeson K.Y., Benos P.V., Bernan B.P., Bhandari D., Bolshakov S.,  
 RA Borokova D., Botchan M.R., Bouck J., Brokstein P., Brotter P.,  
 RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,  
 RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,  
 RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,  
 RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,  
 RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,  
 RA Foeller C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,

Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,  
 Harris N.L., Harvey D.A., Heiman T.J., Hernandez J.R., Houck J.,  
 RA Hostin D., Houston K.A., Howland T.J., Wei M.-H., Ibegwam C.,  
 RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,  
 RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,  
 RA Lasko P., Lei Y., Levitsky A.A., Li J.H., Li Z., Liang Y., Lin X.,  
 RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,  
 RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,  
 RA Mout S.M., Moy M., Murphy B., Murphy L., Muzny D.R., Nelson D.L.,  
 RA Nelson D.R., Nelson K.A., Nixon K., Nuskern D.R., Pacleb J.M.,  
 RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,  
 RA Reinert K., Remington K., Saunders R.D.C., Scheeler F., Shen H.,  
 RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,  
 RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,  
 RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,  
 RA Wang Z.-Y., Wasegama D.A., Weinstein G.M., Weissenbach J.,  
 RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,  
 RA Ye J., Yeh R.-F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,  
 RA Zheng X.H., Zhong F.N., Zhou W., Zhou X., Zhu S., Zhu X., Smith H.O.,  
 RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;  
 RT "The genome sequence of Drosophila melanogaster";  
 RL Science 287:2185-2195(2000).  
 RN [3]  
 RP GENOME REANNOTATION.  
 RX MEDLINE=22426069; PubMed=12537572;  
 RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,  
 RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,  
 RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,  
 RA Bettencourt B.R., Celisner S.E., de Grey A.D.N.J., Drysdale R.A.,  
 RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,  
 RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,  
 RA Lewis S.E.;  
 RT "Annotation of the Drosophila melanogaster euchromatic genome: a  
 RT systematic review";  
 RL Genome Biol. 3:RESEARCH0083.1-RESEARCH0083.22(2002).  
 CC -!- FUNCTION: This protein binds cations of several transition  
 CC elements. Thought to be involved in metal ion homeostasis (By  
 CC similarity).  
 CC -!- DOMAIN: All cysteine residues are arranged in C-X-C groups. These  
 CC are thought to be the metal-binding sites in other  
 CC metallothioneins.  
 CC -!- SIMILARITY: Belongs to the metallothionein superfamily. Family 5.  
 CC -!- CAUTION: Strains Oregon-R and Berkeley have a stop codon in  
 CC position 32 that truncates the sequence.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC -----  
 CC EMBL; AF546903; AAN73050.1; -;  
 DR EMBL; AE003731; AAO41579.1; -;  
 DR FlyBase; FBgn0053192; MtnD.  
 DR InterPro; IPR000966; Metallothion\_5.  
 DR Pfam; PF02067; Metallothio\_5; 1.  
 DR PRINTS; PR00872; MTDIPTERA\_1.  
 KW Cadmium; Copper; Metal-binding; Zinc.  
 SQ SEQUENCE 44 AA; 4545 MW; 34F0847BFA8BCC7B CRC64;  
 MT4\_DROME Length: 44 February 22, 2005 12:25 Type: P Check: 3624 ..  
 1 MGCKACGTNC QCSATKCGDN CACSQCQCQS CKNGPKDKCC STKN  
 !!AA\_SEQUENCE 1.0  
 ID Y856 TREPA STANDARD; PRT; 325 AA.  
 AC O81828;  
 DT 16-OCT-2001 (Rel. 40, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 25-OCT-2004 (Rel. 45, Last annotation update)  
 DE Hypothetical UPF0164 protein TP0856 precursor.

```
GN OrderedLocusNames=TP0856;
OS Treponema pallidum
OC Bacteria; Spirochaetes; Spirochaetales; Spirochaetaceae; Treponema.
OX NCBI_TaxID=160;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Nichols;
RX MEDLINE=98332770; PubMed=9665876; DOI=10.1126/science.281.5375.375;
RA Fraser C.M., Norris S.J., Weinscock G.M., White O., Sutton G.G.,
RA Dodson R.J., Gwinn M.L., Hickey E.K., Clayton R.A., Ketchum K.A.,
RA Sodergren E., Hardham J.M., McLeod M.P., Salzberg S.L., Peterson J.D.,
RA Khalak H.G., Richardson D.L., Howell J.K., Chidambaram M.,
RA Uterback T.R., McDonald L.A., Attiach P., Bowman C., Cotton M.D.,
RA Fujii C., Garland S.A., Hatch B., Horst K., Roberts K.M., Sandusky M.,
RA Weidman J.F., Smith H.O., Venter J.C.;
RT "Complete genome sequence of Treponema pallidum, the syphilis
RT spirochete."
RL Science 281:375-388(1998).
CC -i- SIMILARITY: Belongs to the UPF0164 family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; AE001256; AAC65928.1; -.
DR PIR; H71271; H71271.
DR TIGR; TP0856; -.
DR InterPro; IPR005362; UPF0164.
DR Pfam; PF03687; UPF0164; 1.
KW Complete proteome; Hypothetical protein; Signal.
FT SIGNAL 1 28 Potential.
FT CHAIN 29 325 Hypothetical UPF0164 protein TP0856.
SQ SEQUENCE 325 AA; 34054 MW; F9CFDCBD253C07D2 CRC64;
Y856_TREPA Length: 325 February 22, 2005 12:25 Type: P Check: 1526 ..
1 MVHYKSVFYK SAALVCGFVL AGASVAIASS EAAAKTRSKM SEFKRRVSS
51 PSGGRSLVLD GSFTALANDA SFFEANPAGS ANMTHSELTF AHTVGFNNSH
101 AETLSYVCQS GNGYCGASMR MFFPSGFNF SPSTGPGVCTP ASNPICKLGG
151 LGIVNFSRRF GGLSIGANLK AGFRDAQGLT HLSLGTVDVL QWVGNVAKFF
201 SSAEPNMVVG LSATNLGFTV KLPGSPFVLC RATGEQCKT CSGRCTGVGT
251 CCNKEKPCCK DDCNCPQD EATPGSPHAT DTMLRAGPAY RPLSWFLFSV
301 GVATRVNVSN LQVDHSGSAL PMLRG
!!AA_SEQUENCE 1.0
ID Q16861 PRELIMINARY; PRT; 46 AA.
AC Q16861;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE Super cysteine rich protein (Fragment).
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=I.; Devaux C., Mesnard J.M.;
RL Submitted (JUL-1996) to the EMBL/GenBank/DBJ databases.
DR EMBL; U63332; AAB05810.1; -.
FT NON TER 1 1
SQ SEQUENCE 46 AA; 5061 MW; 311922FE40A44E8F CRC64;
```

```
Q16861 Length: 46 February 22, 2005 12:25 Type: P Check: 7355 ..
1 GCCLCPDRSR CCCCCCCCCC CCCCCCCCCC CCGFCCLKH SKVKYI
!!AA_SEQUENCE 1.0
ID Q6ZQS2 PRELIMINARY; PRT; 201 AA.
AC Q6ZQS2;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein FLJ45585.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Thalamus;
RA Tanai H., Watanabe S., Ishibashi T., Chiba Y., Fujimori K., Hiraoka S.,
RA Kanehori K., Irie R., Otsuki T., Sato H., Wakamatsu A., Ishii S.,
RA Sugiyama T., Isono Y., Kawai-Hio Y., Saito K., Nishikawa T.,
RA Yamamoto J., Matsuo K., Nakamura Y., Sekine M., Kikuchi H., Kanda K.,
RA Kimura K., Takahashi-Fujii A., Oshima A., Sugiyama A., Kawakami B.,
RA Wagatsuma M., Sugano S., Nagahari K., Masuho Y., Nagai K., Isogai T.;
RA Suzuki Y., Sugano S., Nagahari K., Masuho Y., Nagai K., Isogai T.;
RL Submitted (JUL-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK128797; BAC87611.1; -.
DR InterPro; IPR006209; EGF_like.
DR PROSITE; PS01186; EGF 2; UNKNOWN 1.
SQ SEQUENCE 201 AA; 20938 MW; 3408F8E817AA0500 CRC64;
Q6ZQS2 Length: 201 February 22, 2005 12:25 Type: P Check: 571 ..
1 MLRAQGGCEG CVCVCVCVCV LCVSVCVCVC LCVCVCVCVC LCLCVLSVSV
51 CLCVCVSVCL CVCVSVCLVC VCLVCVCVSV LCVCVLCVC VCGFVCLCLC
101 VCVCVLCVCV LHLVCVGLC VSVCFVSVVC VCLVCVCVCIC VFVVCVWVCV
151 LCVCVCLVCV LCLCVLCVC VFVSVVCVSV VCVCMCIGRT VVPAPQGHQA
201 L
!!AA_SEQUENCE 1.0
ID Q17641 PRELIMINARY; PRT; 197 AA.
AC Q17641;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-OCT-2001 (TrEMBLrel. 18, Last sequence update)
DT 01-WAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein C04G6.7.
GN Names=C04G6.7; ORNames=C04G6.7;
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC Rhabditidae; Peloderinae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RX MEDLINE=99069613; PubMed=9851916;
RG WormBase Consortium;
RT "Genome sequence of the nematode C. elegans: a platform for
RT investigating biology. The C. elegans Sequencing Consortium."
RL Science 282:2012-2018(1998).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RA Anderson K., Chisoe S.;
RL Submitted (APR-1996) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RA Waterston R.;
```



RL Submitted (JAN-2003) to the EMBL/GenBank/DBJ databases.  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RG WormBase Consortium;  
 RL Submitted (SEP-2004) to the EMBL/GenBank/DBJ databases.  
 RA Wilson R.;  
 RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.  
 RN [5]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RG WormBase Consortium;  
 RL Submitted (SEP-2004) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; U5854; AAK68161.1; --  
 DR HSP; P10969; IWGI.  
 DR WormBase; WBGene00015457; C04G6.7.  
 DR WormPep; C04G6.7; CE27652.  
 DR InterPro; IPR001450; 4Fe4S ferredoxin.  
 DR InterPro; IPR006209; EGF\_like.  
 DR InterPro; IPR001007; VWF\_C.  
 DR PROSITE; PS00198; 4Fe4S\_FERREDOXIN; UNKNOWN\_1.  
 DR PROSITE; PS00269; DEFENSIN; UNKNOWN\_1.  
 DR PROSITE; PS00222; EGF\_1; UNKNOWN\_1.  
 DR PROSITE; PS01208; VWF\_1; UNKNOWN\_1.  
 KW Hypothetical protein.  
 SQ SEQUENCE 197 AA; 20596 MW; FB5F9457BFB9B8AD CRC64;  
 Q17641 Length: 197 February 22, 2005 12:25 Type: P Check: 8575 ..  
 1 MSKIAVSTLA ILAIIAISQV QSAVLPVSSK EVALVTSSITD ASTTSSSETS  
 51 IDTLGSRVYK RQGGCGCGCG GCGCGCGGG GCGCGCCCCR PRCCCCRRRC  
 101 CTCCTCCCTC RCCTCCRPCC GCGCGCGCG GGGGHFLKST AMARPKPLIE  
 151 EXAKKQENDE KQREASRNC CDLASVEVRR PNFADNYRQ ELPTQR  
 !!AA SEQUENCE 1.0  
 ID Q18238 PRELIMINARY; PRT; 188 AA.  
 AC Q18238;  
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
 DE Hypothetical protein C27A2.5.  
 GN Name=C27A2.5; ORFNames=C27A2.5;  
 OS Caenorhabditis elegans.  
 OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;  
 OC Rhabditidae; Peloderinae; Caenorhabditis.  
 OX NCBI\_TaxID=6239;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RX MEDLINE=99069613; PubMed=9851916;  
 RG WormBase Consortium;  
 RL "Genome sequence of the nematode C. elegans: a platform for  
 RT investigating biology. The C. elegans Sequencing Consortium.";  
 RL Science 282:2012-2018(1998).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RA Nhan M.;  
 RL "The sequence of C. elegans cosmid C27A2.";  
 RL Submitted (MAY-1996) to the EMBL/GenBank/DBJ databases.  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RA Waterston R.;  
 RL Submitted (NOV-2002) to the EMBL/GenBank/DBJ databases.  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RA Wilson R.;  
 RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.  
 RN [5]

RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RG WormBase Consortium;  
 RL Submitted (SEP-2004) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; U58760; AAK31463.1; --  
 DR FIR; T15651; T15651.  
 DR HSP; P10968; 2CWG.  
 DR IntAct; Q18238; --  
 DR WormBase; WBGene00016153; C27A2.5.  
 DR WormPep; C27A2.5; CE04105.  
 DR GO; GO:0005576; Extracellular; IEA.  
 DR GO; GO:0006952; P: defense response; IEA.  
 DR GO; GO:0009613; P: response to pest, pathogen or parasite; IEA.  
 DR InterPro; IPR001450; 4Fe4S ferredoxin.  
 DR InterPro; IPR006081; Defensin\_alpha.  
 DR InterPro; IPR001007; VWF C.  
 DR PROSITE; PS00198; 4Fe4S\_FERREDOXIN; UNKNOWN\_1.  
 DR PROSITE; PS00269; DEFENSIN; 1.  
 DR PROSITE; PS01208; VWF\_1; UNKNOWN\_1.  
 KW Hypothetical protein.  
 SQ SEQUENCE 188 AA; 18878 MW; 0C5D0DC5CA8E0C4B CRC64;  
 Q18238 Length: 188 February 22, 2005 12:25 Type: P Check: 4240 ..  
 1 MNKLYCSTFA ILAIIAISQV QSAVLPVSSK EVALITSSAS TTSSETSID  
 51 TLGSSRVKQK GCGCGCGCG GCGCGCGGG GCGCGCCCCR KCCCCRRCC  
 101 TCCRTCCCTR CCTCCRPCC GCGCGCGCG GCGCGCCCCR LQNLRIALAN  
 151 KIEGIKVKVYK GSAVESVMN ALAPVNDATV EEKDVIN  
 !!AA SEQUENCE 1.0  
 ID Q20000 PRELIMINARY; PRT; 273 AA.  
 AC Q20000;  
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE Hypothetical protein F35A5.4.  
 GN Name=F35A5.4; ORFNames=F35A5.4;  
 OS Caenorhabditis elegans.  
 OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;  
 OC Rhabditidae; Peloderinae; Caenorhabditis.  
 OX NCBI\_TaxID=6239;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RX MEDLINE=99069613; PubMed=9851916;  
 RG WormBase Consortium;  
 RL "Genome sequence of the nematode C. elegans: a platform for  
 RT investigating biology. The C. elegans Sequencing Consortium.";  
 RL Science 282:2012-2018(1998).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RA Leimbach D.;  
 RL "The sequence of C. elegans cosmid F35A5.";  
 RL Submitted (JAN-1996) to the EMBL/GenBank/DBJ databases.  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RA Waterston R.;  
 RL Submitted (JAN-2003) to the EMBL/GenBank/DBJ databases.  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RA Waterston R.;  
 RL Submitted (NOV-2002) to the EMBL/GenBank/DBJ databases.  
 RN [5]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RA Wilson R.;  
 RL Submitted (SEP-2004) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; U46675; AAB52645.1; --  
 DR FIR; T16246; T16246.  
 DR WormBase; WBGene00018026; F35A5.4.  
 DR WormPep; F35A5.4; CE04488.  
 DR InterPro; IPR003341; DUF139.

```

DR Pfam: PF02363; C tripleX; 9.
KW Hypothetical protein.
SQ SEQUENCE 273 AA; 29231 MW; 11542812CC56530 CRC64;

Q20000 Length: 273 February 22, 2005 12:25 Type: P Check: 4997 ..

1 MQYLIAFAV FQLSLGDEFS TGAITSPLYK MNGSLITRVR SKRQCCAMCP
51 SGNGCGGSGS GFTVCPDRQ PMCYQACWA KTSVCVDQCM PKDSSACINL
101 GPSCDQQCMP LCLPACINAI OQFTECAPQC MPSCSSNCIQ QVPFSCFQOC
151 QPVCTPQCIQ SIQVATQPT CASSCMWPCS QSCIQKYEIT VEQETCVFAC
201 MPACSSACVQ AVTCSTCTNN CPSICSQANC IPQCMFRCPL TCIQIQIISV
251 PLPVSKNQSI LKHVSILRNY WPS

!!AA SEQUENCE 1.0
ID Q22048 PRELIMINARY; PRT; 164 AA.
AC Q22048;
DT 01-NOV-1996 (TReMBLrel. 01, Created)
DT 01-NOV-1996 (TReMBLrel. 01, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE Hypothetical protein T01B7.8.
GN ORFNames=T01B7.8;
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC Rhabditidae; Peloderinae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RX MEDLINE=99069613; PubMed=9851916;
RA none;
RT "Genome sequence of the nematode C.elegans: A platform for
investigating biology.";
RL Science 282:2012-2018 (1998).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RA Thomas K.;
RL Submitted (MAR-1996) to the EMBL/GenBank/DBJ databases.
DR EMBL; Z70038; CAA93886.1; -.
DR PIR; T27686; T27686.
DR IntAct; Q23390; -.
DR WormBase; WBGene00004174; ZK1067.7.
DR WormPep; ZK1067.7; CE03844.
KW Hypothetical protein.
SQ SEQUENCE 314 AA; 32803 MW; 8735F50B826ED303 CRC64;

Q23390 Length: 314 February 22, 2005 12:25 Type: P Check: 8047 ..

1 MAARRAASIL LIAVLALSST FVFADEETVK NETGLALSRA KRQCCSSNSN
51 SCGGNNNVQ CIPVCLQCC SSCQTSQCI QCPACNQCC GGNNQVILLP
101 QTNMNCQCCQ QCISCATPI CAQSCNNQCS SSCGNSAPQI VVLQPPQNCQ
151 GSCQSSCQQT CPTCNCQAC APACGGNNNN QIIIVVQDN SCSSNCNQCC
201 SSSCSTPICI QSCQSSCQQA ASQPASHNAC HPARLAAHPT RLQSSSLNKK
251 ETHAPTRAPT SASLPAQLQS VNSATLNVN PSARTLAPET AATNRSLS
301 NKKTTARINV NLPA

!!AA SEQUENCE 1.0
ID Q23947 PRELIMINARY; PRT; 49 AA.
AC Q23947;
DT 01-NOV-1996 (TReMBLrel. 01, Created)
DT 01-NOV-1996 (TReMBLrel. 01, Last sequence update)
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)
DE Testis-specific RNA.
GN Name=Mst87Fa; Synonyms=Dhtc3;
OS Drosophila hydei (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7224;
RN [1]
RP SEQUENCE FROM N.A.
RA Kuech A.; Buenemann H.;
RL Submitted (DEC-1990) to the EMBL/GenBank/DBJ databases.
DR EMBL; X58114; CAA41117.1; -.
DR FlyBase; FBgn0015096; Dhgd\Mst87Fa.
DR InterPro; IPR001450; 4Fe4S ferredoxin.
DR PROSITE; PS00198; 4Fe4S.FERREDOXIN; UNKNOWN 1.
SQ SEQUENCE 49 AA; 4610 MW; BE158FEC51369F01 CRC64;

Q23947 Length: 49 February 22, 2005 12:25 Type: P Check: 9303 ..

1 MCGPGCGGC GPCGCGCGPC YSCGPGCYSC CGPYSCCG CGGCGGPC

!!AA SEQUENCE 1.0
ID Q23390 PRELIMINARY; PRT; 314 AA.
AC Q23390;

```

```

!!AA_SEQUENCE 1.0
ID Q23948 PRELIMINARY; PRT; 49 AA.
AC Q23948;
DT 01-NOV-1996 (TREMBlrel. 01, Created)
DT 01-NOV-1996 (TREMBlrel. 01, Last sequence update)
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)
DE Testis-specific RNA.
GN Name=Met87Fb; Synonyms=DHtC2;
OS Drosophila hydei (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7224;
RN [1]
RP SEQUENCE FROM N.A.
RA Kuech A., Buenemann H.;
RL Submitted (DEC-1990) to the EMBL/GenBank/DBSJ databases.
DR EMBL, X58114; CA441118.1;
DR FlyBase; FBgn0015097; DmDlMet87Fb.
DR InterPro; IPR001450; 4FE4S_ferredoxin.
DR PROSITE; PS00198; 4FE4S_FERREDOXIN; UNKNOWN 1.
SQ SEQUENCE 49 AA; 4550 MW; 24759FEC51369FD CRC64;

Q23948 Length: 49 February 22, 2005 12:25 Type: P Check: 8555

1 MCCGPGCGCC GPCGCGCGPC YSCGPGCYSC CGPCYSCCG CCGCGCGCC

!!AA_SEQUENCE 1.0
ID Q81Q11 PRELIMINARY; PRT; 872 AA.
AC Q81Q11;
DT 01-MAR-2003 (TREMBlrel. 23, Created)
DT 01-MAR-2003 (TREMBlrel. 23, Last sequence update)
DT 01-MAR-2004 (TREMBlrel. 26, Last annotation update)
DE CG17666-PA.
GN ORFNames=CG17666;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RA MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.H., Blazej R.G., Champe M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L.,
RA Abail J.F., Agbayani A., An H.J., Andrews-Pfannkoch C., Baldwin D.,
RA Balow R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA Beeson K.V., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotter P.,
RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferrieria S., Fleischmann W.,
RA Fowler C., Gabriellian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
RA Jatali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA Lasbo P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Mattel B., McIntosh T.C., McLeod M.P., McPherson D.,
RA Merkulov G., Milshina N.V., Moberly C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nusakern D.R., Pacleby J.M.,
RA Palazolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,

```

```

RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.Y., Wassarman D.A., Weinstock G.M., Weissbach J.,
RA Williams S.M., Woodager, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,
RA Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "The genome sequence of Drosophila melanogaster.";
RL Science 287:2185-2195(2000).
RN [2]
RP SEQUENCE FROM N.A.
RA MEDLINE=22426065; PubMed=12537568;
RA Celniker S.E., Wheeler D.A., Kronmiller B., Carlson J.W., Halpern A.,
RA Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,
RA George R.A., Hoskins R.A., Laverly T., Muzny D.M., Nelson C.R.,
RA Pacleb J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,
RA Svirskas R., Tabor P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,
RA Weinstock G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;
RT "Finishing a whole-genome shotgun: Release 3 of the Drosophila
RT melanogaster euchromatic genome sequence.";
RL Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).
RN [3]
RP SEQUENCE FROM N.A.
RA MEDLINE=22426070; PubMed=12537573;
RA Kaminker J.S., Bergman C.M., Kronmiller B., Carlson J., Svirskas R.,
RA Patel S., Frise E., Wheeler D.A., Lewis S.E., Rubin G.M.,
RA Ashburner M., Celniker S.E.;
RT "The transposable elements of the Drosophila melanogaster euchromatin:
RT a genomic perspective.";
RL Genome Biol. 3:RESEARCH0084-RESEARCH0084(2002).
RN [4]
RP SEQUENCE FROM N.A.
RA MEDLINE=22426069; PubMed=12537572;
RA Miera S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochuk S.E.,
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA Bettencourt B.R., Celniker S.E., de Grey A.D., Drysdale R.A.,
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA Lewis S.E.;
RT "Annotation of the Drosophila melanogaster euchromatic genome: a
RT systematic review.";
RL Genome Biol. 3:RESEARCH0083-RESEARCH0083(2002).
RN [5]
RP SEQUENCE FROM N.A.
RA SEQUENCE (SEP-2002) to the EMBL/GenBank/DBSJ databases.
RG FlyBase;
RN Submitted (SEP-2002) to the EMBL/GenBank/DBSJ databases.
RN [6]
RP SEQUENCE FROM N.A.
RA SEQUENCE (MAR-2004) to the EMBL/GenBank/DBSJ databases.
RL EMBL; AE003540; AAN11857.1; -
DR IntAct; Q81Q11; -
DR FlyBase; FBgn0036311; CG17666.
DR InterPro; IPR000345; CytC_heme_BS.
DR InterPro; IPR008197; WAP.
DR PROSITE; PS00317; 4 DISULFIDE CORE; UNKNOWN 1.
DR PROSITE; PS00190; CYTOCHROME C; UNKNOWN 1.
SQ SEQUENCE 872 AA; 95331 MW; B40B5408075FE427 CRC64;

Q81Q11 Length: 872 February 22, 2005 12:25 Type: P Check: 8684

1 MCDPCRYLR CISCHGNGWC CPRPSCCRS CSSNNRNCRV VFSGEFQKFS

51 DMVPPSFLLK TPERPKRKR SKSCSACGDN CKDPCLANMDA CAESCENPCQ

101 DKGNGCKNPE DCAQDQLART GAYGTGFGFG PQQPTIIPCY GTYGTGNPM

151 IFGIPTPTQY GGRGVGPIV LPVAPSSVG QGDPRSIPAA GLPTQYTNKF

201 NPCTGEVYQC GDRQMPGPRP QGTAQVPSYN QFIQGLGMSK APNSQYIPFD

251 ATFOQRFINQ MPVTPYSGGS APAYGRNNQP MNCEPNNQNY SYTVPOSTNQ

```

```
301 VHVGNARSEV YNQOQSAATHS RVPVQLESSK GOLPHGNRRS KSPNQRSRPS
351 GDRSGRAYAN NNFPENVHAS PQAQRKSLS HRNESREGRS GKQASRATT
401 NYHSNSGGDR NVDHRSAPKS MASAGEVRSR DNNRSYDSRN RNKSVGAPT
451 RQVLYDQOR VGMGIDPSNQ YYPYNECAPL NATFVQDHPN FYAQPGHDVN
501 RTQASAPNL SKAGPKKDN SNKVPSFKP SKEKSTKCCC TRFDNNQYY
551 PHYVSESDC PPEENVNGK KKTQEKNCLE LLSRLTESCP PCDLQKWCHL
601 LMPKDKSK KOAKPSAKXN KKSNGSKVN KMSEHSSNEI EGTVASPQET
651 PEDEDAHCPK NCKKPCPTTP TKEMRTGCS ANLPEENEDP PPAPSNPPPA
701 PSNPPVPCN HAPAPYNTCC MPCSNQCWMS WYYPNCTGCV YYCANCNGC
751 RNCNVCYCCSP CGGCCSNSPA AQLEKIPPKP KQKERQDRSS NSTRNSGGTA
801 VSLGSCAPPS TPAWKCPRQ EVSTWPGYSP TASPFFSSPY SGRWKAGCVD
851 SHRNYQRNNQ GPPFNIGRVH HV
```

```
!!AA_SEQUENCE 1.0
ID_Q8MRU2 PRELIMINARY; PRT; 582 AA.
AC Q8MRU2;
DT 01-OCT-2002 (TremBLrel. 22, Created)
DT 01-OCT-2002 (TremBLrel. 22, Last sequence update)
DT 01-MAR-2004 (TremBLrel. 26, Last annotation update)
DE S024632P.
GN ORFNames=CG4496;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RA SEQUENCE FROM N.A.
RA Stapleton M., Brokstein P., Hong L., Agbayani A., Carlson J.,
RA Champe M., Chavez C., Dorsett V., Dreesnek D., Farfan D., Friese E.,
RA George R., Gonzalez M., Guarin H., Kronmiller B., Li P., Liao G.,
RA Miranda A., Mungall C.J., Nunoo J., Pacleb J., Paragas V., Park S.,
RA Patel S., Phouanavong S., Wan K., Yu C., Lewis S.E., Rubin G.M.,
RA Celniker S.;
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY119270; AAM51130.1; -.
DR HSSP; P07248; IARD.
DR FlyBase; FBgn0031894; CG4496.
DR GO; GO:0005634; C:nucleus; IEA.
DR GO; GO:0003676; F:nucleic acid binding; IEA.
DR GO; GO:0008270; F:zinc ion binding; IEA.
DR InterPro; IPR000345; CytC_heme_BS.
DR Pfam; PF00096; zf-C2H2; 5.
DR SMART; SM00355; Znf_C2H2; 6.
DR PROSITE; PS00190; CYTOCHROME_C; UNKNOWN 1.
DR PROSITE; PS00028; ZINC_FINGER_C2H2_1; 6.
DR PROSITE; PS0157; ZINC_FINGER_C2H2_2; 4.
SQ SEQUENCE 582 AA; 66985 MW; A22347D789707ABD CRC64;
```

Q8MRU2 Length: 582 February 22, 2005 12:25 Type: P Check: 2547 ..

```
251 DCGKKVQSNY NLRRHMIHT GERPPCDLC ERRRFESDL KKHRRRHSHD
301 PQEIMICHL GAPLEQDSTR CADCESKNLM VKPQPEELGD KTEEHSDDM
351 EGDDEIEBA ALEKEKQPOV ATQPSLMVTL IPPIQSPPEK VPSHTQPSRP
401 PLPRSCSSAN SSSSMSNDGN IAGKMSRTR RSYPCPLCHR PFGTRHNLKR
451 HYMIHTGEKP PSCSKCRKPF RECSTLKKHM VTHVRDRWYK CLRCPSKPRD
501 YLEYSCHKNN HQDQLSSRKS SIYESDDDDG SSVEDCLECC ECQQRFTELD
551 AVTAHLKKHD LELYGMSIDD VADEEQDDVD VA

!!AA_SEQUENCE 1.0
ID_Q8MZP1 PRELIMINARY; PRT; 872 AA.
AC Q8MZP1;
DT 01-OCT-2002 (TremBLrel. 22, Created)
DT 01-OCT-2002 (TremBLrel. 22, Last sequence update)
DT 01-MAR-2004 (TremBLrel. 26, Last annotation update)
DE AT06220P.
GN ORFNames=CG17666;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RA SEQUENCE FROM N.A.
RA Stapleton M., Brokstein P., Hong L., Agbayani A., Carlson J.,
RA Champe M., Chavez C., Dorsett V., Dreesnek D., Farfan D., Friese E.,
RA George R., Gonzalez M., Guarin H., Kronmiller B., Li P., Liao G.,
RA Miranda A., Mungall C.J., Nunoo J., Pacleb J., Paragas V., Park S.,
RA Patel S., Phouanavong S., Wan K., Yu C., Lewis S.E., Rubin G.M.,
RA Celniker S.;
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY113210; AAM29215.1; -.
DR FlyBase; FBgn0036311; CG17666.
DR InterPro; IPR000345; CytC_heme_BS.
DR Prosite; PS008197; WAP.
DR PROSITE; PS00317; 4_DISULFIDE_CORE; UNKNOWN 1.
DR PROSITE; PS00190; CYTOCHROME_C; UNKNOWN 1.
SQ SEQUENCE 872 AA; 95311 MW; F3730A57C8CC5A6 CRC64;
```

Q8MZP1 Length: 872 February 22, 2005 12:25 Type: P Check: 8826 ..

```
1 MCDPCRYLR CISCHGNGWC CPRPSCERS CSSNMNRCRV VFSGBFQKFS
51 DMVTPSFLK TPERPKRKR SKSCSACGDN CKDPCLNMDA CAESCENPCQ
101 DGWNGCKNPE DCGQDDLART GAYGTGFGFQ PGQPTIIPCY GTYGTGHPM
151 IFGIPTPTQY GGFVPGPIV LPVAPPSSVG QGDPRSIPAA GLPTQYTNKF
201 NPCTGVIYQC GDRQMPGPR QRTAQVPSYN QFTQGLGMSK APNSQCIPFD
251 ATFOQHPINQ MPVTPPSCGS APAYGRNNQP MNCEPNNQNY SYTVQSTNQ
301 VHVGNARSEV YNQOQSAATHS RVPVQLESSK GOLPHGNRRS KSPNQRSRPS
351 GDRSGRAYAN NNFPENVHAS PQAQRKSLS HRNESREGRS GKQASRATT
401 NYHSNSGGDR NVDHRSAPKS MASAGEVRSR DNNRSYDSRN RNKSVGAPT
451 RQVLYDQOR VGMGIDPSNQ YYPYNECAPL NATFVQDHPN FYAQPGHDVN
501 RTQASAPNL SKAGPKKDN SNKVPSFKP SKEKSTKCCC TRFDNNQYY
551 PHYVSESDC PPEENVNGK KKTQEKNCLE LLSRLTESCP PCDLQKWCHL
601 LMPKDKSK KOAKPSAKXN KKSNGSKVN KMSEHSSNEI EGTVASPQEA
651 PEDEDAHCPK NCKKPCPTTP TKEMRTGCS ANLPEENEDP PPAPSNPPPA
```

701 PNPPVPVPCN HAPAPVNTCC MPCSNQCPMS WYNNPTGCV YYCANCCNGC  
 751 RNCNYYCCSP CGCCCSNSPA AQLEKIPPKP KQKEROSS NSTRNSGGAA  
 801 VSLGSCAPPP MPAPWKPCRPQ EVSTMPGVSP TASPFFSSPY SRWKAGCVD  
 851 SHRNRYORNNQ GPPFNIGRVH HV

```

!!AA SEQUENCE 1.0
ID Q8WTI6 PRELIMINARY; PRT; 118 AA.
AC Q8WTI6;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE PFTAIRE-interacting factor 2 (CG31483-PA)
GN Name=Pif2; Synonyms=Pif-2; ORFNames=CG31483;
OS Drosophila melanogaster (Fruit fly)
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephyrdoidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22667250; PubMed=12782278; DOI=10.1016/S0925-4773(03)00019-4;
RA Rasclie A., Stowers R.S., Garza D., Lepesant J.-A., Hogness D.S.;
RT "L63, the Drosophila PFTAIRE, interacts with two novel proteins
  unrelated to cyclins."
RL Mech. Dev. 120:617-628(2003).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.H., Blazer R.G., Champe M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L.,
RA April J.F., Agbayani A., An H.J., Andrews-Pfannkoch C., Baldwin D.,
RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA Beeson K.V., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,
RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotter P.,
RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferrieria S., Fleischmann W.,
RA Foster C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D., Helman T.J., Hernandez J.R., Houck J.,
RA Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwam C.,
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA Laoko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA Merkulov G., Milchuna N.V., Mobarry C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nuskern D.R., Paclele J.M.,
RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA Svirskaas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.Y., Wassarman D.A., Weinstock G.M., Weissenbach J.,
RA Williams S.M., Woodgett, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,
RA Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "The genome sequence of Drosophila melanogaster."
RL Science 287:2185-2195(2000).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426065; PubMed=12537568;

```

```

RA Celniker S.E., Wheeler D.A., Krommiller B., Carlson J.W., Halpern A.,
RA Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,
RA George R.A., Hoskins R.A., Lavery T., Muzny D.M., Nelson C.R.,
RA Paclele J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,
RA Svirskaas R., Tabor P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,
RA Weinstock G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;
RT "Finishing a whole-genome shotgun: Release 3 of the Drosophila
  melanogaster euchromatic genome sequence."
RL Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).
RN [4]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426070; PubMed=12537573;
RA Kaminker J.S., Bergman C.M., Krommiller B., Carlson J., Svirskaas R.,
RA Patel S., Frise E., Wheeler D.A., Lewis S.E., Rubin G.M.,
RA Ashburner M., Celniker S.E.;
RT "The transposable elements of the Drosophila melanogaster euchromatin:
  a genomics perspective."
RL Genome Biol. 3:RESEARCH0084-RESEARCH0084(2002).
RN [5]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426069; PubMed=12537572;
RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA Bettencourt B.R., Celniker S.E., de Grey A.D., Drysdale R.A.,
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA Lewis S.E.;
RT "Annotation of the Drosophila melanogaster euchromatic genome: a
  systematic review."
RL Genome Biol. 3:RESEARCH0083-RESEARCH0083(2002).
RN [6]
RP SEQUENCE FROM N.A.
RG FlyBase;
RL Submitted (SEP-2002) to the ENBL/GenBank/DBJ databases.
RN [7]
RP SEQUENCE FROM N.A.
RG FlyBase;
RL Submitted (MAR-2004) to the ENBL/GenBank/DBJ databases.
DR EMBL; AF273708; AAL35411.1; -
DR EMBL; AE003674; AAF54113.3; -
DR HSP; F21860; IMG6;
DR FlyBase; FBgn0046873; Pif2.
DR PROSITE; PS01208; VMFC 1; UNKNOWN 1.
SQ SEQUENCE 118 AA; 11566 MW; AF6FD15A61FF5C81 CRC64;

Q8WTI6 Length: 118 February 22, 2005 12:25 Type: P Check: 3249 ..

1 MCSPCCGSCC GPCCSPCCSP CCPPCCNDCC GSCCSPCCGP CCSPCCGPPC
51 SPCCSPCCCTP CCTPCCFPCC KCCTPCCVPC CTPCCTPCTC PCCTPCCSPC
101 CGPCCSPCCS PCGSKCK

!!AA SEQUENCE 1.0
ID Q95QY1 PRELIMINARY; PRT; 166 AA.
AC Q95QY1;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DE Hypothetical protein C04G6.10.
GN Name=C04G6.10; ORFNames=C04G6.10;
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC Rhabditidae; Peloderinae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RX MEDLINE=99069613; PubMed=9851916;
RG WormBase Consortium;
RT "Genome sequence of the nematode C. elegans: a platform for
  investigating biology. The C. elegans Sequencing Consortium."

```

```
RL Science 282:2012-2018 (1998).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RA Anderson K., Chissee S.;
RT "The sequence of C. elegans cosmid C04G6."
RL Submitted (APR-1996) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RA Waterston R.;
RL Submitted (JAN-2003) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RA Wilson R.;
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
RN [5]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RG WormBase Consortium;
RL EMBL; U55854; AAK68158.1; -.
DR HSSP; P10969; IWGT.
DR WormBase; WBGene00015458; C04G6.10.
DR WormPep; C04G6.10; CE27649.
DR InterPro; IPR001450; 4Fe4S_ferredoxin.
DR InterPro; IPR006081; Defensin_alpha.
DR InterPro; IPR006209; EGF like.
DR InterPro; IPR001007; VWF C.
DR PROSITE; PS00198; 4FE4S_FERREDOXIN; UNKNOWN_1.
DR PROSITE; PS00269; DEFENSIN; UNKNOWN_1.
DR PROSITE; PS00022; EGF_1; UNKNOWN_1.
DR PROSITE; PS01208; VWFC_1; UNKNOWN_1.
KW Hypothetical protein.
SQ SEQUENCE 166 AA; 16971 MW; 9D9D130351BB50F1 CRC64;

Q95QY1 Length: 166 February 22, 2005 12:25 Type: P Check: 2113

1 MFKLFIFFSTL ILALGAYYGQ VQAAVLVPSV TEVALVRSSA STTSSSETSI
51 DTLGSSRVKR QGGCGCGCGG CGCCGCGGGG GCGGCCCRP RCQCCCRRC
101 TCRTCCCTR CCTCCRPCC CGCGCGCG CGGGRRRS LQNLRIEAN
151 RALGIKRRPT KGDNC

!!AA SEQUENCE 1.0
ID OQAUO PRELIMINARY; PRT; 52 AA.
AC OQAUO;
DT 03-JUL-2004 (TREMBLrel. 27, Created)
DT 05-JUL-2004 (TREMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TREMBLrel. 27, Last annotation update)
DE M5T84DC.
GN Names=Mst84Dc; ORFNames=CGI7945;
OS Drosophila mauritiana (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7226;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=G52;
RA Michalak P., Noor M.A.F.;
RL Submitted (FEB-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; AY549956; AAS55565.1; -.
DR GO; GO:0005576; C:extracellular; IEA.
DR GO; GO:0006952; P:defense response; IEA.
DR GO; GO:0009813; P:response to pest, pathogen or parasite; IEA.
DR InterPro; IPR001450; 4Fe4S_ferredoxin.
DR InterPro; IPR006081; Defensin_alpha.
DR InterPro; IPR001007; VWF C.
DR PROSITE; PS00198; 4FE4S_FERREDOXIN; UNKNOWN_2.
```

```
DR PROSITE; PS00269; DEFENSIN; 1.
DR PROSITE; PS01208; VWFC_1; UNKNOWN_1.
SQ SEQUENCE 52 AA; 4908 MW; DE0F3DE43F686E3A CRC64;

OQAUO Length: 52 February 22, 2005 12:25 Type: P Check: 9784

1 MCGPGCGSCC GCYCGCGCCG PCGPRCGPCG SCGPGCGPCC GPGGSCGCGC
51 WC

!!AA SEQUENCE 1.0
ID Q7PUH8 PRELIMINARY; PRT; 45 AA.
AC Q7PUH8;
DT 01-MAR-2004 (TREMBLrel. 26, Created)
DT 01-MAR-2004 (TREMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
DE ENSANGP00000020863.
GN Name=ENSANGG00000018374;
OS Anopheles gambiae str. PEST.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Nematocera; Culicoidea; Anopheles.
OX NCBI_TaxID=180454;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=PEST;
RA Anopheles Genome Sequencing Consortium;
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AAB01008987; EAA01487.2; -.
DR InterPro; IPR001212; Somatomedin_B.
DR PRINTS; PR00022; SOMATOMEDINB.
SQ SEQUENCE 45 AA; 4332 MW; BF655FFD76C72BB6 CRC64;

Q7PUH8 Length: 45 February 22, 2005 12:25 Type: P Check: 4529

1 MPCKCCGNDK KCTSCGSGSQ PCATDCKCAC ASGGCKEKSQ GCGGK

!!AA SEQUENCE 1.0
ID Q7RQ56 PRELIMINARY; PRT; 402 AA.
AC Q7RQ56;
DT 01-MAR-2004 (TREMBLrel. 26, Created)
DT 01-MAR-2004 (TREMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TREMBLrel. 26, Last annotation update)
DE RING-finger protein.
GN Name=PY01016;
OS Plasmodium yoelii yoelii.
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxID=73239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=17XNL;
RX PubMed=12368865; DOI=10.1038/nature01099;
RA Carlton J.M., Angiola S.V., Suh B.B., Kooij T.W., Pextea M.,
RA Silva J.C., Ermolaeva M.D., Allen J.E., Selengut J.D., Koo H.L.,
RA Peterson J.D., Pop M., Kosack D.S., Shumway M.F., Bidwell S.L.,
RA Shallom S.J., van Aken S.E., Riedmuller S.B., Feidlyum T.V.,
RA Cho J.K., Quackenbush J., Sedegah M., Shoabi A., Cummings L.M.,
RA Florens L., Yates F.R. III, Raine J.D., Sinden R.E., Harris M.A.,
RA Cunningham D.A., Preiser P.R., Bergman L.W., Vaidya A.B.,
RA van Lin L.H., Janse C.J., Waters A.P., Smith H.O., White O.R.,
RA Salzberg S.L., Venter J.C., Fraser C.M., Hoffman S.L., Gardner M.J.,
RA Carucci D.J.;
RT "Genome sequence and comparative analysis of the model rodent malaria
RT parasite Plasmodium yoelii yoelii."
RL Nature 419:512-519 (2002).
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AAB01000270; EAA19831.1; -.
DR InterPro; IPR001450; 4Fe4S_ferredoxin.
DR InterPro; IPR000345; CytC_heme_BS.
```

DR PROSITE; PS00198; 4FB4S\_FERREDOXIN; UNKNOWN\_1.  
 DR PROSITE; PS00190; CYTOCHROME C; UNKNOWN\_1.  
 SQ SEQUENCE 402 AA; 44444 MW; 89CCDFEB6A78CD7 CRC64;  
 Q7RQ56 Length: 402 February 22, 2005 12:25 Type: P Check: 9997 ..  
 1 MKNIIKISF VLLFLSSVYS EINGNVTNKN KYSLRSHITK NEDLNNTLDN  
 51 GNVHGESEDD ISTRGTEQLT KTGATGTLDSS SSOHQAGDVG SSGKGLSQDS  
 101 RTEESCEPGC EGPEDCEGC PECCEGCEPC CEDCHDENCPC DQCTECTDEC  
 151 RECAKLKAA SAQLGEENIQ ICTHSPNGT NCECKKITT TRQTAAPDVR  
 201 DETETTLIQN AIEDITDDTK TMPDENPVC DEQLDEDDGN EBEIEIVDSE  
 251 NIEIIENIEE IENSDSDDI DDSELELEF ELELEPTDI DRDSQENES  
 301 ESGATTNEQ GNNHTNTDE VASNNQTSNN QTNNNQTSNN QTNNNNVSHF  
 351 IKEYKNGSG SKTONENILD NALSGIDDNQ FSSDIQDFVQ DINEFVLMBE  
 401 DI  
 !!IAA\_SEQUENCE 1.0  
 ID Q7YVW7 PRELIMINARY; PRT; 212 AA.  
 AC Q7YVW7;  
 DT 01-OCT-2003 (TRENBLrel. 25, Created)  
 DT 01-OCT-2003 (TRENBLrel. 25, Last sequence update)  
 DT 01-MAR-2004 (TRENBLrel. 26, Last annotation update)  
 DE Hypothetical protein R13H4.8.  
 GN ORFNames=R13H4.8;  
 OS Caenorhabditis elegans.  
 OC Eukaryota; Metazoa; Nematoa; Chromadorea; Rhabditida; Rhabditioidea;  
 OC Rhabditidae; Peloderinae; Caenorhabditis.  
 OX NCBI\_TaxID=6239;  
 RN [1]  
 RC STRAIN=Bristol N2;  
 RX MEDLINE=99069613; PubMed=9851916;  
 RA none;  
 RT "Genome sequence of the nematode C.elegans: A platform for  
 RT investigating biology."  
 RL Science 282:2012-2018 (1998).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RA Kershaw J.K.;  
 RL Submitted (NOV-1996) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; Z81579; CAB17915.1; -.  
 DR WormBase; WBGene00011266; R13H4.8.  
 DR WormPep; R13H4.8; CE34968.  
 DR InterPro; IPR001450; 4FB4S\_ferredoxin.  
 DR InterPro; IPR006209; EGF-like.  
 DR InterPro; IPR001007; VWF C.  
 DR PROSITE; PS00198; 4FB4S\_FERREDOXIN; UNKNOWN\_1.  
 DR PROSITE; PS00022; EGF 1; UNKNOWN\_1.  
 DR PROSITE; PS01208; VWF\_1; UNKNOWN\_1.  
 KW Hypothetical protein.  
 SQ SEQUENCE 212 AA; 22857 MW; 22F62CE4073CCA4E CRC64;  
 Q7YVW7 Length: 212 February 22, 2005 12:25 Type: P Check: 8091 ..  
 1 MQSIRFTLSL IAILGLSLV QAHPSSREA LKSSSETDLA LPGSHETTEV  
 51 ALPDVKTDDI DTLGESNRV KRGGGGGCC GCGCGCCCR PRCCCCRRRC  
 101 CTCCTCCCT RCCTCCRPCC CGCGCGCGCG CGCGGGGGRK RRSLOTLKIK  
 151 LAEKVQREAR QIEQIPETIA PVEITENVET PETVENKPE EVELATQWPE  
 201 PVYELVTETW AH

!!IAA\_SEQUENCE 1.0  
 ID Q9VI99 PRELIMINARY; PRT; 72 AA.  
 AC Q9VI99;  
 DT 01-MAY-2000 (TRENBLrel. 13, Created)  
 DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)  
 DT 01-MAR-2004 (TRENBLrel. 26, Last annotation update)  
 DE CGI7935-PA.  
 GN Name=Met84Dd; ORFNames=CGI7935;  
 OS Drosophila melanogaster (Fruit fly).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
 OC Ephydroidea; Drosophilidae; Drosophila.  
 OX NCBI\_TaxID=7227;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;  
 RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,  
 RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galie R.F.,  
 RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,  
 RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,  
 RA Brandon R.C., Rogers Y.H., Blazej R.G., Champe M., Pfeiffer B.D.,  
 RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L.,  
 RA Abril J.F., Agbayani A., An H.J., Andrews-Pfannkoch C., Baldwin D.,  
 RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,  
 RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,  
 RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotter P.,  
 RA Burtis K.C., Buzam D.A., Butler H., Cadieu E., Center A., Chandra I.,  
 RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,  
 RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,  
 RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,  
 RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,  
 RA Foeller C., Gabrielian A.E., Garg N.S., Gelbart W.M., Glasser K.,  
 RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,  
 RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,  
 RA Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwac C.,  
 RA Jaitani M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,  
 RA Kimmel B.B., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,  
 RA Laeko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,  
 RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,  
 RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,  
 RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,  
 RA Nelson D.R., Nelson K.A., Nixon K., Nuskern D.R., Pacleby J.M.,  
 RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,  
 RA Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,  
 RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,  
 RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,  
 RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,  
 RA Wang Z.Y., Wassarman D.A., Weinstock G.M., Weissbach J.,  
 RA Williams S.M., Woodage, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,  
 RA Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,  
 RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu H.O.,  
 RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;  
 RT "The genome sequence of Drosophila melanogaster."  
 RL Science 287:2185-2195 (2000).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22426065; PubMed=12537568;  
 RA Celniker S.E., Wheeler D.A., Krommiller B., Carlson J.W., Halpern A.,  
 RA Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,  
 RA George R.A., Hoskins R.A., Laverty T., Muzny D.M., Nelson C.R.,  
 RA Pacleby J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,  
 RA Svirskas R., Tabor P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,  
 RA Weinstock G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;  
 RT "Finishing a whole-genome shotgun: Release 3 of the Drosophila  
 RT melanogaster euchromatic genome sequence."  
 RL Genome Biol. 3:RESEARCH0079-RESEARCH0079 (2002).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22426070; PubMed=12537573;  
 RA Kaminker J.S., Bergman C.M., Krommiller B., Carlson J., Svirskas R.,  
 RA Patel S., Frise E., Wheeler D.A., Lewis S.E., Rubin G.M.,  
 RA Ashburner M., Celniker S.E.;  
 RT "The transposable elements of the Drosophila melanogaster euchromatin:

a genomes perspective."; RA  
Genome Biol. 3:RESEARCH0084-RESEARCH0084 (2002). RN  
[4] SEQUENCE FROM N.A. RP  
MEDLINE=22426069; PubMed=12537572; RX  
Miera S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S., RA  
Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E., RA  
Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P., RA  
Bettencourt B.R., Celniker S.E., de Grey A.D., Drysdale R.A., RA  
Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q., RA  
Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M., RA  
Lewis S.E.; RA  
"Annotation of the Drosophila melanogaster euchromatic genome: a RA  
systematic review."; RT  
Genome Biol. 3:RESEARCH0083-RESEARCH0083 (2002). RL  
[5] SEQUENCE FROM N.A. RN  
Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases. RP  
FlyBase; RG  
Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases. RL  
[6] SEQUENCE FROM N.A. RN  
FlyBase; RG  
Submitted (MAR-2004) to the EMBL/GenBank/DBJ databases. RP  
EMBL; AE003672; AAF54026.1; -. RX  
DR FlyBase; FBN0004173; Met84Db. RA  
DR InterPro; IPR001450; 4Fe4S\_ferredoxin. RA  
DR Pfam; PF03940; MSSP; 1. RA  
DR PROSITE; PS00198; 4FE4S\_FERREDOXIN; UNKNOWN 4. RA  
SQ SEQUENCE 72 AA; 6840 MW; 8CE374495F88ABA CRC64; RA

Q9V199 Length: 72 February 22, 2005 12:25 Type: P Check: 8119 ..

1 MGCAPGPGCC GPCGPGCCG CGPCCGPGCG PCGCGPGCC GPCGPGCGC

51 GPCGPGCGTGM EKXNGLQRC PF

!!AA SEQUENCE 1.0

ID Q9V1A1 PRELIMINARY; PRT; 74 AA.

AC Q9V1A1;

DT 01-MAY-2000 (TrEMBLrel. 13, Created)

DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)

DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)

DE CG179334-PA.

GN Name=Met84Db; ORFNames=CG17934;

OS Drosophila melanogaster (Fruit fly).

OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;

OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;

OC Ephydroidea; Drosophilidae; Drosophila.

OX NCBI\_TaxID=7227;

ON [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185; RA  
Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D., RA  
Ananides P.G., Scher S.E., Li P.W., Hoskins R.A., Galle R.F., RA  
George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N., RA  
Sutton G.C., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X., RA  
Brandon R.C., Rogers J.H., Blazej R.G., Champe M., Pfeiffer B.D., RA  
Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L., RA  
Abril J.F., Agbayani A., An H.J., Andrews-Frannkoch C., Baldwin D., RA  
Ballew R.M., Baeu A., Baxendale J., Bayraktaroglu L., Beasley E.M., RA  
Beeson K.V., Benos P.V., Berman B.P., Bhandari D., Bolshakov S., RA  
Borkova D., Botchan M.R., Bouck J., Brokstein P., Brottier P., RA  
Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I., RA  
Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P., RA  
de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M., RA  
Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P., RA  
Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W., RA  
Foeller C., Gabriellian A.E., Garg N.S., Gelbart W.M., Glaeser K., RA  
Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M., RA  
Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J., RA  
Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwam C., RA  
Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,





GN ORFNames=CGI7666;  
 OS Drosophila melanogaster (Fruit fly).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
 OC Ephydroidea; Drosophilidae; Drosophila.  
 OX NCBI\_TaxID=7227;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;  
 RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,  
 RA Ananides P.G., Scher S.E., Li P.W., Hoskins R.A., Galie R.F.,  
 RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,  
 RA Sutton G.G., Wortman J.R., Vandal M.D., Zhang Q., Chen L.X.,  
 RA Brandon R.C., Rogers Y.H., Blazej R.G., Champe M., Pfeiffer B.D.,  
 RA Abril J.F., Agbayani A., An H.J., Andrews-Pfannkoch C., Baldwin D.,  
 RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,  
 RA Beeson K.Y., Benos P.V., Berman B.P., Bhandari D., Bolshakov S.,  
 RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotter P.,  
 RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,  
 RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,  
 RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,  
 RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,  
 RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,  
 RA Folsler C., Gabrieli A.E., Garg N.S., Gelbart W.M., Glasser K.,  
 RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,  
 RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,  
 RA Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwam C.,  
 RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,  
 RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,  
 RA Lasko P., Lei Y., Levitsky A.C., Li J., Li Z., Liang Y., Lin X.,  
 RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,  
 RA Markulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,  
 RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,  
 RA Nelson D.R., Nelson K.A., Nixon K., Nusskern D.R., Pacieb J.M.,  
 RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,  
 RA Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,  
 RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,  
 RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,  
 RA Swirekas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,  
 RA Wang Z.Y., Wassarman D.A., Weinstein G.M., Weissbach J.,  
 RA Williams S.M., Woodage, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,  
 RA Yeh R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,  
 RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Smith H.O.,  
 RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;  
 RT "The genome sequence of Drosophila melanogaster."  
 RL Science 287:2185-2195(2000).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22426065; PubMed=12537568;  
 RA Celniker S.E., Wheeler D.A., Kronmiller B., Carlson J.W., Halpern A.,  
 RA Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,  
 RA George R.A., Hoskins R.A., Lavery T., Muzny D.M., Nelson C.R.,  
 RA Pacleb J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,  
 RA Svirekas R., Taber P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,  
 RA Weinstein G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;  
 RT "Finishing a whole-genome shotgun: Release 3 of the Drosophila  
 melanogaster euchromatin genome sequence."  
 RL Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22426070; PubMed=12537573;  
 RA Kaminker J.S., Bergman C.M., Kronmiller B., Carlson J., Svirekas R.,  
 RA Patel S., Frise E., Wheeler D.A., Lewis S.E., Rubin G.M.,  
 RA Ashburner M., Celniker S.E.;  
 RT "The transposable elements of the Drosophila melanogaster euchromatin:  
 a genomics perspective."  
 RL Genome Biol. 3:RESEARCH0084-RESEARCH0084(2002).  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22426069; PubMed=12537572;  
 RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,  
 RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,  
 RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,  
 RA Hattencourt B.R., Celniker S.E., de Grey A.D., Drysdale R.A.,  
 RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,  
 RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,  
 RA Lewis S.E.;  
 RT "Annotation of the Drosophila melanogaster euchromatic genome: a  
 systematic review."  
 RL Genome Biol. 3:RESEARCH0083-RESEARCH0083(2002).  
 RN [5]  
 RP SEQUENCE FROM N.A.  
 RG FlyBase;  
 RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.  
 RN [6]  
 RP SEQUENCE FROM N.A.  
 RG FlyBase;  
 RL Submitted (MAR-2004) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AF003540; AAF49882.2; -.  
 DR FlyBase; FBgn0036311; CGI7666.  
 SQ SEQUENCE 271 AA; 29417 NW; 2C401E68E25E206A CRC64;  
 Q9VUI2 Length: 271 February 22, 2005 12:25 Type: P Check: 6468 ..  
 1 MPKDKSKK QAKPSAKXNK KNSGKVKXNK MSEHSSNEIE GTVASPQETP  
 51 EDEDAHCPCN CKKPCPTPTT KEMRTGCSA NLPEENEDPP PAPSNNPPAP  
 101 SNPPVPVPCNH APAPVNTCCM PCSNQCPWSW YNPCTGCYY YCANCNGCR  
 151 NCCNYCCSPC GCCCSNSPAA QLEKIPKPK QKERQDRSSN STRNSGGTAV  
 201 SLGSCAPPST FAPWKCPRQE VSTMPGYSPT ASPHFSSPSY GRWKAGCVD  
 251 HRNYQRNQG PPFNIGRVHH V  
 !!AA\_SEQUENCE 1.0  
 ID Q9XVK3 PRELIMINARY; PRT; 152 AA.  
 AC Q9XVK3;  
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)  
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)  
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
 DE Hypothetical protein C06A1.6.  
 GN ORFNames=C06A1.6;  
 OS Caenorhabditis elegans.  
 OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;  
 OC Rhabditidae; Peloderinae; Caenorhabditis.  
 OX NCBI\_TaxID=6239;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RX MEDLINE=99069613; PubMed=9851916;  
 RA none;  
 RT "Genome sequence of the nematode C.elegans: A platform for  
 investigating biology."  
 RL Science 282:2012-2018(1998).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Bristol N2;  
 RA McMurray A.A.;  
 RL Submitted (JUN-1995) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; Z49886; CAA90055.1; -.  
 DR PIR; T18975; T18975.  
 DR HSSP; P02876; 9WGA.  
 DR WormBase; WBGene00007356; C06A1.6.  
 DR WormPep; C06A1.6; CE20484.  
 DR InterPro; IPR001450; 4Fe4S\_ferredoxin.  
 DR InterPro; IPR006209; EGF like.  
 DR InterPro; IPR004035; EndoIII\_FCL.  
 DR InterPro; IPR001007; VWF C.  
 DR PROSITE; PS00198; 4Fe4S\_FERREDOXIN; UNKNOWN\_1.  
 DR PROSITE; PS00222; EGF\_1; UNKNOWN\_1.  
 DR PROSITE; PS00764; ENDONUCLEASE\_III\_1; UNKNOWN\_1.  
 DR PROSITE; PS01208; WFC\_1; 1.  
 KW Hypothetical protein.

SQ SEQUENCE 152 AA; 15646 MW; 6E254F0BE476D354 CRC64;  
Q9XVX3 Length: 152 February 22, 2005 12:25 Type: P Check: 2827 ..  
1 MTKFIIGSTL VVLIIVTSI SQVESGVLPV SITTEISIISS ETSIIIGSSRV  
51 KRNGCCGCG CGGGGGGCG CCCCRPRCC CCRPKCCCTC CRTCCCTRCC  
101 TCRPRCCCG CGCGCCGCG GGGKRRLSLQ KLQIDENRAN LGIKRRPSNG  
151 KC  
!!AA SEQUENCE 1.0  
ID Q9C6G7 PRELIMINARY; PRT; 661 AA.  
AC Q9C6G7  
DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
DE 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
DE Hypothetical protein T1813.4.  
GN Name=T1813.4;  
OS Arabidopsis thaliana (Mouse-ear cress).  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;  
OC eurosid II; Brassicales; Brassicaceae; Arabidopsis.  
OX NCBI\_TaxID=3702;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Lin X., Kaul S., Town C.D., Benito M., Creasy T.H., Haas B.J., Wu D.,  
RA Maiti R., Ronning C.M., Koo H., Fujii C.Y., Utterback T.R.,  
RA Barnstead M.E., Bowman C.L., White O., Nierman W.C., Fraser C.M.;  
RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AC079287; AAG50851.1; -.  
DR PIR; B96596; B96596.  
DR InterPro; IPR011424; Cl\_3.  
DR InterPro; IPR004146; DCI.  
DR Pfam; PF03107; Cl\_2; 3.  
DR Pfam; PF07649; Cl\_3; 3.  
KW Hypothetical protein.  
FT NON TER 1  
SQ SEQUENCE 661 AA; 75500 MW; 5D14692886D4834E CRC64;  
Q9C6G7 Length: 661 February 22, 2005 12:25 Type: P Check: 6340 ..  
1 MEPLPPYFSR AKPCRISDP AQPHMLCRRR RPSHPPLSLIC FSCGKQLKR  
51 NNYYYCATC NLEPHRGCHI FLPEIRHPFH PSHLTFISL LLPKFDVTKI  
101 PKNWDSSSS SDESEDDDD EKSIKECED DGGDDDDGSS DSDDDNNFD  
151 ANNDGASLSD GNHLKCKCCQ VPLEKIYYHC SICKFNLNVE CSMPRPPTTI  
201 SHLKSHEHIL TLPPIRLPLP CGACGLSLSD AEDLVVACLIP CNLLVHRSCI  
251 YLPRVIKTR HPHRLSLTPS LQPGDFSCGV CRQTVDVNNG QYSCDKECHY  
301 AVHSCATRN DVWDGKDLGD VPBPDEFIE PPFLKIDET IQHFSHHHL  
351 KLHEKKTIGG KDKFCEACTL PVMISQRYG CMQCDFVLDE TCASLPRKKN  
401 HPLHGHPLNL HILPLGESAM INKGATSKI FOCICGGRIG CGFYKCKDEK  
451 DCDEFLDVR CASLPDPFVH DCHPHDPLF FNLTKGNMGV CGSDNCSSYF  
501 LECIKCKSFL GIKCATLPCE AHYIHRHPI TLYCGEEDTT SGQYWCICE  
551 LKLPKTFWY SCDFCKITLH VNCLLEDY LKPHFKVG LYKEVEIAR  
601 NDGNSRLFCY TCELRGQTL VFYKIGGCKS FCTLRICNGY FDAKDGWYD  
651 AARNLNIFRR I  
!!AA SEQUENCE 1.0  
ID Q9C8A8 PRELIMINARY; PRT; 599 AA.  
AC Q9C8A8

DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
DE Hypothetical protein F7A10.22 (Fragment).  
GN Name=F7A10.22;  
OS Arabidopsis thaliana (Mouse-ear cress).  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;  
OC eurosid II; Brassicales; Brassicaceae; Arabidopsis.  
OX NCBI\_TaxID=3702;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Lin X., Kaul S., Town C.D., Benito M., Creasy T.H., Haas B.J., Wu D.,  
RA Maiti R., Ronning C.M., Koo H., Fujii C.Y., Utterback T.R.,  
RA Barnstead M.E., Bowman C.L., White O., Nierman W.C., Fraser C.M.;  
RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.  
RN [2]  
RP SEQUENCE FROM N.A.  
RA Town C.D., Kaul S.;  
RL Submitted (JAN-2001) to the EMBL/GenBank/DBJ databases.  
DR EMBL; AC027034; AAG51555.1; -.  
DR InterPro; IPR011424; Cl\_3.  
DR InterPro; IPR004146; DCI.  
DR Pfam; PF03107; Cl\_2; 3.  
DR Pfam; PF07649; Cl\_3; 3.  
KW Hypothetical protein.  
FT NON TER 1  
SQ SEQUENCE 599 AA; 68216 MW; 473EC2403CB0F75E CRC64;  
Q9C8A8 Length: 599 February 22, 2005 12:25 Type: P Check: 2666 ..  
1 EFRHGRCHIFL PEIRHPHPS HPLTFISLL PKFDVTKIPK NMDSSSSSD  
51 ESEDDDDDEK SIKECEDDG DDDGSSDS DDDNNFDPAN NDGASLSDGN  
101 HLKCKCCQVP LEKIYYHCSI CKFNLNVECS MRPPPTTISH LKSHHILTL  
151 FPIRLPLFCG AGLSLSDAE DLVYACLPCN LLVHRSCIYL PRVIKTRHP  
201 HRLSLTSLQ PGDFSCGVCV QTVDVNNGQY SCDKECHYAV HSKCATRNDV  
251 WDGKDLGVP EEPDEFIEPP FLKIDETIQ HFSHHHLKL HEKKTIGGKD  
301 KFCBACTLPV MISQRYGCM QCDFVLDETC ASLPRKKNHP LHKHPLNLHI  
351 LPLGESAMIN KGATSKDIFQ CIGCGRIGCG FFYKCKEKC DEFLLDVRCV  
401 SLPDPFVHDC HPHDHLFPN LTKGNMGCG SDNCSSYFLE CIKCKSFLGI  
451 KCATLPCEAH YIHRHPITL CYGEEDTTSG QYWCEICELK LDPKTFWYSC  
501 DFCKITLHVN CLLGEDIYLK PCHIFKVGILY YKEVEIARND GNSRLFCYTC  
551 ELRCGQTLVF KYIGGCKSFC TLRCIGNYFD AKOGWVYDAA RNLNIFRRI  
!!AA SEQUENCE 1.0  
ID Q9SPL3 PRELIMINARY; PRT; 625 AA.  
AC Q9SPL3  
DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE Vicilin (Fragment).  
GN Name=AMP2;  
OS Macadamia integrifolia (Macadamia nut).  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; Proteales; Proteaceae;  
OC Macadamia.  
OX NCBI\_TaxID=60698;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA TISSUE=Nut kernel;  
RX MEDLINE=20040040; PubMed=10571855;  
RA Marcus J.P., Green J.L., Goulter K.C., Manners J.M.;

RT "A family of antimicrobial peptides is produced by processing of a 7S  
RT globulin protein in Macadamia integrifolia kernels.";  
RL Plant J. 19:699-710(1999).  
DR EMBL; AF161885; AAD54246.1; -.  
DR HSSP; P25974; 1IPJ.  
DR GO; GO:0045735; F:nutrient reservoir activity; IEA.  
DR InterPro; IPR006045; Cupin.  
DR InterPro; IPR007113; Cupin region.  
DR InterPro; IPR011051; RmlC\_like\_cupin.  
DR InterPro; IPR006792; Vicilin\_N.  
DR Pfam; PF00190; Cupin; 2.  
DR Pfam; PF04702; Vicilin\_N; 1.  
FT NON\_TER 1  
SQ SEQUENCE 625 AA; 73586 MW; 415808A89D370296 CRC64;

Q9SPL3 Length: 625 February 22, 2005 12:25 Type: P Check: 7549 ..

1 QCMQLETSGQ MRRCVSQCDK RPEEDIDWSK YDNOEDPQTE CQCQRRRCRQ  
51 QESDPQQQY CQRRCKEICE EBEENRQRD PQQYEQCQK RCQRRETEPR  
101 HMQICQRCCE RRYEKEKRKQ QKRYBEQORE DEEKYERMK EGNKRDPOQ  
151 REVEDCRRHC EQQEPRLQY CQRRCEQQR QHGRGGDLMN PQRGSGRYE  
201 EGEKQSDNP YPFDESLST RRTTEGHIS VLENFYGRSK LLRALKNYRL  
251 VLLEANPNAF VLPTHLDADA ILLVTGGRA LKMTIHRNRE SYNLECGDVI  
301 RIPAGTTFFYL INRDNNERLH IAKFLQTIST PGQYKEFFPA GGQNPEPYLS  
351 TFSKEILEAA LNTQTERLRC VLQQRREGVI IRASQEQIRE LTRDDSESRR  
401 WHIRRGCESS RGPYNLFNKR PLYSNKYQQA YEVPEDYRQ LQDMVSVFI  
451 ANITQSGMMG PPFNTRSTKV VVVASGEADV EMACPHLSGR HGRGGGKGRH  
501 EEEEVHYEQ VRARLSKREA IVLVLAGHPV FVSSGNENLL LFAFGINAQN  
551 NHENFLAGRE RNVLQIQEPQ AMELAFASR KEVEELFNSQ DESIFFPGPR  
601 QHQQSPRST KQOQPLVSIL DFGVF

!!AA SEQUENCE 1.0  
ID Q9SPL4 PRELIMINARY; PRT; 666 AA.

AC Q9SPL4;  
DT 01-MAY-2000 (TReMBLrel. 13, Created)  
DT 01-MAY-2000 (TReMBLrel. 13, Last sequence update)  
DT 01-JUN-2003 (TReMBLrel. 24, Last annotation update)  
DE Vicilin.  
GN Name=AMP2;  
OS Macadamia integrifolia (Macadamia nut).  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; Proteales; Proteaceae;  
OC Macadamia.  
OX NCBI\_TaxID=60698;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Nut kernel;  
RX MEDLINE=20040040; PubMed=10571855;  
RA Marcus J.P., Green J.L., Goulter K.C., Manners J.M.;  
RT "A family of antimicrobial peptides is produced by processing of a 7S  
RT globulin protein in Macadamia integrifolia kernels.";  
RL Plant J. 19:699-710(1999).  
DR EMBL; AF161884; AAD54245.1; -.  
DR HSSP; P25974; 1IPJ.  
DR GO; GO:0045735; F:nutrient reservoir activity; IEA.  
DR InterPro; IPR006045; Cupin.  
DR InterPro; IPR011051; RmlC\_like\_cupin.  
DR InterPro; IPR006792; Vicilin\_N.  
DR Pfam; PF00190; Cupin; 2.  
DR Pfam; PF04702; Vicilin\_N; 1.  
SQ SEQUENCE 666 AA; 78243 MW; 0ECA22F8710F8A7B CRC64;

Q9SPL4 Length: 666 February 22, 2005 12:25 Type: P Check: 911 ..

1 MAINTSNLCS LFLFLSLFL STTVSLAESE FDRQEYEECK RQCMQLETSG  
51 QMRRCVSQCD KRFEEDIDWS KYDNQDDPQT DCQCQRRRCR QQESGPRQOQ  
101 YCQRRCKEIC EEEEBYNRQR DPQQYEQCQ ERCQRHETEP RHMQTCQQRRC  
151 ERYEKEKRK QOKRYEEOQR EDEEYERMM KEEDNKRDPQ QREYEDCRRR  
201 CEQOEPRQOY QCQRRCREQQ RQHGRGGDLI NPQGGSGRY EGEERKQSDN  
251 PYYFDESRSL TRFRTEEGHI SVLENFYGRS KLLRALKNYR LVLLLEANPNA  
301 FVLPTHLDAD AILLVTGGRG ALKMIHRDNR ESYNLECGDV IRIPAGTTFY  
351 LINRDNNERL HIAKFLQITIS TPGQYKEFFP AGQNPEPYL STFSKEILEA  
401 ALNTQAEERL RGVLQQRREGV IISASQEQIR ELTRDDSESRR RWHIRRGES  
451 SRGPYNLFNK RPLYSNKYGQ AYEVKPEDYR LQDMVSVF IANITQSGMM  
501 GPFNTRSTK VVVASGEAD VEMACPHLSG RHGRRGGRK HEEDVDVHYE  
551 QVKARLSKRE AIVVPVGHVP FVSSGNENL LLFAFGINAQ NNHENFLAGR  
601 ERNVLOQIEP QAMELAFAP RKEVEELFNS QDESIFPGP ROHQOQSRS  
651 TKQOQPLVSI LDFVGF

!!AA SEQUENCE 1.0  
ID Q9SPL5 PRELIMINARY; PRT; 666 AA.

AC Q9SPL5;  
DT 01-MAY-2000 (TReMBLrel. 13, Created)  
DT 01-MAY-2000 (TReMBLrel. 13, Last sequence update)  
DT 01-JUN-2003 (TReMBLrel. 24, Last annotation update)  
DE Vicilin.  
GN Name=AMP2;  
OS Macadamia integrifolia (Macadamia nut).  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; Proteales; Proteaceae;  
OC Macadamia.  
OX NCBI\_TaxID=60698;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Nut kernel;  
RX MEDLINE=20040040; PubMed=10571855;  
RA Marcus J.P., Green J.L., Goulter K.C., Manners J.M.;  
RT "A family of antimicrobial peptides is produced by processing of a 7S  
RT globulin protein in Macadamia integrifolia kernels.";  
RL Plant J. 19:699-710(1999).  
DR EMBL; AF161883; AAD54244.1; -.  
DR HSSP; P25974; 1IPJ.  
DR GO; GO:0045735; F:nutrient reservoir activity; IEA.  
DR InterPro; IPR006045; Cupin.  
DR InterPro; IPR007113; Cupin region.  
DR InterPro; IPR011051; RmlC\_like\_cupin.  
DR InterPro; IPR006792; Vicilin\_N.  
DR Pfam; PF00190; Cupin; 2.  
DR Pfam; PF04702; Vicilin\_N; 1.  
SQ SEQUENCE 666 AA; 78217 MW; C752B884B2DF0224 CRC64;

Q9SPL5 Length: 666 February 22, 2005 12:25 Type: P Check: 8155 ..

1 MAINTSNLCS LFLFLSLFL STTVSLAESE FDRQEYEECK RQCMQLETSG  
51 QMRRCVSQCD KRFEEDIDWS KYDNQDDPQT ECQCQRRRCR QQESGPRQOQ  
101 YCQRRCKEIC EEEEBYNRQR DPQQYEQCQ KHCQRRETEP RHMQTCQQRRC  
151 ERYEKEKRK QOKRYEEOQR EDEEYERMM KEEDNKRDPQ QREYEDCRRR

201 CQOEPRQHQ OCQLRCRBOQ RQHGRGGDMM NPORGSGRY EGEGBEQSDN  
251 PYYFDRSLR TRFRTEGHI SVLENFYGRS KILRALKNYR LVLEAPNPA  
301 FVLPTHLAD AILLVIGRG ALKMIHHDNR ESYNLSGCV IRIPAGTTFY  
351 LNRDNNERL HIAKFLQIYS TPGQYKBFPP AGQNPPEYL STFSKEILEA  
401 ALNTQTEKLR GVFGQOREGV IIRASQBQIR ELTRDDSES WHHRRGGES  
451 SRGPYNLFNK RPLYSNKYGO AYEKVPEDYR QLQMDLSVF IANVTQSGNM  
501 GFFNTRSTK VVVASGAD VEMACPLSG RHGGRGGKX HEEEDVHYE  
551 QVRARLSKRE AIVVLAGHPV VVVSNGENL LFPAGGINAQ NNHNFLAGR  
601 ERNVLQIEP QAMELAFAP RKEVEESFNS QDQSIFFPGP ROHQOQSPRS  
651 TKQQPLVSI LDFVGF

!!AA\_SEQUENCE 1.0

ID Q7UIX3 PRELIMINARY; PRT; 110 AA.  
AC Q7UIX3;  
DT 01-OCT-2003 (TReMBLrel. 25, Created)  
DT 01-OCT-2003 (TReMBLrel. 25, Last sequence update)  
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)  
DE Hypothetical protein.  
GN OrderedLocustNames=RB12276;  
OS Rhodopirellula baltica.  
OC Bacteria; Planctomycetes; Planctomycetacia; Planctomycetales;  
OC Planctomycetaceae; Firellula.  
OX NCBI\_TaxID=117;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=1;  
RX MEDLINE=22735913; PubMed=12835416; DOI=10.1073/pnas.1431443100;  
RA Gloeckner F.O., Kube M., Bauer M., Teeling H., Lombardot T.,  
RA Ludwig W., Gade D., Beck A., Borzym K., Heitmann K., Rabus R.,  
RA Schlesner H., Amann R., Reinhardt R.;  
RT "Complete genome sequence of the marine planctomycete Firellula sp.  
strain 1".  
RL Proc. Natl. Acad. Sci. U.S.A. 100:8298-8303 (2003).  
DR EMBL; BX294154; CAD77489.1; -;  
KW Complete proteome; Hypothetical protein.  
SQ SEQUENCE 110 AA; 11911 MW; 8A95FEA6413BEC54 CRC64;

Q7UIX3 Length: 110 February 22, 2005 12:25 Type: P Check: 6414 ..

1 MSTATASMOE CIQNCQECQT ICADMLTSHC LVEGGDHVEQ THVRMLDCI  
51 AACGACIDFM SRNSENHSLY CRACAEICKA CAESCEKVG MEKVCVCCRT  
101 CEQSCSSMAA

!!AA\_SEQUENCE 1.0

ID Q62220 PRELIMINARY; PRT; 223 AA.  
AC Q62220;  
DT 01-NOV-1996 (TReMBLrel. 01, Created)  
DT 01-NOV-1996 (TReMBLrel. 01, Last sequence update)  
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)  
DE Serine 2 ultra high sulfur protein.  
GN Name=Krtap5-4;  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=BALB/c;  
RX MEDLINE=91065960; PubMed=2250030;  
RA Wood L., Mills M., Hatzenbuehler N., Vogeli G.;  
RT "Serine-rich ultra high sulfur protein gene expression in murine hair  
and skin during the hair cycle.";

J. Biol. Chem. 265:21375-21380 (1990).  
[2]  
RN SEQUENCE FROM N.A.  
RP STRAIN=BALB/c;  
RX MEDLINE=91154184; PubMed=1840598;  
RA Wood L., Mills M., Hatzenbuehler N., Vogeli G.;  
RT "Additions and Corrections: Serine-rich ultra high sulfur protein gene  
expression in murine hair and skin during the hair cycle.";  
J. Biol. Chem. 266:4024-4024 (1991).  
DR EMBL; M37760; AAA40107.1; -;  
DR PIR; A38660; B38346.  
DR HSSP; P01064; IPI2.  
DR MGD; MGI:1354758; Krtap5-4.  
DR GO; GO:0045095; C:keratin filament; IEA.  
DR InterPro; IPR001450; 4Fe4S ferredoxin.  
DR InterPro; IPR002494; Keratin\_B2.  
DR InterPro; IPR001007; VWF C.  
DR Pfam; PF01500; Keratin\_B2; 1.  
DR PROSITE; PS00198; 4Fe4S FERREDOXIN; UNKNOWN\_2.  
DR PROSITE; PS01208; WFC 1; UNKNOWN\_2.  
SQ SEQUENCE 223 AA; 21442 MW; C654BDB9FD08C59A CRC64;

Q62220 Length: 223 February 22, 2005 12:25 Type: P Check: 7182 ..

1 MTCCGCGGC GSCGCGGSS CKPVCCVP VCSCSSCGGC KGGCGSCGCG  
51 KGGCGSCGC KGGCGCGGC KGGCGGSSCC KPCCQSSCC KPCCSSGCGS  
101 SCCQSSCKP CCQSSCKP CCSSGCGSSC CQSSCKKPPC CQSSCKKPPC  
151 CQSSCKKPPC SSGCGSSCC SSKCKPCCQ SSKCKPCCQ SSKCKPCCQ  
201 SSKCKPCCQ SSCAPVCCQ CKI

!!AA\_SEQUENCE 1.0

ID Q9D122 PRELIMINARY; PRT; 167 AA.  
AC Q9D122;  
DT 01-JUN-2001 (TReMBLrel. 17, Created)  
DT 01-JUN-2001 (TReMBLrel. 17, Last sequence update)  
DT 01-MAR-2004 (TReMBLrel. 26, Last annotation update)  
DE Mus musculus 18-day embryo whole body cDNA, RIKEN full-length enriched  
DE library, clone:110033F04 product:weakly similar to KERATIN ASSOCIATED  
DE PROTEIN 4.12 (SIMILAR TO RIKEN CDNA 1110054P19 GENE).  
GN Name=1110033F04Rik;  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=C57BL/6J; TISSUE=Whole body;  
RX MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;  
RA Carninci P., Hayashizaki Y.;  
RT "High-efficiency full-length cDNA cloning.";  
RL Meth. Enzymol. 303:19-44 (1999).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=C57BL/6J; TISSUE=Whole body;  
RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;  
RA RIKEN FANTOM Consortium;  
RT "Functional annotation of a full-length mouse cDNA collection.";  
RL Nature 409:685-690 (2001).  
RN [3]  
RP SEQUENCE FROM N.A.  
RC STRAIN=C57BL/6J; TISSUE=Whole body;  
RA The FANTOM Consortium,  
RA the RIKEN Genome Exploration Research Group Phase I & II Team;  
RT "Analysis of the mouse transcriptome based on functional annotation of  
RT 60,770 full-length cDNAs.";  
RL Nature 420:563-573 (2002).  
RN [4]  
RP SEQUENCE FROM N.A.  
RC STRAIN=C57BL/6J; TISSUE=Whole body;

RX MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;  
 RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,  
 RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;  
 RT "Normalization and subtraction of cap-trapper-selected cDNAs to  
 RT prepare full-length cDNA libraries for rapid discovery of new genes.";  
 RL Genome Res. 10:1617-1630(2000).  
 RN [5]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Whole body;  
 RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;  
 RA Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,  
 RA Konno H., Akiyama J., Nishi K., Kitesunai T., Tashiro H., Itoh M.,  
 RA Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,  
 RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,  
 RA Fujiwaka S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,  
 RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,  
 RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;  
 RT "RIKEN integrated sequence analysis (RISA) system-304-format  
 RT sequencing pipeline with 384 multicapillary sequencer.";  
 RL Genome Res. 10:1757-1771(2000).  
 RN [6]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Whole body;  
 RX STRAIN=C57BL/6J; TISSUE=Whole body;  
 RA Adachi J., Aizawa K., Akahira S., Akimura T., Arai A., Aono H.,  
 RA Arakawa T., Bono H., Carninci P., Fukuda S., Fukunishi Y., Furuno M.,  
 RA Hanagaki T., Hara A., Hayatsu N., Hiramoto K., Hiraoka T., Hori F.,  
 RA Imotani K., Ishii Y., Itoh M., Izawa M., Kasukawa T., Kato H.,  
 RA Kawai J., Kojima Y., Konno H., Kouda M., Koya S., Kurihara C.,  
 RA Matsuyama T., Miyazaki A., Nishi K., Nomura K., Numazaki R., Ohno M.,  
 RA Okazaki Y., Okido T., Owa C., Saito H., Saito R., Sakai C., Sakai K.,  
 RA Sano H., Sasaki D., Shibata K., Shibata Y., Shinagawa A., Shiraki T.,  
 RA Sogabe Y., Suzuki H., Tagami M., Tagawa A., Takahashi F., Tanaka T.,  
 RA Teijima Y., Toya T., Yamamura T., Yasunishi A., Yoshida K., Yoshino M.,  
 RA Muramatsu M., Hayashizaki Y.;  
 RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.  
 RL EMBL; AK004055; BAB23145.1; --  
 DR HSSP; O9H2C9; I1VO  
 DR MGD; MGI:1915923; 1110033F04Rik.  
 DR GO; GO:0045095; C:keratin filament; IEA.  
 DR InterPro; IPR006209; EGF like.  
 DR InterPro; IPR002494; Keratin\_B2.  
 DR InterPro; IPR001007; VWF C.  
 DR Pfam; PF01500; Keratin\_B2; 1.  
 DR PROSITE; PS00022; EGF\_1; UNKNOWN\_1.  
 DR PROSITE; PS01208; VWF\_C\_1; UNKNOWN\_1.  
 KW Keratin.  
 SQ SEQUENCE 167 AA; 17537 MW; 2EDF278F108366F1 CRC64;  
 Q9D122 Length: 167 February 22, 2005 12:25 Type: P Check: 8227 ..  
 1 MVSSCGSVCS EKGCGGCGCCQ PSCQTTTCR TTCRPPSCCV SSCCRPSCCV  
 51 SSCCRPSCCR PQCCQSVCCQ PTCRPPSCCI SSCQPSGCS SSCCGSSCCR  
 101 PCRPPCCSPC CSPCCRPCCR PCRCPCRPC CCLRPVCGV CCQTTTCVPT  
 151 CVISTCRPM CCAIPCC  
 !!AA SEQUENCE 1.0  
 ID Q9D228 PRELIMINARY; PRT; 113 AA.  
 AC Q9D228  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
 DE Mus musculus 6 days neonate skin cDNA, RIKEN full-length enriched  
 DE library, clone:A030005L19 product:hypothetical von Willebrand factor,  
 DE type C repeat containing protein, full insert sequence.  
 GN Name:A030005L19Rik;  
 OS Mus musculus (Mouse).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]

RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Skin;  
 RX MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;  
 RA Carninci P., Hayashizaki Y.;  
 RT "High-efficiency full-length cDNA cloning.";  
 RL Meth. Enzymol. 303:19-44(1999).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Skin;  
 RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;  
 RA RIKEN FANTOM Consortium;  
 RT "Functional annotation of a full-length mouse cDNA collection.";  
 RL Nature 409:685-690(2001).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Skin;  
 RA The FANTOM Consortium,  
 RT "Analysis of the mouse transcriptome based on functional annotation of  
 RT 60,770 full-length cDNAs.";  
 RL Nature 420:563-573(2002).  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Skin;  
 RX MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;  
 RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,  
 RA Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;  
 RT "Normalization and subtraction of cap-trapper-selected cDNAs to  
 RT prepare full-length cDNA libraries for rapid discovery of new genes.";  
 RL Genome Res. 10:1617-1630(2000).  
 RN [5]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Skin;  
 RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;  
 RA Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,  
 RA Konno H., Akiyama J., Nishi K., Kitesunai T., Tashiro H., Itoh M.,  
 RA Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,  
 RA Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,  
 RA Fujiwaka S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,  
 RA Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,  
 RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;  
 RT "RIKEN integrated sequence analysis (RISA) system-384-format  
 RT sequencing pipeline with 384 multicapillary sequencer.";  
 RL Genome Res. 10:1757-1771(2000).  
 RN [6]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Skin;  
 RA Adachi J., Aizawa K., Akahira S., Akimura T., Arai A., Aono H.,  
 RA Arakawa T., Bono H., Carninci P., Fukuda S., Fukunishi Y., Furuno M.,  
 RA Hanagaki T., Hara A., Hayatsu N., Hiramoto K., Hiraoka T., Hori F.,  
 RA Imotani K., Ishii Y., Itoh M., Izawa M., Kasukawa T., Kato H.,  
 RA Kawai J., Kojima Y., Konno H., Kouda M., Koya S., Kurihara C.,  
 RA Matsuyama T., Miyazaki A., Nishi K., Nomura K., Numazaki R., Ohno M.,  
 RA Okazaki Y., Okido T., Owa C., Saito H., Saito R., Sakai C., Sakai K.,  
 RA Sano H., Sasaki D., Shibata K., Shibata Y., Shinagawa A., Shiraki T.,  
 RA Sogabe Y., Suzuki H., Tagami M., Tagawa A., Takahashi F., Tanaka T.,  
 RA Teijima Y., Toya T., Yamamura T., Yasunishi A., Yoshida K., Yoshino M.,  
 RA Muramatsu M., Hayashizaki Y.;  
 RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.  
 RL EMBL; AK020696; BAB32178.1; --  
 DR HSSP; P05106; 1L5G.  
 DR MGD; MGI:1925172; A030005L19Rik.  
 DR GO; GO:0005576; C:extracellular; IEA.  
 DR GO; GO:0008305; C:integrin complex; IEA.  
 DR GO; GO:0007160; P:cell-matrix adhesion; IEA.  
 DR GO; GO:0006952; P:defense response; IEA.  
 DR GO; GO:0009613; P:response to pest, pathogen or parasite; IEA.  
 DR InterPro; IPR001450; 4Fe4S ferredoxin.  
 DR InterPro; IPR006081; Defensin\_alpha.  
 DR InterPro; IPR006209; EGF\_like.  
 DR InterPro; IPR001169; Integrin\_beta\_C.  
 DR InterPro; IPR001007; VWF C.  
 DR PROSITE; PS00198; 4Fe4S\_FERREDOXIN; UNKNOWN\_1.

DR PROSITE; PS00269; DEFENSIN; 1.  
 DR PROSITE; PS00222; EGF 1; UNKNOWN 1.  
 DR PROSITE; PS00243; INTEGRIN BETA; 3.  
 DR PROSITE; PS01208; VWFC 1; UNKNOWN 1.  
 KW Hypothetical protein.  
 SQ SEQUENCE 113 AA; 10002 MW; A69A17886401FDA7 CRC64;  
 Q9D228 Length: 113 February 22, 2005 12:25 Type: P Check: 986  
 1 MGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG  
 51 GCGCGCGCGC GCGCGCGCPT VVCCRRSCL RSCGCGCGCG SCGCGCGCGC  
 101 QKCCQKCG CKK  
 !!AA SEQUENCE 1.0  
 ID Q9D230 PRELIMINARY; PRT; 122 AA.  
 AC Q9D230;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
 DE Mus musculus 6 days neonate skin cDNA, RIKEN full-length enriched  
 DE library, clone: A030005K14 product: hypothetical Cysteine-rich  
 DE region/4Fe-4S ferredoxin, iron-sulfur binding domain/von Willebrand  
 DE factor, type C repeat/Cysteine-Knot domain/Integrin beta, C-  
 DE terminus/EGF-like domain/Glycine-rich region/DnaJ central domain  
 DE (CXXCXGKG) containing protein, full insert sequence.  
 GN Name: A030005K14Rik;  
 OS Mus musculus (Mouse);  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Skin;  
 RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;  
 RA RIKEN FANTOM Consortium;  
 RT "Functional annotation of a full-length mouse cDNA collection."  
 RL Nature 409:685-690 (2001).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Skin;  
 RX MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;  
 RA RIKEN FANTOM Consortium;  
 RT "Analysis of the mouse transcriptome based on functional annotation of  
 60,770 full-length cDNAs."  
 RL Nature 420:563-573 (2002).  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Skin;  
 RX MEDLINE=20493774; PubMed=11042159; DOI=10.1101/gr.145100;  
 RA Carninci P., Shibata Y., Hayatsu N., Sugahara Y., Shibata K., Itoh M.,  
 Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;  
 RT "Normalization and subtraction of cap-trapper-selected cDNAs to  
 prepare full-length cDNA libraries for rapid discovery of new genes."  
 RL Genome Res. 10:1617-1630 (2000).  
 RN [5]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Skin;  
 RX MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;  
 RA Shibata K., Itoh M., Aizawa K., Nagao S., Sasaki N., Carninci P.,  
 Konno H., Akiyama J., Nishi K., Kitsuai T., Tashiro H., Itoh M.,  
 Suni N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,  
 Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,  
 Fujiwaka S., Inoue K., Togawa Y., Izawa M., Ohara E., Watahiki M.,  
 Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,

RA Okazaki Y., Muramatsu M., Inoue Y., Kira A., Hayashizaki Y.;  
 RT "RIKEN integrated sequence analysis (RISA) system-384-format  
 sequencing pipeline with 384 multicapillary sequencer."  
 RL Genome Res. 10:1757-1771 (2000).  
 RN [6]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Skin;  
 RA Adachi J., Aizawa K., Akahira S., Akimura T., Arai A., Aono H.,  
 Arakawa T., Bono H., Carninci P., Fukuda S., Fukunishi Y., Furuno M.,  
 Hanagaki T., Hara A., Hayatsu N., Hiramoto K., Hiraoka T., Hori F.,  
 Imotani K., Ishii Y., Itoh M., Izawa M., Kasukawa T., Kato H.,  
 Kawai J., Kojima Y., Konno H., Kouda M., Koya S., Kurihara C.,  
 Matsuyama T., Miyazaki A., Nishi K., Nomura K., Numazaki R., Ohno M.,  
 Okazaki Y., Okido T., Owa C., Saito H., Saito R., Sakai C., Sakai K.,  
 Sano H., Sasaki D., Shibata K., Shibata Y., Shinagawa A., Shiraki T.,  
 Sogabe Y., Suzuki H., Tagami M., Tagawa A., Takahashi F., Tanaka T.,  
 Tejima Y., Toya T., Yamamura T., Yasunishi A., Yoshida K., Yoshino M.,  
 Muramatsu M., Hayashizaki Y.;  
 RA Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.  
 RL EMBL; AK020694; BAB32176.1; -  
 DR HSSP; P10968; 2CWG.  
 DR MGD; MGI:1925171; A030005K14Rik.  
 DR GO; GO:0008305; C:integrin complex; IEA.  
 DR GO; GO:0051082; F:unfolding protein binding; IEA.  
 DR GO; GO:0007160; P:cell-matrix adhesion; IEA.  
 DR GO; GO:0007229; P:integrin-mediated signaling pathway; IEA.  
 DR GO; GO:0006457; P:protein folding; IEA.  
 DR InterPro; IPR001450; 4Fe4S ferredoxin.  
 DR InterPro; IPR006207; Cys\_knot\_C.  
 DR InterPro; IPR001305; DnaJ\_CXXCXXG.  
 DR InterPro; IPR006209; EGF-like.  
 DR InterPro; IPR001169; Integrin\_beta\_C.  
 DR InterPro; IPR001007; VWF\_C.  
 DR PROSITE; PS00198; 4Fe4S\_FERREDOXIN; UNKNOWN 1.  
 DR PROSITE; PS01185; CTCK\_1; UNKNOWN 1.  
 DR PROSITE; PS00637; DnaJ\_CXXCXXG; 1.  
 DR PROSITE; PS00022; EGF\_1; UNKNOWN 1.  
 DR PROSITE; PS00243; INTEGRIN BETA; 1.  
 DR PROSITE; PS01208; VWFC 1; UNKNOWN 1.  
 KW Hypothetical protein; Integrin.  
 SQ SEQUENCE 122 AA; 10716 MW; 7BE071678A5F609 CRC64;  
 Q9D230 Length: 122 February 22, 2005 12:25 Type: P Check: 7679  
 1 MGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG CGCGCGCGCG  
 51 GCGCGCGCGC GCGCGCGCGC GCKPTVWCC CRRSCRRSCG CGSCGCGCGC  
 101 GKGCCQKCC CQKCGCKKC CC  
 !!AA SEQUENCE 1.0  
 ID Q9D230 PRELIMINARY; PRT; 199 AA.  
 AC Q9D230;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
 DE Mus musculus adult male testis cDNA, RIKEN full-length enriched  
 DE library, clone: 1700024J04 product: hypothetical TNFR/CD27/30/40/95  
 DE cysteine-rich region/von Willebrand factor, type C repeat containing  
 DE protein, full insert sequence.  
 GN Name: 1700024J04Rik;  
 OS Mus musculus (Mouse);  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 OX NCBI\_TaxID=10090;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=C57BL/6J; TISSUE=Testis;  
 RX MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;  
 RA Carninci P., Hayashizaki Y.;  
 RT "High-efficiency full-length cDNA cloning."  
 RL Meth. Enzymol. 303:19-44 (1999).  
 RN [2]

allcuni.ref

1:1AA_SEQUENCE 1.0	PRELIMINARY;	PRT;	120 AA.
ID	Q9DAE3		
AC	Q9DAE3;		
DT	01-JUN-2001 (TrEMBLrel. 17, Created)		
DT	01-JUN-2001 (TrEMBLrel. 17, Last sequence update)		
DT	01-MAR-2003 (TrEMBLrel. 23, Last annotation update)		
DE	Mus musculus adult male testis cDNA, RIKEN full-length enriched		
DE	library, clone:1700012F11 product:hypothetical protein, full insert		
DE	sequence.		
GN	Name=1700012F11rik;		
OS	Mus musculus (Mouse)		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.		
OX	NCBI_TaxID=10090;		
OX	[1]		
PC	SEQUENCE FROM N.A.		
RP	STRAIN=C57BL/6J; TISSUE=Testis;		
RP	MEDLINE=99279253; PubMed=10349636; DOI=10.1016/S0076-6879(99)03004-9;		
RP	Carninci P., Hayashizaki Y.;		
RT	"High-efficiency full-length cDNA cloning.";		
RL	Meth. Enzymol. 303:19-44(1999).		
RL	[2]		
RP	SEQUENCE FROM N.A.		
RP	STRAIN=C57BL/6J; TISSUE=Testis;		
RP	MEDLINE=21085660; PubMed=11217851; DOI=10.1038/35055500;		
RC	RIKEN FANTOM Consortium;		
RC	"Functional annotation of a full-length mouse cDNA collection.";		
RT	Nature 409:685-690(2001).		
RL	[3]		
RP	SEQUENCE FROM N.A.		
RP	STRAIN=C57BL/6J; TISSUE=Testis;		
RC	The FANTOM Consortium,		
RC	the RIKEN Genome Exploration Research Group Phase I & II Team;		
RA	"Analysis of the mouse transcriptome based on functional annotation of		
RA	60,770 full-length cDNAs.";		
RT	Nature 420:563-573(2002).		
RL	[4]		
RP	SEQUENCE FROM N.A.		
RP	STRAIN=C57BL/6J; TISSUE=Testis;		
RP	MEDLINE=20499374; PubMed=11042159; DOI=10.1101/gr.145100;		
RC	Carninci P., Shibata Y., Hayatsu M., Sugahara Y., Shibata K., Itoh M.,		
RC	Konno H., Okazaki Y., Muramatsu M., Hayashizaki Y.;		
RA	"Normalization and subtraction of cap-trapper-selected cDNAs to		
RA	prepare full-length cDNA libraries for rapid discovery of new genes.";		
RT	Genome Res. 10:1617-1630(2000).		
RL	[5]		
RP	SEQUENCE FROM N.A.		
RP	STRAIN=C57BL/6J; TISSUE=Testis;		
RP	MEDLINE=20530913; PubMed=11076861; DOI=10.1101/gr.152600;		
RC	Shibata K., Itoh M., Aizawa K., Nagaoka S., Sasaki N., Carninci P.,		
RC	Konno H., Akiyama J., Nishi K., Kitsuai T., Tashiro H., Itoh M.,		
RA	Sumi N., Ishii Y., Nakamura S., Hazama M., Nishine T., Harada A.,		
RA	Yamamoto R., Matsumoto H., Sakaguchi S., Ikegami T., Kashiwagi K.,		
RA	Fujisake S., Inoue K., Togawa Y., Iizawa M., Ohara E., Watahiki M.,		
RA	Yoneda Y., Ishikawa T., Ozawa K., Tanaka T., Matsuura S., Kawai J.,		
RA	Okazaki Y., Muramatsu M., Inoue Y., Kita A., Hayashizaki Y.;		
RA	"RIKEN integrated sequence analysis (RISA) system-384-format		
RT	sequencing pipeline with 384 multiplexed sequencer.";		
RT	Genome Res. 10:1757-1771(2000).		
RL	[6]		
RP	SEQUENCE FROM N.A.		
RP	STRAIN=C57BL/6J; TISSUE=Testis;		
RC	Adachi J., Aizawa K., Akahira S., Akimura T., Arai A., Aono H.,		
RC	Arakawa T., Bono H., Carninci P., Fukuda S., Fukunishi Y., Furuno M.,		
RA	Hanagaki T., Hara A., Hayatsu M., Hiramoto K., Hiraoka T., Hori F.,		
RA	Imoto K., Ishii Y., Itoh M., Iizawa M., Kasukawa T., Kato H.,		
RA	Kawai J., Kojima Y., Konno H., Kouda M., Koya S., Kurihara C.,		
RA	Matsuyama T., Miyazaki A., Nishi K., Nomura K., Numazaki R., Ohno M.,		
RA	Okazaki Y., Okido T., Owa C., Saito H., Saito R., Sakai C., Sakai K.,		
RA	Sano H., Sasaki D., Shibata K., Shibata Y., Shingawa A., Shiraki T.,		
RA	Sogabe Y., Suzuki H., Tagami M., Tagawa A., Takahashi F., Tanaka T.,		
RA	Tejima Y., Toyota T., Yamamuta T., Yasunishi A., Yoshida K., Yoshino M.,		
RA	Muramatsu M., Hayashizaki Y.;		

RA Arai H., Akazawa K., Asanuma S., Asanuma S., Shirai T., Ohno M.  
RA Arakawa T., Bono H., Carninci P., Fukuda S., Fukunishi Y., Furuno M.,  
RA Hanagaki T., Hara A., Hayatsu N., Hiramoto K., Hiraoka T., Hori F.,  
RA Imotani K., Ishii Y., Itoh M., Izawa M., Kasukawa T., Kato H.,  
RA Kawai J., Kojima Y., Konno H., Kouda M., Koya S., Kurihara C.,  
RA Matsuyama T., Miyazaki A., Nishi K., Nomura K., Numasaki R., Ohno M.,  
RA Okazaki Y., Okido T., Owa C., Saito H., Saito R., Sakai C., Sakai K.,  
RA Sano H., Sasaki D., Shibata K., Shibata Y., Shinagawa A., Shiraki T.,  
RA Sogabe Y., Suzuki H., Tagami M., Tagawa A., Taniguchi F., Tanaka T.,  
RA Teijima Y., Toyota T., Yamamura T., Yasenishi A., Yoshida K., Yoshino M.,  
RA Muramatsu M., Hayashizaki Y.



RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.  
 DR EMBL; AK05903; BAB24309.1; -.  
 DR HSP; P21860; IM6B.  
 DR MGD; MGI:1916582; 1700012F11rik.  
 DR InterPro; IPR003267; Small\_pro\_rich.  
 DR PRINTS; PR00021; PR0RICH.  
 KW Hypothetical protein.  
 SQ SEQUENCE 120 AA; 12795 MW; 4806F207E03BA5BD CRC64;  
 Q9DAE3 Length: 120 February 22, 2005 12:25 Type: P Check: 2990 ..  
 1 MSSDKSSDSK NGLKNCDPRC EQKCTKCQP SCLNKLQRC SEKSLDKCP  
 51 PSFNCPCPP CPPCHLVCS QCSPTTSLC PPLCSPRCSG TLACPPRSCP  
 101 QKGVKPCPP KCPSPCLPRK  
 IIAA SEQUENCE 1.0 PRELIMINARY; PRT; 413 AA.  
 ID Q69566  
 AC Q69566;  
 DT 01-NOV-1996 (TREMELrel. 01, Created)  
 DT 01-NOV-1996 (TREMELrel. 01, Last sequence update)  
 DT 01-OCT-2002 (TREMELrel. 22, Last annotation update)  
 DE U88  
 GN Name:U88;  
 OS Human herpesvirus 6.  
 OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;  
 OC Betaherpesvirinae; Roseolovirus.  
 OC NCBI\_TaxID=10368;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=90112641; PubMed=2153237;  
 RA Littler E., Lawrence G., Liu M.Y., Barrell B.G., Arrand J.R.;  
 RT "Identification, cloning, and expression of the major capsid protein  
 RT gene of human herpesvirus 6.";  
 RL J. Virol. 64:714-722(1990).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=90080132; PubMed=2152817;  
 RA Lawrence G.L., Chee M., Craxton M.A., Gompels U.A., Honess R.W.,  
 RA Barrell B.G.;  
 RT "Human herpesvirus 6 is closely related to human cytomegalovirus.";  
 RL J. Virol. 64:287-299(1990).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=91226542; PubMed=1851252; DOI=10.1038/351078a0;  
 RA Thompson B.J., Efsthathiou S., Honess R.W.;  
 RT "Acquisition of the human adeno-associated virus type-2 rep gene by  
 RT human herpesvirus type-6.";  
 RL Nature 351:78-80(1991).  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=91333007; PubMed=1651403;  
 RA Teo I.A., Griffin B.E., Jones M.D.;  
 RT "Characterization of the DNA polymerase gene of human herpesvirus 6.";  
 RL J. Virol. 65:4670-4680(1991).  
 RN [5]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=91374590; PubMed=1654446;  
 RA Martin M.E.D., Nicholas J., Thomson B.J., Newman C., Honess R.W.;  
 RT "Identification of a transactivating function mapping to the putative  
 RT immediate-early locus of human herpesvirus 6.";  
 RL J. Virol. 65:5381-5390(1991).  
 RN [6]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=91237802; PubMed=1851860;  
 RA Chang C.K., Balachandran N.;

RT "Identification, characterization, and sequence analysis of a cDNA  
 RT encoding a phosphoprotein of human herpesvirus 6.";  
 RL J. Virol. 65:2884-2894(1991).  
 RN [7]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=92148942; PubMed=1310766;  
 RA Geng Y., Chandran B., Josephs S.F., Wood C.;  
 RT "Identification and characterization of a human herpesvirus 6 gene  
 RT segment that trans activates the human immunodeficiency virus type 1  
 RT promoter.";  
 RL J. Virol. 66:1564-1570(1992).  
 RN [8]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=92260671; PubMed=1374813;  
 RA Neipel F., Ellinger K., Fleckenstein B.;  
 RT "Gene for the major antigenic structural protein (p100) of human  
 RT herpesvirus 6.";  
 RL J. Virol. 66:3918-3924(1992).  
 RN [9]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=92333249; PubMed=1321206;  
 RA Efsthathiou S., Lawrence G.L., Brown C.M., Barrell B.G.;  
 RT "Identification of homologs to the human cytomegalovirus US22 gene  
 RT family in human herpesvirus-6.";  
 RL J. Gen. Virol. 73:1661-1671(1992).  
 RN [10]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=93187613; PubMed=8383182;  
 RA Ellinger K., Neipel F., Foa-Tomasi L., Campadelli-Fiume G.,  
 RA Fleckenstein B.;  
 RT "The glycoprotein B homologue of human herpesvirus 6.";  
 RL J. Gen. Virol. 74:495-500(1993).  
 RN [11]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=92333248; PubMed=1321205;  
 RA Thomson B.J., Honess R.W.;  
 RT "The right end of the unique region of the genome of human herpesvirus  
 RT 6 U102 contains a candidate immediate early gene enhancer and a  
 RT homologue of the human cytomegalovirus US22 gene family.";  
 RL J. Gen. Virol. 73:1649-1660(1992).  
 RN [12]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=93091236; PubMed=1333836;  
 RA Gompels U.A., Cars A.L., Sun N., Arrand J.R.;  
 RT "Infectivity determinants encoded in a conserved gene block of human  
 RT herpesvirus-6.";  
 RL DNA Seq. 3:25-39(1992).  
 RN [13]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=94181269; PubMed=8134119;  
 RA Thompson J., Choudhury S., Kashanchi F., Doniger J., Berneman Z.,  
 RA Frenkel N., Rosenthal L.J.;  
 RT "A transforming fragment within the direct repeat region of human  
 RT herpesvirus type 6 that transactivates HIV-1.";  
 RL Oncogene 9:1167-1175(1994).  
 RN [14]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=93244892; PubMed=8385692;  
 RA Gompels U.A., Carrigan D.R., Cars A.L., Arno J.;  
 RT "Two groups of human herpesvirus 6 identified by sequence analyses of  
 RT laboratory strains and variants from Hodgkin's lymphoma and bone  
 RT marrow transplant patients.";  
 RL J. Gen. Virol. 74:613-622(1993).  
 RN [15]  
 RP SEQUENCE FROM N.A.

RC STRAIN=U1102;  
 RX MEDLINE=93323202; PubMed=7687301;  
 RA Pfeiffer B., Berneman Z.N., Neipel F., Chang C.K., Tirwatnpong S.,  
 RA Chandran B.;  
 RT "Identification and mapping of the gene encoding the glycoprotein  
 RT complex gp82-gp105 of human herpesvirus 6 and mapping of the  
 RT neutralizing epitope recognized by monoclonal antibodies.";  
 RL J. Virol. 67:4611-4620(1993).  
 RN [16]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=93331710; PubMed=7687803;  
 RA Pelett P.E., Sanchez-Martinez D., Dominguez G., Black J.B., Anton E.,  
 RA Greenmoyer C., Dambaugh T.R.;  
 RT "A strongly immunoreactive virion protein of human herpesvirus 6  
 RT variant B strain Z29: identification and characterization of the gene  
 RT and mapping of a variant-specific monoclonal antibody reactive  
 RT epitope.";  
 RL J. Virol. 195:521-531(1993).  
 RN [17]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=94025598; PubMed=8212582;  
 RA Jones M., Teo I.;  
 RT "Identification and analysis of the transport/capsid assembly protein  
 RT (tp/cap) gene of human herpesvirus-6 (HHV-6).";  
 RL Virology 197:449-454(1993).  
 RN [18]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=93389439; PubMed=8397282;  
 RA Liu D.X., Gompels U.A., Nicholas J., Elliott C.;  
 RT "Identification and expression of the human herpesvirus 6 glycoprotein  
 RT H and interaction with an accessory 40K glycoprotein.";  
 RL J. Gen. Virol. 74:1847-1857(1993).  
 RN [19]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=94118404; PubMed=8289364;  
 RA Nicholas J., Martin M.;  
 RT "Nucleotide sequence analysis of a 38.5-kilobase-pair region of the  
 RT genome of human herpesvirus 6 encoding human cytomegalovirus  
 RT immediate-early gene homologs and transactivating functions.";  
 RL J. Virol. 68:597-610(1994).  
 RN [20]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=94167865; PubMed=8122364;  
 RA Zhou Y., Chang C.K., Qian G., Chandran B., Wood C.;  
 RT "Trans-activation of the HIV promoter by a cDNA and its genomic clones  
 RT of human herpesvirus-6.";  
 RL Virology 199:311-322(1994).  
 RN [21]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=95146989; PubMed=7844567;  
 RA Gompels U.A., Macaulay H.A.;  
 RT "Characterisation of human telomeric repeat sequences from human  
 RT herpesvirus-6 and relationship to replication.";  
 RL J. Gen. Virol. 76:451-458(1995).  
 RN [22]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=94202288; PubMed=8151770;  
 RA Thomson B.J., Dewhurst S., Gray D.;  
 RT "Structure and heterogeneity of the a sequences of human herpesvirus 6  
 RT strain variants U1102 and Z29 and identification of human telomeric  
 RT repeat sequences at the genomic termini.";  
 RL J. Virol. 68:3007-3014(1994).  
 RN [23]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=94025558; PubMed=7692666;

RA Liu D.X., Gompels U.A., Foa-Tomasi L., Campadelli-Piume G.;  
 RT "Human herpesvirus-6 glycoprotein H and L homologs are components of  
 RT the gp100 complex and the gH external domain is the target for  
 RT neutralizing monoclonal antibodies.";  
 RL Virology 197:12-22(1993).  
 RN [24]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=94047392; PubMed=8230490;  
 RA Dewhurst S., Dollard S.C., Pellett P.E., Dambaugh T.R.;  
 RT "Identification of a lytic-phase origin of DNA replication in human  
 RT herpesvirus 6B strain Z29.";  
 RL J. Virol. 67:7680-7683(1993).  
 RN [25]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=94202284; PubMed=8151768;  
 RA Schleue U., Neipel F., Schreiner D., Fleckenstein B.;  
 RT "Structure and transcription of an immediate-early region in the human  
 RT herpesvirus 6 genome.";  
 RL J. Virol. 68:2978-2985(1994).  
 RN [26]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=94378506; PubMed=8091661;  
 RA Thomson B.J., Weindler F.W., Gray D., Schwaab V., Helbronn R.;  
 RT "Human herpesvirus 6 (HHV-6) is a helper virus for adeno-associated  
 RT virus type 2 (AAV-2) and the AAV-2 rep gene homologue in HHV-6 can  
 RT mediate AAV-2 DNA replication and regulate gene expression.";  
 RL Virology 204:304-311(1994).  
 RN [27]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=94267872; PubMed=8207791;  
 RA Inoue N., Dambaugh T.R., Rapp J.C., Pellett P.E.;  
 RT "Alphaherpesvirus origin-binding protein homolog encoded by human  
 RT herpesvirus 6B, a betaherpesvirus, binds to nucleotide sequences that  
 RT are similar to ori regions of alphaherpesviruses.";  
 RL J. Virol. 68:4126-4136(1994).  
 RN [28]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=94267872; PubMed=8207791;  
 RA Qian G., Wood C., Chandran B.;  
 RT "Identification and characterization of glycoprotein gH of human  
 RT herpesvirus-6.";  
 RL J. Virol. 194:380-386(1993).  
 RN [29]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=91116306; PubMed=1846644;  
 RA Martin M., Thomson B.J., Honess R.W., Craxton M.A., Gompels U.A.,  
 RA Liu M.Y., Littler E., Arrand J.R., Teo I., Jones M.D.;  
 RT "The genome of human herpesvirus 6: Maps of unit-length and  
 RT concatemeric genomes for nine restriction endonucleases.";  
 RL J. Gen. Virol. 72:157-168(1991).  
 RN [30]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=89279291; PubMed=2543772;  
 RA Chee M.S., Lawrence G.L., Barrell B.G.;  
 RT "Alpha-, beta- and gammaherpesviruses encode a putative  
 RT phosphotransferase.";  
 RL J. Gen. Virol. 70:1151-1160(1989).  
 RN [31]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=U1102;  
 RX MEDLINE=95266321; PubMed=7747482;  
 RA Gompels U.A., Nicholas J., Lawrence G., Jones M., Thomson B.J.,  
 RA Martin M.E., Efsthathiou S., Craxton M., Macaulay H.A.;  
 RT "The DNA sequence of human herpesvirus-6: structure, coding content,  
 RT and genome evolution.";  
 RL Virology 209:29-51(1995).  
 RN [32]

RP SEQUENCE FROM N.A.  
RC STRAIN=U1102;  
RA Lawrence G.L., Nicholas J., Barrell B.G.;  
RT "Human herpesvirus 6 (strain U1102) encodes homologues of the  
RT conserved herpesvirus glycoprotein gM and the alphaherpesvirus origin-  
RT binding protein.";   
RL J. Gen. Virol. 0:0-0(1994).  
RN [33]  
RP SEQUENCE FROM N.A.  
RC STRAIN=U1102;  
RA Nicholas J.;  
RT "Nucleotide sequence of a 21-kilobase-pair region of the genome of  
RT human herpesvirus-6 containing homologues of human cytomegalovirus  
RT major immediate-early and replication genes.";   
RL Submitted (JUN-1995) to the EMBL/GenBank/DBJ databases.  
DR EMBL; X83413; CAA58337.1; -.  
SQ SEQUENCE 413 AA; 44135 MW; 6306069949151A4D CRC64;  
  
Q69566 Length: 413 February 22, 2005 12:25 Type: P Check: 8293 ..  
1 MYVSVSRVHS VHSVSRVSVR VSVCSVRVS VHSVSRVSVS VRVSVRVSVS  
51 VRVSVRVSVS VHSVVRVSVR VSVSVRVSV ARVCARVCVC ARVCVCARVC  
101 VCARVCVCAR VCARVCVCAC VCVCACLCVC ACLCVCACLC VCACLCVCAC  
151 LCVACLCVC ACLCVCACLC VCVCVCLCVC VCLCVCVCLC VCVCCLCVCVC  
201 LCVCVCLCVC VCLCVCVCLC VCVCVCLCVC LCVCVCVVCVC VCVCVVCVCVC  
251 VCVCVCLCVC VCLCVCVCLC LCVCVVCVCVC LCVCLCVCCLC VCVCVCVCLL  
301 CMSLCMCMCM CMCMCMCMCM CMSLCMSLCM CMCMCMCMCM CCMCMCICI  
351 CMCMCMCMCM CMCMCMCMCM CMCMCMCMCM CMCMCMCMCM CMCMCMCMCM  
401 CMCMCMCIIE GNK

This Page Blank (uspro)

! FINDPATTERNS on pir.\* allowing 0 mismatches

! 1 (Y,F)XXCXXCX(10,12)CXXCXX(Y,F)\* February 18, 2

1 41: DPPKR YEDCRRCEWDTRGKEQQCEESKSY GEKQD

(Y,F)XXCXXCX(10,12)CXXCXX(Y,F)

(Y)XXCXXCX(12)CXXCXX(Y)

(Y)XXCXXCX(10)CXXCXX(F)

87: DPQRR YEECQECRQEEERPOCQCLKRF EQEQQ

(F)XXCXXCX(12)CXXCXX(Y)

124: QSQRQ FQECQHCHQEQRPCKQCVRECRERY QENPW

S08059 ck: 9476 len: 509 ! alpha-globulin type B precursor (tandem 1)

(Y,F)XXCXXCX(10,12)CXXCXX(Y,F)

(Y)XXCXXCX(10)CXXCXX(F)

6: DPQRR YEECQECRQEEERPOCQCLKRF EQEQQ

(F)XXCXXCX(12)CXXCXX(Y)

43: QSQRQ FQECQHCHQEQRPCKQCVRECRERY QENPW

S22477 ck: 3693 len: 566 ! vicilin precursor - cacao

(Y,F)XXCXXCX(10,12)CXXCXX(Y,F)

(Y)XXCXXCX(10)CXXCXX(F)

42: DPRQQ YEQCQRCESEATEEREQCEQRCEREY KEQQR

(Y)XXCXXCX(12)CXXCXX(Y)

85: ELQRQ YQCCQRCQEQEQGQEQEQCQCKWEQY KEQER

S06398 ck: 4376 len: 605 ! alpha-globulin type A precursor - upland co

(Y,F)XXCXXCX(10,12)CXXCXX(Y,F)

(Y)XXCXXCX(10)CXXCXX(Y)

84: DPQRR YQDCRQHCHQEQRLRPHCEQSCREY EKQQQ

(F)XXCXXCX(12)CXXCXX(Y)

122: QPDKQ FKECQRCQEQEQRPCKQCVKECREY QEDPW

T27719 ck: 5111 len: 105 ! hypothetical protein ZK1251.2 - Caenorhabditis

(Y,F)XXCXXCX(10,12)CXXCXX(Y,F)

(F)XXCXXCX(12)CXXCXX(F)

70: IHSYV FAVCGKACESNTEVNIASKCRECTDDF IRKQC

T15330 ck: 8237 len: 95 ! hypothetical protein B0310.6 - Caenorhabditis

(Y,F)XXCXXCX(10,12)CXXCXX(Y,F)

(Y)XXCXXCX(12)CXXCXX(Y)

65: IRAKR YYGCGGCGCATVAASPVPFGCGCGY GK

Databases searched:

NBRF, Release 79.1, Released on 16Aug2004, Formatted on 17Oct2004

Total finds: 11

Total length: 96,216,763

Total sequences: 283,416

CPU time: 03:37.97

*Handwritten signature*

This Page Blank (uspto)

```

!!IAA_SEQUENCE 1.0
P1:FWGNAB*- alpha-globulin B precursor (clone C72) - upland cotton
N:Alternate names: seed storage protein; vicilin precursor
C:Species: Gossypium hirsutum (upland cotton)
C:Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 09-Jul-2004
C:Accession: A30838; S06911
R:Chlan, C.A.; Pyle, J.B.; Legocki, A.B.; Dure III, L.
Plant Mol. Biol. 7, 475-489, 1986
A:Title: Developmental biochemistry of cottonseed embryogenesis and germination
XVIII cDNA and amino acid sequences of members of the storage protein families.
A:Reference number: A30838
A:Accession: A30838
A:Molecule type: mRNA
A:Residues: 1-588 <CHL>
A:Cross-references: UNIPROT:P09801; GB:M16891; NID:g167374; PIDN:AAA33071.1;
PID:g167375
A:Experimental source: var. Coker 201
R:Chlan, C.A.; Borroto, K.; Kamalay, J.A.; Dure III, L.
Plant Mol. Biol. 9, 533-546, 1987
A:Title: Developmental biochemistry of cottonseed embryogenesis and
germination. XIX. Sequences and genomic organization of the alpha globulin
(vicilin) genes of cottonseed.
A:Reference number: S06398
A:Accession: S06911
A>Status: not compared with conceptual translation
A:Molecule type: DNA
A:Residues: 1-81 <CH2>
C:Comment: This is a seed storage protein.
C:Superfamily: glycinin
C:Keywords: glycoprotein; seed; storage protein
F:1-45/Domain: signal sequence #status predicted <SIG>
F:26-588/Product: alpha-globulin storage proprotein #status predicted <MAT>
F:417/Binding site: carbohydrate (Asn) (covalent) #status predicted
FWCNAB Length: 588 February 22, 2005 10:21 Type: P Check: 941 ..
1 MYRNKACVV LLSFLSFG LLCSAKPPG RRGDDPPPKR YEDRRRCWE
51 DTRGQKEQQ CEESKSYG EKQQQRHRP EDQRRRYEC QQCRCQBER
101 ORPQCQRCL KRFEQEQQS QRQFEQQQH CHQEQRPER KQCVCRECE
151 RYQENPWRE REEABEET EGEQEQSHN PFHRRRSFQ SRFREHGNF
201 RVLQRFASRH PILRGINEFR LSILEANPNT FVLPHHCDAE KIYLVNNGRG
251 TLTLFLTHENK ESYNVVPGV VRVPAGSTVY LANQDNKEKL IIAVLHRPVN
301 NRPQEEFPF AGSQRPQSYL RAPSREILEP AFNTRSEQLD ELFGGRQSHR
351 ROQGGMFRK ASQEQIRALS QEATSPREKS GERFAFNLLY RTPRYSNQNG
401 RYEAACPRF RQLSDINTV SALQLNQGS I FVPHYNSKAT FVLVNEGNG
451 YVEMVSPHLR QSSFEDEEE QQQEQECEE RRSQGVRKIR SOLSRGDIFF
501 VPANFPVTFV ASQNQLRMT GFGLYNQIN PDHNQRIFFA GKINHVRQWD
551 SQAKELAFV SSRLVDEIFN NNQESYFVS RQRQASE

!!IAA_SEQUENCE 1.0
F1:S08059 - alpha-globulin type B precursor (tandem 1) - upland cotton
(fragment)
N:Alternate names: seed storage protein
C:Species: Gossypium hirsutum (upland cotton)
C:Date: 31-Mar-1990 #sequence_revision 31-Mar-1990 #text_change 30-Sep-1993
C:Accession: S08059
R:Chlan, C.A.; Borroto, K.; Kamalay, J.A.; Dure III, L.
Plant Mol. Biol. 9, 533-546, 1987
A:Title: Developmental biochemistry of cottonseed embryogenesis and
germination. XIX. Sequences and genomic organization of the alpha globulin
(vicilin) genes of cottonseed.
A:Reference number: S06398

```

```

A:Accession: S08059
A>Status: not compared with conceptual translation
A:Molecule type: DNA
A:Residues: 1-509 <CHL>
C:Superfamily: glycinin

S08059 Length: 509 February 22, 2005 10:21 Type: P Check: 9476 ..
1 DPQRRYECQ QECRQBERQ QPQQQRCLK RFEQEQQSQ RQFECQQHC
51 HQEQRPKK QCVRECREK YQENPWGER EEEAEETE EGEQSQSHNP
101 FHFRRSFQS RFREHGNFR VLQRFASRHP ILRGINEFRL SILEANPNTF
151 VLPFHCDAEK IYLVNNGRG LTFLTHENKE SYNIVGVVV KVPAGSTVYL
201 ANQDNKEKL IAVLHRPVN PGQFEFFPA GSRPQSYLR AFSRILEPA
251 FNRSEQLDE LFGGRQRRR QQGGMFRKA SQEQIRALSQ EATSPREKSG
301 ERFAFNLLSQ TPRYSNQNGR FFEACPPFR QLRDINTVTS ALQLNQGSIF
351 VPHYNSKATF VILTEGNGY AEMVSPHLR QSSYEEEEE DEEBEQEQBE
401 ERRSQYRKI RSLRSGDIF VVPANFPVTF VASQNQLRM TGFGLYNQNI
451 NPDHNQRIFFV AGKINHVRQW DSAKELAFG VSSRLVDEIF NSNPQESYFV
501 SRQQRASE

!!IAA_SEQUENCE 1.0
P1:S22477 - vicilin precursor - cacao
C:Species: Theobroma cacao (cacao)
C:Date: 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change 17-Mar-1999
C:Accession: S22477; S22478; S18105; S22050
R:McHenry, L.; Fritz, P.O.
Plant Mol. Biol. 18, 1173-1176, 1992
A:Title: Comparison of the structure and nucleotide sequence of vicilin genes
of cocoa and cotton raise questions about vicilin evolution.
A:Reference number: S22477; PMID:92288309; PMID:1600151
A:Accession: S22477
A:Molecule type: DNA
A:Residues: 1-566 <MCH>
A:Cross-references: EMBL:X62625
A:Accession: S22478
A:Molecule type: mRNA
A:Residues: 1-452 <MC2>
A:Cross-references: EMBL:X62626
C:Genetics:
A:Introns: 211/1; 269/3; 296/3; 391/3; 502/1
C:Superfamily: glycinin
C:Keywords: seed; storage protein
F:1-24/Domain: signal sequence #status predicted <SIG>
F:25-566/Product: vicilin #status predicted <MAT>

S22477 Length: 566 February 22, 2005 10:21 Type: P Check: 3693 ..
1 MVISKSPFIV LIFSLLLSFA LLCSGVSAYG RKQYERDPQ QYEQQRCE
51 SEATEREQE QCEQRCEY KEQQRQEBE LORQYQQCG RCQEQQQQR
101 EQQQQRKCW EQYKEQERGE HENYHNHKN RSEBEGQQR NNPFYFPKRR
151 SFQTRFDEE GNPKLQFPA ENSPPLKGIN DYRLAMFEAN PNTFILPHHC
201 DAEAIYFTN KGKTFITVTH ENKESYNVOR GTTVSVFAPS TVYVVSQDQ
251 EKLTIATLAL PVNSPGKYL FFPAGNKKPE SYYGAFSYEV LETVNTQRE
301 KLEETLEQR GKQEQQQQG MFKAKPEQI RAISQATSP RHRGGERLAI
351 NLLSQSPYS NQNGRPFEC PEDFSQNM DVVASFAKLN QGAIFVPHYN

```

401 SKATFVVFT DGYGYAQM PHLRSQSGS QSGRQDRREQ EEBSEBETFG  
451 EFQVQKAPLS PGDVFTAPAG HAVTFASKD QPLNAVAFGL NAQNNQRIFL  
501 AGKKNLVROM DSEAKLSFG VPSKLVNIF NNPDESIFMS FSQQRQRGDE  
551 RRGNPLASIL DPARLF

!!AA SEQUENCE 1.0  
P1:S06398 - alpha-globulin type A precursor - upland cotton  
N;Alternate names: seed storage protein  
C;Species: Gossypium hirsutum (upland cotton)  
C;Date: 31-Mar-1990 #sequence\_revision 31-Mar-1990 #text\_change 09-Jul-2004  
C;Accession: S06398  
R;Chian, C.A.; Borroto, K.; Kamalay, J.A.; Dure III, L.  
Plant Mol. Biol. 9, 533-546, 1987  
A;Title: Developmental biochemistry of cottonseed embryogenesis and  
germination. XIX. Sequences and genomic organization of the alpha globulin  
(vicilin) genes of cottonseed.  
A;Reference number: S06398  
A;Accession: S06398  
A;Status: not compared with conceptual translation  
A;Molecule type: DNA  
A;Residues: 1-605 <CHL>  
A;Cross-references: UNIPROT:P09799  
C;Superfamily: glycinin  
F;1-24/Domain: signal sequence #status predicted <SIG>  
F;25-605/Product: alpha-globulin type A #status predicted <MAT>  
  
S06398 Length: 605 February 22, 2005 10:21 Type: P Check: 4376 ..

1 MVRNKSFEVV LFLSLFLSFG LLCSAKDFPG RRSDDPQQR YEDCRKRCQL  
51 ETRGTEQDK CEDRSETQLK EFQQRDGEDP QRRYQDCRQH CQOEERRLRP  
101 HCEQSCREY EKQQQQPDK QFKECQQRCC WQEQRPCKQ QCVKECREQY  
151 QEDPWKGERE NKWREEESE SDEGEQQQRN NPYFPHRRSP QERFREHGN  
201 FRVLQRFADK HHLRLGINEF RTAILEANPN TFVLPHHCDA EKIYVVTNGR  
251 GTVTFVTHEN KESYNVVPVGV VVRIPAGSTV YLANQDNREK LTI AVLHRPV  
301 NNPQFQKFF PAGQNPQSY LRIFSREILE AVFNTREQL DELPGGRQSH  
351 RROQGGQMF KASQEQIRAL SQGATSPRGK GSEGYAFNLL SOTPRYSNQN  
401 GRFYEACPRN FQQLREVD SVAFAEINKG SIFVPHYNSK ATEFVLVTEG  
451 NGHVEVMCPH LSRQSSDWSS REEEQEERQE VERRSGQYKR VRAQLSTGNL  
501 FWPAGHPVT FVASQNEDLG LLGFGLYNGQ DNKRIFVAGK TNNVRQWDRQ  
551 AKELAFGVES RLVDVEFNNN PQESYFVSGR DRRGFDERRG SNNPLSPFLD  
601 FARLF

!!AA SEQUENCE 1.0  
P1:T27719 - hypothetical protein ZK1251.2 - Caenorhabditis elegans  
C;Species: Caenorhabditis elegans  
C;Date: 15-Oct-1999 #sequence\_revision 15-Oct-1999 #text\_change 09-Jul-2004  
C;Accession: T27719  
R;McMurray, A.  
submitted to the EMBL Data Library, December 1995  
A;Reference number: Z20411  
A;Accession: T27719  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: DNA  
A;Residues: 1-105 <WIL>  
A;Cross-references: UNIPROT:Q23430; EMBL:Z68222; PIDN:CAA92498.1;  
GSPDB:GN00022; CESP:ZK1251.2  
A;Experimental source: clone ZK1251  
C;Genetics:

A;Gene: CESP:ZK1251.2  
A;Map position: 4  
A;Introns: 80/1  
C;Superfamily: Caenorhabditis elegans hypothetical protein ZK84.6  
  
T27719 Length: 105 February 22, 2005 10:21 Type: P Check: 5111 ..  
  
1 MPPILVFFL VLI PASQQYP FSLESNDQI INEEVIEYML ENSIRSSRTR  
51 RVPDEKKIYR CGRRHSYVF AVCGKACESN TEVNIASKCC REECTDDFIR  
101 KQCCP  
  
!!AA SEQUENCE 1.0  
P1:T15330 - hypothetical protein B0310.6 - Caenorhabditis elegans  
C;Species: Caenorhabditis elegans  
C;Date: 20-Sep-1999 #sequence\_revision 20-Sep-1999 #text\_change 09-Jul-2004  
C;Accession: T15330  
R;Favella, T.  
submitted to the EMBL Data Library, November 1995  
A;Description: The sequence of C. elegans cosmid B0310.  
A;Reference number: Z18330  
A;Accession: T15330  
A;Status: preliminary; translated from GB/EMBL/DBJ  
A;Molecule type: DNA  
A;Residues: 1-95 <FAV>  
A;Cross-references: UNIPROT:Q10942; EMBL:U40959; NID:g1072284; PID:g1072290;  
PIDN:AAA81770.1; CESP:B0310.6  
C;Genetics:  
A;Gene: CESP:B0310.6  
A;Introns: 23/3  
  
T15330 Length: 95 February 22, 2005 10:21 Type: P Check: 8237 ..  
  
1 MLRWLVFAAI LVFSTANSEI IDKSLEQSGP IQDSSNFALA VNGEELPTDI  
51 ALRGQSEVMI RAKRYGCGC GCGCATVAAV SPVPCGGCCG CGYKG



1 FINDPATTERNS on uniprot:% allowing 0 mismatches

1 1s(M..F)XXCXXCX{10..12}CXXCXXX(Y,F)  
February 18, 2018

1 ALB4\_CAEEL ck: 5111 len: 105 1 Q23430 caenorhabditis elegans. probable inner

70: IHSYV FAVCGKACESNTEVNIASKCRBECTDDF IRKQC

1 VCLA\_GOSHI ck: 4376 len: 605 1 P09799 gossypium hirsutum (upland cotton).

84: DPQR (Y,F)XXCXXCX{10,12}CXXCXXX(Y,F)  
(F)xxCxxCxx{12}CxxCxxx(F)  
YQCRHQCOEERLRPHCEQSCREQ EKQQQ

122: QPDK FKEQQRQWEOERPERKQCVCREQY QEDPW  
(F)xxCxxCxx{12}CxxCxxx(Y)

1 VCLB\_GOSHI ck: 941 len: 588 1 P09801 gossypium hirsutum (upland cotton).

41: DPPKR (Y,F)XXCXXCX{10,12}CXXCXXX(Y,F)  
(Y)xxCxxCxx{12}CxxCxxx(Y)  
YEDCRRCEWDTRGKEQEQCEESCKSQY GEKQD

87: DPQR (Y)xxCxxCxx{10}CxxCxxx(F)  
YBECQOECRQOBERQRPQCQRLKRF EQBQQ

124: QSQR FQEQQHCHQOERPERKQCVCREERY QENPW  
(F)xxCxxCxx{12}CxxCxxx(Y)

1 VCL\_THECC ck: 1307 len: 525 1 Q43358 theobroma cacao (cacao) (cocoa).

42: DPRQ (Y,F)XXCXXCX{10,12}CXXCXXX(Y,F)  
(Y)xxCxxCxx{12}CxxCxxx(Y)  
YEQQRCESEATEERQEQCEQRCERY KEQQR

85: ELQR YQOQGRQOQOGRQEQOQOQRCWEQY KEQER  
(Y)xxCxxCxx{12}CxxCxxx(Y)

1 YWS6\_CAEEL ck: 8237 len: 95 1 Q10942 caenorhabditis elegans. hypothetical

65: IRAKR YYGCGCGCATVAASVPVFCGCCGCGY GK

1 Q8N962 ck: 556 len: 134 1 Q8N962 homo sapiens (human). hypothetical P

4: MWV YVCCVCMCRWCLCVCIYMCVCPVCMCV VCVYV  
(Y,F)XXCXXCX{10,12}CXXCXXX(Y,F)  
(Y)xxCxxCxx{12}CxxCxxx(Y)

1 Q33563 ck: 7624 len: 141 1 Q33563 trypanosoma brucei. eastro 164 kinetoc

80: IFFFY FVLCLFYCGFYLVCLVFFGFCVCLCY FLIYF  
(Y,F)XXCXXCX{10,12}CXXCXXX(Y,F)  
(F)xxCxxCxx{10}CxxCxxx(Y)

1 Q7Y1C1 ck: 9405 len: 481 1 Q7Y1C1 juglans nigra (black walnut). victim

11: DPQQ YHRCRCQIQEQSPERQRCQRCERY KEQQG  
(Y)xxCxxCxx{10,12}CXXCXXX(Y,F)  
(Y)xxCxxCxx{12}CxxCxxx(Y)

```

Databases searched:
  UNIPROT, Release 3.1, Released on 9Nov2004, Formatted on 5Nov2004

Total: 18
Total length: 512,079,187
Total sequences: 1,612,378
CPU time: 19:55.71

```

This Page Blank (usptol)

```

!!AA_SEQUENCE 1.0
ID CLBA_CABEL * STANDARD; PRT; 105 AA.
AC Q23430;
DT 15-JUL-1998 (Rel. 36, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Probable insulin-like peptide beta-type 4 precursor.
GN Name=ins-7; ORFNames=ZK1251.2;
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditidae;
OC Rhabditidae; Peloderinae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RX MEDLINE=99069613; PubMed=9851916;
RG The C. elegans sequencing consortium;
RT "Genome sequence of the nematode C. elegans: a platform for
RT investigating biology.";
RL Science 282:2012-2018(1998).
RN [2]
RP SIMILARITY TO INSULIN.
RX MEDLINE=98217375; PubMed=9548970;
RA Durt L., Guex N., Peitsch M.C., Bairoch A.;
RT "New insulin-like proteins with atypical disulfide bond pattern
RT characterized in Caenorhabditis elegans by comparative sequence
RT analysis and homology modeling.";
RL Genome Res. 8:348-353(1998).
CC -!- SUBCELLULAR LOCATION: Secreted (Potential).
CC -!- SIMILARITY: Belongs to the insulin family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; Z68222; CAA92498.1; -.
DR PIR; T27719; T27719
DR WormBase; WBGene0002090; ins-7.
DR WormPep; ZK1251.2; CB03849.
DR InterPro; IPR004825; Ins/IGF/relax.
DR InterPro; IPR003235; Nmtde_ins_beta.
DR Pfam; PF03488; Ins_beta; 1.
DR ProDom; PD012623; Nmtde_ins_beta; 1.
DR SMART; SM00078; IIGF; 1.
DR PROSITE; PS00262; INSULIN; 1.
KW Insulin family; Signal.
FT SIGNAL 1 18 Potential.
FT PROPEP 19 57 Potential.
FT CHAIN 58 105 Probable insulin-like peptide beta-type
FT
FT
FT DISULFID 61 90 Potential.
FT DISULFID 73 103 Potential.
FT DISULFID 77 104 Potential.
FT DISULFID 89 94 Potential.
SQ SEQUENCE 105 AA; 12198 MW; EB400DDDB7732969 CRC64;

ILB4_CABEL Length: 105 February 22, 2005 10:46 Type: P Check: 5111 ..
1 MPPILVFL VLPASQQYP FSLESINDQI INEEVIEYML ENSIRSSRTR
51 RVPDEKKIYR CGRIHSYVF AVCGKACESN TEVNIASKCC REECTDDFIR
101 KQCCP

!!AA_SEQUENCE 1.0
ID VCLA_GOSHI STANDARD; PRT; 605 AA.
AC P09759;
DT 01-MAR-1989 (Rel. 10, Created)
DT 01-MAR-1989 (Rel. 10, Last sequence update)

```

```

DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Vicilin GC72-A precursor (Alpha-globulin A).
OS Gossypium hirsutum (Upland cotton).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosids II; Malvales; Malvaceae; Malvoideae; Gossypium.
OX NCBI_TaxID=3635;
RN [1]
RP SEQUENCE FROM N.A.
RC Chlan C.A., Borrito K., Kamalay J.A., Dure L. III;
RT "Developmental biochemistry of cottonseed embryogenesis and
RT germination. XIX. Sequences and genomic organization of the alpha
RT globulin (vicilin) genes of cottonseed.";
RL Plant Mol. Biol. 9:533-546(1987).
CC -!- FUNCTION: Seed storage protein.
CC -!- SUBCELLULAR LOCATION: Cotyledonary membrane-bound vacuolar protein
CC bodies.
CC -!- SIMILARITY: Belongs to the 7S seed storage protein family.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL; M19378; AAA33069.1; -.
DR PIR; S06398; S06398.
DR HSSP; P25974; 11PJ.
DR InterPro; IPR006045; Cupin.
DR InterPro; IPR007113; Cupin region.
DR InterPro; IPR011051; RmlC_Like_cupin.
DR InterPro; IPR006792; Vicilin_N.
DR Pfam; PF00190; Cupin; 2.
DR Pfam; PF04702; Vicilin_N; 1.
KW Seed storage protein; Signal.
FT SIGNAL 1 23
FT CHAIN 24 605 Vicilin GC72-A.
SQ SEQUENCE 605 AA; 71049 MW; C9DB9371C76953B CRC64;

VCLA_GOSHI Length: 605 February 22, 2005 10:46 Type: P Check: 4376 ..
1 MYRNKSVFVV LLFSLFLSFG LLCsAKDFPG RRSEDDPQOR YEDCKRKQCL
51 ETRGTEQDK CEDRSETQLK EEQRDGEDP QRRYQDCRQH CQEEERLRP
101 HCEQSCREQY EKQQQQPDK QFKECQORCQ WOEQRPERKQ QCVKECREQY
151 QEDPMKGERE NKWREEEEEE SDEGEQQQRN NPYFTHRRSF QERFEEHGN
201 FRVLQRFADK HLLRGINEF RIALEANPN TPVLPFHCD A EKIYVVTNGR
251 GTVTFTVTHEN KESYNNVPGV VVRIPAGSTV YLANQDNREK LTIIVLHRPV
301 NNPGQFQKFF PAGQENPQSY LRIFSRILE AVFNTSRSEQL DELPGGRQSH
351 RRQQQGMFR KASQEQIRAL SQGATSPRGK GSEGYAFNLL SQTFRYSNQ
401 GRFYBACPRN FQQLREVD SSVVAFINKG SIFVPHYNSK ATFFVLVTEG
451 NGHVMVCPH LSRQSSDWS REEEQEEQE VERRSGQYKR VRAQLSTGNL
501 FVVPAGHPVT FVASQNEDLG LLGFGLYNGQ DNKRIFVAGK TNNVROWDRQ
551 AKELAFGVES RLVDEVFNNN PQESYFVSGR DRRGFDERRG SNNPLSPFLD
601 FARLF

!!AA_SEQUENCE 1.0
ID VCLA_GOSHI STANDARD; PRT; 588 AA.
AC P09801;
DT 01-MAR-1989 (Rel. 10, Created)

```

```

DT 01-MAR-1989 (Rel. 10, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Vicilin C72 precursor (Alpha-globulin B).
OS Gossypium hirsutum (Upland cotton).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eusoids II; Malvales; Malvaceae; Gossypium.
OX NCBI_TaxID=3635;
RN [1]
RP SEQUENCE FROM N.A.
RA Chlan C.A., Pyle J.B., Legocki A.B., Dure L. III;
RT "Developmental biochemistry of cottonseed embryogenesis and
RT germination. XVIII. cDNA and amino acid sequences of the members of
RT the storage protein families.";
RL Plant Mol. Biol. 7:475-489(1986).
CC -1- FUNCTION: Seed storage protein.
CC -1- SUBCELLULAR LOCATION: Cotyledonary membrane-bound vacuolar protein
CC bodies.
CC -1- SIMILARITY: Belongs to the 7S seed storage protein family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; M16891; AAA33071.1; -.
DR PIR; A30838; FWCNAB.
DR HSP; P50477; 2CAU.
DR InterPro; IPR006045; Cupin.
DR InterPro; IPR007113; Cupin_region.
DR InterPro; IPR011051; Rmlc_like_cupin.
DR InterPro; IPR006792; Vicilin_N.
DR Pfam; PF00190; Cupin; 2.
DR Pfam; PF04702; Vicilin_N; 1.
KW Seed storage protein; Signal.
FT SIGNAL 1 25
FT CHAIN 26 588 Vicilin C72.
SQ SEQUENCE 588 AA; 63729 MW; 63E699B29AB8ADEB CRC64;

VCLB_GOSHI Length: 588 February 22, 2005 10:46 Type: P Check: 941 ..

1 MVRNKSACVV LFLSLFLSFG LLCSAKDPFG RRGDDDPKR YEDCRRCWE
51 DTRGQKEQQQ CEBSCKSQYG EKXQQQRHRP EDPQRYEEC QQECRQOEE
101 ORPQCQRCL KRPEQEQQQS QRQFQCQCH CHQEQQRPER KQCVRECRE
151 RYQENPWRE REEABEEET EGEQEQQSHN PFHFRRSFQ SRPREHGNP
201 RVLQRFASRH PILRGINEFR LSILEANPNT FVLPHHCDAE KIYLVNNGR
251 TLTLTLTHENK ESYNVVPGVV VRVPGSTVY LANQDNKEK IIAVLHRPVN
301 NPROFSEFPF AGSQRPQSYL RAFSREILEP AFNTRSQLD ELFGGQSHR
351 RQCGQMFRK ASOEQIRALS QEATSPREKS GERFAFNLLY RTPRYNQNG
401 RFYEACPREF RQLSDINVTV SALQLNQSI FVPHYNSKAT FVVLVNEGG
451 YVEMVSHLP RQGSFEEEEE QQQEQEQQEE RRSQYRKIR SQLSRGDIY
501 VPANFPVTFV ASQNQNLRMT GFGLYNQIN PDHNQRFVA GKINHVRQMD
551 SQAKELAFGV SSRVLDEIFN NNPQSYFVS RQRQASE

!!AA SEQUENCE 1.0
ID VCL_THECC STANDARD; PRT; 525 AA.
AC Q43358; Q9S7V9; Q9SQ35;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)

```

```

DT 05-JUL-2004 (Rel. 44, Last annotation update)
DE Vicilin precursor.
GN Name=CSV; Synonyms=VIC;
OS Theobroma cacao (Cacao) (Cocoa).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eusoids II; Malvales; Malvaceae; Byttnerioideae; Theobroma.
OX NCBI_TaxID=3641;
RN [1]
RP SEQUENCE FROM N.A.
RA TISSUE=Leaf;
RX MEDLINE=92288309; PubMed=1600151;
RA McHenry L., Fritz P.J.;
RT "Comparison of the structure and nucleotide sequences of vicilin genes
RT of cocoa and cotton raise questions about vicilin evolution.";
RL Plant Mol. Biol. 18:1173-1176(1992).
RN [2]
RP SEQUENCE OF 159-397 FROM N.A.
RA Whitlock B.A., Baum D.A.;
RT "Phylogenetic relationships of Theobroma and Herrania (Sterculiaceae)
RT based on sequences of the nuclear gene vicilin.";
RL Syst. Bot. 24:128-138(1999).
CC -1- SIMILARITY: Belongs to the 7S seed storage protein family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; X62625; CAA44493.1; -.
DR EMBL; X62626; CAA44494.1; -.
DR EMBL; AF113046; AAF13477.1; -.
DR EMBL; AF113047; AAF13478.1; -.
DR EMBL; AF113048; AAF13479.1; -.
DR HSP; P02853; 2PHL.
DR InterPro; IPR006045; Cupin.
DR InterPro; IPR007113; Cupin_region.
DR InterPro; IPR011051; Rmlc_like_cupin.
DR InterPro; IPR006792; Vicilin_N.
DR Pfam; PF00190; Cupin; 2.
DR Pfam; PF04702; Vicilin_N; 1.
KW Seed storage protein; Signal.
FT SIGNAL 1 24
FT CHAIN 25 525 Vicilin.
FT DOMAIN 133 136 Poly-Glu.
FT CARBOHYD 130 130 N-linked (GlcNAc...) (Potential).
FT VARIANT 313 313 K -> M.
SQ SEQUENCE 525 AA; 60798 MW; 19114CD5C248905D CRC64;

VCL_THECC Length: 525 February 22, 2005 10:46 Type: P Check: 1307 ..

1 MWTSKSPFIV LIFSLLSFA LLCSGVSAYG RKQYERDPRQ QYEQCQRCE
51 SEATEREQE QCEQCEREY KEQQRQEEE LQRYQCCQG RCQEQQQGR
101 EQQQCKKCW EQYKEQERGE HENYHNHKN RSEEEGQQR NNPPYFPKR
151 SFQTRFDEE GNFKILQRF ENSPPLKGIN DYRLAMFEAN PNTFILPHHC
201 DABAIYFVTN KGKTIFFTH ENKESYVQR GTVVSVFAGS TVVVSQDNQ
251 EKLTIAVLAL PVNSFGKYL FFPAGNNKPE SYYGAFSYEV LETVFNTORE
301 KLEEILEEQR GQKROQGGQ MFRKAKPEQI RAISQQTSP RHGGGERLAI
351 NLLSQSPVTS NONGRFFEAC PEDFSQFQM DVAVSFKLN QGAIFVPHYN
401 SKATFVVFVT DGYGYAQMAG PHLRSQSGS QSGRQDRREQ EEESEETFG
451 EFQQVKAPLS PGDVFVAPAG HAVTFFASKD QPLNAVAFGL NAQNNQRIFL

```

501 AGRPFPLNHK QNTNVIKFTV KASAY

```

!!AA SEQUENCE 1.0
ID YWS6_CABEL STANDARD; PRT; 95 AA.
AC Q10942;
DT 01-NOV-1997 (rel. 35, Created)
DT 01-NOV-1997 (rel. 35, Last sequence update)
DT 25-OCT-2004 (rel. 45, Last annotation update)
DE Hypothetical protein B0310.6 in chromosome X.
GN ORFNames=B0310.6;
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;
OC Rhabditidae; Telodermata; Caenorhabditis.
OX NCBI_TaxID=62239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RX MEDLINE=99069613; PubMed=9851916;
RG The C. elegans sequencing consortium;
RT "Genome sequence of the nematode C. elegans: a platform for
investigating biology.";
RL Science 282:2012-2018(1998).
-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
between the Swiss Institute of Bioinformatics and the EMBL outstation -
the European Bioinformatics Institute. There are no restrictions on its
use by non-profit institutions as long as its content is in no way
modified and this statement is not removed. Usage by and for commercial
entities requires a license agreement (See http://www.isb-sib.ch/announce/
or send an email to license@isb-sib.ch).
-----
DR EMBL; U40959; AAB1770.1; -.
DR PIR; T15330; T15330.
DR WormBase; WBGene00015142; B0310.6.
DR WormPeP; B0310.6; CE03879.
KW Hypothetical protein; Repeat.
FT DOMAIN 67 92 2 X 8 AA approximate repeats.
FT REPEAT 67 74 1.
FT REPEAT 85 92 2.
FT REPEAT 95 92 2.
SQ SEQUENCE 95 AA; 9796 MW; 4C51F824EC5B77CF CRC64;

```

YWS6\_CABEL Length: 95 February 22, 2005 10:46 Type: P Check: 8237 ..

1 MLRVVLFAAI LVFSTANSEI IDKSLEQSGP IQDSSNFALA VNGEELPTDI

51 ALEGQSEVMI RAKRYGCGC GCGATVAAV SPVPCGGCGC CGYKG

```

!!AA SEQUENCE 1.0
ID Q8N962 PRELIMINARY; PRT; 134 AA.
AC Q8N962;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Hypothetical protein FLJ38312.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Brain;
RX PubMed=14702039; DOI=10.1038/ng1285;
RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA Wakatsuki A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA Yamamoto J., Saiko K., Kawai Y., Isono Y., Nakamura Y., Nagahara K.,
RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA Sudo H., Hosoiri T., Kaku T., Kodaira H., Kondo H., Sugawara M.,
RA Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA Abe K., Kimihara K., Katsura N., Sato K., Tanikawa M., Yamazaki M.,
RA Ninomiya K., Ishibashi T., Yamashita H., Murakami K., Fujimori K.,
RA Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,

```

```

RA Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA Kanehori K., Takahashi-Fujii A., Hara H., Tanase T., Nomura Y.,
RA Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata Y., Sano S.,
RA Moriya S., Momiya H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT "Complete sequencing and characterization of 21,243 full-length human
cDNAs.";
RL Nat. Genet. 36:40-45(2004).
DR EMBL; AK095631; BAC04594.1; -.
SQ SEQUENCE 134 AA; 15101 MW; 13348E36AFCD16 CRC64;

```

Q8N962 Length: 134 February 22, 2005 10:46 Type: P Check: 556 ..

1 MWVYVCCVCM CRWCLVCVCIY MCVCVPVCMC VYVYVYVVIC VICVCVCVVFV

51 CAHMCSCVVFV YVCICVCLYV CVFVCVCMYV YLCVFVCMCL CVCICVCVCFV

101 CVCVSSHVLV TMTCRGSSVI NPTLLSTRPR PCQR

```

!!AA SEQUENCE 1.0
ID Q33563 PRELIMINARY; PRT; 141 AA.
AC Q33563;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE EATRO 164 kinetoplast (CR4).
OS Trypanosoma brucei.
OG Mitochondrion.
OC Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae; Trypanosoma.
OX NCBI_TaxID=5691;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=EATRO 164; TISSUE=Blood;
RX MEDLINE=94359538; PubMed=8078524; DOI=10.1016/0166-6851(94)90135-X;
RA Corell R.A., Myler P., Stuart K.;
RT "Trypanosoma brucei mitochondrial CR4 gene encodes an extensively
edited mRNA with completely edited sequence only in bloodstream
forms.";
RL Mol. Biochem. Parasitol. 64:65-74(1994).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=EATRO 164; TISSUE=Blood;
RA Stuart K.D.;
RL Submitted (SSP-1993) to the EMBL/GenBank/DBJ databases.
DR EMBL; U01849; AAA62273.1; -.
SQ SEQUENCE 141 AA; 17711 MW; 977EE1418367662D CRC64;

```

Q33563 Length: 141 February 22, 2005 10:46 Type: P Check: 7624 ..

1 MCIPFFFIWC VCULCTVYGI FYCCFVFCFC CLFVWVVCFCF FVIVVCFPLL

51 FWVIFPYNCF DCIVYFCDV ILFIFFFFVF VLCFLYCCFY LVCLVFFCFIF

101 CCVLCYFLIY FLCFLFWV FLFLFFFFVY VCFYLWLLLF C

!!AA SEQUENCE 1.0

ID Q7YIC1 PRELIMINARY; PRT; 481 AA.

AC Q7YIC1;

DT 01-OCT-2003 (TrEMBLrel. 25, Created)

DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)

DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
DE Vicilin seed storage protein (Fragment).  
OS Juglans nigra (black walnut).  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;  
OC eurosids I; Fagales; Juglandaceae; Juglans.  
OX NCBI\_TaxID=16719;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Ling M., Ye J., Cockrell G., Sampson H., Bannan G.A., Stanley J.S.,  
RL Burks A.W.,  
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.  
DR ENBL; AY102931; AAM54366.1; --  
DR HSSP; P25974; IIPJ.  
DR GO; GO:0045735; F:nutrient reservoir activity; IEA.  
DR InterPro; IPR006045; Cupin.  
DR InterPro; IPR007113; Cupin region.  
DR InterPro; IPR011051; RmlC like cupin.  
DR InterPro; IPR006792; Vicilin\_N.  
DR Pfam; PF00190; Cupin; 2.  
DR Pfam; PF04702; Vicilin\_N; 1.  
FT NON TER 1  
SQ SEQUENCE 481 AA; 55675 MW; BD37001456B450D7 CRC64;  
Q7V1C1 Length: 481 February 22, 2005 10:46 Type: P Check: 9405 ..  
1 GRDRQDFOQQ YHCQRRCQI QFSQPERORQ COQRERQYK EQGRERGPE  
51 ASPRESKGR EERQQRHNP YFHSQISRSR HESBEQEVKY LERFAETEL  
101 LRGIENRVV ILDANPNTFM LPHKDAESV IIVTRGRTL TLVSQETRES  
151 FNLECGDVR VPAGATEYVI NQDSNERLEM VKLIQVNNP GQVREYYAAG  
201 AKSPDQSYLR VFSNDILVAA LNTPRDLRL FFDQEQREG VIIRASQEKL  
251 RALSQHAMA GQRPWGRSS GGPISLKSR PSYSNQGFQF FEACPEHRQ  
301 LOEMDLVNY AETKRGAMV PHNSKATVV VYVEGTGRY EMACPHVSSQ  
351 SFEDQGRREQ EEBESTGRFQ KVTARLARGD IFVIPAGHPI AITASQENEL  
401 RLLGFGINGE NNQRNFLAGQ NSIIQLERE AKELSPNMPR EEIEEIFESQ  
451 MESYFVPTER QSRRGQGRDH PLASILGFAP F  
!!AA SEQUENCE 1.0  
ID Q9SEW4 PRELIMINARY; PRT; 593 AA.  
AC Q9SEW4  
DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
DE Vicilin-like protein (Fragment).  
OS Juglans regia (English walnut).  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;  
OC eurosids I; Fagales; Juglandaceae; Juglans.  
OX NCBI\_TaxID=51240;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Sonatic embryo line;  
RX MEDLINE=20057824; PubMed=10589017;  
RA Teuber S.S., Jarvis K.C., Dandekar A.M., Peterson W.R., Ansari A.A.;  
RT "Identification and cloning of a complementary DNA encoding a vicilin-  
like proprotein, jug r 2, from english walnut kernel (Juglans regia),  
a major food allergen.";  
RL J. Allergy Clin. Immunol. 104:1311-1320(1999).  
DR ENBL; AF066055; AAF18269.1; --  
DR HSSP; P25974; IIPJ.  
DR GO; GO:0045735; F:nutrient reservoir activity; IEA.  
DR InterPro; IPR006045; Cupin.  
DR InterPro; IPR007113; Cupin region.  
DR InterPro; IPR011051; RmlC like cupin.

DR InterPro; IPR006792; Vicilin\_N.  
DR Pfam; PF00190; Cupin; 2.  
DR Pfam; PF04702; Vicilin\_N; 1.  
FT NON TER 1  
SQ SEQUENCE 593 AA; 69990 MW; 9BA127E19B18COD8 CRC64;  
Q9SEW4 Length: 593 February 22, 2005 10:46 Type: P Check: 9797 ..  
1 RGDRDDDEEN PRDPREYRQ COEYCRGQG GQRQOQQCQI RCEERLEEDQ  
51 RSQERERRR GRDVEDDQNP RDEQRYEQC QQCERQRRGQ EQTLCHRRCE  
101 QRQEQERER QRGRDRQDPQ QQYHRCQRRC QIQEQSPERQ RQOQQRCEQ  
151 YKQOQGRERG PEASPRRESR GREEQQRHN PYFHSQSIR SRHSEGEV  
201 KYLERFERT ELLRGIENYR VVILDANPNT SMLPHHKDAE SVAVVTRGRA  
251 TLLVVSQETR ESNLECGDV IRVPAGATVY VINQDSNERL EMVKLLQPVN  
301 NPGQPREYVA AGAKSPDOSY LRVSNDILV AALNTPDRRL ERFFDQEQOR  
351 EGVIIIRASQE KLRALSQHAM SAGQRPWGRR SSGGPISLKS ESPSYSNQFG  
401 OFFEACPEEH RQLQEMDVLV NYAEIKRGAM MVPHYNSKAT VVVVVVEGTG  
451 RYEMACPHVS SOSYEGQGRR EQBEESTGR FQKVTARLAR GDIFVIPAGH  
501 PIATASQNE NLRLGFDIN GENNQDFLA GONNIINQLE REAKELSFNM  
551 PREIEBEIPE SQMESYFVPT ERQSRGQGR DHPLASILDFF AFF  
!!AA SEQUENCE 1.0  
ID Q9SPL3 PRELIMINARY; PRT; 625 AA.  
AC Q9SPL3  
DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE Vicilin (Fragment).  
GN Name=AMP2;  
OS Macadamia integrifolia (Macadamia nut).  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; Proteales; Proteaceae;  
OC Macadamia.  
OX NCBI\_TaxID=60698;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Nut kernel;  
RX MEDLINE=20040040; PubMed=10571855;  
RA Marcus J.P., Green J.L., Goulter K.C., Manners J.M.;  
RT "A family of antimicrobial peptides is produced by processing of a 7S  
globulin protein in Macadamia integrifolia kernels.";  
RL Plant J. 19:699-710(1999).  
DR ENBL; AF161885; AAD54246.1; --  
DR HSSP; P25974; IIPJ.  
DR GO; GO:0045735; F:nutrient reservoir activity; IEA.  
DR InterPro; IPR006045; Cupin.  
DR InterPro; IPR007113; Cupin region.  
DR InterPro; IPR011051; RmlC like cupin.  
DR InterPro; IPR006792; Vicilin\_N.  
DR Pfam; PF00190; Cupin; 2.  
DR Pfam; PF04702; Vicilin\_N; 1.  
FT NON TER 1  
SQ SEQUENCE 625 AA; 73586 MW; 415808A89D370296 CRC64;  
Q9SPL3 Length: 625 February 22, 2005 10:46 Type: P Check: 7549 ..  
1 QCMQLETSGQ MRRCVSQCDK RFEEDIDWSK YDQEDPQTE CQCQQRRCQ  
51 QESDPRQQY CORRCCKICE EEBEYNQRD PQOQYEQCQK RQRRTERPR  
101 HMQICQORCE RRYEKEKRKQ QKRYEEQORE DEEYERMK EGDNRKDPQO

```

151 REYEDCRRHC EQQERLQVQ QORRCQEQOR QHGRGGDLMN PORGGSGRYE
201 EGEEKOSDNP YYFDRSLST RFRTEEGHIS VLENFYGRSK LLRALKNYRL
251 VLLEANPNF VLPETHLADADA ILLVIGRGA LKMIHRDRE SYNLECGDVI
301 RIPAGTTFYL INRDNNERLH IAKFLQITIST PGQYKEFFPA GQONPEPYLS
351 TFSKEILEAA LNTQTERLUG VLGOOREGVI IRASQEQIRE LTRDDSESRR
401 WHIRRGESS RGPYNLFNKR PLYSNKYGQA YEVPEDYRQ LQDMVDVSFVI
451 ANITQSMWG PFFNTRSTKV VVASGEADV EMACPHLSGR HGRGGGKRH
501 EEEEEVHYEQ VRARLSKREA IVVLAGHPV FVSSGNENLL LFAFGINAQN
551 NHENFLAGRE RNVLOQIEPQ AMELAFAPASR KEVEELFNSQ DESIFFPGPR
601 QHQQQSPRST KQQQPLVSIL DFVGF

!!IAA_SEQUENCE 1.0
ID Q9SPL4 PRELIMINARY; PRT; 666 AA.
AC Q9SPL4;
DT 01-MAY-2000 (TRENBLrel. 13, Created)
DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)
DT 01-JUN-2003 (TRENBLrel. 24, Last annotation update)
DE Vicilin.
GN Name=AMP2;
OS Macadamia integrifolia (Macadamia nut).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; Proteales; Proteaceae;
OC Macadamia.
OX NCBI_TaxID=60698;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Nut kernel;
RX MEDLINE=20040040; PubMed=10571855;
RA Marcus J.P., Green J.L., Goulter K.C., Manners J.M.;
RT "A family of antimicrobial peptides is produced by processing of a 7S
  globulin protein in Macadamia integrifolia kernels.";
RL Plant J. 19:699-710(1999).
DR EMBL; AF161884; AADS4245.1; -.
DR HSSP; P25974; IIFU.
DR GO; GO:0045735; F:nutrient reservoir activity; IEA.
DR InterPro; IPR006045; Cupin.
DR TISSUE=Nut kernel;
RC TISSUE=Nut kernel;
RX MEDLINE=20040040; PubMed=10571855;
RA Marcus J.P., Green J.L., Goulter K.C., Manners J.M.;
RT "A family of antimicrobial peptides is produced by processing of a 7S
  globulin protein in Macadamia integrifolia kernels.";
RL Plant J. 19:699-710(1999).
DR EMBL; AF161884; AADS4245.1; -.
DR HSSP; P25974; IIFU.
DR GO; GO:0045735; F:nutrient reservoir activity; IEA.
DR InterPro; IPR006045; Cupin.
DR InterPro; IPR011051; RmlC like cupin.
DR InterPro; IPR006792; Vicilin_N.
DR Pfam; PF00190; Cupin; 2.
DR Pfam; PF04702; Vicilin_N; 1.
SQ SEQUENCE 666 AA; 78243 MW; 0BCA22F8710F8A7B CRC64;

```

Q9SPL4 Length: 666 February 22, 2005 10:46 Type: P Check: 911 ..

```

1 MAINTSNLCS LLFLLSLFLL STTVSLAESE FDRQYEECK RQCMQLETSG
51 QMRRCVSQCD KRFEEDIDWS KYDNQDDPQT DCOQCQRRCR QOESGPRQOQ
101 YCQRCCKEIC EEEEEYNRQR DPQQYEQCQ ERCORHETEP RHMOTCCQRC
151 ERYEKEKRX QKRYEEQOR EDEEKEERM KEEDNKRDPQ QREYEDCRRR
201 CQOQEPQOY QCORRCREQQ RQHGRGGDLI NFQRGSGRY EEEGKQSDN
251 PYPFDRSLS TRFRTEEGHI SVLENFYGRS KLLRALKNYR LVLLLEANPNA
301 FVLPTHLDAD ALLVVTGGRG ALKMIHRDNR ESYNLECGDV IRIPAGTTFY
351 LINRONNERL HIAKFLQITIS TPGQYKEFFP AGGQNPPEYL STFSKEILEA
401 ALNTQAEHLR GVLGOOREGV IISASQEQIR ELTRDDSESER RWHIRRGES
451 SRGPYNLFNK RPLYSNKYGQ AYEVPEDYR QLODMVDVSF IANTQSGMM

```

```

501 GPFNTRSTK VVVASGEAD VEMACPHLSG RHGRRGGKR HEEEDVHYE
551 QVKARLSKRE AIVVPVGHVP VFVSSGNENL LLFAFGINAQ NNHENFLAGR
601 ERNVLQOIEP QAMELAFAP RKEVEELFNS QDESIFFPGP RQHQQSSRS
651 TKQQQPLVSI LDFVGF

!!IAA_SEQUENCE 1.0
ID Q9SPL5 PRELIMINARY; PRT; 666 AA.
AC Q9SPL5;
DT 01-MAY-2000 (TRENBLrel. 13, Created)
DT 01-MAY-2000 (TRENBLrel. 13, Last sequence update)
DT 01-JUN-2003 (TRENBLrel. 24, Last annotation update)
DE Vicilin.
GN Name=AMP2;
OS Macadamia integrifolia (Macadamia nut).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; Proteales; Proteaceae;
OC Macadamia.
OX NCBI_TaxID=60698;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Nut kernel;
RX MEDLINE=20040040; PubMed=10571855;
RA Marcus J.P., Green J.L., Goulter K.C., Manners J.M.;
RT "A family of antimicrobial peptides is produced by processing of a 7S
  globulin protein in Macadamia integrifolia kernels.";
RL Plant J. 19:699-710(1999).
DR EMBL; AF161883; AADS4244.1; -.
DR HSSP; P25974; IIFU.
DR GO; GO:0045735; F:nutrient reservoir activity; IEA.
DR InterPro; IPR006045; Cupin.
DR InterPro; IPR007113; Cupin region.
DR InterPro; IPR011051; RmlC like cupin.
DR InterPro; IPR006792; Vicilin_N.
DR Pfam; PF00190; Cupin; 2.
DR Pfam; PF04702; Vicilin_N; 1.
SQ SEQUENCE 666 AA; 78217 MW; C752B884B2DF0224 CRC64;

Q9SPL5 Length: 666 February 22, 2005 10:46 Type: P Check: 8155 ..

1 MAINTSNLCS LLFLLSLFLL STTVSLAESE FDRQYEECK RQCMQLETSG
51 QMRRCVSQCD KRFEEDIDWS KYDNQDDPQT EQQCQRRCR QOESGPRQOQ
101 YCQRCCKEIC EEEEEYNRQR DPQQYEQCQ KHCQRRETEP RHMOTCCQRC
151 ERYEKEKRX QKRYEEQOR EDEEKEERM KEEDNKRDPQ QREYEDCRRR
201 CQOQEPQOY QCORRCREQQ RQHGRGGDMM NPQRGSGRY EEEGKQSDN
251 PYPFDRSLS TRFRTEEGHI SVLENFYGRS KLLRALKNYR LVLLLEANPNA
301 FVLPTHLDAD ALLVVTGGRG ALKMIHRDNR ESYNLECGDV IRIPAGTTFY
351 LINRONNERL HIAKFLQITIS TPGQYKEFFP AGGQNPPEYL STFSKEILEA
401 ALNTQTEKLR GVFGQOREGV IIRASQEQIR ELTRDDSESER RWHIRRGES
451 SRGPYNLFNK RPLYSNKYGQ AYEVPEDYR QLODMDLVSF IANTQSGMM
501 GPFNTRSTK VVVASGEAD VEMACPHLSG RHGRRGGKR HEEEDVHYE
551 QVKARLSKRE AIVVLGHPV VFVSSGNENL LLFAFGINAQ NNHENFLAGR
601 ERNVLQOIEP QAMELAFAP RKEVEESFNS QDQSIFFPGP RQHQQSSRS
651 TKQQQPLVSI LDFVGF

```

This Page Blank (uspto)



XX WO200253016-A2.  
PN  
XX  
PD 11-JUL-2002.  
XX  
PF 04-JAN-2002; 2002WO-US0000026.  
XX  
PR 05-JAN-2001; 2001US-0260246P.  
PR 15-FEB-2001; 2001US-0269240P.  
PR 25-SEP-2001; 2001US-0325097P.  
XX  
PA (CORI-) CORIXA CORP.  
XX  
PI Homer MJ, Lodes MJ, Houghton RL, Persing DH, Mcneill PD;  
XX  
DR WPI: 2002-583582/62.  
DR N-PSDB; ABK99849.  
XX  
XX Novel polynucleotides encoding polypeptides comprising Babesia wai  
PT antigen, useful for stimulating an immune response in a patient.  
XX  
PS Claim 2; Page 93-94; Opp; English.  
XX  
XX The invention relates to an isolated polynucleotide comprising a Babesia  
CC sp. wai antigen having one of 43 nucleotide sequences appearing as  
CC ABK99825-ABK99867, their complements or degenerate variants, sequences  
CC that hybridize to them under moderately stringent conditions, or  
CC sequences having at least 75, preferably 90 % identity to them. Also  
CC include are the polypeptides encoded by the polynucleotides, an  
CC expression vector comprising the polynucleotide operably linked to an  
CC expression control sequence, a host cell transformed or transfected with  
CC the vector, an isolated anti-wai antigen antibody (Ab), a fusion protein  
CC comprising at least an immunogenic portion of the polypeptides, detecting  
CC Babesia infection in a patient, comprising: (a) contacting a biological  
CC sample of the patient with a binding agent that binds to a the  
CC polypeptides; (b) detecting the amount of polypeptide that binds to the  
CC binding agent; and (c) comparing the amount of polypeptide to a  
CC predetermined cut-off value and determining Babesia infection in a  
CC patient. A composition comprising the protein or antibody is useful for  
CC stimulating an immune response in a patient and for treating Babesia sp.  
CC infection in a patient and for determining the presence of Babesia  
CC infection in a patient. The polypeptide is useful for detecting Babesia  
CC infection in a patient. The fusion protein is useful for detecting  
CC Babesia infection in a patient (causing e.g. Lyme's disease, ehrlichiosis  
CC or babesiosis). The polypeptides are useful for serodiagnosis. The  
CC present sequence represents a Babesia sp. wai antigen protein. (Updated  
CC on 29-AUG-2003 to standardise OS field)  
XX  
XX Sequence 538 AA;  
SQ  
ABG94982 Length: 538 February 22, 2005 10:29 Type: P Check: 8941 ..  
1 EVQMPQAAAE SPAPILETPQ VMTQTAPVEE TQAPVTESP APOQPAQVAA  
51 PEQPAEVAPQ ATAGIQQAQ QPVATETATA EQPVAATTTE VOMPQAAAE  
101 PAPISETPQV MTQTAPVEET QAPVVTESPA PQQPAQVAAP EQPAEVAPOA  
151 TAGIQQAQPO PVAAEAQVQ PPVQTATQTRP VAQFQVVVAE AQVQPPVKA  
201 AAQAPVVVKDQ AAQPVASVAP QATAGIQQAQ PQPVAAEAQV VQPPVKAAPK  
251 KPIVKDQAAQ PVAPVAPQAT AGVAEDQSEA SAGSEAEKK MRKVSTSDVV  
301 EVNDDDDSEE DSEEEEAPEI VORLSRPHS SDKYGYKEPK QVAGRKRERY  
351 GDKGYHADRR YEYDSDDELV APPRHKSVA SGQTHMSCC DNEECSAKSG  
401 DCCTCNMPY FTQNVKTIIL FKWETKTE EYWLSVVVIF FASIFAVCFK  
451 TCRELVRDYL LSCNGCCIFI FGHFVLLMA FISTADFML MLVMTYNYG  
501 IVAAVCAGYT IGYTICTYSM AFLIQKSHL NKVHMDCC

CC on 29-AUG-2003 to standardise OS field)

XX Sequence 727 AA;

ABG69362 Length: 727 February 22, 2005 10:29 Type: P Check: 608 ..

1 YIARSLILEY ILTYGKYIPD AMRKFSKLWL LFAIFGHLIV IQATDVAPSS

51 DQPTQDAQA PSPNTPAST VATPEASQGS ANQQQSQTGA GESQPVLTSE

101 MATVKEETVP ETKVENNVV QEATVTPAQV PAVENVSQPP TQTVAPAAPA

151 PQPAQVAPQ ATAGIQQAQP QPVATETATA EQPVAATTE VQMPQAAAS

201 PAPILETPQV MTQTAPVEET QAPVTTESPA PQPAQVAPQ EQPAEVAPOA

251 TAGIQQAQPQ PVAXETATAE QPVAATTTEV QMPQAAESP APISETPQVM

301 TQTAPVEETQ APVTTESPA QPQAQVAAPE QPAEVAPOAT AGIQQAQPQ

351 VAAEAQVQPV PVQTAQTRPV AQPQVVVAAE QVQPPVKAA QAPVVKDQA

401 AQPVASVAPQ ATAGIQQAQP QPVAAEAQV QPPVKAAPK PIVKDQAAQP

451 VAPVAPQATA GVAEDQSEAS AGSEAEQKMK RKVSFSDVVE VNDDDDSEED

501 SEEEBEAPIV QRLSRMHSS DKYGYKEPKQ VAGRKRGRYG DKGTHADRRY

551 EYDSDEDVLA PPRHKSVMSS GQTGHMSCCD NEECSAKSGD CCTCNMPMYF

601 TQNVKTIILF KMWETKTEE YMLSVVVIFV ASIFAVCFKT CRELVDRYLL

651 SCNGCCIFIF GHFAVLLMAP ISYTADFMLM LVVMTYNYGI VAAVCAGYTI

701 GYTICTYSMA PLIQKSHLN KVHMDCC

!!AA SEQUENCE 1.0

ID \_ABG94981 standard; protein; 727 AA.

XX

AC ABG94981;

XX

29-AUG-2003 (revised)

DT 03-DEC-2002 (first entry)

XX

XX Babesia amino acid sequence for clone WA01.

DE

XX WA1 antigen; Lyme's disease; ehrlichiosis; babesiosis; vaccine;

KW protozoacide; serodiagnosis.

XX

OS Babesia sp. WA1; strain.

XX

PN WO200253016-A2.

XX

PD 11-JUL-2002.

XX

PF 04-JAN-2002; 2002WO-US0000026.

XX

PR 05-JAN-2001; 2001US-0260246P.

PR 15-FEB-2001; 2001US-0269240P.

PR 25-SEP-2001; 2001US-0325097P.

XX

PA (CORI-) CORIXA CORP.

XX

PI Homer MJ, Lodes MJ, Houghton RL, Persing DH, McNeill PD;

XX

XX WPI; 2002-583582/62.

DR N-PSDB; ABK99848.

XX

XX Novel polynucleotides encoding polypeptides comprising Babesia WA1

PT antigen, useful for stimulating an immune response in a patient.

XX

PS Claim 2; Page 91-93; Opp; English.

XX

CC The invention relates to an isolated polynucleotide comprising a Babesia

CC sp. WA1 antigen having one of 43 nucleotide sequences appearing as

CC ABK99825-ABK99867, their complements or degenerate variants, sequences

CC that hybridise to them under moderately stringent conditions, or

CC sequences having at least 75, preferably 90 % identity to them. Also

CC include are the polypeptides encoded by the polynucleotides, an

CC expression vector comprising the polynucleotide operably linked to an

CC expression control sequence, a host cell transformed or transfected with

CC the vector, an isolated anti-WA1 antigen antibody (Ab), a fusion protein

CC comprising at least an immunogenic portion of the polypeptides, detecting

CC Babesia infection in a patient, comprising: (a) contacting a biological

CC sample of the patient with a binding agent that binds to a the

CC polypeptides; (b) detecting the amount of polypeptide that binds to the

CC binding agent; and (c) comparing the amount of polypeptide to a

CC predetermined cut-off value and determining Babesia infection in a

CC patient. A composition comprising the protein or antibody is useful for

CC stimulating an immune response in a patient and for treating Babesia sp.

CC infection in a patient and for determining the presence of Babesia

CC infection in a patient. The polypeptide is useful for detecting Babesia

CC infection in a patient. The fusion protein is useful for detecting

CC Babesia infection in a patient (causing e.g. Lyme's disease, ehrlichiosis

CC or babesiosis). The polypeptides are useful for serodiagnosis. The

CC present sequence represents a Babesia sp. WA1 antigen protein. (Updated

XX on 29-AUG-2003 to standardise OS field)

XX

SQ Sequence 727 AA;

ABG94981 Length: 727 February 22, 2005 10:29 Type: P Check: 464 ..

1 YIARSLILEY ILTYGKYIPD AMRKFSKLWL LFAIFGHLIV IQATDVAPSS

51 DQPTQDAQA PSPNTPAST VATPEASQGS ANQQQSQTGA GESQPVLTSE

101 MATVKEETVP ETKVENNVV QEATVTPAQV PAVENVSQPP TQTVAPAAPA

151 PQPAQVAPQ ATAGIQQAQP QPVATETATA EQPVAATTE VQMPQAAAS

201 PAPILETPQV MTQTAPVEET QAPVTTESPA PQPAQVAPQ EQPAEVAPOA

251 TAGIQQAQPQ PVATETATAE QPVAATTTEV QMPQAAESP APISETPQVM

301 TQTAPVEETQ APVTTESPA QPQAQVAAPE QPAEVAPOAT AGIQQAQPQ

351 VAAEAQVQPV PVQTAQTRPV AQPQVVVAAE QVQPPVKAA QAPVVKDQA

401 AQPVASVAPQ ATAGIQQAQP QPVAAEAQV QPPVKAAPK PIVKDQAAQP

451 VAPVAPQATA GVAEDQSEAS AGSEAEQKMK RKVSFSDVVE VNDDDDSEED

501 SEEEBEAPIV QRLSRMHSS DKYGYKEPKQ VAGRKRGRYG DKGTHADRRY

551 EYDSDEDVLA PPRHKSVMSS GQTGHMSCCD NEECSAKSGD CCTCNMPMYF

601 TQNVKTIILF KMWETKTEE YMLSVVVIFV ASIFAVCFKT CRELVDRYLL

651 SCNGCCIFIF GHFAVLLMAP ISYTADFMLM LVVMTYNYGI VAAVCAGYTI

701 GYTICTYSMA PLIQKSHLN KVHMDCC

!!AA SEQUENCE 1.0

ID \_ABG94982 standard; protein; 538 AA.

XX

AC ABG94982;

XX

29-AUG-2003 (revised)

DT 03-DEC-2002 (first entry)

XX

DE Babesia amino acid sequence for clone WA14.

XX

XX WA1 antigen; Lyme's disease; ehrlichiosis; babesiosis; vaccine;

KW protozoacide; serodiagnosis.

XX

OS Babesia sp. WA1; strain.

DT 03-DEC-2002 (first entry)  
 XX Babesia amino acid sequence for clone WA88.  
 XX  
 XX  
 XX WA1 antigen; Lyme's disease; ehrlichiosis; babesiosis; vaccine;  
 KW protozoacide; serodiagnosis.  
 XX  
 XX Babesia sp. WA1; strain.  
 XX  
 XX WO200253016-A2.  
 XX  
 XX 11-JUL-2002.  
 XX  
 XX 04-JAN-2002; 2002WO-US000026.  
 XX  
 XX 05-JAN-2001; 2001US-0260246P.  
 PR 15-FEB-2001; 2001US-0269240P.  
 PR 25-SEP-2001; 2001US-0325097P.  
 XX  
 XX (CORI-) CORIXA CORP.  
 PA  
 XX Homer MJ, Lodes MJ, Houghton RL, Persing DH, McNeill PD;  
 PI WPI; 2002-583582/62.  
 XX N-PSDB; ABK99851.  
 DR  
 XX Novel polynucleotides encoding polypeptides comprising Babesia WA1  
 PT antigen, useful for stimulating an immune response in a patient.  
 PT  
 XX  
 XX Claim 2; Page 95-96; Opp; English.  
 PS  
 XX  
 XX The invention relates to an isolated polynucleotide comprising a Babesia  
 CC sp. WA1 antigen having one of 43 nucleotide sequences appearing as  
 CC ABK9825-ABK99867, their complements or degenerate variants, sequences  
 CC that hybridise to them under moderately stringent conditions, or  
 CC sequences having at least 75, preferably 90 % identity to them. Also  
 CC include are the polypeptides encoded by the polynucleotides, an  
 CC expression vector comprising the polynucleotide operably linked to an  
 CC expression control sequence, a host cell transformed or transfected with  
 CC the vector, an isolated anti-Wal antigen antibody (Ab), a fusion protein  
 CC comprising at least an immunogenic portion of the polypeptides, detecting  
 CC Babesia infection in a patient, comprising: (a) contacting a biological  
 CC sample of the patient with a binding agent that binds to a the  
 CC polypeptides; (b) detecting the amount of polypeptide that binds to the  
 CC binding agent; and (c) comparing the amount of polypeptide to a  
 CC predetermined cut-off value and determining Babesia infection in a  
 CC patient. A composition comprising the protein or antibody is useful for  
 CC stimulating an immune response in a patient and for treating Babesia sp.  
 CC infection in a patient and for determining the presence of Babesia  
 CC infection in a patient. The polypeptide is useful for detecting Babesia  
 CC infection in a patient. The fusion protein is useful for detecting  
 CC Babesia infection in a patient (causing e.g. Lyme's disease, ehrlichiosis  
 CC or babesiosis). The polypeptides are useful for serodiagnosis. The  
 CC present sequence represents a Babesia sp. WA1 antigen protein. (Updated  
 CC on 29-AUG-2003 to standardise OS field)  
 XX  
 XX Sequence 638 AA;  
 SQ  
 ABG94983 Length: 638 February 22, 2005 10:29 Type: P Check: 6398 ..  
 1 YIARSLILEY ILTYGKYIPD AMRKFSLWL LFAIFGLHIV IQATDVAPSS  
 51 DQPTDRAQA PSNPFPAST VATPESQGS ANQQOSQTGA GESQPLVLS  
 101 MATVKEETVP ETKVENNVV QEATVTPAQV PAVENVSQPP TOTVAPAAPA  
 151 PQQPAQVAPQ ATAGIQQAQ OPVATETATA EQPVAATTE VOMPQAAES  
 201 PAPLETPOV MTQTAPVEET QAPVVTESPA PQQPAQVAP EQPAEVAPOA  
 251 TAGIQQAQPP PVAAEAQVQV PPVQTATQTRP VAQPPQVVAE AQVQPPVKA  
 301 AQAQPVVKDQ AAQPAVASAP QATAGIQQAQ PQPVAEAQV VQPPVKAAP

351 KPIVKDQAAQ PVAPVAPQAT AGVAEDQSEA SAGSEAEKK MRKVSFSDV  
 401 EVNDDDDSEE DSEEEEAPEI VQLRSRMHS SDKYGYKEPK QVAGRKRRCY  
 451 GDKGYHADRR YEYDDEVL APPHKSVGA SGQTHMSCC DNEECSAKSG  
 501 DCCTCNMPY FTQNVKTIIL FKWETKTE EYWLWVVVIF FASIFAVCFK  
 551 TCRELVRDYL LSCNGCCIFI FGHEAVLLMA FISYTADEML MLVWMTYNYG  
 601 IVAAVCAGYT IGYTICTYSM APLIQKSHL NKVHMDCC  
 !!AA SEQUENCE 1.0  
 ID ABG69362 standard; protein; 727 AA.  
 XX  
 AC ABG69362;  
 XX  
 DT 29-AUG-2003 (revised)  
 DT 03-DEC-2002 (first entry)  
 XX  
 XX Babesia amino acid sequence for clone WA1.  
 DE  
 XX WA1 antigen; Lyme's disease; ehrlichiosis; babesiosis; vaccine;  
 KW protozoacide; serodiagnosis.  
 KW  
 OS Babesia sp. WA1; strain.  
 OS  
 PN WO200253016-A2.  
 PN  
 XX 11-JUL-2002.  
 PD  
 XX  
 XX 04-JAN-2002; 2002WO-US000026.  
 PF  
 XX  
 XX 05-JAN-2001; 2001US-0260246P.  
 PR 15-FEB-2001; 2001US-0269240P.  
 PR 25-SEP-2001; 2001US-0325097P.  
 PR  
 XX (CORI-) CORIXA CORP.  
 PA  
 XX Homer MJ, Lodes MJ, Houghton RL, Persing DH, McNeill PD;  
 PI WPI; 2002-583582/62.  
 XX N-PSDB; ABK99838.  
 DR  
 DR Novel polynucleotides encoding polypeptides comprising Babesia WA1  
 PT antigen, useful for stimulating an immune response in a patient.  
 PT  
 XX  
 XX Claim 2; Page 63-64; Opp; English.  
 PS  
 XX  
 XX The invention relates to an isolated polynucleotide comprising a Babesia  
 CC sp. WA1 antigen having one of 43 nucleotide sequences appearing as  
 CC ABK9825-ABK99867, their complements or degenerate variants, sequences  
 CC that hybridise to them under moderately stringent conditions, or  
 CC sequences having at least 75, preferably 90 % identity to them. Also  
 CC include are the polypeptides encoded by the polynucleotides, an  
 CC expression vector comprising the polynucleotide operably linked to an  
 CC expression control sequence, a host cell transformed or transfected with  
 CC the vector, an isolated anti-Wal antigen antibody (Ab), a fusion protein  
 CC comprising at least an immunogenic portion of the polypeptides, detecting  
 CC Babesia infection in a patient, comprising: (a) contacting a biological  
 CC sample of the patient with a binding agent that binds to a the  
 CC polypeptides; (b) detecting the amount of polypeptide that binds to the  
 CC binding agent; and (c) comparing the amount of polypeptide to a  
 CC predetermined cut-off value and determining Babesia infection in a  
 CC patient. A composition comprising the protein or antibody is useful for  
 CC stimulating an immune response in a patient and for treating Babesia sp.  
 CC infection in a patient and for determining the presence of Babesia  
 CC infection in a patient. The polypeptide is useful for detecting Babesia  
 CC infection in a patient. The fusion protein is useful for detecting Babesia  
 CC infection in a patient (causing e.g. Lyme's disease, ehrlichiosis  
 CC or babesiosis). The polypeptides are useful for serodiagnosis. The  
 CC present sequence represents a Babesia sp. WA1 antigen protein. (Updated  
 CC on 29-AUG-2003 to standardise OS field)  
 XX  
 XX Sequence 638 AA;  
 SQ

CC The present sequence is a novel Caenorhabditis elegans insulin  
CC superfamily member found by searching a C. elegans genomic database using  
CC conserved insulin motifs. A number of C. elegans genes have been  
CC identified as homologues of genes in the mammalian insulin signalling  
CC pathway. The C. elegans age-1 gene encodes a homologue of the mammalian  
CC PI 3-kinase whilst the C. elegans PKB kinase and AKT kinase act  
CC downstream of daf-2 and age-1, just as their mammalian homologues act  
CC downstream of insulin signalling. Other daf genes have also been  
CC implicated in the C. elegans insulin signalling pathway. The C. elegans  
CC PTEN lipid phosphatase homologue, DAF-18, has been found to act upstream  
CC of AKT in the pathway. This discovery has enabled mammalian PTEN action  
CC to be mapped to the insulin signalling pathway. Compounds that inhibit  
CC the expression and/or activity of polypeptides encoded by these genes may  
CC be administered to patients to treat or prevent disorders such as obesity  
CC and impaired glucose tolerance

XX Sequence 105 AA;

AA06138 Length: 105 February 22, 2005 10:29 Type: P Check: 5111 ..

1 MPPILIVFL VLPASQQYP FSLESINDQI INEEVIEYML ENSIRSRTR

51 RVPDEKKIYR CGRIHSYVF AVCGKACESN TEVNIASKCC REECTDDFIR

101 KQCCP

!!AA\_SEQUENCE 1.0

ID AAB63438 standard; protein; 100 AA.

XX AC AAB63438;

XX DT 26-MAR-2001 (first entry)

XX DE Human breast cancer associated antigen protein sequence SEQ ID NO:800.

XX KW Human; breast cancer; gastric cancer; prostate cancer; diagnosis;

XX KW cancer associated antigen; cytostatic; cancer vaccine.

XX OS Homo sapiens.

XX FN WO200073801-A2.

XX PD 07-DEC-2000.

XX PF 26-MAY-2000; 2000WO-US014749.

XX PR 28-MAY-1999; 99US-0136526P.

XX PR 10-SEP-1999; 99US-0153454P.

XX PA (LUDW-) LUDWIG INST CANCER RES.

XX PI Obata Y;

XX DR WPI; 2001-025274/03.

XX PT Nucleic acids encoding breast, gastric and prostate cancer associated  
XX PT antigen precursors, useful for diagnosing and treating a condition  
XX PT characterized by expression of an abnormal amount of a protein, e.g.  
XX PT cancer.

XX PS Example 1; Page 566; 799pp; English.

XX CC AAF22422 to AAF22626, AAF22627 to AAF22773 and AAF22774 to AAF23014  
XX CC represent nucleotide sequences encoding human breast, gastric and  
XX CC prostate cancer associated antigen precursors (CAAP) respectively.  
XX CC AAB63232 to AAB63467, AAB63468 to AAB63721 and AAB63722 to AAB63970  
XX CC represent human breast, gastric and prostate CAAP protein sequence  
XX CC respectively. CAAPs have cytostatic activity and can be used in the  
XX CC production of cancer vaccines. The human CAAP proteins, peptides, nucleic  
XX CC acids or anti-CAAP antibodies are useful for diagnosing and treating a  
XX CC condition characterised by expression of an abnormal amount of a protein,  
XX CC e.g. cancer

SQ Sequence 100 AA;

AA063438 Length: 100 February 22, 2005 10:29 Type: P Check: 419 ..

1 DRQGRERDK DRDRERKER DROTERKETQR ERQRTERNR QREGSPVAI

51 QCLFFHFLFL FFSFSLSCIS VCMDCGMVC MYVCMYVCY LFMVYFIWRP

!!AA\_SEQUENCE 1.0

ID AAO07786 standard; protein; 86 AA.

XX AC AAO07786;

XX DT 06-NOV-2001 (first entry)

XX DE Human polypeptide SEQ ID NO 21678.

XX KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
XX KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
XX KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
XX KW nervous system disorders; arthritis; inflammation.

XX OS Homo sapiens.

XX FN WO200164835-A2.

XX PD 07-SEP-2001.

XX PF 26-FEB-2001; 2001WO-US004927.

XX PR 28-FEB-2000; 2000US-00515126.

XX PR 18-MAY-2000; 2000US-00577409.

XX PA (HYSE-) HYSEQ INC.

XX PI Tang YT, Liu C, Drmanac RT;

XX DR WPI; 2001-514838/56.

XX DR N-PSDB; AAI87717.

XX PT Isolated nucleic acids and polypeptides, useful for preventing diagnosing  
XX PT and treating e.g. leukemia, inflammation and immune disorders.

XX PS Claim 20; SEQ ID NO 21678; 1399pp + Sequence Listing; English.

XX CC The invention relates to human polynucleotides (AAI79941-AAI93841) and  
XX CC the encoded proteins (AAO00010-AAO13910) that exhibit activity relating to  
XX CC cytokine, cell proliferation or cell differentiation or which may induce  
XX CC production of other cytokines in other cell populations. The  
XX CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
XX CC peptide therapy. The polypeptides have various cytokine-like activities,  
XX CC e.g. stem cell growth factor activity, haematopoiesis regulating  
XX CC activity, tissue growth factor activity, immunomodulatory activity and  
XX CC activin/inhibin activity and may be useful in the diagnosis and/or  
XX CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
XX CC inflammation. Note: The sequence data for this patent did not form part  
XX CC of the printed specification, but was obtained in electronic format  
XX CC directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

XX SQ Sequence 86 AA;

AA07786 Length: 86 February 22, 2005 10:29 Type: P Check: 3139 ..

1 LGCRRKLYFL NGGLKCLYIK CVCVCVCYIYI GYVIGMCYVI CIYIYLMASX

51 NQVTSFLSFY VFLNRYXIP VKVITVLENL RMTGLP

!!AA\_SEQUENCE 1.0

ID ABG94983 standard; protein; 638 AA.

XX AC ABG94983;

XX DT 29-AUG-2003 (revised)

XX Ruvkun G, Kimura K, Patterson G, Ogg S, Paradis S, Tissenbaum H;  
 PI Morris J, Kowsek A, Pierce S;  
 XX WPI; 1999-045198/04.  
 XX Screening for compounds to treat impaired glucose tolerance conditions -  
 PT comprises use of DAF polypeptides functionally complementing C. elegans  
 PT daf mutation or having identity to C. elegans polypeptide.  
 XX Disclosure; Fig 28; 202pp; English.  
 XX The present invention relates to a method of screening for a compound  
 CC that decreases the activity of a DAF polypeptide. The method comprises:  
 CC (a) exposing a non-human transgenic animal, whose cells comprise a  
 CC transgene coding for a mammalian DAF polypeptide to the test compound,  
 CC and (b) determining activity of DAF polypeptide in animal, a decrease  
 CC indicating compound decreasing DAF activity. DAF polypeptides were found  
 CC to be involved in glucose metabolism; C. elegans daf genes were found to  
 CC be excellent candidate genes and proteins for human diseases associated  
 CC with glucose intolerance, and results indicated that human homologues of  
 CC these daf genes and proteins mediate insulin signalling in normal people  
 CC and may be defective or mis-regulated in diabetes. The screening method  
 CC can therefore be used to identify compounds which are useful to  
 CC ameliorate or delay an impaired glucose tolerance condition (e.g.  
 CC diabetes or atherosclerosis) or obesity. The method may also be used to  
 CC specifically identify compounds decreasing expression or activity of DAF-  
 CC 3 or DAF-16, also useful as above. Such compounds (e.g. DAF polypeptides  
 CC (especially nematode/human DAF-7, anti-diabetic or anti-obesity  
 CC pharmaceuticals) can then be administered therapeutically to treat such  
 CC conditions.  
 XX Sequence 105 AA;

ADF77576 Length: 105 February 22, 2005 10:29 Type: P Check: 5111 ..

1 MPPILVFFL VLPASQQYP FSLESNDQI INEEVIEYML ENSIRSRTR  
 51 RVPDEKKIYR CGRRHSYVF AVCGRACESN TEVNIASKCC REECTDDFIR  
 101 KQCCP

!!AA SEQUENCE 1.0  
 ID \_AAY65660 standard; protein; 105 AA.  
 AC AAY65660;  
 XX 04-FEB-2000 (first entry)  
 XX C. elegans insulin-like protein ZK1251.N.  
 XX Insulin-like protein; diagnosis; insulin-like gene analysis; nematode;  
 XX insulin hormone; aging; senescence; pesticide target; signalling pathway;  
 XX signal transduction pathway.  
 XX Caenorhabditis elegans.  
 XX WO9954436-A2.  
 XX 28-OCT-1999.  
 XX 16-APR-1999; 99WO-US008522.  
 XX 17-APR-1998; 98US-00062580.  
 XX 08-MAY-1998; 98US-00074984.  
 XX 26-MAY-1998; 98US-00084303.  
 XX (EXEL-) EXELIXIS PHARM INC.  
 XX Homburger SA, Platt DM, Ferguson KC, Doberstein SK, Buchman AR;  
 PI Reddy BP;  
 XX WPI; 2000-013239/01.

DR N-PSDB; AA243083.  
 XX Analyzing Caenorhabditis elegans insulin-like gene expression, nucleic  
 PT acids and proteins of the C. elegans insulin-like genes.  
 XX Claim 2; Fig 11; 194pp; English.  
 XX This sequence represents a Caenorhabditis elegans insulin-like protein,  
 CC and can be used in the method of the invention. The method is for  
 CC analysing an effect of expression or mis-expression of a C. elegans  
 CC insulin-like gene, and comprises observing a first nematode genetically  
 CC engineered to express or mis-express a C. elegans insulin-like protein  
 CC (ILP) of any one of groups I, II or IV or a derivative or fragment that  
 CC displays one or more functional activities of the C. elegans ILP. The  
 CC insulin-like genes in C. elegans constitute very useful tools for probing  
 CC the function and regulation of their corresponding pathways. This can be  
 CC expected to lead to the discovery of new drug targets, therapeutic  
 CC proteins, diagnostics and prognostics useful in the treatment of diseases  
 CC and clinical problems associated with the function of insulin hormones in  
 CC humans and other animals, as well as clinical problems associated with  
 CC aging and senescence. The information may also be useful in  
 CC identification and validation of pesticide targets in invertebrate pests  
 CC that are components of these signalling pathways. The genes are also  
 CC useful for identifying factors that are upstream of the receptor in the  
 CC signal transduction pathway. The ligand-encoding C. elegans insulin-like  
 CC genes provide a superior approach for identifying factors that are  
 CC upstream of the receptor in the signal transduction pathway  
 XX Sequence 105 AA;

AAY65660 Length: 105 February 22, 2005 10:29 Type: P Check: 5111 ..

1 MPPILVFFL VLPASQQYP FSLESNDQI INEEVIEYML ENSIRSRTR  
 51 RVPDEKKIYR CGRRHSYVF AVCGRACESN TEVNIASKCC REECTDDFIR

101 KQCCP  
 !!AA SEQUENCE 1.0  
 ID \_AAB06138 standard; protein; 105 AA.  
 AC AAB06138;  
 XX 11-JAN-2001 (first entry)  
 XX Caenorhabditis elegans insulin-like protein ZK1251.2.  
 XX Caenorhabditis elegans; ZK1251.2; daf-18; daf-2; age-1; insulin;  
 XX insulin signalling pathway; insulin receptor; PI 3-kinase; PKB kinase;  
 XX AKT kinase; PTEN lipid phosphatase; antidiabetic; anorectic; obesity;  
 XX diabetes.  
 XX Caenorhabditis elegans.  
 XX WO200033068-A1.  
 XX 08-JUN-2000.  
 XX 02-DEC-1999; 99WO-US028529.  
 XX 03-DEC-1998; 98US-00205658.  
 XX (GEHO) GEN HOSPITAL CORP.  
 XX Ruvkun G, Ogg S;  
 XX WPI; 2000-423022/36.  
 XX Diagnosing and treating obesity and impaired glucose tolerance using  
 XX modulators of daf-18 expression and/or activity.  
 XX Disclosure; Fig 28; 402pp; English.

FT Protein /note= "signal peptide"  
FT 29. .666  
FT /note= "mature protein"  
XX  
PN WO9827805-A1.  
PD  
XX 02-JUL-1998.  
XX  
PF 22-DEC-1997; 97WO-AU000874.  
XX  
PR 20-DEC-1996; 96AU-00004275.  
XX  
XX (RETR-) COOP RES CENT TROPICAL PLANT PATHOLOGY.  
XX  
PI Manners JM, Marcus JP, Goulter KC, Green JL, Bower NI;  
XX WPI; 1998-377279/32.  
DR N-PSDB; AAV42311.  
XX  
XX Novel anti-microbial protein from e.g. Macadamia integrifolia - useful  
PT for controlling microbial infestations of plants or mammals.  
XX  
PS Claim 1; Page 39-41; 96pp; English.  
XX  
XX The sequence is that of an antimicrobial protein which can be used to  
CC control microbial infestations in plants and mammalian animals  
XX  
SQ Sequence 666 AA;  
AAW62829 Length: 666 February 22, 2005 10:29 Type: P Check: 911 ..  
1 MAINTSNLCS LLFLSLFLL STTVSLAESE FDRQEYEECK RQCMQLETSG  
51 QMRRCVSQCD KRFEEDIDWS KYNDQDPQT DCQQCORRCR QESGPRQQQ  
101 YCQRCKEIC EEEBEYNRQR DPQQQYEQCQ ERCQRHETEP RHMQTCQQR  
151 ERYEKEKRK QKRYEEQQR EDESKYEERM KEEDNKRDPQ QREYEDCRRR  
201 CRQQEPRQY QCQRRCRQQ RQHGRGGDLI NPORGSGRY EGESEKQSDN  
251 PYYFDERSLS TRFRTEGHI SVLENFYGRS KLLRALKNYR LVLLEANPNA  
301 FVLPTHLAD AILLVTGGRG ALKMIHRDNR ESYNLECGDV IRIPAGTTFY  
351 LINDNNERL HIAKFLQIS TPGQYKEFFP AGGQNPEPYL STFSKEILEA  
401 ALNTOAERLR GVLGQOREGV IISASQEQIR ELTRDDSESR RWHIRRGGES  
451 SRGPNYLFNK RPLYSNKYGQ AYEVKPEDYR QLQDMDSVVF IANITQGSMM  
501 GPFFNTRSTK VVVVASGAD VEMACPHLSG RHGRRRGGRK HEEEDVHYE  
551 QVKARLSKRE AIVVPVGHVP VFVSSGNENL LLFAFGINAQ NNHENFLAGR  
601 ERNVLQIEP QAMELAFAP RKEVEELFNS QDESIFFPGP RQHQQQSSRS  
651 TKQQQPLVSI LDFVGF  
!!AA SEQUENCE 1.0  
ID \_AAW62832 standard; protein; 590 AA.  
XX  
AC AAW62832;  
XX  
DT 27-OCT-1998 (first entry)  
XX  
DE Gossypium hirsutum antimicrobial protein.  
XX  
KW antimicrobial protein; infestation; control.  
XX  
OS Gossypium hirsutum.  
XX  
PN WO9827805-A1.

XX 02-JUL-1998.  
XX  
PF 22-DEC-1997; 97WO-AU000874.  
XX  
PR 20-DEC-1996; 96AU-00004275.  
XX  
XX (RETR-) COOP RES CENT TROPICAL PLANT PATHOLOGY.  
XX  
PI Manners JM, Marcus JP, Goulter KC, Green JL, Bower NI;  
XX WPI; 1998-377279/32.  
XX  
XX Novel anti-microbial protein from e.g. Macadamia integrifolia - useful  
PT for controlling microbial infestations of plants or mammals.  
XX  
PS Claim 1; Page 49-51; 96pp; English.  
XX  
XX The sequence is that of an antimicrobial protein which can be used to  
CC control microbial infestations in plants and mammalian animals  
XX  
SQ Sequence 590 AA;  
AAW62832 Length: 590 February 22, 2005 10:29 Type: P Check: 9343 ..  
1 MVRNKSACVV LLFSLFLSFG LLCSAKDFFG RRGDDDDPPKR YEDCRRRCWE  
51 DTRGQKEQQQ CEESCKSQYG EKDQQQRHRP EDPQRRYEEC QOECRQQEER  
101 QOPOCQORCL KRFEQEQQS QROFQECQOH CHQEQRPEK KQCVRECRE  
151 KYQENPWRGE REEEAEEET EGEQEQSHN PFHFHRSFQ SRFREEHGNF  
201 RVLQRFASRH PILRGINEFR LSILEANPNT FVLPHHCDAAE KIYLVNTRG  
251 TLTLFTHENK ESYNIVPGVV VKVPAGSTVV LANQDNKEKL IIAVLHRRPVN  
301 NPGQPEEFFP AGSQRPQSYL RAFSREILEP AFNTRSEQLD ELFGGRQSR  
351 RQGGGMPRK ASQEQIRALS QEATSPREKS GERFAPNLLS QTPRYSNQNG  
401 RFEACPPPEF RQLRDINVTV SALQLNQGSI FVPHYNSKAT FVILVTEGNG  
451 YAEWVSPHLP RQSSYEEEEE EDEEEQEQE EERRSGQYRK IRSRLSRGDI  
501 FVVPANFPVT FVASQONLNR MTGFGLYNQN INPDHNQIRF VAGKINHVRQ  
551 WDSQAKELAF GVSSRLVDEI FNSNPQESYF VSRQQRASE  
!!AA SEQUENCE 1.0  
ID \_ADF77576 standard; protein; 105 AA.  
XX  
AC ADF77576;  
XX  
DT 26-FEB-2004 (first entry)  
XX  
DE Caenorhabditis elegans insulin-like molecule, SEQ ID 119.  
XX  
KW DAF; glucose metabolism; glucose intolerance; diabetes; atherosclerosis;  
KW obesity; insulin-like.  
XX  
OS Caenorhabditis elegans.  
XX  
PN WO9851351-A1.  
XX  
PD 19-NOV-1998.  
XX  
PF 15-MAY-1998; 98WO-US010080.  
XX  
PR 15-MAY-1997; 97US-00857076.  
XX 07-JUL-1997; 97US-0088534.  
XX  
PA (GEHO ) GEN HOSPITAL CORP.

XX AAW62830;  
 AC 27-OCT-1998 (first entry)  
 DT Macadamia integrifolia antimicrobial protein.  
 XX antimicrobial protein; infestation; control.  
 DE Macadamia integrifolia.  
 XX  
 OS  
 XX  
 XX Key Location/Qualifiers  
 FT Peptide 1..28  
 FT /note= "signal peptide"  
 FT Protein 29..666  
 FT /note= "mature protein"  
 XX  
 XX WO9827805-A1.  
 PN  
 XX  
 XX 02-JUL-1998.  
 PD  
 XX  
 XX 22-DEC-1997; 97WO-AU000874.  
 PF  
 XX  
 XX 20-DEC-1996; 96AU-00004275.  
 PR  
 XX  
 XX (RETR-) COOP RES CENT TROPICAL PLANT PATHOLOGY.  
 PA  
 XX  
 XX Manners JM, Marcus JP, Goulter KC, Green JL, Bower NI;  
 PI WPI; 1998-377279/32.  
 XX  
 XX N-PSDB; AAV42316.  
 DR  
 XX  
 XX Novel anti-microbial protein from e.g. Macadamia integrifolia - useful  
 PT for controlling microbial infestations of plants or mammals.  
 FT  
 XX  
 XX Claim 1; Page 43-45; 96pp; English.  
 PS  
 XX The sequence is that of an antimicrobial protein which can be used to  
 CC control microbial infestations in plants and mammalian animals  
 CC  
 XX  
 XX Sequence 625 AA;  
 SQ

AAW62830 Length: 625 February 22, 2005 10:29 Type: P Check: 7549 ..

1 QCMQLETSQG MRCVSCQDK REEEDIDWSK YDQEDPQTE CQCCQRRCRQ

51 QESDPQQOY QCRCKEICE EEEYNQRD PQQYEQCQK RCORRETEPR

101 HMQICQORCE RRYEKKRKQ QKRYBEQQRE DEEYERMK EGDNKRDPQQ

151 REYEDCRHC EQEPRLOYQ QCRCEQQR QHGRGDLMN PQRGSGRYE

201 EGEKQSDNP YPFDERSLST RFRTEGHIS VLENFYGRSK LLRALKNYRL

251 VLLEANPNAF VLPTHLDDADA ILLVIGRGA LKMIHRDNR SYNLECGDVI

301 RIPAGTTFYL INRDNNERLH IAKFLOTIST PQQYKEPFA GGQNPPEYLS

351 TFSKEILEAA LNTQTERLRG VLQQQREGVI IRASQEQIRE LTRDDSESRR

401 WHIRRGESS RGPYNLFNKR PLYSNKYGOA YEVPEDYRQ LQMDVDVSFVI

451 ANITQGSMMG PFNTRSTKV VVVASGADV EMACPHLSGR HGGGGGKRH

501 EEEEVHYEQ VRARLSKREA IVVLAGHPV FVSSGNEMLL LFAFGINAQN

551 NHENFLAGRE RNVLQIEPQ AMELAPASR KEVELFNSQ DESIFFPGPR

601 QHQQSPRST KQQQPLVSIL DFVGF

!!AA SEQUENCE 1.0  
 ID -AAW62831 standard; protein; 525 AA.  
 XX

AC AAW62831;  
 XX 27-OCT-1998 (first entry)  
 DT Theobroma cacao antimicrobial protein.  
 XX antimicrobial protein; infestation; control.  
 DE Theobroma cacao.  
 XX  
 OS  
 XX  
 XX WO9827805-A1.  
 PN  
 XX  
 XX 02-JUL-1998.  
 PD  
 XX  
 XX 22-DEC-1997; 97WO-AU000874.  
 PF  
 XX  
 XX 20-DEC-1996; 96AU-00004275.  
 PR  
 XX  
 XX (RETR-) COOP RES CENT TROPICAL PLANT PATHOLOGY.  
 PA  
 XX  
 XX Manners JM, Marcus JP, Goulter KC, Green JL, Bower NI;  
 PI WPI; 1998-377279/32.  
 XX  
 XX Novel anti-microbial protein from e.g. Macadamia integrifolia - useful  
 PT for controlling microbial infestations of plants or mammals.  
 FT  
 XX  
 XX Claim 1; Page 47-49; 96pp; English.  
 PS  
 XX The sequence is that of an antimicrobial protein which can be used to  
 CC control microbial infestations in plants and mammalian animals  
 CC  
 XX  
 XX Sequence 525 AA;  
 SQ

AAW62831 Length: 525 February 22, 2005 10:29 Type: P Check: 1307 ..

1 MVISKSPFIV LIFSLLSFA LLCSGVSAYG RKQYERDPRQ QYECCQRRC

51 SEATEBEREQ QCEQRCEREY KEQQRQEE E LQRQYQCCG RCQEQQQGQR

101 EQQCQCKW EYKEQERGE HENYHNHKN RSEEEGQQR NNPFYFPRR

151 SFQTRFDEE GNFKILQRP ENSPPLKGIN DYRLAMFEAN PNTFILPHHC

201 DAEAIYFVTN GKGITTFVTH ENKESYNVQR GTVVSVFAPS TVVVSQDNQ

251 EKUTIAVLAL FVNSPGKYL FFPAGNNKPE SYYGAFSYEV LETVFNTORE

301 KLBEEILEEQR GQKROQGOQG MFRKAKPEQI RAISQQTSP RHRGGERLAI

351 NLLSQSPVYS NQNGRFFEAC PEDFSQFQNM DVAVSAPKLN QGAIFVPHYN

401 SKATFVVFT DGYGVAQMAC PHLRSQSGS QSGRQDRREQ EEESEETFG

451 EFQQVKAPLS PGDVFVAPAG HAVTFFASKD QPLNAVAFGL NAQNQRIFL

501 AGRPFPLNHK QNTNVIKFTV KASAY

!!AA SEQUENCE 1.0  
 ID -AAW62829 standard; protein; 666 AA.  
 XX  
 XX AAW62829;  
 AC  
 XX  
 XX 27-OCT-1998 (first entry)  
 DT  
 XX Macadamia integrifolia antimicrobial protein.  
 DE  
 XX antimicrobial protein; infestation; control.  
 KW  
 XX Macadamia integrifolia.  
 OS  
 XX  
 XX Key Location/Qualifiers  
 FT Peptide 1..28  
 FT

!!AA SEQUENCE 1.0  
ID AAR20181 standard; protein; 566 AA.  
XX  
AC AAR20181;  
XX  
DT 16-APR-1992 (first entry)  
XX  
DE Sequence encoded by 67 kD T. cacao protein cDNA.  
XX  
KW Cocoa; flavour; vicilin; seed storage protein.  
XX  
OS Theobroma cacao.  
XX  
PN WO9119801-A.  
XX  
PD 26-DEC-1991.  
XX  
PF 11-JUN-1990; 90GB-00013016.  
XX  
PR 11-JUN-1990; 90GB-00013016.  
XX  
PA (MRSC ) MARS UK LTD.  
XX  
PI Spencer ME, Hodge R, Deakin EA, Ashton S;  
XX  
DR WPI; 1992-024418/03.  
XX  
DR N-PSDB; AAQ20377.  
XX  
PT Recombinant cocoa proteins - are responsible for flavour in cocoa beans  
PT and produced in large quantities using yeast and bacterial expression  
PT vectors.  
XX  
PS Claim 4; Fig 2; 59pp; English.  
XX  
CC The inventors claim a 67 kD and 31 kD T. cacao protein, and fragments,  
CC and encoding DNAs. The 47 kD and 31 kD proteins are derived from the 67  
CC kD precursor. T. cacao protein cDNA was detected in a cDNA library  
CC prepared from immature cocoa beans RNA using a probe based on the AA  
CC sequence of a CNBr peptide common to the 47 kD and 31 kD polypeptides.  
CC Homology searches revealed close homologies between the 67 kD polypeptide  
CC and the vicilins, which are seed storage proteins  
XX  
SQ Sequence 566 AA;  
AAR20181 Length: 566 February 22, 2005 10:29 Type: P Check: 4078 ..  
1 MVISKSPFTV LIFSLLSFA LLCGVSAYG RKQYERDPRQ QYEQQRCE  
51 SEATEREQE QCEQRCEREY KEQQRQDEE LQRQYQCCG RCQEQQQGOR  
101 EQQOQKQW EYKEQERGE HENYHNHKN RSEEEGQOR NNPFYFPKRR  
151 SFQTRFDEE GNFKILORFA ENSPLKGIN DYRLAMFEAN PNTFILPHHC  
201 DAEAIYFVN GKGITTFVTH ENKESYVQOR GTVSVVPGS TVYVVSQDNQ  
251 EKLTTAVLAL PNVSPGKVEL FFPAGNNKPE SYGAFSEYV LETVENTORE  
301 KLEEILEEOR QKQKQGGQGG MFRKAKPEQI RAISOQATSP RHRGGERLAI  
351 NLLSQSPVYS NQNGRFFFEAC PEDFSQFQNM DVAVSFAKLN QGAIVPHYN  
401 SKATFVFTV DYGVAQMAC PHLSRQSGS QSGRQRREQ EEESEETFG  
451 EFQQVKAPLS PGDFVAPAG HAVTFFASKD QPLNAVAFGL NAQNNQRIFL  
501 AGKKNLVRQM DSEAKLSFG VPSKLVNIF NNPDESIFYMS FSQQRQRDE  
551 RRGNPLASIL DFARLF  
!!AA SEQUENCE 1.0  
ID AAW62828 standard; protein; 666 AA.  
XX

AAW62828;  
XX  
DT 27-OCT-1998 (first entry)  
XX  
DE Macadamia integrifolia antimicrobial protein.  
XX  
KW antimicrobial protein; infestation; control.  
XX  
OS Macadamia integrifolia.  
XX  
FH Key Location/Qualifiers  
FT Peptide 1..28  
FT /note= "signal peptide"  
FT Protein 29..666  
FT /note= "mature protein"  
XX  
PN WO9827805-A1.  
XX  
PD 02-JUL-1998.  
XX  
PF 22-DEC-1997; 97WO-AU000874.  
XX  
PR 20-DEC-1996; 96AU-00004275.  
XX  
PA (RETR-) COOP RES CENT TROPICAL PLANT PATHOLOGY.  
XX  
PI Manners JM, Marcus JP, Goulter KC, Green JL, Bower NI;  
XX  
DR WPI; 1998-377279/32.  
XX  
DR N-PSDB; AAV42310.  
XX  
PT Novel anti-microbial protein from e.g. Macadamia integrifolia - useful  
PT for controlling microbial infestations of plants or mammals.  
XX  
PS Claim 1; Page 34-36; 96pp; English.  
XX  
CC The sequence is that of an antimicrobial protein which can be used to  
CC control microbial infestations in plants and mammalian animals  
XX  
SQ Sequence 666 AA;  
AAW62828 Length: 666 February 22, 2005 10:29 Type: P Check: 8155 ..  
1 MAINTSNLCS LLFLLSLFLL STTVSLAEE FDRQYEBCK RQCMQLETSG  
51 QMRRCVSQCD KRFEEDIMS KYDNQEDPQT ECQQCQRCR QOESGPROQQ  
101 YCQRCKEIC EEEBEYNQR DPQQVEQCQ KHCQRRETEP RHMOTCQQR  
151 ERYEKEKXK QKRYEQQR EDEEKEERM KEEDNKRDPQ QREYDCRRR  
201 CEQEQFROQH QCQLRCREQQ RQHGRGDMN NPQRGSGRY EGEBEQSDN  
251 PYFDEKSLS TRPTEGHI SVLENFYGRS KLLRALKNVR LVLEAPNA  
301 FVLPHLDAD AILLVICGRG ALKMIHDNR ESYNLECGDV IRIPAGTIFY  
351 LINRDNNERL HIAKFLQIS TPGQYKEFPF AGQNPEPYL STFSKEILEA  
401 ALNTQTEKLR GVFGQREGV IIRASQEQIR ELTRDDSES RWHIRRGES  
451 SRGPNLENK RPLYSNKYQG AYEKPEDYR QLQMDLSVF IANTQSGMM  
501 GPFNTRSTK VVVVASGEAD VEMACPHLSG RHGGRGGKR HEEBEDVHYE  
551 QVRLSKRE AIVVLACHPV VFVSSGNENL LLFAFGINAQ NNHENFLAGR  
601 ERNVLOQIEP QAMELAPAP RKEVEESFNS QDQSIFFGP RHOQQQSPRS  
651 TKQQQPLVSI LDFVGF  
!!AA SEQUENCE 1.0  
ID AAW62830 standard; protein; 625 AA.



This Page Blank (uspio)

1	1	(Y,F)XXCXXCX{10,12}CXXCXXX(Y,F) (F)xxCxxCx{12}CxxCxxx(F) FVCGKACESNTVNIASKCCRECTDDF	IRKQC
1	February 18, 2005	AAR20181 ck: 4078 len: 566 ! Aar20181 Sequence encoded by 67 kD T. cacao	
1		(Y,F)XXCXXCX{10,12}CXXCXXX(Y,F) (Y)xxCxxCx{12}CxxCxxx(Y) YEQORRCESEATEBEQEQRCEY	KEQOR
1	42: DPRQQ	(Y)xxCxxxCx{12}CxxCxxx(Y) YQCCQRCQEQGQEQEQCCQCKWEQY	KEQER
1	85: ELORQ	(Y)xxCxxxCx{12}CxxCxxx(Y) YQCCQRCQEQGQEQEQCCQCKWEQY	KEQER
1	AAB62828 ck: 8155 len: 666 ! Aaw62828 Macadamia integrifolia antimicrobi	(Y,F)XXCXXCX{10,12}CXXCXXX(Y,F) (Y)xxCxxxCx{11}CxxCxxx(F) YBECKRQCWLETSGQMRRCVSQCDKRF	EEDID
1	36: FDRQE	(Y)xxCxxxCx{12}CxxCxxx(Y) YECCQKHQCRRETEPRHMQTCQRCERY	EKEKR
1	126: DPOQQ	(Y)xxCxxxCx{12}CxxCxxx(Y) YECCQKHQCRRETEPRHMQTCQRCERY	EKEKR
1	AAB62830 ck: 7549 len: 625 ! Aaw62830 Macadamia integrifolia antimicrobi	(Y,F)XXCXXCX{10,12}CXXCXXX(Y,F) (Y)xxCxxxCx{12}CxxCxxx(Y) YECCQKHQCRRETEPRHMQTCQRCERY	EKEKR
1	85: DPOQQ	(Y)xxCxxxCx{12}CxxCxxx(Y) YECCQKHQCRRETEPRHMQTCQRCERY	EKEKR
1	AAB62831 ck: 1307 len: 525 ! Aaw62831 Theobroma cacao antimicrobial prod	(Y,F)XXCXXCX{10,12}CXXCXXX(Y,F) (Y)xxCxxxCx{12}CxxCxxx(Y) YECCQKHQCRRETEPRHMQTCQRCERY	EKEKR
1	42: DPRQQ	(Y)xxCxxxCx{12}CxxCxxx(Y) YECCQKHQCRRETEPRHMQTCQRCERY	EKEKR
1	85: ELORQ	(Y)xxCxxxCx{12}CxxCxxx(Y) YQCCQRCQEQGQEQEQCCQCKWEQY	KEQER
1	AAB62829 ck: 911 len: 666 ! Aaw62829 Macadamia integrifolia antimicrobi	(Y,F)XXCXXCX{10,12}CXXCXXX(Y,F) (Y)xxCxxxCx{12}CxxCxxx(Y) YECCQKHQCRRETEPRHMQTCQRCERY	EKEKR
1	36: FDRQE	(Y)xxCxxxCx{12}CxxCxxx(Y) YECCQKHQCRRETEPRHMQTCQRCERY	EKEKR
1	126: DPOQQ	(Y)xxCxxxCx{12}CxxCxxx(Y) YECCQKHQCRRETEPRHMQTCQRCERY	EKEKR
1	AAB62832 ck: 9343 len: 590 ! Aaw62832 Gossypium hirsutum antimicrobial p	(Y,F)XXCXXCX{10,12}CXXCXXX(Y,F) (Y)xxCxxxCx{12}CxxCxxx(Y) YEDCRRCEWTRGQEQEQCCQCKWEQY	GEKQD
1	41: DPPKR	(Y)xxCxxxCx{10}CxxCxxx(F) YECCQKHQCRRETEPRHMQTCQRCERY	EQEQQ
1	87: DPQRR	(Y)xxCxxxCx{12}CxxCxxx(Y) YQCCQRCQEQGQEQEQCCQCKWEQY	QENPW
1	124: QSQRQ	(Y)xxCxxxCx{12}CxxCxxx(Y) YQCCQRCQEQGQEQEQCCQCKWEQY	QENPW
1	ADF77576 ck: 5111 len: 105 ! Adf77576 Caenorhabditis elegans insulin-lik	(Y,F)XXCXXCX{10,12}CXXCXXX(Y,F) (F)xxCxxxCx{12}CxxCxxx(F) FVCGKACESNTVNIASKCCRECTDDF	IRKQC
1	70: IHSYV	(Y,F)XXCXXCX{10,12}CXXCXXX(Y,F) (F)xxCxxxCx{12}CxxCxxx(F) FVCGKACESNTVNIASKCCRECTDDF	IRKQC
1	AAB65660 ck: 5111 len: 105 ! Aay65660 C. elegans insulin-like protein 2M	(Y,F)XXCXXCX{10,12}CXXCXXX(Y,F) (F)xxCxxxCx{12}CxxCxxx(F) FVCGKACESNTVNIASKCCRECTDDF	IRKQC

Databases searched:

EMBL, Release 26.0, Released on 16Dec2004, Formatted on 7Jan2005

Total finds: 21  
Total length: 221,821,841  
Total sequences: 1,377,707  
CPU time: 10:15.99

201 GCAGGGGTG GCAAGGGCC AGTCACCAA ACCATGCCT GTCTCTTCCA  
251 ACACGAGCG GAACGAAGAT GGGTTGGGG AGCGGAGGG GCGGCATCT  
301 CCGGATTCCT CTCTGACCG GTGACCAAG TCCTTACACT CCTATTGGG  
351 CGATCAAGAC GGTGCTTACC TGTTCGAACT TTTCTCTGGAG AGGGAGAAAT  
401 GCGTGATAC CTTAGACTTC TGGTTTGCCT GCAATGGATT CAGGCAGATG  
451 AACCTGAAG ATACCAAAAC TTTACGAGTA GCCAAGCGA TCTACAAAAG  
501 GTACATTGAG AACAACAGCA TTGTCTCAA GCAGCTGAAG CTGCGACCA  
551 AGACCTACAT AAGAGATGCG ATCAAGAAGC AGCAGATTGA TTCCATCATG  
601 TTTGACCAGG CGCAGACCGA GATCCAGTCG GTGATGGAGG AAAATGCCCTA  
651 CCAGATGTTT TTGACTTCTG ATATATACCT CGAATATGTG AGGAGTGGGG  
701 GAGAAACAC AGCTTACATG AGTAATGGG GACTCGGGAG CCTAAAGGTC  
751 GTGTGTGGCT ATCTCCCCAC CTTGAATCAA GRAGAGGAGT GCACCTTGTC  
801 CGACTTCAAG TGCAACTTT CGCCAACCGT GGTGTGGCTG TCCAGCAAAA  
851 CTCTGAGGCG CACGGCGAGT GTGAGGTCCA CGGAACTGT TGACAGTGGA  
901 TACAGN

!!AA\_SEQUENCE 1.0

ID ADP31356 standard; protein; 1001 AA.

XX AC

XX ADP31356;

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2123.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX OS WO2004035732-A2.  
XX PN  
XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-041101P.  
17-SEP-2002; 2002US-041111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
15-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3354; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytosstatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPWEB and is not in the specification.

Sequence 1001 AA;

ADP31356 Length: 1001 February 22, 2005 12:25 Type: P Check: 7035 ..

1 GCTGGTCCGG GAGTTCTGTGG CCCAGAACAA TACCGTGCAG ATCAAGCATG  
51 TGATCCAGAC CCTGTCCCAG GAGTTTGCCC TGTCTCAGCA CCCCCACGC  
101 CGGAAAGGGG GCCTCATCGG CTTGCCCGCC TGCTCCATCG CACTGGGCAA  
151 GGACTCAGGG CTCTACCTGA AGGAGCTGAT CGAGCCAGTG CTGACCTGCT  
201 TCAATGATGC AGACAGAGG CTGCGCTACT ATGCTCTGGA GGCCCTCTAC  
251 AACATCGTCA AGGTGGCCCG GGGCGCTGTG CTGCCCCACT TCAACGTGCT  
301 CTTTGCAGGG CTGAGCAAGC TGGAGCCGA CCCAGACCCC AATGTGAARA  
351 GCGGATCTGA GTCCTAGAC CCGCTTTTAA AGGACATTGT GACTGAGAGC  
401 AACAAAGTTG ACCTGTGTAG TTTCATCCCC TTGTTGGGAG AGAGGATTTA  
451 CTCCAACAAC CAGTATGCC GGCAGTTTAT CATCTCCTGG ATCCTGGTTC  
501 TGGAGTCGGT GCACAGATT AACCTGCTGG ATTACCTGCC GGAGATCCTG  
551 GATGGACTCT TCCAGATCCT GGGTGACAAAT GGCAAAGAGA TTCGCAAAAT  
601 GTGTGAGGTT GTTCTTGGAG AATTCCTTAA AGAAATTAAG AAGAACCCCT  
651 CCAGTGTGAA GTTTGCTGAG ATGGGCAACA TCCTGTGTAT CCACTGCCAG  
701 AACACAGATG ACCTCATCCA GCTGACAGCC ATGTGCTGGA TGGGGGAGTT  
751 CATCCAGCTG GCGGGCCGCG TCATGCTGCC TTACTCCTCC GGGATCCTGA  
801 CTGCTGTCTT GCCTGCTTG GCTTAGGATG ACCGAGAA AATGGACTCA  
851 GGCATCAAAG AAGTGGCCAA CGTGTGCAAC CAGAGCCTGA TGAAGCTGGT  
901 CACCCCGCAG GACGACGAGC TGGATGAGCT GAGACCTGGG CAGAGGCAGG  
951 CAGAGCCCAAC CCCTGAGGAT GGCCTGCCAA AGCAGGAGGG CACAGCCAGT

1001 G

!1AA SEQUENCE 1.0  
ID ADP31508 standard; protein; 1113 AA.  
XX  
AC ADP31508;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2275.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.

29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H,  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3506; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC

CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
SQ Sequence 1113 AA;

ADP31508 Length: 1113 February 22, 2005 12:25 Type: P Check: 2076 ..

1 ATGGAAAAGA TGACGTGCAT AATTTTAACT GGTTCGACA ATGTACAAG  
51 TGCTTGACAA AACACAGCATG AGTTTGGAGA TGTCACCTCTG CTCATTGGTG  
101 AAGGCATCCC CTCACGGCA TGGGACGGT CTCAGATAGG GCGACGGGAC  
151 ACAGAGGTTT CAAGAGCAT GCGTGTGCTT CATGGAGCCT GCTTCAGAGG  
201 GTGCTTAGAA GAACCCCTGC AATATCCACT ATATTCACTA AGTCTGGATG  
251 GCTTCTGTAG CTGGCATCAG CCAAGCTAC AGGCAACATC ATGGCAGGCA  
301 GCAGTGGTGC AAAGAAAAA TCAAAAAGAG TACTGGAGGG GAATTTTCAGG  
351 AGGCTTGTCT GTGCCACCAG TCAGATTTGT GCCTTTTCCA GCCTTAGTTC  
401 CTCACCTGGC TTGTATCAG CTGGCACCCTC TGCAGTGGCG GAAACAGAGT  
451 CCCGTGGGT TTAACATAAT GCGGTGTGGA AAGCAGATGG CTGGTGCATG  
501 GAGTGTCTAG CAGACCCAGT CCACTCTGAC CTTGGGAGTC ACTGCTCTCA  
551 GCAATGTAC CCACAGGAA TGCAGAGAG GCGTGAGAGA CCAGAGCAAA  
601 TGCCAGTGTG TCTTTGAGT GTGGCAGCAT CTTATGTGTT TGAGCTCTGA  
651 TTTGGAGACA TGGACATAT GCATTGACTC TACACCTGAG GGGACTCTTT  
701 CCTTTAAGCA GAAGCTGTG GTTGGAGGA GAGTACTGT TTCCATCACT  
751 ATTCTGTTG AAATCTTTC AGTGGCCAAG TCAGGGCCGA ACCCTTTAAC  
801 TTGGCATCAA GGTACCACAC AATCAATCAG AATCAAACTT AGCTGTCAGC  
851 CGCTCCACA AACGATGCT CTGATCATC TGAATGGGAG TTAATCTCCA  
901 GCTGAACCTG ATACTTCCC AGCTTTCTTT GTAGACTTGC ATTGTCTTTT  
951 CTTTCTATTT AATGATGTTG CCTTAAGGAA TGTGCAAAGT CTTGTAGAA  
1001 TTCAGAGAC AGGAAAGTA CTTCTTGCTG GGGGAGGAG AGAGGATGT  
1051 TCAGGGAAG ATTCCGAGTA TAAATTGTAT TTTAATTGTG CCTTTAAGAA  
1101 TGTGATTAAG TAA

!!AA\_SEQUENCE 1.0  
ID ADP31565 standard; protein; 567 AA.

XX AC ADP31565;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #2332.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN W02004035732-A2.

XX 29-APR-2004.  
PD 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 02-MAY-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 22-MAY-2003; 2003US-0472430P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 09-JUN-2003; 2003US-0476641P.  
XX 08-JUL-2003; 2003US-0485218P.  
XX 08-JUL-2003; 2003US-0485223P.  
XX 08-JUL-2003; 2003US-0485224P.  
XX 08-JUL-2003; 2003US-0485325P.  
XX 14-JUL-2003; 2003US-0486446P.  
XX 15-JUL-2003; 2003US-0486480P.  
XX 15-JUL-2003; 2003US-0486891P.  
XX 15-JUL-2003; 2003US-0486960P.  
XX 08-AUG-2003; 2003US-0493341P.  
XX 08-AUG-2003; 2003US-0493370P.  
XX 08-AUG-2003; 2003US-0493573P.  
XX 08-AUG-2003; 2003US-0493577P.

XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3563; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 567 AA;  
ADP31565 Length: 567 February 22, 2005 12:25 Type: P Check: 6040 ..  
1 ATGCTCTCCG AGTCTGTGCT GAGCAACG CAGCTCCGCC CTCGCAAGG  
51 CACAGCGCGG GCGCAGGCGC GGGCGGTGC ACAGCGCGG CGCAGGCGCC  
101 GAGAGGCGCA CGGAGACCT CAGGCCCCAG CTCACACTCC CAGCTGTGAA  
151 AGGCTGGGTC CCCAGCTGCC TCTCCAGGGA GGAGTGACAG CTGGCCTGTG  
201 CCACACCTC GAGCCCCCCC CCAAGGACTA CCCCCTCCCT GGGCAGGAC  
251 CCTGTGCTGT GGCACAACCA AGGGGCTGTC TGATGGGGGC TCATCTGCT  
301 GGCCAGACCC CCAAGCTAGC CGCGCAGGCC TCCATAGAGC TGCCCGAGCAT  
351 GGCTGCTGCC AGTACCAAGA GTTGTGGGA GACGGGTGAA GTACAGGCTC  
401 AGTCTGGGCG CAAGACTCCA TCTCTCAAGG ATATTGTGGC TGGAGACATG  
451 AGCAAGAAAA GCCTCTGGGA GCAGAAGGGA GGCTCCAAGA CCTCATCAAC  
501 AATTAAGAGA AATAAACTA TCGCCTTCAA GAAACACAG TTAATACAA  
551 AGATGCAAC AGGTTAA  
!!AA SEQUENCE 1.0  
ID -ADP31601 standard; protein; 1815 AA.  
XX  
AC ADP31601;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2368.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3599; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1815 AA;  
ADP31601 Length: 1815 February 22, 2005 12:25 Type: P Check: 3996 ..  
1 ATGGTACTAG AAGCTGTGCA TAAAAACAA TGCAGAGTGA TGAGAACGAA  
51 GAAGAAAAAA ATAGGTGCGA AGTTTGCCAG CCGAGGGGGT CACCTGGAGC  
101 GCATATTTGT GGTGGAATTT CGCCCGGACT CAGACACGCA GTTTGTATCT  
151 GTCCGGGTCA ACATATGAA GTTCTGACC CTGGCAGGCA GCGCCTTGCT  
201 TTACAAGAAA GGGGTATCG GGTCCCTGGG AGCTGCCAAA ATGCAGACGA  
251 TGCTCTCCGT GGCCTTCGGT GCTAACAAATC TCATTTTAC GGGTGCCATC  
301 AATGGAGATG TCTAGTCTG GAAGGACAC TTCTCATCC GCTGGTGGC  
351 CAAGGCTCAC ACAGGCCCG TGTTTCAAT GTACACAAC CTTCCGGGATG  
401 GACTCATAGT GACCGCGGA AAGAGAGGC CGACCAAGA AGGAGGTGCT  
451 GTAAATTGT GGGACACGA GATGAAGGC TGCCGGGCGCT TTCAGCTGA  
501 GACCGGGCAG CTGGTGGAGT GTGTGCGCTC CGTGTCCCGT GGAAAGTGA  
551 GCACAGCCAG CTCCTCTGGG GGCTGGGCCA GGAAGGGGG AGTGTAGTG  
601 TTTCATATAC AACAGGGAAA AATCTTAGTG GGAACCAAG ACGGAGAAAT  
651 AATTGAAGTT GGTGAAAAA ATGCTGCTTC TAACATCCTG ATTGATGGTC  
701 ACATGGAAGG GGAGATCTGG GGCCTGGCCA CTCACCCCTC CAAGGACCTC  
751 TTCATCTCTG CCAGCAACGA TGGCAGAGCC CGGATCTGGG ACCTGGCTGA  
801 CAAGAAGCTG TTAACAAGG TGAGCTTTGG CCATGCGGCC AGGTGTGCAG  
851 CCTACAGCCC TGATGGGAG ATGTGGGCCA TTGGCATGAA GAATGGAGAG  
901 TTTGTATCTT TGTGGTGA CAGCTGAAA GTTTGGGGGA AAAACAGAGA  
951 CCGGAAATCT GCTATCCAAG ATATCAGAAAT CAGCCAGAC AACCGATTCT  
1001 TAGCCGTTGG TTCTTCTGAA CACACAGTTG ACTTCTATGA CCTCACTCAG  
1051 GGCACAAATC TGAACCGAT TGGTACTGC AAGATATCC CAAGCTTTGT  
1101 CATTCAGATG GATTTTCTG CGGATGGCAA ATACATTCAG GTGTCAACAG  
1151 GTGCTATATA CGCCAGGTG CATGAGTCC CCTTGGGAAA CGAGTAACT  
1201 GAAGCGGTGG TCATTGAAA GATCACCTGG GCTCTCTGA CAAGGCTCCT  
1251 GGGAGATGAA GTCATTGAA TCTGGCCAGC AAATGCAGAC AAGGCTGATG

1301 TCAACTGCGC ATGTGTGACC CACGCTGGCC TGAACATTGT CACAGGAGAT  
1351 GACTTTGGGC TGGTGAAGCT CTTTGATTTT CCATGCACAG AAAAATTTGC  
1401 CAAACATAAG CGATACITTCG GTCACTCGGC TCACGTGACG AACATCCGTT  
1451 TCTCTTATGA TGACAAATAT GTGGTCAGCA CTGGAGGAGA CGACTGCAGC  
1501 CTGCTGTGCT GGCTACTTCT GGCATTATA GCCCTTGAGA TAGTACCGCC  
1551 AGCAGCTCCC TGTGAAGTGC TAACACCCCT TCAAAGCAGC ACCAACCCAA  
1601 TTGTGAACAA GCTAGGAGTA AAAGACTGTA TTTGTGTGGC GATGCTCTGA  
1651 AATGCCAGA AGCCTCTTAT GTTATTGCTG CTGCTGCTAC CAGCCAGCNA  
1701 CTGCAGAGGC CATGCTGAGG TGCTCTCTTG CCACCAGCCG TTGGGAAAATG  
1751 CTTACCATGC TGCCCGGAT GCACAAGCTC AAAACGCTGC AGAAGTTACA  
1801 CAACTGCTCC CATAA  
!!AA SEQUENCE 1.0  
ID ADP31626 standard; protein; 194 AA.  
XX AC ADP31626;  
XX AC  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2393.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406656P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.

PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3624; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 194 AA;  
ADP31626 Length: 194 February 22, 2005 12:25 Type: P Check: 619 ..  
1 AGATGGGCTG GAAGATCCCC TGGAGGATAC GGGGCTGTGC CAGCAGCAGT  
51 TGGACCAAGCT GTCCACCAATT GGGCGTTGTG AATATGAA GACGTGTGCA  
101 CTCCTCGTGC AGTTGTTTGA CCAGTCGGCC CAGTCGTACC AGGAGCTGCT  
151 ACAGAGCGCC AGCGCAAGCC CAATGGACAT TGCAGTCGAG GAGG

!1AA\_SEQUENCE 1.0  
ID ADP30537 standard; protein; 1521 AA.  
XX  
AC ADP30537;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1304.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.



PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2535; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antitumorigenic, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 1521 AA;  
ADP30537 Length: 1521 February 22, 2005 12:25 Type: P Check: 8168 ..  
1 AGAATGGCAT CGACATCTAC AGCCTCACCG TGGACTCCAG GGTCTCATCC  
51 CGATTGGCCC ACACGGTCGT CACCAGCGA GTGGTCAATA GGGCCCAATAC  
101 TTGTGAGGAG GCCACCTTTC AGATGGAGCT GCCCAAGAAA GCCTTTCATCA  
151 CCAACTTCTC CATGATCATC GATGGCATGA CCTACCCAGG GATCATCAAG  
201 GAGNAGGCTG AAGCCAGGC ACAGTACAGC GCAGCAGTGG CCAAGGGHAA  
251 GAGCGGTGGC CTCGTCAACA GCAGTGGTC AAGCAGCTGC AGATGGACAT  
301 TCACATCTTC GAGCCCCAGG GCATCAGCTT TCTGGAGACA GAGAGCACTT  
351 TCATGACCAA CCAGCTGGTA GAGCCCTCA CCACCTGGCA GAATAGACC  
401 AAGTCCGCTA TGATGTGGAC CGGGCCATCT CCGGGGGCTC CATTCAGATC  
451 GAGAACGGCT ACTTTGTACA CTACTTTGCC CCGAGGGGCC TAAACACAAT  
501 GCCCAAGNAT GTGGTCTTTG TCATTGNCAA GAGCGGCTCC ATGATGGCA  
551 GGAAATCA CAACACCGG GAAGCCCTAA TCAAGATCTT GGATGACCTC  
601 AGCCCCAGAG ACCAGTTCAA CCTCATCGTC TTCAGTACAG AAGCAACTCA  
651 GTGGAGGCGA TCATGTGGTC CAGCCTCAGC CGAGAACGTC AACAGGCGCA  
701 GGAGCTTTGT TCCAGGGCTC GTGTTCTCTA GGGACCAACA TCAATGATGC

751 "AATGCTGATG GCTGTGCAGT TGCTGGACAG CAGCAACCAG GAGGAGCGGC  
801 TGCCCGAAGG GAGTGTCTCA CTCATCATCC TGCTCACCGA TGGCGGACCC  
851 ACTGTGGGGG AGACTAACCC CAGAGCATC CAGAATAACG TCGGGGAAGC  
901 TGTAAAGTGC CGGTACAGCC TCTTCTGCCT GGGCTTCGGT TTCGACGTCA  
951 GCTATGCTTT CCTGGAGAAG CTGGCACTGG ACAATGGCGG CTTGGCCCGG  
1001 CGATCTCATG AGGACTCAGA CTCTGCCCTG CAGCCTGGCAG GACTTCTTACC  
1051 AGGAAAGTGC CAACCCACTG CTGACAGCAG TGACCTTTGA GTACCCAAGC  
1101 AATGCCGTGG AGGAGTCACT TCAGAACAACT TTCCGGCTCC TCTTCAAGGG  
1151 CTCAGAGATG GTGGTGGCTG GGAAGCTCCA GGACCGGGGG CTTGATGTGC  
1201 TCACAGCCAC AGTCAGTGGG AAGCTGCCTA CACAGAACAT CACTTTCCAA  
1251 ACGGAGTCCA GTGTGGCAGA GCAGGAGGCG GAGTTCCAGA GCCCCAAGTA  
1301 TATCTTCCAC AACTTCATGG AGAGGCTCTG GGCATACCTG ACTATCCAGC  
1351 AGCTGCTGGA GCAAACCTGT TCCGCATCCG ATGCTGATCA GCAGGCCCTC  
1401 CGGAACCAAG CGCTGAATTT ATCAGTTGCC TACAGCTTTG TCACGCTCTT  
1451 CACATCTATG GTAGTACCA AACCCGATGA CCAAGAGCAG TCTCAAGTTG  
1501 CTGAGAAGCC CATGGAAGGC G  
!!AA SEQUENCE 1.0  
ID\_ADP30539 standard; protein; 637 AA.  
XX  
XX AC ADP30539;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #1306.  
XX  
XX Cytostatic; Antitumorigenic; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2537; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC competition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 637 AA;

ADP30539 Length: 637 February 22, 2005 12:25 Type: P Check: 4435 ..

1 GATATGGACC TTCTCAATT CCTGGCCCTTC CTCTTTGTCA CAAGAAGATG  
51 TTTGAGGTGA AGCGGGGGA GCAGCTGTTG GCACTGAAGA ACCTGGCACA  
101 GCTGAAGGAC ATCCACCAGC AGTACAGAT CCTTGATGTC ATGCTCAAGG  
151 GGCTCTTTAA GGTGCTGGAG GACTCCCGGA CAGTGTCTAC CGTGTCTGAT  
201 GTGCTCCAG ATGGGCCCTT CCCCAGGAC GAGAAGCTGA AGGATGCCTC  
251 TCGCCAGCTT TCTCCACGT GGTGAGAAC ACGGCTTCT TCGGGCATGT  
301 GGTGCTGGC TTCCGAGGA TTGTGACTA TTACTTTGAC CACAATCCA  
351 ACTGGAACCT CCTCATCCG TGGGTATCA GTTTCTGCA CCAGACAGGC  
401 GTCTTCAACC AGGGGCCCCA CTCGCCCATC CTCAGCCTGA TGGCCACGGA  
451 GCTGGGGATC AGTGAGAAG ACTCCAACTT CCAGAACCCA TTAAATCG  
501 ACCGCACAGA GTTCATTCC AGCACTGACC CTTTCCAGAA GGCCCTGAGA  
551 GAAGAAGAGA AACGCCGAAA GAAAGAGGAG AAGCGGAAG AGATCCGAAA  
601 AGGCCCAAGG ATCTCCAGAT CCCAGTCTGA GTTATAG

!!AA SEQUENCE 1.0

ID ADP30546 standard; protein; 922 AA.

XX AC ADP30546;

XX DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1313.

DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

XX cancer; inflammatory; immune; human secreted protein.

OS Homo sapiens.

PN WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

PR 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 17-SEP-2002; 2002US-0406666P.

PR 17-SEP-2002; 2002US-0410946P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.

PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2544; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPower and is not in the specification.  
XX  
XX Sequence 922 AA;  
ADP30546 Length: 922 February 22, 2005 12:25 Type: P Check: 7941 ..  
1 CCGACCTCG CCCCCGGGT GCGCGGGT CTGACGGT GCTCATGCTG

51 TCTGTGTGT GCCGCCAGC GTGCGGAGAG CTGCTCAGAT CTGAGCCAT  
101 GCGACGAGAG CAGTGGCCTC TACTGTGATC GCAGCGCGGA CCCAGCAAC  
151 CAGACTGGCA TCTGCACGGC GGTAGAGGGA GATACTGTG TGTTCGATGG  
201 GGTCTCTAC CGCAGTGGAG AGAAATTTCA GCCAAGCTGC AATTTCCAGT  
251 GCACCTGCAG AGATGGGCAG ATTGGCTGTG TGCCCCGCTG TCAGCTGGAT  
301 GTGCTACTGC CTGAGCCTAA CTGCCAGCT CCAAGAAAAG TTGAGGTGCC  
351 TGGAGAGTGC TGTGAAAAGT GGATCTGTGG CCAGATGAG GAGGATTCAC  
401 TGGGAGGCT TACCTTTCA GGAAGCCACC CTAGGAGTAG AAGTCTCTGA  
451 CTCGAAGTGC AACTGCATTG AACAGACCAC AGAGTGGACA GCATGCTCA  
501 AGAGCTGTGG TATGGGTTTCC TCCACCCGGG TCACCAATAG GAACGTCAC  
551 TGTGAGATCC TGAACACAGAC TCGGCTCTGC ATGGTGGGC CCTGTGAACA  
601 AGAGCCAGAG CAGCCAAACAG ATAAGAAAGG AAAAAAGTGT TTCCGCACCA  
651 AGAAGTCACT CAAAGCCATC CACCTGCAGT TCAAGAACTG CACACGCTG  
701 CACACTACA AGCCAGGTT CTGTGGGGTC TGCAGTGTG GCCGCTGTG  
751 CACTCCAC AATACAAA CCATCCAGGC AGAGTTTCAG TGCTCCCCAG  
801 GCGAAATAGT CAAGAAGCCA GTGATGCTCA TTGGGACCTG CACCTGTAC  
851 ACCAACTGTC CTAAGAACAA TGAGGCTTC CTCCAGGAGC TGGAGCTGAA  
901 GACTACCAGA GGGAAATGT AA  
!!IAA SEQUENCE 1.0  
ID \_ADP30665 standard; protein; 625 AA.  
XX  
XX AC ADP30665;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #1432.  
XX  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN WO2004035732-A2.  
XX  
XX FD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kochakota S, Haisan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX  
PS Claim 1; SEQ ID NO 2663; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present

CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 625 AA;  
ADP30665 Length: 625 February 22, 2005 12:25 Type: P Check: 9609 ..

1 ATGGCGCCCC GAACCTCTTT CCTGCTGTC TCGGGGCCCC TGACCCCTGAC  
51 CGAGACCTGG GCGGTTTTC ACACATGCA GTGTATGTAT GGCTGCGACG  
101 TGGGGCCCCG CGGGCGCTTC CTCTCGGGT ATGAACAGCA CGCCTACGAC  
151 GGCAAGGATT ACATCGTCT GAACGAGGAC CTGCGCTCCT GGACCCGGGC  
201 GGACATGGCA GCTCAGATCA CCAAGCGCAA GTGGAGGCG GCCCGTCGGG  
251 CGGAGCAGCG GAGAGTCTAC CTGGAGGGCG AGTTCTGTGA GTGGCTCCGC  
301 AGATACCTGG AGAACGGGAA GGAGACGCTG CAGCGCGCG CGGGATGGGG  
351 AGGACCAGAC CCACACAGG AGCTCGTGA GACCAGGCTT GCAGGGGATG  
401 GAACCTTCCA GAAGTGGGCG GCTGTGTGG TGCCTTCTGG AGAGGAGCAG  
451 AGATACACCT GCCATGTGCA GCATGAGGCT CTGCCAGAGC CCCTCACCTT  
501 GAGATGGGAG CCATCTTCCC AGCCACCATT CCCATCGTG GGCATCGTTG  
551 CTGGCCTGGT TCTACTGTGA GCTGTGTGTA CTGGAGCTGT GGTGCTGTCT  
601 GTAATGTGA GGAAGAAGAG CTCAG

!!AA SEQUENCE 1.0

ID ADP30736 standard; protein; 868 AA.

XX

AC ADP30736;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1503.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

PN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

PR 29-AUG-2002; 2002US-0406576P.

PR

PR 29-AUG-2002; 2002US-0406579P.

PR

PR 29-AUG-2002; 2002US-0406585P.

PR

PR 29-AUG-2002; 2002US-0406588P.

PR

PR 29-AUG-2002; 2002US-0406608P.

PR

PR 29-AUG-2002; 2002US-0406611P.

PR

PR 29-AUG-2002; 2002US-0406612P.

PR

PR 29-AUG-2002; 2002US-0406640P.

PR

PR 29-AUG-2002; 2002US-0406642P.

PR

PR 29-AUG-2002; 2002US-0406646P.

PR

PR 29-AUG-2002; 2002US-0406653P.

PR

PR 17-SEP-2002; 2002US-0406656P.

PR

PR 17-SEP-2002; 2002US-0410946P.

PR

PR 17-SEP-2002; 2002US-0410947P.

PR

PR 17-SEP-2002; 2002US-0410948P.

PR

PR 17-SEP-2002; 2002US-0410949P.

PR

PR 17-SEP-2002; 2002US-0410953P.

PR

PR 17-SEP-2002; 2002US-0410957P.

PR

```
PR 17-SEP-2002; 2002US-0410958P.
PR 17-SEP-2002; 2002US-0410959P.
PR 17-SEP-2002; 2002US-0410960P.
PR 17-SEP-2002; 2002US-0410961P.
PR 17-SEP-2002; 2002US-0410962P.
PR 17-SEP-2002; 2002US-0410963P.
PR 17-SEP-2002; 2002US-0411019P.
PR 17-SEP-2002; 2002US-0411022P.
PR 17-SEP-2002; 2002US-0411023P.
PR 17-SEP-2002; 2002US-0411024P.
PR 17-SEP-2002; 2002US-0411032P.
PR 17-SEP-2002; 2002US-0411035P.
PR 17-SEP-2002; 2002US-0411037P.
PR 17-SEP-2002; 2002US-0411041P.
PR 17-SEP-2002; 2002US-0411045P.
PR 17-SEP-2002; 2002US-0411046P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411052P.
PR 17-SEP-2002; 2002US-0411055P.
PR 17-SEP-2002; 2002US-0411073P.
PR 17-SEP-2002; 2002US-0411082P.
PR 17-SEP-2002; 2002US-0411101P.
PR 17-SEP-2002; 2002US-0411111P.
PR 18-APR-2003; 2003US-0463700P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 18-APR-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467230P.
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 14-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486448P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
PR 08-AUG-2003; 2003US-0493577P.
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Halshan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX WPI; 2004-348438/32.
XX New nucleic acid molecule for diagnosing, preventing or treating diseases
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
XX genetic, bacterial and viral diseases.
XX Claim 1; SEQ ID NO 2734; 428pp; English.
XX The present invention relates to an isolated nucleic acid molecule
XX encoding a polypeptide which is believed to be cytostatic,
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The
XX composition and methods are useful for diagnosing, preventing and
XX treating diseases such as proliferative (e.g. cancer), inflammatory,
XX immune, metabolic, genetic, bacterial and viral diseases. The present
XX sequence represents a human secreted protein. The present sequence is
XX available on WIPONEB and is not in the specification.
XX Sequence 868 AA;

ADP30736 Length: 868 February 22, 2005 12:25 Type: P Check: 1967
1 GCGGCCCTCT TGGCGATCTT CCGGCACCTC TGGGTCAGCA TTGCACCTAA
51 CTTCAGAG TACTGCCACA TCCGCCCTGG AGGCTCCAAG GATCCCCGGG
101 CCTATTTCAA GACCAAGACA TGGTGGCTGG GCCTGTTCTT GATGCTTCTG
151 GCGGAGCTGG GTGTGTTGCG CTCTAGGCC TTGCGCGCGC TGTCACTCAT
201 COTGCCCTTC AGCGAGTTT CTGTGATAG TAGTGCCATC ATAGGAATCA
251 TATTCATCAA GGAAGAGTGG AAACCCGAAAG ACTTCTTGAG GCGCTACGTC
301 TTGTCTTTTG TTGGCTGGG TTTGGCTGTC GTGGGTACCT ACCTGCTGGT
351 GACATTGCA CCCAACAGTC ACGAGAAGAT GACAGGCGAG AATGTCAACA
401 GGCACCTCGT GAGCTGGCCT TTCTTTTGT ACATGCTGGT GGAGATCATT
451 CTGTTCTGCT TGCTGCTCTA CTCTACAG GAGAAGACG CCAACAACAT
501 TGTCTGTGAT TTCTCTTTGG TGGCGTTACT TGGTCCATG ACAGTGGTGA
551 CAGTCAAGGC GTGGCTGGG ATGCTTGTCT TGTCCATTCA AGGGAACCTG
601 CAGCTTGACT ACCCATCTTT CTACGTGATG TTGCTGTGCA TGGTGGCAAC
651 GCGCGTCTAT CAGCTGGTGT ATCAGAACAA TGCACGATAA AGGGATGACT
701 GTCCAGCCTG AACTTAAAGC TTCTTTTTC TATGGGGCTC TGGAAAACAA
751 TGACAACATT TCTGAGATCT ACCTCTCTGC CACCTCTGCA GTCATGCAAG
801 AAGAGCACGG CTCAGAAAGT GCCTCTGGGG TCCCTTACCG AGTCTAGAG
851 CACACCAAGA AGGAATGA

!!AA SEQUENCE 1.0
ID ADP30765 standard; protein; 126 AA.
XX
XX AC ADP30765;
XX
XX DT 12-AUG-2004 (first entry)
XX
XX DE Human secreted protein SEQ ID #1532.
XX
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
XX cancer; inflammatory; immune; human secreted protein.
XX
XX OS Homo sapiens.
XX
XX PN WO2004035732-A2.
XX
XX PD 29-APR-2004.
XX
XX PF 28-AUG-2003; 2003WO-US026780.
XX
XX PR 29-AUG-2002; 2002US-0406576P.
XX PR 29-AUG-2002; 2002US-0406579P.
XX PR 29-AUG-2002; 2002US-0406585P.
XX PR 29-AUG-2002; 2002US-0406588P.
XX PR 29-AUG-2002; 2002US-0406608P.
XX PR 29-AUG-2002; 2002US-0406611P.
XX PR 29-AUG-2002; 2002US-0406612P.
XX PR 29-AUG-2002; 2002US-0406616P.
XX PR 29-AUG-2002; 2002US-0406640P.
XX PR 29-AUG-2002; 2002US-0406642P.
XX PR 29-AUG-2002; 2002US-0406646P.
XX PR 29-AUG-2002; 2002US-0406653P.
XX PR 29-AUG-2002; 2002US-0406655P.
XX PR 29-AUG-2002; 2002US-0406666P.
```

PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0471306P.  
PR 13-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2763; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and

CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX  
SQ Sequence 126 AA;

ADP30765 Length: 126 February 22, 2005 12:25 Type: P Check: 60 ..

1 ATGGTAGGCC CCAAGACAA AGACGAGAAG TACATGAAGA TGCCCAACAAG  
51 CAAAGTCAGGC CGTGCCATTC CTGTTGGTGT GGATGTGCAG GTGGAGAGTT  
101 TGCATAGCAT CTCAGAGGTT GACATG

!1AA\_SEQUENCE 1.0

ID ADP30789 standard; protein; 186 AA.

XX

AC ADP30789;

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1556.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

PN WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 29-AUG-2002; 2002US-0406666P.

PR 17-SEP-2002; 2002US-0410946P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.

PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.

PR 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411022P.

PR 17-SEP-2002; 2002US-0411023P.

PR 17-SEP-2002; 2002US-0411024P.

PR 17-SEP-2002; 2002US-0411032P.

PR 17-SEP-2002; 2002US-0411035P.

PR 17-SEP-2002; 2002US-0411037P.

PR 17-SEP-2002; 2002US-0411041P.

PR 17-SEP-2002; 2002US-0411045P.

PR 17-SEP-2002; 2002US-0411046P.

PR 17-SEP-2002; 2002US-0411048P.

PR 17-SEP-2002; 2002US-0411052P.

PR 17-SEP-2002; 2002US-0411055P.

PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-SEP-2002; 2002US-0463700P.  
PR 18-SEP-2002; 2002US-0463708P.  
PR 18-SEP-2002; 2002US-0463716P.  
PR 18-SEP-2002; 2002US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2787; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 186 AA;  
ADP30789 Length: 186 February 22, 2005 12:25 Type: P Check: 246 ..  
1 ATGGCTACAC TATCTATCC ACCTTTGGAG CTTTCTACAT CCGCTGCTG  
51 CTCATGCTGG TTCTCTATGG GGCATATTC CGAGCTGGCC GCTTCGCCAT  
101 CGCAAGACG GTCAAAAGG TGGAGAAGAC CGGAGCGGAC ACCGCCCATG  
151 GAGCATCTCC GCCTCCGCGAG CCCAAGAAGA GTGTGA  
IIAA SEQUENCE 1.0  
ID ADP30807 standard; protein; 369 AA.  
XX  
AC ADP30807;  
XX  
DT 12-AUG-2004 (first entry)  
XX

DE Human secreted protein SEQ ID #1574.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 08-JUL-2003; 2003US-0485325P.

```
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX
DR WPI; 2004-348438/32.
XX
PT New nucleic acid molecule for diagnosing, preventing or treating diseases
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PT genetic, bacterial and viral diseases.
XX
PS Claim 1; SEQ ID NO 2805; 428pp; English.
XX
CC The present invention relates to an isolated nucleic acid molecule
CC encoding a polypeptide which is believed to be cytostatic,
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
CC composition and methods are useful for diagnosing, preventing and
CC treating diseases such as proliferative (e.g. cancer), inflammatory,
CC immune, metabolic, genetic, bacterial and viral diseases. The present
CC sequence represents a human secreted protein. The present sequence is
CC available on WIPWEB and is not in the specification.
XX
SQ Sequence 369 AA;
ADP30807 Length: 369 February 22, 2005 12:25 Type: P Check: 4498 ..
1 ATGGGGGATG GGCCTGTGAC AGGAGTACC CTGGGTGCC TCCTTCGGCC
51 CCATGGAGTC CTCACCATC CCCAGTCAT CAGGAATCT TTCACCTTG
101 GGGAGGTCCT CTCAAACCC AGGTCCCTCT ACTGCCAGT GGGTCCCGGA
151 GGTGGGGCTA CGGGATGTTG CTTCGGAATC TGTGCCCTC TTCTTCATGC
201 TCCTGCTGGA CTTGACTGCT GTGGCTGGCA ATGCCGCTGT GATGGCGGTG
251 ATGCCCAAGA CGCCTGCCCT CGAAATTT GTCTTCGTCT TCCACCTCTG
301 CCTGGTGGAC CTGCTGGCTG CCCTGACCT CATGCCCTG GCCATGCTCT
351 CCAGCTCTGC CCTCTTTGA
!!AA SEQUENCE 1.0
ID ADP30896 standard; protein; 621 AA.
XX
AC ADP30896;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #1663.
XX
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW cancer; inflammatory; immune; human secreted protein.
XX
OS Homo sapiens.
XX
PN WO2004035732-A2.
XX
PD 29-APR-2004.
XX
PF 28-AUG-2003; 2003WO-US026780.
XX
PR 29-AUG-2002; 2002US-0406576P.
PR 29-AUG-2002; 2002US-0406579P.
PR 29-AUG-2002; 2002US-0406585P.
PR 29-AUG-2002; 2002US-0406588P.
PR 29-AUG-2002; 2002US-0406608P.
PR 29-AUG-2002; 2002US-0406611P.
PR 29-AUG-2002; 2002US-0406612P.
PR 29-AUG-2002; 2002US-0406616P.
PR 29-AUG-2002; 2002US-0406640P.
PR 29-AUG-2002; 2002US-0406642P.
PR 29-AUG-2002; 2002US-0406646P.
PR 29-AUG-2002; 2002US-0406653P.
PR 29-AUG-2002; 2002US-0406655P.
PR 29-AUG-2002; 2002US-0406666P.
PR 17-SEP-2002; 2002US-0410946P.
PR 17-SEP-2002; 2002US-0410947P.
PR 17-SEP-2002; 2002US-0410948P.
PR 17-SEP-2002; 2002US-0410949P.
PR 17-SEP-2002; 2002US-0410953P.
PR 17-SEP-2002; 2002US-0410957P.
PR 17-SEP-2002; 2002US-0410958P.
PR 17-SEP-2002; 2002US-0410959P.
PR 17-SEP-2002; 2002US-0410960P.
PR 17-SEP-2002; 2002US-0410961P.
PR 17-SEP-2002; 2002US-0410962P.
PR 17-SEP-2002; 2002US-0411019P.
PR 17-SEP-2002; 2002US-0411022P.
PR 17-SEP-2002; 2002US-0411023P.
PR 17-SEP-2002; 2002US-0411024P.
PR 17-SEP-2002; 2002US-0411032P.
PR 17-SEP-2002; 2002US-0411035P.
PR 17-SEP-2002; 2002US-0411037P.
PR 17-SEP-2002; 2002US-0411041P.
PR 17-SEP-2002; 2002US-0411045P.
PR 17-SEP-2002; 2002US-0411046P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411052P.
PR 17-SEP-2002; 2002US-0411055P.
PR 17-SEP-2002; 2002US-0411073P.
PR 17-SEP-2002; 2002US-0411082P.
PR 17-SEP-2002; 2002US-0411101P.
PR 17-SEP-2002; 2002US-0411111P.
PR 18-APR-2003; 2003US-0463700P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 18-APR-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467230P.
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
PA
XX
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
PI
```



XX WPI; 2004-348438/32.  
 XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
 PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
 PT genetic, bacterial and viral diseases.  
 XX Claim 1; SEQ ID NO 2894; 428pp; English.  
 XX The present invention relates to an isolated nucleic acid molecule  
 CC encoding a polypeptide which is believed to be cytostatic,  
 CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
 CC composition and methods are useful for diagnosing, preventing and  
 CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
 CC immune, metabolic, genetic, bacterial and viral diseases. The present  
 CC sequence represents a human secreted protein. The present sequence is  
 CC available on WIPOWEB and is not in the specification.  
 XX Sequence 621 AA;  
 SQ

ADP30896 Length: 621 February 22, 2005 12:25 Type: P Check: 8077 ..

1 ATGAGCAGTG GGACTGGAG AGAGCCCATC AATTCCTTCT GGTGGAGCT  
 51 GATGGTGCCT TCAATTTTG TTTCTGCTTC AGATGAATTA AAAAACAATA  
 101 CCGTGTGTGA AGACAAGGAG CTGAAACTGC ACTGCCATGA ATCCAAAGTTC  
 151 CTCACATCT ACTCTGTGAC ATATGGCAGG AGGACCCAGG AAAGGACAT  
 201 CTGCTCTCC AAGCCAGAGC GGCTCCCGCC TTTTCGGCAA AAGGTGTCCA  
 251 ATCTCTACAG ACCACAGAA TCTAATGGAT GTCTCTATAT TCCTCTCTCT  
 301 AGAACACAG AGGATCCAGA ACGCAGCG GTCTCACTG GCCTGTCTCT  
 351 GTCCATGTGC CTGGTCAAG TGCTGGGAA GTGTCTCATC ATGTTGGCCT  
 401 TCAGCCCTGA CTCCACCTC CACACCCACA TGTACTTCTT CCTCTCCAAC  
 451 CTGTCTTGC CTGACATCAG TTTCACTCC ACCATTGTCC CCAAGATGAT  
 501 TGTGGACATC CAGTCTACA GCAGATGAT CTCCTATGCA GGCCGCCCTGA  
 551 CTCAGATGTC TCTCTTGGC ATTTTGGAG GCATGGAAGA CAGAAATGCT  
 601 CTGAGTGTG ATGGCCTATG A

!!AA SEQUENCE 1.0  
 ID ADF30904 standard; protein; 1464 AA.  
 XX  
 AC ADF30904;  
 XX  
 DT 12-AUG-2004 (first entry)  
 XX  
 DE Human secreted protein SEQ ID #1671.  
 XX  
 KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
 KW cancer; inflammatory; immune; human secreted protein.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2004035732-A2.  
 XX  
 PD 29-APR-2004.  
 XX  
 PF 28-AUG-2003; 2003WO-US026780.  
 XX  
 PR 29-AUG-2002; 2002US-0406576P.  
 PR 29-AUG-2002; 2002US-0406579P.  
 PR 29-AUG-2002; 2002US-0406585P.  
 PR 29-AUG-2002; 2002US-0406588P.  
 PR 29-AUG-2002; 2002US-0406608P.  
 PR

(FIVE-) FIVE PRIME THERAPEUTICS INC.  
 Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
 Hallenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
 Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
 WPI; 2004-348438/32.  
 New nucleic acid molecule for diagnosing, preventing or treating diseases

PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2902; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX SQ Sequence 1464 AA;

ADP30904 Length: 1464 February 22, 2005 12:25 Type: P Check: 1579 ..

1 ATGAACGTGG GAATCCAGAT GTCTCTCTCA GATCGTGATT TTATTACCTT  
51 TGAATATATG CCCAACAGAG GCAATTGTTGG ATCTTATGAC ACAGCCGCTG  
101 TCGCTGCCAT GTGGCGCGCC CGAGACTCCC GAGAACAGCC CTGGCTGTCA  
151 GCGGGCACCA GCCGCTTCCT GTGCCATCG CGTAGCTGG AGGGGGCGAC  
201 CACGGCCACC GAGCCAGAGG CGCTTCAGGA AGCAAGAGAA GTCCCGCGCG  
251 GCTCCGGGAC CCGCGCGCAG TCATGGAGCA ACGGCACCGC GTACCCCGGG  
301 CAGTTAGGCG TGTTACCAGCA GCTGGCGCAG GGAATGCGG TGGGGGGCTC  
351 GGCGGGGGCA CCGCCACTGG GCGCCGTGCA GGTGTTACC GCTGCGCTGC  
401 TGGCCCTACT CATCATCTGG ACCTTGCTGG GCAACGTGCT GGTGTCCGCA  
451 GCCATCTGTC GGAGCGGCCA CTGCGCGGCC AAGATGACCA ACGTCTTCAT  
501 CGTGCTCTTA CTGTGTFCAG ACCTCTTGGT GGCGTGCTGT GTCATGTCTT  
551 GGAAGGCAGT CGCCGAGGTG GCGGGTTACT GCGCCCTTGA AGCGTTCTGC  
601 GACGCTGGG TGGCCCTTGA CATCATGTGC TCCACCGCT CCATCCTGAA  
651 CCTGTGCTC ATCAGCGTGG CCGGCTACTG GGCCATCTCC AGGCCCTTCC  
701 GCTACGAGCG CAAGATGACC CAGCGCATGG CCTTGTCTAT GGAGGCGGTT  
751 TGGGAGCCCG ACGTGAGGCG AGAGAACTGT GACTCCAGCC TGAATCGAAC  
801 CTACGCCATC TCTTCTTCGC TCATCAGTTC CTACATCCCC ATGGCCATCA  
851 TGATCGTGAC CTACACGCGC ATCTACCGCA TCGCCCAAGT GCAGATCCGC  
901 AGGATTTCTT CCCTGGAGAG GCGCGCAGAG CACGTGCAGA GCTGCGGAG  
951 CAGCGCAGGC TGGCGGCCCC ACACAGCCTT GCGGTTTTCC ATCAAGAAGG  
1001 AGACCGAGGT TCTCAAGACC CTGTGCGTGA TCATGGGGGT CTTGTTGTGT  
1051 TGCTGGCTGC CCTTCTTCAT CCTTAACTGC ATGGTCCCTT TCTGCAGTGG  
1101 ACACCCCAAA GGGCCTCCGG CCGGCTTCCC CTGCGTTCAGT GAGACCAAT  
1151 TCGACGTCTT CATCTGTTCAC TATGCTTCA ACGCCGACTT CCGGAAGGTG  
1201 TTTGCCCAGC TGCTGGGGTG CAGCCAGCTG TGCTCCCGCA CGCGGTGGA  
1251 GACGATGAAC ATCAGCAATG AGCTATCTC CTACAACAA GACACGGTCT  
1301 TCCACAAGGA AATCGCAGCT GCGTACATCC ACATGATGCC CAAGCGCGTT  
1351 CCCCCCGGG ACCGGGAGGT GGACRACGAT GAGGAGAGG AGAGTCCTTT

1401 CGATCGCATG TCCAGATCT ATCAGACATC CCCAGATGGT GACCCGTGTTG

1451 CAGAGTCTGT CTGA

!!AA SEQUENCE 1.0

ID\_ADP30915 standard; protein; 779 AA.

XX ADP30915;

XX DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1682.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

XX cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 29-AUG-2002; 2002US-0406666P.

XX 17-SEP-2002; 2002US-0410946P.

XX 17-SEP-2002; 2002US-0410947P.

XX 17-SEP-2002; 2002US-0410948P.

XX 17-SEP-2002; 2002US-0410949P.

XX 17-SEP-2002; 2002US-0410953P.

XX 17-SEP-2002; 2002US-0410957P.

XX 17-SEP-2002; 2002US-0410958P.

XX 17-SEP-2002; 2002US-0410959P.

XX 17-SEP-2002; 2002US-0410960P.

XX 17-SEP-2002; 2002US-0410961P.

XX 17-SEP-2002; 2002US-0410962P.

XX 17-SEP-2002; 2002US-0411019P.

XX 17-SEP-2002; 2002US-0411022P.

XX 17-SEP-2002; 2002US-0411023P.

XX 17-SEP-2002; 2002US-0411024P.

XX 17-SEP-2002; 2002US-0411032P.

XX 17-SEP-2002; 2002US-0411035P.

XX 17-SEP-2002; 2002US-0411037P.

XX 17-SEP-2002; 2002US-0411041P.

XX 17-SEP-2002; 2002US-0411045P.

XX 17-SEP-2002; 2002US-0411046P.

XX 17-SEP-2002; 2002US-0411048P.

XX 17-SEP-2002; 2002US-0411052P.

XX 17-SEP-2002; 2002US-0411055P.

XX 17-SEP-2002; 2002US-0411073P.

XX 17-SEP-2002; 2002US-0411082P.

XX 17-SEP-2002; 2002US-0411101P.

XX 18-APR-2003; 2003US-0411111P.

XX 18-APR-2003; 2003US-0463700P.

XX 18-APR-2003; 2003US-0463708P.

XX 18-APR-2003; 2003US-0463716P.

XX 02-MAY-2003; 2003US-0467199P.

XX 02-MAY-2003; 2003US-0467201P.

PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2913; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 779 AA;  
ADP30915 Length: 779 February 22, 2005 12:25 Type: P Check: 1091 ..  
1 AAGCTGGTGA CACCTGTGAG AAGCTGGTGG GATATTCTGC CGTGATATAGA  
51 GTCGTGTTTG GAATGGCTTG TTCTTCTTT ATCTTCTGTC TACTGACCTT  
101 GAAATCAAC AACAGCAAA GTTGTAGAGC TCATATTAC AATGGCTTTT  
151 GGTCTTTAA ACTTCTGCTG TTGGGGGCCA TGTGCTCAGG AGCTTTCTTC  
201 ATTCCAGATC AGGACACCTT TCTGAACGCC TGGCGCTATG TGGGAGCCGT  
251 CGGAGGCTTC CTCCTTCATTG GCATCCAGCT CCTCTGCTC GTGGAGTTTG  
301 CACATAAGTG GAACAAGAAC TGGACAGCAG GCACAGCCAG TAACAAGCTG  
351 TGGTACGCTT CCCTGGCCCT GGTGAGCCTC ATCATGTATT CCATTGCCAC  
401 TGGAGGCTTG GTTTGTATGG CAGTGTTTAA TACACAGAA GACAGCTGCA  
451 TGGAAACAA AATTCTGCTG GAGTAAGT GAGGCCTGTG CCTGTTTATA  
501 TCATTGGTAG CCATCTCACC CTGGGTCCAA AATCGACAGC CACACTCGGG  
551 GCTCTTACA TCAGGGGTCA TAAGCTGCTA TGTACCTTAC CTCACCTTCT  
601 CAGCTCTGTC CAGCAACCT GCAGAGTAG ACATGAGTAG GCAGAGCCG

651 GGAAGGAGG GACCACGGGT CATTTATGAC GAGAAGAAAG GCACCGTCTA  
701 CATCTACTCC TACTTCCACT TCGTGTTCTT CCTAGCTTCC CTGTATGTGA  
751 TGATGACCGT CACCAACTGG TTCAAGTGA  
!!AA SEQUENCE 1.0  
ID ADP30934 standard; protein; 1082 AA.  
XX  
AC ADP30934;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1701.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410982P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.

PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2932; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1082 AA;  
ADP30934 Length: 1082 February 22, 2005 12:25 Type: P Check: 7970 ..  
1 CCCCCAGCAG GCCCCTGAGG GAGGAGCTG TCAGCCAGGG AAAACCGAGA  
51 ACACCATCAC CATGACAACC AGTCACCAGC CTCAGGACAG GTAAGGGCTG  
101 TCTGGCTTAT CTTCTTCATG CTGGGTCCTG GAACGCTGCT CCGTGGGAAT  
151 TTTTTCATGA CGGCCACTCA GTCTCTCAGT GCCATCTTCA ACAATGTCAAT  
201 GACCCTATGT GCCATGTGTC CCGTGTGTTT ATTCACCTAC CTCAACTCCT  
251 TCCTGCATCA GAGGATCCCC CAGTCGGTAC GGATCCTGGG CAGCCTGGTG  
301 GCCATCCTGC TGGTGTCTTCT GATCACTGCC ATCTCTGGTGA AGGTGAGCT  
351 GGATGCTCTG CCCTCTCTTG TCATCACCAT GATCAAGATC GTGCTCATTA  
401 ATTCATTGG TGCCATCCTG CAGGCGAGCC TGGTTGGTCT GGCTGGCCTT  
451 CTGCTCGCCA GCTACAGGC CCCCATCATG AGTGCCAGG GCTAGCAGG  
501 CTTCTTTGCC TCCGTGGCCA TGATCTGGC TATTGCCAGT GGCTCGGAGC  
551 TATCAGAAAG TGCCTTCGGC TACTTTATCA CAGCTGTGTC TGTATTCATT

601 TTGACCATCA TCTGTTACCT GGGCTGCCC CGCTTGAAT TCTACCGCTA  
651 CTACCAAGCAG CTCAGCTTG AGGACCCGG GGAGCAGGAG ACCAAGTTGG  
701 ACCTCATTAG AGAGGAGCCA AGAGCAGGCA AAGAGGAATC TGGAGTTTCA  
751 GTCTCCAACCT CTCAGCCAC CAATGAAAGC CACTCTATCA AAGCCATCCT  
801 GAAAAATATC TCAGTCCTGG CTTTCTCTGT CTGCTTCATC TTCACTATCA  
851 CCATTGGGAT GTTCCAGCC GTGACTGTTG AGGTCAAGTC CAGCATCGCA  
901 GGCAGCAGCA CCTGGGAACG TTACTTCATT CCTGTGTCTT GTTTCCTGAC  
951 TTTCAATATC TTTGACTGTT TGGGCGGAG CCTCACAGCT GTATTCTATG  
1001 GGGCCTGGTT CATCTTCTTC ATGGCTGCTT TTGCCTTCTC CAACGGCTAC  
1051 CTCGCCAGCC TCTGCATGTG CTTGGGGCCC AA  
!!AA SEQUENCE 1.0  
ID ADP30958 standard; protein; 885 AA.  
XX  
XX ADP30958;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1725.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.

PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2956; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 885 AA;  
ADP30958 Length: 885 February 22, 2005 12:25 Type: P Check: 9291 ..  
1 ATGCTGGGCG TCATGTGGCT CTGTGTCTG GGGACTGGCG TGGGTGGCG  
51 TGTGGCGGTC CACATCTTCT CGGAGTTTCAT GATGCAGAAAT CGGAGGCTG  
101 CTGGCCAGGA GCCCGCGCTG CTGCTCTGCG CTCTGTGTGT CGGCCCTCTC  
151 AACCTGGGGG GCCCTACCC GTGCCTTGGC CTGACCGCCC TGGAGCTGCA  
201 TGACTCCCGG GTGCTGGAGT TGTACGTGGC CATCTGCAGG AACCTTCATCC

251 TCAAGCTGGC CATCTGGG ACATGTGCT ACCACTGGCA GGGCCGCGAGG  
301 GTGGGCGCCC TCGAGGGCCA GTGCTGGGAG GAACCCGTCG TGTATGGGTT  
351 CTGTGTGATG GACTGCTCCT CACATCATCA AGCTGTGTCT CBTCTTCTAC  
401 GTCAAGTAGA CCAGCCTTTT GGCCAACTGC CAGGCACTGC TCCGGGCTTG  
451 GCTGGGCTCC CACCATCTG CGGCCCTTC CGGACCTTGG ACACCATGTA  
501 CGAGGCCCGC AGGATGTGGG TGCCCCAACT GGAGGCAGCG GGGCCGCGAGG  
551 GCTCTGTGCT GCCCTGGGCG CACCGTACC TGGTGGAAA CACCTTCTTC  
601 GTCTTCTG TGTTGGCCCT GCTGCTGGCT GTGATCTACC TCAACATCCA  
651 GTGTGTGCTG GACCAAGGA AGTTCATCTG CTGTCTCAAG GACAGATCA  
701 GCAACGAGGG GGAAGACAAA ATCTTCTTAA TCAACAAGCT TCACCTCCATC  
751 TACAGAAGA AGGAGAGGGA GGAGAGGAGC AGGTTGGGA CAACCCAGGA  
801 GGCTGCGCA CCCCTGCCC TGCTCAGAGC AACGGGATGC CTAGGGGGCC  
851 GGCATGTGGC CTCGAGGCC CGCCAGCGC CCTGA  
IIAA SEQUENCE 1.0  
ID ADP30965 standard; protein; 1147 AA.  
XX  
AC ADP30965;  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1732.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX  
PS Claim 1; SEQ ID NO 2963; 428pp; English.  
XX  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1147 AA;  
ADP30965 Length: 1147 February 22, 2005 12:25 Type: P Check: 6768 ..  
1 TTCCAATATG GAGGTGAAGA ACTTTGCACT TTGGGATTTAT GTTGTATTG  
51 CAGCCCTCTT TTTCAATTC TCTGGAATG GGGTGTCTT TGCCATTAA

101 GAGAGAAAA AGGCAACTTC CCGAGAGTTC CTGTTGGGG GAAGGCAAAAT  
151 GAGCTTTGGC CTTGTGGGT TGTCTTGAC AGCAGCTTC ATGTAGCTG  
201 TCACGGTCTT GGGGACCCCT TCTGAAGTCT ACCGCTTTGG GGCATCCTTC  
251 CTAGTCTTCT TCATTGCTTA CCTATTTGTC ATCCTCTTAA CATCAGAGCT  
301 CTTTCTCCCT GTGTCTTACA GATCTGGTAT CACCAGCACT TATGAGTACT  
351 TACAACCTACG ATTCAACAAA CAGTTTCGCT ATGCTGCCAC GGTCACTTAC  
401 ATTGTACAGA CGCTCTGTCT TTGCAACAGG AATTGTTTGC ACATTCTACT  
451 GTACCCCTGT TTGATGTAGA TCCTCTCAGG CGACACACTT TTTGGACTAT  
501 CACAGTGGGA GGAACCTTTTA CTTGGCTCGG AATCTATGGG GTCAATCAAT  
551 CAACTATTCA GCGATGCATC TCTTGCAAAA CAGAAAGCA TGCTAAGCTT  
601 GCCTTGATTT TTAACCTGCT GGGTCTCTGG ATCATTTCTGG TGTGTGCTGT  
651 CTTCTCTGGC TTAATCATGT ACTCTCACTT TAAAGACTGT GACCCTTGG  
701 CTTCTGGCAT CATCTCAGCA CCAGACCAGC TGATGCCGTA CTTTGTCAATG  
751 GAGATATTTG CCACAAATGCC AGGACTGCCA GGACTTTTGG TGGCTTGTGC  
801 CTTCACTGGA ACTCTGAGCA CCGTGGCTTC CAGCATCAAT GCCTTGGCAA  
851 CAGTGACCTT TGAGGATTTT GTCAGAGCT GTTTTCTCTCA TCTCTCGAC  
901 AAGCTGAGCA CTTGGATCAG TAAAGGCTTA TGGTGCACATA GGAGGTCTTC  
951 TTACTTGAAT CACCTTGTCA TTTTGGGTGG CCATTGGGGC CTTCAATTTAC  
1001 CCTGCACCAG CCTCTAAGAC ATGGCCTTTG CCTCTGTCAA CAGACCAATG  
1051 TATCAAATCA AATGTGACAG CAACAGGGCC TCCAGTACTA TCACGAGGT  
1101 ATGCTGACTT TATAGATGCT GCTAAGTCCC AGAGAGTGGG TCACCTG  
!!AA SEQUENCE 1.0  
ID ADP30974 standard; protein; 2148 AA.  
XX  
XX AC ADP30974;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #1741.  
XX  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2972; 428pp; English.

CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX Sequence 2148 AA;

ADP30974 Length: 2148 February 22, 2005 12:25 Type: P Check: 9207 ..

1 TCGTGTGTTG CCACCCATTG ATGTCAAGAT GACTAAGTTT GGATTTTGGC  
51 GATTGTCCTA TGAGAGCAG GACACACTTT TGAAGCTTCT CATTCTGTCA  
101 ATGGCTGTG TATTATCCTT CTCACATCGT CTGTTTGGTG TCCTGAGATT  
151 TGAAGATGTT ATCCATGAGT TTGATCCGTA CTTTAATTAT CGGACTACCA  
201 GGTTCCTGGC TGAGGAGGGG TTTTATAAAT TCCATAACTG GTTTGATGAC  
251 CGAGCCTGGT ACCCTTTGGG AGAATCAATT GGAGGAACAA TTACCCAGG  
301 TTTAATGATC ACCTCTGCTG CAATCTACCA TGTACTCCAT TTTTTCACCA  
351 TCACCATCGA CATTGGGAAT GTCTGTGTGT TCCTGGCCCC TCTCTTCTCC  
401 TCCTTCACCA CCATCGTCAC GTACCACCTT ACCAAGAGC TCAAGGATGC  
451 AGGGGCTGGG CTTCCTGTCTG CTGCCATGAT TGCTGTAGTT CCTGGATATA  
501 TCTCCCGATC TGTGGCTGGC TCCTATGATA ATGAAGGGAT TGCCATCTTT  
551 TGCATGCTAC TCACCTACTA CATGTGGATC AAGGCAGTAA AGACTGGTTC  
601 CATCTGTTGG GCAGCTAAGT GTGCCCTTGC TTAATTTTAC ATGGTCTCGT  
651 CATGGGGAGG TTATGTGTTT CTGATCAACT TAATTCCTCT CCACGTCCTC  
701 GTGCTGATGC TCACAGGCCG TTTCTCTCAC CGGATCTATG TGGCCTACTG  
751 TACTGTTTAC TGCCTGGGCA CTATACTTTC TATGAGATC TCCTTTGTGG  
801 GTTTCAGCC TGTCTTTCA TCAGAGACA TGGCAGCCTT TGGGCTCTTT  
851 GGTCTCTGCC AGATCCATGC CTTTGTGGAT TACCTGGGCA GCAAGTTGAA  
901 TCCACAACAA TTTGAAGTTC TTTTCCGGAG CGTCATCTCT CTGGTAGGCT  
951 TTGTCCTTCT CACCGTGGGA GCTCTCTCTA TGCTGACAGA GGAATAATAT  
1001 CTCCTGGAC GGGCGGTTTC TACTCGCTGC TGGATCCCTC TTATGCTAAG  
1051 AACACATCC CCATCAATGC TTTCTGTCTT GAGCATCAGC CCACAACCTG  
1101 GTCCTCATAC TATTTTGACC TGCAGCTCCT CGTCTTCATG TTTCCAGTTG  
1151 GCCTCTATTA CTGCTTTAGC AACCTGTCTG ATGCCCGGAT TTTTATCATC  
1201 ATGTATGTTG TGACCGCAT GTACTTTTCA GCTGTAATGG TGCCTCTAAT  
1251 GCTAGTGTG GCACCTGTTA TGTGCATTCT CTCTGGCATT GGAGTCTCCC  
1301 AGGTGCTGTC CACATCATG AAGAATCTGG ACATAAGTGG TCCAGACAA  
1351 AAGAGCAAGA AGCAACAGGA TTCCACCTAC CCTATTAAGA ATGAAGTGGC  
1401 AAGTGGGATG ATACTGGTCA TGGCTTTCTT TCTCATCACC TACACCTTTC  
1451 ATTCAACCTG GGTGACCAGT GAGGCTCTACT CTCTCCGTC CATTGTACTA

1501 TCTGCCCGTG GTGGGGATGG CAGTAGGATC ATATTGTGAT ACTTCCGAGA  
1551 AGCATATTAT TGGCTTCGTC ATAATACTCC AGAGGATGCG AAGGTATGTT  
1601 CCTGGTGGGA TTATGGCTAT CAGATTACAG CTATGGCAAA CCGAACAAAT  
1651 TTAGTGGACA ATAACACATG GAATAATACC CATATTCTC GACTAGGGCA  
1701 GCGAATGGCG TCCACAGAGG AAAAGCCTA TGAGATCATG AGGAGGTCG  
1751 ATGTCAGCTA TGTGCTGGTC ATTTTGGAG GCCTCACTGG GTATTCTCT  
1801 GATGATATCA ACAAGTTTCT TTGGATGGTC CGGATTGGAG GGAGCACAGA  
1851 TACAGGCAAA CATATCAAGG AGAATGACTA TTATACTCCA ACTGGGGAGT  
1901 TCCGTGTGGA CCGTGAAGGT TCTCCAGTGC TGCTCAACTG CCTCATGTAC  
1951 AAGATGTGTT ACTATCGCTT TGGACAGGTT TACACAGAG CCAAGCGTCC  
2001 TCCAGGCTTT GACCGTGTCC GAAATGCTGA GATTGGGAAT AAAGACTTTG  
2051 AGCTTGATGT CTGAGAGGAA GCAATATACCA CAGAACAATTG GCTGTCAGG  
2101 ATATACAAGG TAAAGGACCT GGATATCGA GGCTTGTCAA GGACATAA  
!!AA SEQUENCE 1.0  
ID\_ADP30990 standard; protein; 759 AA.  
XX AC ADP30990;  
XX XX  
XX DT 12-AUG-2004 (first entry)  
XX DE  
XX DE Human secreted protein SEQ ID #1757.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX XX  
XX PN WO2004035732-A2.  
XX XX  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.

17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2988; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX CC composition and methods are useful for diagnosing, preventing and  
XX CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX CC immune, metabolic, genetic, bacterial and viral diseases. The present  
XX CC sequence represents a human secreted protein. The present sequence is  
XX CC available on WIPWEB and is not in the specification.  
XX Sequence 759 AA;  
ADP30990 Length: 759 February 22, 2005 12:25 Type: P Check: 3599 ..

1 ATGGGCAATG CCTCCATGA CTCCAGTCT GAGGACTGCG AGACGGGACA

51 GTGGCTTCCC CCAGGCGAAA GCCCAGCCAT CAGCTCCGTC ATGTTCTCGG



101 CCGGGGTGCT GGGGAACCTC ATAGCACTGG CGTGTCTGGC GCGCCCGCTGG  
151 CCGGGGGACG TGGGGTGCAG CCGCGCGCG AGGAGCTCCC TCCTCTGTGT  
201 CCAGCTGCTG GTGACCGAGC TGGTGTTCAC CGACCTGCTC GGGACCTGCC  
251 TCATCAGCCC AGTGTACTAG GCTTCGTACG CGCGGAACCA GACCTCTGGTG  
301 GCACTGGCGC CCGAGAGCCG CGCGTGCACC TACTTCGCTT TCGCCATGAC  
351 CTCTTTCAGC CTGGCCACGA TGCTCATGCT CTTGCGCCATG GCGCTGGAGC  
401 GCTACCTCTC GATCGGGCAC CCCTACTTCT ACAGCGCCCG CGTCTCGCGC  
451 TCCGGGGGCC TGGCCGTGCT GCCTGTATC TATGCACTCT CCCTGCTCTT  
501 CTGCTCGCTG CCGCTGCTGG ACTATGGGCA GTAGCTCCAG TACTGCCCCG  
551 GGACCTGGTG CTTATCCGG CACGGGGCGA CCGTTTACCT GCAGCTGTAC  
601 GCCACCTCTG TGCTGCTTCT CATTTGCTCG GTGCTCGCCT GCAACTTCAG  
651 TGTCTATCTC AACCTCATCC GCATGCACCG CCGAGGCCGG AGNAGCCGCT  
701 GCGGACCTTC CCTGGGCACT GGCCGGGGCG GCGCCGGGGC CCGCAGGAGA  
751 GGGGAAGG

!!AA SEQUENCE 1.0  
ID ADP31056 standard; protein; 2020 AA.

XX AC ADP31056;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1823.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX LW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

PS Claim 1; SEQ ID NO 3054; 428pp; English.

CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMED and is not in the specification.

XX SQ Sequence 2020 AA;

ADP31056 Length: 2020 February 22, 2005 12:25 Type: P Check: 8276 ..

1 AGTGCAATTT TATCTGTGTGTTTGAATATAT GGACCATGAT CTGATGGGAC

51 TACTGGAATC AGGCTTGGTT CATTTTAATG AAAATCACAT AAAGTCATTT  
101 ATGAGACAGC TCATGGAGGG TCTGGATTAT TGTCAATAGA AGAATTTTTT  
151 GCATAGAGAT ATTAATATGTT CCAATATCCT TCTAAATAAT AGAGGGCAGA  
201 TAAACATTGC AGACTTTTGA CTTCGCTCGAT TGTATAGCTC AGAAGAAAGG  
251 CTTAGCCGAA TATGTGGGAG TCCATGTCTCT GCAGTGTGGC CTGATGTAAT  
301 CAARACTACCA TATTTCAACA CCAATGAAACC AAAGAAGCAA TATCGTCGAA  
351 AGTTAAGAGA AGAATTTGTT TTTATTCTTG CAGCTGCGCT AGACTTATTT  
401 GATTACATGC TTGCTTTTGA TCTTAGTAAAG CGTGGCACTG CTGAACAGGC  
451 TCTTCAGTGC GAGTTCCTCC GAGATGTGGA ACCCTCAAAA ATGCCTCCAC  
501 CAGATCTCCC TTTTATGGCAA GATTGTCTATG AGTTATGGAG TAAAAAGCGA  
551 AGAAGACAGA AGCAGATGGG GATGACTGAT GATGTTTCCA CAATTAAGC  
601 CCCAGGAAG GACTTGTCTC TGGGCTTGGG TGACAGCAGA ACCAACACAC  
651 CCCAGGGTGT GCTGCCATCT TCACAGCTGA AATCTCAGG CAGCTCAAAT  
701 GTGGCAGCTG TAAAAACAGG CCTGGACAG CACTTAAACC ACAGTGAAT  
751 GGCAATTCTA CTTAACTTAC TACAATCTAA AACAAAGTGT AATATGGCTG  
801 ATTTTGTCCA AGTGTGTAAC ATTAAGGTAA ACTCTGAGAC TCAACAGCAG  
851 CTAATAAATA TAAACCTTCC TGCTGGAAT TTGGAACAG GTGAAAAACA  
901 GACAGATCCA TCAACACCAC AACAGGAGTC TTCGAAACCG TTGGGAGGAA  
951 TTCAGCCTTC TTCTCAGACC ATCCAGCCTA AAGTGGAGAC TGATGCTGCC  
1001 CAGCGCGCTG TGCAGAGTGC ATTTGAGTGT CTGTTGACTC AGTTAATAAA  
1051 GGCTCAGCAG TCAAAGCAGA AAGATGTGCT ACTAGNAGAG AGGGAATAATG  
1101 GATCGGGACA TGAAGCGTCA TTACAACCTA GGCACCTCC AGAACCTAGC  
1151 ACTCCGGTGT CGGGTAAGTG ACAAGATGAC CTCATCCAGC ATCAAGATAT  
1201 GAGGATCTTG GAGCTAACGC CAGAACCCAGA CCGGCCTCGA ATTCTGCCTC  
1251 CTGACCAACG ACCTCCCGAG CCTCCTGAA CACCACCAGT CACTGAGGAA  
1301 GATCTAGATT ATCGGACAGA AAACAGCAGT GTACCCACCA CAGTTCTTTC  
1351 ATTAACGTAC CCTCATGCCG GAGTGAAGGC AGCCCTGTGA CAGCTGCTTG  
1401 CTCAGCATCA GCCCCAGGAT GACCCCAAAA GAGAAGGTGG GATTGATTAT  
1451 CAACGAGAG ACATTACGT GTCCACTTCA GACTACAGG ACACTTTGG  
1501 ATCCTCTTCT TTCTCTTCTG CTCCTTATGT TAGCAATGAT GGTCTAGGAA  
1551 GCAGTTCTGC TCCACCACTA GAACGACGTA GTTTCATTGG AAATTCAGAT  
1601 ATTCAGTCTT TGGAATACTA CAGTACTGCT TCATCTCAT TCTGGTGTCC  
1651 ACCTCAGCCT CTCGCTTTT CTGAGTCAAT TCCCAGTTCA GTAGCTGGAT  
1701 ATGGAGACAT TTACCTCAAT GCTGTGCCA TGTGTGTTAG TGGAGACAAG  
1751 GACCATAGAT TTGAATATAG CCATGGTCTCT ATTGAGTCC TGGCAACAG  
1801 CAGTGACCCCT TCCACGGGGC CAGAGAGTAC TCATCTCTTG CCAGCAAGA  
1851 TGCACAACCTA TAACTATGGT GGTAACCTTAC AGGAATAATCC GAGTGGCCCC

1901 AGCCTCATGC ATGGACAGAC CTGGACTTCT CTGCCCCAAG GACCTGGATA  
1951 TTCACAAGGA TACAGGGGAC ATATTAGCAC ATCAACTGGC AGAGGCAGAG  
2001 GCAGAGGGTT ACCATACTGA  
11AA\_SEQUENCE 1.0  
ID ADP31089 standard; protein; 457 AA.  
XX  
AC ADP31089;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1856.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.

PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3087; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 457 AA;

ADP31089 Length: 457 February 22, 2005 12:25 Type: P Check: 2900 ..  
1 GGACACACTG CGGGATCGTG GCTCTGCGGT GGATGCAGCC ATTGCAGCCC  
51 TGTGTGTGT GGGGCTCATG AATGCCACA GCATGAGCAT CGGGGGAGGG  
101 CTGTCACTGG CAGTGCCTGG GGAGATCCGA GGCTATGAGC TGGCACACCA  
151 GCGGCATGG CGGCTGCCCT GGGCTCGCCT CTTCACAGCC AGCATCCAGC  
201 TGGCCCGCCA GGGCTTCCCC GTGGGCAAGG GCTTGGCGGC AGTCTGGAA  
251 AACAAAGCGA CCGTCATCGA GCACAGCCT GTTCTGTGGC ATGTCTGTGG  
301 TGAGGTGTTT TGCCGGGATA GAAAGGTGCT TCGGGAGGGG GAGAGACTGA  
351 CCCTGCGGG GTTGCTGAC ACCTATGAGA CGTGGCCAT TGAGGGTGCC  
401 CAGGCTTCT ACAATGGCAG CCTCATGGCC CAGATTGTGA AGGACATCCA  
451 GCGCGCC

!!AA, SEQUENCE 1.0  
ID ADP31098 standard; protein; 3579 AA.  
XX

AC ADP31098;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1865.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406645P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.

PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX  
PS Claim 1; SEQ ID NO 3096; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 3579 AA;  
ADP31098 Length: 3579 February 22, 2005 12:25 Type: P Check: 1031 ..  
1 ATGCAGATTC TCAGGGCCAA ACATACTGAC ACAGACTACC CACAGTGGGG  
51 GAGAGCACCG CGCCTTAGCC GCGAAGTTCT AGTTCTTGCT GCCGGTCCTA  
101 ACGTCCCGCA GTCTTCGCCA GCCAGCCGTC CGCATGGCG GTTTGGCGGG  
151 CGTGGAGCCT GCTGCCATGA AGTCAGCGTG AGTACGAGGC CGCCGAGCAG  
201 GGAGAGAGGG CGGACGGGG CCGAGGCCCTC GGGGCTGGG GCAGGCGTCT  
251 CCACCTCAGG CGCGGCCGTA CGCGGGCAGC CGGACAGCA TCCCGCCCGG  
301 TGCTGTGTCG CGCGCGACCC CAAAGTGGGA ACCTCCACGA GAGCTAAGAC  
351 ACCCGGAAA CCTACCGTGA AAAAGGGTC CCAAACGNAC CTTAAAGACC  
401 CAGTTGGGGT ATACTGTAGG GTGCGCCAC TGGGCTTTCC TGATCAAGAG  
451 TGTTCATAG AAGTGATCAA TAATACAACT GTTCAGTTTC ATACTCTGA  
501 GGGCTACAGA CTCACCGAA ATGGAGACTA TAAGGAGACT CAGTATTTCAT  
551 TTAACAAGT ATTTGGACT CACACACCC AGAAGGAAC CTTTGTATGT  
601 GTGGCTAATC CTTTGTCAA TGACCTCAAT CATGCCAAA ATGGTCTTCT  
651 TTTTACATAT GGTGTACGG GAAGTGGAAA AACTCACACA ATGACTGGTT  
701 CTCAGGGGA AGGAGGGCTG CTTCTCGTT GTTTGGACAT GATCTTTAAC  
751 AGTATAGGT CATTTCAAG TAAACGATAT GTTTTCAAT CTAATGATAG  
801 GAATAGTATG GATATACAGT GTGAGTTGA TGCCTTATTA GAACGTACGA

851 AAAGAGAGC TATGCCAAT CCAGAGACTT CTTTAGCAA ACGACAAGTA  
901 GATCCAGAGT TTGAGATAT GATAACTGTA CAAGAATTCT GCAAAGCAGA  
951 AGAGGTTGAT GAAGATAGTG TCTATGSGTG ATTTGTCTCT TATATTGAAA  
1001 TATATAATAA TTACATATAT GATCTATTGG AAGAGGTGCC GTTTGATCCC  
1051 ATAAACCCCA AACCTCCACA ATCTAAATTG CTTGCTGAAG ATAAGAACCA  
1101 TAACATGTAT GTTGCGAGGAT GTACAGAAGT TGAAGTGAAA TCTACTGAGG  
1151 AGCTTTTGA AGTTTCTGG AGAGCCAGA AAAAGAGACG TATTGCTAAT  
1201 ACCCATTTGA ATCGTGAGTC CAGCGTTCC CATAGCGTGT TCAACATTAA  
1251 ATTAGTTTCAG GCTCCCTTGG ATGCAGATGG AGACAATGTC TTACAGGAAA  
1301 AAGAACAAAT CACTATAGT CAGTTGTCTT TGGTAGATCT TGGTGGAGT  
1351 GAAAGAACTA ACCGGACCAG AGCAGAGGG AACAGATTAC GTGAAGCTGG  
1401 TAATATTAAAT CAGTCACTAA TGACGCTAAG AACATGTATG GATGTCCTAA  
1451 GAGAGAACCA AATGTATGA ACTAACAGA TGGTTCCATA TCGAGATTCA  
1501 AAGTTAACCC ATCTGTTCAA GAATCTATT GATGGGGAAG GAAAAGTGG  
1551 GATGATCGTG TGTGTGAACC CCAAGGCTGA AGATTATGAA GAAAACTTGC  
1601 AAGTCATGAG ATTTGGGNA GTGACTCAAG AAGTTGAACT AGCAAGACCT  
1651 GTAGACAAGG CAATATGTGG TTTAACGCC TGGAGGAGAT ACAGAAACCA  
1701 GCCTCGAGGT CCAGTTGGAA ATGAACCAAT GGTTACTGAC GTGGTTTTC  
1751 AGAGTTTTC ACCTTTGCCA TCATGCGNAA TTTTGGATAT CAACGATGAG  
1801 CAGACACTTC CAAAGCTGAT TGAAGCCTTA GAGAAACGAC ATAACTTACG  
1851 ACAATGATG ATTGATGAT TTAACAAACA ATCTAATGCT TTTAAAGCTT  
1901 TGTTCACAGA ATTTGACAT GCTGTTTAA GTAAAGAAA CCACATGCAA  
1951 GGAATACTAA ATGAAGAGA GAAGATGATC TCAGGACAGA AATTGGAAT  
2001 AGAACGACTG GAAAAGAAA ACAAAACTTT AGAATATAAG ATTGAGATTT  
2051 TAGAGAAAAC AACTACTATC TATGAGNAG ATAAACGCAA TTTGCAACAG  
2101 GAACTTGAAT CTCGAAACCA GAAACTTCAG CGACAGTTTT CTGACAAACG  
2151 CAGATTAGAA GCCAGTTGC AAGCATGGT GACAGAAACG ACAATGAAAT  
2201 GGAGAGAGA ATGTGAGCT AGAGTGGCAG CCAACACAGT GGAGATGCAG  
2251 AATAAACTCT GGGTTAAGA TGAAGAGCTG AAACAACTGA AGGCTATTGT  
2301 TACCGAACCT AAAACTGAGA AGCCAGAGAG ACCCTCTCGG GAGCGAGATC  
2351 GAGAAAAAGT TACTCAAGA TCTGTTTCTC CATCACCTGT GCCTCTTCT  
2401 AGTAACATTA TTGCTCAGAT TTCCAACGGC CAGCAACTCA TGAGCCAGCC  
2451 ACAGCTACAT AGGCGCTCTA ACTCTTGCA GAGCATTTCT GTAGCTTCT  
2501 GTATTTCCGA ATGGGAGCAG AAAATTCCCTA CGTACACAC ACCCTCABA  
2551 GTCACATCTA TTGCAAGGCG TAGGACGAG GAGCCAGGAC AAAGCAAAAC  
2601 TTGTATCGTG TCACAGAGAA GCGAGGGAT GTACTGGACT GAAGGCAGGG





(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H:

XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3246; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 576 AA;  
  
ADP31248 Length: 576 February 22, 2005 12:25 Type: P Check: 2414 ..  
1 ATGCGTGTCA GTCAATTCGT CCGCCTCCT CGGACCGGCC CGGCGCGGCG  
51 GCGCGATCCC GAGAACCCAG CGGCCCGGCG ACTCACTGGT CGTCATGGCG  
101 TGTCGTGCAT GAAGCTGGCC ACACCTTCCA TGGGGTGGG GTCCTGGGAG  
151 TCCTGGCTGG ACCTCATTTGG CTTGTGGCGC CTTCACTCGG AGAGACGGCG  
201 CTCAACCCGG AAGTGTGCGA GCGGAATCT GCCTAGCAAC CGGGGAAGCC  
251 GGCGTGTGAA GCGGGCAATT TCAGTCGGCC GCCCGGGGCG CCACCTGAGG  
301 GAGTCGGCTC CGCGGAGCGC CACAAGACCT GACCGGACTG CGCGCGCCGA  
351 GGCGGTGGCG CGCCGTCAGC GAGGCGCGCG AGCAACTTCG TTAATTAAAT  
401 TGACATTAAT CAAGACCCAG GCGCGGGCGG ACCGGGGGCC CGCTCCAGA  
451 GGCACCTTCA CAGGCTCACT CTGCAGCAA GTTTGAAAA CTGCTGCTAC  
501 CACCTTCGTT CACATCCGCA GAGGAACATT TTTCCTTGTT GCTCAAGTGT  
551 GGCTGGAGAA AGTAGGAGAG TGGTGA  
  
!!AA SEQUENCE 1.0  
ID ADP31249 standard; protein; 816 AA.  
XX  
AC ADP31249;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2016.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411071P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471338P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX Williams IT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.





XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3320; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 237 AA;  
ADP31322 Length: 237 February 22, 2005 12:25 Type: P Check: 1143 ..  
1 ATGGTGGAGG AGCGGAGTTC CATGTTGGAG CTTCTCCCT CAAGTGTCTAC  
51 TGGAGGGGAA GGACTTACGG AGGTCTCCCC AGAAACAACC ACTCTGGAGC  
101 CCCGCTTTC CACTGCAGTT TCTCCGGGA CAGAGGAACC TGCTGGCGAC  
151 ACCAAGAAAA AAATTGACAT TTTGTTAAG GCTGTGGGAG ATACTCCTAT  
201 TATGAAAAAACA AAGAAGTGGG CAGTAGAGCG AACATGA  
11AA SEQUENCE 1.0  
ID ADP31370 standard; protein; 1050 AA.  
XX  
AC ADP31370;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2137.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.

17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411010P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
02-MAY-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
02-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 3368; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1050 AA;  
ADP31370 Length: 1050 February 22, 2005 12:25 Type: P Check: 1970 ..

1	ATGGATAAAG	TCTCGGNAC	ATACTACTTA	TCAAGATTGA	ATCAAGAAGA
51	AACCAAAAC	CTGAAAAAA	CAATTACAGT	ACAGGATCTG	TGGAACCTTGG
101	AACTTGAGAT	GGATGATTTA	GGGTATCCAG	TGGAAGAAAT	TTCTAAGCAG
151	CAAAGTCTTC	AAGATGTGGC	CTGGCTGTTT	CTAACAACTT	ATGCTCATAT
201	GCATACGCA	AGAAATGACC	TGAAACTGGA	ACTTATATTT	AAAGAGGTTT
251	TCTTTACTCA	TGCATTTCAGC	ACATTATTGA	GCACCAACCA	CATGCTGGAA
301	ATAAAAGTG	TCAGTGGCAA	AAACACACAC	AAGGAAAAGT	GTCTCACTAA
351	ACTAGCAGTA	TTATACGCCA	CGGGTTGTCC	GGACACAGAA	AGTCCTCTGT
401	GTCCCTCCTCC	CAACCAAGCTG	CCAGGGAGCA	AAAGCATCCC	CGTCCACAG
451	AAAAGCCGAG	GTCTTCTCTG	AGGCCGTTAC	CTACCTTCCC	GCTCACACA
501	CCCGCGCGCG	CNATGTTTCC	TGCGGTGTCC	TGGTATAGAC	GTAGCAGAAC
551	CTCAGCTGTC	TCTCGGACAT	ACAACAACAT	CCGCGAAAAC	TAGAATACAA
601	TCCGGCGGG	AAAAGGGCG	GGAGTGGCG	GAAGGGAGTG	GAGNAAGGA
651	CGCGGGCGGA	AAAAGCCCG	CTAGCGGTG	CGTGTGTAAC	TGGGCTCAGA
701	GACGGCTGGG	AGAGATAAGA	GGAGATTTTG	CTTCCACGAA	ACAAGAATAT
751	TCAGAGAACA	AAAGTAAGCT	GTAGAAATT	AAAAATATGA	TGCTAAATCT
801	TGTGAAGATT	ACNAGATCC	AGGCCACCAT	GCAGGAGCTG	TCCAAAGAAA
851	TGTTGAAGGC	TGGGATCGTA	GAGGAGATGT	TAGAGGGCAC	TTTTGAAAGC
901	ATAGAAGATC	ACAGGGGCTT	TGGGCAAGC	AAAGTGACTG	CTGTCTTTCT
951	AGAGCCAGAA	TCTTCAAGAG	CGATGGCGGC	CTCAGAGGAC	AAGAGGGAAG
1001	AAGAGGCTCT	GGAGCCCATG	CAGTCTCTGGC	TGTTTACACT	CTGCAGCTAG

29-AUG-2002;	2002US-0406537P
29-AUG-2002;	2002US-0406553P
29-AUG-2002;	2002US-0406566P
17-SEP-2002;	2002US-0410947P
17-SEP-2002;	2002US-0410946P
17-SEP-2002;	2002US-0410948P
17-SEP-2002;	2002US-0410943P
17-SEP-2002;	2002US-0410953P
17-SEP-2002;	2002US-0410957P
17-SEP-2002;	2002US-0410958P
17-SEP-2002;	2002US-0410959P
17-SEP-2002;	2002US-0410960P
17-SEP-2002;	2002US-0410961P
17-SEP-2002;	2002US-0410962P
17-SEP-2002;	2002US-0410969P
17-SEP-2002;	2002US-0411022P
17-SEP-2002;	2002US-0411023P
17-SEP-2002;	2002US-0411024P
17-SEP-2002;	2002US-0411032P
17-SEP-2002;	2002US-0411035P
17-SEP-2002;	2002US-0411037P
17-SEP-2002;	2002US-0411041P
17-SEP-2002;	2002US-0411045P
17-SEP-2002;	2002US-0411046P
17-SEP-2002;	2002US-0411101P
17-SEP-2002;	2002US-0411111P
18-APR-2003;	2003US-0463700P
18-APR-2003;	2003US-0463708P
18-APR-2003;	2003US-0463716P
18-APR-2003;	2003US-0463732P
18-MAY-2003;	2003US-0463719P
18-MAY-2003;	2003US-0463721P
18-MAY-2003;	2003US-0463720P
18-MAY-2003;	2003US-0463723P
18-MAY-2003;	2003US-0463720P
19-MAY-2003;	2003US-0471306P
19-MAY-2003;	2003US-0471336P
22-MAY-2003;	2003US-0472420P
22-MAY-2003;	2003US-0472430P
09-JUN-2003;	2003US-0476609P
09-JUN-2003;	2003US-0476614P
09-JUL-2003;	2003US-0485218P
08-JUL-2003;	2003US-0485223P
08-JUL-2003;	2003US-0485224P
08-JUL-2003;	2003US-0485325P
14-JUL-2003;	2003US-0486446P
14-JUL-2003;	2003US-0486459P
15-JUL-2003;	2003US-0486891P
15-JUL-2003;	2003US-0486960P
08-AUG-2003;	2003US-0493341P
08-AUG-2003;	2003US-0493370P
08-AUG-2003;	2003US-0493573P
08-AUG-2003;	2003US-0493577P

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases such as proliferative (e.g. cancer), inflammatory, immune, metabolic, genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3419; 428pp; English.

The present invention relates to an isolated nucleic acid molecule

CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 204 AA;

ADP31421 Length: 204 February 22, 2005 12:25 Type: P Check: 267 ..

1 ATGGGTAAGG GGATGGTGGC GATGCTCATT CTGGGTCTGC TACTTCTGGC

51 GCTGCTCCTA CCGGTGCAGG TTTCTTCATT TGTCCTTTA ACCAGTATGC

101 CGGAAGCTAC TGCAGCGGAA ACCCAAAGC CCTCCACAG TGCCTACAG

151 CCTACAGCGG GTCTCTTGT GGTCTTGCTT GCCCTTCTAC ATCTCTACCA

201 TTAA

!!AA\_SEQUENCE 1.0  
ID ADP31484 standard; protein; 480 AA.  
XX  
AC ADP31484;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2251.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
PF  
XX 29-AUG-2002; 2002US-0406576P.  
PR  
XX 29-AUG-2002; 2002US-0406579P.  
PR  
XX 29-AUG-2002; 2002US-0406585P.  
PR  
XX 29-AUG-2002; 2002US-0406588P.  
PR  
XX 29-AUG-2002; 2002US-0406611P.  
PR  
XX 29-AUG-2002; 2002US-0406612P.  
PR  
XX 29-AUG-2002; 2002US-0406616P.  
PR  
XX 29-AUG-2002; 2002US-0406640P.  
PR  
XX 29-AUG-2002; 2002US-0406642P.  
PR  
XX 29-AUG-2002; 2002US-0406646P.  
PR  
XX 29-AUG-2002; 2002US-0406653P.  
PR  
XX 29-AUG-2002; 2002US-0406655P.  
PR  
XX 29-AUG-2002; 2002US-0406666P.  
PR  
XX 17-SEP-2002; 2002US-0410946P.  
PR  
XX 17-SEP-2002; 2002US-0410947P.  
PR  
XX 17-SEP-2002; 2002US-0410948P.  
PR  
XX 17-SEP-2002; 2002US-0410949P.  
PR  
XX 17-SEP-2002; 2002US-0410953P.  
PR  
XX 17-SEP-2002; 2002US-0410957P.  
PR  
XX 17-SEP-2002; 2002US-0410958P.  
PR  
XX 17-SEP-2002; 2002US-0410959P.  
PR  
XX 17-SEP-2002; 2002US-0410960P.  
PR  
XX 17-SEP-2002; 2002US-0410961P.  
PR  
XX 17-SEP-2002; 2002US-0410962P.  
PR  
XX 17-SEP-2002; 2002US-0411019P.  
PR  
XX 17-SEP-2002; 2002US-0411022P.  
PR  
XX 17-SEP-2002; 2002US-0411023P.  
PR  
XX 17-SEP-2002; 2002US-0411024P.  
PR  
XX 17-SEP-2002; 2002US-0411032P.  
PR  
XX 17-SEP-2002; 2002US-0411035P.

PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

PS Claim 1; SEQ ID NO 3482; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

SQ Sequence 480 AA;

ADP31484 Length: 480 February 22, 2005 12:25 Type: P Check: 184 ..

1 ATGGAGGCTT TGGCTGGTTA TGTAACAGA GCTAGTGAAT TGGATCCAGG

51 CCTGAACCCA GTTCAGAGG CCTTGCTGTT GAGGCAAGC CTATTTATA

101 CACTCAGTGA CTTACTTAAG GTCACCCAC TGCATATTCT TACTCCCTCT

151 CTTACTTTTA CCAGATTTTT ACCAGATTCA GCACGTGTTT ACAAAATAAA

201 AGAGAAAATT AAAATCCACA AACACAGTAG AAAATCCCAA GCTAAGACCT  
251 TCAGTATT ATTGCACTT TTGGGGGAG GGAGCAATGT TGGATGCAGG  
301 GCAGTCACA AGATGAAAAA CCAGTTAGCT CAGTGTGGCA GGAGCTTAGG  
351 ACCAGTTTAT AGAGTATAT TTACGGGTTT TCTTGAGCTC AGACCTTGCA  
401 CACAGCTATT GCATCTCTAC TTGTGACTG GAACACCTTC CCTCTTTTGG  
451 AGTTTGTAC GTTATCTACA GAATGAATGA

## !!AA\_SEQUENCE 1.0

ID ADP31500 standard; protein; 1269 AA.

XX

AC ADP31500;

XX 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #2267.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

PN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

PR 29-AUG-2002; 2002US-0406576P.

PR

PR 29-AUG-2002; 2002US-0406579P.

PR

PR 29-AUG-2002; 2002US-0406585P.

PR

PR 29-AUG-2002; 2002US-0406588P.

PR

PR 29-AUG-2002; 2002US-0406608P.

PR

PR 29-AUG-2002; 2002US-0406611P.

PR

PR 29-AUG-2002; 2002US-0406613P.

PR

PR 29-AUG-2002; 2002US-0406616P.

PR

PR 29-AUG-2002; 2002US-0406640P.

PR

PR 29-AUG-2002; 2002US-0406642P.

PR

PR 29-AUG-2002; 2002US-0406646P.

PR

PR 29-AUG-2002; 2002US-0406653P.

PR

PR 29-AUG-2002; 2002US-0406655P.

PR

PR 29-AUG-2002; 2002US-0406666P.

PR

PR 17-SEP-2002; 2002US-0410948P.

PR

PR 17-SEP-2002; 2002US-0410947P.

PR

PR 17-SEP-2002; 2002US-0410948P.

PR

PR 17-SEP-2002; 2002US-0410949P.

PR

PR 17-SEP-2002; 2002US-0410953P.

PR

PR 17-SEP-2002; 2002US-0410957P.

PR

PR 17-SEP-2002; 2002US-0410958P.

PR

PR 17-SEP-2002; 2002US-0410959P.

PR

PR 17-SEP-2002; 2002US-0410960P.

PR

PR 17-SEP-2002; 2002US-0410961P.

PR

PR 17-SEP-2002; 2002US-0410962P.

PR

PR 17-SEP-2002; 2002US-0411019P.

PR

PR 17-SEP-2002; 2002US-0411022P.

PR

PR 17-SEP-2002; 2002US-0411023P.

PR

PR 17-SEP-2002; 2002US-0411024P.

PR

PR 17-SEP-2002; 2002US-0411032P.

PR

PR 17-SEP-2002; 2002US-0411035P.

PR

PR 17-SEP-2002; 2002US-0411037P.

PR

PR 17-SEP-2002; 2002US-0411041P.

PR

PR 17-SEP-2002; 2002US-0411045P.

PR

PR 17-SEP-2002; 2002US-0411046P.

PR

PR 17-SEP-2002; 2002US-0411048P.

PR

PR 17-SEP-2002; 2002US-0411052P.

PR

PR 17-SEP-2002; 2002US-0411055P.

PR

PR 17-SEP-2002; 2002US-0411073P.

PR

PR 17-SEP-2002; 2002US-0411082P.

PR

PR 17-SEP-2002; 2002US-0411101P.

PR

17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX

XX

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Hallenbeck RF, Huang MM, Kothakota S, Haishan L, Linemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX

DR WPI; 2004-348438/32.

XX

PT New nucleic acid molecule for diagnosing, preventing or treating diseases

PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

PT genetic, bacterial and viral diseases.

XX

XX

PS Claim 1; SEQ ID NO 3498; 428pp; English.

XX

CC The present invention relates to an isolated nucleic acid molecule

CC encoding a polypeptide which is believed to be cytostatic,

CC anti-inflammatory, immunosuppressive, antibacterial and virucidal. The

CC composition and methods are useful for diagnosing, preventing and

CC treating diseases such as proliferative (e.g. cancer), inflammatory,

CC immune, metabolic, genetic, bacterial and viral diseases. The present

CC sequence represents a human secreted protein. The present sequence is

CC available on WIPWEB and is not in the specification.

XX

SQ

Sequence 1269 AA;

ADP31500

Length: 1269

February 22, 2005

12:25

Type: P

Check: 3635

..

1

ATGGAGAAATG AGTTTGATGA ATTGACAGAA GTAGACTTTA GAAGGTGGGT

51

AATAACAGAC TCCTCCAAGC TAAAGGAGCA TGTCTTAACC CAATGCAAGG

101

AAGTAAGAA CTTTGAAGAA AGGTTAGAGG AATTGCTAAC TAGAGTAACC

151

AGTTTAGAGA AGATAAATGA CCTGATGGAG CTGAAAAACA CAGCACGAGA

201

ACTTCTTGA GCATACACGA GTATCAATAG CCGAATAGAT CAAGTGGNAG

251

AAAGGATATC CGAGATTGAA GATCAACTCA ATGAAAAATA GCCAAACGAG

301

GAAGAAGTCG AATCCCTGAA GAGACCAATA ACAAGTTCTG AAATTGAGGC

351

AGCAATTAA AGCTAGCAA CCAAAAAAG TCCAGGACCA GACGATTCA

401

CAGCGAATT CTACGAGAGA AGTCACCTTT CTAAAGTGA CAAGGTTGGA

451 CAATTCCAAC CTATTAGTGG ABACTCCAAAG GATGTACCAG AGGAAATGGS  
501 GCAGAGACAG GTAGTGGTGG GCACCAACAG GCAGTCTCTGG CAGGATTGTG  
551 TGCCGTGTGGG CTCGTGTGGG ATGTGCATCC CCAGAAGAAG GGCTGCTGTC  
601 AGCACTTCTC ATTCTGGTGT TAAACTCTTA CCAGTCTCTT GCCACCTGT  
651 GCTCTCTCTTA CAAGAGCGAC AGCTGGGAT GGCTGTGGAG GACCGTGGG  
701 TGGCAGAAG GGGTACAGAG TATGAAGGGA GCCCAGATAA TAGAGGCAAA  
751 GGACTTGGAA CTTGGCAGGA TGACAATGGG GAGAGAGCTC TGSCCATGGA  
801 GCAGAGCAT CCGTATTTCAG CAACAACATC CCAGTTTGAC GGTCTCTCTA  
851 CTGACTCTTT CTCCATTGTG TCTCAAATC CTGAGGTGAA AGTCTCAGCA  
901 GCCACACAGC TGCCCCCTGC TCCGAATGCC CAGTTCTCCA CCTAACCA  
951 GGCTGTGCA GACTATCAGC CTGTGGGCC TGAACAGCCC TCACGGGAAG  
1001 ATGTGTGCAT TACTGCGTAT GGAGGAGCTG TTGCTGAGTC TCTGGTTGGG  
1051 GCTCTTAATC AGGCAATAT TTACAGTCCC CATGAGGGTC ATGATACAGT  
1101 GATCAGTAAT GAAATGGGCA TTGTCTCAT CTCTTTGTG CACACTGTGG  
1151 GGAGGGAAAA AGGACCCAGG ACGTTCTTTAA GTGCCAGATT GGAAGCAGCA  
1201 GACATCACTC TCACCGGCAT TCCAGACCTC AGTCATGTAC ACAGGAGGCC  
1251 AGAAATGCTG TCCAGTAG

!!AA SEQUENCE 1.0  
ID ADP31507 standard; protein; 912 AA.

AC ADP31507;  
DT 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #2274.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.  
XX WO2004035732-A2.  
XX  
PD 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.  
XX PF  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406656P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.

17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3505; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPOWEB and is not in the specification.

XX

```
SQ      Sequence 912 AA;
ADP31507 Length: 912 February 22, 2005 12:25 Type: P Check: 3953
1 ATGCTGGCAT CAACAGAGA CCACCAGACC ATTATGGGA GAAACAGGAA
51 TGGGGCAGAA AAGAACCCT TTGCACAAGA TGTGTCACT GTGCACCTTG
101 TTAGGGTGCA AAGGAAAAAT CAAAAAGAGT ACTGGAGGGG AATTTTCAGGA
151 GGCTTGCTG TGCCACCACT CAGATTGTTG CCCTTTCGAG CCTTAGTTCC
201 TCACTTGGCT TGTATCACGC TGGCACCTCT GCATGCGGG AAACAGAGTC
251 CCGTGGGTT TAACATAATG CGGTGTGAA AGCAGATGGC TGGTGATGG
301 AGTGGTCAGC AGACCCAGTC CAGTCTGACC TTGGGAGTCA CTGCCCTCAG
351 CAATGTCAAC CCAGAGGAAT GCCAAGAGG GCTGAGAGAC CAGAGCAAT
401 GCCAGTGTGT CTTTGACGTG TGGCAGCATC TTATGTGTTT GAGCTCTGAT
451 TTGGACATC GCACATATG CATTGACTCT ACACCTGAGG GCATCTTTTC
501 CTTTAAGCAG AAGCCTGTGG TTGAGGTAG GAGTACTGTT TCCATCACTA
551 TTCTGCTTGA AATCCTTCA GTGGCCAACT CAGGGCCGAA CCTTTAACT
601 TGGCATCAAG GTACCACACA ATCAATCAGA ATCAACCTTA CCCTGCAGCC
651 GTTCCACAAA ACGGATGCTC TGATCAATCT GAATGGAGT TATTTCTCCAG
701 CTGAACCTGA TACTTCCCCA GCTTCTTTTG TAGACTTGCA TTTGCTTTTC
751 TTTCTATTTA ATGATGGTGC CTTAAGGAAT GTCAAAGTC CTTGTAGAT
801 TCAGAGGACA GGGAAAGTAC TTCTTGCTGG GGGAGGAGGA GAGAGATGTT
851 CAGGGAAGA TTGGGAGTAT AATTTGTATT TTAATTGTGC CTTTAAGGAT
901 GTGATTAACT AA

!!AA_SEQUENCE 1.0
ID      ADP31550 standard; protein; 1044 AA.
XX
AC
XX
XX      ADP31550;
XX
DT      12-AUG-2004 (first entry)
XX
DE      Human secreted protein SEQ ID #2317.
XX
KW      Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW      cancer; inflammatory; immune; human secreted protein.
XX
OS      Homo sapiens.
XX
PN      WO2004035732-A2.
XX
XX      29-APR-2004.
XX
XX      28-AUG-2003; 2003WO-US026780.
XX
XX      29-AUG-2002; 2002US-0406576P.
XX      29-AUG-2002; 2002US-0406579P.
XX      29-AUG-2002; 2002US-0406585P.
XX      29-AUG-2002; 2002US-0406588P.
XX      29-AUG-2002; 2002US-0406608P.
XX      29-AUG-2002; 2002US-0406611P.
XX      29-AUG-2002; 2002US-0406612P.
XX      29-AUG-2002; 2002US-0406616P.
XX      29-AUG-2002; 2002US-0406640P.
XX      29-AUG-2002; 2002US-0406642P.
XX      29-AUG-2002; 2002US-0406646P.

PR      29-AUG-2002; 2002US-0406653P.
PR      29-AUG-2002; 2002US-0406659P.
PR      29-AUG-2002; 2002US-0406666P.
PR      17-SEP-2002; 2002US-0410948P.
PR      17-SEP-2002; 2002US-0410949P.
PR      17-SEP-2002; 2002US-0410949P.
PR      17-SEP-2002; 2002US-0410949P.
PR      17-SEP-2002; 2002US-0410953P.
PR      17-SEP-2002; 2002US-0410957P.
PR      17-SEP-2002; 2002US-0410958P.
PR      17-SEP-2002; 2002US-0410959P.
PR      17-SEP-2002; 2002US-0410960P.
PR      17-SEP-2002; 2002US-0410961P.
PR      17-SEP-2002; 2002US-0410962P.
PR      17-SEP-2002; 2002US-0411019P.
PR      17-SEP-2002; 2002US-0411022P.
PR      17-SEP-2002; 2002US-0411023P.
PR      17-SEP-2002; 2002US-0411024P.
PR      17-SEP-2002; 2002US-0411032P.
PR      17-SEP-2002; 2002US-0411035P.
PR      17-SEP-2002; 2002US-0411037P.
PR      17-SEP-2002; 2002US-0411041P.
PR      17-SEP-2002; 2002US-0411045P.
PR      17-SEP-2002; 2002US-0411046P.
PR      17-SEP-2002; 2002US-0411048P.
PR      17-SEP-2002; 2002US-0411052P.
PR      17-SEP-2002; 2002US-0411055P.
PR      17-SEP-2002; 2002US-0411073P.
PR      17-SEP-2002; 2002US-0411082P.
PR      17-SEP-2002; 2002US-0411101P.
PR      17-SEP-2002; 2002US-0411111P.
PR      18-APR-2003; 2003US-0463700P.
PR      18-APR-2003; 2003US-0463708P.
PR      18-APR-2003; 2003US-0463716P.
PR      18-APR-2003; 2003US-0463732P.
PR      02-MAY-2003; 2003US-0467199P.
PR      02-MAY-2003; 2003US-0467201P.
PR      02-MAY-2003; 2003US-0467203P.
PR      02-MAY-2003; 2003US-0467230P.
PR      19-MAY-2003; 2003US-0471306P.
PR      19-MAY-2003; 2003US-0471336P.
PR      22-MAY-2003; 2003US-0472420P.
PR      09-JUN-2003; 2003US-0472430P.
PR      09-JUN-2003; 2003US-0476609P.
PR      09-JUN-2003; 2003US-0476641P.
PR      08-JUL-2003; 2003US-0485218P.
PR      08-JUL-2003; 2003US-0485223P.
PR      08-JUL-2003; 2003US-0485224P.
PR      08-JUL-2003; 2003US-0485325P.
PR      14-JUL-2003; 2003US-0486446P.
PR      14-JUL-2003; 2003US-0486480P.
PR      15-JUL-2003; 2003US-0486891P.
PR      15-JUL-2003; 2003US-0486960P.
PR      08-AUG-2003; 2003US-0493341P.
PR      08-AUG-2003; 2003US-0493370P.
PR      08-AUG-2003; 2003US-0493573P.
PR      08-AUG-2003; 2003US-0493577P.
XX
XX      (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
XX      Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI      Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PI      Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX      WPI; 2004-348438/32.
XX
XX      New nucleic acid molecule for diagnosing, preventing or treating diseases
PT      such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PT      genetic, bacterial and viral diseases.
XX
XX      Claim 1; SEQ ID NO 3549; 428pp; English.
XX
XX      The present invention relates to an isolated nucleic acid molecule
CC
```

CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
SQ Sequence 1044 AA;  
ADP31550 Length: 1044 February 22, 2005 12:25 Type: P Check: 7908 ..  
1 ATGCCGAAGA ACAGCAAGT GACCCAGCGT GAGCACAGCA GTGAGCATGT  
51 CACTGAGTCC GTGGCGGACC TGCTGGCCCT CGAGGAGCCT GTGGACTATA  
101 AGCAGAGTGT ACTGAATGTG GCTGTGTAGG CAGCGGGCAA GCAGAAGGCG  
151 GTGGAGGAGG AGCTGGATGC AGAGGACCGG CCGGCCTGGA ACAGTAAGCT  
201 GCAGTATATC CTGGCCCGAGA TTGGCTTCTC TGTGGGCTC GGCACATCT  
251 GGAGGTTCCC CTACCTGTGC CAGAAAAATG GAGGAGGTGC TTACCTGGTG  
301 CCCTACCTGG TGCTGCTGAT CATCATCGGG ATCCCCCTCT TCTTCCTGGA  
351 GCTGGCTGTG GGTCAAGGA TCCGCGCGGG CAGCATGGT GTGTGGCACT  
401 ATATATGTC CCCTCTGGG GGCATCGGT TCTCCAGCTG CATPAAAGGGT  
451 CTGCTCTATG AGCAGTGTCT CCTGCACACA TGTGCTCAGG TCTGTCTCTT  
501 TGTGGGCTG TATTATAATG TGATCATCGG GTGGAGCATC TTTATTTCT  
551 TCAAGTCTTT CCAGTACCCG CTGCCCTGGA GTGAATGTCC TGTGTCAGG  
601 AATGGGAGCG TGSCAGGCAA GTATGGGCGC CAGCTGGGGA TGCCAGCCAG  
651 CCCTGTCCCA GNAAGGCTGG TGAGGCGAGA GTGTGAAAG AGCTAGCCCA  
701 CTACCTACTT CTGGTACCGA GAGGCTTTGG ACATCTCTGA CTCCATCTCG  
751 GAGAGTGGGG GCCTCAACTG GAAGATGACC CTGTGCTCCTC TCGTGGCCTG  
801 GAGCATCGTG GGGATGGCTG TCGTTAAGGG CATCCAGTCC TCGGGGAAGG  
851 TGATGTATTT CAGCTCCCTC TTCCCTTACG TGGTCTGGC CTGCTTCTCG  
901 GTCCGGGGG TGTTGCTGCG AGGGCAGTT GATGGCATCC TACACATGTT  
951 CACTCCCAAG AGCCTTCCAA CATCAGAAAT AATTCAGGCT ATCGGACCTG  
1001 GACTTTTCAG TCCATGCTTT CAAGCAGACA GTTACCGGGT ATGA  
11AA SEQUENCE 1.0  
ID ADP31597 standard; protein; 936 AA.  
XX  
AC ADP31597;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2364.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.

XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;





PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PA  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3652; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1533 AA;  
ADP31654 Length: 1533 February 22, 2005 12:25 Type: P Check: 9373 ..  
1 ATGGGGGAGC GGGCGTACAG GACCAGATG AGCAGCTGCG AGCTGAAGAT  
51 CATGAAGACC TGCTATGAAG CTTACCGCAC CCCACCACATG CAGGAGTGTTG  
101 AGGTGCTGGG AGAGGAGATT GGGCTGCCCA AGAGAGTCAT CCAGGTCGTG  
151 TTCAGAAATG CTGCTGCCAA GGAAAGAAG GCCAACTAC AGGGGACAGC  
201 CGCTGGGAGC ACTGGGGGCA GCGGTGAGGG CCTCTTAGCA GCCACGCGCA  
251 CTGACTGCCC CTATTGTGAT GTCAAGTATG ATTTCTATGT CTCCTGCCGA  
301 GGCATCTCT TTTCCGCTCA GCACCTGGCC AAGCTCAAG AGCGGTTTCG  
351 AGCCACGCTG AAGAGTGAAG GCAAGTGCTA CGACTTGGCC CCAGCACCTG  
401 AGGCTCCCC AGCTCTCAAG GCCCCACCTG CCACCACACC TGCCTCCATG  
451 CCCCTCGGGG CTGCCCAAC CTTGCTCTGC CTGGCGCGGG TCCTCTATTC  
501 TGGCCCCAGCT CTGGCTCAGC CCCCCTGGG CAACTTAGCT CCTTTCAATT  
551 CAGSCCCGGC AGCCTCTCA GSCCTCTCTG GCCTCGCCAC TTGGGTCTTG  
601 CCTTACCACA CAGTGTGCTCA GACTGCTGGC CCAGGCGCGC CTTACTCTCA  
651 GAGACCCATG CCGGACCAAA CCAACACCTC CACAGCAGGC ACCACTGACC  
701 CTGTCCCAGG CCCTCTACT GAGCCCTTGG GGGACAAGGT CTCAGTGAAG  
751 CGAAGCCAG TTGACGGCCC CACAGCTGCC TCCAATGAT CCCTCAAGAA  
801 CCTCAAGACA TTGAAGACCA CTGTCCCGAG CCTGTGGGG GGCAGTTTC  
851 TGCCCTTTCC ATTGCCCCCT GCTGGGGGAA CAGCACCGCC AGCTGCTTT  
901 GGCCCCCAGC TACAGGGGGC CTACTTCOA CAGTCTATG GATGAAGAA  
951 GGGGCTATTT CCCATGAACC CCATGATACC TCAGACCCCT ATTGGGCTGC  
1001 TCCCCATGC CCTCTCTCCAG CGGCCACCCC AGCCCCCTGA GCCCACAGCC

1051 ACAGCACCTC CAAAGCCTCC TGAAGTGCCT GCTCCAGGGG AGGGGGAAGC  
1101 TGGTGAGGTT GATGAGCTGC TGACAGGAG CACTGGCATC TCACCGTGG  
1151 ATGTAACCCA TCGCTACCTG TGCGCCAGT GCAAGATGCC ATTTGACGGG  
1201 GAGGCCCCGG CTACTGCCCA CCAGAGATCC TTCTGCTTCT TTGGGCGGGG  
1251 CTCTGGGGGC TCCATGCCAC CCCAATTGGG GGTGCCCATC TGCACCTACC  
1301 ACTGCCTGGC ATGTGAGGTG CTGCTGAGTG GCGGTGAAGC CCTAGCCTCC  
1351 CACCTCGGCT CCTCGGCCA CAGCGCAAG GCAGCCCCAC CTCAGGGGG  
1401 CCACCCATC TCCATCACA AGCGGGCAC TGTGCTCTCG GCTGCTGTGG  
1451 CTTTGGCCAA AGAGGAAGCA AGATTACCTC ACACGGACTC CAACCCAAAA  
1501 ACTACGACTA CCTCTACACT TCTAGCTTTA TAA  
!!AA\_SEQUENCE 1.0  
ID ADP30518 standard; protein; 279 AA.  
XX  
XX AC ADP30518;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #1285.  
XX  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US036780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX  
XX PR 17-SEP-2002; 2002US-0406666P.  
XX  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX  
XX PR 17-SEP-2002; 2002US-0411022P.  
XX  
XX PR 17-SEP-2002; 2002US-0411023P.  
XX  
XX PR 17-SEP-2002; 2002US-0411024P.  
XX  
XX PR 17-SEP-2002; 2002US-0411032P.  
XX  
XX PR 17-SEP-2002; 2002US-0411035P.  
XX  
XX PR 17-SEP-2002; 2002US-0411037P.



```
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX
XX WPI; 2004-348438/32.
XX
PT New nucleic acid molecule for diagnosing, preventing or treating diseases
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PT genetic, bacterial and viral diseases.
XX
XX Claim 1; SEQ ID NO 2602; 428pp; English.
XX
CC The present invention relates to an isolated nucleic acid molecule
CC encoding a polypeptide which is believed to be cytostatic,
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
CC composition and methods are useful for diagnosing, preventing and
CC treating diseases such as proliferative (e.g. cancer), inflammatory,
CC immune, metabolic, genetic, bacterial and viral diseases. The present
CC sequence represents a human secreted protein. The present sequence is
CC available on WIPOWEB and is not in the specification.
XX
XX Sequence 171 AA;
ADP30604 Length: 171 February 22, 2005 12:25 Type: P Check: 7553 ..
1 ATGACCCCGA CGCCGCGGAG AATGGGCTCC GCACCTACCT GCTCAGCGCG
51 GACGATCAGC GCCTCTTTGG ACTGGACGTT AAGTCCCGCG GCGACGGCAC
101 CAAGTTCCCA GAACCTGGTCA TCCAGAGGC TCTGGACGGC GACCAACAGA
151 ATCACCATAC GCTCGTGCTG A
!!AA SEQUENCE 1.0
ID ADP30634 standard; protein; 189 AA.
XX
XX ADP30634;
XX
XX 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #1401.
XX
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW cancer; inflammatory; immune; human secreted protein.
XX
OS Homo sapiens.
XX
XX WO2004035732-A2.
XX
XX 29-APR-2004.
XX
XX 28-AUG-2003; 2003WO-US026780.
PR 19-MAY-2002; 2002US-0406576P.
PR 29-AUG-2002; 2002US-0406579P.
PR 29-AUG-2002; 2002US-0406585P.
PR 29-AUG-2002; 2002US-0406588P.
PR 29-AUG-2002; 2002US-0406608P.
PR 29-AUG-2002; 2002US-0406611P.
PR 29-AUG-2002; 2002US-0406612P.
PR 29-AUG-2002; 2002US-0406616P.
PR 29-AUG-2002; 2002US-0406640P.
PR 29-AUG-2002; 2002US-0406642P.
PR 29-AUG-2002; 2002US-0406646P.
PR 29-AUG-2002; 2002US-0406653P.
PR 29-AUG-2002; 2002US-0406655P.
PR 29-AUG-2002; 2002US-0406666P.
PR 17-SEP-2002; 2002US-0410946P.
PR 17-SEP-2002; 2002US-0410947P.
PR 17-SEP-2002; 2002US-0410948P.
PR 17-SEP-2002; 2002US-0410949P.
PR 17-SEP-2002; 2002US-0410953P.
PR 17-SEP-2002; 2002US-0410957P.
PR 17-SEP-2002; 2002US-0410958P.
PR 17-SEP-2002; 2002US-0410959P.
PR 17-SEP-2002; 2002US-0410960P.
PR 17-SEP-2002; 2002US-0410961P.
PR 17-SEP-2002; 2002US-0410962P.
PR 17-SEP-2002; 2002US-0411019P.
PR 17-SEP-2002; 2002US-0411022P.
PR 17-SEP-2002; 2002US-0411023P.
PR 17-SEP-2002; 2002US-0411024P.
PR 17-SEP-2002; 2002US-0411032P.
PR 17-SEP-2002; 2002US-0411035P.
PR 17-SEP-2002; 2002US-0411037P.
PR 17-SEP-2002; 2002US-0411041P.
PR 17-SEP-2002; 2002US-0411045P.
PR 17-SEP-2002; 2002US-0411046P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411052P.
PR 17-SEP-2002; 2002US-0411055P.
PR 17-SEP-2002; 2002US-0411073P.
PR 17-SEP-2002; 2002US-0411082P.
PR 17-SEP-2002; 2002US-0411101P.
PR 17-SEP-2002; 2002US-0411111P.
PR 18-APR-2003; 2003US-0463700P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 02-MAY-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467230P.
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
XX
```

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2632; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 189 AA;  
ADP30634 Length: 189 February 22, 2005 12:25 Type: P Check: 776 ..  
1 ATGTGCTACG GCGTTCGAGC TGGGGAGGA CGCCCGCTCT TGTGTGACCA  
51 GTGGGGAAGG ACAGCCGACC CTTGGGGGGA CCGGGGTGCC CACCAGGCGC  
101 CGCCCGGCA CTGCAACGAG CCCGTGCCG CAGAGACAT GCCCAATCAG  
151 GTGTGACGAG AAGCTGGGAG AGACACCACT TGTCCTCGA  
!!AA SEQUENCE 1.0  
ID ADP30639 standard; protein; 291 AA.  
XX  
XX ADP30639;  
XX  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1406.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406578P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406589P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406659P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX

17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2637; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 291 AA;  
SQ

ADP30639 Length: 291 February 22, 2005 12:25 Type: P Check: 2410 ..  
1 ATGACAAGC CCCCCTTC ACCAAACT CCTACACCT GTTCGTCCGC  
51 GAGAACACA GCCCGCCCT GCACATCGC AGTGTACGC CCACAGACAG  
101 AGACTCGGC ACCAAGCCC AGGTACCTA CTCGTGCTG CCGCCCCGGG  
151 ACCGCACCT GCCCTCACC TCCCTGGTCT CCATTACAC GGAACAAGGC  
201 CACCTGTTGC CTCCTCAGTC GCTGACTAC GAGGCCCTGC AGGCTTTGGA  
251 GTTCCGGTGT GGCGCCACAG ACCGGGGCTT CCGCGCGTG A  
!!AA SEQUENCE 1.0  
ID ADP30644 standard; protein; 2142 AA.  
XX  
AC ADP30644;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1411.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.

17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
18-APR-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2642; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 2142 AA;  
ADP30644 Length: 2142 February 22, 2005 12:25 Type: P Check: 8206 ..  
1 ATGCCAGTGA CCAAGAAGGA TCTGGCGGAG GACGCGCGT GGAAGAAGAT  
51 CCAGCAGAAG AGTTTCACAA GCTGTGCGCA CGAGCACCTC AACGACGGGC  
101 TGCGGCCCCAT TGGGTGTCTC GAGGTGTCTA GCCAGAAGCA CATGTACCTC  
151 AGTATCATC AGCGGCCAC CTTTCGCCAG ATGCAGCTCA AGAACGTGTC  
201 CGTGGCGCTC GAGTTCCTGG ACCGTGACAG CATCAAGCTC GTGTCCATCG  
251 ATAGCAAAGC CACTGTGGAT GGGAACCTGA AGCTCATCTT GGTCTCTGGTC  
301 TGGACGCTGA TCCTCGGCTA CTCATCTCC AGCCCCGTGT GTGAGGATGA  
351 AGGGGATGAT GATGCCAAGA AGCAGATCGG GAAGCAGAGG CTGCTGGGGT



PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2682; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX  
XX Sequence 1498 AA;  
ADP30684 Length: 1498 February 22, 2005 12:25 Type: P Check: 9525 ..  
1 CCACAGCCTC GCCGCTCTCTG CTATTGGCA ACCGCCGGGA CGTACGGCTG  
51 GTGGACGCG CGCGAGTCAA GCTGGAGTCC ACCATCGTGG TCAGCGCGCT  
101 GGAGGATGCG GCCGCGAGTGG ACTTCCAGTT TTCCAAGGA GCCGTGTACT  
151 GGACAGACGT GAGCGAGGAG GCCATCAAGC AGACTACCT GAACCAAGC  
201 GGGGCCGCG TGCAGAACGT GGTCTATCC GGCCTGGTCT CTCCCGACGG  
251 CCTCGCTGC GACTGGGTGG GCAAGAGCT GTACTGGACG GACTCAGAGA  
301 CCAACCGCAT CGAGGTGGCC AACCTCAATG GCACATCCG GAAGGTGCTC  
351 TTCTGGCAGG ACCTTGACCA GCGGAGGGCC ATCGCTTGG ACCCTCACA  
401 GGTACATGTA CTGACAGAC TGGGGTGA GCGCCCGAT TGAGCGGGCA  
451 GGGATGGATG GCACGACCG GAAGATCA TTGGACTCGG ACATTTACTG  
501 GCCCAATGGA CTGACCATCG ACCTGGAGGA GCAGAAGCTC TACTGGGCTG  
551 ACGCCAAGCT CAGTTTATC CACCTGGCCA ACCTGGACGG CTGTTCCGG  
601 CAGAAGGTGG TGGAGGCGAG CCTGAGGCAC CCCTTCGCCC TGACGTCTC  
651 CGGGGACACT CTGTACTGGA CAGACTGGCA GACCGCTCC ATCCATGCTT  
701 GCAACAAGCG CACTGGGGGG CATGAGGAAG GAGATCTTGA GTGCCCTCTA  
751 CTCACCCATG GACATCCAGG TGCTGAGCCA GGAGCGGAG CCTTTCTTCC  
801 ACACTCGCTG TGAGGAGGAC AATGGCGGCT GTTCCCACT GTGCCTGCTG

851 TCCCCAAGCG AGCCTTTCTA CACATGGGCC TGCCCCACGG GTGTGCAGCT  
901 GCAGGACAAC GCGAGGAGT GTAAGGCAGG AGCCGAGGAG GTGCTGCTGC  
951 TGGCCCGGGG GACGACCTTA CGGAGGATCT CGTGGACAC GCGGGACTTC  
1001 ACCGACATCG TGCTGCAGGT GGACGACATC CGGCACGCCA TTGCCATCGA  
1051 CTACGACCCG CTAGAGGGCT ATGTCTACTG GACAGATGAC GAGGTGGGG  
1101 CCATCCGCG GCGCTACCTG GACGGGTCTG GGGCGGACAG CTTGGTCAAC  
1151 ACCGAGATCA ACGACCCCGA TGGCATCGCG GTCCACTGGG TGGCCCGAAA  
1201 CCTTCTACTG ACCGACAGG GCACGGACCG CATCGAGGTG ACGGCGCTCA  
1251 ACGGCACCTC CGCAAGATC CTGGTGTGGG AGGACCTGGA CGAGCCCCGA  
1301 GCCATCGCAC TGCACCCCGT GATGGGCTC ATGTACTGGA CAGACTGGGG  
1351 AGAGAACCTT AAAATCGAGT GTGCCNACTT GGATGGGCG GAGCGGCGTG  
1401 TGCTGTCTAA TGCTTCCCTC GGGTGGGCCA ACGGCTTGGC CTGGAACCTG  
1451 CAGGAGGGGA AGCTCTACTG GGGAGACGCC AAGACAGACA AGATCGAG  
!!AA SEQUENCE 1.0  
ID\_ADP30694 standard; protein; 537 AA.  
XX  
XX ADP30694;  
AC  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1461.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.



PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-048646P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX

## (FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX

WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX

PS Claim 1; SEQ ID NO 2692; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX

SQ Sequence 537 AA;

ADP30694 Length: 537 February 22, 2005 12:25 Type: P Check: 3634 ..

1 GTCCGGTGGC AGCTTTCAG GTGCCACGC CGTATTCCT GTATGTCGT

51 CCCGAGGGGC AGAACGTAC CCTCACCTGC AGGCTCTTGG GCCCTGTGGA

101 CAAAGGGCAC CATGTGACCT TCTACAAGAC GTGGTACCGC AGCTCGAGGG  
151 GCGAGGTGCA GACCTGTCTCA GAGCGCGGC CCATCGGCAA CCTCAGTTTC  
201 CAGGACCTTC ACCTGCACCA TGGAGGCCAC CAGGCTGGCA ACACAGCCA  
251 CGACCTGGCT CAGCGCCACG GGCTGGAGTC GGCTCCGAC CACCATGGCA  
301 ACTTCTCCAT CACCATGGC AACCTGACCC TGCTGGATAG CGGCCTCTAC  
351 TCGTGCCTGG TGGTGGAGAT CAGGCACCAC CACTCGGAGC ACAGGTTCCA  
401 TGGTGCCATG GAGTGCAGG TGCAGACAGA CATCACGGT GCAGCCCTGG  
451 CTACGGGTGC CTGATCGTA GGAATCCTCT GCCTCCCCCT CATCTGTCTC  
501 CTGGTCTACA AGCAAAGGCA GGCAGCCTCC AACCGCC

## !!AA SEQUENCE 1.0

ID ADP30698 standard; protein; 967 AA.

XX

AC ADP30698;

XX DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1465.

DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX

OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411037P.

XX PR 17-SEP-2002; 2002US-0411041P.

XX PR 17-SEP-2002; 2002US-0411045P.

PR 17-SEP-2002; 2002US-0411046P.  
 PR 17-SEP-2002; 2002US-0411048P.  
 PR 17-SEP-2002; 2002US-0411052P.  
 PR 17-SEP-2002; 2002US-0411055P.  
 PR 17-SEP-2002; 2002US-0411073P.  
 PR 17-SEP-2002; 2002US-0411082P.  
 PR 17-SEP-2002; 2002US-0411101P.  
 PR 17-SEP-2002; 2002US-0411111P.  
 PR 18-APR-2003; 2003US-0463700P.  
 PR 18-APR-2003; 2003US-0463708P.  
 PR 18-APR-2003; 2003US-0463716P.  
 PR 18-APR-2003; 2003US-0463732P.  
 PR 02-MAY-2003; 2003US-0467199P.  
 PR 02-MAY-2003; 2003US-0467201P.  
 PR 02-MAY-2003; 2003US-0467203P.  
 PR 02-MAY-2003; 2003US-0467230P.  
 PR 19-MAY-2003; 2003US-0471306P.  
 PR 19-MAY-2003; 2003US-0471336P.  
 PR 22-MAY-2003; 2003US-0472420P.  
 PR 22-MAY-2003; 2003US-0472430P.  
 PR 09-JUN-2003; 2003US-0476609P.  
 PR 09-JUN-2003; 2003US-0476641P.  
 PR 08-JUL-2003; 2003US-0485218P.  
 PR 08-JUL-2003; 2003US-0485223P.  
 PR 08-JUL-2003; 2003US-0485224P.  
 PR 08-JUL-2003; 2003US-0485325P.  
 PR 14-JUL-2003; 2003US-0486446P.  
 PR 14-JUL-2003; 2003US-0486480P.  
 PR 15-JUL-2003; 2003US-0486891P.  
 PR 08-AUG-2003; 2003US-0493341P.  
 PR 08-AUG-2003; 2003US-0493370P.  
 PR 08-AUG-2003; 2003US-0493573P.  
 PR 08-AUG-2003; 2003US-0493577P.  
 XX  
 (FIVE-) FIVE PRIME THERAPEUTICS INC.  
 XX  
 PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
 PI Halenbeck RF, Huang MW, Kochakota S, Haishan L, Linnemann T;  
 PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
 XX  
 DR WPI; 2004-348438/32.  
 XX  
 PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
 PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
 PT genetic, bacterial and viral diseases.  
 XX  
 PS Claim 1; SEQ ID NO 2696; 428pp; English.  
 XX  
 CC The present invention relates to an isolated nucleic acid molecule  
 CC encoding a polypeptide which is believed to be cytostatic,  
 CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
 CC composition and methods are useful for diagnosing, preventing and  
 CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
 CC immune, metabolic, genetic, bacterial and viral diseases. The present  
 CC sequence represents a human secreted protein. The present sequence is  
 CC available on WIPOWEB and is not in the specification.  
 XX  
 SQ Sequence 967 AA;  
 ADP30698 Length: 967 February 22, 2005 12:25 Type: P Check: 5109 ..  
 1 ATGCCCAGGC GGAGGTGGC TTGCTGTGAC CCCGCTGGT GGAGGTGATG  
 51 CGAGGAAAGT CTGTCATTCT GGACTGCACC CTTACGGGAA CCACGACCA  
 101 TTATATGCTG GRATGGTTCC TTACCGACGC CTCGGAGCT CGCCCCGCC  
 151 TAGCTCGGC TGAGATGCAG GGCTGTGAC TCCAGGTAC AATGCAGGAC  
 201 ACCCGGGGCC GCAGTCCCC ATACCAGCTG GACTCCGAGG GCGCCCTGGT  
 251 GCTGGCTGAG GCCCAGGTGG GCGACGAGCG AGACTACGTG TCGTGTGTGA

301 GGGCAGGGC GGCAGGCACT GCTGAGGCCA CTGGCGGCT CAACGTGTTT  
 351 GCAAAGCCAG AGGCACCTGA GGTCTCCCC ACAAAGGGA CACTGTCTGT  
 401 GATGAGGAC TCTGCCAGG AGATGCCAC CTGCAACAGC CGGAACGGA  
 451 ACCCGGCCC CAAGATCAG TGGTATCGCA ACGGGCAGC CTGGAGGTG  
 501 CCGGTAGAGA TGAACCCAGC TCCCTCAGCA GCACCTCTTA CTGCGGCTC  
 551 CGCAAGGATG ACCGAGAGCG CAGCTTCCAC TGCGCCGCC ACTACAGCCT  
 601 GCGCGAGGGC CGCCACGCC GCCTGGACAG CCCACCTTC CACCTCACCC  
 651 TGCACATATCC CACGAGCAGC GTGCAGTTCT GGGTGGCAG CCGTCCACC  
 701 CCAGCAGGCT GGGTACGGA GGGTGACACT GTCCAGCTGC TCTGCCGGG  
 751 GGACGGCAGC CCCAGCCGG AGTATACGCT TTTCCGCTT CAGGATGAGC  
 801 AGGAGGAAGT GCTGAATGTG AATCTCAGG GGAACCTTGAC CTGGAGGGA  
 851 GTGACCCGGG GCCAGAGCGG GACCTATGCG TGCAGAGTGG AGGATTACGA  
 901 CGCGGCAGAT GAGGTGCAGC TCTCCAAGAC GCTGGAGCTG CCGTGGCCT  
 951 GTGAGAGCCC TGGGTGA  
 !!AA SEQUENCE 1.0  
 ID ADP30704 standard; protein; 3477 AA.  
 XX  
 AC ADP30704;  
 XX  
 DT 12-AUG-2004 (first entry)  
 XX  
 DE Human secreted protein SEQ ID #1471.  
 XX  
 KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
 KW cancer; inflammatory; immune; human secreted protein.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2004035732-A2.  
 XX  
 PD 29-APR-2004.  
 XX  
 PF 28-AUG-2003; 2003WO-US026780.  
 XX  
 PR 29-AUG-2002; 2002US-0406576P.  
 PR 29-AUG-2002; 2002US-0406579P.  
 PR 29-AUG-2002; 2002US-0406585P.  
 PR 29-AUG-2002; 2002US-0406588P.  
 PR 29-AUG-2002; 2002US-0406608P.  
 PR 29-AUG-2002; 2002US-0406611P.  
 PR 29-AUG-2002; 2002US-0406612P.  
 PR 29-AUG-2002; 2002US-0406616P.  
 PR 29-AUG-2002; 2002US-0406640P.  
 PR 29-AUG-2002; 2002US-0406642P.  
 PR 29-AUG-2002; 2002US-0406646P.  
 PR 29-AUG-2002; 2002US-0406653P.  
 PR 29-AUG-2002; 2002US-0406655P.  
 PR 29-AUG-2002; 2002US-0406666P.  
 PR 17-SEP-2002; 2002US-0410946P.  
 PR 17-SEP-2002; 2002US-0410947P.  
 PR 17-SEP-2002; 2002US-0410948P.  
 PR 17-SEP-2002; 2002US-0410949P.  
 PR 17-SEP-2002; 2002US-0410953P.  
 PR 17-SEP-2002; 2002US-0410957P.  
 PR 17-SEP-2002; 2002US-0410958P.  
 PR 17-SEP-2002; 2002US-0410959P.  
 PR 17-SEP-2002; 2002US-0410960P.  
 PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2702; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 3477 AA;  
ADP30704 Length: 3477 February 22, 2005 12:25 Type: P Check: 7790 ..  
1 ATGGCTGGCG GCGCTGGGCT GCTGCTGTGG CTGCTGTGTC TCCGGCTGCC

51 CTGGCGGGTG CCGGCCAGC TGGACCCAG CACTGGCCGG CGGTTCTCGG  
101 AGCACAACT CTGCGCGGAC GACGAATGCA GCATGTTAAT GTACCGCGGT  
151 GAGGCTCTTG AAGATTTCAC AGGCCCGGAT TGFCTGTTTTG TGAATTTTAA  
201 AAAAGGTGAT CCTGTATATG TTTACTATAA ACTGGCAAGA CGATGGCCTG  
251 AAGTTTGGGC TGGAGTGTGTT GGACGCACTT TTGGATATTT TCCAAAAGAT  
301 TTAATCCAGG TAGTTCATGA ATATACCAA GAAGAGCTAC AAGTTCCAAAC  
351 AGATGAGAGC GATTTTGTGTT GTTTTGATGG AGGAAGAGAT GATTTTCATA  
401 ATTATAATGT AGAAGAACTT TTAGGGTTTT TGGAACGTGA CAATTTCTGA  
451 GCTACAGATT CTGAGAAAGC TGTAGAAAAA ACTTTACAGG ATATGAAAAA  
501 AAACCCCTGAA TTATCTAAGG AAAGGGAACC TGAACCTGAA CCAGTAGAAG  
551 CCAACTCAGA GGAAAGTGAT AGTGATTTCT CAGAAAACAC TGAGGATCTT  
601 CAGGAACAGT TTACAACCTCA GAAGCACACC TCCCATGCAA ACAGCCAAGC  
651 AAATCATGCT CAGGAGAGAG AGGCTTTCATT TGAATCTTTT GAAGAAATGC  
701 TGCAGATGAA ACTAAAGTG CCAGAAAGTG AAACAACAA ACCAGCAAT  
751 AGTTCTCAGG TCTCAATGTA ACAGGATPAG ATTGATGCCT ATAAACTTTT  
801 GAAAAAGAA ATGACTCTAG ACTTGA AACAAATTTGGC TCAACAGCTG  
851 ATGCACCTGT ATCTGATGAT GAGACAACCA GACTCGTTAC TTCATTAGAA  
901 GATGATTTTG ATGAGGAATT GGNATCTGAG TATATGCGAG TTGGAAGAAG  
951 AGATGAGGAG AACCAAGAAG ACTTTGATGA GTTGCCATTA CTTACCTTTA  
1001 CAGATGGGGA AGATATGAAA ACTCCAGCAA AGTCTGGCGT TCAGAAATAT  
1051 CCAACAGATA AAGAGCAGAA TTCAAATGAA GAGGACAAGG TTCAGCTAAC  
1101 TGTGCCCCCT GGCATCAAAA ATGATGATAA AAATATACTA ACNACCTGGG  
1151 GGGACACTAT CTTCTCTATT GTCACAGGAG GTGAGAGAAC AAGGATAGG  
1201 ATGGATTTAG AGAGCTCTAG TTCAGAGGAA GAAAAAGAAG ATGATGATGA  
1251 TGCATTAGTC CCAGATAGCA AACAGGGGMA ACCACAGTCA GCNACAGATT  
1301 ATAGTGACCC TGCAATGTA GATGATGGTC TTTTATTGTT AGACATTCTT  
1351 AAAACAAATA ATGACAAGA AGTAAACGCA GAACATACA TTAAAGGAAA  
1401 AGGGAGGGGA GTTCAGGAAT CCAAGAGGGG CCTGGTACAA GATAAGACAG  
1451 AATTAGAGA TGAATAATCA GAAGGCATGA CTGTGCACAG TTCTGTTTAC  
1501 AGCAATAACC TCAACTCTAT GCCAGTGTCT GAAAAGGGTA AAGACACATT  
1551 AAAATCAGCT TATGATGATA CAGAAAATGA CCTAAAAGGA GCAGCTATTC  
1601 ATATCTCAA AGGAATGCTC CAGCAAGAAA AGCCTGGAGA GCAGATTTTG  
1651 GAAGTGGCT CAGAGATGTA ATCTGCACAG AAAGCTGCAG GGAATCAAT  
1701 GAATGACAGA AAGATTCAAC AGGAATCCCT GGGTAGTGCA CCACTCATGG  
1751 GAGATGACCA CCCTAACGCA TCCAGAGACA GTGTGGAGGG AGACGCTTTG  
1801 GTAAATGGGG CCAAACTGCA CACGCTTTCA GTGGAGCATC AACGTGAGGA

1851 ATTGAAGAG GAATTAGTTC TTAAABACTCA AAACCAACCT AGATTCTCCT  
1901 CTCAGATGA GATTGATTTG CCCAGAGAAC TGGAAAGGA GGTCCCAT  
1951 CTGGGAAGAA ATCTTCCCTG GCAACAAGAA AGAGATGTGG CTGCCACAGC  
2001 CAGTAAGCAA ATCAGTGAGA AGATAAGGCT CTCTGAGGA GAAGCCAAAG  
2051 AGGACTCCTT GGATGAAGAG TTTTTCATC ACAAGGCNAT GCAGGGCACA  
2101 GAGGTAGGAC AGACAGACCA AACTGACAGC ACAGGAGGAC CAGCTTTCCT  
2151 TTCTAAAGTA GAAGAGATG ATTATCCCTC TGAAGAACTA CTAGAGGATG  
2201 AAAACGGTAT AAATGCAAAA CGGTCTAAG AAAAAACCC TGGGAATCAG  
2251 GGCAGGCAGT TTGATGTAA TCTGCAAGTC CCTGACAGAG CAGTTTATAGG  
2301 GACCATTCAT CCAGATCCAG AAATTGAAGA AAGCAAGCAA GAAACTAGTA  
2351 TGATTTTGGG TAGCGAAAA ACAAGTGAGA CTGCTGCCAA AGGGGTCAAC  
2401 ACAGGAGGCA GGGCAACAAA TACAATGGTG GAAAAAGAAC GCCCTCTGGC  
2451 AGATAAGNAA GCACAGAGAC CATTTGAAGC AAGTGACTTT TCTGACAGCA  
2501 TAAAAATTCA GACTCCAGAA TTAGTGAAG TGTTCAGAA TAAAGATTCT  
2551 GATTATCTGA AGAACGACAA CCTGAGGAA CATCTGAAGA CCTCAGGGCT  
2601 TGCAGGGGAG CCTGAGGGAG AACTCTCAA AGAGACCAT GAGAACACAG  
2651 AGAAGTACAT GGGCACAGAA AGCCAGGGGT CTGCTGTGTC AGAACCTGAA  
2701 GATGACTCGT TCCACTGGAC TCCACATACA AGTGTAGAGC CAGGGCATAG  
2751 TGACAAGAGG GAGGACTTAC TTATCATAG CAGCTTCTTT AAAGAACAAC  
2801 AGCTTTTGCA GCGGTTCCAG AAGTACTTTA ATGTCATGA GCTGGAAGCC  
2851 TTGCTACAAG AAATGTCATC AAAACTGAAG TCAGCGCAGC AGGAGAGCCT  
2901 GCCCTATAAT ATGNAAAAAG TCTAGATAA GGTCTTCGT GCTTCTGAGT  
2951 CACAAATTCT GACCATAGCA GAAAAAATGC TTGATACTCG TGTGGCGTAA  
3001 AATAGAGATC TGGGAATGAA CGAAAAATAC ATATTTGAAG AGGCTGCAGT  
3051 GCTTGATGAC ATTCAAGACC TCATCTATTT TGTCAAGGTAC AAGCACTCCA  
3101 CAGCAGAGGA GACAGGCACA CTGGTGATGG CACCACCTCT AGAGGAAGGC  
3151 TTGGGTGGAG CAATGGAAGA GATGCAACCA CTGCATGAAG ATAATTCTC  
3201 ACGAGAGNAG ACAGCAGAAC TTAATGTGCA GGTTCCTGAA GAACCCACCC  
3251 ACTTGGACCA ACCTGTGATT GGGGACACTC ATGCTCTAGA AGTGTACAG  
3301 AAGCCAAATA CTGAGAAAGA CTTGGACCCA GGGCCAGTTA CAACAGAAGA  
3351 CACTCCTATG GATGCTATTG ATGCAAAACA GCAACCAGAG ACAGCCGCGG  
3401 AAGAGCCGGC AAGTGTACCA CTTTGGAAA ACGCAATCCT TCTAATATAT  
3451 TCATTTCATG TTTATTTAAC TAAGTCG

11AA\_SEQUENCE 1.0  
ID\_ADP30724 standard; protein; 2976 AA.  
XX  
AC ADP30724;  
XX  
DT 12-AUG-2004 (first entry)  
XX

DE Human secreted protein SEQ ID #1491.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.

PR 14-JUL-2003; 2003US-0486446P.  
 PR 14-JUL-2003; 2003US-0486480P.  
 PR 15-JUL-2003; 2003US-0486891P.  
 PR 15-JUL-2003; 2003US-0486960P.  
 PR 08-AUG-2003; 2003US-0493341P.  
 PR 08-AUG-2003; 2003US-0493370P.  
 PR 08-AUG-2003; 2003US-0493373P.  
 PR 08-AUG-2003; 2003US-0493577P.  
 XX  
 PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
 XX  
 PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
 PI Halenbeck RP, Huang MM, Kochakota S, Haishan L, Linnemann T;  
 PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
 XX  
 WPI; 2004-348438/32.  
 XX  
 PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
 PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
 PT genetic, bacterial and viral diseases.  
 XX  
 PS Claim 1; SEQ ID NO 2722; 428pp; English.  
 XX  
 CC The present invention relates to an isolated nucleic acid molecule  
 CC encoding a polypeptide which is believed to be cytostatic,  
 CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
 CC composition and methods are useful for diagnosing, preventing and  
 CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
 CC immune, metabolic, genetic, bacterial and viral diseases. The present  
 CC sequence represents a human secreted protein. The present sequence is  
 CC available on WIPWEB and is not in the specification.  
 XX  
 XX Sequence 2976 AA;  
 ADP30724 Length: 2976 February 22, 2005 12:25 Type: P Check: 2492 ..  
 1 GGTTCCAGGA CACCTTCAAC ATGGACACCA GGAAGCCCCG GGTCTCCCTG  
 51 GGCTCCAGGA CCGCCTTCTT TGGCTACACA GTGCAGCAGC ACGACATCAG  
 101 TGGCAATAG TGCACCCCA GGAAGGTCA CCTGTGCCAA CGTGTCCGAG  
 151 CGGAAGACA ACATGCGCT CGGCCTTAGT CTCGCCACCA ACCCCAAGGA  
 201 CAACAGCTTC CTGGCCTGCA GCCCCTCTG GTCTCATGAG TGTGGAGCT  
 251 CCTACTACAC CACAGGGATG TGTTCAAGAG TCAACTCCAA CTTCAAGTTC  
 301 TCCAAGACTG TGTCCCACT TTCAGGGTG CCAGACCTAC ATGGACATCG  
 351 TCATTGTCTT GGATGGCTCC AACAGCATCT ACCCTGGGT GGAGTTTCAG  
 401 CACTTCCTCA TCAACATCCT GAAMAAGTTT TACATTGGCC CAGGCGAGAT  
 451 CCAGGTGGA GTTGTGCAGT ATGGCGAAGA TGTGTGTCAT GAGTTTCACC  
 501 TCAACGACTA CAGGTCTGTA AAGATGTGG TGGAGCTCC CAGCCACATT  
 551 GAGCAGAGG GAGGAACHGA GACCCGACG GCATTGGCA TTGAATTTGC  
 601 ACGCTCAGAG GCTTTCCAGA AGGGTGGAG GAAAGGAGCC AAGAAGGTGA  
 651 TGATTGTGAT CACAGATGGG GAGTCCCAAG ACAGCCACGA CCTGGAGNAG  
 701 GTGATCCAGC AAGCGAAG AGACAGGTA ACAAGATATG CGGTGGCCGT  
 751 CCGGGCTAC TACAACGCA GGGGGATCA TCCAGAAACT TTCTAAATG  
 801 AAATCAAATA CATGCCAGT GACCCTGATG ACAAGCACTT CTTCAATGTC  
 851 ACTGATGAGG CTGCCTTGAA GGACATTGTC GATGCCCTGG GGCACAGAT  
 901 CTTACGCTG GAAGGCACCA ACAAGAACGA GACCTCCTTT GGGCTGGAGA

951 TGTACAGAC GGGCTTTTCC TGCACGTGG TGGAGGATGG GGTTCGTCTG  
 1001 GGAGCCGTG GTGCCTATGA CTGAATGGA GCTGTGCTAA AGGAGACGAG  
 1051 TGCCGGGAAG GTCAATTCCTC TCCGCGAGTC CTACCTGAAA GAGTTCCCGG  
 1101 AGGAGCTCAA GAACCATGGT GCATACCTGG GGTACACAGT CACATCGGTC  
 1151 GTGTCTTCCA GCGAGGGGG GGTGTACGTG GCGGAGGCC CCGGTTTCA  
 1201 CCACAGGGG AAGTCAATCC TGTTCACCAT GCACAAACAC CGAGCCTCA  
 1251 CCATCCACCA GGTATGCGG GGCAGCAGG CTCTTACTTT GGGAGTGA  
 1301 TCACCTCGT GGACATCGAC GGCAGCGCG TGAATGATGT CCTGTCTG  
 1351 GCGCACCCA TGTACTTCAA CGAGGGCCGT GAGCGAGGCA AGGTGTACGT  
 1401 CTATGAGCTG AGACAGAACC TGTTTGTTTA TAACGGAACG CTAAAGGATT  
 1451 CACACAGTTA CCAGATGCC CGATTGGGT CCTCCATTGC CTCAGTTTGA  
 1501 GACCTCAACC AGGATTCCTA CAATGACGTG GTGGTGGGAG CCCCCCTGGA  
 1551 GGACAACCA CAGGAGGCA TCTACATCTT CCACGGCTTC CGAGCAGCA  
 1601 TCCTGAAGAC ACGCCCTGCA GAGAATACA GCTCAGAGC TGGCTACCGG  
 1651 CTTCCAGTAT TTTGGCTGCA GCATCCACGG GCAATTGGAC CTCAATGAGG  
 1701 ATGGGCTCAT CGACCTGGCA GTGGGAGGCC TTGGCAACGC TGTGATTCTG  
 1751 TGGTCCCGCC CAGTGGTTCA GATCAATGCC AGCTTCCACT TTGAGCCATC  
 1801 CAAGATCAAC ATCTTCCACA GAGACTGCAA GCGCAGTGGC AGGATGCCA  
 1851 CTTGCTGCG CCGCTTCTCT TGTTCACGC CCATCTTCTT GGCACCCCAT  
 1901 TTCCAACAA CACTGTTGG CATCAGATAC AAGGCCACCA TGGATGAGAG  
 1951 GCGGTATACA CCGAGGGCCC ACCTGGACGA GGGCGGGGAC CGATTCAACA  
 2001 ACAGAGCGGT ACTGCTCTCC TCCGGCCAGG AGCTCTGTGA CCGGATCAAC  
 2051 TTCCATGTCC TGGACACTGC TGACTACGTG AAGCCAGTGA CCTTCTCAGT  
 2101 CGAGTATTCC CTGGAGGACC CTGACCATGG CCCCATGCTG GACGACGGCT  
 2151 GGCACCCAC TCTCAGAGTC TCGGTGCCCT TCTGGAACGG CTGCAATGAG  
 2201 GATGAGCACT GTGTCCCTGA CTTTGTGTTG GATGCCCGGA GTGACCTGCC  
 2251 CACGGCCATG GAGTACTGCC AGAGGTGCT GAGGAAGCT CCGCAGGACT  
 2301 GCTCGCAT ACGCTGTCC TTGACACCA CAGTCTTCAT CATAGAGAGC  
 2351 ACAGCCAGC GAGTGGCGGT GGAGGCCACA CTGGAGAACA GGGGCGAGAA  
 2401 GCGCTACAGC ACGTCTCTAA ATATCTGCA GTCAGCAAA CTTGCAAGTTG  
 2451 CCAGTTGAT CCAGAGGAG GACTCAGAG GTAGCATTGA GTGTGTGNA  
 2501 GAGGAGGGA GGCTCCAGAA GCAAGTCTGC AAGTCACT ATCCCTTCTT  
 2551 CCGGGCCAA GCAAGGTGG CTTTCCGTCT TGAATTTGAG TTCAGCAAT  
 2601 CCATCTTCTT ACACCACCTG GAGATCGAGC TCGCTGACAG CAGGCTTCC  
 2651 ACCTCAAATA CGAGGCTGAC GTCTCTTCA CCAGAGCAG CAGCCTGAGC  
 2701 CACTACGAGG TCAAGCCCA CAGCTCGCTG GAGAGATACG ATGTTATCGG

2751 GCCTCCCTTC AGTGCATCT TCAGGAGAA CTTGGGCTTG TTCCCATCC  
2801 ACGGGATGAT GATGAGATC ACATTCCCA TCGCCACCAG GAGCGGAAC  
2851 CGCCTACTGA AGCTGAGGA CTTCTTCAG CACGAGGTGG CGAACACGTC  
2901 CTGTAAATC TGGGCAATA GCACTGAGTA CCGGCCACC CCAGTGGAGG  
2951 AAGACTTGG TCGTGCTCCA CAGCTG

!!AA SEQUENCE 1.0  
ID \_ADP30725 standard; protein; 113 AA.  
XX  
AC ADP30725;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1492.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX

XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.

18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
02-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2723; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPONEB and is not in the specification.

XX Sequence 113 AA;

ADP30725 Length: 113 February 22, 2005 12:25 Type: P Check: 1124 ..

1 TCGCGCGCCG CGCGCGCCGC CGCGCCCTCC TCCGGCTCTT CGCTCGGCCC

51 CTCTCCGCCT CCATGTGCGG GATAGCGGGA GCGTGC GGA CCCTGCTGCC

101 GCTGTGCGG GGC

!!AA SEQUENCE 1.0

ID \_ADP30727 standard; protein; 2514 AA.

XX ADP30727;

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1494.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX

PN WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406578P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406659P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 18-APR-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 19-MAY-2003; 2003US-0471316P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 22-MAY-2003; 2003US-0472430P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 08-JUL-2003; 2003US-0485218P.  
XX 08-JUL-2003; 2003US-0485223P.  
XX 08-JUL-2003; 2003US-0485224P.  
XX 08-JUL-2003; 2003US-0485325P.  
XX 14-JUL-2003; 2003US-0486446P.  
XX 14-JUL-2003; 2003US-0486480P.  
XX 15-JUL-2003; 2003US-0486891P.  
XX 15-JUL-2003; 2003US-0486960P.  
XX 08-AUG-2003; 2003US-0493341P.  
XX 08-AUG-2003; 2003US-0493370P.  
XX 08-AUG-2003; 2003US-0493573P.

PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2725; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX Sequence 2514 AA;  
SQ  
ADP30727 Length: 2514 February 22, 2005 12:25 Type: P Check: 7537 ..

1 ATGCGCCGTAT GGGGGACCCA CTGGACCTC ATACAGAAC CCCAGATCCG  
51 TGCCAAGCAT GGAGGGAAGG AGCAGATCAA TATCTGTGAG GTTCTGAACG  
101 CTACTGAGAT GACCTGTCAG GCGCCGCGCC TCGCTCTGGG TCCTGACCAC  
151 CAGTCAGACC TGACCGAGAG GCCCGAGGAG TTGCGCTTCA TCCTGGACAA  
201 CGTCCAGTCC CTGCTCATCC TCAACAAGAC CAACCTTCACC TACTATCCCA  
251 ACCCGGTGTT TGAGGCCCTTT GGTCCCTCAG GAATCCTGGA GCTCAAGCCT  
301 GGCACGCCCA TCATCTTAAA GGGCAAGAAC CTGATCCCGC CTGTGGCTGG  
351 GGGCAACGTG AAGCTGAAT ACACCTGTGCT GGTGGGGAG AAGCCGTGCA  
401 CCGTGACCGT GTCAGATGTC CAGCTGCTCT GCGAGTCCCC CAACCTCATC  
451 GGCAGGCACA AAGTGATGGC CCGTGTCCGT GGCATGGAGT ACTCCCCGGG  
501 GATGTTGTAC ATTGCCCGCG ACAGCCCGCT CAGCCTGCC CCATCGTCA  
551 GCATCGCAGT GGCTGGCGGC CTCCTCATCA TTTTCATCGT GGCGGTGCTC  
601 ATTGCTTATA AAGCAAGTC CCGCGAAAGT GACCTCACGC TGAAGCGGCT  
651 GCAGATGCAG ATGACAACCC TGGAGTCCCG TGTGGCCCTG GAGTGCAAGG  
701 AAGCCTTTCG CGAGCTGCAG ACGGACATCC ATGAGCTGAC CAGTGACCTG  
751 GATGGAGCCG GGATTCGGTT CTGGACTTAT AGAATTACA CCATGCGGGT  
801 GCTGTTCCCA GGAATTGAAG ACCACCCCTGT CCTCGGGAC CTTGAGGTCC  
851 CGGCTACCG GCAGGAGCGT GTGGAGAAG GCCTGAAGCT CTTGCCCCAG  
901 CTCATCAACA ACAAGTGTT CTGTGTGTC TCAATCCGCA CGCTTGAGTC  
951 CCAGCGTAGC TTCTCCATGC GCGACCGTGG CAACGTGGCC TCACTCATCA  
1001 TGACCGTGCT GCAGAGCAAG CTGGAGTAGC CCACTGATGT GCTGAAGCAG  
1051 CTGCTGGCCG ACCTCATTTA CAAGAACCCTG GAGAGCAAGA ACCACCTAA

1101 GCTGCTGCTC AGGAGSACTG AGTCAGTGGC TGAGAAGATG CTGACCAATT  
1151 GGTTTACTTT CTCTCTCTAC AAGTTCCTCA AGGAGTGTGC TGGGGAGCCC  
1201 CTCTTCTCCC TGTTCGTGTC CATCAAGCAG CAGATGGAGA AGGGCCCCAT  
1251 TGACGCCATC ACGGGGAGG CCGCTACTC CTTGAGCGAG GACAAGCTCA  
1301 TCGCCAGCA GATTGACTAC AAACCCCTGG TCCTGAGCTG TGTGAGCCCA  
1351 GACAATGCCA ACAGCCCCGA GGTCCAGTA AAGATCCTCA ACTGTGACAC  
1401 CATCACTCAG GTCAAGGAGA AGATTCTGGA TGCCATCTTC AAGAATGTGC  
1451 CTTGCTCCCA CCGGCCCARA GCTGCAGATA TGGATCTGGA GTGGCGACAA  
1501 GGAAGTGGGG CAAGGATGAT CTTGCAGGAT GAAGACATCA CCACCAAGAT  
1551 TGAGAATGAT TGGAAGCGAG TGAACACACT GGCCCACTAC CAGGTGCCAG  
1601 ATGGTTCCGT GGTGGCATTA GTGTCCARAG AGTGACAGC CTATACGCA  
1651 GTGAACAACCT CCACCGTCTC CAGGACCTCA GCAAGTAAAT ATGAACAACAT  
1701 GATCCGGTAC ACGGGCAGCC CGACAGCCT CCGCTCACGG ACACCTATGA  
1751 TCACTCCTGA CTTGGAGT GGAGTCAAGA TGTGGCACTT AGTGAAGAAC  
1801 CACGAGCACG GAGACCAGAA GGAGGGGAC CGGGGGAGCA AGATGCTGTC  
1851 TGAATCTAC CTGACCCGAC TCCTGGCCAC TAAGGGCACA CTGCAGAACT  
1901 TGTGGATGA CTTCTTTGAG ACCATCTTCA GCACGGACA CGTGGCTCT  
1951 GCCTGCCCC TGGCCATCAA GTACATGTTT GACTTCTCTGG ATGAGCAGGC  
2001 TGATAAACAT GGCATTCTAG ACCGSCAGT CCGCCATACC TGAAGAGCA  
2051 ATTGCTGCCC CTTGAGTTT TGGGTCAACA TGATCAAGAA CCGGCAGTTT  
2101 GTGTTTGACA TCCATAAGAA CAGCATCACA GACGCTGCC TCTCTGTGT  
2151 GGCTCAGACC TTATGGACT CTTGCTCCAC GTCAGAGCAC CGGCTGGCA  
2201 AGSACTGCC CTCCAACAAG CTGCTGTATG CCAAGGACAT CCCCAGCTAC  
2251 AAGAATTGGG TGGAGAGGTA TTACTCAGAC ATAGGGAAGA TGCCAGCCAT  
2301 CAGCGACCAA GACATGAACG CATACTGGC TGAGCAGTCC CGGATGCACA  
2351 TGAATGAGTT CAACACCATG AGTGCACTCT CAGAGATCTT CTCCTATGTG  
2401 GGCAATPACA GCGAGGAGAT COTTGACCT CTGGACCACG ATGACCAGTG  
2451 TGGGAGCAG AAACTGSCCT ACAACTAGA ARAAGTCATA ACCCTCATGA  
2501 GCTTAGACAG CTGA

!!AA\_SEQUENCE 1.0  
ID \_ADP30768 standard; protein; 1041 AA.  
XX  
AC ADP30768;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1535.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.

XX  
PD  
XX  
PF 29-APR-2004.  
XX  
XX  
PR 28-AUG-2003; 2003WO-US026780.  
PR  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.



XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2766; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antineoplastic, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX Sequence 1041 AA;  
SQ  
ADP30768 Length: 1041 February 22, 2005 12:25 Type: P Check: 1707 ..  
1 ATGGATACAG GCCCGACCA GTCTACTTC TCCGGCAATC ACTGTTTCGT  
51 CTTCTCGGTG TACCTTCTCA CTTTCTCGGT GGGGCTCCCC CTCACCTGTC  
101 TGGCCCTGGT GGTCTTCGTG GGCAAGTGC AGCGCGGCC GGTGGCCGTG  
151 GACGTGCTCC TGCTCAACT GACGCGCTCG GACCTGCTCC TGCTGCTGTT  
201 CCTGCTTTC CGCATGTGTG AGGCAGCCAA TGGCATGCACT TGGCCCCCTGC  
251 CCTTCATCTC CTGCCCACTC TCTGGATTCA TCTTCTTAC CACCATCTAT  
301 CTCACGGCCC TCTTCTGGC AGTGTGAGC ATTAAGCGCT TCCTGAGTGT  
351 GGCCACCCCA CTGTGTGACA AGACCCGGCC GAGGCTGGGG CAGGCAGGTC  
401 TGGTGAAGT GGCCTGCTGG CTGTGTCCT CTGCTCACTG CAGCGTGGTC  
451 TACGTCTAG AATTCTCAGG GGACATCTCC CACAGCCAGG GCACCAATGG  
501 GACCTGCTAC CTGGAGTTCC GGAAGGACCA GCTAGCCATC CTCCTGCCCG  
551 TGGCGCTGGA GATGGCTGTG GTCTCTTTG TGGTCCCGCT GATCATCACC  
601 AGCTACTGCT ACAGCGGCT GGTGTGATC CTCGGCAGAG GGGGAGGCCA  
651 CGCCCGCAG AGGAGGTTG CGGGGCTGTT GCGGGCCAG CTGCTCAACT  
701 TCCTTGTCTG CTTTGGGCC TACAACGTGT CCCATGTCT GGGCTATATC  
751 TGGCGTGAAA GCCCGGATG GAGATCTAC GTGACGTTTC TCAGACCCCT  
801 GAATCTCTGT GTCACCCCT TTTCTACTA TTCTCTCTC TCCGGGTTTC  
851 AAGCGACTT TCATGAGCTG CTGAGGAGT TGTGTGGGCT CTGGGGCCAG  
901 TGGCAGCAGG AGACAGCAT GGAGCTGAAG GAGCAGAAG GAGGGAGGA  
951 GCAGAGAGCG GACCGACCAT CTGAAGAAA GACCAGTGA CACTCACAGG  
1001 GCTGTGGAAC TGGTGGCCAG GTGGCCTGTG CTGAAGCTA G

!!AA\_SEQUENCE 1.0

ID ADP30780 standard; protein; 774 AA.

XX

AC ADP30780;  
XX 12-AUG-2004 (first entry)  
DT Human secreted protein SEQ ID #1547.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 18-APR-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 02-MAY-2003; 2003US-0467230P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 09-JUN-2003; 2003US-0476641P.

PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2778; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 774 AA;  
SQ

ADP30780 Length: 774 February 22, 2005 12:25 Type: P Check: 6161 ..

1 ATGGGGGAGG GGATGAGAGG CTGCAGCTGG CTGGGGGAGG GAGGAGGGGG  
51 ACTGGTCTC CTGACACCAC CTGGGAGT GGGGGAGGTG GAGCGTCGCG  
101 CCAGGNAAC CAGCTTACAG ACCCTGAGTC GAGAGCCTCA CTGCCAGAAA  
151 CTCAGITTTT TCACGTATGA AGTGAGGACG TGCTTGCAAC AAGGACAGAT  
201 TGTITGTGAA TGATGCCCC CCTCTATCTT GATCTACACC TATACCTTCA  
251 CCTACATCTA TACTTACACC TATATCTACA CCTACACCTA CACCTATATC  
301 TACATCTTCA CCTACATCTA TATCTACACC TACATCAACA CCTACACCTA  
351 TGCTACACC TACACGTTCA CCTATGTCTA TACTTATACC TACACCTATA  
401 CTTTCACTTA TGTCTATACT TACACCTACA CCTACGTTCTA CACCTACATC  
451 TACACCTACA CTTACACCTA CATCTTATC TACACCAACT TCACCTTACAC  
501 CTCAACTGC ACCTACACC ATATCTGCAC CTACATCTAC ATCAACACCC  
551 ACATCTACAC CCACACCTTC AGCTATATTT ACACCTACAC CTATATCTAC  
601 ACCTCCATCC ACACCTGCAC CTTTACTTAT ACCTACACCT ATGTCTATAC  
651 CTACACCTAC ATCTACATCT ATACCTACAT CTACACCTAC ACCTTCACTC  
701 ACACCTGCAT CTACACCTAC ACCTACGTTCT ACACCTGCAT CTACATCTAC  
751 ACCTACACCT TCACCTTACAC ATAA

! :AA\_SEQUENCE 1.0

ID  
XX  
XX ADP30790 standard; protein; 306 AA.  
AC ADP30790;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1557.  
DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
PN  
XX 29-APR-2004.  
PD  
XX 28-AUG-2003; 2003WO-US026780.  
PF  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406618P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406668P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.



XX PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX  
XX Claim 1; SEQ ID NO 2941; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 951 AA;  
ADP30943 Length: 951 February 22, 2005 12:25 Type: P Check: 102 ..  
1 ATGGCGGTGG CGTGTCTCTG GGCCTGGGG CTCTGGGGG CGGGGAGCCC  
51 TCTGCTTCC TGSCCGCTCC CAAATATAGT ACTGTCTTGG GGTGCTCTGG  
101 GACCTGCAGG TGSCACTGAG GAGCAGCAGG CAGAGTCAGA GAAGGCCCCG  
151 AGGAGGCCCT TGGAGCCCCA GGTCTTCTCAG GACGATCTCC CAATTAGCCT  
201 CAAAAGGTG CTTTCAGACCA GTCTGCCTGA GCCCCTGAGG ATCAAGTTGG  
251 AGCTGGACGG TGACAGTCAT ATCCTGGAGC TGCTACAGAA TAGGGAGTTG  
301 GTCCAGGCC GCCCAACCCT GGTGTGGTAC CAGCCCGATG GCACTCGGGT  
351 GGTCAGTGAG GGACACACTT TGAGGCTTGG TGGTCTTGAC CCAGAGAGA  
401 AGCTATACCC TGGAGCAGGG GCCTGGGAG CTTCAGGGTC CTCCATTAT  
451 TTCCGGAATC CAGATCTCC ACCTGCCAGG CCACACCTGT GCCTGAGCT  
501 GCGCGGAATC TGTACACACT CAGACGCCAC CAGAGCACCC CTTGGGACAG  
551 CGCCACTTCG CCGGAGGCGG GATGTGGTAA CAGAGACCAA GACTGTGGAG  
601 TTGCTGATTG TGCTGTATCA CTCGGAGGCC CAGAAATACC GGGACTTCCA  
651 GCACCTGCTA AACCGCACAC TGGAAAGTGGC CCTCTTGCTG GACACATTCT  
701 TCCGGCCCCCT GAATGTACGA GTGGCACTAG TGGGCTTGA GGCCTGGACC  
751 CAGCGTGACC TGGTGAGAT CAGCCCAAC CCAGCTGTCA CCCTGAATA  
801 CTTCTCTCAC TGGCGCAGGG CACATTTGCT GCCTCGATTG CCCCATGACA  
851 GTGCCCCAGT GGTGACTGGT ACTTCATTCT CTGGGCCTAC GGTGGGCATG  
901 GCCATTAGA ACTCCATCTG TTCTCCTGAC TTCTCAGGAG GTGTGAACAT  
951 G  
11AA SEQUENCE 1.0  
ID ADP30959 standard; protein; 2349 AA.  
XX  
AC ADP30959;  
XX  
DT 12-AUG-2004 (first entry)  
XX

DE Human secreted protein SEQ ID #1726.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.

PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX  
PI Williams LT, Chu K, Lee E, Hestir X, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haisnan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2957; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
XX Sequence 2349 AA;  
SQ  
ADP30959 Length: 2349 February 22, 2005 12:25 Type: P Check: 2576  
1 TAATGCTGGA GCCGGAGGCC ACCAACCTGC AGTTTTTCAGA ATGGCGGTGT  
51 TGGACACTGA TTGGATCAC ATTCTTCAT CTTCGTGTCT TCCTCCATTC  
101 TGGGCTAAGT TAGTAGTGG ATCGGTTGCC ATTGTGTGTT TTGCAGGCG  
151 CTATGATGGA GACTTTGTCT TTGATGACTC AGAAGTATT GTTAAACAATA  
201 AGGACCTCCA AGCAGAAAG CCCCTGGGG ACCTGTGGCA TCATGACTTC  
251 TGGGGCAGTA GACTGAGCAG CAACACGAGC CACAAGTCTT ACGGCGCTCT  
301 CACCGTCTG ACTTTCAGGA TTAAGTACTA CCTCTCGGGA GGCITTCACC  
351 CCGTGGGCTT TCACGTGGTC AACATCTCC TGCACAGTGG CATCTCTGTC  
401 CTCATGGTGG AGCTTCTCTC GGTTCGTGTT GCGGGGCTGC AGTACACGAG  
451 TAAAGCCGG AGGTGACAC TCGCCCCCAG GCGTCCCTG CTGGCCGGCGC  
501 TGTCTGTTGC TGTCCATCT GTGCACACCG AGTGTGTGTC TGGTGTGTC  
551 GCGCGTGCAG ACCTCTCTGT TGCCTCTTTC TTCTTGTATT CTTTCTTGG  
601 CTACTGTAAA GCATTTAGAG AAACAGGTAA CAAGGAGGGA GCGCATTTCT  
651 CCACCTTCTG GGTGTGCTGT AGTATCTTTC TGGGAGCAGT GGCATGCTG  
701 TCGAAGAGC AAGGATCAC TGTCTGGGT TTAATGCGG TATTGACAT  
751 CTTGTGTATA GCGAAATTCA ATGTCTTGA AATTGTCCAG AAGGTACTAC  
801 ATAAGGACAA GTCAATTAG GAGGTGGACA ACCCGGCTC CTTTGTGAC  
851 AGCATGCTGG TGAGGGCGGT AAATACAAT TACTACTATT CATTTGAATGC  
901 CTGGCTGCTG CTGTCTCCT GGTGGCTGTG TTTTGATTGG TCAATGGGCT

951 GCATCCCTT CATTAAGTCC ATCAGCGACT GGAGGGTAAT TGCACTTGCA  
1001 GCACCTGTGT TCTGCCTAAT TGGCCTGATA TGCCAAGCCC TGTGCTCTGA  
1051 AGACGGCCAC AAGAGAAGGA TCCTTACTCT GGGCCCTGGGA TTCTCTGTTA  
1101 TCCCATTTCT CCCCGCGAGT AACCTGTCT TCCGAGTGGG CTTCTGTGTC  
1151 GCAGAGCGTG TCCTCTACCT CCCAGCGTT GGTACTGTG TGCTGCTGAC  
1201 TTTTGGATTC GGAGCCCTGA GCAACATAC CAAGAAAAAG CTGAGATGTG  
1251 TGTCTGGCAG CGGCGAGTGG CCGAGTGAGG AACAGCTTTT CAGAAGTGCT  
1301 CTGTCTGTGT GTCCCTCAA TGCTAAGGTT CACTACAACA TTGGCAAAA  
1351 CTGTGCTGAT AAAGGCAACC AGACAGCTGC CATCAGATAC TACCGGGAG  
1401 TTTTCAATTA AATCCCAAGT ATGTTATGC CATGAATAAT CTTGGAATA  
1451 TCTTAAAGA AAGGAATGAG CTACAGGAAG CTGAGGAGCT GCTGTCTTTG  
1501 GCTGTTCAA TACAGCCAGA CTTTGGCGCT GGTGTGATGA ATCTAGGCAT  
1551 AGTGCAAGAT AGCCTGAAAC GGTTTGAAGC AGCAGAGCAA AGTTACCGGA  
1601 CAGCAATTAA ACACAGAAGG AATATCCAG ACTGTTACTA CAACCTCGGG  
1651 CGTCTGTATG CAGATCTCAA TCGCCAGTG GATGCTTGA ATGCGTGAG  
1701 AAATGCCACC GTGCTGAAAC CAGAGCACAG CCTGGCCTGG AACAAACATGA  
1751 TTATACTCT CGACAATACA GGTAAATTTAG CCCAAGCTGA AGCAGTTGGA  
1801 AGAGAGGCMC TGAATTAAT ACCTAATGAT CACTCTCTCA TGTTCGTGT  
1851 GGCATAACGTG CTGGGGAAT CCCAGAAATA CAAGGAATCT GAAGCTTTAT  
1901 TCCTCAAGGC AATTAAAGCA AATCCAAATG CTGCAAGTTA CCATGGTAAT  
1951 TTGGCTGTGC TTTATCATCG TTGGGGACAT CTAGACTTGG CCAAGAAACA  
2001 CTATGAAATC TCCTTGACGC TTGACCCAC GGCATCAGGA ACTAAGGAGA  
2051 ATTACGGTCT GCTGAGAAGA AAGTAGAAC TAATGCANAA GAAAGCTGTC  
2101 TGATCCTGTT TCCTTCATGT TTTGAGTTTG AGTGTGTGTG TGCAATGAGC  
2151 ATATCATTA TAGTATGTGG TTACATTTAA CCATTTAAAA GTCTTAGACA  
2201 TGTATTTTAA CTGATTTTTT TCTATGAAA CAAAGACATG CAAAAGATT  
2251 ATAGCAGCAG CAATATATCT TTGAATGCGT GATATGATTT TTCAATGAAA  
2301 TTGATTTTTT TCAGACAACT CAAATGTAAT TCTAAAAATC CAAAATGT

!!AA\_SEQUENCE 1.0

ID\_ADP31001 standard; protein; 670 AA.

XX  
XX ADF31001;  
XX

XX DT: 12-AUG-2004 (first entry)

XX  
XX Human secreted protein SEQ ID #1768.XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.XX  
XX Homo sapiens.XX  
XX WO2004035732-A2.

XX

PD	29-APR-2004.	PA	(FIVE-) FIVE PRIME THERAPEUTICS INC.
XX		XX	Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PF	28-AUG-2003; 2003WO-US026780.	PI	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
XX		PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
PR	29-AUG-2002; 2002US-0406576P.	XX	WPI; 2004-348438/32.
PR	29-AUG-2002; 2002US-0406579P.	XX	New nucleic acid molecule for diagnosing, preventing or treating diseases
PR	29-AUG-2002; 2002US-0406585P.	PT	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PR	29-AUG-2002; 2002US-0406588P.	PT	genetic, bacterial and viral diseases.
PR	29-AUG-2002; 2002US-0406608P.	XX	Claim 1; SEQ ID NO 2999; 428pp; English.
PR	29-AUG-2002; 2002US-0406611P.	XX	The present invention relates to an isolated nucleic acid molecule
PR	29-AUG-2002; 2002US-0406612P.	XX	encoding a polypeptide which is believed to be cytostatic,
PR	29-AUG-2002; 2002US-0406616P.	XX	antitumour, immunosuppressive, antibacterial and virucidal. The
PR	29-AUG-2002; 2002US-0406642P.	CC	composition and methods are useful for diagnosing, preventing and
PR	29-AUG-2002; 2002US-0406653P.	CC	treating diseases such as proliferative (e.g. cancer), inflammatory,
PR	29-AUG-2002; 2002US-0406655P.	CC	immune, metabolic, genetic, bacterial and viral diseases. The present
PR	29-AUG-2002; 2002US-0406666P.	CC	sequence represents a human secreted protein. The present sequence is
PR	17-SEP-2002; 2002US-0410946P.	CC	available on WIPOWEB and is not in the specification.
PR	17-SEP-2002; 2002US-0410947P.	XX	Sequence 670 AA;
PR	17-SEP-2002; 2002US-0410948P.	SQ	
PR	17-SEP-2002; 2002US-0410949P.	ADP31001	Length: 670 February 22, 2005 12:25 Type: P Check: 6715 ..
PR	17-SEP-2002; 2002US-0410953P.	1	TGGCTGCCTG AAGTGCAG GTATGATGTG CTGTCAGGGA ACCAGGAAAA
PR	17-SEP-2002; 2002US-0410957P.	51	GGCAATCGCC ACCTTAAAGA GGATAGCAAC TGAANAAGGA GTTCCCATGC
PR	17-SEP-2002; 2002US-0410958P.	101	CGCTGGGGAA ACTCATCATC TCCAGACAGT CCCCTTCCAG GTGTCCTTGT
PR	17-SEP-2002; 2002US-0410960P.	151	GACTCTGTGG ATTATGACC GCCTGGGGCG CAAGAAGACC ATGGCCCTGT
PR	17-SEP-2002; 2002US-0410962P.	201	GCTTTGTCAT CTTCTCCTTC TGCAGCCTCC TGCTGTTTAT CTGTGTGGA
PR	17-SEP-2002; 2002US-0411019P.	251	AGAAATGTGC TCACCTCTGT ACTCTTCATT GCAAGAGCGT TTATTTCTGG
PR	17-SEP-2002; 2002US-0411023P.	301	AGGCTTTCAA GCGGCATATG TTTACACACC TGAGGTCTAC CCCACGGCAA
PR	17-SEP-2002; 2002US-0411041P.	351	CGCGGGCCCT CGGCGTGGGC ACCTGCAGCG GCATGGCAAG AGTGGGTGCT
PR	17-SEP-2002; 2002US-0411052P.	401	CTCATCACTC CGTTTCATCG CCAGGTGATG CTGGAATCCT CTGTGTACCT
PR	17-SEP-2002; 2002US-0411073P.	451	GACTCTGGCA GTTTACAGTG GCTGCTGCT CTGGGTGCC CTGGCCTCCT
PR	17-SEP-2002; 2002US-0411082P.	501	GCTTTTGGCC CATTGAGACC AAAGGCCGAG GACTGCAGGA GTCCAGCCAC
PR	17-SEP-2002; 2002US-0411082P.	551	CGGGAGTGGG GCCAGAGAT GGTGCGCGA GGAATGCACG GTGCAGGTGT
PR	17-SEP-2002; 2002US-041101P.	601	TACCAGTGC AACTCTGGCT CTCAGGATA GTGACCGATG GGGGACTGAG
PR	17-SEP-2002; 2002US-0411101P.	651	CTGGTCTTTG AGGCTGCAGA
PR	17-SEP-2002; 2002US-0411111P.	11AA	SEQUENCE 1.0
PR	18-APR-2003; 2003US-0463700P.	ID	ADP31040 standard; protein; 1464 AA.
PR	18-APR-2003; 2003US-0463708P.	XX	
PR	18-APR-2003; 2003US-0463716P.	AC	ADP31040;
PR	18-APR-2003; 2003US-0463732P.	XX	
PR	02-MAY-2003; 2003US-0467199P.	DT	12-AUG-2004 (first entry)
PR	02-MAY-2003; 2003US-0467201P.	XX	
PR	02-MAY-2003; 2003US-0467203P.	DE	Human secreted protein SEQ ID #1807.
PR	02-MAY-2003; 2003US-0467230P.	XX	
PR	19-MAY-2003; 2003US-0471306P.	XX	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
PR	19-MAY-2003; 2003US-0471336P.	KW	cancer; inflammatory; immune; human secreted protein.
PR	22-MAY-2003; 2003US-0472420P.	XX	
PR	22-MAY-2003; 2003US-0472430P.	XX	Homo sapiens.
PR	09-JUN-2003; 2003US-0476609P.	XX	
PR	08-JUL-2003; 2003US-0485218P.	OS	
PR	08-JUL-2003; 2003US-0485223P.	XX	
PR	08-JUL-2003; 2003US-0485224P.	PN	WO2004035732-A2.
PR	14-JUL-2003; 2003US-0486446P.	XX	
PR	14-JUL-2003; 2003US-0486480P.	XX	
PR	15-JUL-2003; 2003US-0486891P.	PD	29-APR-2004.
PR	15-JUL-2003; 2003US-0486960P.	XX	
PR	08-AUG-2003; 2003US-0493341P.	XX	
PR	08-AUG-2003; 2003US-0493370P.	XX	
PR	08-AUG-2003; 2003US-0493573P.	XX	
PR	08-AUG-2003; 2003US-0493577P.	XX	

PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
FA  
XX

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
DR WPT; 2004-348438/32.  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX  
PS Claim 1; SEQ ID NO 3038; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytosolic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1464 AA;  
ADP31040 Length: 1464 February 22, 2005 12:25 Type: P Check: 5348 ..  
1 ATGTGTGATA ACAGAGAACT GGAAGACAAG CCTCCAGCAC CTCCTCGTGGC  
51 AATGAGCAGG ACCATCTTTA GCACCTGGGG CAAAGACCCCT TTGTACGCCA  
101 ATCACAGTTT GAAACCTTTG CTTCTGTTTC CAGAGGAGAA AAAGCCCAAG  
151 CATAAATCA TCTCCATATT CTCAGGCACA GAGAAAGGAA GTAAAAAGAA  
201 AGAAAAGGAA CGGCCAGAAA TTCTCTCTCC ATCTGATTTT GAACACACCA  
251 TCCATGTTGG CTTTGATGCT GTTACTGGAG AATTCACCTGG CATGCCAGAA  
301 CACTGGGCTC GATTACTACA GACCTCAAAT ATCACCACAA TAGAGCAAAA  
351 GAAGATCCT CAGCTGTGC TGGATGCTA CGACTCCAC ACAGTGAAGC  
401 AGAGTATCT GAGTTTACT CTTCTGAGA AGATGGGCTT CCCTTCTGGA  
451 ACACCAGCAC TGAATGCCA GGAACAGAA GCACCTGCAG TAGTGACAGA  
501 GGAGGAGCAC GATGATGAAG AGACTGCCCC TCCCATTATT GCCCACCAC  
551 CGGATCATAT GAAATCAATT TACACACGGT CTGTAATTGA CCCTGTTTCT  
601 GCACCAGTTG GTGATTCAAA TGTGTATGGT GGTGCCAAGT CTTTAGACAA  
651 ACAGAAAAAG AAGACTAAGA TGACAGATCA AGAGATTATG GAGAAACTAA  
701 GAACATATTA GGTGTGATC AAACAAATTA ATTTACAGAA ACAGCCAAAG  
751 AAGGAATTGA TCATTAATGA GATTTCTGTA ATGAAAGAA TAAAAATCC  
801 CAACATAGTT AACTTCTTGG ACAGTTACCT GGTAGGAGAT GAATTTGTTG  
851 TGGTCGTGGA ATACCTTGCT AGGGGTCTAC TCACGTGATG GGTAAACAGAA  
901 ACCTGCATGG ATGAAGCACA GATTGCCGCT GTATGCAGAG AGAGTTTACA  
951 GGCATTGGAG TTTTACATG CTAATCAAGT GATCCACAGA GACATCAAAA  
1001 GTGACAGTGT ACTTTTGGGA ATGGAAGGAT CGGTTAAGCT CACTGACTTT  
1051 GGTTCCTGTG CCCAGATCAC CCTGAGCAG AGCAACGCA GTACCGTGGT  
1101 CAGAACGCCA TACTGGATGG CACCAGACT GGTACACGG AAGCCTTATG  
1151 GCCTAAAGT CAATGATAGG TCTCTGGGTA TCATGGGTAC TGAGATGGTA

1201 GAAGGAGAGC CTCATACCT CAATGAAAAT CCCTTGAGGG CCTGTGCGCT  
1251 AATAGCAACT AATGGAATCC CGAACTTCA GAATCCAGAG ACACTTTCCC  
1301 CAATATTTCG GGATTTCTTA AATCGATGTT TGGAAACAGA TGTGGAAAAA  
1351 AGGGGTTTCAG CCAAGAAAT ATTACAGCAT CTTTTCTCTGA AACTAGCCAA  
1401 ACTGTTATCT AGCTTGACAC CACTGATCAT GGCAGCTAAA GAAGCAATGA  
1451 AGAGTAACCG TTAA

! /AA SEQUENCE 1.0  
ID\_ADP31086 standard; protein; 939 AA.

XX ADP31086;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1853.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.  
XX  
PN WO2004035732-A2.

XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406855P.  
PR 29-AUG-2002; 2002US-0406866P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411029P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.

17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
08-JUL-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 3084; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

XX Sequence 939 AA;

ADP31086 Length: 939 February 22, 2005 12:25 Type: P Check: 5186 ..

1 ATGATCCAGG TTTTATATCC ACGTCCTTTG ACNAGTTGG TCATGCCCGT

51 GGATGTGGCC ATGAGGCTTT GCTTGGCACA TTCACCACCT GTGAAGAGTT

101 TCCTGGGCC GTACGATGAA TTTCACGAC GACATTTTGT GAATAAATTA

151 AGCCCCCTGA ATCATGTCT CAATATAAAA CACNAAGCCA ATCACAGNA

201 TGACTGGAAG TGCTACACA ACCAAGCCAA GAAGCGGTT GTGTTTGCTG

251 ACTCCAAGGG CCTCTCTCTC ACTGCGATCC ATGCTCTTCT CGACCTCCCA

301 GAAGAACCG CGTGGATCT GCAGTTTGAT CTCCTGGACC TTAATGATAT

351 CTCCTCTGCC TTAACAACC ACAGGAGAA AAACTTGATT TTAGATTTCC

401 CTCAGCCTTC AACGGATTAC TTAAGTTTCC GGAGCCACTT TCAGAAGAAC



451 TTGTCTGTC TGGAGAACTG CTCGTTGCAA GAGCGAACAG TGACAGGGAC  
501 TGTAAAGTC AAAAATGTGA GTTTTGAGAA GAAAGTTTCAG ATCCGTTATCA  
551 CTTTCGATTG TTGGAAAAAC TACACTGACG TAGACTGTGT CTATATGAAA  
601 AATGTGTATG GTGGCACAGA TAGTGATACC TTCTCAATTTG CCAATGACTT  
651 ACCCCCTGTC ATTCCAACCTG AGCAGAAAAA TGAGTTCTGTC ATTCTTTACC  
701 ATGCTAATGG GCAAGTCTTT TGGGACACAA ATGATGGTCA GAAATATAGA  
751 ATTGTTTCATG TTCAATGGAA GCCTGATGGG GTGCAGACAC AGATGGCACC  
801 CCAGGACTGT GCATTCCACC AGACGTCTCC TAAGACAGAG TTAGAGTCAA  
851 CAATCTTTGG CAGTCCGAGG CTGCTAGTG GGTCTTCCC AGAGTGGCAG  
901 AGCTGGGGGA GAATGGAGAA CTTGGCCTCT TATCGATGA  
!!IAA SEQUENCE 1.0  
ID ADP31101 standard; protein; 296 AA.  
XX  
AC ADP31101;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1868.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406578P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406609P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406658P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.

PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3099; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 296 AA;  
SQ  
ADP31101 Length: 296 February 22, 2005 12:25 Type: P Check: 6929 ..  
1 GATGCAGATG TCTCCAGCCC TCACCTGCCT AGTCTCTGGC CTGGCCCTTG  
51 TCTTTGGTGA AGGGTCTGCT GTGCACCATC CCCCATCTTA CGTGGGCCAC  
101 CTGGCCTCAG ACTTCGGGGT GAGGGTGTTC CAGCAGGTGG CGCAGGCCTC  
151 CAAGGACCGC AACGTGGTTT TCTCACCCTA TGGGGTGGCC TCGGTGTGG  
201 CCATGCTCCA GCTGACAACA GGAGGAGAAA CCCAGCAGCA GATTCAAGCA

251 GCTATGGGAT TCAAGATTGA TGGTGAGCCA CGGGACACCA GGGGAG

!!AA SEQUENCE 1.0

ID \_ADP31115 standard; protein; 192 AA.

XX AC

XX ADP31115;

XX XX

DT 12-AUG-2004 (first entry)

XX XX

DE Human secreted protein SEQ ID #1882.

XX XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX XX

OS Homo sapiens.

XX XX

PN WO2004035732-A2.

XX XX

PD 29-APR-2004.

XX XX

PF 28-AUG-2003; 2003WO-US026780.

XX XX

PR 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 29-AUG-2002; 2002US-0406666P.

PR 17-SEP-2002; 2002US-0410946P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.

PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.

PR 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411022P.

PR 17-SEP-2002; 2002US-0411023P.

PR 17-SEP-2002; 2002US-0411024P.

PR 17-SEP-2002; 2002US-0411032P.

PR 17-SEP-2002; 2002US-0411035P.

PR 17-SEP-2002; 2002US-0411037P.

PR 17-SEP-2002; 2002US-0411041P.

PR 17-SEP-2002; 2002US-0411045P.

PR 17-SEP-2002; 2002US-0411046P.

PR 17-SEP-2002; 2002US-0411048P.

PR 17-SEP-2002; 2002US-0411052P.

PR 17-SEP-2002; 2002US-0411055P.

PR 17-SEP-2002; 2002US-0411073P.

PR 17-SEP-2002; 2002US-0411082P.

PR 17-SEP-2002; 2002US-0411101P.

PR 17-SEP-2002; 2002US-0411111P.

PR 18-APR-2003; 2003US-0463700P.

PR 18-APR-2003; 2003US-0463708P.

PR 18-APR-2003; 2003US-0463716P.

PR 18-APR-2003; 2003US-0463732P.

PR 02-MAY-2003; 2003US-0467199P.

PR 02-MAY-2003; 2003US-0467201P.

PR 02-MAY-2003; 2003US-0467203P.

PR 02-MAY-2003; 2003US-0467230P.

PR 19-MAY-2003; 2003US-0471306P.

19-MAY-2003; 2003US-0471336P.

22-MAY-2003; 2003US-0472420P.

22-MAY-2003; 2003US-0472430P.

PR 09-JUN-2003; 2003US-0476609P.

PR 09-JUN-2003; 2003US-0476641P.

PR 08-JUL-2003; 2003US-0485218P.

PR 08-JUL-2003; 2003US-0485223P.

PR 08-JUL-2003; 2003US-0485224P.

PR 08-JUL-2003; 2003US-0485325P.

PR 14-JUL-2003; 2003US-0486446P.

PR 14-JUL-2003; 2003US-0486480P.

PR 15-JUL-2003; 2003US-0486891P.

PR 15-JUL-2003; 2003US-0486960P.

PR 08-AUG-2003; 2003US-0493341P.

PR 08-AUG-2003; 2003US-0493370P.

PR 08-AUG-2003; 2003US-0493573P.

PR 08-AUG-2003; 2003US-0493577P.

XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

PA

XX

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX XX

DR WPI; 2004-348438/32.

XX XX

XX New nucleic acid molecule for diagnosing, preventing or treating diseases

PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

PT genetic, bacterial and viral diseases.

XX XX

PS Claim 1; SEQ ID NO 3113; 428pp; English.

XX XX

CC The present invention relates to an isolated nucleic acid molecule

CC encoding a polypeptide which is believed to be cytostatic,

CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The

CC composition and methods are useful for diagnosing, preventing and

CC treating diseases such as proliferative (e.g. cancer), inflammatory,

CC immune, metabolic, genetic, bacterial and viral diseases. The present

CC sequence represents a human secreted protein. The present sequence is

CC available on WIPWEB and is not in the specification.

XX XX

SQ Sequence 192 AA;

ADP31115

Length: 192

February 22, 2005

12:25

Type: P

Check: 4215

..

1

ATGAAGAAGA

TGAATAGCTC

ATCTAGAAAT

GAGAAGATGA

ACGAGTTCTAT

51

TGGGATTTCG

CTTTATGGAG

CTGTCTGTTGG

TTCACAGATG

CCAAGCAGTT

101

ACATGGTTAA

TCCTCCCTCC

GCCAAACCCC

CCTTCAGCAC

CACGCCCTCC

151

TTCCTAATGG

GCTGAACTT

GCAATTGTCC

AAACATGAGT

GA

!!AA SEQUENCE 1.0

ID \_ADP31120 standard; protein; 2943 AA.

XX AC

ADP31120;

XX XX

DT 12-AUG-2004 (first entry)

XX XX

DE Human secreted protein SEQ ID #1887.

XX XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX XX

OS Homo sapiens.

XX XX

PN WO2004035732-A2.

XX XX

PD 29-APR-2004.

XX XX

PF 28-AUG-2003; 2003WO-US026780.

XX XX

PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Heatir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPT; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3118; 428bp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytosolic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.

SQ Sequence 2943 AA;

ADP31120 Length: 2943 February 22, 2005 12:25 Type: P Check: 6379 ..

1 ATGTTACACC TTCTGGACGT GGTGAACGTC AAGGCCCGCT TCATTCACGA  
51 TGGCCCTGAG GACACCTCTG ACCAGCTGGT GCTGGAGGTG TCAGTGATGG  
101 CTTGGGTGCC TATGCCCTCA TGCCCTCGGA GGGGCCAACC AGACCTCCTG  
151 CCCATCCAGG TCAACCTGT CAATGACCCA CCCCACATCA TCTTCCCACA  
201 TGGCAGCCTT ATGTGATCC TGGAACACAC ACACAAGCT CTGGGGCCTG  
251 AGTTCTCCA GGCCTATGAC CTGGACTCTA CTTGTGAGG CCTCACCTTC  
301 CAGTCTCTTG GCACCCCTC TGCCCTCCCC GTGGAGCACC GAGACCAGCC  
351 TGGGGAGCCG GTGACTGAGT TCTCTGCTG GGAGTTGGAG GCCGGCAGCC  
401 TAGTCTATGT CCATCGGGT GGGCCCTACAG AGGACTTGAC ATTCCGGGTG  
451 AGCAATGGAC TGCAGGCCAG CCCCCCGGCC ATGTGAAAGG TGGTGGGTGT  
501 CCAGCTGGCC ATACAAATCC ACCGCAGCAC AGGGCTGCAT CTGGCCCCAGG  
551 GCTCTGCCAT GCCATCTTG CCTACCAACC TGTGTGTGGA GACCAGGCC  
601 GTGGGGCAGG ATGTGACCGT GCTGTTCCAT GTCACTGGAG GCCTGCCGTT  
651 CAGGAGGCTG CAGAAGCAGG GGGCTGGTGG GGTGGAGGAT GCTGAGTGGT  
701 GGGTCACACA GCGTTCCAC CAGCAGGATG TGGAGCAGGG CCACGTGAGA  
751 TACCTGAGCA CTGACCCACA GCACCTACACC GAGGACACCG TGGAGAACCT  
801 GGATCTGCAG GTGCAGGTGA GCTGGGAAT CCTGAGCAAT CTGTCTTCC  
851 TAGTGACCAT CCAGAGAGCC ACTGTGTGGA TGCTGCAGCT GGAGCCACTG  
901 CACACTCAGA ACACCCAGCA GGAGGCCCTC ACCACAGCCC ACCTGGAGGC  
951 CACCTGGAG GAGGCAGGCC CAAGCCCCCC AACCTTCCAC TGTGAGGTGG  
1001 TTCAGGCTCC CAGGAAGGC AACCTTCAAC TACAGGGCAC GATGATGTCA  
1051 GACGGTCAGG GCTTCAACCA GGATGACGTA CAGGCTGCAG AGGTGACCTA  
1101 TGGGGCCATG GCAGTGCCT CAGTGCAGT GGAGGACACC TTCTGTTTCC  
1151 ATGTACAGC TCCACCATAT TTCTCCCCAC TCTGTACCTT CTCATCCAT  
1201 ATTGGCGGTG ACCCAGACAT GCCTGTCTCTC TGTGTGCCCG AGGCTGGTGA



PR 08-JUL-2003; 2003US-0485224P.  
 PR 08-JUL-2003; 2003US-0485325P.  
 PR 14-JUL-2003; 2003US-0486446P.  
 PR 14-JUL-2003; 2003US-0486480P.  
 PR 15-JUL-2003; 2003US-0486891P.  
 PR 15-JUL-2003; 2003US-0486891P.  
 PR 08-AUG-2003; 2003US-0493341P.  
 PR 08-AUG-2003; 2003US-0493370P.  
 PR 08-AUG-2003; 2003US-0493573P.  
 PR 08-AUG-2003; 2003US-0493577P.  
 XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
 XX  
 XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
 PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
 PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
 XX  
 DR WPI; 2004-348438/32.  
 XX  
 XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
 PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
 PT genetic, bacterial and viral diseases.  
 XX  
 XX Claim 1; SEQ ID NO 3119; 428pp; English.  
 XX  
 XX The present invention relates to an isolated nucleic acid molecule  
 CC encoding a polypeptide which is believed to be cytostatic,  
 CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
 CC composition and methods are useful for diagnosing, preventing and  
 CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
 CC immune, metabolic, genetic, bacterial and viral diseases. The present  
 CC sequence represents a human secreted protein. The present sequence is  
 CC available on WIPWEB and is not in the specification.  
 XX  
 XX Sequence 2832 AA;  
 SQ

ADP31121 Length: 2832 February 22, 2005 12:25 Type: P Check: 3265 ..  
 PA 1 ATGTTACACC TTCTGGACGT GGTGAACATGC AAGGCCCGCT TCATTACGGA  
 CC 51 TGGCCCTGAG GACACCTCTG ACCAGCTGGT GCTGGAGGTG TCAGTGATGG  
 CC 101 CTGGGTGCG TATGCCCTCA TGCCTGCGGA GGGGCCCAAC AGACCTCCTG  
 CC 151 CCCATCCAGG TCACCCCTGT CAATGACCCA CCCACATCA TCTTCCACA  
 CC 201 TGGCAGCTTT ATGTTGATCC TGGAAACAC ACACAAGCCT TTGGGGCCTG  
 CC 251 AGGTTCTCCA GGCCTATGAC CTGGACTCTA CTGTGAGGG CCTCACCTTC  
 CC 301 CAGCTCCTTG GCACCCCTC TGGCCTCCC GTGGAGCACC GAGACGACC  
 CC 351 TGGGGAGCCG GTGACTGAGT TCTCCTGCTG GGAGTTGGAG GCCGGCAGCC  
 CC 401 TAGTCTATGT CCACTGCGGT GGCCCTACAC AGGACTTGAC ATTCCGGGTC  
 CC 451 AGCAATGGAC TGCAGGCCAG CCCCCCGCC ATGCTGAAGG TGGTGGCTGT  
 CC 501 CCAGCTGGCC ATACAAATCC ACCGCAGCAC AGGGCTGTCAT TTGGCCCCAGG  
 CC 551 GCTCTGCCAT GCCCATCTTG CCTACCAACC TGTGTGGTGA GACCAGCGCC  
 CC 601 GTGGGGCAGG ATGTGACCGT GCTGTTCCAT GTCACTGGAG GCCTGCCGTT  
 CC 651 CAGGGAGCTG CAGAAGCAGG GGGCTGGTGG GTTGGAGGAT GCTGAGTGGT  
 CC 701 GGGTCACACA GGCCTTCCAC CAGCAGGATG TGGAGCAGGG CCACGTGAGA  
 CC 751 TACCTGAGCA CTGACCCACA GCATAACCC GAGGACACCG TGGAAACCT  
 CC 801 GGATCTGCAG GTGCAGGTGA GCTGGGAAAT CCTGAGCAAT CTGTCTTTCC  
 CC 851 TAGTGACCAT CCAGAGAGCC ACTGTGTGGA TGCTGCAGCT GGAGCCACTG

901 CACACTCAGA ACACCCAGCA GGAGGCGCTC ACCACAGCCC ACCTGGAGGC  
 951 CACCTGGAG GAGCAGGCC CAAGCCCCC AACCTTCCAC TGTGAGGTGG  
 1001 TTCAGGCTCC CAGGAAGGC AACCTTCAAC TACAGGGCAC GATGATGTCA  
 1051 GACGGTCAGG GCTTCAACCA GGATGACGTA CAGGCTGCAG AGGTGACCTA  
 1101 TGGGGCCATG GCACGTGCCT CAGTGGCAGT GGAGGACACC TTCTGTTTCC  
 1151 ATGTCACAGC TCCACCATAT TTCTCCCCAC TCTGTACCTT CTCCATCCAT  
 1201 ATTGGCGGTG ACCCAGACAT GCCTGTCTCT GTGGTGCCCG AGGGTGGTGA  
 1251 GTGTGCTCTC TCTGCTGACC AGCTCTTCAT CAAGAGTCTC AACAGTGCCA  
 1301 GGTGGCGGCT GCTGACTACA GACAAATGG CCTTCAGCAA TGCTGATTGG  
 1351 GGCTTTGCTG AGGCCAGCT GGTGCTGACC CACCAGGACC TCCTCTCTGG  
 1401 CAGTATCATG GCCACGGATG AGCCCATGCA GCCCATCTGC CGCTTCATCC  
 1451 AGGAGGGGCC TCAGGAAGAG GCGAGTCCTG TGTCCGATGG GCAGCACCAG  
 1501 GCCATCACGG TGCTGGAGGT GCAGGCGCTT GAGCCTTACC TCTGTGTGGC  
 1551 CAATGGCTCC GGCCTCATGG TTCTCNAAG AGGCCAGGT ACCATCAACA  
 1601 TGGCCGAGCT CCACCTGGGC ACCAACTCA ACATCTGCAG TAGGGATGAG  
 1651 GCCCACTACC ACGTACAGA CAGCCCTCAC TGGGGACAGT TGCTCAAAGC  
 1701 CACTCAGCCA GCCACAGCT TCTCTCAGCA GGACCTGCTG GTTGGGGCTG  
 1751 TTCCCTATGG CCACAATGGC AGCCTCAGCT CCCGCAACAC CTTGGCCTTC  
 1801 TCAATGGATG TGGGACCAGT GCACACAGAT GCCACCCTAC AAGTGACCAT  
 1851 TGCCCTAGAG GGCCAGTAG CCCACTGAA GCTGGCCCCAG CACAAGAAGA  
 1901 TCTACATCTT CCAGGGAGAG GCAGCTGAGA TCAGAAAGGA CCAGCTGGAG  
 1951 GTAGCCAGG AGGCAGTGCC GCCAGCAGAC ATCGTTTTCT CAGTGAAGAG  
 2001 CCCACCGAGT GCCGGCTACC TGTGTATGTT GCTGCTGTC ATCTTGGCAG  
 2051 ATGAGCCACC CAGCCTGGAC CCCGTGCAGA GCTTCTCCCA AGAGSCATG  
 2101 GACACAGCCA GGATCTCTA CTGCACTCC CGCCCTGAGG CCCGGAGCCA  
 2151 TGCCCTTCTG CTGGATGGG CTTGGCGCTG GGTGCTCCCC TTGAGGAGCT  
 2201 CACGTGGAGC TGGAGGTGGA AGAGCATCTG ATCCAGTACC TGCAGATGG  
 2251 GAGCAAGACA CTGACGGTTT TGTCTCTGAT GCTAATGCTT CTGAGATGGA  
 2301 CGCCAGAGC CATCCTGTGG CTTTCACTGT CACCATCTCT CTTGTCAATG  
 2351 GCCAACCCCC GACCTCATAC AAACCTCAGG CTTGCAGAGC TCTGAGGAGC  
 2401 ATGGATGTT ACTCTGGGCC CAGGACCTG GTGTACACCA TTAAGCAGCC  
 2451 CAGCAATGGG TGGTAGTGC GGTGGGGGGT GCCGGGCACT GAGGTGCCCA  
 2501 GCTTCATGCA GACCCAGCTG GATGTGGGC TCGTGTGTT CTCACACAGA  
 2551 GGAGCTGGG TGAGCATCTG GACCCAGCAC ATGATCACAA CCCCGAGTT  
 2601 CATCATCTCG GAGCCGCTGG CCAGTATGTA CTCATGTGGG AACCAAGA  
 2651 CACTGATGGA GGATTTGGCA GAGCAGGCAC AGCAGCACGA CGAGATGCTG

2701 CACATGCACC ACGCGTGAA GGAGGGGCTC AGCATCATCG GTGACATCAA  
2751 CAGACCACT GTCACCATGC CCATGCCCCC GCCCGTGGAC GACACCTGGT  
2801 TGCAGGTGCA GAGCATCCCT GAGCACACA GN  
!!AA SEQUENCE 1.0  
ID\_ADP31125 standard; protein; 645 AA.  
XX  
AC ADP31125;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1892.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406555P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.

02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3123; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 645 AA;  
ADP31125 Length: 645 February 22, 2005 12:25 Type: P Check: 3072 ..  
1 ATGGGCCAAA TCAGCGTGCT TTCCTGTCAG CCAGGGGATT ATAGAAGAAC  
51 ACGTCCCTT GATTCACAA GAATTTGCTG CCACTCTGAT GTCTTCATGC  
101 CTCCTAAAGG AAAACAGATG CAAAGCCTTT TATCAATTGC AAAACAGTAT  
151 ACAATGTGTG TTATTACTCA CAGTTGCTT ACTGTGACCA AACACTTTAT  
201 AGCCTGGCGG CAAGTCAGCC TTACTCTCAG GAAGTGGACA ATATTTGGGG  
251 AAGGAGAAGC AGCAGGATAT TTCAGGACAG TAGCCTTGGG CCAGCGCAGC  
301 TACCCGCCCA ACTTCATCCG GAGCGCGCTG TCCTCCGTCG GCCTGGCGGA  
351 CGCTCAGGGC CGCACACAGG GGGCGGGCAG CGACGGCAGG TTCTTCGGGA  
401 GGACGGCGGT CGAGGTCGTG GGGCCGATGG CCGCGGCCAA CGGGGCGAGT  
451 GTCCGGATGC CCTCGCTTC CCGCGCGGCC GCCGCGCGC CCTCTCCTGS  
501 CCCTTGTCCG CTTGTGCGCT CCGGGGCCAG CTGGAGGCC CCTGCCCGC  
551 TTTGCTCCCG CACTCCCGCG TCCTCACCTT CCAGCGCCCC ACTCCGCGCG

601 CGCTCCAGC CTCGCCGGG CACCCGGGAC ACTGGGTCT ATTAG  
!!AA SEQUENCE 1.0  
ID ADP31185 standard; protein; 1989 AA.  
XX  
AC ADP31185;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1952.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406618P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406658P.  
PR 29-AUG-2002; 2002US-0406668P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486425P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3183; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytosolic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1989 AA;  
ADP31185 Length: 1989 February 22, 2005 12:25 Type: P Check: 5132 ..  
1 ATGCACCCAG GGAAGTCCTG GTTCCTGCC TCAGCTCCTT CCTGCTCCAT  
51 CCTCAACCAA GCCACCATGC CTGGTGGGTA CAAAGGGGAG TGTGGGGAGC  
101 ATGTGGACCC TATGCCCTTC CTGGCACCTC CTGAAAAGGA GAGGATTGAA  
151 GCCATGAACA AGCCTATGA CATTAGAGG TCTGCTGGG TCAAAGATGA  
201 GAAGGAAGGC TTGTCGCTG GGGAGATCCA GTCTGAACAG GGTGACCAAG  
251 TCACCGTGAA GACGATCACC AACCAGACAC TCACCTGTGAA GAAGGATGAT  
301 ATCCAGCAGA TGAACCCACC CAATTTCTAC CAGGCCAGTG ACATGGCAGA  
351 CATGACCTTC CTGAATGAGG CCAGTGTCTT AGACAATCTG CGCCAACGCT  
401 ACACCAACAT GAGGATCTAT GTGAGTGCCA GGGATGGGAC CTACTCGGGC  
451 TTGTTCTGGG TGACGGGTCAA CCCTACAAG TGGCTGCCCA TCTACGGGGC  
501 CGGTGTGGCT AACATGTACA AGGGCAAGAA GCGCACAGAG ATGGCGCTC  
551 ACCTCTTCTC CATCTCTGAC AAGCGCTACC ACACATGCT TATGATCGT  
601 GAGAATCAGT CTATGCTAAT CACCGGAGAA TCTGTGTCTG GTAAGACTGA  
651 GAACACGAAG AAGGTATCCT AGTACTTTGC CAACATTGGA GGAACGTGGA

701 AACAGACCAC AGATAAGAAG GGGTCTCTGG AGGATCAAGT CATCCAGGCA  
751 AACCTGTGCG TGGAGGCTTT TGGGAACGCC AAGACCACCA GGAACACAA  
801 CTCCTCTGCG TTGCGCAAGT TCATCCGAAT CCACCTTTGGA ACCACAGGGA  
851 AACTGGGCTGG AGCCGACATA GAGAGCTATC TCTTAGAGAA ATCTCGTGTC  
901 ATCTCACAGC AAGCAGCGGA GAGAAGCTAC CACATCTTCTT ACCAGATTCT  
951 CTCAACAAGG AAGCCTGAAC TTGTTGAGAG TTGCTGCTGT GTCCCAACCC  
1001 CTNAGGAATA CCACCTGGTG AGCCAAAGCG TCACCACTGT GGACAACATG  
1051 GATGACAAGG AGGAGTGC A GATCACAGAT GAAGCCTTTG ACGTACTGGG  
1101 CTTCAGCGCC GAGGAGAAGA TGCCCGTGTA TAAGCTGACG GGAGGTATCA  
1151 TGCACCTTGG GAACATGAAG TTCAAGCAGA AGCCACAGA CGAGCAAGCT  
1201 GAAGTGGACA CCACTGAGGT GCGTGACAAA GTCGCCCATC TCATGGGTCT  
1251 CAACCTCTGT GAACTGCAGA AAGGCATTAC CAGGCCCCGA GTCAAAAGTTG  
1301 GCAATGAGTT TGTGCAAAA GSCCAGAACA TGGAAACAGT CCAAAACTCC  
1351 ATTGGGGCTC TGGGCAAGGC TGTCTATGAC AAGATGTTCA AGTGGTTGGT  
1401 GGCCAGGANT AACAAAGACCT TGGACACCAA GATGCAGAGG CAGTCTCTCA  
1451 TTGAGTGTCT GGACATCGCT GGCCTTGAGA TCTTTGAGTT CAACAGCTTT  
1501 GAGCAGCTAT GCATCAACTT CACCACAGAG AAGTGCAGC AGTCTCTCAA  
1551 CCACCACATG TTGCTGTGAG AGCAGGAGGA GTACAAGAGG GAAGGCATCG  
1601 AGTGGGTCTT CATCGACTTT GGCCTCGACC TTCAGGCCGT CATCGACCTG  
1651 CTGGAAGAAGC CCAATGGGCAT CTTCTCCATC TTGGAGGAC AGTGGGTCTT  
1701 CCCCAGAGCC ACCGATGCCA CGTTCAAGGC AGCCCTGTAC GACAACCCAC  
1751 TGGCAAGTC CAGCAACTTC CTGAAGCCCA AGGGGGGCA GAGCAAGGGG  
1801 CCCAGGTCC ACTTCAGCT GGTTCACATC GCAGGCACCT GGAGGACCT  
1851 GAAAGACTCC TTCTCTCTTA CCCTTGCCAT GGGGACCATG TGGCAAGATG  
1901 GGAAGCAGAA ATTAGTGGAT GTCCAAATAC CTGGATATAT GGAGCCCCCA  
1951 GTGCTGGATG GATGGAGCCC CCTTTCCATC AGCCNATGA

!!AA\_SEQUENCE 1.0  
ID -ADP31260 standard; protein; 4683 AA.  
XX  
AC ADP31260;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2027.  
XX  
DE  
XX Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR

29-AUG-2002; 2002US-0406579P.  
PR  
29-AUG-2002; 2002US-0406585P.  
PR  
29-AUG-2002; 2002US-0406588P.  
PR  
29-AUG-2002; 2002US-0406608P.  
PR  
29-AUG-2002; 2002US-0406611P.  
PR  
29-AUG-2002; 2002US-0406612P.  
PR  
29-AUG-2002; 2002US-0406616P.  
PR  
29-AUG-2002; 2002US-0406640P.  
PR  
29-AUG-2002; 2002US-0406642P.  
PR  
29-AUG-2002; 2002US-0406646P.  
PR  
29-AUG-2002; 2002US-0406653P.  
PR  
29-AUG-2002; 2002US-0406655P.  
PR  
29-AUG-2002; 2002US-0406666P.  
PR  
17-SEP-2002; 2002US-0410946P.  
PR  
17-SEP-2002; 2002US-0410947P.  
PR  
17-SEP-2002; 2002US-0410948P.  
PR  
17-SEP-2002; 2002US-0410949P.  
PR  
17-SEP-2002; 2002US-0410953P.  
PR  
17-SEP-2002; 2002US-0410957P.  
PR  
17-SEP-2002; 2002US-0410958P.  
PR  
17-SEP-2002; 2002US-0410959P.  
PR  
17-SEP-2002; 2002US-0410960P.  
PR  
17-SEP-2002; 2002US-0410961P.  
PR  
17-SEP-2002; 2002US-0410962P.  
PR  
17-SEP-2002; 2002US-0411019P.  
PR  
17-SEP-2002; 2002US-0411037P.  
PR  
17-SEP-2002; 2002US-0411041P.  
PR  
17-SEP-2002; 2002US-0411045P.  
PR  
17-SEP-2002; 2002US-0411046P.  
PR  
17-SEP-2002; 2002US-0411048P.  
PR  
17-SEP-2002; 2002US-0411052P.  
PR  
17-SEP-2002; 2002US-0411055P.  
PR  
17-SEP-2002; 2002US-0411073P.  
PR  
17-SEP-2002; 2002US-0411082P.  
PR  
17-SEP-2002; 2002US-0411101P.  
PR  
17-SEP-2002; 2002US-0411111P.  
PR  
18-APR-2003; 2003US-0463700P.  
PR  
18-APR-2003; 2003US-0463708P.  
PR  
18-APR-2003; 2003US-0463716P.  
PR  
18-APR-2003; 2003US-0463732P.  
PR  
02-MAY-2003; 2003US-0467199P.  
PR  
02-MAY-2003; 2003US-0467201P.  
PR  
02-MAY-2003; 2003US-0467203P.  
PR  
02-MAY-2003; 2003US-0467230P.  
PR  
19-MAY-2003; 2003US-0471306P.  
PR  
19-MAY-2003; 2003US-0471336P.  
PR  
22-MAY-2003; 2003US-0472420P.  
PR  
22-MAY-2003; 2003US-0472430P.  
PR  
09-JUN-2003; 2003US-0476609P.  
PR  
09-JUN-2003; 2003US-0476641P.  
PR  
08-JUL-2003; 2003US-0485218P.  
PR  
08-JUL-2003; 2003US-0485223P.  
PR  
08-JUL-2003; 2003US-0485224P.  
PR  
14-JUL-2003; 2003US-0486446P.  
PR  
14-JUL-2003; 2003US-0486480P.  
PR  
15-JUL-2003; 2003US-0486891P.  
PR  
15-JUL-2003; 2003US-0486960P.  
PR  
08-AUG-2003; 2003US-0493341P.  
PR  
08-AUG-2003; 2003US-0493370P.  
PR  
08-AUG-2003; 2003US-0493573P.  
PR  
08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
DA  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;



XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3258; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antineoplastic, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 4683 AA;  
ADP31260 Length: 4683 February 22, 2005 12:25 Type: P Check: 9825 ..  
1 ATGGGCGCTGG GACCGGTTCC TTGACACTG GGTGGCCAC TGGCAGGGTT  
51 AGCTAAACCC ATAGACAGCA GTGACATGAA GAAAGCAGGT AGAGATGAAC  
101 CCTCGGACCC ACCTGCTGGC TGCCTACTCT CAACCCCGCT GCCCTTCGG  
151 GGCATCTGTT GCACATGAG GAGCACTGGA CTGGGAGTCA GCCTCTCAT  
201 CTGCGCTCTCT CTGGGCTTCT ACTTACACTG TGACGATGTG GCTTGGGAGG  
251 GCGTGGGTCA CTTCTTCCAC GAATTGGCCG AGGAGAAGCG CAAGGGTGCC  
301 TTAAGATGC AAACACGTA TGGCGGCTGC ATTCTTCTCC AGGACATCA  
351 GAACTGGCC CAATTTAGT TAGATAAGAC CTTGGACACG GCTGGACGCC  
401 GATGGGTTCC TCCGAGCGG AGGAAGAGG ATGGCGACCT CGTCGATGCC  
451 GGAGTCAGAG AGGAACGTGG CTACGAAGC CTCGGGCAGC CGCCGATCA  
501 GATGGAGGAG AACGAGGTGG AGAGCAGCAG CGACGCGGCC CTTGGGCGCTG  
551 GCCGCCCCGA GGAGCCCTCT GAGAGCGGCC TGGGTGTGGG CACCTCAGAA  
601 GCCGTGTCCG CCGACAGCAG CGAGCGCCGG GCCGCCCGG GGCAGGCAGA  
651 GCGCGATGAC TCTGGCGTGG GGCAAGCTC GGACCGCGGC AGCCGTTCTC  
701 AGGTATGGAC CCGGCTGGAC GCGGTGGGTG GAGGCAAGGA CCGCGAGCAG  
751 CAGTGCCTGA CAGCAAGAG GAACAAGGC TTGTTGTAG CTAATCTTG  
801 GTGTTTCTGG TTTACTGAGG AGGTATCTGA GAGCAGCTCG AGCGCAGACC  
851 CCTGCCTAA TAGCTACCTC CCGTATTCAT CGTCTGTGTC TCATGGGCA  
901 GTGGCAGGGG TGACAGGGCG TCCCCAGCA CTTGTGCACT CTAGTGCAC  
951 CCCAGACCCC AACATGTGTG TGTCCGACTG CACAGCTTCC TCCTCGGACC  
1001 TGGGCTCGGC CATCGACAAG ATCATCGAGT CCACCATCGG GCCGACCTC  
1051 ATCCAGACT GCATCACTGT GACCACTGCT GAGGATGGCG GGGCCGAGAC  
1101 CACACGGTAC CTGATCTTAC AGGGCCCGA TGATGGAGCC CCTATGACAT  
1151 CACCAATGTC CAGTTCACCC TTGGCCACA GCCTAGCAGC CATTGAGGCC  
1201 CTGGCAGATG GCCCAACATC CACATCAACA TGCCTGGAGG CACAGGGTGG  
1251 GCCAGCTCC CCGGTGCAGC TGCCCCCAGC CTCCGCTGCC GAAGAGCCGG

1301 ACCTGCAGAG CCTGGAGGCC ATGATGGAGG TGGTGGTGGT GCAGCAGTTC  
1351 AAATCAAGA TGTGCCAGTA CCGGAGCAGC ACCAAGGCCA CACTGCTCGG  
1401 CCACATGGGG GAACGCCACT TCCGTCCAGT AGCAGAGGCC GCAGCAGCAG  
1451 CTGGTAAAAA AGGACGTCTA CGGAAGTGA GCACCTCCAC CAAGAGCCAA  
1501 GAGGAAGAGG GACCAGAGGA GGAGGACGAT GATGACATTG TAGACGCTGG  
1551 AGCCATTGAT GACCTGAGG AGGATAGCGA CTATTAATCA CTGAGGATG  
1601 AGCCCCGAGG CCGGACGCTT CCGCTCCAGC GCCCCACCCC CAGTACCCCA  
1651 AGGCCCCGAA GGAGACCTGG CCGGCCCGGG AAGCTGCCCC CCCTGGAGAT  
1701 CTCAGACCTC CCAGATGGTG TGAAGGAGA GCCTCTAGTG AGTCCCACGA  
1751 GTGGACAGAG CCTTCCAGAG CCACAGGATC CCGAGGCTCC CAGCTCCTCA  
1801 GGCCACGAGC ACCTGGTGGC CATGGGCAAG GTGAGCAGGA CCCCTGTGGA  
1851 AGCTGGTGTG AGCCAGTCAG ATGCAGAGAA CGCAGCCCCC TCCTGCCCGG  
1901 ATGAGCATGA CACTCTGCC CCGCGCCGAG GTGACCTTTC CAGCGCTTC  
1951 CTAGGCAAGA AATACCGCAA GTATGTGGAG CAGAGGTACT ATTACAAGTC  
2001 GCCCAAAACA CTTTGTAGGC CTTTCTGTG CCGCATCTGT GGTTCCTGCT  
2051 TTCTGTCCCA CGAGGACCTG CGCTTCCAGC TCAACTCCCA TGAGGCTGGC  
2101 GATCCCCAGC TCTTCAAGTG CTTGCACTGC AGCTATCGTT CCCGCCGCTG  
2151 GTCTCTGCTC AAGGAGCACA TGTTCACCA CGTGGGCGAG AAGCCCTACA  
2201 AGTGTGACGA GTGCAGCTAC ACCAGTGTCT ACCGGAAGGA CGTCAATTCG  
2251 CACGCCGTG TGCACAGCCG GGNCCGGAAG AAGAGGCCAG ATCCGACTCC  
2301 AAAGCTGAGC TCTTTCCCTT GCGCTGTGTG TGGCCGTGTG TACCCCATGC  
2351 AGAAAAGACT CAGCGACGAC ATGAGACGCG ACAGCACTGA GAAGCCCCAC  
2401 ATGTGTGACA AGTGTGAAA GTCCCTTAAAG AAGCCTACA CCTTCAAAAT  
2451 GCACCTGCTC ACGCACATCC AGGCTGTTGC CAACCGCAGG TTCAAGTGTG  
2501 AGTTCTGTGA GTTTGTTTGT GAAAGACAAGA AGGCACCTGT GAACCAACAG  
2551 TTGTCCCAAG TCAGTGACAA GCCCTTCAAA TGCAGCTTTT GTCCCTACCG  
2601 CACCTTCCGA GAGGACTTCT TGTGTCCCA TGTGGCTGTC AAGCACACAG  
2651 GGGCAAGCC CTTCCGCTGT GAGTACTGCC ACTTCAGCAC ACGGCACAAG  
2701 AAGAACCTGC GCCTGACAGT ACGGTGCCGA CACGCAAGCA GCTTCGAGGA  
2751 ATGGGGGAGG CGCCACCCCTG AGGAGCCCCC CTCGCGCGCT CGCCCCCTTCT  
2801 TCTCTCTGCA GCAGATTGAG GAGCTGAAGC AGCAGCACAG TCGCGGCCCT  
2851 GGACCACTC CAGTTTCCCC AGGACCTCCT GAGATACCCC CAGAGGGGAC  
2901 AACTTTCCAG TCATCTGAGG CTCCTCTCAT GCTCTGTTCT GACACCTGG  
2951 GCGGGGCCAC CATCATCTAC CAGCAAGGAG CTGAGGAGTC GACAGCGATG  
3001 GCCAGGCAGA CAGCCTTGA TCTTCTGTG AACATGAGTG CTCAGCGGGA  
3051 ACTGGGGGGC ACAGCCCTGC AGGTGGCTGT GGTGAAGTCG GAAGATGTGG



PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3273; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 849 AA;  
ADP31275 Length: 849 February 22, 2005 12:25 Type: P Check: 5171 ..  
1 ATGGAGCAGG GGGCGGCGCT CGTCGGGGAG GCTCAGGCAT GGCCGACTGC  
51 AGGTCAAGGC AGAATCAG CACAGCAGCT GTGGCCCCAG GGTGAACAGG  
101 TCGAAGTGC GCTGGAGCA TCGGGCAGC GGCCGAGCGC GGGGAACATG  
151 GAGAGGAGC GGCATGTA CCGCAGTTC CAGGACTGGT GCCTCAGGAC  
201 TTACGGGAGC TCAGCAAGA CCAAGACGGT GACCCGTAAA AAATACGAAC  
251 GGATCGTCCA GCTCTCAAT GGCTCCGAGT CGAGCTCCAC GGACAACGCC  
301 AAATTAAAT TCTGGTCAA ATCGAAGGC TTCCAGCTGG GCCAGCCGGA  
351 CGAGGTCCGC GGGGAGGCG CGGCGGCCAA GCAAGTGCTC TACGTGCTGT  
401 TCAAGACCAC GGTGAGTCA TCGCTTCTC CTGTTATTG TCTGCCGGAG  
451 CAGCCGGCG GGGAGGAGG AAGGAGAG GGGGAGAGA GGGGAGCGG  
501 TGAGCCGCG TTGGCTGCTG TGCCCCCTAC CTTCTCTAAC CCCCTCCCA  
551 AGTCGTCCC ACTCGATTA GCCAGGCGG TTTTCCCCAC TGACAGTCT  
601 TTGTGCTCT TATTTTAAA CGGCAGCGC ACCTCAGAG CTGGGCTCCC  
651 TCCCCGCTC GGGTCCCG ACCGGTGA GAGGCTTCTT TCCCGGGTC  
701 GGGCGGCGC GTCTGGCTG CTGGGCTGG GCCATTGTCC CATGTCCTTC  
751 TCTGGGCGC TGGCGGCTGT CCACGCCG CCACGCCG TAAAGGCCAG  
801 GCTGAAGCC CGGCGCAG CTCTGAGC AGACGAGTCT GATCGATAG  
IIAA SEQUENCE 1.0  
ID\_ADP31302 standard; protein; 1536 AA.  
XX  
AC ADP31302;  
XX

DT 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #2069.  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0410963P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.

PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RE, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3300; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
XX Sequence 1536 AA;  
SQ  
ADP31302 Length: 1536 February 22, 2005 12:25 Type: P Check: 6514 ..  
1 TCACCAACTG CAAAGGCCCC TCCCTCTGG GCGCTCCCC TGGCACAATT  
51 CCGCTTCGAG AGTGACCTGC ACTCGCTGCT TCAACTGGAT GCACCCATCC  
101 CCAATGCACC CCTGTCTGCG TGGCAGCGCA AAGCCNAGAA AGCCACAGGC  
151 CCGGCCCCCT CACCCATGGG GGCOCGCCAAC CGATCCCA CA GCGCCAGCAG  
201 GACTCCGGGC CGAACTCCCTG GCMAATCCAG TTCCAAGGTT CAGACCACTC  
251 CTAGCAAAACC TGGCGGTGAC CGCTATATCC CCCATCGCAG TGTGCCCCAG  
301 ATGAGAGTTG CCAGCTTCCT CCTGAGCAAG GAGAACGAGC CTGAAACAG  
351 CCAGACGCC ACCAGAAGG AACATCAGAA AGCCTGGACT TTGAACCTGA  
401 ACGGTTTGA TGTAGAGGAA GCCAGATCC TTCGGCTCAG TGGAAACCA  
451 CAAATGGCG CAGAGGGTTA CCAGAACAGA CTGAAAGTAC TCTACAGCCA  
501 AAAGGCCACT CCTGGTCCA GCGCGAAGAC CTACCAATTAC ATTCTTCCC  
551 TGCAGACCA TAACCTGGAT GCCCTGAA TCCGAATGA CTACTACCTG  
601 AATCTTGGG ACTGGAGTTC TGGGAATGTA TTGGCCGTGG CGTGGACAA  
651 CAGTGTGTAC CTGTGGAGCG CAAAGCTCTGG TGACATCCTG CAGCTTTTGC  
701 AATGGAGCA GACTGGGAAA TATGTATCTT CTGCGGCGTG GATCAAGAG  
751 GGCAACTACT TGGCTGTGG CATTAGCAGT GCTGAGGTGC AGCTTTGGGA  
801 TGTGCAGCAG CAGAAACGGC TTGCAATAT GACCAATTCAC TCTGCCCCGAG  
851 TGGGCTCCTT AAGCTGGAAC AGCTATATCC TATCCAGTGG TTCACATTCT

901 GGCCACATCC ACCACCATGA TGTTCGGGTA GCAGAACACC ACGTGGCCAC  
951 ACTGAGTGGC CACAGCCAGG AAGTGTGTGG GCTGCGCTGG GTCCCAGATG  
1001 GACGACATTT GGCACAGTGT GGCAATGATA ACTTGGTCMA AGTGTGGCCT  
1051 AGTGCTCTTG GAGAGGGTGG CTGGGTTCTT CTGCAGACAT TCACCCCTTA  
1101 AGGGGCTGTC AAGGCCGTAG CATGGTGTCC CTGGAAGTCC AATGTCCCGG  
1151 CACACAGGAG GGGCACCAGT GATGCACACA TTTGCATCTG GAAAGTGTGC  
1201 TCTGGGGCCT GTCTGAGTGC CGTGGATGCC CTTTCCAGG TGTGCTCCAC  
1251 CCTCTGGTCT CCCCCTACA AGGAGCTCAT CTCAGGCCAT GGCCTTTGCAC  
1301 AGAACCCAGCT GGTATTATGG AAGTACCMAA CCATGGCCAA GGTGGCTGAA  
1351 CTCAAAGGTC ACACATCCCG GGTCTGACT CTGACCATGA GCCCAGATGG  
1401 GGCCACAGTG GCATCTGCAG CAGCAGATGA GACCCCGAGG CTATGGCACT  
1451 GTTTTGAGTT GGACCTCTGT TGGCGGCGG AGCGGAGAA GGCCAGTGCA  
1501 GCCAAAAGCA GCTTCATCCA CCAAGGCATC CGCTGA  
!!AA\_SEQUENCE 1.0  
ID ADP31437 standard; protein; 1464 AA.  
XX  
AC ADP31437;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2204.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-04111022P.  
PR 17-SEP-2002; 2002US-04111023P.  
PR 17-SEP-2002; 2002US-04111024P.  
PR 17-SEP-2002; 2002US-04111032P.  
PR 17-SEP-2002; 2002US-04111033P.  
PR 17-SEP-2002; 2002US-04111037P.  
PR 17-SEP-2002; 2002US-04111041P.  
PR 17-SEP-2002; 2002US-04111045P.  
PR 17-SEP-2002; 2002US-04111046P.  
PR 17-SEP-2002; 2002US-04111048P.  
PR 17-SEP-2002; 2002US-04111052P.  
PR 17-SEP-2002; 2002US-04111055P.  
PR 17-SEP-2002; 2002US-04111073P.  
PR 17-SEP-2002; 2002US-04111082P.  
PR 17-SEP-2002; 2002US-04111010P.  
PR 17-SEP-2002; 2002US-04111111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471308P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
FA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3435; 428pp; English.  
PS  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1464 AA;  
ADP31437 Length: 1464 February 22, 2005 12:25 Type: P Check: 4380 ..  
1 ATGAGGAAAA AGTCAAAAA GGCTGAAAT TCAAAAAACC AGATTGCGCTT  
51 TTCCTTCTCA AAGGATCACA ACTCTCGCC AGCAAGGGAA CAAAACCGAA

101 CAGGGAATAT ATTTGACGAA TTGACAGAAA TAGGCTTCAG AAGSTGGGTA  
151 ATGAGAAACT CCTCGAGCT AAAGGAGCAT GTTCTAACCC AATGCAAGGA  
201 AGCTAAGAAC CTTGAAAAAA CGTTAGAGGA ATTGCTAACT AGAATAACCA  
251 GTTTAGAGAA GAACATGAAA GACCTGATGG AGCTGAAAAA CACATCAAAA  
301 GAACTTTGTG AAGCATACAC AAGTATCAAT AGCCAAATTG ATATAGCAGA  
351 AGATATATCA GAGATTGAAG ATCAACTTAA TGAATATAAG CATGAAGACA  
401 AGATTAGAGA AAAAAGAATG AAAAGGAACA AAAAAAGCCT CCAAGAAATA  
451 TGGGACTATG TGAAGAAGATC AAACCTACTT TTGATTGGTG TACCTGAAAC  
501 TGATGGGGAT AATGGAACCA AGTTGGAAAA CACTCTTCAG GATATTATCC  
551 AGGAGAAGCTT CCCCAAGCTA GCAAGACAGG CAAACATTCA AATTGAGGAA  
601 ATACAGAGAA CACCACAAAG ATACTCTCG AGAAGAGCAA CCCCAGACA  
651 CATAATCATC AGATTCACCA AGTTGGAAT GAAAAAAA AAAAATTTTA  
701 AGGGCAGCCC AAGAGAAAGC ATAATCTCTG TACCAAAACC TGGCAGAGAC  
751 ACAACAAAAA AAGAAATTTT CAGGCCAATA TCCCTGATGA ACACGTGTC  
801 AAAAATCCTC AATAAATAC TGTCAACCA AATCCAGCAG CACATTGAAA  
851 AGCTTATCCA CCATGATCAA GTTGGTTTCA TCCCTGGGAT GCAAGGCTGG  
901 TTTAACATAT GCAATCAAT AAACGTAATC CATCACATAA ACAGAGCCAA  
951 CGACAAAAAC CACTTGATTA TCTCAACAGA TGCAGAAAG GCCTTCGATA  
1001 AAATTCAACA CCCCTTCATG ATAAAAACTC TCAATAAACT TGGTAGTGAG  
1051 GGAACATATC TCAAAATAAT AAGAGCTATT TATGACAAAC CCACAGCCAA  
1101 TATACTGAAT GGGGAAAGC TGGAAAGCATT TCGTTTGAAA ACTAGACAA  
1151 GACAGAGATA CCTCCGTC TCACTCCTAT TCAACATAGT GTTGGAGTTT  
1201 ATGGCTGGGG CAATCAGGCA AGAAGAAAGAA ATAAAGGGA TTCAATAGG  
1251 AAGAGAGGAA GTCAATTTGT CTCTGTTTGC AGGTGACTTG ACTGTATATT  
1301 TAGAAAAACC CATTTGCTCA GCCCAAAATC TCCTTAAAGCT GATAAGCAAC  
1351 TTCCTCAAG TCITAGGATA CAATATCAAT GTGCAAAAAT CACAAGCATT  
1401 CTTATCTCAG GAAAACACTG TCATTATCAA ATTAAGTTAT CATGTAGTTG  
1451 GTTACCATTA TTAG  
IIAA SEQUENCE 1.0  
ID\_ADP31449 standard; protein; 546 AA.  
XX  
XX ADP31449;  
XX AC  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2216.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX W02004035732-A2.  
XX  
XX

PD	29-APR-2004.	PA	(FIVE-) FIVE PRIME THERAPEUTICS INC.
XX		XX	Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
XX	28-AUG-2003; 2003WO-US026780.	PI	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnenmann T;
PR	29-AUG-2002; 2002US-0406576P.	PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
PR	29-AUG-2002; 2002US-0406579P.	XX	WPI; 2004-348438/32.
PR	29-AUG-2002; 2002US-0406585P.	XX	New nucleic acid molecule for diagnosing, preventing or treating diseases
PR	29-AUG-2002; 2002US-0406588P.	PT	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PR	29-AUG-2002; 2002US-0406608P.	PT	genetic, bacterial and viral diseases.
PR	29-AUG-2002; 2002US-0406611P.	XX	Claim 1; SEQ ID NO 3447; 428pp; English.
PR	29-AUG-2002; 2002US-0406612P.	XX	The present invention relates to an isolated nucleic acid molecule
PR	29-AUG-2002; 2002US-0406640P.	XX	encoding a polypeptide which is believed to be cytostatic,
PR	29-AUG-2002; 2002US-0406642P.	CC	antiinflammatory, immunosuppressive, antibacterial and virucidal. The
PR	29-AUG-2002; 2002US-0406653P.	CC	composition and methods are useful for diagnosing, preventing and
PR	29-AUG-2002; 2002US-0406655P.	CC	treating diseases such as proliferative (e.g. cancer), inflammatory,
PR	17-SEP-2002; 2002US-0410946P.	CC	immune, metabolic, genetic, bacterial and viral diseases. The present
PR	17-SEP-2002; 2002US-0410947P.	CC	sequence represents a human secreted protein. The present sequence is
PR	17-SEP-2002; 2002US-0410948P.	CC	available on WIPWEB and is not in the specification.
PR	17-SEP-2002; 2002US-0410949P.	XX	Sequence 546 AA;
PR	17-SEP-2002; 2002US-0410953P.	SQ	
PR	17-SEP-2002; 2002US-0410957P.	ADP311449	Length: 546 February 22, 2005 12:25 Type: P Check: 9923 ..
PR	17-SEP-2002; 2002US-0410958P.	1	ATGGCTATAA ACAACGGCTT TGAACCTTCT GGACAAGAAAT GGACAAGTAC
PR	17-SEP-2002; 2002US-0410960P.	51	AGAAGAGGAGA ATGAATAATA TACTTAACAA TCAGGATTCT AGTAAATTCA
PR	17-SEP-2002; 2002US-0410961P.	101	GATGTTGGTC TTCGGAGTTC TCCGGGGCCA GCAGCTGCCT GACCAGGGGC
PR	17-SEP-2002; 2002US-0410223P.	151	CCGGGGCCAC GGGCTCAGCC GACGACCATA GGCTCCGTGT CCACCCAGCA
PR	17-SEP-2002; 2002US-041023P.	201	GTTTGCAAGT GGCTCGCCA AGCGGCAGA AGAGGCACCC GAGGAGGCGC
PR	17-SEP-2002; 2002US-0411022P.	251	CGGAGGATGC GGGCCGGGCG GCGGACGAGG CTCAGCTGCT GCACGGTGAG
PR	17-SEP-2002; 2002US-0411024P.	301	GGCATCTGTA AGTGTTTCA CTTCGGCATG GGATTCCGCT TACTGTCCGT
PR	17-SEP-2002; 2002US-0411032P.	351	GACTGCCCGC GCCGTGGTGC CGCTCGACCC ACCAGTGGAC GTCTTTGTGC
PR	17-SEP-2002; 2002US-0411035P.	401	ACCAGAGTAA GCTGCCCATG GAAGCTTCC GGAGCTTGAA GGAGGGTGAG
PR	17-SEP-2002; 2002US-0411041P.	451	GCAGTGGAGT TCACCTTAA GAATCAGCC AAGGCTCTGG AATCCATCCG
PR	17-SEP-2002; 2002US-0411045P.	501	TGTCACCGGA CCTGGTGGG CGTTCCGTAT TGGGAGTGAG AGGTAG
PR	17-SEP-2002; 2002US-0411048P.	!!AA	SEQUENCE 1-0
PR	17-SEP-2002; 2002US-0411052P.	ID	ADP31462 standard; protein; 1101 AA.
PR	17-SEP-2002; 2002US-0411055P.	XX	ADP31462;
PR	17-SEP-2002; 2002US-0411073P.	XX	12-AUG-2004 (first entry)
PR	17-SEP-2002; 2002US-0411082P.	DT	Human secreted protein SEQ ID #2229.
PR	17-SEP-2002; 2002US-0411101P.	DE	
PR	17-SEP-2002; 2002US-0411111P.	XX	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
PR	18-APR-2003; 2003US-0463700P.	KW	cancer; inflammatory; immune; human secreted protein.
PR	18-APR-2003; 2003US-0463708P.	XX	Homo sapiens.
PR	18-APR-2003; 2003US-0463716P.	XX	WO2004035732-A2.
PR	18-APR-2003; 2003US-0463732P.	XX	29-APR-2004.
PR	02-MAY-2003; 2003US-0467199P.	XX	28-AUG-2003; 2003WO-US026780.
PR	02-MAY-2003; 2003US-0467201P.	XX	29-AUG-2002; 2002US-0406576P.
PR	02-MAY-2003; 2003US-0467203P.	XX	29-AUG-2002; 2002US-0406579P.
PR	19-MAY-2003; 2003US-0471306P.	XX	29-AUG-2002; 2002US-0406585P.
PR	19-MAY-2003; 2003US-0471336P.	XX	29-AUG-2002; 2002US-0406588P.
PR	22-MAY-2003; 2003US-0472420P.	XX	
PR	09-JUN-2003; 2003US-0472430P.	XX	
PR	09-JUN-2003; 2003US-0476609P.	XX	
PR	09-JUN-2003; 2003US-0476641P.	XX	
PR	08-JUL-2003; 2003US-0485218P.	XX	
PR	08-JUL-2003; 2003US-0485223P.	XX	
PR	08-JUL-2003; 2003US-0485224P.	XX	
PR	08-JUL-2003; 2003US-0485325P.	XX	
PR	14-JUL-2003; 2003US-0486446P.	XX	
PR	15-JUL-2003; 2003US-0486891P.	XX	
PR	15-JUL-2003; 2003US-0486960P.	XX	
PR	08-AUG-2003; 2003US-0493341P.	XX	
PR	08-AUG-2003; 2003US-0493370P.	XX	
PR	08-AUG-2003; 2003US-0493573P.	XX	
XX	08-AUG-2003; 2003US-0493577P.	XX	

PR	29-AUG-2002;	2002US-0406508P
PR	29-AUG-2002;	2002US-0406611P
PR	29-AUG-2002;	2002US-0406612P
PR	29-AUG-2002;	2002US-0406616P
PR	29-AUG-2002;	2002US-0406640P
PR	29-AUG-2002;	2002US-0406642P
PR	29-AUG-2002;	2002US-0406646P
PR	29-AUG-2002;	2002US-0406653P
PR	29-AUG-2002;	2002US-0406655P
PR	29-AUG-2002;	2002US-0406666P
PR	17-SEP-2002;	2002US-0410946P
PR	17-SEP-2002;	2002US-0410947P
PR	17-SEP-2002;	2002US-0410948P
PR	17-SEP-2002;	2002US-0410949P
PR	17-SEP-2002;	2002US-0410953P
PR	17-SEP-2002;	2002US-0410957P
PR	17-SEP-2002;	2002US-0410958P
PR	17-SEP-2002;	2002US-0410959P
PR	17-SEP-2002;	2002US-0410960P
PR	17-SEP-2002;	2002US-0410961P
PR	17-SEP-2002;	2002US-0410962P
PR	17-SEP-2002;	2002US-0411019P
PR	17-SEP-2002;	2002US-0411022P
PR	17-SEP-2002;	2002US-0411023P
PR	17-SEP-2002;	2002US-0411024P
PR	17-SEP-2002;	2002US-0411045P
PR	17-SEP-2002;	2002US-0411046P
PR	17-SEP-2002;	2002US-0411048P
PR	17-SEP-2002;	2002US-0411052P
PR	17-SEP-2002;	2002US-0411055P
PR	17-SEP-2002;	2002US-0411073P
PR	17-SEP-2002;	2002US-0411082P
PR	17-SEP-2002;	2002US-0411101P
PR	17-SEP-2002;	2002US-0411111P
PR	18-APR-2003;	2003US-0463700P
PR	18-APR-2003;	2003US-0463708P
PR	18-APR-2003;	2003US-0463716P
PR	18-APR-2003;	2003US-0463723P
PR	02-MAY-2003;	2003US-04671199P
PR	02-MAY-2003;	2003US-0467201P
PR	02-MAY-2003;	2003US-0467203P
PR	02-MAY-2003;	2003US-0467230P
PR	02-MAY-2003;	2003US-0471306P
PR	19-MAY-2003;	2003US-0471336P
PR	19-MAY-2003;	2003US-0472420P
PR	22-MAY-2003;	2003US-0472430P
PR	09-JUN-2003;	2003US-0476609P
PR	09-JUN-2003;	2003US-0476641P
PR	08-JUL-2003;	2003US-0485219P
PR	08-JUL-2003;	2003US-0485223P
PR	08-JUL-2003;	2003US-0485224P
PR	08-JUL-2003;	2003US-0485325P
PR	14-JUL-2003;	2003US-0486446P
PR	14-JUL-2003;	2003US-0486450P
PR	15-JUL-2003;	2003US-0486891P
PR	15-JUL-2003;	2003US-0486960P
PR	08-AUG-2003;	2003US-0493341P
PR	08-AUG-2003;	2003US-0493370P
PR	08-AUG-2003;	2003US-0493573P
PR	08-AUG-2003;	2003US-0493577P

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
 PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
 PT genetic, bacterial and viral diseases.  
 XX  
 PS Claim 1; SEQ ID NO 3460; 428pp; English.  
 XX  
 CC The present invention relates to an isolated nucleic acid molecule  
 CC encoding a polypeptide which is believed to be cytostatic,  
 CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
 CC composition and methods are useful for diagnosing, preventing and  
 CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
 CC immune, metabolic, genetic, bacterial and viral diseases. The present  
 CC sequence represents a human secreted protein. The present sequence is  
 CC available on WIPONBBS and is not in the specification.

```

!!AA_SEQUENCE 1.0
ID   ADP31478 standard; protein; 444 AA.
XX
XX
AC   ADP31478;
XX
DT   12-AUG-2004 (first entry)
XX
DE   Human secreted protein SEO ID #2245

```

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW Cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
PN  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.

PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3476; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 444 AA;  
ADP31478 Length: 444 February 22, 2005 12:25 Type: P Check: 6367 ..  
1 ATGGATGAAG ATGGAATATCA TCATTCTGAG CAAACTATTG CAAGGACAGA  
51 AAAGCAATA CCACGTGTC TCACTCATAG GTCTTGCTAT ACCGTGTTTG  
101 GCAAAGGGTT AGAATTGTGT GGAACAGGGC TGGGGGACAT TGACTTTTGA  
151 TCTGCTCTT TAGTTAAAC CCCACTGTTT CATGCCATAG ATCATGGAAG  
201 AGATGACTTG GCCCTGGAAA ATGTTAAGC AGGATTGGAT GTGGCGACAG  
251 CGACTGTAAC CAAGCCGACA CAAAGGCAC CATCTGCTCC TCTGTCGTC  
301 CTTCTCTGCAC TCCCACTCCC ATGCCAGTTC TCTCATCCCC CATGCCGTGC  
351 TCATGGTACA TGGCTCCCTG GCTGTCCCA TCTTGTCCTT GCTTGTACG  
401 GCAGTGCCTC ACATTCTGCG ATTGTGATG TTTGCTTGGT GTGA  
!!AA SEQUENCE 1.0  
ID ADP31505 standard; protein; 312 AA.  
XX  
AC ADP31505;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2272.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.



```
PR 29-AUG-2002; 2002US-0406576P.
PR 29-AUG-2002; 2002US-0406579P.
PR 29-AUG-2002; 2002US-0406585P.
PR 29-AUG-2002; 2002US-0406588P.
PR 29-AUG-2002; 2002US-0406608P.
PR 29-AUG-2002; 2002US-0406611P.
PR 29-AUG-2002; 2002US-0406612P.
PR 29-AUG-2002; 2002US-0406616P.
PR 29-AUG-2002; 2002US-0406640P.
PR 29-AUG-2002; 2002US-0406642P.
PR 29-AUG-2002; 2002US-0406646P.
PR 29-AUG-2002; 2002US-0406653P.
PR 29-AUG-2002; 2002US-0406655P.
PR 29-AUG-2002; 2002US-0406666P.
PR 17-SEP-2002; 2002US-0410946P.
PR 17-SEP-2002; 2002US-0410947P.
PR 17-SEP-2002; 2002US-0410953P.
PR 17-SEP-2002; 2002US-0410957P.
PR 17-SEP-2002; 2002US-0410958P.
PR 17-SEP-2002; 2002US-0410959P.
PR 17-SEP-2002; 2002US-0410960P.
PR 17-SEP-2002; 2002US-0410961P.
PR 17-SEP-2002; 2002US-0410962P.
PR 17-SEP-2002; 2002US-0411019P.
PR 17-SEP-2002; 2002US-0411022P.
PR 17-SEP-2002; 2002US-0411023P.
PR 17-SEP-2002; 2002US-0411024P.
PR 17-SEP-2002; 2002US-0411032P.
PR 17-SEP-2002; 2002US-0411035P.
PR 17-SEP-2002; 2002US-0411037P.
PR 17-SEP-2002; 2002US-0411041P.
PR 17-SEP-2002; 2002US-0411045P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411052P.
PR 17-SEP-2002; 2002US-0411055P.
PR 17-SEP-2002; 2002US-0411073P.
PR 17-SEP-2002; 2002US-0411082P.
PR 17-SEP-2002; 2002US-0411101P.
PR 17-SEP-2002; 2002US-0411111P.
PR 18-APR-2003; 2003US-0463700P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 18-APR-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467203P.
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 08-JUL-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485323P.
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
PR
XX
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
PI Williams LT, Chu K, Lee E, Heatir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linneemann T;
```

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 3503; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytosolic,  
anti-inflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPWEB and is not in the specification.  
SQ Sequence 312 AA;  
ADP31505 Length: 312 February 22, 2005 12:25 Type: P Check: 6823  
1 ATGACAGGAC ACCCAAGC AGCCAGGAGG TTCCCAAGAC CCGACATGT  
51 GCAGCAGCTG CAGCCTGATG CAGAGCCCGT CATGCAATC CACACAGGAA  
101 CAAAACATTG CTACAAGTAT GGAGCAGACG AGTGTGGGG GTATACTGGG  
151 CTGGAGAGAC AGAAGGGAAT GCATGAACA CTCAAGGGAA ATCCAATAAA  
201 GACCTGGACT AAGAAAGACA GTGATGATGG AGATGGAGAG GAGATGGTGA  
251 CTGAAGATTC CGTGACCAAT GGNATGGAG GGATGGAGGG AAAAACAAAA  
301 GCAAAGGGAAT AG  
!!AA SEQUENCE 1.0  
ID \_ADP31567 standard; protein; 471 AA.  
XX  
AC ADP31567;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2334.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485232P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493373P.  
PR 08-AUG-2003; 2003US-0493377P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3565; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present

CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

XX Sequence 471 AA;

SQ ADP31567 Length: 471 February 22, 2005 12:25 Type: P Check: 8022 ..

1 ATGAGGACAC AACAGAAGG AACCATCTAT GAACACGAAA ATGGGCCCTC  
51 ACCAAGCACT GAATCTGCTG GTGCCCTGAT GTTGGACTTT CCAGCTTCCA  
101 GACTAGAATC TCAAGCAATC TCCAAAAAGT TCCTCAAAC TCAAGAGTAT  
151 GGGAAAAATGG CTTGCGGTTT GAATACCACC GAGAAGCCAG TGGCTCTGCA  
201 GGCAGTCATA TCAGTGTCTG CTCGAGTCT CTGCCCTCTCA ACAGCATGGC  
251 ATGACCGGTC TCTCCTGGAT AAGAAGGAC CAGCTCAAAT TTCCTCTCTG  
301 ACAAGTTGGG ATACTATGTG TTTCTCAAG GACCAAGNAG ATAAAATTAG  
351 GGAGGTTTAT GAGCAATTC TCAACGTCAA ACTAGCAGAG AAATATGAAT  
401 CGTTTGTGAA ACTTACATGT GATCAGATCA TACAGTCAAG TGGCAGAGGG  
451 CCAACCAAGCA ATGTTTCTTG A

!IAA SEQUENCE 1.0

ID ADP31570 standard; protein; 1560 AA.

XX  
AC ADP31570;

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2337.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 17-SEP-2002; 2002US-0410946P.

XX 17-SEP-2002; 2002US-0410947P.

XX 17-SEP-2002; 2002US-0410948P.

XX 17-SEP-2002; 2002US-0410953P.

XX 17-SEP-2002; 2002US-0410957P.

XX 17-SEP-2002; 2002US-0410958P.

XX 17-SEP-2002; 2002US-0410959P.

XX 17-SEP-2002; 2002US-0410960P.

XX 17-SEP-2002; 2002US-0410961P.

XX 17-SEP-2002; 2002US-0410962P.

XX 17-SEP-2002; 2002US-0411019P.







401 CTCGGGCGG AGCTGATCCG AGAGGACATC CAGGGGGCTC TGCACAATTA  
451 CCGCTCGGC CGCGGGGAGC GCAGGGCGGC GGCCTCAGC TGGCGTTTCT  
501 GCAGGCGGAG CGGGAAGTGG ACATCCTGAA CCACGTGTTT GACGACGTAG  
551 AGAGCTTTGT ATCGAGGCTG CAGAAGTCGG CGGAGGGCGC CAGGTTGCTG  
601 GAGCACCGG AACCGCGCG CAGGAGCGCG CGCCGGGCGG CTGGGAGGG  
651 CTTGCTGACG CTCGGGGCCA AGCCGCCCTC GGAGGCCGAG TACACGACG  
701 TGTGTCAGAA GATCAAGTAC GCCTTCAGC TGTGGCCCG GCTGCGCGC  
751 AACATCGCG ACCCTTCCTC TCCGAGCTG TTGCACCTCC TTTTCGGGC  
801 TCTGCAGATG ATTGTGAACA CGTCGGGGG GCGGAGTTC GCAGCAGTG  
851 TGGCGCGGC GCATCTGACA TCGGATGCG TGGCGCTGCT GCGGACAAC  
901 GTCACTCCAC GTGAAAACA GCTCTGGACC TCGTGGGGG ACTGTTGGAC  
951 CCGCCCCGGG GCTGGAGCC GCGGTCACT GACCCGCAGA GCCGCGCTG  
1001 GGAGGACCCA GTTGAGAAAC AGCTACAGCA CGAGCGGAG CGCCGCGAGC  
1051 AAGCGGCCCC CAGGTCGCT GTCAATGGGA AATGGGTCC TGTGTAATTA  
1101 TGACTTCCAG GCCCGCAACA CAGTGAGCT GTCGGTCAAG CAGCGGAGC  
1151 TACTGGAGGT CCTGGATGAC AGTCGTAAGT GGTGGAAGT TCGGACCCA  
1201 CGGGGGCAGG AGGGATATGT GCCCTACAA ACCTGCAC CCTACCCCG  
1251 ACCCGGCTG CACCACAGCC AAAGCCCTGC CCGCAGCCTG CCACGAGGA  
1301 AGGAGAAATT CTCACAGATG CTCATCGTCA ACAGGAACT GCAGGCGCGC  
1351 CTGGCCCGAG GCGCTCGGG ACGGAGCGC GCAGTCCAG GGGCCCGCGC  
1401 CCGGGAACCG CAGCTCAGCC CGGGCTCGGA CGCTCCGAG GTCCGCGCTT  
1451 GGCTGCAGG CAAAGGCTTT AGCTCGGGA CCGTGGAGC GCTGGGTGTG  
1501 CTGACCGGG CGCAGCTTTT CTCGTGCGAG AGGAGGAGC TGGCGGGGT  
1551 GAGCCCCGAG GAGGGGGCAC GTGTGTACAG CCAGGTCAAC GTGACGCT  
1601 CGCTGTCTGA GGACAAAGAG AAGTGTACAG AGCTGGAGG AGTGATGGAG  
1651 AAGCAAAAGA AGAAGTGGA AGGCGAGGTG GAAATGGAG

!!AA\_SEQUENCE 1.0  
ID -ADP30476 standard; protein; 312 AA.

AC ADP30476;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1243.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

29-AUG-2002; 2002US-0406579P.  
29-AUG-2002; 2002US-0406585P.  
29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411019P.  
18-APR-2003; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486891P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2474; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 312 AA;  
ADP30476 Length: 312 February 22, 2005 12:25 Type: P Check: 5106 ..  
1 ATGAGCGCG CGAGCTCCG TGGCGCGCC GCGGGTTGG GGCTGCTGCT  
51 GTGCGCGGTG CTGGGGCGCG CTGGCCGGTC AGACAGCGGC GGTCCGCGGG  
101 AACTCGGGCA GCCCTCTGGG GTAGCGCGCG AGCGCCCATG CCCCACTACC  
151 TCCCGTGGC TCGGGGACCT GTGGACTGC AGTCGTAAGC GGCTAGCGCG  
201 TCTTCCCGAG CCATCTCCGT CTTGGGTGCG TCGGCTGGAC TTAAGTCACA  
251 ACAGATTATC TTTTCATCAAG GCAAGTTCCA TGAGCCACCT TCARAAGCCTT  
301 CGAGAGTGT GA  
!!IAA SEQUENCE 1.0  
ID ADP30615 standard; protein; 153 AA.  
XX  
AC ADP30615;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1382.  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Hallenbeck RF, Huang MM, Kothakota S, Haishan L, Linemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2613; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.  
XX  
XX Sequence 312 AA;  
ADP30476 Length: 312 February 22, 2005 12:25 Type: P Check: 5106 ..  
1 ATGAGCGCG CGAGCTCCG TGGCGCGCC GCGGGTTGG GGCTGCTGCT  
51 GTGCGCGGTG CTGGGGCGCG CTGGCCGGTC AGACAGCGGC GGTCCGCGGG  
101 AACTCGGGCA GCCCTCTGGG GTAGCGCGCG AGCGCCCATG CCCCACTACC  
151 TCCCGTGGC TCGGGGACCT GTGGACTGC AGTCGTAAGC GGCTAGCGCG  
201 TCTTCCCGAG CCATCTCCGT CTTGGGTGCG TCGGCTGGAC TTAAGTCACA  
251 ACAGATTATC TTTTCATCAAG GCAAGTTCCA TGAGCCACCT TCARAAGCCTT  
301 CGAGAGTGT GA

CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 153 AA;  
ADP30615 Length: 153 February 22, 2005 12:25 Type: P Check: 6416 ..  
1 ATGAGGAAAC CGGATGCTG GAGATTGACG TGCAGGCCCG AGACCTGGGG  
51 CCTAACCTTA TCCAGCCCA CTGCAAGTC ACGETCAAGC TCATCGACCG  
101 CAACGACAAT GCGCCGTCCA TCGGTTTCGT CTCGTGCGC CAGGGGGCGC  
151 TGA  
!!AA SEQUENCE 1.0  
ID\_ADP30623 standard; protein; 213 AA.  
XX  
AC ADP30623;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1390.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.

PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haisan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2621; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 213 AA;  
ADP30623 Length: 213 February 22, 2005 12:25 Type: P Check: 3925 ..  
1 ATGCAGACGA GGGAGCCAC GGGGAGCTGG CGTTCGAGCT GCAGCAGCAG  
51 GAGCCGCGCG AAGCCTTCGC CATCGGCCGC CGCACGGGGG AGATACTGCT  
101 CACCGGGGAC CTCGCGCAGG AGCCACCGCG TCGGTGTTTC AGGGCGCTCC  
151 TGGTCTATTC CGACGGCGGC GTCCCCCGC TCACCACCAC CGCAACTGTC  
201 AGCTTCGTGG TAA  
!!AA SEQUENCE 1.0  
ID\_ADP30638 standard; protein; 291 AA.  
XX  
AC ADP30638;  
XX  
DT 12-AUG-2004 (first entry)



```
XX DE Human secreted protein SEQ ID #1405.
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
XX KW cancer; inflammatory; immune; human secreted protein.
XX OS Homo sapiens.
XX PN WO2004035732-A2.
XX PD 29-APR-2004.
XX PF 28-AUG-2003; 2003WO-US026780.
XX PR 29-AUG-2002; 2002US-0406576P.
XX PR 29-AUG-2002; 2002US-0406579P.
XX PR 29-AUG-2002; 2002US-0406585P.
XX PR 29-AUG-2002; 2002US-0406588P.
XX PR 29-AUG-2002; 2002US-0406608P.
XX PR 29-AUG-2002; 2002US-0406611P.
XX PR 29-AUG-2002; 2002US-0406612P.
XX PR 29-AUG-2002; 2002US-0406616P.
XX PR 29-AUG-2002; 2002US-0406640P.
XX PR 29-AUG-2002; 2002US-0406642P.
XX PR 29-AUG-2002; 2002US-0406646P.
XX PR 29-AUG-2002; 2002US-0406653P.
XX PR 29-AUG-2002; 2002US-0406655P.
XX PR 29-AUG-2002; 2002US-0406666P.
XX PR 17-SEP-2002; 2002US-0410946P.
XX PR 17-SEP-2002; 2002US-0410947P.
XX PR 17-SEP-2002; 2002US-0410948P.
XX PR 17-SEP-2002; 2002US-0410949P.
XX PR 17-SEP-2002; 2002US-0410953P.
XX PR 17-SEP-2002; 2002US-0410957P.
XX PR 17-SEP-2002; 2002US-0410958P.
XX PR 17-SEP-2002; 2002US-0410959P.
XX PR 17-SEP-2002; 2002US-0410960P.
XX PR 17-SEP-2002; 2002US-0410961P.
XX PR 17-SEP-2002; 2002US-0410962P.
XX PR 17-SEP-2002; 2002US-0411019P.
XX PR 17-SEP-2002; 2002US-0411022P.
XX PR 17-SEP-2002; 2002US-0411023P.
XX PR 17-SEP-2002; 2002US-0411024P.
XX PR 17-SEP-2002; 2002US-0411032P.
XX PR 17-SEP-2002; 2002US-0411035P.
XX PR 17-SEP-2002; 2002US-0411037P.
XX PR 17-SEP-2002; 2002US-0411041P.
XX PR 17-SEP-2002; 2002US-0411045P.
XX PR 17-SEP-2002; 2002US-0411046P.
XX PR 17-SEP-2002; 2002US-0411048P.
XX PR 17-SEP-2002; 2002US-0411052P.
XX PR 17-SEP-2002; 2002US-0411055P.
XX PR 17-SEP-2002; 2002US-0411073P.
XX PR 17-SEP-2002; 2002US-0411082P.
XX PR 17-SEP-2002; 2002US-0411101P.
XX PR 17-SEP-2002; 2002US-0411111P.
XX PR 18-APR-2003; 2003US-0463700P.
XX PR 18-APR-2003; 2003US-0463708P.
XX PR 18-APR-2003; 2003US-0463716P.
XX PR 18-APR-2003; 2003US-0463732P.
XX PR 02-MAY-2003; 2003US-0467199P.
XX PR 02-MAY-2003; 2003US-0467201P.
XX PR 02-MAY-2003; 2003US-0467203P.
XX PR 02-MAY-2003; 2003US-0467230P.
XX PR 19-MAY-2003; 2003US-0471306P.
XX PR 19-MAY-2003; 2003US-0471336P.
XX PR 22-MAY-2003; 2003US-0472420P.
XX PR 09-JUN-2003; 2003US-0472430P.
XX PR 09-JUN-2003; 2003US-0476609P.
XX PR 08-JUL-2003; 2003US-0485218P.
XX PR 08-JUL-2003; 2003US-0485223P.
XX PR 08-JUL-2003; 2003US-0485224P.
XX PR 08-JUL-2003; 2003US-0485325P.
XX PR 14-JUL-2003; 2003US-0486446P.
XX PR 14-JUL-2003; 2003US-0486480P.
XX PR 15-JUL-2003; 2003US-0486891P.
XX PR 15-JUL-2003; 2003US-0486960P.
XX PR 08-AUG-2003; 2003US-0493341P.
XX PR 08-AUG-2003; 2003US-0493370P.
XX PR 08-AUG-2003; 2003US-0493573P.
XX PR 08-AUG-2003; 2003US-0493577P.
XX PA (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX WPI; 2004-348438/32.
XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases
XX PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
XX PT genetic, bacterial and viral diseases.
XX PS Claim 1; SEQ ID NO 2636; 428pp; English.
XX CC The present invention relates to an isolated nucleic acid molecule
XX CC encoding a polypeptide which is believed to be cytosstatic,
XX CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
XX CC composition and methods are useful for diagnosing, preventing and
XX CC treating diseases such as proliferative (e.g. cancer), inflammatory,
XX CC immune, metabolic, genetic, bacterial and viral diseases. The present
XX CC sequence represents a human secreted protein. The present sequence is
XX CC available on WIPWEB and is not in the specification.
XX SQ Sequence 291 AA;
ADP30638 Length: 291 February 22, 2005 12:25 Type: P Check: 1379 ..
1 ATGACAACGC CCCACCTTC ACCCAAACCT CCTACACCTT GTTCGTCGCG
51 GAGAACAAACA GCCCGGCCCT GCACATCGGC AGTGTCAGCG CTACAGACAG
101 AGATCAGGC ACCAAGCCCC AGGTCAACTA CTCGCTACTC CCGCCCCCAGG
151 ACCTGCACCT GCCCTCGCC TCCTGTGTCT CCATCAACAC AGACAACGCG
201 CACCTGTTGG CCCTCAGGTC GCTGGACTAC GAGGCCCTGC AGGCTTTGGA
251 CTTCGCGTGG GCGGCCACAG ACCGCGGCTC CCGGCTTTG A
!!AA SEQUENCE 1.0
ID _ADP30647 standard; protein; 1134 AA.
XX AC ADP30647;
XX DT 12-AUG-2004 (first entry)
XX DE Human secreted protein SEQ ID #1414.
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
XX KW cancer; inflammatory; immune; human secreted protein.
XX OS Homo sapiens.
XX PN WO2004035732-A2.
XX PD 29-APR-2004.
XX PF 28-AUG-2003; 2003WO-US026780.
XX PR 29-AUG-2002; 2002US-0406576P.
XX PR 29-AUG-2002; 2002US-0406579P.
XX PR 29-AUG-2002; 2002US-0406585P.
XX PR 29-AUG-2002; 2002US-0406588P.
```





PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411053P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493373P.  
PR 08-AUG-2003; 2003US-0493377P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX

DR WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2705; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 354 AA;  
SQ  
ADP30707 Length: 354 February 22, 2005 12:25 Type: P Check: 1208 ..  
1 ATGGCTGGG GCCTGGGCT GCTGCTGG CTGCTGTCG TCCTGCTGC TCGGCTGCC  
51 CTGGCGGGTG CCGGCCACG TGGACCCAG CACTGGCCG CGGTTCTCGG  
101 AGCACAAACT CTGGCGGAC GACGAATGCA GCATGTTAAT GTACCGCGGT  
151 GAGGCTCTTG AAGATTTCAC AGGCCCGAT TGTGCTTTTG TGAATTTTAA  
201 AAAAGGTGAT CTTGTATATG TTTACTATAA ACTGGCAAGA GGATGGCCTG  
251 AAGTTTGGGC TGGAACTGTT GGACGCAC TTGGATATTT TCCAAAAGAT  
301 TTAATCCAGG TAGTTCATGA ATATACCAA GAAGAGCTAC AAGTTCCAAAC  
351 AGAT  
11AA SEQUENCE 1.0  
ID ADP30928 standard; protein; 1133 AA.  
XX AC ADP30928;  
XX DT 12-AUG-2004 (first entry)  
DE Human secreted protein SEQ ID #1695.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.  
XX WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472436P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486892P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Hallenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2926; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present

CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1133 AA;  
ADP30928 Length: 1133 February 22, 2005 12:25 Type: P Check: 237 ..  
1 TCTGATCGTG AAGTAGAAG AAGTCTCACA AACAGCCATT TGGAAAAAAA  
51 GAAGTGTGAT GAGTATATTC CAGGTACAAC CTCCTTAGGC ATGTCGTGTT  
101 TTAACCTAAG CAACGCCATT ATGGGCAGTG GGAATTTGGG ACTGCGCTTT  
151 GCCCTGGCAA ACACCTGGAAT CCTACTTTTT CTGGTACTTT TGACTTCAGT  
201 GACATTGCTG TCTATATATT CAATAAACCT CCTATTGATC TGTTCAAAAG  
251 AACAGGCTG CATGGTGTAT GAAAAGCTGG GGGAAACAAG CTTTGGGACC  
301 ACAGGGAAGT TCGTAATCTT TGGAGCCACC TCTCTACAGA ACACGTGGAGC  
351 AATGCTGAGC TACCTCTTCA TCGTAAAAA TGAACCTACCC TCTGCCATAA  
401 AGTTTCTAAT GGGAAAGGAA GAGATGCATT TTCCCCAGAC CTGGTACGTG  
451 GATGGCCGCG TTCTGGTGGT GATAGTTACC TTGGCATAA TTCTCCCTCT  
501 GTGTCCTTTG AAGAACCTAG GGTATCTTGG CTATACTAGT GGATTTTCTT  
551 TGAGCTGTAT GGTTTTTTTC CTAATTGTGG TGTATGTGG ACCACCCATT  
601 GCATTTGCAAT TTGTTTGCCA CCGTCAAGTC CTGCCAATTT ACAGTGAGCT  
651 TAAAGACCGA TCACAGAAAA AATGCAGAT GGTTCACAA ACCTCTCTTT  
701 TCGCCATGTT TGTATGTAC TTCTTGACTG CCAATTTTGG CTACTTGACA  
751 TTCTATGACA ACGTGCAGTC CGACCTCCTT CACAAATATC AGAGTAAAGA  
801 TGACATTCTC ATCTGACAG TGGGGCTGGC TGTCAATTGT GCTGTGATCC  
851 TCACAGTGCC GGTGTTAATT TTCACTTAT CAACTTGTTG GTGATCTTCA  
901 TACCCTCCAT GAAGGATATT TTGGAGTGG TAGGAGTTAC ATCTGCTAAC  
951 ATGCTTATT TCATCTCTCC TTCATCTCTT TATTTAAAA TCACAGACCA  
1001 GGATGGAGAT AAAGGAACAT AAGAATTTG GGCTGCCCTT TTCTTGGGCC  
1051 TGGGGGTGTT GTTCTCCTTG GTCAGCATTC CTTGGTCAAT CTATGACTGG  
1101 GCCTGCTCAT CGAGTAGTGA CGAAGGCCAC TGA  
!!AA SEQUENCE 1.0  
ID ADP30935 standard; protein; 1205 AA.  
XX  
AC ADP30935;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1702.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX

PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI  
XX  
XX  
XX  
PT  
PT  
XX  
PS  
XX  
CC  
CC  
CC  
CC  
CC  
CC  
XX  
SQ

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 2933; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPWEB and is not in the specification.

Sequence 1205 AA;

ADP30935 Length: 1205 February 22, 2005 12:25 Type: P Check: 6813 ..

1 CCCCCAGCAG GCCCTGTAGG GAGGAGCTG TCAGCCAGGG AAAACCGAGA  
51 ACACCATCAC CATGACAACC AGTCACCAGC CTCAGGACAG GTAAGGGCTG  
101 TCTGGCTTAT CTTCTTCATG CTGGGTCTGG GAACGGTGCT CCGTGGGANT  
151 TTTTTCATGA CGGCCACTCA GTCTCTCAGT GCCATCTTCA ACAATGTGAT  
201 GACCCATATG GCCATGTGCG CCCTGCTGTT ATTCACCTAC CTCAACTCCT  
251 TCCTGCATCA GAGGATCCCC CAGTCCGTAC GGATCCTGGG GAGCCTGGTG  
301 GCCATCCTGC TGGTGTCTTCT GATCACTGCC ATCCTGGTGA AGGTGCGAGT  
351 GGATGCTCTG CCGTTCTTTG TCATCACCAT GATCAAGATC GTGCTCATTA  
401 ATTCATTGG TGCATCTCTG CAGGGGAGCC TGTTTGGTCT GGCTGGCCTT  
451 CTGCTTGCCA GCTACACGCG CCCCATCATG AGTGGCCAGG GCCTAGCAGG  
501 CTTCTTTGCC TCCGTGGCCA TGATCTGGC TATTGCCAGT GGCTCGGAGC  
551 TATCAGAAAG TGCCTTCGCG TACTTTATCA CAGCCTGTGC TGTATCATTT  
601 TTGACCATCA TCTGTACCT GGGCTGCCC CGCCTGGAAT TCTACCGCTA  
651 CTACCAGCAG CTCAGCTTGG AAGGACCCGG GGAGCAGGAG ACCAAGTTGG  
701 ACCTCATTAG AGAGGAGCCA AGACGAGCA AGAGGAATC TGGAGTTTCA  
751 GTCTCCAAT CTCAGCCAC CAATGAAAGC CACTCTATCA AAGCCATCCT  
801 GAAATATC TCAGTCTGCG CTTTCTCTGT CTGCTTCATC TTCACTATCA  
851 CATTGGGAT GTTCCAGCC GTGACTGTTG AGTCAAGTC CAGCATCGCA  
901 GGCAGCAGCA CCTGGGAACG TTACTTCATT CCTGTGTCTT GTTCTTGAC  
951 TTTCAATATC TTTGACTGGT TGGCCCGGAG CCTCACAGCT GTATTCACT  
1001 GGGCCTGGTT CATCTTCTTC ATGCTGGCTT TCGCTTCTC CAACGGCTAC  
1051 CTGCCAGCC TCTGCATGCT CTTCCGGCCC AAGAAAGTGA AGCCAGCTGA  
1101 GGCAGAGACC GCAGGAGCCA TCATGGCCTT CTTCTGTGTG CTGGGTCTGG  
1151 CACTGGGGG TGTTTTCTCC TTCTGTCTCC GGGCAATTGT GTGATCCATG  
1201 TCCCC

!!AA\_SEQUENCE 1.0  
ID ADP30962 standard; protein; 1789 AA.  
AC ADP30962;  
XX  
XX  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1729.  
DE  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO2004035732-A2.  
XX  
XX  
XX 29-APR-2004.  
XX  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410945P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411043P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2960; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 1789 AA;  
SQ  
ADP30962 Length: 1789 February 22, 2005 12:25 Type: P Check: 6075 ..  
1 TCTGTTCCTC CGCTAATCTG GGTAAAGTTA GTAGTGGGAT CGGTGGCCAT  
51 TGTGTGTTTT GCAGCAGCT ATGATGGAGA CTTTGTCTTT GATGACTCAG  
101 AAGCTATTGT TAACAATAAG GACCTCCAAG CAGAAACGCC CTTGGGGGAC  
151 CTGTGGCATC ATGACTTCTG GGGCAGTAGA CTGAGCAGCA ACACCAGCCA  
201 CAAGTCCCTAC CGGCTCTCA CCGTCTCTGAC TTTCAGGATT AACTACTACC  
251 TCTCGGGAGG CTTCCACCCC GTGGGCTTTC AGTGGTCAA CATCCTCTG  
301 CACAGTGGCA TCTCTGTCTT CATGTGGGAC GTCTTCTCGG TTCTGTTTGG  
351 CGGCCTGCAG TACACCAGTA AAGGCCGGAG GCTGCACCTC GCCCCCAGGG  
401 CGTCCCTGCT GGCCGGCGTG CTGTTTGTGT TCCATCTCTGT GCACACCGAG  
451 TGTCAAGGTA CAAGGAGGGA GGCATTTCTT CCACCTTCTG GGTGCTCTGT  
501 AGTATCTTTC TGGGAGCAGT GCCCATGCTG TGCAAGAGAGC AAGGATCAC  
551 TGTCTGGGT TTAATGCGG TATTGACAT CTTGGTGATA GGCAAAATCA  
601 ATGTTCTGGA AATTGTCCAG AAGTACTAC ATAAGGACAA GTCATTAGAG  
651 GTGAGTCTGT AGAGGTGGAC AACCCGGCCT CCTTTGCTGA CAGCATGCTG  
701 GTGAGGATC CTTACTCTGG GCCTGGGATT TCTGTTATC CCATTTCTCC

751 CCGCGAGTAA CCTGTCTCTC CGAGTGGGCT TCGTGGTGGC AGAGCGTGTC  
801 CTCTACCTCC CCAGCGTTGG GTACTGTGTG CTGCTGACTT TTGGATTCCG  
851 AGCCCTGAGC AAACATACCA AGAAAAAGAA ACTCAITGGC GCTGTGTTGC  
901 TGGGAATCTT ATTCACTCAAC ACGCTGAGAT GTGTGCTGGC CAGCGGCGAG  
951 TGGCGGAGTG AGGAACAGCT TTTCAGAACT GCTCTGTCTG TGTGTCCCTT  
1001 CAATGCTAAG CAGGTTCACT ACAACATTGG CAAAAACCTG GCTGATAAAG  
1051 GCAACCAGAC AGCTGCCATC AGATACTACC GGAAGTTTC AGATTAAATC  
1101 CCAAGTATGT TCATGCCATG AATTAATCTTG GAATATCTTT AAAGNAAGG  
1151 AATGAGCTAC AGGAAGCTGA GGAGCTGCTG TCTTTGGCTG TTCAAATACA  
1201 GCCAGACTTT CGCGTGCTGT GGATGAATCT AGGCATAGTG CAGAAATAGC  
1251 TGAACGGT TTGAAGCAGA GAGCAAGTT ACCGGACAGC AATTAACAC  
1301 AGAAGGAAT ACCCAGACTG TTACTACAAC CTCGGGCGTC TGTATGCAGA  
1351 TCTCAATCGC CACGTGGATG CTTGAAATGC GTGGAGAAAT GCCACCGTGC  
1401 TGAACACAGA GCACAGCCTG GCCTGGAACA ACATGATTAT ACTCTCGAC  
1451 AATACAGGTA ATTAGCCCA AGCTGAAGCA GTTGAAGAG AGGCACCTGA  
1501 ATTAATACCT AATGATCACT CTCATCATGT CTCGTTGGCA AAGGTGCTGG  
1551 GGAATACCCA GAAATACAG GAACTGGAAG CTTTATTCCT CAAGGCAATT  
1601 AAGCAAAATC CAAATGCTGC AAGTTACCAT GGTAATTGG CTGTGCTTTA  
1651 TCATCGTTGG GCACATCTAG ACTTGGCCA GAAACACTAT GAAATCTCCT  
1701 TGCAGCTTGA CCCCAGGCA TCAGAACTA AGGAAATTA CGTCTGCTGG  
1751 AGAAGAAAGC TAGAACTAAT GCAAAAGAAA GCTGTCTGA

!!AA SEQUENCE 1.0  
ID ADP30963 standard; protein; 417 AA.  
XX  
AC ADP30963;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1730.  
DE  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.

29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406668P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410951P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-041101P.  
17-SEP-2002; 2002US-041111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485233P.  
08-JUL-2003; 2003US-0485242P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486466P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 2961; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule



CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 417 AA;  
ADP30963 Length: 417 February 22, 2005 12:25 Type: P Check: 9300 ..  
1 CTCGCCACTG CAGGCTCCTT GTTCTCACC CTGAAGCCCC CGAGCCCGGT  
51 GTTCAAGGTG GTGTTCTGGC TGGGCTACTT CAACAGCTGC CTCACCCCA  
101 TCATCTACCC ATGCTCCAGC AAGGAGTTCA AGCGCGCTTT CGTGGCATC  
151 CTCGGGTGCC AGTCCCGGG CGCGGGCCGC CGCCGACGCC GCCGCCGCCG  
201 TCGCCTGGGC GGCTGCGCCT ACACCTACCG GCGGTGGAGC CGCGGGCGCT  
251 CGCTGGAGCG CTCGAGTCG CGCAAGGACT CGCTGGACGA CAGCGGCAGC  
301 TGCCTGAGCG GCAGCCAGCG GACCCTGCC TCGGCTTCGC CGAGCCCGGG  
351 CTACCTGGGC CGCGGGCGGC CACCGCCAGT CGAGCTGTGC GCCTTCCCCG  
401 AGTGAAGGC GCCCGGC  
IIAA SEQUENCE 1.0  
ID ADP30970 standard; protein; 1070 AA.  
XX  
AC ADP30970;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1737.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX  
XX 29-AUG-2002; 2002US-0406579P.  
XX  
XX 29-AUG-2002; 2002US-0406585P.  
XX  
XX 29-AUG-2002; 2002US-0406588P.  
XX  
XX 29-AUG-2002; 2002US-0406608P.  
XX  
XX 29-AUG-2002; 2002US-0406611P.  
XX  
XX 29-AUG-2002; 2002US-0406612P.  
XX  
XX 29-AUG-2002; 2002US-0406616P.  
XX  
XX 29-AUG-2002; 2002US-0406640P.  
XX  
XX 29-AUG-2002; 2002US-0406642P.  
XX  
XX 29-AUG-2002; 2002US-0406646P.  
XX  
XX 29-AUG-2002; 2002US-0406653P.  
XX  
XX 29-AUG-2002; 2002US-0406655P.  
XX  
XX 29-AUG-2002; 2002US-0406666P.  
XX  
XX 17-SEP-2002; 2002US-0410947P.  
XX  
XX 17-SEP-2002; 2002US-0410947P.  
XX  
XX 17-SEP-2002; 2002US-0410948P.  
XX  
XX 17-SEP-2002; 2002US-0410949P.  
XX  
XX 17-SEP-2002; 2002US-0410953P.  
XX  
XX 17-SEP-2002; 2002US-0410957P.  
XX  
XX 17-SEP-2002; 2002US-0410958P.  
XX  
XX 17-SEP-2002; 2002US-0410959P.  
XX  
XX 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2968; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 1070 AA;  
SQ

ADP30970 Length: 1070 February 22, 2005 12:25 Type: P Check: 2852 ..

1 TCTGTTCTTC TCCTCACTCTG GCTTAAGTTA GTAGTGGGAT CGGTTGCCAT  
51 TGTGTGTTTT GCACGAGCT ATGATGGAGA CTTTGTCTTT GATGACTCAG  
101 AAGCTATTGT TTAACAATAAG GACTTCCAAG CAGAAAGCCG CTTGGGGGAC  
151 CTGTGGCATC ATGACTTCTG GGGCAGTAGA CTGAGCAGCA ACACCAAGCCA  
201 CAAGTCTTAC CGGCCTCTCA CCGTCTTGAC TTTTCAGATT AACTACTACC  
251 TCTCGGAGG CTTTCAACCCG GTGGGCTTTC ACGTGGTCAA CATCTTCCTG  
301 CACAGTGGCA TCTCTGTCTT CATGTGTGAC GTCTTCTCGG TTTCTGTTGG  
351 CGGCCTGCAG TACACCAGTA AAGCCGGAG GCTGCACCTC GCCCCCAGGG  
401 CGTCCCTGCT GGGCCGGCTG CTGTTTGCTG TCCATCTCTG GCACACCGAG  
451 TGTCAAGTAA CAAGGAGGGA GCGCATTCTT CCACCTTCTG GGTGCTGCTG  
501 AGTATCTTTC TGGGAGCACT GGCCTGCTG TGCMAAGAGC AAGGGATCAC  
551 TGTGCTGGGT TTAATAGCGG TATTGACAT CTTTGGTGATA GGCAAATTCA  
601 ATGTTCTGGA AATTGTCCAG AAGGTACTAC ATAAGGACAA GTCATTAGAG  
651 GAGGTGGACA ACCCGCCTC CTTTGCTGAC AGATGCTGG TGAGGGCCGT  
701 AAATACAAT TACTACTATT CATTGAATGC CTGGCTGCTG CTGTGTCCTT  
751 GGTGGCTGTG TTTTGATTGG TCAATGGGCT GCATCCCCCT CATTAGTCC  
801 ATCAGCGACT GGAGGGTAA TGCATTGCA GCACTCTGGT TCTGCCTAAT  
851 TGGCCTGATA TGCCAAGCCG TGTGCTCTGA AGACGGCCAC AAGAGAAGGA  
901 TCCTTACTCT GGGCCTGGGA TTCTCGTTA TCCATTCT CCOCGGAGT  
951 AACTGTTCT TCGAGTGGG CTTGCTGTC GCAGAGCGTG TCCTCTACCT  
1001 CCCAGCGTT GGGTACTGTG TGCTGCTGAC TTTTGGATTC GGAGCCCTGA  
1051 GCAACATAC CAAGAAAAG

!1AA SEQUENCE 1.0  
ID\_ADP30973 standard; protein; 1065 AA.

XX ADP30973;  
AC  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1740.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.

29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 2971; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1065 AA;

ADP30973 Length: 1065 February 22, 2005 12:25 Type: P Check: 2928 ..

1 AGACCTTTTC TGGAGATTTT ATGCATCGAC TGCCTCTTTT AGGAGAAAAA  
51 CAGGAGGCTA AGGAGATGG AACAAACCTT ACCTTTATTG GAGACAAAAAC  
101 CGCAATGCAT GAACCATTGC AACCTTGGCA AGATGCACCA TACATTTTTTA  
151 TTGTACATAT TGGCATTTCA TCCTCAAAGG AATCATCAAA AGAAAAATTCA  
201 CTGAGTAATC TTTTACCAT GACTGTTGAA GTGAAGGGTC CCTATGAATA  
251 CCTCACACTT GAAGACTATC CTTTGATGAT TTTTTCATG GTGATGTGTA  
301 TTGTATATGT CTTGTTTGGT GTTCTGTGGC TGGCATGGTC TGCTGTGCTAC  
351 TGGAGAGATC TCCTGAGNAT TCAGTTTGGG ATTGTGTGCTG TCATTTTCTT  
401 GGAATGCTTT GAGAAAGCTG TCTTCTATGC GGAATTTTCAG AATATCCGAT  
451 ACAAGAGGAG ATCTGTCCAG GGTGCTTTGA TCCTTGCAGA GCTGCTTTCA  
501 GCAGTGAAC GCTCACTGGC TCGNACCTTG GTCATCATAG TCAGTCTGGG  
551 ATATGGCATC GTCAAGCCAC GCCTTGGAGT CACTCTTTCAT AAGTGTGTAG  
601 TAGCAGGAGC CCTCTATCTT TTGTTCTCTG GCATGGAAGG GGTCTCTAGA  
651 GTTACTGGGT ATTTTCTTCTA TCCTTTGACT CTGATAGTAA ACCTGGCCCT  
701 CTCAGCAATT GACGCTGTG TTATTTTATG GATATTTATT AGCCTGACTC  
751 AAACAATGAA GCTATTAAAA CTTCGGAGGA ACATTGTAAA ACTCTCTTTG  
801 TATCGGCATT TCACCAACAC GCTATTATTG GCAGTGGCAG CATCCATTGT  
851 GTTTATCATC TGGACAACCA TGAAGTTTCAG AATAGTGACA TGTCAGTGGG  
901 ACTGCGGGA GCTGTGGGTA GACGATGCCA TCTGGGCGCTT GCTGTTCTCC  
951 ATGATCCTCT TTGTATCATG GTTCTCTGCG GCACCATCTG CAACAACCA  
1001 GAGAAAGGAT GAAATGAGA AGTACCACAA AAGAACCCAA TGGAAATAGT  
1051 AAAGTTAACA AAGCA

IIAA\_SEQUENCE 1.0

ID\_ADP30989 standard; protein; 2934 AA.

XX

AC ADP30989;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1756.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

FN WO2004035732-A2.

XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2987; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
XX Sequence 2934 AA;  
ADP30989 Length: 2934 February 22, 2005 12:25 Type: P Check: 5153 ..  
1 ATGGCCTTCCA GCCCATGGGG CTGTGTATGT GGCCTTCTGC TGTGTGTGCT  
51 GCCACTCCTG GGGACTGGCC CTGCGCTGGG GAGGGGCTTT CCAGAGCCAC  
101 TTGAAACTC CGAATATCCCT ATGATCCCTG GAGCCACCC CAAGGGCTCT  
151 GTGGGCTCAG AGCCCCAGGC CTTTGACGTG TTCCCGGAGA ACCCCAGAGC  
201 TGACAGTCAC AGGAATCTG ATGTCGGCCA CGCCCCCTGCT GAAGAGATGC  
251 CTGAGAAGCC TGTAGCTCTT CCCCCTGGCC GAGCCCTGTA CGGGCCCCAA  
301 GCAGACAAG GAGCTCAGAG AGAAGCACTC CCAGTAACTG ATGACCTCCA  
351 GATGGCTCAA GGACCAAGCT CCCACGGCTG GACAGGACCT CTGGACTCAC  
401 AAGAGTTCT CTGAGCAAGAA CAGATGGGCT CCAACCCAGT GGGCCACCC  
451 CATCTCACTT TCATCCCCAC AACTCCCCAGA CGTCAACTCA GGGTAGCCAC  
501 AGTTCTCTCC TCCCTGCAGC ATGAAGGCCA AGAGGGACAG TGSCCACCTA  
551 GAGATGAGGG TCTGAAGGCC AAACCTAAGA GCAGGGTCCC ACCCACTTCT  
601 CCCTCAGACC ACCAGGGCCC ACCCCACACC CTTGTTTCCC ACTCAGGTAC  
651 TGTCAAGAGG CCACTGCTG AAGGACAGG TGGGTTTGAG GAACACTTGC  
701 AGGAGGCAGC TCAGGTCCC CACTTCACCC AGCAGATCC AGCAGCCCC  
751 GATGTTGGCT CAGTACCCCC AGTTGAGGTG GTGTACTCTC AGGAGCCAGG  
801 GGCCACCCA GACTTGGCAT TGGCCAGAAG CTTTCTCTCT GCTGAGGAGC  
851 TGCCGGTTGA GACCCCCAAG AGGGCTGGGG CTGAGGTGTC CTGGGAAGTC  
901 AGCTCCCCAG GTCCCCCGCC CAAGCAGGCT GACCTTCTCT ACCTAAGGA  
951 TTCACAGGA CCCCACCCA CCGATCCACC CGCCTCAGAG GCTCTGATC  
1001 GGCGTCTAA GCCAGTGAAT GGAGCAGACC CCATCTCCCC CCAGCGGGTG  
1051 AGAGGAGCTG TGGAGGGCCC AGGCACCCCC AAGTCTCTCA TCCCTGGTCC  
1101 CTCAGACCCT GGCCAGCTG TAAACCGAAC AGAGAGCCCC ATGGGGGCCC

1151 TGCAGCCAGA TGAAGCCGAG GAGTGGCCGG GCGCCCCCCA AAGCCATCCC  
1201 CCAGACACCC CAGTCCAGGC CCCCTCGAGC TCAGGCGGGG GCCTCATTTG  
1251 AGTCACACG CAGCGAGCCC TGGGCCAGCC TCCCCCTCCG GAGCCACCG  
1301 CNACTCCAT GGTTCAGCC CCAGCTCCA GCCCCCAGC CAACGCCACT  
1351 GCACCCCGC FAGCTGGGG CCCCCTTCGG CGGGTCTCTGA GCTTCTCTG  
1401 GAGCTGTCA GTCACGGGG TGGGGTACT CTTTCTGCTG CCGCGCTTGT  
1451 TGGCGCTGGC TGGCTGGCA GCGCCCCAG CAGGGCCCCG GCTGGCATTG  
1501 GTGGCCGGG TGCTGGTGT CTTGGCTTCG GCCTGGGAT CCGCTTACAT  
1551 GCTTACCGAC CTTTACGGCT CGCAGGGCGG GCTGGGGGTT CCGGGGGGC  
1601 TGGTGTCTA CAACCTGCCC TTCCCCTTGC TGCTTACGGC GCTGGCAGCC  
1651 CTGACTCTG CTGGCTGGG CGCGGGGCTG CCGCCACCGC TGAAMACCC  
1701 ACTCTGCTG GAGCAGTGG CGCTGGTCCA TGCTGTAGGG TTGCTGCGA  
1751 CAGACCTGCT GTCCACATGG TCTGTGTCA ACCTCCTGAC GCAGGGCTTG  
1801 TGTGTGCTT GGGGCGCGC GGTGGCTCTG GGCACGCTCT GCTGTGCGG  
1851 TCGCGCTCT CTGAGCGCC CACGGGCTG GATGCGAGC CCGGGCCCTC  
1901 GGTGTGTCG TGTGGGGGG CGCTGGGGG TGCTGGCTAG CGGCTTGCAG  
1951 CTGGCGGCTG GCTCTGCTT GTACCCGGGC CAGGGCGCGG TGGGCCGCTT  
2001 CTGCTGGGC TGGTGGGCTG TCCACTTCTG GCTGCGCTC CTGGAGCTGA  
2051 CATGGGGCT CGCCCTGGG TTGGCCGGG TGCTGCCCG GAGACCCAG  
2101 CGCCCCACG AGCAGCTTG CTGGGCTAAG CTGATGCTC TGGCGTGGCC  
2151 GCGCGCTCA GGAAGAGCG AGTGGCCGA GCGACCCAAT AACTGCTATG  
2201 CAGGGCCAG CAACGTTGT GCAGGAGCT TGGACATCAG CAAGAGCTC  
2251 ATCCGCAAC CGCGGAGAG TGGGAGCTG GCCACGCCCA GTTCAGGGC  
2301 CTGGGGCTG GCTGCTGCT TGGGTGCGG ACCCCAGGGT GCGCCGGGAC  
2351 TGTCCCGCA CGGTGTGGA CCGCGCCAT CGCTGAGCGA GCTGGATCTG  
2401 CGCGCGCAT CGCCCATCA CCTAGCGGC AGCATGAGC CCGCGCTCTT  
2451 CCGCAGCAC CTAGTCCGAG ACAGTGTGTT CCAGCGCTGC GCGCTCCGG  
2501 GCTTGGCTC CCGCGGCTT GGAGCGCTC TGGCGCGCG CCGGGGSCAGC  
2551 CATCCAAAG CCGAGCTGA CAGCGTGGC TCCTGCTCC TCGCGGGCGG  
2601 CTGAGGTCT CTACGAGC TCGCGCTG CCGGGCCGGT CCACAGCAG  
2651 TAGTGAAGC ACCCGAGCG GCAGCGCTG CGGCTTCTG CAGCTCCCTC  
2701 GACAGTTCT CCAGGGGTT ACTCAAGATC AGTTGMAAC CTGGGGCCCA  
2751 CGGGCTGTCA TCAGTGAACA GTCTGCCCT AGATGAGTTG CCGAGCACCG  
2801 TACAGTACT GCTGCCCG ACCCCAGGCC CTGATTCTAC CGCGGCTCG  
2851 CAGGGGAGC GCCAGGAGA GGTCCAGCG CCGGGCAAGC CTGGGGAATC  
2901 CCGCAGCGC TCCAGTGATA CCATCGAGCT TTGA

!!AA SEQUENCE 1.0  
ID ADP31005 standard; protein; 1306 AA.  
AC ADP31005;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1772.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411077P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Heatir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3003; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1306 AA;  
ADP31005 Length: 1306 February 22, 2005 12:25 Type: P Check: 8133 ..  
1 ATGCAGGAGC CGCTGTCTGG AGCCGAGGGC CGGACTACG ACACCTTCCC  
51 CGAGAGCGG CCCCCTGCG CAGGGACAG GCGCGGGTC GGGACCCCTG  
101 CAGAACAAA GGGTGTCTT GGCACCTTC GCCGCAGTGC TCGCAATTT  
151 CAGCTTTGGG TATGCCCTGG TCTACACATC CCTGTGCATC CCAGCCCTGG  
201 AGCGCTCCTT GGATCCTGAC CTGCATCTGA CCAATATCCA GGCATCCTGG  
251 TTTGGGTCCG TGTTACACCT GGGAGCAGCG GCCGGAGGCC TGAGTGCCAT  
301 GATCCTCAAC GACCTCCTGG GCGGAAGCT GAGCATCATG TTCTCAGCTG  
351 TGCCGTCCGC GCGCGGCTAT CGCTCATGG CCGGTGCGCA CGGCTCTGG  
401 ATGTGTCTGC TCGGAAGGAC GTGACGGGC TTGCGCGGGG GGCTCACAGC  
451 TGCTTGCAATC CCGGTGTACG TGCTCAGAT TGCTCCCCCA GCGCTCTGG  
501 GGGCTCTGGG GGCACACACC CAGTCTATGG CAGTGTTCGG ATCCTGTCC  
551 CTCTACGCC TTGGCTTCTT GCTGCCGTGG CGCTGGCTGG CTGTGGCCGG  
601 GGAGCGGCT GTGCTCATCA TGATCTGCT GCTCAGTTC ATGCCCACT  
651 GCGCGGCTT CCGTCTCTCT CCGGGCAGGG AGCAAGAGGC CTGCGGGCG  
701 CTGGCCTGGC TGCGTGGGAC GGACGTCTGAT GTCCACTGGG AGTTCTGAGCA

751 GATCCAGGAC AAGTCCGGA GACAGAGCAG CCGAGTATCG TGGGCTGAGG  
801 CAGGGGCCCC ACAGGTGTGC CGGCCCATCA CCGTGGCCTT GCTGATGGCG  
851 CTCCTGCAGC AGCTGACGGG CATCAGGCC ATCCTGGTCT ACCTGCAGTC  
901 CATCTTCGAC AGCAGCGCTG TCCTGCTGTC ACCATGGACC TCGCAGGCCG  
951 CAGGTGCTG CTCTTGTCT CAGCCCCCTGC TGGCCACCAT GCTCTTCATC  
1001 ATGGGCTACG CCGTGGGCTG GGGTCCCATC ACCTGGCTGC TCATGCTGA  
1051 GGTCTGCCCC CTGCGTGCCC GTGGCGTGGC CTCAGGCTC TGGTGTCTGG  
1101 CCAGCTGGCT CACCGCCTTC GTCTCACCAG AGTCCCTTCT GCAGTGGTG  
1151 AGCACTTTCG GCCTCAGGT GCCTTTCTTC TTCTTCGCGG CCATCTGCTT  
1201 GGTGAGCCTG GTGTTCCACAG GCTGCTGTGT GCCCGAGACC AAGGACGGT  
1251 CCCTGGAGCA GATCAGTCC TTCTTCCGCA TGGGAGAAG GTCCTTCTTG  
1301 CGCTAG

!!AA SEQUENCE 1.0  
ID\_ADP31009 standard; protein; 549 AA.

XX AC ADP31009;  
XX DT  
XX DX 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1776.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX XX  
XX PN WO2004035732-A2.

XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406577P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.  
XX PR 17-SEP-2002; 2002US-0411023P.  
XX PR 17-SEP-2002; 2002US-0411024P.

17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
08-AUG-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3007; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPOWEB and is not in the specification.

Sequence 549 AA;

ADP31009 Length: 549 February 22, 2005 12:25 Type: P Check: 1806 ..

1 ATGGGGGCCC CCGGCTCGGG CAAGGGCACT GTGTCGTCG GTATCACTCA

51 ATACTTCGAG CTAAGCACC TTTCAGCGG GGACCTGCTC CGGGACAACA

101 TGCTGCGGG CGCAGAAATT GGCCTGTTAC ATGTTCTCAC TCATAGGACA

151 CTTCACAGG CAGAGCCCT AGATAAGCT GATCAGACCG ACACAGTGAT  
201 TAACCTGAAT ATGTCCTTTG AGTCAATPAA ACAACGCCCTT ACTGCTCACT  
251 GGATTCATCT CACCAATGCG CAAGTCTACA ACATTGGATT CAACCCCTCCC  
301 ACAACTGTGG GAATTGATGC TGTGACAGGG GAGCCGCTCA TTCAGCGTGA  
351 GGATGATAAA CCAGAGATGG TTATCAAGAG ACTAAAGGCT TATGAAGCCA  
401 AACAAAGCCA GTCCTGGACT ATTACCAGAA AAAAGCGGT GTTGGAAACA  
451 TTCTCCAGAA CAGAAACCA CAAGATTGG CCTGTGGAT ATGCTTTCTT  
501 CCAAAGTAC GTTCTCAA CAAGCCAGGA AGTTCAGTT ACTCTATAA  
!!AA SEQUENCE 1.0  
ID ADP31023 standard; protein; 2415 AA.  
XX  
AC ADP31023;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1790.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.

17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486466P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX  
PI Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX  
DR WPI; 2004-348438/32.  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3021; 428pp; English.  
XX  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
SQ Sequence 2415 AA;  
ADP31023 Length: 2415 February 22, 2005 12:25 Type: P Check: 2920 ..  
1 ATGGCCTCAG AATCAGGCCT GGTGTGGCCA GGGGCTGATC TCACAGTAGA  
51 CAGGAAGTGT GGCCCGAGGG CCATGGCTGC CCCCTCAGAA GGCCCTGTGG  
101 AGTGGCTGGC CGAGCCTCAG CAGCCTCCTG TGAAGGAGG AAGGCTCTTC  
151 CTGCCGGCCT CTGGAGATCA GTATGGGAAT GCACAAGATG GTGGTTTTGG  
201 TTCCTCCATC TTGTGATGT ACAAGTGTGA TGTTCCTCCC CCACAGACAA  
251 CAGCCCTGGA GCCTGTGGG GGCTTTGAGC AGCTGCTGCC AAGCAGGCC  
301 TCACCCGACA CTCTGTATGG CACGGCCATG GTGGCAGGGG CTTGACGCT

351 GCCAGGAAGG TCCCTGCC CCAACTCTC CCACATGTG GCGGGCCCC  
401 GCTTGTCTTT AGNAGCCAG CTGAAGTCTT TCCTGAAGGA ACCCTTCCAG  
451 AACCTCTCAG ACCAGAGTGC AGGACTCAGC AAGGCCACCC CCAGCCACAC  
501 ACAGATACAG TTCCAGGACT CAGAAGTCTCAG CGAGGCCAC CCAGCCACA  
551 TGCAGGTCCA GTTCCAGGAT TCAGACACA GTGAGGCCA CCGAGCCAC  
601 ATCCAGTCC AGTTCAGGA CTCAGATTTC AGTGAGGCC ACCCAGCCA  
651 CACACAGTTC CAGTTCAGG ACTCAGGACT CAGCAGGCC CACCCAGCC  
701 ACATGCAAGT CCAAGTCCAG GATTTCAGAC ACAGTGAGGC CCACCCAGC  
751 CATATCCAGG TTCAAGTTCCA GACCATCCAG GAGGTGGCTG GTTATGTCTT  
801 CATTCGCCCTC AACACAGTGG AGCGAATTCC TTGGAAAAAC CTGCAGATCA  
851 TCAGAGGAAA TATGTACTAC GAAATTTCTT ATGCTTTAGC AGTCTTATCT  
901 AACTATGATG CAAATAAAG CCGACTGAAG GAGCTGCCCA TGAGAAATTT  
951 ACAGGAAATC CTGCATGGCG CCGTGGGTTT CAGCAACAAC CTGCGCTGT  
1001 GCAACGTGGA GAGCATCCAG TGGCGGGACA TAGTCAGCAG TGACTTTCTC  
1051 AGCAACATGT CGATGAGCTT CCAGAACCCAC CTGGGCAGCT GCCAAAAGTG  
1101 TGATCCAAAG TGTCCTCAATG GGAGCTGCTG GGGTGCAGGA GAGGAGAACT  
1151 GCCAGAACT GACCAAAATC ATCTGTGCC AGCAGTGCTC CGGGCGCTGC  
1201 CGTGGCAAGT CCCCCAGTGA CTGTGCCAC AACCAAGTGT CTGCAAGCTG  
1251 CACAGGCCCC CGGGAGAGCG ACTGCTGTGT CTGCCGAAA TTCCGAGAGC  
1301 AAGCCAGTGT CAAGGACACC TGCCCCCAC TCATGCTCTA CAACCCACC  
1351 ACGTACCAGA TGGATGTGAA CCCCCAGGCG AAATPACAGCT TTGGTGCCAC  
1401 CTGGGTGAAG AAGTGTCCCC GTAATTATGT GGTGACAGAT CACGGTCTGT  
1451 GCGTCCAGC CTGTGGGGCC GACACTATG AGATGGAGGA AGACGGGCTC  
1501 CGCAAGTGTG AGAAGTGCGA AGGGCCTTGC CGCAAGTGT GTAACGGAAT  
1551 AGGTATTGGT GAATTTAAAG ACTCACTCTC CATAAATGCT ACGAATATTA  
1601 AACACTTCAA AAATCGACC TCCATCAGTG CGATCTTCCA CATCTGCCG  
1651 GTGGCATTTA GGGGTGACTC TTTCACATC ACTCTCTCTC TGGATCCACA  
1701 GGAAGTGGAT ATTCTGAAA CGTAAAGGA AATCACAGG TTTTGTCTGA  
1751 TTCAAGCTTG GCTGAAAAC AGGACGGACC TCCATGCTT TGAGAACCTA  
1801 GAAATCATAC CGCGCAGGAC CAAGCAACAT GGTCAAGTTTT CTCTGCAGT  
1851 CGTCAGCCTG AACATAACAT CCTTGGGATT ACGTCCCTC AAGGAGATAA  
1901 GTGATGAGA TGTGATAATT TCAGAAAACA AAATTTGTG CTATGCAAT  
1951 ACAATAAAGT GGAATAAAGT GTTTGGGACC TCCGGTCCAG AAACAAAAT  
2001 TATAAGCAAC AGAGGTGAAA ACAGCTGCAA GGCCACAGGC CAGGTCTGCC  
2051 ATGCTTTGTG CTCCCCGAG GCTCTCTGG GCCCGAGCC CAGGACTGC  
2101 GTCTCTTGGC GGAATGTAC CCGAGGCAGG GAATSCGTGG ACAAGTGCAA  
2151 CTTTCTGGAG GGTGAGCCAA GGGATTTGT GGAGAACTCT GAGTGATAC

2201 AGTGCCACCC AGAGTGCCTG CCTCAGGCCA TGAACATCAC CTGCACAGGA  
2251 CGGGGACCAG ACAACTGTAT CCACTGTGCC CACTACATTG ACGGCCCCCA  
2301 CTGCGTCAAG ACCTGCCCGG CAGGAGTCAT GGGAGAAAAC AACACCTGG  
2351 TCTGGAAGTA CGCACAGCC GGCCATGTGT GCCACCTGTG CCATCCAAAC  
2401 TGCACCTACG GGTGA  
!!AA SEQUENCE 1.0  
ID ADP31057 standard; protein; 992 AA.  
XX  
AC ADP31057;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1824.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 17-SEP-2002; 2002US-0411111P.



PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3055; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 992 AA;  
ADP31057 Length: 992 February 22, 2005 12:25 Type: P Check: 759 ..  
1 AGCCTCCAG GGCATGGG AACATCAACC TGGGGCCTTC AGCCAAACCCA  
51 AATGCCCAGC CCACGGACTT CGACTTCCTC AAGTCAATCG GCMAAGGAA  
101 CTACGGGAAG GTCCTACTGG CCAAGCCAA GTCTGATGG GCGTCTATG  
151 CAGTGAAGGT ACTACAGAAA AAGTCCATCT TAAAGAAGAA AGAGAGCAGA  
201 GCACATCAT GGCAGAGCGC AGTGTGCTTC TGAAGAACGT GGGGCACCCC  
251 TTCCTCGTG GCTTGGGCTA CTCCTCCAG ACACCTGAGA AGCTTACTTT  
301 CGTGTCTGAC TATGTCAACG GGGGAGAGCT CTTCTTCCAC GTGACGCGG  
351 AGCGCGGTT CTTGGAGCCC CCGGCCAGGT TCTACGCTGC TGAGTGCC  
401 AGCGCCATTG GCTACCTGCA CTCCTCAAC ATCATTACA GGGATCTGAA  
451 ACCAGAGAAC ATTCTCTTGG ACTGCCAGTA CTGGCACCT GAAGTGCTTC

501 GGAAGAGACC TTATGATCGA GCAGTGGACT GGTGGTGCTT GGGGGCAGTC  
551 CTCTACGAGA TGCTCCATGG CCTGCCGCC TTCTACAGCC AAGATGTATC  
601 CCAGATGTAT GAGAACATTC TGACACAGCC GCTACAGATC CCGGAGGCC  
651 GGACAGTGGC GCGCTGTGAC CTCCTGCAAA GCCTTCTCCA CAAGGACCAG  
701 AGGCAGCGGC TGGGTCCAA AGCAGACTTT CTTGAGATTA AGAACCATGT  
751 ATTCTTCAGC CCATAAACT GGGATGACCT GTACCACAAG AGGCTAACTC  
801 CACCCTTCAA CCCAAATGTG GTAAGAGACA GGACCTGTGT ACTTGAAGCA  
851 TTTTGACCCA GAGTTCACCC AGGAAGCTGT GTCCAAGTCC ATTGGCTGTA  
901 CCCTGACAC TGTGGCCAGC AGCTCTGGGG CCTCAAGTGC ATTCCTGGGA  
951 TTTTCTTATG GCCCAGAGGA TGATGACATC TTGGATTGCT AG  
!!AA SEQUENCE 1.0  
ID\_ADP31068 standard; protein; 5397 AA.  
XX  
AC ADF31068;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1835.  
XX  
XX Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.

PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3066; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 5397 AA;  
ADP31068 Length: 5397 February 22, 2005 12:25 Type: P Check: 5232 ..  
1 ATGGTGCCAG CATCTGCTTC TGGTGAGGCG TTCAGGCTGC TTCCACTCAT  
51 GGCAGAAGCA GAAGAACTC GACAGACAA ATTGGCTGTA GCCAATACAA  
101 AGGTCGACCT CCTGGGCTC TTTCGGCTGG CGTCTCCAAG GAGCTGGTTC  
151 CCAACCTGT GTTTCCTCC CCCATCATGG AGCAGCAACT CAGACATCGT  
201 GCTGATGCC CTCCCATGA CCAGAAGGCT GGAATGTAGT GATGTACAAA

251 TCCACCTGGG AACTGTCAAT ACTGAAGAC CAGCCTTTGA TCTTATGACC  
301 CAGTCCCTTA AGCGTTGTCA CCCCATTTCT GATTCCTCTG GTCACAGCAC  
351 AAATTTCCAG CTGCAAGGG AATGAGATT ATGGGACCTA GGAGCAAGAG  
401 GTTTCAGGCT GCCTTACTCC CTTAAACATAG ACACTGACAG TGGGAAAGAC  
451 CTACACTTCC CCCATGAGCT CAACAAGTTA ACAGTGTCTC TGGGTGGCNA  
501 TGGGAGAATT GGTTTGTAA AGAATATTG GCAGAAAAAC AGCCCTTAGAG  
551 TTCCAGAAGG AGCCAAAGAG AACAGGAAA CAAATGCGAG TATCCCTGAG  
601 ACAGCCACTT CTGGTGGTGG CCAGTCACCT GGGGATGTGA GTCTTGGCTG  
651 GCCAGGCTTC TGGGACACAG GGGCCCAAGG GGCAATAGAA GTCAGCAACA  
701 GGTATCCACG GGGAGGGCCC TACATCATCT GCTACCTCTGA AGGATCTGGA  
751 GAGCCCGTGC CAGAGGCCAG CAGTAGTCTCT GAACCCAAGG TCGGTAAAAA  
801 TCAGTCAACT GAAGAACACC ATCAATCTT TGAACAACA GAAGAAACAA  
851 GTGGAACATC AGCTGGAAGA AGTAACGTGA TTTCTTTATT TGCTCGCGAC  
901 ACGACTGCTG GGGTCCCTGA TAACCTGTC CCAATGGTGG GCCTGTCTCG  
951 GGGCAATTGGT GGCATTTCTGG GGGCATGTCT CTTCGTGTGC CGTCTCTGGG  
1001 TCTCCCTGGT AAGAGCTCTG TCTTCTCTTT CCTATAGGAA AAGCAAAACGA  
1051 GAACAACAAA GCCAAAAGGG AGCTAGAGTT CTCGAGCCCG AGCAGAGCAC  
1101 ATACGGAGTG GGGATTAGAG CAGTCCCTAC AGGAGAAGGC ACGGTGAAG  
1151 GCATAGCTAA CACAGGTGAG GTTTTGCAGA GGGAGGGATG TGGNAGGAAG  
1201 ATGACCCCGAG GTGGCCACGA GCAGTTGAAG GAGTCGTTT ACAAGTCCA  
1251 ATTACAGAGA GATACTATG CTCACAAAT AAAAGAGAG AGGGCCCGGT  
1301 GGCAGCAGAG GATGAGAAA ATGTCGCAGG AGGTTTACAC ACTGAAGACA  
1351 GAGAAGGAGC ATTATACACA TCGGGTAGAG GGGCTGGAGA GGAGCTTGTCTC  
1401 CAAACTCAA AACAGATGG CTGAACCCCT GCCTCCAGAG CCCCAGCAG  
1451 TGCCCTCTGA GGTGGAGCG CAGCACCTGA GGAAGGAACT AGATAGAGTG  
1501 GCAGGAGAGC TCCAGTCCA GGTCAAAAAC ATCAGGGCA TAAGTCTCCT  
1551 GAAGTGGGA CAAGACGAGA GGATTCGAGA GCAGGAAGAG AGGCTTCGGA  
1601 AGCAGGAGGA GAGGCTCTTC CTGCAGGTGG AGCTGAAGAG CCAAGAGGCT  
1651 CAGAGTCTGC AGCAGACGCC AGACATTAC CTGGGTCAACC TGCAGCAGTA  
1701 CGTGGCCACC TATCAGCAGC AGGTGGCCGC CTATCAGCAG CTGACCTGTG  
1751 AGAAGGAGGC GCTGTACAGG CAGTGCCTGC AACAGACCCA GCTAATGAAA  
1801 CAGCTCAGC AGCAGGAAGA GCACCTGAA GCGGCCAGCC AGCAGNACCA  
1851 GCAGCTAAGC GCCCAGCTGA GCCTCATGGC TCTCCCTGGG GAAGGACAG  
1901 GAGGAGAACA TCTGGACAGT GACGGGAGG AGGCACCTCG GCCCATGCCG  
1951 AGTGTCCCAG AGGACCTGGA GAGCAGGGAG GCCATGGTGG CATTTTCAA  
2001 GTCCGTGGA GCTAGTGCCC AGGAGAAGCA GGCACAGTTA CAAGAGCAGG

2051 TGAAGAGCA GAGGCTGTC TGCCAGCGCC TGCGTCACCC GGTGGCCTCG  
2101 GCCAGAAAG AGCCAGAGGC AGCCAGAGGC CCTGGAGCCC CAGGGCCTGG  
2151 GGGCGAGTCT GTGAGTGGGG AGACCCACTG GGCCTCTGCAG GAAGTCACGG  
2201 AGAAGCTGSC CCATGCCAGG ACTCACCTCC GCCTTCTCCA TGACTTGAAA  
2251 ATGCCACCTG AGGCAGGTC GCTGCCGAGA TGTGACTGCA ATATTTTGGC  
2301 TCCAGAGCAG CTTTATGGAC CAACTGGAGG AGAAGGCAGA CCTGAGAAAA  
2351 TCCATCACCT TTTATCAGAA CCAGGGGGCC GTGCCAAAAG TCGCGCACTG  
2401 GTAGGAGGAC ACCATCAGGC TGGAGCTCAG GGAAGGAGATG AAGGTGAAGC  
2451 TGCTGGAGCT GCAGCAGATG GTGTTGCGGC TTATAGCAAC TACNACAATG  
2501 GGCACAGAAA ATTCTGGCC ACTGCCCAGA ACCCTGCTGA TGAGCCCGGT  
2551 CCAGGAGCCC CAGCCCCCCA GGAGCTTGGG GCTGCAGGCA AGCATGCTGG  
2601 ACTGCCCAAT TTAAGATTAA GTTTTAACT GCGCTTATT AGAGATATGG  
2651 CCATTTTGGC ATTTCACTGG AACCTTTTAA TCAGCTTTAA TGCTGTCTTA  
2701 GGTTTTGGTAT TTTCTGGGG TGATGTGAC TTTTGAAAAAT TGGGCCGGGG  
2751 CGGAAGTGA GGTGCAACA TTCCCCAGAA CATTGAGAGA CTAAATGGAC  
2801 AGGGGTGTG CCAGATTGAG TGTGGAGCTC AGTTCTTACT GGCGCTCACC  
2851 AAGTCTGGAG TGGTGTGAC ATGGGGAAG GGGGATTACT TCAGGTTGGG  
2901 CCACCGCTCT GACGTGCAG TTCCGAAGCC GCAGGTGGTG GNAAGGCTGA  
2951 GAGGAAGAA GATCGTGAT GTGGCTGTG GGGCCACAGA TTGCTGTGGC  
3001 GTCATGGACT CAGGCGAGGT GTATGCTTGG GGTGACAATG ACCACGGCA  
3051 GCAGGGCAAT GGCAGGACCA CGGTAAACAG GAAGCCCATG CTCGTGCAAG  
3101 GCTTAGAAG CCAGAAGATC ATGTGTGTG CTTGGGGTTC GTCCACAGT  
3151 GTGGCGTGA CAACTATGGA TGTGGCCACG CCTCTGTCC ACGAGCCCGT  
3201 CCTCTTCAG ACTGCAAGG ACCCTTTAGG TGTTCCTTAT TTAGCGTGC  
3251 CTTGAGATGT CAATTCTTCT GCTGCCAGTA ATAAAATAAG TGGTCAAGT  
3301 AATTCTAAGC CATATCACCC TTCTCTTGGC AAGATTCTCT TGTCAATTGA  
3351 TGGAAACCTG GCCAAACAGC AGGCTTATC GCATATTCTT ACAGATTTC  
3401 AAATCATGTA TGCCAGAGAT GCGCTAGTGG GGGCCCTGAT CCGGCCGCC  
3451 ATGATCGCCC CGGTGGAGTG CCCCTCTGCG GCTGCTTGGC ACGCATTTGC  
3501 GATGGCTAGT CCCATGAATG GAGAAGATG CATGCTGGCT GTTGATATCG  
3551 AAGACAGACT GAGTCCAAAT CCGTGGCAAG AAAAGAGAGA GATTGTTTCC  
3601 TCTGAGGACG TGGTGACCCC CTCTGCAGTG ACTCCATCGG CCTCTCAGC  
3651 CTCGCTGGG CCATTATCA CAGTGACGGA TGACCCGGGA GCTGCAAGCA  
3701 TCTTTGCAGA AACCATGACC AAAACTGAAG AGGTAAAGAG GCATTCTTTT  
3751 TTCGCTTTGT ATTGTGAAAT TACCAAATGG CAGGTGGAGC GGCAGATCGA  
3801 TGACCCCAAC AGCAACCTTG AGGAGTGTAT TAAATAGGCA GAGGCCATCA  
3851 CCTCTGAGAA CAGCCTGGGA TTGATCTCCA GGTGGCCGGC TTTATTCTCA

3901 CAAATTACG CCGATGACTC AGTCCTTCCA GGAATGGTGG TACGTGAATC  
3951 TCAACAGCCT AATGGACCAG GCCTTTGACCC CACAGTGTGG CAGTGGCAGA  
4001 TATGCTGTTG GAGCTCTGTG TCACCGAGTT GGAGGATGTG GCCACAAGAC  
4051 TTGCAGAGCG GCCGCTCTC TTCTCAGCCT GTGGTGGTGG AGAGTAGCCA  
4101 CCCTTACACC GACGACACCT CCACCAGTGG CACAGTGAAG ATACCAGTGC  
4151 CATCTCTGCG TAGATCTTCC AGCCTGAAGG AAAACTCTTG TGCTCTGCT  
4201 CGCACACCTC TCACACCAGA TGTGCGGGTT CTCCACACCA AGCGTTCTC  
4251 CAGTTCTCTG GACACGCCAG AAGTTGAGGT GCTCCTCACC TCCATGCGG  
4301 CTCACTCCCC AGGTGCAGAA GGACTCAGGG TGGAAATTTGA CCGGCAGTGC  
4351 TCCTCAGAGT GGCACCACGA CCCTCTCACA ATCATGGATG GCGTCAACAG  
4401 GATCGTCTCC GTGTGGTCAG GCCCCGTTGA GCGGTGGAAC AGAACACAGA  
4451 GAACTGTCCC AGCGTCCAA CTATCAGGCT CACACTCTC CTCACCTGGT  
4501 GTGGAAGGAG TTGTTGCTGG TGTCAATCTT AGGCTTTTGG TTTACAGTGG  
4551 AAGTGTGAGT GTGAAGACA AGGCTCACCG ACTCGCAGTG GCATGCGTGG  
4601 GCACACCAGC TGTGCGCTTC TGGTGGGTGG GCGTGGGTGG AGCCACCTTT  
4651 GTTTGTTGGC TTCTTATGGG TTGTTCCCTA GCTTGTGAAA CACAGGGGTG  
4701 TTTACAGTGC TCATTACAG GCCCTAAGA ACTCCTCTCT GACTGCTGG  
4751 TCCTCTCTTG TCCATCCACG GACTTGGTGA CGTGTCTGTT AGACTTCGA  
4801 CTCACCTTG CCTCTAACAG AAGTGTGCTC CCTTGCCTTG TGGCCTTGCT  
4851 GGCAGCTTGT GCACAGCTGA GTGGCCTAGC CACCAGTAC AGAATGTGGG  
4901 CCCTTCAGAA ATTGAGGAAG CTGCTTACAA CTGAATTTGG GCAATCAATT  
4951 AACATAATA GGCTGCTTGG AGAAAATGAT GGGGAAGCAA GAGCTTTGAG  
5001 TTTTACAGGT AGTCTCTTG CTGCTTTGGT GAAAGGTCTT CCAGAGCTT  
5051 TGCAAAAGCA GTTTGAATAT GAAGATCCTA TTGTGAGGGG TGGCAAAACAG  
5101 CTGCTCCACA GCCCATTTCT TAAGGTACTG GTAGCTCTTG CTTGTGACCT  
5151 GGAGCTGGAC ACTTGGCTTT GCTGTGCCGA GACGCACAAG TGGGCTGGT  
5201 TCCGAGGCG ACCAGATGAT TGGAAATCTGT CTGCTGGTGG CAGTGGAAAC  
5251 ATTTATGGTT GGGGACATGA TCATAGGGGC CAGCTCGGGG GCATTGAAGG  
5301 TGCAAAAGTC AAAATTCCCT CTCCCTGTGA AGCCCTCACA ACTCTCAGAC  
5351 CCATGCAAGT AATCGGAGGG GAACAGACCC TCTGCTGTGA CAGCTGA

IIAA SEQUENCE 1.0

ID\_ADP31145 standard; protein; 611 AA.

XX

AC ADP31145;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1912.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX

OS	Homo sapiens.	PR	08-AUG-2003; 2003US-0493370P.	XX	08-AUG-2003; 2003US-0493370P.
XX	WO2004035732-A2.	PR	08-AUG-2003; 2003US-0493573P.	PR	08-AUG-2003; 2003US-0493573P.
PN		XX	(FIVE-) FIVE PRIME THERAPEUTICS INC.	XX	
PD	29-APR-2004.	PA	William LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;	PI	William LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
XX		PI	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;	PI	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
XX		PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;	PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX		XX	WPI; 2004-348438/32.	XX	WPI; 2004-348438/32.
XX		XX	New nucleic acid molecule for diagnosing, preventing or treating diseases	XX	New nucleic acid molecule for diagnosing, preventing or treating diseases
XX		XX	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,	XX	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
XX		XX	genetic, bacterial and viral diseases.	XX	genetic, bacterial and viral diseases.
XX		XX	Claim 1; SEQ ID NO 3143; 428pp; English.	XX	Claim 1; SEQ ID NO 3143; 428pp; English.
XX		XX	The present invention relates to an isolated nucleic acid molecule	XX	The present invention relates to an isolated nucleic acid molecule
XX		XX	encoding a polypeptide which is believed to be cytostatic.	XX	encoding a polypeptide which is believed to be cytostatic.
XX		XX	antitumour, immunosuppressive, antibacterial and virucidal. The	XX	antitumour, immunosuppressive, antibacterial and virucidal. The
XX		XX	composition and methods are useful for diagnosing, preventing and	XX	composition and methods are useful for diagnosing, preventing and
XX		XX	treating diseases such as proliferative (e.g. cancer), inflammatory,	XX	treating diseases such as proliferative (e.g. cancer), inflammatory,
XX		XX	immune, metabolic, genetic, bacterial and viral diseases. The present	XX	immune, metabolic, genetic, bacterial and viral diseases. The present
XX		XX	sequence represents a human secreted protein. The present sequence is	XX	sequence represents a human secreted protein. The present sequence is
XX		XX	available on WIPWEB and is not in the specification.	XX	available on WIPWEB and is not in the specification.
XX		XX	Sequence 611 AA;	XX	Sequence 611 AA;
XX		XX	ADP31145 Length: 611 February 22, 2005 12:25 Type: P Check: 1395 ..	XX	ADP31145 Length: 611 February 22, 2005 12:25 Type: P Check: 1395 ..
XX		1	CCACAGGCC CTACATGCT GTGGATCCC TGGGTGACCA GGTGATCTAC	1	CCACAGGCC CTACATGCT GTGGATCCC TGGGTGACCA GGTGATCTAC
XX		51	CCGAGCTCAG TGGAGGACAT GCGAAGGAAG GGCTACTCGG AGCAGGACCT	51	CCGAGCTCAG TGGAGGACAT GCGAAGGAAG GGCTACTCGG AGCAGGACCT
XX		101	GGAAGCCATC CTGGATATCG TGCACCCACA CCACATCCTG CAGTGGGAGG	101	GGAAGCCATC CTGGATATCG TGCACCCACA CCACATCCTG CAGTGGGAGG
XX		151	GAGGTGGGA GCGTATGTT GACTTGGAGG ACATCCTGCC AGTGGTGAG	151	GAGGTGGGA GCGTATGTT GACTTGGAGG ACATCCTGCC AGTGGTGAG
XX		201	AGCAGAGAA TCGGATGCG CCGCATGTTT TACCACAGGC CCAAGTACGC	201	AGCAGAGAA TCGGATGCG CCGCATGTTT TACCACAGGC CCAAGTACGC
XX		251	CCTCTGGAT GAAAGCACCA GTGCCGTGAG CATCGACGTG GAAGGCAAGA	251	CCTCTGGAT GAAAGCACCA GTGCCGTGAG CATCGACGTG GAAGGCAAGA
XX		301	TCTTCCAGT GGCACAGGAC GCAGGCATTG CCCTGCTCTC CATCACCTTC	301	TCTTCCAGT GGCACAGGAC GCAGGCATTG CCCTGCTCTC CATCACCTTC
XX		351	CAGCCTCCC TGTGGAGTA CCACACAC TGTGTACAGT TCGATGGGA	351	CAGCCTCCC TGTGGAGTA CCACACAC TGTGTACAGT TCGATGGGA
XX		401	GGTGGCTGG AAGTTCGAGA AGCTGGACTC AGCTGCCCCC CTGAGCCTGA	401	GGTGGCTGG AAGTTCGAGA AGCTGGACTC AGCTGCCCCC CTGAGCCTGA
XX		451	CAGAGGAGAA GCAGCGGCTG GAGCAGCAGC TGGCGGSCAT TCCCAAGATG	451	CAGAGGAGAA GCAGCGGCTG GAGCAGCAGC TGGCGGSCAT TCCCAAGATG
XX		501	CAGCGGCACC TCCAGAGCT GTGCCAAATC CTGGCGGAGG CCGTGGCCCC	501	CAGCGGCACC TCCAGAGCT GTGCCAAATC CTGGCGGAGG CCGTGGCCCC
XX		551	AGCGCACGTG CCGGCACCTA GCCTGCAAGG CCCTGGTGA CTCCAGGGTG	551	AGCGCACGTG CCGGCACCTA GCCTGCAAGG CCCTGGTGA CTCCAGGGTG
XX		601	CCTCCACCTG A	601	CCTCCACCTG A
XX		!!AA	SEQUENCE 1.0	!!AA	SEQUENCE 1.0
XX		ID	ADP31258 standard; protein; 2808 AA.	ID	ADP31258 standard; protein; 2808 AA.
XX		XX	ADP31258;	XX	ADP31258;
XX		XX	12-AUG-2004 (first entry)	XX	12-AUG-2004 (first entry)
XX		XX	Human secreted protein SEQ ID #2025.	XX	Human secreted protein SEQ ID #2025.
XX		XX	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;	XX	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
XX		XX	cancer; inflammatory; immune; human secreted protein.	XX	cancer; inflammatory; immune; human secreted protein.
XX		XX	Homo sapiens.	XX	Homo sapiens.
XX		XX	WO2004035732-A2.	XX	WO2004035732-A2.

PD	29-APR-2004.	PA	(FIVE-) FIVE PRIME THERAPEUTICS INC.
XX		XX	Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
XX		PI	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
XX		PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
PR	28-AUG-2003; 2003WO-US026780.	XX	WPI; 2004-348438/32.
PR	29-AUG-2002; 2002US-0406576P.	XX	New nucleic acid molecule for diagnosing, preventing or treating diseases
PR	29-AUG-2002; 2002US-0406579P.	PT	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PR	29-AUG-2002; 2002US-0406585P.	PT	genetic, bacterial and viral diseases.
PR	29-AUG-2002; 2002US-0406588P.	XX	Claim 1; SEQ ID NO 3256; 428pp; English.
PR	29-AUG-2002; 2002US-0406608P.	XX	The present invention relates to an isolated nucleic acid molecule
PR	29-AUG-2002; 2002US-0406611P.	CC	encoding a polypeptide which is believed to be cytostatic,
PR	29-AUG-2002; 2002US-0406612P.	CC	antiinflammatory, immunosuppressive, antibacterial and virucidal. The
PR	29-AUG-2002; 2002US-0406616P.	CC	composition and methods are useful for diagnosing, preventing and
PR	29-AUG-2002; 2002US-0406618P.	CC	treating diseases such as proliferative (e.g. cancer), inflammatory,
PR	29-AUG-2002; 2002US-0406640P.	CC	immune, metabolic, genetic, bacterial and viral diseases. The present
PR	29-AUG-2002; 2002US-0406642P.	CC	sequence represents a human secreted protein. The present sequence is
PR	29-AUG-2002; 2002US-0406646P.	XX	available on WIPOWEB and is not in the specification.
PR	29-AUG-2002; 2002US-0406653P.	SQ	Sequence 2808 AA;
PR	29-AUG-2002; 2002US-0406655P.		
PR	29-AUG-2002; 2002US-0406666P.	ADP31258	Length: 2808 February 22, 2005 12:25 Type: P Check: 4592 ..
PR	17-SEP-2002; 2002US-0410946P.	1	ATGAAGAAAG CAGGTAGAGA TGAACCTCG GACCCACCTG CTGGCTGCCT
PR	17-SEP-2002; 2002US-0410947P.	51	ACTCTCAACC CCGCTGCCCT TCCGGGGCAT CTGGTGTCAAC ATGAGGAGCA
PR	17-SEP-2002; 2002US-0410948P.	101	CTGGACTGGG AGTCAGCCTC CTCATCTGCC TCTCTCTGGG CTCTACTTTA
PR	17-SEP-2002; 2002US-0410949P.	151	CACTGTGAGC ATGTGGCTTG GGAGGGCGTG GGTCACTTCT TCCACGAATT
PR	17-SEP-2002; 2002US-0410953P.	201	GGCCGAGGAG AAGCGCAAGG GTGCCCTTAA GATCAAAAC CAGTATGCGG
PR	17-SEP-2002; 2002US-0410957P.	251	GCTGCATTCT CTTCCAGGAC ATCCAGAAAC TGGCCCAAT TGAGTTAGAT
PR	17-SEP-2002; 2002US-0410958P.	301	AAGACCTTGG ACACGGCTGG ACGCCATGG GTTCCTCCG AGCGGAGGAA
PR	17-SEP-2002; 2002US-0410959P.	351	AGAGGATGGC GACCTCGTGG ATGCCGGAGT CAGAGAGGAA CGTGGCTACG
PR	17-SEP-2002; 2002US-0410960P.	401	AAAGCCTCGG GCAGCCCGCC GATCAGATGG AGGAGAAGCA GGTGGAGAGC
PR	17-SEP-2002; 2002US-0410961P.	451	AGCAGCGAGC CGGCCCTTGG GCCTGGCCGG CCGGAGGAGC CCTCTGAGAG
PR	17-SEP-2002; 2002US-0410962P.	501	CGGCTTGGGT GTGGGCACCT CAGAAGCCGT GTCCGCCGAC AGCAGCGAGC
PR	17-SEP-2002; 2002US-0410963P.	551	CCGCGCCGCG CCGGGGCGAG GCAGAGGCGG ATGACTCTGG CGTGGGGCAA
PR	17-SEP-2002; 2002US-0410964P.	601	AGCTCGGACC CGGCGAGCGG TTCTCAGGTA TGGACCCGGC TGGACGGCGT
PR	17-SEP-2002; 2002US-0410965P.	651	GGGTGGAGGC AAGGACCGCG AGCAGCAGTG CCTGACAGCC AAGAGGAAAC
PR	17-SEP-2002; 2002US-0410966P.	701	AAGGCTTGTT TGTAGTAAAT ACTTGTGTT TCTGGTTTAC TGAGGAGGTA
PR	17-SEP-2002; 2002US-0410967P.	751	TCTGAGACCA GCTCGAGCGC AGACCCCTCG CCTAATAGCT ACCTCCCTGA
PR	17-SEP-2002; 2002US-0410968P.	801	TTCATCGTCT GTGTCTCATG GGCCAGTGGC AGGGGTGACA GGCGGTCCCC
PR	17-SEP-2002; 2002US-0410969P.	851	CAGCACTTGT GCATCTAGT GCACTCCAG ACCCCAACAT GCTGCTGCC
PR	17-SEP-2002; 2002US-0410970P.	901	GACTGCACAG CTTCTCTCTC GGACCTGGGC TCGGCCATCG ACAAGATCAT
PR	17-SEP-2002; 2002US-0410971P.	951	CGAGTCCACC ATCGGGCCCG ACCTCATCCA GAATGTCATC ACTGTGACCA
PR	17-SEP-2002; 2002US-0410972P.	1001	GTGCTGAGGA TGGCGGGGCC GAGACCACAC GGTACCTGAT CCTACAGGGC
PR	17-SEP-2002; 2002US-0410973P.	1051	CCAGATGATG GAGCCCCCAT GACATCACC AATGTCAGTT CCACCTTGGC
PR	17-SEP-2002; 2002US-0410974P.	1101	CCACAGCCTA GCAGCCATG AGGCCCTGGC AGATGGCCCC ACATCCACAT

1151	CCACATGCCT	GGAGGCACAG	GGTGGGCCCA	GCTCCCCGGT	GCAGCTGCCC
1201	CCAGCCTCCG	GTGCCGAAGA	GCCGACCTTG	CAGAGCCCTGG	AGGCCATGAT
1251	GGAGTGGTG	GTGGTGCAGC	AGTTCAAATG	CAAGATGTGC	CAGTACCGBA
1301	GCAGCACCA	GGCCACACTG	CTGCGCCACA	TGCGGNAACG	CCACTTCCGT
1351	CCAGTAGCAG	CAGCCCGAGC	AGCAGCTGGT	AAAAAAGGAC	GTCTACGGAA
1401	GTGGAGCAC	TCCACCAAGA	GCCAAAGGA	AGAGGGACCA	GAGGAGGAGG
1451	ACGATGATGA	CATTGTAGAC	GCTGGAGCCA	TTGATGACCT	GGAGGAGGAT
1501	AGCGACTATA	ATCCAGCTGA	GGATGAGCCC	CGAGGCCCGC	AGCTTTCGGT
1551	CCAGCGCCC	ACCCCCAGTA	CCCCAAGGCC	CCGAAGGAGA	CCTGGCCGGC
1601	CCCGAAGCT	GCCCGGCTG	GAGATCTCAG	ACCTCCAGA	TGGTGTGGAA
1651	GGAGAGCCTC	TAGTGAATTG	CCAGAGTGG	CAGAGCCCTC	CAGAGCCACA
1701	GGATCCCGAG	GCTCCCACT	CCTCAGGCC	AGGACACCTG	GTGGCCATGG
1751	GCAAGGTGAG	CAGGACCCCT	GTGGAAGCTG	GTGTGAGCCA	GTCCAGATGCA
1801	GAGAACGCAG	CCCCCTTCCTG	CCCGGATGAG	CATGACACTC	TGCCCCGGCG
1851	CCGAGGTGCA	CCTTCCAGGC	GCTTCTTAGG	CAAGAAATAC	CGCAAATGATG
1901	TGGAGCAGAG	GTACTATTAC	AGTTCGCCCA	AACCACITTT	GAGGCCCTTC
1951	CTGTGCCGCA	TCTGTGGTTC	TGCTTTTCTG	TCCCAGAGG	ACCTGGGCTT
2001	CCAGGTCAAC	TCCCATGAGG	GTGGCGATCC	CCAGCTCTTC	AAGTGCCTGC
2051	AGTGCAGCTA	TGTTTCCCG	CGCTGGTCTT	CGCTCAAGGA	GCACATGTTT
2101	AACCACGTGG	GCAGCAAGCC	CTACAAGTGT	GACGATGCA	GCTACACACG
2151	TGCTTACCGG	AAGGAGGTCA	TTGCGCACGC	CGCTGTGCAC	AGCCGGGACC
2201	GGAAGAAGAG	GCCAGATCCG	ACTCCAAAGC	TGAGCTCTTT	CCCCTGCCCT
2251	GTGTGTGCC	GTGTGTACCC	CATGCAGAAA	AGACTCAGC	AGCACATGAA
2301	GACGCACAGC	ACTGAGAAGC	CCACATGTG	TGACAAGTGT	GGAAAAGTCT
2351	TTAAGNAGCG	CTACACCTTC	AAATGCAAC	TGCTCACGCA	CATCCAGGCT
2401	GTTGCCAACC	GCAGGTTCAA	GTGTGAGTTC	TGTGAGTTTG	TTTGTGAAGA
2451	CAAGAAGSCA	CTGCTGAACC	ACCAGTTGTC	CCACGTCAGT	GACAAAGCCT
2501	TCAAATGCAG	CTTTTGTCCC	TACCGCACTT	TCCGAGAGGA	CTTCTTTGCTG
2551	TCCCATGTGG	CTGTCAAGCA	CACAGGGGCC	AAGCCCTTCG	CCTGTGAGTA
2601	CTGCCACTTC	AGCACACGGC	ACAAGAAGAA	CCTGCGCCTG	CACGTACGGT
2651	GCCGACACGC	AAGCAGCTTC	GAGGAATGGG	GGAGGCGCCA	CCCTGAGGAG
2701	CCCCCTCCC	GCGTGCGCC	CTTCTCTCT	CTGCAGCAGA	TTGAGGAGCT
2751	GAAGAGACAG	CACAGTGGCG	CCCTTGGACC	ACCTCCAGT	TCCCACGAGC
2801	CTCCTGAG				

!!AA SEQUENCE 1.0  
ID \_ADP31270 standard; protein; 1782 AA.  
XX  
XX  
AC ADP31270;  
XX

PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hesir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3268; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1782 AA;  
ADP31270 Length: 1782 February 22, 2005 12:25 Type: P Check: 8870 ..  
1 ATGGCCATAC TGCTCAAGGT AATTATAGA TTCAATGCCA TCCCCATCAA  
51 GCTACCAATG ACTTCTTTCA CAGAAATGGA AAAAATCTACT TTAAAGTTCA  
101 TATGGAAACA AAAAAGAGCC CACATGCCA AGTCAATCTT AAGCCAGAAG  
151 AACAAAGCTG GAGGCATCAC ACTACTGAC TTCAAACTAT ACTACAAGGC  
201 TACAGTCACC AAACAGCAT GGTACTGTA CCAAAACAGA GATATAGTC  
251 AATGGACAG AACAGAGCCC TCAGAAATAA TGCCGCATAT CTACAACTAT  
301 CTGATCTTTG ACNAACTGTA GAAAAACAAG CAATGGGAA AGGATTCCTT  
351 ATTAAATAA TGGTGCTGGG AAACTGGCT AGCCATATGT AGAAAGCTGA  
401 AACTGATCC CTTCCTTACA CTTTATACA AAATCAATTC AAGATGGATT  
451 AAGGACTTAA ACGTTAGACC TAACATCATA AAAACCCCTAG AAGAAACCTT  
501 AGGCATTACC ATTGAGGACA TAGGCATGGG CAAAGACTTC ATGTCTAAA  
551 CACCAAAGC AATGGCAACA AAAGCCAAA TTGACAAATG GGATTAATT  
601 AAATAAAGA GCTTCTGCAC AGCAAAAGAA ACTACCATCA GAGTGAACAG  
651 GCAACTTACA AAATGGGAGA AAATTTTCG AACCTACTCA TCGGACAAAG  
701 GGCTAATATC CAGAACTTAC AATGAATCA ACAAAATTTA CAAGAAAAA  
751 ACAAAACACC CCATCAAAA GTGGGTGAAG GACATGAACA GACACTTCTC  
801 AAAGNAGAC ATTATGAG CCAAAAACA CATGAAAAA TGCTCATCAT  
851 CACTGGCCAT CAGAGAAATG CAAATCAAAA CCACAAATGAG ATACCATCTC

901 ACACCAGTTA GAATGGCAAT CATTAATAAG TCAGAAACA ACAGCCGAC  
951 GCGGAATCGG GGCACAGCGG GAGCCCGTGC AGGGCGGGCG CGGGCGGCT  
1001 GGGCGGGCGT GCGCGCGGTC CATGCGGCGG CGCTCGGGGC TGCCCGGGCG  
1051 CCGGAACAC CCGGGGGCGA GGCAGGCGA GCGGCGGCGC GGTGCTCCG  
1101 GGACGGGAC GGCAGACTC ACTGTGAATT TCTTTTGGGA CCGAGCGAG  
1151 TGCTCAGGA GAAAGACCAG GGTGGGTTTG TTCAAGAGCC CCAAGTTGCT  
1201 TGGTTTGGGA CCCCCCGAAT AGGCTGGAC AGGCAAGCC AGCCCTTTCC  
1251 TCCCTGCAGG CACGAGCAGA CAAGTACCCA GGACCTGCTT GACTTTAGCG  
1301 ATATTTAGT TGAGGCCAG GATTTCAATC TCGTTGAAGT TCAGAGGATC  
1351 TTCTGGTCAG CTAAGCGGG AGGAGCTGCC ATTACAGAGC TCCGTGTGAG  
1401 GAGTAGGGTG GAGAATGTCA TGTTAATTT AGAAACAGCA GAAGAATGGA  
1451 GTGGCTGTTT GGATCTGGG CTGCGCAGTG GTGCTCTAGA CAGCAGCAC  
1501 AATCTGCAT GAAAAAGAAA GCGCCACCT GAGTTTGAAT GGAAGACCTT  
1551 TCTGTCATCG GGAACACCTG CTCACCCCA GGCAGGAGC AGCTGGAAT  
1601 GTGACCGGC CTGGGGCTCC AAGTCAGCG TCCCTGAATA CTTCTGGGCT  
1651 GGGCAGGAT TTCTGAAAG GGCTGTGAGC ATTGATGACC GCCACAGAG  
1701 AGCTCAGGAG GGTGGACCT CCACAGAGG AGCGTGCATC TGCAGTGGCT  
1751 TAGCGCTTC AGCGCTTCA TTCTCTCCT AG  
!!AA SEQUENCE 1.0  
ID ADP31296 standard; protein; 1010 AA.  
XX  
XX AC ADP31296;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #2063.  
XX  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; Inflammatory; Immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN W02004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Reaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3294; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present

CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1010 AA;  
ADP31296 Length: 1010 February 22, 2005 12:25 Type: P Check: 3575 ..

1 TTTTTTAGGA TAAGGAAGCC TGTGTGGGTA CCAACAATCA AAGCTACATC  
51 TGTGACACAG GACACTGTGT TGGACAGTCT CAGTGTGCA ACTACTACTA  
101 TGAACCTCTG TGGTTCTGGC TGGTGTGGAC CATCATCATC ATCCTGAGCT  
151 GCTGCTGTGT TTGCCACCAC CGCCGAGCCA AGCACCGCCT TCAGGCCCCAG  
201 CAGCGGCAAC ATGAATCAAA CCTGATGCTT TACCGAGAAG CCACANATTA  
251 CTCAGCGCTG CCATTTTATT TCAGGTTTTT GCCAAACTAT TTACTACCTC  
301 CTTATGAGGA AGTGTGTAAC CGACCTCCAA CTCCTCCCCC ACCATACAGT  
351 GCCTTCAGC TACAGCAGGA GCAGCTGTGT CTCCACAGT GTGGCCCTGC  
401 AGGTGGCAGT CCCCAGGGCA TCGATCCCAAC CAGGGGATCC CAGGGGGCAC  
451 AGAGCAGCCC CTTGTCTGAG CCGAGCAGAA GCAGCACAAG ACCCCCAAGC  
501 ATCGCTGACC CTGATCCCTC TGACCTACCA GTTGACGGAG CAGCCACCAA  
551 AGCCCCAGGG ATGAGAGCCA GTGGCTCTGT GGCTGGCCTG GGGGAGCTGG  
601 ACCCGGGGGC CTTCTGGAC AAGATGCAG AATGTAGGGA GGAGCTGTGT  
651 AAGATGACA GCTCTGAACA CGGCGCACCC GACAGCAAAG AGAAGACGCC  
701 TGGGAGACAT CGCCGCTTCA CAGGTGACTC GGGCATTGAA GTGTGTGTGT  
751 GCAACCGGGG CCACCATGAC GATGACCTCA AAGAGTTCAA CACACTCATC  
801 GATGATGCTC TGGATGGGCC CCTGGACTTC TGGACAGCT GCCATGTGGG  
851 GCCCCCTGGT GATGAGGAGG AAGGCCTCTG TCAGTCTCTT GAGGAGCAGG  
901 CTCGAGAGCC TGGGCACCCG CACCTGCCAC GGCCGCCCGC ATGCCCTGTG  
951 CTGAACACCA TCAACGAGCA GGACTCTCCC AACTCCCGA GCAGCAGCTC  
1001 CCCCAGCTAG  
IIAA SEQUENCE 1.0  
ID ADP31366 standard; protein; 2391 AA.  
XX  
AC ADP31366;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2133.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
XX WO2004035732-A2.  
PN  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.



PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406648P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471338P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Hallenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
PS Claim 1; SEQ ID NO 3364; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC anti-inflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.

SQ Sequence 2391 AA;

ADP31366 Length: 2391 February 22, 2005 12:25 Type: P Check: 5977 ..

1 ATGAAGAAAC AACAGCTGC CAGTGATATA GGCTCATCCG ATGAGTATAC  
51 CCAAGCAGAG GAAAAAATGG CCTCCACCTT CAACCCACAGA AATGGGCAAA  
101 CACAAGTGT CATGCTGCTT GCACCCCTCAG AGAAAGCCCT GGAGATGTC  
151 CTGCAGACAG GGAGGGAGCG CGGCTGGGCC AGAAGGCTGA TCACCGCCTG  
201 CCCCCTGCTG GCCAGTGTCA GTATTGAGCC CGCTGCCGT CGACCAGAAC  
251 GTCCACGGGA TGGAAATGAG GTGCGGGCAT TTATGAGGG CCTGCTGTTT  
301 GTCAGGCGAG GTACTGATAA GCGCTGGAGT GTAAGGATGT ACGTGACCTG  
351 CTCTCAGAGT TCAATTATA ATGAAGAGAT ATACATTAA CAAGTAGTCA  
401 TTCAGCAAA TATGAATTA CAACTGTGGG CTATCGGAAC AGATGACGGC  
451 AGGGGCTGT CCAGTCTGGG AGATACGGCA CCAGCCATGA ACTACGTGGG  
501 GCAGCTGGCG GAGACGGTGT TTGGGACGCT GAAGGAGCTG TACCGGGGCC  
551 TGAACCCAGC CACACTGAGC GGGGGCATTTG ACGTCTGCT GGTGAAGCAG  
601 GTGGACGGCT CGTTCCGGTG CTCACCCCTT CACGTGCGTT TTGGCAAAGCT  
651 GGGCGTCTCG CGGTGCGGG AGAAGTGTGT AGACATTGAG CTCAATGGGG  
701 AGCTGTGGA CTTGCAATG AAGCTTGGGG ACAGGGGGGA GGCCTTCTTT  
751 GTTCAGGAGC TGGAGAGCGA TGATGAACAT GTGCCCTCCG GCCTGTGCAC  
801 CTCACCCATC CCTTGGGGGG GTCTGTCTGG CTTCCTCCCG GACTCCACAG  
851 TGGGCACTGC CAGTGAGCCT GAGGGCTCG TCATGGCAGG CACGGCTCC  
901 ACTGGGCGGA GGAAGAGGCG TCGCAGAGG AAACCCAAAG AGAAAGAGGA  
951 TGCAGTGGCA ACTGATTCTA GTCCAGAGGA ACTGGAGGA GGCCTGAGA  
1001 GTGAGCTATC CTTGCCCGGAA AAGCTGAGGC CAGAGCCCCC AGGCAGTGTCT  
1051 CAGTTGGAAG AGAAGTCTTC ACTGCAGCCC AAAGACATCT ACCCTACTC  
1101 GGATGGCGAG TGGCCCCCCC AGGCCAGCCT CTCAGCAGGT GAGCTACAT  
1151 CCCCTAAGAG CGACTCGGAG CTGGAGGTGC GGACCCCGGA GCCCAGTCCC  
1201 CTAAGAGCCG AGTCCACACAT GCAGTGGGCC TGGGGAGGC TGCCTAAGCA  
1251 AACAGAGGCT GGTGCCGACC TTCAGCCTGA CACAGAGAT CCCACTCTAG  
1301 TGGGTCCCCC TCTCCACACC CCAGAGACAG AGGAAGCAA GACTCAGAGC

1351 TCTGGGACA TGGGCTCTCC TCCTGCCTCC AAGTCATGGA GCTGGGCCAC  
1401 TCTGGAGGTT CAGTTTCCA CGGGCAGCC AGAGAGGTC TCAGGGGGA  
1451 AAGGCTCCC AAGAAGAAGC CAGCACCTGG GCCCAGTGA CATCTACCTG  
1501 GATGACTTGC CTTCCCTGGA CTCTGAGAA CTGAGCGCTTT ACTTCCCCCA  
1551 AAGTGACTCT GGGCTGGGG CCAGAGATG GAGTGAACCC AGCAGTCAGA  
1601 AGTCCCTGAG GGACCCCAAC CCTGAACATG AACCTGAACC CACTCTGGAC  
1651 ACAGTGGATA CAATAGCACT GTCCCTCTGT GGTGAGCTGG CTGACAGCGG  
1701 GGACATCTCC CTAGAGAAAT TCACCAGCA CAGGCTCTCT TACCAAGACC  
1751 TCACCAAAA CCCCAGACTT TTGATGACC CAAACCTAGT GGTGAANAATC  
1801 AATGGAAGC ATTATAACTG GGCTGTGGCT GCCCCCATGA TCCTCTCCCT  
1851 GCAGCCTTC CAGAAAACCT TGCCCAAGAG CACCATGGAC AAGCTGGAGA  
1901 GGGAGAAGAT GCCCCGGAAG GGTGGGCGAT GGTGGTTTTT CTGGCGACGC  
1951 AGGACTTCC TGCCCGAGGA GCGCAGTGCC CAGAAGGAGA AGACTGCAGC  
2001 CAAGGACGAG CAGGGGGAGA AGACAGAAGT CTTGAGCAGT GATGACGATG  
2051 CCCAGACAG CCTGTGATC CTGGAGATCC CCTCCTTTGCC ACCCTCCACT  
2101 CCACCTCCA CTCCTACCTA CAAGAAGTCC CTCGCGCTCT CTTCCGATCA  
2151 GATCCGGGC CTGAACCTGC AAGAAGTGC CAATGATGTG GTCTTCAGCG  
2201 TGACCACTCA GTACCAAGGC ACCTGCCGCT GCAAGGCCAC CATCTACCTG  
2251 TGGAAATGGG ACGACAAGT GTCATCTCT GACATCGAGC GCACCATCAC  
2301 CAAGTCAGAT GCTCTGGGCC ATATCTCTGCC CCAGCTGGGG AAGACTGGA  
2351 CACACCAAGG CATCACAGT CTCTATCACA AAATCCAAC N

!1AA SEQUENCE 1.0  
ID ADP31407 standard; protein; 1566 AA.

XX AC ADP31407;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #2174.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.

29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411049P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-041101P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463718P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471308P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-047240P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486466P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases

such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3405; 428pp; English.

The present invention relates to an isolated nucleic acid molecule

CC

CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1566 AA;

ADP31407 Length: 1566 February 22, 2005 12:25 Type: P Check: 8427 ..  
1 ATGCTGTGTG CCTGCTCTCT CTGTCGCCAGC CTCCTGGGGG CCACAGGGC  
51 CAGCCCCACC TCAGGCCCCC AGGAGTGTGC AAAGGGCTCC ACGGTGTGGT  
101 GTCAGGATCT GCAGACAGCT GCCAGGTGCG GGGCTGTGGG GTACTGCCAA  
151 GGGGGCGTAT GGAACAAACC CACGGGAAG TCTCTGCCCT GCGAGTATG  
201 CCAGGACATA GCAGCGCGCG CTGGCAATGG GCTGAACCTT GACGCCACGG  
251 AGTCTGACAT CCTGCTTTG GTGATGAGA CTTGTGAGTG GCTCCCCAGC  
301 CAGGAGTCTT CAGCGGGATG CAAGTGGATG GTGGATGCC ACAGTTCGGC  
351 CATCTGAGC ATGCTCCGTG GGGCCCCGGA CAGTGCCCCG GCACAGGTGT  
401 GCACAGCGCT CAGCTCTGT GAGCGGTGC AGAGGCACTT GGCNACCCTG  
451 AGGCCACTCT CCAAGAGGA CACCTTTGAG GTGTGGTCTC GTTTCATGGC  
501 CAATGGGCC CTTACCTTCC ACCCCGCCA GGGCGCTGAA GGAGTCTGT  
551 GCCAAGACTG TGTACGGCAG GTCTCCGCAC TCCAGGAGCG TGTCCGGTCC  
601 AACTTGACTT TGGCCGACTT GAACATCCAG GAGCAGTGTG AGTCTTGGG  
651 GCCTGGCCTG GCCGTCCTCT GCAAGAACTA CCTCTTCCAG TTTTGTGTC  
701 CTGCTGACCA AGCACTGAGG CTTCTCCCC CCGAGGAGCT CTGCAGGAG  
751 GGGGATTTCT GTGAGGAGCT AGGGGCACCT GCCCGTTTGA CTCAGTATG  
801 GSCCATGAC GGGTCCCTT CCCTGGAGCT GGGTTTGCCA AGGAAACAGA  
851 GCGAGATGCA GATCAAGGCC GGTGTGACCT GTGAGTGTG CATGAACGTG  
901 GTGCAGAGC TGGACCACTG GCTCATGTCC AACAGTCTG AGCTCATGAT  
951 CACCCATGCC CTGGAGCGCG TGTGCTCGGT AATGCTGCC TCTATCAGA  
1001 AGGAGTGAT CATCTTGGTG GACACCTACA GCCCTCCTT GGTGAGCTT  
1051 GTGGCCAAA TCACCCACGA GAAGGTGTGC AAGTTTCATCC GTCTGTGTGG  
1101 CAACCGGAG GGGCCCCGGG CAGTCCATGA TGCTTATGCC ATCGTGCGGT  
1151 CCCCAGAGT GGAGCGCGAG AACCAAGGCA GCTTCTGCA TGGGTGCAAG  
1201 AGGTGTCTCA CGGTGTCTC CCACAACTTG GAGAGCAAGA GCACCAAGCG  
1251 AGACATCTG GTGGCTTCA AGGGTGGCTG CAGCATCTCG CCGCTGCCCT  
1301 ATATGATCCA GTGCAAGCAC TTGCTCACC AGTACAGGCC GTGCTCATTT  
1351 GAGAGTCTCA AGGACATGAT GGACCCCGTG GCTGTGTGCA AGAAGTGGG  
1401 GGCCTGCCAC GGCCCCAGGA CCCCCTGCT GGGCACCGAC CAGTGTGCC  
1451 TGGGCCCAAG CTTCTGTGTC AGGAGCCAGG AGGCCGCCAA GCTGTGCAAC  
1501 GCTGTGCAAC ACTGCCAGAA GCATGTATGG AAAGAGATGC ACCTCCACGC

1551 TGGGAACAC GCGTGA  
!!AA SEQUENCE 1.0  
ID ADP31422 standard; protein; 204 AA.  
XX  
AC ADP31422;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2189.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.

PR 19-MAY-2003; 2003US-0471306P.  
 PR 19-MAY-2003; 2003US-0471336P.  
 PR 22-MAY-2003; 2003US-0472420P.  
 PR 22-MAY-2003; 2003US-0472430P.  
 PR 09-JUN-2003; 2003US-0476609P.  
 PR 09-JUN-2003; 2003US-0476641P.  
 PR 08-JUL-2003; 2003US-0485218P.  
 PR 08-JUL-2003; 2003US-0485223P.  
 PR 08-JUL-2003; 2003US-0485224P.  
 PR 08-JUL-2003; 2003US-0485325P.  
 PR 14-JUL-2003; 2003US-0486446P.  
 PR 14-JUL-2003; 2003US-0486480P.  
 PR 15-JUL-2003; 2003US-0486891P.  
 PR 15-JUL-2003; 2003US-0486960P.  
 PR 08-AUG-2003; 2003US-0493341P.  
 PR 08-AUG-2003; 2003US-0493370P.  
 PR 08-AUG-2003; 2003US-0493573P.  
 PR 08-AUG-2003; 2003US-0493577P.  
 XX  
 PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
 XX  
 PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
 PI Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;  
 PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
 XX  
 XX WPI; 2004-348438/32.  
 XX  
 PR New nucleic acid molecule for diagnosing, preventing or treating diseases  
 PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
 PT genetic, bacterial and viral diseases.  
 XX  
 PS Claim 1; SEQ ID NO 3420; 428pp; English.  
 XX  
 CC The present invention relates to an isolated nucleic acid molecule  
 CC encoding a polypeptide which is believed to be cytostatic,  
 CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
 CC composition and methods are useful for diagnosing, preventing and  
 CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
 CC immune, metabolic, genetic, bacterial and viral diseases. The present  
 CC sequence represents a human secreted protein. The present sequence is  
 CC available on WIPWEB and is not in the specification.  
 XX  
 SQ Sequence 204 AA;  
 ADP31422 Length: 204 February 22, 2005 12:25 Type: P Check: 267 ..  
 1 ATGGGTAAGG GGATGGTGGC GATGCTCATT CTGGGTCTGC TACTTCTGGC  
 51 GCTGCTCCTA CCGGTGCAGG TTCTTCTATT TGTTCCTTTA ACCAGTATGC  
 101 CGGAGGCTAC TCGAGCCGNA ACCCAAGC CTCCAACAG TGCCTACAG  
 151 CCTACAGCG GTCTCTTGT GTCTTGTCTT GCCTTCTAC ATCTCTACCA  
 201 TTAA  
 !!AA SEQUENCE 1.0  
 ID ADP31452 standard; protein; 1119 AA.  
 XX  
 AC ADP31452;  
 XX  
 DT 12-AUG-2004 (first entry)  
 XX  
 DE Human secreted protein SEQ ID #2219.  
 XX  
 KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
 KW cancer; inflammatory; immune; human secreted protein.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2004035732-A2.  
 XX  
 XX 29-APR-2004.  
 XX

XX 28-AUG-2003; 2003WO-US026780.  
 PF  
 XX 29-AUG-2002; 2002US-0406576P.  
 PR 29-AUG-2002; 2002US-0406579P.  
 PR 29-AUG-2002; 2002US-0406585P.  
 PR 29-AUG-2002; 2002US-0406588P.  
 PR 29-AUG-2002; 2002US-0406608P.  
 PR 29-AUG-2002; 2002US-0406611P.  
 PR 29-AUG-2002; 2002US-0406612P.  
 PR 29-AUG-2002; 2002US-0406616P.  
 PR 29-AUG-2002; 2002US-0406642P.  
 PR 29-AUG-2002; 2002US-0406646P.  
 PR 29-AUG-2002; 2002US-0406653P.  
 PR 29-AUG-2002; 2002US-0406655P.  
 PR 29-AUG-2002; 2002US-0406666P.  
 PR 17-SEP-2002; 2002US-0410947P.  
 PR 17-SEP-2002; 2002US-0410948P.  
 PR 17-SEP-2002; 2002US-0410949P.  
 PR 17-SEP-2002; 2002US-0410953P.  
 PR 17-SEP-2002; 2002US-0410957P.  
 PR 17-SEP-2002; 2002US-0410958P.  
 PR 17-SEP-2002; 2002US-0410959P.  
 PR 17-SEP-2002; 2002US-0410960P.  
 PR 17-SEP-2002; 2002US-0410961P.  
 PR 17-SEP-2002; 2002US-0410962P.  
 PR 17-SEP-2002; 2002US-0411019P.  
 PR 17-SEP-2002; 2002US-0411022P.  
 PR 17-SEP-2002; 2002US-0411023P.  
 PR 17-SEP-2002; 2002US-0411024P.  
 PR 17-SEP-2002; 2002US-0411032P.  
 PR 17-SEP-2002; 2002US-0411035P.  
 PR 17-SEP-2002; 2002US-0411037P.  
 PR 17-SEP-2002; 2002US-0411041P.  
 PR 17-SEP-2002; 2002US-0411045P.  
 PR 17-SEP-2002; 2002US-0411046P.  
 PR 17-SEP-2002; 2002US-0411048P.  
 PR 17-SEP-2002; 2002US-0411052P.  
 PR 17-SEP-2002; 2002US-0411055P.  
 PR 17-SEP-2002; 2002US-0411073P.  
 PR 17-SEP-2002; 2002US-0411082P.  
 PR 17-SEP-2002; 2002US-0411101P.  
 PR 17-SEP-2002; 2002US-0411111P.  
 PR 18-APR-2003; 2003US-0463700P.  
 PR 18-APR-2003; 2003US-0463708P.  
 PR 18-APR-2003; 2003US-0463716P.  
 PR 18-APR-2003; 2003US-0463732P.  
 PR 02-MAY-2003; 2003US-0467199P.  
 PR 02-MAY-2003; 2003US-0467201P.  
 PR 02-MAY-2003; 2003US-0467203P.  
 PR 02-MAY-2003; 2003US-0467230P.  
 PR 19-MAY-2003; 2003US-0471306P.  
 PR 19-MAY-2003; 2003US-0471336P.  
 PR 22-MAY-2003; 2003US-0472420P.  
 PR 22-MAY-2003; 2003US-0472430P.  
 PR 09-JUN-2003; 2003US-0476609P.  
 PR 08-JUL-2003; 2003US-0476641P.  
 PR 08-JUL-2003; 2003US-0485218P.  
 PR 08-JUL-2003; 2003US-0485223P.  
 PR 08-JUL-2003; 2003US-0485224P.  
 PR 08-JUL-2003; 2003US-0485325P.  
 PR 14-JUL-2003; 2003US-0486446P.  
 PR 14-JUL-2003; 2003US-0486480P.  
 PR 15-JUL-2003; 2003US-0486891P.  
 PR 15-JUL-2003; 2003US-0486960P.  
 PR 08-AUG-2003; 2003US-0493341P.  
 PR 08-AUG-2003; 2003US-0493370P.  
 PR 08-AUG-2003; 2003US-0493573P.  
 PR 08-AUG-2003; 2003US-0493577P.  
 XX  
 XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnenmann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3450; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1119 AA;

ADP31452 Length: 1119 February 22, 2005 12:25 Type: P Check: 2960 ..

ID ADP31506 standard; protein; 543 AA.  
XX  
AC ADP31506;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2273.  
XX  
KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406656P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.

PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493373P.  
PR 08-AUG-2003; 2003US-0493377P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3504; 429pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 543 AA;  
SQ  
ADP31506 Length: 543 February 22, 2005 12:25 Type: P Check: 4906 ..  
1 ATGGGGTTTC GCCATGTAGA CCAGGCTGGT CTCAAACTCC TGACCTCAGA  
51 CAGCCCGCTC TGCCACACTC CCACCCAGCC CTCGTGCTATC AGAGCTCTGA  
101 ACACCCAAAA AGGAAAAACG ATTTGTGCTG AGCGCGAAGA CAGAGCCAGG  
151 GAGGAAGGGA AGGGCTGCTC GCTGCCAGCT GACGTTCTGC AGACTGAGCT  
201 GCCTGTGTCT GTGCCAAGGT CCTCAAGTCC TGATCGGCTT GCTCGGTATT  
251 TGCACCAAGT GCTTACTCTC TGTCCTCTGC TCCTACACTC TCACCTGTGA  
301 GATATTTTCA AGCTGTTTTA TTTTCAGACA GTCTTCTGCA TTGCCATCAG  
351 CTGCCTATTT GAGGGAACA AACTGTCTGT GTTTGCCAG GTTCCAGATA  
401 TTTTCTCAGG TGCAGGACTT TCAGTGCCAA AACTAGACAA ATTGAGCCAG  
451 CTGGGACTGG ACTCTGGCAC TTCTACAAAT AGAGCTGTGC CAGAAGAAA  
501 GGAAGTTTCA GCNCTCAGTC CATCCACACC CCCACCCCC TGA  
!!AA\_\_SEQUENCE 1.0  
ID ADP31520 standard; protein; 735 AA.  
XX  
AC ADP31520;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2287.  
XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
PN  
XX  
PD  
XX 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.

PR 15-JUL-2003; 2003US-0485891P.  
PR 15-JUL-2003; 2003US-0485960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3518; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 735 AA;  
SQ  
ADP31520 Length: 735 February 22, 2005 12:25 Type: P Check: 4274 ..  
1 ATGGACATCC TGGTCCCACT CTGCAGCTG CTGGTGTCTG TTCTTACCTT  
51 GCCCTGAC CTCATGGCTC TGCTGGGCTG CTGGAGCCCT CTGTGCAAAA  
101 GCTACTTCCC CTACCTGATG GCGTGTCTGA CTCCCAAGAG CAACCGCAAG  
151 ATGGAGAGCA AGAAAGGGA GCTCTTCAGC CAGATAAGG GCGTTACAGG  
201 AGCTCCGGG AAGTGGCCC TACTGGAGCT GGGCTCGGA ACCGGAGCCA  
251 ACTTTAGTT CTACCCACCG GGCTGCAGG TCACCTGCCT AGACCCAAAT  
301 CCCCACTTTG AGAAGTTCTT GACAAAGAGC ATGGCTGAGA ACAGGCACCT  
351 CCAATATGAG CGGTTTGGG TGGCTCTCGG AGAGGACATG AGACAGCTGG  
401 CTGATGGCTC CATGATGTG GTGGTCTGCA CTCTGGTGTCT GTGCTCTGTG  
451 CAGAGCCCAA GGAAGTCTT GCAGGAGTC CCGAGAGTAC TGAGACCGGG  
501 AGGTGTGCTC TTTTCTGGG AGCATGTGGC AGAACCATAT GGAAGCTGGG  
551 CCTTCATGTG GCAGCAAGTT TTCAGGCCA CCTGGAACA CATTGGGGAT  
601 GGCTGCTGCC TCACCAGAGA GACCTGGAAG GATCTTGAGA AGCCCACTT  
651 CTCGAAATC CAATGGAAAC GACAGCCCCC TCCCTTTGAAG TGGCTACCTG  
701 TTGGGCCCCA CATCATGGA AAGCTGTCA AATAA  
IIAA SEQUENCE 1.0  
ID\_ADP31531 standard; protein; 225 AA.  
XX  
XX ADP31531;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2298.  
XX  
XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411033P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411011P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 18-APR-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 02-MAY-2003; 2003US-0467230P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 22-MAY-2003; 2003US-0472430P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 09-JUN-2003; 2003US-0476641P.  
XX 08-JUL-2003; 2003US-0485218P.  
XX 08-JUL-2003; 2003US-0485223P.  
XX 08-JUL-2003; 2003US-0485224P.  
XX 08-JUL-2003; 2003US-0485325P.  
XX 14-JUL-2003; 2003US-0486446P.  
XX 14-JUL-2003; 2003US-0486480P.  
XX

PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486860P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3529; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 225 AA;  
ADP31531 Length: 225 February 22, 2005 12:25 Type: P Check: 1758 ..  
1 ATGSCACGGC TGSCACCATG GACGCCCTCA CCCAGGCCCTA CTCAGGAATT  
51 CAACAGTACG CAGCCGCCGC GCTGCCCACT CTGTACAGCC AGAGCTGTCT  
101 GCAGCAGCAG AGGCTGTCAG GCAGCCAGAA GGAAGGTAGG TGCCGCCCTT  
151 GGCCCCAGGC AGGGCCCGAG CCAACAGGCA GCACTGGCCT CTAGAGCAGC  
201 GTTAGAGGT ATCAATTGA ACTGA  
!!AA SEQUENCE 1.0  
ID ADP31532 standard; protein; 1518 AA.  
XX  
AC ADP31532;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2299.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR

29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
02-MAY-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX  
PS Claim 1; SEQ ID NO 3530; 428pp; English.

(FIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 3530; 428pp; English.



XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1518 AA;

ADP31532 Length: 1518 February 22, 2005 12:25 Type: P Check: 1764 ..

1 ATGGAGGAGC CGCCGCGCC GGGCGGACC GAGGGGTCC TTGAAGGCA  
51 AGGAGCGCCG CCAGCTGCAG GCCAGGGAGG AGCCTGGTG GAGCTCACCC  
101 CGACCCCGCG CGGCTTGGCC CTGGTGAGCC CTTACACAC CCACCGGGCC  
151 GGGGACCCCT TAGACCTCGT GCGCTCGCA GAGCAGGTGC AGAAGGCTGA  
201 TGAATTTCAT CGAGCAATG CCACCAACA GCTGACAGTC ATAGCTGAGC  
251 AATCCAAACA TTGCAAGAA CAAGCCAGGA AGTACTGGA AGATGCTAC  
301 AGAGATGCCA ACCTGCACCA TGTAAGTTGT AATATAGTGA AAAAACCTGG  
351 CAACATTTAC TATCTCTATA AACGGGAGG TGCTCAGCAG TATTTTCCA  
401 TCATTTCTCC AAGGAATGG GGGACAAGTT GTCCACATGA CTTCTTGCT  
451 GCTACAAAC TACAGCATGA CTTCTCTCG ACTCCGTATG AGGACATTGA  
501 GAAGCAAGAT GCTNAATCA GCATGATGA CAGTTTGCTA AGCCAGATGG  
551 GAATGTAAC ACTAAGCTCA GTTTGCCGCC TCCAAGCCGC CTGCGCTTC  
601 CTGCGCGTGT CTGACAAAGA CTCTGCTCCC TTACTGAACA CCACAGTGCC  
651 CGCCACGGGC TGCCACTCA GGAAGCCAG TGTAAGCGGT GCCCAACAG  
701 AGTGCCAAGT GTACATGGT AAGGGTACCA GTTTCTTCCT GAGCCATGAC  
751 CAGAGCCATT CCCAGATAA TGAGGTTTCC TGGAAGGATG TTACCAAGTGC  
801 CTTATCTCTG GCCACATGG TGCTGGGGCT CTTCTCCATC ATCTTCAGCT  
851 TCAGCAGGAA ATGCCACTAT GCCTCCCGGA TGCTCTGGT CAGCTTCCTG  
901 TTAGACATGG CAGTCAGGCG AATGACCAGC CACATCAACA TATGCTCAA  
951 ATTGGAGCC GAGCTGAATG ACTTTGCGT CTTCAACCACC TTCGGCTTGG  
1001 CTTCCGCTCT GCTCTAGGC GTGGAATGAC TTCTGAGTG GATCTGGCC  
1051 ATCATCTATG TGTGAGTGC TTCTTTCCAC TTGTGCTTTT ATTCACTGG  
1101 AGTCCCTCC ACATACAGG GTCTACCTG CCCTATGCT TCCTGCATCT  
1151 TGGCTTCCAC CTCCTTCTG ACCAAGGCA ACAGGTTTAT CTTCTGCTGC  
1201 ATGGGCTCAC TCATGATTCT CTTTCATATG GACCAGAGCT ACTATCCATA  
1251 TGACAAATC CTGGNGTCTG AGAAGTGA AAATTTGGTT TATATAGGAG  
1301 ATGTAAGCT TCAAAATAT CTCGTGTACT TTGAGAACT GGGGATGGAC  
1351 CACATCAGGA TGAGGGAATT CTGGGCAGAG TGTTTCTCCA CGACAAGAA  
1401 ATACCCNAGG CTGAGATG TTAATACAAG CAGTTCCCAA CTAAGAACT  
1451 TTCCAGACAA TGATCATGTC TTTCTGCTT ATGTGAATC TGAAAACATT

1501 TCCCATGAAA CAATCTGA  
!!AA SEQUENCE 1.0  
ID ADP31566 standard; protein; 1380 AA.  
XX ADP31566;  
AC ADP31566;  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #2333.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.

PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348439/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3564; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1380 AA;  
ADP31566 Length: 1380 February 22, 2005 12:25 Type: P Check: 9888 ..  
1 ATGGGGTTTC ACCATGTGG TCAGGCTGGT CTCGAACATCC TTACCTCAGT  
51 TCCAGGGGCA GTGTTTGATT TACAACCTGC AGAGTAGAA TCCACGCAAG  
101 TAAGAATTAC TTGAAGAAA CCAGACACAC CAATGGNAT TATTAACCAA  
151 TACCGAGTGA AAGTGTGAGT TCCAGAGACA GGAATAATTT TGGAAATATC  
201 TTTGCTCACT GGAATAATG AGCTGTGCGA AAACCTCATG CAACAATGCG  
251 AAATGCCACA CAGCGAGAAG CTGGCCCCCTC CTAACCCATT TGACCTTCTT  
301 CCTGGAGAAA GTAGACCCCT AGAGTCTCTG GCCAAGCTGC ATAGACAATC  
351 AGTTATTACA GTTGCCAAAG CAGTAACACT AAGGAATCAG TATATTACTG  
401 ACATTGAGC TGAACAGCTG TCTTATGTTA TCAGAGACT TGACCTTCTT  
451 ACTGAGCACA TGATTAGTGT ATCTGCTTTC ACCATCATGG GAGAAGGACC  
501 ACCAACAGTT CTCAGTGTTA GGACAGCTCA GCAAGGGTTA AAGAAATACA  
551 CAATAACAA AATGAGAGTG GCAGCCTCNA CCCAGTTGG AGAAGTTCT  
601 TTGTCTGAAG AAAATGACAT CTTTGTGAGA ACTTCAGAA ATGAACCGGA  
651 ATCATCACT CAAGATGTGC AAGTAATTGA TGTACCSCA GATGAAATAA

701 GGTTGAAGTG GTCACCACC GAAAGGCCA ATGGATCAT TATTGCTTAT  
751 GAAGTGCTAT ATAAAATAT AGATACTTTA TATATGAAGA ACACATCAAC  
801 AACAGACATA ATATTAAGGA ACTTAAGACC TCACACCCCTC TATAACATTT  
851 CTGTAAGGTC TTACACCAGA TTTGGTCATG GCAATCAGGT ATCTTCTTTA  
901 CTCTCTGTAA GGACTTCGA GACTGTACTG AAGAAATATA CCCAATATAT  
951 CATTGAGGTG TCTGCTAGTA CACTCAAAGG TGAAGGAGTT CGGAGTGTCT  
1001 CCATAAGTAT ACTGACGGAG GAAGATGGAC AGAGGGCTTT CTGTATATCCG  
1051 GGGTTTCTTG CTTTGGAGTA CCAGAACTGG ATCACAGCTG GCGTTGGAGA  
1101 GCACGATTTA TTGAGTGGAG ATAACTCTCA GCAGAGGGGG GAGCCAGAGG  
1151 GAAATGGAGT GGGNAAGTGG TTTTCCCTCG GAGTCGGGCC ACTCAGCAGC  
1201 GACTCTCTCT CATCTCACC GCCCAAACCTG TCGTGTGTTT CGTGTTGTTGA  
1251 TGGCCTGCTG GCCTCGGGCG TCTGTCACTG TGTGCTGTTA GGCCTGCTGA  
1301 TTCTCTCTCGA TGTCCAGCGG TTGTGTCTTA CGCCAAAGTG TTCTCTGTCAA  
1351 GTGCCAGCGG CTTGTGTGTG TGCCCGTTAG  
!!AA SEQUENCE 1.0  
ID ADP30486 standard; protein; 1179 AA.  
XX  
AC ADP30486;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1253.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-047240P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-048646P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2484; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPower and is not in the specification.  
XX  
XX Sequence 1179 AA;  
ADP30486 Length: 1179 February 22, 2005 12:25 Type: P Check: 9155 ..  
1 ATGCCGCGCT TGTCTCTGCT CTTGCCGCTG CTGCTTCTGC TGTGCTGCC

51 GCTGCTGCCG CCGCTGTCCC CGAGCCTTGG GATCCGCGAC GTGGCGCGCC  
101 GGCGCCCCAA GTGTGTCCG TGCCGGCCAG AGGGCTGCCC GGCGCTGCG  
151 CCCTGCCCGG CGCCGGGAT CTCGGGCTC GAGGAGTGG GCTGTGCGC  
201 CCGTGCCTG GAGCCGAGG GCGCGAGCTG CGGGGGCCGC GCCGCGGGC  
251 GCTGTGGCCC CGGCTGTGTA TGC CGCAGCC AGGCCGCTGG GCGACGGCCC  
301 GAGGACCG GGCTCTGGT GTCCGGCAG CGGGCACC G TCTGCGGCTC  
351 CGACGGTGC TGTACCCCA GCGTCTGCG GCTGCGCCTG CGCGCTCGC  
401 ACACGCCCG CGCGACCCC GGTCACTGC ACAAGCGCG CGACGGCCT  
451 TCGAGTTGG TTCTATCAC TCGTTTTAT AACTGCTTTC CTCAGCCGTT  
501 AATTCACAG CAATTCTTT TGTCTCAGA CAGGAGACAG AGTGAGACCC  
551 TGTCTAATA GAAGAAGAG AAGGAGGAG AGGAGGAGG TCCAACACAC  
601 GGGGAGGAG AGAAGGAAGA AGAAGGATG AAAAGCAATT TTTTCATTCC  
651 CATTAACCTT AAGAAATCT CAGAGGAT TGGGAAGATT TTTTCATTCC  
701 AGCCATCAAT GATCGATATA ATTGACGAG CCTCTACACT GCACGTTGCC  
751 CAACACGCTG TGTGTCTGGA TGCAGGGTG GCTGAGTTGC TGTCCAATGC  
801 AGCTCCTGTG GTCTGCTTTC CTCGCCGAG TGTTCACAA GTCACCGGG  
851 CGCAGGTGG CTTGCTCTGT GAAGTGAGG CTGTGCCTAC CCAGTCACT  
901 ACGTGGAGAA AGTTCACGAA GTCCCTCTAG GGCACCCCAAG CACTGGAGGA  
951 GCTGCTGGG GACCATGTCA ATATAGCTGT CCAAGTGCGA GGGGGCCCTT  
1001 CTGACCATGA GGCCACGGCC TGGATTTTGA TCAACCCCTC GCGAAGGAG  
1051 GATGAGGTG TGTACCAAGT CCATGAGCC AACATGGTGG GAGAGGCTGA  
1101 GTCCACAGC ACAGTGACGG TTCTAGATCT GAGTAAATAC AGGAGCTTCC  
1151 ACTTCCCAGC TCCGATGAC CGCATGTGA  
!!AA SEQUENCE 1.0  
ID ADP30494 standard; protein; 786 AA.  
XX  
XX AC ADP30494;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #1261.  
XX  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX  
XX PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Korhakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2492; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 786 AA;

ADP30494 Length: 786 February 22, 2005 12:25 Type: P Check: 2291 ..

1 CTGTTCTCTG TCCTCTCTGT GCCCTGTGAG CTGAGCCTGG CAGGCGCCCT  
51 TGCACCTGGG ACCCTCTGCC GGAACCTCCC TGAGAATCAC ATTGACCTCC  
101 CAGGCCCAGC GCTGTGAGC CCTCAGGCCA GCCACCACCG CCGGCGGGGC  
151 CCGGCAAGA AGGAGTGGGG CCCAGGCGCTG CCCAGCCAGG CCCAGGATGG  
201 GGCTGTGGTC ACCGCCACCA GGCAGGCGTC CAGGCTGCCA GAGGCTGAGG  
251 GGCTGTGGCC TGAGCAGAGT CTTGACGGCC TGCTGGCAGG CAAGGACCTG  
301 CTCTGGGAC TGGCATTTGCC CTACCCCGAG AAGGAGAACC GACCTCCAGG  
351 TTGGGAGAGG ACCAGGAAC GCACGAGGA GCACAAGAGA CGCAGGGACA  
401 GGTGAGGCT GCACCCAGC TCCCTGATGA AGAAGGCAGA GCTCTCCGAA  
451 GCCAGGTGC TGGATGCAGC CATGGAGGAA TCCTCCACCA GCCTGGCGCC  
501 CACCATGTTT TTCTCACCA CTTTGAGGC AGCACCTGCC ACAGAAGAGT  
551 CCTGATCCT GCCCTCACC TCCTGCGGC CCACGGCACA GCCCAGGTCT  
601 GACGGGAGG TGATGCCAC GCTGGACATG GCCTTGTTTC ACTGGACCGA  
651 TTATGAAGAC TTAARACCTG ATGCTTGCC CTCTGCAAG AGAAGAGA  
701 AACACCGCGG TAAACTCTCC AGTGATGGTA ACGAAACATC ACCAGCCGAA  
751 GGGGAACCAT GCGACCATCA CCAAGACTGC CTGCCA

!!AA SEQUENCE 1.0

ID ADP30511 standard; protein; 2020 AA.

XX AC ADP30511;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1278.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX FN WO2004035732-A2.

XX PD 29-APR-2004.

XX PP 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411071P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471338P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
PS Claim 1; SEQ ID NO 2509; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
SQ Sequence 2020 AA;  
ADP30511 Length: 2020 February 22, 2005 12:25 Type: P Check: 723 ..  
1 CAGATCCTGG GGCAGAGTCC AGGGCAGCTC AAGGCTCCTC CACACACACA  
51 CCGGCTGAAC CCTGAGCACC CTGAGCTGCT GAGATGGGGC GGGCCGGGGC  
101 TCCCGCCGTG ATCCCGGGCC TGGCCCTGCT CTGGGCAGTG GGGCTGGGGA  
151 GTGCGCGCCC CAGCCCCCAC GCCTTCGGCT CTCCTTCCAA GAGCTCCAGG  
201 CCTGSCATGG TCTCCAGACT TTCAGCCTGG AGCGAACCTG CTGCTACCAG  
251 GCCTTGCTGG TGGATAGGA GCGTGGAGCG CTGTTTGTGG GTCCGGAGAA  
301 CCATGTGGCC TCCCTCAACC TGGACAACAT CAGCAAGCGG GCCAAGAAGC  
351 TGGCCTGGCC GGCCCTGTG GAATGGCGAG AGGAGTGCAA CTGGCAGGG  
401 AAGGACATTG GTACTGAGTG CATGAACCTC GTGAAGTTGC TGCATGCCTA  
451 CAACCGCACC CATTTGCTGG CTTGTGGCAC GGGAGCCTTC CACCAACCT  
501 GTGCCTTTGT GGAAGTGGG CACCGGGCAG AGGGCAAGGG GAAGAGTCTT  
551 TATGACCCCA GGCATCGGGC TGCCTCCGTG CTGTTGGGGG AGGAGCTATA  
601 CTCAGGGGTG GCAGCAGACC TCATGGGAGG AGACTTTACC ATCTTTCGA  
651 GCCTAGGGCA ACGTCCAACT CTCCGAACAG AGCCACAGA CTCCCGCTGG  
701 CTCATGTGTT GGCAGATCT GCGGGAACGA CGTGGGGCGG CAGCGCAGCC  
751 TGGTCAACAA GTGGACGACG TTCCTGAAGG CCGGGCTGGT GTGCTCGGTG  
801 CCGGGCGTGG AGGGCGACAC CCACCTTCGAT CAGCTCCCTC TATGCCGTCT  
851 TCTCCACGTC CAGGTAGGG CATCTTCCAG GGCCTGCGGG TGTGGGTGTA  
901 CAGCATGAAC GAGTGGGCC GGGCCTTCTT GGGACCTTTT GCACACAAGG  
951 AGGGGCCCAT GCACCACTGG GTGTACATCC AGGGTCGGCT CCCCTACCCG  
1001 CGGCCAGGCA TGTGCCCCAG CAAGACCTTT GGCACCTTCA GTTCACCAA  
1051 GGACTTCCCA GAGCATGTCA TCCAGTTTGC GCGGAACCAAC CCCCTCATGT  
1101 ACAACTCTGT CTTGCCCACT GGGGGGGGCC CTCCTTTCTT ACNAGTTGGA  
1151 GCCAATTACA CTTTCACTCA AATTGCCGGG GACCGGGTTG CAGCGGTGTA  
1201 CGGACACTAT GAGCTCCTCT TCATTGGCAC AGACGTTGGC ACGGTGTGTA  
1251 AGGTGATCTC GGTCCCCAAG GGCAGTAGGC CCAGCGCAGA GGGGCTGCTC  
1301 CTGGAGGAGC TGCACGTGTT TGAGGACTCG GCCGCTGTCA CCAGATGCA

1351 AATTCTTCC AAGAGTACT GCGCCTGGGA CGGGTCCGG TGCAACGCGT  
1401 TCAGCCAG TGCAGAGG CGTTCCGGC GGCAGAGCT AGGAATGC  
1451 GACCCAGCA CGTTGCTC CGAGACTCG TCTCGTCCG CGCTGCTGA  
1501 ACAAGGTG TTGCGGTG AGGGCAGCAG CGCTTTCTG GAGTGTGAGC  
1551 CCGCTCGCT GAGGGCGC GTGAGTGA CTTTCCAGC CGCAGGGTG  
1601 ACAGCCACA CCAGTGTCT GGCAGAGG GGCAGCAGC GCACCCCGC  
1651 GGGACTACTG CTCGCGAGC TCGCGCGCG GGACTCGGC GTGTACTTGT  
1701 GCGCGCGCT CGAGCAGGC TTACGCCAC CGTGTGCTG CTTGTGCTG  
1751 CAGGTGTGA GTGCTACGA GCGCGAACA CTGGCGCGG CCGAGGAGC  
1801 TGCGCCGCC GCGCGCGCG GCCCAAACT CTGTTACCG GACTTTCTG  
1851 AGTGTGTGA GCGCGCGGA GTTGCAGG CGAAGTCCCT GGCATGTGC  
1901 GCGCGCAGC CTCGCTGCA GTCACTGCC CTGGAGTGC GGAGAAAGG  
1951 CCGTAACCG AGGACCAAC CCCTGAGC TCGGCTGAG CGGGGCGCG  
2001 GCAGCGCAAC GCACTGTGA

!!AA\_SEQUENCE 1.0  
ID\_ADP30512 standard; protein; 2020 AA.  
XX  
AC ADP30512;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1279.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406840P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.

17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471338P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476509P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
15-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
08-AUG-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 2510; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPWEB and is not in the specification.  
Sequence 2020 AA;  
ADP30512 Length: 2020 February 22, 2005 12:25 Type: P Check: 723 ..

1 CAGATCCTGG GGCAGAGTCC AGGCAGCTC AAGGCTCCTC CACACACACA

51 CCGCTGAAC CCTGAGCACC CTGAGCTGCT GAGATGGGGC GGGCCGGGGC  
101 TGC CGCGCTG ATCCCGGGC TGGCCCTGCT CTGGGAGTG GGGCTGGGA  
151 GTGCCGCC CAGCCCCCAG GCCTTCGGCT CTCCTTTCCAA GAGCTCCAGG  
201 CTTGGGATGG TCTCAGACT TTCAGCCTGG AGCAACCTG CTGCTACGAG  
251 GCCTTGCTGG TGGATGAGGA GCGTGGAGC CTGTTTGTGG GTGCCGAGAA  
301 CCATGTGGCC TCCCTCAACC TGGACAACAT CAGCAAGCGG GCCAAGAGC  
351 TGGCCTGGCC GCGCCCTGTG GAATGGCGAG AGGAGTGCAA CTGGGAGGG  
401 AAGGACATTT GTACTGAGTG CATGAACCTC GTGAAGTTGC TGCATGCCCTA  
451 CAACGCAACC CATTTGCTGG CCTGTGCAC GGGAGCCTTC CACCCAACCT  
501 GTGCCCTTGT GGAAGTGGGC CACCGGGGAG AGGGCAAGGG GAAGAGTCTT  
551 TATGACCCCA GGCATCGGC TGCCTCGGTG CTGGTGGGG AGGAGCTATA  
601 CTCAGGGTG GCAGCAGACC TCATGGGAG AGACTTTACC ATCTTTCGA  
651 GCCTAGGGCA AGTCCAAAGT CTCGGAACAG AGCCACACGA CTCGCCGTGG  
701 CTCATGGTT GCCAGATCT GCCGGAACGA CGTGGCGGC CAGCGCAGCC  
751 TGGTCNACAA GTGGAGGAG TTCTCTGAAG CGCGGTGTT GTGCTCGGTG  
801 CCGCGGTG AGGGGACAC CCACTTCGAT CAGTCCCTC TATGCCGTCT  
851 TCTCCACGTC CAGGTGAGG CATCTTCCAG GGTCTGCGG TGTGGGTGTA  
901 CAGCATGAAC GACGTGCCC GGGCTTCTT GGGACCTTT GCACACRAGG  
951 AGGGGCCAT GCACAGTGG GTGTATACC AGGTGCGGT CCCCTACCG  
1001 CGGCCAGGA TGTGCCCCAG CAAGACCTTT GGCACCTTCA GTTCCACCAA  
1051 GGACTTCCA GACGATGTA TCCAGTTTG CCGGAACCA CCCCCTATGT  
1101 ACACTCTGT CTGCCCCACT GGGGGGGCC CTCTTTTCT ACAAGTTGGA  
1151 GCCAATTACA CTTTCACTCA AATTGCCGCG GACCGGGTTG CAGCGCTGA  
1201 CGGACACTAT GACGTCTCT TCATTGGCAG AGAGTTGGC ACGGTGCTGA  
1251 AGGTGATCT GGTCCCCAAG GGCAGTAGGC CCAGGCGAGA GGGGCTGCTC  
1301 CTGGAGGAG TGCAGTGT TTGAGGACTCG GCGGCTGTCA CCAGCATGA  
1351 AATTTCTTCC AAGAGTACT CGCGTGGGA CGGGTCCGG TGCAGCGCT  
1401 TCCAGCCAG TGCCAAGAG CGGTTCGCG GCAAGACGT AAGGAATGGC  
1451 GACCCAGCA GTTGTGCTC CGGAGACTCG TCTCGTCCG CGCTCTGGA  
1501 ACACAAGTG TTCGCGTGG AGGCAGCAG CGCCTTTCTG GAGTGTGAGC  
1551 CCCGCTCGT GCAGGCGCG GTGAGTGA CTTTCCAGCG CCGAGGGGTG  
1601 ACAGCCACA CCCAGTGTCT GGCAGAGGAG CGCACCGAGC GCACGCCCG  
1651 GGGACTACT CTGGCAGGC TGGGGGCCG GGACTCGGC GTGTACTTGT  
1701 GCGCCCGCT CGAGCAGGC TTATCGCAAC CGCTGCGTGG CTTGTGCTG  
1751 CACGTGTTGA GTGCTACGA GGCAGACGA CTGGCGCGG CCGAGGAGC  
1801 TCGCGCCGC GCGCGCGG GCCCAAACT CTGTTACCG GACTTCTGC  
1851 AGCTGGTGA GCCGGCGGA GGTGGCAGC CGAACTCCCT CGCATGTGC

1901 CGCCGCGAG CTGCGCTGCA GTCACTGCC CTGGAGTCGC GGAGAAAGG  
1951 CGTAAACGG AGGACCCAG CCCTGAGCC TCGCGCTGAG CGGGGCGCG  
2001 GCAGCGCAAC GCCTGTGTA

## !!AA\_SEQUENCE 1.0

ID ADP30517 standard; protein; 195 AA.

XX ADP30517;

XX

DT 12-AUG-2004 (first entry)

XX

XX Human secreted protein SEQ ID #1284.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

PN W02004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

PR 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 29-AUG-2002; 2002US-0406666P.

PR 17-SEP-2002; 2002US-0410946P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.

PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.

PR 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411023P.

PR 17-SEP-2002; 2002US-0411024P.

PR 17-SEP-2002; 2002US-0411032P.

PR 17-SEP-2002; 2002US-0411035P.

PR 17-SEP-2002; 2002US-0411037P.

PR 17-SEP-2002; 2002US-0411041P.

PR 17-SEP-2002; 2002US-0411045P.

PR 17-SEP-2002; 2002US-0411046P.

PR 17-SEP-2002; 2002US-0411048P.

PR 17-SEP-2002; 2002US-0411052P.

PR 17-SEP-2002; 2002US-0411055P.

PR 17-SEP-2002; 2002US-0411073P.

PR 17-SEP-2002; 2002US-0411082P.

PR 17-SEP-2002; 2002US-0411101P.

PR 17-SEP-2002; 2002US-0411111P.

PR 18-APR-2003; 2003US-0463700P.

PR 18-APR-2003; 2003US-0463708P.

PR 18-APR-2003; 2003US-0463716P.

PR 18-APR-2003; 2003US-0463732P.





XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2558; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 2124 AA;  
SQ  
ADP30560 Length: 2124 February 22, 2005 12:25 Type: P Check: 9801 ..  
1 GGAGGAGGGA GGGACCAGAG GAGAGGCGA GAGAGGGNAC CAGACCCCGAG  
51 TTCGGCGACT AAGCAGAAGA AAGATCAAAA ACCGSAAGAG AGGAGAAGAG  
101 CAAACAGGCA CTTTGAGGAA CAATCCCTTT TAACTCCAAG CCGACAGCGG  
151 TCTAGGAATT CAAGTTTCACT GCCTACCGAA GACAAAGGCG CCCCCAGGGA  
201 GTGGCGGTGC GACCCGAGG CGTGGGCGCG GCGCGGAGC CCACACTGCC  
251 CGGCTGACCC GGTGTCTCTG GACCATGTCT CCGGCCCCAA GACCCCGCCG  
301 TTGTCTCTCG CTCGCCCTGC TCAGCTCGG CACCGCGCTC GCCTCCCTCG  
351 GTCGCGCCCA AAGCAGCAGC TTCAGCCCGG AAGCTTGGCT ACAGCAATAT  
401 GGCTACCTGC CTCGCGGGA CCTACGTACC CACACACAGC GCTCACCCCA  
451 GTCACCTCA GCGGCCATCG CTGCCATGCA GAAGTTTAC GGCTTGCAG  
501 TAACAGGCAA AGCTGATGCA GACACCATGA AGGCCATGAG GCGCCCCCGA  
551 TGTGGTGTTC CAGACAAAGT TGGGGCTGAG ATCAAGGCCA ATGTTTGAAG  
601 GAAGCGCTAC GCCATCCAGG GTCTCAATG GCACACATAAT GAATCACTT  
651 TCTGCATCCA GAATTAACCC CCCAAGGTGG GCGAGTATGC CACATACGAG  
701 GCCATTGCGA AGGCGTTCCG CGTGTGGGAG AGTGCCACAC CACTCGCGTT  
751 CCGCGAGGTG CCCTATGCCT ACATCCGTGA GGGCCATGAG AAGCAGGCGG  
801 ACATCATGAT CTTCTTTGCC GAGGGCTTCC ATGGGAGACAG CACGCCCTTC  
851 GATGGTGAAG GCGGCTTCTT GGCCCATGCC TACTTCCGAG GCCCAACAT  
901 TGGAGGAGAC ACCCACTTGG ACTCTGCCGA GCTTTGGACT GTCAGGAATG  
951 AGGATCTGAA TGGAAATGAC ATCTTCTCTG TGGCTGTGCA CGAGCTGGGC  
1001 CATGCCCTGG GGCTCGAGCA TTCCAGTGAC CCTCGGCCA TCATGGCACC  
1051 CTTTACCAG TGGATGGACA CGGAGAAATT TTGTGTGCCC GATGATGACC  
1101 GCCGGGGCAT CCAGCAATT TATGGCGAGT ATCAGGGTTC CCCACCAAGA

1151 TGCCCCCTCA ACCCAGGACT ACCTCCCGGC CTTCTGTTCC TGATAAAGCC  
1201 AAAAAACCCA CCTATGGGCC CAACATCTGT GACGGNACT TTGACACCGT  
1251 GGCCATGCTC CGAGGGGAGA TGTTTGTCTT CAAGGAGCGC TGGTTCTGGC  
1301 GGGTGAGGAA TAACCAAGTG ATGGATGGAT ACCCAATGCC CATTTGGCCAG  
1351 TTCTGGCGGG GCCTGCTGCG GTCCATCAAC ACTGCTTACG AGAGAAAGGA  
1401 TGGCAAAATC GTCTTCTTCA AAGGAGACAA GCATTTGGGTG TTTGATGAGG  
1451 CGTCCCTGGA ACTTGGCTAC CCCAAGCACA TTAAGGAGCT GGGCCGAGGG  
1501 CTGCTACCG ACAAGATTGA TGCTGCTCTC TTCTGGATGC CCAATGGAAA  
1551 GACCTACTTC TTCCGTGGAA ACNAGTACTA CCGTTTCAAC GAAGAGCTCA  
1601 GGGCAGTGGG TAGCGAGTAC CCCAAGAACA TCAAAAGTCTG GGAAGGGATC  
1651 CCGTGTCTC CCAGAGGGTC ATTCTATGGC AGCGATGAAG TCTTCACTTA  
1701 CTTCTACAAG GGGACAAAT ACTGGAATT CAACAACAG AAGCTGAAGG  
1751 TAGAACCGGG CTACCCCAAG TCAGCCCTGA GGGACTGGAT GGGCTGCCCA  
1801 TCGGAGGCC GCGCGATGA GGGACTGAG GAGGAGACGG AGGTGATCAT  
1851 CATTGAGGTG GACGAGGAG GCGGCGGGG GGTGAGCGCG GCTGCCGTGG  
1901 TGCTGCCCGT GCTGCTGCTG CTCCTGGTGC TGGCGGTGGG CCTTGCAGTC  
1951 TTCCTTCTCA GACGCCATGG GACCCCGAGS CGACTGCTCT ACTGCCAGCG  
2001 TTCCTGTGTG GACAAGTCT GACGCCACG GCGGCCCGCG CCCTCTCTAC  
2051 CACAAGGACT TTGCCTCTGA AGGCCAGTGG CAGCAGGTGG TGGTGGGTGG  
2101 GCTGTTCCTCA TCGTCCCGAG CCCC  
!!AA SEQUENCE 1.0  
ID ADP30595 standard; protein; 279 AA.  
XX AC ADP30595;  
XX DE  
XX DT 12-AUG-2004 (first entry)  
XX DE  
XX DE Human secreted protein SEQ ID #1362.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX XX  
XX PD 29-APR-2004.  
XX XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406656P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411059P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2593; 428pp; English.  
PS The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC

CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 279 AA;  
ADP30595 Length: 279 February 22, 2005 12:25 Type: P Check: 8866 ..  
1 ATGGCGAGCC TCCGGCTCG GCCACCGCCA CGCTGCAAGT GCTCCTGTGTG  
51 GAGGGCTTCT CTCAGCCCTA CCTGCCGCTC CCAGAGGCGG CCCCAGGCCA  
101 AGCCAGGCC GACTCGCTTA CCGTCTACCT GGTGTGGCA TTGGCCTCGG  
151 TGTCTTCGCT CTTCCTCTTC TCGGTGTTC TGTTCGTGGC AGTGGCGGTG  
201 TGCAGGAGGA GCAGGGCGGC CTCAGTGGGT CGCTGTCTGG TGCCCGAGGG  
251 CCCCTTTCCA GGGCATCTGG TGGACGTGA  
!!AA SEQUENCE 1.0  
ID ADP30636 standard; protein; 291 AA.  
XX  
AC ADP30636;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1403.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW Cancer; inflammatory; Immune; human secreted protein.  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406668P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411032P.

```
PR 17-SEP-2002; 2002US-0411035P.
PR 17-SEP-2002; 2002US-0411037P.
PR 17-SEP-2002; 2002US-0411041P.
PR 17-SEP-2002; 2002US-0411045P.
PR 17-SEP-2002; 2002US-0411046P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411052P.
PR 17-SEP-2002; 2002US-0411055P.
PR 17-SEP-2002; 2002US-0411073P.
PR 17-SEP-2002; 2002US-0411082P.
PR 17-SEP-2002; 2002US-0411101P.
PR 17-SEP-2002; 2002US-0411111P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 18-APR-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467230P.
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX
XX WPI; 2004-348438/32.
XX
XX New nucleic acid molecule for diagnosing, preventing or treating diseases
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PT genetic, bacterial and viral diseases.
XX
XX Claim 1; SEQ ID NO 2634; 428pp; English.
XX
XX The present invention relates to an isolated nucleic acid molecule
CC encoding a polypeptide which is believed to be cytostatic,
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
CC composition and methods are useful for diagnosing, preventing and
CC treating diseases such as proliferative (e.g. cancer), inflammatory,
CC immune, metabolic, genetic, bacterial and viral diseases. The present
CC sequence represents a human secreted protein. The present sequence is
CC available on WIPOMEB and is not in the specification.
XX
XX Sequence 291 AA;
ADP30636 Length: 291 February 22, 2005 12:25 Type: P Check: 2410 ..
1 ATGACAACGC CCCGCGCTTC ACCAAACCT CCTACACCTT GTTCGTCGCG
51 GAGACAACA GCCCGCGCCT GCACATCGGC AGTGTCAGCG CCACAGACAG
101 AGACTCGGCG ACCAAGCGCC AGGTACCTTA CTCGCTGCTG CGGCCCCGGG
151 ACCCGCACTT GCCCCTCACC TCCTGTGTCT CCAATTAACG GGACAACGGC
```

201 CACCTGTTTG CTCTCCAGTC GCTGGACTAC GAGGCCCTGC AGGCTTTTGA  
251 GTTCGGCGTG GGGCCACAG ACCGGCGCTT CCGGGGCTG A

!!AA\_SEQUENCE 1.0  
ID ADF30734 standard; protein; 1464 AA.  
XX ADF30734;  
XX  
DT 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1501.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003MO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.

PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2732; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPONEB and is not in the specification.  
XX  
XX Sequence 1464 AA;  
SQ

ADP30734 Length: 1464 February 22, 2005 12:25 Type: P Check: 1579 ..  
1 ATGAACGTGG GAATCCAGAT GTCTCTCTCA GATGCTGATT TTATTACCTT  
51 TGAATATATG CCCAACAGAG GCAITGTGTGG ATCTTATGAC ACAGCCGCTG  
101 TCGCTGCCAT GTGGCGCGCC CGAGACTCCC GAGAACAGCC CTGGCTGTCA  
151 GCGGGACCA GCGCTTCTT GTGCCCATCG CGTAGACTGG AGGGGCGCAC  
201 CACGGCCACC GAGCCAGAGG CGCTTCAGGA AGCAAGAGAA GTCCCCGCGC  
251 GCTCCGGGAC CCGGCGCAGC TCATGGAGCA ACGGCACCGC GTACCCGGGG  
301 CAGTTAGCGC TGTACCAGCA GCTGGCGGAG GGGATGCCG TGGGGGGCTC  
351 GGGGGGGGCA CCGCCACTGG GGCCTGTGCA GGTGGTCACC GCTGCTCTGC  
401 TGGCCCTACT CATCATCTGG ACCTTGTCTGG GCACAGTGCT GGTGTCCGCA  
451 GCCATCGTGC GGAGCCGCCA CTTGGCGGCC AAGATGACCA ACCTCTTCAT  
501 CGTGTCTCTA CTGTGTCTAG ACCTCTTCTGT GGCCTGCTGT GTCATGTCTT  
551 GGAAGGAGT GCGCGAGGTG GCGGTTTACT GGCCCTTTGA AGCGTTCTGC  
601 GACGTCTGGG TGGCCTTCGA CATCATGTGC TCCACCGCCT CCATCTGTGA

651 CCTGTGCTC ATCAGCGTGG CCGCTACTG GGCCATCTCC AGGCCCTTCC  
701 GTTACGAGCG CAAGATGACC CAGGCGATGG CTTTGTGTCAT GGAGGCGGTT  
751 TGGGAGCCCG ACGTGAGGGC AGAGAACTGT GACTCCAGCC TGAATCGAAC  
801 CTACGCCATC TCTTCTCTGC TCATCAGCTT CTACATCCCC ATGGCCATCA  
851 TGATGTGTAC CTACACGCGC ATCTACCGCA TGCCCCAGGT GCAGATCCGC  
901 AGGATTTCCT CCGTGGAGAG GGCCGCGAG CACGTGCAGA GCTGCCGGAG  
951 CAGCGCAGGC TGGCGGCCGG ACACCAGCCT GCGGTTTTCC ATCAAGNAGG  
1001 AGACCGAGGT TCTCAAGACC CTGTGCGTGA TCATGGGGGT CTTGTGTGT  
1051 TGCTGGCTGC CTTTCTTTCAT CCTTAACTGC ATGTTCCCTT TCTGCAGTGG  
1101 ACACCCCAA GGCCCTCCGG CCGGCTTCCC CTGCGTCAGT GAGACCACAT  
1151 TGAAGTCTTT CATCTGTGTC TATGCCCTTCA ACGCCGACTT CCGGAAGGTG  
1201 TTGTCCCGAG TGTGGGGTGG CAGCCAGCTC TGCTCCCGCA CGCCGGTGA  
1251 GAGGATGAAC ATCAGCAATG AGCTCATCTC CTACAACCAA GACACGGTCT  
1301 TCACAAGGA AATCGCAGCT GCCTACATCC ACATGATGCC CAACGCCGTT  
1351 CCCCCCGGG ACCGGGAGGT GGACACAGAT GAGGAGAAGG AGAGTCTCTT  
1401 CGATCGCATG TCCCAGATCT ATCAGACATC CCACAGATGTT GACCCCTGTTG  
1451 CAGAGTCTGT CTGA

!!AA SEQUENCE 1.0  
ID ADP30737 standard; protein; 240 AA.  
XX  
AC ADP30737;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1504.  
DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.



PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467206P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476611P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486991P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID.NO 2752; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 249 AA;  
ADP30754 Length: 249 February 22, 2005 12:25 Type: P Check: 8386 ..  
1 ATGCTTATTT CAATGGCTGC TCCTCACCA CCGCTCCCTT CTGCGCTATG  
51 TCTCTCTCTG GGTACAAGCT GGTACTGGC GACAGAAACA ATTCTTCTTG  
101 CCGCAATTAC ACGAGCAAG CAAGTGACA AACTGGGCT AATTACATG  
151 CAGAACAAAA TCGAATGGGG CAGCGGGAA GCACCATCTC TAACTCCCAT  
201 GCACAGCCTT TTGATTTCCT CGATGATTAAC CAGAATTTCTA AAAAAGTAG  
!!AA SEQUENCE 1.0  
ID ADP30760 standard; protein; 195 AA.  
XX  
AC ADP30760;  
XX

DT 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1527.  
DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.

PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486691P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493373P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2758; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPONEB and is not in the specification.  
XX  
XX Sequence 195 AA;  
ADP30760 Length: 195 February 22, 2005 12:25 Type: P Check: 2069 ..  
1 ATGGGGCGTCT ACCCACTCCC TGCCTCTGCT CCTCTTCATC CTGTGCTCAA  
51 TCACCTTACCT CACCTGCAGC CTTCTGGCCC ACCTGCTGCA GTCCAAGTCA  
101 GAGCTCTCCC ACTACACCTT CTACTTTGTG GACTATGTTG GCGTGAGCGT  
151 TTACCAATAT GGCAGTGCTT TGGCTCATTT CTCTACAGC TCTGA  
!!AA SEQUENCE 1.0  
ID ADP30776 standard; protein; 573 AA.  
XX  
XX ADP30776;  
XX  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1543.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2774; 428pp; English.  
PS  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 573 AA;  
ADP30776 Length: 573 February 22, 2005 12:25 Type: P Check: 6346 ..  
1 ATGCTGCGCG GACCTCGGCT TCTTCTATG CTCTATGTAC ACGCCCATCT  
51 GTCTGCGCGA CTACCAACAG CGCTGCCGC CCTGCCGCTC GGTGTGCGAG  
101 CGCGCCRAGG CCGGTGCTC GCGCTGATG CGCCAGTAGC GCTTCGCTTG  
151 GCCGAGCGC ATGAGTGGC ACCGCTCCC GGTGCTGGC CGCGACGCCG  
201 AGGTCTCTG CATGATTAC AACCGACGG AGGCCACAC GGGGCCCCCC  
251 AGGCTTTCC CAGCAAGCC CACCCTTCA GGGCGGCAG GGGCGCGGC  
301 CTCGGGGGGC GAATGCCCG CTGGGGGCC GTTCGTGTGC AAGTGTGCGG  
351 AGCCCTTCTG GCCATTCTG AAGGAGTCA ACCCGCTCA CAACAAGGTG  
401 CGGACGGGCC AGTGGCCAA CTGCGGGTA CCTGTCTACC AGCGTCTCTT  
451 CAGTGGCGAC GAGCGCACGT TCGCCACCTT CTGGATAGGC CTGTGTCGG  
501 TGCTGTGCTT CATCTCCAG TCCACCACAG TGGCCACCTT CCTCATCGAC  
551 ATGGAACGCT TCGCTATCC TGA  
!!AA SEQUENCE 1.0  
ID -ADP30781 standard; protein; 774 AA.  
XX  
AC  
XX ADP30781;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1548.  
XX  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX  
XX 29-AUG-2002; 2002US-0406579P.  
XX  
XX 29-AUG-2002; 2002US-0406585P.  
XX  
XX 29-AUG-2002; 2002US-0406588P.  
XX  
XX 29-AUG-2002; 2002US-0406611P.  
XX  
XX 29-AUG-2002; 2002US-0406612P.  
XX  
XX 29-AUG-2002; 2002US-0406616P.  
XX  
XX 29-AUG-2002; 2002US-0406840P.  
XX  
XX 29-AUG-2002; 2002US-0406642P.  
XX  
XX 29-AUG-2002; 2002US-0406646P.  
XX  
XX 29-AUG-2002; 2002US-0406653P.  
XX  
XX 29-AUG-2002; 2002US-0406655P.

29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411010P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471338P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
08-JUL-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
15-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2779; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The



CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 774 AA;  
ADP30781 Length: 774 February 22, 2005 12:25 Type: P Check: 6161 ..  
1 ATGGGGGAGG GGATGAGAGG CTGCAGCTGG CTGGGGGAGG GAGGAGGGGG  
51 ACTGGTCTCT CTGACACACAC CTGGGGAGT GGGGGAGGTG GAGCTCCGC  
101 CCCAGGAACC CAGCTTACAG ACCCTGAGTC GAGAGCCTCA CTGCCAGAAA  
151 CTCAGTTTTC TCACGTATGA AGTGAGGACG TGCTTGCAAC AAGGACAGAT  
201 TGTGTTGTGA TGCATGCCCC CCTTATCTTT GATCTACACC TATACCTTCA  
251 CCTACATCTA TACTTACACC TATATCTACA CCTTACACCTA CACCTATATC  
301 TACATCTACA CCTACATCTA TATCTACACC TACATCAACA CCTACACCTA  
351 TGTCTACACC TACAGTTTCA CCTATGCTTA TACTTATACC TACACCTATA  
401 CTTTCACTTA TGTCTATACT TACACCTACA CCTACGCTTA CACCTACATC  
451 TACACCTACA CTTACACCTA CATCTTCATC TACACCAACT TCACCTACAC  
501 CTACACTGCG ACCTACACCC ATATCTGCAC CTACATCTAC ATCAACACCC  
551 ACATCTACAC CCACACCTTC AGCTATATTT ACACCTACAC CTATATCTAC  
601 ACCTGCATCC ACACCTGCAC CTTTACTTAT ACCTACACCT ATGCTCTATC  
651 CTACACCTAC ATCTACATCT ATACCTACAT CTACACCTAC ACCTTCACCT  
701 ACACCTGCAT CTACACCTAC ACCTACGCTCT ACACCTGCAT CTACATCTAC  
751 ACCTACACCT TCACCTACAC ATAA  
!!AA\_SEQUENCE 1.0  
ID ADP30787 standard; protein; 186 AA.  
XX  
AC  
AC  
ADP30787;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1554.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.

29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 17-SEP-2002; 2002US-041111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467159P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2785; 428pp; English.  
PS  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC

CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX Sequence 186 AA;  
SQ  
ADP30787 Length: 186 February 22, 2005 12:25 Type: P Check: 246 ..  
1 ATGGCTACAC TATCTATTCC ACCTTTGGAG CTTTCTACAT CCGGCTGCTG  
51 CTCATGCTGG TTCTCTATGG GGGCATATTC CGAGCTGGC GCTTCGCGAT  
101 CCGCAAGACG GTCAAAAGG TGGAGAAGAC CGGAGCGGAC ACCCGCCATG  
151 GAGCATCTCC CGCCCCGCAG CCCAAGAAGA GTGTGA  
!!AA SEQUENCE 1.0  
ID ADP30809 standard; protein; 372 AA.  
XX  
AC ADP30809;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1576.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.

PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 17-SEP-2002; 2002US-041111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2807; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
XX Sequence 372 AA;  
ADP30809 Length: 372 February 22, 2005 12:25 Type: P Check: 4224 ..  
1 ATGGGCTTCC CAAGATGCCT TGCACGTGCC CAGAAACGGA TGTGCCCCAG  
51 CTCTTCCGGG AGCCTTACAT CCGCACCGCG TACCGCCCCA CGGGGCACCA  
101 GTGGCGCTAC TACTCTTCA GCCTCTTCA GAAACACAAC GAGGTGGTCA  
151 AGCTCTGGAC CAATTTACTG GCAGCCTTGG CCGTCTCTTT GCGATTCTGG  
201 GCCTTTGCCG AGGCTGAGGC CTTGCCATGG GCGTCTACCC ACTCCTCTCC

```
251 TCTGCTCCTC TTCATCTCTGT CGTCAATCAC TTACCTCACC TGCAGCCTTC
301 TGGCCCCACCT GCTGCAGTCC AAGTCAGAGC TCTCCCACTA CACCTTCTAC
351 TTGTGGACT ATGTTGGCGT GA

!!AA_SEQUENCE 1.0
ID ADP30830 standard; protein; 186 AA.
XX
XX
XX ADP30830;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #1597.
XX
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW cancer; inflammatory; immune; human secreted protein.
XX
XX Homo sapiens.
XX
XX WO2004035732-A2.
XX
XX 29-APR-2004.
XX
XX 28-AUG-2003; 2003WO-US026780.
XX
XX 29-AUG-2002; 2002US-0406576P.
XX
XX 29-AUG-2002; 2002US-0406579P.
XX
XX 29-AUG-2002; 2002US-0406585P.
XX
XX 29-AUG-2002; 2002US-0406588P.
XX
XX 29-AUG-2002; 2002US-0406608P.
XX
XX 29-AUG-2002; 2002US-0406611P.
XX
XX 29-AUG-2002; 2002US-0406613P.
XX
XX 29-AUG-2002; 2002US-0406616P.
XX
XX 29-AUG-2002; 2002US-0406640P.
XX
XX 29-AUG-2002; 2002US-0406642P.
XX
XX 29-AUG-2002; 2002US-0406646P.
XX
XX 29-AUG-2002; 2002US-0406653P.
XX
XX 29-AUG-2002; 2002US-0406655P.
XX
XX 29-AUG-2002; 2002US-0406666P.
XX
XX 17-SEP-2002; 2002US-0410948P.
XX
XX 17-SEP-2002; 2002US-0410949P.
XX
XX 17-SEP-2002; 2002US-0410949P.
XX
XX 17-SEP-2002; 2002US-0410953P.
XX
XX 17-SEP-2002; 2002US-0410957P.
XX
XX 17-SEP-2002; 2002US-0410958P.
XX
XX 17-SEP-2002; 2002US-0410959P.
XX
XX 17-SEP-2002; 2002US-0410960P.
XX
XX 17-SEP-2002; 2002US-0410961P.
XX
XX 17-SEP-2002; 2002US-0410962P.
XX
XX 17-SEP-2002; 2002US-0411019P.
XX
XX 17-SEP-2002; 2002US-0411022P.
XX
XX 17-SEP-2002; 2002US-0411023P.
XX
XX 17-SEP-2002; 2002US-0411024P.
XX
XX 17-SEP-2002; 2002US-0411032P.
XX
XX 17-SEP-2002; 2002US-0411035P.
XX
XX 17-SEP-2002; 2002US-0411037P.
XX
XX 17-SEP-2002; 2002US-0411041P.
XX
XX 17-SEP-2002; 2002US-0411045P.
XX
XX 17-SEP-2002; 2002US-0411046P.
XX
XX 17-SEP-2002; 2002US-0411048P.
XX
XX 17-SEP-2002; 2002US-0411052P.
XX
XX 17-SEP-2002; 2002US-0411055P.
XX
XX 17-SEP-2002; 2002US-0411073P.
XX
XX 17-SEP-2002; 2002US-0411082P.
XX
XX 17-SEP-2002; 2002US-0411101P.
XX
XX 17-SEP-2002; 2002US-0411111P.
XX
XX 18-APR-2003; 2003US-0463700P.
XX
XX 18-APR-2003; 2003US-0463708P.
XX
XX 18-APR-2003; 2003US-0463716P.
XX
XX 02-MAY-2003; 2003US-0467199P.
XX

102-MAY-2003; 2003US-0467201P.
102-MAY-2003; 2003US-0467203P.
102-MAY-2003; 2003US-0467230P.
19-MAY-2003; 2003US-0471306P.
19-MAY-2003; 2003US-0471336P.
22-MAY-2003; 2003US-0472420P.
22-MAY-2003; 2003US-0472430P.
09-JUN-2003; 2003US-0476609P.
09-JUN-2003; 2003US-0476641P.
08-JUL-2003; 2003US-0485218P.
08-JUL-2003; 2003US-0485223P.
08-JUL-2003; 2003US-0485224P.
08-JUL-2003; 2003US-0485325P.
14-JUL-2003; 2003US-0486446P.
15-JUL-2003; 2003US-0486480P.
15-JUL-2003; 2003US-0486891P.
15-JUL-2003; 2003US-0486960P.
08-AUG-2003; 2003US-0493341P.
08-AUG-2003; 2003US-0493370P.
08-AUG-2003; 2003US-0493573P.
08-AUG-2003; 2003US-0493577P.
XX
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
XX Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX WPI; 2004-348438/32.
XX
XX New nucleic acid molecule for diagnosing, preventing or treating diseases
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
XX genetic, bacterial and viral diseases.
XX
XX Claim 1; SEQ ID NO 2828; 428pp; English.
XX
XX The present invention relates to an isolated nucleic acid molecule
XX encoding a polypeptide which is believed to be cytostatic,
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The
XX composition and methods are useful for diagnosing, preventing and
XX treating diseases such as proliferative (e.g. cancer), inflammatory,
XX immune, metabolic, genetic, bacterial and viral diseases. The present
XX sequence represents a human secreted protein. The present sequence is
XX available on WIPWEB and is not in the specification.
XX
XX Sequence 186 AA;
XX
ADP30830 Length: 186 February 22, 2005 12:25 Type: P Check: 4939
1 ATGGGCATCA GATCTTCCAT GCATTTCTGT CCATCTGTAC GCTCTCCAG
51 CTGGAGGCCA TCCTCCTGGA CTACACAGGGG CGGCAGGAGA TCTTCCTGCA
101 GCGCCATGGA CCCATATCTG TCCACATGGC CTGCCTCTCC TCTTCTTCC
151 TGGCTGCTCG CAGTGTGCC ACGCAGGCC TTCTGA

!!AA_SEQUENCE 1.0
ID ADP30850 standard; protein; 681 AA.
XX
XX ADP30850;
XX
XX 12-AUG-2004 (first entry)
XX
XX Human secreted protein SEQ ID #1617.
XX
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW cancer; inflammatory; immune; human secreted protein.
XX
XX Homo sapiens.
XX
XX WO2004035732-A2.
XX
```

```
PD 29-APR-2004.
XX 28-AUG-2003; 2003WO-US026780.
PF 29-AUG-2002; 2002US-0406576P.
XX 29-AUG-2002; 2002US-0406579P.
PR 29-AUG-2002; 2002US-0406585P.
PR 29-AUG-2002; 2002US-0406588P.
PR 29-AUG-2002; 2002US-0406608P.
PR 29-AUG-2002; 2002US-0406611P.
PR 29-AUG-2002; 2002US-0406612P.
PR 29-AUG-2002; 2002US-0406616P.
PR 29-AUG-2002; 2002US-0406640P.
PR 29-AUG-2002; 2002US-0406642P.
PR 29-AUG-2002; 2002US-0406646P.
PR 29-AUG-2002; 2002US-0406653P.
PR 29-AUG-2002; 2002US-0406655P.
PR 29-AUG-2002; 2002US-0406666P.
PR 17-SEP-2002; 2002US-0410946P.
PR 17-SEP-2002; 2002US-0410947P.
PR 17-SEP-2002; 2002US-0410948P.
PR 17-SEP-2002; 2002US-0410949P.
PR 17-SEP-2002; 2002US-0410953P.
PR 17-SEP-2002; 2002US-0410957P.
PR 17-SEP-2002; 2002US-0410958P.
PR 17-SEP-2002; 2002US-0410959P.
PR 17-SEP-2002; 2002US-0410960P.
PR 17-SEP-2002; 2002US-0410961P.
PR 17-SEP-2002; 2002US-0410962P.
PR 17-SEP-2002; 2002US-0411019P.
PR 17-SEP-2002; 2002US-0411022P.
PR 17-SEP-2002; 2002US-0411023P.
PR 17-SEP-2002; 2002US-0411024P.
PR 17-SEP-2002; 2002US-0411032P.
PR 17-SEP-2002; 2002US-0411035P.
PR 17-SEP-2002; 2002US-0411037P.
PR 17-SEP-2002; 2002US-0411041P.
PR 17-SEP-2002; 2002US-0411045P.
PR 17-SEP-2002; 2002US-0411046P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411052P.
PR 17-SEP-2002; 2002US-0411055P.
PR 17-SEP-2002; 2002US-0411073P.
PR 17-SEP-2002; 2002US-0411082P.
PR 17-SEP-2002; 2002US-0411101P.
PR 17-SEP-2002; 2002US-0411111P.
PR 18-APR-2003; 2003US-0463700P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 18-APR-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467230P.
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485325P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486901P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493373P.
PR 08-AUG-2003; 2003US-0493577P.
XX

PA (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Haimann L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX WPI; 2004-348438/32.
XX New nucleic acid molecule for diagnosing, preventing or treating diseases
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PT genetic, bacterial and viral diseases.
XX Claim 1; SEQ ID NO 2848; 428pp; English.
XX The present invention relates to an isolated nucleic acid molecule
CC encoding a polypeptide which is believed to be cytostatic,
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
CC composition and methods are useful for diagnosing, preventing and
CC treating diseases such as proliferative (e.g. cancer), inflammatory,
CC immune, metabolic, genetic, bacterial and viral diseases. The present
CC sequence represents a human secreted protein. The present sequence is
XX available on WIPWEB and is not in the specification.
XX SQ Sequence 681 AA;
ADP30850 Length: 681 February 22, 2005 12:25 Type: P Check: 1058 ..
1 GTGTATGTGG GTACCCGTTG GGCTCTACCT CCAGGAAGGT CACAAAGTGC
51 CTCAGTTCCA TGGTGGCCCT TCTCCGGTT CTGTTTCTTT CAAGAGCCGG
101 CATCGCCCGT GGCCTCGTTT CTCAATGGCC TGSCCAGCCT GGTGATGCTC
151 TGCCTGTACC GCACCTTCGT GCCAGCCTCC TCCCCCATGT ACCACACCTG
201 TGTGGCCTTC GCCTGGTGT CCCTCAATGC ATGTTTCTGG TCCACAGTTT
251 TCCACACCAG GGACACTGAC CTCACAGAGA AATGGACTA CTTCTGTGCC
301 TTCACGTGCA TCCTACACTC AATCTACCTG TGTGTGGTCA GGACCGTGGG
351 GTGCAGCAC CCAGCTGTGG TCAGTGCCTT CCGGGCTCTC CTGCTGCTCA
401 TGCTGACCGT GCACGCTCC TACCTGAGCC TCATCCGCTT CGACTATGSC
451 TACAACCTGG TGGCCAAAGT GGCTATTGGC CTGGTCAACG TGGTGTGGTG
501 GCTGGCCTGG TGCTGTGGA ACCAGCGCGG GCTGCCCTAC GTGCGCAAGT
551 GCCTGTGGT GGTCTTGCTG CTGCAGGGGC TGTCCTTGCT CGAGCTGCTT
601 GACTTCCCAC GCCTCTTCTG GGTCTGGAT GCCCATGCCA TCTGGACAT
651 CAGCACCATC CCGTGTCCAG TCCTCTTTT C
!!AA SEQUENCE 1.0
ID ADP30851 standard; protein; 894 AA.
XX
AC ADP30851;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #1618.
XX
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW cancer; inflammatory; immune; human secreted protein.
XX Homo sapiens.
OS
XX WO2004035732-A2.
XX
PD 29-APR-2004.
```

PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471308P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2849; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytosolic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 894 AA;  
ADP30851 Length: 894 February 22, 2005 12:25 Type: P Check: 674 ..  
1 CTCTCGGCAG TCACAGAGAG GTGCCCTTCAG GTTGAGAAATG AGCATGTCTCT  
51 GAAGTCAATG AAGCCCTGGC TGAGTGGAGC CCTGAGCATG CTGGGCCACG  
101 ACTTTGGTCA GCTGCTGGAG CTGGCCCTGA CACGGGAGGT TCAGGCATG  
151 GTGAGAAAA TTGATGCTC AGACAAATATC TACACCACAG AGTCACCCAC  
201 AGGGAACCTG TTCAGCCTGA CCAGGAGGG GGTCTCCCTG TGCCGCATCA  
251 TAGCCAAGGA GGGTGGGGTC GTAGCACTCT TCAAGGTTTG CCGGAGGAC  
301 AGTTTCGGT GCTTGTACCC CCAGGGGCTC CGCAGGCTGG CTTCCATCTG  
351 CTGCGTGGAA GAGGCTGTCC ACCAGCTGGA GAAGGCTGAG GCTGGGGCTG  
401 TGGTGGCCCA GGTCACCTCC CCACACCTGC CCGTCACCCA GCACCTCAGT  
451 AGCTTCCTGG AGAGCATGGA GGAGATCGTG ACAGCCCTCG TCAAACTGTG  
501 CCAAGAGGCC TCATCAGGGG AGTCTTCTCT ACTGGCCTCT CGGGCCCTTG  
551 CCAACATCAC GTTCTTTGAC ACAATGGCCT GCGAGATGCT CTTGAGTTG  
601 AATGCCATCC GTGTTCTCTT GGAAGGCTGC AGTGACAAAGC AGAGAGTGGA  
651 CACGCCCTTAC ACTCGGACC AGATTGTGAC CATCTTGGA AACATGCTG  
701 TCCTAGAACA GTGTGCTCTT GACATCATTC AGGAAAATGG GGTCCAGCTT  
751 ATCATGGGCA TGCTGTCTGA AAAACCAAGG TCTGGGACTC CTGCTGAAGT  
801 GGCAGCCTGT GAGGAGTCC AGCAGAAAGC TGCAGTGACC CTGGCTGCTC  
851 TCAGCCGAGA CCAGATGTG GCACGGGAGG CCGTCCGGCT CAGC  
!!AA SEQUENCE 1.0  
ID ADP30860 standard; protein; 1038 AA.  
XX  
XX ADP30860;  
AC  
XX  
XX 12-AUG-2004 (first entry)  
DT  
XX  
XX Human secreted protein SEQ ID #1627.  
DE  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX



!!AA\_SEQUENCE 1.0  
ID ADP30866 standard; protein; 1002 AA.  
XX AC ADP30866;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1633.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410945P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Hallenbeck RF, Huang MN, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2864; 428pp; English.  
XX CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 1002 AA;  
ADP30866 Length: 1002 February 22, 2005 12:25 Type: P Check: 8260 ..  
1 TGCTTTAGTT CTGAGACCT CTTCACGTCC CACAATTTCA GCGAGCAGTC  
51 GCGATTGGG AGCAGCGAGC TCCAGGAGTT CTGCCCCACC ATCCTCAGC  
101 AGCTGGATT CCGGGCCTGC ACCTCGGAGA ACCAGGAAAA CGAGGAGAAT  
151 GAGCAGACGG AGGAGGGGCG GCCAAGCGCT GTTGAAGTGT GGGGCTTTGG  
201 TTTTCTCAGT GTCTCACTGA TTAACCTGCG CTCTCTCCTG GGAGTCTCTG  
251 TCCTGCCCTG CACAGAGAAA GCGTTTTTCA GCGGTGTGCT CACTTACTTC  
301 ATCGCCCTGT CCATTGGAAC GCTGCTGTCT AACGGCTAT TCCAGCTCAT  
351 CCCAGAGGCA TTTGGTTTCA ACCCTCTGGA AGATTATTAT GTCTCCAAGT  
401 CTGCACTGGT GTTTGGGGCG TTTTATCTTT TCTTTTTCAC AGAAGAATC  
451 TTGAAGATT TTTCTAAGCA GAAAAATGAG TCCAAGAAGG ACCAGGAGGA  
501 GGGGGTGATG GAGAAGCTGC AGAACGGGGA CCTGGACCAC ATGATTTCTC  
551 AGCACTGCAG CAGTGAGCTG GACGGCAAGG CGCCATGGT GGACGAGAAG  
601 GTCATTGTGG GCTCGCTCTC TGTGCAGGAC CTGCAGGCTT CCCAGAGTGC  
651 TTGCTACTGG CTGAAAGGTG TCGGCTACTC TGATATGGC ACTCTGCGCT  
701 GGATGATCAC TCTGAGCGAC GGCCTCCATA ATTTATCGA TGGCCTGGCC

751 ATCGGTGCTT CTTCACTGT GTCAGTTTTC CAAGGCATCA GCACCTCGGT  
801 GGCCATCTC TGTGAGAGT TCCACATGA GAGGAGACTT TGTCACTCTG  
851 CTCACGCTG GGATGAGCAT CCAACAAGCT CTCTTCTTCA ACTTCCTTTT  
901 TGCCTGCTGC TGCTACTCG GTCTGGCCTT TGGCATCTG GCGGCGAGCC  
951 ACTTCTCTGC CAACCTGATT TTTCGCTAG CTGGAGGAAT GTTCTTGTAT  
1001 AT

!!AA SEQUENCE 1.0

ID \_ADP30944 standard; protein; 1420 AA.

XX AC ADP30944;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1711.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406555P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411037P.

XX PR 17-SEP-2002; 2002US-0411041P.

XX PR 17-SEP-2002; 2002US-0411045P.

XX PR 17-SEP-2002; 2002US-0411046P.

XX PR 17-SEP-2002; 2002US-0411048P.

XX PR 17-SEP-2002; 2002US-0411052P.

XX PR 17-SEP-2002; 2002US-0411055P.

XX PR 17-SEP-2002; 2002US-0411073P.

XX PR 17-SEP-2002; 2002US-0411082P.

XX PR 17-SEP-2002; 2002US-0411101P.

17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2942; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The

CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX SQ Sequence 1420 AA;

ADP30944 Length: 1420 February 22, 2005 12:25 Type: P Check: 6837 ..

1 CCTAGTTGAC GCCAGAGGA GGCATCAAAA AAAGATTGG AGCAAACTC

51 AGAATTACCT CAACGTGTAT GCGGCGGAAG GCCTGGGCAC CTGTGTCATC

101 GCCAAGAGAG TTCTGAGTAA AGAAGAGTAT GCCTGCTGGT TGCAAAGCCA

151 CCTAGAAGCC GAATCCTCCC TGGAACACAG CGAGGAGCTC CTCTTCCAGT

201 CTGCCATTGC CCGTGAGACC AACCTGCACT TGTAGTAGTC CACTGGGATT

251 GAAGACCGCC TGCAGGACGG AGTCCCTGAA ACTATTTCTA AATTGCGTCA

301 AGCGGGCCTG CAGATTGGG TTCTCACTGG TGACAAACAA GAAACAGCTG

351 TCAACATTGC ATATGCCTGC AAATCTGTGG ACCACGACGA GGAGGTCTATC

401 ACCCTGAATG CCACCTGGCC TACGCTCTCG AGAAAAACCT GGAGGACAAA



451 TTCTCTTCC TTGCCAGCA GTGGCGTCC GTCTCTGCT GTCGGTGAC  
501 GCCTGTCAG AAGAGCATGG TGGTGAAGCT GGTGCGGAGC AAGCTCAAGG  
551 CCATGACCCCT GGCCATAGCT GATGAGGCCA ATGATGTCAG CATGATCCAG  
601 GTGGCAGATG TGGGTGTGGG AATCTCCGGC CAGAGGGGTA TGCAGGCAGT  
651 GATGGCCAGC GACTTTGCCAG TGCAGAAATT CCGATACCTG GAGAGGCTCT  
701 TGATTCTTCA CGGGCATTGG TGCTACTCCC GACTTGCCAA CATGGTGTG  
751 TACTTCTTCT ACAAAACAC AATGTTGCTG GGCCTCTGCT TTTGGTTCCA  
801 GTTTTCTGCT GGCCTTCTCT CATCTACCAT GATTGACCAG TGGTATCTAA  
851 TCTTCTTTAA TCTGCTCTTC TCGTCACCTC CCGCGCTCGT GACTGGGGTG  
901 CTGGACAGGG ATGTGCCAGC CAATGTGCTG CTGACCAACC CCGAGTCTTA  
951 CAAGAGTGGC CAGAACATGG AGGAATACCG GCCACGAACG TTCTGGTTTA  
1001 ACATGSCCGA CGCCGCCCTC CAGAGCCTGG TTTGCTTTTC CATTCCTTAC  
1051 CTGGCCTACT ATGACTCGAA CGTGGACCTG TTTACCTGGG GGACCCCTAT  
1101 TGTGACAATC GCGCTGCTCA CTTTCTCTGCT CCACCTGGGC ATTGAAACCA  
1151 AAACCTGGAC CTGGCTCAAC TGGATAACGT GTGGCTTCAG TGTCTTTTG  
1201 TTTTTCACCG TGGCTTTGAT TTACAATGCG TCTTGTGCCA CBTGCTATCC  
1251 TCGTCCCAAC CCTTACTGGA CTATGCAAGC CTTTACTGGGT GACCCAGTGT  
1301 TTTACTTGAC TTGCTCTGAT AGCCTGTGCG CTGCACTGCT GCCCAGGTGG  
1351 GTGTGCGAGC GGGATAGTGC CTCTGAGCCC CGAGTGAGCC CAGACGACAT  
1401 TGGCATTGCT TCTGCTCTAT

!!AA SEQUENCE 1.0  
ID ADP30948 standard; protein; 1481 AA.

AC ADP30948;

DT 12-AUG-2004 (first entry)

DE Human secreted protein SEQ ID #1715.

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.

OS Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406589P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406648P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472430P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases

such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 2946; 428pp; English.

The present invention relates to an isolated nucleic acid molecule

encoding a polypeptide which is believed to be cytostatic,

antiinflammatory, immunosuppressive, antibacterial and virucidal. The

CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
SQ Sequence 1481 AA;

ADP30948 Length: 1481 February 22, 2005 12:25 Type: P Check: 6814 ..

1 ATGCGCGCGC CCGGAGAGC CCGGAGCG CTGCTCGTGG CGCTGTGCG  
51 GCTGGCGTGG CTGGCGCAGG CCGGCTGCG CCGCGCGCGG GGCTCTGTGC  
101 GCCTGGCGGG CGGCTTGACG CTGGGCGGCC TGTTCCTGGT GCACGGCGGG  
151 GCGCGCGCGG GCGGCGGCTG CCGGCGGCTG AAGAAGGAGC AGGCGGTGCA  
201 CCGGCTGGAG GCCATGCTGT ACGCGCTGGA CCGCGTCAAC GCGGACCCCG  
251 AGCTGCTGCC CGGCGTGGCG CTGGGCGGCG GGCTGCTGGA CACTGCTCG  
301 CCGGACACCT ACGCGTGGGA CGAGCGCTG AGCTTCGTGC AGGCGTGTAT  
351 CCGCGGCGCG GCGGACGGCG ACGAGGTGGG CGTGGCTGCG CCGGAGGGCG  
401 TCCCTCGCT GCGCGCGCGG CCCCCGAGC GCGTGGTGGC CGTCTGGGCG  
451 GCCTCGGCCA GTCTCGTCTC CATCATGTGC GCCAACGTGC TGGCGCTGTT  
501 TGGGATACCC CAGATCAGCT ATGCTCTCCAC AGCCCGGAG CTGAGCGACT  
551 CCACACGCTA TGACTTCTTC TCCCGGTTGG TGCCACCCGA CTCTACCGAG  
601 GCGCAGGCCA TGGTGGACAT CGTAGGGCA CTGGGATGGA ACTATGTGTC  
651 CAGCTGGGCC TCGGAGGGCA ACTATGGCGA AAGTGGGGTT GAGGCTCTCG  
701 TTGATGCTC CCGAGAGGCT GGGGGGTTCT GTATTGGCCA GTCTATCAAG  
751 ATTCCTCAGG AACCAAGCC AGGAGAGTTC AGCAAGTGA TCAGGAGACT  
801 CATGGAGACG CCCAACGCC GGGGATCAT CATCTTTGCC AATGAGGATG  
851 ACATCAGGTG GAGGCGCTGC AGTGTCTTGG CGACCCCGAC GAGTGCCTCT  
901 CGTCTCTGTG CAGCTGSCCC TCGCGGCGCG GGGAGCGGAA GAAGATGGTG  
951 AAGGGCGTCC CCGTCTGTTG GCACTGCGAG GCCTGTGACG GGTACCGCTT  
1001 CCAGGTGGAC GAGTTCACAT GCGAGGCTTG TCCTGGGGAC ATCAGGCCCA  
1051 CGCCCAACCA CAGGGGCTGC CGCCCGACAC CTGTGGTGGC CTTGAGCTGG  
1101 TCCTCCCGCT GGGCAGCCCC CGCGTCTCTC CTGGCGCTGC TGGGCATCGT  
1151 GGCACATACC ACGGTGGTGG CCACCTTGT GCGGTACAAC AACACGCCCA  
1201 TCGTCCGGGC CTGGGCGCGA GAGCTCAGCT ACGTCTCTCT CACCGGCATC  
1251 TTCTCTATCT ACGCCATCAC CTTCTCTCAT GTGGCTGAGC CTGGGCGCGC  
1301 GGTCTGTGCC GCGCGGAGGC TTTCTCTGGG CTTGGGCAAG ACCTCAGCT  
1351 ACTCTGCCCT GGTCAACAAG ACCAACCGTA TCTACCGCAT CTTTGGACAG  
1401 GGCAAGGGCT CGGTACACC CCTCCCTTC ATCAGGCCCA CCTCAGCT  
1451 GGTCAATACC TTCAGGCTCA CCTCCTGCA G

!!AA SEQUENCE 1.0  
ID ADP30980 standard; protein; 1171 AA.  
XX

AC ADP30980;  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1747.  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
KW Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 18-APR-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 02-MAY-2003; 2003US-0467230P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 09-JUN-2003; 2003US-0476641P.

PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2978; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antitumour, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1171 AA;  
ADP30980 Length: 1171 February 22, 2005 12:25 Type: P Check: 3887 ..  
1 ATGGCCTCCA GCCCATGGGG CTGTGTATGT GGCCTTCTGC TGTGCTGCT  
51 GCACCTCTCT GGGACTGGCC CTGCGCTGGG GAGGGGCTTT CCCAGGCCAC  
101 TTGAAAACCT CGAAATCCCT ATGATCCCTG GAGCCCCACCC CAAGGGCTCT  
151 GTGGGGCTAG AGCCCCAGGC CTTTGACGTG TTCCCGGAGA ACCCCAGAGC  
201 TGACAGTCAC AGGAACCTGT ATGTCCGCCA CGCCCCCTGCT GAAGAGATGC  
251 CTGAGAAGCC TGTAGCCTCT CCCCTTGGCC CAGCCCTGTG CGGGCCCAAA  
301 GCAGCACAGC GAGTCAAGC AGACGACTC CCAGTAACTG ATGACTCTCA  
351 GATGGCTCAA GGACCAAGCT CCCACGGCTG GACAGGACCT CTGGACTCAC  
401 AAGAGCTTCT GCAGCAAGAA CGATGGCTC CCCACCCAGT GGGCCACCTT  
451 CATCTCATTT TCATCCCCAC AACTCCAGA CGTCAACTCA GGTAGCCAC  
501 AGTTCTCTCC TCCCTGCAGC ATGAAGCCCA AGAGGGACAG TGGCCACCTA  
551 GAGATGAGGG TCTGAAGGCC AAAACTAAGA GCAGGGTCCC ACCCACTTCT  
601 CCCTCAGACC ACCAGGGCCC ACCCACCAC CTTGTTTCCC ACTCAGGTAC  
651 TGTCAAGAGG CCAGTGTCTG AAGSACAGGG TGGGTTTGG AGAACCTTGC  
701 AGGAGGCAGC TCAAGGTCCC CACTTCACC AGCAGGATCC AGCAGCCCTT  
751 GATGTTGGCT CAGTACCCCC AGTTGAGGTG GTGTACTCTC AGGAGCCAGG  
801 GGGCCAGCCA GACTTGGCAT TGGCCAGAAG CTTTCTCTCT GCTGAGGAGC

851 TGCCGGTTGA GACCCCCAAG AGGGCTGGCG CTGAGGTGTC CTGGGAAGTC  
901 AGCTCCCCAG GTCCCCCGCC CAAGCAGGCT GACCTTCTCTG ACGCTAAGGA  
951 TTCACAGGA CCCAGGCCA CGGATCCACC CGCCTCAGAG GCTCCTGATC  
1001 GCGCGTCTAA GCCAGAGAGA GCAGCAATGA ATGGAGCAGA CCCATCTCC  
1051 CCCAGCGGG TGAGGAGGC TGTGGAGGCC CCAGGCACCC CCAAGTCTCT  
1101 CATCCTGTGT CCTCAGACC CTGGCCGAGC TGTAAACCGA ACAGAGAGCC  
1151 CCATGGGGGC CCTCAGCCA G  
!!AA SEQUENCE 1.0  
ID ADP30981 standard; protein; 3638 AA.  
XX  
AC ADF30981;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1748.  
XX  
KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0410966P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.

PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang NM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2979; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 3638 AA;  
ADP30981 Length: 3638 February 22, 2005 12:25 Type: P Check: 4607 ..  
1 GACAGAGGTT TGCCAGCCGT TGACATTAAG AGGCATGTTT AACGTGCGCA  
51 ACAGCATCTC CTTTTCCTTC TCCTCTTCT CTTCCTTCTC TTCTCTCTCC  
101 TCCTCTCTCTT TTTCTCTCTC CTCGTCTTCC TCCCATCAGC AAGAACACAA  
151 ACCGAGGACA GTCTTGAAAT ATCGAAATTT CCTCTTTGGG ATTGCGCAGC  
201 GCCAAGACTG TCGGAATAAA GGACGCTGAC TATTGTATTA TTGTTATTTT  
251 ATTAATTAAGT CAGTGGAAAG ATTACAGATG AGGAAAGGG ACCCTGTGCA  
301 CCCTTCTCTGT GCTAAGATTT AAAAAAAAT GAGGCTGGAT TGCGGGAAGC  
351 TCTAAATGA AGCAAAAGGA GTAAGATTTT TAAAGACAGA AAGCCACAGG

401 AGCCCCACG TAGCGACTT TTAATTGTAT TTTTTCAGAT TTTTTCAGT TTTTTCAGT  
451 TTCGTGCTGG TGGGGGAGGT GATTGGGTGG CTGACTGGCT GCGGGNAGCT  
501 ACTTCCTTTC CTTTTCGAGA TGATTGTGCT ATTAATTGTTT GCCTTGCTCT  
551 GGATGTGGA AGGAGCTTTT TCCCAGCTTC ACTACACGGT ACAGGAGGAG  
601 CAGGAACATG GCATTTTCGT GGGGAATATC CTTGAAGATC TGGGTCTGGA  
651 CATTACAAA CTTTCGGCTC GCGGGTTTCA GACGGTGCCC AACTCAAGGA  
701 CCCCCTTACTT AGACCTCAAC CTGGAGACAG GGGTGTCTGA CGTGAACGAG  
751 AATAAGACC GGAACAAAT CTGCAACAC AGCCCCCTCT GTGTCTCTGA  
801 CTTGGAGGTC TTTCTGAGA ACCCCCTGGA GCTGTTCAG GTGGAGATCG  
851 AGGTGCTGGA CATTAATGAC AACCCCCCTT CTTTCCCGGA GCCAGACCTG  
901 ACGGTGAAA TCTCTGAGAC GGCACGGCA GGCATCTGCT TCCCCTTGA  
951 GAGCGCATTC GACCAGACG TGGGCACCAA CTCCTTTCGC GACTACGAGA  
1001 TCACCCCCAA CAGCTACTTC TCCCTGGACG TGCAGACCCA GGGGGATGCG  
1051 AACCAGTTG CTGAGCTGCT GCTGGAGAAG CACTGGACC GAGAGCAGCA  
1101 AGCGGTGCAC CGCTACGTGC TGACCGCGGT GGACGGAGGA GGTGGGGGAG  
1151 GAGTAGGAGA AGGAGGGGGA GGGGAATGGC GGGGGACAGG CTGCCCCCCC  
1201 CAGCAGACG GCACCGGGGA CCGCCCCCTAC TCACCATCCG AGTGTCTGAC  
1251 TCCAATGACA ATGTGCCCGC CTTTCGACCA ACCCGCTAC ACTGTGTGTT  
1301 CTACCCAGAG AACTCTCCC CCAAGGCACT CTCGCGAATC CAGCTCAACG  
1351 CMACCGACC CGAGCAGGGG CCAGAACGGT GAGTGTGTT ACTCTTTCAG  
1401 CAGCCACATT TCGCCCCCGG CCGCGGAGCT TTTTCGAGCT TCGCCCGCGA  
1451 CTGGCAGACT GGAGGTAAGC GCGAGTTGG ACTATGAAGA GAGCCAGTG  
1501 TACCAAGTGT ACGTCAAGC CAAGGACTGT GGGCCCAACG CCGTGCCTGC  
1551 GCACTGCAAG GTGCTAGTGC GAGTACTGGA TGCTAATGAC AACGCGCCAG  
1601 AGATCAGCTT CAGCACCGTG AAGGAAGCGG TGAGTGAGGG CCGCGCGCCC  
1651 GGCACTGTGG TGGCCCTTTT CAGCGTACT GACCGGACT CAGAGAGAA  
1701 TGGGCAGGTG CAGTGCAGC TACTGGGAGA CGTGCCTTTC CGCCTCAAAT  
1751 CTTCCCTTAA GAATTACTAC ACCATCGTTA CCGAAGCCCC CTGGACCGA  
1801 GAGCGGGGG ACTCTACAC CCTGACTGTA GTGGCTCGGG ACCGGGGCGA  
1851 GCCTGCGCTC TCCACCAGTA AGTCGATCCA GGTACAAGTG TCGGATGTGA  
1901 ACGACAACG GCGCGTTTC AGCCAGCGG TCTACGACGT GTATGTGACT  
1951 GAAACAACG TGCCTGGCGC CTACATCTAC GCGGTGAGG CCACCGACCG  
2001 GGATGAGGG GCCAACGCC AGCTTGCCTA CTCTATCCTC GAGTGCAGA  
2051 TCCAGGGCAT GAGCGCTTTC ACCTACGTTT CTATCACTC TGAGAACGCG  
2101 TACTGTAGC CCCTGGGCTC CTTGACTAT GAGCAGCTGA AGGACTTCAG  
2151 TTTTCAGGTG GAAAGCCCGG ACGTGGCAG CCCCAGGGG CTGGCTGGTA





PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3009; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 885 AA;  
ADP31011 Length: 885 February 22, 2005 12:25 Type: P Check: 9367 ..  
1 ATGGAGGGGG AGGAGAAGGA GAAGGAGGAG GAGGAGGAGG AAGAGCAGGA  
51 GGAGGAAGAG GAGGAGCAGG AAGAGAAGGA GGAGAAGGAG AAGGAGAAGA  
101 GGAAGAGGAA GAGGAGGAGG AGGAAGAGGA GGAGAAGACT GACTGACTCC  
151 TCTGGCTCCA AAAACTCTGA TGTTCGCCT CTCTTTTCCC AGCATTGTGA  
201 TTCCCTCCAC GCCAAGTTCA GCCAAGAAGG AATGTCCTTT AATAACCAAG  
251 ACTCAGACAG CCCAGCAGTC ATTGCCTTTG GATGTCTTTC CATCCCTGAG  
301 ATGTTGGATT CAAGGAGGC TGTACAGAA GCACGTGCT GCACATCTGC  
351 TCAGCTTCTG GGAAGGCTCA GGGAGCTTTT ACTCATGGCA GAAGGTGAAG  
401 CAAGAGCAGG CACATCACAT GGCAAGAGCA AGAGCAAGAA GGGTCGCTTC  
451 GAGGAGCGG TAGTGCACCT CGCGCGGCG CACTTTCCAC GGCAGAGCT  
501 GGAGCTGGGC TCTGGGCAGC CTTTCGGCTC TCTCGTGGG GAGCTGAGTC  
551 CCGGGTTGTT GAGGCGGGGG TCCTTAAGA CCGCTACCGG CCCCTCGGG  
601 CTGACGGGCC CGGAGGGGGC TCACCTCCG AAGGAGCCT CGCCGAAGGC  
651 AGACGCGGAC CGGACTTGGT CTTGCACAGC AGCGCGGAG CAGCGCAGCG  
701 GGAGGACGGG AGAGGTGCTG CCCTCCCCC GGAGTTGGAA GCGCCTTAGT  
751 CCGGTTCAAA ATGCCAAGA AGACGCGGAC GCCCATCCAG CTGACCCGAG  
801 CCCCCGAGG CTCACGCCGT GGTTACGGG ACCAGTCTG CGGAACCAA

851 CTTGGAGGCC TTGAGAAGA AGCTGGAAGA GCTAG  
!!AA SEQUENCE 1.0  
ID ADP31151 standard; protein; 1546 AA.  
XX  
AC ADP31151;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1918.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.

PR 19-MAY-2003; 2003US-04711306P.  
PR 19-MAY-2003; 2003US-0471136P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang NM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3149; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1546 AA;  
ADP31151 Length: 1546 February 22, 2005 12:25 Type: P Check: 126 ..  
1 CACAGGGCTG CTCTCCAGA GCTTGGAGTT CAACTCTCTT GCGGACAACT  
51 ACACAGTGTG TGAAGTGAC NAGGCCACCC TCAGTGTCTT CATCGACGAG  
101 CACGTGACCC GGTGGGCTG GGTGAACCGC TCCAACATCC TGTATGCCGG  
151 CAATGACCGC TGGACCAGCG ACCCGGGGT GCGGTGTGTC ATCAACACCC  
201 CCGAGGAGTT CTCCATCTC ATCACCGAGG TGGGGCTCGG CGACGAGGGC  
251 CTCTACACCT GTCCTTTCCA GACCCGCCAC GAGCGGTACA CCACTCAGGT  
301 CTACCTCATT GTCCACGTCC CTGCCCGCAT TGTGAACATC TCGTCGCGCTG  
351 TGACGGTGAA TGAGGGGGGC NATGTGAACC TGCTTTGCTT GGCCGTGGGG  
401 CGGCCAGAGC CACAGGTGAC CTGGAGACAG CTCGAGAGCG GCTTCACCTC  
451 GGAGGGAGAG ATCTCTGAGA TCTCTGACAT CCAGCGGGGC CAGGCCGGGG  
501 AGTATGAGTG CGTGACTCAC NAGCGGGTTA ACTCGGGCC CGACAGCGCG  
551 CGCGTGTGG TCACTGTCAA CTATCTCCG ACCATCAGG ACGTGACCAG  
601 CGCCCGCACC GCGCTGGGCC GGGCGGCCCT CCGTGTGTC GAAGCCATGG  
651 CGGTTCCCC CGCGGATTC CAGTGTACA AGGATGACAG ACTGCTGAGC

701 AGCGCACG CCGNAGGCT GAAGTGCAG ACGGAGCGCA CCGCTCTCGAT  
751 GCTTCTCTTT GCCAACGTGA GCGCCCGGCA TTACGGGAAC TATAGTGTGC  
801 GCGCCGCCAA CCGACTGGGA GCGTCCAGCG CTTCATGCG GCTCTGCGC  
851 CCAGGATCCC TGGAGNACTC AGCCCCGAGG CCCCCAGGC TCCTGGCCCT  
901 CTTCTCGGC CTGGGCTGGC TGTGGTGGAG AATGTAGGCG CAACCCAGTG  
951 GAGTCACTT CCCCCTGCAG GGGGCCTCAG GCCAAGAGTG AGAGAAACGG  
1001 GGGAGCAAGA GCGGTGGGTC TCGTGGGGGC AGAAGAGCTC TCGGCCACCA  
1051 AGGAAGAAGA GAGACGAGAG GAAGAAAGAT CTTCAGAGAA CCCATCAGTG  
1101 TGAGGGATAA CGAAAAATTA TGCATCTTTC TACAGGCATT CTCGCCACCC  
1151 GTTCAGTTT CCGATTGTGA CCCACTCCG CCACCCATA CCCCTCTCTC  
1201 TTAGTTCAGG CTGTCAACTG GCTTGTGTGG GTGTGGGTGT GTGAGTCTGG  
1251 CTCAGTGGCC TGAGACCTTC CCACTTTTCC TGTCCCTCCA CACCCCTGGAT  
1301 TTTCTGCCCC CCTCCTGGGC CAATCGGTGC TTCCATCCAA CTGTCACT  
1351 GGTGGGAGGA GTCACTGTGC TGTTCAGTG CTTTGGCCTA CCGTTGCCAC  
1401 CACTCCCTT GGCCTTGATT TCCCCACCTG CGGCACCAGC CAGCTGCCCT  
1451 TGGGGCTTT GCAGCTGGCC CACAGGTGTG AGCTTGTGTG TCTATCACTT  
1501 CTGGGCTCT CCACCAACTG TACCTCCAA AGGCTACCTG ACGGCC  
! !AA SEQUENCE 1.0  
ID ADP31173 standard; protein; 330 AA.  
XX  
AC ADP31173;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1940.  
DE  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.



PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485323P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Hatahan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3171; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMED and is not in the specification.

XX Sequence 330 AA;  
SQ  
ADP31173 Length: 330 February 22, 2005 12:25 Type: P Check: 9167 ..  
  
1 ATGACCTTCA GCCAGTACCC CTATAGCAAC CTCTGCAAGG GCTTGGGGGC  
51 CTTGCTCTCA GAACAGGGCT TTCATCTTAC GAACAAGTTC CTGACCTACT  
101 TCCCCGGGAG GAGCACTGAG GATGGCCGCA AGCGAGGAGG CCTGGGCTAC  
151 ACCCAGCTGG GTGAGGACCA CGTGAAGGAG ACTGGCTTCC ACTTCACCAT  
201 CACGAACCAG GCGCCCTCGG TTCCGGGCCC GGCCTTCAGCC TCAAGTTCTG  
251 GCAAGGTCAG AGCCGACTCC AGTCATGGG GAGGATTACG CCGGACCAC  
301 GGGGAGCTG CTACGGCTGA GCTGCCTTGA  
  
!!IAA SEQUENCE 1.0  
ID ADP31186 standard; protein; 5514 AA.  
XX  
AC ADP31186;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1953.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.



2101 CCTCATCTGC GTCCGGAAGG AAGTCATCCG CCCGTCCCTC ATCTGGTGCC  
2151 GGAAGGAAGT CATCCGCCCG TCCCTCATCT GCGTCTGGAA GGAAGTCATC  
2201 TGTCTGTTCC TCATCTGCGT CCGAAGGAA GTCATCTGCT CGTTCTCTAT  
2251 CTGCGTCCGG AAGGAAGTCA TCCGCCCATC CTTTCTCTGC GTCTGGAAGG  
2301 AAGTCATCCA CCCGTGCGTC ATCTGCGTCC GGAAGGAAGT CATCCGCCCG  
2351 TCCCTCATCT GCGTCCGGA GGAATCATCC GCCCGTCCCT CATCTGCGTC  
2401 TGAAGGAAG TCATCCGCCG GTCCCTCATC TCGTCTCTGA AGGAAGTCAT  
2451 CCGCCCTTTC CTCATCTGCG TCTGGAAGGA AGTCATCCGC CGTTTCTCTCA  
2501 TCTGGGTCTT GAAGGAATCA TCCACCCGTT CCTCATCCGC GTCCCGAAGG  
2551 AAGTCATCCG CCGTCCCTC ATCTGGGTCC GGAAGGAATC ATCCGCCCGT  
2601 CCTCATCTG GGTCTGGAAG GAAGTCATCC GCCCGTCCCT CATCTGCGTC  
2651 TGAAGGAAG TCATCCGCCG GTCCCTCATC TCGTCTCTGA AGGAATCATC  
2701 CCGCGTCCCT TCATCTGCGT CTGGAAGGAA GTCATCCGCC GTCCTCTCAT  
2751 CTGCGTCTGG AAGGAAGTCA TCCGCCCGTC CCTCATCTGC GTCTGGAAGG  
2801 AAGTCATCCA CCGTCCCTC ATCTGGGTCC TGAAGGAATC ATCCACCCGT  
2851 TCTCATCCGG CGTCCCGAAG GAAGAATCAT CCACCCGTTT CTCACTGGCG  
2901 TCCCGAAGGA AGTCATCCAC CCGTTCTCTCA TCTGCGTCTG GAAGGAAGTC  
2951 ATCCACCCGT CCTCATCTG CGTCTCTGAAG GAATCATCCG CCGTCCCTC  
3001 ATCTGGGTCT GGAAGGAAGT CATCCGCCCG TCCCTCATCT GCGTCTGGAA  
3051 GGAAGTCATC CGCCCGAATC ATCCGCCCGT CCTCATCTG GGTCTGGAA  
3101 GAAGTCATCC GCCGTCCCT CATCTGGGTC TGAAGGAAG TCATCCGCCG  
3151 GTCCCTCATC TCGTCTGGA AGGAAGTCAT CCACCCGTCC CTCATCTGCG  
3201 TCTTGAAGGA ATCATCCACC CGTTCTCTCAT CGCGGTCCCG AAGGAAGTCA  
3251 TCCGCCCGTT CCTCATCTGC GTCTGGAAG AATCATCCAC CCGTTCTCTCA  
3301 TCGCGGTCCC GAAGGAAGAA TCATCCACC GTTCTCTCAT GCGTCCCGA  
3351 AGGAAGTCAT CCGCCCGTTT CTCATCTGCG TCTGGAAGGA AGTCATCCAC  
3401 CCGTCCCTCA TCTGGTCTCT GAAGGAATCA TCGGCCCGTC CCTCATCTGC  
3451 GTCTGGAAGG AAGTCATCCA CCGTCCCTC ATCTGCGTCT GGAAGGAAGT  
3501 CATCCGCCCG TCCCTCATCT GCGTCCGGA GGAAGTCATC CACCGTCCC  
3551 TCATCTGCGT CCGGAAGGAG GTCATCCGCC CGTTCTCTAT CTGCGTCTGG  
3601 AAGGAATCAT CCACCCGTCC CTCATCTGCG TCCGAAGGAA GTCATCCGCC  
3651 CGTCCCTCAT CTGCGTCCGG AAGGAGTCA TCCGCCCGTT CCTCATCTGC  
3701 GTCTTGAAGG AGTTCATCCG CCGTTCCTC ATCTGGGTCT GGAAGGAAT  
3751 CATCCGCCCG TTTCTCATCT GCGTCCGGAAG GAAGTCATCC ACCCGTCCCT  
3801 CATCTGCGTC CCGAAGGAAG TCATCCGCCG GTCCCTCATC TCGTCTCTGA  
3851 AGGAAGTCAT CCGCCCGTTT CTCATCTGCG TCTGGAAGGA AGTCATCCGC  
3901 CCGTCCCTCA TCTGCGTCTT GAAGGAATCA TCCACCCGTC CCTCATCTGC

3951 GTCCGGAAGG AATCATCCAC CCCTCCCTCA TCTGGGTCCG GAAGGAGTCT  
4001 ATCCGCCCGT TCCTCATCTG CGTCCAGAAG GAATCATCCA CCGTCCCTC  
4051 ATCTCGGTCC AGAAGGAAGT CATCCACCCG TCCCTCATCT GCGTCCGGA  
4101 GGAAGTCATC CACCGTCCC TCATCTGCGT CCGAAGGAA GTCATCCGCC  
4151 CGTTCTCTAT CTGCGTCTGG AAGGAAGTCA TCCGCCCGTC CCTCATCTGC  
4201 GTCCGGAAGG AATCATCCGC CCGTCCCTCA TCTGGGTCTG GAAGGAAGAA  
4251 TCATCCACCC GTTCTCTATC GCGTCCCGA AGGAAGTCAT CCGCCCGTCC  
4301 CTCATCTGG TCTGGAAGGA AGTCATCCGC CCGTCCCTCA TCGGCATCCT  
4351 GAAGGAATCA TCCACCCGTT CCTCATCCGC GTCCCGAAGG AAGTCATCCG  
4401 CCGTCCCTC ATCTGCGTCT GGAAGGAAGT CATCCGCCG TCCCTCATCT  
4451 GCGTCCGGA GGAAGTCATC CGCCCGTCCC TCATCTGCGT CCTGAAGAA  
4501 GTCATCCGCC CGTCCCTCAT CTGCGTCTGG AAGGAATCAT CCACCCGTCC  
4551 CTCATCTGCG TCTGGAAGGA AGAATCATCC ACCCGTCCCT CATCTGCGTC  
4601 TGAAGGAAG TCATCCGCCG GTCCCTCATC TCGTCTGGA AGGAAGTCAT  
4651 CCGCCCGTCC CTCATCTGCG TCGGAAGGA GGTTCATCCG CCGTCCCTCA  
4701 TCTGCGTCT GAAGGAATCA TCCACCCGTT CCTCATCCGC GTCCCGAAGG  
4751 AAGTCATCCG CCGTCCCTC ATCTGCGTCT GGAAGGAAGT CATCCGCCG  
4801 TCCCTCATCT GCGTCTGAA GGAATCATCC GCCCGTCCCT CATCTGCGTC  
4851 CCGAAGGAAG CTCATGGAGT ATGTTCCGGG CTGTGAGTCT TCCAGCTACC  
4901 TCGCCACCG GGGCTCTTC TACTCTGCAG AGATCATCTG TGCATCTCTG  
4951 CACTCTAAG AGATCATCTA CAGGACTTGG AAGCCGGA ACATCTCTCT  
5001 GGATAGGAC GGACACATCA AGCTCACGGA CTTTGGGTTT GCCAAGAAGC  
5051 TGGTAGACAG GACTTGGACC CTCTGCGGAA TACCAGGTA CCTGGCCCCC  
5101 GAAGTCAATC AGAGCGAGG TCACGGAAGG GCTGTGSACT GGTGGGCCCT  
5151 CAGCATCTG ATATTGAGA TGCTCTCGG ATTTCTCCA TTTGTGTGTA  
5201 AATTTCTGC AGACAAGATA GATTTCCCA GACATTTGGA TTTCCATGTG  
5251 AAAGATCTCA TTAAGAAACT GCTCGTGGTT GACAGAACA GGTGGTTAGG  
5301 AATATGAAG AACGGGCGA ATGATGTGAA ACGCCATCGG TGGTTCCGCT  
5351 CTGTGGACTG GGAAGCTGTT CCTCAGAGNA AACTGAAGCC TCCCATCTG  
5401 CCCAAGATAG CCGCGGAAGG CGACACCTCC AACTTCGGA CTTACCCGGA  
5451 GAATGACTGG GACACAGCCG CGACCGTGCC GCAGAAGGGT TTAGAAATCT  
5501 TCAAGAAATTT CTGA

IIAA SEQUENCE 1.0

ID ADP31201 standard; protein; 1539 AA.

XX

AC ADP31201;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1968.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 03-JUN-2003; 2003US-0476609P.  
PR 03-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.

PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3199; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 1539 AA;

ADP31201 Length: 1539 February 22, 2005 12:25 Type: P Check: 5537 ..

1 ATGCTCATGA AAAATGACCA GAAACAGTT ACAATTACA ATGTTGGCAA  
51 CGATGATGCT GAGGAGGAAG AGCAGGGGCC CATGGAGAG GACAGGGTCC  
101 ATACACCAG CCTAACGGA TGGACATGCG TATTATTC CATTCACAG  
151 ATGCAGAAAC TGAGCTTCAG GGAAGCTGAG GAGCTCACCC TGGGTCATAC  
201 GGCCAGCAAG TGGCACAGTC AAGATCCGAA CCCAGGGGAT GCTGCTGAGC  
251 TGCTTGGAGC CTTATGATCG GACATCCAGA CATGCCGCGAG CAGCAGTGCC  
301 AAACCTTCTGC TTGCCCCCGAG AAGCCAGCTG AGTCTTTCCAG GTCAAAGTCCC  
351 TCTCTGCTC CCCACAGTCC TGTCACACCC CTGGCTGCTC CCAGGACTC  
401 TTTCTGGGGG GAGCTTGGGC CACATGGAGT TCTTGGGAGC TGTGAAGAAG  
451 GAGGACTTCA CCAGGCTGGC TCTGTGCCCT GCAAGAACCA TCTGTGTGGAG  
501 CCGAGCAGAG GCTGCTCCT TTGAACGGA CTTGTACCCT CCACCTCCCCT  
551 ACCGCTGCAC CACACCAATC CATCATCACA CTTATGATGT CATCTTCTCA  
601 GAGGTGGGGA AGCTGAGGCC CAGAGAGGTG AGTGGCATGT CCGAAGCAGC  
651 CCAGCGCAGG GTGCGAGATT CTTTAAGCCG GTTTACATCA GGATTCCTTT  
701 TACTTGACCC CGAAGACATC CTTAATGATG CTTCTGGTTA TTTTGGTCTTT  
751 TGTGAGCCGT GTCTGCCTGA CTGTGCCAGG ATAAATGCCA GTGTTATTCC  
801 CATTTTTCAG CTGCCAGCGA AGAGCTCAAG AAGTGAAC TGCTCCCATTTG  
851 GCACGGCAGA AGGAGCCGTG GTAAGGCCGT ATCCTGGGCC AGATGCCAGA  
901 GGGCCCTTCC TGTGGCATC TCTGCAAGC CTGATGTGTT GTCTGATGCG

951 AACATCGTAC TGGAGAGCC CTGAGGCCT GGAGCAGGAC CAAAGGACAG  
1001 TCAAGTGGAC AAAGGCCITT CTGAGGAGGA AGCAGACTCC AGTTACCCAG  
1051 GACTCTGGGT TCTCTCTITT TGACTTGGAC TATGACTTTC AACGGGATTA  
1101 TGNATAGGATG TACAGTTACC CAGCAGTGT ACCTCTCTCT CTTCTTATTTG  
1151 CTGGGCTGT AGTGCCCTTG AACATCAGC GTGTATCAGG AACACCTCA  
1201 CAAAGGGCA AAGTGGCTT CAATTCTAAG AGTGGACAGC GGGGATCTTC  
1251 CRAGTTCTGA AAGTTGAAAG GAGATGACCT TCAGGCCATT AAGCAGGAGT  
1301 TGACCCAGAT AAAACAAAA GTGGATTCTC TCCTGGAAGA CCGCGAAAAA  
1351 ATGGAAGAACA AACAGAGCA ARAAGCAGTA GAGATGAAGA ATGGTAAGTC  
1401 AGAAGAGAAG CAGAGCAGCA GCTCACGTGA GACTCATGTG AAGATAGAGT  
1451 CTGAAGGTGG TGCAGATGAC TCTCTGAGG AGAGGGACCT ACTGGATGAT  
1501 GAGGATAATG AAGATTGGG GATGACCAGC TGGAGTTGA

!!AA\_SEQUENCE 1.0

ID ADP31203 standard; protein; 1116 AA.

XX ADP31203;

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1970.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406613P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 17-SEP-2002; 2002US-0410948P.

XX 17-SEP-2002; 2002US-0410949P.

XX 17-SEP-2002; 2002US-0410953P.

XX 17-SEP-2002; 2002US-0410957P.

XX 17-SEP-2002; 2002US-0410958P.

XX 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Hallenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

DR WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 3201; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX Sequence 1116 AA;

ADP31203 Length: 1116 February 22, 2005 12:25 Type: P Check: 5545 ..

1 ATGGAGTTCC TGGCAGCTGT GAAGAAGGAG GACTTCACCA GGCTGGCTCT

51 GTGCCCTGCA AGAACATCT GCTGGAGCG AGCAGAGCT GCCTCCTTTG

101 AACGGGACCT GTACCTCTCA CTTCCCTACC GGTGCACCAC ACCAATCCAT

151 CATCACACTT ATGATGTCAT CTTCTCAGAG GTGGGAAGC TGAGGCCACG  
201 AGAGGTGAGT GGCATGTCG RAGCAGCCCA GCGCAGGGTG CGAGATTCCT  
251 TAAGCCGGTT TACATCAGGA TTCCTTTTAC TTGACCCCGA AGACATCCCT  
301 AATGATCCCT CTGGTTATTT TGGTCTTTGT GAGCCGCTGC TGCCTGACTG  
351 TGCAGAGATA AATGCCAGTG TTAATCCCAT TTTTCAGCTG CGACGCAAGA  
401 GCTCAAGAAG TGAACCTGGCT CCCATTGGCA CGGCAGAAGG AGCCGTGGTA  
451 AGGCTGATC CTGGGCCAGA TGCCAGAGGG CCCCTCCTGT TGGCATCTCT  
501 GCAAGCCTC ATGTGTTGTC TGATGGCAAC ATCGTACTGG GAGAGCCCTG  
551 GAGGCCCTGA GCAGGACCAA GGGACAGTCA AGTGGACAAA GGCCTTTCTG  
601 AGGAGGAAGC AGACTCCAGT TACCCAGGAC TCTGGGTTCT CCTCTTTTGA  
651 CTTGGACTAT GACTTTCAAC GGGATTATGA TAGGATGTAC AGTTACCCAG  
701 CACGTGACC TCCTCTCCT CCTATTGCTC GGCCTGTAGT GCCCTTGAAG  
751 CATCAGCGTG TATCAGAAA CACCTCACAA AGGGCAAAA GTGGCTTCAA  
801 TTCTAAGAGT GGCACGGGG GATCTTCCAA GTCTGGAAG TTGAAGGAG  
851 ATGACCTTCA GGCCATTAA GAGGAGTTGA CCCAGATAAA ACAAAAAGTG  
901 GATTCTCTCC TGGAGACCC GGAAGAAATG GAAAAGAAAC AGAGCAAAAC  
951 AGCAGTAGAG ATGAAGAAATG GTAATCTAGA AGAAGCAG AGCAGAGCT  
1001 CACGTGAGAC TCATGTGAAG ATAGAGTCTG AAGTGGTGC AGATGACTCT  
1051 GCTGAGGAGA GGGACCTACT GGATGATGAG GATAATGAG ATTGGGGGAT  
1101 GACCAGCTGG AGTTGA

!!AA SEQUENCE 1.0

ID -ADP31233 standard; protein; 2724 AA.

XX ADP31233;

XX DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2000.

DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX

OS Homo sapiens.

XX WO2004035732-A2.

XX PD 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411010P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467203P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471338P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3231; 428pp; English.

PS The present invention relates to an isolated nucleic acid molecule

CC encoding a polypeptide which is believed to be cytostatic,

CC antinflammatory, immunosuppressive, antibacterial and virucidal. The

CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 2724 AA;

ADP31233 Length: 2724 February 22, 2005 12:25 Type: P Check: 3065 ..

1 ATGCAGAGCA TCCTCTATCA CGGCTTATC CGTGACCAGG CGTGCGCGCG  
51 CCAGACGGAT TACTGGCAGT TCGTAAAGA CATCCGGTGG CTCAGTCCCC  
101 ACTCAGCCCT TCACGTGGAG AAGTTCTACA GCGTGCACGA GAACGACCAG  
151 AGCAGTGCTG ATGGTGCCAG TGAAGTGCT GTTGCCGAGC TGTGCTGCA  
201 GCACGCCCTG CAGTACCAGT GCCTCTCAGC CCAGCTCCGG CCCCTGTGCG  
251 GGGATAGACA GTATATCAGA AAATTTCTACA CAGCTTCTCT CAAGGCCTCC  
301 CTGATGGGCT CTATCACTGT GGCAGCTTTT CTCTCCCCAG ATGCTGCCCT  
351 CTGTCTAAGT GACGCTCATG TCACGGCCAT GTGCGAGTGC TTGGAAGCAG  
401 TGGAAACAGAA CAACCCCGCG CTCCTGGCTC AGATCGATGC GTCCATGTTT  
451 GCAGAAAGC ACAGAGGCC GCTCCTGGTG ACAAGAGCC AGAGCCTGAC  
501 AGCCTGCCC AGTTCCACAT ACACCCCTCC AACAGCTAT GCTCAGCATT  
551 CCTACTTTGG GTCTCTTCTT AGCCTCCACC AATCCGTGCC CAACAATGSC  
601 TCAGAGAGAA GATCTACTTC CTTTCCACTC TCTGGCCCTC CCGGAAACC  
651 TCAAGAAAGC AGAGGGCAGC TCTCACAGC AGAGATCAA ACCATCCAAG  
701 CCCCCCAGT TTCAGTCTCT GCACTAGCCA GGGATTTCCC TTGACCCCA  
751 AATGAAATGA GTCACAGTAC TGTACACAG CCCATAGAGG CATCTGGGT  
801 CAGCAGCCAG AATGATTTCC CAGGTGATGC CAGTGAGGGG CCGTAGTACC  
851 TGCCCATTTG CAACTTGGAC CCCGAGGCC GGAATGCCAG CTGTCAAGAT  
901 CACAGCAGCA ATGCCGAGAG CAGCAGTTCC AATTTGTTCT CTTCCAGAG  
951 CTCCCAGNAG CCAGATTCTG CTGCTCTTTC CTTAGGGGAC CAGGAAGGAG  
1001 GTGGGGAGAG CCAGCTGTCC AGTGTCTCTC GCAGGTCCAG CTTCTCAGAG  
1051 GGGCAGACAC TCAGTGTAC CAGTGGGGCA AAGAAAGCC ACATTGCTC  
1101 CCATTCCGAT ACCAGCATTT CTTCCAGGGG AGCTCCAGAA GGTGTCGGT  
1151 ACCTGTGCTC AGGGGAAGGC ATGTTCCGAA GACCATCAGA AGGACAGTCC  
1201 CTCATCAGCT ACCTCTCTGA GCAAGACTTC GGCAGCTGTG CCGACTGGA  
1251 AAAGGAGAAT GCCCACTTCA GCATCTCAGA GTCTTTAATT GCTGCCATCG  
1301 AGCTAATGNA GTGCAACATG ATGAGCCAGT GCCTAGAGGA GGAGGAAGTG  
1351 GAAGAGGAAG ACATGTATAG AGAGATCCAG GAGCTGAAGC AGAAGATCCG  
1401 CCTTCGGCGC CAGCAAAATCC GCACCAAGAA CTTGCTCCCC ATGTACCAGG  
1451 AGGCTGAGCA CGGAAGCTTT CCGGTACCTT CCAGCAGCTC CCAGTTACAG  
1501 TCACGTGATT CGGCACAGCT CTCTGACTCT GGCCTGTGCT ATGAGGTTGA  
1551 TGAATTTGAA ATCCAAGCAA AGCAGGGATC CGGGAAGCTG TGCAGTCTCT

1601 CCCACTGCTT CTGCACCTCC ACGTCTGCTG AGGCGGTGGC CATGGGGCTC  
1651 CTGAAGCAGT TTGAGGGGAT GCAGCTTCCA GCGCCTCGG AGCTGGAGTG  
1701 GCTTGTCCCG GAGCATGATG CCCCTCAGAA GATGACGGGC AGCACACTGA  
1751 CACGAGCTTA CCCCAACTGT GCTTCTCTCC TGCAGCTCCT GCCCATTCCT  
1801 GACTCACTGC CCATCTCACC GGATGACGGG CAGCAGCTG ACATCTACAA  
1851 GCTGGCGGAT CGTGTTCTGT GCAACTTGGG GTGGGCCCCG CCCCAGCTC  
1901 AGATAAATTT TAATGTTTCAAT CCAGCCCCCA CGAGGAAAT TGCCGTGGCC  
1951 AAGCAGAATT ACCGCTGTGC AGGATGTGGC ATCCGAGCTG ACCCTGATTA  
2001 CATCAAGCGA CTGCGGTACT GTGAGTACCT GGGCAAGTAC TTCTGCCAGT  
2051 GCTGCCACGA GAATGCCCAG ATGCCCATCC CCAGCCGGGT TCTGCGCAAG  
2101 TGGGACTTCA GCAAGTACTA CGTCAGCAAC TTCTCCAAGG ACCTGCTCAT  
2151 TAAGATCTGG AATGATCTCT TCTTCAAGCT GCAGGACATA AACAGTCCCC  
2201 TCTATAGGAA GGTCAAGCTG CTCAATCAAG TCCGGCTGCT GCGGTCCAG  
2251 CTGTCTCACA TGAAGAACAT GTTCAAGACT TGCCGACTGG CCNAGGAGCT  
2301 TCTGGATTCC TTTGACACAG TCCCAGGCCA CTTGACAGAG GACCTCCACC  
2351 TGTACTCACT GAATGACCTG ACTGCGACCA GGAAGGGGGA GCTGGGGCCC  
2401 CGGCTTGTCT AGCTCACCAG GGCAGGGGCT ACCCATGTGG AGAGATGCAT  
2451 GCTGTGCCAA GCCAAAGGCT TCATCTGTGA GTTCTGTGAG AATGAGGATG  
2501 ACATCATCTT TCCCTTTGAG CTCATAAGT GCGGACCTG TGAAGAGTGT  
2551 AAAGCGTGT ACCATAAGC CTGCTTCAAG TCTGGAAGCT GTCCGCGCTG  
2601 CGAGCGGCTG CAGGCCCGG GGGAGGCACT GGCCAGGCAG AGCCTGGAGT  
2651 CTTACTCTGC AGACTAGCAG GAGGAGCCCG CGGAAGCGCT GGCCCTGGAA  
2701 GCCGCCGTCC TGGAGGCCAC CTGA

!!AA SEQUENCE 1.0

ID ADF31341 standard; protein; 2382 AA.

AC ADF31341;

XX  
DT 12-AUG-2004 (first entry)

XX  
DE Human secreted protein SEQ ID #2108.

XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX  
PN WO2004035732-A2.

XX  
PD 29-APR-2004.

XX  
PF 28-AUG-2003; 2003WO-US026780.

XX  
PR 29-AUG-2002; 2002US-0406576P.

XX  
PR 29-AUG-2002; 2002US-0406579P.

XX  
PR 29-AUG-2002; 2002US-0406585P.

XX  
PR 29-AUG-2002; 2002US-0406588P.

XX  
PR 29-AUG-2002; 2002US-0406608P.

XX  
PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485225P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT

PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3339; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 2382 AA;

ADP31341 Length: 2382 February 22, 2005 12:25 Type: P Check: 4037 ..

1 ATGAAGACGG CAGCGGAGCA ACAGAAGACG CTGAGAGAGT TCGTGGTGGT  
51 GATGGGCACT GAGCAGGACC GGGCCTGCTT CTTCTCGAG TCGGTACCT  
101 GGGACTTGCA GATTGCGCTA GCGAGCTTTT ATGAGGACAG AGGGAAGAA  
151 GACATCATAA CCAITTCACA GGCAACCCCC AGTTCAGTGT CCAGAGGCAC  
201 AGCCCTAGT GATAATAGAG TGACATCCTT TAGAGATCTC ACTCATGACC  
251 AAGATGAGGA TGAGGAAGAG GAGGAAGGCC AGAGGTTTTA TCCGGGGGCC  
301 TCAGAGAGAA GTGGACAGCA GATTGTTGGC CTTCCAGAA AGANAAGTTC  
351 CAATGAGCTG GTGGATGATC TCTTTAAAGG TGCCAAAGAG CATGGAGCTG  
401 TAGCTGTGGA GCGAGTGACC AACAGACCTG GAGAGACCAG TACACCAAGA  
451 CCATTTGCCG GAGATGGCTA TGGCCTTTGGG GCAGCACCAG AGGAAGAGTC  
501 TGCTTATGTG GCAGGAGAAA AGAGACATCA TTCCAACCAA GATGTTCTAG  
551 TAGTGTGTAG TACCATCTCT CCAGTCCAAC TGSCAGAAAA TGAAGCCAAA  
601 GCCAGCTCTT CCATCTTAAT CGTGAATCA GAGACTACCA CAAACATCCA  
651 AATTGGCTTT GCAGACGGTG GGAGGCTGGT GCAGAAATTT AACCACAGCC  
701 ACAGGATCAG CAACATCCAA CTCTTCATTT TGGATGCCCG GCCAGCCATG  
751 GCTGCCACCA GCTTTATCCT CATGACTACT TTCCCAAAACA AAGAGCTGGC  
801 TGACGAGAGC TGGACCCCTGA AGGAAGCCAA CTTGCTCAAT GCTGCCATCA  
851 TGCAGTGCCC TGTGAGAAG ACATATAGT CTTTGAGAT GACAGTGGAT  
901 TATACCAAAAC TTTATCAAGG AGAACTCCA GTTAAATCAA CTCAGTATAT  
951 CAAGTCAATG CATTCCTTTA TCTGGTGTGC AGCTACTGAT ATGACAAAAG  
1001 TGCCCCCCCAC CAGGCTCAT GGGAAAGTCT GCATGACCAG CTGTCTGAGG  
1051 AGCTCGTATC CAGATGGAGC AACACGATAT GAGCAGCTGA AATCGGCTGT  
1101 TACAGCTTTG CAGCTTCCTT CACAGNAGGC CCTGACAGAG GAGCAGAGCT  
1151 TCCCATGGCA TGTCTTGGGT CCAGTGGGTA GGAAGAGCC AAACATGTTT  
1201 TGGTTAGAAA GCCTGCCTGT GATTCTGTCA TCTGCAACTG AGCTCTCAAC  
1251 TCTTGTAGCA TTACAAGAAA CAAAGGAGGA ACAGCTCCAG TCTACAGCTC  
1301 CAGCGGTGAC CAACCGCAA GACCGGGGAT TTCTGCATTT CCAACTGAGG  
1351 TATGCACTG GGGAGTATCG GAAACCTAAC TGGGAGGCAC CTTTCAGTAG



1401	GGGCGAGCTG	ACACCTCACA	CGGCGGGGTA	CTCCGCTGAG	ACAAACTTC	PR	29-AUG-2002; 2002US-0406666P.
1451	CAGAGAAACG	ATCAGGCAGC	AACATTGCT	GTTCACCAAT	ATCAGCCACT	PR	17-SEP-2002; 2002US-0410946P.
1501	CTGCACGGTC	TGCTGCTGAT	ATCCAGGCAA	ACAGSGTCTG	GAGTGGACCT	PR	17-SEP-2002; 2002US-0410948P.
1551	CCGGCAAACT	CCAACAGACC	TGCAGCTGAG	GGTCTTGACT	GTTAGAAGGA	PR	17-SEP-2002; 2002US-0410949P.
1601	AAACTAACAG	AAAGGATATC	CACTCCAAAA	CCCCATCTCT	AAAGGAGGAA	PR	17-SEP-2002; 2002US-0410953P.
1651	GTTCGCACCC	ATGGCAAAGA	AGTTAAAAAC	CTTGAAAAAA	GATTAGACGA	PR	17-SEP-2002; 2002US-0410957P.
1701	ATGGCTAACT	AGATAAACCA	ATGCAGAGAA	GTCTTTAAAG	GACCTCATGG	PR	17-SEP-2002; 2002US-0410958P.
1751	AGCTGAAAA	CAAGGCACGA	GAACATATGT	ACAAATGCCAC	AAGCCTCACT	PR	17-SEP-2002; 2002US-0410959P.
1801	AGCCGATTCT	ATCAACTAGA	AGAAAGGTA	TCAGTGNATG	AGATCAAAAT	PR	17-SEP-2002; 2002US-0410960P.
1851	GAATGAATGT	AATGACGAGG	AGAATGGAAC	CAAGCTGGAA	AACACTCTGC	PR	17-SEP-2002; 2002US-0410961P.
1901	AGGATATTAT	CCAGGAGAAC	TTCCCAATC	TAGCAAGGCA	GGCCAAACAT	PR	17-SEP-2002; 2002US-0410962P.
1951	CAAAATTCAG	AAATACAGAG	AACCCACAA	AGACATCTCT	CGAGAGAGCC	PR	17-SEP-2002; 2002US-0410963P.
2001	AACTCCAAGA	CACATAATTG	TCAGATTCAAC	CAAGGTTGAA	ATGGAGGAAA	PR	17-SEP-2002; 2002US-0410964P.
2051	AAACGTTAAC	AGCACCCAGA	GAGAAAGGTG	AGGTTACCCA	CAAAAGGGAAG	PR	17-SEP-2002; 2002US-0410965P.
2101	CCATCAGAC	TAACAGCTGG	TCTCTCGCA	GAACCTCTAC	AAGCCAGGAG	PR	17-SEP-2002; 2002US-0411010P.
2151	AGAGTGGGG	CCAATATTCA	ACATTCITTA	AGAAAAGAA	TTTCAACCCA	PR	17-SEP-2002; 2002US-0411011P.
2201	GAATTTTATA	TCCAGCCAAA	CTAAGCTTCA	TGAGTGAAGG	AGAAATAAAA	PR	17-SEP-2002; 2002US-0411012P.
2251	TCCTTTACAG	ACAAACAAAT	GCTCAGAGAT	TTTGTCAACA	CCAGSCCTGC	PR	17-SEP-2002; 2002US-0411013P.
2301	CTTAAAGAG	CTCTGGAAGG	AAGCACTAAA	CATGGAAGG	AACAACCGGT	PR	17-SEP-2002; 2002US-0411014P.
2351	ACCAGGCACT	GCMAAACAT	GCCAAATTGT	AA		PR	17-SEP-2002; 2002US-0411015P.
11AA	SEQUENCE 1.0					PR	17-SEP-2002; 2002US-0411016P.
ID	ADP31416	standard; protein; 555 AA.				PR	17-SEP-2002; 2002US-0411017P.
XX	AC					PR	17-SEP-2002; 2002US-0411018P.
XX	ADP31416;					PR	17-SEP-2002; 2002US-0411019P.
XX	DT					PR	17-SEP-2002; 2002US-0411020P.
XX	12-AUG-2004	(first entry)				PR	17-SEP-2002; 2002US-0411021P.
XX	Human secreted protein	SEQ ID #2183.				PR	17-SEP-2002; 2002US-0411022P.
DE	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;					PR	17-SEP-2002; 2002US-0411023P.
KW	cancer; inflammatory; immune; human secreted protein.					PR	17-SEP-2002; 2002US-0411024P.
XX	Homo sapiens.					PR	17-SEP-2002; 2002US-0411025P.
XX	WO2004035732-A2.					PR	17-SEP-2002; 2002US-0411026P.
XX	29-APR-2004.					PR	17-SEP-2002; 2002US-0411027P.
XX	28-AUG-2003; 2003WO-US026780.					PR	17-SEP-2002; 2002US-0411028P.
XX	29-AUG-2002; 2002US-0406576P.					PR	17-SEP-2002; 2002US-0411029P.
PR	29-AUG-2002; 2002US-0406579P.					PR	17-SEP-2002; 2002US-0411030P.
PR	29-AUG-2002; 2002US-0406585P.					PR	17-SEP-2002; 2002US-0411031P.
PR	29-AUG-2002; 2002US-0406588P.					PR	17-SEP-2002; 2002US-0411032P.
PR	29-AUG-2002; 2002US-0406608P.					PR	17-SEP-2002; 2002US-0411033P.
PR	29-AUG-2002; 2002US-0406611P.					PR	17-SEP-2002; 2002US-0411034P.
PR	29-AUG-2002; 2002US-0406612P.					PR	17-SEP-2002; 2002US-0411035P.
PR	29-AUG-2002; 2002US-0406616P.					PR	17-SEP-2002; 2002US-0411036P.
PR	29-AUG-2002; 2002US-0406640P.					PR	17-SEP-2002; 2002US-0411037P.
PR	29-AUG-2002; 2002US-0406642P.					PR	17-SEP-2002; 2002US-0411038P.
PR	29-AUG-2002; 2002US-0406646P.					PR	17-SEP-2002; 2002US-0411039P.
PR	29-AUG-2002; 2002US-0406653P.					PR	17-SEP-2002; 2002US-0411040P.
PR	29-AUG-2002; 2002US-0406655P.					PR	17-SEP-2002; 2002US-0411041P.
PR						PR	17-SEP-2002; 2002US-0411042P.
PR						PR	17-SEP-2002; 2002US-0411043P.
PR						PR	17-SEP-2002; 2002US-0411044P.
PR						PR	17-SEP-2002; 2002US-0411045P.
PR						PR	17-SEP-2002; 2002US-0411046P.
PR						PR	17-SEP-2002; 2002US-0411047P.
PR						PR	17-SEP-2002; 2002US-0411048P.
PR						PR	17-SEP-2002; 2002US-0411049P.
PR						PR	17-SEP-2002; 2002US-0411050P.
PR						PR	17-SEP-2002; 2002US-0411051P.
PR						PR	17-SEP-2002; 2002US-0411052P.
PR						PR	17-SEP-2002; 2002US-0411053P.
PR						PR	17-SEP-2002; 2002US-0411054P.
PR						PR	17-SEP-2002; 2002US-0411055P.
PR						PR	17-SEP-2002; 2002US-0411056P.
PR						PR	17-SEP-2002; 2002US-0411057P.
PR						PR	17-SEP-2002; 2002US-0411058P.
PR						PR	17-SEP-2002; 2002US-0411059P.
PR						PR	17-SEP-2002; 2002US-0411060P.
PR						PR	17-SEP-2002; 2002US-0411061P.
PR						PR	17-SEP-2002; 2002US-0411062P.
PR						PR	17-SEP-2002; 2002US-0411063P.
PR						PR	17-SEP-2002; 2002US-0411064P.
PR						PR	17-SEP-2002; 2002US-0411065P.
PR						PR	17-SEP-2002; 2002US-0411066P.
PR						PR	17-SEP-2002; 2002US-0411067P.
PR						PR	17-SEP-2002; 2002US-0411068P.
PR						PR	17-SEP-2002; 2002US-0411069P.
PR						PR	17-SEP-2002; 2002US-0411070P.
PR						PR	17-SEP-2002; 2002US-0411071P.
PR						PR	17-SEP-2002; 2002US-0411072P.
PR						PR	17-SEP-2002; 2002US-0411073P.
PR						PR	17-SEP-2002; 2002US-0411074P.
PR						PR	17-SEP-2002; 2002US-0411075P.
PR						PR	17-SEP-2002; 2002US-0411076P.
PR						PR	17-SEP-2002; 2002US-0411077P.
PR						PR	17-SEP-2002; 2002US-0411078P.
PR						PR	17-SEP-2002; 2002US-0411079P.
PR						PR	17-SEP-2002; 2002US-0411080P.
PR						PR	17-SEP-2002; 2002US-0411081P.
PR						PR	17-SEP-2002; 2002US-0411082P.
PR						PR	17-SEP-2002; 2002US-0411083P.
PR						PR	17-SEP-2002; 2002US-0411084P.
PR						PR	17-SEP-2002; 2002US-0411085P.
PR						PR	17-SEP-2002; 2002US-0411086P.
PR						PR	17-SEP-2002; 2002US-0411087P.
PR						PR	17-SEP-2002; 2002US-0411088P.
PR						PR	17-SEP-2002; 2002US-0411089P.
PR						PR	17-SEP-2002; 2002US-0411090P.
PR						PR	17-SEP-2002; 2002US-0411091P.
PR						PR	17-SEP-2002; 2002US-0411092P.
PR						PR	17-SEP-2002; 2002US-0411093P.
PR						PR	17-SEP-2002; 2002US-0411094P.
PR						PR	17-SEP-2002; 2002US-0411095P.
PR						PR	17-SEP-2002; 2002US-0411096P.
PR						PR	17-SEP-2002; 2002US-0411097P.
PR						PR	17-SEP-2002; 2002US-0411098P.
PR						PR	17-SEP-2002; 2002US-0411099P.
PR						PR	17-SEP-2002; 2002US-0411100P.
PR						PR	17-SEP-2002; 2002US-0411101P.
PR						PR	17-SEP-2002; 2002US-0411102P.
PR						PR	17-SEP-2002; 2002US-0411103P.
PR						PR	17-SEP-2002; 2002US-0411104P.
PR						PR	17-SEP-2002; 2002US-0411105P.
PR						PR	17-SEP-2002; 2002US-0411106P.
PR						PR	17-SEP-2002; 2002US-0411107P.
PR						PR	17-SEP-2002; 2002US-0411108P.
PR						PR	17-SEP-2002; 2002US-0411109P.
PR						PR	17-SEP-2002; 2002US-0411110P.
PR						PR	17-SEP-2002; 2002US-0411111P.
PR						PR	17-SEP-2002; 2002US-0411112P.
PR						PR	17-SEP-2002; 2002US-0411113P.
PR						PR	17-SEP-2002; 2002US-0411114P.
PR						PR	17-SEP-2002; 2002US-0411115P.
PR						PR	17-SEP-2002; 2002US-0411116P.
PR						PR	17-SEP-2002; 2002US-0411117P.
PR						PR	17-SEP-2002; 2002US-0411118P.
PR						PR	17-SEP-2002; 2002US-0411119P.
PR						PR	17-SEP-2002; 2002US-0411120P.
PR						PR	17-SEP-2002; 2002US-0411121P.
PR						PR	17-SEP-2002; 2002US-0411122P.
PR						PR	17-SEP-2002; 2002US-0411123P.
PR						PR	17-SEP-2002; 2002US-0411124P.
PR						PR	17-SEP-2002; 2002US-0411125P.
PR						PR	17-SEP-2002; 2002US-0411126P.
PR						PR	17-SEP-2002; 2002US-0411127P.
PR						PR	17-SEP-2002; 2002US-0411128P.
PR						PR	17-SEP-2002; 2002US-0411129P.
PR						PR	17-SEP-2002; 2002US-0411130P.
PR						PR	17-SEP-2002; 2002US-0411131P.
PR						PR	17-SEP-2002; 2002US-0411132P.
PR						PR	17-SEP-2002; 2002US-0411133P.
PR						PR	17-SEP-2002; 2002US-0411134P.
PR						PR	17-SEP-2002; 2002US-0411135P.
PR						PR	17-SEP-2002; 2002US-0411136P.
PR						PR	17-SEP-2002; 2002US-0411137P.
PR						PR	17-SEP-2002; 2002US-0411138P.
PR						PR	17-SEP-2002; 2002US-0411139P.
PR						PR	17-SEP-2002; 2002US-0411140P.
PR						PR	17-SEP-2002; 2002US-0411141P.
PR						PR	17-SEP-2002; 2002US-0411142P.
PR						PR	17-SEP-2002; 2002US-0411143P.
PR						PR	17-SEP-2002; 2002US-0411144P.
PR						PR	17-SEP-2002; 2002US-0411145P.
PR						PR	17-SEP-2002; 2002US-0411146P.
PR						PR	17-SEP-2002; 2002US-0411147P.
PR						PR	17-SEP-2002; 2002US-0411148P.
PR						PR	17-SEP-2002; 2002US-0411149P.
PR						PR	17-SEP-2002; 2002US-0411150P.
PR						PR	17-SEP-2002; 2002US-0411151P.
PR						PR	17-SEP-2002; 2002US-0411152P.
PR						PR	17-SEP-2002; 2002US-0411153P.
PR						PR	17-SEP-2002; 2002US-0411154P.
PR						PR	17-SEP-2002; 2002US-0411155P.
PR						PR	17-SEP-2002; 2002US-0411156P.
PR						PR	17-SEP-2002; 2002US-0411157P.
PR						PR	17-SEP-2002; 2002US-0411158P.
PR						PR	17-SEP-2002; 2002US-0411159P.
PR						PR	17-SEP-2002; 2002US-0411160P.
PR						PR	17-SEP-2002; 2002US-0411161P.
PR						PR	17-SEP-2002; 2002US-0411162P.
PR						PR	17-SEP-2002; 2002US-0411163P.
PR						PR</	

CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX  
SQ Sequence 555 AA;

ADP31416 Length: 555 February 22, 2005 12:25 Type: P Check: 6553 ..

1 ATGAATAGGC AGATTTCTTAA GGCATGTGGA CTACAGTATG TAGAGAACAT  
51 ACACATATGAT GCTGTCTATGG TGGATGATGC CATTATAGGC CTGTCAAGAAC  
101 CCATAGAGG CACACACCA AGAGTGAATG CTGATAACT GTGGACTTGG  
151 GTGATGATGA TGTGTCAATT CACATGCGAC ACTTACATGA ATGCCCTGGGT  
201 ACTGATAAAA CTTTATTATC AAAACACAGG TCATCTGCAA ACCCTGTCT  
251 TAGAAGTCAG ATTTTCTCA GTGATCTACT CAATACCCCT CCGTGGGTTT  
301 CGTCCCACGC AGAAGACCG CATACAAAGA AAGCAACAG GGCTCTGGGC  
351 CCCACTGCC CCAGTCACTC AGGAGGTCTC CCTCTCACTT GCTGCTCCAG  
401 TGTCGGTCTT GCTGACCCAA GCATCAGGC TCATCTCTGC TCGGGCTGT  
451 GTTCTCATCG TCCACCACC CGGCGATCAT GCAGCCACC CCGACCACAC  
501 ATGCAGAGTC GCTGTCCCCA CCGTCACAA CTGCCCCCA CTTCTCTCG  
551 TTTAG

!!AA SEQUENCE 1.0

ID -ADP31424 standard; protein; 204 AA.

XX  
AC ADP31424;

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2191.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 29-AUG-2002; 2002US-0406666P.

XX 17-SEP-2002; 2002US-0410946P.

XX 17-SEP-2002; 2002US-0410947P.

XX 17-SEP-2002; 2002US-0410948P.

XX 17-SEP-2002; 2002US-0410949P.

XX 17-SEP-2002; 2002US-0410953P.

17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471338P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnenmann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3422; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPOWEB and is not in the specification.

XX

SQ	Sequence 204 AA;	
ADP31424	Length: 204 February 22, 2005 12:25 Type: P Check: 267	
1	ATGGGTAAGG GGATGGTGGC GATGCTCATTT CTGGGTCCTGC TACTTCTGGC	PR 17-SEP-2002; 2002US-0411082P.
51	GCTGCTCCTA CCGTGCAGG TTTCTTCATT TGTTCTTTTA ACCAGTATGC	PR 17-SEP-2002; 2002US-0411101P.
101	CGGAAGCTAC TGCAGCGGAA ACCAAGAAGC CTTCCAACAG TGCCCTACAG	PR 18-APR-2003; 2003US-0463700P.
151	CCTACAGCG GTCTCTTGTT GGCTTTCGTT GCCTTCTTAC ATCTCTACCA	PR 18-APR-2003; 2003US-0463708P.
201	TTAA	PR 18-APR-2003; 2003US-0463716P.
!!AA	SEQUENCE 1.0	PR 02-MAY-2003; 2003US-0467199P.
ID	ADP31425 standard; protein; 8976 AA.	PR 02-MAY-2003; 2003US-0467201P.
XX		PR 02-MAY-2003; 2003US-0467203P.
AC	ADP31425;	PR 19-MAY-2003; 2003US-0471306P.
XX		PR 19-MAY-2003; 2003US-0471336P.
DT	12-AUG-2004 (first entry)	PR 22-MAY-2003; 2003US-0472420P.
XX		PR 22-MAY-2003; 2003US-0472430P.
DE	Human secreted protein SEQ ID #2192.	PR 09-JUN-2003; 2003US-0476609P.
XX		PR 09-JUN-2003; 2003US-0476641P.
KW	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;	PR 08-JUL-2003; 2003US-0485218P.
KW	cancer; inflammatory; immune; human secreted protein.	PR 08-JUL-2003; 2003US-0485223P.
XX		PR 08-JUL-2003; 2003US-0485224P.
OS	Homo sapiens.	PR 14-JUL-2003; 2003US-0486446P.
XX		PR 14-JUL-2003; 2003US-0486480P.
PN	WO2004035732-A2.	PR 15-JUL-2003; 2003US-0486891P.
XX		PR 15-JUL-2003; 2003US-0486960P.
FD	29-APR-2004.	PR 08-AUG-2003; 2003US-0493341P.
XX		PR 08-AUG-2003; 2003US-0493573P.
PF		PR 08-AUG-2003; 2003US-0493577P.
XX		XX
XX	28-AUG-2003; 2003WO-US026780.	XX
PR	29-AUG-2002; 2002US-0406576P.	PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PR	29-AUG-2002; 2002US-0406579P.	PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;
PR	29-AUG-2002; 2002US-0406585P.	PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
PR	29-AUG-2002; 2002US-0406588P.	XX WPI; 2004-348438/32.
PR	29-AUG-2002; 2002US-0406608P.	XX
PR	29-AUG-2002; 2002US-0406611P.	PT New nucleic acid molecule for diagnosing, preventing or treating diseases
PR	29-AUG-2002; 2002US-0406612P.	PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PR	29-AUG-2002; 2002US-0406616P.	XX genetic, bacterial and viral diseases.
PR	29-AUG-2002; 2002US-0406640P.	XX Claim 1; SEQ ID NO 3423; 428pp; English.
PR	29-AUG-2002; 2002US-0406642P.	XX
PR	29-AUG-2002; 2002US-0406646P.	XX The present invention relates to an isolated nucleic acid molecule
PR	29-AUG-2002; 2002US-0406653P.	CC encoding a polypeptide which is believed to be cytostatic,
PR	29-AUG-2002; 2002US-0406655P.	CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
PR	29-AUG-2002; 2002US-0406666P.	CC composition and methods are useful for diagnosing, preventing and
PR	17-SEP-2002; 2002US-0410946P.	CC treating diseases such as proliferative (e.g. cancer), inflammatory,
PR	17-SEP-2002; 2002US-0410947P.	CC immune, metabolic, genetic, bacterial and viral diseases. The present
PR	17-SEP-2002; 2002US-0410948P.	CC sequence represents a human secreted protein. The present sequence is
PR	17-SEP-2002; 2002US-0410949P.	CC available on WIPOWEB and is not in the specification.
PR	17-SEP-2002; 2002US-0410953P.	XX
PR	17-SEP-2002; 2002US-0410957P.	XX
PR	17-SEP-2002; 2002US-0410958P.	XX
PR	17-SEP-2002; 2002US-0410959P.	XX
PR	17-SEP-2002; 2002US-0410960P.	XX
PR	17-SEP-2002; 2002US-0410961P.	XX
PR	17-SEP-2002; 2002US-0410962P.	XX
PR	17-SEP-2002; 2002US-0411019P.	XX
PR	17-SEP-2002; 2002US-0411023P.	XX
PR	17-SEP-2002; 2002US-0411024P.	XX
PR	17-SEP-2002; 2002US-0411032P.	XX
PR	17-SEP-2002; 2002US-0411035P.	XX
PR	17-SEP-2002; 2002US-0411037P.	XX
PR	17-SEP-2002; 2002US-0411041P.	XX
PR	17-SEP-2002; 2002US-0411045P.	XX
PR	17-SEP-2002; 2002US-0411046P.	XX
PR	17-SEP-2002; 2002US-0411048P.	XX
PR	17-SEP-2002; 2002US-0411052P.	XX
PR	17-SEP-2002; 2002US-0411055P.	XX
PR	17-SEP-2002; 2002US-0411073P.	XX
ADP31425	Length: 8976 February 22, 2005 12:25 Type: P Check: 4665	
1	ATGCAGATTC AAGNATGGCT TTGTTTAAAT TGCCAAACCC AGAGAGCAAT	1 ATGCAGATTC AAGNATGGCT TTGTTTAAAT TGCCAAACCC AGAGAGCAAT
51	ATCAGGACAG CTTGGAGACA TAGGCAAAAT GCCACCTGCA CCATCAGGAC	51 ATCAGGACAG CTTGGAGACA TAGGCAAAAT GCCACCTGCA CCATCAGGAC
101	CCAAAGCATC TCCTATGCCT GTTCCTACAG AATCATCATC TCAGAAAACA	101 CCAAAGCATC TCCTATGCCT GTTCCTACAG AATCATCATC TCAGAAAACA
151	GCAGTGCTC CCCAAGTAAA ATTAGTGAAA AAGCAAGAAC AAGAAGTAAA	151 GCAGTGCTC CCCAAGTAAA ATTAGTGAAA AAGCAAGAAC AAGAAGTAAA
201	AACGGAAGCT GAAAAAGTCA TTCTGGAAAA AGTAAAGAA ACTATATCAA	201 AACGGAAGCT GAAAAAGTCA TTCTGGAAAA AGTAAAGAA ACTATATCAA
251	TGGAATAAAT TCCTCCTATG GTAACCCACAG ATCAAAAACA AGAAGAGAGT	251 TGGAATAAAT TCCTCCTATG GTAACCCACAG ATCAAAAACA AGAAGAGAGT
301	AAACTAGAGA AAGACAAGC TTCAGTCTTT CAAGAAAAAA AGCCACTCCC	301 AAACTAGAGA AAGACAAGC TTCAGTCTTT CAAGAAAAAA AGCCACTCCC
351	TGAAGAAAAA AAACTAATCC CTGAAGAAGA AAGATACGTT TCTGAAGAAA	351 TGAAGAAAAA AAACTAATCC CTGAAGAAGA AAGATACGTT TCTGAAGAAA

401 AAAAGCCACT CCTAGAAGAA AAAAAGCCAA CCCCTGAAGA CAAAAAGCTA  
451 CTCCAGAGG CAAAACATC AGCCCCAGAA GAACAGAAAC ATGACTTACT  
501 TAAATCTCAA GTACAAATTG CTGAAGAAAA GCTTGAAGGC AGAGTGGCTC  
551 CAAAGACAGT GCAAGAAGG AACAACACC AGACCAAGT GGAAGGTTTA  
601 CCATCTGGCA CACCTCAGAG TTATCTTAA GNAGATGATA AGACAACCAA  
651 AACAAATAAA GAACAGCCAC AGCCACCATG CACAGCAAAA CTTGATCAGG  
701 TGGAACTTGG GAAAGAAAA ACAGAAAAAGG AAGATGACAA ATCAGACACC  
751 TCAAGTTCTC AGCAGCCTAA RAGCCCCCA GGTCTGAGG ACAGGGATA  
801 TTCTTCCGAT GGAATATCAA GCTCACTTGG TGAATTTCCA AGTCTTATTTC  
851 CAACTGATGA AAGGATATT CTCAGGGAC TCNAAAAGGA CTCTTTTTCA  
901 CAAGAAAGCA GCCCTTCCAG CCCCTCAGAT TTGGCTAAGT TAGAAAGTAC  
951 AGTCCTATCT ATTTTGGAA GCTCAAGCAAG TACACTTTGCT GATGAAAAAGT  
1001 CAGAAAAGAA AACACAACC CATGAAGTTT CTCCTGAACA GCCTAAAGAC  
1051 CAAGAGAAAA CTCAGAGTTT ATCTGAAACC TTGGAATTTA CTAATTTAGA  
1101 AGAGGAGATC AAGAGAGTC AAGAAGAAAG GAAAGACACT TTTAAAAAAG  
1151 ATAGCCAACA AGATAATTCT TCCAGCAAGG ACCATAAAGA GAACTCTGAG  
1201 TTTGTTGATG ACATACTAC TAGAAGAGAG CCTTATGATT CAGTTGAAGA  
1251 GAGTAGTGA AGTGAAAACT CACCTGTGTTCC ACNAAAGAAA CGAAGAACTA  
1301 GTGTTGGCTC ATCAAGCAGT GATGAGTATA AACAGGAAGA CAGCCAAAGGA  
1351 TCAGGGGAAG AGGAGGACTT CATTGAAAA CAATCATAG AATGAGTGC  
1401 TGATGAAGAT GCTTCAAGTT CTGAAGATGA TGAGTTTCATC AGNAAACCAGC  
1451 TCAAGAGAT TAGTAGCAGT ACTGAGAGCC AGAAGAAAGGA AGNAAACAAAG  
1501 GGAAGAGGCA AATATACAGC AGGGAACAC AGCAGCTGA CTCGAAAAAG  
1551 TAGCACAAGC ATTGATGAAG ATGCAGGAAG ACGTCACTCA TGGCATGATG  
1601 AAGACGATGA AGCATTTGAT GAAAGTCCTG AACTTAAATA CAGAGAACT  
1651 AAAAGTCAGG AAGTGAAGA ACTTGATGTT ACTGGAGGAG GAGGGCTACG  
1701 CCGATTTAAA ACAATTGAGC TCNACAGTAC AATAGCAGAT AATATTTCTG  
1751 CAGAGTCATC ACAGAAAAAA ACAAGTTTGT ATTTTGACGA AGAGCCAGAA  
1801 TTGGAATGG AAGCCTGAC AGACTCACT GAAGATAGGT CAAAGGGAGA  
1851 GGGATCTTGG AGTCTGCATG CTTCCAGCTT CACTCTGGT ACATCCCTTA  
1901 CATCAGTATC ATCAGTTGAT GAGGACAGTG ACAGTAGCCC GAGTCACAAA  
1951 AAGGAGAGA GMAACAGCA AGGAAAGCT CGGCACAGAC CACATGGCCC  
2001 TCTTTTGCCT ACTATTGAAG ATTCTTCAGA GGAAGAAAGAA TTGAGAGAGG  
2051 AAGAAGAAAT ATTAAAGGAG CAAGAAAAAGC AGAGGGAAT AGAACAGCAA  
2101 CAAAGAAAGA GTTCTAGTAA AATATCAAG AAGACAAAG ATGAATCTTG  
2151 AGCTCAGAGA AGAAGGGAAG GGCNAAAGC ACCACCTAGT AATCTCTCTC  
2201 CCATTGAAGA TGCATCTCG ACAGAAGAGT TACGTCAGGC TGCAGAAATG

2251 GAGGAGCTCC ATGATCTTC TTGTTCTGAA TATTCACCTA GCATAGAGTC  
2301 AGACCAGAA GGTTTTGAAA TAAGCCGGGA AAAAAATAA GAAGTACAAA  
2351 AAGTTTATAA ATTGCCACA GCTGTTTCAT TATACTCACC AACAGATGAG  
2401 CAACTATTAA TGCAGAAAGA AGGTAGCAA AAGGCGTTAA AAGTGCTGA  
2451 GGAGATGTTAT GAAGAAATGA TGCATAAAAC ACACAATATC AAGCTTTTC  
2501 CAGCTCAAA TGAACGAGAT GAAGTGTGTTG AAAAAAGACC TTTGTATGTT  
2551 GGGATGCTAA TAGAGGATTA TATTTATGAA TCTTTAGTAG AAGACACGTA  
2601 CAATGGATCG GTAGATGGCA GTCTGTAAAC AAGGCAAGAA GAAGAAAATG  
2651 GATTTATGCA GCAGAAAGGA AGAGAGCAAA AGATAAGACT TTCAGAACAG  
2701 ATTTATGAAG ATCCTATGCA GAAAATTTACA GACCTCCAGA NAGGTTTTTA  
2751 TGAGTTAGAA AGCTTACATT CTGTTGTGCC TCAGGAAGAT ATTGTTTCAA  
2801 GCTCTTTTAT CATCCAGAA AGCCATGAGA TAGTGGACCT GGGTACTATG  
2851 GTAACCTTCTA CAGAAGAGA AAGGAAACTA CTAGATGCTG ATGCTGCTTA  
2901 TGAAGAACTT ATGAAGAGGC AACAGATGCA ATTAACACCT GGAATCTAGC  
2951 CRACCCAGGC CCCCATTTGT GAGGATATGA CAGAGTCCAC CATGGACTTT  
3001 GACAGAATGC CAGATGCTCT TTTGACATCA AGTGTCTCT CAGGAGCGTC  
3051 TCTTACAGAT TCGACCAGCA GTGCAACACT CTCTATCCCA GATGTTAAAA  
3101 TRACCCAACA TTTTTCACAA GAAGAAATG AGGATGAATA TGTAAACCGAT  
3151 TATACAAGAG AATTTCAAGA GATAATTTGCC CATGAATCGC TGATTTTGAC  
3201 CTACTCGAG CTTTCAGAAA GTGCTACATC TGTCCCAACC TCTGACACAC  
3251 CTCTCTCAC ATCATCTGTT TCTTCGGTCT GTACCACAGA TAGCTCTTCA  
3301 CCATTTACTA CCTCGATAG CATAACCCACA GTTTATACAG AGCCAGTGA  
3351 CATGATAACT AATTTGAAG ATTCTGAGGA AATTTCTTCA TCAACTTATT  
3401 TTCAGGCAG CATTATAGAC TATCCAGAAG AATAAGTGT ATCTTTAGAT  
3451 CGGACTGCCC CACCAGATGG TAGAGTAGT GCTGATCATA TTGTTATTTT  
3501 CTTATCTGAT ATGGCATCTT CTATCATAGA ATCTGTAGTA CCTAAACCTG  
3551 AAGGGCCAGT TGCTGACACT GTTTCTACTG ACTTACTTAT ATCTGAAAAG  
3601 GACCCAGTGA AGAAGCCCA GAAGNAACT GGGAAATGGA TCATTCTGGA  
3651 AGTTTGGAA GCTTACAGAG ATAAAAAGGA GTTGGAGGCC GAACGNACAA  
3701 AAGTAGCTT ATCCGAAACC GTGTTTGATC ACCACCTTC TTCTGTAAAT  
3751 GCCTTTCCAA TGAAGAGCA GCTTTCAACT ACATACTTTA CATCTGGAGA  
3801 GACCTTTGGT CAGGAAAAAC CTGCATCTCA GTTACCATCT GGCAGTCTCT  
3851 CTGTTTCTCT TCTCCAGCT AAACCTGGCC CATTCTTTAG AAGTTCTCTT  
3901 TTGATATAT CAGCTCAACC TCCTCCCCCT CCTCCCCCTC CCCCCTCTCC  
3951 TCCTCTCCA CCACCACCCC CTCTCTCCCC ACCACTTCTT CCACCACTT  
4001 CACCTAAACC AACTATTCTT CCTAAAAAAA AGTTAACAGT TGCATCTCCA

4051 GTGACTACAG CTACACCTCT GTTTGATGCT GTTACTACTC TAGAGACCAC  
4101 AGCTGTTCTG AGAAGTAATG GATTACTGTG TACAAGAATA TGTACTACTG  
4151 CACCTCCTCC TGTTCCTCTC AAGCCATCTT CAATTCCATC TGGACTTGTA  
4201 TTTACCCACA GGCCTGAGCC AAGCAAACTT CCAATCGCCC CCAAAACCAAT  
4251 GATTCCTCAG TTTCOAACAA CTACACAAA ACCAACAGAT ATACACCCCA  
4301 AACCAACAGG CCTATCTTTA ACTTCAAGTA TGACCTTAAA TTTAGTGACT  
4351 TCAGCAGATT ATAAATTGCC TTCCCTTACC TCCCACCTTT CCCACACTC  
4401 CAACAAGTCT TCACCAAGAT TTTCCAAATC CCTCACAGAA ACTTATGTAG  
4451 TTATTACATT GCCATCTGAA CCAGGGACTC CAACAGATT CTTCTGCTAGT  
4501 CAAGCAATTA CAGTTGGCC CTGCGGATCA CCTCCAAAG ATCTGGTTTC  
4551 TGTGAACTT GTGTTTCTG TAGTTCCTCC TGTGACAGCT ATGAGAAATTC  
4601 CAATTTCCTC AGAACAGACC TTCTACATCT CTGGAGCTTT ACAGACATTT  
4651 TCTGTACCC CTGTCACAGC ACCCTCTTCA TTTCAAGCAG CTCGCCATFC  
4701 AGTTACACAG TTTCTCACTA CTGAAGTTTC CAAGACTGAG GTTTCAGCAA  
4751 CCAGAAGTAC AGCTCCTAGT GTTGGTCTCA GCAGCATTTT CATACAAAT  
4801 CTTCCAGAGC CTCTGCTCT AGATAACATA CATTTAGAGA AGCCTCAGTA  
4851 TAAAGAAGAT GGAATAATGC AACTTGTGTTG TGAATGTAAT GATTTCGGTA  
4901 CAGTACCAA GGTAGAACTT AAAACAACATG ATAAATGTAT TGATCTTCT  
4951 GCTTCTACAA TGGATGTGAA AAGCAGATC ACAGCAAATG AAGTTTATGG  
5001 GAAACAAATT AGTGTGTGCC AACCCTCTAT TATAATCTT AGTGTGACAT  
5051 CATCAATAGT GACTCTCTGA TCTCTGGCCA CTGAGACAGT GACCTTTGTC  
5101 ACATGCACAG CTAGTGCAAG TTACACTACA GGCACAGAAA GCCTAGTGGG  
5151 TGCAGAACAT GCAATGACAA CACCCTCCA ACTTACAACA TCAAAAGCATG  
5201 CTGAGCCCC ATACAGGATA CCAAGTGACC AGGTCTTTCC TATAGCTAGG  
5251 GAAAGAGCAC CAATAAACTT ATCTCTAGGT ACTCCAGCAC ATGCAAGTAC  
5301 ATTGCTATT ACAAAACCTG TCACTGTGCC TCTGTGTGGT GTCAAAAATG  
5351 GATGGACTGA TAGCACCCTA TCCAGGGAA TCACTGATGG GGAAGTAGTG  
5401 GATCTCAGTA CAACCAAGTC TCACAGAAC A GTCGTAAACAA TGGATGAGTC  
5451 TACTTCAAGT GTGATGACCA AAATAATAGA AGATGAAAAA CCGCTTGATT  
5501 TAACCGCAGG GAGAGAGCT GTGTGCTGTG ATGTGTTTTA TAATTACCA  
5551 TTTGGAAGGA GCTGCACAGC ACAGAGCCTT GCAACTPACTC TTCTTGAGGA  
5601 TCGTTTTGTT TATAGGGATG ACCACTATCA GTATGATGGA TCAGGGCCAT  
5651 ATGGTTATAG AGGATTTGGG GGAATGAGC CTTCCATGTC TGACACAAAT  
5701 TPAGCAGAAG CTGACATTTT TTTCTATAA AGTAAGAATG CTTTGTGATTA  
5751 TTCTGAAGGA ACTGACACAG CAGTAGATCT GACTTCAGGG AGAGTTACTA  
5801 CAGGTGAGGT AATGGATTAT TCAGCAGAGA CTACAGGTCC ATATCCAGAA  
5851 ACACGACAAG TCATTTTCAGG AGCTGGGATT AGTACCCAC AGTATTCAC

5901 AGCAAGAATG ACACCACCAC CAGGACCCCA GTATTGTGTG GGGAGTGTTC  
5951 TCAGGTCTATC TAATGGTGTG GTCTATTCTT CAGTAGCAAC TCCAACACCC  
6001 TCTACATTTG CTATCACCAC ACAACCTGGC TCCATTTTCA GCACCACAGT  
6051 GAGGATTTG TCTGTTATTC ATACGGCTGA TGCAGTGACT TCATTTACCTG  
6101 CCATGCACCA TAGCCAGCCA ATGCTAGAT CATATTTTAT AACAAACAGT  
6151 GCATCTGAAA CCGACATTCG AGTAACCTGGT ATTGATATCA GTGCCAGTTT  
6201 GCAAACTATT ACTATGGAGT CTCTTACTGC TGAGACGATA GACTCTGTTC  
6251 CCACCTTTAA CACAGCATCC GAAGTGTTC CTGAAGTGTG GGGAGATGAA  
6301 AGTGTCTTTT TAATTTGTCG TGAAGAAGAT AAACAACAGC AGCAGCTAGA  
6351 CTTGGAGCGT GAGCTCCTGG AACTGGAGAA AATTAAGCAA CAGCGCTTTG  
6401 CTGAGGAATT GGAGTGGGAA CGTCAGGAAA TTCAAAGGTT CCGAGAACAA  
6451 GAAAAGATCA TGGTTTCAGAA AAAGTTGGAG GAGCTGCACT CTATGAAGCA  
6501 ACACCTTCTC TTTCAGCAAG AAGAAGAGCG GCAAGCCCAG TTTATGATGA  
6551 GGCAGGAGAC GTTAGCTCAG CAACAGTTAC AGCTTGAGCA GATCCAACAG  
6601 CTGCAACAA CAGTTTCACCA GCAGCTGGAG GAGCAAAAAG TTCGGCAGAT  
6651 CTACCAGTAT AACTATGACC CTTCTGGAAC TGCTTCTCCA CAAACCACTA  
6701 CAGACGAGC AATTTTGAA GGTCACTATG CTGCTCTGGA AGGCAGTCAA  
6751 TTTTGGGCAA CTGAAGATGC AACCACCACA GCTTCAGCTG TTGTGGCAAT  
6801 TGAATATCCA CAAAGCCAAG GATGTTACAC CGTTCAGTCT GATGTTGTTA  
6851 CTCAGTACAT TGCCCCACCT GGTATCCTGA GCATCTGTTT AGAAATACCT  
6901 CTAACAGATG TTGTTGTGAA AGAGGAAAAA CAACCCAAAA AGAGAAGTTC  
6951 TGGAGCTAAA GTCCGAGGAC AGTATGATGA CATGGGAGAA AATATGACAG  
7001 ATGATCCCCG AAGTTTAAA AAGATAGTG ACAGTGGTGT ACNACGGAT  
7051 GACGAAGATG CCACAGATCG GAGCTATGTG AGTAGGAGAA GGAGAACTAA  
7101 AAAGAGTGTG GATACAAAGC TCCAAACTGA TGATGAAGAT CAGGATGAGT  
7151 GGGATATGCC TACTAGATCA AGGAGGAAAG CTCGTGTAGG GAAATATGGT  
7201 GACAGCATGA CAGAGGCTGA CAAGACCAA CCCCTTTTCCA AAGTCTCCAG  
7251 CATAGCAGTT CAAACGGTAG CAGAGATATC TGTGCAAACT GAACCACTG  
7301 GAACCATTAAG AACACCTCC ATACGGGCAC GAGTGGATGC CAAGGTAGAA  
7351 ATAATTAAAC ACATTTGAGC ACTTGAAAA AGTTACAAAG GGGGAGGTTT  
7401 AGGATGTCAA ACAGAAGCAG ATTCAGACAC ACAAACTCTT CAATATCTGA  
7451 GTGCCACATC TCCACCCAAA GACAAGAAC GCCCAACACC TTTAGAGATT  
7501 GGTATTTCAT CTCACCTCCG GGCAGATTCC ACAGTACAGC TGGCTCTCTC  
7551 CCCACCCAAA TCCCCAAAAG TCCTTTACTC ACCCATCTCA CCACTTTTAC  
7601 CAGGCAAGC CTTAGATCA GCCTTTGTAC CTTATGAAAA ACCCTCCCT  
7651 GATGATATAA GTCCACAGAA AGTACTGCAT CCAGATATGG CTNAAAGTTC

7701 CCCAGCAAGT CCTAAGACAG CCAAGATGAT GCAGGTTCT ATGCTGTGACC  
7751 CCAAGCCTCT GAGTCAACA CGACAGGAAA GTTCCAGGGC TCCTTTTCAG  
7801 TATACCGAGG GCTATACGAC TAAAGGTTCT CAACACCATGA CAPCTCTGTG  
7851 AGCCAGAAA AAGTTAAAA GAACCTCTGC AATCCACCT CCTGAGGAGA  
7901 TTTCACAGG AACTCAATCC ACAITTCAGCA CAATGGGAC AGTTTCAGG  
7951 AGAAGGATCT CGACAAACCAA CACAATGGCA CGAGCCAAAGA TTCTCCAGGA  
8001 CATAGACAGA GAGCTTGATC TTGTGGAAG GAGTCTGCA AAACCTTCGAA  
8051 AGAACAAAGC AGAGCTTGAT GAAGAAGAAA AGGAGATTGA TGCTAAGCTA  
8101 CGATACCTGG AAATGGGAAT TAACAGGAGG AAGAGGCCCC TATTAAGGA  
8151 GAGAGAAAAG AGAGAACGAG CCTACTCCA GGGAGTAGCT GAGGATCGTG  
8201 ATTACATGTC TGCAGTGAA GTGAGTAGCA CAAGACCAAC CCGAATAGAA  
8251 AGTCAGCATG GCATTGAGCG ACCAAGAAT GCTCCCCAAA CTGAATTCAG  
8301 CCAGTTTATA CCACCACAAA CCCAAACAGA ATCTCAACTA GTTCTCTCGA  
8351 CAAGTCCTTA CACACAATAC CAGTACTCTT CCCCTGCTCT TCTACCCAA  
8401 GCACCCACCT CATACACTCA ACAGTCTCAT TTTGAGCAAC AAACCTTTGTA  
8451 CCATCAGCAA GTTTCACCTT ATCAGACTCA GCCAACATTC CAAAGTGTGG  
8501 CAACAATGTC CTTACACACT CAAAGTTCAC CTACACCAAC CCACAGCCT  
8551 TCTTATCAGT TACCTTCACA GATGATGGT ATACAACAGA AGCCACGGCA  
8601 AACTACATTA TATTTGGAGC CCAAGATAAC CTCAAACTAT GAAGTGATTC  
8651 GCACCAACCC CTTTATGATA GCACCTGTTT CTACGGATAA CACATTTGCT  
8701 GTTTCCCATC TTGGTAGTAA GTACAATAGT TTAGACTTGA GAATAGTTT  
8751 GGAGGAAAGA AGTAGCATGG CAAGCAGTCC AATATCAAGC ATATCTGCAG  
8801 ATTCCTTTCTA TGCAGATATT GATCACCATA CTCACAGAAA TTATGTCTTA  
8851 ATTGACGACA TTGGAGAGAT CACCAAAGGA ACAGCGGCAT TAAGCACCGC  
8901 ATTTAGCCTT CATGAAAAGG ATCTGTCAA AACAGACCGT CTCCTTCGAA  
8951 CCACTGAGAC ACCTCGGTCT CAAGAA

!AA\_SEQUENCE 1.0  
ID -ADP31433 standard; protein; 450 AA.  
XX  
AC ADP31433;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2200.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR

29-AUG-2002; 2002US-0406579P.  
PR  
29-AUG-2002; 2002US-0406585P.  
PR  
29-AUG-2002; 2002US-0406588P.  
PR  
29-AUG-2002; 2002US-0406608P.  
PR  
29-AUG-2002; 2002US-0406611P.  
PR  
29-AUG-2002; 2002US-0406612P.  
PR  
29-AUG-2002; 2002US-0406616P.  
PR  
29-AUG-2002; 2002US-0406640P.  
PR  
29-AUG-2002; 2002US-0406642P.  
PR  
29-AUG-2002; 2002US-0406646P.  
PR  
29-AUG-2002; 2002US-0406653P.  
PR  
29-AUG-2002; 2002US-0406655P.  
PR  
29-AUG-2002; 2002US-0406666P.  
PR  
17-SEP-2002; 2002US-0410946P.  
PR  
17-SEP-2002; 2002US-0410947P.  
PR  
17-SEP-2002; 2002US-0410948P.  
PR  
17-SEP-2002; 2002US-0410949P.  
PR  
17-SEP-2002; 2002US-0410953P.  
PR  
17-SEP-2002; 2002US-0410957P.  
PR  
17-SEP-2002; 2002US-0410958P.  
PR  
17-SEP-2002; 2002US-0410959P.  
PR  
17-SEP-2002; 2002US-0410960P.  
PR  
17-SEP-2002; 2002US-0410961P.  
PR  
17-SEP-2002; 2002US-0410962P.  
PR  
17-SEP-2002; 2002US-0411019P.  
PR  
17-SEP-2002; 2002US-0411022P.  
PR  
17-SEP-2002; 2002US-0411023P.  
PR  
17-SEP-2002; 2002US-0411024P.  
PR  
17-SEP-2002; 2002US-0411032P.  
PR  
17-SEP-2002; 2002US-0411035P.  
PR  
17-SEP-2002; 2002US-0411037P.  
PR  
17-SEP-2002; 2002US-0411041P.  
PR  
17-SEP-2002; 2002US-0411045P.  
PR  
17-SEP-2002; 2002US-0411046P.  
PR  
17-SEP-2002; 2002US-0411048P.  
PR  
17-SEP-2002; 2002US-0411052P.  
PR  
17-SEP-2002; 2002US-0411055P.  
PR  
17-SEP-2002; 2002US-0411073P.  
PR  
17-SEP-2002; 2002US-0411082P.  
PR  
17-SEP-2002; 2002US-0411101P.  
PR  
17-SEP-2002; 2002US-0411111P.  
PR  
18-APR-2003; 2003US-0463700P.  
PR  
18-APR-2003; 2003US-0463708P.  
PR  
18-APR-2003; 2003US-0463716P.  
PR  
18-APR-2003; 2003US-0463732P.  
PR  
02-MAY-2003; 2003US-0467199P.  
PR  
02-MAY-2003; 2003US-0467201P.  
PR  
02-MAY-2003; 2003US-0467203P.  
PR  
02-MAY-2003; 2003US-0467230P.  
PR  
19-MAY-2003; 2003US-0471306P.  
PR  
19-MAY-2003; 2003US-0471336P.  
PR  
22-MAY-2003; 2003US-0472420P.  
PR  
22-MAY-2003; 2003US-0472430P.  
PR  
09-JUN-2003; 2003US-0476609P.  
PR  
09-JUN-2003; 2003US-0476641P.  
PR  
08-JUL-2003; 2003US-0485218P.  
PR  
08-JUL-2003; 2003US-0485223P.  
PR  
08-JUL-2003; 2003US-0485224P.  
PR  
08-JUL-2003; 2003US-0485325P.  
PR  
14-JUL-2003; 2003US-0486446P.  
PR  
14-JUL-2003; 2003US-0486480P.  
PR  
15-JUL-2003; 2003US-0486891P.  
PR  
15-JUL-2003; 2003US-0486960P.  
PR  
08-AUG-2003; 2003US-0493341P.  
PR  
08-AUG-2003; 2003US-0493370P.  
PR  
08-AUG-2003; 2003US-0493573P.  
PR  
08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3431; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 450 AA;  
ADP31433 Length: 450 February 22, 2005 12:25 Type: P Check: 8464 ..  
1 ATGGGCCAGG AGTGAATGA AGGAAGTGC TGGGAGGAAT TTGAGATGTC  
51 CCAGATCTCA GCCCTACCAC GCCTTCTGAA AGAGGAAAAA GAATTCCTCC  
101 CGGACCCCGC CCTAACACC AGTCACCTCT TGTGGGATGC TCCTCATTC  
151 ATTCTGTGCC ACGCAGACGC GAGTTTCTGT AGAGTTGTAA CCACATATA  
201 CATGCAGGCC CAAGGTACCA GGAGGCAGAT GCTGACAGAT GCATCTCAGT  
251 ATGCCCGGCA CTCCACCAC ACAAGGCTG TGCTGGTTGC TGTGGGAATG  
301 CTGCAGGCGA CAAACGGAT AATCTCGAG GGNAGAGACA GCAACACAA  
351 GGCTCAAGAA ACTCCAGTAT GTAAGAAGAG GACATCACA ATGGAAGAGG  
401 GAAGCCACCA TGCAGATGT CGGGTGCAC TTTTAAATGG GACATCAAG  
!!AA SEQUENCE 1.0  
ID ADP31438 standard; protein; 675 AA.  
XX  
AC ADP31438;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2205.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.

PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MW, Kochakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3436; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The





CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPoWEB and is not in the specification.  
XX  
SQ Sequence 240 AA;  
ADP31475 Length: 240 February 22, 2005 12:25 Type: P Check: 1185 ..  
1 ATGGTCTCTGC TCCCTGTCTCA GAACGTTTCAG ATGAACACCAA CGCACACTGG  
51 ACCACCGTGC CTGCAGCCCA AGTTCTGGGC TGCTTACCTG GTGTCCTTCA  
101 GGGCTGCATA CTTGTGTGCC TGCAGGGCTG TGTACCTGGT GTCCTGCAGG  
151 GCTGTGTACT TAGTGTCTCA CAGGGCTGCT TACCTGGTGT CTTGCAGGGC  
201 TGCTTACATT GCAAAACAGT TAGATGCTGA CACACCATGA  
!!AA SEQUENCE 1.0  
ID ADP31490 standard; protein; 171 AA.  
AC ADP31490;  
DT  
DT  
XX  
XX 12-AUG-2004 (first entry)  
DE Human secreted protein SEQ ID #2257.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410944P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3488; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPoWEB and is not in the specification.  
XX  
SQ Sequence 171 AA;  
ADP31490 Length: 171 February 22, 2005 12:25 Type: P Check: 3147 ..  
1 ATGTGTGTCC AGACCTCTG GGCATCTCAG ATTCTACAG TCCCTCTG  
51 CCGGCCCCCT CAGCTCCCC ACCACGGCA GTGGCCACTG TGTCCATCTG  
101 GAGCCAGCC TCAGATCCC CTTTGCCTGA GCGCAGCGG GCTGGGCTGG  
151 TGGCCTCAGG GCGCTCTCTG A  
!!AA SEQUENCE 1.0  
ID ADP31611 standard; protein; 1472 AA.  
XX  
XX AC ADP31611;

XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #2378.  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406577P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.

PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnenann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3609; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1472 AA;  
ADP31611 Length: 1472 February 22, 2005 12:25 Type: P Check: 6702 ..  
1 CTTTAAACACC TCCCGGTGCA GGCATGCTTG GGTTCCTAC TTCAGTACT  
51 TCGTCTCCTG CCCTGTCTCT CAGCAGTGCC CCCACCAAAAC CTTTGCTGCA  
101 GACTCCACCA CCTCCACCAC CTCCTCCTCC TCCTCCTCT TCATCCTCTC  
151 TGTCAAGACA GCAGACCCGAG CAACAGACA AAGATCTGA GAAAAGCAA  
201 ACTAAGCCAA ACAAGGTGAA AAAAATCAA GAGGAGGAAT TAGAGGCCAC  
251 CAAACCCGAA AAACACCCCA AAAAAGAGGA AAAAATCTCA TCTGCTCTTT  
301 CAGTGTGGG CAAAGTTGTA GGTGAACAC ATGTCGATCC TATTCAGTTG  
351 CAGGCATTAC AGAATGCAAT TGCTGGTGAC CCAGCTTCTCT TTATAGGCGG  
401 ACAGTCTTGG CCATACTTTA TCCCTGGGTT TGCTTCTTAT TTTACACCTC  
451 AGTCCCTGG AACAGTGCAG GGGGGTACT TCCACCTGT CTGTGGCATG  
501 GAGAGCCTCT TTCTTATGG CCCTACAATG CCCACAGACAC TGGCAGGCTT  
551 GTCCCCAGGT GCATGTTGC AGCAGTACCA ACAGTATCAG CAGAACCTGC  
601 AGGAGTCCCT GCAAAGCAG CAAAAGCAAC AGCAAGNACA GCAGCAGAAA  
651 CCAGTTTCAGG CAAAGACATC CAAAGTAGAA AGTGACCAGC CGCAAAACTC  
701 CAACGATGCT TCAGAAACAA AGGAAGCAA AAGTACTGCT ACAGAAAGCA  
751 CAAAAGAAGA ACCCAGTTA GAATCCAAA GTGCAGACTT TTCAGACACT  
801 TACGTTGTTT CATTCGTCAA GTATGAGTTT ATATGCAGAA AGTGCCAGAT

851 GATGTTTACT GATGAAGAGG CCGCAGTAAA TCATCAAAAG TCCTTCTGTT  
901 ATTTCGGTCA GCTTTTGATT GACCACAAG AGACAGTGCT TCGTGTCCTCA  
951 GTGAGCAAT ATCAGTGCT TGCCTGTGAT GTGGCTATCA GTGGGAATGA  
1001 AGCACTTAGC CAACACCTCC AGTCAAGCTT GCACAAAGAG AAAACAATCA  
1051 AACAAGCAAT GAGAAATGCC AAAGAGCATG TTAGATTATT ACCTCACTCA  
1101 GTCTGCTCCC CTAATCCTAA CACCACATCT ACCTCGCAGT GTGACGCTTC  
1151 TTCTAATAAC ACCTATCTCT ATCTTTCTTG CTCTCTCAGT AGTCTCTGGC  
1201 CTAATATCTT TTTCGAAGG TCTGCCAGGA GAGCTGCTTC TCCCTCTTCT  
1251 TCTCTCTCTT CCCTTTCTCT GCCTTCAACG GTTACCTCAA GTTTGTGCAG  
1301 CACCTCAGGG GTTCAAACTT CACTACCAC AGAAAGTTGT TCAGATGAGT  
1351 CTGACAGTGA GCTGAGCCAG AAGCTAGAAG ACTTAGATAA TTCTTTGGAA  
1401 GTGAAGGCTA AGCCTGCTTC TGGCTAGAT GGTAATTTC AATGATCCG  
1451 AATGGATATG TTCAGTGTGT AG

!!AA SEQUENCE 1.0  
ID ADP31643 standard; protein; 300 AA.

XX ADP31643;

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2410.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 29-AUG-2002; 2002US-0406666P.

XX 17-SEP-2002; 2002US-0410946P.

XX 17-SEP-2002; 2002US-0410947P.

XX 17-SEP-2002; 2002US-0410948P.

XX 17-SEP-2002; 2002US-0410949P.

XX 17-SEP-2002; 2002US-0410953P.

XX 17-SEP-2002; 2002US-0410957P.

XX 17-SEP-2002; 2002US-0410958P.

XX 17-SEP-2002; 2002US-0410959P.

XX 17-SEP-2002; 2002US-0410960P.

XX 17-SEP-2002; 2002US-0410961P.

XX 17-SEP-2002; 2002US-0410962P.

XX 17-SEP-2002; 2002US-0411019P.

XX 17-SEP-2002; 2002US-0411022P.

PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 3641; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.

XX SQ Sequence 300 AA;

ADP31643 Length: 300 February 22, 2005 12:25 Type: P Check: 3052 ..

1 ATGGCTCTTG TGCAGGTGCA GGCACCCAGA GAAAAAGTGA AGCTACTGAT

51 CCTGTGAAGG GAGAATGAAT ATCTAGCAGA TGGACAGTGG GGAGCCACGA

101 CGTGGCTCGG CTTGCTCGTG CCAGAAATA GAGTTAAGCT GCTAACCCCTA  
151 GAGCTGCCT TGCAGCTGG CCATGCAGCT GTGCATGGGA GCCAGCTGCT  
201 TAGACGAGCT GAAGAGCCAG AGCAGGCAGC CGAGATAAAG CTGGGGCAGG  
251 AACCTGACCC TGAGCATGAC AACTGCTTAA AGGGAATCA TACTATATGA

!!AA SEQUENCE 1.0  
ID ADP30473 standard; protein; 1083 AA.

AC ADP30473;  
XX  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1240.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
XX  
PD 29-APR-2004.  
XX

PF 28-AUG-2003; 2003WO-US025780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406656P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.

18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Hsieh L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2471; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1083 AA;

ADP30473 Length: 1083 February 22, 2005 12:25 Type: P Check: 6643 ..

1 ATGTTGGCCA GGGCTTCTG CCTCTGGCG GTGGCCTTGG CGACCGAGT  
51 GAAGAAACCT GCAGCCACAG CAGCTCCTGG CACCGCAGAG AAGCTGAGCC  
101 CNAAGCAGC CAGCTGGCC GAACACAGG CCGGCCTGGC CTTACGCTTG  
151 TACCAAGCCA TGGCCAAGGA CCAGGCGGTG GAGAACATCC TGGTGTGCGC  
201 CGTGTGGTG GCTCGTCTGT TGGGCTCGT GTCGCTGGG GGCNAAGGCGA  
251 CCACGGCGTC GGAGCCCAAG GCAGTGTGA GTCCCAAGCA GCTGAGCGAC  
301 GAGGAGGTGC AGCGCGCGT GGGCAGCGG CTGCGTTTAC TCAGCAACTC  
351 CACCGCGCGC AACGTGACCT GGAAGCTGTG CAGTCGCCCT AGCAAGCAGC  
401 ACTACAACCTG CGAGCACTCC AAGATCAATT TCCATGACAA GCGCAGTGG  
451 CTGCACTCCA TCCAGAGTG GCGCGTGAG ACCACCGAGC GCAAGCTGCC  
501 CAAGGTCACC AAGGACATGG AGTGCATGGA TGGCGCCTG CTTGTCAACA

551 CCATGTTCTT CAAGCCACAC TGGAAATGAGA AATTCCACCA CAAGATGGTG  
601 GAAAACCGTG GTTTCATGGT GACTCGGTTT TATACCGTGG GTGTCATGGT  
651 GATGCACCG AGAGGCTCT ACACTACTA TGACAATGAG AAGGAAAGC  
701 TGCAATCGT GGAGATGCC CTGGCCACA AGCTCTCCAG CCTCATCATC  
751 CTCATGCCCC ACCACGTGGA GCCCTCGAG GCCTTAAAAA GTTGGCTTGG  
801 CCTGACTGAG GCCATTGACA AGACAAGGC AACTTGTCA CGCATGCCAC  
851 ACAGAAGGA CTGTACCTG ACCAGCGTG TCCAGGCCAC CGCCTTTGAG  
901 TTGGACACAG ACGGCAATC CTTTGACCAG GACATCTATG GGAGCAAGGA  
951 GCTGCGCAGC CCCAAGCTGT TCTACTCGA CCACCCCTTC ATCTTCCTGG  
1001 TGTGGGACAC CCAGAGCGC TCCCTGCTGT TCACTGGGCA CTTGTCGGG  
1051 CCTAAGTTG ACAAGATGCA AGACGAGTTT TAG

!!AA SEQUENCE 1.0  
ID ADP30487 standard; protein; 882 AA.  
XX  
AC ADP30487;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1254.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.

17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
02-MAY-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
08-JUL-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haisan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2485; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 882 AA;  
ADP30487 Length: 882 February 22, 2005 12:25 Type: P Check: 2343 ..  
1 ATGCCGCGCT TGTCTGTCT GTTGGCGCTG CTGCTTCTGC TGCTGCTGCC  
51 GCTGCTGCCG CCGCTGTCCC CGAGCCTTGG GATCCGCGAC GTGGCGCGCC  
101 GCGGCCCCAA GTGTGGTCCG TGCCGCGCCAG AGGGCTGCCC GCGGCTGCG  
151 CCTGCGCCGG CGCCCGGGAT CTCGGCGCTC GACGAGTGCG GCTGCTGCGC

201 CCGCTGCTG GAGCGCAGG GCGGAGCTG CGGGGCGCG GCGCGGGCG  
251 GCTGTGCCCC CGCCCTGGTA TCGGGAGCC AGGCGGCTGG GGCAGGCCCC  
301 GAGGCGACCG GGCTCTGGT GTGCGGCAG CGCGGCACCG TCTGCGGCTC  
351 CGACGGTGGC TCGTACCCCA GGGTCTGGC GCTGCGCTG CGCGCTCGGC  
401 ACAGCCCCG CGCGCACCC GGTCACTGC ACAAGGCGCG CGACGGCCCT  
451 TGCAGTTG TTTCTATCAC TCGTTTTTAT AACTGCTTTC CTCAGCGGTT  
501 AATTACACAG CAACTCTCTT TGTCTCCAGA CAGGAGACAG AGTGAGACCC  
551 TGTCTAAAA GAGAGAAG AGGAGGAGG AGGAGGAGGA GGAGGAGGAG  
601 GGGGAGGAG AGAAGAAGA AGAAGGATGC AAAAGCAATT TCCAACACAC  
651 CATTAACTTT AAGAAAATCT CAGAGGGATT TGGAAGATT TTTTCATTCC  
701 AGCATCAAT GATCGATATA ATTGACGAGA TCCACACAGT TAATAACACA  
751 GTCACATCCA TTTTCTCCCT TCACCCCCAAG GATCGGAGGC TGGGTCATC  
801 ATCTTCATTT GCAGATAAAA AGGAAATGAT TAGCAACTTG CCCAAGCTCA  
851 AGTGGTTGGC AGCGAGACCC CTGGGCATTT GA

!!AA SEQUENCE 1.0  
ID ADP30527 standard; protein; 701 AA.  
AC ADP30527;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1294.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.

PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 17-SEP-2002; 2002US-041111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-047420P.  
PR 22-MAY-2003; 2003US-047430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
PI Williams LT, Chu X, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2525; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 701 AA;  
SQ  
ADP30527 Length: 701 February 22, 2005 12:25 Type: P Check: 323 ..

1 GTGCCCCCGC GCGGGAGCTA CTGCGTGCTG GCGGCTGGC CCGCGGCGCT

51 GCAGATGGCC TACTTCTGCG AGCGGCTGG ACGGACTAC GCAGTGTTCG  
101 AGCGGGCCC GGGGCCGCG AGCTTCTTCA CAGCTACCC GGGCACCOC  
151 AGCTCATCA GCATCAACA GGGTACACG GCGAAGCTA ACGCGAGTT  
201 CAACCTCCGC CAGGACTGA ACTCTGTCT CAGCAGGAC CCGCGGCTGC  
251 TCTTCAGACA CTACTGGCT GCCTACTTCC CCGACGCCCG CGACATGGTG  
301 CGCTACTCGG GTGACTTGGC GGACACGCTG GGGCTCGTG TCCAGTACAA  
351 CACCACATC GCCCAGTCA CTCTGGACA GGCACCGAC GCGTGAATG  
401 GCCACTACTT CATCTAACT GACCAGAGG GCCAGGTGCA TCAGTGCAGC  
451 GTCTCTTTG TAGCCACTGG TTTATCAGTC CCCAACCCAGG TTGACTTCCC  
501 TGCTCTCGAA TATGAGAGG GTTAGAGTC CGTGTCCGTG GACCTGAGG  
551 ACTTTGTAGG CCAGAAATGT CTGATCTCTG GTCTGGGAA CTCGGCCTTT  
601 GAGACAGCAG AGAATCATCTT GGTGTACACA AACTTTATCC ATATGCTCAG  
651 CGCTCCCGG GTCCGTCTGT CCTGGGCCAC CCACTAGTT GGAGACCTCA  
701 G

!!AA SEQUENCE 1.0  
ID ADP30528 standard; protein; 626 AA.  
XX  
AC ADP30528;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1295.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406648P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.

17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE)- FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2526; 428bp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytosolic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 626 AA;  
ADP30528 Length: 626 February 22, 2005 12:25 Type: P Check: 8255 ..

1 GATATGGACC TTCTCAATT CTGTGGCCTTC CTCCTTTGTCA CAAGAAGATG

51 TTTGAGGTGA AGCGGGGGA GCAGCTGTTG GCACTGAAGA ACCTGGCACA  
101 GCTGAAGCAG ATCCACGAGC AGTACAGAT CTTGATGTC ATGCTCAAGG  
151 GGCTCTTTAA GFGCTGGAG GACTCCCGGA CAGTGCTCAC CGTGCTGAT  
201 GTGCTCCAG ATGGGCCCTT CCCCAGGAC GAGAAGCTGA AGGATGCTTT  
251 CTCCAGGTG GTGGAACA CGGCTTCTT CGGCGATGTG GTGCTGGCT  
301 TCCGAGGAT TGTGACTAT TACTTTGACC ACAACTCAA CTGGAACCTC  
351 CTCATCCGCT GGGGTATCAG TTTCTGCAAC CAGACAGCG TCTTCAACCA  
401 GGGGCCCCAC TCGCCATCC TCAGCTGAT GGGCAGGAG CTGGGATCA  
451 GTGAGAAGA CTCCACTTC CAGAACCCAT TTAAATCGA CCGCACAGAG  
501 TTTATTCCCA GCACCTACCC TTTCCAGGAG GCCCTGAGAG AAGAAGAGAA  
551 ACGCCGAAG AAGAGAGA ACGGGAAGGA GATCCGAAA GGGCCAGGA  
601 TCTCCAGATC CCACTCTGAG TTATAG

!!AA SEQUENCE 1.0  
ID\_ADP30565 standard; protein; 1478 AA.  
XX  
AC ADP30565;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1332.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.

17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0486466P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 2563; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPOWEB and is not in the specification.

SQ Sequence 1478 AA;

ADP30565 Length: 1478 February 22, 2005 12:25 Type: P Check: 8339 ..

1 TCTATGAAG TGGCATCAA AGCCACAGAT GGGGGAGGTC TTTCAGGAAA

51 GTGCACTCTT CTCCTGCAGG TGGTGGACGT GAATGACAAT CCCCCACAGG

101 TGACCATGTC TGCACCTACC AGCCCCATCC CAGAGAACTC GCCTGAGATA



151 GTAGTTGCTG TTTTCAGCGT TTCAGATCCT GACTCCGGAA ACAATGGGAA  
201 GACGATTTCC TCCATCCAGG AAGACCTTCC CTTTCTTCTA AAACCTTCAG  
251 TCAAGAACTT TTACACCTTG GTAACGGAGA GAGCACTCGA CAGAGAAGCA  
301 AGAGTCACT GGACAGAG AGCAAGCTG AGTACACAT CACCATCACC  
351 GTCACGTACT TGGGACACC CAGGCTGAAA ACCGAGCACA GCATAACCTT  
401 GCAGGTCTCC GACGTCAATG ACAAGCCCC CGCTTTCACC CAAACTCTCT  
451 ACACCTCTGT CGTCCGGAG AACACAGCC CGCCCTGCA CATCGCGAGT  
501 GTCAGCGCCA CAGACAGAGA CTCAGGCACC AAGCCCCAGG TCACCTACTC  
551 GCTGTGCGC CCCAGGACC CACACCTGCC CCTCGCCTCC CTGCTCTCCA  
601 TCACCGCGA CNAATGCCAC CTGTTTGCC TCAGGTGCTT GGACTACGAG  
651 GCCCTGACG CTTTCGACTT CCGCGTGGC GCCTCAGACC GCGGCTCCCC  
701 GCGTTTGAGC AGCAGGCGC TGTGCGGCT ACTGCTGCTG GAGGCCAAGG  
751 ACAACTCGCC CTTCTGTGTG TACCCGTGTC AGAACGGCTC CGCGCCCTGC  
801 ACCGAGCTGG TGCCCCGGC GCGCGAGCCG GGCTACTCTG TGACCAAGGT  
851 GGTGGCGGTG GACGGGACT CGGCCAGAA CGCTCTCTGC TCGGCCACCG  
901 TGTCTAAGGC CACGAGGCC GGGCTGTTCG GTGTGTGGG GCACAATGGG  
951 GAGGTGCGCA CGCCAGGCT GCTGAGCGAG CGCGAGCGAG CCAAGCACAG  
1001 GCTGTGTGTG CTTGTCAAG ACRATGCGA GCCTCTCTGC TCGGCCACCG  
1051 CCACGTGCA CGTGCTCTG GTGACGGCT TCTCCAGCC CTACCTGCTT  
1101 CTCGCGAGG CGGCCCGGC CAGGCCCCAG CGCGACTTGC TCACCGTCTA  
1151 CTTGTGTGTG GGTGTGGCT CGGTGTCTT CTTCTTCTTC CTCTCGGTGC  
1201 TCTGTTCGT GCGGTGCGG CTGTGCAAG GAGCAGGGC GGCCTCGGTG  
1251 GGTGCTGTCT CGGTGCCGA GGGTCTCTTT CCAGGCGATC TGGTGGAGCT  
1301 GAGCGGCACC GGGACCTGT TCCAGAGCTA CCAGTACGAG GTGTGCTCTA  
1351 CTGGAGTTT AGAGACGGC GAGTTCAGT TCTTGAAGCC GATTACCCCC  
1401 CACCTCCCCC CCCATAGGG TGGAAAGAA ATAGAGGAAA ATTCTACTCT  
1451 CCCCAATAGC TTTGGATTTA ATTATTGA

!!AA\_SEQUENCE 1.0

ID ADP30574 standard; protein; 1099 AA.

XX

XX

AC ADP30574;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1341.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

XX WO2004035732-A2.

PN

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

XX

PI

29-AUG-2002; 2002US-0406576P.  
29-AUG-2002; 2002US-0406579P.  
29-AUG-2002; 2002US-0406585P.  
29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411011P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2572; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1099 AA;  
ADP30574 Length: 1099 February 22, 2005 12:25 Type: P Check: 6607 ..  
1 CTGCTGCTCA GCAAAGTGA CAAAGTGAGC CGGCACCGTC GCCTGCTGAC  
51 ACCGCGCTTC CACTTTGACA TCTGAAGCC TTACATGAG ATCTTCAACC  
101 AGAGCGCTGA CATTATGCAT GCTAAATGGC GGCATCTGGC AGAGGGCTCA  
151 GCGGTCTCCC TTGATATGTT TGAGCATATC AGCCTCATGA CCCTGGACAG  
201 TCTTCAGAAA TGTGCTTCA GCTCAACAG CAACTGCCAA GAGAAATGA  
251 GTGATTATAT CTCGCTATC ATTGAACCTGA GCGTCTGTCT TGTCCGCGCC  
301 CAGTATCGCT TGCACCACTA CCTGACATTC ATTTACTACC GCTCGGCGGA  
351 TGGCGGAGG TTCCGGGAGG CTTGTGACAT GGTGCACCAC TTCACCACTG  
401 AAGTCAATCCA GGAACGGCGG CGGGCACTGC GTACAGAGGG GGGCGAGGCC  
451 TGGCTTAAGG CCAAGCAGGG GAAGACCTTG GACTTTATTG ATGTGCTGCT  
501 CTGGCCAGG AGTCAAGAC ACAACATCCA GTGGATCTCT TTGGATGCTG  
551 TTCAATTTGG CAAAGTATCC GGAATACCAG GAGAAATGCC GAGAAGAGAT  
601 TCAGGAAGTC ATGAAGGCC GGGAGCTGGA GGAGCTGGAG TGGGACGATC  
651 TGACTCAGCT GCCCTTACA ACTATGTGGA TTAAGGAGAG CTGCGGCCAG  
701 TACCCACCTG TCACCTTTGT CTCTCGCCAA TGCACGGAGG ACATCAAGCT  
751 CCCAGATGGG CCTTTCCCA CAGGAATCAT CTGCTTGTCT AGCATCTATG  
801 GAACCCACCA CAACCCACA GTGTGGCTGT ACTCCAAGGT GTACACCCCC  
851 TACCGCTTTG ACCCGGACAA CCCACAGCAG CGCTCTCCAC TGGCCTATGT  
901 GCCCTTCTCT GCAGGACCCA GGAATTGCAT CGGACAGAGC TTCGCCATGG  
951 CCGAGTTGGC CGTGGTTGTG GCACTAACAC TGTACGTTT CCGCCTGAGC  
1001 GTGGACCGAA CGCGCAAGGT CGCGGGGAAG CCGGAGCTCA TACTGGCCAC  
1051 GGAGAACGGG CTCTGGCTCA AGGTGGAGCC GCTGCCCTCG CGGGCCTGA  
!!AA SEQUENCE 1.0  
ID ADP30601 standard; protein; 879 AA.  
XX  
AC ADP30601;  
XX

DT 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1368.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 02-MAY-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 22-MAY-2003; 2003US-0472430P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 09-JUN-2003; 2003US-0476641P.  
XX 08-JUL-2003; 2003US-0485218P.  
XX 08-JUL-2003; 2003US-0485223P.

PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2599; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antitumour, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 879 AA;  
SQ  
ADP30601 Length: 879 February 22, 2005 12:25 Type: P Check: 8766 ..  
1 ATGCAGAGGA GACACAGAGC CGGGGGGCGCA AGAGGACGAT CGGGCGCGTG  
51 CACGAGGGC GGGAGGGCAT GGAGGCTGCC CGGCGCTTGC GCTCTCTGCT  
101 CGTGTGTGC GGCTGCCCTG CGTCCCGCC GGTGCCGAGC CGGTGTGCC  
151 GGAGCGCTGC GACTGCCAGC ATCCCCAGCA TCTCTGTGTC ACCAACAGGG  
201 GGCTCGGCT AGTGCCCAAG ACCAGCTGCG TGCCGAGCCC CCACAGCTG  
251 CTCACCTACA GCCTGGCGGG CAATTCATA ACCAACATCA CGGCTTCTGA  
301 CTTCCACCGT CTGGGGCAGC TCAGACGGCT GGACCTGTCAG TACAACCCAGA  
351 TCCGCTCTCT GCACCCCAAG ACCTTCAGA AGCTCTCGGG GCTGGAAGAG  
401 CTGTACTTGG GGAACAACCT CTTCGAGGG CTGCGCCCGG GCAGCTGCGC  
451 CCGCTGCGC AAGCTGCGCA TCCTCTACGC CAACGGGAAC GAGATCAGCC  
501 GCCTAAGCG CGGCTCCTTC GAGGGCTGAG AGAGTCTAGT CAAGCTGCGG  
551 CTGGACGGGA ACGCCCTGGG GGCCTGTSCG GAGCGGGTCT TCGTCCCTTT  
601 GGGCAACCTG CTCTACCTAC ATCTGGAGTC CAACCGGATC CGCTTTCTGG  
651 GCAAGACGCG CTTCGCCAG CTAGGCAAGC TGGGCTTCTCT CAACCTCTCT  
701 GCCAACGAGC TACAGCCCTC CTTCGCCAC GCGGCCACCT TCGCACCGCT  
751 GCGCTCCCTC TCCTCCCTCA TCCTCTCGGC CAACACCTG CAGCACCTCG  
801 GCGCGGCAT CTTGAGAC CTGCGAGTC TCGGCTGTCT CTCGCTCAGG  
851 GCGAACGAGC TCAGGCACCT CGGCGCTGA

!!AA SEQUENCE 1.0  
ID ADP30616 standard; protein; 300 AA.  
XX  
XX ADP30616;  
AC  
XX 12-AUG-2004 (first entry)  
DT  
XX  
XX Human secreted protein SEQ ID #1383.  
DE  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
PN  
XX  
XX 29-APR-2004.  
PD  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
PF  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR  
XX 29-AUG-2002; 2002US-0406579P.  
PR  
XX 29-AUG-2002; 2002US-0406585P.  
PR  
XX 29-AUG-2002; 2002US-0406588P.  
PR  
XX 29-AUG-2002; 2002US-0406608P.  
PR  
XX 29-AUG-2002; 2002US-0406611P.  
PR  
XX 29-AUG-2002; 2002US-0406612P.  
PR  
XX 29-AUG-2002; 2002US-0406616P.  
PR  
XX 29-AUG-2002; 2002US-0406640P.  
PR  
XX 29-AUG-2002; 2002US-0406642P.  
PR  
XX 29-AUG-2002; 2002US-0406646P.  
PR  
XX 29-AUG-2002; 2002US-0406653P.  
PR  
XX 29-AUG-2002; 2002US-0406655P.  
PR  
XX 29-AUG-2002; 2002US-0406666P.  
PR  
XX 17-SEP-2002; 2002US-0410946P.  
PR  
XX 17-SEP-2002; 2002US-0410947P.  
PR  
XX 17-SEP-2002; 2002US-0410948P.  
PR  
XX 17-SEP-2002; 2002US-0410949P.  
PR  
XX 17-SEP-2002; 2002US-0410953P.  
PR  
XX 17-SEP-2002; 2002US-0410957P.  
PR  
XX 17-SEP-2002; 2002US-0410958P.  
PR  
XX 17-SEP-2002; 2002US-0410959P.  
PR  
XX 17-SEP-2002; 2002US-0410960P.  
PR  
XX 17-SEP-2002; 2002US-0410961P.  
PR  
XX 17-SEP-2002; 2002US-0410962P.  
PR  
XX 17-SEP-2002; 2002US-0411019P.  
PR  
XX 17-SEP-2002; 2002US-0411022P.  
PR  
XX 17-SEP-2002; 2002US-0411023P.  
PR  
XX 17-SEP-2002; 2002US-0411024P.  
PR  
XX 17-SEP-2002; 2002US-0411032P.  
PR  
XX 17-SEP-2002; 2002US-0411033P.  
PR  
XX 17-SEP-2002; 2002US-0411035P.  
PR  
XX 17-SEP-2002; 2002US-0411037P.  
PR  
XX 17-SEP-2002; 2002US-0411041P.  
PR  
XX 17-SEP-2002; 2002US-0411045P.  
PR  
XX 17-SEP-2002; 2002US-0411046P.  
PR  
XX 17-SEP-2002; 2002US-0411048P.  
PR  
XX 17-SEP-2002; 2002US-0411052P.  
PR  
XX 17-SEP-2002; 2002US-0411055P.  
PR  
XX 17-SEP-2002; 2002US-0411073P.  
PR  
XX 17-SEP-2002; 2002US-0411073P.  
PR  
XX 17-SEP-2002; 2002US-0411073P.  
PR  
XX 17-SEP-2002; 2002US-0411101P.  
PR  
XX 17-SEP-2002; 2002US-0411111P.  
PR  
XX 18-APR-2003; 2003US-0463700P.  
PR  
XX 18-APR-2003; 2003US-0463708P.  
PR  
XX 18-APR-2003; 2003US-0463716P.  
PR  
XX 18-APR-2003; 2003US-0463732P.  
PR  
XX 02-MAY-2003; 2003US-0467199P.  
PR  
XX 02-MAY-2003; 2003US-0467201P.  
PR  
XX 02-MAY-2003; 2003US-0467203P.  
PR  
XX 02-MAY-2003; 2003US-0467230P.  
PR  
XX 19-MAY-2003; 2003US-0471306P.  
PR  
XX 19-MAY-2003; 2003US-0471336P.

```
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RE, Huang MM, Kochakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX
XX WPI; 2004-348438/32.
XX
PT New nucleic acid molecule for diagnosing, preventing or treating diseases
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PT genetic, bacterial and viral diseases.
XX
XX Claim 1; SEQ ID NO 2614; 428pp; English.
XX
CC The present invention relates to an isolated nucleic acid molecule
CC encoding a polypeptide which is believed to be cytostatic,
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
CC composition and methods are useful for diagnosing, preventing and
CC treating diseases such as proliferative (e.g. cancer), inflammatory,
CC immune, metabolic, genetic, bacterial and viral diseases. The present
CC sequence represents a human secreted protein. The present sequence is
CC available on WIPOWEB and is not in the specification.
XX
SQ Sequence 300 AA;
ADP30616 Length: 300 February 22, 2005 12:25 Type: P Check: 613 ..
1 ATGACCTCCC GGCACCTCGAG AACGCCACGG GCTCGGCTGC AGAGATCTCC
51 ACCATTGCCA AGGAGGTGGA CAAGGTCAAC CAGATCATTG ACAACTGCGAT
101 CGATGCTCTC AAGCTGGAAT CGGCCTCTTT TCTGGGAGGC GGCAGCAGCA
151 GTGGGGACCC CGAGCTGGCC TTCGAGTGCC AGTCCCTCCC TGCACTGTCT
201 GCGCGCTCCT CAGCCACTGG CCCCAGGGGC CTGGAGCGGC CCAGCTTCCT
251 TTCGCTCTCC TACAAGAGA GCTCCACCA CCCACTACAG CGCCAGCTGA
IIAA SEQUENCE 1.0
ID ADP30667 standard; protein; 3411 AA.
XX
AC ADP30667;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #1434.
XX
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW cancer; inflammatory; immune; human secreted protein.
XX
OS Homo sapiens.
XX
PN WO2004035732-A2.
XX
XX 29-APR-2004.
XX
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.
```

```
XX
PF 28-AUG-2003; 2003WO-US026780.
XX
PR 29-AUG-2002; 2002US-0406576P.
PR 29-AUG-2002; 2002US-0406579P.
PR 29-AUG-2002; 2002US-0406585P.
PR 29-AUG-2002; 2002US-0406588P.
PR 29-AUG-2002; 2002US-0406608P.
PR 29-AUG-2002; 2002US-0406611P.
PR 29-AUG-2002; 2002US-0406612P.
PR 29-AUG-2002; 2002US-0406616P.
PR 29-AUG-2002; 2002US-0406640P.
PR 29-AUG-2002; 2002US-0406642P.
PR 29-AUG-2002; 2002US-0406646P.
PR 29-AUG-2002; 2002US-0406653P.
PR 29-AUG-2002; 2002US-0406655P.
PR 29-AUG-2002; 2002US-0406666P.
PR 17-SEP-2002; 2002US-0410946P.
PR 17-SEP-2002; 2002US-0410947P.
PR 17-SEP-2002; 2002US-0410948P.
PR 17-SEP-2002; 2002US-0410949P.
PR 17-SEP-2002; 2002US-0410953P.
PR 17-SEP-2002; 2002US-0410957P.
PR 17-SEP-2002; 2002US-0410958P.
PR 17-SEP-2002; 2002US-0410959P.
PR 17-SEP-2002; 2002US-0410960P.
PR 17-SEP-2002; 2002US-0410961P.
PR 17-SEP-2002; 2002US-0410962P.
PR 17-SEP-2002; 2002US-0411019P.
PR 17-SEP-2002; 2002US-0411022P.
PR 17-SEP-2002; 2002US-0411023P.
PR 17-SEP-2002; 2002US-0411024P.
PR 17-SEP-2002; 2002US-0411032P.
PR 17-SEP-2002; 2002US-0411035P.
PR 17-SEP-2002; 2002US-0411037P.
PR 17-SEP-2002; 2002US-0411041P.
PR 17-SEP-2002; 2002US-0411045P.
PR 17-SEP-2002; 2002US-0411046P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411052P.
PR 17-SEP-2002; 2002US-0411055P.
PR 17-SEP-2002; 2002US-0411073P.
PR 17-SEP-2002; 2002US-0411082P.
PR 17-SEP-2002; 2002US-0411101P.
PR 17-SEP-2002; 2002US-0411111P.
PR 18-APR-2003; 2003US-0463700P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 18-APR-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467230P.
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
PA
```

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2665; 420pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 3411 AA;  
ADP30667 Length: 3411 February 22, 2005 12:25 Type: P Check: 2439 ..  
1 ATGGCCTCTC CAAGGAAGGT AACTGAGAAG CGGCATAACC CAGTGGAAAG  
51 CATCTGTAGA AAGATCAGAG CCATCCACAA GAGAGAAGCA ATTTCAAATC  
101 CAATTACAGCA GATTATCAAA TACCATCTTA GCAGTTTGA TAGCCACAG  
151 ACGAACACCA AGAATATATT TGAAGAGGTA CTGAGGAAAA TGACTGTCTGC  
201 TTGTGTCTCT ACGCCCGCT CTCATTGGTC AGTTCTGAG GAAGTCGATG  
251 CCTTCATTTT ATCGCTCAA ATATATCTC CAAGAACCCC ATCCACTCTT  
301 CACCTCAGCT CCCCTGAGC TGCAACATAC TCTGTTATTTC TCACAAGTTTC  
351 TGAAAACGTC TCAAGCCGA AGTCACAGAG CAACAAGAT TATACATCTT  
401 TGATGTACA GATCAGAAAA GCAGAGTTTT TCTCTAACAA GATTGTGAAT  
451 AACTATTGTA GTGAAAATAA TTTTAGTACC TTAACACTTG ACTTTGATTC  
501 CACCTTTGTT CAAGCTTGA AGTCTTTGA TCCTCAGGAT TCAGTGGTAA  
551 AAAAATTATC TCTGAATGAA GATGGATGGA AACAGAAGC TGATGATGGT  
601 AAAGAAGATG TAATATACAG CATCAACAGG GCCTGTAAAG AAGAGGCACT  
651 CACAAGTATT TTTAATGAT GTGACATCAA ACGGAAGGC TCAGTCGGAG  
701 TGGCCAAAT AATCAATTTT CTGAGACAAA CAACTAGCCA AANITCTGAA  
751 GACAGTGGCC TTGACAGTT GTGMACATG CTTGATCCTG AGAAGAGAGA  
801 CCCACATGG GACCTGGAAA CTTTCCAGGC CATGATGAAA GACTGGATGG  
851 CTTACTGTGG AAACACATGG GAAGGAGTGA ATCATAGATT AAGCAGCATC  
901 ATCGATGATT CTGTTTGTGA ACAGGATGGC ATAAATATCAG ATGGAACAAAG  
951 TATAGAGGTG TCTGATTGA TTGCCTACGT AGCAGACCTT CATTTCAACA  
1001 AAAGAAACT TGAGGAAGAA AATAATAAGT TTAAGTTGGC TTTAGAAACC  
1051 CTGGAAGAAA CTAACAGCCA GTTATCAGAG GACTGTACCG AATTGCGCTT  
1101 TCAGGTAAA AGTCCCNACC AGCTATTAT GAGACAATAT CTGTTAAAG  
1151 AAGAACTGGA GGAAC TGAA CTTAGTATGA ATGCTTCAGA AGAGCAGAAG

1201 AGCATGATTG TAGCCAGAG CAAACAATTA GAGACAGAAA ACCGGGCTCT  
1251 GATTCTTAAG ATTCGGATTC TACAGGAAGA GAATTTCAAG AACATCATGG  
1301 ATATAGACAG ACTGAAAAG AAGATTGAAG ACTTGTCTAA AACTGAGACA  
1351 GAGCACCAAA ATTTACGAGG GAAAAAAGT AAACCTGGCTC ATGAGTTACA  
1401 GCACTTGCAA CAGCACTCA TCACAAATGG GATCCAGTTG AATGTTAATG  
1451 GAGAGTGTA CAGTATCATC TCTGAAGGAG AAAAGTCTTT ACATTACGAA  
1501 CTCACCTCTG CTCAGTCTGC AGAACAACACT GAAACAGAAA GGCAGACAAA  
1551 TGTATATCAAC TTGTCATCTC TGGACGCCAT GATGATCAG GAAATGTCTC  
1601 TATTACTAAG AGACCCGCA CAGAAGGCAG TGGAAATTCAC AGCCACGGTT  
1651 CAGAAAGCTGC ACGAAGAAAT TTCTAAAAAT GCAACCCCTCA TTGAAAACCTC  
1701 TCGACGGTGG GTAACTAATC CAGAAATTAC TGTGAAAGAA AAGTGGGAGG  
1751 AGCAGCTTAC TGAATTCAC AATATCATGG AAGAGAAGCT AGATCTTTGC  
1801 ATATTAAATGC TGAACATCTT GGGAAACCAC AAGAGTCTC TTGATAAAGA  
1851 ATTTGCCAAA TTAATAGAGA TTTTGAAGAG ATTCAGGCAG GAATATTTTT  
1901 ATTTCAGAAA AGAATTTCTT GCCAGTCAGA AACAACTAGA AGCCATTAAA  
1951 CAACTACAGG AAGATGTGT CAACACAGAA GGCATCCTTA GGAAGAGGCT  
2001 CCAAGAAACC AGCCAACGGC TGGAGGATGT GGAGGAGCAG GGTAAAGGATC  
2051 GAGATCGAGA AGCCACACT GCCAGTGAAA AAGTACGTC TTTACTGAT  
2101 AAATTAGAGG AAGCAATTTT GGAACAACGG AACCTTCAA CTATAAATAC  
2151 TGAATTATCG AACACTTGCC AGGCATCTCA GCAGAAGACA AGGAACCTGA  
2201 AGAATGCTTT ATCTCTGGAT AGTTTTCAG CAGTTCCAA CCGGAATCA  
2251 ACACCTTTCT CAGGTGTAGC CAACCAAATC CACACTCTGT GTGAAAGGCC  
2301 CACATATGGA GAAGAGCTTG GCAGGTTGGA GTTGAAGTT CCAACGCTCA  
2351 AACACAGAT TGGTTCCCTT GGCAACCAGC CCCTCATCCT GAGCTATCC  
2401 AGAAGCCAC CAAGAGATAC CGCGTTAGAA CAGAAGATGC TCGTAATACT  
2451 CAGGNAATTT CAAGAGATTC AGGAGCTTCG CGTCAACAC TCCTATCACT  
2501 CGGGAATTA CAAGGAGAA GGTGTTGAAC GCGTGTGTC TGAGAGCGTG  
2551 CTGCACTCCA GCGAATATTC CTCACTACCA TTACCCAGAC ACCTTCATC  
2601 GACAGACGGT ACTATACTT CAAGTGATCC TGGATTAGAA ATTCTGAATA  
2651 TGGCTTCTTG TGACCTTGAC AGAACTGCG TCTGTAAGAA AGAGGAGGAT  
2701 ACAAGATCAG CTTCTCCAC GATAGAGGCC CAAGSCAAA GTCCAGCTCA  
2751 TGATAATATT GCATTCCAAG ACTCTACGAG TAAGGATAAA ACCATATTA  
2801 ATCTGATTGG AAGGCCCTT GCAGCAATT TTATTTCTT CTTAACAGCA  
2851 TTAATAACTG TAGAGCAGG GTCCCGAGTC GCTGCTGAGC CAGGGATCAG  
2901 AACCATTCG AGGCTGTTAG GAATTGCGCC GCACAGCAGG AGCACTTCTG  
2951 CTAATAGAA GGAGGTGGAG GCAGAAATTC TCAGATTATC TTTGGGATTT

3001 AAGTGTGACT GGTTTACCTT GGAGAAGAGA GTGAAGCTTG AAGAGAGTGC  
3051 CCGTGACTTG GCAGAGAAA ATTGAAGAA AGAATCACT AACTGTTTAA  
3101 AACTATTAGA GTCTTTAACA CCTCTGTGTG AAGATGACAA CCAGGCACAG  
3151 GMAATCATT AAGAAGTGG AAGAGTATA AAGTTTCTTA GCCAGTGTGC  
3201 AGCAGAGTG GCCAGTAGG CTGAGATGTT GGGAGCCATC AATCAGGAAA  
3251 GCCGGGTAG TAAAGCAGTT GAAGTGATGA TTCAGCAGT AGAAAATTG  
3301 AAGAGGATGT ATGCCAAGA GCACGCTGAA TTAGAAGAAC TGAACAGGT  
3351 TCTTCTCAG AATGAAGGT CTTTCAATCC TCTTGAAGAT GATGGTAATA  
3401 AAGATTTATG A

!!AA\_SEQUENCE 1.0  
ID\_ADP30681 standard; protein; 2827 AA.  
XX  
AC ADP30681;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1448.  
DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX  
XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406555P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.

17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-041101P.  
17-SEP-2002; 2002US-041111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463718P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471308P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 2679; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPOWEB and is not in the specification.

Sequence 2827 AA;

ADP30681 Length: 2827 February 22, 2005 12:25 Type: P Check: 7952 ..  
1 GGSCCACTGT CCCAGTCCC GGCCCGGAGC TATGGAGCG CGCTGGCCCC  
51 TGGGGGTAGG GCTGTGTGCTG CTGCTCTGCG CCCCGTGCC CCGGGGGGG  
101 CGGCCCAAGG AAGTTACTT GATGACACA AGCAAGGCAC AGGGAGAGCT  
151 GGCTGGCTG CTGGATCCC CAAAAGATGG GTGGAGTGAA CAGCAACAGA  
201 TACTGAATG GACACCCCTG TACATGTACC AGGACTGCCC AATGCNAGA  
251 CGCAGAGACA CTGACCACTG GCTTCGTCC AATTGGATCT ACCGCGGGA

301 GGAGGCTTCC CGCGTCCAGG TGGAGCTGCA GTTACCGTG CGGAGCTGCA  
351 AGAGTTTCCC TGGGGGAGCC GGGGCTCTGG GCTGCAAGGA GACCTTCAAC  
401 CTTCTGTACA TGGAGAGTGA CCAGGATGTG GGCATTACAGC TCCGAGGGCC  
451 CTTGTTCCAG AAGGTAACCA CGGTGGGTGC AGACGAGAGC TTACACATTTC  
501 GAGACCTTGT GTCTGGCTCC GTGAAGCTGA ATGTGGAGCG CTGCTCTCTG  
551 GGCGGCTGA CCCGCGGTGG CCTTACCTC GCTTTCCACA ACCCGGTGC  
601 CTGTGTGGCC CTGGTGTCTG TCCGGGTCTT CTACGAGCGC TGTCCTGAGA  
651 CCCTGAATGG CTTGGCCCAA TTCCAGACA CTCTGCTGG CCCGCTGGG  
701 TTGGTGGNAG TGGCGGGGAC CTGCTTGCCC CAGCGGGGG CCAGCCCCAG  
751 GCCTCAGGT GCACCCCGCA TGCATGAG CCCTGATGGC GAGTGGCTGG  
801 TGCTGTAGG ACGGTGCCAC TGTGAGCTG GCTATGAGGA AGGTGGCAGT  
851 GGGGAAGCAT GTGTGTTGT CTACGTGCC CCCAGCAGAG CACTGCTGAG  
901 TGTGAGGGG CCACCATCTG TACCTGTGAG AGCGGCCATT ACAGAGCTCC  
951 CGGGGAGGGC CCCAGGTGG CATGCACAGG TCCCCCTCTG GCCCCCCGAA  
1001 ACTGAGCTT CTCTGCTCA GGGACTCAG CTCTCCTGGG TTGGGAACCC  
1051 CCAGCAGATA CGGGGGGAGC CCAGGATGTC AGATACAGTG TGAGGTGTC  
1101 CCAGTGTGAG GGCACAGCAC AGGACGGGG GCGCTGCCAG CCCTGTGGG  
1151 TGGGCGTGCA CTTCTCGCG GGGGCCCGG GCGTACCAC ACCTGCAGTG  
1201 CATGCAATG GCCTTGAACC TTATGCCAAC TACACCTTTA ATGTGGAAAGC  
1251 CCANAATGGA GTGTGAGGC TGGCAGCTC TGSCCATGCC AGCACCCTCAG  
1301 TCAGCATCAG CATGGGGCAT GCAGCTGGT AGAAGAAGAC CGAGGCAACT  
1351 AGAGCTGACC TGGGCGGGGT CCGGCCCGG AAGCCCTGGG GCGAACCTGA  
1401 CCTATGAGCT GCAGTGTCTG AACCAGGATG AAGAAGGTA CCAGATGTT  
1451 CTAGAACCA GGTCTTGCT GACAGAGCTG GAGCTGACA CCACATACAT  
1501 CGTCAGAGTC CGAATGTGA CCCACTGGG TCCTGGCCCT TTCTCCCTG  
1551 ATCATGAGTT TCGGACCAGC CCACAGTGT CCAGGGGCTT GACTGGAGGA  
1601 GAGATTGTAG CCGTATCTT TGGGCTGCAG CAGAGGCAGC GTGACCGGCG  
1651 CACCGATGTG GATCGAGAGG ACAAGCTGTG GCTGAAGCCT TATGTGACC  
1701 TCCAGGCATA CGAGGACCT GCACAGGGAG CCCTGGACTT TACCGGGAG  
1751 CTTGATCCAG CGTGGCTGAT GGTGGACACT GTCATAGGAG AAGGAGATT  
1801 TGGGGAAGTG TATCGAGGGA CCCTGAGGCT CCCCAGCCAG GACTGCAAGA  
1851 CTGTGGCCAT TAAGACCTTA AAGACACAT CCCCAGGTGG CCAGTGGTGG  
1901 AACTTCCTTC GAGAGGCAAC TATCATGGGC CAGTTTAGCC ACCGCAATAT  
1951 TCTGCATCTG GAAGGCGTCG TCACAAAGCG AAGCGCATC ATGATCATCA  
2001 CAGAAATTTAT GGAGNATGGA GCCTGGATG CTTTCTCTGAG GGAGCGGAG  
2051 GACCAGCTGG TCCCTGGGCA GCTAGTGGCC ATGTGTCAGG GCATAGCATC  
2101 TGGCATGAAC TACCTCAGTA ATCACAATTA TGTCCACCGG GACCTGGCTG

2151 CCAGAAACAT CTTGGTGAAT CAAAACCTGT GCTGCAAGGT GTCTGACTTT  
2201 GGCCTGACTC GCCTCTCGGA TGACTTTGAT GGCACATACG AAACCCAGG  
2251 AGGAAAGATC CCTATCCGTT GGACAGCCC TGAAGCCATT GCCCATCGGA  
2301 TCTTACCAC AGCCAGCGAT GTGTGGAGCT TTGGGATTGT GATGTGGAG  
2351 GTGCTGAGCT TTGGGGACAA GCCTTATGGG GAGATGAGCA ATCAGGAGGT  
2401 TATGAAGAGC ATTGAGGATG GGTACCGGTT GCCCCTCTCT GTGAGTGGC  
2451 CTGCCCTCT GTATGAGCTC ATGAAGAACT GCTGGGCATA TGACCGTGCC  
2501 CGCGGGCAC ACTTCCAGAA GCTTCAGGCA CATCTGGAGC AACTGCTTGC  
2551 CAACCCCAAC TCCCTGCGGA CCATTGCCAA CTTTGACCCC AGGATGACTC  
2601 TTGCGCTGCC CAGCCTGAGT GGCTCAGATG GGATCCATA TCGAACCGTC  
2651 TCTGAGTGGC TCGAGTCCAT ACGCATGAAA CGCTACATCC TGCATTCCA  
2701 CTCGGCTGGG CTGGACACCA TGGAGTGTGT GCTGGAGCTG ACCGCTGAGG  
2751 ACCTGACGCA GATGGGAATC ACACTGCCCG GGCACCAGAA GCGCATTCTT  
2801 TGCAGTATTC AGGATTCAA GNACTGA

## !!AA SEQUENCE 1.0

ID ADP30700 standard; protein; 3070 AA.

XX

AC ADP30700;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1467.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

OS

XX WO2004035732-A2.

PN

XX

XX

PD 29-APR-2004.

XX

XX 28-AUG-2003; 2003WO-US026780.

XX

PR 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 29-AUG-2002; 2002US-0406666P.

PR 17-SEP-2002; 2002US-0410946P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.

PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2699; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 3070 AA;  
SQ

ADP30700 Length: 3070 February 22, 2005 12:25 Type: P Check: 6107 ..

1 TTGCTCTCTC CTAGCCACAG CAGGCTGCTT TGCTGACTTG AACGAGGTCC

51 CTCAGGTAC CGTCCAGCCT GCGTCCACC GGCAGAACCC TCCAGAACCC CGGAGGCACT  
101 GTGATCTTGG GCTGGTGGT GGAACCTCCA AGGATGAATG TAACTCTGGG  
151 CTTGAATGGA AAGGAGCTGA ATGGCTCGGA TGATGCTCTG GGTGTCTCTA  
201 TCACCCACGG GACCTCTGTC ATCACTGCCC TTAACAACCA CACTGTGGGA  
251 CGGTACCAGT GTGTGGCCGG GATCCCTGGG GGGGCTGTGG CCAGCGTGCC  
301 AGCCACTGTG AACTAGCCA ATCTCAGGA CTTCAAGTTA GATGTGCAGC  
351 ACGTGATTGA AGTGATGAG GGAACACAG CAGTCATTGC CTGCCACCTG  
401 CTTGAGAGCC ACCCCAAAGC CCAGTCCGG TACAGCGTCA AACAAGAGTG  
451 GTTGGAGGCC TCCAGAGGTA ACTACCTGAT CATGCCCTCA GGAACCTTCC  
501 AGATTGTGAA TGCCAGGCAG GAGGACGAGG GCATGTACAA GTGTGCAGCC  
551 TACAACCCAG TGACCCAGGA AGTGAAGAAC TCCGGGCTCCA GCGACAGGCT  
601 ACGTGTGCGC CGCTCCACCG CTGAGGCTGC CCGCATCATC TACCCCCCAG  
651 AGGCCCAAAAC CATCATCGTC ACCAAAGGCC AGAGTCTCAT TCTGGAGTGT  
701 GTGGCCAGTG GNATCCACCC CCCACGGGTC ACCTGGGCCA AGGATGGGTC  
751 CAGTGTCAAC GGCTACAACA AGACGCGCTT CTGTGTGAGC AACCTCCTCA  
801 TCGACACCAAC CAGCGAGGAG GACTCAGGCA CTTACCGCTG CATGGCCGAC  
851 AATGGGGTTG GCGAGCCCGG GGCAGCGGTC ATCCTCTACA ATGTCCAGGT  
901 GTTTGAACCC CCGTAGGTC AATGGAGCT ATCCAGCTG GTCATCCCCCT  
951 GGGGCCAGAG TGCCAAGCTT ACCTGTGAGG TGCGTGGGAA CCCCCCGCCC  
1001 TCCGTGCTGT GGCTAGGANA TGCTGTGCCC CTCTCTCCA GCCAGGCGCT  
1051 CCGGCTCTCC CCGAGGCGCC TGCGCGTGCT CAGCATGGGG CTTGAGGAGC  
1101 AAGGCGTCTA CCAGTGTCATG GCGAGAACG AGGTGGGAG CGCCCCATGCC  
1151 GTAGTCCAGC TCGGACCTC CAGGCCAATG TCCAGGAGAG AAGGGGCAGS  
1201 GGGTCCCCG CGAGGCTCCC ATCATCTCTA GCTCGGCCCG CACCTCCAAG  
1251 ACAGACTCAT ATGAAGTGGT GTGGCGGCGT CGGCATGAGG GCAGTGGCGG  
1301 GGCGCCATC CTCTACTATG TGGTGAACA CCGCAAGTCC TCTGAGATT  
1351 GGACCATCTC TGGCATCCA GCCAACCCAG ACCGCTCTGAC CTTACCCAGA  
1401 CTTGACCCCG GGAGCTTGTA TGAAGTGGAG ATGSCAGCTT ACAACTGTGC  
1451 GGAGAGAGGC CAGACAGCCA TGCTACCTT CCGAACTGGA CGGCGGCCCA  
1501 AACCCGAGAT CATGGCCAGC AAAGAGCAGC AGATCCAGAG AGACGACCTT  
1551 GGAGCCAGTC CCCAGAGCAG CAGCAGCCA GACCACGGCC GCCTCTCCCC  
1601 CCAGAAAGCT CCGCAGCAGC CCACCATCTC CACGGGCTCC GAGACCTCAG  
1651 TGTACCTGAC CTGGATTCCC CGTGGGAATG GTGGGTTCCC AATCCAGTCC  
1701 TTCCGTGTGG AGTACAAGAA CTTAAAGAAA GTGGGAGACT GGATTCGTGC  
1751 CACAGGGGCC ATCCCCCCTAT CGCGCTGTC CGTGGAGATC ACGGGCCTAG  
1801 AGAAGGCAC CTCCTACAG TTTCAGTCC GGGCTCTGAA CATGCTGGGG



1851 GAGAGCGAGC CCAGCGCCCC CTCGCGCCC TAGTGGTGT CGGGCTACAG  
1901 CGTGCGGTG TAGAGAGAGC CCGTGGCAGG TCCTTATATC ACCTTCACGG  
1951 ATCGGGTCAA TGAGACCACC ATCATGCTCA AGTGGATGTA CATCCACGCA  
2001 AGTAACACAA ACACCCCAAT CCATGGCTTT TATATCTATT ATCGACCCAC  
2051 AGACAGTGAC AATGATAGTG ACTACAAGAA GGATATGGTG GAAGGGGACA  
2101 AGTACTGGCA CTCCATCAGC CACCTGCAGC CAGAGACCTC CTACGACATT  
2151 AGATGCAGT GCTTCATGA AGGAGGGAG AGCGAGTTCA GCAACGTGAT  
2201 GATCTGTGAG ACCAAAGCGG CCGGTGGGCA CTGGGGCCAT GGTGGCTGCG  
2251 TCCAGCGACC TGCCCTATCT GATTGTGCGG GTCGTCTCTGG GCTCCATCGT  
2301 TCTCATCATC GTCACCTTCA TCCCTTTCTG CTTGTGGAGG GCTGGTCTTA  
2351 AGCAAAAACA TACAACAGAC CTGGGTTTTT CTCGAAGTGC CTTCCACCCC  
2401 TCCTGCCCGT ATACTATGTT GCCATTGGGA GGACTCCCAG GCCACACGCG  
2451 CAGTGGACAG CCCTACCTCA GTGGCATCAG TGGACGGGCC TGTCGTAATG  
2501 GGATCCACAT GAATAGGGGC TGCCCTCTGG CTGCAGTGGG CTACCCGGGC  
2551 ATGAAGCCCC AGCAGCACTG CCCAGGCGAG CTTTCAGCAGG TAGCGCATTC  
2601 TTGGGTGTGG GGGGAGGGT CTCAGGCTGG GCTGCTGGGC CAGGCTTTCT  
2651 TTAGTCAGGA GCAGATGCTC CTGTGTTGA GTGAAGACTG GAAAGTTACC  
2701 TGGACTCCCC GSGGTGGCG TCTCATTAAT CTTTCTTTTG AGCAGCAGAG  
2751 TGACACCAGC AGCCTGCTGA GGCAGACCCA TCTTGGCAAT GGATATGACC  
2801 CCCAAAGTCA CCAGATCAGC AGTGGGACCC TCCATTTCAC TCAGGGCCCC  
2851 CATGCTGCTT GGGCCTTGTG CCAGTTGAAG AGGTGGACAG TCCTGACTCC  
2901 TGCCAAGTGA GTGGAGGAGA CTGTGTGCCC CAGCACCCCG TAGGGGCCCTA  
2951 CGTAGGACAG GAACTGGGAA TGCAGCTCTC CCGGGGCCCA CTGTGCGGTG  
3001 TGCTTTTTGA AACACCACCT CTCACAAATT AGGCAGAAGC TGATATCCCA  
3051 GAAAGACTAT ATATTGTTTT

!!AA\_SEQUENCE 1.0  
ID -ADP30721 standard; protein; 1008 AA.

XX ADP30721;

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1488.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Heetir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2719; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytosolic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC competition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1008 AA;  
ADP30721 Length: 1008 February 22, 2005 12:25 Type: P Check: 8192 ..  
1 TCTTTGAGTT GGTGTTCCCT CCCCGGGGCC CCATGTAGC TGGGAAGTGG  
51 GACCTGGGGG TGGTTGGACC CTTGGGATCC TAAAGGAGGG GCAGGGAGGG  
101 GCGAGAACTC CGCTTCGTGT CTTTGTACC AGGACGGCGG GCCTCCTCAG  
151 CCTCTTTCCCT CCCGCTGCCA TGCACCTGCG AGCCTTCCCG CTTCTGTGG  
201 TTGTGGCCGC TGTGCTGTGG GGAGCGGCC CCACCCGGGG GCTCATTTGGA  
251 GCGACCTCGG ACCACAATGC CAGCATGGAC TTTCAGAGCC TTCCAGCTCT  
301 GTTTGGGGCT ACCTTGAGCC AGGAGGCGCT TCAGGGGGTTC CTTGTGGAGG  
351 CTCACCCAGA CAATGCCCTGC AGCCCCATTG CCCCACCACC CCAGCCCCCG  
401 GTCAATGGGT CAGTCTTTAT TGCCTCTCTT CGAAGATTGC ACTGCAACTT  
451 TGACCTCAAG GTCCCTAAATG CCCAGAAGGC TGSATATGTT GCCGCTGTAG  
501 TACACAATGT GAATTCCAAT GAATCTCTGA ACATGGTGTG GAATAGTGAG  
551 GAAATCCAGC AGCAGATCTG GATCCCGTCT GTATTATTG GGGAGAGAAG  
601 CTCGAGTAC CTGCGTGCC CTCTTGCTA CGAGAAGGCG TGGTTTGGC  
651 CATGGGAGCA GTAATGGTGA GTAGCTGAGG GAACATGAT GGAAGAATAG  
701 CTGTTGTGAT CCAGCACCGG AAACGGCTCC AGCGGAATG ACTTACAAA  
751 GAGCAACTGA AACAGATTCC TACACATGAC TATCAGAGG GAGACCAGTA  
801 TGATGCTGT GCCATTGGC TGGATGAATA TGAGGATGGG GACAAGCTGC  
851 GGGTACTCCC CTGTGCTCAT GCCTACCACA GCCGCTGCGT GGACCCCTGG  
901 CTCACTCAGA CCGGGAAGAC CTGCCCCATT TGCAAGCAGC CTGTTTCATCG  
951 GGGTCTCTGG GACGAAGACC AAGAGGAAGA AACTCAGGG CCAGAGGAGG  
1001 TCTTCTGA  
IIAA SEQUENCE 1.0  
ID\_ADP30729 standard; protein; 411 AA.  
XX  
XX ADP30729;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1496.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2727; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 411 AA;  
ADP30729 Length: 411 February 22, 2005 12:25 Type: P Check: 4018 ..  
1 ATCACGTTTT ATATTCTGGT GAAGGCCATT TATACACTGG GCTACAGTGT  
51 CTCCTCGATG TCTCTTGCAA CAGAAGCAT AATTCGTGTC CTCCTCAGGT  
101 GGGCTGCAAG CTGAGCTGG TCTTCTTGCA GTACTGCATC ATGGCCAACT  
151 TCTTCTGGCT GCTGTGGGAG GGGCTCTACC TCCACACCCT CCTGTGGGCC  
201 ATGCTCCCCC CTAGAGGTG CTTCCTGGCC TACCTCCTGA TCGGATGGGT  
251 TCGTGGGATA CAACGACCA CAGTGTGCC TGGTGGGTCA TACGAATACC  
301 GATTTTAATT TCCATCATCG TCAATTTTGT CCTTTTCATT AGTATTATAC  
351 GAATTTTGTG GCAGAGTTA ACATCCCCAG ATGTCGGCGG CAACGACCAG  
401 TCTCAGTACA A  
!!AA SEQUENCE 1.0  
ID ADP30746 standard; protein; 710 AA.  
XX  
XX ADP30746;  
AC  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1513.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR

29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR

```
XX New nucleic acid molecule for diagnosing, preventing or treating diseases
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PT genetic, bacterial and viral diseases.
XX
PS Claim 1; SEQ ID NO 2744; 428pp; English.
XX
CC The present invention relates to an isolated nucleic acid molecule
CC encoding a polypeptide which is believed to be cytostatic,
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
CC composition and methods are useful for diagnosing, preventing and
CC treating diseases such as proliferative (e.g. cancer), inflammatory,
CC immune, metabolic, genetic, bacterial and viral diseases. The present
CC sequence represents a human secreted protein. The present sequence is
CC available on WIPWEB and is not in the specification.
XX
SQ Sequence 710 AA;
ADP30746 Length: 710 February 22, 2005 12:25 Type: P Check: 3709 ..
1 ATGGATCATTT CCATCATATC GGGGATGAGC TGATGGACT CCACAGTATC
51 CATGCAACGT CCTCACCATC ACCCAACCAC TTCAGCCTCA CACTCCCGTG
101 GTGGAGGAGA CAGCACATG ATGATGATGA TGCCTATGAC CTTCTACTTT
151 GGCTTTAAGA ATGTGGAATC ACTGTTTCCC AGTTTGGTGA TCATACAGC
201 TGGAGAAATG GCTGGAGCTT TTGTGGCAGT GATTATACTA GCAGTGTCTT
251 ATGAAGGACT CGATAGCCCA AGAGAGCCTG CTGTGACCAA ATGGAACCAT
301 CCTATGATAG ACACAAAAA CTGTTGGGCA GCAGATCGTG AGCTTTCCTC
351 ACCTCTGSCA AACAGTGTG CACATCATCC AGGTGGTCAAT AAGCTACCTC
401 CTCATGCTCA TCTTCATGAC CTCACATGGG TACCTCTGCA TTGCAGTAAC
451 AGCAGGGGCC GGTACAAGAT ACTTCTCTTT CAGCTGGAAG AAGGCAGTGG
501 TAGTGGACAT CACAGAGTAT TGCCATTGAC GTCAAACTCT ATGGCATGGC
551 CTTATCGATT GCAGTGGGAA GCTGTTCAAG ACTTGAAGAC GTGACAAGGA
601 ATGTATACTT GTATGGCTTT GAACCAAGAG AGGTTATGA GCCTACTGGA
651 TTGAGGTAA AATCCAAGAA CCAACATTTA GAGATTTGTG CTTTCTCTC
701 ATTCCATCAC
!!AA SEQUENCE 1.0
ID ADP30772 standard; protein; 222 AA.
XX
AC ADP30772;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #1539.
XX
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW cancer; inflammatory; immune; human secreted protein.
XX
OS Homo sapiens.
XX
PN WO2004035732-A2.
XX
PD 29-APR-2004.
XX
PF 28-AUG-2003; 2003WO-US026780.
XX
PR 29-AUG-2002; 2002US-0406576P.
PR 29-AUG-2002; 2002US-0406579P.
PR 29-AUG-2002; 2002US-0406585P.
PR
```

```
29-AUG-2002; 2002US-0406588P.
29-AUG-2002; 2002US-0406608P.
29-AUG-2002; 2002US-0406611P.
29-AUG-2002; 2002US-0406612P.
29-AUG-2002; 2002US-0406616P.
29-AUG-2002; 2002US-0406640P.
29-AUG-2002; 2002US-0406642P.
29-AUG-2002; 2002US-0406646P.
29-AUG-2002; 2002US-0406653P.
29-AUG-2002; 2002US-0406655P.
29-AUG-2002; 2002US-0406666P.
17-SEP-2002; 2002US-0410946P.
17-SEP-2002; 2002US-0410947P.
17-SEP-2002; 2002US-0410948P.
17-SEP-2002; 2002US-0410949P.
17-SEP-2002; 2002US-0410953P.
17-SEP-2002; 2002US-0410957P.
17-SEP-2002; 2002US-0410958P.
17-SEP-2002; 2002US-0410959P.
17-SEP-2002; 2002US-0410960P.
17-SEP-2002; 2002US-0410961P.
17-SEP-2002; 2002US-0410962P.
17-SEP-2002; 2002US-0411019P.
17-SEP-2002; 2002US-0411022P.
17-SEP-2002; 2002US-0411023P.
17-SEP-2002; 2002US-0411024P.
17-SEP-2002; 2002US-0411032P.
17-SEP-2002; 2002US-0411035P.
17-SEP-2002; 2002US-0411037P.
17-SEP-2002; 2002US-0411041P.
17-SEP-2002; 2002US-0411045P.
17-SEP-2002; 2002US-0411046P.
17-SEP-2002; 2002US-0411048P.
17-SEP-2002; 2002US-0411052P.
17-SEP-2002; 2002US-0411055P.
17-SEP-2002; 2002US-0411073P.
17-SEP-2002; 2002US-0411082P.
17-SEP-2002; 2002US-0411101P.
17-SEP-2002; 2002US-0411111P.
18-APR-2003; 2003US-0463700P.
18-APR-2003; 2003US-0463708P.
18-APR-2003; 2003US-0463716P.
18-APR-2003; 2003US-0463732P.
02-MAY-2003; 2003US-0467199P.
02-MAY-2003; 2003US-0467201P.
02-MAY-2003; 2003US-0467203P.
02-MAY-2003; 2003US-0467230P.
19-MAY-2003; 2003US-0471306P.
19-MAY-2003; 2003US-0471336P.
22-MAY-2003; 2003US-0472420P.
22-MAY-2003; 2003US-0472430P.
09-JUN-2003; 2003US-0476609P.
09-JUN-2003; 2003US-0476641P.
08-JUL-2003; 2003US-0485218P.
08-JUL-2003; 2003US-0485223P.
08-JUL-2003; 2003US-0485224P.
08-JUL-2003; 2003US-0485325P.
14-JUL-2003; 2003US-0486466P.
14-JUL-2003; 2003US-0486480P.
15-JUL-2003; 2003US-0486891P.
15-JUL-2003; 2003US-0486960P.
08-AUG-2003; 2003US-0493341P.
08-AUG-2003; 2003US-0493370P.
08-AUG-2003; 2003US-0493573P.
08-AUG-2003; 2003US-0493577P.
(FIVE-) FIVE PRIME THERAPEUTICS INC.
Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;
Halenbeck RF, Huang MM, Kothakota S, Linnemann T;
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
WPI; 2004-348438/32.
DR
```

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2770; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 222 AA;  
ADP30772 Length: 222 February 22, 2005 12:25 Type: P Check: 4426 ..  
1 ATGGCACCAA GACCGAGAAG CTGGAGAAGC TCATGGTGGC CATTGGCGTC  
51 TTCAGGGTGC TGTACACTGT GCCAGCCACC ATCGTCATCG CTTGCTACTT  
101 CTACGAGCAG GCCTTCCGGG ACCAGTGGGA ACGCAGCTGG GTGGCCCGAGA  
151 GCTGCAAGAG CTACGCTATC CCCTGCCCTC ACCTCCAGGC GGGCGGAGGC  
201 GCCCGCGCGC ACCCGCCCAT GA  
!!AA\_SEQUENCE 1.0  
ID ADP30796 standard; protein; 159 AA.  
XX  
AC ADP30796;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1563.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406583P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406615P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Hallenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2794; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 159 AA;

1 ATGCTGACAT GCTGGACATC CTCAGCCACA CTCGTGGGGA GGCGCTGCTC  
51 CGCGTGCCCA TGTACGCACC CCCAGAGCCC ATCATCGACT ACAACATGCT  
101 GGTCAATCTT ATCCTGGCTG TGGGCACAGT GGCTGCAGGC GGCTACTGGG  
151 CCGGCCTGA

!!AA SEQUENCE 1.0  
ID\_ADP30816 standard; protein; 186 AA.

XX AC ADP30816;

DT 12-AUG-2004 (first entry)

DE Human secreted protein SEQ ID #1583.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406577P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406808P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411037P.

XX PR 17-SEP-2002; 2002US-0411052P.

XX PR 17-SEP-2002; 2002US-0411055P.

XX PR 17-SEP-2002; 2002US-0411073P.

XX PR 17-SEP-2002; 2002US-0411082P.

XX PR 17-SEP-2002; 2002US-0411101P.

XX PR 17-SEP-2002; 2002US-0411111P.

XX PR 18-APR-2003; 2003US-0463700P.

XX PR 18-APR-2003; 2003US-0463708P.

XX PR 18-APR-2003; 2003US-0463716P.

18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-047609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases

XX PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

XX PT genetic, bacterial and viral diseases.

XX PS Claim 1; SEQ ID NO 2814; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule

XX CC encoding a polypeptide which is believed to be cytostatic,

XX CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The

XX CC composition and methods are useful for diagnosing, preventing and

XX CC treating diseases such as proliferative (e.g. cancer), inflammatory,

XX CC immune, metabolic, genetic, bacterial and viral diseases. The present

XX CC sequence represents a human secreted protein. The present sequence is

XX CC available on WIPWEB and is not in the specification.

XX SQ Sequence 186 AA;

ADP30816 Length: 186 February 22, 2005 12:25 Type: P Check: 630 ..

1 ATGAGACCCAC GGAGACCCAG AGGACCCCTCC TCAATGGAGA CCTCCNAACC

51 AGTATCTGAA CTGCTTGGGG GGTGGGAAAG AACCAAGCCA TGCTCTGTCT

101 ACTGGCAATG GGCCTCCCTAC CCACACTGGC TTCCTGCCTC CCACCCCTCA

151 CACCTGGCTT CTAGAATAGA GGATTGCTCA GCATGA

!!AA SEQUENCE 1.0

ID\_ADP30829 standard; protein; 345 AA.

XX ADP30829;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1596.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

PN WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
PD 29-AUG-2002; 2002US-0406579P.  
PF 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406645P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.

PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2827; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX Sequence 345 AA;  
ADP30829 Length: 345 February 22, 2005 12:25 Type: P Check: 7109 ..  
1 ATGCCAGCTG TGCCACCCCGT CGCCGGTGCCA CGCCGCGCGC CACCTGAGCC  
51 TGGAGACTCT GACCGCTTTC GTGCTTTCCTT TCGGGCTGAT GCTCGGCTGC  
101 TACAGCGTGA CGTTGGCAGC GCTGCGGGGC GCCCGCTGGG GCTCGGGGCG  
151 GCACGGGGCG CGGTGGGGCC GGCTGGTGAG CGCCATCGTG CTTCGCTTCG  
201 GCTTGCTCTG GGGCCCCCTAC CACGCAGTCA ACCTTCTGCA GCGGCTGCGA  
251 GCGCTGGCTC CACCGGAAGG GGCCTTGGCG AAGCTGGGCG GAGCCGGGCA  
301 GCGCGCGCGA GCGGGAACTA CGGCTTGGC CTTCCTTCAGT TCTAG  
!!AA SEQUENCE 1.0  
ID \_ADP30863 standard; protein; 1032 AA.  
XX ADF30863;  
AC ADF30863;  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1630.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 03-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kochakota S, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2861; 428pp; English.  
XX

CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1032 AA;

ADP30863 Length: 1032 February 22, 2005 12:25 Type: P Check: 5112 ..

1 TTCCAGGCCT TGATTCACCT GGTGAAGGC AACATGGCA CAGGGATCCT  
51 GGGACTACCC CTCGCTGTGA AGAAGCGGG CATCTGTATG GGGCCACTCA  
101 GTCTGCTGGT GATGGGCTTC ATTGCTTGCC ACTGTATGCA CATCTGGTGC  
151 AAGTGTGCCC AGCGCTTCTT CGTGAGCTTC TTCCTTATTA TCACCCAACT  
201 TGGCTTCTGC TGTGTGTACA TTGTGTTTTT GGCTGATAAT TTAACAACAGG  
251 TAGTGAAGC TGTTAATAGC ACACCAACA ACTGCTATTTC CAATGAGAGC  
301 GTGATTCTGA CCCCACCAT GGACTCGGA CTCTACATGC TCTCCTTCCT  
351 GCCCTTCCTG GTGTGTGGG TCCTCATCCG GAACCTCAGG ATCTTGACCA  
401 TCTTCTCCAT GCTGGCCAAAC ATCAGCATGC TGGTCAGCTT GGTCTATCATC  
451 ATACAGTACA TTACCCAGGA AATCCAGAC CCCAGCCGGT TGCCACTGGT  
501 AGCAAGCTGG AAGACTACC CTCTCTCTTT CGGAACAGCC ATTTTCTTCT  
551 TTGAAGACAT TGGTGTGGTT CTGCTCTCTGG AAAACAAGAT GAAGAATGCC  
601 CGCCACTTCC CAGCCATCCT GTCTTTGGGA ATGTCCATCG TCACTTCCCT  
651 ATACATTGGC ATGGCGGCTC TGGGCTACCT GCGTTTGGGA GATGACATCA  
701 AGGCCAGCAT AAGCCTTAAC CTGCTTAAC TCAAGGTCCC TCTCAGTCAAT  
751 TTTCAGAAAG GGAAACAAA GCCCAAGTCA TTGTCCCAAG GTCAGAGGTG  
801 TTCCAAGGAG GCCAGTGTCA GAACACAGTG GCGGTGGAGA GCAGCTCTGT  
851 GGTCTTTGCAG GCTGTACCAG TCTGTCAAGC TTCTCTACAT TGCCGGCATC  
901 CTGTGCACCT ATGCCCTGCA GTTCTACGTC CCTGCAGAAA TCATCATCCC  
951 CTTTGGCATC TCCGGGTGT CAACACGCTG GGCACCTGCC CTGGATCTGT  
1001 CCATTCGCCT CGTCATGGTC TGCCTGACAT GC

!!AA SEQUENCE 1.0

ID \_ADP30945 standard; protein; 1629 AA.

XX

AC ADP30945;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1712.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

FN WO2004035732-A2.

XX

PD 29-APR-2004.

XX



PF Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2943; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1629 AA;

ADP30945 Length: 1629 February 22, 2005 12:25 Type: P Check: 3974 ..

1 TTCCACGGGG AGAAGGCGCAT CTCCATCCCG GACCACGGCT TGTGCCAGGC

51 CATCTCCATC CCGCTGTGCA CGGACATCGC CTCACACGAG ACCATCATGC

101 CAAACCTTCT GGCCACACAG AACGAGGAG ACAGAGGCTT AGAGTGTCAC

151 CAGTTCTATC CGCTGTGTGA GGTGCACTGC TCGCCGGAAC TGCGCTTCTT

201 CCTGTGCTCC ATGTAGCAC CCGTGTGCAC CGTGTGCAA CAGGCCATCC

251 CGCGGTGCCG CTCTATTCTG GAGCGCGGCG GCCAGGGCTG CGAAGCCCTC

301 ATGAACAAGT TCGGTTTTCA GTGGCCCGAG CGCTGCGCT GCGAGCACTT

351 CCCGGCCAC GGGCCGAGC AGATCTGCTT CGGCCAGAAC CACTCCGAGG

401 ACGAGCTTCC CGCGTACTC ACCACCGGCG CGCGCGCGGG ACTGCAGCGG

451 GGTGCCGGG GCACCCCGGG TGGCCCGGGG GGGGGGGGNC GNNTCNCCCC

501 GCGTACGCC ACGCTGGAG ACCCTTTCCA CTGCCCGGCG GTCTCTAAGG

551 TGCCATCCTA TCTACGTAC AAGTTTCTGG GCGAGCGTGA TTGTGCTGGG

601 CCCTGCGAAC CTGCGCGGCG CGATGTTTCC ATGTTCTTCT CACAGGAGCA

651 GACGGTTTC GCGCGCTCT GATCTCTCAC CTGTCGGTG CTGTGCTGGG

701 CTTCCACCTT CTTACTGTG ACCAGTACT TGGTAGACAT GCAGCGCTTC

751 CGCTACCCAG AGCGGCTTAT CATTTTTCTG TCGGGCTGCT ACACCATGCT

801 GTCGGTGCC TACATCGCG GCTTCTGCTT CCAGGAGCGG GTGGTGTGCA

851 ACGAGCGCTT CTCGAGGAC GGTACCSCA CGGTGTGTGA GGGCACAAG

901 AAGGAGGCT GCACCATCTT CTTATGATG CTCTACTTCT TCAGCATGCG

951 CAGCTCCATC TGGTGGGTCA TCCTGTGCTT CACTGTGCTT CTGGCAGCGG

1001 GCATGAAGTG GGGCCACGAG GCCATCGAGG CCAACTCTCA GTACTTCCAC

1051 CTGCGCGCTT GGGCGGTGCC GGGCGTCAAG ACCATCACCA TCCTGGCCAT

1101 GGGCCAGATC GACGGCGACC TGCTGAGCGG CGTGTGCTTC GTAGGCTCA

1151 AAGCCTGGA CCGCTGCGG GCGTCTGTC TAGCGCGCTT CTTGCTGTAC

(FIVE-) FIVE PRIME THERAPEUTICS INC.

1201 CTGTTTCATCG GCACGTCCITT CCTCCTGGCC GGCTTCGTGT CGCTCTTCGG  
1251 CATCCGACC ATCATGAGC ACAGCGGCAC CAAGACCGAA AAGCTGGAGC  
1301 GGCTCATGGT GGCATCGGC GTCTTCTCGG TGCTTACAC AGTGGCCGGC  
1351 ACCATCGTCA TCGCTTGCTA CTTCTACGAG CAGGCGCTTC GCAGCACTG  
1401 GGAGCGCTCG TGGGTGAGCC AGCACTGCAA GAGCTTGCC ATCCCGTGCC  
1451 CGGCGCACTA CACGCCGCG ATGTGCGCG ACTTACGGT CTACATGATC  
1501 AAATACCTCA TGACGCTCAT CGTGCGCATC ACGTCGGGCT TCTGGATCTG  
1551 GTCCGGCAAG ACCTGCACT CGTGAGGAA GTTCTACT CGCTCACCA  
1601 ACAGCCGACA CGGTGAGACC ACCGTGTGA  
IIA SEQUENCE 1.0  
ID ADP30964 standard; protein; 1192 AA.  
AC ADP30964;  
XX  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1731.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406598P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.

17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471308P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2962; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 1192 AA;  
SQ  
ADP30964 Length: 1192 February 22, 2005 12:25 Type: P Check: 7390 ..  
1 GTCCGGCGTG CTGCTGGTCC CCGGGCAGAG GAGGCGTGG CGGCTCCGGG  
51 ACCACGAGC CTGGTGACGC GGCCTCCCC TGCCCGGGTC GGGTTGCCCA  
101 GGCGCGCGCG CGGCGGCTGC TGCTGTGCT GCCTGTGCTG CTGGGTAGGG  
151 GACTTCGAGT AACGCCGAG GCCTCGGCTT CCTCCTCTGG GCGCGCGGTC  
201 GAGACAGCA GGGCATGGA GGAGCTGCT ACTGAGAAG AGCGGGAAGA  
251 GAGCCACCGG CCAGACAGT TGAGCCTGCT CACCTTCATC CTGCTGCTCA

```
301 CGCTGGCCAT CCTACCATTA TGGCTCTTCA AGTACTGCCG GGTGCACTTT
351 CTGCATGAGA CCGGGCTGCG CATGATCTGT GGGCTCATCG TTGGGCTGAT
401 CCTGAGGTAT GGTACCCCTG GCACACGGG CCGTGACAAA TTACTCAATT
451 GCACTCAAGA AGATCAGGCC TTCAGACTTT TAGTAGTGGG GTCTACGGGT
501 AAATTCTTCG AATACACCTT GAAAAGAGAA ATCAGCCCTG GCAAGATCAA
551 CAGCGTAAAG CAGAAATGACA TGCTAGGAA GCAGAGAACT TCATCTTCTC
601 CTGCATGATC CTGGGCTAT TTACTTTCCA GAAGCAGTTT TTGAGCCCTG
651 TTTTCATCAT TGGAGCTTTT GTTGTGTCTT TCCTGGGCAG AGCCGCCCAT
701 ATCTACCCGC TCTCTTTCTT CCTCAGCTTG GGCAGAAAGC ATAAGATTGG
751 CTGGAATTTT CACACACGA TGATGTTTTT AGCCTCAGG GGAGCAATGG
801 CATTTCGGTT GGCCATCTGT GACACGGCAT CCTATGCTCG CCAGATGAGG
851 TTCCCCACCA CGCCTTTCAT CGTGTCTTTC ACCATCTGGA TCATTGGAGG
901 AGGCACGACA CCCATGTTGT CATGGCTTAA TATCAGAGTT AGCATCAAGG
951 AGCCCTCCAA AGAGGACCAC AACGAACACC ACCGACAGTA CTTTCAGATT
1001 GGTGTTGACC CTGATCAAGA TCCACCACCC AACANTGACA GCTTTCAAGT
1051 CTTACAAGGG GACACCCGAG ATTCTGCCAG AGGAAACTGG ACNAAACAGG
1101 AGAGCACATG GATATTGAGG CGGTGTGACA GCTTTGATCA CAATTACCTG
1151 AAGCCCATCC TCACACAGAG CGGCTCCCG CTAACACCA CT

!!AA_SEQUENCE 1.0
ID ADP30992 standard; protein; 1746 AA.
XX
AC ADP30992;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #1759.
XX
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW cancer; inflammatory; immune; human secreted protein.
XX
OS Homo sapiens.
XX
PN WO2004035732-A2.
XX
PD 29-APR-2004.
XX
PF 28-AUG-2003; 2003WO-US026780.
XX
PR 29-AUG-2002; 2002US-0406576P.
PR 29-AUG-2002; 2002US-0406579P.
PR 29-AUG-2002; 2002US-0406585P.
PR 29-AUG-2002; 2002US-0406588P.
PR 29-AUG-2002; 2002US-0406608P.
PR 29-AUG-2002; 2002US-0406611P.
PR 29-AUG-2002; 2002US-0406612P.
PR 29-AUG-2002; 2002US-0406616P.
PR 29-AUG-2002; 2002US-0406640P.
PR 29-AUG-2002; 2002US-0406642P.
PR 29-AUG-2002; 2002US-0406646P.
PR 29-AUG-2002; 2002US-0406653P.
PR 29-AUG-2002; 2002US-0406655P.
PR 29-AUG-2002; 2002US-0406666P.
PR 17-SEP-2002; 2002US-0410948P.
PR 17-SEP-2002; 2002US-0410947P.
PR 17-SEP-2002; 2002US-0410949P.

17-SEP-2002; 2002US-0410949P.
17-SEP-2002; 2002US-0410953P.
17-SEP-2002; 2002US-0410957P.
17-SEP-2002; 2002US-0410958P.
17-SEP-2002; 2002US-0410959P.
17-SEP-2002; 2002US-0410960P.
17-SEP-2002; 2002US-0410961P.
17-SEP-2002; 2002US-0411019P.
17-SEP-2002; 2002US-0411022P.
17-SEP-2002; 2002US-0411023P.
17-SEP-2002; 2002US-0411024P.
17-SEP-2002; 2002US-0411032P.
17-SEP-2002; 2002US-0411035P.
17-SEP-2002; 2002US-0411037P.
17-SEP-2002; 2002US-0411041P.
17-SEP-2002; 2002US-0411045P.
17-SEP-2002; 2002US-0411046P.
17-SEP-2002; 2002US-0411048P.
17-SEP-2002; 2002US-0411052P.
17-SEP-2002; 2002US-0411055P.
17-SEP-2002; 2002US-0411073P.
17-SEP-2002; 2002US-0411082P.
17-SEP-2002; 2002US-0411101P.
17-SEP-2002; 2002US-0411111P.
18-APR-2003; 2003US-0463700P.
18-APR-2003; 2003US-0463708P.
18-APR-2003; 2003US-0463716P.
18-APR-2003; 2003US-0463732P.
02-MAY-2003; 2003US-0467199P.
02-MAY-2003; 2003US-0467201P.
02-MAY-2003; 2003US-0467203P.
02-MAY-2003; 2003US-0467230P.
19-MAY-2003; 2003US-0471306P.
19-MAY-2003; 2003US-0471336P.
22-MAY-2003; 2003US-0472420P.
22-MAY-2003; 2003US-0472430P.
09-JUN-2003; 2003US-0476609P.
09-JUN-2003; 2003US-0476641P.
08-JUL-2003; 2003US-0485218P.
08-JUL-2003; 2003US-0485223P.
08-JUL-2003; 2003US-0485224P.
08-JUL-2003; 2003US-0485325P.
14-JUL-2003; 2003US-0486446P.
14-JUL-2003; 2003US-0486480P.
15-JUL-2003; 2003US-0486891P.
15-JUL-2003; 2003US-0486960P.
08-AUG-2003; 2003US-0493341P.
08-AUG-2003; 2003US-0493370P.
08-AUG-2003; 2003US-0493573P.
08-AUG-2003; 2003US-0493577P.
XX
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX
XX WPI; 2004-348438/32.
XX
XX New nucleic acid molecule for diagnosing, preventing or treating diseases
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PT genetic, bacterial and viral diseases.
XX
XX Claim 1; SEQ ID NO 2990; 428pp; English.
XX
XX The present invention relates to an isolated nucleic acid molecule
CC encoding a polypeptide which is believed to be cytostatic,
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
CC composition and methods are useful for diagnosing, preventing and
CC treating diseases such as proliferative (e.g. cancer), inflammatory,
CC immune, metabolic, genetic, bacterial and viral diseases. The present
CC sequence represents a human secreted protein. The present sequence is
```

CC available on WIPWEB and is not in the specification.

XX  
SQ Sequence 1746 AA;

ADP30992 Length: 1746 February 22, 2005 12:25 Type: P Check: 1449 ..

1 CTCATTGCC GGGCCAGTGC GGGAGCCGGA GCGGAGCCGG GCGCGGAGCG  
51 GGGGGAATGG AGCCCTCTGG GCGGCCCGGG CTGCGCGCGC TGTGTCGGCC  
101 GCTGCTGCTC TGTCTGCTGT CACTGCCGCC CCGCGCCCGG GCCAAGTAGG  
151 TGCGGGGCAA CCTCAGTTCC AAGGAGGACT GGGTGTTCCT GACAAATTTT  
201 TGTTCCTCT CCGATTACGG CCGACTGGAC TTCCGTTTCC GCTACCTGA  
251 GGCCAAGTGC TGTCAAGACA TCCTCCTCTA TTTTGATGAC CCATCCCACT  
301 GGCAGCCGT GTACRAGGCA GGGGACNAGG ACTGCCTGGC CRAAGGAGTCA  
351 GTGATCCGGC CGGAGAACAA CCAGTCAATC AACCTACCA CCAGTATGC  
401 CTGTCGGCGC TGTCAAGTGG TATCAGAGGA GGGAAACCCG TACCTGAGCT  
451 GCTCCAGTGG CCGCAGCTTC CGCTCAGTGC GTGAACGGTG GTGGTATATT  
501 GCGCTCAGCA AGTGTGGGGT AAGGGGCTGG GCTGGAGTAT GAGATGGTCC  
551 TCACCAATGG CAAGTCTTTC TGGACACGAC ACTTCTCCGC TGATGAGTTT  
601 GGGATCCTGG AGACAGATGT GACCTTCTCT CTCATCTTCA TCCATCATTT  
651 CTCCTCTCT TGTACTTTTG GATATTGGT GAAAGTTCGT CAGTTGCTCC  
701 ACACAACTTA TAAATGTTC ATGGCCGCGC CAGGAGTAGA GGTCTTGAGC  
751 CTCCTATTTT TCTGCATCTA CTGGGGTCAA TATGCCACCG ATGGCATTGG  
801 CAACGAGAGT GTGAAGATCT TGGCCAAAGT GCTCTTCTCC TCAGGTTTCC  
851 TCATCTTCTT GCTGATGCTT ATCTCTCTGG GGAAGGGATT CAGGTTGACA  
901 CCGGGCCGCA TCAGCCACGC GGGCTCCGTG AAGTTGCTG TCTACATGAC  
951 CCTGTACAG CTCACCCATG TGGTCTGCT CATCTACGAG CGGGAATTTT  
1001 TTGACCCAGG CCAGGTACTG TACAGTATG AGTCGCGCGC CGGCTACGGG  
1051 CTCATTGGAC TGCAGTGGC GGCCTACGTG TGGTTCTGCT ATGCTGTGCT  
1101 TGTCTCACTG CGACACTTTC CTGAGAAGCA GCCTTTTAT GTGCCCTTCT  
1151 TTGCTGCTTA TACCTCTGTT TTCTTTGGG TTCCTGTCTAT GGCCCTGATT  
1201 GCCAATTTTC GCATCCCAAA GTGGGCCCGG GAGRAGATT TCAATGGCAT  
1251 CCAGCTGGG ATCCACTTGT AGCCCATGAG GGTGTTTCTG ATCATGACCC  
1301 GCCCATCAGC GGGCAACAAG AACTTCCCGT ACCACGTGGC CAGTGGCAG  
1351 ATCGCTTTCAG CCGGATCCC TGGACCCGGA GGGAGCCCAT CCGCTGACAA  
1401 GGCCTTCCCG CAGCAGTCTT ATGGAAAGT GACGTTTATC AGGCACTCGG  
1451 TGCCCAACTT CAGGAGCTC TTCTCCATCC CCGCGCCCGC CAGCTCCGCC  
1501 GGGNAGCAGG TGGAGGAGAC AGCGTGGG GCGCGGTGG CCCCAGGGG  
1551 CCGGTTGGTG ACCATGGCG AGCGGGGGC AGCTCCCCC CCACTTCCCG  
1601 CTCGGTTCCC CAAGGGGCG GACTCGGGT GGGACGGCCC GAGCGCGCCC  
1651 TACAGCCGC TCGTGCCCCA GACGCGAGC CCGCACACCG GCTTACCGA

1701 ATACTTCAGC ATGCACACGG CCGGGGGCAC TGCACCCCCG GTCTGA  
!!AA SEQUENCE 1.0  
ID ADP31012 standard; protein; 762 AA.  
XX  
AC ADP31012;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1779.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN W02004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.

PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0482218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3010; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 762 AA;  
ADP31012 Length: 762 February 22, 2005 12:25 Type: P Check: 8731 ..  
1 ATGGAGGGGG AGGAGAAGGA GAAGGAGGAG GAGGAGGAGG AAGACGACGA  
51 GGAGGAGAGAG GAGGAGCAGG AAGAGAAGGA GGAGAAGGAG AAGGAGAGA  
101 GGAAGAGGAA GAGGAGGAGG AGGAAGAGGA GGAGAAGACT GACTGACTCC  
151 TCTGGCTCCA AAAACTCTGA TGTTTGCCTT CTCTTTTCCC AGCAGTTGTA  
201 TTCCCTCCAC GCCAAGTTCA GCCAAGAAGG AATGTCCTTT AATAACCAAG  
251 ACTCAGACAG CCCAGCAGTC ATTGCCTTTG GATGCTTTTC CATCCCTCAG  
301 ATGTTGGATT CAAGGAGGG TCGCTTCGAC GAGCGGCTAG GTGCACTCGG  
351 GCGGCAGCAC TTTCACGGC AGGAGCTGGA GTGGGGCTCT GGGAGCCCTT  
401 TCGGCTCTCT CGGTGGGGAG CTGAGTCCCG GGTGTTTGAG GCGGGGGTCC  
451 CTTAGACCG CTACGGGCC CTGGCGCTG ACGGGCCCGC GAGGGGCTCA  
501 CCCTCCGAAG CGAGCTCGC CGAAGGCAGA CGCGGACCGG ACTTGTCCTT  
551 GCACAGCAGG CGCGAGCAG CGCAGCGGGA GGACGCGGGA GGTGCTGCC  
601 TCCCCCGGA GTTGGNAGG CCTTAGTCGG GTCCAAAATG CCCAAGAAGA  
651 GCGCAGCGCC CATCAGCTG ACCCCAGCC CCGACGGCTC CAGCCGTGGT

701 TAACGGGACC AGCTCTGCGG AAACCAACTT GGAGGCTTTS CAGAAGAAGC  
751 TGAAGAGACT AG  
!!AA\_SEQUENCE 1.0  
ID ADP31014 standard; protein; 486 AA.  
XX  
AC ADP31014;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1781.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.

PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3012; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 486 AA;  
ADP31014 Length: 486 February 22, 2005 12:25 Type: P Check: 5040 ..  
1 ATGTTCTGCG AGGCTGTACA GGAAGCACAG TGCTGCACAT CTGCTCAGCT  
51 TCTGGGAAGG CTCAGGGAGC TTTTACTCAT GGCAGAAGGT GAAGCAAGAG  
101 CAGGCACATC ACATGGGCGAG CCCTTCGGCT CTCTGCGTGG GGAGCTGAGT  
151 CCCGGTGTG TGAGGGCGGG GTCCCTTAAG ACCGCTACCG GCCCTCGGC  
201 GCTGACGGGC CCGCAGGGGG CTCACCTCTCC GAAGGACGCC TCGCCGAAGG  
251 CAGACGCGGA CCGGACTTGG TCCTGCACAG CAGGCGCGGA GCAGCGCAGC  
301 GGGAGGACGC GAGAGTGTCT GCCCTCCCCC CGGAGTTTGA AGCGCTTAG  
351 TCGGTCCAA AATGCCAAG AGAGCGCGA CGCCATCCA GCTGACCCCA  
401 GCCCCGACG GCTCCAGCG TGTTTAACGG GACCAGTCT GCGGAACCA  
451 ACTTGGAGGC CTTGCAGAAG AAGCTGGAG AGCTAG  
IIA-SEQUENCE 1.0  
ID\_ADP31028 standard; protein; 1789 AA.  
XX  
AC ADP31028;  
XX

DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1795.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411011P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.

PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3026; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1789 AA;  
SQ  
ADP31028 Length: 1789 February 22, 2005 12:25 Type: P Check: 9653 ..  
1 ACAAGGAGGA CGTGATGACG TGCCTGATTA AGGGGTGCAA CTTCTGTCTC  
51 AAGACATCC CCCATGAGGC CTTCTGTGTAC CAGAAGGATT CCGACCCCTGA  
101 GTTCCGGTTC CAGACCAACC ACCCCACAT TTTCCCTTAT CTTCTTGTC  
151 ATATCGGCTC TGGAGTCTCC ATCGTGAAGG TGGAGACGGA GGACAGGTTT  
201 GAGTGGTTCG CGGCAGCTC CATTGGAGGC GGCACCTTCT GGGGGCTTGG  
251 CGCTCTGCTC ACCAAMACGA AGAAGTTTGA CGAGCTCCTG CACCTGGCCT  
301 CGAGGGGCCA GCACAGCAAT GTGGACATGC TGGTGGCGGA CGTCTACGGC  
351 GGGCCCCACC AGACTCTCGG GCTGAGCGGG AACCTCATCG CCAGCAGCTT  
401 CGGGAAGTCG GCCACCGCCG ACCAAGAGAG TTCTCCAAAG AAGACATGGC  
451 GAAGAGCCTG CTGCACATGA TCAGCAACGA CATTGGGCGAG CTGGCCTGCC  
501 TCCACGCAGC GCTGCACAGC CTGACCGCGG TGTACTTTGG AGGCTTCTTT  
551 ATCCGGGGCC ACCCGGTGAC CATGCGCACC ATCACCTATA GCATCAACTT  
601 CTTCTCCAAG GGGGAAGTGC AGGCGCTGTT TCTGAGGCAC GAAAGCTACC  
651 TGGGAGCCAT CGGAGCGTTC CTGNAAGGAG CTGAGCAGGA CAATCCTAAC  
701 CAGTACAGCT GGGGAGAGAA CTATGCAGGC AGCTCGGGC TGAATGAGTC  
751 ATCACCAGAG CTCGGCCCGG CGCAGCGGGC GCGAGTGGC ACTTTTGACT  
801 TGCTGGAAT GGACGGGCTG GAGAGGCCAC TGGTTGACCT GCGGCTCCTC  
851 CTGGACCCGC CCTCTACGT GCCCGACAG GTGGACCTCA CCGATGACGC

901 TCTGGCCCGA AAATACTGGC TCACCTGCTT TGAGGAGGCC CTGGACGGGG  
951 TAGTGAAGCG CGCAGTGGCG AGCCAGCCAG ACTCTGTGGA TGCAGCCGAG  
1001 AGGGCGGAGA AGTTCCGGCA GAAGTACTGG AACAGCTTC AGACCCCTGAG  
1051 GCAGCAGGCC TTCCGCTATG GGACCCCTGAC CGTGGCGCAG CTGCTGGACA  
1101 CCAGGGAGCA CTGTCTGAAC GAGTTCAACT TCCCGGATCC CTACTCCAAA  
1151 GGCTGGGAGG AACGGCAGCT GCGCTGGTG AAAGGCCTCC TGGCGGGGAA  
1201 TGTCTTCGAC TGGGGGGCCA AAGCCGTGTC TGCTGTCTTT GAATCCGACC  
1251 CCTACTTTGG GTTTGAAGAA GCAAAGAGGA AGTTACAAGA AAGACCCCTGG  
1301 CTCGTGGATT CCTACAGGA GTGGCTTCAG AGATTAAAGA TAACAGTGA  
1351 APAGACATCA TTTTGGGAGT CTTCCCTTTT GTCAGGGAGC TACTCCTTAG  
1401 AGGGACAGAG GTCATCTGCG GTGCAACTC AGGCCCGGCC CTGAACGACG  
1451 TGACCCACAG CGAGTCCCTC ATCGTGGCAG AGCGTATTGC GGGCATGGAC  
1501 CCTGTCTCTT GCGCTCCAGG AAGAGAGGCT GCTGTCTGGT CAGACGGGCT  
1551 CCAGCTCCCC GTGCTCTGAC CTCAGCCGCC TGGATAAGGG GCTGGCCGCA  
1601 CTGGTGGCGG AGCGTGGCGG GATCTGGTGG GTCATCGAGG GCATGGGGCG  
1651 TGCTGTCCAC ACAAACTACC ACGCAGCCCT GCGCTGCGAG AGCCTCAAGC  
1701 TGGCGGTGAT CAAGAACGCG TGGCTGGCGG AGCGGCTGGG CGGCGGGGCTC  
1751 TTCACGCTCA TCTTCAAGTA CGAGGTCCCA GCCGAGTGA  
!!IAA SEQUENCE 1.0  
ID ADP31037 standard; protein; 848 AA.  
XX  
XX ADP31037;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1804.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; Inflammatory; Immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.







1551 TTTGGGACAC CTACTCTAGA TGAGCCGTGG CTGGAGTGG AAAACGACCG  
1601 AGAAGAGCTG CAGACTGCT TGAATTAAGGA GCAGCTGTCC CAGTTGAGCC  
1651 TTGCAGGAGC CTTGATGTC CCCCACGCCG AACTCGTTCC GACAGAGTGC  
1701 CAGGCTGTCA CGGCTCTGT-GTGCTCTGTC GATCTGGGAG GCAGAGACCT  
1751 GTGGGTGGC TGCACGGGCA GCTCTCAGC CTGCTATGCC TTGGCCACGG  
1801 ACTTCCCTGG GGGCTTGGAA CAGTGGAGG CCCAGGAGGT TGAATGTAAT  
1851 TCGTTTTCCT GGAACCTCAA GGAACCTCTT TTCACTGACC AGACAGACCA  
1901 AACGTATCA AATTGTTCT GTGCTAGTC TGAACCTAGA GAGACACCT  
1951 CTTCTTTGGC AGTGGCTCC GATCCAGATG TAGGCACTCT CCAGGAACAG  
2001 GGGTCGTGTG TCCTGGATGA CAGGAGCTG TTACTACTGA CCGGCACCTG  
2051 TGTGACCTT GGCCAAGGCC GAGGTTCCG GGAGAGCTGT GTGGGACATG  
2101 ATCCAACAGA ACCGCTTGA GTTTCTTTGG TGTCTCTGA GCATTATGCA  
2151 GCAAGCGACA GAGAAAGCCC AGGACACGTT CTTTCCAGT TGGATGCTGG  
2201 CCCTGAGGAC ACGTGCCAT CAGCAGAGGA GCCAAGGCTG AAGCTCAGG  
2251 TCACCTCCAC GCCCGTGATC GTGATGCGG GGGCTGCTGG CTTGACGCGG  
2301 GAGATCCAGG AGGGTGCCTA CTCGGGAGC TGCTACCATC GAGATGGCTT  
2351 ACGGCTGAGT ATACAGTTTG AGGTAGGGG GGTGAGCTC CAGGGCCCCA  
2401 CACCTCTGTT CTGCTGCTGG CTGTTGAAG ACTTCTTCCA CAGCCAAACG  
2451 GACTCAGCCG CCAGGACCCG CCGTTTCTT GCCAGCCTGC CCGGCTCCAC  
2501 CCACCTTACC GCTGCTGAGC TCACGGGACC CAGCCTGGT GAAAGTGCT  
2551 CAGAGCCAGA CCTGTGTTTG AGGAGCCCCC CAAGGCTGTG GAACTGGAGG  
2601 GTTTGGCGGC CTGTGAGGGC GAGTACTCCC AAAAGTACAG TACCATGAGC  
2651 CCGCTGGGCA GTGGGGCTT CGGCTTCTG TGGACTGCTG TGGACAAAGGA  
2701 AAAAAACAAG GAGGTGGTGG TGAAGTTTAT TAAGAAGGAG AAGGTCTTGG  
2751 AGGATTGTTG GATTGAGGAT CCCAAACTTG GGAAGTTTAC TTTAGAGATC  
2801 GCAATTCAT CAGGTTGGA GCACGCCAAT ATCATCAGG TATTGGATAT  
2851 ATTTGAAAAC CRAAGGTTCT TCCAGTTGT GATGGAGAAG CAGGCTCCG  
2901 GCCTAGACCT CTTGCTTTC ATCGACCCGC ACCCCAGGCT GGATGAGCCC  
2951 CTGGCGAGCT ACATCTCCG ACAAGACATC AAGATGAGA ACATCTGAT  
3001 CGCGAGGAC TTCAACATCA AGCTGATAGA CTTTGGCTCG GCCGCTACTT  
3051 TGGAAAGGGG AAAATTTATT TATACTTTT GTGGGACCAT CGAGTACTGT  
3101 GCACCGAAG TTCTATGGG GAATCCCTAC AGAGGGCGG AGCTGGAGAT  
3151 GTGGTCTCTG GGAGTCACTC TGTACACGCT GGTCTTTTGA GAGAACCCCT  
3201 TCTGTAGCT GGAGGAGACC GTGGAGGCTG CCATACACCC GCCATACCTG  
3251 GTGTCCAAAG AACTCATGAG CTTTGTGCT GGGCTGTGTC AGCAGTCCC  
3301 TGAGAGACGC ACCACCTTGG AGAAGCTGTT GACAGACCCG TGGGTAAACAC  
3351 AGCCTGTGAA TCTTGTGAC TATACATGGG AAGAGGTGTT TCGAGTAAAC

3401 AAGCCAG

!!AA\_SEQUENCE 1.0  
ID ADP31108 standard; protein; 222 AA.  
XX  
AC ADP31108;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1875.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.

PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3106; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antineoplastic, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 222 AA;  
ADP31108 Length: 222 February 22, 2005 12:25 Type: P Check: 4537 ..  
1 ATGGAGAGCA AAGCCCTGCT CGTCTGACT CTGGCCGTGT GGCTCCAGAG  
51 TCTGACCGCC TCCCGCGGAG GGGTGGCCGC CGCCGACCGT AAGTTTTCGG  
101 CGCAAACTCC CTCCACCTG CAGACCCGGC GGGTGGCCAC TGCCACCCGA  
151 ACTGAGGATG AGAAGAAGGA AGTTGGAGG GCGGCTGGAT GCGCCACGGG  
201 ACTCTCCAG CCTGGGCTCT AG  
!!AA SEQUENCE 1.0  
ID ADP31127 standard; protein; 888 AA.  
XX  
AC ADP31127;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1894.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406656P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC. PA

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kohakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3125; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 888 AA;  
ADP31127 Length: 888 February 22, 2005 12:25 Type: P Check: 3950 ..  
1 ATGCACATAG CAGTACCCA AGATGATCTA TGCCACAGAG AAGCAGGAGC  
51 CAAATTTTCA GCGACTTTAC AGGGTACTGT TCCTGTCAACC CCTGAGCAAC  
101 ATCCTTCTCT CCCTATACC CCACCTCAT CTGTGAAGCA TGCCGCCCTT  
151 ATTCAGAGT CCTCTGATGT CAGAGTAAG AGATTGAGA GTAGAAAAG  
201 AACAGACAG TTCAGTGCAA CCCCACCTT GTCATTTCTCC ATGGATGCCC  
251 ACAAGTCAG TGGAAAGCAG CTGCAACCTA CAGGGGCAGG GGCCACAGCC  
301 ATCCCCGGCG TTGGAGGGG ACAACGCACC CCTGCCAGAG GTGGAACCC  
351 CGGAGACCCC GTCTGTGGC GCCACTGCCA CACCGACTGC CTGGAGGCGC  
401 CGCTCTTCTT CCAGTGGCG AGGTGGCAGG TGGACGGCGA CCCTTGATC  
451 TTCCTGTGG CGCCCATGAT GCTGACGGCC GTGCTGGGGC CGGCTTCCT  
501 TCACCTTTCC AAGGACGAAG AGGAAGATCT GCAGGAGCAG TGCACTCCCG  
551 TGGGGAGCCC GGCCNAGGCG GAGACACGCT TTGTGCAGGG CTATTTCAAC  
601 ACCAACGATT CCTACCGCCT CTCACCTCC AGGAGGTGCA CTCAGGCCAA  
651 TTTCACTGG ATTCTCAAC CCACCTGTGG AACCGACAT CTTTGCAAAG  
701 TCAGTAATT GGACAGCAG GTGCAGGATC TACGTGTGGC ACAGGGAAC  
751 GGAAGCCAGA TCCAGTACGA GCAGGTGTGC GTGAGGTACA AGAGGCTCTG  
801 TGTGTCCTCC AACCCGTTCC TGGATGTCTG GCAAGTGGAC AAAACGTTG  
851 ACCTGAGCTA CAAACACAGT GAGCATCCCT CTGTCTGA  
!!AA SEQUENCE 1.0  
ID\_ADP31143 standard; protein; 575 AA.  
XX  
AC ADP31143;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DS Human secreted protein SEQ ID #1910.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.

PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3141; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 575 AA;  
ADP31143 Length: 575 February 22, 2005 12:25 Type: P Check: 8931 ..  
1 GGACTGGCTC ACCCACTCT TCGTGGGCTA CGTGTCCGTG AACTTCCTGC  
51 AGCCGCGACA CGCGAGCGT GCTCTGGCCA CCAATGAAC TT TGATGTTATA  
101 AAGGGCAAGC CAAATGGAAA GGAGTTCAGT GGAAGTCTC GTAACCAACA  
151 CTCTGAGACC AGCTTCTTCA CAGGTTCCAC CAGTCATGTC CACACAGTAT  
201 GTTGCTAACT CATCAATACA GACAAATTAGT CCAATGCTCTG TAGCTGCTGC  
251 TGTGCTCTCC ACTCTGCGG TCTACATCAT TCCACAGTAC AAATATGCTT  
301 CAGGAATTCT CATTCCTCAG CAGCATCTTA AAGCACATCC ACAGGTTACC  
351 AGNAGCAGC TTGCTGTTCA TGTCACAGGT CAAAACCTTT TGACTGCTTC  
401 CATGTTAGCA TCTGCCCTC TTCAGCAGCA GAAGCAGATA TTGGGTGAAA  
451 GACTCTTCC TCTATTCAA GCCACGCACC CTACTCTTGC TGGTAAATC  
501 ACTGGCATGT TATGGAGCT TGATAATTTA AACTTCTTTC ATATGCTTGT  
551 GTCTCCGGAG TCTCTGAAGC TGTAG  
IIAA SEQUENCE 1.0  
ID \_ADP31285 standard; protein; 811 AA.  
XX  
AC ADP31285;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2052.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX

XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-048691P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

XX PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RE, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX DR WPI; 2004-348438/32.  
XX DR  
XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX PS Claim 1; SEQ ID NO 3283; 428pp; English.  
XX CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX SQ Sequence 811 AA;  
ADP31285 Length: 811 February 22, 2005 12:25 Type: P Check: 2882 ..  
1 CTGCCCCCTCA ATGCGCGCC ACCATCTCTT GTGCCCCCTG TACACCCCTC  
51 AGAGGCCCTG CCCCCACCTG CGTGCCCCCTC AGCCCCCGCC CCATGCGGTA  
101 GCATCATCTC TAGGCTGTTT GGGAGCTGTC CTGCGCGCGA GGCAGGCCAT  
151 CCACCTCCAG GTGGGGCCCT GAAATTGCGA GCGTCCGCA CTTCCTCCTG  
201 CTGTGCCAG TCCACGGGC ACATCCCGG TGGCCTTGGC TTGGGGTTGG  
251 GTGCAGTGAG GGTTCGGTG CCGAGTGAAG AGGACCCAGC GTCACTGTTC  
301 ACAGAGCCAG TCCGGCGCG AGAGSCCCA GCACAGTCC AGAGTGTGA  
351 GGACTTCGTT GCCAATGACC GCCTGGACCG CAGCTTCTGT GAAGACATGA  
401 CCCCCGCCAG GGACGAGAAG AAGGTGGGGG CCAAGGCTGC CCAGCAGGAC  
451 AGCAGACGG GGAGGTCAA GTGAGGAGGA AGCAGAGTG GCGATCCCC  
501 CAAAAGGCC TGCCCCAGCT CCCCAGCAGT GCTCAGAGCC AGAGACGTCC  
551 TCCATACCAG CTTCGAAGCC ACAGAGGGGG ACAGTCCCA TGACGGCGCG  
601 AGCATCCCC TGCGCAGGTG GTGCTCTGT TCACACAGGT CTGGAGAGT  
651 GCAGCAGCAC CAGGCCCCCT GCTGAGATTG AGCCAGGGAA GGGTGAGCAG  
701 GCCTCTCTGT CCGAGAGTGA CCCCAGGGG CCCATCGCTG CACAAATGCT  
751 GTCCTTCGTC ATGGATGACC CCGACTTTGA GAGCGAGGCA TCAGACACAC  
801 AGTSCAGGC A  
!!AA SEQUENCE 1.0  
ID \_ADP31293 standard; protein; 1221 AA.  
XX AC ADP31293;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2060.  
XX CC Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.

XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406618P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406668P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.

PR 08-AUG-2003; 2003US-0493573P.  
XX 08-AUG-2003; 2003US-0493577P.  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3291; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1221 AA;  
SQ  
ADP31293 Length: 1221 February 22, 2005 12:25 Type: P Check: 3462 ..  
1 ATGAACAAC CQTATATCAG AACCTCAGC GAGAAGCCGC CCCCTTTGGA  
51 CCTAGAAGGT ATCTTGAAGG ACGCCAAGAT CCCCGTGTGC GGACCCCTTCC  
101 TGGTGAAGAT TGGCTACGG TTCGTGGACT GCCCAGACGA GATCTGGGCC  
151 CTCAGGCCCA TTGAGGCGCT TTCAGGTAAA ATAGAAGTGC ACGGAAACCC  
201 CATAGAAGTT GAGCACTCGG TCCCAAAAAG GCAAGGATT CGGAAACTTC  
251 AGATACGMAA TATCCCTCCT CACTTACAGT GGGAGCCCCG AGGTGCGCGG  
301 GGGCTTGGGC AGAGGGGCTC CTCAAGGCAG GGGTCTCCAG GATCCGTGTC  
351 CAAGCAGAAA CCAATGTGATT TGCCTCTGTG CTTGCTGGTT CCCACCCAAAT  
401 TTGTTGGAGC CATTATAGA AAGAAGGTG CCACCATTCG GNACATCACC  
451 AAACAGACCC AGTCTAAAT CGATGTCCAC CGTAAAGAAA ATGCAGGGGC  
501 TGCTGAGAAG TCGATTACTA TCCTCTCTAC TCCTGAAGGC ACCTCTGCGG  
551 CTTGTAAATC TATTCTGGAG ATTATGGTA AGGAACTCA AGATGTAAA  
601 TTCACAGAAG AGATCCCTTT GAAGATTTTA GCTCAAAATA ACTTTGTTGG  
651 CGCTCTTATT GGTAAAGAAG GAAGAAATCT TAAAAAATTT GAGCAAGACA  
701 CAGACACTAA AATCAGATA TCTCCATGTC AGGAATGAT GCAGTATAAT  
751 CCAGAACACA CATTACAGC TAAAGGCAAT GTTGAGACAT GTGCCAAGC  
801 TGAGGAAGAG ATCATGAAGA AAATCAGGGA CGGGCCCCCT TCAGCCATGA  
851 CTCCTCCCTC CCCGAGTCT GAGCAATCAG AATCCAGAC TGTTCATCTG  
901 TTTATCCCGG CTCATCAGT CAGAGCCCTC ATCAGCAAGC AGGGCCAGCA  
951 CATCAAGCAG CTTTCTCGCT TTGCTGGAGC TTCAATTACT GGAAAAAGGAG  
1001 GCAAAACGGT GAATGAATTT CAGAAATTTG CAAGTCAGA AGTTGTTGTC  
1051 CCTTGTGACC AGACACCTGA TGAGAATGAC CAAGTGGTTG TCAAAATAAC

1101 TGGTCACTTC TATGCTGCC AGTTTGCCA GAGAAAAATT CAGGAAATTC  
1151 TGACTCAGGT AAGCAGCAG CAACAACAGA AGGCTCTGCA AAGTGGACCA  
1201 CCTCAGTCAA GACGGAAGTA A  
!!AA\_SEQUENCE 1.0  
ID ADP31310 standard; protein; 11328 AA.  
XX  
AC ADP31310;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2077.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.

PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 03-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3308; 428bp; English.  
PS  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 11328 AA;  
ADP31310 Length: 11328 February 22, 2005 12:25 Type: P Check: 8623 ..  
1 ATGGGAAATT CACTGGGCTG TTTTAAAGGAG CCGAAAGAGT CAATAGCTAT  
51 TCCTGAGAAG GTCCTCATAT CTCCTAAGAA AAGGGTTGGG TTCAAAAGGA  
101 GGTGGAGAGG GAAGAAAATC CCTACTCCAG AGGCATCTCA CCAGGAAGAA  
151 ACCTCAGAAG GAACCTGAGT CATTTGAAGAG ACTGAAACCC TAACGAAGTT  
201 AACAGAGAGT CTCCTAAAAGG AAGACGGAGT GGGAGGGGTA GAGCATACCC  
251 CCCAGATAT TTTGCTGCCT GGGGACTCAG CCCCACACTC ACGGGTAGTC  
301 GATCGGGGGA TGATAGTACA GGTAAAGGAG AGATTCCNAG GGGAGGTCCA  
351 GACCGCCAC CTTTGTGTAG AGAATGAGTC ATCAGTTGCT GGAGGGGTCT  
401 GGGATTCCCT GGAAGAGGGG ATGACTGTCA TTGCTCACCT GCTTGATAAC  
451 CCAGCAGAAA GGAACCTGCGA GAAGTCAGTG AGCCAACTGG TGGAAATTTCC  
501 TAGGACAGCA TCCTGCAGCA CGAGGGCTGT GTTGCTGCCT TTGCAAGGAG  
551 AGACTGCAGT GGAGAAAGGA AATATTTCAG GTGGGTTTCG GAGCTGTGCT

601 TTGCTTAGGA CAGACTACCC CACTGATAAA GGAATCAAG ACAAATTTTC  
651 AAGGGCTGG AGTGTGGAGG AAGGAACAA GAGTGTTC A GGTGCCCTC  
701 AGACAGCTTC CTGGATTATA GAATGTTCTG TTTCTTCAIT ACTACTGGAC  
751 CAGCCTGGAG GCCAAGAGC CACGGAGCCT TCCCATGTGG GTCAAAGTGC  
801 CCCCCAGGAT TCCAGACTGC CTACTTCTCA GAGTGATTG TCCATCAGTG  
851 GTGTGACTGT GAGCAATTTG CCCTCCTCCT CTGGCTATGG CAGTGATGG  
901 CCACACATAC ATGGGATCCA GCCTAAAGAT ACAGAACCCTG AAAAGAGCTC  
951 TACTTCTTTC TCAGAAGAGG ATGGCACTCT TTCTCTGGAG GCAAGCCACA  
1001 CCCCATCATG GGGTCTGGAA GAGATCTCTG ACATCTACAT TAGTGGAGAA  
1051 TCAGGGGATA TGTAGCCAA GGAGAAACTA CTCCTGTGGA CCAGAAGGT  
1101 GACAGCTGGT TACACAGGAA TCAATGACAC CAACCTTTTC TCTGTCTGA  
1151 GTGATGGGAA GATGTTCAAT GCACTCATTC ACCGATACCG ACCCGATCTA  
1201 GTAGACATG AGAGGGTGCA AATCCAAAGT AACCGAGAGA ATCTGGAACA  
1251 GGGTTTTGAA GTGGCAGAAA GACTGGGGGT CACTCGCCTG CTGGATGCGAG  
1301 AAGATGTGGA TGTGCCATCT CCAGATGAAA AGTCTGTAAT CACTTATGTG  
1351 TCTTCGATT ATGATGCCTT CCCTAAAAGT CCTGAGGGTG GAGAAGGGAT  
1401 CAGTGTACG GAAGTGGACT CCAGGTGGCA AGAATACCAA AGCCGAGTGG  
1451 ACTCCCTCAT TCCCTGGATC AAACAGCATA CAATACTGAT GTCAGATAAA  
1501 ACTTTTCCCC AAAACCCCTGT TGAACCTAAG GTCTGGATTG AATTTGGCCG  
1551 AATTAACCTG CCTCAAGGTT ATCACTCTAA TGATGTGGAA GAAGAGTGGG  
1601 GAAAGCTCAT CATAGAGATG CTGGAACGAG AGAAATCACT TCGGCCGGCT  
1651 GTGAGAGGC TGGATTGCT GCTACAGATT GCAACAAAAA TCCAGAATGG  
1701 TGCTTTGAAC TGTGAAGAAA AACTGACACT AGCTAAGAT ACCTGTCAGG  
1751 CTGATGCTGC TCACCTGGAA TCAGGACAAC CGGTACAATG TGAGTCAGAT  
1801 GTCATTATGT ACATTCAGGA GTGTGAAGGT CTCATCAGGC AGCTGCAGGT  
1851 GGNATCCAG ATCCTGGCGG ATGAGAATTA CTACCAGCTA GAAGAGCTGG  
1901 CTTTAAAGGT CATGCTCTT CAGGATGAGC TGGTCACCTT GCGTCTAGAG  
1951 TGTACAAACC TGTACCGGAA GGGTCATTTT ACTTCACTTG AATTGGTTCC  
2001 ACCCTCTACT TTAACCAACA CTCATCTGAA AGCAGAACCC TTAACCAAGG  
2051 CAACCCATTC TTCTTCTACC TCCTGGTTCC GAAAGCCTAT GACTCGGGCT  
2101 GAACTTGTGG CCATCAGCTC CTCTGAAGAT GAAGGCAATC TCCGATTTGT  
2151 GTATGAACCTA CTGTCTTGGG TAGAAGAGAT GCAGATGAAA CTGGAGCGAG  
2201 CAGAGTGGGG CAATGACCTG CCTAGTGTGG AGTTGCAGCT AGAAACACAG  
2251 CAGCACATCC ATACGAGTGT AGNAGAGCTG GGCTCAAGTG TCAAGGAGGC  
2301 CAGGTTGTAT GAGGAAAGA TGTCCCGAAA TTTCCATACC AGCTATGCTG  
2351 AAACCTCTGG AAAGCTGGAG ACACAGTATT GTAAATTGAA GGAAACTTCT



2401 AGCTTCGGGA TGAGGCACCT TCAGAGCCTG CATAAATTTG TTTCAGAGC  
2451 TACAGCTGAG TTGATCTGCT TGAATGAGAA GGAGGAGGAG GAACTAGCAT  
2501 ATGACTGGAG TGACAACAAT TCCAATATCT CAGCCAAGAG AAATTACTTC  
2551 TCTGAGTTGA CAATGGAACCT GGAGAGAAA CAGGATGTGT TTCGTTCTCT  
2601 ACAAGATACA GCAGAACTAC TTTCACTTGA GAACCCACCCA GCCAAGCAGA  
2651 CAGTGAGGC TTACAGTGT GCTGTCCAGT CCCAGTTGCA GTGGATGAG  
2701 CAGCTGTGCC TGTGTGTTGA GCAGATGTG AAAGAGAATA CTGCTTATTT  
2751 TCAGTTCTTC AGTGATGCAC GAGAGCTGGA GTCAATCTTG AGGAACCTCC  
2801 AAGATTCAT TAAACGAAA TATTCTCTG ACCACAACAC CAGCTTATCC  
2851 CGCTTTGAAG ACCTGCTGA GACTCCATG GTCAGGGTCA TCGGGTTGGC  
2901 GCGCTCATCG GGGCATGGAG TCACCTGGGA TGAAGAAGAG CAGCTTATAC  
2951 AGTCCAAGAG TTCCGTGACC AGTCTCGTTG GGAGATCMAA RACCATCGTT  
3001 CAGCTAAAAC CAGGCAGTCC AGACCATGTG TTAAGAACA CCATTTCTGT  
3051 CAAGGCTGTC TGTGACTACA GGCAGATCGA GATTACTATT TGCAAAAATG  
3101 ATGAATGTGT GCTAGAAGAT AATTCTCAGC GGACCAATG GAAATGATC  
3151 AGCCCAACAG GGAACGAGGC AATGGTGCCG TCAGTCTGCT TCCTCATCCC  
3201 CCCACCCAAT AAGGATGCCA TTGAGATGGC CAGCAGGGTC GAAACAATCTT  
3251 ATCAGAGGT TATGCCCTT TGGCATCAGC TGCATGTTAA CACCAAAAGC  
3301 CTATCTCTTT GGAATATCT CCGTAAAGAC CTTGACCTTG TACAGACCTG  
3351 GAACCTAGAA AAGCTTCGAT CCTCAGCACC AGGGAGTGC CATCAGATTA  
3401 TGAGNAACCT TCAGGCCAC TATGAAGACT TTCTGCAGGA TAGTCTGAC  
3451 TCTGTCTGT TCTAGTGGC TGATCGTTG CCGTTGGAAG AGGAGGTGA  
3501 AGCTTGTAAG GCCCGCTTCC AGCACCTGAT GAACTCCATG GAGATGAGG  
3551 ACAAGAGGA GACTGTGCC AAGATGTACA TTTCAGAGTT GAAGAACATC  
3601 CGGCTACGC TGGAGGAGTA TGAACAGAGG GTGGTCAAA GAAITTCAGTC  
3651 TCTAGCCAGC TCTAGGACTG ACAGAGATGC CTGGCAGGAC AATGCATTA  
3701 GGATTCAGA GCAAGAGCAC ACCAGAGG ATTTACAGCA ATTGAGTCA  
3751 GACTTGGATG CAGTTTCTAT GAAATGTGAC AGCTTTCTCC ATCAGTCTCC  
3801 ATCTAGTTCA AGTGTCCAA CTCTGCGCTC AGAAGTGAAT CTGCTGGTGG  
3851 AGAAGATGA CCATGTCTAT GGTCTCTCTA CTGTATATCT GAATGAATTA  
3901 AAGACAGTTG ATGTTATAGT ACGTAGCATA CAGGATGCTG AACTCTGGT  
3951 CAAAGGTTAT GAGATTAAGC TGAGTCAAGA AGAAGTAGTA CTGGCAGATC  
4001 TCTCAGCTCT GGAGGCCCAT TGGTCGACAT TACGGCACTG GCTTAGTAT  
4051 GTGAAGGACA AGAATTCAGT GTTTTCAGTC CTGGATGAGG AAATTCGCAA  
4101 GGCCAAGSTA GTGGCAGAGC AGATGAGTCG TCTGACACCA GAGCGAAATC  
4151 TGGATTTGGA GCGTATACG GAAAAAGGCT CCCAGCTGCA GGAGGTTGG  
4201 CACCGAGTCA TTGCCAGCT CGAATTCGC CAATCTGAGC TAGAAGTAT

4251 CCAGGAAGTT CTGGAGATT ACCGAGCCTG CCATGGAAT CTCATCAAGT  
4301 GGATTTAGGA AACCACTGCC CAGCAGAAA TGATGAAGCC AGGCCAGCA  
4351 GAGGATAGCA GAGTGCTTTC GGAGCAGCTC AGCCAGCAGA CGGCCCTATT  
4401 TGCAGAAAT GAGAGAAATC AGACAAAAT GGATCAATGT CAAAAATTTT  
4451 CCCAGCAGTA CTCTACTATT GTAAAGGTAA CTTTACCACA TCCCAAAAAG  
4501 AACATGAATC ATCACCAGCT CAGAAAAACC TACATCTTCA CTGACTATGA  
4551 ATTGCAACTG ATGACATACA AGGCCTTTGT GGAATCGCAG CAGAAATCCC  
4601 CTGGCAAGCG CCGTCGCATG CTTTCTCTCT CAGATGCCAT CACTCAAGAG  
4651 TTCTATGGACT TAAGGACTCG CTACACGGCA TTGGTGACTT TAACNACTCA  
4701 GCACGTGAAA TACATCAGTG ATGCACCTCG GCGTCTGGAG GAGGAGGAGA  
4751 AAGTGGTAGA AGAGGAGAAA CAAGAACATG TGGAGAAGGT TAAAGAACTT  
4801 TTGGGCTGGG TGTCTACCCT AGCGAGGAAT ACACAAGGAA AAGCTACCTC  
4851 ATCCGAGACC AAAGAATCAA CAGACATTGA AAAAGCTATT TTGGAACAGC  
4901 AGTTCTCTGC AGAAGAGCTG ACAACAAGA AAGAACAAAT CTCTGAAGCT  
4951 ATTAACAAT CACAGATCTT CTTGGCCAAAG CATGTCTATA AGCTCTCAGA  
5001 AAAAGAGAAG AACAAAATAT CTGAGCAATT GAAATGCCCTA AACAAAGGCTT  
5051 ACCATGACCT TTGTGATGGT TCTGCAAATC AGCTTCAGCA GCTTCAGAGC  
5101 CAGTTGGCTC ACCAGCAGA ACAAAGGAA TGCAGAGCAG TTGCTGGGGT  
5151 GATTGACCTA GGCACAGTGG AGATATTTCC CATCTTCAA GCCATGCAAA  
5201 AGGCTCTCT TGACCAAGAC ACAGGCTAG TGCTTCTGA ATCTCAGGTT  
5251 ATCATGTCTG CCTCATTTGC CCTTGAGAGG GGTGAAAACC TCTCTTTGGA  
5301 GGAGGCATA GCCAGAAACC TCATTAATCC CCAGATGTAC CAGCAGCTCC  
5351 GGGAGCTACA GGATGCCCTG GCCTTAATAA GCAGGCTTAC TGAGAGCAGA  
5401 GGCCCTCTTT CTGTGTGGA AGCAATTGAA AAGAGAAATA TCAGTGAGAC  
5451 AGTTGGACTG AAAATCTTAG AAGCTCACCT GGCMACTGA GGTTCAGTC  
5501 TTTCCCTAG TGAGAACTGT ATTAACCTGG AAGAGGCTTT TCATCAAGGC  
5551 CTCATTTCTG CATGGCTTCA TTCAGTATTA GAGTCTTATC TTAGAACATC  
5601 CAAGAATTTG ATAGACCTA ACACAGCTGA GAAAATTTGT TTGCTGGATC  
5651 TGATGCAGCG ATGTATTGTC CACCAGGAAT CAGGATTCNA ATTACTGCTT  
5701 GTCAAAACAAT TGGCAGGGG GATGTGAGC TTGAAATCAG GCCGGAAGGT  
5751 TAGCATTTTC CGTGCAGTTC AGGAAGGCT AATAGATAGG CAGGCTACTG  
5801 TCCGGTTGCT GGAAGCTCAG CTTTTTGCTG GTGGCATAGT AGATCCAAGA  
5851 ACAGACACA GACTTACAGT GGAAGAGGCT GTAAGACATA ATCTGATGA  
5901 CCAAGATATG GCCTGTGCTA TCTCATAAG GCAGCTTCAG ACAGGAGCA  
5951 TCATAGACAC TGTACGGGG CAAAGGCTAA CAATAGATGA AGCAGTGAGC  
6001 AATGATCTAG TAGCTGCTAA GATCGCCCTT GTGATTTCTGG AGTCCCTCTG

6051 GTCAATCATG GGGTTGCTGT GGCCTGAATC TGGAGAGATC CTCCCAATTA  
6101 CAGATGCCCT AGAACAGGT ATTGTGCTTA CTGAACCTAGC ACATAAAATC  
6151 CTTAGTAACC GACAGCATAT TAAGGCTCTG TTCTTACCAG CAACCAAGA  
6201 GATTTTGTCC TGGAGAAAG CAATAGAAAG TGGTATCTTG GATAGAGATC  
6251 TTGGCAATAA CTTAAATCG ATTTGTATAC CTGATGTGAT GCCCCACATG  
6301 CAACCTAGCAG ACTCTGCAGA ACAAATATT AATCCTGGAG CAGCAGTTCT  
6351 ACCGTGCAGC AAGAGCCACC CTAAGSCCAG AGCAAGCCAG AGTGAGAATC  
6401 TGTGTGTCCA GCTGTGACT CACAGTATA TTAATGTGCA AATGTGACAG  
6451 AGGCTGCTTC TGTTAGATAA AGAGCTGATG GAGACACTAA CATCCAGAGA  
6501 TGAGTATCAA ACAAGTCTC CAAAAGTGGT TGAATTTGGG CATCAAGGC  
6551 AAAAACTCC TGAGGATTTG CAAGATCAG CTAATGTGAA AATCTCAGGA  
6601 ACTTTCAGCA GTGGGTGGAC TGTGAGGCTG CCTGAGTTCC AGTTTCTTC  
6651 TCAGAACAAA GAATATCCCG ATCGGGAAGA TTGCACCTACA GAAAAAGGCA  
6701 AAAAGACCAC TGTAGAAACA GAAGATTCTT CTGTAGAGAA CCTGTGACAG  
6751 GATCTGTTTG TAGAACAAAA AGAGAGAAAT CCNAACTATT ATGCTTTGAA  
6801 GGTAAATAAT AAAGTCAAAT TAGAGTACA AAGCAGTTG ATAGGTACCC  
6851 AAAGGGAAGA CCAACAGCA GTGTCTGTCA GAGAAATGC CAGCAGGGA  
6901 CACCTCCTGA CCATACCTCC TCGTGAGCG GAAGGTGTGC CGTTGTGTT  
6951 TGACAAAGAT GTTTTTCTG TTGAAACACC AAAGAAAGAA CATCAACCTC  
7001 TAAGAAACAC TTCCTTTACA TGTCAAGATG AACAGCNCA CACTCTTGAG  
7051 ACTGAATATA TTCATGATGA AACTGGAGGA TCTCACATAA AACCCCAAG  
7101 CAAAAAGTTA CAAGTTCAGG TAAAGAAAC TCTAGGTATA AAGTTAGAAC  
7151 TAAAGTCTGA AACTGTGGG AATGTTATC CTCTGGACAA AAAGGAAATG  
7201 TTAAGAAAAA CATTTCTGGC TAAGGATGAC CATAAAGAAA GTCAAGAAGC  
7251 ACAGAACATC GCAGGTGGTA GTATGATGAT GTCAGAAAAG ACCGATGAGG  
7301 AAGATAGTGG CAGGGAATTT TTTCTGTCTAT GCAGTCATCC ATTAGAATTG  
7351 CTTGAAGAAG CTACCTTAAA TGTATTATCT GCACAGTTAC TAGATGGTGG  
7401 TATCTTTTCAAT GAACAAACAG GTCAAAAGCT CTTACTRAAT GAAGCAATAT  
7451 CCCAGGCGAT TGTGCCAAGT CACACTGCCG TGAAGCTTAT GGAGAGCTG  
7501 AACATGTTTC AGGGGTCTTT TGACTCTCAG ACTTGTGAGT CTTTGACAAC  
7551 TGAAGAAGTC ATTAATGAAG GTCTGATGGA TGAGAAATTA TTACATAATG  
7601 TCCTCATGGC AGACAAAGCT ATAAGTGGTG TCTTAGACCC CCGTACCCAG  
7651 ACACGTGCT CTGTAAAGGA TGCAGTTACA GTTGGACTTC TTGACAAGGA  
7701 AACAGCCACC AGAATTTTAG AGAGGCAGGT GGTGACTGGT GGAATTATTG  
7751 ATCTGAACG AGCAAAAAA GTTTCAGTAA CTTTGGCCTC AACTCTTGGC  
7801 TTGGTGGACG TTGCTGACCA GCCAGAACTT ATAAATCTGG AGAAAGCTTC  
7851 CAAAGGTAGA GATGCTGAAA AAACAGTTAG GGAGAGATTA ATTAGTTTAC

7901 AAATGGAAC AACAGGACTT ATAGACCCTG ATAGTAAAGC ACCTTTAAAC  
7951 GTTGTGCAGT CCATTGCACAG AGGTCTTTTG GAGAGAGAGG AGCCCGTTTG  
8001 TTTGTTGACT AAGCAAGTGG TAGATGGAGG TATCATTTAC CATATATCTG  
8051 GGATGAGACT TTCTGTTGAT AATGCCTTCA GACATGGCTT AATTGGTGAA  
8101 GATTTAGCCG AGAAACTCAA AAGAGTTGAG AACTTAAACA TCCATCAGAT  
8151 TTTTAATCCT GAAACGAAGG AAAATATTTC CTCCCTTAAA GCCATAAAAT  
8201 TAGATCTTAT TACCTCAGAC CTGAAAAGAG AAATCCAGGA GGTTCAGGCC  
8251 TTTTACTGGAA ACTTTGTGGA TCTCATTTCT GGTCAAGAT TGCCTTGGC  
8301 AGAAGCTAAA AAAGAAGGAC TGTAACTTAA TGAAGCAGTA TTGTCTCCAG  
8351 GAATGATGCA TGGCATTGTA GATCCCGAGA ACTGCAGAA TGTCCCTTAC  
8401 TCAGAATTAG TCAAGAAATG TAAGATTGAT ATTGAATCTG GACAGAGATA  
8451 TCTAGAAGTA ATTCCCTTCT CAGACATTAA AGATGGGGTG AGCGACAAAG  
8501 TGCTTACATT GTCTCAAGCA ATTCAGCTTG GAAAAGTAGA CTTTGCATCT  
8551 ACCTGAAGG TTCTAGAAGC CCAGGCAAT ACTGGTGGAA TCATAGATAC  
8601 TGCTACTGGA AAAGACTGTA CATTTGGCAT AGCTTTGGAA GAGAACTGG  
8651 TGGATGAAAA CATGCTCAGA ATTATTGCAT CTCATCAGGT GTTAAATGGA  
8701 GGAATTGTTG ACATATTTAG TGATCAGAGA GTCACTTTAG TAGAAGCTAT  
8751 TGAGAAAAGA CTGATCAGCC CTGAACCTGC AAATATGATC CAAATAGATA  
8801 GTTCAGAGTT CAGCGATCAC AGGCTCAGA TTGAAAAGCA AGAAGGGATT  
8851 GAAGTGTGTG CATTACAAAA TGAATTTCTA GGAAGGATA TGTTAATTGC  
8901 TTGTAATCAG ACTGCTGAAA TGAGTTGTAA TAAAGTAGAA GAGAGTGAGA  
8951 GATTATTCCA AGTTGAAAAT CAGCTGCAC AAGAAAAGGT TAAAGTGAGA  
9001 GTTCTGTATG GGGAGCAGGC AAAAAAGAGC AGGAAATTTT CCTTAAAGGA  
9051 ATTTGGGTGC AAGGATCAAC GTAAAGCCAAG AATGTCTTCA GATGCTAAAG  
9101 AATTTATCAG TATCATAAAT CCTCATATC TTAAGAGTAA ATCCTTGGGC  
9151 CAAGTGTCTAT TGACACACC TTACTCTGAA TGTGATTTTA AACTTAAAGA  
9201 AGTGGCTAGA AATAACATGG GAAATGATAC AAATGAAGAG CAGGAAAAAG  
9251 CACTGCACAA AATAGAAAT ATTTCCTATA TGAAGCAGTC TACCTCATGT  
9301 CTGATTTCTG AAGAAATAG AGAAAATCAA GGGGAAGTGA TTTTGGAAAT  
9351 ACAAGAAAAA TATTGTGAAA CGTCAGGCCAA ATTGCCAGT GAGCAGTTTT  
9401 TGCAGCAACC AATGAATGCT CGGGTGAATA GTAAGAGAGA GAAGAGGAG  
9451 GTGATTGTAG AAGAAAGTAT CAGAACATGC AAACCAGCAT TTCTTTCTGA  
9501 AGAAAAGTTG TATCAGGAAA CTGCCATTAG AGATGAGCAT GACTCCATA  
9551 TAAAGAGCCA ACCTAGGGA ATGACCTCAA GTGAAAAAGG GAAAGAAGCT  
9601 GATACAGAAA TGGGATTTTC TATTACTTTT AAAATTGAAG AGTCCTCTTC  
9651 CCAAGTGGTA CCTCAAGGAA TTTCTGTAAA ACATTTAGAT GCTTTTACAC

9701 TCTTCAGCTC TAAACAGGCC AATGAAGGAA AAGTAAACAA TTTAAGTCTC  
9751 TGCTTGACTT TAAAAACGAGA AGAAAACCTTA TCTCGAGAAA TTGCTGTGG  
9801 GGCCACAGAGT GAACCATTCCT CTTGTATGAC CCCAAGACCT GAAGGATTGC  
9851 ACTACCAGGA ATCAGATGGA AAAGCCCAAG TGACAGGCC ATCCCAAAAT  
9901 TCAAAACAG ACAAGTCTTT CCAAGGAACC ACCAGACAGG AGACCAACTA  
9951 TCAAGATTCC TGGGTTACTT CGAAAACCTAA GGAACCCAAA CATCAAAATTT  
10001 CCTCATCTAA TGAATGTAAA GAAAGTCAT ACCAAGAGT ATCTTTTGAC  
10051 CCAGCAAGAG GTCTTAAATTT GGAAGAAATC ACAGTTTCTA GACCAGATTG  
10101 AAAAGAAGTC AGGTATCTAG AATTCTCAGA CAGAAAAGAC CTTTCATCATC  
10151 AGGGCAGCAA AAGTGATGAT AACTTTTGTG GAACTCTCAA ATCTGAAATA  
10201 GCAACACAGG AACTAACTGG AGAGAAATTT CTAGAAATGG CAAACCCCTAA  
10251 TGTTCAGGT CTAGAGCAG GATCCATTGA GGACATAGTG ACTCAGAGAG  
10301 GTTCCAGAGT CTTGGGATCC TTTCTTCCAG AGAACTGTT CAAAGAGTG  
10351 TCTCAAAAG AGAATACAGG GCAACAGAA GCCATCATTA GTCTACTGT  
10401 TCTAGAGACC AGTGAAGAA AGACAGTGT CCTAACAGTA TGCTCTGCAG  
10451 TGAAGACAGA GAAGACACA CAGGAAAGC TCAGAGAAAG CCTTGGCAGT  
10501 GAACAAACTC CTTTCATGAC TGCACCTGAA GGAAGGGGAA ATGGAGGTGT  
10551 AAACCCAGAG CCCTTCAGAG CAACTCAGAA TGTATTTACC CGCAACTCT  
10601 GTTTAGAAC TGATGAAAG CTAGTATCCT ATCTGTCTCT GTTACGGAAC  
10651 ATTGAAATGA GGACCAACAA GATTCAACCT TTGGAGCTAA ACCTGGCAGA  
10701 ACTACAGGAT CTGCTGTGTC AGGCCNAGGT ATTAGAAAGG GAGTTAAAGG  
10751 ATCTGACCAC CTTGTGTCAGT CAGGAGTGG AGTGTGTGAA TCAGATTATC  
10801 ATCAGCCAGC CTCAGAAAGT TCCTGTCTCA CTGTTGAAGG CTCCTAGAGAA  
10851 AGATGCCAAG AATCTTCAGA AGTCTCTCAG CTCTGTGAGT GACACTTGA  
10901 ATTCCAGGCT ACTCCACTTC CAGAACTGTG TGGAAATAGA AAAGACTAAA  
10951 GTGTTAAATC AGCACACACA GCTAGAAGGC CGACTTCAAG ATCTGAGAGC  
11001 CTGGGTTGCC AATAAAATC TTATTTCTGAA CAGCAGGGA TCTACAGTG  
11051 AAATGATGT TGACAGCTG AACCTCTGCC TCCAACAGTA TGAGGATTGG  
11101 AAACAGCCCA TGGCTGAAAG GAAAGCTCAG CTGATGCTC TTGCTTTTGA  
11151 TATTCAGTTC TTTATCTCAG AACATGCCCC GGNCTTGTCC CCTCAGCAGA  
11201 ATCGACAGAT GCTGAGGTTT CTGAATGAAC TGCAGAGGTC CTTCCAGGAC  
11251 ATTTTGGAA AGACTGCCGC TCAGGTGGAT GCCTTCAGG GCCATCTTCA  
11301 ACAATGGAG CAGNAGCCCC TGGTGAAG

!!AA\_SEQUENCE 1.0  
ID ADP31311 standard; protein; 10944 AA.  
XX  
AC ADP31311;  
XX  
DT 12-AUG-2004 (first entry)  
XX

DE Human secreted protein SEQ ID #2078.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX PD 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485225P.

PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3309; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 10944 AA;  
XX  
ADP31311 Length: 10944 February 22, 2005 12:25 Type: P Check: 4390 ..  
1 ATGGGAATT CACTGGGCTG TTTTAAGGAG CCGAAAGAGT CAATAGCTAT  
51 TCCTGAGAAG GCTCCCATAT CTCCTAAGAA AAGGTTTCGG TTCAAAGGA  
101 GGTGGAGAGG GAAGAAATC CTACTCCAG AGGCATCTCA CCAGGAAGAA  
151 ACCTCAGAAG GAACTGGAGT CATTGAAGAG ACTGAACCC TAACGAAGTT  
201 AACAGAGAGT CTCCTAAAGG AGACGGAGT GGGAGGGGTA GAGCATACCC  
251 CCCAGATAT TTGCTGCTT GGGGACTCAG CCCCCTCAGT ACGGGTAGTC  
301 GATCGGGGGA TGATAGTACA GGTAAAGGAG AGATTCCAAG GGGAGGTCCA  
351 GACGGCCAC CTTTGTGTTAG AGAATGATGC ATCAGTTGCT GGGGGGGTCT  
401 GGGATTCCTT GGAAGAGGGG ATGACTGTCA TTGCTCACCT GCTTGATAAC  
451 CCAGCAGAAA GGAAGTGGCA GAAGTCAGTG AGCCAAGTGG TGGAAATTC  
501 TAGGACAGCA TCCTGAGCA CGAGGGCTGT GTTGCTGCTT TGCARAGGAG  
551 AGACTGCAGT GGAGAAAGGA AATATTACG GTGGGTTTCG GAGCTGTGCT  
601 TTGCCTAGGA CAGACTACCC CACTGATAAA GGAATCAAG AACAAATTC  
651 AGAGGGCTGG AGTGTGGAGG AAGGAACCA GAGTGTTC A GGTGCCCTTC  
701 AGACAGCTTC CTGGATTATA GAATGTTCTG TTTCTTCATT ACTACTGGAC  
751 CAGCCTGGAG GCCARAGAGC CACGAGCCT TCCCATGGG GTCAGTGCC  
801 CCCCCAGGAT TCCAGACTGC CTACTTCTCA GAGTGATTG TCCATCAGTG  
851 GTGTGACTGT GAGCAATTTG CCCCTCCTCT CTGGCTATGG CAGTGATGGG  
901 CCACACATAC ATGGGATCCA GCCTAAAGAT ACAGAACCTG AAAAGAGCTC

951 TACTTCTTC TCAGAAGAGG ATGCACTCT TTCTCTGGAG GCAAGCCACA  
1001 CCCCATCATG GGGTCTGAA GAGATCTCTG ACATCTACAT TAGTGGAGAA  
1051 TCAGGGGATA TGTACGCCAA GGAGAAACTA CTCCTGTGGA CCCAGAAGGT  
1101 GACAGCTGCT TACACAGGAA TCAATGCAC CAACTTTTCC TCCTGCTGGA  
1151 GTGATGGGAA GATGTTCAAT GCACTCATTC ACCGATACCG ACCCGATCTA  
1201 GTAGACATGG AGAGGGTGCA AATCCAAAGT AACCGAGAGA ATCTGGAACA  
1251 GCGTTTTGAA GTGGCAGAAA GACTGGGGGT CACTCGCCTG CTGGATGCGAG  
1301 AGATGTGGA TGTGCCATCT CCAGATGAAA AGTCTGTAAT CACTTATGTG  
1351 TCTTCGATTT ATGATGSCCT CCCTAAAGTT CCTGAGGGTG GAGAAAGGAT  
1401 CAGTGTCTACG GAAGTGGACT CCAGGTGSCA AGAATACCAA AGCCGAGTGG  
1451 ACTCCCTCAT TCCCTGGATC AAACAGCATA CAATACTGAT GTCAGATAAA  
1501 ACTTTTCCCC AAAACCCCTGT TGAACCTAAG GTGTGGATTG AATTTGGCGG  
1551 AATTAAACTG CCTCAAGGTT ATCACCCTAA TGATGTGGAA GAAGAGTGGG  
1601 GAAAGTCTAT CATAGAGATG CTGGAACGAG AGAATCACT TCGGGCGGCT  
1651 GTGAGAGGCG TGAATTTGCT GCTACAGATT GCAAAACAAA TCCAGAAATGG  
1701 TGCCTTGAAC TGTGAAGAAA AACTGACACT AGCTAAGAAAT ACACGTGCGG  
1751 CTGATGCTGC TCACCTGGAA TCAGGACAAC CGGTACAATG TGAGTCAGAT  
1801 GTCATTTATGT ACATTCAGGA GTGTGAAGGT CTCATCAGGC AGCTGCAGGT  
1851 GGATCTCCAG ATCTGCGGG ATGAGNATTA CTACCAGCTA GAAGAGCTGG  
1901 CTTTTAGGCT CATGCTCTT CAGGATGAGC TGGTACACCT GGTCTAGAG  
1951 TGTACAAACC TGTACCGGAA GGGTCATTTT ACTTCACCTG AATTTGGTTCC  
2001 ACCCTCTACT TTAACCAACA CTCATCTGAA AGCAGAACCC TTAACCAAGG  
2051 CAACTCATTC TTCTCTACC TCCTGGTTCC GAAAGCCTAT GACTCGGGCT  
2101 GAACTTGTGG CCATCAGCTC CTCGAAAGAT GAAGGCAATC TCCGATTTGT  
2151 GTATGAACCTA CTGTCTTGG TAGAAGAGAT GCAGATGAAA CTGGAGCGAG  
2201 CAGAGTGGGG CAATGACCTG CCTAGTGTGG AGTTGCAGCT AGAAACACAG  
2251 CAGCACATCC ATACAGTGT AGAAGAGCTG GGCTCAAGTG TCAAGGAGGC  
2301 CAGTTGTAT GAGGGAAGA TGTCCAGAA TTTCCATACC AGCTATGCTG  
2351 AAACCTTGG AAAGCTGGAG ACACGATTT GTAAATTTGA GGAAACTTCT  
2401 AGCTTCCGGA TGAGGCACCT TCAGAGCCTG CATAAAATTTG TTTCCAGAGC  
2451 TACAGCTGAG TTGATCTGTT TGAATGAAA GGAGGAGGAG GAACTAGCAT  
2501 ATGACTGGAG TGACAACAA TCCAATATCT CAGCCAAGAG AATTAATCTT  
2551 TCTGAGTTGA CAAATGAACT GGAGGAGAAA CAGGATGTGT TTCGTTCTCT  
2601 ACAGATACA GCAGAACTAC TTTCACTTGA GAACCAACCA GCCAAGCAGA  
2651 CAGTGGAGGC TTACAGTGT GCTGTCCAGT CCAGTTGCA GTGGATGAAG  
2701 CAGCTGTGCC TGTGTGTTGA GCAGCATGTG AAAGAGATA CTGCTTATTT

2751 TCAGTTCTTTC AGTGATGCAC GAGAGCTGGA GTCAATCTTG AGGAACCTCC  
2801 AAGATTCCAT TAAACGAAA TATTCTGTG ACCACAACAC CAGCTTATCC  
2851 CGCCTTGAAG ACCTGCTCA GGACTCCATG GTCAGGGTCA TCGGGTTGCG  
2901 GGGGTCAATCG GGGCATGGAG TCACCTGGGA TGAAGAAGGAG CAGCTTATAC  
2951 AGTCCAAGAG TTCCGTTGCC AGTCTCGTTG GGAGATCAAA AACCATCGTT  
3001 CAGCTAAAC CACGCAGTCC AGACCATGTG TTAAGNACA CCATTTCTGT  
3051 CAAAGCTGTC TGTGACTACA GGCAGATGGA GATTACTATT TGCAAAATG  
3101 ATGAATGTGT GCTAGAAGAT AATTCTCAGC GGACCAATG GAAAGTGATC  
3151 AGCCCCACAG GGAACGAGC AATGGTGCCG TCAGTCTGCT TCCTCATCC  
3201 CCACCCCAAT AAGGATGCGA TTGAGATGGC CAGCAGGGTC GAACAATCTT  
3251 ATCAGAAGGT TATGGCCCTT TGGCATCAGC TGCATGTAA CACCAAAAGC  
3301 CTTATCTCTT GGAATCTACT CGGTAAGAC CTTGACCTTG TACAGACCTG  
3351 GAACCTAGAA AAGCTTCGAT CCTCAGCAC AGGGAGTGC CATCAGATTA  
3401 TGAAGAACCT TCAGGCCAC TATGAAGACT TTCTGCAGGA TAGTCGTGAC  
3451 TCTGTGCTGT TCTCAGTGGC TGATCGCTTG CGTTTGAAG AGGAGTGGA  
3501 AGCTTGTAAG GCCCGCTTCC AGCACTGAT GAAGTCCATG GAGAAATGAGG  
3551 ACAAGAGGA GACTGTGGC AAGATGTACA TTTTCAGAGT GAAGAACATC  
3601 CGGCTACGCC TGGAGGATG TGAACAGAG GTGGTCAAC GAATTCAGTC  
3651 TCTAGCCAGC TCTAGGACTG ACAGAGATGC CTGGCAGGAC AATGCATTAA  
3701 GGATTGCAGA GCAAGAGCAC ACCCAGGAGG ATTTACAGCA ATTGAGGTCA  
3751 GACTTGGATG CAGTTTCTAT GAAATGTGAC AGCTTTCTCC ATCAGTCTCC  
3801 ATCTAGTTCA AGTGTCCTAA CTCTGCGCTC AGAAGTGAAT CTGCTGGTGG  
3851 AGAAGATGGA CCATGTCTAT GGTCTCTCTA CTGTATATCT GAATAAGTTA  
3901 AAGACAGTTG ATGTTATAGT ACGTAGCATA CAGGATGCTG AACTCTTGGT  
3951 CAAAGGTTAT GAGATTAAAG TGAGTCAAGA AGAAGTAGTA CTGGCAGATC  
4001 TCTCAGCTCT GGAGGCCCAT TGGTCGACAT TACGGCACTG GCTTAGTGAT  
4051 GTGAAGGACA AGAATTCAGT GTTTTCAGTC CTGGATGAGG AAATTGCCAA  
4101 GGCCAAGGTA GTGGCAGAGC AGATGAGTGC TCTGACACCA GAGCGAAATC  
4151 TGGATTGGA CGCTATCAG GAAAAAGGCT CCCAGCTGCA GGAGCGTTGG  
4201 CACCGAGTCA TTGCCAGCT CGAGATTGCG CAACTGTAGC TAGAAAGTAT  
4251 CCAGGAAGTT CTGGGAGATT ACCGAGCTG CCATGGAAT CTCTCAAGT  
4301 GGATTGAGGA AACCACTGCC CAGCAGGAAA TGATGAAGCC AGGCCAGGCA  
4351 GAGGATAGCA GAGTGTCTTC GGAGCAGCTC AGCCAGCAGA CGGCCCTATT  
4401 TGCAGAAATT GAGAGAAATC AGACAAAAT GGATCAATGT CAAAAATTTT  
4451 CCCAGCAGTA CTCTACTATT GTAAAGGTAA CTTTACCACA TCCCAAAAG  
4501 AACATGAATC ATCACCAGCT CAGGAAAACC TACATCTTCA CTGACTATGA  
4551 ATTGCAACTG ATGACATACA AGGCCTTTGT GGAATCGCAG CAGAAATCCC

4601 CTGGCAAGCG CCGTCGCATG CTTTCTCTTT CAGATGCCAT CACTCAAGAG  
4651 TTCATGGACT TAAGGACTCG CTACACGGCA TTGGTGACTT TAAACAATCA  
4701 GCAGGTGAAA TACATCAGTG ATGCATCCG GGGTCTGGAG GAGGAGGAGA  
4751 AAGTGTAGA AGAGAGAAA CAAGAACATG TGGAGAAGGT TAAAGAACTT  
4801 TTGGGCTGGG TGTCTACCCT AGCGAGGAAT ACACAAGGAA AAGCTACCTC  
4851 ATCCGAGACC AAAGAATCAA CAGACATTGA AAAAGCTATT TTGGAACAGC  
4901 AGGTTCTGTC AGAAGAGCTG ACAACAAGA AAGAACAAGT CTCTGAAGCT  
4951 ATTAACAAT CACAGATCTT CTTGGCCAAG CATGGTCATA AGCTCTCAGA  
5001 AAAGAGAG AAACAATAT CTGAGCAATT GAATGCCCTA ACAAAGGCTT  
5051 ACCATGACCT TTGTGATGGT TCTGCAATC AGCTTCAGCA GCTTCAGAGC  
5101 CAGTTGGCTC ACCAGACAGA ACAAAGGAA TGCAGAGCAG TTGCTGGGGT  
5151 GATTGACCTA GGCACAGTG AGATATTTCC CATCTTCAAA GCCATGCAAA  
5201 AGGGCTCTCT TGACCAAGAC ACAGGCCTAG TGCTTCTGGA ATCTCAGGTT  
5251 ATCATGTCTG CCCTCATTGC CCTTGAGACG GGTGAAAACC TCTCTTTGGA  
5301 GGAGGACATA GCCAGAAACC TCATTAAATC CCAGATGTAC CAGCAGCTCC  
5351 GGGAGTACA GGATGCCCTG GCCTTAATAA GCAGGCTTAC TGAGAGCAGA  
5401 GGCCCTCTTT CTGTGGTGA AGCAATTGAA AAGAGNATAA TCAGTGAAC  
5451 AGTTGGACTG AAAATCTTAG AAGTCACCT GGCAACTGGA GGTTCAGTC  
5501 TTTCCCTTAG TGAGAACTGT ATTAACCTGG AAGAGGCTTT TCATCAAGGC  
5551 CTCATTTCTG CATGGCTTCA TTCAGTATTA GAGTCTTATC TTAGAACATC  
5601 CAAGAATTG ATAGACCTTA ACACAGCTGA GAAAATTGGT TTGCTGGATC  
5651 TGATCAGCG ATGTATTGTC CACCAGGAAT CAGGATTCAA ATTACTGCCT  
5701 GTCAAAAT TGGCAGGGGG GATGGTGAGC TTGAAATCAG GCCGGAAGGT  
5751 TAGCATTTTC CGTGCAGTTC AGGAAGGGCT AATAGATAGG CAGGTCACTG  
5801 TCCGGTTGCT GGAAGCTCAG CTTTTTGCTG GTGGCATAGT AGATCCAAGA  
5851 ACAGGACACA GACTTACAGT GGAAGAGGCT GTAAGACATA ATCTGATTGA  
5901 CCAAGATATG GCCTGTGCTA TCCTCATAAG GCAGCTTTCAG ACAGAGGCA  
5951 TCATAGACAC TGTACCGGG CAAAGGCTAA CAATAGATGA AGCAGTGAGC  
6001 AATGATCTAG TAGCTGTCTA GATCGCCCTT GTGATCTGG AGTCCCTCTG  
6051 GTCAATTCATG GGGTTGCTGT GGCCTGAATC TGGAGAGATC CTCCCAATTA  
6101 CAGATGCCCT AGAACAAGGT ATTGTGTCTA CTGAACCTAG ACATAAAATC  
6151 CTTAGTAACC GACAGCATAT TAAGGCTCTG TTTCTACCAG CAACCACAGA  
6201 GATTTTGTCC TGAAGAAAG CAATAGAAAG TGGTATCTCG GATAGAGATC  
6251 TTGCCAATA CTTAAATTCG ATTTGTATAC CTGATGTGAT GCCCACAATG  
6301 CAACTAGCAG ACTCTGCAGA ACAAATATT AATCCTGGAG CAGCAGTTCT  
6351 ACCGTGCAGC AAGAGCCACC CTAAGGCCAC AGCAAGCCAG AGTGAGAAATC

6401 TGTGTTTCCA GCTGATGACT CACAGCTATA TTAATGTGCA AAATGACAG  
6451 AGGCTGCTTC TGTAGATATA AGAGCTGATG GAGACATAA CATCCAGAGA  
6501 TGAGTATCAA ACNAGTCCTC CAAAAGTGGT TGAATTTGGG CATCAAAGGC  
6551 AAAAACTCC TGAGGATTC CAAGAATCAG CTAATGTGAA AATCTCAGGA  
6601 ACTTTACGA GTGGGTGGAC TGTGAGGCTG CCTGAGTTC AGTTTCTTC  
6651 TCAGAACAAA GAATATCCCG ATCGGGAAGA TTGCACFACA GAAAAAGGCA  
6701 AAAAGACCAC TGTAGAAACA GAAGATTCTT CTGTAGAGAA CCTGAACAG  
6751 GATCTGTTTG TAGAACAAA AGAGAGAAAT CCAACATTG ATGCTTTGAA  
6801 GGTAAATAAT AAGTCAAAAT TAGAGGTACA AAGCAGTTG ATAGTACCC  
6851 AAAGGGAAGA CCAACAGCA GTGCTGTCA GAGAAATGC CAGCAGGGA  
6901 CACCTCCTGA CCNATCCTCC TGCTGAGGG GAAGGTGTGC CGTTGTTGT  
6951 TGACAAAGAT GTTTTTCTG TTGAACACC AAAGAAAGAA CATCAACCTC  
7001 TAAGAAACAC TTCCTTTTACA TGTCAGAATG AACAAACACA CACTCTTGAG  
7051 ACTGAATATA TTCATGATGA TACTGGAGA TCTCACATAA AACCCCAAAG  
7101 CAAAAAGTTA CAACTTCAGG TAAAGAAAAC TCTAGGTATA AGTTTGAAC  
7151 TAAAGTCTGA ACTGATGGG AATGTTTCAT CTCTGGCAA AAAGGAAATG  
7201 TTAAGAAAAA CATTCTGCG TAAGATGAC CATAAAGAAA GTCAAGAGC  
7251 ACAGAACATC GCAGGTGGTA GTATGATGAT GTCAAGAAAG ACCGATGAGG  
7301 AAGATAGTGG CAGGGAATTT TTCTGTGAT GCAGTCATCC ATTAGAATTG  
7351 CTTGAAGAAG CTACCTTAA TGTATTATCT GCACAGTTAC TAGATGGTGG  
7401 TATCTTTTCAAT GAACAAACAG GTCAAAAGCT CTTACTAAAT GAAGCAATAT  
7451 CCCGAGGCAT TGTGCCAAGT CACACTGCCG TGAAGCTTAT GGAGAAGCTG  
7501 AACATGTTTC AGGGTTCTT TGACTCTCAG ACTTGTGAGT CTTTGACAAC  
7551 TGAAGAAGTC ATTAATGAAG GTCTGATGGA TGAGAAATTA TTACATAATG  
7601 TCCTCATGGC AGACAAAGCT ATAAGTGGTG TCTTAGACCC CCGTACCCAG  
7651 ACCTGTGCT CTGTAAAGGA TGCAGTTACA GTTGGACTTC TTGACRAGGA  
7701 AACAGCCACC AGAATTTTAG AGAGCAGGT GGTGACTGGT GGAATTTATTG  
7751 ATCTGAACG AGSCAAAAA GTTTCAGTAA CTTTGGCCTC AACTCTTGGC  
7801 TTGGTGAAG GTTCTGACCA GCCAGACTT ATAAATCTGG AGAAGCTTC  
7851 CAAAGGTAGA GATCTGAAA AAACAGTTAG GGAGAGATTA ATTAGTTTAC  
7901 AAATGGAAC AACAGACTT ATAGACCCCTG ATAGTAAAGC ACCTTTAAACA  
7951 GTTGTGAGT CCATTCACAG AGGTCTTTTG GAGAGAGGG AGGCCGTTG  
8001 TTTGTTGACT AAGCAAGTGG TAGATGGAGG TATCATTTAC CATPATCTG  
8051 GGATGAGACT TTTCTGTTGAT AATGCCCTCA GACATGGCTT AATTGGTGA  
8101 GATTTAGCCG AGAACTCAA AAGATTGAG AACTTAAACA TCCATCAGAT  
8151 TTTTAACTCT GAAACGAAGG AAAATATTTC CCTCCCTAAA GCCATAAAT  
8201 TAGATCTTAT TACCTCAGAC CTGAAAAGAG AAATCCAGGA GGTTCAGGCC

8251 TTTTACTGGA ACTTTGTGGA TCTCATTTCT GGTCAAGAT TGACCTTGCC  
8301 AGNAGCTAAA AAAGAAGGAC TGTTAACTAA TGAAGCAGTA TTGTCTCCAG  
8351 GAATGATGCA TGGCATTTGA GATCCGAGA ACTGCAGAA TGTCCCTTAC  
8401 TCAGAAATTAG TCAAGAAATG TAAGATTGAT ATTGAATCTG GACAGAGATA  
8451 TCTAGAAGTA ATTCCTTCT CAGACATTAA AGATGGGGTG ACGGACAAAG  
8501 TGTGTTACAT GTCTCAAGCA ATTCAGCTTG GAAAAGTAGA CTTTGCATCT  
8551 ACGCTGAAGG TTCTAGAAGC CCAGGCAAACT ACTGGTGGAA TCATAGATAC  
8601 TGTCTACTGA AAAGACTGA CATTGGGCATC AGCTTTGGAA GAGAAACTGG  
8651 TGGATGAAAA CATGGTCAGA ATTATTGCAT CTCATCAGGT GTTAAATGGA  
8701 GGAATTTGTT ACATATTTAG TGATCAGAGA GTGACTTTAG TAGAAGCTAT  
8751 TGAAAAAGA CTGATCAGCC CTGAACCTGG AAATATGATC CAAATAGATA  
8801 GTTCAGAGTT CAGCGATCAC AGGCTCAGA TTGAAAAGCA AGAAGGGATT  
8851 GAAGTGTGT CATTACAAAA TGAATTTCTA GGAAGGATA TGTTAATTGC  
8901 TTGTAATCAG ACTGCTGAAA TGAGTTGTAA TAAAGTAGAA GAGAGTGAGA  
8951 GATTATTCCA AGTTGAAAAT CAGTCTGCAC AAGAAAAGGT TAAAGTGAGA  
9001 GTTTCGTGAT GGGCAGGCG AAAAAAGAGC AGGAAAATTT CCTTAAAGGA  
9051 ATTTGGGTGC AAGGATCAAC GTAAGCCAAG AATGTCTTCA GATGCTAAG  
9101 AATTTATCAG TATCATAAAT CCTCATAATC TTAAAGGTAA ATCTTTGGGC  
9151 CRAGTGTCAT TGACACACCC TTACTCTGAA TGTGATTTTA AACTTAAAGA  
9201 AGTGGCTAGA AATAACATGG GAATGATAC AAATGAAGAG CAGGAAAAAG  
9251 CAGTGACAAA AATAGAAATTT ATTTCTCATA TGAAGCAGTC TACCTCATGT  
9301 CTAGATTCTG AAGAAATAAG AGAAAAATCAA GGGGAAAGTGA TTTTGGAACT  
9351 ACNAGAAAAA TATTGTGAA CGTCAGSCAA ATTGCCGAGT GAGCAGGTTT  
9401 TGCAGCAACC AATGAATGCT CGGCTGAAAA GTAAAGAGAG GAAGAGGGAG  
9451 GTGATTTGTAG AAGAAAGTAT CAGAACATGC AAACCAGCAT TTCTTTCTGA  
9501 AGNAAAGTTG TATCAGGAAA CTGCCATTAG AGATGAGCAT GACTCCCAT  
9551 TAAAGAGCCA ACCTAGGGAA ATGACCTCAA GTGAAAAAGG GAAAGAAGT  
9601 GATACAGAAA TGGGATTTTC TATTACTTTT AAAATTGAAG AGTCTCTTTC  
9651 CCAAGTGGTA CCTCAAGGAA TTTCTGTAAA ACATTTAGAT GCTTTAACAC  
9701 TCTTCAGCTC TAAACAGGCC AATGAAGGAA AAGTAAACAA TTTAAGTCTC  
9751 TGCTTGACTT TAAAACCAGA AGAAAACTTA TCTCGAGAAA TTGCCCTGTG  
9801 GGGCCAGAGT GAACCATTCCT CTTGTATGAC CCCAAGACCT GAAGNATTC  
9851 ACTTACCAGGA ATCAGATGGA AAAGCCCAAG TGACAGGCC ATCCCAAAT  
9901 TCCAAACAG ACAAGTCTTT CCAAGGAACC ACCAGACAGG AGACCAACTA  
9951 TCAAGATTCC TGGGTTACTT CGAAAACTAA GGAACCACAA CATCAAATTT  
10001 CCTCATCTAA TGAATGTAAA GAAAAAGTCA ACCAAGAAGT ATCTTTTGAC

10051 CCAGCAAGAG GTCCTAAATT GGAAGAAATC ACAGTTTCTA GACCAGATTG  
10101 AAAAGAAGTC AGGTATCTAG AATTCTCAGA CAGAAAAGAC CTTATCATC  
10151 AGGCAGCAA AAGTGATGAT AAACCTTTGTG GAACTCTCAA ATCTGAAATA  
10201 GCAACACAGG AACTAAGTCG AGAGAAATTT CTAGAAATGG CAAACCTTAA  
10251 TGTTCAGGCT CTAGAAGCAG GATCCAATTGA GGACATAGTG ACTCAGAGAG  
10301 GTTCCAGAGT CTTGGGATCC TTTCTTCCAG AGAAACTGTT CAAAGGAGTG  
10351 TCTCAAAAG AGAATACAGG GCAACAGAAAT GCCATCATTA GTCTACTGTT  
10401 TCTAGAGACC AGTGAAGAA AGACAGTGTG CCTAACAGTA TGCTCTGCAG  
10451 TGAAGACAGA GAAGACACCA CAGGAAAGC TCAGAGAAAG CCTGGCAGT  
10501 GAACAACTC CTTTCATGAC TGCACCTGAA GGAAGGGAA ATGGAGGTGT  
10551 AAACCCAGAG CCTTCAGAG CAATCTCAGAA TGTATTTTACC CGGCAACTCT  
10601 GTTTAGAACA TGATGAAGAG CTAGTATCTT ATCTGTCTCT GTTACGGAAC  
10651 ATTGAATGA GGACCAACCA GATTCAACCT TTGGAGCTAA ACCTGGCAGA  
10701 ACTACAGGAT CTGCTGTGTC AGGCCAAGGT ATTAGAAAGG GAGTTAAAGG  
10751 ATCTGACCAC CTTGTCTAGT CAGGAGCTGG AGTGTGTGAA TCAGATTATC  
10801 ATCAGCCAGC CTCAGAAGT TCCTGTCTCAA CTGTTGAAGG CTCTAGAGAA  
10851 AGATGCCAAG AATCTTTCAGA AGTCTCTCAG CTCTGTGAGT GACACTTGGA  
10901 ATTCCAGGCT ACTCCACTC CAGATGCTG TGGAAATAGA AAAG

!!AA\_SEQUENCE 1.0  
ID ADP31349 standard; protein; 420 AA.

AC ADP31349;  
XX  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX  
DE Human secreted protein SEQ ID #2116.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX  
PD 29-APR-2004.  
XX  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.

17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee S, Hestir K, Beaurang PA, Behrens D;  
Hallenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3347; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is





151 ATTTCTAAGC AGCAAAGTCT TCAAGATGTG GCCTGGCTGT TTCTAACAC  
201 CTATGCTCAT ATGCATACGC AAGAATAATGA CCTGAACATG GAACTTATAT  
251 TTAAGAAGAG TTCTTTACT CATGCATTCA GCACATTTAT GAGCACCAAC  
301 CACATGCTGG AATAAAGG TGTCAATGGC AAAACACAC ACAGGAAAA  
351 GTGCTCTGACT AAATAGCAG TATTATAGC CACGGTTGT CCGACACAG  
401 AAAGTCCCTC GTGTCCTCC CCCAACAGC TGCACGGAG CAAAGCATC  
451 CCGTCCCGAG AGAAAAGCG AGTCTTCTT CCTGAGCGGTT ACTACCTTC  
501 CCGCTCACAA CACCCGCGC CGCATGTTT CCTGCGGTG CTTGTTAATG  
551 ACGTAGCAGA ACCTCAGGTG TCTCTGGAC ATACAACAC ATCCGCGAAA  
601 ACTAGAAATA CATCCGGCGG GAAAAGGCG GGGAGTGGC GGAAGGGAG  
651 TGAAGGAAAG GAGCCGGCGG GAAAAAGCC GCCTGACGG TCGTGCTGA  
701 ACTGGGCTCA GAGACGGCTG GGACAGATAA GAGGAGATTI TCGTCCACG  
751 AAACAAGAAT ATTACAGNA CAAAGTAAG CTGTTAGAAA TTAAAAATAT  
801 GATGCTAAT CTGTGAAGA TTACAGAAGT CCAGGCCACC ATGCAGGAGC  
851 TGTCCAAAGA AATGTTGAAG GCTGGATCG TAGAGGAGAT GTTAGAGGCG  
901 ACTTTTGAAG GCATAGAGA TCACAGGGCG CTTGGGCAAA GCAAGTGAAC  
951 TCGTGTCCTT CTAGAGCCAG AATCTTCAAG AGCGATGGCC GCCTCAGAGG  
1001 ACAAGGAGCA AGAAGAGGCT CTGAGGCCA TGCAGTCTTG GCTGGTTACA  
1051 CTCGACGCT AG

!!AA SEQUENCE 1.0  
ID ADP31446 standard; protein; 1755 AA.

AC ADP31446;  
XX  
XX  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #2213.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406618P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406668P.  
XX 17-SEP-2002; 2002US-0410946P.

17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
02-MAY-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
19-MAY-2003; 2003US-0471386P.  
22-MAY-2003; 2003US-0472420P.  
09-JUN-2003; 2003US-0476609P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases such as proliferative (e.g. cancer), inflammatory, immune, metabolic, genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3444; 428pp; English.

The present invention relates to an isolated nucleic acid molecule encoding a polypeptide which is believed to be cytostatic, antiinflammatory, immunosuppressive, antibacterial and virucidal. The composition and methods are useful for diagnosing, preventing and treating diseases such as proliferative (e.g. cancer), inflammatory,

CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX

SQ Sequence 1755 AA;  
ADP31446 Length: 1755 February 22, 2005 12:25 Type: P Check: 7494 ..  
1 ATGGTTGTCA TCCTGTCTGG TGGTGAAACT TCAAGTCAG AGGGCAGACA  
51 GTCGGGAAGA GAAGATGAAT GTTATGTGGG AGTAAGCAAG ATCAAGCTAG  
101 AACCACAGTC ACAAGCGGA GCCACAAGC ACAGACAGAA ACCCCGTCT  
151 GTTCTTCTTA CAGTGGGTGT CCTACAGAG CTAGGCATTT CCCTCACAGA  
201 ACTACACACA CATCTGACCC AAGAGTTGCA AGAATTGGAG GCAGATCCAA  
251 GGGAAAGTGA AATGGTTGTG GGCTGTCTCC GGCCTCACAC CAAAGTGTG  
301 GAACCTTCTGG CNAAGGCAAT TAGGCAGGAG AAGGAATAA AGGTATTCA  
351 ATTAGGAAAA GAGGAAGTCA AACTGTCCCT GTTTSCAGAT GACATGATAG  
401 TATATCTAGA AAACCCCAAT GTCTCAGCCC AAAATCTCCT TAAGCTGATA  
451 AGCACTTCA GCNAAGTCTC AGGATACAAA ATAAATGTAC AAAAATCACA  
501 AGCATTTCTTA TACACCAATA ACAGACAAAC AGAGAGCCAA ATCATGAGTG  
551 AACTCCCAATT CACAATTGCT TCMAAGAGAA TAAAATACCT AGGAATCCAA  
601 CTTACAGGG ACGTGAAGGA CCTCTTCAAG GAGNACTACA AACCCTGTCT  
651 CAAGGAAATA AAGAGGATA CAAACAATG GAAGAACATT CCATGCTCAT  
701 GGGTAGGAAG AATCAATATC GTGAAATGG CCATACTGCC CRAAGTAAIT  
751 TATAGATTCA ATGCCATCCC CATCAAGCTA CCAATGACTT TCTTCACAGA  
801 ATTGAAAAAA ACTACTTTCA AGTTCATATG GAACCAAAAA AGAGCCTGCA  
851 TCGCCAAGTC AATCCTAAGC CAAAAGAACA AAGCTGGAGG CATCAGCTA  
901 CCTGACTTCA AACTATACTA CNAAGCTACA GTACACAAA TAGCATGGTA  
951 CTGGTACCAA AACAGAGATA TAGATCAATG GAACATAACA GAGCCCTCAG  
1001 AAATAACGCC GCATATCTAC AACTATCTGA TCTTTGACAA ACCTGACAAA  
1051 AACNAGCAAT GGGGAAGGA TTCCCTNTTT ATTAATGGT GCTGGGAAAA  
1101 CTGGCTAGCC ATAAITCTCT TTCTTGGTCT GCCTGACTCC GTCTTCTTGC  
1151 AGGCAAGATA CTTCCACCTG CTGGGAATGA TGGCCACTGG CRAAGGAAGA  
1201 AGAAGAGAA AGAAGAAG AGAAGAAG AAGAAGAAG AAGAAGAAG  
1251 AGAAGAAG AGAAGAAG AAGAAGAAG AAGAAGAAG AAGAAGAAG  
1301 GAAGGAAGGA AGGAAGGAAG GAAGGAAGA AAGAAGAAG AAGAAGAAG  
1351 AAGNAAGAAA AAGNAAGAA AAGAGAGAA AGGAAGAAG AAGNAAGAAA  
1401 GACGAAGAG AAGAAGAA AAGAAGAAA AAGAAGAAA AAGAAGAA  
1451 AAGAAAGAA AAGAAGAA AAGAAGAA AAAAAACAAG GCTACACTAC  
1501 ACCTGGGTCA TTACATTCTT ATTGAGAAA TCCAGCTGTA GCCCAAGGA  
1551 AGAAGAGCA GAGGCTCTCA CTATTTTCTT CAATCAACCA TTGCAAGTTT  
1601 TAAGATAAAT CTGCTGCCAA ACACATGTTT CCTGGGATAT GCTGTGGCCT

1651 GAGGACAGTG AGGAGTATGT TGTCAATGGG TACTGCATAG CTTCAGGGAT  
1701 GCCCCAGAT GTTAGCCGAG CAAGGAAGCA GCATTATCAT GATGAGTGA  
1751 CATAG

IIAA SEQUENCE 1.0  
ID ADP31494 standard; protein; 9195 AA.  
XX  
AC ADP31494;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2261.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.

PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR  
XX  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3492; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 9195 AA;  
SQ  
ADP31494 Length: 9195 February 22, 2005 12:25 Type: P Check: 3228 ..  
1 ATGCAGATTC AAGATGGCT TTGTTTAAAT TGCCAAACCC AGAGAGCAAT  
51 ATCAGAGACG CTTGGAGACA TAGCAGAAAT GCCACCTGCA CCATCAGGAC  
101 CCAGAGCATC TCCTATGCCT GTTCCTACAG AATCATCATC TCAGAAAAACA  
151 GCAGTGCCTC CCCAAGTAAA ATTAGTGAAA AGCAAGAAGC AAGAAGTAAA  
201 AACGGAAGCT GAAAAAGTCA TTCTGAAAA AGTAAAGGAA ACACATATCAA  
251 TGGAAAAAAT TCCTCCTATG GTAACACAG ATCAAAAAACA AGAAGAGAGT  
301 AAACCTAGAGA AAGACAAAGC TTCAGTCTTT CAAGAAAAAA AGCCACTCCC  
351 TGAAGAAAAA AAACATAATCC CTGAAGAGA AAGATAAGCT TCTGAAGAAA  
401 AAAGCCACT CCTAGAAGAA AAAAAGCCAA CCCCTGAAGA CAAAAAGCTA  
451 CTCCAGAGG CAAAACATC AGCCCCAGAA GAACAGAAAC ATGACTTACT  
501 TAAATCTCAA GTACAAATTG CTGAAGAAA GCTTGAAGGC AGAGTGGCTC  
551 CAAAGACAGT GCAAGAAGG AACAACCCAC AGACCAAGAT GGAAGTTTAA

601 CCATCTGGCA CACCTCAGAG TTTACCTAAA GAAGATGATA AGACAACCAA  
651 AACAAATAAA GAACAGCCAC AGCCACCATG CACAGCAAAA CCTGATCAGG  
701 TGGAACTCTGG GAAAGAAAAA ACAGAAAGG AAGATGACAA ATCAGACACC  
751 TCAAGTTCTC AGCAGCCTAA AAGCCCCCAA GGTCTGAGCG ACACGGGATA  
801 TTCTTCCGAT GGAATATCAA GCTCAGCTGG TGAATTTCCA AGTCTTATTC  
851 CAACTGATGA AAAGGATATT CTCAGGGAC TCAAAAAGGA CTCCTTTTCA  
901 CAAGAAAGCA GCCCTTCCAG CCCTCAGAT TTGGCTAAGT TAGAAAGTAC  
951 AGTCCTAICT ATTTTGGNAG CTCAGCAAG TACACTTGCT GATGAAAGT  
1001 CAGAAAAGAA AACACAACC CATGAAGTTT CTCCTGAACA GCCTAAAGAC  
1051 CAAGAGAAAA CTCAGAGTTT ATCTGAAACC TTGGAAATTA CTAATTTTCA  
1101 AGAGGAGATC AAAGAGAGTC AAGAGNAAG GAAAGACACT TTTAAAAAAG  
1151 ATAGCCAAAC AGATATTCTT TCCAGCAAGG ACCATAAAGA GAAGTCTGAG  
1201 TTTGTTGATG ACATAACTAC TAGAAGAGAG CCTTATGATT CAGTTTGAAGA  
1251 GAGTAGTAAA AGTGAAAACT CACCTGTTC ACAAAGAAA CGAAGAACTA  
1301 GTGTTGGCTC ATCAAGCAGT GATGATATA AACAGNAAGA CAGCCAAGGA  
1351 TCAGGGGAAG AGGAGGACTT CATTCGAAAA CAAATCATAG AAATGAGTGC  
1401 TGATGAAGAT GCTTCAGGTT CTGAAGATGA TGAGTTCATC AGAAACCAGC  
1451 TCAAGAGAT TAGTAGCAGT ACTGAGAGCC AGAAGAGGA AGAAACAAG  
1501 GGAAGAGCA AATAACAGC AGGGAAACAC AGACGACTGA CTCGAAAAAG  
1551 TAGCACAAGC ATTGATGAG ATCAGGAAG' ACGTCACTCA TGGCATGATG  
1601 AAGACGATGA AGCATTTGAT GAAAGTCTTG AACTTAAATA CAGAGAAACT  
1651 AAAAGTCAGG AAAGTGAAGA ACTTGTAGTT ACTGGAGGAG GAGGCTACG  
1701 CCGATTTAAA ACAATTGAGC TCAACAGTAC AATAGCAGAT AAATATTCTG  
1751 CAGAGTCATC ACAGAAAAAA ACAAGTTTGT ATTTTGACGA AGAGCCAGAA  
1801 TTGGAATGG AAAGCCTGAC AGACTCACCT GAAGATAGT CAAGGGGAGA  
1851 GGGATCTTCG AGTCTGATG CTTCCAGCTT CACTCCTGGT ACATCCCCCTA  
1901 CATCAGTATC ATCACTTGTAT GAGGACAGTG ACAGTAGGCC GAGTCACAAA  
1951 AAAGGAGAGA GCACACAGCA AGCAAGCT CGGCACAGAC CACATGGCCC  
2001 TCTTTTGCCT ACTATTGAAG ATTCTTCAGA GGAAGAAGAA TTGAGAGAGG  
2051 AAGAAGATT ATTAAGGAG CAAGAAAAAGC AGAGGGAAT AGAACAGCAA  
2101 CAAGAAAGA GTTCTAGTAA AAATCAAAG AAAGACAAAG ATGAACCTCG  
2151 AGCTCAGAGA AAGAGGAAA GGCCTAAGAC ACCACTAGT AATCTCTCTC  
2201 CCATTTGAAG TGCATCTCCG ACAGAGAGT TACGTGAGGC TGCAGAAATG  
2251 GAGGAGCTCC ATAGATCTTC TTGTTCTGAA TATTCACCTA GCATAGAGTC  
2301 AGACCCAGAA GGTTTTGAAA TAAGCCCGGA AAAAATAATA GAAGTACAAA  
2351 AAGTTTATAA ATTGCCACA GCTGTTTCAT TATACTCACC AACAGATGAG

2401 CAATCTATT TGCAGAAAGA AGGTAGCCAA AAGGCGTTAA AAAGTGCTGA  
2451 GGAGATGTAT GAAGAAATGA TGCATAAABAC ACACAAATAC AAAGCTTTTC  
2501 CAGCTGCAAA TGAACGAGAT GAAGTGTTTG AAAAAGAGCC TTGTGTATGGT  
2551 GGGATGCTAA TAGAGGATTA TATTTATGAA TCTTTAGTAG AAGACACGTA  
2601 CAATGGATCG GTAGATGGCA GTCTGCTAAC AAGGCAGAA GAAGAAATG  
2651 GATTTATGCA GCAGAAAGA AGAGAGCAAA AGATAAGACT TTCAGAACAG  
2701 ATTTATGAAG ATCCTATGCA GAAAATTACA GACCTCCAGA AAGAGTTTAA  
2751 TGAGTTAGAA AGCTTACATT CTGTTGTGCC TCAGGAAGAT ATTGTTTCAA  
2801 GCTCTTTTAT CATCCAGAA AGCCATGAGA TAGTGGACCT GGGTACTATG  
2851 GTAACTTCTA CAGAAGAAGA AAGGAAACTA CTAGATGCTG ATGCTGCCTA  
2901 TGAAGAATCT ATGAAGAGC AACAGATGCA ATTAAACCTT GGATCTAGCC  
2951 CAACCCAGGC CCCATTTGT GAGGATATGA CAGAGTCOAC CATGGACTTT  
3001 GACAGAATGC CAGATGCCTC TTTGACATCA AGTGTCTCT CAGGAGCGTC  
3051 TCTTACAGAT TCGACACGA GTGCAACACT CTCTATCCCA GATGTTAAMA  
3101 TAACCCAAACA TTTTCAACA GAAGAAATTG AGGATGAATA TGTAACCGAT  
3151 TATACAAGAG AAATTCAGA GATAATTGCC CATGAATCGC TGATTTTGAC  
3201 CTACTCGAG CCTTCAGAA GTGCTACATC TGTCCCAACC TCTGACACAC  
3251 CTCTCTCAC ATCATCTGTT TCTTCGGTCT GTACCACAGA TAGCTTTTCA  
3301 CCCATTACTA CCTGTGATAG CATAACCACA GTTTATACAG AGCCAGTGGA  
3351 CATGATAACT AAATTTGAAG ATTCGAGGA AATTTCTTCA TCAACTTATT  
3401 TTCAGGCAG CATATPAGAC TATCCAGAAG AAATAAGTGT ATCTTTAGAT  
3451 CGGACTGCC CACCAGATGG TAGAGCTAGT GCTGATCATA TTGTTATTTT  
3501 CTATCTGTAT ATGGCATCTT CTATCATAGA ATCTGTAGTA CCTAAACCTG  
3551 AAGGGCCAGT TGTGTACACT GTTCTTACTG ACTTACTTAT ATCTGAAAAG  
3601 GACCCAGTGA AGAAAGCCAA GAAGGAAACT GGAATGGA TCATTCTGGA  
3651 AGTTTGGAA GCTTACAGAG ATAAAAGGA GTTGGAGGCC GAACGAACAA  
3701 AAAGTAGCTT ATCCGAAACC GTGTTTGATC ACCACCTTC TTCTGPAATA  
3751 GCCCTTCAA TGAAGAGCA GCTTTCAACT ACATACTTTA CATCTGGAGA  
3801 GACCTTTGGT CAGGAAAAC CTGCACTCA GTTACCATCT GGCAGTCCCT  
3851 CTGTTTCCCT TCTTCCAGCT AAACCTCGCC CATTTCTTTAG AAGTTCTTCT  
3901 TTGGATATAT CAGCTCAACC TCCTCCCTCT CCTCCCTCC CCCCTCCTCC  
3951 TCCTCTCCCA CCACACCCC CTCCTCCCCC ACCACTTCCT CCACCACTT  
4001 CACCTAAACC AACTATTCTT CCTAAAAAAA AGTTAAACAGT TGCATCTCCA  
4051 GTGACTACAG CTACACCTCT GTTTGATGCT GTTACTACTC TAGAGACCAAC  
4101 AGCTGTTCTG AGAAGTAATG GATTACCTGT TACAAGATA TGTACTACTG  
4151 CACCTCCTCC TGTTCTCTCT AAGCCATCTT CAATTCCATC TGGACTTGTA  
4201 TTTACCCACA GGCCTGAGCC AAGCAAACTT CCAATCGCCC CCAAAACCACT

4251 GATTCTCTAG CTTCACAA CAACACAAA ACCAACAGAT ATACACCCCA  
4301 ACCAACAGG CCTATCTTTA ACTTCAAGTA TGACCTTTAA TTTAGTGACT  
4351 TCAGCAGATT ATAAATGGC TTCCCCTACC TCCCCTTTT CCCCACATC  
4401 CAACAAGTCT TCACCAAGAT TTTCCAAATC CCTCACAGAA ACTTATGTAG  
4451 TTATTACATT GCCATCTGNA CCAGGGACTC CAACAGATTC TTCTGCTAGT  
4501 CRAACAATTA CCAGTTGGCC CTTCGGATCA CCTTCCAAAG ATCTGGTTTC  
4551 TGTTGAACCT GTGTTTCTG TAGTTCCTCC TGTGACAGCT GTAGAAATTC  
4601 CAATTTCTTC AGAACAGACC TTCTACATCT CTGGAGCTTT ACAGACATTT  
4651 TCTGCTPACC CTGTCACAGC ACCCTCTTCA TTTCAAAGCAG CTCGCCACATC  
4701 AGTTACACAG TTTCTCACTA CTGAAGTTTC CAAGACTGAG GTTTCAGCAA  
4751 CCAGAAGTAC AGCTCCTAGT GTTGGTCTCA GCAGCATTTT CATACAAATT  
4801 CCTCCAGAG CTCTTGCTCT AGATAACATA CATTTAGAGA AGCCTCAGTA  
4851 TAAAGAAGAT GGAATAATGC AACTTGTG TGATGTAATT GATTTGCGTA  
4901 CAGTACAAA GGTAGAAGTT AAAACAATG ATAAATGTAT TGATCTTTCT  
4951 GCTTCTACAA TGGATGTGAA AAGCAGATC ACAGCAAAATG AAGTTTATGG  
5001 GAAACAAATT AGTGTCTGCC AACCTCTAT TATAAATCTT AGTGTGACAT  
5051 CATCAATAGT GACTCTCTGA TCTCTGGCCA CTGAGACAGT GACCTTTGTC  
5101 ACATGCACAG CTAGTGCAG TTACACTACA GGCACAGAAA GCCTAGTGGG  
5151 TGCAGAACAT GCAATGACAA CACCCTCCA ACTTACAACA TCAAAGCATG  
5201 CTGAGCCCC ATACAGGATA CCAAGTGACC AGGTCTTTTC TATAGCTAGG  
5251 GAAGAAGCAC CAATAAACTT ATCTTAGGT ACTCCAGCAC ATGCAGTGAC  
5301 ATTTGGTATT ACAAAACCTG TCACTGTGCC TCCTGTGGT GTCACAAATG  
5351 GATGGACTGA TAGCACCCTA TCCAGGGAA TCACTGATGG GGAAGTAGTG  
5401 GATCTCAGTA CAACCAAGTC TCACAGAAC GTCGTAAACA TGGATGAGTC  
5451 TACTTCAAGT GTGATGACCA AATAATAGA AGATGAAAAA CCCGTTGATT  
5501 TAACCCGAGG GAGAAGCT GTGTGCTGTG ATGTGTTTAA TAAATTACCA  
5551 TTTGGAAGGA GCTGCACAGC ACAGCAGCCT GCAACTACTC TTCCTGAGGA  
5601 TCCTTTTGGT TATAGGATG ACCACTATCA GTATGATCGA TCAGGGCCAT  
5651 ATGGTTATAG AGGGATTGGG GGAATGAAGC CTTCCATGTC TGACACAAAT  
5701 TTAGCAGAAG CTGGACATTT TTTCTATAAA AGTAAGAATG CTTTGTATTA  
5751 TTCTGAAGGA ACTGACACAG CAGTAGATCT GACTTCAGGG AGAGTTACTA  
5801 CAGGTGAGGT AATGATTAT TCAAGCAAGA CTACAGSTCC ATATCCAGAA  
5851 ACAGACAAG TCAATTTCCAG AGCTGGGATT AGTACCCAC AGTATTTCCAC  
5901 AGCAAGATG ACACCAACCAC CAGGACCCCA GTATTGTGTG GGGAGTGTIT  
5951 TGAGGTATC TAATGGTGT GTCTATTCTT CAGTAGCAAC TCCAACACCC  
6001 TCTACATTTG CTATCACCAC ACAACCTGGC TCCATTTTCA GCACCACAGT

6051 GAGGGATTGG TCTGGTATTTC ATACGGCTGA TGCAGTGACT TCATTACCTGG  
6101 CCATGCACCA TAGCCAGCCA ATGCCTAGAT CATATTTTAT AACAAACAGGT  
6151 GCATCTGAAA CGGACATTGC AGTAACTGGT ATTGATATCA GTGCCAGTTT  
6201 GCAAACTATT ACTATGGAGT CTCCTACTGC TGAGACGATA GACTCTGTTC  
6251 CCACCTTTAAC CACAGCATCC GAAGTGTTC CTGAAGTGGT GGGAGATGAA  
6301 AGTGCTCTTT TAATTGTCCC TGAAGAAGAT AAACAACAGC AGCAGCTAGA  
6351 CTTGGAGCGT GAGCTCCTGG AACTGGAGAA AATTAAGCAA CAGCGCTTTG  
6401 CTGAGGAATT GGAGTGGGAA CGTCAGGAAA TTCAAAGGTT CCGAGAACAA  
6451 GAAAAGATCA TGGTTTCAGAA AAGTTGGAG GAGCTGCAGT CTATGAAGCA  
6501 ACACCTTCTC TTTAGCAAG AAGAAGAGCG GCAAGCCCAG TTCAATGATGA  
6551 GGCAGGAGAC GTTAGCTCAG CAACAGTTAC AGCTTGAGCA GATCCAACAG  
6601 CTGCAACAAC AGCTTCACCA CGAGCTGGAG GAGCAAAAGA TTCGGCAGAT  
6651 CTACCAAGTAT AACTATGACC CTTCTGGAAC TGCTTCTCCA CAAACCACTA  
6701 CAGAGCAGGC AATTTTGGAA GGTCAGTATG CTGCTCTGGA AGGCAGTCAA  
6751 TTTTGGGCAA CTGAAGATGC AACCACCACA GCTTCAGCTG TTGTGGCAAT  
6801 TGAATACCA CAAAGCCAG GATGGTACAC CGTTCACTGT GATGGTGTTA  
6851 CTCAGTACAT TGCCCCACCT GGTATCCTGA GCACGTGTTT AGAATAACCT  
6901 CTAACAGATG TTGTTGTGAA AGAGGAAAA CAACCCAAAA AGAGAGTTTC  
6951 TGGAGCTAAA GTCCGAGGAC AGTATGATGA CATGGGAGAA AATATGACAG  
7001 ATGATCCCCG AAGTTTAA AAGATAGTGG ACAGTGGTGT ACAAACGGAT  
7051 GACGAAGATG CCACAGATCG GAGCTATGTG AGTAGGAGAA GGAGAACTAA  
7101 AAGAGTGTG GATACAAGG TCCAACTGA TGTATGAAGAT CAGGATGAGT  
7151 GGGATATGCC TACTAGATCA AGGAGGAAAG CTCGTGTAGG GAAATATGGT  
7201 GACAGCATGA CAGAGGCTGA CAAGACCAA CCCCTTTCCA AGTCTCCAG  
7251 CATAGCAGTT CAAACGGTAG CAGAGATATC TGTGCAAACT GAACCAAGTTG  
7301 GAACCAATAG AACACCCCTCC ATACGGGCAC GAGTGGATGC CAAAGGTAGAA  
7351 ATAATTAAAC ACATTTACG ACCTGAAAAG ACTTACAAAG GGGGAGTTT  
7401 AGGATGTCAA ACAGAAGCAG ATTCAGACAC ACAAAGTCCT CAATATCTGA  
7451 GTGCCACATC TCCACCCAAA GACAAGAAAC GCCCAACACC TTTAGAGATT  
7501 GGTATTTCAT CTCACCTCGG GGCAGATTCC ACAGTACAGC TGGCTCCTTC  
7551 CCCACCCAAA TCCCCCAAAG TCCTTTACTC ACCCATCTCA CCACTTTCAC  
7601 CAGGCAAGC CTTAGAAATCA GCCTTTGTAC CTTATGAAAA ACCCTCCCT  
7651 GATGATATAA GTCCACAGAA AGTACTGCAT CCAGATATGG CTAAAGTTCC  
7701 CCCAGCAAGT CTAAGACAG CCAAGATGAT GCAGCGTTCT ATGTCTGACC  
7751 CCAAGCCTCT GAGTCCAACA GCAGACGAAA GTTCCAGGGC TCCTTTTCAG  
7801 TATACGAGG GCTATACAC TAAAGTTCT CATCCATGA CATCTCTGG  
7851 AGCCCAAGAA AAGTTAAAA GAACTCTGCC AATCCACCT CCTGAGAGA

7901 TTTCCACAG AACTCAATCC ACATTCAGCA CAATGGGCAC AGTTTCCAGG  
7951 AGAAGATCT GCAGAACCAA CACAATGGCA CGAGCCAAGA TTCTCCAGGA  
8001 CATAGACAGA GAGCTTGATC TTGTGGAAAG GGAGTCTGCA AAAC TTCGAA  
8051 AGAAACAAGC AGAGCTTGAT GAAGAAGAAA AGGAGATTGA TGCTAAGCTA  
8101 CGATACCTG AATGGGAAT TAACAGAGG AAAGAGGCC TATTAAAGGA  
8151 GAGAGAAAAG AGAAGACGAG CTTACCTCCA GGGAGTAGCT GAGGATCGTG  
8201 ATTACATGTC TGACAGTGAA GTGAGTAGCA CAAAGACCAAC CGAATAGAA  
8251 AGTCAGCATG GCATTGAGCG ACCAAGAACT GCTCCCCAAA CTGAATTTCAG  
8301 CAGTTTATA CCACCACAAA CCCAAACAGA ATCTCAACTA GTTCTCCGA  
8351 CAAGTCTTTA CACAATATAC CAGTACTCTT CCCCTGCTCT TCCTACCCAA  
8401 GCACCCACCT CATACACTCA ACAGTCTCAT TTTGAGCAAC AAAC TTTGTA  
8451 CCATCAGCAA GTTTCACCTT ATCAGACTCA GCCAACATTC CAAGCTGTGG  
8501 CAACAATGTC CTTACACCT CAAAGTTCAAC CTACACCAAC CCCACAGCCT  
8551 TCTTATCAGT TACCTTACA GATGATGGTG ATACNAACAGA AGCCAGGGCA  
8601 AACTACATTA TATTTGGAGC CCAAGATAAC CTCAAAATAT GAAGTGATTTC  
8651 GCAACCAACC CTTATGATA GCACCTGTTT CTACGGATAA CACATTTGCT  
8701 GTTCCCCTC TTGGTAGTAA GTACAATAGT TTAGACTTGA GAATAGTTT  
8751 GGAGGAAAGA AGTAGCATGG CAAGCAGTCC AATATCAAGC ATATCTGCAG  
8801 ATTCTTCTA TGCAGATATT GATCACCATA CTCACGAAA TTATGCTCTA  
8851 ATTGACGACA TTGGAGAGAT CACCAAGGA ACAGCGGCAT TAAGCACCGC  
8901 ATTTAGCCTT CATGAAAAGG ATCTGTCAA AACAGACCGT CTCCTTCGAA  
8951 CCACTGAGAC ACGCGGTCT CAAGAAGTGA CAGATTTCTT AGCACCTTTA  
9001 CAGTCTTCT CTAGATTGCA TAGTTATGTG AAGGCGGAGG AAGACCCAT  
9051 GGAGGATCCT TACGAGTTAA AGCTTCTGAA ACATCAGATT AAACAGGAAT  
9101 TTCTGTAGAG GACAGAGAGC TTAGATCACC TTGCTGGTCT TTCTCATTAT  
9151 TACCATGCTG ATACTAGCTA CAGACATTTT CCAAAATCTG AGAAN

!!AA SEQUENCE 1.0

ID ADP31514 standard; protein; 240 AA.

XX

AC ADP31514;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #2281.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

PN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 13-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3512; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 240 AA;  
SQ

ADP31514 Length: 240 February 22, 2005 12:25 Type: P Check: 7610 ..  
1 ATGCAGGCAG CAGCGACAGC AGCAGAAACA GCAGCAGCAG CCCCCAGGGG  
51 GCCAGGCCAA GSCCCGGCCT GCCAAGAGGA AGCGGGGCAC GTCCCCAAGA  
101 CCTCCACAG ATGTGTGTC AGACCTCTG GGCATCTCAG ATTCCTACAG  
151 TCCCCCTCTG CCGGGCCCT CAGGCTCCCC AACCACGGCA GTGGCCACTG  
201 TGTCCATCTG GAGCCAGCC TCAGAGTCCC CTTTGCCTGA

!!AA SEQUENCE 1.0  
ID ADP31537 standard; protein; 1134 AA.  
XX  
AC ADP31537;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2304.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

PA Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3535; 428pp; English.  
PS The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
CC antitumour, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX Sequence 1134 AA;

ADP31537 Length: 1134 February 22, 2005 12:25 Type: P Check: 6431 ..  
1 ATGGCAGAGA TAAATTCAGGA ACACAAAGAA GATCAGCTCC CTGAATTTGGA  
51 ACAGCTAGAG CACATTGGAC TGTTCACTCA TGCAGAGATT AAGGCTATCA  
101 TTAAGAAGGC TTCTGATCTA CAGTACAGAA TCCAGGAAAG AGCCCTTTTC  
151 AAGGACGACT TTATCAATTA TGTTCAACAT GAAATTAATC TTTTGAACA  
201 GATCCAGAGA AGACACGCA TTGGATATTC ATTTAAGAAG GATGAGATTG  
251 AGAATTTCTAT TGTACACCAG GTACAAGGTG TTTTCCGNAAG TGCCTCAGCA  
301 AAGAGGAAAG ACGATGTTCA ACTTTGGCTC TCCTATCCAG CTTTGTGGAT  
351 TATGGCAGCC AAATGGGAAA TGGNAGACTG CTTGTCTTCA GAAAGTGCAA  
401 GGCAACTATT TCTTTGGGCA CTGCACTTTC ATCCAGAGGG CCCAAAACTT  
451 TATCAAGACT ACTTTAGGAT GGAGCTGATG CATGCTGAAA NAATCAGAGAA  
501 GGAAGAAGCAA GAATTTCAA AAGCCAACAT GGATGTGGAG AATCCTGATT  
551 ATTCTGAAGA AATCCTTAAG GGCAAAATGG CACGGATCAT CTATGAAAAT  
601 TCTGGACCAG TTCAAGTAAC ATTCTGCGAG AGGCTCCCTC TGTGTGCTAT  
651 ACCAGATTCA GGCAGTGGGA GAAGAAAGA GGAACAGATT TCTTCTGAGA  
701 GCAGACAGAT CAACCCGGTG AATGCAAGGG CAGCCACATT TCAATCACAA  
751 AAAGGTGTG CCTTAAGTTT TGGCTCCGCC ACTCCGCCG CCCACTTTCA  
801 ACAAGCCGAA GCCTTTGAAG GAGCTCGGT GCCATCTCG TGTGATCGG  
851 TCCCGCGGAC GCTGGCCACC ATGGCCGGTG CGACTCCCTA CCCGCGCCGG  
901 CAGACGGACT TCCTGGAAG CACCGGCGTG GGCCTACCTG ACTGGCGCCC  
951 GCAGGGGCGG CCGACTCTTT CACAGACCCA CGGAAACTGC CGGCGCGAAG  
1001 CCGAGGCTCG GTTCCAGCA CCCGCGCGTA TGGGTTTCGG GGATGATGTA  
1051 GCTATTGCAG GGCAGTTTCT GCCATCCTA TCTTCCCTTT CCATCTTCAA  
1101 GCTCTACACC AGCGGTGGG GCTGGCTGCT GTAG

!!AA SEQUENCE 1.0

ID ADP31568 standard; protein; 936 AA.

XX ADP31568;  
AC ADP31568;

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2335.

XX Cytostatic; Antitumour; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MW, Kochakota S, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3566; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX Sequence 936 AA;  
ADP31568 Length: 936 February 22, 2005 12:25 Type: P Check: 2180 ..  
1 ATGCTGTGCA AAGAGAAAGG GATCACCCTG CTGGGTGGA ACGTGGTGTT  
51 TGACATCTTG GTGAGAGGCA AATTCAATGT TCTGGAATTT GTCCAGAAGG  
101 AACCGGGAAT CCTCTTCAGA ATGACCCCTGC TCGCCTCCGG AGGGGCTGGG  
151 ATGCTCTCCG TCGGCTGGAG GATCATAGGC CCGGGCCCCG CGGCCTTCAC  
201 CGAGGAGGAC AACTGGGCTT CCTTTGCTGA CCGGTGCTG GCGAGGGCCA  
251 TAAACGACAA TTACTCTTAT TCATTGAATG CCTGGCTGCT GCTGTGCTGT  
301 CCCTGGTGGC TGTGTTTGA TTGCTCAGTG GGCTGCAGCC CCTCATGAA  
351 GTCCCTCAGC GACTGGAGGG TAATGCAATT TGCAGCGCTC TGGTTCCGCC  
401 CAGTTGGCCT CATACGCCAA GCCCTGTGCT CTGCAGACGG CCACCAAGAG  
451 AGGATCCTTA CTCTGGGCTT GGGATTGCTC GTTATCCCGT TTCTCCCCGC  
501 AAGTAACCTG TTCTCCGAG CCGGCTTCTG GTGCCGAGC GTGGGTGCTG  
551 AGGTTGCTG CAACATCGCC AGAAACCTGG CTGCTAAAGG CAACCAAGCG  
601 GCGGCCATCA GATACACCG GGAAGCTGTA AGCTTAATC CCAAGTATGT  
651 TCATGCCGTG AATAATCTTG CAATGTCTT AAAAGAAAGG AATGAGCTAC  
701 AGGAAGCTGA GGAGCTGCTG TCTTTGGCTG TTCAAATGCA GCCAGACTTT  
751 GCTGCTGCTT GGATGAGTCT AGGCATAGCG CCGAGCAGCC TGAACGCTT  
801 TGAACCGCC AAGCAAAGTT ACCGACGGC GAGTAAACAG AAGGAAATAC  
851 CCAGACCGTT ACTACAGCCT CCGGCTGCTG CTGATCTCAA TCGCCAGGTG  
901 GACGCTTCA ATGCGTGGAG AAATGCACCG AGCTGA  
!!AA\_SEQUENCE 1.0  
ID ADP31588 standard; protein; 1389 AA.  
XX  
AC ADP31588;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2355.  
DE  
XX Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX



PD 29-APR-2004. XX  
XX 28-AUG-2003; 2003WO-US026780. PR  
XX 29-AUG-2002; 2002US-0406576P. PR  
XX 29-AUG-2002; 2002US-0408579P. PR  
XX 29-AUG-2002; 2002US-0408585P. PR  
XX 29-AUG-2002; 2002US-0408588P. PR  
XX 29-AUG-2002; 2002US-0406608P. PR  
XX 29-AUG-2002; 2002US-0406611P. PR  
XX 29-AUG-2002; 2002US-0406612P. PR  
XX 29-AUG-2002; 2002US-0406616P. PR  
XX 29-AUG-2002; 2002US-0406640P. PR  
XX 29-AUG-2002; 2002US-0406642P. PR  
XX 29-AUG-2002; 2002US-0406646P. PR  
XX 29-AUG-2002; 2002US-0406653P. PR  
XX 29-AUG-2002; 2002US-0406655P. PR  
XX 29-AUG-2002; 2002US-0406668P. PR  
XX 17-SEP-2002; 2002US-0410946P. PR  
XX 17-SEP-2002; 2002US-0410947P. PR  
XX 17-SEP-2002; 2002US-0410948P. PR  
XX 17-SEP-2002; 2002US-0410949P. PR  
XX 17-SEP-2002; 2002US-0410953P. PR  
XX 17-SEP-2002; 2002US-0410957P. PR  
XX 17-SEP-2002; 2002US-0410958P. PR  
XX 17-SEP-2002; 2002US-0410959P. PR  
XX 17-SEP-2002; 2002US-0410960P. PR  
XX 17-SEP-2002; 2002US-0410961P. PR  
XX 17-SEP-2002; 2002US-0410962P. PR  
XX 17-SEP-2002; 2002US-0410963P. PR  
XX 17-SEP-2002; 2002US-0411013P. PR  
XX 17-SEP-2002; 2002US-0411014P. PR  
XX 17-SEP-2002; 2002US-0411045P. PR  
XX 17-SEP-2002; 2002US-0411046P. PR  
XX 17-SEP-2002; 2002US-0411048P. PR  
XX 17-SEP-2002; 2002US-0411052P. PR  
XX 17-SEP-2002; 2002US-0411055P. PR  
XX 17-SEP-2002; 2002US-0411073P. PR  
XX 17-SEP-2002; 2002US-0411082P. PR  
XX 17-SEP-2002; 2002US-0411101P. PR  
XX 17-SEP-2002; 2002US-0411111P. PR  
XX 18-APR-2003; 2003US-0463700P. PR  
XX 18-APR-2003; 2003US-0463708P. PR  
XX 18-APR-2003; 2003US-0463716P. PR  
XX 18-APR-2003; 2003US-0463732P. PR  
XX 02-MAY-2003; 2003US-0467199P. PR  
XX 02-MAY-2003; 2003US-0467201P. PR  
XX 02-MAY-2003; 2003US-0467203P. PR  
XX 02-MAY-2003; 2003US-0467230P. PR  
XX 19-MAY-2003; 2003US-0471306P. PR  
XX 19-MAY-2003; 2003US-0471336P. PR  
XX 22-MAY-2003; 2003US-0472420P. PR  
XX 22-MAY-2003; 2003US-0472430P. PR  
XX 09-JUN-2003; 2003US-0476609P. PR  
XX 09-JUN-2003; 2003US-0476641P. PR  
XX 08-JUL-2003; 2003US-0485218P. PR  
XX 08-JUL-2003; 2003US-0485223P. PR  
XX 08-JUL-2003; 2003US-0485224P. PR  
XX 08-JUL-2003; 2003US-0485325P. PR  
XX 14-JUL-2003; 2003US-0486448P. PR  
XX 14-JUL-2003; 2003US-0486480P. PR  
XX 15-JUL-2003; 2003US-0486891P. PR  
XX 15-JUL-2003; 2003US-0486960P. PR  
XX 08-AUG-2003; 2003US-0493341P. PR  
XX 08-AUG-2003; 2003US-0493370P. PR  
XX 08-AUG-2003; 2003US-0493573P. PR  
XX 08-AUG-2003; 2003US-0493577P. PR

PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3586; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1389 AA;  
ADP31588 Length: 1389 February 22, 2005 12:25 Type: P Check: 2404 ..  
1 AGGTGGCGGG CTCGCGACC CTGCGAGGCA GCGCGCTCA ACCTTGGCGA  
51 CCCAGCCTGG GATCCCTTAC CGTACTAC GAGAGCTTGA GGAGACCTCC  
101 AGCCCCCAT CCCTGGCTCC CGGTAAC TGTTCCTTT TGCTTTTGA  
151 GATGACGGG ACAGAGGCA GTCCGGGCA GCCCGGCCC GCTGAGCGAT  
201 CCCACGGAAG CAGCGTGTCC TCCGTGGGAG CCCGAGGTGC CCCTGGCTGT  
251 GGAGAACCTG CCCTCGCTCA GTCCCCATGA GCTGCACCGC GCTGTCCCGG  
301 AGGTCCTGCA GCTTCCAGAC ATCGCCCTGG ATGCTCTTCC GCTCTGGCTG  
351 GTCTCCCTC TGAGAGTGC AGCTGAACC CAAGCACCAG CCTACAAAGC  
401 TGGGACGCCA GTGGCCGGAG CTGCTGCTGC GTTTCACCAG TGCCCCAGAT  
451 GATGACGTGG CCATGGATGA GCCTTTCTTG CAGTTCCGAA GGAACGTGTT  
501 CTTCCCAAAG CGGCGGGAGC TCCAGATCCA TGACGAGGAG GTCTTGGCGC  
551 TGCTCTATGA GGAGGCCAAG GGCAACGTGC TGGCTGCACG GTACCCGTGC  
601 GACGTGGAGG ACTCGAGGC TCTGGGGGCC CTGGTGTGCC GCGTGCAGCT  
651 TGGGCCCTTAC CAGCCCGGCC GGCCGGCAGC CTGCGACCTG AGGGAGAAGC  
701 TGGACTCCTT CCTCCCTGCC CACCTCTGTA AGCGGGGCCA GAGTCTCTTT  
751 GCTGCCCTCC GGGGCCGTGG GGCACGGGCC GGGCCGGGGC AGCAGGGCCT  
801 GCTGAACGCC TACCGCCAGG TGCAGGAGGT CAGCAGCGAC GCGGGGTGCG  
851 AGGCGGCCCT GGGCACCCAC TACCGGCCT ATCTCTCAA GTGCCACGAG  
901 CTGCCGTTTT ATGGGTGTC TTCTCTCCAC GGTGAGTTG ACAAGCCGGC  
951 CCAAGGCTTT TTGCACCGGG GTGGGGCCAA GCCAGTTTCT GTGGCCATCA  
1001 GTCTGGAAGG CGTGCACGTC ATCGATAGCA GAGAGAAAGCA TGTCTGTCTG  
1051 GGCCTGCGCT TCCAGGAGCT GTCGTGGGAC CACACTCCC CCGAGGAGGA  
1101 GGAGCCCATC TTGTGGCTGG AGTTGACGCG GGACAGCGAG GGCACACCTG

1151 TCACAAAGCT CCTCAAGATC TACTCCAAAG AGGTAGCGCA GCGCCCAAG  
1201 CTGCGGAGGC AGGGCAGTGT GGTGTCCAGC CGGATCCAGC ATCTCTCCAC  
1251 CATCGACTAC GTGGAGGACG GCAAGGGGAT CAGCGAGTG AACCCGAAGC  
1301 GCACCACATC CTTCTTCAGC CGGCAGCTGT CTTGGGCCA GGGGAGCTAC  
1351 ACCGTGGTGC AGCCCGGCGA CAGCCTGGAG CAGGCTGA

## !!AA\_SEQUENCE 1.0

ID -ADP31618 standard; protein; 471 AA.

AC ADP31618;

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2385.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406840P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 29-AUG-2002; 2002US-0406666P.

XX 17-SEP-2002; 2002US-0410946P.

XX 17-SEP-2002; 2002US-0410947P.

XX 17-SEP-2002; 2002US-0410948P.

XX 17-SEP-2002; 2002US-0410949P.

XX 17-SEP-2002; 2002US-0410953P.

XX 17-SEP-2002; 2002US-0410957P.

XX 17-SEP-2002; 2002US-0410958P.

XX 17-SEP-2002; 2002US-0410959P.

XX 17-SEP-2002; 2002US-0410960P.

XX 17-SEP-2002; 2002US-0410961P.

XX 17-SEP-2002; 2002US-0410962P.

XX 17-SEP-2002; 2002US-0411019P.

XX 17-SEP-2002; 2002US-0411022P.

XX 17-SEP-2002; 2002US-0411023P.

XX 17-SEP-2002; 2002US-0411024P.

XX 17-SEP-2002; 2002US-0411032P.

XX 17-SEP-2002; 2002US-0411035P.

XX 17-SEP-2002; 2002US-0411037P.

XX 17-SEP-2002; 2002US-0411041P.

XX 17-SEP-2002; 2002US-0411045P.

XX 17-SEP-2002; 2002US-0411046P.

XX 17-SEP-2002; 2002US-0411048P.

XX 17-SEP-2002; 2002US-0411052P.

XX 17-SEP-2002; 2002US-0411055P.

XX 17-SEP-2002; 2002US-0411073P.

XX 17-SEP-2002; 2002US-0411082P.

XX 17-SEP-2002; 2002US-0411101P.

XX 17-SEP-2002; 2002US-0411111P.

XX 18-APR-2003; 2003US-0463700P.

18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
19-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 3616; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX Sequence 471 AA;

ADP31618 Length: 471 February 22, 2005 12:25 Type: P Check: 7920 ..

1 TCTCTTACTT AGGATCCCAA GTATCCTGTA GAGAACTTGC TAAACCCAGA

51 TAGTCCAAAG AGACCTTGGC TCGGCTGCC TCAGGACAAG AGTGGGCAAT

101 TGAAGTAGA ACTACAGCTG GAGAGGGCAG TGCCCACTGG CTACATTGAT

151 GTGGGTAAC GTGGCTGTGC GTTCTGCAA ATTGATGTGG GCCATTCTTC

201 CTGGCCCCCTG GACACACCTT TCATAACCTT GCTCCCTGCA ACCACGCTAA

251 TGTCTCTAAC TGAITCAAAG CAGGGGAAGA ACCGCTCCGG GGTCCGCATG

301 TTTAAAGATG CCTCAGGAGA GTTATGGGAT CGACTTCGCC TGACCTGCTC

351 CCGACCCCTC ACGCGTCATC AGTCCTTGG CTTGGGCTTT CTACGGGTGT

401 GTTCTTCTCT GGACTCCCTTA GATGACTCTG TGGTGGGTCC CTCAGCCCTT

451 CTGAGCTCTG TGCTGAACAA G

PR	22-MAY-2003; 2003US-0472430P.	XX
PR	09-JUN-2003; 2003US-0476609P.	XX
PR	09-JUN-2003; 2003US-0476641P.	XX
PR	08-JUL-2003; 2003US-0485218P.	XX
PR	08-JUL-2003; 2003US-0485223P.	XX
PR	08-JUL-2003; 2003US-0485224P.	XX
PR	08-JUL-2003; 2003US-0485325P.	XX
PR	14-JUL-2003; 2003US-0486446P.	XX
PR	15-JUL-2003; 2003US-0486891P.	XX
PR	15-JUL-2003; 2003US-0486960P.	XX
PR	08-AUG-2003; 2003US-0493341P.	XX
PR	08-AUG-2003; 2003US-0493370P.	XX
PR	08-AUG-2003; 2003US-0493573P.	XX
PR	08-AUG-2003; 2003US-0493577P.	XX
PA	(FIVE-) FIVE PRIME THERAPEUTICS INC.	XX
PI	Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;	PI
PI	Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;	PI
PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;	XX
DR	WPI; 2004-348438/32.	XX
PT	New nucleic acid molecule for diagnosing, preventing or treating diseases	PT
PT	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,	PT
PT	genetic, bacterial and viral diseases.	XX
PS	Claim 1; SEQ ID NO 2511; 428pp; English.	XX
CC	The present invention relates to an isolated nucleic acid molecule	CC
CC	encoding a polypeptide which is believed to be cytostatic,	CC
CC	anti-inflammatory, immunosuppressive, antibacterial and virucidal. The	CC
CC	composition and methods are useful for diagnosing, preventing and	CC
CC	treating diseases such as proliferative (e.g. cancer), inflammatory,	CC
CC	immune, metabolic, genetic, bacterial and viral diseases. The present	CC
CC	sequence represents a human secreted protein. The present sequence is	CC
CC	available on WIPOWEB and is not in the specification.	XX
SQ	Sequence 638 AA;	XX
ADP30513	Length: 638 February 22, 2005 12:25 Type: P Check: 545 ..	
1	TCCATGGCTC CCTTAGCCGA AGTCGGGGC TTTCTGGCG GCCTGGAGGG	
51	CTTGGGCCAG CAGTGGGTT CGCATTTCT GTTCCCTCTT GCCGGGGAGC	
101	GGCCGCCGCT GCTGGCGGAG CGCAGGAGCG CGCGCGAGCG GAGCGCGCGC	
151	GGCGGGCGCG GGGCTCGGCA GCTGGCGCAC CTGCACGGCA TCCTGGCGCG	
201	CGGCAGCTCT ATTGCCGCAC CGGCTTCCAC CTGCAGATCC TGCCCCACGG	
251	CAGCGTGCAG GGCACCCGGC AGGACCACAG CCTCTTCGGT ATCTTGGAAAT	
301	TCATCAGTGT GGCAGTGGGA CTGGTCAGTA TTAGAGGTGT GGACAGTGGT	
351	CTCTATCTTG GAATGAATGA CAAAGGAGAA CTCTATGGAT CAGAGAACT	
401	TACTTCCGAA TGCATCTTTA GGGAGCAGTT TGAAGAGAAC TGGTATAACA	
451	CCTATTTCATC TAACATATAT AAACATGAGC AACTGGCCG CAGGTATTTT	
501	GTGGCACTTA ACAAGACGG AACTCCAGA GATGGGCCCA GTTCCAGAG	
551	GCATCAGAAA TTTACACATT TCTTACCTAG ACCAGTGGAT CCAGAAAGAG	
601	TTCCAGAAAT GTACAAGGAC CTACTGATGT ACATTCA	
IIAA	SEQUENCE 1.0	
ID	ADP30545 standard; protein; 204 AA.	
XX		
AC	ADP30545;	

XX 12-AUG-2004 (first entry)  
DT Human secreted protein SEQ ID #1312.  
DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
PN  
XX 29-APR-2004.  
PD  
XX 28-AUG-2003; 2003WO-US026780.  
PF  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406589P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 18-APR-2003; 2003US-0463739P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.

PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnenann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2543; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 204 AA;  
ADP30545 Length: 204 February 22, 2005 12:25 Type: P Check: 9625 ..  
1 ATGGCTGCTG GCTGCTGCT GGCTTGACT CTGACACTTT TCGAATCTTT  
51 GCTCATCGGC CCCTGCTGG AGGAGCCGTT CCCTCGGCC GTCACATGCC  
101 AAACCTCGTT TATCCACGT TACTGGATGC ACTTGACAGC CTTCCGATTA  
151 GACGCTGCT GGCTCCCGC GGCCGAGCGT GCTGTCCACG CAGGGGGCTC  
201 GCAG  
!IAA SEQUENCE 1.0  
ID ADP30598 standard; protein; 681 AA.  
XX  
AC ADP30598;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1365.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.  
XX  
XX WO2004035732-A2.  
PN  
XX 29-APR-2004.  
PD  
XX 28-AUG-2003; 2003WO-US026780.  
PF  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406589P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 18-APR-2003; 2003US-0463739P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.

PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2596; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
SQ Sequence 681 AA;  
ADP30598 Length: 681 February 22, 2005 12:25 Type: P Check: 695 ..  
1 ATGGATAATA AATTAGATGA ACGGGTCACCT CAAGGGTCCT TTGGTGATGG  
51 GCGAGACAGA GAAAGGGGCA GGAAGCGTAA GAAGGTTGGA ACTTTCTACC  
101 AGAGACAGGG CAGGCTACAC CGAGGAGGTG ATATTGAAGC AGAGACCCAG  
151 AGGAGAGCAC ACGGCCGCGG AGATGACGTC ACGCAAGCAA CGGCCGCTGAC  
201 GTACATATC ACCGTGGTGA TGGCGTCACG TGGCCATGTA GACGTCACGA  
251 AGAGATATAG CGATGGCGTC GTGCAGATGC AGCAGTCGC ACACAGACAT  
301 GGGGAACCTTG GCATGACGTC ACACCGAGAT GCAGCAACGA COTCACGGGC  
351 CATGTCGAGC TCACACATAT TATGTGACA CAGACGGGC GATGGCATCA  
401 CACAGACGGT GATGATGTCA CACACAGACA CAGTGACAAC ACACACCATG  
451 ACAACGACAC CTATAGATAT GGCACCAACA TCACTGACAC GCATGCCCTT  
501 TCACACACAC TTTCTACCCA ATTCTACCT AGTGTCACGT TCCCCGGACC  
551 CTGGCACACG GGCACAAGCCA CTTCTCACC CCCAGTGCCT GGACCCGGAG  
601 GTGAGAACAG GAAGCCATTTC ACCTCCGCTC CTTGAGCGTG AGTGTTCCA  
651 GGACCCCTC GGGGCCCTGA GCCGGGGGTG A  
!!AA SEQUENCE 1.0  
ID ADP30611 standard; protein; 279 AA.  
XX  
AC ADP30611;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1378.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PP 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR

PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406656P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 13-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT

PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2609; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 279 AA;  
ADP30611 Length: 279 February 22, 2005 12:25 Type: P Check: 9382 ..  
1 ATGGCGAGCC TCCGGCTCG GCCACCGCCA CGCTGCACGT GCTCCTGGTG  
51 GACGGCTTCT CCAGCCCTA CTGCTGCTC CCGAGGCGG CACCGGCCCA  
101 GGCCAGGCC GACTTGCTCA CCGTCTACCT GGTGGTGGCG TTGGGCTCGG  
151 TGTCTTCGCT CTTCCTCTTC TCGGTGCTCC TGTTCGTGGC GGTGCGGCTG  
201 TGCAGGAGGA GCAGGCGGC CTCGGTGGGT CGCTGCTCGG TGCCCGAGGG  
251 CCCCTTTCCA GGGCAGATGG TGGACGTGA  
!!AA SEQUENCE 1.0  
ID ADP30624 standard; protein; 642 AA.  
XX  
AC ADP30624;  
XX  
DT 12-AUG-2004 (first entry)  
DE Human secreted protein SEQ ID #1391.  
XX  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX  
PS Claim 1; SEQ ID NO 2622; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPower and is not in the specification.  
XX  
SQ Sequence 642 AA;  
ADP30624 Length: 642 February 22, 2005 12:25 Type: P Check: 2154 ..  
1 ATGCGAATGA CCACAGCCCG GCCTTCCCG AGGGCGCCGT GCGCGAAGTG

51 GAGCTGGCGG AAGACGCGCC CGTGGGTCC CTGCTTTCTCG ACCTGGACGC  
101 AGCCGACCCC GACGAGGAC CTAACGGCGA CGTGGTGTTC GCATTGGCG  
151 CCGGACACCC GCCGAGGCG CGCCGCTCTT TCGGCTTGA CCGGATCA  
201 GCGCGCTCA CCTGGCCGG GCCGTGGAC TACGAGGTC AGGACACCTA  
251 CGAGCTGGAC GTGCGGGCG AGGACCGCG ACCCGGGCCC CGCGTGCCA  
301 CTGCAAGT CATGTGCGC ATCCGAGAC TCAATGACAA CGCACCCGAC  
351 ATGCCATCA CCCCCTGGC GCGCCAGGC GCGCCGCGAA CCTACCCCTT  
401 CGCGCTGCC GCGCGCGCG CTGCACTCG GGGAGCGAC GCTAGCTCGC  
451 CGCGGGAGC GGGAGCGCG GAGGCTGGT CCACTTCGCT GGTGCGGAG  
501 GGGGCGGCG GCGAGAGCCT GGTGGCCCTG GTCAGCACCT CGGACAGGGA  
551 CTCGGGCGC AACGGCAAG TGGCTGCGC CCTCTATGG CACGAGCACT  
601 TCCGCTGCA GCGGCGCTAC GCGGCGAGCT ACCTGCTGGT GA  
!!AA SEQUENCE 1.0  
ID ADP30643 standard; protein; 189 AA.  
XX  
AC ADP30643;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1410.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.

PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485232P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2641; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX  
SQ Sequence 189 AA;

ADP30643 Length: 189 February 22, 2005 12:25 Type: P Check: 776 ..

1 ATGTGCTACG GGTTCGAGC TGGGAAGA GGGCGGTCT TGTGTACCA

51 GTGGGAAGG ACAGCCGACC CTTGGGGGA CCGGGGTGCC CACGAGCGC

101 CCGCGGCGCA CTGCAACCG CCGCGTGCG CAGAGACAT GGCCAATCAG

151 GGTGAGGAG AGCTGGGAG AGACACCACT TGTCCCTGA

!!AA\_SEQUENCE 1.0

ID ADP30675 standard; protein; 1289 AA.

XX AC ADP30675;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1442.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411037P.

XX PR 17-SEP-2002; 2002US-0411041P.

XX PR 17-SEP-2002; 2002US-0411045P.

XX PR 17-SEP-2002; 2002US-0411046P.

XX PR 17-SEP-2002; 2002US-0411048P.

XX PR 17-SEP-2002; 2002US-0411052P.

XX PR 17-SEP-2002; 2002US-0411055P.

XX PR 17-SEP-2002; 2002US-0411073P.

XX PR 17-SEP-2002; 2002US-0411082P.

XX PR 17-SEP-2002; 2002US-0411010P.

XX PR 18-APR-2003; 2003US-0463700P.

XX PR 18-APR-2003; 2003US-0463708P.

XX PR 18-APR-2003; 2003US-0463716P.

XX PR 18-APR-2003; 2003US-0463732P.

XX PR 02-MAY-2003; 2003US-0467199P.

XX PR 02-MAY-2003; 2003US-0467201P.

XX PR 02-MAY-2003; 2003US-0467203P.

XX PR 02-MAY-2003; 2003US-0467230P.



PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-048218P.  
PR 08-JUL-2003; 2003US-048223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2673; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1289 AA;  
ADP30675 Length: 1289 February 22, 2005 12:25 Type: P Check: 8906 ..  
1 ATGAGACAGA CTTTGCCCTG TATCTACTTT TGGGGGGGCC TTTTGCCCTT  
51 TGGGATGCTG TGTGATCCT CCACCACAA GTGCACTGTT AGCCATGAAG  
101 TTGCTGACTG CAGCCACCTG AAGTTGACTC AGGTACCCGA TGATCTACCC  
151 ACAACATPAA CAGTGTGAA CCTTACCCAT ATCAACTCA GAAGATTACC  
201 AGCCGCCAAC TTCACAGGT ATAGCCAGCT AACTAGCTTG GATGAGGAT  
251 TTAACACCAT CTCAAAACCTG GAGCCAGAAT TGTGCCAGAA ACTTCCCATG  
301 TTAAGATT TTGAACCTCCA GCACATGAG CTATCTCAAC TTTCTGATAA  
351 AACCTTTGCC TTCTGCAGGA ATTTGACTGA ATCCATCTC ATGTCCAACT  
401 CAATCCAGAA AATTAAAAAT AATCCCTTTG TCAAGCAGAA GAATTTAATC  
451 ACATTAGATC TGTCTCATAA TGCCTTGTC TCTACAAAT TAGGAACTCA  
501 GGTTCAGCTG GAAATCTCC AAGAGCTTCT ATTATCAAAC AATAAAATTC  
551 AAGCGCTAAA AAGTGAAGAA CTGATATCT TTGCCAATTC ATCTTTAAAA  
601 AAATTAGAGT TGTATCGAA TCAAAATAA GAGTCTCTAA AGTCATTGAA  
651 CTTTCAGAG AATCTCATAA CATCCGTTGA GAAGAAGGTT TTCGGGGCAG

701 CTTTCAGGAA CTTGACTGAG TTAGATATGC GCTTTAATCC CTTTGATTGC  
751 ACGTGTGAAA GTATTGCTG GTTTGTTAAT TGGATTAAAG AGACCCATAC  
801 CAACATCCCT GAGCTGTCAA GCCACTACCT TTGCAACACT CCACCTCACT  
851 ATCATGGGTT CCCAGTGAGA CTTTTTGATA CATCATCTTG CAAAGACAGT  
901 GCCCCCTTTG AACTCTTTTT CATGATCAAT ACCAGTATCC TGTGATTTTT  
951 TATCTTTAAT GTACTTCTCA TCCACTTTGA GGGCTGGAGG ATATCTTTTT  
1001 ATTGAATGT TTCAGTACAT CGAGTTCTTG GTTTCAAAGA AATAGACAGA  
1051 CAGACAGAAC AGTTGAATA TGCAGCATAT ATAATTCTAG CCTATAAAGA  
1101 TAAGGATTGG GTCGGGAAC ATTTCTCTTC AATGGAAGA GAAGACCAAT  
1151 CTCTCAAAAT TTGCTCGAA GAAAGGACT TTGAGCGGG TGTTTTGA  
1201 CTAGAAGCAA TTGTTAAGAG CATCAAAAGA AGCAGAAAAA TTAATTTTGT  
1251 TATAACACAC CATCTATTA AAGACCCATT ATGCAAAAG  
!!IAA SEQUENCE 1.0  
ID ADP30749 standard; protein; 2803 AA.  
XX  
AC ADP30749;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1516.  
XX  
KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.

PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MX, Kothakota S, Haishan L, Linnenmann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2747; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 2803 AA;  
SQ

ADP30749 Length: 2803 February 22, 2005 12:25 Type: P Check: 2904 ..  
1 CGCAGACGGC CGGGCGGGCG GCATGGAGGC GGCGCATCTG CTCGCCGCGG  
51 CCGACGTGCT GCGCCACTTC TCGGTGACAG CCGAGGGCGG CTGAGCCCG  
101 GCGCAGGTGA CCGGCGCGCG GGAGCGGTAC GGCCCCAAGC ACCCCCGTTC

151 CCAGGGAAGT CCTGTGGGA GCTGGTGCTG GAACAGTTTG AGGACCTCTCT  
201 GGTGGCATC CTGCTGTGG CTGCCCTTGT CTCCTTTGTC CTGGCGTGGT  
251 TCGAGGAGG CGAGGAGACC ACGACCCCT TCGTGAGCC CTTGTGTCATC  
301 ATGCTGATCC TCGTGGCAA CGCATTGTG GCGTGTGGC AGGAACGCAA  
351 CGCCGAGAGT GCCATCGAGG CCCTGAAGGA GTATGAGCCT GAGATGGGCA  
401 AGGTGATCCG CTCGACCOC AAGGGCGTGC AGAGGATCCG TGCCCGGGAC  
451 ATCGTCCCAG GGCATTTGT AGAAGTGGA GTGGGGGACA AAGTCCCTGC  
501 TGACCTCCGC CTCATCGAGA TCAAGTCCAC CACGCTGCGA GTGGACCAGT  
551 CCATCCTGAC GGGTGAATCT GTGTCCGTGA CCAAGCACAC AGAGGCCATC  
601 CCAGACCCCA GAGCTGTGAA CCAGGACAAG AAGAACATGC TGTTTTCTGG  
651 CACCAATATC ACATCGGGA AAGCGTGGG TGTGGCCGTG GCCACGGGC  
701 TGCACACGGA GCTGGCAAG ATCCGAGCC AGATGGCGG AGTCGAGCCC  
751 GAGCGGACG CGCTGCAGG CAAGCTGGAC GAGTTTGGAC GGCAGCTGTC  
801 CCAGGCCATC TCTGTGATCT CGTGGCCGT GTGGGTCTATC AACATCGGCC  
851 ACTTCCCGA CCGGCCAC GGTGGTCTCT GGTGGGTG GGTGGTCTCTAC  
901 TACTTCAAGA TCGCGTGGC CTGGCCATCC CCGAGGGCCT  
951 CCGCGTGTG ATCACTACAT GCCTGGCACT GGGCAGCGG CGCATGGCAC  
1001 GCAAGAACGC CATCTGCGA AGCTGCCGT CGGTGGAGAC CTTGGGCTGC  
1051 ACCTCAGTCA TCTGTCGA CAAGACGGG ACCTCACCA CCAATCAGAT  
1101 GTCTGTCTG CGATGTTTCG TGGTAGCCGA GGCAGATGG GGTCTCTGCC  
1151 TTTTGACGA GTTACCATC TCGGTTACCA CGTATACCC CGAGGGCGAA  
1201 GTCTGGACTA CAACGAGCC AAGGTGTGT ATGAGAAGT GGGAGAGGCC  
1251 AGGAGACAG CTCTGACTTG CTGTGTGGAG AGATGAACG TGTTCGACAC  
1301 CGACCTGCAG GCTCTGTCCC GGTGGAGCG AGCTGGCGC TGTAAACCGG  
1351 TCATCAAGCA GCTGATCGG AAGGAGTTCA CCTGGAGTT CTCGCCGAGAC  
1401 CGGAATCCA TGTGGTGTGA CTGCACGCC ACCCGCCTC ACCCTACTGG  
1451 CCAGGGCAG AAGATGTTTG TGAAGGGGG TCTGTAGAGT GTGATCGAGC  
1501 GCTGTAGCTC AGTCGCGTG GGGAGCCGCA CAGCACCCCT GACCCCCACC  
1551 TCCAGGAGC AGATCCTGGC AAAGATCCGG GATTGGGGCT CAGGCTCAGA  
1601 CACGCTGCCG TGCCTGGCAC TGGCCACCCG GGAACGCCCC CCAAGGAAGG  
1651 AGGACATGA GCTGACACG TGCAGCAAGT TTGTGCAGTA CGAGACGGAC  
1701 CTGACCTTCG TGGGTGCGT AGGCATGCTG GACCCGCCG GACCTGAGGT  
1751 GGTGCTGCTC ATCACACGCT GCTACCAGGC GGGCATCCGC GTGGTCATGA  
1801 TCACGGGGA TAACAAAGC ACTGCCGTGG CCATCTGCCG CAGGCTTGC  
1851 ATCTTTGGG ACACGGAAGA CGTGGCGGGC AAGGCCCTACA CGGGCGGGA  
1901 GTTTGATGAC CTCAGCCCG AGCAGCAGCG CCAGGCTGTC CGCACCGCC

1951 GCTGCTTCGC CGCGTGGAG CCCGACACA AGTCCCGCAT CGTGAGAAC  
2001 CTGCACTCT TTAACAGAT CACTGCTATG ACTGGCGATG GAGTGAACGA  
2051 CGCACCAGCC CTGAAGAAAG CAGAGATCGG CATCGCCATG GCGTCAGGCA  
2101 CGGCGGTGCG CNAGTGCGGG GCAGAGATGG TGCTGTGAGA TGACAACTTT  
2151 GCCTCCATCG TGGCTGCGGT GGAGGAGGGC CGGGCCATCT ACAGCAACAT  
2201 GAAGCAATTC ATCCGCTACC TCATCTCCTC CAATGTTGGC GAGGTGCTCT  
2251 GCATCTTCT CACGCCAAT CTGGGCTGCG CCGAAGCCCT GATCCCTGTG  
2301 CAGCTGCTCT GGGTGAACCT GGTGACAGAC GGCCTACCTG CCACGGCTCT  
2351 GGGCTTCAAC CGCCAGACC TGGACATCAT GGAGAGCTG CCGCGGAGCC  
2401 CCGGAGAAGC CCTATCAGT GGCTGGCTCT TCTTCGATA CTTGGCTATC  
2451 GGAGTGTACG TAGGCTTGGC CACAGTGGCT GCGCCACCT GGTGGTTTGT  
2501 GTATGAGCC GAGGACCTC ACATCAACTT CTACCAGCTG AGGAACCTCC  
2551 TGAAGTGCTC CGAAGAAC CCGCTCTTTG CCGGCATCGA CTGTGAGGTG  
2601 TTGAGTCAAC GCTTCCCCAC CACCATGGCC TTGTCCGTGC TCGTGACCAT  
2651 TGAATGTGC AATGCCCTCA ACAGTAGGC TGGGCGCTCT CGGAGAACCA  
2701 GTGCTGCTG CGGATGCGGC CTGTGATGAA CCGCTGGCTG CTGTGGGTG  
2751 TGCCCATGTC CATGGCCCTG CACTTCTCA TCTGTCTCT GCGGCCCTG  
2801 CCT

!!AA\_SEQUENCE 1.0  
ID ADF30752 standard; protein; 1849 AA.  
XX  
AC ADF30752;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1519.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Hallenbeck RF, Huang MM, Kothakota S, Haishan L, Linemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2750; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is

CC available on WIPWEB and is not in the specification.

XX  
SQ

Sequence 1849 AA;

ADP30752 Length: 1849 February 22, 2005 12:25 Type: P Check: 2971 ..

1 TGTGTGTGTCAGTGCACAAT ACCCCAGAG ATGAATAATGA GGCACAAGCT  
51 GGCTGGATTG AGGGGCGAGC CATCTTTTTC TCAGTGATCA TCGTGTGTGT  
101 AGTGAATGCC TTTAATGATT GGAGCAAGA GAAGCAATTC CGGGGGCTGC  
151 AGTGCCGCAT TGAACAGGAG CAAGAATCTT CCATCATCCG AAACGCTCAA  
201 CTATCAGC TCCTGTGGC TGAGATTGTG GTTGGTGATA TTGCCAAGT  
251 CAAATACGGG ACCCATGTCA TGAAGGTTT TGGCCGGATG GTGGTGACAG  
301 CTGTGTGTGT CAACTCTCAG ACTGGAATCA TCCTTACTCT CTTGGGGGTC  
351 AATGAGGATG ACGAGGGGA GAAAGAAG AAAGCAAGA CCCAAGACGG  
401 AGTGGCCCTG GAAATCCAGC CACTCAACAG CCAGGAGGGA ATCGACAATG  
451 AGGAAAGGA CAAGAGGCA GTCAAGGTGC CTAAGAAAGGA GAAGTCAGTG  
501 CTGAGGGCA AGCTGACTCG CTTGCTGTT CAGATTGGGA AGCCGAAAA  
551 TGATGAAGA CAATACCTTA GTACGGCACT TGGATGCTTG TGAGACCATG  
601 GGCAAGCCCA CGCCATCTG CTCTGATAAG ACAGGCACGT TGACCATGAA  
651 CCGATGACT GTGGTACAAG CTTATATTGG GGGCATCCAT TACCGTCAAA  
701 TCCCAAGCCC TGATGTTTTC GTGCCAAAG TCCTGGACCT CAFTGTCAAT  
751 GGCATTTCTA TCAACAGTGC TTATACCTCC AAGATTCTGC CTCACAGAA  
801 GGAGGGAGGC GTGCCCTGGC AGGTGGGCA CAAGACCGAG TGTGCTCTGC  
851 TAGGCTTTGT CACAGATCTG AAGCAGGATT ATCAGGCTGT GCGTAAATGA  
901 GTGCCCCGAG AGAAGCTCTA CAAGGTGTAC ACCTTTAACT CAGTGGCGAA  
951 GTCAATGAGC ACGTCATCA GGAATCCAA CGGTGGCTTC CGTATGTACA  
1001 GCAAGGCGC CTCTGAGATC ATCTTTCGCA AGTGTAAATCG AATCTTGGAC  
1051 CGGAAAGGGG AAGCAGTGCC ATTCAGAAT AAAGACAGAG ATGATATGTT  
1101 ACGACTGTC ATGAGGCCA TGGCCTGTGA TGGACTCCGG ACTATCTGCA  
1151 TAGCTTACCG GGACTTCGAT GACACAGAG CCTCTTGGGA CAATGAGAAT  
1201 GAGATCCTCA CCGAATGAC CTGTATCGG GTGGTGGGCA TTGAGGACCC  
1251 TGTGCGCCCA GAGGTGCCAG ATGCTATTGC CAAATGCAAA CAACTGGCCA  
1301 TTAATGTGAG AATGTGTACA GGTGACAACA TCAACACAGC CCGGGCCATT  
1351 GCCACCAAT GTGGCATTCT GACACCTGGG GATGACITTC TGTGCTTAGA  
1401 AGGCAAGAA TTCAACCGGC TCATCCGCA CGAGAAAGGC GAGGGCATCG  
1451 CAGGCACAGA TGTAGCAAG GAGGCTTCAG ACATCATCTT AACAGATGAC  
1501 AACTTCACCA GCATTGTGAA GGCAGTGATG TGGGGACGAA ATGTCTATGA  
1551 CAGCATCTCC AAGTTCCTGC AGTTCACGCT CACTGTCAAT GTGGTGGCCG  
1601 TGATTTGAGC CTTCACTGGA GCGTGTATCA CTCAGGATTC CCCATTGAAA  
1651 GCTGTGCAGA TGTGTGGGT TAATCTGATC ATGGACACTT TTGCTTCATT

1701 GGCCCTGGCC ACAGAGCCCC CTACGGAATC TCTGTTGAAG CGGCGCCCT  
1751 ATGGCGGAAA TAAGCCTCTG ATCTCAGCA CTATGATGAA GAACATCTTG  
1801 GGCCATGCAT TCTATCAGCT CATTGTCACT TTTATCCTTG TCTTTGGCG

!!AA SEQUENCE 1.0

ID ADP30782 standard; protein; 1209 AA.

XX

AC ADP30782;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1549.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

PN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

PR 29-AUG-2002; 2002US-0406576P.

PR

PR 29-AUG-2002; 2002US-0406579P.

PR

PR 29-AUG-2002; 2002US-0406585P.

PR

PR 29-AUG-2002; 2002US-0406588P.

PR

PR 29-AUG-2002; 2002US-0406608P.

PR

PR 29-AUG-2002; 2002US-0406611P.

PR

PR 29-AUG-2002; 2002US-0406612P.

PR

PR 29-AUG-2002; 2002US-0406616P.

PR

PR 29-AUG-2002; 2002US-0406642P.

PR

PR 29-AUG-2002; 2002US-0406646P.

PR

PR 29-AUG-2002; 2002US-0406653P.

PR

PR 29-AUG-2002; 2002US-0406655P.

PR

PR 17-SEP-2002; 2002US-0410946P.

PR

PR 17-SEP-2002; 2002US-0410947P.

PR

PR 17-SEP-2002; 2002US-0410948P.

PR

PR 17-SEP-2002; 2002US-0410949P.

PR

PR 17-SEP-2002; 2002US-0410953P.

PR

PR 17-SEP-2002; 2002US-0410957P.

PR

PR 17-SEP-2002; 2002US-0410958P.

PR

PR 17-SEP-2002; 2002US-0410959P.

PR

PR 17-SEP-2002; 2002US-0410960P.

PR

PR 17-SEP-2002; 2002US-0410961P.

PR

PR 17-SEP-2002; 2002US-0410962P.

PR

PR 17-SEP-2002; 2002US-0411019P.

PR

PR 17-SEP-2002; 2002US-0411022P.

PR

PR 17-SEP-2002; 2002US-0411023P.

PR

PR 17-SEP-2002; 2002US-0411024P.

PR

PR 17-SEP-2002; 2002US-0411032P.

PR

PR 17-SEP-2002; 2002US-0411035P.

PR

PR 17-SEP-2002; 2002US-0411037P.

PR

PR 17-SEP-2002; 2002US-0411041P.

PR

PR 17-SEP-2002; 2002US-0411045P.

PR

PR 17-SEP-2002; 2002US-0411046P.

PR

PR 17-SEP-2002; 2002US-0411048P.

PR

PR 17-SEP-2002; 2002US-0411052P.

PR

PR 17-SEP-2002; 2002US-0411055P.

PR

PR 17-SEP-2002; 2002US-0411073P.

PR

PR 17-SEP-2002; 2002US-0411082P.

PR

PR 17-SEP-2002; 2002US-0411011P.

PR

PR 17-SEP-2002; 2002US-0411111P.

PR

PR 18-APR-2003; 2003US-0463700P.

PR

PR 18-APR-2003; 2003US-0463708P.

PR

PR 18-APR-2003; 2003US-0463716P.

PR

PR 18-APR-2003; 2003US-0463732P.

PR

PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX

PS Claim 1; SEQ ID NO 2780; 428pp; English.  
XX

CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1209 AA;

ADP30782 Length: 1209 February 22, 2005 12:25 Type: P Check: 4195 ..

1 ATGACAATGA CTAATTCAAT CATTACGGCT TTGAAAAAG CAAGACCTGC  
51 TCAGCCAGAG GTGAGAAAG GATGGCTCTG GACAGTGACA GGAGAGGAAG  
101 GGGTTTCCCT GCAGGGCAAT GACCTGGCTT GTGCCCTTGA GGCAGGTGAA  
151 TGTGTCCGCA AGAGTGAGTT CTCACAAGAT CTGATGGTTT TACAAGGAGC  
201 TCTTCTGCT TCCATCAGCA CTCTCCCTC CTGCTGCCCT GTGAAGAAGG  
251 TGTCTTGTCT CCTCTTCCG TTTACACACA ATTGTAAGTT TCCTGAGGTC  
301 TCCCGGATA TGCTGAATC CCAGCCCTCC TGGTTATATG GGCCATTGGA  
351 ACTGTCCGTG GAATTGGNAG GGACATCAG CAGTGGGTTT GGCAGTGCC  
401 TCAGCAGCAC AGTGCTCATG GGCTGGAAT CTGTGTGTCA GGGCAGTGTG  
451 GACCTTGCCT CCTGCACAGA GGTGGTAGGA GGGATGAACA CACAGCAACA  
501 GCAGCAGCAA GTCTTGAGC AGCCACAGCA ACCGAGCCAT CATGGGCCCC  
551 AGGCTGCCAC AGACCCCTGG GCTCCCAAGC TCCACTACCC GAGAGTCTTC

601 TGTCTGTCT TCTTCCTCAA GGTCTTACTA CTGTCTTCC CTGTGGCTGA  
651 CCTCTCTTG ATCTTGATCT ACACCTATAC CTTACCTTAC ATCTATACTT  
701 ACACCTATAT CTACACCTAC ACCTACACCT ATATCTACAT CTACACCTAC  
751 ATCTATATCT ACACCTACAT CAACACCTAC ACCTATGTCT ACACCTACAC  
801 GTTCACTAT GTCTATACTT ATACCTACAC CTATACTTTT ACTTATGTCT  
851 ATACTTACAC CTACACCTAC GTCTACACCT ACATCTACAC CTACACTTAC  
901 ACCTACATCT TCATCTACAC CAACTTCCAC TACACCTACA ACTGCACCTA  
951 CACCCATATC TGCACCTACA TCTATACATA CACCCACATC TACACCCACA  
1001 CTTTCACTA TATTACACCT TACACCTATA TCTACACCTC CATCCACACC  
1051 TGCACCTTTA CTTATACCTA CACCTATGTC TATACCTACA CCTACATCTA  
1101 CATCTATACC TACATCTACA CCTACACCTT CACCTACACC TGCATCTACA  
1151 CCTACACCTA CGTCTACACC TGCATCTACA TCTACACCTA CACCTTACCC  
1201 TACACATAA  
IIAA SEQUENCE 1.0  
ID\_ADP30786 standard; protein; 186 AA.  
XX  
AC ADP30786;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1553.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.



PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2817; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 423 AA;  
ADP30819 Length: 423 February 22, 2005 12:25 Type: P Check: 2567 ..  
1 ATGCTTGTGT GCGCCCTGGC CGCGCTGCC CTCTGCCCGC CTCCTACCCC  
51 TCGGAGCCGC CGCCTAAGTC GAGGAGGAGA GAATGACCGA GGTGCTGTGG  
101 CCGGCTGTCC CCAAGGGAC GGAGCTGCC TTCTGGCCG GTCCGGGTTC  
151 GTCTGTGGGG AACAGACGG TCGCCTCCAC TGCCGCCGTC TCCTCGTGGT  
201 TCAATATGCC CTTGACCAAG ACGGGCTTC AGTTTACTA CTTGCCGCGT  
251 GTCTACATCT TGGTATTCTAT CATCGGCTTC CTGGGCAACA GCGTGGCCAT  
301 CTGGATGTTT GTCTTCCACA TGAAGCCGTG GAGCGGCATC TCCGRTACA  
351 TGTTCAAATT GGCTCTGGCC GACTTCTTGT ACGTGTGTAC TCTGCCAGCC  
401 CTGATCTTCT ACTACTTCAA TAA  
IIAA SEQUENCE 1.0  
ID ADP30824 standard; protein; 318 AA.  
XX  
AC ADP30824;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX

DE Human secreted protein SEQ ID #1591.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406656P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR

PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2822; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 318 AA;  
ADP30824 Length: 318 February 22, 2005 12:25 Type: P Check: 9825 ..  
1 ATGCTAAGAT CGCTACAG CAAACAAGG CCAACACAGC CCAGGAACAG  
51 CAGTATGGCA GCCATGAGGA GAACTTCCCA GCTGACCTGG AGGCTCTGCA  
101 GCGGGAGATC AGGATGGCTC AGGAACGCTT GGATCTGGCA GTTCAGGCCT  
151 ACAGTCACCA AAACAACCCCT CATGGTCCCC GGGAGAAGAA GGCCAAAGTG  
201 GGGTCCAAAG CTGGGTCCAA CAAAGACACT GCCAGTAGCA AATCAGGGGA  
251 TGGGAAGACC TCGCTCTGGA TTTAATCCTG GCGGGCTTAA AACCTGTGCT  
301 TTTCATAGTT TATGGTAA  
IIAA SEQUENCE 1.0  
ID -ADP30857 standard; protein; 750 AA.  
XX  
AC ADP30857;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1624.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR

29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486448P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
08-AUG-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PA  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.



XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2855; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 750 AA;  
ADP30857 Length: 750 February 22, 2005 12:25 Type: P Check: 6986 ..  
1 ATGAGCAGTG AATATAAATA TGTGTCATA GGTACAGCAG AATTTCAAGC  
51 TGGAAAACT TCCAGGCTC ATCAGAGTAA TAGTAATGCA GATGTGAAT  
101 TTGGAAAAAG TATTAAAGAT TTTCAGCTG CTCTAAAGAA TTGTAGTAAG  
151 AATGCTGTCT TTATGTGTTT AGTTCTATCA ACTTCTTCAG AAGCCTTAAT  
201 TACTACTGGA TTGTGTACAT TTTTACCTAA ATTATAGAA ATCAATTGCG  
251 GATTGACATC CAGCTTTCGA GCTACTCTTG GAGGGACAAT TCCTGGACCA  
301 ATTATATTGG GTTTCACAAT AGACAGCACA TGTATTCTTT GGGATATAAA  
351 TGNATTGTGA ATTAAGNGG CTTCTCGAT TTATGATAC ATCAAGATGG  
401 CCCATATGCT AGTAGCCATA AGTGTACTT GTAAAGTTAT CACCATGTTT  
451 TTCAATGGAT TTGCAATCTT TTTGTATAAA CCACCTCCAT CAGCCACAGA  
501 TGTGTCATTT CATAAAGAGA ATGCAATGTT GACTAATGTT TTAGCAGAAC  
551 AGGATCTCAA CAAATAGTA AAGAAGGGC TTGCGCAGCA GAGCAGGCGA  
601 CGAGAAGATG AAAAGCAGT GGACATTTGA AACTGGTTTG GGGCTGGAGA  
651 GAAGAAGTCC AGGCACCTGG ACTTCAGGAA AGATCATCT TCCTGCTCTA  
701 TCCCTTTTCC AGTCCCTT AGGCTGAGA GCCACTTTCA TAGGCAATAA  
!!AA SEQUENCE 1.0  
ID -ADP30868 standard; protein; 681 AA.  
XX  
AC ADP30868;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1635.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406578P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493373P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Heetir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR





```
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
XX 08-AUG-2003; 2003US-0493577P.
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX WPI; 2004-348439/32.
XX New nucleic acid molecule for diagnosing, preventing or treating diseases
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PT genetic, bacterial and viral diseases.
XX Claim 1; SEQ ID NO 2977; 428pp; English.
XX The present invention relates to an isolated nucleic acid molecule
CC encoding a polypeptide which is believed to be cytostatic,
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
CC composition and methods are useful for diagnosing, preventing and
CC treating diseases such as proliferative (e.g. cancer), inflammatory,
CC immune, metabolic, genetic, bacterial and viral diseases. The present
CC sequence represents a human secreted protein. The present sequence is
CC available on WIPOWEB and is not in the specification.
XX Sequence 414 AA;
ADP30979 Length: 414 February 22, 2005 12:25 Type: P Check: 4705 ..
1 ATGACGATGG AGACTCTCCC CAAAGTTCTTA GAGTCCGATG AGAAGTCTCC
51 AGAAGCCCAAG GACCTGCTGC CCAGCCAGAC CGCCAGCTCC CTGTGCATCA
101 GCTCCAGGAG CGAGTCTGTC TGGACCACCA CCCCAGGAG TAACTGGGAA
151 ATCTACCGCA AGCCCCATCGT TATCATGTCA GTGGGCGGTG CCATCCTGCT
201 TTTCGGCGTG GTCATCACCT GCTTGCCTTA CACCTTGAAG CTGAGTGACA
251 AGAGTCTCTC CATCTCAAA ATGGTAGGC CTGCTTCCTT GTCCCTGGGA
301 CTCATGATGC TGGTGTGCGG GCTGGTGTGG GTGCCCATCA TCAAAAAGAA
351 ACAGAAGCAC AGACAGAAGT CGAATTCTTT ACGCAGCCTC AAGTCCTTCT
401 TCCTGACTCG CTGA
!!AA SEQUENCE 1.0
ID ADP30993 standard; protein; 1191 AA.
XX
AC ADP30993;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #1760.
XX
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW cancer; inflammatory; immune; human secreted protein.
XX
OS Homo sapiens.
XX
PN WO2004035732-A2.
XX
PD 29-APR-2004.
XX
PF 28-AUG-2003; 2003WO-US026780.
XX
XX 29-AUG-2002; 2002US-0406576P.
PR 29-AUG-2002; 2002US-0406579P.
PR 29-AUG-2002; 2002US-0406585P.
PR 29-AUG-2002; 2002US-0406588P.
PR 29-AUG-2002; 2002US-0406608P.
PR 29-AUG-2002; 2002US-0406611P.
PR 29-AUG-2002; 2002US-0406612P.
PR 29-AUG-2002; 2002US-0406616P.
PR 29-AUG-2002; 2002US-0406640P.
PR 29-AUG-2002; 2002US-0406642P.
PR 29-AUG-2002; 2002US-0406646P.
PR 29-AUG-2002; 2002US-0406653P.
PR 29-AUG-2002; 2002US-0406655P.
PR 29-AUG-2002; 2002US-0406666P.
PR 17-SEP-2002; 2002US-0410946P.
PR 17-SEP-2002; 2002US-0410947P.
PR 17-SEP-2002; 2002US-0410948P.
PR 17-SEP-2002; 2002US-0410949P.
PR 17-SEP-2002; 2002US-0410953P.
PR 17-SEP-2002; 2002US-0410957P.
PR 17-SEP-2002; 2002US-0410958P.
PR 17-SEP-2002; 2002US-0410959P.
PR 17-SEP-2002; 2002US-0410960P.
PR 17-SEP-2002; 2002US-0410961P.
PR 17-SEP-2002; 2002US-0410962P.
PR 17-SEP-2002; 2002US-0411019P.
PR 17-SEP-2002; 2002US-0411022P.
PR 17-SEP-2002; 2002US-0411023P.
PR 17-SEP-2002; 2002US-0411024P.
PR 17-SEP-2002; 2002US-0411032P.
PR 17-SEP-2002; 2002US-0411035P.
PR 17-SEP-2002; 2002US-0411037P.
PR 17-SEP-2002; 2002US-0411041P.
PR 17-SEP-2002; 2002US-0411045P.
PR 17-SEP-2002; 2002US-0411046P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411052P.
PR 17-SEP-2002; 2002US-0411055P.
PR 17-SEP-2002; 2002US-0411073P.
PR 17-SEP-2002; 2002US-0411082P.
PR 17-SEP-2002; 2002US-0411101P.
PR 17-SEP-2002; 2002US-0411111P.
PR 18-APR-2003; 2003US-0463700P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 18-APR-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467230P.
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
PA
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
```

XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2991; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX Sequence 1191 AA;  
SQ  
ADP30993 Length: 1191 February 22, 2005 12:25 Type: P Check: 2924 ..  
1 ATGAGTTGGA GCTTCTGTAC TCGCTGTCTA GAGGAGATTC ACAACCATTC  
51 CACATTTGTG GGAAGATCT GGTCACATGT TCTGATTGTC TTCCGGATCG  
101 TCCTTACAGC TGTAGGAGGA GAATCCATCT ATTACGATGA GCAAAGCAAA  
151 TTTGTGTGCA ACACAGNACA GCCGGGCTGT GAGAAATGCT GTTATGATGC  
201 GTTTGCACCT CTCTCCCATG TACGCTTCTG GGTGTTCCAG ATCATCTCTGG  
251 TGSCAACTCC CTCTGTGATG TACCTGGGCT ATGCTATCCA CAAGATTGTC  
301 ABAATGGAGC ACGGTGAAGC AGACAAGNAG GCAGCTCGGA GCAAGCCCTA  
351 TGCATATGCC TGGAAACAAAC ACCGGGCTCT GGAAGAAACG GAGGAGGACA  
401 ACGAAGAGGA TCCTATGATG TATCCAGAGA TGGAGTTAGA AAGTGATTAAG  
451 GAAATPAAAG AGCAGAGCCA ACCCAACCT AAGCATGATG GCGGACGAG  
501 GATTCGGGAA GATGGGCTCA TGAATACTA TGTGCTGTCAG TTGCTGGCAA  
551 GGACCTGTGT TGAGGTGGGT TTTCTGATAG GGCAGTATTT TCTGTATGCG  
601 TTCCAGTCC ACCCGTTTTA TGTGTGAGC AGACTTCCTT GTCCTCATNA  
651 GATAGACTGC TTTATTTCTA GACCCACTGA AAAGACCATC TTCTTTCTGA  
701 TAATGTATGG TGTACAGGC CTTTGCCTCT TGCTTAACAT TTGGGAGATG  
751 CTTCAATTTAG GTTTGGGAC CATTCGAGAC TCACTAACA GTAAAGGAG  
801 GGAACCTTAG GATCGGGTG CTTATTAATTA TCCTTTCACT TGAATAACAC  
851 CATCTGCTCC CCCTGGCTAT AACATTGCTG TCAAAACAGA TCAAAATCCAG  
901 TACACCGAAC TGTCCAATGC TAAGATGCC TACAAGCAA ACAAGGCCAA  
951 CACAGCCCAAG GAACAGCAGT ATGGCAGCCA TGAGGAGAAC CTCCAGCTG  
1001 ACTGGAGGC TCTGCAGCGG GAGATCAGGA TGGCTCAGGA ACGCTTGGAT  
1051 CTGGCAGTTC AGGCTACAG TCACCAAAAC AACCTCATG GTCCCGGGA  
1101 GAAGAAGGCC AAGTGGGGT CCAAGCTGG GTCCAACAAA AGCACTGCCA  
1151 GTAGCAATC AGGGATGGG AAGACCTCCG TCTGGATTTA A

!!AA\_SEQUENCE 1.0

ID ADP31058 standard; protein; 2027 AA.

XX

AC ADP31058;  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1825.  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
KW Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 02-MAY-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 22-MAY-2003; 2003US-0472430P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 09-JUN-2003; 2003US-0476641P.

PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3056; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 2027 AA;  
SQ  
ADP31058 Length: 2027 February 22, 2005 12:25 Type: P Check: 6937 ..  
1 TTTCGATTTG TGTATGAAGC TCAAGATGTG GGGAGTGGCA GAGAGTATGC  
51 ATTAAGGCT ATTATCCAAT GAAGAGGAAA AGAACAGAGC CATCAATTCA  
101 GAAGTTTGTT CTGAAGATCT TCTACAGAC GTGCGGGGCC GTGCAGCACA  
151 TGCACCGGCA GAAGCGGCC ATCATCCACA GGGACCTCAA GGTGGAAC  
201 TTGTTGCTTA GTAACCAAGG GACCATTAAG CTGTGTGACT TTGGCAGTGC  
251 CACGACCATC TGCATACC CTGACTACAG CTGGAGCGCC CAGAGGGGAG  
301 CCCTGTGTGA GGAAGAGATC ACGAGGAATA CAACACCAAT GTATAGAACA  
351 CCAGAAATCA TAGACTTGTA TTCCAACTTC CCGATCGCGC AGAAGCAGGA  
401 TATCTGGGCC CTGGGTGCA TCTTTGACCT GCTGTGCTTC CGGAGCACC  
451 CTTTGTAGGA TGGAGCGAAA CTTGCAATAG TCAATGGGAA GTACTCGATC  
501 CCCCCGACG ACAGGCAGTA CAGGTCCTTC CACAGCTCA TCCGCGCCAT  
551 GCTGCAGGTG AACCCGAGG AGCGGTGTC CATCGCGAG GTGGTGCAAC  
601 AGCTGCAGGA GATCGGGGCC GCCCGCAAG TGAACCCCAA GTCTCCCATC  
651 ACAGAGATTC TGGCGGGTGG GACAGAGCG CTCTTACCA ACCTCAAGGA  
701 CACCTCTCC AAGGTATCC AGTCGTGCGC TAATTATGCA AAGGTGACC  
751 TGGACATATC TTATCATACA TCCGAATTG CAGTGATGTC ATTCCAGCA  
801 GAAGGTGTGG AGTCAGCGCT CAAAACACAC ATCGAAGATG TGCGGTGTTT

851 CCTGGACTCC AAGCACCAG GGCATATGC CGTCTACAAC CTGTCCCCGA  
901 GGACCTACCG GCCCTCCAGG TTCCACAACC GGGTCTCCGA GTGTGGCTGG  
951 GCAGCAGCGC GGGCCCCACA CTGCACACC CTGTACAACA TCTGCAGGAA  
1001 CATGCACGCC TGGCTGCGGC AGGACCACAA GAACGTCTGC GTCGTGCACT  
1051 GCATGTTTCT GTGCTTCTGC CGTCTCTTCA GCACCGGGGA GGCGCCGCTG  
1101 TACATGTTCA GCATGAAGCG CTGCCACCA GGCATCTGGC CATCCACAA  
1151 AAGGTACATC GAGTACATGT GTGACATGGT GGCAGGAGG CCATCACAC  
1201 CCACAGACAA GCCCATCTCG GTGAGGGCGG TGGTCATGAC ACCGTGCGG  
1251 CTGTTCAACA AGCAGAGGAG CGGCTGCAGG CCTTCTGCG AGGTCTACGT  
1301 GGGGAGCAGG CGTGTGGCCA GCACCTCCA GAGTACGAC AAGATCGTGT  
1351 TAAATTTGAA GATGCAAGG CGGTGATTCC CTGGGGGCTC ACGTGCAGG  
1401 GAGACGTGCT CATCGTCTATC TATCACGCC GGTCCACTCT GGGCGGCCGG  
1451 CTCGAGGCCA AGATGGCATC CATGAAGATG TTCCAGATTG AGTTCCACAC  
1501 GGGGTTTGTG CTTCCGAAGC CCACACTGT GAAATTTGCC AAGTACGTTG  
1551 GTACCGCTTG TGCTCGGTGA ACCTGGAAGT GGAGGTGGAG CCCAGGGACA  
1601 GGGGAGGCC GGAAGCCCC ACCATGGGAG AACTCGAGCA TGAGGGGGCT  
1651 GAACCCCAA ATCTGTTTTT CCAGCGGGGA GGAGCAGCAA GACATTTCTGT  
1701 CTAAGTTTGG GAAAGCGGAG CTTCCCGGCG AGCTGGCTC CAGGGCTCAG  
1751 TATGATGCTG GGGCAGGGTC CCGGAGGCC GAACCCACAG ACTCTGACTC  
1801 ACGCCNAGC AGCAGGGGG AGCCAGTGC CTTCTTGCAC ACGTGGACT  
1851 GGCAGGCCCC CAGTGTCTCG CCCCCATCTT GCAGCGCCGA CTTCTTGCAC  
1901 CTGGGGGATC TGCCAGGAGA GCCCAGCAAG ATGACAGCCT CGTCCAGCAA  
1951 CCAGAGCTGT CTGGGAGGAT GGGTGCCTG GACCGAGACT GCAGCATCGG  
2001 CAGTGGCCCC CACGCCAGCC ACAGAAAG  
!!AA SEQUENCE 1.0  
ID ADP31123 standard; protein; 831 AA.  
XX  
XX ADP31123;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #1890.  
XX  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN W02004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
PS Claim 1; SEQ ID NO 3121; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
SQ Sequence 831 AA;  
ADP31123 Length: 831 February 22, 2005 12:25 Type: P Check: 1270 ..  
1 ATGTATGAGG GCAGCAGAGG AAGAAGAGTT GGCAAGAGCAG CCCAGAAACA  
51 CATGAAGAGG AGGAGTGAAT ATTCCCTCCG GCCCCGGGAG CCGCAGCAGG  
101 ACCGGCCGGG AGGCGCCGGG GAGGGGAGTC GCATCCCGGT GCGGACAGTG  
151 CCCACCGCGC CTTGCGAGGA CCGGCGACCC ACCGGCCTCT TCCAGGGCCA  
201 GGCAGCTAC CCGCCCAACT TCATCCGGAG CGCGCTGTCTG TCCGTCGACC  
251 TCGCGACGG TCAGGGCCGC ACCACGGGGG TGGGAGCGA CCGCAGGTAC  
301 TTCGGCAGGA CGGCGCTCGA GATAAAGACG CAGAGCCTCA GAGAAGTTAA  
351 ACGATTGATC CTATGTGAGG GGTAGAGTC AAGACTCATA CCTATGCCTT  
401 TTAACCTCAA GATTGGACGA CTGATTATTG GACAGAATGG CATCTTGTGG  
451 ACACCTGGCG TCTCTGTCAT TATCAGGAAG ATCAAGGCAG CTGGTGGAAAT  
501 CATTCCTACA GCCAGCCACT GCCTGGAGG ACCAGGGGGA GAGTTTGGAG  
551 TGAAGTTTAA TGTTGCCAAT GGAGCCAGGG GCATCTGGCA TCCGGCAAGT  
601 GGCAGTCCC TCATCATCCT GTCTGATCCA AATTCAAACC ACATTCAGCC  
651 AGGTGACCAT GGTGGCTCCC CCCAGGGTG GAGAGGCACC AAGCTGCTTG  
701 TGGTCTTGTG TATTCCCACT CCCTGCCTGA CTGAACATTT TCTCACCTC  
751 CTGATCATCA GCAGCAGAAA CTGGCTGCTC TTCTCTCTGG GTAGACAGCC  
801 AGACTGTATT TCCAGCTGC CCCTGCAGTG A  
!!AA SEQUENCE 1.0  
ID ADEP31155 standard; protein; 1173 AA.  
XX  
AC ADP31155;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1922.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX

PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 13-MAY-2003; 2003US-0471306P.  
PR 13-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3153; 428pp; English.  
PS The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX Sequence 1173 AA;  
SQ

ADP31155 Length: 1173 February 22, 2005 12:25 Type: P Check: 3659 ..

1 ATGACTAGAC AGGGAGAACC CCAGGTCCAG TTCAAACTTG TATTGGTTGG  
51 TGATGGTGGT ACTGGGAAAA CGACCTTCGT GAAACATCAT TTGACTGGTG  
101 AATTGAGAA GTGTATAGCC ACCTTAGGTG TTGAGGTTCA TCCCTAGTGG  
151 TTCCACACCA ACAGAGGACC TATTAAGTTC AATGTATGGG ACACAGCCAG  
201 CAGGGAGAAA TTCGGTAGAC TGAGAGATGG CTATTATATC CAAGCCCACT  
251 GTGCCATTAT AATGTTTGAT GTAACATCAA GAGTTACTTA CATGTGCTTA  
301 TCTGGCATAG AGATCAGTGC CCAAGCACAT GCCCAGTGGC CTAAGGATGA  
351 GCCCAACCAA CCTGCCACTA CCACCACAGC TGGCATTCAT CCACCAAAAC  
401 CACCTGCAGG CCCGAAACT AACCTGGCCA GGCCGTGACA GCACACACA  
451 ACACCAGCAC AGACCACATG GAAGCCAGAG GGTACTCCCA CCACCTGTAC  
501 TGCCATTGTC CATGTCATGC CCACCTGCCA AGGGCTCAAG GACCTTCCCA  
551 CTTGCTGAT TAACATTTGCC ACTGCTTCCA CACCTGAATC AACGAGACAG  
601 AAAATTAAAC AGGATATTCA GGACTTGAAC ACAGCTCTGC AACAAGAAGA  
651 CCTAACAGAC ATCTACAGAA TGCTCCACCC CAAATCAACA GAGCATACAT  
701 TCTTCTCAGC ACCATGTAGC ACTTATTCTA AATTGGCCA CATATTTGGA  
751 AGTAAACAAA TTCTCAGCAA GTGCAAAAAGA ATGGAATAA TAACAAACAG  
801 TTCTTTAGAC CACAGTGAAA TCRAACTAGA ACTCAGGATT AAGAAACTCA  
851 CTCAAAACCTG CACAACCTACA TGGAACTGA ACAACCTTCT CTTGAATGAC  
901 TACTGGGTAA ATAATGAAAT GAAGGCAGAA ATAAAGATGT TCTTTGAGAC  
951 CAATGAGAAC AAAGACACNA CATACCAGGA TCCTCTGGAC ACAGCTTAAG  
1001 CAGTGATTAG AGGGAATTC ATAGACTAA ATGCCACAG GAGAAACCCAG  
1051 GAAAGATCTA AAATCGACAC CCTAACATCA CAACTAAAAG AAGTGATGTC  
1101 CTTCTCTAGA AAGAGAGAAG AACAAACAAA TTCAAAGAA AGAGAAGAAA  
1151 GACCAACAA ATTCAAAAGC TAG

!IAA\_SEQUENCE 1.0  
ID ADP31184 standard; protein; 849 AA.



XX AC ADP11184;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1951.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX OS cancer; inflammatory; immune; human secreted protein.  
XX PN Homo sapiens.  
XX PD WO2004035732-A2.  
XX PF 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-040576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406656P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.  
XX PR 17-SEP-2002; 2002US-0411023P.  
XX PR 17-SEP-2002; 2002US-0411024P.  
XX PR 17-SEP-2002; 2002US-0411032P.  
XX PR 17-SEP-2002; 2002US-0411035P.  
XX PR 17-SEP-2002; 2002US-0411037P.  
XX PR 17-SEP-2002; 2002US-0411041P.  
XX PR 17-SEP-2002; 2002US-0411045P.  
XX PR 17-SEP-2002; 2002US-0411048P.  
XX PR 17-SEP-2002; 2002US-0411052P.  
XX PR 17-SEP-2002; 2002US-0411055P.  
XX PR 17-SEP-2002; 2002US-0411073P.  
XX PR 17-SEP-2002; 2002US-0411082P.  
XX PR 17-SEP-2002; 2002US-0411101P.  
XX PR 17-SEP-2002; 2002US-0411111P.  
XX PR 18-APR-2003; 2003US-0463700P.  
XX PR 18-APR-2003; 2003US-0463708P.  
XX PR 18-APR-2003; 2003US-0463716P.  
XX PR 18-APR-2003; 2003US-0463732P.  
XX PR 02-MAY-2003; 2003US-0467199P.  
XX PR 02-MAY-2003; 2003US-0467201P.  
XX PR 02-MAY-2003; 2003US-0467203P.  
XX PR 19-MAY-2003; 2003US-0467230P.  
XX PR 19-MAY-2003; 2003US-0471306P.  
XX PR 22-MAY-2003; 2003US-0471336P.  
XX PR 22-MAY-2003; 2003US-0472420P.  
XX PR 09-JUN-2003; 2003US-0476609P.

PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX PR New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX PT genetic, bacterial and viral diseases.  
XX PS Claim 1; SEQ ID NO 3182; 428pp; English.  
XX CC The present invention relates to an isolated nucleic acid molecule  
XX CC encoding a polypeptide which is believed to be cytostatic,  
XX CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX CC composition and methods are useful for diagnosing, preventing and  
XX CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX CC immune, metabolic, genetic, bacterial and viral diseases. The present  
XX CC sequence represents a human secreted protein. The present sequence is  
XX CC available on WIPWEB and is not in the specification.  
XX SQ Sequence 849 AA;  
ADP31184 Length: 849 February 22, 2005 12:25 Type: P Check: 4817 ..  
1 ATGAATCCAG GATTAGATC AGAACCCAGA ACATTACCAG CACCAGAAA  
51 CCTTCCTGCA CCTCTTCCA CTGAGTGGCC CTTTCAAGCC TTACAAAGCC  
101 GGAGAGCTCA AGTTCTGGC CCGTGGCCT TGGTGAGCAA CACCTTGAC  
151 CGATCAGAAC GACCCAGGC GCGCACCTT GGGGGATCG TCCAGCTCCA  
201 GAAGTTTCTT CGTCTAAAT ACTTGGAGTT GATCTTTCTA AACAGGATTG  
251 CTCAGACACA CCTGCGCTTC TCGAACAGG AAAGAACTCT ACCCATCCCA  
301 CTCAACTGCC ATGTACGACC GCGTGAGCC TCATCAGAG GCACTTCCCA  
351 TAACATCCTA CCACCGCGGA CCCAGGCCT CGCCCTTAAA GCCCGAGCCC  
401 TGACATCCTG CAGCTGGAA TCGCACATCT CCAGTCAGT GGCCACTGGC  
451 CCGGTTTCGC CAAACATGTC CGGAACCGAA CCCATCTTCT TGCACCAAAAC  
501 CTTCTTGTGC TCTTCTCTT CCTTCTCTGA ACAAGTCGC CCTAAAGCCA  
551 CAGCCAGTTC CTCTCGTCT CTTGGAGCCA GCCCTGGAGC TTCCTTAGAC  
601 AGATTCCAGG GACAGTCTCT CCAGGCACAA GGTCTATGAT GCGGTGATGG  
651 CAAATTATTG CAATGGCTTG TTTTCTTACG TTTCTCCACC CACACTAGTG  
701 AGCTGGATGC TGAACCTGTG AAGAGCATTC TGGCTGAATA CAAGATTCTAT  
751 AATGCCGATG TGACTCTACG TAGTGATGCT ACAGCTGATG ACCTCATTTGA

801 TGTGTGGAA GGAAACAGAG TTTATATCCC CTGTATCTAT GTTAATAA

!IAA SEQUENCE 1.0

ID ADP31211 standard; protein; 1344 AA.

XX AC ADP31211;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1978.

XX DE Human secreted protein SEQ ID #1978.

XX DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

XX DE cancer; inflammatory; immune; human secreted protein.

XX KW Homo sapiens.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411037P.

XX PR 17-SEP-2002; 2002US-0411041P.

XX PR 17-SEP-2002; 2002US-0411045P.

XX PR 17-SEP-2002; 2002US-0411046P.

XX PR 17-SEP-2002; 2002US-0411048P.

XX PR 17-SEP-2002; 2002US-0411052P.

XX PR 17-SEP-2002; 2002US-0411055P.

XX PR 17-SEP-2002; 2002US-0411073P.

XX PR 17-SEP-2002; 2002US-0411082P.

XX PR 17-SEP-2002; 2002US-0411101P.

XX PR 17-SEP-2002; 2002US-0411111P.

XX PR 18-APR-2003; 2003US-0463700P.

XX PR 18-APR-2003; 2003US-0463708P.

XX PR 18-APR-2003; 2003US-0463716P.

XX PR 18-APR-2003; 2003US-0463732P.

XX PR 02-MAY-2003; 2003US-0467199P.

XX PR 02-MAY-2003; 2003US-0467201P.

XX PR 02-MAY-2003; 2003US-0467203P.

XX PR 02-MAY-2003; 2003US-0467230P.

XX PR 19-MAY-2003; 2003US-0471306P.

19-MAY-2003; 2003US-0471336P.

22-MAY-2003; 2003US-0472420P.

22-MAY-2003; 2003US-0472430P.

09-JUN-2003; 2003US-0476609P.

09-JUN-2003; 2003US-0476641P.

08-JUL-2003; 2003US-0485218P.

08-JUL-2003; 2003US-0485223P.

08-JUL-2003; 2003US-0485224P.

08-JUL-2003; 2003US-0485325P.

14-JUL-2003; 2003US-0486446P.

14-JUL-2003; 2003US-0486480P.

15-JUL-2003; 2003US-0486891P.

08-AUG-2003; 2003US-0493341P.

08-AUG-2003; 2003US-0493370P.

08-AUG-2003; 2003US-0493573P.

08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MM, Kothakota S, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases

such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3209; 428pp; English.

The present invention relates to an isolated nucleic acid molecule

encoding a polypeptide which is believed to be cytosolic,

antiinflammatory, immunosuppressive, antibacterial and virucidal. The

composition and methods are useful for diagnosing, preventing and

treating diseases such as proliferative (e.g. cancer), inflammatory,

immune, metabolic, genetic, bacterial and viral diseases. The present

sequence represents a human secreted protein. The present sequence is

available on WIPWEB and is not in the specification.

Sequence 1344 AA;

ADP31211 Length: 1344 February 22, 2005 12:25 Type: P Check: 9462 ..

1 ATGCCAGCG CCCAGAGCTG GGTGTTGTC CAAACTTATG TGACCCCTGCA

51 GAGACCCCTTC GAGAAACCTC ATCTCGACCA AAAGCTAAAG CTGATTGCTG

101 AGTATGGGCT CCAGAACAA TGTGAGTCT GGAGGGCTCAA ATTTACCCCTG

151 GTCAAGATCC ATAAGCCGC CCGGAGCTG CTGACGCTTG ATGAGAAGGA

201 CCCACGGCT CTGTTCTGAAG GCATTGCCCT GCTGCAGTGG CTGGTCCGCA

251 CTGGGTGCT GGATGAGGC AAGATGAAG TGGATTACAT CTGGGSCCTG

301 AAGATCAATG ATTTCTTAGA GATTCCTACA GACCCAGGTG GTCCGAAGCC

351 CGGTCCGCC TCCAGCAGG TGCCCCGCG TCCCCGCTCA GCATGTCTGT

401 CTGACAGCG CGTGGCGTG GTGACCGGG CCAACAGGGG CATCGGCTTG

451 GCCATCGCG CGGAAGTGT CCGACAGTTC TCTGGGGATG TGGTGCTCAC

501 CGCGCGGAC GTGGCGCGG GCCAGGCGG CGTGCAGCAG CTGCAGGCGG

551 AGGGCTGAG CCCGCGCTT CACCACTGG ACATCGACGA CTTCGAGAGC

601 ATCCGGGCCC TGCGGACTT CTTCGGCAAG GAGTACGGGG GGCTCAAGCT

651 ACTGGTCAAC AACCGGCGG TCGCTTTCAA GAGTGATGAT CCAATGCCCT

701 TTGACATTAA AGCTGAGATG ACACCTGAAGA CAAATTTTTT TCCCACTAGA  
751 AACATGTGCA ACGAGTTACT GCCGATAATG AACCTCATG GGAGAGTGTG  
801 GAATATCACT AGTTTGCACT GTTTAAGGGC TTTTGAAGAC TGCAGTGAAG  
851 ATCTGCAGGA AAGGTTCCAC AGTGAGACAC TCACAGAAGG AGACCTGGTG  
901 GATCTCATGA AAAAGTTTGT GGAGGACACA AAAAATGAGG TGCATGAGAG  
951 CGAAGGCTGG CCCAACTCAC CTTATGGGT GTCCAAAGTTG GGGTCAACGG  
1001 TCTTATCGAG GATCTTGCC AGGCGTCTGG ATGAGAAGAG GAAAGCTGAC  
1051 AGGATTTCTG TGAATGCGTG CTGCCAGGA CCAGTGAAGA CAGACATGGA  
1101 TGGGAAGAC AGCATCAGGA CTGTGGAGGA GGGGGCTGAG ACCCTGTCT  
1151 ACTTGGCCCT CTGCTCTCA GATGCCACTG AGCCACAAGG CCAGTTGGTC  
1201 CATGACAAAG TTGTGCAAAA CTGCTGCAGC TGCCACAAGG TGACCTTGCC  
1251 TCTGTTGACT GCTCCAGCTA TAGGTTTTTC CTCCTAAAG ACCAGCTGG  
1301 ATGGATCAG AGTTGTTACT GTGCATCTCA CCCCCTGTGC CTGA

!!AA SEQUENCE 1.0  
ID ADP31237 standard; protein; 945 AA.

XX AC ADP31237;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #2004.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

XX Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;

XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 3235; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.

XX SQ Sequence 945 AA;

ADP31237 Length: 945 February 22, 2005 12:25 Type: P Check: 5429 ..

1 ATGGACGCCC CGAGGCACGT GGTCAACTTC GGGCTGGTC CCGCCAAGCT

51 GCCTCACTCA GTGTTGTTAG AGATAAAAAA GGAATTATTA GACTACAAAG

101 GAGTTGGCAT TAGTGTCTT GAAATGAGTC ACAGGCCATC AGATTTTGCC  
151 AAGATTTATTA ACATACAGA GAATCTTGTG CGGAANTGC TAGCCGTTCC  
201 AGACAGCTGT AAGTGATTT TTGTGCAAGG AAGTGGTCTT GGCCAGTTGG  
251 GTGCTGTCCC CTTAAACCTG ATTGCTTTGA AGCAGGAAG ATGTGGGAC  
301 TATGTGGTGA CAGGGACTTG GTCAGCTAAG GCCGACAAG AGCCCAAGAA  
351 GTTTGGGACT ATAAATPATCA TTCAACCCTAA ACTTGGGAGT TATACAAAAA  
401 TTCCAGATCC AGCACCTCG AACCTCAACC CGATGCGTC CTATGTGTAT  
451 TATTGCCCAA ATGAGTGGT GCATGGTGTG GAGTTTGAAT TTATACCTTA  
501 TGTCAGGGA GCAGTACTGG TTGTGACAT GTCCTCAAC TTCTGTCCA  
551 AGCCAGTGA TGTCCAAGTT TGCACTCTATG TCATGGGCTT GGTCTCTGGAG  
601 TGGATTHAAA ACAATGGAGG TGCCCGGGCC ATGGAGAAGC TTAGCTCCAT  
651 CAATCTCAA ATGATTTATG AGATTATTGA TAATTTCTAA GGATTTCTAGC  
701 TATGTCGGT GGAGCCCCAA AATAGAACA AGATGAATAT TCCATTTCTG  
751 ATTTGCATG CCAAGGAGA TGATGCTTTA GAAAAAGAC TTTTGTATAA  
801 AGCTCTTTGAA CTTAATPATGT TGCCCTTGAA AGGTATATAGG TCTGTGGGAG  
851 GCATCCGGG CTCTCTGTAT AATGCTGTCA CTATTGAAGA TGTTCAAGAG  
901 CTGCGCCCT TCATGAAAAA TTTTGTGGAG ATGCATCAGC TATGA

!!AA\_SEQUENCE 1.0  
ID ADP31376 standard; protein; 1050 AA.

AC ADP31376;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2143.  
DE  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW Cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.

XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406840P.  
PR 29-AUG-2002; 2002US-0406842P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.

17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467206P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471338P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnenmann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3374; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

```
SQ      Sequence 1050 AA;
ADP31376 Length: 1050 February 22, 2005 12:25 Type: P Check: 446
1 ATGGCTTTAG AGTGGAAG CTGTAAGACT TGGCAGCTTC CATCTGGTGT
51  TAAGCCTGTG GGTGCACAGT GTGCAAGAGT AATGAGGCT TGGCACCTTC
101 CATCAGATTT CAAGAATGT GTGAAAAGT CTGGATGCC AGATGCTGAC
151 AGTGAACCG TAAAGGCAGC AAACGTGTG AAATTTGCAG AGGTCTTAGT
201 GGCTAGGAAG CAGCAGTCC AGATGCCAA GACCCAGCAA AAGGAGCAGA
251 TGGTGCTGCT GGAGAAGAAG AGTGCCACCT ACTTCCAGGT GCTTCTCTGC
301 TGCCCTCATTT TGCTGCAGAG GCTTCTTCAG GACACAGGC TGAAGACTCA
351 CTCGAGGTTA GACCAATCA ATGCCAGTA CTGGAAGTC AAGTGTGTTG
401 CTATGATACT TAAGCTGAGG ATGGAAGAGT TAAATATTT GTCCAACACA
451 CTGCTGAGAA AGTGAAGTT CATTTGTCGA TTAGGAGCCG TTGAGGGA
501 GCGATTACCC TACGGGAGCA GCACATGGAG AAGTCAAGAC AGACTATTGT
551 GGGGCCAAGA TGTGAAGAAA CTGTACACAC CACAGCTGTC TGCCCGTGTCT
601 GCTCCCACTG AGATGGGAC TGCCCTCCCT GGTAGCAGGC CCACAGCCAG
651 TGCCATTTTG ACAGCCGAGC CTCAAAAGCA CTGTGATCTT CCCTGGGGCC
701 ACCAGGCCAA AGAAGGAGAG AGAAAGCTGG GCACTTTAAC AAGCCCCGAG
751 GACAAATACC ACTGCCACTG CTATAGCTG CTAAGAGACC AAGCTGGCAG
801 TCACCACAT GAGCCACCTG CAGGTCAGCA GACTGGCCCA CCCAACTTAT
851 CACAACCCAC ACCAATACCA GAATGGACTA CCTGGGGTCC AGTGGGTTGC
901 TCACCACCTG CTCCTGCCGT CACCCATC ACACCACTGC CTGGAGACCT
951 AAGAACCAC CCGATGCGT TGCCACAGC TGCCACTACT GGCCTACCTG
1001 GACCTGCTAA TACCAGTGGC AGCATACAT ACTCTGAGC TCAAGGACAG

!!AA SEQUENCE 1.0
ID ADP31394 standard; protein; 2307 AA.
XX
AC
ADP31394;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #2161.
XX
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
XX cancer; inflammatory; immune; human secreted protein.
XX
OS Homo sapiens.
XX
PN WO2004035732-A2.
XX
PD 29-APR-2004.
XX
PF 28-AUG-2003; 2003WO-US026780.
XX
PR 29-AUG-2002; 2002US-0406576P.
PR 29-AUG-2002; 2002US-0406579P.
PR 29-AUG-2002; 2002US-0406585P.
PR 29-AUG-2002; 2002US-0406588P.
PR 29-AUG-2002; 2002US-0406608P.
PR 29-AUG-2002; 2002US-0406611P.
PR 29-AUG-2002; 2002US-0406612P.
```

```
PR 29-AUG-2002; 2002US-0406616P.
PR 29-AUG-2002; 2002US-0406640P.
PR 29-AUG-2002; 2002US-0406642P.
PR 29-AUG-2002; 2002US-0406646P.
PR 29-AUG-2002; 2002US-0406653P.
PR 29-AUG-2002; 2002US-0406655P.
PR 29-AUG-2002; 2002US-0406666P.
PR 17-SEP-2002; 2002US-0410946P.
PR 17-SEP-2002; 2002US-0410947P.
PR 17-SEP-2002; 2002US-0410948P.
PR 17-SEP-2002; 2002US-0410949P.
PR 17-SEP-2002; 2002US-0410953P.
PR 17-SEP-2002; 2002US-0410957P.
PR 17-SEP-2002; 2002US-0410958P.
PR 17-SEP-2002; 2002US-0410959P.
PR 17-SEP-2002; 2002US-0410960P.
PR 17-SEP-2002; 2002US-0410961P.
PR 17-SEP-2002; 2002US-0410962P.
PR 17-SEP-2002; 2002US-0411019P.
PR 17-SEP-2002; 2002US-0411023P.
PR 17-SEP-2002; 2002US-0411024P.
PR 17-SEP-2002; 2002US-0411032P.
PR 17-SEP-2002; 2002US-0411035P.
PR 17-SEP-2002; 2002US-0411037P.
PR 17-SEP-2002; 2002US-0411041P.
PR 17-SEP-2002; 2002US-0411045P.
PR 17-SEP-2002; 2002US-0411046P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411052P.
PR 17-SEP-2002; 2002US-0411055P.
PR 17-SEP-2002; 2002US-0411073P.
PR 17-SEP-2002; 2002US-0411082P.
PR 17-SEP-2002; 2002US-0411101P.
PR 17-SEP-2002; 2002US-0411111P.
PR 18-APR-2003; 2003US-0463700P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 18-APR-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467230P.
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486446P.
PR 15-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
```

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348436/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

XX  
PS Claim 1; SEQ ID NO 3392; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 2307 AA;

ADP31394 Length: 2307 February 22, 2005 12:25 Type: P Check: 8083 ..

1 ATGATTATCT CAATAGATGC AGAAAAGGCC TTGACAAAA TTCAACAACG  
51 CTTTCATGCTA AAAACTCTCA ATAAATTAGG TATTGATGGG ATGTATCTCA  
101 AAATAATAAG AGCTATCTAT GACAAACCCA CAGCCAATAT CATACTGAAT  
151 GGACAAAAAC TGGAGCATT CCCTTTGAAA ACTGGCACA GACAGGGATG  
201 CCCTCTCTCA CCACTCCTAT TCAACATAGT GTTGGAAAGT CTGGCCAGGG  
251 CAATTAGGCA GNGAAGGAA ATAAAGGATA TTGATTTAGG AAGAAGGAA  
301 GTCAAAATTGT CCCTGTTTGC AGATGACATG ATTGTATATC TAGAAAACCC  
351 CATTGTCTCA GCCCAAAATC TCCTTAAAGT GATAAGCAAC TTCAGCAAAAC  
401 TCTCAGGATA CAATAATCAAT GTACAAAAT CACAAGCATT CTTATACACC  
451 AATAACAGAC AAACAGAGAG CCAAAATCATG AGTGAACCTC CATTCACAAT  
501 TGCTTCAAAG AGAGTAAAT ACCTAGGAAT CCAACTTACA AGGGATGTGA  
551 AGGACCTCTT CAGGAGAAC TACAACACAC TGCTCAGTGA AATAAAGAG  
601 GATACAACA NATGGAAGAA CATTCCATGC TCATGGGTAG GAAGATCAA  
651 TATCGTGAAA ATGGCCATGC TGCCCAAGGT AATTATAGA TTCAATGCCA  
701 TCCCATCAA ACTACCAATG ACTTCTTCA CAGAAATTGA AAAAATCTACT  
751 TTAAGTTCA TGTGAAACCA AAAAAGAGCC CACATGCCA AGTCAGTCCT  
801 AAGCCAAAAG AACAAAGCTG GAGGCATCAC GCTACCTGAC TTCAAAATAT  
851 ACTACAAGC TACAGTAACC AAACAGCAT GGTACTGGTA CCAAAACAGA  
901 GATATAGATC NATGGAACAG AACAGAGCCC TCAGAAATAA CGCCGCATAT  
951 CTACAACATC CTGATCTTTG ACAAACCTGA GAAAAACAAG CAATGGGAA  
1001 AGGATTCCTT ATTTATATAA TGGTCTGGG AAAACTGGCT AGCCATATGT  
1051 AGAAAGCTGA AACTGGATCC CTTCCTTACA CCTTATACAA AATTAATTC  
1101 AACATGGATT AAAGACTTAA ACGTTAGACC TAAATCATATA AAAACCTTAG  
1151 AAGAAACCTT AGGCATTACC ATTACGAGA TAGGCATGGG CAGGACTTC  
1201 ATGTCTAAAA CACCAAAAGC AATGGCAACA AAAGCCAAAA TTGACAAATG  
1251 GGATCTTAAT AACTAAAGA GCTTCTGCAC AGCAAAAGAA ACTAACATCA  
1301 GAGTGAACAG GCNACTGACA AAATGGGAGA AATTTTCAC AACCTACTCA  
1351 TCTGACAAAG GGCTAATATC CAGAATCTAC AATGAACCTCA ACAAATTTTA  
1401 CAAGAAAAAA ACAACAACCC CCATCAAAAA GTGGGCAAG GACATGAACA

1451 GACACTTCTC AAAAGAAGAC ATTTATGCAG CCAAAAGACA CATGAAAAAA  
1501 TGTCTACCAT CACTGGCCAT CAGAGAAATG CAATCAAAA CCACATGAG  
1551 ATACCATCTC ACACAGTTA GAATGGCAAT CATTAAGGAG TCAGGAACA  
1601 ACAGGTGCTG GAGAGGATGT GGAGAAATAG GAACACTCTT ACACGTGTTG  
1651 TGGGACTATA AACTAGTTCA ACCATTGTGG AGTCACTGT GCGATTCCT  
1701 CAAGGATCTA GAACTAGAAA TACCATTTGA CCAGCCATC CCATTACTGG  
1751 ATGCTGCTGC TGCGGGAGC CCGTACTAT CAGCCGTGGT TAACCCACC  
1801 GTGTTCTTGG ACATTGTGTT CAACAGGAG CCCTTGGGCC ATGTCTCTT  
1851 CAAGCTATTT GCAGACAAGG TTCCAAAAGC AGCAGAAAAA TTTCGTGCTC  
1901 TGAGCACTGG AGAGAAAGGA TTGTTTATA AGGTTTCCTG CTTTCACAGA  
1951 ATTATTCCAG GTTTATGTG TCAGGGTGGT GACTTCACAC ACCATAATGG  
2001 CACTAGCAGC AAGTCCATCT ACGGGAGAA ATTGATGAT GAGAACTTCA  
2051 TCCTAAAGCA TACAGTCTCT GGCATCTTGT CCATGGCAAA TGCTGGACCC  
2101 AACACAACA GTTCCAGTTT TTTCACTCTG ACTGCCAAGA CTGAGTGGTT  
2151 GGATGGCAAG CATGTGTCTT TTGGCAAGGC GAAAGAAGGC ATGAATATTG  
2201 TGGAGGCCAT AGAGCACTTT GGGTCCAGGA ATGGCAAGAC CAGCAAGAAG  
2251 ATCACCACTG CTGACTGTGG ACAACTCTTA ATAACTTTGA CTTGTGTTTT  
2301 ATCTTAG

!!AA SEQUENCE 1.0  
ID ADP31545 standard; protein; 3201 AA.

XX AC ADP31545;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2312.  
XX DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
DR WPI; 2004-348438/32.  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3543; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present

CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.

SQ Sequence 3201 AA;

ADP31545 Length: 3201 February 22, 2005 12:25 Type: P Check: 5669 ..

1 ATGGAACAAA GCTGGATGGA GAACGACTTT GACCAGCTGA GAGAAGAAGG  
51 CTTACAGAGA TCAATTACT CTGAGCTACG GGAGGACATT CAACCAAAAG  
101 GCAAGAAGT TGAATACTTT GAAAAAATT TAGAAGAATG TATAACTAGA  
151 ATAACCAATA CAGAGAAGTG CTTAAAGGAG CTGATGGAGC TGAAAACCAA  
201 GGCTCGAGAA CTACGTGAAG AATGCAGAAG CCTCAGGAGC CGATCGGATC  
251 AACTGGAAGA AAGGTGTGCA GTGATGGAAG ATGAAATGAA TGAATGAAA  
301 CCAATCTAC GTCTGATTGG TGTACCTGAA ACTAACGGGG AGAATGGAAC  
351 CAAGTTGGA AACACTCTGC AGGATATTAT CCAGGAGAAC TTCCCAATC  
401 TAGCAAGGA GCCAACGTT CAGAATCAGG AAATACAGAG AACACCAAA  
451 AGATACTCTT CGAGAAGAGC AACTCCACGA CACATAATTG TCAGATTAC  
501 CAAAGTTGAA ATGAAGGAAA AAATGTTAAG GGCAGCCAGA GAGAAGCAC  
551 CACACACAC CTATTCCAAA ATTGACCACA TACTTGGAAG TAAAGCTCTC  
601 CTCAGCAAT GTAAGAAGAC AGAAATTATA ACAAATATC TCTCAGACCA  
651 CAGTGCATC AACTAGAAC TACAGATTAA GAATCTACT CAAAACCGCT  
701 CAACTACATG GAAACTGAAC AACCTGCTCC TGAATGACTA CTGCGTACAT  
751 AACGAAATGA AGGCAGAAAT AAAGATGTTT TTTGAAACCA ACAGAACAA  
801 AGACACAACA TACCAGATC TCTGGGACGC ATTCAGAGCA GTGTGTAGAG  
851 GGAACCTTAT AGCACTAAAT GCCACAAGA GAAAGCAGGA AAGATCCAAA  
901 ATTGACACC TAACATCACA ATTAAAAAGAA CTAGAAAAGC AAGAGCAAAC  
951 ACATTCAAAA GCTAGCAGAA GGCAAGAAAT AACTAAAATC AGAGCAGAAC  
1001 TGAAGGAAAT AGAGACACAA AAAACCCCTTC AAAAAATTAA TGAATCCAGG  
1051 AGCTGGTTTT TTGAAAGGAT CACAAAAATA TATAGACCAC TAGCAAGACT  
1101 AATAAAGAAA AAAAGAGAGA AGAATCAAT AGACCAATA AAAAATGATA  
1151 AAGGGATAT CACCACCGAT CCCACAGAAA TACAAATTAC CATCAGAGAA  
1201 TACTACAAAC ACCTCTATGC AAATAAATA GAAATCTAG AAGAAATGGA  
1251 TAAATTCCTC AACACATACA CTCTCCCAAG ACTAAACCAG GAAGAAGTTG  
1301 AATCTCTGAA TAGACCAATA ACAGGATCTG AAATTTGTGC AATAATCAAT  
1351 AGCTTACCNA CCAAAAGAG TCCAGGACCA GATGGATTCT CAGCCGAATT  
1401 CTACCAAGG TACNAGGAGG AACTGGTACC ATTCCTCTG AACTATTTC  
1451 AATCAATAGA AAAAGAGGGA ATCTCTCCCTA ACTCATTTTA TGAGGCCAGC  
1501 ATCATTTCTGA TACCAAGCC GGCAGAGAG ACAACCAAAA AAGAGATTT  
1551 TAGACCAATA TCCTTGATGA ACATTGATGC AAAATCTCTC AATAAATAC  
1601 TSGCAAAACG AATCCAGCAG CACATCAAAA AGCTTATCCA CCATGATCAA

1651 GTGGCTTCA TCCTGGGAT GCAAGGCTGG TTCAATATAT GCAATCAAT  
1701 AATGTATATC CAGCATATAA ACAGAGCCAA AGACAAAAC CACATGTTA  
1751 TTCTAATAGA TGCAGAAAAG GCCTTTGACA AAATTCAACA ACCCTTCCTG  
1801 CTAAAAACTC TCAATAAATT AGGTATTGAT GGGTCGTATT TCAATAAAT  
1851 AAGAGCTATC TATGACAAAC CCACAGCCAA TATCATACTG AATGGGCAAA  
1901 AACTGGAAGC ATTCCCTTTG AAAACTGGCA CAAGACAGAG ATGCCCTCTC  
1951 TCACCACTCC TATTCAACAT AGTGTGGAA GTTCTGGCCA GGGCAATCAG  
2001 GCAGGAGAG GAATAAAGG GTATTCAATT AGGAAAGAG GAAGTCAAT  
2051 TGTCCCTGTT TGCAGACGAC ATGATTTGTAT ATCTAGAAAA CCCCACTGTC  
2101 TCAGCCCAA ATCTCCTTAA GCTGATAAGC AACTTCAGCA AAGTCTCAGG  
2151 ATACAAATC AATGTACAA ATACAAGA ATTCTTATAC ACCAACACA  
2201 TACAAACAGA GAGTCAAATC ATGAGTGAAC TCCCAATTCAC AATTGCTTCA  
2251 AAGAGATAA AATACCTAGG AATCCAACTT ACAAGGGATG TGAAGAACCT  
2301 CTTCAAGGAG AACTACAAAC CACTGCTCAA TGAATAAATA GAGGATACAA  
2351 ACAATGGAA GAACATTTCCA TGCTCATGGG TAGGAAGAT CAATATGCTG  
2401 AAAATGGCCA TACTGCCCCA GGTAATTTAC AGATTCRAAT CCATCCCCAT  
2451 CAAGCTACCA ATGCCCTTCT TCACAGAAAT GGAAGAGCT ACTTTAAGT  
2501 TCATATGGAA CCAAAAAGA GCCCGCATTG CCAAGTCAAT CCTAAGCCAA  
2551 AAGAACAAAG CTGGAGGCAT CACACTACCT GACTTCAAAC TATACTACAA  
2601 GGCTACAGTA ACCAAACAG CATGGTTCA GCAGCGAGT CCGGCTAATG  
2651 ATGGCACCAC AAGATCCCCA TCAATAGACA GCATTCAGAA GGACCCCAAGC  
2701 GAGTTTGCTT GCGGTGATCC TGAGTTGCCCT GAGGTCAATC ACATCCTTCA  
2751 GCACCAAGTC CCATCTGTTT AGGCAATGC AGCAGCCTAC CTGACGACC  
2801 TGTGGTTTGG TGACAACAAC GTGAAGATGA AGGTGTGTAG GTTATGGGGA  
2851 ATCAAGCTTC TGGTTTACCT TTTGGGCCAC AGAGTTTGG AAGTTCAGAA  
2901 GAATGCTTGT GATGCCCTTC GAATCTCTTT TTTGGCCNAG TCTACAGGTG  
2951 AAAATAAAAT AACAAATGAAG GATGTGTAAG CTCGGAAGCA AATGCGGGCC  
3001 TGTGAGGGGC TGTGTGACTC GCTGTGTCAT GTAACTTACA CGTGTATGAA  
3051 CACATCCGAT TAGCAGACGA AGATGAGNAA TTGGTGTGTC ACCCTGAGGA  
3101 ACCTGTCTTA TTGGCTGGAG GTGCAAGTGC CCCAGGCCCA GTTACTGGGA  
3151 CTGAACGAAT GGGATGACTT ACTAGAAAA GTTTCCCCAGC GAAGACTCTG  
3201 A

!!AA SEQUENCE 1.0  
ID -ADP31598 standard; protein; 669 AA.  
XX  
AC ADP31598;  
XX  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2365.  
XX

Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.  
Homo sapiens.  
W02004035732-A2.  
29-APR-2004.  
28-AUG-2003; 2003WO-US026780.  
29-AUG-2002; 2002US-0406576P.  
29-AUG-2002; 2002US-0406579P.  
29-AUG-2002; 2002US-0406585P.  
29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0486466P.  
14-JUL-2003; 2003US-0486480P.



PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493373P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3596; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antineoplastic, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 669 AA;  
SQ  
ADP31598 Length: 669 February 22, 2005 12:25 Type: P Check: 954 ..  
1 ATGGAGCTGA AAACCAAGGC TCGAGACTA TGTGAGAAAT GCAGAGCGT  
51 CAGGAGCCGA TCGATCAAC TGGAGAAAG GGTATCAGCA ATGGAAGATG  
101 AAATGAATGA AATGAAACCA AATCTAGCTC TGATTGGTGT ACCTGAAAGT  
151 GATGGGGAGA ATGGAACCA GTTGGAAAC ACTCTGCAGG ATATTATCCA  
201 GGAGAAATTC CCCAATCTAG CAAGGCAGGC CAACGTTTCAG ATTCAGGAAA  
251 TACAGAGAAT GCCACAAAGA TACTCTTTGA GAAGAGCAAC TCCAAGACAC  
301 ATAATAGTCA GATTCACCA AGTTGAATG AGGAAAAAA TGTTAAGGGC  
351 AGCCAGAGAG AAAGTGGGG TTACCTCTAA AGGGAAGCCC ATCAGACTAA  
401 CAGCGGATCT CTCGGCAGAA ACCCTACAAG CCAGAGAGAGA GTGGGGGCCA  
451 ATATTCAACA TTCTTAAGA AAGAATTTT CAACCTAGAA TTTCATATCC  
501 AGCCAAACTA AGTTTCATAA GTGAAGGAGA AATAAATAAC TTTCAGACA  
551 AGCAATGCT GAGAGATTTT GTCAACACCA GGCCTGCCCT AAAAGAGCTC  
601 CTGAGGAGAG CAGTAAACAT GGAAGGAAC AACCGGTACC AGCCGCTGCA  
651 AAATCATGCC AAAATGTAA  
!!IAA SEQUENCE 1.0  
ID ADP31650 standard; protein; 1494 AA.  
XX  
XX AC ADP31650;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #2417.  
XX  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX  
OS Homo sapiens.  
XX WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.

PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493373P.  
PR 08-AUG-2003; 2003US-0493377P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PA  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3648; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 1494 AA;  
SQ  
ADP31650 Length: 1494 February 22, 2005 12:25 Type: P Check: 77 ..  
1 CCTCTGGGG GCCACACAGG CAGCCCCACC TCAGGCCCC AGGAGTGTGC  
51 AAAGGGCTCC ACGGTGTGGT GTCAGGATCT GCAGACAGCT GCCAGTGGC  
101 GGGCTGTGGG GTACTGCCAA GGGGCCGTAT GGAACAAACC CACCGCGAAG  
151 TCTCTGCCT CGACGTATG CCAGACATA GCAGCCGCG CTGGCAATGG  
201 GCTGAACCTT GAGCCACCG AGTCTGACAT CCTGGCTTTG GTGATGAAGA  
251 CCTGTAGTG GCTCCCGAGC CAGGAGTCTT CAGCCGGATG CAAGTGGATG  
301 GTGATGCC CCAGTTGCGC CATCTGAGC ATGCTCGTG GGGCCCCGGA  
351 CAGTCCCCCG GCACAGTGT GCACAGCGCT CAGCTCTGT GAGCCGCTGC  
401 AGAGGCACCT GGCCACCCTG AGGCCACTCT CCAAAGAGGA CACCTTTGAG  
451 GCTGTGCTC CGTTCATGGC CAATGGGCC CTTACCTTCC ACCCCGCCA  
501 GGCCTCTGAA GGAGCTCTGT GCCAAGACTG TGTACGGCAG GTCTCCGAC  
551 TCCAGGAGG TGTCGGTCC AACTTGACCT TGGCCGACTT GAACATCCAG  
601 GAGCAGTGTG AGTCTTTGGG GCGTGGCTGG CCGTCTCTCT GCAAGAACTA  
651 CCTCTTCCAG TTTTGTGTC CTGCTGACCA AGCAGTGGG CTTCTCCCCC  
701 CGCAGGAGCT CTCAGGAAG GGGGATTTCT GTGAGGAGCT AGGGGCACCT  
751 GCCCGTTTGA CTCAGTAGT GGCCATGGAC GGGGTCCCTT CCTGGAGCT  
801 GGGGTTGCCA AGGAAACAGA GCGAGATGCA GATGAAGGCC GGTGTGACCT  
851 GTGAGGTGTG CATGAACGTG GTGCAGAAC TGGACCACTG GCTCATGTCC  
901 AACAGTCTG AGTCTATGAT CACCATGCG CTGGAGCGCG TGTGCTCGGT  
951 AATGCCTGCC TCTATCACGA AGGAGTGCAT CATCTTGGT GACACCTACA  
1001 GCCCTCCTT GGTGCAGCTT GTGGCCAAAA TCACCCACGA GAAGGTGTGC

1051 AAGTTCATCC GTCTGTGTGG CAACCGGAG CGGGCCCCGG CAGTCCATGA  
1101 TGCCTATGCC ATCGTGCCTT CCCAGAGTG GACGCGGGAG AACACAGGCA  
1151 GCTTCTGCAA TGGGTGCAAG AGGCTGCTCA CGGTGTCTTC CCACAACCTG  
1201 GAGAGCAAGA GCACCAAGCG AGACATCCTG GTGGCCTTCA AGGGTGGCTG  
1251 CAGCATCCTG CGGTGCGCTT ATATGATCCA GTGCAAGCAC TTCGTACCCC  
1301 AGTACGAGCC CGTCTCTATT GAGAGTCTCA AGGACATGAT GGACCCCGTG  
1351 GCTGTGTGCA AGAAGGTGGG GGCCTGCCAC GGCCCCAGGA CCCCACTGCT  
1401 GGGCACCAGC CAGTGTGCCC TGGGCCCAAG CTTCTGTGTG AGGAGCCAGG  
1451 AGGCCGCCAA GCTGTGCAAC GCTGTGCAAC ACTGCCAGAA GCAT  
!!AA SEQUENCE 1.0  
ID ADP31690 standard; protein; 2358 AA.  
XX  
XX ADP31690;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2457.  
XX  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406589P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.

PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476611P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3688; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antitumour, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 2358 AA;  
SQ  
ADP31690 Length: 2358 February 22, 2005 12:25 Type: P Check: 1533 ..  
1 GAAATTAAGT GTTAAATCCA TTACGACCC TCGATACCTG GACAGCCTGG  
51 GGAACCCATC GGCAACGGC CTGTACGATT TAGCTTTGGG CCCTGCAGAT  
101 TCCAAAGAGG TGTGCTCCAC CTGCGTGCAG GACTTCAGCA ACTGTTCTGG  
151 GCACCTGGGC CACATTGAGC TCCCACTCAC AGTGATATAAC CCTCTCCTCT  
201 TCGATAAGCT GTACTGCTG CTTCGGGGCT CTTGTTTAAA GTGCCACATG  
251 CTGACTTGTG CCCGGGGCGT GATTTCACCTC TTACTCTGCC AGCTGAGGCT

301 TCTGGAAGTC GGGGCCCTAC AAGCAGTCTA CGAGCTTGAG AGAATTCTGA  
351 ACAGGATTTC TTTCTGAACT ACCTTTTTTC GGAATGGAT GATGATGGTA  
401 TGAATCCAG ATTCATCCCC AGTGTGTTCT TTCTAGATTT CTGTGGTGTG  
451 CGCCCTCAA GGTATCGCCC AGTCAGTCG CTAGGAGACC AGATGTTTAC  
501 TAATGCCAG ACGTGAACT TGCAGGCTGT CATGAAGGAT GTAGTTCTGA  
551 TTCGAAACT TCTGGATTG ATGCCCCAAG AACAGAAATT GCCAGAGAA  
601 GTGGCCACAC CCACTACAGA TGAGAAACTT TACAACATTT GGAATTCGCT  
651 TCAGAGCCAC GTCAATATTG TGTTTGATAG CGAGATGGAC AAACATAATGA  
701 TGGACAAGTA CCCAGGCATT AGCAGATCC TGGAGAGAA AGAAGGCCTG  
751 TTCCGAAAC ACATGATGGG AAAGCGAGTG GACTAGCTG CGCGCTCAGT  
801 CATCTGCCA GACATGTACA TCAACACCAA CGAAATTGGA ATTCCCATGG  
851 TGTTTGGCAC AAAACTGACC TACCCACAGC CAGTTACCCC ATGGAATGTT  
901 CAGGAACTTA GSCAAGCGGT CATCAACGGC CCTAATGTGC ACCCAGGAGC  
951 CTCCATGTC ATCAATGAGG ACGCAGCGG CACAGCCCTG AGCGTGTGG  
1001 ACATGACCA GCGAGAGGCC GTGCGCAAGC AGCTTCTGAC CCCAGCCACG  
1051 GGGGCACCTA AGCCCCAGGG GACAAAAATT GTGTGCCGGC ATGTGAAGAA  
1101 TGGGGACATT CTGCTACTGA ACCGACGCC CACACTGCAC AGACCTCCA  
1151 TCCAGGCCA CCGTGCCTG ATCTGCCTG AAGAGAAAGT GCTGCGGCTC  
1201 CACTATGCCA ACTGCAAGC CTATAATGCC GACTTTGATG GAGACGAGAT  
1251 GAATGCCAT TTCCCCCAGA GTGAGCTGG CCGGGCCGAG GCCTACGTCC  
1301 TGGCCTGCAC TGATCAGCAG TACCTTGTTC CCAAGATGG CCAACCATTTG  
1351 GCGGACTGA TCCAGGATCA CATGTTTCA GGGGCAAGCA TGACTACTCG  
1401 GGGTTGCTTT TTCACCCGG AGCACTATAT GGAGCTGGT TACCGAGGAC  
1451 TCACGGCAA AGTGGGGCG GTGAAGCTCC TTCTCTCTTC CATCTGAAG  
1501 CCTTTCCGC TGTGGACAGG AAAACAGGTT GTGTCAAGC TGCTCATAAA  
1551 TATAATCCA GAGGACCACA TCCCCTGAA CTTATCTGA AAGCGGAAA  
1601 TCACCTGGA AGCTGGGTG AAGGAACTC CTCGATCCGT TCCTGGCTTT  
1651 AACCTGACT CGATGTGCGA GTCCCAGCAG GTGATCATCA GGAAGAGGGA  
1701 GCTGCTCTGC GGAGTGTGG ACNAGCGCA CTATGGGAGC TCCGCTTACG  
1751 GCCTGGTCCA CTGCTGCTAT GAGATCTATG GAGCGAGAC CAGCGCAAG  
1801 GTTCTAACCT GCCTGGCCCG CCTCTTCACC GCCTACCTGC AGCTCTACAG  
1851 AGGCTTACC TTGGGCGTGG AAGACATTTT GGTGAAGCCA AAGCAGATG  
1901 TCAAGAGCA ACGTATCATT GAAGAATCCA CCCACTGCG GCCCAGGCT  
1951 GTCAGGGCTG CATTAAACCT GCCAGAAGC GCATCATATG ATGAGGTCG  
2001 AGGAAATGG CAGATGCCC ATCTGGGCAA GGACCAGAGG GATTTTAAAC  
2051 TGATTGATCT GAAGTTCAAG GAGGAAGTGA ACCATTACAG CNAATGAGAT

2101 AACAAAGCAT GCATGCCCTT TGGCCTACAC AGACAGTTCC CAGAGAACAG  
2151 CCTGCAGATG ATGCTGAGT CGGGAGCCNA AGTTTCACT GTGAACAGA  
2201 TGCAGATCTC GTGCCGTGCTG GGCCAGATTG AACTGGAAGG TCGGAGACCC  
2251 CCGCTGATGG CGTCTGGCAA GTCACTGCC TCCTTTGAGC CTTATGAGTT  
2301 CACCCCCAGG GCTGGTGGCT TTGTCACTGG CAGTTCTCTC ACCGGCATCA  
2351 AACCTCCT  
!AA SEQUENCE 1.0  
ID \_ADP30468 standard; protein; 357 AA.  
XX AC ADP30468;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1235.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406555P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.  
XX PR 17-SEP-2002; 2002US-0411023P.  
XX PR 17-SEP-2002; 2002US-0411024P.  
XX PR 17-SEP-2002; 2002US-0411032P.  
XX PR 17-SEP-2002; 2002US-0411035P.  
XX PR 17-SEP-2002; 2002US-0411037P.  
XX PR 17-SEP-2002; 2002US-0411041P.  
XX PR 17-SEP-2002; 2002US-0411045P.  
XX PR 17-SEP-2002; 2002US-0411046P.  
XX PR 17-SEP-2002; 2002US-0411048P.  
XX PR 17-SEP-2002; 2002US-0411052P.  
XX PR 17-SEP-2002; 2002US-0411055P.  
XX PR 17-SEP-2002; 2002US-0411073P.  
XX PR 17-SEP-2002; 2002US-0411082P.  
XX PR 17-SEP-2002; 2002US-0411101P.

PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471308P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476509P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX PS Claim 1; SEQ ID NO 2466; 428pp; English.  
XX CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX SQ Sequence 357 AA;  
ADP30468 Length: 357 February 22, 2005 12:25 Type: P Check: 8242 ..  
1 ATGGCGCTCC ACCTGCTCCT GCTGCTCGG CTGTGCGGTG CAGGCACCAC  
51 CGCCGCGGAG CTCAGTTACA GCTTGCCTGG CAACTGGAGC ATCTGCAATG  
101 GGAACGGCTC GCTGGAGCTG CCGGGGCGG TCCCTGGCTG CGTGACACAGC  
151 GCCTTGTTC ACAGGGCCT GATCCAGTA TGGCGTGGG CCGACCCGGG  
201 GCGAGCCTGC GCCGCCCTTC TTCTGGTGCT GAGAGGGGCC CAGGAACCGC  
251 CTGGCAGCCC CCAGCTCTGG GCCATTCTCG TCGGTTTGGT AGTAACTTCC  
301 CCTTTCATC TTGTGATCTG CGGGGGGAAA TGCCCAAGCT ATGGGGTAOG  
351 GGCTTGA  
!AA SEQUENCE 1.0  
ID \_ADP30482 standard; protein; 1107 AA.

XX AC ADP30482;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1249.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX OS cancer; inflammatory; immune; human secreted protein.  
XX PN Homo sapiens.  
XX PD WO2004035732-A2.  
XX PF 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406578P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.  
XX PR 17-SEP-2002; 2002US-0411023P.  
XX PR 17-SEP-2002; 2002US-0411024P.  
XX PR 17-SEP-2002; 2002US-0411032P.  
XX PR 17-SEP-2002; 2002US-0411035P.  
XX PR 17-SEP-2002; 2002US-0411037P.  
XX PR 17-SEP-2002; 2002US-0411041P.  
XX PR 17-SEP-2002; 2002US-0411045P.  
XX PR 17-SEP-2002; 2002US-0411048P.  
XX PR 17-SEP-2002; 2002US-0411048P.  
XX PR 17-SEP-2002; 2002US-0411052P.  
XX PR 17-SEP-2002; 2002US-0411055P.  
XX PR 17-SEP-2002; 2002US-0411073P.  
XX PR 17-SEP-2002; 2002US-0411082P.  
XX PR 17-SEP-2002; 2002US-0411101P.  
XX PR 17-SEP-2002; 2002US-0411111P.  
XX PR 18-APR-2003; 2003US-0463700P.  
XX PR 18-APR-2003; 2003US-0463708P.  
XX PR 18-APR-2003; 2003US-0463716P.  
XX PR 18-APR-2003; 2003US-0463732P.  
XX PR 02-MAY-2003; 2003US-0467199P.  
XX PR 02-MAY-2003; 2003US-0467201P.  
XX PR 02-MAY-2003; 2003US-0467203P.  
XX PR 19-MAY-2003; 2003US-0467230P.  
XX PR 19-MAY-2003; 2003US-0471306P.  
XX PR 22-MAY-2003; 2003US-0471336P.  
XX PR 22-MAY-2003; 2003US-0472420P.  
XX PR 09-JUN-2003; 2003US-0472430P.  
XX PR 09-JUN-2003; 2003US-0476609P.

PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PI Williams LT, Chu K, Lee S, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX PT genetic, bacterial and viral diseases.  
XX PS Claim 1; SEQ ID NO 2480; 428pp; English.  
XX CC The present invention relates to an isolated nucleic acid molecule  
XX CC encoding a polypeptide which is believed to be cytostatic,  
XX CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX CC composition and methods are useful for diagnosing, preventing and  
XX CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX CC immune, metabolic, genetic, bacterial and viral diseases. The present  
XX CC sequence represents a human secreted protein. The present sequence is  
XX CC available on WIPONWEB and is not in the specification.  
XX SQ Sequence 1107 AA;  
ADP30482 Length: 1107 February 22, 2005 12:25 Type: P Check: 9461

1 ATGCATCGCC GGAGACTGGC CTGGGGTCTG GGGTCTCTGCC TGTGGCGGGG  
51 CACAAGCCTC AGTGCTCTGT GGGTGTATCT TGAGAACTGG CTGCCAGTCT  
101 CCTATGTCCT CTATATATCTC CCTGCCCCAG AGATCTTCAA CATGAAGCTG  
151 CACTACAAGA GGGAGAAGCC ACTCCAGCCC GTGGTATGGT CACAGTACCC  
201 TCAGCCCAAG CTGCTGGAGC ACAGGCCCCAC ACAGCTGTCTG ACACCTACAC  
251 CCTGGTTGGC GCCCATCGTC TCCGAGGGAA CTTTCAACCC AGAGTTCTTG  
301 CAGCACATCT ACCAGCCACT GAACTGTACC ATTTGGGGTCA CGGTGTTTGC  
351 CGTGGGAAC ACACAGTGGG GACCCCTGGCA GGCTGCTGCT GTAGCAGTGG  
401 GTGACCGGGT GATCATCACT AGGTACACTC ATTTTCATCA GTCTCTCTCG  
451 GAGTCAGCCG AGGAGTTCTT CATGCGTGGG TACCGGGTGC ACTACTACAT  
501 CTTCACTGAC AACCTGTGAG CGGTTCCCGG GGTCCCGCTG GGTCCCCACC  
551 GGCTTCTCAG CTCATCCCCC ATCCAGGGTC ACTCCCCACTG GGAGGAGACA  
601 TCCATGCGCC GGATGGAGAC CATACGCCAG CACATTGTCTA AGAGGGTCTCA  
651 CCGGAGGTG GACTACCTCT TCTGCCTTGA TGTGGACATG GTGTTTCGGA  
701 ACCCGTGGG CCTTGAGACC TTGGGAGACC TGGTGGCTGC CATTACCCCA  
751 AGCTACTACG CCGTTCCCGC CCAGCAGTTC CCCTATGAGC GCAGGCGTGT

801 TTCCACTGCC TTTGTGGCAG ACAGCGAAGG GGACTTCTAT TATGCTGGGG  
851 CAGTCTTCGG GGGGAGGTG GCCAGGTAT ATGAGTTTAC TAGGGCTGC  
901 CACATGCCCA TCTGTGGGA CAAGCCCAAT GGCATCATGG CTGCTGGGG  
951 GGAGGAAAGC CACCTGAACC GTCACTTTCAT CTCAACAAG CCGTCCAAGG  
1001 TGCTGTCCCC CGAGTACCTC TGGGAGGACA GGAAGCCCCA GCCACCCAGC  
1051 CTGAAGCTGA TCGCTTTTTC TACACTGGAC AAGGATATCA GCTGCTGTGAG  
1101 GAGCTGA

!!NA SEQUENCE 1.0  
ID\_ADP30510 standard; protein; 2044 AA.

XX  
AC ADP30510;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1277.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS  
XX  
PN WO2004035732-A2.  
XX  
XX  
PD 29-APR-2004.  
XX  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX

XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411057P.

PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-047609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2508; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 2044 AA;

ADP30510 Length: 2044 February 22, 2005 12:25 Type: P Check: 7647 ..

1 TGGGGACCTT GTCTATGCT CCAGTATCC CTCCTCCAG GTCTAGGCTG  
51 GCATGAATC CTGGGGCAGA GTCCAGGGA GCTCAAGGCT CCTCCACACA  
101 CACACCCGCT GAACCTGAG CACCTGAGC TGCTGAGATG GGGCGGGCGG  
151 GGGCTCGGC CGTATCCCG GGCCTGGGCC TGCTCTGGGC AGTGGGGCTG  
201 GGGAGTGGCG CCCCCAGGCC CCAGCCTTC GGCTCTCTT CCAAGAGCTC  
251 CAGGCTGGC ATGCTCTCA GACTTTCAG CTGGAGGAA CCTGTGCTA  
301 CCAGGCTTG CTGGTGGATG AGGAGGTGG ACGCTGTTT GTGGGTGGCG  
351 AGAACCATGT GGCCTCCCTC AACCTGGACA ACATCAGAA GCGGGCCAAG

401 AAGCTGGCCT GCCCGGCCCT TGTGGATGG CGAGAGAGT GCAACTGGGC  
451 AGGGAAGGAC ATTGTTACTG AGTGCAAGAA CTTTCGTGAAG TTGCTGCATG  
501 CTTACAACCG CACCCATTTC CTGGCTGTG GCACGGGAGC CTTCCACCCA  
551 ACCTGTGCCT TTGTGGAAGT GGGCCACCGG GCAGAGGGCA AGGGGAAGAG  
601 TCCTTATGAC CCCAGGCATC GGGCTGCCTC CGTGCTGGTG GGGGAGGAGC  
651 TATACTCAGG GGTGGCAGCA GACCTCATGG GACGAGACTT TACCATCTTT  
701 CGCAGGCTAG GGCACAGTCC AAGTCTCGGA ACAGAGCCAC AGCACTCCCG  
751 CTGGCTCAAT GGTGGCCAG ATTCGCCGA ACAGCTGGG CGGCCAGCGC  
801 AGCCTGGTCA ACAAGTGGAC GACGTTCTTG AAGCGCGGC TGGTGTGCTC  
851 GGTGCCCGGC GTCGAGGGG ACACCCACTT CGATCAGTC CTTCTATGCC  
901 GTCTTCTCCA COTCCAGGTG AGGCAATCTT CCAGGGCTCT GCGGTGTGCG  
951 TGTACAGCAT GAAAGACGTG CGCCGGGCTT TCTTGGGACC CTTTGCACAC  
1001 AAGGAGGGC CCATGCACCA GTGGGTGTCA TACCAGGGTC GCGTCCCTTA  
1051 CCGCGGCCA GGCATGTGCC CCAGCAAGAC CTTTGGCACC TTCACTTCCA  
1101 CCAAGGACTT CCCAGACGAT GTCATCCAGT TTGCGCGGAA CCACCCCTTC  
1151 ATGTACAAT CTGTCTGCC CACTGGGGGG CGCCCTCTTT TCCTACAAGT  
1201 TGGAGCCAAT TACACTTCA CTCAAATTGC CGCGGACCG GTTGACGCGG  
1251 CTGACGGACA CTATGACGTC CTCTTCATTG GCACAGACTT TGGCAGCGTG  
1301 CTGAAGGTGA TCTCGGTCCC CAAGGCGAGT AGGCCCAGCG CAGAGGGGCT  
1351 GCTCTGGAG GAGCTGCACG TGTTTGAGGA CTCGGCCGCT GTCACCAGCA  
1401 TGCAAAATTC TTCCAGAGG CGCTTCAGC CNAGTGCCAA GAGGCGGTTT  
1451 CGGCGGCAAG ACGTAAGGAA TGGCGACCCC AGCACCTTGT GTCGCGGAGA  
1501 CTCGTCTCGT CCCGCGCTGC TGGAAACAA GGTGTTCCGG GTGAGGGCA  
1551 GCAGCGCCTT TCTGAGTGT GAGCCCCGCT CGCTGCAGC GCGCGTGGAG  
1601 TGGACTTTCC AGCGGCAGG GGTGACAGCC CACACCCAGG TGCTGGCAGA  
1651 GGAGCGCACC GAGCGCACCG CCGCGGACT ACTGCTGCGC AGGCTGCGGC  
1701 GCCGGACTC GGGCGTGTAC TTGTGCGCGG CCGTCGAGCA GGGCTTTAGG  
1751 CAACCGCTGC GTCGCTGTG CTTGCACGTG TTGAGTGCTA CGCAGGCCGA  
1801 ACGACTGGCG CGGCGCGAGG AGGCTGCGCC CGCCCGCGCG CGGCGCCCA  
1851 AACTCTGTA CCGGACTTTT CTGCACTGG TGGAGCCGGG CGGAGTGGC  
1901 AGCGGAACT CCCTGCGCAT GTGCCGCCCG CAGCCTGCGC TGCACTACT  
1951 GCCCTGGAG TCGCGGAGAA AGGCGCGTAA CCGGAGGACC CAGCGCCCTG  
2001 AGCCTGCGC TGAGCGGGG CCGCGAGCG CAAAGCACTG GTGA

!!AA SEQUENCE 1.0  
ID ADF30516 standard; protein; 195 AA.  
XX  
AC ADF30516;  
XX  
DT 12-AUG-2004 (first entry)  
XX

DE Human secreted protein SEQ ID #1283.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX PD 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.

PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
PT  
XX Claim 1; SEQ ID NO 2514; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 195 AA;  
SQ  
ADP30516 Length: 195 February 22, 2005 12:25 Type: P Check: 5109 ..  
1 ATGGCGTGCT CGCGGGAGG CGTCTGGGTG GCGTGGCGG CGTGGCTCCT  
51 GCAGCTGCTC CTCAGAGCG AGTTCAGAG GAAGCTTTAC AAGGAGCTGG  
101 TCAAGAACTA CAATCCCTTG GAGAGGCCCG TGGCCAAATGA CTCGCAACCA  
151 CTCACCGTCT ACTTCTCCT GAGCCTCCTG CAGATCATGG ACGTG  
LIP SEQUENCE 1.0  
ID ADP30532 standard; protein; 1401 AA.  
XX  
AC ADP30532;  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1299.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
PN  
XX 29-APR-2004.  
PD  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
PF  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR

29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
29-AUG-2002; 2002US-0406667P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
PT  
XX Claim 1; SEQ ID NO 2530; 428pp; English.



XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.  
SQ Sequence 1401 AA;

ADP30532 Length: 1401 February 22, 2005 12:25 Type: P Check: 1001 ..

1 ATGGAAGA TGCTCGCAGG CTGCTTTCTG CTGATCCTCG GACAGATCGT  
51 CTTCTCCCT GCGGAGGCA GGGAGCGTC ACGTGGGAGG TCCATCTCTA  
101 GGGGAGACA CGCTCGGACC CACCGGAGA CGGCCCTTCT GGAGAGTTCC  
151 TGTGAGAACA AGCGGGCAGA CTTGGTTTTC ATCATTGACA GCTCTCGCAG  
201 TGTCAACACC CATGACTATG CAAGGTCAA GGAGTTTCATC GTGGACATCT  
251 TGCATTTCTT GGACATTTGG CTTGATGTCA CCGAGTGGG CTTGCTCAA  
301 TATGGCAGCA CTGTCAAGAA TGAGTTCTCC CTCAGACCT TCAAGAGGAA  
351 GTCCGAGTG GAGCTGTCTG TCAAGAGAT CGGGATCTG TCCACGGGCA  
401 CCATGACTGG GCTGGCCATC CAGTATGCC TGAACATCGC ATTCTAGAA  
451 GCAGAGGGGG CCCGCCCTT GAGGAGAAAT GTGCCACGGG TCATAATGAT  
501 CTGTACAGAT GGGAGACCTC AGGACTCGT GCGCGAGTGG GCTGTAAGG  
551 CACGGGACAC GGGCATCTTA ATCTTTGCCA TTGGTGTGGG CCAGTAGAC  
601 TTCAACACCT TGAAGTCCAT TGGAGTGAG CCCATGAGG ACCATGTCTT  
651 CTTGTGGCC AATTTCAGCC AGATTGAGC GGTGACTCC GTGTTCCAGA  
701 AGAAGTTGTG CACGGCCCAT ATGTGCAGCA CCTTGAGCA TAACTGTGCC  
751 CACTTCTGCA TCAACATCCC TGGCTCATAC GTCTGCAGGT GCAACAAGG  
801 CTACATTCTC AACTCGGATC AGACACTTG CAGATCCAG GATCTGTGTG  
851 CCATGGAGGA CCACAACTGT GAGCAGTCT GTGTGAATGT GCCGGGCTCC  
901 TTGCTGTGCC AGTGCTACAG TGGCTACGCC CTGGCTGAGG ATGGGAAGG  
951 GTGTGTGGCT GTGACTACT GTGCTCAGA AACACAGGA TGTGAACATG  
1001 AGTGTGTAAA TGCTGATGGC TCCTPACCTTT GCCAGTGCCA TGAAGGATTT  
1051 GCTCTTAACC CAGATAAAAA AACGTGCACA AACACACCC CTTGGCTGGG  
1101 GTCACCTGAT TTCACCCAG CTGTAACTAT CCTCACCATC CATCTCCAGA  
1151 ACTTTTCATC ACCCCAACT GAAACGCTGT ACCCATTGAA CAATAACTCC  
1201 CCATTGCTGG CCTGTCAAC CACCATCTTA CTTTCTGTCT GTGAATTTCA  
1251 CCACCTCTGG CACTTCATAA ATGAACAAA CAAATTTGGC TACTTGCCTT  
1301 CTTTGTGGCC ACTAAGATT TTTGGGAGC AGGTGGTGTG TGGTTATATG  
1351 GACAAATTCT TTAGTGGTGA TTCTGAGATT TTTGGTGCAA CCATCACCTG  
1401 A

!!AA\_SEQUENCE 1.0

ID ADP30572 standard; protein; 2835 AA.  
XX AC ADP30572;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1339.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.

DR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2570; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 2835 AA;  
ADP30572 Length: 2835 February 22, 2005 12:25 Type: P Check: 4349 ..  
1 ATGCGTTTTC CTGCTGCATC AGATTCCAGT GATGAACGG TACCAGACA  
51 ACAGCTCCTC ACTTACTACA TGTGTAGGCC TGGGACAGT TACTTAGAGT  
101 CACTGAGCAT CAGTTCCCGG CCACCTGTACA CAGAAGGAGC AGGTGAAAT  
151 CGGTACTTAA AGGAGATGCT GTGTGTAGAA CAGTTGGTGG AGCTGGCTGC  
201 CAGTCCACA CCGTGTGCC ACATCTCTCA GCCTTGTGT GTCTGGAAT  
251 GGTGGGTCT TGGTCTCACT GACTTCAAGA ATGAAGCTGC ACACCTGGC  
301 GGGATTGAAT GTCATGCTGA GCACCCAACA CTAGTTCTGA TGTCTTTGC  
351 CAGTGTGCTG GTGACTTGCC TTGAGGCTGC TAAACTCACC GTAGGCTTCC  
401 AGACCCCTCG GAACATCTCC CATCCATTCA GCATGCAAG GCTGGGTGA  
451 GGCTCCAGA TTGCCATGGA CAAGTCAAC TCAGAGCTAG TGGACCTTG  
501 AAATTTTACC ACTTACACA ACTAGCCTG CAGCACCAG GAGTCTCTTG  
551 CTATTTTCAA CAACAGGTC CAGAAGCAAC AGATTCTCGC CTGTTTGA  
601 CCAGCATGCC CAGAAGCAGC TGAGGACATT GGTGATGTC TCAGGAAAG  
651 TCTCCAGTAC GTGGGCTGGA AACACATTGG GATGTTTGA GGTACTCTG  
701 GGGCTTCTC CTGGGATGGA GTGGATGAAC TGTGAGGGT TGTAGAGAAT  
751 GAACTCAAT CCATTTTAT CATCACTGCC AGCATGAGAT ACACCAACA

801 TAGTCTAGTC CTTCTTCAAG AGCATCTTTG GAGGATATCA TCAATTGCCA  
851 GGGTTATCAT CTTAAGTGC AGCTCAGAGG ATGCAAAAAT TATTTCTCTG  
901 GCTGCAGCAA ACCTGGGACT CAGCACTGGA GAATTTGTTT TCATCATTTT  
951 GCAGCAGTTG GAGGACCGTT TTTTGAAGGA AGTACTGACA AATCAGAAAA  
1001 TGATGACACT CCAAAAGGTG TATGGGTAC TGCTTCTCAT TGCCCTCAGC  
1051 TCCTACAGAA AAGGCGGTGG AGACGAAGGC TTTTGGAAAC AAGTCTACCA  
1101 AACACCGAGG AGTGCCTCT TCCGACGAC CATCTCTCTG GAGGAGCAGG  
1151 TGAGCCCTTA CTCTGCCTAC CTTACAGAGC CCGTCTCTGT CTATGCTGAG  
1201 ACCGTGAAGC AGGTGTTAAA GGCTGGAGGC GACTTCCAGG ATGGGTGGCA  
1251 GCTGGTCAAG GCTCTGAAGG GTTCCAGTCA GACCACAGTG CAGGGAATCA  
1301 CAGGCCCTGT GTTTGTGGAT GCCCAGGAG AAAGGCACAT GGATTACTCT  
1351 GTCTATGCC TGCAGAGTC TGAATAATGG CCCCTTTTAC TTTCTTTTCT  
1401 TCATTATGAC AGTTATCAA GCGTGACTGC TGTGCTTCTG ACATTGATGA  
1451 TCTCATTCCT TGTCTTGGGA CTGCCATCA TAGGTCTGAT TTTAAGGATG  
1501 CAGAGGCAAA ACAAGACAT CTGTTGGCAA ATCAATTTTG ATGATATCAC  
1551 CATTCTTCCC CAGACAAGC CATCCAGAG AGCCACACCT GTGTCAAAAG  
1601 GCATCAACAG TAACTCATCT AGTGTGATGA TTTCTGTGGA CCTCAGCTCT  
1651 TTTGTCAAGA GCCAGCAGTG GGAAGAGCTC TTCTATGCCG CAGTAGGGCT  
1701 TTATCAGGA AACCATGTGG CCATCCGTTA CGTTGGTGAC CAAGCAGAAG  
1751 CTGGGTTAG GAAGCCGATT GTGCTACAGG AAATACAGCT GCTTGTGCTC  
1801 TATACTTTTA CCACCAAGAG CGACAAAGCC AGTGACCTGG GAGTCAGTCC  
1851 GGGCATGCTG TTCCTCCACA GGAGCCCTCT GGGCTCCAC AGCAACCTGA  
1901 AACCTTCCAA CTGCTGTATG GATGGTCGGC TGCAGGTATC CACAGGTGGG  
1951 CCTTCTCTCT GAGCTGTATGA TATGTGGCTG TTCCGTTCAA CTGAGGAGAA  
2001 CGAGRAAAG AAAAGTATC TGCAGTACCC TCACTCCATG CGGACATCCC  
2051 ATTCTTTTGC AGAGCTCTAC TGGACTGCCC CAGAGCTGCT GCAGTTCCGG  
2101 GAGATGCCCT GGTCCGGTAC CCGCAAGGA GATGTTTACA GCTTCGCCAT  
2151 TCTGATGAGG GAGCTGATCT ACCATTGGGA CCACGGGCTT TTTGATGACC  
2201 TCACAGAGGC ACCGATGAA ATCATCAACC AAATCAAGA CCTGTGAGCA  
2251 GCAGTCCCAC TGCACCTTC CTGCCCCGAG GAGAAGGGA ATGAAAAAGAT  
2301 CGTGGCCATG GTGAGGTGT GTTGGGATGA ATCTCTGGAG AAAGACCCA  
2351 GTTCTCTTTC CATCAAGAAA ACTTTACAG AGGCCAGTCC CAGAGGTCTAT  
2401 GTGAGCATAC TGGCCAGTGT GATGAGCAAG CTGGAAGTGT ATGCCAATTA  
2451 CTTGGAGGAA GTGGTGCAAG AGAGGACCAG CCAGCTGACT GCAGAGNAGA  
2501 GGAAGGTGGA GAAGCTTCTG TCCACCAAG TGCCCCAGCTT CACTGGAGAA  
2551 CAACTACTAG CCGGAAGGTC CGTGGAAACCA GAACATTTTG AATCTGTGAC



501 AAACATCCTT CTGAACCCGG CCTATGACGT CTACCTGATG GTGGGAACCT  
551 CCATTACTA CRAAGTGCAG AAGATCAGGC AAGGAAAT TACA

!!AA SEQUENCE 1.0

ID ADP30692 standard; protein; 659 AA.

XX AC ADP30692;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1459.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485221P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases

genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 2690; 428pp; English.

The present invention relates to an isolated nucleic acid molecule encoding a polypeptide which is believed to be cytostatic, antiinflammatory, immunosuppressive, antibacterial and virucidal. The composition and methods are useful for diagnosing, preventing and treating diseases such as proliferative (e.g. cancer), inflammatory, immune, metabolic, genetic, bacterial and viral diseases. The present sequence represents a human secreted protein. The present sequence is available on WIPOWEB and is not in the specification.

Sequence 659 AA;

ADP30692 Length: 659 February 22, 2005 12:25 Type: P Check: 9178 ..

1 TAATACCGCC ACGAGTCTCA AAGTCGCTGG ACTACGAGGC COTGCAGGCT

51 TTCGAGTTCC GCGTGGGCGC CACAGACCGC GGCTTCCCGG CGTTGAGCAG

101 CGAGGGGCTG GTGCGGTGCG TGGTGTGGA CGCCAAGGAC AACTGCGCCT

151 TCGTGCTGTA CCCGCTGCAG AACGGCTCCG CGCCCTGCAC CGAGCTGGTG

201 CCCCGGGCGG CCGAGCCGGG CTACCTGGTG ACCAAGGTGS TGGCGGTGGA

251 CGGCGACTCG GGCCAGAACG CTTGGGTGTC GTACCAAGCTG CTCGAAGGCCA

301 CGGAGCCCGG GCTGTTCGCG GTGTGGGCGC ACAATGGCGA GGTGGCGCAC

351 GCCAGGCTGC TGAGCGAGCG CGAGCTGGCC AAGCACAGGC TAGTGGTGCT

401 GGTCAAGGAC AATGGCGAGC CTCGGCGCTC GGCCACCGCC AGCTGTCGAG

451 TGCTCTGTGT GGACGGCTTC TCTCAGCCCT ACCTGCCGCT CCCAAGAGCG

501 GCCCGGGCCC AAGCCAGGC CGACTCGCTC ACTGTCTACC TGGTGGTGCG

551 GTTGGCCTCG GTGTCGTGCG TCTTCCTCTT CTGGTGCTC CTGTTCTGCG

601 CGGTGCGGCC TGTGAGGAG GAGCAGGGCG GCCCGGTCG GTCGCTGCTC

```
651 GGTGCTTGA
!!AA_SEQUENCE 1.0
ID ADP30753 standard; protein; 183 AA.
AC ADP30753;
DT 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #1520.
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW cancer; inflammatory; immune; human secreted protein.
XX
OS Homo sapiens.
PN WO2004035732-A2.
PP
XX 29-APR-2004.
XX
XX 28-AUG-2003; 2003WO-US026780.
PR 29-AUG-2002; 2002US-0406576P.
PR 29-AUG-2002; 2002US-0406579P.
PR 29-AUG-2002; 2002US-0406585P.
PR 29-AUG-2002; 2002US-0406588P.
PR 29-AUG-2002; 2002US-0406611P.
PR 29-AUG-2002; 2002US-0406612P.
PR 29-AUG-2002; 2002US-0406616P.
PR 29-AUG-2002; 2002US-0406640P.
PR 29-AUG-2002; 2002US-0406642P.
PR 29-AUG-2002; 2002US-0406646P.
PR 29-AUG-2002; 2002US-0406653P.
PR 29-AUG-2002; 2002US-0406655P.
PR 29-AUG-2002; 2002US-0406668P.
PR 17-SEP-2002; 2002US-0410946P.
PR 17-SEP-2002; 2002US-0410947P.
PR 17-SEP-2002; 2002US-0410948P.
PR 17-SEP-2002; 2002US-0410949P.
PR 17-SEP-2002; 2002US-0410953P.
PR 17-SEP-2002; 2002US-0410957P.
PR 17-SEP-2002; 2002US-0410958P.
PR 17-SEP-2002; 2002US-0410959P.
PR 17-SEP-2002; 2002US-0410960P.
PR 17-SEP-2002; 2002US-0410961P.
PR 17-SEP-2002; 2002US-0410962P.
PR 17-SEP-2002; 2002US-0411019P.
PR 17-SEP-2002; 2002US-0411022P.
PR 17-SEP-2002; 2002US-0411023P.
PR 17-SEP-2002; 2002US-0411024P.
PR 17-SEP-2002; 2002US-0411032P.
PR 17-SEP-2002; 2002US-0411035P.
PR 17-SEP-2002; 2002US-0411037P.
PR 17-SEP-2002; 2002US-0411041P.
PR 17-SEP-2002; 2002US-0411045P.
PR 17-SEP-2002; 2002US-0411046P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411052P.
PR 17-SEP-2002; 2002US-0411055P.
PR 17-SEP-2002; 2002US-0411073P.
PR 17-SEP-2002; 2002US-0411082P.
PR 17-SEP-2002; 2002US-0411101P.
PR 17-SEP-2002; 2002US-0411111P.
PR 18-APR-2003; 2003US-0463700P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 18-APR-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467230P.
PR 19-MAY-2003; 2003US-0471306P.
PR
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX
DR WPI; 2004-348438/32.
XX
PT New nucleic acid molecule for diagnosing, preventing or treating diseases
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PT genetic, bacterial and viral diseases.
XX
XX Claim 1; SEQ ID NO 2751; 428pp; English.
XX
CC The present invention relates to an isolated nucleic acid molecule
CC encoding a polypeptide which is believed to be cytostatic,
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
CC composition and methods are useful for diagnosing, preventing and
CC treating diseases such as proliferative (e.g. cancer), inflammatory,
CC immune, metabolic, genetic, bacterial and viral diseases. The present
CC sequence represents a human secreted protein. The present sequence is
CC available on WIPWEB and is not in the specification.
XX
XX Sequence 183 AA;
SQ
ADP30753 Length: 183 February 22, 2005 12:25 Type: P Check: 3809 ..
1 ATGACCACCTT TGTCTATGTC ACCATTGGGA TCTTTGGCCT GGGTGCTGGC
51 ATTGGCCTCT ACAGCTGCCT GTACCCCTG GTGTGCCACC TGTCCCTCGG
101 GCATATACCAG AGGCTCCGC ACAGCCTCTG GGCCTCTCTG CCGCTGCCTC
151 TGCTGCTGCT GCGAGCCTG TGGCGAACCG TGA
!!AA_SEQUENCE 1.0
ID ADP30815 standard; protein; 162 AA.
XX
XX ADP30815;
XX
DT 12-AUG-2004 (first entry)
XX
XX Human secreted protein SEQ ID #1582.
XX
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
XX cancer; inflammatory; immune; human secreted protein.
XX
XX Homo sapiens.
OS
XX WO2004035732-A2.
XX
XX 29-APR-2004.
XX
XX 28-AUG-2003; 2003WO-US026780.
XX
```

```
PR 29-AUG-2002; 2002US-0406576P.
PR 29-AUG-2002; 2002US-0406579P.
PR 29-AUG-2002; 2002US-0406585P.
PR 29-AUG-2002; 2002US-0406588P.
PR 29-AUG-2002; 2002US-0406608P.
PR 29-AUG-2002; 2002US-0406611P.
PR 29-AUG-2002; 2002US-0406612P.
PR 29-AUG-2002; 2002US-0406616P.
PR 29-AUG-2002; 2002US-0406640P.
PR 29-AUG-2002; 2002US-0406642P.
PR 29-AUG-2002; 2002US-0406646P.
PR 29-AUG-2002; 2002US-0406653P.
PR 29-AUG-2002; 2002US-0406655P.
PR 29-AUG-2002; 2002US-0406666P.
PR 17-SEP-2002; 2002US-0410946P.
PR 17-SEP-2002; 2002US-0410947P.
PR 17-SEP-2002; 2002US-0410948P.
PR 17-SEP-2002; 2002US-0410949P.
PR 17-SEP-2002; 2002US-0410953P.
PR 17-SEP-2002; 2002US-0410957P.
PR 17-SEP-2002; 2002US-0410958P.
PR 17-SEP-2002; 2002US-0410959P.
PR 17-SEP-2002; 2002US-0410960P.
PR 17-SEP-2002; 2002US-0410961P.
PR 17-SEP-2002; 2002US-0410962P.
PR 17-SEP-2002; 2002US-0411019P.
PR 17-SEP-2002; 2002US-0411022P.
PR 17-SEP-2002; 2002US-0411023P.
PR 17-SEP-2002; 2002US-0411024P.
PR 17-SEP-2002; 2002US-0411032P.
PR 17-SEP-2002; 2002US-0411035P.
PR 17-SEP-2002; 2002US-0411037P.
PR 17-SEP-2002; 2002US-0411041P.
PR 17-SEP-2002; 2002US-0411045P.
PR 17-SEP-2002; 2002US-0411046P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411052P.
PR 17-SEP-2002; 2002US-0411055P.
PR 17-SEP-2002; 2002US-0411073P.
PR 17-SEP-2002; 2002US-0411082P.
PR 17-SEP-2002; 2002US-0411101P.
PR 17-SEP-2002; 2002US-0411111P.
PR 18-APR-2003; 2003US-0463700P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 18-APR-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467230P.
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493373P.
PR 08-AUG-2003; 2003US-0493377P.
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PI
```

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 2813; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPWEB and is not in the specification.  
Sequence 162 AA;  
ADP30815 Length: 162 February 22, 2005 12:25 Type: P Check: 1520 ..  
1 ATGCCTGTCAT GTGCTGGTTC AGGACTAC CACCTGGCG TCCTCCCTTC  
51 TTCTCTTGCA GAGCCTGAGC CACCCAGGG CTGCCGCCAT GGAGCCCCCTG  
101 TTCCCAGCCT CCACGCCAG CTGGAAGGCC TCCTCCCGG GGGCTGCCTC  
151 TGGAGGCGGT GA  
!!AA SEQUENCE 1.0  
ID ADP30878 standard; protein; 828 AA.  
XX AC ADP30878;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1645.  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.  
XX WO2004035732-A2.  
PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.



PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H,  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2889; 428pp; English.  
FS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX  
SQ Sequence 762 AA;  
ADP30891 Length: 762 February 22, 2005 12:25 Type: P Check: 607 ..  
1 AGGGTCGAGC ACGCAGCAT GCATGCCAAG CACCGTGGCC ATGAAGCTAT  
51 GCATGCTGAA ATGGTCCTCA TCCTCATGCG AACCTTGGTG GTGGCCGAGC  
101 TGCTCTCTGGT GCAGTGGAG CAGAGGCACC CACGCTCCTA CAATGGTGAC  
151 CCTCTTTTCAG ATGTGGGTG TTCCCTCTTA TTTCACAGTG AAGCTGCACT  
201 GGTGGAGGTT CCTAGTGATC TGGATCTTGT TCCTCTGCTGT CACAGCCTTT  
251 GTTACCTTCC GAGCACCGG AAAACCTCTA GTACAGACAA CCCCAAGTT  
301 GGTTTATAAG TGGTTCTGCG TAATCTATAA AATCAGCTAT GCCACTGGCA  
351 TTGTTGGCTA CATGCTGTC ATGTTTACCC TCCTTGTGCT TAACCTATTGA  
401 TTCAAGATCA AACCAGAAGA TGCCATGGAC TTGGGCACTT CCTTCTCTTT  
451 CTATGGCCTC TACTATGGAG TTCTGGAACG GGACTTTTGA GAAATGTGTG  
501 CAGACTACAT GGCATCTACC ATAGGGTTCT ACAGCGAGTC GGGCATGCGCT  
551 ACCAAACAIC TTTCAGACAG TGTGTGTGCT GTGTGTGGGC AGCAGATCTT  
601 TGTGGACGTC AGTGAAGAGG GGATCAATTGA GAACACGATAT AGGCTGTCTC  
651 GCAATCATGT CTTCCACGAG TTCTGCATCC GTGGCTGGTG CATCGTGGGA  
701 AAGAAGCAA CGTGCTCCTA CTGCAAGAG AGGTAGACC TCAAGAGGAT  
751 GTTCAGCAAT CC  
!!AA SEQUENCE 1.0  
ID ADP30898 standard; protein; 1215 AA.  
XX  
XX ADP30898;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1665.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.



PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471338P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

DR WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.

PS Claim 1; SEQ ID NO 2896; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present

CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

SQ Sequence 1215 AA;

ADP30898 Length: 1215 February 22, 2005 12:25 Type: P Check: 8357 ..

1 ATGAGTCAAA GCACCAATGA GCACAAGGAA TGGCTCATCA CTCTGGGCTT  
51 TGGGAACATA ACAACAGTTT TAGATGACCA CACACGCAA TGTAAGTCA  
101 CGCCCCAAC TCTCTGCACC ACCATCTCCC ACGGGATCTA CTATATCTAC  
151 TACCTCTACC CTTTCAACAT AGAGTATCAG ATCTTGGCCT CCACAGTGCT  
201 CTACGTCTTA TGGAGAACA TCGGGCGCAA AGTTGACAGC CATCAGCACC  
251 AGAAGATGCA GTTCAAGCCT GATGGGGTCA CAGTGGGCAC AGTCTGGGGC  
301 CTGACCGGCG TGGCGGCCAC CATTTGCCGTG GTGACCAAGA GCAAGTCAGC  
351 ACTCATCAGG TTCTACCTGT ATGTCATCAC CCTGATGAAG CTTATGGGGG  
401 CTGGGGGCT GGCTGGGAATC CGGATTTACA GGACAGATGA GAAGTCACTG  
451 GATGAGTCCA AAAATCCGCC CCGCAAACTG GACTCGGACC TCTTGGTGGG  
501 CACTGCCTCA GGCTCCTGGC TTATCTCCTG GGGCTCAACT TTGGCCATCC  
551 TTTGTGCCGA GGACACCCC CACTACACCT GGTACAACCT GCCCTACTCC  
601 ATCGTGGTGA TCGTGGAGAA GTACATCCAG AACCTCTTCA TCTTTGAATC  
651 CATTCAACGA GAGCTAATAA NAATCTCTGA GGACATCCAA ACCCTTGGGA  
701 TGGTCACAGT CTGCAATGGC AACACCATGC CCCTTGGTTC CTCTGCGCTC  
751 AAGAGTGGAG GTGTGGCGCG AGACGTGGCT CCCTGGGGCA GGGACATGCC  
801 ACCAGCAGCC AATGGNAATG TGTGCCCTGAG AGAAAGCTGT GACAAGGAGG  
851 AGAAGCAGCA GGAGAGCAGC TGGGGAGGGA ACCCAAGCCC AGTCCACCTT  
901 CCTGGTTTCT TACAGGGCAA CGCCAAGAGA AAAGTCCTGA GGAATATTGC  
951 AGCCTTCTTG TTCTCTGCA ATACTTTGGT TCAAGGGGTA CGCATGCAGA  
1001 TTTGTTACAT GGGTAATATG CGTGTGCTG AGGTTTGGTG CACAAATGAT  
1051 CCCGTACACC AGCTTTGGAT ACCTCCCGCT TTTGGCTGTC GACCTGAGTA  
1101 TGACAAATGA TTGGAGGAGA TTGTCTTTGG CTTTGAACCC TGGATAATTG  
1151 TGGTCAACCT GGCATGGCT TTTTCTATTT TCTATGCAAT GCACGCAGCT  
1201 GCCTCCCTCT TTGAG

IIAA\_SEQUENCE 1.0

ID\_ADP30900 standard; protein; 1215 AA.

XX AC ADP30900;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1667.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX FN W02004035732-A2.

XX XX

PD	29-APR-2004.	PA	(FIVE-) FIVE PRIME THERAPEUTICS INC.
XX		XX	
PI	28-AUG-2003; 2003WO-US026780.	PI	Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
XX		PI	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PR	29-AUG-2002; 2002US-0406576P.	PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
PR	29-AUG-2002; 2002US-0406579P.	XX	WPI; 2004-348438/32.
PR	29-AUG-2002; 2002US-0406585P.	XX	
PR	29-AUG-2002; 2002US-0406588P.	XX	
PR	29-AUG-2002; 2002US-0406608P.	XX	
PR	29-AUG-2002; 2002US-0406611P.	PT	New nucleic acid molecule for diagnosing, preventing or treating diseases
PR	29-AUG-2002; 2002US-0406612P.	PT	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PR	29-AUG-2002; 2002US-0406616P.	PT	genetic, bacterial and viral diseases.
PR	29-AUG-2002; 2002US-0406640P.	XX	
PR	29-AUG-2002; 2002US-0406642P.	XX	Claim 1; SEQ ID NO 2898; 428pp; English.
PR	29-AUG-2002; 2002US-0406646P.	XX	
PR	29-AUG-2002; 2002US-0406653P.	CC	The present invention relates to an isolated nucleic acid molecule
PR	29-AUG-2002; 2002US-0406655P.	CC	encoding a polypeptide which is believed to be cytostatic,
PR	29-AUG-2002; 2002US-0406666P.	CC	antiinflammatory, immunosuppressive, antibacterial and virucidal. The
PR	17-SEP-2002; 2002US-0410946P.	CC	composition and methods are useful for diagnosing, preventing and
PR	17-SEP-2002; 2002US-0410947P.	CC	treating diseases such as proliferative (e.g. cancer), inflammatory,
PR	17-SEP-2002; 2002US-0410947P.	CC	immune, metabolic, genetic, bacterial and viral diseases. The present
PR	17-SEP-2002; 2002US-0410948P.	CC	sequence represents a human secreted protein. The present sequence is
PR	17-SEP-2002; 2002US-0410949P.	CC	available on WIPWEB and is not in the specification.
PR	17-SEP-2002; 2002US-0410953P.	XX	
PR	17-SEP-2002; 2002US-0410957P.	SQ	Sequence 1215 AA;
PR	17-SEP-2002; 2002US-0410958P.	ADP30900	Length: 1215 February 22, 2005 12:25 Type: P Check: 8357 ..
PR	17-SEP-2002; 2002US-0410959P.		
PR	17-SEP-2002; 2002US-0410960P.		
PR	17-SEP-2002; 2002US-0410961P.		
PR	17-SEP-2002; 2002US-0410962P.		
PR	17-SEP-2002; 2002US-0411019P.		
PR	17-SEP-2002; 2002US-0411022P.		
PR	17-SEP-2002; 2002US-0411023P.		
PR	17-SEP-2002; 2002US-0411024P.		
PR	17-SEP-2002; 2002US-0411032P.		
PR	17-SEP-2002; 2002US-0411035P.		
PR	17-SEP-2002; 2002US-0411037P.		
PR	17-SEP-2002; 2002US-0411041P.		
PR	17-SEP-2002; 2002US-0411045P.		
PR	17-SEP-2002; 2002US-0411046P.		
PR	17-SEP-2002; 2002US-0411048P.		
PR	17-SEP-2002; 2002US-0411052P.		
PR	17-SEP-2002; 2002US-0411055P.		
PR	17-SEP-2002; 2002US-0411073P.		
PR	17-SEP-2002; 2002US-0411082P.		
PR	17-SEP-2002; 2002US-0411101P.		
PR	17-SEP-2002; 2002US-0411111P.		
PR	18-APR-2003; 2003US-0463700P.		
PR	18-APR-2003; 2003US-0463708P.		
PR	18-APR-2003; 2003US-0463716P.		
PR	18-APR-2003; 2003US-0463732P.		
PR	02-MAY-2003; 2003US-0467199P.		
PR	02-MAY-2003; 2003US-0467201P.		
PR	02-MAY-2003; 2003US-0467203P.		
PR	02-MAY-2003; 2003US-0467230P.		
PR	19-MAY-2003; 2003US-0471306P.		
PR	19-MAY-2003; 2003US-0471336P.		
PR	22-MAY-2003; 2003US-0472420P.		
PR	22-MAY-2003; 2003US-0472430P.		
PR	09-JUN-2003; 2003US-0476609P.		
PR	09-JUN-2003; 2003US-0476641P.		
PR	08-JUL-2003; 2003US-0485218P.		
PR	08-JUL-2003; 2003US-0485223P.		
PR	08-JUL-2003; 2003US-0485225P.		
PR	08-JUL-2003; 2003US-0485325P.		
PR	14-JUL-2003; 2003US-0486446P.		
PR	14-JUL-2003; 2003US-0486480P.		
PR	15-JUL-2003; 2003US-0486891P.		
PR	15-JUL-2003; 2003US-0486960P.		
PR	08-AUG-2003; 2003US-0493341P.		
PR	08-AUG-2003; 2003US-0493370P.		
PR	08-AUG-2003; 2003US-0493573P.		
PR	08-AUG-2003; 2003US-0493577P.		
XX			
		1	ATGAGTCAAA GCACAAATGA GCACAAGAA TGGCTCATCA CTCCTGGGCTT
		51	TGGGAACATA ACAACAGTTT TAGATGACCA CACACCGCAA TGTAACGTGA
		101	CGCCCCCAAC TCTCTGCACC ACCATCTCCC ACGGGATCTA CTATATCTAC
		151	TACCTCTACC CTTCAACAT AGAGTATCAG ATCCTGGCCT CCACAGTGCT
		201	CTACGTCCTA TGAAGAACA TCGGGCGCAA AGTTGACAGC CATCAGCACC
		251	AGNAGATGCA GTTCAAGCCT GATGGGTCA CAGTGGGCAC AGTCCTGGGC
		301	CTGACCGCGC TGGCGGCCAC CATTGCCGTG GTGACCAAGA GCAAGTCAGC
		351	ACTCATCAGG TTCTACCTGT ATGTCATCAC CCTGATGAAG CTTATGGGGG
		401	CTGCGGGGCT GGCTGGAATC CGGATTTACA GGACACATGA GAAGTCAC TG
		451	GATGAGTCCA AAATCCGCC CCGCAAAC TG GACTCGGACC TCTTGGTGGG
		501	CACTGCCTCA GGCTCCTGGC TTATCTCCTG GGGCTCAATC TTGGCCATCC
		551	TTTGTGCCGA GGACCACCCC CACTACACCT GGTACAACCT GCCTTACTCC
		601	ATCGTGGTGA TCGTGGAGAA GTACATCCAG AACCTCTTCA TCTTTGAATC
		651	CATTCACCGA GAGCCTAAAA AACTCTCTGA GGACATCCAA ACCCTTCGGA
		701	TGGTACACGT CTGCAATGCG AACACCATGC CCCTTGCTTC CTCCTGSCCTC
		751	AAGAGTGGAG GTGTGGCCGG AGAGTGGCT CCCTGGGGCA GGGACATGCC
		801	ACCAGCAGCC AATGGAATG TGTGCTTGAG AGAAAGCTGT GACAAAGGAG
		851	AGNAGCACCA GGAGAGCAGC TGGGGAGGGA ACCCAAGCCC AGTCCACCTT
		901	CCTCGTTTCT TACAGGGCAA CGCCAAGAGA AAGTCTCTGA GGAATATTGC
		951	AGCCTTCTTG TTCTCTGCA ATACTTTGGT TCAAGGGGTA CGCATGSCAGA
		1001	TTTGTACAT GGGTAAATTG CGTGTGCTG AGGTTTGGTG CACAAATGAT
		1051	CCCGTACCCC AGCTTTGGAT ACCTCCGCT TTTGGCTGTC GACCTGAGTA
		1101	TGACAAATGA TTGGAGGAGA TTGTCTTTGG CTTTGAACCC TGGATAATTG

1151 TGGTCAACCT GCCATGGCT TTTTCTATTT TCTATGCAAT GCACGCAGCT

1201 GCCTCCCTCT TTGAG

!!AA SEQUENCE 1.0

ID ADP30918 standard; protein; 525 AA.

XX AC ADP30918;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1695.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX FN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406656P.

XX PR 17-SEP-2002; 2002US-0406662P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411037P.

XX PR 17-SEP-2002; 2002US-0411041P.

XX PR 17-SEP-2002; 2002US-0411045P.

XX PR 17-SEP-2002; 2002US-0411046P.

XX PR 17-SEP-2002; 2002US-0411048P.

XX PR 17-SEP-2002; 2002US-0411049P.

XX PR 17-SEP-2002; 2002US-0411052P.

XX PR 17-SEP-2002; 2002US-0411055P.

XX PR 17-SEP-2002; 2002US-0411073P.

XX PR 17-SEP-2002; 2002US-0411082P.

XX PR 17-SEP-2002; 2002US-0411101P.

XX PR 18-APR-2003; 2003US-0463700P.

XX PR 18-APR-2003; 2003US-0463708P.

XX PR 18-APR-2003; 2003US-0463716P.

XX PR 02-MAY-2003; 2003US-0463732P.

XX PR 02-MAY-2003; 2003US-0467199P.

XX PR 02-MAY-2003; 2003US-0467201P.

XX PR 02-MAY-2003; 2003US-0467203P.

PR 02-MAY-2003; 2003US-0467230P.

PR 19-MAY-2003; 2003US-0471306P.

PR 19-MAY-2003; 2003US-0471336P.

PR 22-MAY-2003; 2003US-0472420P.

PR 22-MAY-2003; 2003US-0472430P.

PR 09-JUN-2003; 2003US-0476609P.

PR 09-JUN-2003; 2003US-0476641P.

PR 08-JUL-2003; 2003US-0485218P.

PR 08-JUL-2003; 2003US-0485223P.

PR 08-JUL-2003; 2003US-0485224P.

PR 08-JUL-2003; 2003US-0485325P.

PR 14-JUL-2003; 2003US-0486466P.

PR 14-JUL-2003; 2003US-0486480P.

PR 15-JUL-2003; 2003US-0486891P.

PR 15-JUL-2003; 2003US-0486906P.

PR 08-AUG-2003; 2003US-0493341P.

PR 08-AUG-2003; 2003US-0493370P.

PR 08-AUG-2003; 2003US-0493573P.

PR 08-AUG-2003; 2003US-0493577P.

XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

XX PA

XX PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases

PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

PT genetic, bacterial and viral diseases.

XX PS Claim 1; SEQ ID NO 2916; 428pp; English.

XX PS The present invention relates to an isolated nucleic acid molecule

CC encoding a polypeptide which is believed to be cytoskeletal,

CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The

CC composition and methods are useful for diagnosing, preventing and

CC treating diseases such as proliferative (e.g. cancer), inflammatory,

CC immune, metabolic, genetic, bacterial and viral diseases. The present

CC sequence represents a human secreted protein. The present sequence is

CC available on WIPOMEB and is not in the specification.

XX SQ Sequence 525 AA;

ADP30918 Length: 525 February 22, 2005 12:25 Type: P Check: 131 ..

1 ATGAAAGTGC TGTGTTCGC CCTGGGTTA CTGTTTCTTC TCCTCACACA

51 GTTTGGCTGC CGTGGGCGCT TCCCAAGCT GGGCATCTGT GTTGGCCTTC

101 AGTGGTGTCT GGGGCTGCC TTCTGTCTGG AGAAGCCCAAC TGGCTACCTG

151 TCTCGCTCCT TTGACCTTGG CCGCCAGTTT CTGTTTCTGT GGACAATGAA

201 CTGGTGCTTC CTCACGGGG CTCTCTGCCT GCACCGTGCC TTCCACCTGG

251 CCCTGATGGC CACCCACCTC ACCTTGCTCT TGCTGTTTAC CCTCTACTGG

301 TGGCCCCAGGA TGGGGGAATG TATCTTGTCA CTGATGAAGG ATCCCTCCAA

351 AAGGAAGGTT CCACCAAGC CCTTCATAGC CAACCAGATC GTTTCTACCC

401 TCTTCACCTC TAATTCATT GGCATCTGCT TTAGCCACCT CCCTCCACTA

451 CCAGTTCTGT GTCTGTCTG GTTGGGCGCTG CAGCGGTTCC CCAAGAGCAT

501 CCAACACAGC AAGAAAGTTC CCTGA

!!AA SEQUENCE 1.0

ID ADP30920 standard; protein; 1125 AA.

XX AC ADP30920;

XX 12-AUG-2004 (first entry)  
DT Human secreted protein SEQ ID #1687.  
XX  
DE  
DE Human secreted protein SEQ ID #1687.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
PN  
XX  
XX  
XX 29-APR-2004.  
PD  
XX  
XX  
XX 28-AUG-2003; 2003WO-US025780.  
PF  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR  
PR 29-AUG-2002; 2002US-0406579P.  
PR  
PR 29-AUG-2002; 2002US-0406585P.  
PR  
PR 29-AUG-2002; 2002US-0406588P.  
PR  
PR 29-AUG-2002; 2002US-0406608P.  
PR  
PR 29-AUG-2002; 2002US-0406611P.  
PR  
PR 29-AUG-2002; 2002US-0406612P.  
PR  
PR 29-AUG-2002; 2002US-0406616P.  
PR  
PR 29-AUG-2002; 2002US-0406640P.  
PR  
PR 29-AUG-2002; 2002US-0406642P.  
PR  
PR 29-AUG-2002; 2002US-0406646P.  
PR  
PR 29-AUG-2002; 2002US-0406653P.  
PR  
PR 29-AUG-2002; 2002US-0406655P.  
PR  
PR 29-AUG-2002; 2002US-0406666P.  
PR  
PR 17-SEP-2002; 2002US-0410946P.  
PR  
PR 17-SEP-2002; 2002US-0410947P.  
PR  
PR 17-SEP-2002; 2002US-0410948P.  
PR  
PR 17-SEP-2002; 2002US-0410949P.  
PR  
PR 17-SEP-2002; 2002US-0410953P.  
PR  
PR 17-SEP-2002; 2002US-0410957P.  
PR  
PR 17-SEP-2002; 2002US-0410958P.  
PR  
PR 17-SEP-2002; 2002US-0410959P.  
PR  
PR 17-SEP-2002; 2002US-0410960P.  
PR  
PR 17-SEP-2002; 2002US-0410961P.  
PR  
PR 17-SEP-2002; 2002US-0410962P.  
PR  
PR 17-SEP-2002; 2002US-0411019P.  
PR  
PR 17-SEP-2002; 2002US-0411022P.  
PR  
PR 17-SEP-2002; 2002US-0411023P.  
PR  
PR 17-SEP-2002; 2002US-0411024P.  
PR  
PR 17-SEP-2002; 2002US-0411032P.  
PR  
PR 17-SEP-2002; 2002US-0411035P.  
PR  
PR 17-SEP-2002; 2002US-0411037P.  
PR  
PR 17-SEP-2002; 2002US-0411041P.  
PR  
PR 17-SEP-2002; 2002US-0411045P.  
PR  
PR 17-SEP-2002; 2002US-0411046P.  
PR  
PR 17-SEP-2002; 2002US-0411048P.  
PR  
PR 17-SEP-2002; 2002US-0411052P.  
PR  
PR 17-SEP-2002; 2002US-0411055P.  
PR  
PR 17-SEP-2002; 2002US-0411073P.  
PR  
PR 17-SEP-2002; 2002US-0411082P.  
PR  
PR 17-SEP-2002; 2002US-0411101P.  
PR  
PR 17-SEP-2002; 2002US-0411111P.  
PR  
PR 18-APR-2003; 2003US-0463700P.  
PR  
PR 18-APR-2003; 2003US-0463708P.  
PR  
PR 18-APR-2003; 2003US-0463716P.  
PR  
PR 18-APR-2003; 2003US-0463732P.  
PR  
PR 02-MAY-2003; 2003US-0467199P.  
PR  
PR 02-MAY-2003; 2003US-0467201P.  
PR  
PR 02-MAY-2003; 2003US-0467203P.  
PR  
PR 02-MAY-2003; 2003US-0467230P.  
PR  
PR 19-MAY-2003; 2003US-0471306P.  
PR  
PR 19-MAY-2003; 2003US-0471336P.  
PR  
PR 22-MAY-2003; 2003US-0472420P.  
PR  
PR 22-MAY-2003; 2003US-0472430P.  
PR  
PR 09-JUN-2003; 2003US-0476609P.  
PR  
PR 09-JUN-2003; 2003US-0476641P.  
PR  
PR 08-JUL-2003; 2003US-0485218P.

PR 08-JUL-2003; 2003US-0485223P.  
PR  
PR 08-JUL-2003; 2003US-0485224P.  
PR  
PR 08-JUL-2003; 2003US-0485325P.  
PR  
PR 14-JUL-2003; 2003US-0486448P.  
PR  
PR 14-JUL-2003; 2003US-0486480P.  
PR  
PR 15-JUL-2003; 2003US-0486891P.  
PR  
PR 15-JUL-2003; 2003US-0486960P.  
PR  
PR 08-AUG-2003; 2003US-0493341P.  
PR  
PR 08-AUG-2003; 2003US-0493370P.  
PR  
PR 08-AUG-2003; 2003US-0493573P.  
PR  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
PT  
XX  
XX Claim 1; SEQ ID NO 2918; 428pp; English.  
PS  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1125 AA;  
ADP30920 Length: 1125 February 22, 2005 12:25 Type: P Check: 6653 ..  
1 ATGCACAAG ACTGGTGGT CTTGTATGTG TCTGGAGAAC ACAAGAAGC  
51 CCTGTGTCAT GAGCTGCAGC TGTGTGACAG CACACTCAAG CCGGCTGCC  
101 ATGGACAGAC GCGACTTGT GACTTGTGCG TGAGTGAACA CAAAGCCCAG  
151 GGAACAGGTG CTCATGTCTA TGAGGAGAGA CACCAAGTGT CCGTCTCTCG  
201 AACAGATGAT GTGGGCTGCG TGGTCCGCTC CGAGTGCCTG CCGGGCCTGG  
251 GGGCCGAGGT CGGCTGCTCC AACATCGCCT ACCCCAAGCT GGTCAATGAA  
301 CTGATGCCCA TCGGTCTGGG GGGGCTGATG ATCGCAGTGA TGCTGGCGGC  
351 GCTCATGTG TCGTGAACCT CCATCTTTCA CAGCAGCAGC ACCCTCTTCA  
401 CTATGGACAT CTGGAGGCGG CTGGCTCCCC GCTCCGCGGA GCGGGAGCTC  
451 CTGCTGGTGG GAGCAGCTGG GATACCTTCA ACACCCCGAG CCGCTCAAG  
501 CCGTCTCAGC TTCTCTCTGC CCGAAACACC ACCATTGGAG CCGTATCTCC  
551 TAGGCCTCGT GGTCAATGAT CTCTGGCTGG TCATAGTGGC ACTCATCGGC  
601 GTGAGTGTGG CTTGATATCC CGTCTGACAG GACTCCNACA GCGGGCAACT  
651 CTTCACTTAC ATGAGTACAG TGACCAGCTC CTTGGGCCCA CCAGTGACTG  
701 CAGTCTTTGT CCTGGGCGTC TTCTGGCGAC GTGCCAACGA GCAGGGGGCC  
751 TTCTGGGGCC TGATAGCAGG CTGCTGGTGT GGGGCCNACA GGTGTGCTCT  
801 GGAATTCCTG AACCCAGCCC CACGTCGGG AGAGCCAGAC ACGCGGCCAG

851 CCGTCTCTGGG GAGCATCCAC TACCTGCAC TCGCTGTGGC CCTCTTTGCA  
901 CTCAGTGGTG CTGTTGTGGT GGCTGGAAGC CTGCTGACCC CACCCCCACA  
951 GAGTGTCAG ATTGAGAACC TTACTCTGGT GACCCCTGGCT CAGGATGTC  
1001 CCTTGGGAAC TAAACAGGT GATGGCCAAA CACCCAGAAA ACACGCTTTC  
1051 TGGGCCCGTG TCTGTGGCTT CAATGCCATC CTCCTCATGT GTGTCAACAT  
1101 ATTCTTTTAT GCCTACTTCG CCTGA

!!AA\_SEQUENCE 1.0  
ID ADP30924 standard; protein; 1134 AA.

XX AC

XX DT

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1691.

DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

OS WO2004035732-A2.

XX PN

XX PD

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406589P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 29-AUG-2002; 2002US-0406666P.

XX 17-SEP-2002; 2002US-0410945P.

XX 17-SEP-2002; 2002US-0410947P.

XX 17-SEP-2002; 2002US-0410949P.

XX 17-SEP-2002; 2002US-0410953P.

XX 17-SEP-2002; 2002US-0410957P.

XX 17-SEP-2002; 2002US-0410958P.

XX 17-SEP-2002; 2002US-0410959P.

XX 17-SEP-2002; 2002US-0410960P.

XX 17-SEP-2002; 2002US-0410961P.

XX 17-SEP-2002; 2002US-0410962P.

XX 17-SEP-2002; 2002US-0411019P.

XX 17-SEP-2002; 2002US-0411022P.

XX 17-SEP-2002; 2002US-0411023P.

XX 17-SEP-2002; 2002US-0411024P.

XX 17-SEP-2002; 2002US-0411032P.

XX 17-SEP-2002; 2002US-0411035P.

XX 17-SEP-2002; 2002US-0411037P.

XX 17-SEP-2002; 2002US-0411041P.

XX 17-SEP-2002; 2002US-0411045P.

XX 17-SEP-2002; 2002US-0411046P.

XX 17-SEP-2002; 2002US-0411048P.

XX 17-SEP-2002; 2002US-0411052P.

XX 17-SEP-2002; 2002US-0411055P.

XX 17-SEP-2002; 2002US-0411073P.

XX 17-SEP-2002; 2002US-0411082P.

XX 17-SEP-2002; 2002US-04110101P.

17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
15-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
08-AUG-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

XX Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;

XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2922; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX SQ Sequence 1134 AA;

ADP30924 Length: 1134 February 22, 2005 12:25 Type: P Check: 7005 ..

1 TTCCGACTCG ACTCATTACA TACCATCCTG CAACAGGAAG TCCTGTTACA

51 AGAGGATGTG GAGCTGATTG AGCTACTTGA TCCCAAGTATC CTGTCTGCAG

101 GGCAATCTCA ACAACAGGAA AATGGACACC TTCCAACACT TTGTCCTCTG

151 GCAACCCCTA ATATTGGGA TCTCTCAATG CTATTGCTT TCATTAGCTT

201 GCTCGTTATG CTTCCCACTT GGTGGATTGT GTCTTCCTGG CTGCTATGGG

251 GAGTGATTCT ATTGTGTAT CTGGTCATAA GAGCTTTGAG ATTATGGAGG

301 ACAGCCAAAC TACAAGTGAC CCTAAAAAAA TACAGCGTTC ATTTGGAAGA

351 TATGGCCACA AACAGCGGAG CTTTACTATA CCTCGTGAGA AAAGCTTTAC

401 GTCTCATTCA AGAAACCGAA GTGATTCCA GAGGATTTAC ACTAACCTAC

451 CCCCTGAAC CTGAGAGTGA CAATGTAACC AACTACATCT GTGTGGTGCC  
501 TTTTAAAGAG CTGGGCTTGG GACTTAGTGA AGACAGATT TCAGAAGAG  
551 AAGCACATAA CTTTACAGAT GGCCTTCAGCC TGCCTGCATT GAAGGTTTTG  
601 TTCCAACCTCT GGGTGGCACA GAGTTTCAGAG TTCTTCAGAC GGTTAGCCCT  
651 ATTACTTTCT ACAGCAAACT CACCTCCCTGG GCCCTTACTT ACTCCAGCAC  
701 TTTCGCCCTCA TCGTATCTTA TCTGATGTA CTCAAGTCT ACCTCATGCT  
751 CATCTCGCT GTTTGGAAGA GCTTAAGCGC AGCTATGAGT TCTATCGGTA  
801 CTTTGAACCT CAGCACAGT CAGTACCGCA GTGTTTATCC AAACTCAAC  
851 AGAAGTCAAG AGAACTGAAT AATGTTTACA CAGCAGTGG TAGCTTGCAG  
901 CTCATCTGA AAGCATTACT GAATCAGAAT TAGAAGCTTA TGTAGATGAT  
951 ATAGATATTG ATAGTGATTT CAGAAAGGAT GATTTTATT ACTTGTTCTCA  
1001 AGAAGACANA GAGAGACAGA AGCGTGAGCA TGAAGAAATCC AAGAGGGTGC  
1051 TCCAAGAAAT AAATCTGTG CTGGGATTTA AAGCTTCAGA GGCAGAAAGG  
1101 CAGNAGTGA AGCAACTTCT ATTAGTGAT CATG

## 11AA SEQUENCE 1.0

ID -ADP30957 standard; protein; 915 AA.

AC ADP30957;

XX 12-AUG-2004 (first entry)

DT Human secreted protein SEQ ID #1724.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.

OS Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 29-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406840P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 29-AUG-2002; 2002US-0406666P.

XX 17-SEP-2002; 2002US-0410946P.

XX 17-SEP-2002; 2002US-0410947P.

XX 17-SEP-2002; 2002US-0410948P.

XX 17-SEP-2002; 2002US-0410949P.

XX 17-SEP-2002; 2002US-0410953P.

XX 17-SEP-2002; 2002US-0410957P.

XX 17-SEP-2002; 2002US-0410958P.

XX 17-SEP-2002; 2002US-0410959P.

XX 17-SEP-2002; 2002US-0410960P.

XX 17-SEP-2002; 2002US-0410961P.

XX 17-SEP-2002; 2002US-0410962P.

17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-041101P.  
17-SEP-2002; 2002US-041111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

PS Claim 1; SEQ ID NO 2955; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX Sequence 915 AA;

SQ ADP30957 Length: 915 February 22, 2005 12:25 Type: P Check: 2327 ..

1 CTGGCGAGCG GCTCCAGGG CGACCGTGAG CCGGTGTACC GCGACTGCGT

51 ACTGCAGTGC GAAGAGCAGA ACTGCTCTGG GGGCGCTCTG AATCACTTCC  
101 GTTCCCGCCA GCCAATCTAC ATGAGTCTAG CAGGCTGGAC CTGTGGGAC  
151 GACTGTAAGT ATGAGTGAT ATGGGTACAC GTTGGGCTCT ACCTCCAGGA  
201 AGGTACAAA GTGCTCAGT TCCATGGCAA GTGGCCCTTC TCCCGTTCC  
251 TGTCTTTTCA AGAGCGGCA TCGGCCGTGG CCTCGTTTCT CAATGGCCTG  
301 GCCAGCCTGG TGATGCTCTG CCGTACCGC ACCTTCGTGC CAGCCTCTTC  
351 CCCATGTAC CACACTGTG TGGCTTGGC CTGGGTGTC CTCAATGCA  
401 GGTTCGTGC CACAGTTTC CACACAGGG ACACAGCTT CACAGAGAA  
451 ATGGACTACT TCTGTGCCTC CACTGTATC CTACACTCAA TCTACCTGG  
501 CTGGCTCAGG ACCGTGGGC TGCAGCACC AGCTGTGGT AGTGCTTCC  
551 GGGCTCTCCT GCTGCTCATG CTGACCGTGC ACCTCTCCTA CCTGAGCCTC  
601 ATCCGCTTCG ACTATGGCTA CAACCTGGT GCCAACGTGG CTATTGGCCT  
651 GGTCACAGTG GTGTGGTGG TGGCTGGTG CCTGTGGAAC CAGCGCGGC  
701 TGCCCTCACGT GGCACAGTC GTGTGGTGG TCTTGTGCT GCAGGGGCTG  
751 TCCCTGCTCG AGCTGCTTGA CTTCCACCG CTCTTCTGGG TCTTGGATGC  
801 CGATGCCATC TGGACATCA GCACATCCC TGTCACGTC CTCTTTTCA  
851 GCTTTCTGGA AGATGACAGC CTGTACCTGC TGAAGGAATC AGAGGACAA  
901 TTCAAGCTGG ACTGA

!!AA\_SEQUENCE 1.0  
ID ADP31114 standard; protein; 1288 AA.  
XX  
AC ADP31114;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1881.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-040585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-040666P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410948P.

17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPT; 2004-348438/32.  
DR  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3112; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX anti-inflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is

CC available on WIPWEB and is not in the specification.

XX  
SQ Sequence 1288 AA;

ADP31114 Length: 1288 February 22, 2005 12:25 Type: P Check: 658 ..

1 GCCAAGCTCC TTACCATGAG CAGACAAGCC AGCAAGACAT CTGGTGGCGG  
51 GAGCCAGGGT TTCTCCGGCC GCTCTGCTGT GGTCTCCGGC AGCAGCAGGA  
101 TGAGCTGTGT GGCCTACTCT GGGGAGCTGT GCGGAGGGGC CTATGCTTTC  
151 CGGAGCGGAG CAGGTGGCTT TGGCAGTCCG AGCCTCTACA ACCTGGCGGG  
201 CAACAAGAGC ATCTCATCA GGTGGCGAGC TGGCGGCTCC CGGGCTGGAG  
251 GCTTTGGGGG AGGGCGGAGC AGCTGTGCTT TTGCAGGTGG CTATGGAGGT  
301 GGCTTTGGTG GTGGCAGAGG AATGGAGGT GTTTGGAGG GGCTGGTGGC  
351 TTGGTGGTCT CTGGTGGCTT TGGTGGTCTT GGTGGCTTTG GCCTGGGGG  
401 CTTTCTGGG GGAATTCAGS AAGTGACTAT CAACCAGAGT CTCTGCAGC  
451 CCCTCAATGT GGAGATCGAC GGCAGATTG GGCAAGTAAA GGCCCAAGGAG  
501 CGMAACAGA TCAAGACCCT CAACAACAG TTTGCCCTCT TCAATTACAA  
551 GGAGCTGAAG AACATGGAGG ACCTGGTGGG AGACTTCAAG AAGAAATATG  
601 AGGATGAAT CAAATACGT ACAGCTGCTG AGATGAATT TGTGACTCTG  
651 AAGAAGGATG TGGACAGTGC CTATATGAAC AAGTGGAGC TTCAAGCCAA  
701 AGTGGATGCC TTGATAGATG AGATCGACTT CTTAAGGACC CTCTACGAGC  
751 CTTCAAGTAC ACATCTGTGG TGCTGTCCAT GGACAATAAT CGCTCCCTGG  
801 ACTTGGACAG CATCATTTGCT GAAGTTCTGT CACAGTATGA GGATATCGCT  
851 CAGAGAAGCA AGGCCGAAGC TGAGGCCCTTG TACCAGACCA AGTTGGGGGA  
901 GCTGCAGACC ACGGCTGGCA GSCATGGGGA TGACCTAAGA AATACCAAGA  
951 GCGAGATCAT AGAGCTCAAC AGAATGATCC AGAGCTTGGC GGCAAGATC  
1001 GAGGGTGTCA AGAAGCAGTA CCAGGAGCTG ATGAATGTCA AGCTGGCCCT  
1051 GGACGTGAGA TCCCCCAGG GCTTCCCTGG AGGCCGCCAT TGCAGATGCC  
1101 GAGCAGCGTG GAGAGCTGGC CATTAAGGAT GCCAAGGCCA AGTTGTCCGA  
1151 GCTGGAGGCC GCCCTGCAGC GGGCCAAGCA GGACATGGCG CGCAGCTGC  
1201 GTGAGTACCA GGAGCTGATG AAGCTCAAGC TGGCCCTTGA CATCGAGATC  
1251 GCCACCTTACA GGAAGTGTCT GGAGGGCGAG GAGAGCCG

!AA SEQUENCE 1.0  
ID -ADP31228 standard; protein; 582 AA.

AC ADP31228;

XX  
DT 12-AUG-2004 (first entry)

XX  
DE Human secreted protein SEQ ID #195.

XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.

XX  
OS Homo sapiens.

XX  
PN WO2004035732-A2.

XX  
PD  
XX  
PF 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486452P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.



XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3226; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 582 AA;  
ADP31228 Length: 582 February 22, 2005 12:25 Type: P Check: 7949 ..  
1 ATGGCATGGA AGCCCACTT CCACAAGGAC TGSCAGCTGG CTCGTGGCCA  
51 CATGTTTCAA CCAGCGGGCC GGAAGATCCG CAGATCGAAG GCCGGGCAAG  
101 CTAAGTGGCC CCACATTGCC CTGCACACCG CGTTGGGACC CATCCGGGCC  
151 ATCGTGTGTT GCCGCACAGT GCGAATAC ACCAAGTGC GCACCGGCGG  
201 CAGCTGCAGC TTGAGGAGC TCAGGGTGGC TGGCATTCAC AAGAAGTGG  
251 CCCAGACCAT TAGCATCTCT GTGGATCCAA GGAGGCAGTA CGAGTCCACC  
301 GAGTCCCTGC AGGCCAAGT GCGGGGCTG AGGAGCACC ACTCCAACCT  
351 CACCTCTTAC CCGAGGAAGC CTCGGGCCAC CAGGAAGGGA GACAGTTCTG  
401 CTGAAGAAT GAAACTGGCC ACCCAGCTGA CAGGACCGGT CATGCCCATC  
451 CCAACGTTT GTAAGAAGA GAAAGCCAA GTCATCACCG AGGAGAAGAA  
501 TTTCAGGCC TTCGTAGTC TCACATGGT CCATGCTGAC GCCCGGCTCT  
551 TTGGCATACC GGCAAGAGA CAAGGAAGCT GA  
!!AA\_SEQUENCE 1.0  
ID\_ADP31250 standard; protein; 453 AA.  
XX  
XX ACP31250;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2017.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR

29-AUG-2002; 2002US-0406579P.  
29-AUG-2002; 2002US-0406585P.  
29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493373P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.  
DR  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX  
PS Claim 1; SEQ ID NO 3248; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 453 AA;  
ADP31250 Length: 453 February 22, 2005 12:25 Type: P Check: 2456 ..  
1 ATGAGGCAAG AAGTTCAGAA TCAAGTGAAG GGGGAAGACA CAAGTGAAGG  
51 CCCTGATCCC TGGATGCCTG TCAGTCAATC CGTCCCGCCT CTCGGACCC  
101 GCCCGGCGG CGGCGCGGAT CCCGAGAAC AGCCGGCCCG CGCACTCACT  
151 GGTGCTCATG CGCTGTCTGT CATGAAGCTG GCCACACCTT CCATGGGGTG  
201 CGGTCTCTGG GAGTCTCTGG TGGACCTCAT TGGCTTGTGG CGCCTTCACT  
251 CGGAGACG CGCCTCAAC CGGAAGTGTG CGAGCGGAAA TCTGCCTAGC  
301 AACCGGGGAA GCGGGCTGT GAAGCGGCA ATTTCACTCG GCGCGCGCGG  
351 GCGCACCTG AGGGAGTCTG CTCGCGGGA CGCCACAAGA CTGACCGGA  
401 CTGCGCGGCC CGAGGCGGTC GGCCCGGTC AGCGAGGCGG CGAGCACT  
451 TCG  
!!AA SEQUENCE 1.0  
ID ADP31259 standard; protein; 4848 AA.  
XX  
AC ADP31259;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #206.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.

29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463718P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471308P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486466P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3257; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule

CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

XX  
SQ Sequence 4848 AA;

ADP31259 Length: 4848 February 22, 2005 12:25 Type: P Check: 9146 ..

```
1  ATGGAGGTGA AAGAGAAATGG GCCTGGGACC GGTTCCTTTG ACACATGGGTT
51  GCCCACTGGC AGATGTAGAA GTACAGAGAA GTTAAAGTAA TTAGCAAGA
101 TTTACACAGT ACCCTGCGC GTGGTCCCCA AGGTCCGCCT GGATGGGCA
151 CTGGACAGT CTCAGGCCG GCCTCCTGGT TCAGGTCTGG GAGACTGGT
201 GGAGGCAGCG GGGTTAGCTA AACCATAGA CAGCAGTGAC ATGAAGAAG
251 CAGGTAGAGA TGAACCTCG GACCCACCTG CTGGCTGCCT ACTCTCAAC
301 CCGCTGCCCT TCCGGGGCAT CTGGTGCAAC ATGAGGAGCA CTGGACTGGG
351 AGTCAGCCTC CTCATCTGCC TCTCTCGGG CTTCTACTTA CACTGTGACG
401 ATGTGGCTTG GGAGGGCGTG GGTCACTTCT TCCACGAATT GGCCGAGGAG
451 AAGCGAAGG GTGCCTTAAA GATGCAAAAC CAGTATGGCG GCTGCATTCT
501 CTTCCAGGAC ATCCAGAAAC TGGCCCCAAT TGAGTTAGAT AAGACCTCTG
551 ACACGGCTGG ACGCGGATGG GTTCTCCGC AGCGAGGAA AGAGATGGC
601 GACCTCTGCG ATGCGGGAGT CAGAGAGGAA CGTGGCTACG AAAGCCTCGG
651 GCAGCCCGCC GATCAGATGG AGGAGAACGA GGTGGAGAGC AGCAGCGACG
701 CGGCCCTTGG GCCTGGCCGG CCGGAGAGC CCTCTGAGAG CGGCCTGGGT
751 GTGGGACCTC CAGAAGCCGT GTCCGCCGAC AGCAGCGACG CCGCGGCCGC
801 CCGGGGCGAG GCAGAGCGCG ATGACTCTGG CBTGGGGCAA AGCTCGGACC
851 GCGGCAGCGG TTCTCAGTA TGGNCCCGGC TGGACGGCGT GGGTGGAGGC
901 AAGGACCGGG AGCAGCAGTG CTTGACAGCC AAGAGGAAAC AAGGCTTGT
951 TGTAGCTAAT ACTTGGTGT TCTGGTTTAC TGAGGAGGTA TCTGAGACA
1001 GCTCAGCGC AGACCCCTG CTTAATAGCT ACCTCCCTGA TTCATCGTCT
1051 GTGTCTCATG GGCCAGTGGC AGGGGTGACA GCGGTGCCCC CAGCACTTGT
1101 GCACCTTAGT GCACCTCCAG ACCCAACAT GCTGGTGTCC GACTGCACAG
1151 CTTCTCTCTC GGACTTGGG TCGGCCATCG ACAAGTATAT CGAGTCCACC
1201 ATCGGGCCCG ACCTCATCCA GAATCTGATC ACTGTGACCA GTGCTGAGGA
1251 TGGCGGGGCC GAGACCACAC GGTACCTGAT CCTACAGGCG CCAGATGATG
1301 GAGCCCCCAT GACATACCA ATGTCCAGTT CCACCTTGGC CCACAGCCTA
1351 GCAGCCATTG AGGCCCTGGC AGATGGCCCC ACATCCACAT CCACATGCCT
1401 GGAGGCACAG GGTGGGCCCA GCTCCCCGGT GCAGCTGCCC CCAGCCTCGG
1451 GTGCCGAGA GCCGACCTG CAGAGCCTGG AGGCCATGAT GGAGTGGTG
1501 GTGGTGCAGC AGTTCAAATG CAAGATGTGC CAGTACCGGA GCAGACCAA
```

```
1551 GGCCACACTG CTGCGCCACA TGCGGGAACG CCACCTTCCGT CCAGTAGCAG
1601 CAGCCGCGAG AGCAGCTGGT AAAAAAGGAC GTCTACGGAA GTGGAGCACC
1651 TCCACCAAGA GCCAAGAGGA AGAGGAGCCA GAGGAGGAGG AGGATGATGA
1701 CATTTGTAGC GCTGGAGCCA TTGATGACCT GGAGGAGGAT AGCGACTATA
1751 ATCCAGCTGA GGATGAGCCC CGAGGCCGGC AGCTTCGGCT CCAGCGCCCC
1801 ACCCCAGTA CCCAAGGCC CCGAAGAGA CCTGGCCGCG CCGGAAGCT
1851 GCCCGCCTG GAGATCTCAG ACCTCCAGA TGGTGTGGA TGGAGCCCTC
1901 TAGTGAGTTC CCAGATGGA CAGAGCCCTC CAGAGCCACA GATCCCGAG
1951 GCTCCAGCT CCTCAGGCC AGGACACCTG GTGGCCATGG GGAAGGTGAG
2001 CAGGACCCCT GTGGAAGCTG GTGTGAGCCA GTGATGCA GAGAAGCAG
2051 CCCCCTCTG CCGGATGAG CATGACACTC TGCCCCGGCG CCGAGGTGGA
2101 CTTCCAGGC GTTCTCTAGG CAAGAAATAC CGAAAGTATG TGGAGCAGAG
2151 GTACTATTAC AAGTCGCCA AACCACTTTT GAGGCCCTTC CTGTGCCGA
2201 TCTGTGGTTC TCGCTTCTG TCCACAGAG ACCTGGCTT CCACGTCAAC
2251 TCCCATGAGG CTGGCGATCC CCAGCTCTTC AAGTGCCTGC AGTGAGCTA
2301 TCGTTCCGCG CGCTGTCTT CGCTCAAGGA GCACATGTTT AACCACTGG
2351 GCAGCAAGCC CTACAAGTGT GACGAGTGA GCTACACCAG TGTCTACCGG
2401 AAGGACGTCA TTCGGCACGC CGCTGTGCAC AGCCGGGACC GGAAGAAGAG
2451 GCCAGATCCG ACTCCAAAGC TGAGCTCTTT CCCCTGCCCT GTGTGTGSCC
2501 GTGTGTACCC CATGCAGAA AGACTCACGC AGCACATGAA GACGCACAGC
2551 ACTGAGAAGC CCCATGTGT TGACAAAGTGT GGAAGTCTCT TTAAGAAGCG
2601 CTACACCTTC AAAATGCACC TGCTCACGCA CATCCAGGCT GTTGCCAAAC
2651 GCAGTTCAA GTGTGAGTTC TGTGAGTTG TTTGTGAAGA CAAGAGSCA
2701 CTGCTGAACC ACCAGTTGTC CCACGTGAGT GACAAGCCCT TCAAAATGAG
2751 CTTTGTGCC TACCGCACCT TCCGAGAGGA CTTCTTGCTG TCCCATGTGG
2801 CTGTCAAGCA CACAGGGGCC AAGCCCTTCG CTTGTGAGTA CTGCCACTTC
2851 AGCACACGCG ACAAGAAGAA CTTGCGCCTG CACGTACCGT GCCGACAGCG
2901 AAGCAGCTTC GAGGAATGGG GGAGGGGCCA CCCTGAGGAG CCCCCTCCC
2951 GCGTTCGCCC CTTCTTCTCT CTGCAGCAGA TTGAGGAGCT GAAGCAGCAG
3001 CACAGTGGCG CCCCTGGACC ACCTCCAGT TCCCCAGGAC CTCCTGAGAT
3051 ACCCCAGAG GCGACAACCT TCCAGTCAATC TGAGGCTCCC TCATTGTCTCT
3101 GTTCTGACAC CTTGGGGCGG GCCACCATCA TCTACCAGA AGGAGCTGAG
3151 GAGTGCACAG CGATGGCCAC GCAGACAGCC TTGGATCTTC TGCTGAACAT
3201 GAGTGTCTAG CCGGAACCTG GGGGCACAGC CCTGCAGGTG GCTGTGGTGA
3251 AGTCGGAAGA TGTGGAAGCA GGGTTAGCAT CCCCTGGTGG GCAGCCCTCC
3301 CCTGAAGGTG CCACTCCACA GGTGTGTACC CTCCACGTGG CAGAGCCAGG
```



PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3274; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 849 AA;  
SQ  
ADP31276 Length: 849 February 22, 2005 12:25 Type: P Check: 5171 ..  
1 ATGGAGCAGG GGGGGGGGCT GTTCGGGGAG GTCAGGGCAT GGCCGACTGC  
51 AGGTCAGGCG AGAATTCGAG CACAGCAGCT GCTGGCCCCAG GGTGAACAGG  
101 TCGGAAGTGC GCTGGAGCA TCCGGCCAGC GGCCGAGCGC GGGGACATG  
151 GAGAGGGAGC GGCACATGTA CCGCCAGTTC CAGGACTGGT GCCTCAGGAC  
201 TTACGGGGAC TCAGGCAAGA CCAAGACGGT GACCCGTAAG AAATACGAAC  
251 GGATCGTCCA GCTCTCAAT GGCTCCAGT CGAGCTCCAC GGACACGCC  
301 AAATTAAAT TCTGGGTCAA ATCGAAGGC TTCCAGCTGG GCCAGCCGGA  
351 CGAGGTCCCG GGGGAGGCG CGCGGCCAA GCAAGTGCTC TACGTGCGCTG  
401 TCAAGACCAC GGTGAGTAC TCGCTTCCT CTGTTATTG TCTGCGGAG  
451 CAGCCCGGCG GGGAGGGAGG AAGGAGAG GCGGGAGAGA GGGGAGCGG  
501 TGAGCCGCGG TTGGTCGTG TGCCCCCTAC CTTCTCTAAC CCCCTCCCA  
551 AGTCGTCCC ACTCGATTA GCCAGGCGG TTTTCCCCAC TGTACAGTCT  
601 TTGTGCTCT TTAATTTAA CGCGCAGCG ACCTCCAGAG CTGGCCTCCC  
651 TCCCGCGCTC GGGTTCCCG ACCGGTGCA GGAGCTTCCT TCCCGGGTTC  
701 GGGCGGCGG GTCTGGCGTC CTGGGGCTGG GCCATTGTCC CATGTCTTC  
751 TCTGGCGGC TGGCGGTGT CCCACGCGG CCACCGCGC TAAAGGCCAG  
801 GCTGAAGCC CGGCGGCAG CTCGAGAGC AGACGAGTCT GATCGATAG  
!!AA\_SEQUENCE 1.0  
ID\_ADP31303 standard; protein; 900 AA.  
XX  
XX ADP31303;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2070.  
XX  
XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR

PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3301; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 900 AA;  
ADP31303 Length: 900 February 22, 2005 12:25 Type: P Check: 3085 ..  
1 ATGGGGGTCC GGCACATGCA CACAGCCAGG CTTGCTGGCT GTGGCAGAGC  
51 AGGCGCGCCC CAGGTGCCAG CAAGGTTGCT GTCTCCCTGC AAGGCTGCAG  
101 CTGGACCAGG CCTACCACAA CGAGCTTCCA TGACTGGCAC CAGGGACAC  
151 AGTGGTACCC AGAACTTGG AAACACCAGG CAGAGCCCTA AAGAGGCTCT  
201 CAGCAGAGAG GGTGACTCCT CTCTGCAGCT GGTCATCCCA TTATCTCTTT  
251 GGGTCCGGCT GACTATGGG CTTTATGGG CATTAGAGG GAGGAAGTTC  
301 ATGCCAACTG GTCCACGGG AGCCATTGGC AGGCGTGGAA AAAGCAACAG  
351 TTCCCACTCT GGTCCACAGG ATCAGCAGCT CGGCCCCCGC GCTCCAGGCC  
401 TTCCCTGGCT TGAAGAAGGA GCAAGGCTCC CACTTGTCCA TGGCTCCAC  
451 TGGCTCCATG GAGTGACAG CCCTGGCCAC ATTTTCCCCA CAGCAACAGC  
501 AGGTGAGGTG CAGGTGATGC CACACCCCTGG CCAACCGGCAC ACAACAAAT  
551 TCGATGTCTC CAGCGTGGC TCCCCACTCG TGCTGGCCACC ACCTGACCT  
601 CCCCACTGGG GCCAGCATGA CGGCAGTGGC TGCTTCAGAT GGCCTACTGC  
651 TGCCATCAAT AGCGCGCGCC GCCAGACCG GACCCGGAGC CGCATGCCCC  
701 AAGTGCCCCA AGTGCCACAA GGAAGTTTAC TTCCCGGAGA GGGTGACCTC  
751 TCTGGGCAAG GACTTGCCCT GGCCTTGCTT GAAGTGGCAG AATGTGGGAA  
801 GAGCTGACC TCGAGGGGCC AGCGTGAGCA CGAAAGCAAG CCTACTGCA  
851 ACCACTTGCT ATGCCGCCAT GTTTGGGCAA AAAGGCTCTG GCCGGGGTGA  
!!A SEQUENCE 1.0  
ID ADP31350 standard; protein; 306 AA.  
XX

AC ADP31350;  
XX  
XX 12-AUG-2004 (first entry)  
DE Human secreted protein SEQ ID #2117.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.

PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3348; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antineoplastic, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 306 AA;  
SQ  
ADP31350 Length: 306 February 22, 2005 12:25 Type: P Check: 7643 ..  
1 ATGGACGTGT TCCTGCTGAT CCGCGGCCAC AAGACCACCA TCTTCACTGA  
51 CCGCAAGGAG TCCAGCACGG TGTTGAGCT GAAGCGCGTC GTGGAGGGAA  
101 TCCTCAAGCG GCCGCCGCAC GAGCAGCGGC TGTACAAGGA CTACCAACTC  
151 TTGGATGATG GCNAGACACT GGGCGAGTGT GGTTCACCA GCCAACCGC  
201 ACGGCGCAGG CCCCAGCCAC AGTGGGCGTG GCCTCCGGG CACAGCAGCG  
251 CTTTGAGGCC CTGTGCATCG AGCGTTCTC CAGCCCGCCC GAGCTGCTCG  
301 ACGTGA  
!!IAA\_SEQUENCE 1.0  
ID ADP31361 standard; protein; 615 AA.  
XX  
XX ADP31361;  
AC  
XX  
XX 12-AUG-2004 (first entry)  
DT  
XX  
XX Human secreted protein SEQ ID #2128.  
DE  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX  
OS Homo sapiens.  
XX  
XX WO2004035732-A2.  
PN  
XX  
XX 29-APR-2004.  
PD  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
PF

XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3359; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 615 AA;  
ADP31361 Length: 615 February 22, 2005 12:25 Type: P Check: 6006 ..  
1 ATGCTGGAGA AGCAGGGCCC GGGCCCGGTG CGGGAACGGG GAGGAGTGGT  
51 TGTGTCCTTA GCAACTAAG CTGGCAACTG GGACATGTC CGTGCTGCA  
101 GGTCTCAGCC GAAGGGCGTC GGAAACTGGG CTCGCATCGA GCAGTTTCCA  
151 GCCTCCTGGG TAAAGGACGA GTCCTCTCC TTGCTTGGG CTCGGACGC  
201 ATCTCATTC GGTGAAGAG ATGGGGGCTG CGGTACTCG CGGGATCAGG  
251 AATTTCAGA GAACCGAGCG GAAGGGGAAA TCCGAACAT GAAGCCCTCT  
301 CTCGCTCCA GGCACCCCTC TACCAGCAGC CTCCTGCCAG AGCAGATTAG  
351 TCTCTATCCA GAATTAAGG GAGAGATTGC TCGTAAGATG GACAAGTGC  
401 TGTCAATTCT AAAATATGTG TGTGTTGATT CCAAAGATCC TGTGCTCTCC  
451 GTGCAGCTGA AAGCTGCTGA AACAGCTCAG GAGCAAGA AATTCAGATT  
501 GCCGAAAGGC CATCATTGG ATATGATATA TATTAAGAGC ATTCCCAAG  
551 GCAAAATTTT CACTGTAGAA GCATTGACAC TTTTCAATAA TCATAAATTT  
601 TATCCAGAAA CATGA  
!!AA SEQUENCE 1.0  
ID \_ADP31401 standard; protein; 263 AA.  
XX  
AC ADP31401;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2168.  
DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
PN  
XX 29-APR-2004.  
PD  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR

29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.



XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3399; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 263 AA;  
SQ  
ADP31401 Length: 263 February 22, 2005 12:25 Type: P Check: 2174 ..  
ID 1 TCGCGCGCCG CACGCCCGCG ACGCTGTCCA GCGTTGCCG CCTGAGCAGA  
XX 51 GCGTCCGCGG GAGCTAAGAC ACCGCCGTT TCACCCAGCC AGCGGGCCCA  
AC 101 GCCCGCGGAG GAGGGCGGCA TGCAGCTCCG CGTTGCCCTGG CTCTCGGGGC  
XX 151 ACGCGGGGCTA CGATCTGTAC AGTGCCTGTG ATTACACACC ACCACCTATG  
DE 201 GAGAGGCTC TTGTGAACAC GGACATTCAG ACAGCGCTTC CTTCTGGATG  
XX 251 TTATGGAGAG TAG  
!!IAA\_SEQUENCE 1.0  
ID ADP31420 standard; protein; 204 AA.  
XX  
XX ADP31420;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2187.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406618P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406658P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX

PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3418; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 204 AA;  
SQ

ADP31420 Length: 204 February 22, 2005 12:25 Type: P Check: 267 ..  
1 ATGGGTAAAG GAGTGTGGC GATGCTCAT TTGGGTCTGC TACTTCTGGC  
51 GCTGCTCCTA CCGTGCAGG TTCTTCATT TGTTCCTTTA ACCAGTATGC  
101 CGGAAGCTAC TGCAGCGGAA ACCACAAGC CCTCCAACAG TGCCCTACAG  
151 CCTACAGCG GTCTCTTGT GGTCTTGCTT GCCCTTCTAC ATCTTACCA  
201 TTAA  
!!AA SEQUENCE 1.0  
ID \_ADP31423 standard; protein; 177 AA.  
XX AC ADP31423;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2190.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406855P.  
PR 29-AUG-2002; 2002US-0406866P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.

PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471308P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3421; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 177 AA;  
SQ  
ADP31423 Length: 177 February 22, 2005 12:25 Type: P Check: 5997 ..  
1 ATGGACATGA TGCTTTGGT GCAGGGTCT TGTGTCTGA ACCAGTGGCT  
51 GGGGGCGGTG CTCCTCAGCC TGTGCTGCCT GTTACCTCC TGCCTCCCGG  
101 CTGGACAGAG TGTGACTTC CCTGGGCGG CCGTGGACAA CATGATGGTC  
151 AGAAAGGGG ACACGGCGGT GCTTAGN  
!!AA SEQUENCE 1.0  
ID \_ADP31491 standard; protein; 1596 AA.  
XX AC ADP31491;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2258.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;



1001 TCATGCCAAA GAGCGTCAAC CGGGAATGTG TCTTCTTTCT TGAATAACGT  
1051 TATGGATCAG CAGGAGACCC CCTAAGACC CCAGCAATGA AGTCGCTTG  
1101 TAGCCCCGCA CACAGTAACC CAGAAACATA TGTGACGAGG TCTGGATTAC  
1151 ATGCAGTGAA CGTCTGTAGC CATGCTGGG ACCAGGACCT CTTTGGAGAG  
1201 TCCACACTAG GGACAGAGAG CACCTTGAAG ATTTCAAGT TTCTTTTCAG  
1251 TCAAGGCCAA ATCATGCAAA ATATTTTGTT ACCTGTTGAT GAACTCACGG  
1301 GATTTAACGC TGTGGCCTCT TTATCACAGA GAAAGGCGTT TTGGCCAGCT  
1351 CCCTGCATCT CTGACCCCTAG GCGGTGTGGA TCTGGAAGAA ACAGGGAATA  
1401 TTACCATCTT CTCCAAAGAT GTAAAGCCT GGAATAATTG CCGAGGCTG  
1451 GGAGTGACTC CAGCTGCCAA GCATCTCCAT CTCCAGTGT CCAATTTTIG  
1501 GCAGCCTCGG GGGAGATGGG AGCATGCAGA TGGAAATGTGA GGTCTGTGTC  
1551 CTCAATGCCT CATCTCAGTG CACTGAGGAG ATGTCAAAGTC CCCTAG  
!  
!1AA SEQUENCE 1.0  
ID \_ADP31533 standard; protein; 1260 AA.  
XX AC ADP31533;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2300.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.  
XX PR 17-SEP-2002; 2002US-0411023P.  
XX PR 17-SEP-2002; 2002US-0411024P.

17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 3531; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic.  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPWEB and is not in the specification.  
Sequence 1260 AA;  
ADP31533 Length: 1260 February 22, 2005 12:25 Type: P Check: 3976 ..

1 ACAATGGCCA AAAAGATTGC TGTGATTGGA GCTGGGAATTA GCGGACTGGG  
51 GGCCATCAAG TGCTGCCTGG ATGAAGATCT GGAGCCCAACC TCGTTTGA  
101 GAAATGATGA TATTGGACAT CTCTGGAAT TTCAAAAAA TACTTCAGAG

151 AAMATGCCTA GTATCTACA ATCTGTGACC ATCAATACATT CCAAGGAGAT  
201 GATGTGCTTC AGTGACTTCC CTGTCCCTGA TCAATTTCCC AACTACATGC  
251 ACAAATCCAA ACTCATGGAC TACTTCGGGA TGTATGCCAC ACACITTTGCC  
301 CTCTGAATY ACATTCGTTT TAAGACTGAA GTGCAAAAGTG TGAGGAAGCA  
351 CCAGATTTT TCTATCAATG GACAATGGGA TGTGTGTTGT GAGACTGAAG  
401 AGAAACAAGA GACTTTGGTC TTGATGGGG TCTTAGTTTG CAGTGGACAC  
451 CACACAGATC CCTACTTACC ACTTCAGTCC TTCCCAGCAG GCATGAGAA  
501 ATTGAAGGC TGTATTATCC ATAGTCGGGA ATACAAAAGT CCCGAGGACT  
551 TTTCAGGGAA AAGATACATA GTGATCGGCA TTGGAAATTC TGGAGTGGAT  
601 ATTGCGGTG AGCTCAGTCG TGTAGCAAAA CAGATATTC TTAGTACTAG  
651 ACGTGGATCA TGAATTTTAC ACCGTGTTTG GGATATGGG TATCCCATGG  
701 ATAGTTCAAT TTTCACTCGG TTCATAGTT TTTCTCCAGAA AATACTAAT  
751 ACACCACAAA TAAATAACCA GCTAGAGAAA ATAATGAAT CAAGATTTAA  
801 TCATGCGCAC TGTGCCCTGC AGCCTCAGCA CAGATGTCAG CATCCAACTG  
851 TCAGTGATGA CTGCGCAAT CACATATTT CTGAAAAGT CCAAGTAAAG  
901 CCAGCGTGA AGGAGTTCAC AGAAACAGAT GCCATTTTTG AAGACAGCAC  
951 TGTAGAGGAG AATATTGATG TTGTCACTTT TGCTACAGGA TACAGTTTTT  
1001 CTTTTTCTTT CCTTGATGGT CTGATCAAGG TTAATAACAA TCAAGTATCT  
1051 CTGTATAAGC TTATGTTCCC TCCTGACCTG GAGAAGCCAA CCTTGGCTGT  
1101 CATCGGTCTT ATCCAAACCAC TGGGCATCAT CTTACCTAAT GCAGAGCTCC  
1151 AATCTCGTTG GGCTACAGCA GTGTTCAAAG CTGATCAAT TACCCTCAGC  
1201 GGAGAACATG ATGCCAGATA TTGCCAGAG GAAAGGGCT ATGGAAAAAC  
1251 GATATGTAAA

## IIAA\_SEQUENCE 1.0

ID ADP31587 standard; protein; 1358 AA.

AC ADP31587;

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2354.

DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

KW Homo sapiens.

OS Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases

such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

genetic, bacterial and viral diseases.

XX PS Claim 1; SEQ ID NO 3585; 428pp; English.  
XX CC The present invention relates to an isolated nucleic acid molecule  
XX CC encoding a polypeptide which is believed to be cytostatic,  
XX CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX CC composition and methods are useful for diagnosing, preventing and  
XX CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX CC immune, metabolic, genetic, bacterial and viral diseases. The present  
XX CC sequence represents a human secreted protein. The present sequence is  
XX CC available on WIPOWEB and is not in the specification.  
XX SQ Sequence 1358 AA;

ADP31587 Length: 1358 February 22, 2005 12:25 Type: P Check: 1874 ..

1 AGGTGGCGGG CTCTGGGACC CTGCGAGGCA GCGCCGGTCA ACCTTGGGA  
51 CCCAGCCTGG GATCCCTTAC CGTACTCACC GAGAGCTTGA GGAGACCTCC  
101 AGCCCCCAT CCTGTGCTCC CGGTAACTGC TGTTCCTTT TGCCCTTGCA  
151 GATGGACGGG ACAGAAAGCA GTGCGGGCA GCCCGGCCCC GTTGAGCGAT  
201 CCCACCGAAG CAGCGTGTCC TCCGTGGGAG CCCGAGTCAG TGCCCATGAG  
251 CTGCACCGCG CTGTCCGCGA GGTCTTGAG CTTCAGACA TGCCCTTGA  
301 TGTCTTCGCG CTCTGGCTGG TCTCCCTCTT GAGAGGTGCA GTTGAACCC  
351 AAGCACCAGC CTTACAAGCT GGGAGCCGAG TGGCCGGAGC TGCTGTGGG  
401 CTTCCACAGT GCCCAGATG ATGAGCTGGC CATGAGTAG CTTTCTCTG  
451 AGTTCGAAAG GAACGTGTTT TTCCCAAAG GCGGGAGCT CCAGATCCAT  
501 GACGAGGAG TCCTGCGGCT GCTCTATGAG GAGGCCAAGG GCAACGTGCT  
551 GGCTGCACGG TACCGTGGG AGTGGAGGA CTGCGAGGCT CTGGGCGCCC  
601 TGTGTGTCGG CGTGCACTTT GGGCCCTTACC AGCCCGGCCG GCGCGAGCC  
651 TGCACCTCTA GGGAGAAGCT GGAATCTTTC CTCCCTGCC ACCTCTGTAA  
701 GCGGGGCCAG AGTCTCTTGG CTGCCCTCCG GGGCGGTGGG GCCAGGGCCG  
751 GCGCGGCGCA GCAGGCGCTG CTGAACGCTT ACCGCCAGGT GCAGGAGGTC  
801 AGCAGCGACG GCGGGTGCGA GCGCGCCCTG GGCACCCACT ACCGCGCTA  
851 TCTCTCAAG TGCCACGAGC TGCCGTTTGA TGGGTGTGCC TTCTTCCAG  
901 GTGAGGTGTA CAAGCCGGCC CAAGGCTTTT TGCACCGGGG TGGCGCAAG  
951 CCAGTCTCTG TGCCCATCAG TCTGGAAGC GTGCACGTCA TCGATAGCAG  
1001 AGAGAAGCAT GTCTCTCTGG GCTCTGGCTT CCAGGAGCTG TCGTGGGACC  
1051 ACACCTCCCC CGAGGAGGAG GAGCCCATCT TGTGGCTGGA GTTTCAGGGG  
1101 GACAGCGAGG GCACACCTGT CAACAAGCTC CTCAAGATCT ACTCCAAGCA  
1151 GGTAGCGCAG CGCCCCAAGC TCGGAGGCA GGGCAGTGTG GTGTCCAGCC  
1201 GGATCCAGCA TCTCTCCACC ATCGACTACG TGGAGGACGG CAAGGGGATC  
1251 AGGCGAGTGA AGCCGAAGCG CACCACATCT TTCTTCAGCC GGCAGCTGTC  
1301 CTGCGGCCAG GGGAGGTACA CCGTGTGCA GCCCGGCGAC AGCCTGGAGC  
1351 AGGCTGA

! IAA\_SEQUENCE 1.0

ID XX ADP31591 standard; protein; 5514 AA.  
AC XX ADP31591;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2358.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-047240P.  
PR 22-MAY-2003; 2003US-0472430P.

PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PA  
XX PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX PI  
XX DR WPI; 2004-348438/32.  
XX  
XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX PT  
XX PS Claim 1; SEQ ID NO 3589; 428pp; English.  
XX PS  
XX CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX CC  
XX SQ Sequence 5514 AA;  
ADP31591 Length: 5514 February 22, 2005 12:25 Type: P Check: 1415 ..  
1 ATGCCGCCAG ACCATCATGT AGCGGTGGAC ATGCTGGCTT TAGCTAATGC  
51 TGTGTTTGCAA GCTGTGAATT CGGGGTTGTT GAAGACACTG TCTGTTTATG  
101 AAAACATTTC CTTTTTGGG GGTGATGNAG TTCAACTGTA ATGTGAACTT  
151 ATCCTAGTGC CAGATCATGT GATCCTTAGA GCAGCAAGCT TAGTTATAAT  
201 GAAATCCTTA GAAATCAAAG TTCAAAATTA TTCTTCAGCA AGTGAAGTGA  
251 AAGTTGACTT ACAGAGGTTT ATGCTGAGT TACTGACCTT CTTAAGCCTT  
301 CATCTTCAGC CCTCTCTGCA ATTACAAAT CCGTGCAAAAT GGCTGTCTCG  
351 GGTGTTTCATA GAACAAGACG ATGACATGCT GGAGGCTGCC AAGGCATCAC  
401 TGGGCATCTA CTTAACAATG ACCAGAGAT GTGAAGCCAC TGAAGCTTTG  
451 ACTCAGGAAA AAGAAATGTG GGACCATCAC ACACATGAAA ATGGCTATAA  
501 TCTCACTGT ATTTTCTTGT TCTTCTTGA AAATATAGGA TTTGATTCCA  
551 CAGTTCTTCT TGACTTTTGT ATTTTCATCAG AAACCTGTTT TCTTGAATAT  
601 TTTGTTAGAT ATTTAAATTT ACTGCAAAAG GACTGGGATA ATTTTTCAC  
651 CATTTGCAAT AACTTTTGATG CAACTGAATC TAAATATGAC ATAAGTATTT  
701 GTGGCTGTGT CCCCTCACTT GTCCAAGACC AAAGCTCCAA CCAACAATA  
751 CCCCATCGTT TGACTGTCTC TCATAGTCAC AGAGATGTGT GTGCTCGGCA

801 CTCCTGGGCT TCCGATGCTC CCTCTGAACC ACTGAAAGCT GTGATGTCCA  
851 AGGGGGCTCA CACCATGTGT GCTTCTAGTC TGTCTTCCCC CGGGSCCTCT  
901 CAAAGTCTGG TAGATTACGA CAGTCTGAC GATTCTGAGG TGGAAATCCAC  
951 AGAGCAGTGT TTAGTAAACA GTAAACAGAC ATCTTTTACAC CAGCAAGCAA  
1001 CTAAGGAGAT TCAGGATGCA GCTGGGACAA GCAGGGGATAA AAAAGAAATTT  
1051 AGCCTTGAGC CTCATCAAG GCCTCTGGTT CTGAAAGAAT TTGATACTGC  
1101 CTTCTCCTTT GATTGTGAAG TAGCCCCAAA TGATGTCTGC TCTGAAGTGG  
1151 GAATATTTTA CAGAATAGTA AAATGCTTCC AGGAACCTACA AGATGCCATC  
1201 TGCCTTTTGC AAAAGAAAAA TCTTTTCCCA TATAATCCAA CTGCACTTTT  
1251 GAAGTTGTTA AAATACATAG AGACACCCAC TAACACAAAG AAAGAGGCCA  
1301 AATCAACAGC AACAGACAC ATGGGACAA AATGGAANAG GAGNAACAAA  
1351 TTTTGAAGC TCAAGACACA GCGTGGCATC CAGCAGAGAG TTAGAAATGC  
1401 TCTGTTGGAA ATTAGAAGGA CAGAGCCAAA TATGAGTCAT TTGTGTACAA  
1451 GTATTATGAA AATCGTAGAA GAAAGTGTGA TTGCGCTGAG AGTGAGAGA  
1501 GAAAGGGCTG CGTCCCGGGA AGCCCGGCTA CCGGAGCGCT CGGGCTGGC  
1551 CGGCTGCCCC GGACCTGAGT GTGTCCGCAT GGAGGAGCCC CGACTGGCCC  
1601 AGGCGGCCGT GCGGAGAGC GACCCCGAG AGGACTTGA CACACTGGCC  
1651 ACCGTGGGCA CTGGAGGTT CGGGCGGCTG CACCCGGTGA AGGAGAAAC  
1701 CGCCAAGCAT TTCTTCGCC TCAAAGTTGAT GAGCATTTCT GATGTCTATC  
1751 GCCTGGCAGG AGCAGCACGA ATCCCTTCTCT CATCTGCGTC CGGAAGGAAG  
1801 TCATCCGCC GTCGCTCATC TGGCTCCGGA AGGAAGTCAT CGGCCCGTCC  
1851 CTCATCTGCG TCCGGAAGGA AGTCATCCGC CCGTCCCTCA TCTGCGTCCG  
1901 GAAGGAGTTC ATCCGCCGT CGCTCATCTG CGTCCGGAAG GAAGTCATCC  
1951 GCCCGTCCCT CATCTGCGTC CGGAAGGAAG TCATCCGCC GTCCCTCATC  
2001 TCGTCCCGGA AGGAATCATC CGCCCGTCCC TCATCTGCGT CCGGAAGGAA  
2051 GTCATCCGCC CGTCCCTCAT CTGTGTCCGG AAGGAAGTCA TCAGCCCGTC  
2101 CCTCATCTGC GTCGGAAGG AAGTCATCCG CCGGTCCCTC ATCTGCGTCC  
2151 GGAAGGAAGT CATCCGCCCG TCCCTCATCT GCGTCTGGAA GGAAGTCATC  
2201 TGCTGTTTCC TCATCTGGGT CCGGAAGGAA GTCATCTGCT CGTTCTCAT  
2251 CTGCGTCCGG AAGGAAGTCA TCGGCCCATC CCTCATCTGC GTCTGGAAGG  
2301 AAGTCATCCA CCGTCCGCTC ATCTGCGTCC GGAAGGAAGT CATCCGCCCG  
2351 TCCCTCATCT GCGTCCCGAA GGAATCATCC GCCCGTCCCT CATCTGCGTC  
2401 TGGGAAGGAAG TCATCCGCC CTTCCCTCATC TGGCTCTGTA AGGAAGTCAT  
2451 CGGCCCTTTC CTCATCTGCG TCTGGAAGGA AGTCATCCGC CCGTTCTCTCA  
2501 TCTGGTCTCT GAAGGAATCA TCCACCCGTT CCTCATCCGC GTCCCGAAGG  
2551 AAGTCATCCG CCGTCCCTC ATCTGCGTCC GGAAGGAATC ATCCGCCCGT

2601 CCCTCATCTG CGTCTGGAG GAAATCATCC GCCCGTCCCT CATCTGGCTC  
2651 TGGAGGAAG TCATCGGCC GTCCCTCATC TGGTCTCTGA AGGAATCATC  
2701 GGCCCGTCCC TCATCTGGT CTGSAAGGAA GTCATCCGCC CGTCCCTCAT  
2751 CTGGCTCTGG AAGGAAGTCA TCCGCCCGTC CCTCATCTGC GTCTGGAAGG  
2801 AAGTCATCCA CCGTGCCTC ATCTGGTCC TGAAGGAATC ATCCACCGGT  
2851 TCCTCATCGG CGTCCGAAG GAAGAATCAT CCACCGGTTT CTCATCGGG  
2901 TCCCGAAGGA AGTCATCCAC CGGTTCTCTCA TCTGGTCTG GAAGGAATC  
2951 ATCCACCGGT CCTCATCTG CGTCTCTGAG GAATCATCCG CCGTGCCTC  
3001 ATCTGCGTCT GGAAGGAAGT CATCCGCCG TCCCTCATCT GCGTCTGGAA  
3051 GGAAGTCATC CGCCGAATC ATCCGCCGT CCTCATCTG CGTCTGGAAG  
3101 GAAGTCATCC GCCGTCCCT CATCTGGCTC TGGAGGAG TCATCCGCC  
3151 GTCCCTCATC TGGCTCTGGA AGGAAGTCAT CCACCGGTTT CTCATCTGG  
3201 TCCTGMAAGGA ATCATCCACC CGTTCTCTCAT CGGCTCCCG AAGGAAGTCA  
3251 TCCGCCCGTT CCTCATCTGC GTCTGGAAG AATCATCCAC CCGTCTCTCA  
3301 TCGCGGTCCC GAAGGAAGAA TCATCCACC GTTCTCATC GCGTCCCGA  
3351 AGGAAGTCAT CCGCCCGTTC CTATCTGG TCTGSAAGGA AGTCATCCAC  
3401 CCGTCCCTCA TCTGCTGCTT GAAGGAATCA TCCGCCCGTC CCTCATCTGC  
3451 GTCTGGAAGG AAGTCATCCA CCGTCCCTC ATCTGCTCT GGAAGGAAGT  
3501 CATCGGCCG TCCCTCATCT GGTCCGGAA GGAAGTCATC CACCGTCCC  
3551 TCATCTGGGT CCGGAGGAG GTCATCCGCC GTTCTCTCAT CTGGTCTGG  
3601 AAGGAATCAT CCACCGTCC CTATCTGG TCCGAAGGAA GTCATCCGCC  
3651 CGTCCCTCAT CTGCGTCCG AAGGAGTCA TCCGCCCGT CCTCATCTGC  
3701 GTCTGGAAG AGTCATCCG CCGTCTCTC ATCTGCTCT GGAAGGAAT  
3751 CATCCGCCG TTCTCATCT GGTCCGAAG GAAGTCATCC ACCGTCCCT  
3801 CATCTGGCTC CGGAAGGAAG TCATCCGCC GTCCCTCATC TGGTCTCTGA  
3851 AGGAAGTCAT CCGCCCGTTC CTATCTGG TCTGGAAGGA AGTCATCCGC  
3901 CCGTCCCTCA TCTGCTGCTT GAAGGAATCA TCCACCGTTC CCTCATCTGC  
3951 GTCCGAAGG AATCATCCAC CCTCCCTCA TCTGGTCCG GAAGGAGTTC  
4001 ATCCGCCGT TCCTCATCTG GTCTCGAAG GAATCATCCA CCGTGCCTC  
4051 ATCTGCGTCC AGAAGGAAGT CATCCACCG TCCCTCATCT GCGTCCGGAA  
4101 GGAAGTCATC CACCGTCCC TCATCTGGT CCTGAAGGA GTCATCCGCC  
4151 GGTCTCTCAT CTGGTCTGG AAGGAAGTCA TCCGCCGTTC CCTCATCTGC  
4201 GTCCGAAGG AATCATCCGC CCGTCCCTCA TCTGCTCTG GAACGAAGAA  
4251 TCATCCACCC GTTCTCATC GCGTCCCGA AGGAAGTCAT CCGCCGTCC  
4301 CTCATCTGGC TCTGGAAGGA AGTCATCCG CCGTCCCTCA TCGGCATCTT  
4351 GAAGGAATCA TCCACCGTTC CCTCATCCG GTCCCGAAG AGTCATCCG  
4401 CCGTCCCTC ATCTGCTCT GGAAGGAAGT CATCCGCCG TCCCTCATCT

4451 GCGTCCGGAA GGAAGTCATC GCGCGTCCC TCATCTGGT CCTGAAGGAA  
4501 GTCATCCGCC CGTCCCTCAT CTGGTCTGG AAGGAATCAT CCACCGTCC  
4551 CTCATCTGG TCTGGAAGGA AGAATCATCC ACCGTCCCT CATCTGGCTC  
4601 TGAAGGAAG TCATCCGCC GTCCCTCATC TGGTCTGGA AGGAAGTCAT  
4651 CCGCCCGTCC CTCATCTGG TCCGAAGGA GGTATCCGC CCGTCCCTCA  
4701 TCTGCTGCTT GAAGGAATCA TCCACCGTTC CCTCATCCG GTCCCGAAG  
4751 AAGTCATCC CCGTCCCTC ATCTGCTCT GGAAGGAAGT CATCCGCCG  
4801 TCCTCATCT GGTCTCTGAA GGAATCATCC GCCGTCCCT CATCTGGCTC  
4851 CGGAAGGAAG CTCATGGAGT ATGTTCCGG CTGTGAGTC TTGAGCTACC  
4901 TGGCAACCG GGGGCTCTT TACTCTGCAG AGATCATCTG TGCATCTCTG  
4951 CACTCTAAG AGATCATCTA CAGGACTTG AAGCCGAGA ACATCTGCT  
5001 GGTAGGGAC GGACACATCA AGCTCACGGA CTTTGGGTTT GCCAAGAAGC  
5051 TGGTAGACAG GACTTGGACC CTCTGGGAA TACCCGAGTA CTTGGCCCCC  
5101 GAAGTCATTC AGAGCGAGG TCACGGAAG GCTGTGACT GGTGGGCCCT  
5151 CAGCATCTG ATATTGAGA TGCTCTCGG ATTTCTCCA TTGTTGTTGA  
5201 AATTTCTTG AGACAAGATA GATTTCCCA GACATTTGGA TTTCCATGTG  
5251 AAGATCTCA TTAAGAACT GCTGTTGTT GACAGAACA GGTGTTAGG  
5301 AATATGAAG AACGGGCGA ATGATGTGA ACGCCATCG TGGTTCCGCT  
5351 CTCTGACTG GGAAGCTGTT CCTCAGAA AACTGAAGCC TCCCATCGT  
5401 CCCAAGTAG CCCGGAAGG CGACACCTCC AACTTCGGAA CTTACCCCGA  
5451 GAATGACTG GACACAGCG CGACCGTCC GCAGAAGGT TTAGAATCT  
5501 TCAAGAAATT CTGA

!!AA SEQUENCE 1.0  
ID\_ADP31606 standard; protein; 660 AA.  
XX  
AC ADP31606;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2373.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.  
XX  
PN W02004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.



PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411057P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476509P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PR (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX

PS Claim 1; SEQ ID NO 3604; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 660 AA;  
ADP31606 Length: 660 February 22, 2005 12:25 Type: P Check: 9398 ..  
1 ATGCCGGAAC TCCACGGCAA AGGTGCCAAA ATAAGACAGG AAGCACATGA  
51 CCAGGCCCCA CTGACCCCTG GCTGCATACA TGTGGATGCT TTGGGCCATG  
101 AGGATGAAGT CTGGGGAGAA GCAGTCAAGG AAAATACCTT CATCAGCCAC  
151 ATTAAGACTG GAATCTTTTC AGGGCAGAGA CAGATTATAG GAAAAGTCTG  
201 GCTTTCTTCA TCACTAGAAA AACTGACNAT ACTGTATAGA CCAGTTTCAT  
251 TCCTCGTATC AGTCTAAAC TTGTATGATA AACAGATGAG GCCAGATTCT  
301 GAGAAGATCT GGCAGATAT CCTAACCCAC TGGGTTCTTC TACAGAGACA  
351 ACTTACTTGT TTTTCATCTTA CTGGCAAAAG AAGCTTTTCA GTTCAAAGG  
401 ATACAGAGGA CCACACAGAG AGTGATAGAT GCCGACAGAA TAACCCGTGG  
451 AATTCCAAC CTCCGTCTCTT CATTTCTGAT GTTGACCTTG AGTGTCAGCG  
501 CAGCTGGAT CCACGAGTCA AATGTGCCAA ATCCAAAGST CAAGGAAGTT  
551 CCGACGTTAT GGATTTCTTC ATCATTTGTG AGCTTAGGGA TGAATGGATA  
601 ATGACACATG AAGGCCCATT CAGCAAAAGAA GACAGGCAAG TTGAAGGAAT  
651 GAATATATGA  
!!AA SEQUENCE 1.0  
ID ADF31675 standard; protein; 2419 AA.  
XX  
AC ADF31675;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2442.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kochakota S, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3673; 428pp; English.

CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 2419 AA;

SQ

ADP31675 Length: 2419 February 22, 2005 12:25 Type: P Check: 4672 ..

1 GACTTCAGGS CCACAGGTGC TGCCAGATG CTCACGGGCA CTGTCTCCGT  
51 GCTCCTGCTC TGGGGAATCC TGGGGGCCAT CAGGGCCGAG CAGCAGGAGG  
101 TCATCTCGCC GGACACTACC GAGAGAAACA ACAACTGCCC AGCAGAGAAG  
151 ACCGACTGCC CCATCCACGT GTACTTCGTG CTGGACACCT CGGAGAGCGT  
201 CACCATGCAG TCCCCACGG ACATCCTGCT CTTCCACATG AAGCAGTTCCG  
251 TGCCGCAGTT CATCAGCCAG CTGCAGAACG AGTTCTACCT GGACCAGGTG  
301 GCGCTGAGCT GCGCTACGG CGGCTGCAC TTCTCTGACC AGTGTGAGGT  
351 GTTCAGCCCA CCGGGCAGG ACCGGGGCTC CTTTCATCAAG AACCTGTCAGG  
401 GCATCAGCTC CTTCCGCCGC GGCACCTTCA CCGACTGCCG GCTGGCCAAAC  
451 ATGACGGAGC AGATCCGGCA GGACCGCAGC AAGGGCACCG TCCACTTCGC  
501 CGTGTGTCAT ACCGAGGGCC ACGTACCGG CAGCCCTCTGC GGGGGCATCA  
551 AGCTGCAGGC CAGCGGGGCC CGCAGGAGG GCATCCGGCT CTTCCGCCGTG  
601 GCCCCCAACC AGAACCCTGAA GGACGAGGGC CTGCGGGACA TCGCCAGCAC  
651 GCGGCACGAG CTCCTACCGA ACGACTAGC CACCATGTCTG CCGGACTCCA  
701 CCGAGATCGA CCAGGACACC ATCAACCGCA TCATCAAGGT CATGTGTAGC  
751 CCGGGCGGG ATGCTACAAG GTGAGCTGCC TGGAAATCCC TGGGCCCTCT  
801 GGCCCCAAGG GCTACCGTGG ACAGAAAGGT GCCAAGGGCA ACATGGGTGA  
851 GCGCGGAGAG CCTGGCCAGA AGGAAGACA GGGAGACCCG GGCATCGAAG  
901 GCCCCATTGG ATTCCAGGA CCCAAGGGCG TTCCTGGCTT CAAAGGAGAG  
951 AAGGGTGAAT TTGGAGCCGA CGTTCGCAAG GGGGCCCTTG GCCTGGCTGG  
1001 CAAGAACGGG ACCGATGGAC AGAAGGGCAA GCTGGGGCGC ATCGGACCTC  
1051 CTGGCTGCAA GGGACACCTT GGAACCCGGG GCCCCGACGG TTACCCGGGG  
1101 GAAGCAGGGA GTCCAGGGA GCGAGGAGAC CAAGGCGGCA AGTATCAAGG  
1151 CAACAGTGA GCCCCAGGAA GTCCTGGTGT GAAAGGAGCC AAGGGCGGCG  
1201 CTGGGCCCCG CGGACCCCAA GGCAGCCGG GGCAGAGGG AGACCCCGGC  
1251 ACCAAGGGCA GCCCAGGAG CGATGGCCCC AAGGGGAGA AGGTGAGTCC  
1301 CTGGCCCTGA GGGGCCCGCG GGCCTGGCTG GAGAGGTTGG CAACAAGGA  
1351 GCCAAGGGAG ACCGAGGCTT GCCTGGACCC AGAGGCCCC AGGGAGCTCT  
1401 TGGGGAGGCC GGAAGCAGG GATCTCGGG AGACCCGGT GATGCAGGAC  
1451 CCCGTGGAGA CTCAGGACAG CCAGGCCCCA AGGGAGACCC CGGCAGGCCT



CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

XX  
SQ Sequence 1107 AA;

ADP30504 Length: 1107 February 22, 2005 12:25 Type: P Check: 7471 ..

1 GTGGATCATTT TCAGAGAGTCC GTCCTGTGAAA TGGTTGGCAC TTTGTACTATT  
51 TATTGCTTCT TTCTGGCGAC AGTTCCAGCA CTCGCCGAGA CCGGCGGAGA  
101 AAGGCAGCTG AGCCCGGAGA AGAGCGAAAT ATGGGACCC GGGCTAAAG  
151 CAGACGTCGT CCTTCCGCC CGCTATTCTT ATATTACGC AGTGGATACA  
201 TCAGGGAATA AATTACATC TTCTCCAGC GAAAAGTCTT TCAGGTGAA  
251 AGTCTCAGCA CCAGAGGAGC AATTCACCTAG AGTTGGAGTC CAGGTTTTAG  
301 ACCGAAAGA TGGGTCCTTC ATAGTAAGAT ACAGAAATGA TGCAGCTAC  
351 AAAAATCTGA AGGTGGAAAT TAAATTCCAA GGGCAACATG TGGCCAAATC  
401 CCCATATATT TTAAGAGGTT TACCATGAGA ACTGTGACTG TCCTCTGCAA  
451 GATAGTCGAG CTGGCTACG GGAGATGAAC TGCCCTGAAA CATTGCTCA  
501 GATTACAGCA GATCTGGCAC ATTTCCCTGC TGTGGATCCA GAAAAGATTG  
551 CAGTAGAAAT CCCAAAAGA TTGGACAGA GGCAGAGCCT ATGCTACTAC  
601 ACCTTAAAGG ATACAAAGGT TTATATCAAG ACTCATGGTG AACATGTAGG  
651 TTTTGAATTT TTCATGGATG CCATCTACT TTCTTTGACT AGAAGGTGA  
701 AGATGCCAGA TGTGGAGCTC TTGTGTAATT TGGGAGACTG GCCTTTGGAA  
751 AAAAGAAAT CCAATTCAAA CATCATCG ATCTTTTCTT GGTGTGGCTC  
801 CACAGATTCC AAGGATATCG TGATGCCCTAC GTACGATTTG ACTGATTTCTG  
851 TTCTGGAAC CATGGCCGG GTAAGTCTGG ATATGATGTC CGTGCAGCT  
901 AACACGGGTC CTCCTCGGGA AAGCAAAAT TCCACTGCG TCTGGAGAGG  
951 GCGAGACAGC CGCAAGAGA GACTCGAGCT GGTAAATCTC AGTAGAAAAC  
1001 ACCCAGAACT CATAGACGCT GCTTTACCA ACTTTTCTT CTTTAAACAC  
1051 GATGAAACC TGTATGGTCC CATTGTGAAA CATATTTTAT TTTTGTATT

1101 CTTCAAG

!!AA SEQUENCE 1.0

ID \_ADP30509 standard; protein; 2020 AA.

XX

AC ADP30509;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1276.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

FN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

29-AUG-2002; 2002US-0406576P.  
29-AUG-2002; 2002US-0406579P.  
29-AUG-2002; 2002US-0406585P.  
29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-041101P.  
18-APR-2003; 2002US-041111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-047609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

XX

XX

PI

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2507; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 2020 AA;  
ADP30509 Length: 2020 February 22, 2005 12:25 Type: P Check: 723 ..  
1 CAGATCTCTGG GGCAGAGTCC AGGCGAGCTC AAGGCTCTTC CACACACACA  
51 CCGCGTGAAC CTTGAGCACC CTGAGCTGCT GAGATGGGGC GGGCCGGGGC  
101 TGCCGCGGTG ATCCCGGGCC TGGCCCTGCT CTGGGCAGTG GGGCTGGGGA  
151 GTGCGCGCCC CAGCCCCCAC GCCTTGGGCT CTCCTTCCAA GAGCTCCAGG  
201 CTTGGCATGG TCTCCAGACT TTCAGCCTGG AGCGAACCTG CTGCTACCAG  
251 GCCTTGCTGG TGGATGAGGA GCGTGGAGCG CTGTTTGTGG GTGCCGAGAA  
301 CCATGTGGCC TCCCTCAACC TGGACAACAT CAGCAAGCGG GCCAAGAAGC  
351 TGGCCTGGCC GGGCCCTGTG GAATGGCGAG AGGAGTGCAA CTGGGCAGGG  
401 AAGGACATTT GTACTGAGTG CATGAACTTC GTGAAGTTGC TGCATGCCCTA  
451 CAACCGCACC CATTTGCTGG CTTGTGGCAC GGGAGCGCTTC CACCCAACTT  
501 GTGCTTTTGT GGAAGTGGGC CACCGGGCAG AGGGCAAGGG GAAGAGTCTT  
551 TATGACCCCA GGCATCGGGC TGCTCTCGTG CTGGTGGGGG AGGAGCTATA  
601 CTCAGGGGTG GCAGAGACC TCATGGGACG AGACTTTACC ATCTTTCCGA  
651 GCCTAGGGCA ACGTCCAGT CTCCGAACAG AGCCACACGA CTCCCGCTGG  
701 CTCATGTGTT GGCAGATCT GCCGGAACGA CGTGGGGCGC CAGCGCAGCC  
751 TGGTCAACAA GTGACGACG TTTCTGAAG CCGCGCTGCT GTGCTCGGTG  
801 CCGCGCGTGG AGGCGACAC CCACTTCGAT CAGCTCCCTC TATGCCGTCT  
851 TCTCCACGTC CAGGTGAGG CATCTTCCAG GACTCTGGCG TGTGGGTGTA  
901 CAGCATGAAC GACTGCGCC GGGCCTTTCTT GGGACCTTTT GCACACAAGG  
951 AGGGGCCCCA GCACAGTGG GTGTATACC AGGGTGGCT CCCCTACCCG  
1001 CGGCCAGGCA TGTGCCCGAG CAAGACTTTT GGCACCTTCA GTTCACCAA  
1051 GGACTTCCCA GACATGTCA TCCAGTTTG CCGGAACCA CCGCTCATGT  
1101 ACAACTCTGT CTTGCCACT GGGGGGGGCC CTCTTTTCT CAAAGTTGGA  
1151 GCCAATTACA CTTTCACTCA AATTGGCGG GACCGGGTTG CAGCGGTGTA  
1201 CGGACACTAT GACGTCTCTT TCATTGGCAC AGACGTGGC ACGGTGCTGA

1251 AGGTGATCTC GGTCCCAAG GGCAGTAGGC CCAGCGCAGA GGGGCTGCTC  
1301 CTGGAGGAGC TGCAGCTGTT TGAGGACTCG GCCGCTGTCA CCAGCATGCA  
1351 AATTTCTTCC AAGAGTACT GCGCTTGGGA CGGGGTGCGG TGCACGCGCT  
1401 TCAGCCCAAG TGCCAAGAGG CGGTTCCGGC GGCAGAAGCT AAGGAATGGC  
1451 GACCCCAACA GTTGTGCTC CGGAGACTCG TCTCGTCCCG CGCTGCTGGA  
1501 ACACAAGTGG TTCGGCTGG AGGCGAGCAG CGCCTTTCTG GAGTGTGAGC  
1551 CCGCTGCTGT GCAGCGCGC GTGAGTGGGA CTTTCCAGCG CGCAGGGGTG  
1601 ACAGCCCCCA CCCAGGTGCT GGCAGAGGAG CGCACCGAGC GCACCGCCCG  
1651 GGGACTACTG CTGCGCAGGC TGGCGGCGCG GGACTCGGGC GTGTACTTGT  
1701 GCGCGCGCT CGAGCAGGGC TTTACGCAAC CGCTGCTCG CTTGTGCTG  
1751 CACGTGTTGA GTGCTACGCA GCGCGAAGCA CTGGCGCGGG CCGAGGAGGC  
1801 TCGCGCCGCC GCGCGCGCG GCGCCAACT CTGGTACCAG GACTTTCTGC  
1851 AGCTGTTGGA GCGCGCGGA GTTGGCAGCG CGAACTCCCT CGCATGTGC  
1901 GCGCGCAGC CTGCGCTGCA GTCACCTGCC CTGGAGTGGC GGAGAAAGG  
1951 CGGTAAACGG AGGACCCAG CCCTGAGCC TCGCGCTGAG CGGGGGCGCG  
2001 GCAGCGCAAC GCATGTTGA  
!!AA SEQUENCE 1.0  
ID ADP30520 standard; protein; 279 AA.  
XX  
AC ADP30520;  
XX  
DT 12-AUG-2004 (first entry)  
DE Human secreted protein SEQ ID #1287.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485225P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348439/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2518; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX Sequence 279 AA;

ADP30520 Length: 279 February 22, 2005 12:25 Type: P Check: 9327 ..  
1 ATCGCGTGTCT CGCGGGGAGG CGTCTGGCTG GCCTGGCCG CGTGGTCTCT  
51 GCACGTGTCC CTGCAAGGCG AGTTCCAGAG GAAGCTTTAC AAGGAGCTGG  
101 TCAAGAACTA CAATCCCTTG GAGAGGCCCG TGGCCAATGA CTCGCAACCA  
151 CTCACGCTCT ACTTCTCCTT GAGCTCTCTG CAGATCATGG ACGTGCCAAG  
201 GAGGGACCTG GTAAAGCTTA TTCCATCACC CTGGCCACCT GTGCATGGTT  
251 ACTTGGGTCC CACCTTTCTC TCAGGTTAG  
!!AA\_SEQUENCE 1.0  
ID ADP30541 standard; protein; 729 AA.  
XX  
AC ADP30541;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1308.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.

PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

DR WPI; 2004-348438/32.

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2539; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

XX SQ Sequence 729 AA;

ADP30541 Length: 729 February 22, 2005 12:25 Type: P Check: 9574 ..

1 TGGGTCTGTT TCAGCAATGC AAACCTCAC AGAGGCCTGT GTGTGGCAGT

51 AATGGAAGA CTTACTCAA CCACCTGTGAA CTGCATCGAG ATGCCTGCCT

101 CACTGGATCC AAAATCCAGG TTGATTACGA TGGACACTGC AAAGAGAAGA

151 AATCCGTAG TCCATCTGCC AGCCAGTTG TTGCTATCA GTCCAACCGT

201 GATGAGCTCC GACGTGCGAT CATCCAGTGG CTGGAAGCTG AGATCATTTCC

251 AGATGCTCG TTCTTAAAG GCAGCAACTA CAGTGAATC CTAGACAAGT

301 ATTTTAAGA CTTTGATAAT GGTGATTCTC GCTTGACTC CAGTGAATTC

351 CTGAAGTTTG TGAACAGAA TGAACCTGCC ATCAATATTA CAACGTATCC

401 AGACCAGGAG AACAACAATT TCAGGGGACT CTGTGTTGAT GCTCTCATTTG  
451 AACTGTCTGA TGAATACTCT GATTGGAAC TCAGCTTCCA AGAGTTTCTC  
501 AAGTGCCTCA ACCCATCTTT CAACCCCTCT GAGAAGAAGT GTGCCCTGGA  
551 GGATGAAACG TATGCAGATG GAGCTGAGAC CGAGGTGGAC TGTAAACCGCT  
601 GTGTCTGTGC CTGTGGAAT TGGTCTGTGA CAGCCATGAC CTGTGACGGA  
651 AGAATCAGA AGGGGGCCCA GACCAGACA GAGGAGAGA TGACCAGATA  
701 TGTCCAGGAG CTCCAAAGC ATCAGGTGA

!IAA SEQUENCE 1.0

ID ADP30577 standard; protein; 1179 AA.

XX AC ADP30577;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1344.

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411037P.

XX PR 17-SEP-2002; 2002US-0411041P.

XX PR 17-SEP-2002; 2002US-0411045P.

XX PR 17-SEP-2002; 2002US-0411046P.

XX PR 17-SEP-2002; 2002US-0411048P.

XX PR 17-SEP-2002; 2002US-0411052P.

XX PR 17-SEP-2002; 2002US-0411055P.

PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2575; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 1179 AA;  
ADP30577 Length: 1179 February 22, 2005 12:25 Type: P Check: 3242 ..  
1 ATGGAGACAA TGGAGAAAGG CCAACCACAC TSCAAAGTTT ATCATGCCTC  
51 GCTGTTGTT CGGACCTCA TTCTCATCA CGACGGGTC TCAGTGTGGA  
101 GCAGAAAGCA GCGAAGAGT AAGCACTGCA TCTTACCAT CATTTACCA  
151 AATGGAACAA TTGCGACCCC AGTGCAAAAG ATCACTGCT CCCTGCCCTC  
201 AAGTAACAAG CAGTCTCTGCA TGCAGAGAG CAAGGCCAA GTCAGTGCAC  
251 CCACAGTATA CACTCTCTTG GTATGGGAAC CAATCCAAATG CCGCACCCCC  
301 AGGAAGGCTA CCCCTAAGCC AGTGACCCCA CTGAGTTTCAT CCCTTCAGCT  
351 TAGGAACCAG CCCAGTGTCC CAACCCGAGC AAGGCCACCA CAAATGCCCC

401 TTAGCTTGAG AAACAACCTG ATGCTTTTCC CTGGATTTT TCTTCTAACA  
451 ATCCCTATTG CTCTGTTGAT GGCAGCAGCA GGCCATTCAA ACGGGTGTCT  
501 GCCATGGCAC CTGCTGCGGT GGGGTGTGGG CCTGGCCAC CGGTCTCTCAG  
551 GTGCTGACGC TGAGGCAAAAC GGTGTCTGGG GCTTGGCACC TGGGAGCTGC  
601 TGCAGTGGGG CCAGACAGGG CCAGGCCACC CTCAGCAAG GGAATGGCAT  
651 AGTCAGGCAT GAGAGGGTCC CAAGCACCTG CTCGATCTT GAAGCAGAGT  
701 TGGGGCACTG TTGCAGCCCA GCTGGGTATG TGCAGGCTCA GGGAAAGTGTCT  
751 GACATGCTGG TCCCATGCCA CCTCAGCCCC TCTGGACTTT GGGCACCATT  
801 GGAGGGAGGC CAAGATGGGG CTCGAGAGCA GCTCAGAACT GGCCTGCAGC  
851 AGCCCTTGG CTCCAGCAGC CTGGATGCCA TGGGTAGGAG GATGCACACA  
901 GGCTCTTGGG TTCACAAACC ACAAGCTGT GTACATAAAG TGTGGGGAGA  
951 GGAGCAGGAA GCAGATATCT GGGAGACTTT GGAATAAACT GGAATCTCCT  
1001 CRAAGGAGAG TGCCCCAAGCA AGTAGGGCAG CTGTGAGCCA GAGAAAGGAA  
1051 AAATATACAG CGGCAAGCA GGTAGCAAAAT GCTAAATAAGA GATGCAGTGA  
1101 TGTAAGAGA AGCCCTCTAG CACTTTCTCA GCAGGCCATC CCTCGCAAG  
1151 TATCACCTTT GGCATTGCT GACTCTTAA  
!!AA\_SEQUENCE 1.0  
ID ADP30591 standard; protein; 1587 AA.  
XX  
XX AC ADP30591;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #1358.  
XX  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.



PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2589; 428pp; English.  
PS The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antitumour, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX Sequence 1587 AA;  
SQ

ADP30591 Length: 1587 February 22, 2005 12:25 Type: P Check: 7859 ..

1 ATGGGGGAAA ATGATCGGCC TGCTGTTGAA GCCCCTTCT CATTCGGATC  
51 GCTTTTGGC CTTGATGATT TGAATAAG TCTGTGTGA CAGATGAG  
101 ATGCTGTTGC TGCACAGATC CTGTCACTGC TGCCATTGAA GTTTTTCGA  
151 ATCATCGTCA TTGGGATCAT TGCATTGATA TTAGCACTGG CCATTGGTCT  
201 GGGCATCCAC TTGACTGCT CAGGGAAGTA CAGATGTCGC TCATCCTTTA  
251 AGTGTATCGA GCTGATAGCT CGATGTGACG GAGTCTCGGA TTGCAAGAC  
301 GGGGAGGACG AGTACCGCTG TGTCGGGGTG GGTGGTTCAG ATGCCGTGCT  
351 CCAGGTGTTT ACAGCTGCTT CGTGGGAAGC CATGTGCTCC GATGACTGGA  
401 AGGGTCACTA CGCAATGTT GCCTGTGCC AACCTGGGTTT CCCAAGAAGA  
451 CCTGTGTCCT GGCACGTGAA AATGAGCTG GGCTCTGGTG TCGTGGGAAT  
501 CGCTTTCTTG TTTGTGTTCA TCTCTTTCCA GTGGGGCTCT GCGCTGGTCC  
551 TGGGCAGCTA TGTGAGTTCA GATAACCTCA GAGTGAGCTC GCTGGAGGGG  
601 CAGTTCCGGG AGGAGTTTGT GTCCATCGAT CACCTCTTGC CAGATGACAA  
651 GGTGACTGCA TTACACCACT CAGTATATGT GAGCTTGTATC CTCCCAAGT  
701 CATGGACCAT CCAGGTGGGT CTAGTTTCCC TGTGTGACAA TCCAGCCCCA  
751 TCCCACCTGG TGGAGAAGAT TGCTACCAC AGCAAGTACA AGCCAAAGAG  
801 GCTGGGCAAT GACATCGCCC TTATGAAGCT GGCCGGGCCA CTCAGTTCA  
851 ATGACATTTT ACTGGACACA GCCACACCTA TGTGGGTACC TGTACCTGG  
901 GGCTGTCTTC ATGCTCCAAAT GGCAGCCAGA GACCGCACAG CCCACGAAGC  
951 CTACAACATT GACTATTGAG CCCTTTCCAC AAAAGCAGAA ATGATCCAGC  
1001 CTGTGTGCTT GCCCACTCT GAAGAGAACT TCCCGGATGG AAAAGTGTGC  
1051 TGGACGTGAG GATGGGGGGC CACAGAGGAT GGAGGTGAGC CTTCCCTGT  
1101 COTGAACCAAC GCGGCCGTCC CTTTGATTTT CAACAAGATC TGCAACCAAC  
1151 GGGACGTGTA CCGTGGCATC ATCTCCCTT CCATGCTCTG CGCGGGCTAC  
1201 CTGACGGGTG GCGTGGACAG CTCGCCAGGG GACAGGGGGG GGCCCTTGGT  
1251 GTGTCAAGAG AGGAGGTGT GGAAGTTAGT GGGAGCGACC AGCTTTGGCA  
1301 TCGGTGCGC AGAGTGAAC AAGCCTGGGG TGTACACCCG TGTCACTCC  
1351 TTCTTGGACT GGATCCACGA GCAGATGGAG AGCTGGCAGC CCCAGGGGGA  
1401 GGCCAACTTT GTCTTCATCG TGGAGAACAG CCCCACAAAT CCCACAGGGC  
1451 AAAATGCAGG TGCCCGCTCC GTCATCATGT TGGACGGATG GCTGGAAGTG  
1501 CTAATAACAA TAAGCCCTTT GTTTTCATTT ATAGAGAGAC CTAAACCT  
1551 GAAGAGGAAG GGGACAAGTA GCCACCTGAG TTCCTGA

!!AA SEQUENCE 1.0

ID \_ADP30630 standard; protein; 291 AA.

XX ADP30630;  
XX

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1397.  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406577P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406555P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 03-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.

PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2628; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 291 AA;  
SQ  
ADP30630 Length: 291 February 22, 2005 12:25 Type: P Check: 1138 ..  
1 ATGACAACGC CCCCGCCTTC ACCCAACCT CCTACACCT GTTCGTCCGC  
51 GAGAACACA GCGCCGCCCT GCATCGGC AGCGTCAGC CCACAGACAG  
101 AGACTCGGC ACCAAGGCC AGTCACTA CTCGTGCTG CGCCCCCAGG  
151 ACCCGCACCT GCGCCTCGC TCCCTGTCT CCATCAAGC GGACAACGC  
201 CACCTGTTG CTCCTCAGTC GCTGGACTAC GAGGCCCTGC AGCGTTCA  
251 GTTCGCGTG GCGCGCCGAG ACCGCGCTC CCGCGCTTG A  
IIAA SEQUENCE 1.0  
ID ADP30672 standard; protein; 2042 AA.  
XX  
AC ADP30672;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1439.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.  
XX  
XX WO2004035732-A2.  
PN  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406555P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 03-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.

PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485242P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
PS Claim 1; SEQ ID NO 2670; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 2042 AA;

ADP30672 Length: 2042 February 22, 2005 12:25 Type: P Check: 3506 ..

1 CACCACACC CACTCTGGCC GGAGCAGGCC AAGCAGCTCC CCATCGCTCC  
51 GGAAACGGCT GCAGCTCTG CCCCAGGCC GGGCCGCCACC TGAGCCAGAA  
101 CCAGGCACCA TGGTGGAGAA GGGATCAGAT AGCTCTCTCAG AGAAGGGTGG  
151 GGTGCTGGG ACCCCAGCA CCCAGAGCCT AGGCAGCCGG AACTTCATCC  
201 GCAACAGCAA GAAGATGAG AGCTGGTACA GTATGCTGAG CCCCACTTAT  
251 AAGCAGCGTA ATGAGGACTT CCGAAACTG TTCAGCAAC TCCCGAAGC  
301 AGAAGCCTC ATTGTGGATT ACTCTGCGC CCTGCAGCCT GAGATCTGTC  
351 TCCAGGGCG CCTCTACCTC TCTGAGACT GATCTGCTT CTACAGCAAC  
401 ATCTTCGGT GGGAGACCAC GATCTCCATC CAGCTGAAG AAGTGACATG  
451 TCTGAAGAAG GAAAGACGG CCAAGCTGAT CCCCAGGCC ATCCAGATCT  
501 GCACGGAGAG CGAAGACAT TTCTTCACIT CTTTGGGGC CGTGACCGC  
551 TGCTTCTCTC TCATCTTCOG CTCTGGCAG AATGCACTGC TTGAAAAGAC  
601 GCTGAGTCCC CGCAGCTCT GGCACCTGGT GCATCAGTGC TACGGCTCAG  
651 AGCTGGGCT CACAGTGAG GATGAGACT ATGCTCTCCC CTTCAGCTG  
701 AACGGTCTGG GGACCCCAA GGAAGTGGGA GATGTGATG CCTGAGCGA  
751 CATCACCTCC TGGGGGCGAG CTGACCGCAG CCAGGAGCCA AGCCAGTGG  
801 GTTCGGCGG TGGCCATGTC ACGCCCAACC TTTCCGGAGC CAGCAGCGAC  
851 GCAGACCATG GGTGGGAGAA GAACAGCGGA CAGGACAGCC AGACGCTTCC  
901 TCCAGCCAGA CAGTGACCCC GGTGGGTGAA CCCCCGAGCA CAGAGCCAC  
951 CCAGCCTGAC GGGCCACCA CCTTGGGCC CTTGGATCTG CTGCCCAGTG  
1001 AGGAGCTATT GACAGACACA AGTAATCTCT TTTCATCCAC TGGGGAGGAA  
1051 GCGGACTTGG CTGCGCTGCT TCCCGACCTC TCCGGCCGCC TCCTCATCAA  
1101 CTCTGTCTTC CATGTGGGG CTGAGCGGCT CCAGCAGATG CTCTTCTCGG  
1151 ACTGCGCTT CTTCAGGGC TTCTTACAGC AGTGCAAGTT CACAGACGTG  
1201 ACGCTGAGCC CTTGGAGTGG GGACAGCAAAG TGCCACCAGC GCCGGGTGCT  
1251 GACGTACACC ATCCCCATCA GCNAACCACT GGGCCCCAAG AGCGCTCCG  
1301 TGGTGGAGAC ACAGACGCTG TTCCGGCGCG GCCCCCAGGC CGCGGGGTGT

1351 GTGGTGACT CCGAGTGTCT GACGCAGGCG ATCCCTTACC AGGACTACTT  
1401 CTACACTGCC CACCGTACT GCATCTCTGG TCTGGCCCGG AACAAAGCGC  
1451 GGCTCCGGAG ATCCGCTACC GAAAGCAGCC GTGGAGCCTG GTGAAGTCGC  
1501 TCATTGAGAA GAACTCGTGG AGCGGCATTG AAGACTATTT CCACCATCTG  
1551 GAGGAGAGC TCGCCAAGC TGAGAAGCTG TCTCTGGAGG AAGGCGGGAA  
1601 GGATGCCCGG GGCTTGCTAT CCGGCTCTGC GCGCGGAAG CGGCCCTCGA  
1651 GCTGGCGGC TCACGGGGAC GSGGCCCATC ACCAGATCC TGACCCCTGT  
1701 GCCGGGCGG GCATTCACAC CTCGGGCTCC CTGAGCTCCC GCTTCTCCGA  
1751 ACCATCTGTG GACCAAGGCC CCGGGGCAGG CATCCCAAGT GCCTGTGTTT  
1801 TCATCAGCAT TGTCTTATC ATCTCTCATC CCCTCAAGT CTGTCTCTTC  
1851 TACGGCTCTT GGTCCCTGGA AAGGACAGC CACACCTTTG AGTCCTGGCA  
1901 CAGCTTGGCC CTGGCCAAGG GCAAGTTCCC CCAGACGGCC ACAGATGGG  
1951 CCGAGATCCT GCGGCTGCAG AAGCAATTCC ACAGCGTGA GGTGCACAAG  
2001 TGGAGGCAGA TCTCTGGGCG CTCCTGGAG CTCCTGTATG AG

!!AA SEQUENCE 1.0  
ID ADP30679 standard; protein; 821 AA.

XX AC ADP30679;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1446.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406666P.

17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

PS Claim 1; SEQ ID NO 2677; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPOWEB and is not in the specification.

XX Sequence 821 AA;

ADP30679 Length: 821 February 22, 2005 12:25 Type: P Check: 9429 ..

1 TGACCCCGAG CATGAAGATC TACATGATC CTTTCACCTA CGAGGACCCC

51 AACGAGCAG TCGGGAGTT TGCCAAGGAA ATTGACATCT CTTGTGTCAA  
101 AATTGACGAG GTGATCGGAG CAGGCCACCC TGAAGCTGCC AGGCAAGAGA  
151 GAGATCTTTG TGGCCATCAA GACGCTCAAG TCGGGCTACA CGGAGAGCA  
201 GCGCCGGGAC TTCCTGAGGG AAGCCTCCAT CATGGGCCAG TTCGACCATC  
251 CCAACGTCAT CCACCTGGAG GGTGCTGTGA CCAAGAGCAC ACCTGTGATG  
301 ATCATCACCG AGTTTCATGA GAATGGCTCC CTGGACTCCT TTCTCGGCA  
351 AAACGATGGG CAGTTCACAG TCATCCAGCT GGTGGGGATG CTTCCGGGCA  
401 TCGCAGCTGG CATGAAGTAC CTGGCAGACA TGAATATGT TCACCGTGCAC  
451 CTGGCTGCCC GCAACATCCT CGTCAACAGC AACCTGGTCT GCAAGGTGTC  
501 GGACTTTGGG CTCTCACGCT TTCTAGAGGA CGATACCTCA GACCCACCT  
551 ACACCACTGC CCTGATTGTC ATGTGGGAGG TGATGTCCTA TGGGGAGCGG  
601 CCTACTGGG ACATGACCAA CCAGGATGTA ATCAATGCCA TTGAGCAGGA  
651 CTATCGGCTG CCACGCCCA TGGACTGCC GAGCGCCCTG CACCAACTCA  
701 TGCTGACTG TTGGCAGAAG GACCGCAACC ACCGGCCCAA GTTCGGCCAA  
751 ATTGTCNACA CGTAGACAA GATGATCGC ATCCCAACA GCCTCAAGC  
801 ATGGCGCCC CTCTCCTCTG G  
!!IAA SEQUENCE 1.0  
ID\_ADP30705 standard; protein; 6465 AA.  
XX  
AC ADP30705;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1472.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406651P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2703; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 6465 AA;  
SQ

ADP30705 Length: 6465 February 22, 2005 12:25 Type: P Check: 3137 ..

1 ATGCTGGG CGCTGGCT GCTGCTGG CTGCTGTCG TCCGGCTGCC  
51 CTGGCGGGTG CCGGGCCAGC TGGACCCGAG CACTGGCGGG CGGTTCTCGG  
101 AGCACAAACT CTGCGGGGAC GACGAATGCA GCATGTTAAAT GTACCCGGGT  
151 GAGGCTCTTG AGATTTCAC AGGCCGGAT TGTGTTTTTG TGAATTTTAA  
201 AAAAGGTGAT CCTGTATATG TTTACTATAA ACTGGCAAGA GGATGCGCTG  
251 AAGTTTGGGC TGGAAGTGTT GGACGCACTT TTGGATATTT TCCAAAAGAT  
301 TTAATCCAGG TAGTTTCATGA ATATACCAA GAAGAGCTAC AAGTTCCAAC  
351 AGATGAGACG GATTTTGTGT GTTTTGATGG AGGAAGAGAT GATTTTCATA  
401 ATTATAATGT AGAAGAACTT TTAGGGTTTT TGGAACTGTA CAATTTCTGCA  
451 GCTACAGATT CTGAGAAAGC TGTAGAAAAA ACTTTACAGG ATATGGAATA  
501 AAACCCTGAA TTATCTAAGG AAAGGGAACC TGAACCTGAA CCAGTAGAAG  
551 CCAACTCAGA GGAAGGTGAT AGTGATTCTT CAGAAAAACAC TGAGGATCTT  
601 CAGGAACAGT TTACAACCTA GAAGCACCAC TCCCATGCAA ACAGCCAAGC  
651 AAATCATGCT CAGGGAGAGC AGGCTTCATT TGAATCTTTT GAAGAAATGC  
701 TGCAAGATAA ACTAAAAGTG CCAGAAAGTG AAAACAACAA ACCAGCAAT  
751 AGTTCTCAGG TCTCAATGA ACAGGATAAG ATTGATGCTT ATAACTTTT  
801 GAAAAAGAA ATGACTCTAG ACTTGAAAAC CAAATTTGGC TCAACAGCTG  
851 ATGCACTTGT ATCTGATGAT GAGACAACCA GACTCGTTAC TTCAATTAGAA  
901 GATGATTTTG ATGAGGAATT GGATCTGAG TATTATGCGAG TTGGAAGGA  
951 AGATGAGGAG AACCAGAAG ACTTTGATGA GTTGCCATTA CTTTACCTTTA  
1001 CAGATGGGGA AGATATGAAA ACTCCAGCAA AGTCTGGGT TGAGAAATAT  
1051 CCAACAGATA AAGAGCAGAA TTCAATGNA GAGGACAAGG TTCAGGTAAC  
1101 TGTGCCCCCT GGCATCAAAA ATGATGATAA AAATATACTA ACAACCTGGG  
1151 GGGACACTAT CTTCTCTATT GTCAAGAGGAG GTGAAGAAAC AAGAGATACG  
1201 ATGGATTTAG AGAGCTCTAG TTCAGAGGNA GAAAAAGNAG ATGATGATGA  
1251 TGCATTAGTC CCAGATAGCA AACAGGGGAA ACCACAGTCA GCACAGATT  
1301 ATAGTGACCC TGACAATGTA GATGATGGTC TTTTATTGTT AGACATTCTT  
1351 AAAACAATA ATGACAAGA AGTAAACGCA GAACATCACA TTAAGGAAA  
1401 AGGGAGGGGA GTTCAGGAAT CCAAGAGGGG CCTGGTCAAA GATPAGACAG  
1451 AATTAGAGGA TGAATAATCA GAAGGCATGA CTGTGCACAG TTCTGTTTCA  
1501 AGCNATAACC TCNACTCTAT GCCACTGCT GAAAAGGGTA AAGACATTT  
1551 AAATCAGCT TATGATGATA CAGAAAATGA CCTAAAAGGA GCAGCTATTTC  
1601 ATATCTCAA AGGAATGCTC CACGAAGAAA AGCCTGGAGA GCAGATTTTG  
1651 GNAGGTGGCT CAGAGAGTGA ATCTGCACAG AAAGCTGCAG GGAATCAAT  
1701 GAATGACAGA AAGATTCAAC AGGAATCCCT GGGTAGTGCA CCACTCATGG  
1751 GAGATGACCA CCCTAACGCA TCCAGAGACA GTGTGGAGGG AGACGCTTTG

1801 GTAAATGGGG CCAAACTGCA CACGCTTTCA GTGGAGCATC AACGTGAGGA  
1851 ATTGAAGAG GAATTAGTTC TTAATACTCA AAACCAACCT AGATTCTCTT  
1901 CTCAGATGA GATTGATTTG CCCAGAGAAC TGAAGACGA GGTTOCCATT  
1951 CTGGGAAGAA ATCTTCCCTG GCAACAAGAA AGAGATGTGG CTGCCACAGC  
2001 CAGTAAGCAA ATGAGTGAGA AGATAAGGCT CTCTGAGGGA GAAGCCAAAG  
2051 AGGACTCTCT GGATGAAGAG TTTTTCATC ACAAGGCAAT GCAGGGCACA  
2101 GAGGTAGGAC AGACAGACCA AACTGACAGC ACAGGAGGAC CAGCTTTCCT  
2151 TTCTAAAGTA GAAGAGGATG ATTATCCCTC TGAAGAACTA CTAGAGGATG  
2201 AAAACGCTAT AAATGCAAAA CGGTCTAAAG AAAAAAACC TGGGAATCAG  
2251 GGCAGGCAGT TTGATGTTAA TCTGCAAGTC CCTGACAGAG CAGTTTTTAGG  
2301 GACCATTCAI CCAGATCCAG AATTGAAGA AGCAAGCAA GAACTAGTA  
2351 TGATTTTGGG TAGCGAAAAA ACRAAGTGAGA CTGCTGCCAA AGGGGTCAAC  
2401 ACAGGAGGCA GGGAAACCAA TACAATGGTG GAAAAAGAAC GCCCTCTGGC  
2451 AGATAAGAAA GCACAGAGAC CATTTGAACG AAGTGACTTT TCTGACAGA  
2501 TAAAAATTCA GACTCCAGAA TTAGGTGAAG TGTTCAGAA TAAAGATTCT  
2551 GATTATCTGA AGAACGCAA CCCTGAGGAA CATCTGAAGA CCTCAGGGCT  
2601 TGCAGGGGAG CCTGAGGAG AACTCTCAA AGAGGACCAT GAGAACACAG  
2651 AGAAGTACAT GGGCACAGAA AGCCAGGGGT CTGCTGCTGC AGAACCCTGAA  
2701 GATGACTCGT TCCACTGGAC TCCACATACA AGTGTAGAGC CAGGGCATAG  
2751 TGACAAGAGG GAGGACTTAC TTATCATAAG CAGCTTCTTT AAAGAACAAC  
2801 AGTCTTTGCA GCGGTTCCAG AAGTACTTTA ATGTCCATGA GCTGGAAGCC  
2851 TTGCTACAAG AAATGTCATC AAAACTGAAG TCAGCGCAGC AGGAGAGCCT  
2901 GCCTATATAT ATGNAAAAG TCCTAGATAA GGTCTTCCGT GCTTCTGAGT  
2951 CACAAATCTT GAGCATAGCA GAAAAATGC TTGATACTCG TGTGGCTGAA  
3001 AATAGAGATC TGGGAATGAA CGAAAAATAAC ATATTTGAAG AGGCTGCAGT  
3051 CTTTGTATGAC ATTCAGACC TCATCTATTT TGTCAAGTAC AAGCACTCCA  
3101 CAGCAGAGGA GACGCCACA CTGGTGATGG CACCACCTCT AGAGGAAGGC  
3151 TTGGGTGGAG CAATGGAAGA GATGCAACCA CTGCATGAAG ATAATTTCTC  
3201 ACAGAGAAG ACAGCAGAAC TTAATGTGCA GGTTCTGTAA GAACCCACCC  
3251 ACTTGACCA ACGTGTGATT GGGGACACTC ATGCCTCAGA AGTGTACAG  
3301 AAGCCAAATA CTGAAAAA CTTGGACCCA GGGCCAGTTA CAACAGAAGA  
3351 CACTCTATG GATGCTATTG ATGCAAAACA GNAACCAGAG ACAGCGCGCG  
3401 AAGAGCGGC AAGTGTACA CCTTTGGAAA ACGCAATCCT TCTAATATAT  
3451 TCATTCAATG TTTATTTAAC TAAGTCCAGT GTCGGCAAGA ATGTGAGACA  
3501 GCGAGGCCAA TGGAGGTCTG GAGCGGAAC AGTAAGCAGA GGACTGAGTG  
3551 GGCAGGAAG AAAGCCGCG CACTGCAGTG GCGCCCATC TGAGCGGTGG

3601 TCCCTCCAG CTGTGACAGG AAGGCCAGC TCCGGGCCGG CACGAGAGAC  
3651 CTGCTTTTCT CTTTTTCCC AGTCGCGCC CACAATCCTC CTCAGCCCT  
3701 ATTGCTCTT CTCTCCGTC CCCTCGATAG TTGTTCCGT CGCTCTGCG  
3751 CCGCCCTCG CCGCGCGGT CTTTGGTGC CTTGAGTGC GCCAGGGCA  
3801 GTGGCTGATG ACGTGTTTTA TAGCGGCAT AAAGCGAAG TGCAGGCAGC  
3851 TGTGAAGGC GAAGTTCAAT CCCAGAGTCC GCCCCTGAA TTGGGGCCTT  
3901 TCCGGAGGAG GAAGCTCTGA AAAACAGGG GCCAGTGCC ATTCCGAGG  
3951 GAATTGTGCG TTGCGTTTCA CTGTTTACA CAATGGACTC AGTACCTGCC  
4001 ACTGTGCCIT CTATGCCGC TACCCGGGG GACCCGGAC TTGTGGGACC  
4051 CTTGTCTGTG CTCTAGCGAG CTTTCATAGC CAAGCTGCTG GAGGTGACAG  
4101 TCCCGATTCC CCGGGAGGGA CCCAAGCTGT CACAGCGGG TGGATGAGTT  
4151 CTAAGCAGAG TGGTGCCT GATTGTCTGT GCAAGGAGA AATGAGTGT  
4201 GTCAGATCG AGGAAGCAA GACGTTTCTA TGCTGTTTAG GGAGGAGCT  
4251 AGTTGTACA TTGCTGTATG ATGTTAGCC TGGGCCGTAT TTTTATGGAC  
4301 TGCCATGGAA ACCTGTATTT ATCACTGCCT TCTTGGGAAT TGCTTCGTTT  
4351 GCATTTTCT TATGAGAAC TGTCTTTGTT GTGAAGGATA GAGTATATCA  
4401 AGTCACGGA CAGCAAAATTT CTGAGAAGTT GAAGACTATC ATGAAAGAA  
4451 ATACAGACT TGTACAAA TGTCAAAAT ATCAACAGAA GGTAAATATC  
4501 AAGACACTTG AAAAAATCA GGAATTTCTG GATGACACAG CTAAAAATCT  
4551 TCGTGTATG CTAGAATCTG AGAGAGAACA GAATGTCAAG AATCAGGACT  
4601 TGATATCAGA AACNAGAA TCTATAGAGA AGTTAAGGA TGTATTTC  
4651 ATGAATGCT CAGAAATTTT AGAGTTTCAG ATTGCACCTA ATGAAGCTAA  
4701 GCTTAGTGAA GAGAAGTGA AGTCTGAATG CCATCGGTT CAAGAAGAA  
4751 ATGCTAGGCT TAAGBAGAA AAAGAGCAGT TGCAGCAGGA AATCGAAGC  
4801 TGGAGTAAAT TACATGCTGA GCTCAGTGAG CAAATCAAT CATTTGAGAA  
4851 GTCTCAGAA GATTTGGAAG TAGCTCTTAC TCACAGGAT GATAATATTA  
4901 ATGCTTTGAC TAAGTGCATT ACACAGTTGA ATCTGTTAGA GTGTGAATCT  
4951 GAATCTGAGG GTCAAAATPA AGGTGGAAT GATTCAGATG AATTAGCAA  
5001 TGCAGAAGTG GGAGTGACC GGAATGAGAA GATGAATAAT CAAATTAAGC  
5051 AGATGATGA TGTCTCTCG ACACAGACTG CAATATCGGT AGTTGAAGAG  
5101 GATCTAAAGC TTTTACAGCT TAAGCTAAGA GCCTCGTGT CCCTAAATG  
5151 TAACCTGGAA GACCAGGTAA AGAAATTGGA AGATGACCGC AACTCACTAC  
5201 AAGCTGCCAA AGCTGGACTG GAAGATGAAT GMAAACCTTT GAGGCAGAA  
5251 GTGGAGATTC TGAATGAGCT CTATCAGCAG AAGGAGATGG CTTTGCAAAA  
5301 GAACTAGTCT CAAGAAGAGT ATGAACGGCA AGAAAGAGAG CACAGGCTGT  
5351 CAGCTGCAGA TGAAGGCCA GTTTCGGCTG CAGAGGAAGT AAAAATCTAC  
5401 AAGCGGAGAA TTGAAGAAAT GGAGGATGAA TTACAGAAGA CAGAGCGGTC

5451 ATTTAAAC CAGATCGCTA CCCATGAGAA GAAAGCTCAT GAAACTGCGC  
5501 TCAAAGCTCG TGCTGCAGAA AGAGCTATAG CTGAAGAGAA AAGGAAAGCT  
5551 GCCAATTTGA GACACAAAT ATTAGAATTA ACACAAAAGA TGGCAATGCT  
5601 GCAAGAAGAA CCTGTGATTG TAAACCAAT GCCAGGAAAA CCAATACAC  
5651 AAAACCTCC ACGGAGAGGT CCTCTAGCC AGAATGGCTC TTTTGGCCCA  
5701 TCCCTGTGA GTGTGGAGA ATGCTCCCT CCAATTGACAG TGGAGCCACC  
5751 TGTGAGACCT CTCTCTGCTA CTCTCAATCG AAGAGATATG CCTAGAAATG  
5801 AATTTGGATC AGTGGACGG CCTCTACCTC ATCCTCGATG GTCAGCTGAG  
5851 GCATCTGGGA AACCTCTCC TTCTGAGTAC ACAAGTCAGA ATAAATGCTAC  
5901 ATCAGTTCTC TGTCTTTTAA CAGATCCAGG ATCTGTTACA GCTACCATGA  
5951 TGAACAGCAG CTCAGAGGC TCTTTCCCTA CCAGGTTACT CGATGAAGGC  
6001 AAGGTTAATA TGGCTCCAAA AGGCCCCCTT CCTTTCCGAG GAGTCCCTCT  
6051 CATGAGCACC CCCATGGGAG GCCTGTATCC ACCACCCATT CGATATGGAC  
6101 CACCACCTCA GCTCTGCGA CTTTTTGGG CTCGCCACT TCCTCCACCC  
6151 TTTGGCCCTG GTATGCTCC ACCACTAGGC TTAAGAGAAAT TTGCACCAAGG  
6201 CTTCCACCA GGAAGACGG ACCTGCTCT CCACCTCGG GGATTTTAC  
6251 CTGGACACGC ACCATTTAGA CTTTAGGTT CACTTGGCCC AAGAGAGTAC  
6301 TTTATCTCTG GTACCCGATT ACCACCCCA ACCATGGTC CCCAGGAATA  
6351 CCCACACCA CTTGCTGTAA GAGACTTACT GCGTCAAGC TCTAGAGATG  
6401 AGCTCCACC TGCCTCTCAG AGCACTAGCC AGGACTGTTC ACAGGCTTTA  
6451 AAACAGAGCC CATAA

## !!AA SEQUENCE 1.0

ID ADP30730 standard; protein; 420 AA.

XX ADP30730;

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1497.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 02-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RE, Huang MW, Kochakota S, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2728; 428pp; English.  
XX

CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 420 AA;  
ADP30730 Length: 420 February 22, 2005 12:25 Type: P Check: 5510 ..  
1 GTGGCCATGG TGGAGGTGCA GCTGGAGAGT GACCACGAGT ACCCACCAGG  
51 CCTGCTGGTG GCGTTTCAGTG CCTGCACCAAC CGTGTGGTG GCTGTGCACC  
101 TCTTTGCACT CATGTCTCC ACGTGTCTGC TGCCCCACAT TGAAGCTGTG  
151 AGCAACATCC ACAACCTCAA CTCTGTCCAC CAGTCGCCAC ACCAGAGACT  
201 GCACCGCTAC GTGGAGCTGG CCTGGGGCTT CTCCACTGCC CTGGGCACCT  
251 TTCTCTTCTT TGTCTGAAGTT GTCTGTGGTTG CCATCATGGT ACCCGTGGGG  
301 CTCGTGTTTG TGGCCTTTGC CCTGCATTTC TACCGCTCCT TGGTGGCACA  
351 CAAGACAGAC CGCTACAAGC AGGAACTAGA GGAACCTGAAT CGCCTGCAGG  
401 GGGAGCTGCA GGCTGTGTGA  
IIAA SEQUENCE 1.0  
ID ADP30732 standard; protein; 1339 AA.  
XX  
AC ADP30732;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1499.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.



PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.

DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX

PS Claim 1; SEQ ID NO 2730; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX

SQ Sequence 1339 AA;

ADP30732 Length: 1339 February 22, 2005 12:25 Type: P Check: 881 ..

1 AGGCTTGAAG AAGACCAAGG GCATAACAGT GTTCCAGGCC TTGATTACCC  
51 TGGTGAAGG CAACATGGG ACAGGATCC TGGGACTACC CCTGCTGTG  
101 AAGAAGGGG GCATCCTGAT GGGCCCACTC AGTCTGCTGG TGATGGGCTT  
151 CATTCCTGC CACTGTATGC ACATCCTGGT CAAAGTGTGCC CAGCGCTTCT  
201 TCGTGAGCTT CTTCCTTATT ATCACCCAAC TTGGCTTCTG CTGTGTGTAC  
251 ATTGTGTTTT TGGCTGATAA TTTAAACACG GTAGTGGAAG CTGTTAATAG  
301 CACAACCAAC AACTGTATT CCAATGAGAC GGTGATTCTG ACCCCACCA  
351 TGGACTCGG ACTCTACATG CTCTCCTTCC TGCCCTTCTT GGTGTGTCTG  
401 GTCCTCATCC GGAACCTCAG GATCTTGACC ATCTTCTCCA TGCTGGCCAA  
451 CATCAGCATG CTGCTCAGCT TGGTCACTAT CATAAGTAC ATTACCCAGG  
501 AAATCCCAAG CCCAGCCGG TTGCCACTGG TAGCAAGCTG GAAGACCTAC  
551 CCTCTCTTCT TCGGAACAGC CATTTTTTCT TTTGAAAGCA TTGGTGTGGT  
601 TGTGCTCTG GAAACAAGA TGAAGAATGC CCGCCACTTC CCAGCCATCC  
651 TGTCTTTGGG AATGTCCATC GTCACTTCCC TATACATTGG CATGGCGGCT  
701 CTGGGCTACC TGGGTTTGG AGATGACATC AAGGCCAGCA TAAGCCTTAA  
751 CCTGCCTAAC TGTGTAAGGT CCCTCTCAGT CATTTTTCAG AAGGGAACA  
801 AAAGCCCAAG TCATTGTCCC AAGTCCAGAG GTTAATGTTT CAAGGAGGCC  
851 AGTGTACAG CACAGTGGCC GTGGAGAGCA GCTCTGTGGT TTGCTTGTCA  
901 GGCTGTACCA GTCTGTCAAG CTTCCTTACA TTGCCCGGCAT CCTGTGCACC  
951 TATGCCCTGC AGTTCTAGT CCCTGCAGAA ATCATCATCC CCTTTGCCAT  
1001 CTCGCCGGTG TCAACACGCT GGGCACTGCC TCTGGATCTG TCCATTCGCC  
1051 TCGTCATGGT CTGCCTGACA TGCTCTCTGG CCATCCTCAT CCCCCTGCTG  
1101 GACCTGGTCA TCTCCCTGGT GGGCTCCGTG AGTGGCACCG CCCTGGCCCT  
1151 CATCATCCCA CCGCTCCTGG AGGTACACCAC GTTCTACTCA GAGGGCATGA  
1201 GCCCCCTCAC CATCTTCAAG GACGCCCTGA TCAGCATCCT GGGCTTGTGT  
1251 GGCCTTGTGG TGGGGACCTA CCAGGCCCTG GACGAGCTGC TCNAGTCAGA  
1301 AGACTCTCAC CCCTTTTCCA ACTCCACCAC TTTTGTTCG

!!!AA SEQUENCE 1.0

ID ADP30802 standard; protein; 243 AA.

XX

AC ADP30802;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1569.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

PN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406555P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485225P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
PT  
XX Claim 1; SEQ ID NO 2800; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 243 AA;  
ADP30802 Length: 243 February 22, 2005 12:25 Type: P Check: 5842 ..  
1 ATGTTGGGGC CCCCTCTTCC TGCTGCTGTT GCTCGAGGTG GCGTGCCCGG  
51 CGGGACACCTG TCCTGTACTC CTGACGGCGG ATCCCTTCCT GGGACTGGCC  
101 ATGGCCAACT CACTTCTGAA CCCCATCATC TACACGCTCA CCAACGGCGA  
151 CCTGCGCCAC GCGCTCCTGC GCCTGGTCTG CTGCGGACGC CACTCTCTGG  
201 GCAGAGACCC GAGTGGCTCC CAGCAGTCGG CGAGCGGGC TGA  
!!AA SEQUENCE 1.0  
ID ADP30880 standard; protein; 730 AA.  
XX  
AC ADP30880;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1647.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406555P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485225P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX

PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0478609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2878; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX Sequence 730 AA;  
SQ  
ADP30880 Length: 730 February 22, 2005 12:25 Type: P Check: 9773 ..  
  
1 CCCACAGCA CTGCTTACT AGTGGCTT CTCCCAGCTG CTGGGCTTGA  
51 CTTGGTGGC CATGACCGC GCGTGGCTG GCGTGTACC AGGCGGCATT  
101 GCCTGGGAGA GCGACCTGCA GTTCAACGG CACCCCTCT GCATGGTCAT  
151 AGCCTGATC TTCTGCAGG GAAATGCCCT GCTGTTTAC CGTGTCTTCA  
201 GGAACGAAGC TAAACGCACC ACCAAGGTCC TGCACGGCT GCTGCACATC  
251 TTTCGCTCG TCATCGCCTT GGTGGCTTG GTGGGGTGT TCGACTACCA  
301 CAGGAAGAAG GGCTACGCTG ACCTGTACAG CCTACACAG TGGTGGGGA  
351 TCCTTGTCTT TGTCTGTAC TTGTGCAGT GGCTGGTGG CTTCAGCTTC  
401 TTCTGTTC CCGAGCTTC ATTCTCCTG CGGAGCGCT ACCGCCACA  
451 GCACATCTTC TTGCTGCTA CCACTTCTCT CCTTCCGTG GGACCGCCC  
501 TGCTGGGCTT GAAGGAGGCA CTGCTGTTC ACCTCGGGG CAAGTATAGC  
551 GCATTTGAGC CCGAGGTGT CCGTGGCAAC GTGCTGGGC TGCTGTGGC  
601 CTGCTTCGT GGGCGGTGC TCTACATCTT GACCCGGGC GACTGGAAGC  
651 GGCCTTCCCA GCGGAAGAG CAGGCCCTCT CCATGACTT CAAGACGCTG  
701 ACGGAGGAG ATAGCCCGG CTCCCAGTGA  
  
!!AA\_SEQUENCE 1.0  
ID ADP30889 standard; protein; 1933 AA.  
XX  
AC ADP30889;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1656.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO2004035732-A2.  
XX  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467209P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RE, Huang MM, Korhakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2887; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPONEB and is not in the specification.

XX  
SQ Sequence 1933 AA;  
ADP30889 Length: 1933 February 22, 2005 12:25 Type: P Check: 2807 ..  
1 TCTGTTCTTC CTCATTCTG GGCTAAGTTA GTAGTGGAT CGGTTGCCAT  
51 TGTGTGTTTT GCACGAGCT ATGATGAGA CTTTGTCTTT GATGACTCAG  
101 AAGCTATTGT TAACAATAAG GACCTCCAAG CAGAAAGCC CCTGGGGAC  
151 CTGTGGCATC ATGACTTCTG GGGCAGTAGA CTGAGCAGCA ACACCAAGCA  
201 CAAGTCCTAC CGGCTCTCTA CCGTCCCTGAC TTTCAGGATT AACTACTACC  
251 TCTCGGGAGG CTTCCACCCC GTGGGCTTTC ACGTGTCAA CATCTCTCTG  
301 CACAGTGGCA TCTCTGTCTT CATGGTGGAC GTCTTCTCGG TTCTGTCTTG  
351 CGGCTCTGAG TACACCAGTA AAGGCCGGAG GCTGCACCTC GCGCCAGGG  
401 CGTCCCTGCT GGCCGCGCTG CTGTTTGTCTG TCCATCTCTG GCACACCGAG  
451 TGTCAAGTAA CAAGGAGGGA GCGCATTTCT CCACCTTCTG GGTGTCTCTG  
501 AGTATCTTTC TGGGAGCAGT GGCCATGCTG TGCAAGAGC AAGGGATCAC  
551 TGTGCTGGGT TTAATGCGG TATTTGACAT CTTGGTGATA GGCAAATTCA  
601 ATGTTCTGGA AATTGTCAG AAGGTACTAC ATAAGGACAA GTCATTTAGAG  
651 GAGGTGGACA ACCCGGCTC CTTTGTCTGAC AGCATGCTGG TGAGGGCCGT  
701 AACTACAAT TACTACTATT CATTGAATGC CTGGCTGCTG CTGTGTCCCT  
751 GGTGGCTGTG TTTTGATTGG TCAATGGCT GCATCCCCCT CATTAAGTCC  
801 ATCAGGACT GGAGGTAAT TGCATTGCA GCACTCTGCT TCTGCTTAAT  
851 TGSCCTGATA TGCCAAAGCC TGTGCTCTGA AGAGGCCAC AAGAGNAGA  
901 TCCTTACTCT GGGCTCGGA TTTCTCGTTA TCCCATTTCT CCGCCGAGT  
951 AACCTGTTCT FCCGATGGG CTTGCTGTC GCAGAGGGTG TCCTCTACCT  
1001 CCCAGCGTT GGGTACTGTG TGTGCTGAC TTTTGGATTG GGAGCCCTGA  
1051 GCAACATAC CAAGAAAAAG CTGAGATGTG TGCTGCGCAG CGCGGAGTGG  
1101 CGGAGTGAGG AACAGCTTTT CAGAAGTGTCT CTGCTGTGTG GTCCCTCAA  
1151 TGCTAAGTTT CACTACAACA TTGGCAAAAA CTGGGCTGAT AAGGCAACC  
1201 AGACAGCTGC CATCAGATAC TACCGGGAAG TTTTCAGATTA AATCCCAAGT  
1251 ATGTTTCATG CATGAATAAT CTTGGAATA TCTTAAAGA AAGGATGAG  
1301 CTACAGNAG CTGAGGAGCT GCTGTCTTTG GCTGTCTCAA TACAGCCAGA  
1351 CTTTGGCGCT GCGTGGATGA ATCTAGCAT AGTGCAAGAT AGCCTGAAAC  
1401 GGTTTGAAGC AGCAGACAA AGTTACCGGA CAGCAATTA ACACAGNAGG  
1451 AATACCCAG ACTGTTACTA CAACCTCGGG CGTCTGTATG CAGATCTCAA  
1501 TCGCCACGTG GATGCTTGA ATGCGTGGAG AAATGCCACC GTGCTGAAAC  
1551 CAGAGCACAG CTTGCGCTGG AACAACTGA TTATCTCTCT CGACATACA  
1601 GGTAAATTAG CCCAAGCTGA AGCAGTTGGA AGAGAGGCAC TGGAAATTAAT  
1651 ACCTAATGAT CACTCTCTCA TGTCTCGTT GGCAAGCTG CTGGGGAAAT

1701 CCAGAAATA CAGGAAATCT GAAGCTTTAT TCCTCAAGGC AATTAAGCA  
1751 AATCCAAATG CTGCAAGTTA CCATGGTAAT TTGGCTGTGC TTATCATCG  
1801 TTGGGGACAT CTAGACTTGG CCAAGAAACA CTATGAATC TCCTTCGAGC  
1851 TTGACCCAC GGCATCAGGA ACTAAGGAGA ATTACGGTCT GTTGAGAAGA  
1901 AAGCTAGAAC TAATGCAAAA GAAAGCTGTC TGA

IIAA SEQUENCE 1.0  
ID ADP30910 standard; protein; 2700 AA.  
XX  
AC ADP30910;  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1677.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX

29-APR-2004.

28-AUG-2003; 2003WO-US026780.

29-AUG-2002; 2002US-0406576P.

29-AUG-2002; 2002US-0406579P.

29-AUG-2002; 2002US-0406585P.

29-AUG-2002; 2002US-0406588P.

29-AUG-2002; 2002US-0406608P.

29-AUG-2002; 2002US-0406611P.

29-AUG-2002; 2002US-0406612P.

29-AUG-2002; 2002US-0406616P.

29-AUG-2002; 2002US-0406640P.

29-AUG-2002; 2002US-0406642P.

29-AUG-2002; 2002US-0406646P.

29-AUG-2002; 2002US-0406653P.

29-AUG-2002; 2002US-0406655P.

29-AUG-2002; 2002US-0406669P.

17-SEP-2002; 2002US-0410946P.

17-SEP-2002; 2002US-0410947P.

17-SEP-2002; 2002US-0410948P.

17-SEP-2002; 2002US-0410949P.

17-SEP-2002; 2002US-0410953P.

17-SEP-2002; 2002US-0410957P.

17-SEP-2002; 2002US-0410958P.

17-SEP-2002; 2002US-0410959P.

17-SEP-2002; 2002US-0410960P.

17-SEP-2002; 2002US-0410961P.

17-SEP-2002; 2002US-0410962P.

17-SEP-2002; 2002US-0411019P.

17-SEP-2002; 2002US-0411022P.

17-SEP-2002; 2002US-0411023P.

17-SEP-2002; 2002US-0411024P.

17-SEP-2002; 2002US-0411032P.

17-SEP-2002; 2002US-0411035P.

17-SEP-2002; 2002US-0411037P.

17-SEP-2002; 2002US-0411041P.

17-SEP-2002; 2002US-0411045P.

17-SEP-2002; 2002US-0411048P.

17-SEP-2002; 2002US-0411048P.

17-SEP-2002; 2002US-0411052P.

17-SEP-2002; 2002US-0411055P.

17-SEP-2002; 2002US-0411073P.

17-SEP-2002; 2002US-0411082P.

17-SEP-2002; 2002US-0411101P.

17-SEP-2002; 2002US-0411111P.

18-APR-2003; 2003US-0463700P.

18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467203P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486466P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PA  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2908; 428pp; English.  
XX  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 2700 AA;

ADP30910 Length: 2700 February 22, 2005 12:25 Type: P Check: 8814 ..

1 ATGGCCAGGC ATGGCTGTCT AGGGCTGGGA CTGTTCTGCT GCGTCTGT  
51 TGCTGTACT GTGGGCCCC AGCCACACCC CTCCATCCCA GGTGCCCTCG  
101 CCACCACATT GACCCCCGTA CCTCAAGTG AGGCCTCTAT GCTGTCTCTC  
151 AACCTGGGAC TTAATCTCAA ATTCCATCTT CGGGGACCTG CTGCTGTCTG  
201 GGGGAGCCCA GTCACAGAGA CCCAGCCACT CTCTCTGGG CCAGGCCCAGG  
251 AGCCAGGGA AGAGGTGGCC AGTGGGCTGA GGACTGACCC CTTTGGGAA  
301 TTGCTGGTGG GCTCCTCAGG GAATCTCTC ACTGAGTGGG GCTCCACCGA  
351 AGGTGGCTCA AAGCCCCGGG CTTCTCCCT GCTTCGGAG TCCACATCCC  
401 GCGGCTCTGG GCCCAGCGAT GGGCCCACTG CCCCCTATCA GCCCAGGAGG  
451 AGCACTGTGA CTGGGACAC TGCTCTGATG GTGACAGCAC TTCCATCCAG

501 TGCTCCAGG CCCACCAGA GCGAGCTGGA GCTGAAGTTT GACATGGCAC  
551 TGAGAGCAGG TGCAGCCCCC ACGCTTGGC ATCGAACGCT GCCCCTGCTG  
601 CCCAGCCTGC GGGCCAGCCT GGCAGAGATT GCTGGGCGCC TGGGACCCCTT  
651 TGAATTCTTT GGCACACTAC TGTCGCCACT CCGGAACCTT TC CGGCTGA  
701 GCGCCCCAGG TGAACACTACA TCCACAAGCT CTGCTCTGG AGTTTCGGGT  
751 TCTCTGGGGT TCCTTGATAC CACTCTGTCC CTGCCCCCAT ACTCCCTGGA  
801 GAGGAAGCTC TCCAGGCCAA GTCTCTTGA CCGAGCTGCT TCCTTAAGTT  
851 TTGCTCGAT TGCAACAACA TCATTAGACC CCACAGTCCC CATCTTGCC  
901 CCAGATGACC TCTCTCTCC GCCACGCTC GGAACCCCTT CGGGGAGCC  
951 AGAGTGTTGG CCAGGCTCCT GCAGCGTGG AGAATTGCTT GAACGGGAGG  
1001 GGCAGCTCC CGAGGGCCG AGGCCCTCT TTTTCTTGAC CTTGGAGGCC  
1051 GACTGGCAG AGCCCAAGGC TCGCTGGGG CTGCCCTGG AGCCCAAGT  
1101 GTACGGGTA GCGCGCTCT TCGGCTGCT TGCCTTGCT GCGCTGCTGG  
1151 CTCTGGCCT CTTCGCCCTG CGGTGCCGC CCGGGCCCC CTGCCCTGGG  
1201 CTGCTGACC TGCTGTGCT GTGCGCCGG ACCACGCGG CTTTCCCGCT  
1251 CTTCTAGCAC GCCTATGGG ACAGGATCG ACTGCCCGG CTGCCCTGGC  
1301 TGCTGTGCA GACCTTCCG CTGCCCTGCT TGGCTGCCG CTTGGGGCTG  
1351 GCTTGCCTG TGCTGCCCG GCGCGCCCG CCGCGGTGCC CCACCGCCT  
1401 GGTGCGCTG CTGCTCTGG GGTGGGCT GCGCGCGCC GCCGCCCTCG  
1451 GGAGCGCGC GCATCGCCG CTGCGGCC CTTGCGCTCG CTGCGCGGG  
1501 CTGCACGCCT TTTCTCGCG TTTCCTTTCC GGGCTGTGTC TGGCGTCTC  
1551 CTGCTGGGC GGGCGCGGC GCGCGCCGG GCGCCCCCTG GAGGGTCTGG  
1601 GCTTCAAGG CGCCACACC CTGCCCGAG GCGCAGCCC CTTGCGCCCT  
1651 CGGAGTCTT GCGCGCGCG GCGCGCACG GCCCGGTGG CGGGCACCTT  
1701 CCGGCTGCT AGCGGAGCCC TGCAGGGCTA TGAGTGTCT CACGCCCTGG  
1751 GCTACGGCG CCAATCGGC CTGGAAGGC CTTGCCCTG GTGGGCTTC  
1801 CAGCTAGGCC TGCCTTGG CGAGTGGGC GTGCGGTTC CGTTGGCGT  
1851 GCTGGGCTC TACCGCGCG TCTCAGTCC TCGGTGCGG CCGGCTGCT  
1901 GGGCCAGCT CTTCCGCTT TCCTCGGTC CCGCGGCC CCGGCTGCC  
1951 GAGGCTGG TCACTGGCC CCGACACAAG GAGCCCCCTG GAGCGCCAT  
2001 CGCTCGCGG GACGCGGAG TGTGAGCT GTGCGCGCTG GCAGGGCCAG  
2051 GCCCAGACT CTACTTCCAG GCGGAGGTT GCGGGGCTT CGAAGGGCG  
2101 GCGGCCAACC CGGCCCGTC CCGGCTTCC TCTCCCTGCA GCATTACAC  
2151 CGTGGACTC CGGCCGCC CCCCATAA CTTGCGAGC AGCATCGAGG  
2201 AGGCCCTCT CAGCAGGCC CTGCTTGGC CTGGCCTCTT CAGGGCCCT  
2251 GCCTTCGAG ACCTCTGCC TGGGCTCGGA CTCTACGCA CCGCTCGCT  
2301 GGGACCGGG GGCAGGGCCA GTGAGATC AGGGAGGCC TCTGGCCCCG

2351 CTGCGCCCC GGAGCTCCC TCCCTGGG CTTGGCCCG AGGCAGCAGC  
2401 GTCTCATCTG GCTCGTTCTG CGGACTCTCG CGGACAGCT CGTCCATGCT  
2451 GCTGTGTTCC AGCCCCGACA GCGCCCCGCG CTGCCCTCTG GTCTGGTCC  
2501 TCAGTCCCC GCGGCCCTCA GGAAGCAGCC CCAGCCTCCC GGCCTCAGGA  
2551 TCTACACAG CCTGTCCCC ACCCTCTGC GACTCCCCAG AGCCTGCTTC  
2601 TGAGCTGCAG GCCGAGGAG CTTTGTGCA GGAGCAGTTC CTGGACGCTT  
2651 GCGACAGAT CGACGAGCTG AGCGTGGCA GCGACACCAT AGACCTGTGA

!!AA\_SEQUENCE 1.0  
ID ADP30942 standard; protein; 1655 AA.

XX  
AC ADP30942;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1709.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX

29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.

PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2940; 428pp; English.

XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antineoplastic, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX

SQ Sequence 1655 AA;

ADP30942 Length: 1655 February 22, 2005 12:25 Type: P Check: 5326 ..

1 GAGACCATCT ACACAGGCGT CTGAGGTAC AACTGGCTCC TCTCTGCAT  
51 CGGCATCGGA GGCATGTTCT ATGCCCTCAC CTGGCAGACT CACCTGCTGG  
101 CCTCATCTG TGCCCTGTTT TGTCATACA TGGAGCAGC CATCTCCAAAC  
151 ATCATGTGAC TGGTGGGGT GCCACGAGC ACCTGGGCGT TCTGCTTGC  
201 CACCATCATC TTCCTGCTCC TGACGACAAA CAACCCAGCC ATCTTCAGAC  
251 TCCCACTCAG CAAAGTCACC TACCCGAGG CCAACCGCAT CTACTACCTG  
301 ACAGTGAAA GGGGTGAGA AGAAGGCC CCCAGCGGTG ATATGCCAAG  
351 CACAGGAGTG TATTTACAT CGAGTGGTCA TCCATTGCGA GGAGGAGCAA

401 AGTGTTTTGA AAAGCGAAC ACCAGGAAG ACAAAACAAA GACCCATTTC  
451 CCTATCGATA CGGAAGCCC ACATCGAGC TGCTTGTGAG ATCTGGACAC  
501 CATGGAGGAG AGCTCTGAGA TAAAGTGA AACAACATT TCCAAGACAT  
551 CTGTGATTCC GAGTTCCATG GCTGCCAGT GGAAGAGGT CAGCAAGGCC  
601 CTCAGCTACA TCACAGGAGA GATGAAGGAG TGTGGAGAGG GACTTTAAAGA  
651 CAAGTCCCCA GTGTTCCAGT TCTTTGACTG GGTCCCTCCG GGCACATCTC  
701 AAGTGATGTT TGTGAACAA CCCCACAGC GCATCCTCAT CATCTCGGC  
751 CTCTTCATCC AGAACCCCTG GTGGGCGATC TCAGGCTGCC TGGGTACCAT  
801 CATGTCCACC TTGACAGCCC TCATCCTGAG TCAGGACAAG TCGGCCATGG  
851 CTGCAGGATT TCAGGCTTAC AATGGGGTGC TGGTGGGGCT GCTGATGGCC  
901 GTGTTCTCAG ACAAAGGTGA CTACTACTGG TGGCTGTTGC TACCCGTCTAT  
951 CATCATGTCC ATGTCTTGCC CCATCTCTCTC CAGTGCCTTG GGTACCATCT  
1001 TCAGCAAGTG GGACCTCCCA GTCTTCACAC TGCCCTTTCAA TATCACTGTG  
1051 ACTTTGTACC TGGCAGCCAC GGGCCACTAC AACCTTTTCT TCCCCACAAC  
1101 GCTGCTGAG CTTGATCCG CCATGCCCCA CATCACCTGG TCAGAGGTCC  
1151 AAGTGCCCTT GCTTTTGAGA GCCATCCCCG TTGGAATTGG CCAAGTGTAC  
1201 GCGTGTGATA ACCCTGGAC TGGAGGCATC TTCCCTCATAG CTCGTTTCAT  
1251 ATCTCTACCT CTCATTTGCT TGCATGCAGC AATTGGATCC ACCATGGGGA  
1301 TGCTAGCAGC ACTCACTATT GCGACGCCCT TTGACTTCCAT CTACTTCGGC  
1351 CTGTGTGGCT TCAACAGCAC CCTCGCATGC ATAGCGATAG GAGGCATGTT  
1401 CTACGTCTATC ACCTGGGAGA CGCACCCTCT CGGCATCGCC TGGCAGCTGT  
1451 TTGCTGCCTA CCTGGTGTCT GCGCTGGCTA ACATGTTATC TGTGCTCTCA  
1501 CCTTCTGTCT CCTGACGACC AATAACCCCG CCATCTACAA GCTCCCGCTC  
1551 AGCAAGTCA CCTACCAGA GGCACACCGC ATCTACTACC TGTCCCAAGA  
1601 GAGAAACAGA AGGCAATCAA TCATAACAAA GTATCAGGCC TACGATGTCT  
1651 CCTAA

!!AA SEQUENCE 1.0

ID ADF31000 standard; protein; 930 AA.

XX

AC ADF31000;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1767.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

OS

XX WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

PR	29-AUG-2002;	2002US-0406576P.	PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
PR	29-AUG-2002;	2002US-0406579P.	XX	
PR	29-AUG-2002;	2002US-0406585P.	DR	WPI; 2004-348438/32.
PR	29-AUG-2002;	2002US-0406588P.	XX	
PR	29-AUG-2002;	2002US-0406608P.	PT	New nucleic acid molecule for diagnosing, preventing or treating diseases
PR	29-AUG-2002;	2002US-0406611P.	PT	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PR	29-AUG-2002;	2002US-0406612P.	PT	genetic, bacterial and viral diseases.
PR	29-AUG-2002;	2002US-0406616P.	PS	Claim 1; SEQ ID NO 2998; 428pp; English.
PR	29-AUG-2002;	2002US-0406640P.	XX	
PR	29-AUG-2002;	2002US-0406642P.	CC	The present invention relates to an isolated nucleic acid molecule
PR	29-AUG-2002;	2002US-0406646P.	CC	encoding a polypeptide which is believed to be cytostatic,
PR	29-AUG-2002;	2002US-0406653P.	CC	antiinflammatory, immunosuppressive, antibacterial and virucidal. The
PR	29-AUG-2002;	2002US-0406655P.	CC	composition and methods are useful for diagnosing, preventing and
PR	29-AUG-2002;	2002US-0406666P.	CC	treating diseases such as proliferative (e.g. cancer), inflammatory,
PR	17-SEP-2002;	2002US-0410946P.	CC	immune, metabolic, genetic, bacterial and viral diseases. The present
PR	17-SEP-2002;	2002US-0410947P.	CC	sequence represents a human secreted protein. The present sequence is
PR	17-SEP-2002;	2002US-0410948P.	CC	available on WIPOWEB and is not in the specification.
PR	17-SEP-2002;	2002US-0410949P.	XX	
PR	17-SEP-2002;	2002US-0410953P.	XX	
PR	17-SEP-2002;	2002US-0410957P.	SQ	Sequence 930 AA;
PR	17-SEP-2002;	2002US-0410958P.		
PR	17-SEP-2002;	2002US-0410959P.	ADP31000	Length: 930 February 22, 2005 12:25 Type: P Check: 4287 ..
PR	17-SEP-2002;	2002US-0410960P.		
PR	17-SEP-2002;	2002US-0410961P.	1	ATGAATGGCA CCTACAACAC CTGTGGCTCC AGCGACCTCA CTGGCCCCC
PR	17-SEP-2002;	2002US-0410962P.	51	AGCGATCAAG CTGGGCTTCT AGCGCTACTT GGGCGTCTCTG CTGGTGCTAG
PR	17-SEP-2002;	2002US-0411019P.	101	GCCTGTCTGT CAACAGCCTG GCGCTCTGGG TGTTCGTGCTG CCGCATGCGAG
PR	17-SEP-2002;	2002US-0411022P.	151	CAGTGGACGG AGACCCGCAT CTACATGACC AACCTGGCGG TGGCCGACCT
PR	17-SEP-2002;	2002US-0411032P.	201	CTGCCTGCTG TGCACCTTGG CCTTCGTGCT GCACTCCCTG CGAGACACCT
PR	17-SEP-2002;	2002US-0411035P.	251	CAGACAGGCC GCTGTGCAG CTCTCCAGG GCATCTACCT GACCAACAGG
PR	17-SEP-2002;	2002US-0411041P.	301	TACATGAGCA TCAGCCTGCT CACGCCCATC GCGTGGACCC GCTATGTGCG
PR	17-SEP-2002;	2002US-0411045P.	351	CGTGGCGCAC CCGCTGGCTG CCGCGGGGCT GCGTCCCCC AGGCAGGCTG
PR	17-SEP-2002;	2002US-0411073P.	401	CGGCCGTGTG CCGCGTCTCT TGGGTGCTGG TCATCGGCTC CTGTGTGGCT
PR	17-SEP-2002;	2002US-0411101P.	451	CGCTGGCTCC TGGGGATTCA GGAGGGCGGC TTCTGTCTTA GGAGCACCCG
PR	18-APR-2003;	2003US-0463700P.	501	GCACAATTTC AACTCCATGG GGTCCCCGCT GCTGGGATTC TACCTGCCCC
PR	18-APR-2003;	2003US-0463708P.	551	TGGCCGTGGT GGTCTTCTGC TCCCTGAAGG TGGTACTGC CTGGGCCGAG
PR	18-APR-2003;	2003US-0463716P.	601	AGGCCACCCA CCGACGTGGG GCAGGCAGAG GCCACCCGCA AGGCTGCCCG
PR	02-MAY-2003;	2003US-0463732P.	651	CATGGTCTGG GCCAACCTCC TGGTGTTCGT GGTCTGTCTC CTGCCCTGTC
PR	02-MAY-2003;	2003US-0467199P.	701	ACGTGGGGCT GACAGTGGCG CTCGAGTGG GCTGGAACGC CTGTGCCCTC
PR	22-MAY-2003;	2003US-0472420P.	751	CTGGAGACGA TCCGTGCGCG CCTGTACATA ACCAGCAAGC TCTCAGATGC
PR	09-JUN-2003;	2003US-0476609P.	801	CAACTGCTGC CTGGAGCCA TCTGCTACTA CTACATGGCC AAGGAGTTCC
PR	08-JUL-2003;	2003US-0476641P.	851	AGGAGCGTC TGCATGGCC GTGGCTCCCA GTGCTAAGGC CCACAAAAGC
PR	08-JUL-2003;	2003US-0485223P.	901	CAGGACTCTC TGTGGGTGAC CTGCGCCTAA
PR	14-JUL-2003;	2003US-0486446P.		
PR	14-JUL-2003;	2003US-0486480P.		
PR	15-JUL-2003;	2003US-0486891P.	IIAA_SEQUENCE 1.0	
PR	15-JUL-2003;	2003US-0486960P.	ID	ADP31042 standard; protein; 1059 AA.
PR	08-AUG-2003;	2003US-0493341P.	XX	
PR	08-AUG-2003;	2003US-0493370P.	AC	ADP31042;
PR	08-AUG-2003;	2003US-0493573P.	XX	
PR	08-AUG-2003;	2003US-0493577P.	DT	12-AUG-2004 (first entry)
XX	(FIVE-) FIVE PRIME THERAPEUTICS INC.		XX	Human secreted protein SEQ ID #1809.
PA	Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;		XX	
PI	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;		KW	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
PI			XX	cancer; inflammatory; immune; human secreted protein.



OS Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX PD  
XX 28-AUG-2003; 2003WO-US026780.  
XX PF  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406648P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471308P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PA  
XX Williams LT, Chu K, Lee E, Heatir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX DR  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX PT  
XX Claim 1; SEQ ID NO 3040; 428pp; English.  
XX PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX CC  
XX Sequence 1059 AA;  
ADP31042 Length: 1059 February 22, 2005 12:25 Type: P Check: 1520 ..  
1 ATTCAGCTTT TGCAGAAATT GAAGCACCCCT AATGTGATTG CATTGCAGAA  
51 GGTGTTCCCTT TCTCACAGTG ACAGGAAGGT ATGGCTGCTG TTTGATTATG  
101 CAGAGCATGA CTTGTGGCAT ATTATTAAGT TTCACCGTGC ATCAAAAGCA  
151 AATAAAAGC CCATGCAGTT GCCAAGATCT ATGGTTAAAT CCTTACTTTA  
201 CCAGATTCTT GATGGTATCC ATTACCTCCA TGCAAATTGG GTGCTTCACA  
251 GAGACTTGAG ATATATGGGC AATAGTTTGT ATATTGCTG AATTGTTGAC  
301 TTCGGAACCT ATTTTTCACG GTCGTACGGA AGATATAAAA ACAAGCAATC  
351 CCTTTCATCA TGATCAACTG GATCGGATAT TTAGTGTGAT GGGGTTTCCT  
401 GCAGATAAAG ACTGGGAAGA TATTAGAAAG ATGCCAGAAAT ATCCACACT  
451 TCAAAAAGAC TTTAGAAAGA CAACGTATGC CAACAGTAGC CTCATAAAGT  
501 ACATGGAGAA ACACNAGGTC AAGCCTGACA GCNAAAGTGT CCTCTTGCTT  
551 CAGAAACTCC TGACCATGGA TCCAACCAAG AGAATTACCT CGGAGCAAGC  
601 TCTGCAGGAT CCCTATTTTC AGGAGGACCC TTTTGCCAACA TTAGATGTAT  
651 TTGCGGGCTG CCAGATTCCA TACCCCAAC GAGATTCTCT TAATGAAGAT  
701 GATCTTGAAG AAAAAGGTGA CAAGTGCAGC ACAGCCAGGA CTCGAGCCTG  
751 AACCAGGTGC CTCNAAACAA GAAGCCACGG CTAGGGCCTT CAGGCGGAAA  
801 CTCAGGTGGA CTTGTGATGC CCTCGGATTA TCAGCACTCC AGTTCTCGCC  
851 TGAATTACCA AAGCAGGCTT CAGGGATCCT CTCAGTCCCA GAGCACACTT  
901 GGCTACTCTT CCTCGTCTCA GCAGAGCTCA CAGTACCACC CATCTCACCA  
951 GGCCACCGG TACTGACCCA GCACCTTCTGT AACCTTCAGC ATTTCTTTGA  
1001 AGGATTTCTT GGTGCACCTT TCTCATGCTG TAGCAATCAC TATGGTTTAT

```
1051 CTTTCAAA
!!AA SEQUENCE 1.0
ID _ADP31067 standard; protein; 645 AA.
XX
AC ADP31067;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #1834.
XX
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW cancer; inflammatory; immune; human secreted protein.
XX
XX Homo sapiens.
XX
XX WO2004035732-A2.
XX
XX 29-APR-2004.
XX
XX 28-AUG-2003; 2003WO-US026780.
XX
XX 29-AUG-2002; 2002US-0406576P.
XX
XX 29-AUG-2002; 2002US-0406579P.
XX
XX 29-AUG-2002; 2002US-0406585P.
XX
XX 29-AUG-2002; 2002US-0406588P.
XX
XX 29-AUG-2002; 2002US-0406608P.
XX
XX 29-AUG-2002; 2002US-0406611P.
XX
XX 29-AUG-2002; 2002US-0406612P.
XX
XX 29-AUG-2002; 2002US-0406616P.
XX
XX 29-AUG-2002; 2002US-0406640P.
XX
XX 29-AUG-2002; 2002US-0406642P.
XX
XX 29-AUG-2002; 2002US-0406646P.
XX
XX 29-AUG-2002; 2002US-0406653P.
XX
XX 29-AUG-2002; 2002US-0406655P.
XX
XX 29-AUG-2002; 2002US-0406666P.
XX
XX 17-SEP-2002; 2002US-0410946P.
XX
XX 17-SEP-2002; 2002US-0410947P.
XX
XX 17-SEP-2002; 2002US-0410948P.
XX
XX 17-SEP-2002; 2002US-0410949P.
XX
XX 17-SEP-2002; 2002US-0410953P.
XX
XX 17-SEP-2002; 2002US-0410957P.
XX
XX 17-SEP-2002; 2002US-0410958P.
XX
XX 17-SEP-2002; 2002US-0410959P.
XX
XX 17-SEP-2002; 2002US-0410961P.
XX
XX 17-SEP-2002; 2002US-0410962P.
XX
XX 17-SEP-2002; 2002US-0411019P.
XX
XX 17-SEP-2002; 2002US-0411022P.
XX
XX 17-SEP-2002; 2002US-0411023P.
XX
XX 17-SEP-2002; 2002US-0411024P.
XX
XX 17-SEP-2002; 2002US-0411032P.
XX
XX 17-SEP-2002; 2002US-0411035P.
XX
XX 17-SEP-2002; 2002US-0411037P.
XX
XX 17-SEP-2002; 2002US-0411041P.
XX
XX 17-SEP-2002; 2002US-0411045P.
XX
XX 17-SEP-2002; 2002US-0411046P.
XX
XX 17-SEP-2002; 2002US-0411048P.
XX
XX 17-SEP-2002; 2002US-0411052P.
XX
XX 17-SEP-2002; 2002US-0411055P.
XX
XX 17-SEP-2002; 2002US-0411073P.
XX
XX 17-SEP-2002; 2002US-0411082P.
XX
XX 17-SEP-2002; 2002US-0411101P.
XX
XX 17-SEP-2002; 2002US-0411111P.
XX
XX 18-APR-2003; 2003US-0463700P.
XX
XX 18-APR-2003; 2003US-0463708P.
XX
XX 18-APR-2003; 2003US-0463716P.
XX
XX 18-APR-2003; 2003US-0463732P.
XX
XX 02-MAY-2003; 2003US-0467199P.
XX
XX 02-MAY-2003; 2003US-0467201P.
XX
XX 02-MAY-2003; 2003US-0467203P.
XX
XX 19-MAY-2003; 2003US-0467230P.
XX
XX 19-MAY-2003; 2003US-0471306P.
XX
```

```
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486466P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
XX Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX
XX WPI; 2004-348438/32.
XX
XX New nucleic acid molecule for diagnosing, preventing or treating diseases
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
XX genetic, bacterial and viral diseases.
XX
XX Claim 1; SEQ ID NO 3065; 428pp; English.
XX
XX The present invention relates to an isolated nucleic acid molecule
XX encoding a polypeptide which is believed to be cytostatic,
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The
XX composition and methods are useful for diagnosing, preventing and
XX treating diseases such as proliferative (e.g. cancer), inflammatory,
XX immune, metabolic, genetic, bacterial and viral diseases. The present
XX sequence represents a human secreted protein. The present sequence is
XX available on WIPWEB and is not in the specification.
XX
XX Sequence 645 AA;
XX
ADP31067 Length: 645 February 22, 2005 12:25 Type: P Check: 2601 ..
1 ATGGCGGACT TCAAAGTGCT CAGTAGTCAG GACATCATGT GGGCCCTGCA
51 CGAGCTCAAA GGACACTATG CAATCACCCG AAAGGACTTT GAGAGTCATC
101 AGCATATGGA AAATCTACC AGCAGGATG AGGTACCCAG AGATACCAGG
151 TGCATGCAGG AGCGGGGGCA GGGGCTGCTG GTGTGGCAGC AGGAGGAGCC
201 CTCTGAGTTT GACTTGGCCT ACGCCAAATTT CCTCTCCCTG GATATCAGCA
251 TGCTGGGCTT CTTTGAGACC TTGGAGACGG CACCACAGCT CACGCTGTGTG
301 CTGGGCATCA TGCTGCAGAG TGGCTGGGCT GAGTACTACC AGTGGGTGGG
351 CATCTGCACA TCCTTCTCTG GCATCTGCTG GGCACCTGCTC GATTACCACC
401 AGGCCTTGCA CACCTGCCCT CCCTCCAAGC CCCTCCTGGG CCTGGGCTCC
451 TCTGTGATCT AGTCTCTGTG GAACCTGCTG CTACTGTGGC CCGGAGTCCT
501 AGCTGTGGCC CTGTTCTCAG CCCTCTTCCC CAACAGACCA GTGGAACAGA
551 ATAAAGAGCG CGGAATAAAA GCCAATACT ACAGCCAACA GATCATCGAC
601 AGATGTGCC TAGAAGAAGG AGACAATGCT CTCCTGGACT GTTGA
!!AA SEQUENCE 1.0
ID _ADP31118 standard; protein; 5820 AA.
```

XX AC	ADP31118;	XX PR	09-JUN-2003; 2003US-0476641P.
XX DT		XX PR	08-JUL-2003; 2003US-0485218P.
XX DE	12-AUG-2004 (first entry)	XX PR	08-JUL-2003; 2003US-0485223P.
XX KW	Human secreted protein SEQ ID #1895.	XX PR	08-JUL-2003; 2003US-0485224P.
XX OS	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;	XX PR	08-JUL-2003; 2003US-0485325P.
XX PN	cancer; inflammatory; immune; human secreted protein.	XX PR	14-JUL-2003; 2003US-048646P.
XX PD	Homo sapiens.	XX PR	14-JUL-2003; 2003US-0486480P.
XX PF	WO2004035732-A2.	XX PR	15-JUL-2003; 2003US-0486891P.
XX PI		XX PR	15-JUL-2003; 2003US-0486960P.
XX PP	29-APR-2004.	XX PR	08-AUG-2003; 2003US-0493341P.
XX PR		XX PR	08-AUG-2003; 2003US-0493370P.
XX PR		XX PR	08-AUG-2003; 2003US-0493573P.
XX PR		XX PR	08-AUG-2003; 2003US-0493577P.
XX PR		XX PR	(FIVE-) FIVE PRIME THERAPEUTICS INC.
XX PR		XX PR	Williams LT, Chu K, Lee B, Hestir K, Beurang PA, Behrens D;
XX PR		XX PR	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
XX PR		XX PR	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX PR		XX PR	WPI; 2004-348438/32.
XX PR		XX PR	New nucleic acid molecule for diagnosing, preventing or treating diseases
XX PR		XX PR	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
XX PR		XX PR	genetic, bacterial and viral diseases.
XX PR		XX PR	Claim 1; SEQ ID NO 3116; 428pp; English.
XX PR		XX PR	The present invention relates to an isolated nucleic acid molecule
XX PR		XX PR	encoding a polypeptide which is believed to be cytostatic,
XX PR		XX PR	antiinflammatory, immunosuppressive, antibacterial and virucidal. The
XX PR		XX PR	composition and methods are useful for diagnosing, preventing and
XX PR		XX PR	treating diseases such as proliferative (e.g. cancer), inflammatory,
XX PR		XX PR	immune, metabolic, genetic, bacterial and viral diseases. The present
XX PR		XX PR	sequence represents a human secreted protein. The present sequence is
XX PR		XX PR	available on WIPOMEB and is not in the specification.
XX PR		XX PR	Sequence 5820 AA;
XX PR		XX PR	ADP31118 Length: 5820 February 22, 2005 12:25 Type: P Check: 7832 ..
XX PR		XX PR	1 ATGTTACACC TTCTGGACGT GGTGAACATGC AAGGCCCGCT TCATTACAGA
XX PR		XX PR	51 TGGCCCTGAG GACACCTCTG ACCAGCTGGT GCTGGAGGTG TCAGTGATGG
XX PR		XX PR	101 CTTGGGTGCC TATGCCCTCA TGCTCGGGA GGGGCCAACC AGACCTCCTG
XX PR		XX PR	151 CCCATCCAGG TCAACCTGT CAATGACCCA CCCACATCA TCTTCCCACA
XX PR		XX PR	201 TGGCAGCCTT ATGTGTATCC TGGAACACAC ACACAAGCCT CTGGGCGCTG
XX PR		XX PR	251 AGGTTCTCCA GGCCTATGAC CTGGACTCTA CCGTGTAGGG CTCACCTTC
XX PR		XX PR	301 CAGCTCCTTG GCACCCCTC TGGCCTCCCG GTGGAGACCC GAGACACGCC
XX PR		XX PR	351 TGGGAGCGG GTGACTGAGT TCTCTGCTG GAGTTGGAG GCCGCGCACC
XX PR		XX PR	401 TAGTCTATGT CCACTGCGGT GGCCTATAC AGGACTTGAC ATTCCGGGTC
XX PR		XX PR	451 AGCAATGGAC TGCAGGCCAG CCCCCCGGCC ATGCTGAAGG TGGTGGCTGT
XX PR		XX PR	501 CCAGCTGGCC ATACAAATCC ACGCAGCAC AGGGCTGCAT CTGGCCCCAGG
XX PR		XX PR	551 GCTCTGCCAT GCCCATCTTG CCTACCAACC TGTGTGTGA GACACGCC
XX PR		XX PR	601 GTGGGGCAGG ATGTGACCGT GCTGTTCCAT GTCACTGGAG GCCTGCCGTT
XX PR		XX PR	651 CAGGGAGCTG CAGAAGCAGG GGGCTGCTG GGTGGAGGAT GCTGAGTGGT
XX PR		XX PR	701 GGGTCACACA GGGCTTCCAC CAGCAGGATG TGGAGCAGG CCAGTGAGA
XX PR		XX PR	751 TACCTGAGCA CTGACCCACA GCCTACACC GAGGACACCG TGGAGAACCT

801 GGATCTGCAG GTGCAGGTGA GCTGGAAAT CCTGAGCAAT CTGTCCTTCC  
851 TAGTGACCAT CCAGAGAGCC ACTGTGTGA TGTGTCAGCT GGAGCCACTG  
901 CACACTCAGA ACACCCAGCA GGAGGCCCTC ACCAGAGCCC ACCTGAGGC  
951 CACCCTGGAG GAGGCAGGCC CAAGCCCCCC AACCTTCCAC TGTGAGGTGG  
1001 TTCAAGGTCC CAGGAAGGC AACCTTCAAC TACAGGGCAC GATGATGTCA  
1051 GACGGTCAGG GCTTCAACCA GGAAGACGTA CAGGCTCAG AGGTGACCTA  
1101 TGGGGCCATG GCACGTGCCT CAGTGGCAGT GGAGGACACC TTCTGTTTCC  
1151 ATGTACAGC TCCACCATAT TTCTCCACAC TCTGTACTCT CTCCATCCAT  
1201 ATTGGCGGTG ACCAGACAT GCCTGTCTC GTGGTGCCG AGGGTGGTA  
1251 GTGTGTCTC TCTGCTGACC AGCTTTCAT CAAGAGTCTC AACAGTGCCA  
1301 GTTGGCGGCT GCTGACTACA GACAACATGG CCTTCAGCAA TGTGTATTGG  
1351 GGCTTTGCTG AGGCCAGCT GGTGTGACC CACCAGACC TCCTCTCTGG  
1401 CAGTATCATG GCCACGGATG AGCCCATGCA GCCCATCTGC CGCTTCAACC  
1451 AGAGGGGCC TCAGGAAGAG GGGAGTCTG TGTCCGATGG GCAGCACCAG  
1501 GCCATCAGG TGTGGAGGT GCAGSCCTTG GAGCCTTACC TCTGTGTGGC  
1551 CAATGGCTCC GGCTCATG TTTCTCAAGG AGGCCAGGT ACCATCAACA  
1601 TGGCCGAGCT CACCTGGGC ACCAACCTCA ACATCTCAG TAGGGATGAG  
1651 GCCCACTACC ACGTCAAGA CAGCCCTCAC TGGGACAGT TGTCTCAAGC  
1701 CACTCAGCCA GCCACAGCT TCTCTCAGA GAACCTGCTG GTTGGGGCTG  
1751 TTCCCTATGG CCACATGGC AGCTCAGT CCGCAACAC CTTGGGCTTC  
1801 TCAATGGATG TGGGACCACT GCACACAGAT GCCACCCCTAC AAGTGACCAT  
1851 TGCCCTAGAG GCCCCAGTAG CCCCAGTAA GCTGGGCCAG CACAAGAAGA  
1901 TCTACATCTT CMAGGAGAG CGAGCTGAGA TCAGAAGGA CMAGCTGGAG  
1951 GTAGCCCAGG AGGCAGTGCC GCCAGCAGC ATCGTTTTCT CAGTGAAGAG  
2001 CCCACCGAGT GCGGCTACC TGGTGATGTT GCTGCGTGGC ATCTTGGCAG  
2051 ATGAGCCACC CAGCCTGGAC CCGGTGCAGA GCTTCTCCCA AGAGGCAGTG  
2101 GACACAGCCA GGATCCTCTA CTTGCACCTC CGCCCTGAGG CCGGAGCCA  
2151 TGCTTCTCG CTGATGTGG CTTGGGCTG GGTGCTCCCC TTGAGGACGT  
2201 CAGGTGAGC TGGAGTGA AGAGCATCTG ATCCAGTACC TGCACGATGG  
2251 GAGCAAGACA CTGACGGTTT TGTCTGTATG GCTAATGCCT CTGAGATGGA  
2301 CCGCAGAGC CATCTGTGG CTTTCACTGT CACCATCTG CTTGTCAATG  
2351 GCCAACCCCC GACCTCATAC AAATCAGGC CTGCAGAGGC TGTGAGGAGC  
2401 ATGGATGGTT ACTCTGGGCC CAAGGACCTG GTGTACACCA TTAAGCAGCC  
2451 CAGCAATGGG TGGGTAGTGC GGTGGGCGT GCCGGCACT GAGGTGCGCA  
2501 GCTTTCATGA GACCCAGCTG GATGTGGGC TCGTGTGTTT CTCACACAGA  
2551 GGAGGCTGCG TGAGCATCTG GACCAGCAC ATGATCAAA CCCCAGATT  
2601 CATCATCTCG GAGCGCTGG CCAGTATGTA CTCATGTGGG AACCAAGACA

2651 CACTGATGA GGAGTTGGA GAGCAGCAC AGCAGCACGA CGAGATGCTG  
2701 CACATCACCC AGCGCTGAA GGAGCGCTC AGCATCATCG GTGACATCAA  
2751 CAGGACCACT GTCAACATGC CCATGCCCCC GCCGTGGAC GACCTGGT  
2801 TGCAGGTGA GAGCATCCT GAGCACACA GGCCAGAGGC TTCCCTGTAT  
2851 CCCTTTGGCC CTACCCCCCT GGTGCTCTTG TGCCCCAGCC GGGGTCCCCA  
2901 GTGTGCCGAG TGGCTGCACG CCCAGATCC ATCGGCACG TGCCGGCCCG  
2951 GCCCGTGGG TCTCCCAA CACAGACTCA CCCCCTCT CTGGGSGCTG  
3001 GGCCGTACC TCTGGCTTTT TCTGGAGGA GGCCACTGGG TGAGCCAGGG  
3051 GCTGGCAGA CACCCTTTGT TCCTCTGGG CACTGGCTCC AGCGGAGTTG  
3101 AAAATGCCA CCTGAAGACA AGAGACTAA AGGCTCTTG GCACATACAC  
3151 CACCCCTTGA ATTTCCAGTT CACCACACC AGCCCGACA GTGATCACAT  
3201 TCTCATCAA GTCAAATTT CTATTCTTAT CCCACTTCT GCCAACCTTA  
3251 AACCTACTTT AAGTCGCTTA TACGGCATAG GAGCCAAAT AGCAGGGACA  
3301 CATCTTATAG AATCCTTTGA AATGATTTT ATTACTTTCT CACCTCTCTC  
3351 ACCTCTTCT ACATCTCTC TCAACGAAAC CGCTGTTCTT CTTCAACCA  
3401 AGGATAAAT CAAGCACTTG TTGCGGCGC GGACTCCACA CCGCGGCGC  
3451 CCGCCCCAGG GGAGAGTGA GTCCGCCCA GCGCGGCCA CCGGGGACC  
3501 CGGGGCAAG GTTCGGGCC ATCCGCGCC GGGCGGCC CCAATCCGA  
3551 AAGCGCGAC GGGCCCCAAG TTGGGCTCG GAGTGGGAG CCGCGCGAGC  
3601 CCCAAGCAGA CAATGCGGA GAAGGCTCTG CAGGTAGCCC CAGCCACCCC  
3651 GCGCACCGC TACAAGCGC CCGGGGTGG CCGGGGCACG CAAGAGGGA  
3701 GTAACGTCTG CGAGTCTCC CGTGAGTACA CGCGGAGCAA GGGCTCGAG  
3751 CTGGGATTC ACGCAGAGC TGCCCATCCC GCTCCAGAG ACCAATACTG  
3801 CAAAGGACCT CAGAAATCAT CGGATTGCTT TGAGAAACAA AATGTGTTCC  
3851 GTGTACCAAC GCGGCGCAG GAGAAATAT TAGCTGAAA NACACAACAG  
3901 GGGAAATTGG CCGCAGCCAA GAAAAAGTTA AAGCATATT GGCAGAGGA  
3951 GAGCCCTGGC ATTCAGCAG GAGCTAACAG GAAAAAGAAA ATCAATGGCA  
4001 GTAGCCCTGA CACAGCCACT TCTGTGTTT ACCACTCACC TGGGGATTCA  
4051 GCACAGGTA TCTACGGGA GGGCGGTGCA TCCTCTACTA CCTTGAGGA  
4101 TCTGGAGAGC CAGTACCAAG AACTATCAGT GGCCCTGGAT TCAAGCTCG  
4151 CAATATCAG TCAACTCACT GAAACATCA ATTCACTGGT TCGCATCT  
4201 AAGGAGGAGA AGAAGCATGA GATACATCTG GTACAGAGC TTGGGAGGAG  
4251 CTGTGTTCAA CTCAAAAACC AGCGGTGA ACCCTGGCC CCAGAGCCCC  
4301 CAGCAGGCC ATCTAAGGTG GAGCAGCTAC AAGATGAGC CAACCACTTA  
4351 AGAAGGAGC TAGAGGTGT GGAAGACAG CTCAGGCTG AGGTGAAAA  
4401 CAATCAGATG TTGAGTCTCC TGAACAGAG ACAGGAGG AGGCTACGTG

4451 AACAGAGGA GAGGTACAT GAACAGGAGG AGAGGCTACA TGAACAGGAG  
4501 GAGAGCTGT GTGAACAGGA GGAGAGGCTA CGTGAACAGG AGGAGAGGCT  
4551 GTGTGAACAG GAGGAGAGGC TACGTGAACA GGAGGAGAGG CTACATGAAC  
4601 AGGAGGAGG GCTACGTGA CAGGAGAGGA GGTACGTGA ACAGGAGGAG  
4651 AGGCTACATG AACAGGAGGA GAGGCTGTGT GAACAGGAGG AGAGGCTACG  
4701 TGAACAGGAG GAGAGGCTGT GTGAACAGGA GGAGAGGCTA CGTGAACAGG  
4751 AGGAGGCT GTGTGAACAG GAGGAGAGG TACGTGAACA GGAGGAGGAG  
4801 CTGTGTGAAC AGGAGGAGG GCTATGTGAA CAGGAGGAGA GGCCTGTGTA  
4851 ACAGGAGAG CTGCCAGGC AGGAGAGGCT CTTGGGAAGAG GTGGAGAAGC  
4901 TGTTTAGAACA GGAGAGGCGG CAGGAGAGGC AGGAGAGGCT GCTGGAGAGG  
4951 GAGAGGCTGC TGGACGAGGT GGAGGAGCTC CTGGAGCAGG AGAGGCTTCG  
5001 GCAACAGGAT GAGAGGCTGT GGCAGCAGGA GACTCTGCGG GAGCTGGAGA  
5051 GGCTGCGGGA GCTGGAGAGG ATGCTGAGC TGGGGTGGGA AGCCCTGTAC  
5101 GAGCAGCGG CCGAGCCACG CAGCGGCTTC GAGGAGCTGA ACAACGAGAA  
5151 CAAGAGCACA CTGCAGTTGG AGCAGCAAGT AAAGGAGCTG GAGAGTCTGG  
5201 GTGAGCTGAA AGAGACTGTA ACTCCGACC CATCCAAGAA GATGTGGGAG  
5251 GCGGGCACCA GCCTCTGGG AGGGAGGTG CCAGGCGACA GGCAGCTGCA  
5301 GCCTGGGAC AGGCTCTTCC GGCAGTGGA GCTGAAGAGC CAAGAGGCTC  
5351 CGAGTCTGCA GCAGAGGACA GACCAGTACC TGGAGCCCCA GTCCCAACAAG  
5401 GAGCTTGGAT GTGCGGACAA GCAGGCTGCC CTACTCCGAC TAGAGTTGAG  
5451 GCATCAGGA GAGGGGAGC TGGGAGAGCG CGCCGAGAG GTCCCGCGGG  
5501 TGGTTGCGGC CGTACAGCG GCTCCGACG GGTCACTT CCGCGCCCTT  
5551 CCCGCCAGAG GAGAAACTAA CAATGAATAA GGAAGTCTTG ATGGAGGAGA  
5601 AGTTGGAATG CAGCCTCTGG TGCTGTTTGA GCGATCCCTC TACCCCGGGT  
5651 CGCTGCTGTG TTCTGGAAG GCGATTTGTA CCTTGGATGC AGCAGACCTT  
5701 CTCCATTCAA AGCCCTCTT CAACTGCCCC CCCCCCACTA CCTCCAAGAC  
5751 AGAGATTCTG GGTCTTGCA ACTGCAGCCC CTCAGAGAGT GTNAGAGGGG  
5801 CAGAAAAAGG AGATCAGGAG

!AA SEQUENCE 1.0  
ID -ADP31152 standard; protein; 771 AA.

XX ADP31152;

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1919.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

OS WO2004035732-A2.

XX 29-APR-2004.

XX PD

28-AUG-2003; 2003WO-US026780.  
29-AUG-2002; 2002US-0406576P.  
29-AUG-2002; 2002US-0406579P.  
29-AUG-2002; 2002US-0406585P.  
29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406656P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
15-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
08-AUG-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493373P.  
08-AUG-2003; 2003US-0493377P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX PA



XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3353; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 346 AA;  
ADP31355 Length: 346 February 22, 2005 12:25 Type: P Check: 6338 ..  
1 ATGGCAGCTT GTGTCTGCCA CTGCCCTTG GCCATCACAC TGATGCACCG  
51 GGTCCCGTGC TGGCCACAGC CTGCTGCTCA GCATCGCCTG TGCTCTGTGG  
101 GGACTCTGAT GAGGCTGGGG CTTTGCAGCT GGCTCCACAG CGGGCTTTGG  
151 TGCTTGGCGA CGTGTGGT AGAAGTTACA CAGTCGTGCT GTCAGTATAG  
201 TGACTTGGCC CTTTGTGATG TAGAGGGAAT CGAAGACTGT CTTCTTTATA  
251 TCTTGAACCC CTGTGACAGG ATTGACCCAG AGAAGCTCTC AGTGAATTCT  
301 TACTTTATGA AAGACTGTG CTGGACAGT TTGACCACAG TAGAGA  
!!AA\_SEQUENCE 1.0  
ID ADP31375 standard; protein; 378 AA.  
XX  
XX  
AC ADP31375;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2142.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-0036780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-040558P.  
PR 29-AUG-2002; 2002US-040558P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406613P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR

29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467159P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3373; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC

CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 378 AA;  
  
ADP31375 Length: 378 February 22, 2005 12:25 Type: P Check: 2345 ..  
1 ATGGTGA AAA TGTCCTATAT CTACACAGTC CAGTATGATA GGAACATGC AA  
51 ATTAACACAG CAAATATGATA CCACATACACA TGTATTAGAA AAACAAAT  
101 ATAGAACACT GACAACACCA AATGCTGGCA AGGATGTGGA GCAACAGGAA  
151 CTCTCATTTCA TTGCTGTGAA AATACAATCC AAACCTCTGTG ACATGGCGCA  
201 CATGGCCCTTT TGTAACTAG ACTACTTAA ACCTCCAACT TCATCTCCTA  
251 CTTGCCCAACC AGGCCCCAAC TATACCCCAAC TACTTGGCAG TCAGGATCTC  
301 GCCAGCCTTC ATCTAGCCTT GACACATGCA GCATCCCCCTG CTGTAAAGAC  
351 TCATACCAAT CTCCAGATC TCAATTGA  
  
11AA SEQUENCE 1.0  
ID -ADP31388 standard; protein; 627 AA.  
AC ADP31388;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2155.  
DE  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX  
XX 29-AUG-2002; 2002US-0406579P.  
XX  
XX 29-AUG-2002; 2002US-0406585P.  
XX  
XX 29-AUG-2002; 2002US-0406588P.  
XX  
XX 29-AUG-2002; 2002US-0406608P.  
XX  
XX 29-AUG-2002; 2002US-0406611P.  
XX  
XX 29-AUG-2002; 2002US-0406612P.  
XX  
XX 29-AUG-2002; 2002US-0406616P.  
XX  
XX 29-AUG-2002; 2002US-0406640P.  
XX  
XX 29-AUG-2002; 2002US-0406642P.  
XX  
XX 29-AUG-2002; 2002US-0406646P.  
XX  
XX 29-AUG-2002; 2002US-0406653P.  
XX  
XX 29-AUG-2002; 2002US-0406655P.  
XX  
XX 29-AUG-2002; 2002US-0406666P.  
XX  
XX 17-SEP-2002; 2002US-0410946P.  
XX  
XX 17-SEP-2002; 2002US-0410947P.  
XX  
XX 17-SEP-2002; 2002US-0410948P.  
XX  
XX 17-SEP-2002; 2002US-0410949P.  
XX  
XX 17-SEP-2002; 2002US-0410953P.  
XX  
XX 17-SEP-2002; 2002US-0410957P.  
XX  
XX 17-SEP-2002; 2002US-0410958P.  
XX  
XX 17-SEP-2002; 2002US-0410959P.  
XX  
XX 17-SEP-2002; 2002US-0410960P.  
XX  
XX 17-SEP-2002; 2002US-0410961P.  
XX  
XX 17-SEP-2002; 2002US-0410962P.

PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3386; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 627 AA;  
  
ADP31388 Length: 627 February 22, 2005 12:25 Type: P Check: 7274 ..  
1 ATGACCAGCT TAGTGCTGGT ACTGAGAAGA AACTCCAAG CACTTCCCAA



```
51 AGCAAACTT GCACCAAGG TCCTGGTCAC TGTTTGGTGG TCTGCTGTCA
101 GTCTGATCCA CCACAGTTT CTGAATCCCA GCGAAACCAT TACATCTGAG
151 AAGTATGCTC AACAAATTGA TGAGATGCAC CAAAATTGA AACGCTGCA
201 GCAGCATTTG ATCAACAGAA GGAGCCCNAT TCTTCTCCAT GACAAGGCCC
251 TACTGCATGT CACACAACCA ACAATTCAAA AGTTGAACAA GGCCAGACAT
301 GACTACTACT TCTTCAAGCA TTGTGAGAAC TTGTGTCAGG GAAACACAA
351 CCAGAAGGAT GCAGAAATG CTTTCCRAGA GTTCATTGAA TCCCAAAGCA
401 CAGATTTTGA TGCTCCAACC ACTTGAAGA AGCTGACCGG CGCCCTCCTG
451 CCTATCTGT TTAACGCGAGT TGCAGAATGC TGCATTATAG AAAGCTACAG
501 AGCACTGGTG GAGTGGATTG ATAATGAATC TGCTGACACA CTTGGAGTAA
551 CTCCAAGACA CAGGCTGTGAG GATAACGCAA CTTTACTAAA ACCTGTGGAA
601 GCCTTTAAGS AATGAAGGA TGGATAA

!!AA_SEQUENCE 1.0
ID ADP31426 standard; protein; 1224 AA.
XX
AC
XX
XX
DT 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #2193.
XX
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
XX cancer; inflammatory; immune; human secreted protein.
XX
OS Homo sapiens.
XX
PN WO2004035732-A2.
XX
XX
PD 29-APR-2004.
XX
PF 28-AUG-2003; 2003WO-US026780.
XX
PR 29-AUG-2002; 2002US-0406576P.
PR 29-AUG-2002; 2002US-0406579P.
PR 29-AUG-2002; 2002US-040585P.
PR 29-AUG-2002; 2002US-040588P.
PR 29-AUG-2002; 2002US-0406608P.
PR 29-AUG-2002; 2002US-0406611P.
PR 29-AUG-2002; 2002US-0406612P.
PR 29-AUG-2002; 2002US-0406616P.
PR 29-AUG-2002; 2002US-0406640P.
PR 29-AUG-2002; 2002US-0406642P.
PR 29-AUG-2002; 2002US-0406646P.
PR 29-AUG-2002; 2002US-0406653P.
PR 29-AUG-2002; 2002US-0406655P.
PR 29-AUG-2002; 2002US-0406666P.
PR 17-SEP-2002; 2002US-0410947P.
PR 17-SEP-2002; 2002US-0410949P.
PR 17-SEP-2002; 2002US-0410953P.
PR 17-SEP-2002; 2002US-0410957P.
PR 17-SEP-2002; 2002US-0410958P.
PR 17-SEP-2002; 2002US-0410959P.
PR 17-SEP-2002; 2002US-0410960P.
PR 17-SEP-2002; 2002US-0410961P.
PR 17-SEP-2002; 2002US-0410962P.
PR 17-SEP-2002; 2002US-0411019P.
PR 17-SEP-2002; 2002US-0411022P.
PR 17-SEP-2002; 2002US-0411023P.
PR 17-SEP-2002; 2002US-0411024P.

1011 AGCAAACTT GCACCAAGG TCCTGGTCAC TGTTTGGTGG TCTGCTGTCA
1012 GTCTGATCCA CCACAGTTT CTGAATCCCA GCGAAACCAT TACATCTGAG
1013 AAGTATGCTC AACAAATTGA TGAGATGCAC CAAAATTGA AACGCTGCA
1014 GCAGCATTTG ATCAACAGAA GGAGCCCNAT TCTTCTCCAT GACAAGGCCC
1015 TACTGCATGT CACACAACCA ACAATTCAAA AGTTGAACAA GGCCAGACAT
1016 GACTACTACT TCTTCAAGCA TTGTGAGAAC TTGTGTCAGG GAAACACAA
1017 CCAGAAGGAT GCAGAAATG CTTTCCRAGA GTTCATTGAA TCCCAAAGCA
1018 CAGATTTTGA TGCTCCAACC ACTTGAAGA AGCTGACCGG CGCCCTCCTG
1019 CCTATCTGT TTAACGCGAGT TGCAGAATGC TGCATTATAG AAAGCTACAG
1020 AGCACTGGTG GAGTGGATTG ATAATGAATC TGCTGACACA CTTGGAGTAA
1021 CTCCAAGACA CAGGCTGTGAG GATAACGCAA CTTTACTAAA ACCTGTGGAA
1022 GCCTTTAAGS AATGAAGGA TGGATAA

101117 SEP-2002; 2002US-0411032P.
101118 SEP-2002; 2002US-0411035P.
101119 SEP-2002; 2002US-0411037P.
101120 SEP-2002; 2002US-0411041P.
101121 SEP-2002; 2002US-0411045P.
101122 SEP-2002; 2002US-0411046P.
101123 SEP-2002; 2002US-0411048P.
101124 SEP-2002; 2002US-0411052P.
101125 SEP-2002; 2002US-0411055P.
101126 SEP-2002; 2002US-0411073P.
101127 SEP-2002; 2002US-0411082P.
101128 SEP-2002; 2002US-0411101P.
101129 SEP-2002; 2002US-0411111P.
101130 APR-2003; 2003US-0463700P.
101131 APR-2003; 2003US-0463708P.
101132 APR-2003; 2003US-0463716P.
101133 APR-2003; 2003US-0463732P.
101134 MAY-2003; 2003US-0467199P.
101135 MAY-2003; 2003US-0467201P.
101136 MAY-2003; 2003US-0467203P.
101137 MAY-2003; 2003US-0467230P.
101138 MAY-2003; 2003US-0471306P.
101139 MAY-2003; 2003US-0471336P.
101140 MAY-2003; 2003US-0472420P.
101141 MAY-2003; 2003US-0472430P.
101142 JUN-2003; 2003US-0476609P.
101143 JUN-2003; 2003US-0476641P.
101144 JUL-2003; 2003US-0485218P.
101145 JUL-2003; 2003US-0485223P.
101146 JUL-2003; 2003US-0485224P.
101147 JUL-2003; 2003US-0485325P.
101148 JUL-2003; 2003US-0486446P.
101149 JUL-2003; 2003US-0486480P.
101150 JUL-2003; 2003US-0486891P.
101151 JUL-2003; 2003US-0486960P.
101152 AUG-2003; 2003US-0493341P.
101153 AUG-2003; 2003US-0493370P.
101154 AUG-2003; 2003US-0493573P.
101155 AUG-2003; 2003US-0493577P.
101156 (FIVE-) FIVE PRIME THERAPEUTICS INC.
101157 Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
101158 Hallenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
101159 Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
101160 WPI; 2004-348438/32.
101161 New nucleic acid molecule for diagnosing, preventing or treating diseases
101162 such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
101163 genetic, bacterial and viral diseases.
101164 Claim 1; SEQ ID NO 3424; 428pp; English.
101165 The present invention relates to an isolated nucleic acid molecule
101166 encoding a polypeptide which is believed to be cytostatic,
101167 anti-inflammatory, immunosuppressive, antibacterial and virucidal. The
101168 composition and methods are useful for diagnosing, preventing and
101169 treating diseases such as proliferative (e.g. cancer), inflammatory,
101170 immune, metabolic, genetic, bacterial and viral diseases. The present
101171 sequence represents a human secreted protein. The present sequence is
101172 available on WIPWEB and is not in the specification.
101173 Sequence 1224 AA;
101174 ADP31426 Length: 1224 February 22, 2005 12:25 Type: P Check: 1405
101175
101176 1 ATGTTCTTTT AAACCAACGA GAACAAAGAC ACAACATACC AGAATCTCTG
101177
101178 51 GGACGCATTC AAAGCAGTGT GTAGAGGGAA ATTTATAGCA CTAATGCCCC
101179
101180 101 ACAAGAGAAA GCAGGAAGA TCCAAATTG ACACCTTAAC ATCAATTA
```

151 AAGAAGCTAG AAAAGCAAGA GCAACACAT TCAAAGCTA GCAGAAGGCA  
201 AGAAATAACT AAATCAGAG CAGAAGTGA GGAATAGAG ACACAAAAA  
251 CCCTTCAAAA AATCAATGAA TCCAGGAGCT GGTTTTTTGA AAGGATCAAC  
301 AAAATTGATA GACCGGTAGC AAGACTAATA AAGAAAAAAA GAGAGAAGAA  
351 TCAATAGAC ACNATAAAA ATGATAAAGG GGATATCACC ACCGATCCCA  
401 CAGAAATACA AACTACCATC AGAGAATACT ACAACACCT CTACACAAAT  
451 AAACTAGAAA ATCTAGAAGA AATGATATAA TTCTCAACA CATACACTCT  
501 CCCAAGACTA ACCAGGAAG AGTTGAATC TCTGAATAGA CCAATACAA  
551 GAGCTGAAAT TGTGGAATA ATCAATAGTT TACCAACCAA AAAGATCCCA  
601 GGACCAGATG GATTCACAGC TGAATTCTAC CAGAGGTACA AGGAGGAACT  
651 GGTACCAATC CTCTGAAAC TATTCCAATC AATAGAAAAA GAGGGATCC  
701 TCCCTAACTC ATTTATGAG GCCAGCATCA TTCTGATACC AAAGCCGGGC  
751 AGAGACACAA CCAAAAAAGA GAATTTTAGA CCAATATCCT TGATGAACAT  
801 TGATGCAAAA ATCCTCAATA AATACTGCGC AAACCGAATC CAGCAGCACA  
851 TCAAAAAGCT TATCCACCAT GATCAAGTGG GCTTCATCCC TGGGATGCAA  
901 GGCTGGTTCA ATATAGGCAA ATCAATAAAT GTAATCCAGC ATATAAACAG  
951 AGCAAAGAC AAAAACACA TGATTTATCTC AATAGATGCA GAAAAAGCCT  
1001 TTGACAAAAA TCAACAACCC TTATGCTAA AACTCTCAA TAAATTAGGT  
1051 ATTGATGGGA CGTATTTCAA AATAATAAGA GCTATCTATG ACACCCACAG  
1101 CCAATACCAT ACTGAATGGG CMAAACTGG AAGCATTCCTC TTGAAAACCT  
1151 GGCACAAGAC AGGGATGCCC TCTCTACCA CTCTATTTCA ACATAGTGT  
1201 GGAAGTTCTG GCCAGGGCAA TTAG  
IIIA SEQUENCE 1.0  
ID\_ADP31471 standard; protein; 960 AA.  
XX AC ADP31471;  
XX AC  
DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2238.  
XX DE  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406589P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.

29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411033P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
02-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(PIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haisan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 3469; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 960 AA;

ADP31471 Length: 960 February 22, 2005 12:25 Type: P Check: 7368 ..

1 ATGAGTGAAC TCACATTCAC AATTACTTCA AAGAAAATAA AATATCTAGG  
51 AATCCAACTT ACNAGGGATG TGAAGGACCT CTTCAAGGAG AACTACAAAT  
101 CACTGCTCAA TGAATAAAT GAGGATACAA ACAAATGGAA GAACATTTCA  
151 TGCTCATGGA TAAGAAGAAT CAATATCGTG AAAATGGCCA TACTGCCCAA  
201 GGTAAATTGAC AGACTCAATG CCATCCTCCC CATCAAGCTA CCAATGACTT  
251 TCTTCACAGA ATTGAAAAA ACTACTTTAA AGTTCTATAG GAACCAAAAA  
301 AGAGCCCA CA TTGCCAAGTC AATCCTAAGC CAAAAGAACA AAGCTGGAGG  
351 CATCACACTA CTGACCTCA AACTATCCTA CRAAGGTGCA GTCACCAAAA  
401 CAGCATGGTA CTGGTACC AAACAGAGATA TAGACCAATG GAACAGAACA  
451 GAGCCCTCAG AAATAATGCC GCATATCTAC AGCTATCTGA TCTTTGACAA  
501 ACCTGACAAA AACRAGCAAT GGGGAAGGA TTCCCTATTT AATAAATGGT  
551 GCTGGGAAA CTGGGTAGCC ATATGTAGAA AGCTGAAACT GGATCCCTTC  
601 CTTACACTTT ATACAAAAA TAATTCAAGA TGGATTAAAG ACTTAAATGT  
651 TAGACCTAAA ACCGTAAAA CCCTAGAGA AATCCTAGGC AATACCATTC  
701 AGGACATAGG CATGGGCAAG GACTTCATGT CTAAACACCC AAAACAATG  
751 GCAACAAAAG CCAAAACTGA TAAACGGGAT CTAATTTAAAC TAAAGAGCTT  
801 CTGCACAGCA AAGAANACTA TCATCAGAAAT GAACAGAAA CCTACAGAAAT  
851 GGGAGAAAAT GTTTGCAATC TACTCATCTG ACAAGGGGCT AATATCTAGA  
901 ATCTACAAAG AACTCAACA AATTACAAG AAAAAAACA CCCCATCAAC  
951 AAGTGGGTGA

!!AA SEQUENCE 1.0  
ID ADP31502 standard; protein; 591 AA.

XX

AC ADP31502;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #2269.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.

XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411011P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX  
PI

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3500; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 591 AA;  
SQ  
ADP31502 Length: 591 February 22, 2005 12:25 Type: P Check: 6597 ..  
1 ATGGCTGTGG AGGACCGCTG GTGGCAAGA AGGGTACAG AGTATGAAGG  
51 GAGCCACGAT ATATGAGGCA AAGGACTTGG AACTTGGCAG GATGACAATG  
101 GGGAGAGAGC TCTGGCCATG GAGCCAGAGC ATCCGTATTC AGCAACAAC  
151 ACCCACGTTG ACGGTCCTTC TACTGACTCT TTCTCCATTG TCTCTCAAC  
201 TCCTGAGGTG AAGTCTCAG CAGCCACACA GTCGCCCTCT GCTCCGAATG  
251 CCCAGTTCTC CACCTACAC CAGGCTGTG CAGACTATCA GCCTGTGGGC  
301 CCTGAACAGC CCTCCACGGA AGATGTGTG ATTACTGGT ATGGAGGAGC  
351 TGTTCCTGAG TCTCTGGTTG GGGCTCTTAA TCAGGCAAT ATTACAGTC  
401 CCCATGAGG TCATGATACA GTGATCAGTA ATGAAATGG CATGTGCTTC  
451 ATCTCTCTTG TGCACACTGT GGGGAGGAA AAGGACCCA GGACGTTCTT  
501 AAGTGCCAGA TTGGAGCAG CAGACATCAC TCTCACCGC ATTCCAGACC  
551 TCAGTCATGT ACACAGGAGG CCAGAAATGC TGTCCAGCTA G  
!!AA\_SEQUENCE 1.0  
ID ADP31644 standard; protein; 2001 AA.  
XX  
AC ADP31644;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2411.  
DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
FN  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR

29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406668P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411013P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
02-MAY-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT

PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

PS Claim 1; SEQ ID NO 3642; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

XX Sequence 2001 AA;

ADP31644 Length: 2001 February 22, 2005 12:25 Type: P Check: 8651 ..

1 ATGCACATAA ACCAGAAAT CTACAAGAA CTGATATATT TTGGACATA

51 TACACTCCCA AGATTGGACC AGGAAGAGAT TCGGTCCCTG AATAGACCAA

101 TAACAAGTTC TGAATTGAA TCAGCATAA ATAGCCTACC RACCAAAAA

151 TTTCAGAGAC CAGATGGATT CACAGTTGAA TTCTACCAGA TGTACAAAGA

201 AGAGCTGCAT CATCTGATA TCAAAACCTG GCAGACACAC AACAAGAAAA

251 GAAAGTTCA GGCCATATC CTTGATGAC ATCAATGCAA AAAATCCTCA

301 AGAAATCCG GAAACTGAA TCCAGCAGCA CATGAAAGC TAATCCACCA

351 TGATCAAGCA GGCCTTATC CTGGGATGCA AGCTCTGTC TGCTGGATAA

401 CAGTCTCTC CTCCAGTGT TCAAAAGAA CTACAGGTAA GGACAGGACA

451 GGGAAAAATG AGGAGGGAAG AGTGTGTGT GGGAAAAAGAG ACTGGGAATT

501 GAGTATCTGT TCTTCTTGG ATGTACACCA TCAATGTCTG CCCCAGACGG

551 CTCCTGTTGG CTCAGGACTG TGGCTGTGCC AGCCGACACC CAGGTGTGGG

601 AACAGATCT ACAACCTTTC AGAGCAGTGC TGTATGATG ATGCCATCTT

651 ATCTTAAAG GAGACCCGCC GCTGTGGCTC CACCTGCACC TTCTGGCCCT

701 GCTTTGAGCT CTGCTGTCCC GAGTCTTTTG GCCCCAGCA GAACTTTCTT

751 GTGAAGTTGA GGGTTCTGGG TATGAACTCT CAGTGTCACT TATCTCCCAT

801 CTCCCGGAGC TGTACCAGAT GCTGCTGCAG GGCCAGTACA CAGTTGTGCT

851 CTGCGCAGTG CCCAAGACAC ACCTACCCGG GCTCCTGCAT CCCCTTGCGG

901 GCAAGCTGCA CCCCACCCCC ACCCCACCCA CTGGTTCTCA GACCTCTGGG

951 CAGCTGGTGT GGCATGGGAG ATAGCAGTAG CAGTGGTAGA ACAGTCACT

1001 GGGACCCCAAG CCTTCCATGT TGGTGTTACA AGAAGATGCG ATCAGTTGGC

1051 AGGCTTGTCC CCAGTCCAC AGTCACCTGT AGTACTGCAG TGGTCACATGT

1101 CCTAAGTGTG GTGTACCCTG GAGAGCTTGG ACTACCCCTGT TTGCATTTTT

1151 ACAGAAACCC ACAAGTAGAT ATTGCCAGCA ATGCATTATC AACGTGTGTG

1201 CTGCCAGAAA GACAACGAGA GCTCTTTTCT GAAAAATGA CCCATCATCA

1251 GTCACCAAGA CCTGAGAACA GAGAGTGGCA GCCCCTTTCAC ACAGCGGCA

1301 GAGCAAGNA GCTGTCAGCC GGCAGCCTC CTGGAGTATA CTGAGATGG

1351 GCAGAACTGG GGACATCAGT TCTCTACAGC AGCCCTGCAA TGAGGGGCTG

1401 GAGTGTATA GAAAAAATTC CAACGCTTTT TGCTGTGCTT TGAAAAATTC

1451 TGAATACATC CAACAACAGT CTGACTTCAG GCTATGAACA AAATGGCATA

1501 CCAGGAAAGT GCAGAACACA TCCTGTCTGG AGGAGTGATA CACAGACAT

1551 CCCCTCCACC AAGGACAAC TAGAGTGTTT CATTAAAGTGG GTCCCGGATC

1601 CTGTGCCCG CGACTGGGTG AGACCCCCAC CAACCCAGGGG TCACCAGACA

1651 CCTTATACAG AAGGTTCTCT ACCAGATCA GGTCAGTGCC CCTCGAGAC

1701 AGAGATCCCA GAGGAAGGAG CAGGCATCCA TCTTTGCTGT TCTCCAGCTT

1751 CCTCGGTGA CATCTCCAGC TGCAGAAGGG ACCCAGCCCA AAAGCTCCTT

1801 AAGCTGACAA GCACTTCAG CAAAGTCTCA GGTATATAAA TCATTGTGCA

1851 AAAATCACAA GCATTCTTAT ACACCAACAA CAGACAAGCA GAGAGACAAA

1901 TCATGGATGA ACTCCATTC ACAATTGCTA CAAAGAGAAT AAAATACCTA

1951 GAAATACAGC TAACAAGGA TGTGAAGAAC CCTTCAAGG AGTACTACTA

2001 A

!!AA SEQUENCE 1.0

ID\_ADP31687 standard; protein; 478 AA.

XX ADP31687;

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2454.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.

OS Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 17-SEP-2002; 2002US-0410946P.

XX 17-SEP-2002; 2002US-0410947P.

XX 17-SEP-2002; 2002US-0410948P.

XX 17-SEP-2002; 2002US-0410949P.

XX 17-SEP-2002; 2002US-0410953P.

XX 17-SEP-2002; 2002US-0410957P.

XX 17-SEP-2002; 2002US-0410958P.

XX 17-SEP-2002; 2002US-0410959P.

XX 17-SEP-2002; 2002US-0410960P.

XX 17-SEP-2002; 2002US-0410961P.

XX 17-SEP-2002; 2002US-0410962P.

XX 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3685; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 478 AA;  
ADP31697 Length: 478 February 22, 2005 12:25 Type: P Check: 5813 ..  
1 ATGCTCTCG GAGCTTCCCT GACTTCACAG AGCTCGACCT CCAGGCAAG  
51 GTGCTGCTG AGGGCGTCGG GCCCGGGGAC ATCAAGCCT TCCAGGTCCT

101 GTACCGGAA CACTGTGAGG CCATTGTGGA CGTCATGGTG AACCTGCACT  
151 TCACCTCTGGT GGAGAGGCTG TGAAGACCT TCTGGAGGTA CAACCTCAGC  
201 CAGCCCCAGTG AGGCCCCACC GCTGGCTGTC ATGACGAGGC CGAGAAGCGA  
251 CTGCCCAAAG CCATCCTGGT GCTCCTCTCC AAGTTCGAGC CCGTGTCTCA  
301 ATGGACCAAG CACTGTGACA ACGTGTCTGTA CAGGGGCTG GTGGAATCC  
351 TCATTCCCGA CGTGTGCGG CCATCCCCA GTGCTTTGAC CCAAGCGATC  
401 CGGAACCTTG CCAAGAGCCT GGAGAGCTGG CTCACCCACG CCATGTCTAA  
451 CATCCCCGAG GAGATGCTGC GGGTGAAG  
!!AA SEQUENCE 1.0  
ID ADP30483 standard; protein; 1128 AA.  
XX  
AC ADP30483;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1250.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.

PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2481; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1128 AA;  
ADP30483 Length: 1128 February 22, 2005 12:25 Type: P Check: 7591 ..  
1 ATGATAGTGG TGAATTTATT TGTGTAGCC AATGGCTTGG TACAAGTTGG  
51 AGTTTTGGAT AATGTTGAGC AAGATTACA ATCATATAGC TATGTCAACC  
101 TTTCTGCATG TAAAGTGCA TATAGTTGA TTATAGATGT TTCGGATTCA  
151 CTAAAGGAG ACACGGGCTG TCGTGGCTTC TCAGATTTCC AAAAGATCAA  
201 TGCTCTCAAG TACCCAAAC TTACTGGGG TTTTCAAGAT TATGCAGCTA  
251 GGAAGTTGG AGTCAGACCT CTGGCCNATA GAAGGGCACT GACGATCCC  
301 TACACAGCCC GGCACATAAA ATATTTATAC TCAGAGAAAG CTACACTAAG

351 TACTGAATTC TTTCTTCTGA GGAGGCAAGA ATTCAAGTTG CTGCAGACCC  
401 GACCGGATTT ACCGCTGGTA GCTCAGATAA CTTCTGCTGC TGGTAACAAA  
451 TTTGTGCAG AGGCAAGGAT GAGAAAGGTC AAAACTTTAG ATTTCTTTCC  
501 ATTTCTGGTA TGGCTGAACA AGCTCTTACT GCCTGACACT CTTGGAGATA  
551 ACACTTATAA ACTGTGGGA AAAAAATAC AGAGAGACAA TGACTCAAAG  
601 CCGGTTATG AGGCTCTCAA CCTATCCCT GTTCGGCTCG ATAATGAGGC  
651 CCTCAACGCT ATCTCTGCAC TCAATTTCTG CTTTCTTTCT ATGCATCAGG  
701 CTCCTCAGAA GTCTGACTTG CAGTCAGTGC ACCAGCCTGG AACTCAGGCC  
751 CTGCAGTCAA TGCACAGGCC TGGAACTCAG GCGCTGCAAT CAATGCAGCA  
801 GCCTGGAGTT CAGGCTCTTG AAAGACCTGC ACAGCAGGCA ACCGGCGCTC  
851 AGCCTGGCTT AAGGCTCTC AATTTCTCCT CTATTCAAAA CTCCAATTC  
901 CTTTCTGCTT CTGCTCCGGT CACAATGCT GTTACTACCC ATAAGCAACA  
951 GGTACATAC CTTCTTGATA ATGACACCCC TCTTATGAGG GCCATTTCTC  
1001 AGGCAAGGGA ATATGGGGAT CCGGAGGCAT GGCAGTTTCC TGTATTATTA  
1051 CAATCTGCTA TACCTGTGTC CTCTATTCTT GCGGCCCTCG CTCCAGCTGG  
1101 CTGCACCACT TCAGCCACAG CCCTTTGA  
!!AA SEQUENCE 1.0  
ID\_ADP30515 standard; protein; 1676 AA.  
XX  
XX ADP30515;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1282.  
XX  
XX Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2513; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX competition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX Sequence 1676 AA;

ADP30515 Length: 1676 February 22, 2005 12:25 Type: P Check: 3245 ..

1 ACAGTGCAGC CTCACGACAG AAGGATGGGG TGGCTCCAC TCCTGCTGCT  
51 TCTGACTCAA TGCTTAGGGG TCCCTGGGCA GCGCTGGCCA TTGAATGACT  
101 TCCAAGTGCT CCGGGGCACA GAGCTACAGC ACCTGCTACA TGGGGTGGTG  
151 CCGGGCCCTT GGCAGGAGA TGTGGCAGAT GCTGAAGAGT GTGCTGGTGG  
201 CTGTGGGCCC TTAATGGACT GCCGCTCTTC CAGAAGAAAG CCACAAGTAC  
251 ACGCCCACTC TCCGGNATGG CCTGGAAGAG AACTTCTGCC GTAACCCCTGA  
301 TGGGACCCCC GGAGTCTCTT GGTGCTACAC AACAGACCTT GCTGTGGCTG  
351 TCCAGAGCTG CGGCATCAAA TCCTGCCGGG AGGTTCTCTC GACCAAGTTC  
401 TGGACGACAA CTATTGCCGG AATCTGACG GCTCCGAGCG GCCATGGTGC  
451 TACACTACGG ATCCGACAGT CGAGCGAGAG TTCTGTGACC TCCCCCGCTG  
501 CCGGTCCGAG GCACAGCCCC GCCAAGAGGC CACAACCTGTC AGCTGCTTCC  
551 GCGGGAAGGG TGAGGGCTAC CGGGGCACAG CCAATACCAC CACCTGCGGG  
601 GGTACTTTC CAGCGTTGGG ACGGCAAAAT CCGCATCAG CACCGATTTA  
651 CGCCAGAAAA ATACGCTGC AAGTGAGAGA CTTTCGGGAG AACTTCTGCC  
701 GGAACCCCGA CGGCTCAGAG CGGCCCTGGT GCTTCACACT GCGGCCCGGC  
751 ATGCGCGCGG CCTTTTGCTA CCAGATCCGG CGTTGTACAG AGACGTGGG  
801 GCCCCAGGAC TGCTACCACG CGCAGAGGGA GCAGTACCCG GGCACGGTCA  
851 GCAGACCCCG CAAGGTGTCT CAGTGCCAGC GCTGGTCCCG TGAGACGCCG  
901 CACAAGCCGC AGATGGGGAT AGCCATGGGC CTGTGGTCTA CACGATGGAC  
951 CCAAGGACCC CATTGCACTA CTGTGCCCTG CGACGCTGCG CTGATGACCA  
1001 GCGGCCATCA ATCCTGGACC CCCAGGTCA GCTTGGGAA TCGGCAGGGC  
1051 CAGCATTTCT GCGGGGGGTC TCTAGTGAAG GAGCAGTGA TACTGACTGC  
1101 CCGGCAGTGC TTCTCTCTCT GCCATATGCC TCTACGCGGC TATGAGGTAT  
1151 GGTGGGGCAC CCTGTTCAG AACCCACAGC ATGGAGAGCC AAGCCTACAG  
1201 CCGGTCCCAG TAGCCAAGAT GGTGTGTTGG CCCTCAGGCT CCAGCTTGT  
1251 CCTGCTCAAG CTGGAGAGAT CTGTGACCCCT GAACACAGCT GTGGCCCTGA  
1301 TCTGCTGCC CCTGNAATGG TATGTGGTGC CTCACGGGAC CAAGTGTGAG  
1351 ATTCAGGCT GGGGTGAGAC CAAAGGTAAG AGCACAAAC AGTCCTAAAT  
1401 GTGGCCTTGC TGAATGTCAAT CTCCAACCAG GAGTGTAAACA TCAAGCACCG  
1451 AGACGTGTG CCGGAGAGTG AGATGTGCAC TGAGGGACTG TTGGCCCCCTG  
1501 TGGGGGCGCT TGAGGGTGAC TACGGGGGCC CACTTGGCTG CTTTACCCAC  
1551 AACTGTGGG TCTTGAAGG AATTATAATC CCCAACCGAG TATGCGCAAG  
1601 GTCCCGCTGG CCAGCTGTCT TCACGCGTGT CTCTGTGTTT GTGGACTGGA  
1651 TTCACAAGGT CATGAGACTG GGTGAG

!!AA SEQUENCE 1.0  
ID ADP30544 standard; protein; 95 AA.



XX AC ADP30544;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1311.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.  
XX PR 17-SEP-2002; 2002US-0411023P.  
XX PR 17-SEP-2002; 2002US-0411024P.  
XX PR 17-SEP-2002; 2002US-0411032P.  
XX PR 17-SEP-2002; 2002US-0411033P.  
XX PR 17-SEP-2002; 2002US-0411037P.  
XX PR 17-SEP-2002; 2002US-0411041P.  
XX PR 17-SEP-2002; 2002US-0411045P.  
XX PR 17-SEP-2002; 2002US-0411046P.  
XX PR 17-SEP-2002; 2002US-0411048P.  
XX PR 17-SEP-2002; 2002US-0411052P.  
XX PR 17-SEP-2002; 2002US-0411055P.  
XX PR 17-SEP-2002; 2002US-0411073P.  
XX PR 17-SEP-2002; 2002US-0411078P.  
XX PR 17-SEP-2002; 2002US-0411082P.  
XX PR 17-SEP-2002; 2002US-0411101P.  
XX PR 17-SEP-2002; 2002US-0411111P.  
XX PR 18-APR-2003; 2003US-0463700P.  
XX PR 18-APR-2003; 2003US-0463708P.  
XX PR 18-APR-2003; 2003US-0463716P.  
XX PR 18-APR-2003; 2003US-0463732P.  
XX PR 02-MAY-2003; 2003US-0467199P.  
XX PR 02-MAY-2003; 2003US-0467201P.  
XX PR 02-MAY-2003; 2003US-0467203P.  
XX PR 19-MAY-2003; 2003US-0467230P.  
XX PR 19-MAY-2003; 2003US-0471306P.  
XX PR 22-MAY-2003; 2003US-0471336P.  
XX PR 22-MAY-2003; 2003US-0472428P.  
XX PR 22-MAY-2003; 2003US-0472430P.  
XX PR 09-JUN-2003; 2003US-0476609P.

PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Hatenbeck RF, Huang MM, Kothakota S, Haisan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX PT genetic, bacterial and viral diseases.  
XX PS Claim 1; SEQ ID NO 2542; 428pp; English.  
XX CC The present invention relates to an isolated nucleic acid molecule  
XX CC encoding a polypeptide which is believed to be cytostatic,  
XX CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX CC composition and methods are useful for diagnosing, preventing and  
XX CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX CC immune, metabolic, genetic, bacterial and viral diseases. The present  
XX CC sequence represents a human secreted protein. The present sequence is  
XX CC available on WIPWEB and is not in the specification.  
XX SQ Sequence 95 AA;  
ADP30544 Length: 95 February 22, 2005 12:25 Type: P Check: 1818 ..  
1 ATGCTGGATG GGTCCCGCT GCGCGCTGG CTGGCGCGG CCTTCGGGCT  
51 GACGCTGCTG CTCGCCGCGC TCGCCCTTC GCGCGCTAC TTCGG  
!!AA SEQUENCE 1.0  
ID ADP30553 standard; protein; 583 AA.  
XX AC ADP30553;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1320.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0410966P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang NM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

PS Claim 1; SEQ ID NO 2551; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX Sequence 583 AA;  
SQ  
ADP30553 Length: 583 February 22, 2005 12:25 Type: P Check: 2168 ..  
1 GGTGTGCAGC AATGACAACA AGACCTTCGA CTCTTCTGCG CACTTCTTTG  
51 CCACAAAGTG CACCCTGGAG GGCACCAAGA AGGGCCACAA GCTCCACCTG  
101 GACTACATCG GGCCTTGCAA ATACATCCCC CTTTGCTTGG ACTCTGAGCT  
151 GACCGAATTC CCCCTGGCGA TGCGGGACTG GCTCAAGAAC GTCTGGGTCA  
201 CCCTGTATGA GAGGGATGAG GACAACAACC TTCTGACTGA GAAGCAGAAG  
251 CTGCGGGTGA AGAAGATCCA TGAGAATGAG AAGGCGCTGG AGGCAGGAGA  
301 CCACCCCGTG GAGCTGCTGG CCCGGGACTT CGAGAAGAAC TATAACATGT  
351 ACATCTTCCC TGTACACTGG CAGTTGCGCC AGCTGGACCA GCACCCCAT  
401 GAGGGGTACC TCTCCACAC CGAGCTGGCT CCACTGGGTG CTCCTCTCAT  
451 CCCCATGGAG CATTGCACCA CCCGCTTTT CGAGACCTGT GACCTGGACA  
501 ATGACAAAGTA CATCGCCCTG GATGAGTGGG CCGGCTGCTT CGGCATCAAG  
551 CAGAAGGATA TCGACAAGGA TCTTGTGATC TAA  
!!AA\_SEQUENCE 1.0  
ID ADP30608 standard; protein; 279 AA.  
XX  
AC ADP30608;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1375.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.

PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

## (FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Halshan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2606; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and

CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

SQ Sequence 279 AA;

ADP30608 Length: 279 February 22, 2005 12:25 Type: P Check: 9382 ..

1 ATGGCGAGCC TCCGGCTCG GCCACGCCCA CGTGCACGT GCTCCTGGTG

51 GAGGGTTCT CCAGCCCTA CTGTGCTC CCGAGGCGG CACCGGCCCA

101 GCCCAGGCC GACTTGCTCA CCGTCTACCT GGTGTGGCG TTGGCCTCGG

151 TGTCTTGGCT CTTCTCTTC TCGGTGCTCC TGTTCGTGC GGTGGGGCTG

201 TCACAGGAG CAAGGGCGG CTCGGTGGGT CGCTGCTCGG TGCCCGAGGG

251 CCCCTTTCCA GGGCAGATGG TGGACGTGA

!!AA SEQUENCE 1.0

ID ADP30642 standard; protein; 1833 AA.

XX ADP30642;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1409.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411037P.

PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2640; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1833 AA;  
ADP30642 Length: 1833 February 22, 2005 12:25 Type: P Check: 2854 ..  
1 ATGGTCAACG TCGACACGTG CTATGGGAC CTCAGAGGCA TCATGAGGCT  
51 GGACGACCTT GCGTACGAAA TCAAAACCCCT CCAGGATTCC CGCAGGTTTG  
101 AACATGTTGT TTTTCAGATA GTGGCCGAGC CCAACGCAAC AGGGCCACCA  
151 TTTAGAGATG ATGACAATGA GACAGACCCC CTGTTCTCTG AAGCAAAATGA  
201 CAGCATGAAT CCCAGGATAT CTAATTCGCT GTATAGTTCT CATAGAGGCA

251 ATATAAAGG CCACGTCAA TGTTCGAATT CATATTATCG CATATATGCG  
301 AATATTACAA CTGTGTCGAA AGAGTGGTC CAGATGTTCA GTCTCATTTGA  
351 CAGCATTTGCT CAAAATAATTG ATCTGCGGTA CTATATTTAT CTTTGGACCA  
401 TATATAATAA TCGTGACCCA GCCCCTGTGA ATGAATATCG AATTACAGAT  
451 GCAATGTTTA CCTATTTTAA AACAACTTTT TTTGATACTT TTCATGTTCA  
501 TTTATCCACA CTACTTAATTA AATACGTGCC ACATGAATCT AACTATGAAC  
551 CTGAAAGGTA TAACTTCTGT TCCCGTATAG CCCTGTTTACA CATTGCTACT  
601 CCAGGCAGAC ATTATTTATT GGTAGCCGTC ATAAATACCC AGACACAGAT  
651 GAGAGTATT GGTCTGGAGT ATGATGATAA CTACTGCACA TGTGAGAGAA  
701 GGGCCTCCTG CATTATGCAG CGATTTCTCG GGATGACAGA TGGTTCAGT  
751 AACTGTTCTT ATGGACATGC AAAAAATTGT TTTATACATT CAGGCCGGTG  
801 TGTGTTTGAA ACACTTGCTC CTGTGTATAA CGAAACCATG ACAACGGTTC  
851 GCTGTGGA A CCTCATAGTG GAGGGGAGG AGGAATGTGA CTGTGGCTCC  
901 TTAACGAGT GTTATGCCAG TTATTGCTGC CAAAGTGACT GTCACTTAAC  
951 ACCGGGAGC ATCTGCCATA TAGGAGAGTG CTGTACAAAC TGCAGTTCTT  
1001 CCCACCAGS GACTCTCTGC AGACCTATCC AAAATATATG TGACCTTCCA  
1051 GAGTACTGTC ACGGACCAC CGTGACATGT CCCGCAACG TTTATATGCA  
1101 AGATGGAACC CCGTGCACGT AGAAGGCTA CTGCTATCGT GGGAACTGCA  
1151 CTGATCGCAA TGTGCTCTGC AAGCGATCT TTGTTGTCAG TGCTGAGGAT  
1201 GCTCCGAGG TCTGCTATGA CATAAATCTT GAAAGCTACC GATTTGGACA  
1251 TTGTATTAGA CAACAAACAT ATCTCAGCTA CCAGGCTTGT GCAGGAATAG  
1301 ATAAAGTTTG TGGAAAGCTG CAGTGTACCA ATGTGACCCA TCTTCCCGG  
1351 CTCAGAGAAC GTGTTTCATT CCATCCTCA GTGAGAGGAG GGTTCAGTGT  
1401 TTTTGGACTG GATGAACACC ATGCAACAGA CACGACTGAT GTTGGGCGTG  
1451 TGATAGATGS CACTCCTTGT GTTCATGAA ACTTCTGTAA TAACACCCAG  
1501 TGCAATGTGA CTATCCTTC ACTGGGCTAC AACTGCCACC CTCAGAAATG  
1551 CGGTACATGA GGAGTCTGCA ACAACAGAG GAACTGCCAT TGCCATATAG  
1601 GCTGGGATCC TCCACTGTGC CTAAGAAGAG GTGCTGTGG GAGTGTCAAC  
1651 AGGGGCCAC CTCCAAAAG AACACGTTCC GTCAACAAA GCAGCAATC  
1701 AGTGATGTAT CTGAGAGTGG TCTTTGGTGC TATTTAGGCC TTCATAATTG  
1751 CACTGCTCTT TGGGACAGCC AAAAATGTGC GAACTATCAG GACCACCACC  
1801 GTTAAAGGAG GGACAGTTAC TAACCTTGAA TAA

!!AA SEQUENCE 1.0  
ID ADP30674 standard; protein; 1771 AA.  
XX  
AC ADP30674;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1441.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX PD 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 02-MAY-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 19-MAY-2003; 2003US-0467230P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 22-MAY-2003; 2003US-0472430P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 08-JUL-2003; 2003US-0476641P.  
XX 08-JUL-2003; 2003US-0485218P.  
XX 08-JUL-2003; 2003US-0485223P.  
XX 08-JUL-2003; 2003US-0485224P.  
XX 14-JUL-2003; 2003US-0485325P.  
XX 14-JUL-2003; 2003US-0486446P.

PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2672; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX SQ Sequence 1771 AA;

ADP30674 Length: 1771 February 22, 2005 12:25 Type: P Check: 3272 ..

1 TTCTCAGCTA ACTGGATGGC AGTAATTTTC TTTATCTCTG GAATGAAGG  
51 AAATTGGTTT GAGATAGAAA TGAATGAAAG AACAAATGTG GGAATTTTAA  
101 AGTTTGTTAA GCCCTTAGAT TATGAGCTA TGCAGAGTCT GCAACTCAGT  
151 ATTGGTGTC A GAATAAAGC TGAATTTTCAT CATTCAAATTA TGTCTCAATA  
201 TAAACTGAAA GCATCTGCAA TTTCTGTGAC TGTGTTAAAT GTAATTGAAG  
251 GCCCAGTGT TCGTCCAGGT TCAAGACAT ATGTTGTAAC TGGTAATATG  
301 GGATCAAATG ATAAAGTGGG AGACTTTGTA GCTACTGACC TGGACACAGG  
351 TAGACCTTCA ACGACTGTTA GTGGTCCCAT TTTTGATGAT CTGTTGTGAT  
401 TGTGGAGGTG CTCCTCGTAG TGCAGCTGGC TTTGAGCCCTG TTCCCGAATG  
451 TTCAGATGGA GCAATTCATT CATGGGCAGT AGAAGGACCA CAGCCTGAAC  
501 CCAGGAGGAG TTTATACAAA TGAGTATGTT GGCAGAGAAA TGCAAGATCT  
551 GGGAGGAGGA GAGAGATGA CAGGATTTGA ACTAACAGAG GGAGTTAAAA  
601 CTTCAGGAAT GCCTGAGATA TGTCAAGAAT ACTCTGGAAC ATTAAGAAGA  
651 AATTCTATGA GGGAAATGAG AGAAGGAGGT CTGAATATGA ATTTTCATGGA  
701 AAGCTACTTC TGTGAGTAA GAAAGCATAT GCTTAGCGAG ATGAAGATGA  
751 AGGACGCCCA TCTAATGACT GTTTGTCTCAT ATATGACATC GAAGGTGTAG  
801 GTTCCCTGCG TGGCTCTGTG GGTGTTGTTA GCTTCATTGG AGAAGACCTG  
851 GATGACAGCT TCTGGATAC CTTGGGACCT AAATTTAAGA AGTTGGCAGA  
901 CATCAGCCTA GAAAAGAAT CATATCCAGA CTTTGATCCT TCTTTGGCCAC

951 CACAAAGCAC TGAACCAAGTT TGCCTTCCTC AGGAAACAGA GCCCGTTGTT  
1001 AGTGGACACC CACCAATCTC CCCAATTTT GGCCTACCA CAGTAATTTT  
1051 TGAGAGACACC TATCCCTCGG GACCTGGTGT ACTGCATCTT AAGCCTATTCT  
1101 TCGATCCTCT GGGCTATGGT AATGTCACTG TGACCGAGTC TTACACCAACC  
1151 TCTGACACTC TGAAGCCCTC TGTGACAGTT CACATTAACC GACCAGATC  
1201 AAACGTGGTA GTGACAGAGA GAGTGGTCGG CCCAATCTCT GCGCCTGATT  
1251 TGCATGGAAT GTTAGAGATG CCTGACTTGC GAGATGGGTC GAATGTTATA  
1301 GTGACAGAAA GGGTATAGC ACCAAGCTCT AGTCTACCCA CCTCTCTGAC  
1351 TATCCATCAT CCTAGAGAGT CTTCAAATGT GGTAGTGACA GAAAGAGTAA  
1401 TCCAACCAAC TTCCGGCATG ATAGGTAGTC TGAGTATGCA CCCCAGTTTA  
1451 GCCAATGCCC ACAATGTCAT TGTGACAGAG AGGTTTGTCT CTGGTCTGCG  
1501 CGTAACTGGA ATTAGTGGA CCACTGGGAT CAGCGGTGGC ATAGGACAGA  
1551 GTGGCCTGGT TGGCACCAGC ATGGGTGCTG GGAGCGGTGC CCTGAGTGGA  
1601 CTGGGCATAA GTGGTGGTGG CATTGGCCTG AGCAGCTTGG GAGGGACAGC  
1651 CAGCATTGGC CACATGAGGA GTTCCTCTGA CCATCACTTT AACCAACCA  
1701 TTGGGTCGCG CTCCTCTAGC ACAGCTCGAA GTCGAATCAC AAAGTATAGT  
1751 ACCGTGCAAT ATAGCAAGTA G

!!AA\_SEQUENCE 1.0  
ID ADP30718 standard; protein; 967 AA.

AC ADP30718;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1485.  
DE  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR  
PR 29-AUG-2002; 2002US-0406579P.  
PR  
PR 29-AUG-2002; 2002US-0406585P.  
PR  
PR 29-AUG-2002; 2002US-0406588P.  
PR  
PR 29-AUG-2002; 2002US-0406608P.  
PR  
PR 29-AUG-2002; 2002US-0406611P.  
PR  
PR 29-AUG-2002; 2002US-0406612P.  
PR  
PR 29-AUG-2002; 2002US-0406616P.  
PR  
PR 29-AUG-2002; 2002US-0406640P.  
PR  
PR 29-AUG-2002; 2002US-0406642P.  
PR  
PR 29-AUG-2002; 2002US-0406646P.  
PR  
PR 29-AUG-2002; 2002US-0406653P.  
PR  
PR 29-AUG-2002; 2002US-0406655P.  
PR  
PR 29-AUG-2002; 2002US-0406666P.  
PR  
PR 17-SEP-2002; 2002US-0410946P.  
PR  
PR 17-SEP-2002; 2002US-0410947P.  
PR  
PR 17-SEP-2002; 2002US-0410948P.  
PR  
PR 17-SEP-2002; 2002US-0410949P.  
PR  
PR 17-SEP-2002; 2002US-0410953P.  
PR

17-SEP-2002; 2002US-0410957P.  
PR  
PR 17-SEP-2002; 2002US-0410958P.  
PR  
PR 17-SEP-2002; 2002US-0410959P.  
PR  
PR 17-SEP-2002; 2002US-0410960P.  
PR  
PR 17-SEP-2002; 2002US-0410961P.  
PR  
PR 17-SEP-2002; 2002US-0410962P.  
PR  
PR 17-SEP-2002; 2002US-0411019P.  
PR  
PR 17-SEP-2002; 2002US-0411022P.  
PR  
PR 17-SEP-2002; 2002US-0411023P.  
PR  
PR 17-SEP-2002; 2002US-0411024P.  
PR  
PR 17-SEP-2002; 2002US-0411032P.  
PR  
PR 17-SEP-2002; 2002US-0411035P.  
PR  
PR 17-SEP-2002; 2002US-0411037P.  
PR  
PR 17-SEP-2002; 2002US-0411041P.  
PR  
PR 17-SEP-2002; 2002US-0411045P.  
PR  
PR 17-SEP-2002; 2002US-0411046P.  
PR  
PR 17-SEP-2002; 2002US-0411048P.  
PR  
PR 17-SEP-2002; 2002US-0411052P.  
PR  
PR 17-SEP-2002; 2002US-0411055P.  
PR  
PR 17-SEP-2002; 2002US-0411073P.  
PR  
PR 17-SEP-2002; 2002US-0411082P.  
PR  
PR 17-SEP-2002; 2002US-0411101P.  
PR  
PR 17-SEP-2002; 2002US-0411111P.  
PR  
PR 18-APR-2003; 2003US-0463700P.  
PR  
PR 18-APR-2003; 2003US-0463708P.  
PR  
PR 18-APR-2003; 2003US-0463716P.  
PR  
PR 18-APR-2003; 2003US-0463732P.  
PR  
PR 02-MAY-2003; 2003US-0467199P.  
PR  
PR 02-MAY-2003; 2003US-0467201P.  
PR  
PR 02-MAY-2003; 2003US-0467203P.  
PR  
PR 02-MAY-2003; 2003US-0467230P.  
PR  
PR 19-MAY-2003; 2003US-0471306P.  
PR  
PR 19-MAY-2003; 2003US-0471336P.  
PR  
PR 22-MAY-2003; 2003US-047420P.  
PR  
PR 22-MAY-2003; 2003US-047430P.  
PR  
PR 09-JUN-2003; 2003US-0476609P.  
PR  
PR 09-JUN-2003; 2003US-0476641P.  
PR  
PR 08-JUL-2003; 2003US-0485218P.  
PR  
PR 08-JUL-2003; 2003US-0485223P.  
PR  
PR 08-JUL-2003; 2003US-0485224P.  
PR  
PR 08-JUL-2003; 2003US-0485325P.  
PR  
PR 14-JUL-2003; 2003US-0486446P.  
PR  
PR 14-JUL-2003; 2003US-0486480P.  
PR  
PR 15-JUL-2003; 2003US-0486891P.  
PR  
PR 15-JUL-2003; 2003US-0486960P.  
PR  
PR 08-AUG-2003; 2003US-0493341P.  
PR  
PR 08-AUG-2003; 2003US-0493370P.  
PR  
PR 08-AUG-2003; 2003US-0493573P.  
PR  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2716; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX

SQ Sequence 967 AA;  
ADP30718 Length: 967 February 22, 2005 12:25 Type: P Check: 5109 ..  
1 ATGCCCAGGC GGAGGTGGCG TTGCTGTATC CCCCGCTGGT GGAGGTGATG  
51 CGAGGAAAGT CTGTATTCT GGATGACCC CTTACGGGAA CCACAGACCA  
101 TTATATGCTG GAATGTTTC TTACCGACCG CTCGGGAGCT CGCCCCCGCC  
151 TAGCCTCGGC TGAGATGCGG GGCTCTGAGC TCCAGGTAC ATGACACGAC  
201 ACCCGGGGC GAGTCCGCC ATACAGCTG GACTCCAGG GCGGCTGGT  
251 GTTGGCTGAG GCCCAGTGG GCGACGAGC AGACTACGTG TCGGTGGTGA  
301 GGCAGGGGC GGCAGGCACT GCTGAGGCA CTGCGGGCT CAACGTGTT  
351 GCAAAGCCAG AGGCACCTGA GGTCTCCGCC ACAAAGGGA CACTGTCTGT  
401 GATGGAGGAC TCTGCCCAGG AGATCGCCAC CTGCAACAGC CGGAACGGGA  
451 ACCCGCCCC CAAGATCAGG TGGTATCGCA ACGGGCAGCG CTTGGAGTGG  
501 CCGGTAGAGA TGAACCCAGC TCCCTACCA GCACCTCTTA CTTGGGGTTC  
551 CGCAAGGATG ACCGAGAGCG CAGCTTCCAC TGGCGCGCCC ACTACAGCCT  
601 GCCCGAGGCG CGCCAGGCCC GCCTGGACAG CCCACCTTC CACCTCACCC  
651 TGCATATACC CACGAGGAC GTGCAGTTCT GGGTGGGCGAG CCGGTCCACC  
701 CCAGCAGGCT GGTACGCGA GGTGACACT GTCCAGCTGC TCTGCCGGGG  
751 GGACGCGCAG CCCAGCCCGG AGTATACGCT TTTCGCCCTT CAGGATGAGC  
801 AGAGGAAGT GCTGATGTG AATCTCAGG GGAATCTGAC CTTGAGGAGA  
851 GTGACCCGGG GCCAGAGCGG GACCTATGGC TGCAGAGTGG AGGATTACGA  
901 CCGGCGAGAT GACGTGCAGC TTCCAAGAC GCTGGAGCTG CCGTGGGCTT  
951 GTGAGAGCCC TGGGTGA  
!!IAA SEQUENCE 1.0  
ID -ADP30720 standard; protein; 659 AA.  
XX  
AC ADP30720;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1487.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US062680.  
XX  
PR 29-AUG-2002; 2002US-0406578P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX  
FA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Heestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2718; 428pp; English.  
PS

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 659 AA;  
  
ADP30720 Length: 659 February 22, 2005 12:25 Type: P Check: 9178 ..  
  
1 TAATACCGCC ACAGTCTCA AAGTCGTGG ACTAGAGGC CTGCGAGCT  
51 TTCAGATTCC GCGTGGCGC CACAGACGC GGCTTCCCGG CGTTGACGAG  
101 CGAGGCGCTG GTGCGGTGC TGGTGTGGA GCCCAACGAC AACTCGCCCT  
151 TCGTGTGTA CCGCTGTCAG AAGGCTCGG CGCCCTGCAC CGAGCTGGTG  
201 CCCCGGCGG CCGAGCCGG CTACCTGGTG ACCAAGGTGG TGGCGGTGGA  
251 CGGGACTCG GGCAGAACG CCTGGCTGTC GTACCAGTG CTCAGGCCA  
301 CGAGCCCGG GCTGTTGGC GTGTGGGCG ACAATGGGA GTTGGCGACC  
351 GCCAGGTGC TGAGCGAGC CGACGTGGC AAGCACAGG TAGTGGTGCT  
401 GGTCAAGGAC AATGGCGAG CTCGCGTGC GGCCACCGCC ACGCTGCAAG  
451 TGCTCTGGT GGAGGGTTC TCTAGCCCT ACCTGCGCT CCCAAGAGG  
501 GCCCGGCCC AAGCCAGGC CGACTGCTC ACTGTCTACC TGGTGGTGGC  
551 GTTGGCCTCG GTGTGTCGC TCTTCTCTT CTGCTGTCTC CTGTTCTGTG  
601 CGGTGCGGCC TGTGCGAGG GAGCAGGGG GCCCGGTGCG GTGCTGTCTC  
651 GGTGCTTGA  
  
IIA SEQUENCE 1.0  
ID ADP30770 standard; protein; 780 AA.  
XX  
AC ADP30770;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1537.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406577P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.

29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-040666P.  
29-AUG-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RP, Huang MM, Kochakota S, Haiehan L, Linnenmann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 2768; 428pp; English.

The present invention relates to an isolated nucleic acid molecule



CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPoWEB and is not in the specification.  
XX  
SQ Sequence 780 AA;

ADP30770 Length: 780 February 22, 2005 12:25 Type: P Check: 8882 ..

1 ATGCTGGAC CCACCTGTG GGGCCCTGG TACTGTGCT GGGGTGGCC  
51 CTCTTTTGG AGACCGTGA CTTCGGGGA GACCCACAG CCGTCCCTT  
101 CTTTCATCT GTCTTGCCT CTTTCACCTA CCTCTCCTT AGTGCTTGG  
151 CTCACCTCT CGAGCCCAAG TGTGAGTCT GGCATTACAG CTTCTCTTC  
201 CTGGACTATG TGGGGGTGG CGTGTACCAG TTTGGCAGTG CCGTGGCACA  
251 CTTCTACTAT GCTATCGAG CCGCTGGCA TGCCCAAGTG CAGGCTGTT  
301 TTCTGCCCC GGTCGCTTT CTGCGCTGG TTTCTGCAAT TGGCTCCTGC  
351 TATAACAAGT ACATCCAGAA ACCAGGCTG CTGGGCCGCA CATGCCAGGA  
401 GGTGCCCTCC GTCTGGGCT ACGCACTGGA CATTAGTCT GTGGTGCATC  
451 GTATCTTCT GTCTCTCGAC CCCACACAG ATGATCCAG TCTTCTCTAC  
501 CACAAAGTGC AGGTGCTCT CTTTCTGCTG GCTGTGCTT TCTTCTCTAC  
551 CTTTCATGCC GAGCGTGGT TCCTTGGCAG CTGCCATGC TTGGGGCAGG  
601 GCCACAACT TTTCACATC TTTCTGCTGC TGTGACGCT GGCTCAGCTG  
651 GAGGCTGTGG CACTGGACTA TGAGGCCGGA CGGCCCATCT ATGACCTCT  
701 GCACAGGCAC TGGGCTCACA ACTTTTCTGG CCTCTTCTTG CTCAGGTGG  
751 GCAGCAGCAT CCTCACTGCA TTCTCTCTGA

IIAA SEQUENCE 1.0  
ID ADP30795 standard; protein; 198 AA.

XX  
AC ADP30795;

XX  
DT 12-AUG-2004 (first entry)

XX  
DE Human secreted protein SEQ ID #1562.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX  
OS Homo sapiens.

XX  
PN WO2004035732-A2.

XX  
PD 29-APR-2004.

XX  
PF 28-AUG-2003; 2003WO-US026780.

XX  
PR 29-AUG-2002; 2002US-0406576P.

XX  
PR 29-AUG-2002; 2002US-0406579P.

XX  
PR 29-AUG-2002; 2002US-0406585P.

XX  
PR 29-AUG-2002; 2002US-0406588P.

XX  
PR 29-AUG-2002; 2002US-0406608P.

XX  
PR 29-AUG-2002; 2002US-0406611P.

XX  
PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406656P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 2793; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 198 AA;  
ADP30795 Length: 198 February 22, 2005 12:25 Type: P Check: 6255 ..  
1 ATGGCGGCGG TGGCGGCGG AGCAGTTTG AGTCCAGTC CTGCTCAGC  
51 AGCGCGGCCA CGGCGGTGGA CCCACCTGC GCCCGGCTCC GTGCATCGGA  
101 GAGCCCAAGT CACCGCGCGG GTCCTTCCC CTGGCGCGG CGGGGCCCTT  
151 CGAGTCCG CCGGCTCCG CTGCCGAGG AGACCCGAT GGCATTGA  
!!AA\_SEQUENCE 1.0  
ID ADP30803 standard; protein; 615 AA.  
XX  
AC ADP30803;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1570.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR  
XX 29-AUG-2002; 2002US-0406579P.  
PR  
XX 29-AUG-2002; 2002US-0406585P.  
PR  
XX 29-AUG-2002; 2002US-0406588P.  
PR  
XX 29-AUG-2002; 2002US-0406608P.  
PR  
XX 29-AUG-2002; 2002US-0406611P.  
PR  
XX 29-AUG-2002; 2002US-0406612P.  
PR  
XX 29-AUG-2002; 2002US-0406616P.  
PR  
XX 29-AUG-2002; 2002US-0406640P.  
PR  
XX 29-AUG-2002; 2002US-0406642P.  
PR  
XX 29-AUG-2002; 2002US-0406646P.  
PR  
XX 29-AUG-2002; 2002US-0406653P.  
PR  
XX 29-AUG-2002; 2002US-0406655P.  
PR  
XX 29-AUG-2002; 2002US-0406666P.  
PR  
XX 17-SEP-2002; 2002US-0410946P.  
PR  
XX 17-SEP-2002; 2002US-0410947P.  
PR  
XX 17-SEP-2002; 2002US-0410948P.  
PR  
XX 17-SEP-2002; 2002US-0410949P.  
PR  
XX 17-SEP-2002; 2002US-0410953P.  
PR  
XX 17-SEP-2002; 2002US-0410957P.  
PR  
XX 17-SEP-2002; 2002US-0410958P.  
PR  
XX 17-SEP-2002; 2002US-0410959P.  
PR  
XX 17-SEP-2002; 2002US-0410961P.  
PR  
XX 17-SEP-2002; 2002US-0410962P.  
PR  
XX 17-SEP-2002; 2002US-0410963P.  
PR  
XX 17-SEP-2002; 2002US-0411019P.  
PR  
XX 17-SEP-2002; 2002US-0411022P.  
PR  
XX 17-SEP-2002; 2002US-0411023P.  
PR  
XX 17-SEP-2002; 2002US-0411024P.  
PR  
XX 17-SEP-2002; 2002US-0411032P.  
PR  
XX 17-SEP-2002; 2002US-0411035P.  
PR

PR 17-SEP-2002; 2002US-0411037P.  
PR  
PR 17-SEP-2002; 2002US-0411041P.  
PR  
PR 17-SEP-2002; 2002US-0411045P.  
PR  
PR 17-SEP-2002; 2002US-0411048P.  
PR  
PR 17-SEP-2002; 2002US-0411052P.  
PR  
PR 17-SEP-2002; 2002US-0411055P.  
PR  
PR 17-SEP-2002; 2002US-0411073P.  
PR  
PR 17-SEP-2002; 2002US-0411082P.  
PR  
PR 17-SEP-2002; 2002US-0411101P.  
PR  
PR 17-SEP-2002; 2002US-0411111P.  
PR  
PR 18-APR-2003; 2003US-0463700P.  
PR  
PR 18-APR-2003; 2003US-0463708P.  
PR  
PR 18-APR-2003; 2003US-0463716P.  
PR  
PR 18-APR-2003; 2003US-0463732P.  
PR  
PR 02-MAY-2003; 2003US-0467199P.  
PR  
PR 02-MAY-2003; 2003US-0467201P.  
PR  
PR 02-MAY-2003; 2003US-0467203P.  
PR  
PR 02-MAY-2003; 2003US-0467230P.  
PR  
PR 19-MAY-2003; 2003US-0471306P.  
PR  
PR 19-MAY-2003; 2003US-0471336P.  
PR  
PR 22-MAY-2003; 2003US-0472420P.  
PR  
PR 22-MAY-2003; 2003US-0472430P.  
PR  
PR 09-JUN-2003; 2003US-0476609P.  
PR  
PR 09-JUN-2003; 2003US-0476641P.  
PR  
PR 08-JUL-2003; 2003US-0485218P.  
PR  
PR 08-JUL-2003; 2003US-0485223P.  
PR  
PR 08-JUL-2003; 2003US-0485224P.  
PR  
PR 14-JUL-2003; 2003US-0485325P.  
PR  
PR 14-JUL-2003; 2003US-0486446P.  
PR  
PR 15-JUL-2003; 2003US-0486480P.  
PR  
PR 15-JUL-2003; 2003US-0486891P.  
PR  
PR 15-JUL-2003; 2003US-0486960P.  
PR  
PR 08-AUG-2003; 2003US-0493341P.  
PR  
PR 08-AUG-2003; 2003US-0493370P.  
PR  
PR 08-AUG-2003; 2003US-0493573P.  
PR  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2801; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 615 AA;  
ADP30803 Length: 615 February 22, 2005 12:25 Type: P Check: 6543 ..  
1 ATGATTGCTG AATGGTATTA TGAGAGCATG TTTAGTTTAA TAAGAAACTG  
51 CCAAACTATC TTCCAAGAG GCTGTACCAT TTGTCATTCC CATCAGCAAG  
101 GAATGAGAGT TCCTGTTGCT CCATATTCTC ACGGACCTTT GGTGTTGTCA  
151 GTGTTCTGGA TTTTGGCCAT TCTAATAGTC CTTGCTTATG ACCTCTCTTC

201 TTCTGGGACA TCACGTGGCTG CTGCTTCTTCA GTCTTCTTTG CTGGTTCCTC  
251 CTTACTTCCC CATCATCCTG CCATTGGAGT GCCATAAGGC TCAGGACGTG  
301 GCTTCTCTTC TGTGTACCA CTCCTAGGT GGTTCACAGC AGTCTCAAGG  
351 CTTTCTTACA CACGAGCATG ACAAATCCT TGGAGTCGTC TTTGTCTTTT  
401 TTTTCTCTCAT ATACCTTATA TCCTCTCCAT TAGCAAAGAC TGTTCGCTGT  
451 TCCTCCAAAT ATATTGAGAA TCTTACCACT TTCCACTGGC TTCACTGGCA  
501 GCACCCCGAT GTGAGATGCC ATCCCTGTG CTCGGAGAGA AGCCGCCCTCC  
551 CTGCGGGTCT CTTGCTTCCA CCGCTTCCG CTCAGAAGCT GGGCTCAACA  
601 CAGCAGACAC AGTGA

!!AA SEQUENCE 1.0  
ID ADP30812 standard; protein; 243 AA.

XX AC ADP30812;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1579.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406668P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2810; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC anti-inflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.  
XX  
XX Sequence 243 AA;

ADP30812 Length: 243 February 22, 2005 12:25 Type: P Check: 4081 ..

1 ATGGCTCCC GTCCTCTGTG GCCCACAGC CCCCTGGGC CAGGGGAAGC

51 GCCCAGAG CCGNAGTCC CACCATGGGC RACCACAGT GGGAGGGCTG

101 CCACGTGGAC TCGCGCGTGG ACCACCTCTT TCCGCCATCC CTCTACATCT

151 TTGTATCGG CGTGGGCGTG CCCACCAACT GCTGGCTCT GTGGGCGGCC

201 TACGCCAGG TGCNACAGG CACAGAGCTG GCGCTCTACC TGA

!!AA SEQUENCE 1.0

ID ADP30897 standard; protein; 779 AA.

XX AC ADP30897;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1664.  
XX DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.  
XX PR 17-SEP-2002; 2002US-0411023P.  
XX PR 17-SEP-2002; 2002US-0411024P.  
XX PR 17-SEP-2002; 2002US-0411032P.  
XX PR 17-SEP-2002; 2002US-0411035P.  
XX PR 17-SEP-2002; 2002US-0411037P.  
XX PR 17-SEP-2002; 2002US-0411041P.  
XX PR 17-SEP-2002; 2002US-0411045P.  
XX PR 17-SEP-2002; 2002US-0411046P.  
XX PR 17-SEP-2002; 2002US-0411048P.  
XX PR 17-SEP-2002; 2002US-0411052P.  
XX PR 17-SEP-2002; 2002US-0411055P.  
XX PR 17-SEP-2002; 2002US-0411073P.  
XX PR 17-SEP-2002; 2002US-0411101P.  
XX PR 17-SEP-2002; 2002US-0411111P.  
XX PR 18-APR-2003; 2003US-0463700P.  
XX PR 18-APR-2003; 2003US-0463708P.  
XX PR 18-APR-2003; 2003US-0463716P.  
XX PR 18-APR-2003; 2003US-0463732P.  
XX PR 02-MAY-2003; 2003US-0467199P.  
XX PR 02-MAY-2003; 2003US-0467201P.  
XX PR 02-MAY-2003; 2003US-0467203P.  
XX PR 02-MAY-2003; 2003US-0467230P.  
XX PR 19-MAY-2003; 2003US-0471306P.  
XX PR 19-MAY-2003; 2003US-0471336P.  
XX PR 22-MAY-2003; 2003US-0472420P.  
XX PR 22-MAY-2003; 2003US-0472430P.  
XX PR 09-JUN-2003; 2003US-0476609P.

PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX PS Claim 1; SEQ ID NO 2895; 428pp; English.  
XX CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX SQ Sequence 779 AA;

ADP30897 Length: 779 February 22, 2005 12:25 Type: P Check: 1091 ..

1 AAGCTGGTGA CACCTGTGAG AAGCTGGTGG GATATTCTGC CGTGATATAGA  
51 GTCGTGTTTG GAATGGCTTG TTTCTTCTTT ATCTTCGTGC TACTGACCTT  
101 GAAATCAAC AACAGCAAAA GTTGTAGAGC TCATATTAC AATGGCTTTT  
151 GGTTCCTTAA ACTTCTGCTG TTGGGGGCCA TGTGCTCAGG AGCTTTCTTC  
201 ATTCCAGATC AGGACACCTT TCTGAACGCC TGGCGCTATG TGGAGCCCGT  
251 CGGAGGCTTC CTCCTTCATTG GCATCCAGCT CTCCTGCTC GTGGAGTTTG  
301 CACATAAGTG GAACAAGAAC TGGACAGCAG GCACAGCCAG TAACAAGCTG  
351 TGGTAGCCTT CCTTGGCCTT GGTGACGCTC ATCATGTATT CCATTGCCAC  
401 TGGAGGCTTG GTTTTGATGG CAGTGTTTTA TACACAGAAA GACAGCTGCA  
451 TGGAAAAACA AATTCTGCTG GGAGTAAATG GAGGCCTGTG CCTGCTTATA  
501 TCATTGGTAG CCATCTCACC CTGGGTCCAA AATCGACAGC CACACTCGGG  
551 GCTCTTACAA TCAGGGGTCA TAAGCTGCTA TGTCACTTAC CTCACCTTCT  
601 CAGCTCTGTC CAGCAAACT GCAGAAGTAG ACATGAAGA GCAGCAGCGG  
651 GGAAGGAGG GACCACGGT CATTATGAC GAGNAGAAAG GCACCTCTTA  
701 CATCTACTCC TACTTCCACT TCGTGTCTT CTTAGCTTCC CTGTATGTGA  
751 TGATGACCGT CACCAACTGG TTCAAGTGA

!!AA\_SEQUENCE 1.0  
ID ADP30899 standard; protein; 1434 AA.  
XX AC  
XX ADP30899;  
XX DT  
XX 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1666.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PA  
XX PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Hallenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX PT genetic, bacterial and viral diseases.  
XX PS Claim 1; SEQ ID NO 2897; 428pp; English.  
XX CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX SQ Sequence 1434 AA;  
ADP30899 Length: 1434 February 22, 2005 12:25 Type: P Check: 8711 ..  
1 ATGTCCATGG CCAGAGAGT GATCCAGCTC CTAGAAGATG AGGAGAGACC  
51 GAAGCCAGAC ACAGCCGCTG TCGCTGCCAT CTGGCGCGCC GCAGACTCCC  
101 GAGAACAGCC CTGGCTGTCA GCGGGCACCA GCGCTTCCT GTGCCCATCG  
151 CGTAGACTGG AGGGGCGCAC CACGGCCACC GAGCCAGAGG CGTTTCAGGA  
201 AGCAAGAGAA GTCCCCCGC GCTCCGGGAC CCGGCGCAGC TCATGGAGCA  
251 ACGACACCGC GTACCCGGGG CAGTTAGCGC TATACAGCA GCTGGCGCAG  
301 GCGAATGCCG TGGGGGGCTC GCGGGGGGCA CGCCACTGG GCGCCGTGCA  
351 GGTGGTCACC GCCTGCCTGC TGACCTACT CGTCATCTGG ACCTTGCTGG  
401 GCAACGTGCT GGTGTCGCA GCCATGCTGT GGAGCCGCCA CTTGCGCGCC  
451 AAGATGACCA ACCTCTTCAT CGTGTCTCTA CTTGTGTGAG ACCTCTTCGT  
501 GCGCTGCTG GTCATGTCTT GGAAGGCAGT GCGCGAGGTG GCCGGTTACT  
551 GGCCCTTTGA AGCGTTCTGC GACGCTCTGG TGGCCTTCGA CATCATGTGC  
601 TCCACCGCCT CCATCTGAA CCTGTGCGTC ATCAGCGTGG CCGCTACTG  
651 GGCCATCTCC AGGCCCTTCC GCTACGAGCG CAAGATGACC CAGGCGCATG  
701 CCTTGGTCAT GGAGGCGGTT TGGGAGCCCG ACGTAGGGC AGAAGACTGT

751 GACTCCAGCC TGAATCGAAC CTACGCCATC CTTTCTCTCGC TCATCAGCTT  
801 CTACATCCCC ATGGCCATCA TGATCGTGAC CTACACGGC ATCACCAGCA  
851 TCGCCCCAGGT GCAGATCCGC AGGATTTCTT CCCTGGAGAG GCGCCGAGAG  
901 CACGTGCAGA GCTGCCGGAG CAGCGCAGGC TGCACGCCCG ACACAGCCT  
951 CGCGTTTTCC ATCAAGAAGG AGACCGAGGT TCTCAAGACC CTGTCCGTGA  
1001 TCATGGGGGT CTTCTGTGTG TGCTGGCTGC CTTTCTTTCAT CTTAACTGC  
1051 ATGTTTCTTT TCTGCAGTGG ACACCCCAA GGCCTCCGG CCGCTTCCC  
1101 CTGGTTCAGT GAGACACAT TCGATGTCTT CATCTGTAC TATGCTTCA  
1151 AGCCCGACTT CCGGAAGGTG TTTGCCACG TGCTGGGGTG CAGCCACGTC  
1201 TGCTCCCGCA CGCCGTGGA GAGGTGAAC ATCAGCAATG AGCTCATCTC  
1251 CTACAACAA GACACGGTCT TCACAAGGA AATCGCAGCT GCTATATCC  
1301 ACATGATGCC CACGCCAAT CCCCCCGGG ACCGGAGGT GGACAACGAT  
1351 GAGGAGGAGG AGAGTCTTT CGATCGCATG TCCCAGATCT ATCAGACATC  
1401 CCCAGATGGT GACCATGTTG CAGATCTGT CTGA

!!AA SEQUENCE 1.0  
ID -ADP30905 standard; protein; 1434 AA.

AC ADP30905;  
XX  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1672.  
DE  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX  
XX Homo sapiens.

OS  
XX  
XX WO2004035732-A2.

PN  
XX  
XX 29-APR-2004.

PD  
XX  
XX 28-AUG-2003; 2003WO-US026780.

PF  
XX  
XX 29-AUG-2002; 2002US-0406576P.

PR  
XX  
XX 29-AUG-2002; 2002US-0406579P.

PR  
XX  
XX 29-AUG-2002; 2002US-0406585P.

PR  
XX  
XX 29-AUG-2002; 2002US-0406588P.

PR  
XX  
XX 29-AUG-2002; 2002US-0406608P.

PR  
XX  
XX 29-AUG-2002; 2002US-0406611P.

PR  
XX  
XX 29-AUG-2002; 2002US-0406612P.

PR  
XX  
XX 29-AUG-2002; 2002US-0406616P.

PR  
XX  
XX 29-AUG-2002; 2002US-0406640P.

PR  
XX  
XX 29-AUG-2002; 2002US-0406642P.

PR  
XX  
XX 29-AUG-2002; 2002US-0406646P.

PR  
XX  
XX 29-AUG-2002; 2002US-0406653P.

PR  
XX  
XX 29-AUG-2002; 2002US-0406655P.

PR  
XX  
XX 29-AUG-2002; 2002US-0406666P.

PR  
XX  
XX 17-SEP-2002; 2002US-0410946P.

PR  
XX  
XX 17-SEP-2002; 2002US-0410947P.

PR  
XX  
XX 17-SEP-2002; 2002US-0410948P.

PR  
XX  
XX 17-SEP-2002; 2002US-0410949P.

PR  
XX  
XX 17-SEP-2002; 2002US-0410953P.

PR  
XX  
XX 17-SEP-2002; 2002US-0410957P.

PR  
XX  
XX 17-SEP-2002; 2002US-0410958P.

PR  
XX  
XX 17-SEP-2002; 2002US-0410959P.

PR  
XX  
XX 17-SEP-2002; 2002US-0410960P.

PR  
XX  
XX 17-SEP-2002; 2002US-0410961P.

PR  
XX  
XX 17-SEP-2002; 2002US-0410962P.

17-SEP-2002; 2002US-0411019P.  
PR  
17-SEP-2002; 2002US-0411022P.  
PR  
17-SEP-2002; 2002US-0411023P.  
PR  
17-SEP-2002; 2002US-0411024P.  
PR  
17-SEP-2002; 2002US-0411032P.  
PR  
17-SEP-2002; 2002US-0411035P.  
PR  
17-SEP-2002; 2002US-0411037P.  
PR  
17-SEP-2002; 2002US-0411041P.  
PR  
17-SEP-2002; 2002US-0411045P.  
PR  
17-SEP-2002; 2002US-0411046P.  
PR  
17-SEP-2002; 2002US-0411048P.  
PR  
17-SEP-2002; 2002US-0411052P.  
PR  
17-SEP-2002; 2002US-0411055P.  
PR  
17-SEP-2002; 2002US-0411073P.  
PR  
17-SEP-2002; 2002US-0411082P.  
PR  
17-SEP-2002; 2002US-0411101P.  
PR  
17-SEP-2002; 2002US-0411111P.  
PR  
18-APR-2003; 2003US-0463700P.  
PR  
18-APR-2003; 2003US-0463708P.  
PR  
18-APR-2003; 2003US-0463716P.  
PR  
18-APR-2003; 2003US-0463732P.  
PR  
02-MAY-2003; 2003US-0467199P.  
PR  
02-MAY-2003; 2003US-0467201P.  
PR  
02-MAY-2003; 2003US-0467203P.  
PR  
02-MAY-2003; 2003US-0467230P.  
PR  
19-MAY-2003; 2003US-0471306P.  
PR  
19-MAY-2003; 2003US-0471336P.  
PR  
22-MAY-2003; 2003US-0472420P.  
PR  
22-MAY-2003; 2003US-0472430P.  
PR  
09-JUN-2003; 2003US-0476609P.  
PR  
08-JUL-2003; 2003US-0476641P.  
PR  
08-JUL-2003; 2003US-0485218P.  
PR  
08-JUL-2003; 2003US-0485223P.  
PR  
08-JUL-2003; 2003US-0485224P.  
PR  
14-JUL-2003; 2003US-0485325P.  
PR  
14-JUL-2003; 2003US-0486446P.  
PR  
15-JUL-2003; 2003US-0486480P.  
PR  
15-JUL-2003; 2003US-0486891P.  
PR  
15-JUL-2003; 2003US-0486960P.  
PR  
08-AUG-2003; 2003US-0493341P.  
PR  
08-AUG-2003; 2003US-0493370P.  
PR  
08-AUG-2003; 2003US-0493573P.  
PR  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnenmann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

DR WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases

PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2903; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX Sequence 1434 AA;

SQ ADP30905 Length: 1434 February 22, 2005 12:25 Type: P Check: 8711 ..

1 ATGTCCATGG CCAGGAGGT GATCCAGTC CTAGAAGATG AGGAGAGACC

51 GAAGCCAGAC ACAGCCGCTG TCGCTGCCAT CTGGCGGCC GCAGACTCCC  
101 GAGAACAGCC CTGGCTGTGA GCGGSCACCA GCGCTTCTCT GTGCCCATCG  
151 CGTAGACTGG AGGGGCGCAC CACGCCACCC GAGCCAGAG CGCTTCAGGA  
201 AGCAAGAGAA GTCCCCGCGC GTCCGGGAC CCGGCGCAGC TCATGGAGCA  
251 ACGACACCCG GTACCCGGGG CAGTTAGCGC TATACCAGCA GTTGGCGCAG  
301 GGGAAATCCG TGGGGGGCTC GSCGGGGCA CCGCCACTGG GGCCCGTGCA  
351 GGTGGTCACC GCTGCTCTGC TGACCTTACT CGTCATCTGG ACCTTCTCTGG  
401 GCAACGTGCT GGTGTCCGCA GCCATCGTGT GGAGCCGCCA CTTGCGCGCC  
451 AAGATGACCA ACGTCTTCAT CGTGTCTCTA CTTGTGTGAC ACCTCTTCTGT  
501 GCGCTGCTGT GTCATGTCTCT GGAAGGCAGT GCGGAGGTTG GCGGTTTACT  
551 GGCCCTTTGA AGCGTTCTGC GACGTCTGGG TGGCCTTTGA CATCATGTGC  
601 TCCACCGCCT CCATCTGAA CCTGTGCGTC ATCAGCGTGG CCGCTACTTG  
651 GGCCATCTCC AGGCCCTTCC GCTACGAGCG CAAGATGACC CAGCGCATGG  
701 CTTGTGTCTAT GGAGGCCGTT TGGAGGCCCG ACGTGAGGGC AGAGAACTGT  
751 GACTCCAGCC TGAATCGAAC CTACGCCATC CCTTCTCTGC TCATCAGCTT  
801 CTACATCCCC ATGGCCATCA TGATGTGTAC CTACAGCGC ATCTACCGCA  
851 TCGCCCAGGT GCAGATCCCG AGGATTTCTT CCTTGAGAG GCGCGCAGAG  
901 CAGCTGCAGA GTGCGCGGAG CAGCGCAGGC TGCAAGCCCG ACACAGCCT  
951 GCGGTTTTCC ATCAAGAGG AGACCGAGGT TCTCAAGACC CTGTGGTGA  
1001 TCATGGGGGT CTTCTGTGTG TGCTGGGTGC CTTTCTTCAT CCTTAACTGC  
1051 ATGGTTCCCT TCTGAGTGG ACACCCCAA GGCCTTCCGG CCGGTTTCCC  
1101 CTGCGTCACT GAGACCAAT TCAGTGTCTT CATCTGTTCAC TATGCTTTCA  
1151 ACGCCACTT CGGAAGGTG TTTGCCCAGC TGCTGGGGTG CAGCCACGTC  
1201 TGCTCCCGCA CGCCGGTGA GACGTGAAC ATCAGCAATG AGCTCATCTC  
1251 CTACAACCAA GACACGTCT TCCAAAGGA AATCGCAGCT GCCTACATCC  
1301 ACATGATGCC CAACGCCATT CCCCCCGGG ACCGGGAGGT GGACAACGAT  
1351 GAGGAGGAGG AGAGTCCTTT CGATCGCATG TCCAGATCT ATCAGACATC  
1401 CCAGATGCT GACCATGTTG CAGAGTCTGT CTGA

!!AA SEQUENCE 1.0  
ID ADP30949 standard; protein; 930 AA..  
XX  
AC  
XX ADP30949;  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1716.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
XX 29-APR-2004.

28-AUG-2003; 2003WO-US026780.  
29-AUG-2002; 2002US-0406576P.  
29-AUG-2002; 2002US-0406579P.  
29-AUG-2002; 2002US-0406585P.  
29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
17-SEP-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
22-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
15-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493373P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC. PA

XX PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Korchakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2947; 428pp; English.  
XX  
XX CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPONEB and is not in the specification.  
XX  
XX SQ Sequence 930 AA;  
ADP30949 Length: 930 February 22, 2005 12:25 Type: P Check: 7913 ..  
1 CTGGACGAGT CTGTGATAAC GAGCATTTGCC ACTGGTGATG AGTCCCTGAG  
51 GAACCACAGT CTCATCCAGA TCTGTGGCCA CCCGACTCC TTACAGTGCA  
101 CCTGCCTCAT CCTCCTAGTC AAGATGCTCA ACTCCCTGCT CAAGGGCCAA  
151 GTGGCCAAAG TCATCCAGAA GTCATCAAT ACGGACTCC CTGCCCCCTT  
201 CACCTGGGTC ACAGGTACT TTGCCATGGT GGTGGGGGCC AGCATGACCT  
251 TCGTGGTGCA GAGCAGTTCT GTGTTACCT CGGCCATCAC CCCACTCATC  
301 GGTCTTGGTG TGATCAGCAT TGAGAGGGCC TACCGGTCA CATGGGTTT  
351 CAACATCGGC ACCACCACCA CGGCCATCCT GGCTGCCCTG GCAGGCCCA  
401 GGGAGAAGCT GTCCAGCGCT TTCCAGATTG CCTCTGTGCA CTTCTTCTTC  
451 AACATCTCGG GTATCTTCT GTGTACCCTG CTGCGCTGCA CAGCCTGCC  
501 CATCCGCATG GCCAAGGCG TGGGAAAGC CACGGCCAAAG TACCGTGGT  
551 TTGCGGTCCT CTATCTCCTT GTCTGCTTCC TGCTGCTGCC CTCACTGGTG  
601 TTTGGCATCT CCATGGCAGG CTGGCAGGTC ATGGTAGGTG TGGGCAGGCC  
651 CTTCCGGGCC CTGCTGCCT TCGTGGTGCT CATCAATGTC CTCAGAGTC  
701 GGAGTCCCGG GCACCTGCC AGTGGTTAC AGACATGGA CTTCTGCTCT  
751 CGCTGGATGC ACTCCCTGAA GCGCTTGAC CACCTCATCA CCGCGCCAC  
801 CCTATGCTGT GCCAGGCTG AGCCCGGCTC ACCCCGCGTG CCCCCAGGG  
851 TCTTCTCGGA GGAGCTACCC CCGGCCACAC CCTCCCCCG TCITGCACTG  
901 CCGCTCACC ACAATGCCAC CCGCTCTAG  
!!AA SEQUENCE 1.0  
ID -ADP30998 standard; protein; 1041 AA.  
XX  
XX AC ADP30998;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #1765.  
XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0474202P.  
PR 22-MAY-2003; 2003US-0474303P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.



PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2996; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1041 AA;  
ADP30998 Length: 1041 February 22, 2005 12:25 Type: P Check: 4521 ..  
1 ATGGCCATGG CCCAGAACT CAGCCACTC CTGCCAGTC TCGGCAGGT  
51 CATCCAGGAG CTTACGATAT CTTGCGACC AGAGCCTGTC TTCACGGTGG  
101 ATCGAGCTGA GGTGCGCGCG CTCCTCTGGA AGCCGTACAT CTATCGGGCG  
151 TACCGGCCGC TGCATCAGC CTGGCGGCTC TATTTCGGA CGCTGTTCCA  
201 GCAGCACAAC GAGGCCGTGA ATGCTCTGAC CCACCTGCTG GCGGCCCTGG  
251 TACTGTGCTG GCGGTGCGCC CTCCTTGTGG AGACCGTGGA CTTCTGGGGA  
301 GACCCACAG CCCTGCCCTT CTTTCATATT GTCTTGCTCT CTTTCACCTA  
351 CTTCTCCTTC AGTGCTTTGG CTCACCTCCT GCAGGCCAAG TCTGAGTTCT  
401 GGCATTACAG CTTCTTCTTC CTGGACTATG TGGGGGTGGC CGTGATCCAG  
451 TTTGGCAGTG CTTGGGCACA CTTCTACTAT GCTATGAGC CGCCTGGCA  
501 TGCCACAGTG CAGGCTGTTT TTTGCCCCAT GGTGCTCTTT CTGCGCTGGC  
551 TTTCTGTGAT TGGCTCCTGC TATAACAAGT ACATCCAGAA ACCAGGCCTG  
601 CTGGGCCGGA CATGCCAGGA GGTGCCCCCT CCCTGCGCTT ACGCACTGGA  
651 CATTAGTCTT GTGGTGATC GTATCTTCTG GTCTCTCCGAC CCCACACGG  
701 ATGATCCAGC TCTTCTCTAC CACAAGTGCC AGGTGCTCTT CTTTCTGCTG  
751 GCTGCTGCTT TCTTCTCTAC CTTTCATGCC GAGCGCTGTT TCCCTGGCAG  
801 CTGCCATGTC TTGGGGCAGG GCCACCAACT TTTCCACATC TTTCTGTTGC  
851 TGTGCACGCT GGCTCAGCTG GAGGCTGTGG CACTGGACTA TGAGGCCCGA  
901 CGGCCCATCT ATGAGCTTCT GCACAGCAC TGGCCTCACA ACTTTTCTGG  
951 CCTCTTCTGT CTCACGGTGG GCAGCAGCAT CCTCACTGCA TTTCTCTCTGA

1001 GCCAGCTGCT ACAGGCAAA CTTGATCAGA AGACCAAGTG A  
!!AA SEQUENCE 1.0  
ID ADF31078 standard; protein; 573 AA.  
XX  
XX ADF31078;  
XX  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1845.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 18-APR-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 02-MAY-2003; 2003US-0467230P.

```

PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486466P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
PA
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGR, Wu G, Zhang H;
XX
XX WPI; 2004-348438/32.
DR
XX New nucleic acid molecule for diagnosing, preventing or treating diseases
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
XX genetic, bacterial and viral diseases.
XX
XX Claim 1; SEQ ID NO 3076; 428pp; English.
XX
XX The present invention relates to an isolated nucleic acid molecule
XX encoding a polypeptide which is believed to be cytostatic,
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The
XX composition and methods are useful for diagnosing, preventing and
XX treating diseases such as proliferative (e.g. cancer), inflammatory,
XX immune, metabolic, genetic, bacterial and viral diseases. The present
XX sequence represents a human secreted protein. The present sequence is
XX available on WIPWEB and is not in the specification.
XX
XX Sequence 573 AA;
SQ
ADP31078 Length: 573 February 22, 2005 12:25 Type: P Check: 5263 ..
1 ATGACATATT TGACTATT GTATAAAAA ATCACCCGGA AGCAGAGCCG
51 GAAGTGGGGT TGGTCAGGTT ATCTCCACGG GTGGAAGAAGC GGAGGCCCCAG
101 GAGGAGGGGT GAAAGAAGG TGGAGGATCC TGGCTACCAC TGAATCCCAT
151 ACTGCTTCTC CTAGACCTCA GAGACAGAA AAGAAGAAGG TGTGTATCC
201 CCCTTCTCC TTTCTCCTCT CTCCTGAGGC AGGGGCTGGG CTGAGCGAGA
251 CCGTCACTGA GACAACAGTT ACCGTGACAA CCGAGCCCGA GAACCGGAGC
301 CTTACCATCA AACTTCCGAA ACGGAAGCCA GAGAAAAAGG TGGAAATGGAC
351 AAGTGACACT GTGGACAATG AACGCATGG CCGCCGCTCA TCAAAATGCT
401 GCTCTATTTA TGA AAAATCC CGGGCCTTTG GCGAGAGCTC CACGAAAGT
451 GATGAGGAGG AAGAAGAAGG CTGTGGTCTAT ACACACTGTG TACGTGCCCA
501 CCGCAAAAGG TGGCGTCTGT CAACCTCTGG ACGACCCCCC ACCACCCCTC
551 CCGGCGCTCC TGACCTTCCC TAG
11AA SEQUENCE 1.0
ID _ADP31087 standard; protein; 621 AA.
XX

```

PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3085; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 621 AA;  
ADP31087 Length: 621 February 22, 2005 12:25 Type: P Check: 3134 ..  
1 CAGTCTGTTT CCAGTCTGG CGGGGGCCG GGCTGGGGTG GCGGAGCGG  
51 TGGGAGATGC CGGGCGGCC GCGGAGGTC CATGTGGCGC TCTAGTGGG  
101 ATGCCAGCCT CTGAAGGCG GAGGCCCTGG CCTCTCTCCC CTGCGGCCGTG  
151 GCATGGCAT TCTCCAGTC CCAGTGATG GCGGCTCGGC GGCACACGA  
201 CAGCCGGCTC ATCATCGAGG TGGACGAGTA CAGTCCAAAC CCCACCCAGG  
251 CCTTCACCTT CTACAACATC AACCAGGGCC GCTTCCAGCC ACCGCATGTG  
301 CAGATTACGG CGAGTGTGTG ATCCACGCTG GGGACTTTCAC TGAGTGGGG  
351 CTCGCCAGCG AGGTGAAGAA GTTCAACGAG TGCTGGGGTA GGCAGCTGTC  
401 CCTACGAGTA CAAGATCTGT ATCCAGGCA ACCACGAGCT GACCTTTGAC  
451 CAGGAGTTCA TGGCGGACCT CATCAGCAG GACTTTTACT ACTTCCCATC  
501 TGTGTGGAAG CTGAAGCCGG AGAAGTATGA GAATGTGACG TCGTGTGTA  
551 CCAACTGCAT CTACTTTCAG GACTCGGAGG TCACCGTGGG GGGCTTCGG  
601 ATCTATGCT CCCATGGTG A  
!!AA SEQUENCE 1.0  
ID ADP31138 standard; protein; 1350 AA.  
XX  
AC ADP31138;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
DT

DE Human secreted protein SEQ ID #1905.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
PN  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471356P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.

PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H,  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3136; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1350 AA;  
ADP31138 Length: 1350 February 22, 2005 12:25 Type: P Check: 330 ..  
1 ATGGCAGTGA TTCAGCCTTT GTCGGTGGG AAATGATGA ATCCCTTTGA  
51 TTATTTCCCA AGAAGACAC AGCAGACCTT GGCTCGACAG GGACAGTGC  
101 AAATGTCTGA TAAGCAGGAC TTTCAGCAA AAGGAGCAG AACCAAGGGT  
151 GTGATGCAGT CAACTTTTGA GCAGAAGTTG CAGAACAACCT CAGAAGAAAC  
201 ACACGGCAG GGGGAGATG TGGGCTTCAA AACTTTAGG ATCTCAGATG  
251 CTCTGATCAA GCGCTGCCAG GTGTCTCAGG AGCAGTGGGT CAAAGCGGCC  
301 CTGGAGCCGA AAGTGTCTGC GGAGTTTGAT CTGACTTTGG ACAGCGAGCC  
351 GCTGCTGCAG GCATCCACC AGCTGCACCTT CATTGAGATG AATGTAGGG  
401 GTGAGGAGGA GGAAGTGGTG GCAGAGGAGG AGGAGGTGGA GGAGGTAGTC  
451 ATGGAGGAGG AGATGGAGGA GGAGGAGGTG GTGGCTAAGA TAATGAGGA  
501 GGAGGAGGAG GTAATGGTGG AGGAGAGATG GGAGGAGGAG GAAGAGGTAG  
551 CGGAGGAGGA GGTAGTGGAG GAGGAGGTGG AAGAGGAGGA GTGTGGTGGT  
601 GAGATAGTGG AGGAGGAGGA GCTGGAGAAA TGCTGCACCC GTAAACAACAG  
651 GGTACACCTG GCTTGAGGA TGCCACCTTT CACCCACAGC CCGTGGAGC  
701 GCTACATCTT GGAGCTGGAC GACGGTGGCG GGGGACAGTT CCGGGAAGTG  
751 TACGTGGTA AGGAGACTTT GTGTACCATC GACGGTCTTC ACTTCAACAG  
801 CACCTACAAC GCCCGAGTCA AAGCTTTTCAA CTCTTCTGGT GTCGGGCTTT  
851 ACAGTAAAC TGTGCTCTTG CAGACATCCG ATGTGGCCTG GTTCACTTT  
901 GACCCCAACT CTGGGCATCG GGACATCATT TTATCCAATG ACAACAGAC

951 AGCCACCTGC AGCAGTATG ACGACCGGGT GGTGCTGGGC ACAGCTGGCT  
1001 TTCTCCAGGG GTGCACTAC TGGAGCTGC AGGTGACCG GTACGACAC  
1051 CACCCAGACC CCGCTTGGG GGTGGCCAGG GCCAGCGTGG TCAAGGACAT  
1101 GATGCTGGGC AAGGATGACA AGGCCTGGC CATGTATGTG GACAACAACC  
1151 GCAGCTGGTT CATGCACTGC AACTCCACA CCAACAGGAC GGAAGGTGGC  
1201 GTGTGCAAGG GGGCCACCGT GGGCGTCTG CTGGACCTGA ATAAGCACAC  
1251 TCTCACCTTC TTCATCAACG GGCAGCAGCA GGSCCCACCA GCCTTCAGCC  
1301 ACGTGGACGG GGTCTTCATG CCAGCCCTCA GCCTCAACCG CAACTGCGAG  
!!AA SEQUENCE 1.0  
ID ADP31139 standard; protein; 1560 AA.  
XX  
AC ADP31139;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1906.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.

PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3137; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
XX Sequence 1560 AA;  
ADP31139 Length: 1560 February 22, 2005 12:25 Type: P Check: 5154 ..  
1 ATGGGTCTGG ATTTCACGGA AAGCGGAGAC CTCGAGGTGC AGGACTGTGC  
51 GGGCGAGGTG GCCGAGGCAG GTAAGTGGGC CTGCAAGGT GAATTCATG  
101 CTAAATCCAA AGACATATG CATTTGAAAC TGTTTTGGC AGCCCTCAG  
151 TGGCGGCTTG CTCCTTTCTC TCGCTCCGAG CCAGACACAG CCGCTGTGCG  
201 TGCCATCTGG CGCGCGCAG ACTCCCGAGA ACAGCCCTGG CTGTCAGCGG  
251 GCACACGGG CTTCTGTGCG CNAATCGGTA GACTGGAGGG GCGCACACAG  
301 GCCACCGAGC CAGAGGCGCT TCAGGAAGCA AGAGAAGTCC CCGCGCGCTC

351 CCGGACCCGG CGCAGTCAAT GGAGCAACGA CACCGCGTAC CCGGGCGAGT  
401 TAGCGCTATA CCAGCAGCTG GCGCAGGGA ATGCGGTGGG GGGCTCGGG  
451 GGGGCACCGC CACTGGGGCC CGTGCAGGTG GTCACGGCCT GCCTGCTGAC  
501 CCTACTCGTC ATCTGGACCT TGCTGGGCAA CGTGTCTGGT TCCGAGGCA  
551 TCGTGTGGAG CCGCCACCTG CGGCGCAAGA TGACCAACGT CTTTCATCGT  
601 TCTCTACCTG TGTCAACCTT CTTCTGGGGG CTGCTGGTCA TGTCTGGAA  
651 GGCAGTGGCC GAGTGGCCG GTTACTGGCC CTTTGAAGCG TTCTGCGAGG  
701 TCTGGGTGGC CTTTCGACATC ATGTGCTCCA CCGCCTCCAT CTTGAACCTG  
751 TCGTCAATCA CGTGGGGCG CTACTGGGCC ATTCACAGGC CTTCCGGTA  
801 CGAGCGCAAG ATGACCCAGC GCATGGCCTT GGTCAATGGAG GCCGTTTGGG  
851 AGCCCGACGT GAGGGCAGAG AACTGTGACT CCAGCCTGAA TCGAACCTAC  
901 GCCATCCCTT CTTGCTCAT CAGCTTCTAC ATCCCCATGG CCATCATGAT  
951 CGTGACCTAC ACGCGCATCT ACCGCATGCG CCAGGTGCGAG ATCCGCGAGG  
1001 TTTCTCTCCT GGAGGGGCC GCAGAGCAGG TGCAGAGCTG CCGGAGCAGC  
1051 GAGGCTGCA CGCCCGACAC CAGCCTGGCG TTTTCCATCA AGAAGGAGAC  
1101 CGAGTTCTC AAGACCCCTGT CGGTGATCAT GGGGGTCTTC GTGTGTTGCT  
1151 GGTGCCCCCT CTTTCATCCTT AACTGCATGG TTCTTTCTG CAGTGGACAC  
1201 CCCAAGGCC CTCGGCCGG CTTCCCTGCG GTCACTGAGA CCACATTCGA  
1251 TGTCTTCATC TGTCACTATG CTTTCAACGC CGACTTCCGG AAGGTGTTTG  
1301 CCCAGCTGCT GGGGTGCAGC CAGCTCTGCT CCGGCACGCC GGTGGAGAGC  
1351 GTGAACATCA GCATGAGCT CATCTCTTAC AACCAAGACA CGGTCTTCCA  
1401 CAAGGAATC GCAGTGCCT ACATCCACAT GATGCCCAAC GCCATTCCCC  
1451 CCGGGGACC GAGGTGGAC AACGATGAGG AGGAGGAGAG TCCTTTCGAT  
1501 CGCATGTCCC AGATCTATCA GACATCCCCA GATGCTGACC ATGTTGCGAG  
1551 GTCTGTCTGA

!!AA\_SEQUENCE 1.0

ID\_ADP31277 standard; protein; 702 AA.

XX AC

ADP31277;

XX AC

XX DT

12-AUG-2004 (first entry)

XX DE

Human secreted protein SEQ ID #2044.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX FN WO2004035732-A2.

XX PD 29-APR-2004.

XX XX 28-AUG-2003; 2003WO-US026780.

XX XX 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476509P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

DR WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3275; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX SQ Sequence 702 AA;  
ADP31277 Length: 702 February 22, 2005 12:25 Type: P Check: 430 ..  
1 ATGGAGAGCG AGCGGACAT GTACCGCAG TTCAGGACT GGTGCTCAG  
51 GACTTACGGG GACTCAGGCA AGACCAAGAC GGTGACCCGT AAAAAATACG  
101 AACGGATCGT CCAGCTCCTC AATGGCTCCG AGTCGAGCTC CACGGACAAC  
151 GCCAATTATTA AATTCGGGT CAATCGAAG GGCTTCAGC TGGGCCAGCC  
201 GGACGAGGTC CGCGGGGAG CGCGGGGCGC CAAAGCAAGTG CTCTACGTGC  
251 CTGTCAAGAC CACGGTGAGT GACTCGCCTT CCTCTGTTAT TTGTCCTCCG  
301 GAGCAGCCCG CGGGGAGGG AGAAGGAGA GAGCGGGGAG AGAGGGGGAG  
351 CCGTGAGCCG CCGTTGGGTC GTGTGCCCC TACCTTCTC AACCCCTCC  
401 CCAAGTCGTC CCCACTCGCA TTAGCCAGGC GCGTTTTCCC CACTGTACAG  
451 TCTTTGTGGT CTTTATTTT AAAGCGGCG CACACCTCCA GAGCTGGCCT  
501 CCCTCCCGC CTCGGGTTCC CGGACCGGCT GCAGGAGCTT CCTTCCCGG  
551 GTCGGCGGC GCGGTCGCG GTCTCGGGC TGGGCCATTG TCCCATGTCC  
601 TTCTCTGGG GCTGGCGCG GTGCCACCG CGCCACCGC GCCTAAGGC  
651 CAGGCTGGAA GCCCGGCCG ACCTCTGAG AGCAGACGAG TCTGATCGAT  
701 AG  
!!AA\_SEQUENCE 1.0  
ID ADP31299 standard; protein; 2833 AA.  
XX  
AC ADP31299;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2066.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX

DR WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

PS Claim 1; SEQ ID NO 3297; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX Sequence 2833 AA;

ADP31299 Length: 2833 February 22, 2005 12:25 Type: P Check: 3827 ..

1 AGGCCTATGT GCTCAGAGGC TGGGTGGACC TGACCTCAGA CAAGCCCCAC

51 ACTGCGAAGA AAGCCATTGA GTACCTGGAA CAAGGAATTC AGGACCCAA

101 AGATGTGCTG GGGCTGATGG GAAAGGCAAT GTACTTTCATG ATGCAGCAGA

151 ACTACTCAGA GGCCCTGGAG GTGGTGAACC AGATCACTGT GACTTCAGGG

201 AGCTTCCTGC CAGCCCTCGT CTTGAAGATG CAGCTGTTCT TAGCTCGGCA

251 GGACTGGGAG CAGACAGTAG AAATGGGACA CAGCTGGAGG AAGCTGAGTA

301 CCGGCTGGAA TTCTCTGAAG AGGTGCAGAA GTCCCTTGGG AAGTCTGAGG

351 TGCTAAATTT CTCTCAAGCC CTCTGATGT CCAGGAAGCA CAAGGGGAGG

401 GAAGAGACCA CAGCGCTCCT GAAGGAGGCA GTGGAGCTTC ACTTCTCCAG

451 CATGCAAGGC ATCCCTCTTG GCTCTGAGTA CTTTGAAAG CTGGACCCGT

501 ACTTCCTGGT CTGCAATGGT AAGGATGACT TGCTCTTCTG CCCAAGCAG

551 CCCAGTTTAC CAGGCCAGAT CGTGTCTCCA CTTCTTAAAC AAGTCGCCGT

601 GATCTTGAAT CTTGTAGTCA AAGCAGCACC AGCTCTGATC GACCCCTGT

651 ATTTGATGGC TCAGTATTTT TAGGAGAGCT AGAGAATGCC CAGAGCATCC

701 TGCAGCGTTG CTTGGAGCTG GACCCCGCCT CGTGGATGC CCATCTCCTC

751 ATGTGTCAGA TCTACTTGGC TCAGGGCAAC TTTGGCATGT GCTTCCACTG

801 CTTAGAGCTG GGTGTACGCC ACAACTTCCA GGTCCGAGAT CACCCCTCT

851 ACCACCTCAT CAAGGCCAGG GCCTCAACA AGGCTGGAGA CTATCCAGAG

901 GCCATAAGA CGCTGAAAT GGTCACTAAA TTGCCAGCTC TGAAGAAGGA

951 AGAAGGCAGA AAGTTCTCA GGCCTCTCTGT GCAGCCTAGC CAGCGGGCAT

1001 CCATCTTATT GGAACCTGGT GAGGCCCTCC GGTGAATGG GGAGCTACAT

1051 GAGGCCACCA AGGTCATGCA GGNACCATC AATGAGTTGG GTGGCACACC

1101 AGAAGAGAAC CGCATCACA TTGCCAACGT GGACTTGGTC CTGAGCAAGG

1151 GCAATGTGGA CGTGGCGCTG AACATGCTAA GGAACATCTT GCCCAAGCAG

1201 TCCTGCTATA TGGNAGCCAG AGAGAAGATG GCCACATCT ACCTGCAGAC

1251 CCTCAGAGAC AGGCGCTCT ACATCAGATG CTACCGTGAG CTCTGTGAAC

1301 ATCTGCTGG CCCCCACACC AGCCTGTCTAC TGGCGGATGC CTTAATGAGC  
1351 ATTCTGAGC CCGAGAAGGC CCTGAGGTC TATGATGAGG CTTATAGACA  
1401 GAACCCACAT GAGCGCTCCC TGGCCAGCAG AATTGGGCAC GCTTATGTGA  
1451 AGGCCACCA GTATATGAG CAGGCACTGG AACATGACAT TGTCCAAGAC  
1501 ATCCATCCA TGTATGAATGA TGTTAAGTGC CTGCTTTTGC TGGCAAGGT  
1551 TTACAAGAGC CATAAAAAAG AAGCTGTGAT AGAAACTTTG AACAGGCCT  
1601 TGGACCTCCA GTCTCGGATA CTGAAGCGAG TTCCACTGGA GCAACAGAA  
1651 ATGATTCCCT CCAGAAGCA ACTGCGAGC TCTATCTGCA TCCAAATTGC  
1701 AGAGCACTAC CTGGCAGAGA AAGAGTAGTA CAAGGCGGTA CAGTCTTATA  
1751 AGGATGTCTT CTCCTACTTG CCAACTGACA ATAAGGACCT GATGTTTAGA  
1801 AAACAGAAAC ATGAAGCGGC CATCAATCTT TACCACCAAG TCTTGAGAA  
1851 AGGCCAGAC AATTTTTTGG TATTCATATA ATTAATCGAT CTGCTAAGAA  
1901 GAAGTGAAA ACTTGAAGAC ATTCTGCTCT TCTTTGAATT GGCCAAGAAG  
1951 GTGTCTAGCC GGGTGCCTTT GGAACCAAGG TTCAATTACT GCAGAGTAT  
2001 CTACTGTGG CACATAGGC AGCCCAACGA AGCCTTAAAG TTCTTGAACA  
2051 AGGCACCAA GGACAGCACT TGGGCCAGA GCGCCATCTA CCACATGGTG  
2101 CAGATCTGTC TGNATCGA CACAGAGTT GTGGCGGAG AGCTTTTGA  
2151 GAACCAAGGA GCTGAGAGCA AGTCTAACAC CTGCAGCTAC ATGGAGAAGA  
2201 AGGAGTTTGA GCAGCAGGCT GTGACACCG CCGAGAAACT GCTGCGTGAG  
2251 TTTTACCAC ATTCAACTC CAGCAGACC CAGCTGGCGC TGTGCAAGG  
2301 CCTCTGCCG CTGGCCACCA GGGAGAAGC TAACATGAG GCTGCGCTGG  
2351 GCAGCTTCAT CCAGATAGC CAGGCTGAGA AGACAGCGT CCCTGCCCTG  
2401 CTGGCCTTGG CACAAGCCTA CGTGTCTCTG AAGCAGATCC CCAAGCGCG  
2451 TATGCACTTG AAGCGCTG CCAAGACCCC CTGGGTGCTG AGTGAAGCTG  
2501 AGGACCTGGA GAAGAGCTGG CTCCTGTCTG CTGACATTTA CTGCCAGGCG  
2551 AGCAGTTGC ACCTCGCTT AGAATGCTG CCGCGCTGGC CTATGAGTAC  
2601 ATGGGCTTCA TCAATGAGAA GGAGCAGTCC TACAAGGATG CAGTCAACAA  
2651 CTACAAACTG GCCTGGAAGT ACAGTCATCA CGCCAACCCCT GCCATTGGCT  
2701 TCAAACTTGC TTTCAACTAC CTGAAGGACA AGAAATTGT GAGGGCCATC  
2751 GAAATGTCT CAGGAGACAC CCGCACTACC CCAAGATCAG GGAGGAAATT  
2801 TTGAAAAGG CCGGAAAGTC CCTGAGGCC TAG

IIIA SEQUENCE 1.0  
ID\_ADP31408 standard; protein; 1749 AA.  
XX AC  
XX ADP31408;  
XX  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2175.  
XX DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.  
OS WO2004035732-A2.  
XX  
XX PD  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-047240P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.



PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3406; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX Sequence 1749 AA;  
ADP31408 Length: 1749 February 22, 2005 12:25 Type: P Check: 8569 ..  
1 ATGGCAAGGG CGCTTCCCTC TCCTGCCGGC CTGCGCCTCC COTGCACCTC  
51 GCCAGCCCT CGGCACCCAC ACTCAGCTCA GCCTCTCTGG GGCCACCAGG  
101 GCAGCCCCAC CTCAGGCCCC CAGAGGTGTG CAAAGGGCTC CACGGTGTGG  
151 TGTCAAGGAT TGCAGACAGC TGCCAGGTGC GGGGCTGTGG GGTACTTGCA  
201 AGGGGCGGTA TGGACAAAC CCACCGCGAA GTCTCTGCCC TGGCAGGTAT  
251 GCAGGACAT AGCAGCCGCC GTGGCAATG GGCTGAACCC TGACGCCACG  
301 GAGTCTGACA TCCTGGCTTT GGTGATGAAG ACCTGTGAGT GGCTCCCCAG  
351 CCAGGAGTCT TCAGCCGGAT GCAGTGGAT GGTGGATGCC CACAGTTCCG  
401 CCATCTGAG CATGCTCCGT GGGGCCCCGG ACAGTCCCCC GGCACAGGTG  
451 TGCACAGCGC TCAGCCTCTG TGAGCCCGCTG CAGAGGCACC TGGCCACCTT  
501 GAGGCCACTC TCCAAAGAGG ACACCTTTGA GGCTGTGGCT CCGTTTCATGG  
551 CCAATGGGCC CTTACCTTC CACCCCGGCC AGCGGCTGA AGGAGCTGTG  
601 TGCCAAAGACT GTGTACGGCA GGTCTCCCGA CTCACAGGAG GTGTCCGGTC  
651 CAACTTGACC TTGGCCGACT TGAACATCCA GGAGCAGTGT GAGTCTCTGG  
701 GGCCTGGCCT GGCCGTCTTC TGCAGAAACT ACCTCTTCCA GTTTTTTGTG  
751 CCTGCTGACC AAGCACTGAG GCTTCTCCCC CCGCAGGAGC TCTGACGAA  
801 GGGGGGATTC TGTGAGGAGC TAGGGGACC TGCCCGTTTG ACTCAAGTAG  
851 TGGCCATGGA CGGGGTCCCC TCCTGTGAGC TGGGGTTGCC AAGNAACAG  
901 AGCGAGATGC AGATGAAGGC CCGTGTGACC TGTGAGGTGT GCATGAACGT  
951 GGTGCAGAAG CTGGACCACT GGCTCATGTC CAACAGCTCT GAGCTCATGA  
1001 TCACCCATGC CTTGGAGCGC GTGTGCTCGG TAATGCTGTC CTCTATCAGC

1051 AAGGAGTGCA TCATCTTTGGT GGACACCTAC AGCCCCCTCT TGGTGCAGCT  
1101 TGTGGCCAAA ATCACCCAG AGAAGGTGTG CAAGTTTCATC CGTCTGTGTG  
1151 GCAACGGAG GCGGCGCGG GCAGTCAATG ATGCCATATG CATCGTGCGG  
1201 TCCCCAGAGT GGGACGCGGA GAACACAGGC AGCTTTCTGCA ATGGGTGCAA  
1251 GAGGCTGTCT ACGGTGTCTT CCCACAACCT GGAGAGCAAG AGCACAAGC  
1301 GAGACATCTT GGTGGCTTTC AAGGTGGCT GCAGCATCTT GCCGCTGCC  
1351 TATATGATCC AGTCAAGCA CTTCTGTACC CAGTACGAGC CCGTGTCTAT  
1401 TGAGAGTCTC AAGGACATGA TGGACCCCGT GGCTGTGTGC AAGAAGGTGG  
1451 GGGCTTGCCA CCGCCCCAGG ACCCACTGC TGGGCACCGA CCAGTGTGCC  
1501 CTGGCCCCAA GTTCTGTGTG CAGGAGCCAG GAGGCCGCGA AGCTGTGCAA  
1551 CGCTGTGCAA CACTGCCAGA AGCATACCTT CCGCTGCCCT GGTAATGAGC  
1601 AGAAGGAAG TCTTGGGGTG TGCTCAAGT CAGGAGAGCA AATATGCGA  
1651 GGCAAAAGCT CCGGGGAAAA GCGGAGGAG TCTGGGGTGG CCACCGGGAT  
1701 GTGGAGCAGC GAGGGCAAG ACGTGAACA CAGCCCTCCA GCTGTCTGA  
!!AA\_SEQUENCE 1.0  
ID ADF31410 standard; protein; 717 AA.  
XX AC ADF31410;  
XX AC ADF31410;  
DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2177.  
XX DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX DE cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX OS WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476509P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3408; 428pp; English.  
PS  
PS The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 717 AA;  
ADP31410 Length: 717 February 22, 2005 12:25 Type: P Check: 450 ..

51 GGATGGACTC ATCTCCACC CTGCTACTGG ACTTGTCCTT GTACTCTCAA  
101 AGCAGTGTGA GGAGATTTCAT CAACCGGTGG TGTGGACATG TGAACAGCGT  
151 GAGGCAGAGA GTTTAAATC TATCAAGAAC GACAACCTAA TGTCTCTGTC  
201 ATTTTATGCT TATGTTAATA CTTATGTATT TTTAGTACT GSCCCCGTGC  
251 CCCGGCCCCA CCCGGCCCC CTTACCATGT TCTCGGGGCC GACTCGGCTT  
301 CCGCTCGGCC GCGCGCCCTC CCGCTGCCGA CCGCGCCCGC GCGCCCGGCT  
351 CTGCAGCAC CGACGCGCG CGCGGAGCC GGACAATACC CCGTCCCGC  
401 CTGCGCTGCG TGTGGCCAAT GCGCGCTTGT CTTGCTGGTT CGAACCCCNAG  
451 CCGCTGTTCA ATCGCGGCC TCCTTCTAGC CAGACCCCGC CCCCCCGGCA  
501 CCGCTTCTCT AACGCTGTT TGTCTTTTGA CACGGCACGC GGAGGCGGGG  
551 CTTCCAGCCC CAATAGTGAC GCGCTCTCTG CTTTTCACCA GCGGCCCAAG  
601 CTTGACGAAC AGAAGGCCAA ACCAATGAGA TTGGACGCTT CCGACACGAA  
651 AGCCRAATAA AATATCGCCC GCGAGCAAGG GAGGCGGGCC ACTGGGAAGG  
701 ACAGCAAAAT TAGCTAA  
!!AA SEQUENCE 1.0  
ID ADP31428 standard; protein; 741 AA.  
XX  
AC ADP31428;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2195.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406668P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410951P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3426; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 741 AA;  
ADP31428 Length: 741 February 22, 2005 12:25 Type: P Check: 3911 ..  
1 ATGAGGACTG GCCACGGCGG GCAGAGGCC ATGAGGCCT GGGCCTTGCT

51 TCACACGAGC TGGCCCTGG AGCCAGCTGG TCCAGCAGAG GACCAGACAG  
101 CTGAAGAGCT CAGCAAACTC AAGCCAGCA TGAGTGAGG GGGCTTCGCG  
151 ACAGGCTCT CCAACCTTGT GGGCTCTCCC TTGTGGGATC CTTGTGGGAT  
201 CTCCTTTGT GGAATCTCAC CCCTAGCAGT GGCTGATCAC TGTGCAAGG  
251 TATTCTGTG ACCTGAACTG CCCAGTGTGA GCCAGATGCC CGGCCCTGGA  
301 GCAGAGCCAC AGCCAGCCCC TGACCCCTGC ACTTACGCTT GGAGACACAG  
351 ACAGGAGCT CTCAGTTGG ACACACCCC TCAGGAGGCC TTTCCTGCCT  
401 TCCCCACGGC ACCCAGCGTT GACACGCTGA TGTCTGTCTT CCCTGAAGCT  
451 GCTGTCTTGT CCCTGTGTCT CTGAGGCCG CTAGCAACCA GATGGAGCG  
501 GAACCACTGC TCCAGCGCCA AGCGGTGCT CAGCAAGTGT CGGCTGAATG  
551 AGGGATGAG GAATGGGACA GGCTCCCTGT ACAGGGAAT GGGGAATGCT  
601 GGGCCGGCAG ACAAGCCCAT CTGTACTGTG CACTTTTATG GGGCGTTGAG  
651 GGAGCTAGCT CTGAGTGAAG CTCCTCCAGG CCCCAGCCAT CCTTACCACC  
701 TGTCCACCA CACCCGAGCT GCCACATTC CCAAGCCCTG A

!!AA\_SEQUENCE 1.0  
ID ADF31482 standard; protein; 1065 AA.  
XX  
XX ADF31482;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #2249.  
XX  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 17-SEP-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.

PR	17-SEP-2002	2002US-0410962P.
PR	17-SEP-2002	2002US-0411019P.
PR	17-SEP-2002	2002US-0411022P.
PR	17-SEP-2002	2002US-0411023P.
PR	17-SEP-2002	2002US-0411024P.
PR	17-SEP-2002	2002US-0411032P.
PR	17-SEP-2002	2002US-0411035P.
PR	17-SEP-2002	2002US-0411037P.
PR	17-SEP-2002	2002US-0411041P.
PR	17-SEP-2002	2002US-0411045P.
PR	17-SEP-2002	2002US-0411046P.
PR	17-SEP-2002	2002US-0411048P.
PR	17-SEP-2002	2002US-0411052P.
PR	17-SEP-2002	2002US-0411055P.
PR	17-SEP-2002	2002US-0411073P.
PR	17-SEP-2002	2002US-0411082P.
PR	17-SEP-2002	2002US-041101P.
PR	17-SEP-2002	2002US-0411111P.
PR	18-APR-2003	2003US-0463700P.
PR	18-APR-2003	2003US-0463708P.
PR	18-APR-2003	2003US-0463716P.
PR	18-APR-2003	2003US-0463732P.
PR	02-MAY-2003	2003US-0467198P.
PR	02-MAY-2003	2003US-0467201P.
PR	02-MAY-2003	2003US-0467203P.
PR	02-MAY-2003	2003US-0467230P.
PR	19-MAY-2003	2003US-0471306P.
PR	19-MAY-2003	2003US-0471336P.
PR	22-MAY-2003	2003US-0472420P.
PR	22-MAY-2003	2003US-0472430P.
PR	03-JUN-2003	2003US-0476609P.
PR	03-JUN-2003	2003US-0476641P.
PR	08-JUL-2003	2003US-0485218P.
PR	08-JUL-2003	2003US-0485223P.
PR	08-JUL-2003	2003US-0485224P.
PR	14-JUL-2003	2003US-0485325P.
PR	14-JUL-2003	2003US-0485446P.
PR	15-JUL-2003	2003US-0486480P.
PR	15-JUL-2003	2003US-0486891P.
PR	13-AUG-2003	2003US-0493360P.
PR	08-AUG-2003	2003US-0493341P.
PR	08-AUG-2003	2003US-0493370P.
PR	08-AUG-2003	2003US-0493573P.
PR	08-AUG-2003	2003US-0493577P.

51	ACCCGAGGAG	ATGGGAGGGA	CAGCTTCCTG	GCCCCCTTCC	CTCTTCACCC
101	TGAATCACT	TTTGTTCCTG	GAGGCTGAGC	TATCTTGGAG	TTTTCGGCAT
151	GCAATAAAT	ATGCTCAACC	ACAAGGCCTG	TGTCGAGCCA	GGACGGCTGG
201	AGGAGAAAGC	CAAGCCCGCT	GGCGGACCG	TCCTCATGGG	AGGAGCCCTC
251	CACAGCCTCT	CCCCAAGCAT	GGCAITTTACA	GTATACCCTAT	GGACGACCGT
301	CAGAATTCCAC	AGTCAGTTAC	AGCTCCTGTT	GAATCCGGCC	TTCTGTGGGC
351	AGTTCTGTAC	ATGACTCAAA	ATGCCAAATC	TCTCAGGATT	TTGGCAATTT
401	CTTTCAAGCC	AATGCTTCTG	AGAGCTTTTAG	ACAATTTACTT	TAGATCAATTT
451	CTTCAGAGAA	AGACCCCTCA	GGCATGGTGT	GAGTTTCTTC	CAGTGTCTCT
501	TACCTCTAGT	GACCTGCTGT	CTTCAGGCC	AAACATGCAC	TCCCTTATGG
551	ATTTCAAGTA	TTTCTACAAA	CTCCCAAGTG	GAAGCAGTAA	GGATAAATCA
601	TCAAGAGCCA	CAAGATCTAC	CTGGGTGAGC	AGACCTTACAT	TTCTGTGCNA
651	CAGAAAGCAG	AGGCAGCAA	CAGGGCTGCG	GAACAAGAAC	CCAAAAATAT
701	CCAAACAAGT	TTCACTGGGC	TACACCGTGG	GCCAGTTGAG	AATAGCAGCT
751	GAACAGAGCG	CAGGGCTTGC	TCTCTCTCAT	TACAGTGCCT	GCACACACCA
801	GTGCCCAGCA	GCAATAGCTG	CCACTATGAT	TGTCCCTCTG	GAATTTAAAC
851	CAGGACCTGT	GAGGAGCTTC	ATGGGACCTC	AACATGCTTC	CAATGTGGTT
901	GAGGACAAAT	GGGAGTGTGA	CATCATGTCT	TCTGGCTTGT	ATGTCAATGGG
951	ACAATGGCTC	CGGTACAGAA	TGCTTGCAGC	CCAGAGGAGA	CAGCAGTGGC
1001	CAGGGGCTGG	AGTGGTCAGC	AGAGACTTTA	CTGAGAAAGG	GATCTCTGTC
1051	TTAATGGGTG	TTTAG			
!!!AA_SEQUENCE 1.0					
ID	ADP31483 standard; protein; 267 AA.				
XX					
XX	ADP31483;				
XX					
XX	12-AUG-2004 (first entry)				
DT					
XX					
DE	Human secreted protein SEQ ID #2250.				
XX					
KW	Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial;				
KW	cancer; inflammatory; immune; human secreted protein.				
XX					
OS	Homo sapiens.				
XX					
FN	W02004035732-A2.				
XX					
PD	29-APR-2004.				
XX					
PF	28-AUG-2003; 2003WO-US026780.				
XX					
PR	29-AUG-2002; 2002US-0406576P.				
PR	29-AUG-2002; 2002US-0406579P.				
PR	29-AUG-2002; 2002US-0406585P.				
PR	29-AUG-2002; 2002US-0406588P.				
PR	29-AUG-2002; 2002US-0406608P.				
PR	29-AUG-2002; 2002US-0406611P.				
PR	29-AUG-2002; 2002US-0406612P.				
PR	29-AUG-2002; 2002US-0406616P.				
PR	29-AUG-2002; 2002US-0406640P.				
PR	29-AUG-2002; 2002US-0406642P.				

PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471338P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PR (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3481; 428pp; English.  
XX

CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 267 AA;  
ADP31483 Length: 267 February 22, 2005 12:25 Type: P Check: 4020 ..  
1 ATGTGCTTTG CACTATGTAC ACAGATATTA TGGACCCAAT GCTTAACGCA  
51 GTCCAGGAGC AGTTGGCGG CAATCCCTTT GCCACTGCCA CTACTGATAA  
101 TGCCACCAACC ACCACCAACC AACCTTCAAG GATGGAGAAT TGTGACCCCTC  
151 TCCCAACCC CTGACTTCC ACACATGGAG GCTCAGGTAG CAGGCAAGGA  
201 AGGCAGGATG GGGATCAGGA TGCACCTGAC ATTAGAAATA GGTTCACAA  
251 CTTTCTGGGT ATTATAA  
!!IAA SEQUENCE 1.0  
ID\_ADP31555 standard; protein; 1911 AA.  
XX  
AC ADP31555;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2322.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.



11AA\_SEQUENCE 1.0  
 ID ADP31581 standard; protein; 816 AA.  
 AC ADP31581;  
 XX  
 XX  
 DT 12-AUG-2004 (first entry)  
 XX  
 DE Human secreted protein SEQ ID #2348.  
 XX  
 KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
 KW cancer; inflammatory; immune; human secreted protein.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO2004035732-A2.  
 XX  
 XX  
 PD 29-APR-2004.  
 XX  
 PF 28-AUG-2003; 2003WO-US026780.  
 XX  
 PR 29-AUG-2002; 2002US-0406576P.  
 PR 29-AUG-2002; 2002US-0406579P.  
 PR 29-AUG-2002; 2002US-0406585P.  
 PR 29-AUG-2002; 2002US-0406588P.  
 PR 29-AUG-2002; 2002US-0406608P.  
 PR 29-AUG-2002; 2002US-0406611P.  
 PR 29-AUG-2002; 2002US-0406612P.  
 PR 29-AUG-2002; 2002US-0406616P.  
 PR 29-AUG-2002; 2002US-0406640P.  
 PR 29-AUG-2002; 2002US-0406642P.  
 PR 29-AUG-2002; 2002US-0406646P.  
 PR 29-AUG-2002; 2002US-0406653P.  
 PR 29-AUG-2002; 2002US-0406655P.  
 PR 29-AUG-2002; 2002US-0406666P.  
 PR 17-SEP-2002; 2002US-0410946P.  
 PR 17-SEP-2002; 2002US-0410947P.  
 PR 17-SEP-2002; 2002US-0410948P.  
 PR 17-SEP-2002; 2002US-0410949P.  
 PR 17-SEP-2002; 2002US-0410953P.  
 PR 17-SEP-2002; 2002US-0410957P.  
 PR 17-SEP-2002; 2002US-0410958P.  
 PR 17-SEP-2002; 2002US-0410959P.  
 PR 17-SEP-2002; 2002US-0410960P.  
 PR 17-SEP-2002; 2002US-0410961P.  
 PR 17-SEP-2002; 2002US-0410962P.  
 PR 17-SEP-2002; 2002US-0411019P.  
 PR 17-SEP-2002; 2002US-0411022P.  
 PR 17-SEP-2002; 2002US-0411023P.  
 PR 17-SEP-2002; 2002US-0411024P.  
 PR 17-SEP-2002; 2002US-0411032P.  
 PR 17-SEP-2002; 2002US-0411035P.  
 PR 17-SEP-2002; 2002US-0411037P.  
 PR 17-SEP-2002; 2002US-0411041P.  
 PR 17-SEP-2002; 2002US-0411045P.  
 PR 17-SEP-2002; 2002US-0411046P.  
 PR 17-SEP-2002; 2002US-0411048P.  
 PR 17-SEP-2002; 2002US-0411052P.  
 PR 17-SEP-2002; 2002US-0411055P.  
 PR 17-SEP-2002; 2002US-0411073P.  
 PR 17-SEP-2002; 2002US-0411082P.  
 PR 17-SEP-2002; 2002US-0411101P.  
 PR 17-SEP-2002; 2002US-0411111P.  
 PR 18-APR-2003; 2003US-0463700P.  
 PR 18-APR-2003; 2003US-0463708P.  
 PR 18-APR-2003; 2003US-0463716P.  
 PR 18-APR-2003; 2003US-0463732P.  
 PR 02-MAY-2003; 2003US-0467199P.  
 PR 02-MAY-2003; 2003US-0467201P.  
 PR 02-MAY-2003; 2003US-0467203P.  
 PR 02-MAY-2003; 2003US-0467230P.  
 PR 19-MAY-2003; 2003US-0471306P.  
 PR 19-MAY-2003; 2003US-0471336P.  
 PR 22-MAY-2003; 2003US-0472420P.  
 PR

22-MAY-2003; 2003US-0472430P.  
 PR 09-JUN-2003; 2003US-0476609P.  
 PR 09-JUN-2003; 2003US-0476641P.  
 PR 08-JUL-2003; 2003US-0485218P.  
 PR 08-JUL-2003; 2003US-0485223P.  
 PR 08-JUL-2003; 2003US-0485224P.  
 PR 08-JUL-2003; 2003US-0485325P.  
 PR 14-JUL-2003; 2003US-0486446P.  
 PR 15-JUL-2003; 2003US-0486891P.  
 PR 15-JUL-2003; 2003US-0486960P.  
 PR 08-AUG-2003; 2003US-0493341P.  
 PR 08-AUG-2003; 2003US-0493370P.  
 PR 08-AUG-2003; 2003US-0493573P.  
 PR 08-AUG-2003; 2003US-0493577P.  
 XX  
 PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
 XX  
 PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
 PI Halenbeck RF, Huang NM, Kothakota S, Haishan L, Linnemann T;  
 PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
 XX  
 DR WPI; 2004-348438/32.  
 XX  
 PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
 PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
 PT genetic, bacterial and viral diseases.  
 XX  
 PS Claim 1; SEQ ID NO 3579; 428pp; English.  
 XX  
 CC The present invention relates to an isolated nucleic acid molecule  
 CC encoding a polypeptide which is believed to be cytostatic,  
 CC anti-inflammatory, immunosuppressive, antibacterial and virucidal. The  
 CC composition and methods are useful for diagnosing, preventing and  
 CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
 CC immune, metabolic, genetic, bacterial and viral diseases. The present  
 CC sequence represents a human secreted protein. The present sequence is  
 CC available on WIPOWEB and is not in the specification.  
 XX  
 SQ Sequence 816 AA;  
 ADP31581 Length: 816 February 22, 2005 12:25 Type: P Check: 5133 ..  
 1 ATGGGGAAAA AACAGAGCAG AAAAACCGGA AACTCTAAAA ATCAGAGTCG  
 51 CTCCTCTCCT CAAAGGAAC GGAGCTCCTC ACCAGCAACG GAACAAGCT  
 101 GGACGAAGAA TGACTTTGAT GAGTTGAGAG AAGAAGGCTT CAGAAGATCA  
 151 AACTATTCTG AGCTAAAGGA GGAAGTTCTG ACCAATGGCA AAGNAGTTAA  
 201 AAACTTTGGG AAAAATTAG ATGAATGAT ACTAGAATA ACCAATGTCAG  
 251 AGAAGTACTT AAGGGACCTG ATGGAGCTGA AAACCATGGC ACAGATCTTA  
 301 CGTGACGAAT GCACAGCCT CAGTAACCGA TGGGATCAAC TGAAGAAAG  
 351 GGTATCAGCG GTGGAAGATA AAATGAATGA ATGAAGCGT GAAGAACT  
 401 TTAGAGAAAA AAGAATAAAA AGAAATGAAC AAAGCCTCCA AGAAATATGG  
 451 GACTATGTGA AAGACCCAAA TCTACATCTG ATTGGTGTAC CTGAAAGTAA  
 501 CGGGGGAAT GGAACCAAGT TGGAAAAAC TCTGCAGGAT ATTATCCAGG  
 551 AGAACTTCCC CAATCTAGCA AGGCAGGCCA ACATTCAAAT TCAGGAAATA  
 601 CAGAGACGC CACNAAGTTA CTCTTCAGA AGAGCAACTC CAAGACACAT  
 651 AATTGTCAGA TTCACCAAG TTGAATGAA GGAATAAAG TTAAAGGCAG  
 701 CCAGAAAGAA AGTTCGGGTT ACCCACAAAG GGAAGGCCAT CAGACTAACA

751 ACTGATCTCT CGGCAGAAAC TCTACAAGCC AGAAGAGAGT GGGGGGCCAA  
801 TATTCACAT TCTTAA

!!AA SEQUENCE 1.0  
ID ADP31627 standard; protein; 1404 AA.

AC ADP31627;

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2394.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW Cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 29-AUG-2002; 2002US-0406666P.

XX 17-SEP-2002; 2002US-0410946P.

XX 17-SEP-2002; 2002US-0410947P.

XX 17-SEP-2002; 2002US-0410948P.

XX 17-SEP-2002; 2002US-0410949P.

XX 17-SEP-2002; 2002US-0410953P.

XX 17-SEP-2002; 2002US-0410957P.

XX 17-SEP-2002; 2002US-0410958P.

XX 17-SEP-2002; 2002US-0410959P.

XX 17-SEP-2002; 2002US-0410960P.

XX 17-SEP-2002; 2002US-0410961P.

XX 17-SEP-2002; 2002US-0410962P.

XX 17-SEP-2002; 2002US-0411019P.

XX 17-SEP-2002; 2002US-0411022P.

XX 17-SEP-2002; 2002US-0411023P.

XX 17-SEP-2002; 2002US-0411024P.

XX 17-SEP-2002; 2002US-0411032P.

XX 17-SEP-2002; 2002US-0411035P.

XX 17-SEP-2002; 2002US-0411037P.

XX 17-SEP-2002; 2002US-0411041P.

XX 17-SEP-2002; 2002US-0411045P.

XX 17-SEP-2002; 2002US-0411046P.

XX 17-SEP-2002; 2002US-0411048P.

XX 17-SEP-2002; 2002US-0411052P.

XX 17-SEP-2002; 2002US-0411055P.

XX 17-SEP-2002; 2002US-0411073P.

XX 17-SEP-2002; 2002US-0411082P.

XX 17-SEP-2002; 2002US-0411101P.

XX 17-SEP-2002; 2002US-0411111P.

XX 18-APR-2003; 2003US-0463700P.

XX 18-APR-2003; 2003US-0463708P.

XX 18-APR-2003; 2003US-0463716P.

XX 18-APR-2003; 2003US-0463732P.

XX 02-MAY-2003; 2003US-0467199P.

XX 02-MAY-2003; 2003US-0467201P.

XX 02-MAY-2003; 2003US-0467203P.

02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471338P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases

XX PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

XX PT genetic, bacterial and viral diseases.

XX PS Claim 1; SEQ ID NO 3625; 428pp; English.

XX CC The present invention relates to an isolated nucleic acid molecule

XX CC encoding a polypeptide which is believed to be cytostatic,

XX CC antinflammatory, immunosuppressive, antibacterial and virucidal. The

XX CC composition and methods are useful for diagnosing, preventing and

XX CC treating diseases such as proliferative (e.g. cancer), inflammatory,

XX CC immune, metabolic, genetic, bacterial and viral diseases. The present

XX CC sequence represents a human secreted protein. The present sequence is

XX CC available on WIPWEB and is not in the specification.

XX SQ Sequence 1404 AA;

ADP31627 Length: 1404 February 22, 2005 12:25 Type: P Check: 2048 ..

1 TCCTCACAGG GACAAAGCGAG CCCCAGATG CGCAGACAGT GCGCGCTGCG

51 GAGGACGAGA CTCTGCAAAA CGAGGGCGGAC ACCCAGGAGA ACGTTTATC

101 TCAGTTGCTG GGGGACTATG ACAAGGTCAA GGCTATGTCT GAGGGCTCGG

151 ACTGTCAGTG CAAAGTGTGT GTGAGACCCC TGGGCCGGGA TGCCTGCCAG

201 AGGATCAATG CGGGGGCCTC CAGGAAGGAA GACTTCTATA CGGTGGAAC

251 CATCACTCA GCGTCGTGCT GCAAGTGTGC CTGTGTAGCA CCCCCATCGG

301 CCCTCAATCC CTGCGAGGGA GACTTCAGGC TCCAGAAGCT GCGGGAGGCA

351 GACAGCCAGG ACTTGAAGCT CTCCACAATC ATAGACATGT TGGAAGGAGC

401 GTTCTATGGC CTGGATCTCC TGAAGCTACA TTCAGTCACC ACCAACTGG

451 TGGGGCGAGT GGATAAAGTG GAGGAGGAAG TGTCTAAAAA CCTCACCAG

501 GAAATGAAC AAATCAAGA GGACATGAA GAAATTCGAA CCGAGATGAA

551 TAAGCGAGGC AAAGAAATTT GCTCTGAAAA CATCTTAGAT AGCATGCCAG

601 ACATCCGCTC AGCCCTGCAG AGGGATGAGC CAGCAGCCTA CGCCCCACCA





ADP30465	Length: 918	February 22, 2005 12:25	Type: P	Check: 9623	..
1	TGGTCAGAGC	GCAGCGAGCC	CTGTGAGCTG	GTGGTGACAG	GTAAGAGGAC
51	AGAGCCCAACA	GAAAAACCCAC	TCTCTCAGCC	CTGCCGAGCC	CTGTGTGAC
101	CTCAGGAGAG	AACGTGACCA	TCCAGTGTAG	CTCAAGGCGT	GGATTTCACA
151	GGTTCAATTT	GATTGAGAA	GGAGAAACA	AGCTCTCCTG	GATGCTGGAC
201	TCACAGGAAC	TCTCCAAGGG	GCTGTCCCTT	GTCCCTGACC	CTGTTCCCTG
251	TGGCCCGTGT	GGCTGCCAGT	CACCGGTGGA	TGTTTCAGATG	CTATGGGCAT
301	TACAGGAACT	TCCCTGGGC	GTGCTAGGA	AGCCTCCCTC	CTGACCCCTG
351	CAGGGCCCTG	TGCTGGCCCC	TGGGAGAAAT	CTGACCCCTCC	AGTGTGGCTC
401	TGATGTCCGC	TATGACAAAT	TCACTCTGTA	CAAGGAGGGG	GGACATGACC
451	TCGTCCAGGG	CTCTGGCCGG	CAGCCCCCAGG	CTGGGCTCTC	CCAGGGCCAAC
501	TTCACCCCTGG	GCCTGTGAG	GGTCTCCAC	GGGGGCCAGT	ACAGATGCTA
551	CGGTGCACAC	MACTCTCCT	CCGAGTGGTC	GGCCCCCAGT	GACCCCTGTA
601	GCATCTTGAT	CGCAGACAG	ATCCGTGGCA	GACCCTCGCT	CTCGTGCAG
651	CCGGGCCCCCA	CGGTGGCCTC	AGGAGAGAAC	GTGACCCCTGC	TGTGTGAGTC
701	ACGGGAGCAG	TTGGACACTT	TCCTTCTGAC	CAAGGAGGGG	GCAGGCCATC
751	ACCACCTGGC	TCTGAGATCA	GAGCACCAG	CTCAGCAGCA	CCAGGCTGAA
801	TTCCCCATGA	GTCTGTGAC	CTCAGCCAC	GCGGGGACCT	ACAGTGTGCTA
851	CAGCTCACGC	AGATTCTTCC	CCTACTGTCT	GTCTCACCCC	AGTGACCCCC
901	TGGAGCTCGT	GGTCTCAG			
!!AA	SEQUENCE 1.0				
ID	ADP30502	standard; protein; 1167 AA.			
AC	ADP30502;				
XX	12-AUG-2004	(first entry)			
DT	Human secreted protein	SEQ ID #1269.			
DE	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;				
KW	cancer; inflammatory; immune; human secreted protein.				
XX	Homo sapiens.				
XX	WO2004035732-A2.				
XX	29-APR-2004.				
XX	28-AUG-2003;	2003WO-US026780.			
XX	29-AUG-2002;	2002US-0406576P.			
PR	29-AUG-2002;	2002US-0406579P.			
PR	29-AUG-2002;	2002US-0406585P.			
PR	29-AUG-2002;	2002US-0406588P.			
PR	29-AUG-2002;	2002US-0406608P.			
PR	29-AUG-2002;	2002US-0406611P.			
PR	29-AUG-2002;	2002US-0406612P.			
PR	29-AUG-2002;	2002US-0406616P.			
PR	29-AUG-2002;	2002US-0406640P.			
PR	29-AUG-2002;	2002US-0406642P.			
PR	29-AUG-2002;	2002US-0406646P.			
PR	29-AUG-2002;	2002US-0406653P.			
PR	29-AUG-2002;	2002US-0406655P.			
PR	29-AUG-2002;	2002US-0406666P.			
PR	17-SEP-2002;	2002US-0406666P.			
PR	17-SEP-2002;	2002US-0410946P.			
PR	17-SEP-2002;	2002US-0410947P.			
PR	17-SEP-2002;	2002US-0410948P.			
PR	17-SEP-2002;	2002US-0410949P.			
PR	17-SEP-2002;	2002US-0410953P.			
PR	17-SEP-2002;	2002US-0410957P.			
PR	17-SEP-2002;	2002US-0410958P.			
PR	17-SEP-2002;	2002US-0410959P.			
PR	17-SEP-2002;	2002US-0410960P.			
PR	17-SEP-2002;	2002US-0410961P.			
PR	17-SEP-2002;	2002US-0410962P.			
PR	17-SEP-2002;	2002US-0411019P.			
PR	17-SEP-2002;	2002US-0411022P.			
PR	17-SEP-2002;	2002US-0411023P.			
PR	17-SEP-2002;	2002US-0411024P.			
PR	17-SEP-2002;	2002US-0411032P.			
PR	17-SEP-2002;	2002US-0411035P.			
PR	17-SEP-2002;	2002US-0411037P.			
PR	17-SEP-2002;	2002US-0411041P.			
PR	17-SEP-2002;	2002US-0411045P.			
PR	17-SEP-2002;	2002US-0411046P.			
PR	17-SEP-2002;	2002US-0411048P.			
PR	17-SEP-2002;	2002US-0411052P.			
PR	17-SEP-2002;	2002US-0411055P.			
PR	17-SEP-2002;	2002US-0411071P.			
PR	17-SEP-2002;	2002US-0411082P.			
PR	17-SEP-2002;	2002US-0411101P.			
PR	17-SEP-2002;	2002US-0411111P.			
PR	18-APR-2003;	2003US-0463700P.			
PR	18-APR-2003;	2003US-0463708P.			
PR	18-APR-2003;	2003US-0463716P.			
PR	18-APR-2003;	2003US-0463732P.			
PR	02-MAY-2003;	2003US-0467199P.			
PR	02-MAY-2003;	2003US-0467201P.			
PR	02-MAY-2003;	2003US-0467203P.			
PR	02-MAY-2003;	2003US-0467230P.			
PR	19-MAY-2003;	2003US-0471306P.			
PR	19-MAY-2003;	2003US-0471338P.			
PR	22-MAY-2003;	2003US-0472420P.			
PR	22-MAY-2003;	2003US-0472430P.			
PR	09-JUN-2003;	2003US-0476609P.			
PR	09-JUN-2003;	2003US-0476641P.			
PR	08-JUL-2003;	2003US-0485218P.			
PR	08-JUL-2003;	2003US-0485223P.			
PR	08-JUL-2003;	2003US-0485224P.			
PR	08-JUL-2003;	2003US-0485325P.			
PR	14-JUL-2003;	2003US-0486446P.			
PR	14-JUL-2003;	2003US-0486480P.			
PR	15-JUL-2003;	2003US-0486891P.			
PR	15-JUL-2003;	2003US-0486960P.			
PR	08-AUG-2003;	2003US-0493341P.			
PR	08-AUG-2003;	2003US-0493370P.			
PR	08-AUG-2003;	2003US-0493573P.			
PR	08-AUG-2003;	2003US-0493577P.			
XX	(FIVE-)	FIVE PRIME THERAPEUTICS INC.			
PA	Williams LT,	Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;			
XX	Halenbeck RF,	Huang MM, Kothakota S, Haishan L, Linnemann T;			
PI	Pierce K,	Wang Y, Wong JGP, Wu G, Zhang H;			
XX	WPI;	2004-348438/32.			
DR	New nucleic acid molecule	for diagnosing, preventing or treating diseases			
XX	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,				
PT	genetic, bacterial and viral diseases.				
PT	Claim 1; SEQ ID NO 2500; 428pp; English.				
PS	The present invention relates to an isolated nucleic acid molecule				
XX	encoding a polypeptide which is believed to be cytostatic,				
CC	antiinflammatory, immunosuppressive, antibacterial and virucidal. The				

CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

XX  
SQ Sequence 1167 AA;

ADP30502 Length: 1167 February 22, 2005 12:25 Type: P Check: 4227 ..

1 ATGCCGCAGC TGAGCCTGTC CTGGCTGGGC CTCGGGCAGG TGGCAGCATT  
51 CCGGTGGCTG CTCCTGTGTC TGGCTGGGGC CTCCTGGCTC CTGGCGGGCT  
101 TCGTGGCCTG GACCTATGCC TTCTATGACA ACTGCGCGCG CCTTCAGTAC  
151 TTTCACAAAC CCCCAAAACA GAATGTTT TGGGTCAAC CAGGACCTCA  
201 GGAAGCCTTG AAGAACTTGA CCAGATGTC AGCCACTAT CCCAGGGCT  
251 TTAGGATATG GCTGGGTCCC ATCTTCCCTT TCATCGTTTT ATGCCACCTT  
301 GACATCGTCC GGTCTATCAC CAATGCCCTCA GCTGCTATTG CGCCCAAGGA  
351 TGATCTCTCC ATCAGGTTC TGAAGCCCTG CTGGGAGAA GGGATACTGC  
401 TGAGTGGCGG TGACAAAGTG AGCGCCACC GTCGATGCT GACGCCCGCC  
451 TTCCATTCCA ACATCCTGAA ACCCTATATA AGATCTTCA ACAGAGTGT  
501 GAACATCATG CACGACAAGT GGCAGCACCT GGCCTCAGAG GGCAGAGTC  
551 GTCTGACAT GTTTGAGCAC ATCAGCCTCA TGACCTTTGA CAGTCTGCAG  
601 AATGATCT TCAGCTTTGA CAGCATGT CAGGAGGC CCAGTGAATA  
651 TATGTGATC ATCTTGAGC TCAGTGCCTT TGTAGAAAA AGAAACCAGC  
701 ATATCCTCCA GCACATGGAC TTTCTGTATT ACCTCTCCCA TGACGGGTGG  
751 CGCTTCCGCA GGGCTGCGG CTTGGTGCAC GACTTCACAG ATGCCGTCTAT  
801 CCAGGAGCGG CGCCATACC TTCCACTCA GGGCCATGAC ACCACAGCCA  
851 GTGGTCTCTC CTGGTCTCTG TACAACCTCG CGAGGCACCC AGAATACCAG  
901 GAGCACTGCC GGCAGGAGGT GCAGAGCTT CTGAAGGACC GGCATCCTAA  
951 AGAGATTGAA TGGTACGACC TGGCCAGCT GCCCTTCCTG ACCATGTGCG  
1001 TGAAGGAGAG CTGCGGTTG CATCCCCCTG TTCCGTACAC CTCGCCAC  
1051 CGCATCTGGG ACATTGTGCT CCAGATGGT AGGGTCTACA ACCCTTCCG  
1101 CTTCAACTCA GAGAACAGCA AGGAGAGTC ACCTCTGGCT TTTATTCCT  
1151 TCTCTGCGG ACCCAGN

!!AA SEQUENCE 1.0  
ID ADP30562 standard; protein; 1803 AA.

XX  
AC ADP30562;

XX  
DT 12-AUG-2004 (first entry)

XX  
DE Human secreted protein SEQ ID #1329.

XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX  
OS Homo sapiens.

XX  
PN WO2004035732-A2.

XX 29-APR-2004.  
PD 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 17-SEP-2002; 2002US-041111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486453P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RE, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2560; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 1803 AA;  
SQ  
ADP30562 Length: 1803 February 22, 2005 12:25 Type: P Check: 8514 ..  
1 ATGCTTAGCG TTCCAGTAAT GGAACACAGG CATAAATGGA AGCTTTACAA  
51 ACTTTACAAA AATGTGCATC ACTGGGAAG TAACAGGACT TGCCTTACCC  
101 TGTGTGAGG CTTATAACGC AGGCCAATGG TACATGTGGT GACAGACGA  
151 GAAGAGAAGG GCAGAGGGCA TCAAGTTTCAT TTGGGGAAC ATTCCCTTAT  
201 GTACTGGAAT TTTAAGCTT TGATTTTGA CCAGAGTATG AATGGTGGAA  
251 GCTGCTTTAA CTTGGAAATA CAGGGGAAA GGAGGGTGCA TGGGATGGTT  
301 TTTTATGGGT TCCTGGCTGC ACTCTTCTCA TTCACGATGT GGGTTATGCT  
351 TCAGACTCTC AAGGATGAGG TTCCAABATA CCGTGACCAG ATTCTTAGCC  
401 CAGACTCAT GGTTTTCCA AAACAGTGA CCGCATTTGA ATATACATTC  
451 AGTAGGTCTG ATCCAACTTC GTATGCAGGG TACATTGAAG ACCTTAAGAA  
501 GTTTCTAAAA CCATATACCT TAGAAGAAC GAAGAACCTC ACAGTCTGTC  
551 CTGATGAGC ACTTTTGA CAGAAGGTC CAGTTTATGT TGCATGTCAG  
601 TTTCTATTTT CATTACTTCA AGCATGTCAGT GGTATGAATG ATCCTGATTT  
651 TGGCTATTTCT CAGGAAACC CTTGPTATTT TGTGAAAATG AACAGAAATG  
701 AAGATATACC AAATGTAGCA GTTATCTCTC ATATGGAAT GATAGACTTA  
751 AAATATTTCC CATATTATGG GAAAAAATG CATGTTGGGT ATCTACAGCC  
801 ATTGGTTGCT GTTCAGGTCA GCTTTGCTCC TAACAACACT GGGAAAGAA  
851 TAACAGTTGA GTGCAAGATT GATGATCAG CCAACCTAAA AGTCAAGGAT  
901 GATCGTGACA AGTTTTTGGG ACGAGTTATG TTCAAAAATCA CAGCAGTGC  
951 ATATGTGAC GGTGGGCGAT GCTAGAGGG GACGAAACAG CCAGAGCTG  
1001 GGAGGAGGAA CCGAGTGGGG TGTGCTGGC GGAGATGCCC AMACTTCAG  
1051 CTGAGCACT TCAGACACC CTTACAGAGC GATTCATCCC GAAGTGGACC  
1101 TGTGCTGAT GAAGTCAATG TGGTAGGAG AATTGCAGC CCATGACCT

1151 TCACGTTCTG GGGCATGCC CATGGTTATG CTCTATCACG TGGCAAGAGG  
1201 GCGTTTGCAG ATGAATTA GAAACAGATT CACCTTGTCTG GTGGGGAGAG  
1251 AAGGGTGCA GCGTGGGGG ACCTGGGCTG GTGGGAAAAG CAGTCGGGTT  
1301 ATTGTTCTG TGCTACAAAG GATGAGGAAT TCAGTCCCCA GGATCCACGG  
1351 GAGGAGCTGG CTGAGACCTT GGGGCCCGGC CTTCTTCCCA AGAGTCCATT  
1401 TTCCCTTGGG ATTAACCTTAC TTTATTGTTT CTACCGTCCC ATGACTTCTG  
1451 AGTTTATGTG TAGACAAGTC TCCGGTGGC GGCCACGACG GCAGGTGACA  
1501 GCGGCCCTTG CGGAGTGCAT CCTTAACCAA GCAGTTTTCAG AAATGTTTCT  
1551 TGAGAAACTG TTTCCGGAAG TCCGGGAGCC TGTGTTGCCC ATTGACAAGC  
1601 CTTGTCGGTC TCAGAAGACA GACTCCGGGG GTCTACATCC AGAGACCCGG  
1651 CTGAGGACTG AAGCCCGGGG TTTCCAAGCG GCTGCCTTCT CCGTCTGTGA  
1701 GCAGGCTGCG AGTCAACCGC CTTGGCTAAG GGAGCAAGGA ACCCCGCCA  
1751 TGCTGTGTCC CCTCCCCCA TTCCCCGAAT GCCCGTCTGT TCAGAGAGGG  
1801 TGA  
!!AA SEQUENCE 1.0  
ID ADP30568 standard; protein; 276 AA.  
XX  
AC ADP30568;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1335.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406618P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406668P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485235P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX

## (FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
DR WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX

PS Claim 1; SEQ ID NO 2566; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX

SQ Sequence 276 AA;

ADP30568 Length: 276 February 22, 2005 12:25 Type: P Check: 4280 ..

1 ATGAAGAAAG ACGTGTGGAT CCTGCTGGTG GGAGAACCTA GAGTTGGGAA

51 GACATCAATG ATTATGCTC TGCTCAGTGA AGAATTTCCA GAAGAGGTTT  
101 CTCCCGGGC AGAAGAAATC ACCGTTCCAG CTGATGTCAC CCCAGAGAGA  
151 GTTCCAACAC ACATTGTAGA TTACTCAGAA GCAGAACAGA GTATGAACA  
201 ACTTCATCAA GAAATATCTC AGGCTAATAT CATCTGTATA TTGTATGCTG  
251 TTAACAACAA GCATCTATT GATAAG

## !!AA\_SEQUENCE 1.0

ID ADF30583 standard; protein; 171 AA.

XX ADF30583;

XX AC

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1350.

DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX

OS Homo sapiens.

XX WO2004035732-A2.

PN 29-APR-2004.

PD

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 17-SEP-2002; 2002US-0410946P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.

PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.

PR 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411022P.

PR 17-SEP-2002; 2002US-0411023P.

PR 17-SEP-2002; 2002US-0411032P.

PR 17-SEP-2002; 2002US-0411035P.

PR 17-SEP-2002; 2002US-0411037P.

PR 17-SEP-2002; 2002US-0411041P.

PR 17-SEP-2002; 2002US-0411045P.

PR 17-SEP-2002; 2002US-0411048P.

PR 17-SEP-2002; 2002US-0411052P.

PR 17-SEP-2002; 2002US-0411055P.

PR 17-SEP-2002; 2002US-0411073P.

PR 17-SEP-2002; 2002US-0411082P.

PR 17-SEP-2002; 2002US-0411101P.

PR 17-SEP-2002; 2002US-0411111P.

PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476509P.  
PR 09-JUN-2003; 2003US-0476541P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493373P.  
PR 08-AUG-2003; 2003US-0493377P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H,  
XX WPI; 2004-348438/32.  
DR  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2581; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 171 AA;  
ADP30583 Length: 171 February 22, 2005 12:25 Type: P Check: 5578 ..  
1 ATGCGCGCGC GGGCGCGGG GCTGCTGCTG CTGACGCTGT CGGTGCTGTT  
51 GCGCGCGGGC CCTCGCGCG CTGCGGCCAA GCTCAACATC CCCAAGTGC  
101 TGTGTCCTTT CACGCGGGCC ACGCGCGTTA ACTTCAGCT GGAGGCTCG  
151 GAGGGCTGCT ACGCTGGTG A  
!!AA SEQUENCE 1.0  
ID ADP30602 standard; protein; 171 AA.  
XX  
AC ADP30602;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1369.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX  
OS Homo sapiens.  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406589P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476509P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.

PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2600; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 171 AA;  
SQ  
ADP30602 Length: 171 February 22, 2005 12:25 Type: P Check: 7553 ..  
1 ATGACCCCGA CGCCGGCGAG AATGGGCTCC GCACCTACCT GCTCAGCGCG  
51 GACGATCAG GCCTCTTTGG ACTGGAGTT AGTCCCGCG GCGAGCGGAC  
101 CAAGTTCCCA GAACGTGGTCA TCCAGAAGGC TTGGACCGCG GAGCAACAGA  
151 ATCACCATAC GCTCGTGCTG A  
!!AA SEQUENCE 1.0  
ID \_ADP30618 standard; protein; 153 AA.  
XX AC ADP30618;  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1385.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406658P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467198P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2616; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The

CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX  
SQ Sequence 153 AA;

ADP30618 Length: 153 February 22, 2005 12:25 Type: P Check: 6416 ..

1 ATGAGGAAAA CGGGATGCTG GAGATTGACG TGCAGGCCCG AGACTGGGG

51 CCTAACCCCTA TCCCAGCCCA CTGCAAAGTC ACGGTCAAGC TCATCGACCG

101 CAACGACAAT GGGCCGTCCA TCGGTTTCGT CTCGGTGGCG CAGGGGGCGC

151 TGA

!!AA SEQUENCE 1.0  
ID ADP30663 standard; protein; 843 AA.

XX  
XX AC ADP30663;  
XX DT DT  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1430.

DE  
XX  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO2004035732-A2.  
PN  
XX  
XX PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.

XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR PR 29-AUG-2002; 2002US-0406579P.  
PR PR 28-AUG-2002; 2002US-0406588P.  
PR PR 29-AUG-2002; 2002US-0406588P.  
PR PR 29-AUG-2002; 2002US-0406588P.  
PR PR 29-AUG-2002; 2002US-0406611P.  
PR PR 29-AUG-2002; 2002US-0406612P.  
PR PR 29-AUG-2002; 2002US-0406616P.  
PR PR 29-AUG-2002; 2002US-0406640P.  
PR PR 29-AUG-2002; 2002US-0406642P.  
PR PR 29-AUG-2002; 2002US-0406646P.  
PR PR 29-AUG-2002; 2002US-0406653P.  
PR PR 29-AUG-2002; 2002US-0406655P.  
PR PR 29-AUG-2002; 2002US-0406668P.  
PR PR 17-SEP-2002; 2002US-0410946P.  
PR PR 17-SEP-2002; 2002US-0410947P.  
PR PR 17-SEP-2002; 2002US-0410948P.  
PR PR 17-SEP-2002; 2002US-0410949P.  
PR PR 17-SEP-2002; 2002US-0410953P.  
PR PR 17-SEP-2002; 2002US-0410957P.  
PR PR 17-SEP-2002; 2002US-0410958P.  
PR PR 17-SEP-2002; 2002US-0410959P.  
PR PR 17-SEP-2002; 2002US-0410960P.  
PR PR 17-SEP-2002; 2002US-0410961P.  
PR PR 17-SEP-2002; 2002US-0410962P.  
PR PR 17-SEP-2002; 2002US-0410963P.  
PR PR 17-SEP-2002; 2002US-0411022P.  
PR PR 17-SEP-2002; 2002US-0411023P.  
PR PR 17-SEP-2002; 2002US-0411024P.  
PR PR 17-SEP-2002; 2002US-0411032P.  
PR PR 17-SEP-2002; 2002US-0411035P.  
PR PR 17-SEP-2002; 2002US-0411037P.  
PR PR 17-SEP-2002; 2002US-0411041P.  
PR PR 17-SEP-2002; 2002US-0411045P.  
PR PR 17-SEP-2002; 2002US-0411046P.



301 TTGCACCTTC CCATCCAGTA CGAAGATGTT CATACCAATG GAGACCAGGA  
351 CTGCTGCCTA CTGCAGGTCA CCACCTCAAA TTTTCATCTTT ATTCCGATTG  
401 TCATGGGAAT GATATTTACT CTGTTTACTG TCAATGGAG CACGGACACG  
451 CGGCATCATC GAGTGAGACT GGTGTTCCAA GATTCCTCTG TTCATGGTGG  
501 TCAGAAACTG TGCAGTGAAC AGSAGTGTTC TGCACAATAT GGAAAAACCA  
551 CCAAAAGTGA ACATCTGCAG CACTGTCCAG CTTTCTTAAG ATATATCTCT  
601 GACAACTCT GTGGAGGGA AATCTACTCA GTGGGAGAA CGTTAGACAA  
651 GGCACCTGTC TGTGCACCTT TCTTGGAGGG AGAAAAAGCC AGCTGTGAAA  
701 TTATATGCAA TTCCTGGGTT GTGACCAATA GTTCAGCTGG AGGACCAGGG  
751 ACTTGAAGG AATATGATGG AAGACTGGTG ACAAAGACAT TTGGGAATGA  
801 CATGTGGGA CAGATCTCTC TGAGTGGGA AAAAATAATG TGA  
!!AA SEQUENCE 1.0  
ID ADP30689 standard; protein; 1968 AA.  
XX  
AC ADP30689;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1456.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406648P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.

17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
02-MAY-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Halshan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2687; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.  
SQ Sequence 1968 AA;  
ADP30689 Length: 1968 February 22, 2005 12:25 Type: P Check: 5223 ..  
1 CAGATGAGAC ACCAATATT GCGGTGATGG TGGCCCTGTC CTCTCTGCTA  
51 GTGATCGTGT TTATTATCAT AGTTTGTATC ATGTTAAGGT TTAAGAAATA  
101 CAAGCAAGCT GGGAGCCATT CCAATTCCTTT CGCTTATCC AACGGCCGCA  
151 CTGAGGATGT GGAGCCCCAG AGTGTGCCAC TTCTGGCCAG ATCCCCAAGC

201	ACCAACAGGA	AATACCACC	CCTGCCCGTG	GACAAAGCTGG	AAGAGGAAAT
251	TAACCGGAGA	ATGGCAGAG	ACAATAAGCT	CTTCAGGGAG	GAATTCACG
301	CTCTCCCTGC	ATGTCTATC	CAGGCCACCT	GTGAGGTGC	TTCCAAGGAG
351	GAACAACAGG	AAAAAATCG	ATATGTAAC	ATCTTGCTT	ATGACCACTC
401	TAGAGTCCAC	CTGACACCG	TTGAGGGGT	TCCAGATTCT	GATTACATCA
451	ATGCTTCATT	CATCAACGC	TACCAAGAAA	AGAACAAATT	CATTGCTGCA
501	CAAGGACCAA	AGAAGAAGC	GGTGAATGAT	TTCTGGCGGA	TGATCTGGGA
551	ACAAAACACA	GCCACCATG	TCATGGTTAC	CAACTGAAG	GAGAGAAAGG
601	AGGTAATGCG	CCAGTACTG	GCCAGACCAA	GGTGCTGGA	CCTATGGGAA
651	TATTCGGGTG	TCTGTAGAG	ATGTGACTGT	CCTGGTGGAC	TACACAGTAC
701	GGAGTTTCTG	CATCCAGCAG	GTGGCGGACA	TGACCAACAG	AAAGCCACAG
751	CGCCTCATCA	CTCAGTTCCA	CTTTACCAGC	TGGCCAGACT	TTGGGGTGCC
801	TTTTACCCTG	ATCGGCATGC	TCAAGTTCTT	CAAGAAGGTG	AAGGCCCTGTA
851	ACCTCTAGTA	TGCAGGGGCC	ATCGTGGTCC	ACTGCAGTGC	AGGTGTAGGG
901	CGTACAGGTA	CCTTTGTGCT	CATTGATGCC	ATGCTGGACA	TGATGCATAC
951	AGAACGGAAG	GTGGACGTGT	ATGGCTTTGT	GAGCCGGATC	CGGGCACAGC
1001	GCTGCCAGAT	GGTGCAACC	GATATGTCAGT	ATGTCITTCAT	ATACCAAGCC
1051	CTTCTGGAGC	ATTATCTCTA	TGGAGATACA	GAACGTGAAG	TGACCTCTCT
1101	AGAAACCCAC	CTGCAGAAA	TTTACAACAA	AATCCAGGG	ACCAGCAACA
1151	ATGATTATGA	GGAGGAGTTT	AGAAGTTAA	CATCAATCAA	AATCCAGNAT
1201	GACAAGATGC	GGACTGGAAA	CCTTCCAGCC	AACATGAAGA	AGAACCGTGT
1251	TTTACAGATC	ATTCCATATG	AAATCAACAG	AGTGATCATT	CCAGTTAAAGC
1301	GGGCGGAAGA	GAATACAGAC	TATGTGAAG	CATCCTTTAT	TGATGGCTAC
1351	CGGCAGAAGG	ACTCTPATAT	CGCCAGCCAG	GGCCCTCTTC	TCACACAAT
1401	TGAGGACTTC	TGGCGAATGA	TCTGGGAGTG	GAATCTCTGC	TCTATCGTGA
1451	TGCTTAACAGA	ACTGGAGGAG	AGAGGCCCAG	AGAAGTGTGC	CCAGTACTGG
1501	CCAFCTGATG	GACTGTGTGC	CTATGGAGAT	ATTACAGTGG	AACGTGAAGAA
1551	GGAGGAGGAA	TGTGAGAGCT	ACACCGTCCG	AGACCTCTGT	GTCAACCAACA
1601	CCAGGGAGAA	TAAAGCCCG	CAGATCCCGC	AGTTCACATT	CCATGGCTGG
1651	CCTGAAGTGG	GCATCCCCAG	TGACGGAAAG	GGCATGATCA	GCATCATCGC
1701	CGCCGTGCAG	AAGCAGAGC	AGCATCTCAG	GAACCAACCC	ATCACCGTGC
1751	ACTGCAGCGC	CGGGGAGGGA	AGGACGGGGA	CCTTCTGTGC	CCTGAGCACC
1801	GTCCTGGAGC	GTGTGAAAGC	AGAGGGGATT	TTGGATGTCT	TCCAGACTGT
1851	CAAGAGCCTG	CGSCTACAGA	GSCCACAAT	GGTCCAGACA	CTGGAACAGT
1901	ATGAGTTCTG	CTACAAGGTG	GTGCAGGAGT	ATATTGATGC	ATTCTCAGAT
1951	TATGCCAACT	TCAAGTAA			

ID	ADP30735 standard; protein; 1434 AA.
XX	ADP30735;
AC	
XX	12-AUG-2004 (first entry)
DT	
XX	Human secreted protein SEQ ID #1502.
DE	
XX	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW	cancer; inflammatory; immune; human secreted protein.
XX	
OS	Homo sapiens.
XX	WO2004035732-A2.
PN	
XX	29-APR-2004.
PD	
XX	28-AUG-2003; 2003WO-US026780.
PF	
XX	29-AUG-2002; 2002US-0406576P.
PR	29-AUG-2002; 2002US-0406579P.
PR	29-AUG-2002; 2002US-0406585P.
PR	29-AUG-2002; 2002US-0406588P.
PR	29-AUG-2002; 2002US-0406608P.
PR	29-AUG-2002; 2002US-0406611P.
PR	29-AUG-2002; 2002US-0406612P.
PR	29-AUG-2002; 2002US-0406616P.
PR	29-AUG-2002; 2002US-0406640P.
PR	29-AUG-2002; 2002US-0406642P.
PR	29-AUG-2002; 2002US-0406646P.
PR	29-AUG-2002; 2002US-0406653P.
PR	29-AUG-2002; 2002US-0406655P.
PR	29-AUG-2002; 2002US-0406666P.
PR	17-SEP-2002; 2002US-0410946P.
PR	17-SEP-2002; 2002US-0410947P.
PR	17-SEP-2002; 2002US-0410948P.
PR	17-SEP-2002; 2002US-0410949P.
PR	17-SEP-2002; 2002US-0410951P.
PR	17-SEP-2002; 2002US-0410957P.
PR	17-SEP-2002; 2002US-0410958P.
PR	17-SEP-2002; 2002US-0410959P.
PR	17-SEP-2002; 2002US-0410960P.
PR	17-SEP-2002; 2002US-0410961P.
PR	17-SEP-2002; 2002US-0410962P.
PR	17-SEP-2002; 2002US-0411019P.
PR	17-SEP-2002; 2002US-0411022P.
PR	17-SEP-2002; 2002US-0411023P.
PR	17-SEP-2002; 2002US-0411024P.
PR	17-SEP-2002; 2002US-0411032P.
PR	17-SEP-2002; 2002US-0411035P.
PR	17-SEP-2002; 2002US-0411037P.
PR	17-SEP-2002; 2002US-0411041P.
PR	17-SEP-2002; 2002US-0411045P.
PR	17-SEP-2002; 2002US-0411046P.
PR	17-SEP-2002; 2002US-0411048P.
PR	17-SEP-2002; 2002US-0411052P.
PR	17-SEP-2002; 2002US-0411055P.
PR	17-SEP-2002; 2002US-0411073P.
PR	17-SEP-2002; 2002US-0411082P.
PR	17-SEP-2002; 2002US-0411101P.
PR	17-SEP-2002; 2002US-0411111P.
PR	18-APR-2003; 2003US-0463700P.
PR	18-APR-2003; 2003US-0463708P.
PR	18-APR-2003; 2003US-0463716P.
PR	18-APR-2003; 2003US-0463732P.
PR	02-MAY-2003; 2003US-0467199P.
PR	02-MAY-2003; 2003US-0467201P.
PR	02-MAY-2003; 2003US-0467203P.
PR	02-MAY-2003; 2003US-0467230P.
PR	19-MAY-2003; 2003US-0471306P.
PR	19-MAY-2003; 2003US-0471336P.
PR	22-MAY-2003; 2003US-0472420P.
PR	22-MAY-2003; 2003US-0472430P.

PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX  
PS Claim 1; SEQ ID NO 2733; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1434 AA;  
ADP30735 Length: 1434 February 22, 2005 12:25 Type: P Check: 8711 ..  
1 ATGTCCATGG CCAGAGGAGT GATCCAGCTC CTAGAAGATG AGGAGAGACC  
51 GAAGCCAGAC ACAGCCGCTG TCGCTGCCAT CTGGCGCGCC GCAGACTCCC  
101 GAGACAGCC CTGGCTGTCA CGCGGCACCA GCGGCTTCCT GTGCCCATCG  
151 CGTAGACTGG AGGGGCGCAC CACGGCCACC GAGCCAGAGG CGCTTTCAGGA  
201 AGCAAGAGAA GTCCCGCGGC GTCCCGGCAC CCGGCGCAGC TCATGGAGCA  
251 ACACACCCG GTACCCGGGG CAGTTAGCGC TATACCAGCA GCTGGCGCAG  
301 GGGAAATGCG TGGGGGGGCT GGGGGGGGCA CCGCCACTGG GCGCCGTCGA  
351 GGTGTCTACC CGCTGCCTGC TGACCCCTACT CGTCATCTGG ACCTTGCTGG  
401 GCAACGTGCT GGTGTCCGCA GCCATCGTGT CCGCCAGAGT GCGCGTTACT  
451 AAGATGACCA ACGTCTTTCAT CGTGTCTCTA CTTGTGTCTAG ACCTTTTCGT  
501 GCGCGTGTGT GTCATGTCTT GGAAGGCAGT CCGCCGAGGT GCGCGTTACT  
551 GGCCCTTTGA AGCCTTCTGC GAGCTCTGGG TGGCCTTCTGA CATCATGTGC  
601 TCCACCGCCT CCATCTCTGAA CTTGTGCTC ATCAGCGTGG CCGGCTACTG  
651 GGCCATCTCC AGGCCCTTCC GCTACGAGCG CAAGATGACC CAGCGCATGG  
701 CTTGGTCTAT GGAGCGCGTT TGGAGCCCG ACGTGAGGCG AGAGAACTGT  
751 GACTCCAGCC TGAATCGAAC CTACGCCATC CTTCTCTCGC TCATCAGCTT

801 CTACATCCCC ATGCCATCA TGATCGTGAC CTACAGCGC ATCTACCGCA  
851 TGCCCCAGGT GCAGATCGC AGGATTTTCT CCTTGGAGAG GCGCCGAGAG  
901 CACGTGCAGA GCTGCCGAG CAGGCGAGG TGACGCCCG ACACAGCCT  
951 GCGGTTTTCC ATCAAGAAGG AGACCGAGGT TCTCAAGACC CTGTGGGTGA  
1001 TCATGGGGGT CTTCTGTGTG TGCTGGCTGC CCTTCTTCAT CTTTAACTGC  
1051 ATGGTTCTTT TCTGCAGTGG ACACCCAAA GGGCCCTCCGG CCGGCTTCCC  
1101 CTGCGTCACT GAGACCACAT TCGATGTCTT CATCTGTCTAC TATGCTTTCA  
1151 AGCCCGACTT CCGGAAGGTG TTTGCCCAGC TGCTGGGGTG CAGCCACGTC  
1201 TGCTCCCCGA CGCCGGTGA GACGGTGAAC ATCAGCAATG AGCTCATCTC  
1251 CTACAACCAA GACACGGTCT TCCACAAGGA AATCGCAGCT GCCTACATCC  
1301 ACATGATGCC CAACGCCATT CCCCCCGGG ACCGGGAGGT GGACAAACAT  
1351 GAGGAGGAGG AGAGTCTTTT CGATCGCATG TCCCAGATCT ATCAGACATC  
1401 CCAGATGCT GACCATGTTG CAGAGTCTGT CTGA

## IIAA SEQUENCE 1.0

ID ADP30785 standard; protein; 186 AA.

XX  
AC ADP30785;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1552.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX



PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX

PS Claim 1; SEQ ID NO 2854; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

XX Sequence 750 AA;

ADP30856 Length: 750 February 22, 2005 12:25 Type: P Check: 6986 ..

1 ATGAGCAGTG AATATAAAAA TGTGGTCATA GGTACAGCAG AAATTCAAAGC  
51 TGGAAAAAAT TCCCAGGCTC ATCAGAGTAA TAGTAATGCA GATGTGMAAT  
101 TTGGAAAAAG TATTAAAGAT TTTCCAGCTG CTCTAAAGAA TTTGATGAAG  
151 AATGCTGTCT TTATGTGTTT AGTTCTATCA ACTTCTTCAG AAGCCTTAAT  
201 TACTACTGGA TTGTGTACAT TTTTACCTAA ATTATAGAA AATCAATTGG  
251 GATTGNATC CAGCTTCGCA GCTACTCTTG GAGGGACAAT TCTTGGACCA  
301 ATTATATTTG GTTTCACAAAT AGACAGCACA TGTATTCTTT GGGATATAAA  
351 TGATTGTGGA ATTTAAAGGAG CTTCCTCGAT TTATGATAAC ATCAAGATGG  
401 CCCATATGCT AGTAGCCATA AGTGTACTTT GTAAAGTTAT CACCATGTTT  
451 TTCAATGGAT TTGCAATCTT TTTGTATAAA CCACCTTCCAT CAGGCCACAGA  
501 TGTGTCTATT CATTAAGAGA ATGCAGTTGT GACTAATGTT TTAGCAGAAC  
551 AGGATCTCAA CAAATAGTA AAGAAGGGC TTTCACAGCA GAGCAGGCGA  
601 GGAGAAGATG AAAAGCAGCT GGACATTGGA AACTGGTTTTG GGGCTGGAGA

651 GAAGAAGTCC AGGCCACTGG ACTTCAGGAA AAGATCATCT TCCTGCTCTA  
701 TCCCTTTTCC AGTCCCTT GCGCTGAGA GCCACTTTCA TAGGCAATAA

IIAA SEQUENCE 1.0

ID ADP30902 standard; protein; 1933 AA.

XX AC ADP30902;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1669.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

PR 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 17-SEP-2002; 2002US-0410946P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.

PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.

PR 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411022P.

PR 17-SEP-2002; 2002US-0411023P.

PR 17-SEP-2002; 2002US-0411024P.

PR 17-SEP-2002; 2002US-0411032P.

PR 17-SEP-2002; 2002US-0411035P.

PR 17-SEP-2002; 2002US-0411037P.

PR 17-SEP-2002; 2002US-0411041P.

PR 17-SEP-2002; 2002US-0411045P.

PR 17-SEP-2002; 2002US-0411046P.

PR 17-SEP-2002; 2002US-0411048P.

PR 17-SEP-2002; 2002US-0411052P.

PR 17-SEP-2002; 2002US-0411055P.

PR 17-SEP-2002; 2002US-0411073P.

PR 17-SEP-2002; 2002US-0411082P.

PR 17-SEP-2002; 2002US-0411101P.

PR 18-APR-2003; 2003US-0463700P.

PR 18-APR-2003; 2003US-0463708P.

PR 18-APR-2003; 2003US-0463716P.

PR 18-APR-2003; 2003US-0463732P.

PR 02-MAY-2003; 2003US-0467199P.

PR 02-MAY-2003; 2003US-0467201P.

PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2900; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1933 AA;  
ADP30902 Length: 1933 February 22, 2005 12:25 Type: P Check: 2807 ..  
1 TCTGTTCTTC CTCATTCTG GGCCTAAGTTA GTAGTGGGAT CGGTTGCCAT  
51 TGTGTGTTTT GCACGCAGCT ATGATGGAGA CTTTGTCTTT GATGACTCAG  
101 AAGCTATTGT TACAATAAG GACCTCCAAG CAGAAACGCC CTGCGGGGAC  
151 CTGTGGCATC ATGACTTCTG GGGCAGTAGA CTGACGACGA ACACGAGCCA  
201 CAAGTCTTAC CGGCTCTCA CCGTCTGCAC TTTCAGGATT AACTACTACC  
251 TCTCGGAGG CTTCCACCCC GTGGCTTTTC ACGTGGTCAA CATTCTCTTG  
301 CACAGTGGCA TCTCTGTCTT CATGTGGGAC GTCTTCTCGG TTCTGTTTGG  
351 CGGCTGCGAG TACACACAGTA AAGGCCGGAG GCTGCACCTC GCCCCAGGG  
401 CGTCCCTGCT GGGCCGCGCTG CTGTTTGTCT TCCATCTCTG GCACACCGAG  
451 TGTCAAGTAA CAAGGAGGGA GGGCATTCTT CCACCTTCTG GGTGCTGCTG  
501 AGTATCTTTC TGGGACAGT GGCCTATGCTG TGCAAGAGAGC AAGGGATCAC  
551 TGTGCTGGGT TTAATGCGG TATTTGACAT CTTGGTGATA GGCAAATTCA  
601 ATGTTCTTGA AATTGTCCAG AAGGTACTAC ATAGGACAA GTCAITTAGAG

651 GAGGTGGACA ACCCGCCTC CTTTGCTGAC AGCATGCTGG TGAGGGCCCT  
701 AACTACAAAT TACTACTATT CATTGAATGC CTGGCTGCTG CTGTGTCCCT  
751 GGTGGCTGTG TTTTGATTGG TCAATGGGCT GCATCCCCCT CATTAAAGTCC  
801 ATCAGGGACT GGAGGGTAAT TGCATTGGA GCACCTCTGGT TCTGCTTAAT  
851 TGGCCTGATA TGCCAAGCCC TGTGCTCTGA AGAGGGCCAC AAGAGAAGA  
901 TCCTTACTCT GGGCCTGGGA TTTCTCGTTA TCCCATTTCT CCCCAGAGT  
951 AACCTCTTCT TCCGAGTGGG CTTGCTGTGC GCAGAGCGTG TCCTCTACCT  
1001 CCCAGCGTT GGGTACTGTG TGTGCTGAC TTTTGGATTG GGAGCCCTGA  
1051 GCAACATAC CAAGAAAAAG CTGAGATGTG TGTGCGCAG CGGCGAGTGG  
1101 CGGAGTGAGG AACAGCTTTT CAGAAGTGCT CTGTCTGTGT GTCCCCCTCA  
1151 TGCTAAGGTT CACTACAACA TTGGCAAAAA CTGGGCTGAT AAGGCAACC  
1201 AGACAGCTGC CATCAGATAC TACCGGAAG TTTCAGATTA AATCCCAAGT  
1251 ATGTTTCATGC CATGAATAAT CTTGGAATA TCTTAAAAA AAGGAATGAG  
1301 CTACAGGAAG CTGAGGAGCT GCTGTCTTTG GCTGTTCAA TACAGCCAGA  
1351 CTTTGGCGCT GCGTGGATGA ATCTAGGCAT AGTGCAGAAT AGCCTGAAAC  
1401 GGTTTGAAGC AGCAGACAA AGTTACCGGA CAGCAATTAA ACACAGAAGG  
1451 AATATCCAG ACTGTTACTA CAACCTCGG CGTCTGTATG CAGATCTCNA  
1501 TGCCACGCTG GATGCTTTGA ATGCGTGGAG AATGCCACC GTGCTGAAC  
1551 CAGAGCACAG CCGTGCCTGG AACAACTAGA TTATCTCTCT CGACAATACA  
1601 GGTATTTTAG CCCAAGCTGA AGCAGTTGGA AGAGAGGCAC TGGAAATTAAT  
1651 ACCTAATGAT CACTCTCTCA TGTTCCTGTT GGCAAAAGTG CTGGGGAAAT  
1701 CCCAGAAATA CAAGGAATCT GAAGCTTTAT TCCTCAAGGC AATTAAGCA  
1751 AATCCAATG CTGCAAGTTA CCATGGTAAT TTGGCTGTGC TTATCATCG  
1801 TTGGGGACAT CTAGACTTGG CCAAGAAACA CTATGAAATC TCCTTGCAGC  
1851 TTGACCCAC GGCATCAGGA ACTAAGGAGA ATTACGGTCT GCTGAGAGA  
1901 AAGCTAGAAC TAATGCAAAA GAAAGCTGTC TGA

!!AA SEQUENCE 1.0  
ID ADP30903 standard; protein; 1434 AA.  
XX  
AC ADP30903;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1670.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX

PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406658P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Halen L, Linnewann T;  
PI

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2901; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 1434 AA;  
SQ

ADP30903 Length: 1434 February 22, 2005 12:25 Type: P Check: 8711 ..

1 ATGTCATGG CCAGAGGAGT GATCCAGCTC CTAGAGATG AGGAGAGACC  
51 GAAGCCAGAC ACAGCCGCTG TCGCTGCCAT CTGGCGCGCC GCAGACTCCC  
101 GAGAACAGCC CTGCTGTCA CGCGGCACCA GCGCTTCTCT GTGCCCATCG  
151 CGTAGACTGG AGGGGGCGAC CACGGCCACC GAGCCAGAGG CGTTTCAGGA  
201 AGCAAGAGAA GTCCCCGCGC GCTCCGGGAC CGGCGCGCAG TCATGGAGCA  
251 ACGACACCGC GTACCCGGGG CAGTTAGGCG TATACCAGCA GCTGGCGCAG  
301 GGGAAATGCG TGGGGGGGCT GGGCGGGGGA CCGCCACTGG GGCCTGTGCA  
351 GGTGGTCACC GCCTGCCTGC TGACCCCTACT CGTCATCTGG ACCTTGTCTGG  
401 GCAACGTGCT GGTGTCCGCA GCCATCGTGT GGAGCGGCCA CTTGGCGGCC  
451 AAGATGACCA ACGTCTTCAT CGTGTCTCTA CTTGTGTGAG ACCTTTCTGT  
501 GGCGCTGCTG GTCATGTCTT GGAAGGCAGT CGCCGAGGTT GCGCGTTACT  
551 GGCCCTTTGA AGCCTTCTGC GAGCTCTGGG TGGCCTTGA CATCATGTGC  
601 TCCACCGCCT CCATCTTGAA CTTGTGGTGC ATCAGCGTGG CCGCTACTG  
651 GGCCATCTCC AGGCCCTTCC GCTACGAGCG CAAGATGACC CAGCGCATGG  
701 CCTTGGTCAAT GGAGGCGGTT TGGGAGCCCG AGCTGAGGGC AGAGACTGT  
751 GACTCCAGCC TGAATCGAAC CTACGCCATC CTTCTCTGCG TCATCAGCTT  
801 CTACATCCCC ATGGCCATCA TGATCTGTGAC CTACACGGCG ATCTACCACA  
851 TCGCCCAAGT GCAGATCCGC AGAATTTCTT CCTTGGAGAG GGCCGCGAGG  
901 CACGTGCAGA GCTGCCGAG CAGCGCAGGC TGCACGCCCG ACACGAGCCT  
951 GCGGTTTTCC ATCAAGAAGG AGACCCAGGT TCTCAAGACC CTGTCTGGTA  
1001 TCATGGGGGT CTTCTGTGT TGTGTGCTGC CTTTCTTCTT CTTTACTGTC  
1051 ATGTTCTCTT TCTGCACTGG ACACCCCAAA GGCCCTCCGG CCGGCTTCCC  
1101 CTGCTCAGT GAGACACAT TCGATGTCTT CATCTGTAC TATGCTTCA  
1151 AGGCGACTT CCGAAGGTG TTTGCCCAGC TGCTGGGGTG CAGCACGTC  
1201 TGCTCCCCGA CGCGGTGGA GACGGTGAAC ATCAGCAATG AGCTCATCTC





551 CTCAGCACTG CAGCAGTGAG CTGACAGGCA AGCGGCCCAT GGTGACGAG  
601 AAGGTCATTG TGGGTCGCT CTCTGTGCAG GACCTGCAGG CTTCCAGAG  
651 TGCTTGCTAC TGGCTGAAG GTGTCCGCTA CTCTGATATC GGCACCTCTGG  
701 CTTGGATGAT CACTCTGAGC GACGCGCTCC ATAATTTTCAT CGATGGCCTG  
751 GCCATCGGTG CTTCTTTCAC TGTGTCAAGT TTCCAAGGCA TCAGCACCTTC  
801 GGTGGCCATC CTCTGTGAGG AGTTCCACACA TGAGCTAGGA GACTTTGTCA  
851 TCTCTGCTCAA CCTGGGATG AGCATCCAC AAGCTCTCTT CTTCAACTTC  
901 CTTTCTGCTC GCTGTGCTA CTTGGGTCTG GCCTTTGGCA TCTTGGCCGG  
951 CAGCCACTTC TCTGCCAACT GGAATTTTGC GCTAGCTGGA GGAATGTTCT  
1001 TGTATATTTC TCTGCTGAT ATGTTCCCTG AGATGAATGA GGTCTGTCAA  
1051 GAGGATGAAG GGAAGGCGAG CATCTTGATT CCATTTATCA TCCAGAACCT  
1101 GGGCTCTCTG ACTGGATTCA CCATCATGGT GGTCTCTACC ATGTATTGAG  
1151 GACAGATCCA GATTGGGTAG

!!AA\_SEQUENCE 1.0  
ID ADP30926 standard; protein; 922 AA.

AC ADP30926;

DT 12-AUG-2004 (first entry)

DE Human secreted protein SEQ ID #1693.

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

OS Homo sapiens.

PN WO2004035732-A2.

PD 29-APR-2004.

PF 28-AUG-2003; 2003WO-US026780.

PR 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 17-SEP-2002; 2002US-0406668P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.

PR 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411022P.

PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2924; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
SQ Sequence 922 AA;

ADP30926 Length: 922 February 22, 2005 12:25 Type: P Check: 4100 ..

1 ATGGCCCCCG CTCGGCCCCC CGCGCGCTCC TTCTCGCCCT CCGAGGTCCA

51 GCGGCGCCTG GCGCGCGGCG CGTGTGGGT CGCGCGGCG GCGCGCTCT

101 ACGACCTCTC CAGCTTCGTG CGGCACCACC CGGGGGCGA GCAGCTGCTG  
151 CGGCCACAGG CGGGCCAGGA CATCAGCGCC GACCTGAAG GGGCGGGCA  
201 CAGGCACTCG GCCAACGGC CGCGCTGGCT GGAGCAGTAC TACGTGGAG  
251 AGCTCCGGG GGAGCAGCAG ACTCAGAGA CAGATCCTGC TATGGAACCA  
301 CGGTTCAAAG TGGTGAATTG GGACAAGAC CTGGTGAAGT GGGAAAGCC  
351 TCTCCTGTGG CAGGTGGGCC ACTTGGGAGA GAAGTACGAT GAGTGGGTTT  
401 ACCAGCGGT GACCAGGCC ATCCGCTCTT TCCACTCAGA CCTCATTTAG  
451 GGCCTCTCTA AGACTGTCTG GTACAGTCTC CCATCATCT GGGTGGCCTT  
501 GGTGCTGTAT CTCAGCTGGT CCTACTACCG AACCTTTGCC CAGGGCAAGC  
551 TCCGACTCTT CAGTCTATT ACAACAGTCA TCCACCGCTT CTGTGTTCCAC  
601 ATGAAGCCCC CGAGCAGCAG CTTATTACCTC ATCATGCTGC ACTTCGTAT  
651 GCACGGCCAG CACCACAAG CACCCTTCGA CGGCTCCGC CTGGTCTTCC  
701 CCCCTGTGCC AGCTCCCTG GTGATCGGG TCTTTACTT GTGCATGCAG  
751 CTCATCTGCG CGAGGCAGT AGGGGCACT GTGTTTGGG GGGGCTCCT  
801 GGGCTACGTC CTCATATGACA TGACCCATTA CTACCTGCAC TTTGGCTCGC  
851 CGCACAGGG CTCCTACCTG TACAGCCTA AGGCCCAACA CGTCAAGCAC  
901 CACTTTGCAC ATCAGAAGTC AG

!!AA SEQUENCE 1.0  
ID \_ADP30929 standard; protein; 1142 AA.  
XX  
AC ADP30929;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1696.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PF 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.

17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnenmann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2927; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.

```
SQ      Sequence 1142 AA;
ADP30929 Length: 1142 February 22, 2005 12:25 Type: P Check: 9283
1  ATGGAAACCC TTTCGCTCAG GGCATCCTTT TGCGTGGCAC TGGTTGGATG
51  TGTATATCAGT GATATCTCTG AGAGATACAG CACAATCTTA AGCAATCATG
101  TGGATGATTT CACCACTTTT CGTGGCACAG AGCTCAGCTT CCGTGTTCAC
151  ACTCATCAAC CCACATAATT GGTCTACCC AGCAATGGCT CAATGCACAA
201  CTATTGCCCA CAGCAGACTA AATTACTTC AGCTTTCAAA TACATTAACA
251  CTGTGATATC TTGTACTATT TTATCTGTTG GAATGGTGGG GAATGCAACT
301  CTGCTCAGGA TCATTTACCA GAACAAATGT ATGAGGAATG GCCCCACGCG
351  GCTGATAGCC AGCTTTGCCG TTGAGAGACT TATCTATGTG GTCATTTGATC
401  TCCCTATCAA TGTATTTAAG GTACAGAGCA GTTGCCTCCT GGAGTCGTGT
451  TCAGGGAATT GGGATTCCTT TGTTAACTGC CATTTGAAAT GTCTCCATCT
501  GGATCTGTGC CTTTATCTCG GCATTCCTG AGCGATTGG GTTCGTCTATG
551  GTACCCCTTG AATATAGGGG TGAACAGCAT AAAACCTGTA TGCTCAATGC
601  CACATCAAAA TTCATGGAGT TCTACCAAGA TGTAAAGGAC TGGTGGCTCT
651  TCGGGTTCTA TTTCTGTAAG CCCTTGTGTG GCACTCGGAT CTTCTACACC
701  CTCATGACTT GTGAGATGTT GAACAGAAGG AATGGCAGCT TCAGAATTGC
751  CCTCAGTGAA CATCTTAAGC AGAGCGTGA GAAGTGGCAA AAACAGTTTT
801  CTGCTTGGTT GTAATTTTGG CTCTTTGCTG GTTCCCTCTT CATTTAAGCC
851  GTATATTGAA GAAAACCTGT TATAACGAGA TGGACAAGAA CCGATGTGAA
901  TTATCTAGTT TCTTACTGCT CATGGATTAC ATCGGTATTA ACTTGGCAAC
951  CATGAATTC TGTATAACC CCATAGCTCT GTATTTTGTG AGCAAGAAAT
1001  TTAATAAATG TTTCAGTCA TGCTCTGCT GCTGCTGTGA CCAGTCCAAA
1051  AGTCTGATGA CCTCGTCCC CATGAACGGA ACAAGCATCC AGTGAAGAA
1101  CCACGATCAA AACAAACCACA ACACAGCCG GAGCAGCCAT AA

!!AA SEQUENCE 1.0
ID      ADP30953 standard; protein; 2141 AA.
XX
XX
AC      ADP30953;
XX
XX
DT      12-AUG-2004 (first entry)
XX
XX
DE      Human secreted protein SEQ ID #1720.
XX
XX
KW      Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW      cancer; inflammatory; immune; human secreted protein.
XX
XX
OS      Homo sapiens.
XX
XX
PN      WO2004035732-A2.
XX
XX
PD      29-APR-2004.
XX
XX
PF      28-AUG-2003; 2003WO-US026780.
XX
XX
PR      29-AUG-2002; 2002US-0406576P.
PR      29-AUG-2002; 2002US-0406579P.
PR      29-AUG-2002; 2002US-0406585P.
PR
```

```
PR      29-AUG-2002; 2002US-0406588P.
PR      29-AUG-2002; 2002US-0406608P.
PR      29-AUG-2002; 2002US-0406611P.
PR      29-AUG-2002; 2002US-0406612P.
PR      29-AUG-2002; 2002US-0406615P.
PR      29-AUG-2002; 2002US-0406640P.
PR      29-AUG-2002; 2002US-0406642P.
PR      29-AUG-2002; 2002US-0406646P.
PR      29-AUG-2002; 2002US-0406653P.
PR      29-AUG-2002; 2002US-0406655P.
PR      29-AUG-2002; 2002US-0406656P.
PR      17-SEP-2002; 2002US-0410946P.
PR      17-SEP-2002; 2002US-0410947P.
PR      17-SEP-2002; 2002US-0410948P.
PR      17-SEP-2002; 2002US-0410949P.
PR      17-SEP-2002; 2002US-0410953P.
PR      17-SEP-2002; 2002US-0410957P.
PR      17-SEP-2002; 2002US-0410958P.
PR      17-SEP-2002; 2002US-0410959P.
PR      17-SEP-2002; 2002US-0410960P.
PR      17-SEP-2002; 2002US-0410961P.
PR      17-SEP-2002; 2002US-0410962P.
PR      17-SEP-2002; 2002US-0411019P.
PR      17-SEP-2002; 2002US-0411022P.
PR      17-SEP-2002; 2002US-0411023P.
PR      17-SEP-2002; 2002US-0411032P.
PR      17-SEP-2002; 2002US-0411033P.
PR      17-SEP-2002; 2002US-0411035P.
PR      17-SEP-2002; 2002US-0411037P.
PR      17-SEP-2002; 2002US-0411041P.
PR      17-SEP-2002; 2002US-0411045P.
PR      17-SEP-2002; 2002US-0411048P.
PR      17-SEP-2002; 2002US-0411052P.
PR      17-SEP-2002; 2002US-0411055P.
PR      17-SEP-2002; 2002US-0411073P.
PR      17-SEP-2002; 2002US-0411082P.
PR      17-SEP-2002; 2002US-0411111P.
PR      17-SEP-2002; 2002US-0411111P.
PR      18-APR-2003; 2003US-0463700P.
PR      18-APR-2003; 2003US-0463708P.
PR      18-APR-2003; 2003US-0463716P.
PR      18-APR-2003; 2003US-0463732P.
PR      02-MAY-2003; 2003US-0467199P.
PR      02-MAY-2003; 2003US-0467201P.
PR      02-MAY-2003; 2003US-0467203P.
PR      02-MAY-2003; 2003US-0467230P.
PR      19-MAY-2003; 2003US-0471306P.
PR      19-MAY-2003; 2003US-0471336P.
PR      22-MAY-2003; 2003US-0472420P.
PR      22-MAY-2003; 2003US-0472430P.
PR      09-JUN-2003; 2003US-0476609P.
PR      09-JUN-2003; 2003US-0476641P.
PR      08-JUL-2003; 2003US-0485218P.
PR      08-JUL-2003; 2003US-0485224P.
PR      08-JUL-2003; 2003US-0485325P.
PR      14-JUL-2003; 2003US-0486446P.
PR      14-JUL-2003; 2003US-0486480P.
PR      15-JUL-2003; 2003US-0486891P.
PR      15-JUL-2003; 2003US-0486960P.
PR      08-AUG-2003; 2003US-0493341P.
PR      08-AUG-2003; 2003US-0493370P.
PR      08-AUG-2003; 2003US-0493573P.
PR      08-AUG-2003; 2003US-0493577P.
XX
XX
```

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Heestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2951; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
SQ Sequence 2141 AA;  
ADP30953 Length: 2141 February 22, 2005 12:25 Type: P Check: 7719 ..  
1 GCGGCTGCCC CTCGACGCA AGGGGTGGG GCGGAGCCG GCGGACCCC  
51 AGTCCCTTGG GCTGTGCGA AAGCCGCTGG TGTGACGCC GAGGGCCATC  
101 CCGGGCCACA GGGAGSCAG TGGGTGCGA GGAGCCGGC CAGGAGATGT  
151 GCGGGGGGG TGTGNACCA GGAGATTGG GAGGAGCTGG GGGCTGGGG  
201 CTCAGCACCT AGGACCCACC AGTGGCGGAC CTGGTTGCG TGTCCCGTGG  
251 CTCGGGCCA TGCCCTTCG TCACAACACC TCCGGTTTT GGTCTGGTTA  
301 CCCGGTATC CTGTGGGTGA CTGGCTCTG GGTGACCTGT TATCCGGCCT  
351 GAGTGTGGCC ATCATGCAG TTCCGACGG CTGCGCCTAC GCCCTCCTGG  
401 CTGGATTGCC CCGCGTTTT GGCCTCTATA GCTCCTTCTA CCTGTGCTTC  
451 ATCTACTTCC TGTTTGGCAC TTCCGGCAC ATCTCGTGG GTAAGTGGAG  
501 GCAGGCGTAG CGGACCTTTG CTGTGCATGC TGTGATGGT GGCAGTGTGA  
551 CAGAATCCCT GGCCCGCAG GCCTTGAAG ACTCCATGAT CAATGAGACA  
601 GCACAGATG CTGCCCGGGT ACAGTGGCC TCACACTCA GTGTCTGTGT  
651 TGGCCTTTC CAGTCCCTT CAGTGTGGC CTGGCCGCC CCACAGGTGG  
701 GGCTGGGCTT GATCCACTTC GCTTCGTGG TCACCTACCT GTCAGAACCT  
751 CTGTGCGGAG GCTATACAC AGCTGCAGT GTGCAGTCT TCGTCTCACA  
801 GCTCAAGTAT GTGTTTGGCC TCCATCTGAG CAGCCACTCT GGGCCACTGT  
851 CCCTCATCTA TACAGTCTG GAGTCTGCT GGAAGCTGCC CCAGAGCAAG  
901 GTTGGCACCG TGTCTACTGC AGCTGTGGCT GGGTGTGTGC TCGTGTGGT  
951 GAAGCTGTTG AATGACAAG TCACAGCA GCTGCCCATG CCGATACCCG  
1001 GGGAGCTGCT CAGGCTCATC GGGGCCACAG GCATCTCCTA TGGCATGGGT  
1051 CTAAGCACA GATTGAGT AGATGCTGT GGCACATCC CTGCAGGGCC  
1101 ATTGCCATCT CACTGGGAA GATCTTCGCC CTGAGGCACG GTTACCGGCT  
1151 GGACAGCAAC CAGGAGCTGG TGGCCCTGG CCTCAGTAAC CTTATCGGAG  
1201 GCATCTTCCA GTGCTTCCCC GTAGTTGCT CTATGTCTCG GAGCCTGGTA  
1251 CAGGAGAGCA CCGGGGGCAA CTCGAGGTT GCTGGAGCCA TCTCTTCCT  
1301 TTTTCATCTC CTCATCATTTG TCAAACTTGG GGAATCTTC CATGACCTGC

1351 CCAAGCGGT CTGCGACCC ATCATCATTTG TGAACCTGAA GGGCATGCTG  
1401 AGCGAGCTCA CGGACATCG CTCCCTCTGG AAGGCCAATC GGGCGGATCT  
1451 GATCTGGCTG GTGACCTTCA CGGCCACCAT CTTGTCTGAAC CTGGACCTTG  
1501 GCTTGTGTGT TCGGTCTATC TTCTCCCTGC TGCTCGTGGT GGTCCGGACA  
1551 CAGATGCCCC ACTACTCTGT CTGGGGCGAG GTGCCAGACA CGGATATTTA  
1601 CAGAGATGTG GCAGAGTACT CAGAGGCCAA GGAAGTCCCG GGGGTGAAGG  
1651 TCTTCGCTC CTCGCCACC GTGTACTTTG CCAATGCTGA GTTCTACAGT  
1701 GATGCGCTGA AGCAGAGGTG TGGTGTGGAT GTGCACTTCC TCATCTCCA  
1751 GAAGAAGAAA CTGCTCAAGA AGCAGGAGCA GCTGAAGCTG AAGCAACTGC  
1801 AGNAAGAGGA GAAGCTTCGG AAGCAGCAG GGGCCCTTTT GTCTGCACTG  
1851 AAGGCCCTGG GCCTGCCTCA GCACAGCTTC CACAGCCTCA TCCTGGACCT  
1901 GGGTGGCCTC TCCTTTGTGG AACTGTGTG CCTCAAGAGC CTGAAGAATA  
1951 TTTTCCATGA CTTCCGGGAG ATTGAGGTGG AGGTGTACAT GCGCGCCTGC  
2001 CACAGCCCTG TGGTCAGCCA CTTGAGGCT GGGCACTTCT TCGATGCATC  
2051 CATCACCAAG AAGCATCTCT TTGCTCTGTT CCATGATGCT GTACCTTTTG  
2101 CCTCCACA CCGAGGCT GTCCCGACA GGCCTGTTTC G  
!!AA\_SEQUENCE 1.0  
ID ADP31088 standard; protein; 2091 AA.  
XX  
AC ADP31088;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1855.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.

	PR	17-SEP-2002;	2002US-04I0958P.
	PR	17-SEP-2002;	2002US-04I0960P.
	PR	17-SEP-2002;	2002US-04I0960P.
	PR	17-SEP-2002;	2002US-04I0961P.
	PR	17-SEP-2002;	2002US-04I0962P.
	PR	17-SEP-2002;	2002US-04I1019P.
	PR	17-SEP-2002;	2002US-04I1022P.
	PR	17-SEP-2002;	2002US-04I1023P.
	PR	17-SEP-2002;	2002US-04I1024P.
	PR	17-SEP-2002;	2002US-04I1032P.
	PR	17-SEP-2002;	2002US-04I1035P.
	PR	17-SEP-2002;	2002US-04I1037P.
	PR	17-SEP-2002;	2002US-04I1041P.
	PR	17-SEP-2002;	2002US-04I1045P.
	PR	17-SEP-2002;	2002US-04I1046P.
	PR	17-SEP-2002;	2002US-04I1101P.
	PR	17-SEP-2002;	2002US-04I1111P.
	PR	17-SEP-2002;	2002US-04I11052P.
	PR	17-SEP-2002;	2002US-04I11058P.
	PR	17-SEP-2002;	2002US-04I11055P.
	PR	17-SEP-2002;	2002US-04I1073P.
	PR	17-SEP-2002;	2002US-04I1082P.
	PR	17-SEP-2002;	2002US-04I1101P.
	PR	17-SEP-2002;	2002US-04I1111P.
	PR	18-APR-2003;	2003US-04G63700P.
	PR	18-APR-2003;	2003US-04G63708P.
	PR	18-APR-2003;	2003US-04G63716P.
	PR	18-APR-2003;	2003US-04G63716P.
	PR	18-MAY-2003;	2003US-04G63732P.
	PR	02-MAY-2003;	2003US-04G67199P.
	PR	02-MAY-2003;	2003US-04G67201P.
	PR	02-MAY-2003;	2003US-04G67203P.
	PR	02-MAY-2003;	2003US-04G67230P.
	PR	19-MAY-2003;	2003US-04J11306P.
	PR	19-MAY-2003;	2003US-04J1136P.
	PR	22-MAY-2003;	2003US-04T2420P.
	PR	22-MAY-2003;	2003US-04T2430P.
	PR	09-JUN-2003;	2003US-04F6609P.
	PR	09-JUN-2003;	2003US-04F6614P.
	PR	08-JUL-2003;	2003US-04S8218P.
	PR	08-JUL-2003;	2003US-04S8223P.
	PR	08-JUL-2003;	2003US-04S8224P.
	PR	08-JUL-2003;	2003US-04S8325P.
	PR	14-JUL-2003;	2003US-04S8446P.
	PR	14-JUL-2003;	2003US-04B8480P.
	PR	15-JUL-2003;	2003US-04B8691P.
	PR	15-JUL-2003;	2003US-04B8960P.
	PR	08-AUG-2003;	2003US-04Q9334P.
	PR	08-AUG-2003;	2003US-04Q9337OP.
	PR	08-AUG-2003;	2003US-04Q93573P.
	PR	08-AUG-2003;	2003US-04Q93577P.

ADP31088 Length: 2091 February 22, 2005 12:25 Type: P Check: 8726 .

1	GCAATTTCCAG	AAC TGGTTCAG	CC CAGACATC	TT CATGCACT	CT CACTCGGA
51	AAATGCAATT	TCA GTCAAG	AA ATTGTCAC	TG AAAATTGAG	TCC ATCAGTC
101	AAGGAGTTGG	GC AGATTCAA	CT GAAAGGAG	AC ATCTTACC	CA ACCCATGC
151	CATACACAA	AGA AGAACAG	CAT CCAATGAG	CT GCTCCTTG	AG AGGGCCCA
201	GACTCCAGAG	AACA AACCTG	GAC ATATGGA	GCA AGATGAG	GACT CCTGCA
251	CAGCCCGCC	TGA ACTAGCC	AA AGACTCAG	GG ATGTGCA	CC CAGAAGGC
301	TGCTTAACCA	CACA CTATC	TAT AGCAGAC	TT GGAAGAG	GGG AACCAAGC
351	TGAGGGGAA	CA AGAGCTCC	AG GGTCTCAGS	GAT GCACCCA	GGT GCAAGT
401	GGTACCTGG	GT CTGTGAGG	CG AGCCACCT	TGG AGTTGCA	AG AGCGCTTA
451	CGG CAGGAGC	AG AGCATCA	TGG TGTGTGCC	CCA CATGTA	CCT CATTTGTC
501	CAC TCGTAAG	AA TTCAAAGA	AT GATTCTTC	TGT GGCAGAC	CT AGCACCAA
551	AAGGMAAAG	TG ATGAGCC	CCCC CAGAAC	ATT CATTTGT	CCT CAAGGAA
601	CCAGAAATGA	GCA AAGGCCA	AG GGAATATC	AG TGGGTCTG	AGG CTGGCTC
651	ACTGTCCAT	TCT GAGCAGA	AT GCCACTGT	TCC AGCTCCC	AGG GTGCTGG
701	AGTTTGACCA	CT TTGCCAGAT	CCT CAGGAGS	GCCC AGGGTC	AG ATACTGGA
751	ACACAGCAGG	AAG GATCCT	GA AGGATCTG	AG GACTGTGA	TT CCTATACCA
801	GGAGTCTGAA	ACA CAGCAG	TGC CTCTTCC	CCT TCCCAAG	AGG GTAGAAA
851	TCATTGGAATA	TAC CCACATA	GT TATCATC	CCA ATCAC	TGG GCCCAGGG
901	AGTGAATAG	CC ACCAGTGA	GA AGACGGGA	GAG CAAAGGC	TG AGGAAAGT
951	GAACATGMA	AA ATCTGTGA	CT GTGCTCTG	CAC ACTGGAT	GAA ATCTAA
1001	ACAGGACTCT	GG ACCCCAAAC	CAG GTTTCTC	TGC ACCCCCC	AGT GCTACCT
1051	CTGCTCTATT	CT TCTCTCCC	TG AGCACAAAC	AG ACCCACTG	ACC ATCCAAC
1101	CTCCATCCTG	AG TAGCCCTG	NAG ACAGAGG	CAG CAGCCTG	TCC ACAGCCC
1151	TGGAGACAGC	AG CACCTTTT	GT CAGTCA TA	CA ACCCATTT	ACT GTCTGCC
1201	AGTTTGGATT	AC CTGCATCC	CC AGACTATG	GT TCACTCTG	AGG GCTTCAAC
1251	AGACGAGNC	AG CACTTACAG	AT GAGCCCTC	TGC AGAACAG	GT TAGCTGGG
1301	AAGAAATGA	GG AGAGCCCT	CT CTCCAGTG	GC AGTGAAGT	GCC ATATAAG
1351	GACTCCCAGC	TAA GTAGCGC	AG ACCTAAGT	TTA ATTAGCA	AA CTTGGTGA
1401	CAACACTGGG	GAG TTACAGG	AG AAAATGGA	CCC ATTGCTC	GT AGCCCTGTC
1451	GACTCCACCA	TAG CTCTAGT	AGT GAAACA	TAA AGAGTCT	CAG CCACAGC
1501	CCCGGTGTGG	TGA AGAGCG	TG CTTAAAGAA	AT CAGAGTCT	GAG TGGTTTT
1551	CCAGGCGAGG	CT CACCACAAAC	CAT CCAAAAT	GAG GCGCTCA	GCT TCTCTCG
1601	CCAAATTAGG	TT ACTTTGGAC	CT CTGTAAAG	ACT GCTTACC	AG AGAGGGAG
1651	CCTGCCTCCT	GT GAAATCCCC	TCA TCTCAAA	CT GTTTCAGC	CT TTTCTCAG
1701	AACAGACTCA	GG CATGCACG	CG ATGGAGGA	CCA AGAGTCC	CT AGAAAACC



401 TAGTCTATGT CCACTGCGGT GGCCTTACAC AGGACTTGAC ATTCCGGGTC  
451 AGCAATGGAC TGCAGGCCAG CCCCCGGCC ATGCTGAAGG TGGTGGCTGT  
501 CCAGCTGGCC ATACAAATCC ACCCAGCAC AGGCTTGCAAT CTGGCCCCAGG  
551 GCTCTGCCAT GCCCATCTTG CTTACCAACC TGTGTGTGGA GACCAGCGCC  
601 GTGGGCAGG ATGTGACCGT GCTGTTCCAT GTCAACCGAG GCTTGCCTTT  
651 CAGGGAGCTG CAGAAAGCAG GGGCTGTGTG GGTGGAGGAT GCTGATGCT  
701 GGGTCACACA GCGTTTCCAC CAGCAGGATG TGGAGCAGGG CCACGTGAGA  
751 TACCTGAGCA CTGACCCACA GCACTACACC GAGGACACCG TGGAGAACCT  
801 GGATCTGCAG GTGCAGGTGA GCTGGGAAT CCTGAGCAAT CTGTCTTTCC  
851 TAGTGACCAT CCAGAGACC ACTGTGTGGA TGTGTGAGCT GGAGCCACTG  
901 CAACTTCAGA ACACCCAGCA GGAGGCCCTC ACCACAGCCC ACCTGGAGGC  
951 CACCTTGGAG GAGCAGGCC CAAGCCCCC AACCTTCCAC TGTGAGGTGG  
1001 TTCAGGCTCC CAGGAAAGGC AACCTTCAAC TACAGGGCAC GATGATGCA  
1051 GACGGTCAAG GCTTCACCCA GGATGACGTA CAGGCTGCAG AGGTGACCTA  
1101 TGGGGCCATG GCACGTGGCT CAGTGGCAGT GGNAGGACCC TTCTGTTTCC  
1151 ATGTCAACAG TCCACCATPAT TTCTCCCCAC TCTGTACTTT TCCATCCAT  
1201 ATTGGCGGTG ACCCAGACAT GCCTGTCTCT ATGTTGCCCG AGGGTGTGA  
1251 GTGTGTCTC TCTGTGACC AGCTCTTCAT CAAGACTCTC RACAGTGCA  
1301 GGTGGGGGTG GCTGACTACA GACAACATGG CTTTACAGAA TGCTGATTCG  
1351 GGCTTTGTGT AGGCCACAGT GGTGTGACC CACCAGGACC TCCTCTCTGG  
1401 CAGTATCATG GCCACGGATG AGCCCATGCA GCCCATCTGC CGCTTCATCC  
1451 AGGAGGGGCC TCAGGAAGAG GCGAGTCTGT TGTTCGATGG GCGACACCAG  
1501 GCCATCACGG TGCTGGAGGT GCAGGCTTAC GAGCCTTACC TCTGTGTGGC  
1551 CAATGGCTCC GGCCTCATGG TTCTCAAGG AGGCCAGGCT ACCATCAACA  
1601 TGGCCGAGCT CCACCTGGGC ACCAACCTCA ACATCTGCAG TAGGGATGAG  
1651 GCCCACTACC ACGTCACAGA CAGCCCTCAC TGGGGACAGT TGCTCCAAGC  
1701 CACTCAGCCA GCCACAGCT TCTCTCAGCA GGNCTGTCTG GTTGGGGCTG  
1751 TTCCCTATGG CCACAATGGC AGCCTCAGCT CTTGCAACAC CCTGGCCTTC  
1801 TCAATGGATG TGGACCAAGT GCACACAGAT GCCACCCTAC AAGTGACCAT  
1851 TGCCCTAGAG GGCCCAAGTAG CCCCACGTAA GCTGGCCCCAG CACAAGAAGA  
1901 TCTACATCTT CCAGGGAGAG GCAGCTGAGA TCAGAAGGGA CCAGCTGGAG  
1951 GTAGCCCAAG AGGCAGTGCC GCCAGCAGAC ATCGTTTTCT CAGTGAAGAG  
2001 CCCACCGAGT GCCGGCTACC TGTGTGAGT GCTGTGTGSC ATCTTGGCAG  
2051 ATGAGCCACC CAGCCTGGAC CCGCTGCCA GCTTCTCCCA AGAGSCAGTG  
2101 GACACAGGCA GGATCTCTTA CTTGTCACTC CGCCCTTAGG CCCCAGGCA  
2151 TGCCTTCTCG CTGATGTGG CTTGGGCTG GGTGTCTACC TTGAGGACGT  
2201 CACGTGGAGC TGGAGGTGGA AGAGCATCTG ATCCAGTACC TGCACGATGG

2251 GAGCAAGACA CTGACGGTTT TGTCTTGATG GCTAATGCTT CTGAGATGGA  
2301 CGCCCAGAGC CATCTGTGG CTTTCACTGT CACCATCCTG CCTGTCAATG  
2351 GCAACCCCC GACCTCATAC AAATCTAGGC CTGCAGAGGC TCTGAGGAGC  
2401 ATGATGTGT ACTCTGGCC CAAGGACCTG GTGTACACCA TTAAGCAGCC  
2451 CAGCAATGG TGGTAGTGC GGTGGCGGT GCCGGCACT GAGATCCGT  
2501 CCAGCCACTC AGCAGCCAGA GCCTCAGAGC CAGCAGGCAC CGACCCCCAG  
2551 CTCTGTCTT ACCATGTGT GCGGGCCTC CAGTAGGCCC GCTCTTTCCA  
2601 CCCCCAGCAT GACAGCAG GGGAGGACCT GGTGAATTC ACTCAGGCAG  
2651 AGACCCCGA GTTTCATATC TCGAGCGCG TGGCCNATAT GTACTCATGT  
2701 GGGAAACCAGA ACACACTGAT GGAGGAGTTG GCAGAGCAGG CACAGCAGA  
2751 CGACGAGATG CTGCACATGC ACCACGCGT GAAGGAGGCG CTCAGCATCA  
2801 TCGGTGACAT CAACAGGACC ACTGTTACCA TGCCCCCGCC CGTGACGAC  
2851 ACCTGTTGC AGGTGCAGAG CATCCCTGAC GCACACAGGC CAGAGGCTTC  
2901 CCTGATCCC TTTGGGCCCT ACCCCCCTGG TGCTCTTGTG CCCCAGCCGG  
2951 GGTCCCCAGT GTGCCGAGTG GGTGCACGCC CCAGATCCAT GCGGCACGTG  
3001 CCGGCCGGC CCGTGGGTG TCCCCAAACA CAGACTCACC CCCACTCTT  
3051 GGGGTGGGG CCGTACTCTC TGCTTTCTTC TGGGACTTGG TTCTCTCTGG  
3101 GCCTGGCTC CAGCGAGTT GAAAAATGCC ACCTGAAGAC AAGAGGACTA  
3151 AAGGCTCTT GGCACATACA CCACCCCTTG AATTTCCAGT TCACCACCAC  
3201 CAGCCCGGAC AGTGACCACA TTCTCATCAA AGTGCAATT TCTATTTTA  
3251 TCCCCACTTC TGCCAACCTT AAACCTACTT TAAGTGGCTT ATAGGCATA  
3301 GGAGCAAAA TAGCAGGGAC ACATCTTATA GAATCTTTG AAATGCAATT  
3351 CATTACTTC TCACCTCTC CACCTCTTC TACACTCTCT CTCACGAAA  
3401 CCGTGTCTT TCCTTCAACC AAGGATAAAA TCAAGACTTT GTTCGCGGG  
3451 CCGACTCCAC ACCGCGCGC CCGCCCCAG GGGAGGAGTG AGTCGCCCC  
3501 AGCGCGCCA ACCCGGGAC CCGGGGCAAG GGTTCGGGC CATCCGCGC  
3551 CCGGGCGCC CCCCCTCCG AAGCGGCGA CCGCCCCCAA GTTGGGCTGC  
3601 GGAGTGGAG GCGCGCGAG CCCCAGCAG ACAATGCGGG AGAAGGCTCT  
3651 GCAGTAGCC CCAGCCACC CCGCACCAG CTACAAGCG CCGGGGGTG  
3701 CCGGGGGCAC GCAAGAGGG AGTAAGTCT GCGAGTCTCT CCGTAGTAC  
3751 ACGCGGAGCA AGGCTGCGA GCTGGGATTG CACGCAGAG CTGCCCATCC  
3801 CGCTCCAGA GACCAACT GCAAGGACC TCAGAAATCA TCGGATTGCT  
3851 TTGAGAAA CAATGTGGT CGTGTACCA CCGCGGCGGA GGAGAAATA  
3901 TTAGCTGAAA AACACAA CA GGGAAATTTG GCGCAGGCA AGAAAAAGTT  
3951 AAAGCATAT TGGCAGAGGA AGAGCCCTGG CATTCAGCA GGAGCTAACA  
4001 GAAAAAGAA AATCAATGG AGTAGCCCTG ACACAGCCAC TTCTGGTGGT

4051 TACCACTCAC CTGGGATTG AGCAACAGGT ATCTACGGGG AGGGCGGTGC  
4101 ATCTCTACT ACCCTGGAG ATCTGGAGAG CCAGTACCAA GAACTAGCAG  
4151 TGCCCTCTGA TTCAAAGCTCC GCAATAATCA GTCAACTCAC TGAANAACATC  
4201 AATTCACTGG TTCCGCACATC TAAGGAGGAG AAGAAGCATG AGATACATCT  
4251 GGTACAGAAG CTTGGGAGGA GCTTGTTCAA ACTCAAAAAC CAGACGGCTG  
4301 AACCCTTGGC CCCAGAGCCC CCAGCAGGGC CATCTAAGGT AGAGCAGCTA  
4351 CAAGATGAGA CCAACCACCT AAGGAAGGAG CTAGAGAGTG TGGGAAGACA  
4401 GCTCCAGGCT GAGGTGGAAA ACAATCAGAT GTTGAGTCTC CTGAACAGGA  
4451 GACAGGAGGA GAGGTACGT GAACAGSAGG AGAGGCTACG TGAACAGGAG  
4501 GAGAGGCCAAC GTGACAGGA GGATAGGCTA CATGAACAGG AGGAGGGCT  
4551 ACGTGAACAG GAGGAGAGG TGTGTGAACA GGAGGAGAGG CTGTGTGAAC  
4601 AGGAGGAGAG GCTACGTGA CATGAGGAGA GGCTGTGTGA ACAGGAGGAG  
4651 AGGCTACGTG AACAGGAGGA GAGGCTGTGT GAACAGGAGG AGAGGCTACG  
4701 TGAACATGAG GAGAGGCTGT GTGAACAGGA GGAGAGGCTA TGTGAACAGG  
4751 AGGAGAGGCT ACATGAACAG GAGGAGAGGC TACGTGAACA GGAGGAGAGG  
4801 CTGTGTGAAC AGGAGGAGAG GCTACGTGAA CATGAGGAGA GGCTGTGTGA  
4851 ACAGGAGGAG AGGCTACGTG AACATGAGGA GAGGCTGTGT GAACAGGAGG  
4901 AGAGGCTACG TGAACAGGAG GAGAGGCTGT GTGAACAGGA GGAGAGGCTA  
4951 CGTGAACAGG AGGAGAGGCT GTGTGAACAG GAGAAGCTGC CAGGGCAGGA  
5001 GAGGCTCTG GAAGAGTGG AGAAGCTGTT AGAACAGGAG AGCGCGCAGG  
5051 AGGAGCAGGA GAGGCTGCTG GAGAGGGAGA GGCTGTCTGA AGAGTGGAG  
5101 AAGCTGTTAG AACAGGAGAG GCAGCAGGAG GAGCAGGAGA GGCTGCTGGA  
5151 GAGGAGAGG CTGCTGGAAG AGGTGGAGAA GCTGTTAGAA CAGGAGAGCC  
5201 GGCAGGAGGA GCAGGAGAGG CTGCTGGAGA GGGAGAGGCT GCTGGACGAG  
5251 GTGGAGGAGC TCCTGGACGA GACTCTGCAG GAGCTGGAGA GGCTGCGGGA  
5301 CTTGGAGAGG CTGCGGGAGC TGGAGAGGAT GCTGGAGCTG GGTGGGAAG  
5351 CCTGTGACGA GCACGCGGCC GAGCCACGCA GCGGCTTTGA GGAGCTGAAC  
5401 AACGAGAACA AGAGCACACT CAGGTTGGAG CAGCAAGTAA AGGAGCTGAA  
5451 GAAGTCGGT GAGCTGAAG AGACTGTAACT CTCGACCCCA TCCAAAGAAG  
5501 TGTGGGAGCC AATCGTGTTT AAGGAGAAAC TAACAATGAA AACGGACTCG  
5551 TTGATGGAGG AAAAGTTGGA ATGCAGCTC TGGTGCTGTT TGAGCAATCC  
5601 CTCTATCCCG GGTGCTGTCT GTGTTCTGGA AAGGGCATTT GTACCTTGA  
5651 TGCAGCAGGA ATCTATTTCA TCTTCTTAC CGATATGATGTC TGTGACTCT  
5701 GATGAGCCAA ATCTGACATC AGTTCTGGAA CGTCTAGAAG ATACTAAGGA  
5751 GAACAGTTG CCCCTTTCA ACTGCCCCC CCCCACTACC TCCAAAGACAG  
5801 AGATTCTGGA TTCTTGCAAC TGCAGCCCCT CAGAGAGTGT AAGAGGGGCA  
5851 GAAAAAGGAG ATCAGGAGCT GCTAGCGAAT ATAAAGCAGG CAGAAAAACA

5901 TGAANAAGAAC CACCGGAGG TGAAGTGGC CATGGCTCTG ACTGACATAG  
5951 ACTTGAGCT GCAGTTCTCC ATGTCCCAAC CCGAAGCCCT CCTTCTCCTG  
6001 GCAGCAGGCC CAGCTGACCA CCTCTGCTG CAGCTCTACT CTGGACACCT  
6051 GCAGGTTCAGS CTTGTCTGG GCCAGGAGGA GCTGAGGCTG CAGACCCAG  
6101 CAGAAATTCT ACTGAGTAC TCCGTCCCC ACACCACAGT TCTGACTGTC  
6151 TCAGAGGACT GGGCCACATT GTCAAGTCAAT GGGTTTCTGA ATGCCTCTTC  
6201 TGTAGTCTG GAGCCCCC TAGAAGTCCC CTATGGCTC TTTGTTGGGA  
6251 GCACTGGGAG ACTTGGCCTG CCTACCTGA GGGGAACCCAG CCATCCCCCTG  
6301 AGGGGTTGCC TCCATGACG CGCTCTCAAT GGCCGCAGAC TCTTCAGCC  
6351 TCTGACCCCC AATAAGCATG AGGCTGTGC TGAAGAGTTT TCTGCCAATG  
6401 ACGATGTGC CCTGGGCTTC TCTGGGTCCC ACTCTCTGGC TGCCTTGCCT  
6451 GCCTGGGGCA CTCAGGATGA AGGAACCCCTG GAGTTTACAC TCACCACACA  
6501 GAGCTGGCAG GCACCCCTGG CTTCCAGGC AGCAGGCTGG CATGGGACT  
6551 TCATCCATGT GGCATATATT GAGGGCCACC TGTGGTCCAT GGTGAGAG  
6601 GGCCAGGGTA CTGTATTGT CCTCAACAGT GTGCTGTGTA CTGACGACA  
6651 GCCCCACAAG GTCAGCATCC ACATCAACAT TCACCAGCTA GAAATCTCCA  
6701 TGGACACAGTA CCCACACGA ACTGAGGAGT CTTGAGCTAC CTGGAGCCAC  
6751 GAACACCGCT CAGGCTTGAC ACCAGGGGCT GCCAATGCTT CCTGTGTTGG  
6801 CTGGCTGCAT GGAAGACCTC AGTGTCAATG GCTAGAGGCA GGGGCTGTGG  
6851 GAAGCCTTGC TGACGACAA CATGTTGGCT GGCTGCAGAC TGGAGGAGCT  
6901 GCTATCAGCG CAGTGTGTGT GACCGAGGCT GGACACAGCTT GGTGTGAGTG  
6951 GTGGCATGTG CAGCCCATGC TGGCACTGAT GGAGGCTGAA CTGCGTAAAT  
7001 CCCAGSCCG CTTATCCAC GATGGCCCTG AGGACACCTC TGACCAGCTG  
7051 GTGCTGGAGG TGTCAAGTAT GGTGTGGTTG CCAATGCTT CATGCTTGG  
7101 GAGGGGCCAA ACAGACCTCC TGCCCATCCA GGTCAACCTT GTCAATGACC  
7151 CACCCACAT CATCTTCCA CATGGCAGCC TTATGGTGAT CTTGGAAACAC  
7201 ACACAGAAGC CTCTGGGGCC TGAGGTTCTC CAGGCCCTATG ACTGGACTC  
7251 TGCCCTGTGAG GGCCTGCTT TCCAGCTCCT TGGCACCCCC TCTGGGCTCC  
7301 CCGTGGATCA CCGAGACCAG CTTGGGAGC CGGTGACTGA GTTCTCTGC  
7351 TGGGAGTTGG AGGCCGGCAG CTTAGTCTAT GTCCACTGTG GTGGCCCTAC  
7401 ACAGGACTTG ACATTCGCGG TCAGCAATGG ACTGCAGGCC AGCCCCCGG  
7451 CCAATGTGAA GGTGTGGCT GTCCAGCTGG CCATACAAAT CCACCCGAGC  
7501 ACAGGGCTGC ATCTGGCCCA GGGCTCTGCC ATGCCCATCT TGCCTACCAA  
7551 CCTGTTGGTG GAGACAGCG CCGTGGGCA GGATGTGACC GTGCTGTCTC  
7601 ATGTACCCG AGGCTTGGG TTCAGGGAGC TGCAGAGCA GGGGGCTGGT  
7651 GGGGTGGAGG ATGCTGAGTG GTGGGTCA CAAGCGTTCC ACCAGCAGGA



7701 TGTGGAGCAG GSCCAGCTGA GGTACCGCAG CACTGACCCA CAGCACTACA  
7751 CCGAGACAC CCGTGAGAAC CTGGATCTGC AGGTGCAGGT GAGCTGGGAA  
7801 ATCCTGAGCA ATCTGTCTTT CCTAGTGACC ATCCAGAGAG CCACCTGTGTG  
7851 GATGCTGCAG CTGGAGCCAC TGCACACTCA GAACACCCAG CAGGAGGCC  
7901 TCACCACAGC CCACCTGGAG GCCACCTGG AGGAGGCAGG CCCAAGCCCC  
7951 CCAACCTTCC ACTGTGAGGT GGTTCAGGCT CCCAGGAAAG GCAACTTTCA  
8001 ACTACAGGCG AGGATGCTGT CAGAGGTCA GGGCTTCACC CAGGATGAGG  
8051 TACAGGCTGC AGAGGTGACC TATGGGGCCA TGGCACGTGC CTCAGTGCCA  
8101 GTGGAGGACA CTTCTGTGTT CCATGTTCACA GCTCCACCAT ATTTCTCCCC  
8151 ACTCTGTACC TTCTCCATCC ATATTGGGG TGACCCAGAC ATGCTGTGCC  
8201 TCACCAATGT CTTCTGTGGT CCCAGGGGTG GTGGGTGTGT CCTCTCTGCT  
8251 GACCACTCT TCGTCAAGAG CCTCAACAGT GCCAGGTGGC AGCTGCTGAC  
8301 TACAGACAC ATGGCTTCA GCAATGCTGA TTGGGGCTTT GGTGATGCC  
8351 AGCTGTGTCT GACCCACAAG GACCTCTCT CTGGCAGTAT CATGGCCACG  
8401 GATGAGCCA TGCAGCCCAT CTGCTGCTTC ATCCAGGAGG GGCCTCAGGA  
8451 AGAGGGAGT CCGTTTCAG CACTCAGGCT GACTACAGCT GGATCCTGCT  
8501 GCAGGCAGCA CCAGGCCATC ATGTGTCTGG AGGTGCAGGC CTTGGAGCCT  
8551 TACCTCTGTG TGGCCAAGG CTCAGGCTC ATGTTCCCTC AAGGAGACCA  
8601 GGGTACCATC AACATGGCG AGTCCACCT TGGCACCAC CTGACATCC  
8651 GCAGCGGGA TGAGTCCAC TACCACCTC AGTCCCGCA ACACCTGGC  
8701 CTTCTCAATG GATGTGGGC CTTCTCAATG GATGTGGGC CAGTGCACAC  
8751 AGATGCCACC CTACAGTGA CCATGGCCT AGAGGCCCA CTAGCCCCAC  
8801 TGAAGCTGCG CTGGCACAA GAAATCTACA TCTTCCAGG AGAGCAGCT  
8851 GAGATCAGAA GAGACCAGT GGAGGTGAGG AGCTGGGGT GTGATATTT  
8901 CATCAGGCTG GTGTCTACAG CTGCTGCGTA CCTCAGTTG CTGGGAGCCT  
8951 TCATCAAGAA TGCCGAGGAA TGA

!!AA SEQUENCE 1.0  
ID \_ADP31148 standard; protein; 3390 AA.

XX AC

XX ADP31148;

XX XX

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1915.

XX Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX EN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

29-AUG-2002; 2002US-0406579P.  
29-AUG-2002; 2002US-0406585P.  
29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
02-MAY-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-04637199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
19-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PA

XX

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3146; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 3390 AA;  
ADP31148 Length: 3390 February 22, 2005 12:25 Type: P Check: 173 ..  
1 ATGGTAAAGG GATCAATCCA ACAAGAGGAG CTAACATATCC TAAATATTTA  
51 TGCACCCCAAT ACAGGAGCAC CCAGATTTCAT AAGCAAAGTC CTGAGTGACC  
101 TACAAAGAGA CTTAGACTCC CACACATTA TAAATGGAGA CTTTAACACC  
151 CCACCTGTCAA CATTAGACAG ATCAACGAGA CAGAAAGTCA ACAAGGATAC  
201 CCAGGAATTG AACTCAGCTG TGCACCAAGC GGACCTAATA GACATCTACA  
251 GAACCTCTCCA CCCCAATCA ACAGAAATTA CATTTTTTTC AGCACACAC  
301 CACACCTATT CCAAATTTGA CCACATAGTT GGAAGTAAAG CTCTCCTCAG  
351 CAAATGTAAA AGAACAGAAA TTATAACAAA CTATCTCTCA GACCACAGTG  
401 CATCAAACT AGACTCAGG ATTAGAATC TCACTCAAG CGCTCAACT  
451 ACATGGAAAC TGAACAACCT GCTCCTGAAT GACTACTGGG TACATAACGA  
501 AATGAAGGCA GAAATAAGA TGTCTTTGA ACCCAACGAG AACAAAGACA  
551 CCACACACCA GAATCTCTGG GACGATTTCA AGCAGTGTG TAGAGGGAAA  
601 TTTATAGCAC TAAATGCTTA CAAGAGAAAG CAGGAAAGAT CCAAAATTGA  
651 CACCCTAACA TCACAATTAA AAGAACTAGA AAGCAAAGAG CAAACATATT  
701 CAAAAGCTAG CAGAAGGCAA GAATAACTA AATCAGAGC AGNACTGAAG  
751 GAAATAGAGA CACAAAAAC CTTTCAAAA ATCAATGAAT CCAGGAGCTG  
801 GTTTTTTTGAA AGGATCAACA AATTTGATAG ACCGCTAGCA AGACTAATAA  
851 AGAAAAAAG AGAAGAAGAT CAATAGACA CAATAAAAA TGATAAAGGG  
901 GATATCACCA CCGATCCCAC AGAATACAA ACTACCATCA GGAATPACTA  
951 CAAACACCTC TAGGCAATAA AACTAGAAA TCTAGAGAA ATGGATACAT  
1001 TCCTCGNAC ATACTCTCTC CCAAGACTTA ACCGGAAGA AGTTGACCT  
1051 CTGAATAGAC CAATACAGG CTCTGAAATT GTGGCAATA TCAATAGTTT  
1101 ACCAACCAA MAGAGTCCAG GACCAGATGG ATTACAGACC GAATCTACC  
1151 AGAGGTACAA GGAGGACTGT GTACCAITCC TTCTGAACT ATTCCNATCA  
1201 ATAGAAAAAG AGGGAATCCT CCCTAACTCA TTTTATGAGG CCAGCATCAT  
1251 TCTGATACCA AAGCGGGCA GAGACACAAC CAAAAAGAG AATTTTAGAC

1301 CAATATCCTT GATGAACATT GATGCAAAAA TCCTCAATAA AATACTGGCA  
1351 AACCGAATCC AGCAGCACAT CAAAAAGCTT ATCCACCATG ATCAAGTGGG  
1401 CTTTCATCCCT GGGATGCAAG GCTGGTTCAA TATACGAAA TCAATAAATG  
1451 TAATCCAGCA TATAACAGA GCCAAAGACA AAAACCCACAT GATTATCTCA  
1501 ATAGATGCGAG AAAAGCCTT TGACAAAATT CAACAACCCCT TCATGCTAAA  
1551 AACTCTCAAT AAATTAGGTA TTGATGGGAC GTATTTTCAA ATAATAAGAG  
1601 CTATCTATGA CAAACCCACA GCCAATATCA TACTGAATGG GCAAAAACATG  
1651 GAAGCATTCCT CTTTGAANAAC TGGCACAAGA CAGGGATGCC CTCTCTCACC  
1701 GCTCCTATTTC AACATAGTGT TGGAAATTTCT GGCCAGGGCA ATCAGGCAGG  
1751 AGAAGGAAAT AAAGGTATT CAATTAGGAA AAGAGGAAGT CAAATTGTCC  
1801 CTGTTTGGAG AGGACATGAT TGTTTATCTA GAAAAACCCCA TCGTCTCAGC  
1851 CCAAAATCTC CTTAAGCTGA TAAGCAACTT CAGCAAAAGTC TCAGGATACA  
1901 AAATCAATGT ACAAAAATCA CAAGCATTTCT TATACACCAA CAACAGACAA  
1951 ACNAGAGCC AGATCATGAG TGAACCTCCA TTCACAATTG CTTCAAGAG  
2001 AATAAAATAC CTAGGAATCC AACTTACAAG GGATGTGAAG GACCTCTTCA  
2051 AGGAGAACTA CAACCACTG CTCAATGAAA TAAAAGAGGA CACAAAACAA  
2101 TGAAGAACA TTCCATGCTC ATGGGTAGGA AGAATCAATA TCGTGAATAT  
2151 GGCCATACTG CCCAAGGTAA TTTACAGATT CAATGCCATC CCCATCAAGC  
2201 TACCATGAC TTTCTTACA GAATTTGAAA AACTACTTTT AAGTTTCATA  
2251 TGGAAACAAA AAAGAGCCCG CATGCCAAG TCAATCCTAA GCCAAAAGAA  
2301 CAAAGCTGA GGATCATCAC TACCTGACTT CAAACTATAT TACAAGGCTA  
2351 CAGTRACCAA AACAGCATGG TACTGGTACC AAAACAGAGA TATAGATCAA  
2401 TGAACAGAA CAGAGCCCTC AGAATAATG CCGCATATCT ACACTATCT  
2451 GATCTTTGAC AAACCTGAGA AAAACAAGCA ATGGGGAAAG GATTCCTAT  
2501 TTAATAAATG GTGCTGCGAA AACTGGCTAG CCATATGTAG AAGCTGAAA  
2551 CTGGATCCCT TCCTTACACC TTATACAAA ATCAATTTCAA GATGGATTHA  
2601 AGATTTAAAC GTTAGACCTA AAACCATAAA AACCTTAGAA GAAAACCTAG  
2651 GCATTACCAT TCAGGACATA GGCGTGGGCA AGGACTTCAT GTCCAAAACA  
2701 CCAAAAGCAA TGGCAACAAA AGCCAAAATT GACAAATGGG ATCTAATTHA  
2751 ACTAAAGAGC TTCTGCACAG CAAAAGAAAC TACCATCAGA GTGAACAGGC  
2801 AACCTACAAA ATGGGAGAAA ATTTTCGCAA CCTACTCATC TGACAAAGGG  
2851 CTAATATCCA GAATCTACA TGAATCAAA CAAATTTACA AGAAAAAAC  
2901 AAACRACCCC ATCAAAAAGT GGGCGAAGGA CATGAACAGA CACTTCTCAA  
2951 AAGAAGACAT TTATCAGCC AAAAAACACA TGAANAATG CTCATCATCA  
3001 CTGGGCATCA GAGAAATGCA AATCAAAACC ACTATGAGAT ATCATCTCAC  
3051 ACCAGTTAGA ATGGCAATCA TTAATAAAGTC AGGAAACAAAC AGGAAAGAT

3101 ATAAAGCTGG CAGAAATAAG ATACATTATA AACAGGGTCC ACTGATATAAA  
3151 CTGCTTTCCA AAGAAATGAA GCTTCTTTAAT CTGGGAAGC TCCAGCTGTG  
3201 GCTCTCCAGG GTTCTCTGCT TAAGCTCTCT GCAGCTGCTC CTCTCAGTAT  
3251 TGAATGGCTC CAGTCAGCAG TTGAGCTCAG CAATTATAGC CTCCTACAAAC  
3301 TGCTCCCCAG AGTCTCCCAT TTTCCCCATT GCTTCTACAT GCTCAAAACA  
3351 CCTCCAAGCC ATCTCCAGCT CCGAGGAGCT GTACATTGTA

!!AA\_SEQUENCE 1.0  
ID ADP31202 standard; protein; 1116 AA.

ADP31202;

12-AUG-2004 (first entry)

Human secreted protein SEQ ID #1969.

Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

OS WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406589P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410945P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
08-JUL-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Heatir K, Beaurang PA, Bahrens D;

XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 3200; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX SQ Sequence 1116 AA;

ADP31202 Length: 1116 February 22, 2005 12:25 Type: P Check: 5275 ..

1 ATGGAGTTCC TGGCAGCTGT GAAGAAGGAG GACTTCACCA GGCTGGCTCT

51 GTGCCCTGCA AGAACCATCT GCTGGAGCCG AGCAGAGGCT GCCTCCTTTG

101 AACGGGACCT GTACCTTCCA CTCCTCTACC GCTGCACCCAC ACCAATCCAT

151 CATCACACTT ATGATGTGTC TTCTCAGAG GTGGGAGAGC TGAGGCCCCAG

201 AGAGGTGAGT GGCATATCCG AGCAGCCCCA GCGCAGGGTG CGAGATTTCTT

251 TAAGCCGGTT TACATCAGGA TTCCTTTTAC TTGACCCCCGA AGACATCCTT

301 AATGATGCCT CTGCTTATTT TGGTCTTTGT GAGCCGTGTC TGCCTGACTG

351 TGCCAGGATA AATGCCAGTG TTATTCCCAT TTTTCAGCTG CGAGCCAGA

401 GCTCAAGAAG TGAAGTGGCT CCATTTGGCA CGGCAGAAGG AGCCGTGGTA

451 AGGCTGATC CTGGGCAGA TGCCAGAGG CCCTTCCTGT TGGCATCTCT  
501 GCAAGCCTC ATGTGTTGTC TGATGGCAAC ATCGTACTGG GAGAGCCCTG  
551 GAGGCTTGA GAGGACCAA GGGACAGTCA AGTGACAAA GGCCTTTCTG  
601 AGGAGGAAGC AGACTCCAAT TACCAGGAC TCTGGGTTCT CCTCTTTTGA  
651 CTTGGACTAT GACTTTCAC GGGATTATGA TAGGATGTAC AGTATCCAG  
701 CAGGTGACC TCCTCTCTCT CTAATGTCG GGGCTGTAGT GGCCTTGAAA  
751 CATCAGGTG TATCAGAAA CACCTCACAA AGGGCAAAA GTGGCTTCAA  
801 TTCTAAGAT GGAAGCGGG GATCTTCAA GTCTGGAAG TTGAAGGAG  
851 ATGACCTTCA GGCAATTAAG CAGGAGTTGA CCAGATATAA ACAAAAAGTG  
901 GATTCCTCC TGGAGACCC GAAAAAATG GAAAAAAGC AGAGCAACAA  
951 AGCAGTAGAG ATGAGAATG GTAAGTCAGA AGAAGCAG AGCAGAGCT  
1001 CACGTGAGAC TCATGTGAAG ATAGAGTCTG AAGGTGGTGC AGATGACTCT  
1051 GCTGAGGAGA GGGACCTACT GGATGATGAG GATAATGAAG ATTGGGGGAT  
1101 GACCAGCTGG AGTTGA

## !!AA\_SEQUENCE 1.0

ID ADP31204 standard; protein; 345 AA.

XX AC ADP31204;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1971.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.  
XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US025780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.

17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471338P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3202; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 345 AA;  
SQ ADP31204 Length: 345 February 22, 2005 12:25 Type: P Check: 5371 ..

1 ATGTCGGCTG CCTAGTCCG GGCAATGTC TGGGCTGTGA GCAAGAGGAA

```

51  ACTTCAGCCC ACCTGGGCGG CCCTCACCCCT GACACCTTCA GCAGTAACA
101 AGATAAACA ACTTCTTAAA GATAAGCCTG AGCATGTAGG TGTAAAAGTT
151 GAATATACAA AGACAAAAGG AGATTCTGGT GAAGTTATTTC AAGATGGAGT
201 CAGAGTATTTC ATTGAAAGA AGCAAAAGCT AACACTTTTA GGAACAGAGA
251 TGGACTATGT TGAAGAAAAA TTATCCAGTG AGTTTGTGTT CAATAACCCA
301 AACATCAAG GAACTTGTGG CTGGGAGAA AGCTTTAATA TTGTA

!!AA_SEQUENCE 1.0
ID  ADP31261 standard; protein; 799 AA.
XX
AC  ADP31261;
XX
DT  12-AUG-2004 (first entry)
XX
DE  Human secreted protein SEQ ID #2028.
XX
KW  Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW  cancer; inflammatory; immune; human secreted protein.
XX
OS  Homo sapiens.
XX
FN  WO2004035732-A2.
XX
PD  29-APR-2004.
XX
PF  28-AUG-2003; 2003WO-US026780.
XX
PR  29-AUG-2002; 2002US-0406576P.
PR  29-AUG-2002; 2002US-0406579P.
PR  29-AUG-2002; 2002US-0406585P.
PR  29-AUG-2002; 2002US-0406588P.
PR  29-AUG-2002; 2002US-0406608P.
PR  29-AUG-2002; 2002US-0406611P.
PR  29-AUG-2002; 2002US-0406612P.
PR  29-AUG-2002; 2002US-0406616P.
PR  29-AUG-2002; 2002US-0406640P.
PR  29-AUG-2002; 2002US-0406642P.
PR  29-AUG-2002; 2002US-0406646P.
PR  29-AUG-2002; 2002US-0406653P.
PR  29-AUG-2002; 2002US-0406655P.
PR  29-AUG-2002; 2002US-0406666P.
PR  17-SEP-2002; 2002US-0410946P.
PR  17-SEP-2002; 2002US-0410947P.
PR  17-SEP-2002; 2002US-0410948P.
PR  17-SEP-2002; 2002US-0410949P.
PR  17-SEP-2002; 2002US-0410953P.
PR  17-SEP-2002; 2002US-0410957P.
PR  17-SEP-2002; 2002US-0410958P.
PR  17-SEP-2002; 2002US-0410959P.
PR  17-SEP-2002; 2002US-0410960P.
PR  17-SEP-2002; 2002US-0410961P.
PR  17-SEP-2002; 2002US-0410962P.
PR  17-SEP-2002; 2002US-0411019P.
PR  17-SEP-2002; 2002US-0411022P.
PR  17-SEP-2002; 2002US-0411023P.
PR  17-SEP-2002; 2002US-0411024P.
PR  17-SEP-2002; 2002US-0411032P.
PR  17-SEP-2002; 2002US-0411035P.
PR  17-SEP-2002; 2002US-0411037P.
PR  17-SEP-2002; 2002US-0411041P.
PR  17-SEP-2002; 2002US-0411045P.
PR  17-SEP-2002; 2002US-0411048P.
PR  17-SEP-2002; 2002US-0411052P.
PR  17-SEP-2002; 2002US-0411055P.
PR  17-SEP-2002; 2002US-0411073P.
PR  17-SEP-2002; 2002US-0411082P.
PR  17-SEP-2002; 2002US-0411101P.

17-SEP-2002; 2002US-0411111P.
18-APR-2003; 2003US-0463700P.
18-APR-2003; 2003US-0463708P.
18-APR-2003; 2003US-0463716P.
18-APR-2003; 2003US-0463732P.
02-MAY-2003; 2003US-0467139P.
02-MAY-2003; 2003US-0467201P.
02-MAY-2003; 2003US-0467203P.
02-MAY-2003; 2003US-0467230P.
19-MAY-2003; 2003US-0471336P.
22-MAY-2003; 2003US-0472420P.
22-MAY-2003; 2003US-0472430P.
09-JUN-2003; 2003US-0476609P.
08-JUL-2003; 2003US-0485218P.
08-JUL-2003; 2003US-0485223P.
08-JUL-2003; 2003US-0485224P.
08-JUL-2003; 2003US-0485325P.
14-JUL-2003; 2003US-0486446P.
14-JUL-2003; 2003US-0486480P.
15-JUL-2003; 2003US-0486891P.
15-JUL-2003; 2003US-0486960P.
08-AUG-2003; 2003US-0493341P.
08-AUG-2003; 2003US-0493370P.
08-AUG-2003; 2003US-0493573P.
08-AUG-2003; 2003US-0493577P.
(FIVE-) FIVE PRIME THERAPEUTICS INC.
Williams LT, Chu K, Lee E, Heetir K, Beurang PA, Behrens D;
Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
WPI; 2004-348438/32.
New nucleic acid molecule for diagnosing, preventing or treating diseases
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
genetic, bacterial and viral diseases.
Claim 1; SEQ ID NO 3259; 428pp; English.
The present invention relates to an isolated nucleic acid molecule
encoding a polypeptide which is believed to be cytostatic,
antiinflammatory, immunosuppressive, antibacterial and virucidal. The
composition and methods are useful for diagnosing, preventing and
treating diseases such as proliferative (e.g. cancer), inflammatory,
immune, metabolic, genetic, bacterial and viral diseases. The present
sequence represents a human secreted protein. The present sequence is
available on WIPOWEB and is not in the specification.
Sequence 799 AA;
ADP31261 Length: 799 February 22, 2005 12:25 Type: P Check: 2841 ..
1  CAGCTTTGGC CAAGACCGTG ACTTCAGTAA AGGGAACCCG GGGCTCTCGC
51  AGCCAGCCCT CCGGCCCATG GAGGACAGTT TCCTTCAATC TTTTGGGAGG
101 CTGAGCCTCC AGCCCCAGCA GCAGCAGCAG CGGCAGCGGC CGCCCCGGCC
151 GCCCCCCGGG GGGACACCTC CTCGCCGCA CAGCTTTAGG AACACCTCT
201 ACCTCTCTGG AGGCTTCCCG GCGTCCGGGA AACCTACACT GGCAGACAA
251 TTGAGCATG ACTTTCCAG GGCCTTGATT TTCAGCAGG ATGATTTTTT
301 CTTCAGGAA GATGGTGCCT ATGAGTTCAA TCCTGACTTC CTGAGGGAAG
351 CTCATGAATG GAACCAAAA AGAGCAAGAA AAGCAATGAG GAATGGGATA
401 TCCCCCAATTA TTATTGATTA TACCAACCTC CACGCTGGG AAATGAAGCC
```

451 CTATGCAGTC ATGGCACTTG AAATAACTA TGRAAGTTATA TTCCGAGAAC  
501 CTGACACTCG CTGGAATTC AACGTTCAAG AGTTAGCAAG AGAAACATT  
551 CATGGTGCTT CAAGAGAAA AATCCACCGA ATGAAGAAGC GGTATGAACA  
601 CGATGTTACT TTTCACAGTG TGCTTCATGC AGAAAGCCCA AGCAGAATGA  
651 ACAGAAACCA GNCAGGAAT AATGCAITGC CTTCCAACAA TGCCAGATAC  
701 TGGAAITCCT ACACAGAGTT TCCAACCGG AGGCCCCACG GTGGAITTC  
751 AAATGAGAGC TCCTATACA GAAGGGCGG TTGTCAACAT GGATATTAG

!!AA-SEQUENCE 1.0  
ID\_ADP31290 standard; protein; 1470 AA.

AC ADP31290;  
DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2057.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

OS WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.

17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471366P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3288; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 1470 AA;

ADP31290 Length: 1470 February 22, 2005 12:25 Type: P Check: 1374 ..

1 ATGGCGGCTC AGAGCCAC CCAGGCCGA GCCAGGCTGA AGGAATCCAT  
51 GCTGGCGCA CGGATCCAGC ACGGAAGTG TCGCGAGAAA CGCTCTGCAG  
101 AGCCTGAGCG GGGAGCTTC CAGAGTGGG GAGCCTTGAC TTCCTCCCTG  
151 TTTTACTGGC CCAAGTCCAT TGATAATGGT ATCAGTGTCC ACCGCTCTTG  
201 GGTGCTACA ATGCGCTGGA TCCTCAATAT TCATGGTCCT CGAGCCACAC  
251 AGCAATGCTG CAAGCATTA CGCATTACAC AACTGCTGC TGGTTCTCAG  
301 AGAAATAGCC ACGTGAACGG GAAGGAAGAA AGTGTGTCCA CGGGCTGCGG  
351 AATCGGTTGC CGACCTGCG GCAGGGGGG AGATGGGGG GCCTCCCTCC

401 CGGGCGACGA CGACGACGAC GACGAGGAGC AGCGCGCGCC GCGCGCGCGC  
451 ACCGCGCGCC GCTGGGCACG GCGCGGGGGA AGCGCGCTCC CCGTGAGCGG  
501 GGGGCGCGAG GCGGCTTGGC CGCCCCGGGC CGCCCCGGCC GCGCGGGGCC  
551 CCGCGGGGCG CCGCGGGGCG CCGCGCGGCC GCGCGCTGAC GGGAGCCTTG  
601 CCGCGCGCGG GTCCCGCGCC CCGCGCGCGC GCGCGCGCGG CCGCGGGCGC  
651 CCGCGCGCGC TCGCGCGGAC CCGCGCGCGG CCGCGCGGTC CCGGTCCTCG  
701 GCGCGCGCGC GCGCGGGGCC CCGCGCGGCC CCGCGCGGCC CCGCGGGGTC  
751 CCGCGCGCGC GGTGCGGGCG CCGCGCGGGC GGCAGCATGG TGGAGAAGCG  
801 CTGCCCGCTG CAGAGGGAGC GCGGTATCCG CTGTTTCTCG GAGCTGCCGT  
851 GCGCGCAGCG CGTGAGTTC CTGTGGGCGC TGCTGGACCT GTGCATCCGG  
901 CTGAGCTTTC GCTTCTCGG CTCGTGCTG GAGGACCTGG CCGCAAGGA  
951 CTACCACTCG CTGCGCGACT CGGAGATCAA GGCACAAC CCGCGCGACC  
1001 TGGGAGCCTT CACCAACTG ACGACAGAG TGGTGGCGAG CAAGCTGCTG  
1051 GTGTGCTGCG CGCTGCTGG CTCGGAGCAG CCGGAGGCGG CGGGCGTGT  
1101 CTACGCGCAG CTCACGCACA TCGACTCCAT CATCCACAAC TACGGGCTGC  
1151 AGCTTAAAGA GGGCGCGCAG GCGATGAGT TCCTGTGTCT GTTCAACATG  
1201 GCCTCAACC ACCCGGCTT CAGCTTCCAC CAGAAGCAGG TGCTGGGCA  
1251 GGAGCTCAGC CAGATCCAGA GCACCTGAA CGCGGGCGG GCGCAGGCG  
1301 GCAAGGGCGC GCGCGGGCGG GCGGGGCGG TGCCCCACTTG CCCAGCCTGC  
1351 CACAAGGTGC GTGCCCGGCC CGAGCTGTGC CTGTATACCC AGTCTGCAT  
1401 CCCCACTCT GCACCTCAAG CTTCCAGCCT GCACCGCGAC CCCCCAGCC  
1451 AGCCTCCAG CTTGCACCTGA  
!!AA SEQUENCE 1.0  
ID ADP31294 standard; protein; 903 AA.  
XX  
AC ADP31294;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2061.  
XX  
KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; Immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406609P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.

29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3292; 428pp; English.  
PS





XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3314; 428pp; English.  
PS The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 453 AA;  
SQ

ADP31316 Length: 453 February 22, 2005 12:25 Type: P Check: 9046 ..  
1 CCCTCCCTC AGCTCCGCC AAGCTGCTCG GTCCTTCCGA GGAAGCTAAG  
51 GCGCGTTGG GGTAAAGGCC TCACCTCATC CTGGGACTAG CACCGCGTCC  
101 GGCAGCGCAT GGCCTCCGTC TCCAAGCTCG CCTGCATCTA CTCGGCCCTC  
151 ATTCTGCACG ACGATGAGGT GACAGTCACG GAGGATAAGA TCAATGCCCT  
201 CATTAAAGCA GCCGTGTAA ATGTTGAACC TTTTGGCCT GCGTTGTTTG  
251 CAAAGGCCCT GGCCTCCGTC AACATTGGGA GCCTCATCTG CAATGTAGGG  
301 GCTGTGGGAC CTGCTCCAGC AGCTGTGCT GCACCAAGCAG GAGTCCTGCG  
351 CCCTCCACT GCTGTGCTC CAGCTGAGGA GAAGAAAGTG GAAGCAAGA  
401 AAGAAGAATC CAAGGAGTCT GATGATGACA TGGGCTTGG TCTTTTTCAG  
451 TAA

IIAA\_SEQUENCE 1.0  
ID ADP31321 standard; protein; 270 AA.  
XX  
AC ADP31321;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2088.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-040585P.  
XX 29-AUG-2002; 2002US-040658P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.

29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411010P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
22-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 3319; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule

CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 270 AA;  
ADP31321 Length: 270 February 22, 2005 12:25 Type: P Check: 9096 ..  
1 ATGTGAGCCG CGTGGCAGC CATGTGCCC GCCACCTGGA AGGCCACCGC  
51 GCGGTGATT TTCTTCATG GATTGGGAGA TACTGGGCAC CGATGGATAG  
101 AAGCCTTTGC AGATTCACAG GAGSACGAAC CTGGGATTAA ACAGGCAGCA  
151 GAAATATATAA AAGCTTTGAT CGATCAAGAA GTGAAGAATG GCATTCCTTC  
201 TAACCGAATT ATTGTAGGAG GATTTTCTCA GGGAGGAGCT TTATCTTTAT  
251 ATACTGCCCT TACCACGTAG  
!AA SEQUENCE 1.0  
ID\_ADP31403 standard; protein; 437 AA.  
XX AC ADP31403;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2170.  
XX CYTOSTATIC; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410346P.  
PR 17-SEP-2002; 2002US-0410347P.  
PR 17-SEP-2002; 2002US-0410348P.  
PR 17-SEP-2002; 2002US-0410349P.  
PR 17-SEP-2002; 2002US-0410353P.  
PR 17-SEP-2002; 2002US-0410357P.  
PR 17-SEP-2002; 2002US-0410358P.  
PR 17-SEP-2002; 2002US-0410359P.  
PR 17-SEP-2002; 2002US-0410361P.  
PR 17-SEP-2002; 2002US-0410362P.  
PR 17-SEP-2002; 2002US-0410362P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.

PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411011P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3401; 428pp; English.  
PS The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 437 AA;  
ADP31403 Length: 437 February 22, 2005 12:25 Type: P Check: 4344 ..  
1 GTGCATGTGG AAGAGAAGA AGGAGAAAA ACAGAGATG AATCTGTGT  
51 AGAAATAAT GATAGCATAG ATGAGAACAG TACCTGGAG CCTAGACCA  
101 TCTCCTTGCA GAGACCCACT ACCAGCTGGG CTGGCTTAT GGTACAAC

151 TTCAGTATGA TGAGGAGTG GCACAGTTCA GCAATCTAT TGAAGTCATT  
201 GAGAAGAGAA TGGCTGTACT AAACGAGCAG GTGAAGGAGG CTGAAGGATC  
251 GTCTGCTGAA TACAAGAAAG AAATTGAGGA ACTGAAGGAA CTGCTACCGG  
301 AAATTACAGA AAAGACAGAA GATCAAGG AGTCTCAGAC TACTGGGAAT  
351 GTAGCTGAAC TGGCTCTGAA AGCTACTCTG GTGGAGAGCT CTACTTCAGG  
401 TTTCACTCTCT AGTGGAGGAG GCTCTTCAGT CTCCTGA

!!AA\_SEQUENCE 1.0  
ID ADP31448 standard; protein; 432 AA.

XX AC

XX DT

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2215.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

XX cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0405858P.

XX PR 29-AUG-2002; 2002US-0405888P.

XX PR 29-AUG-2002; 2002US-0406088P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

XX Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;

XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 3446; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.

XX SQ Sequence 432 AA;

ADP31448 Length: 432 February 22, 2005 12:25 Type: P Check: 5912 ..

1 ATGAGGGCGG CACTCCAGCA TCCATCAGC CGCGGGCAC CCCGTCTTCG

51 GAGCACTCCA GAATCCATGC AGAGCGCAGC ACCCCACATC CAGAGCGCTC

101 CAGAATCCAT GAAGCAGCG GCACCCCTTC GTGAGAGTGC TCCAGAAATCC

151 ATGAAGTGGC CAGCACCCCT TAATCGGAGC GCTCTAGAAC CCGTGCAGCG

201 AGCAGCACCC CACACCCGGA GCGCTCCAGA ATCCATGAAG CCAGCAGCAC

251 CCCACACCCG GAGTGTCTCA GAATCCACGC AGCAGCTGGC ATCTCTCTGT

301 CATAGCGTTC TAGAATCCAT GCAGCGAGCA GTACCCACCA CCGGGAGCGC

351 TCCAGAAATCC AGCAGCGTC TGGCACATCT TTATCAGAGC GCTCCAGAGT

401 CCATGCAGCC ACAGTCTCTCC AACGGACCCT GA

!!AA\_SEQUENCE 1.0  
ID\_ADP31470 standard; protein; 960 AA.  
XX ADP31470;  
AC  
XX  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2237.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
PN  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
PF  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR

22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486466P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3468; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 960 AA;

ADP31470 Length: 960 February 22, 2005 12:25 Type: P Check: 6977 ..

1 ATGAGTGAAC TCACATTCCAC AATTACTTCA AAGAAATAA AATATCTAGG  
51 AATCCAACTT ACAAGGGATG TGAAGGACCT CTTCAAGGAG AACTACAAAT  
101 CACTGTCTAA TGAATAAAT GAGGATACAA ACAATGGAA GAACATTCCA  
151 TGCTCATGGA TAAGAAGAAT CAATATCGTG AAAATGCCA TACTGCCCAA  
201 GGTAATTGAC AGACTCAATG CCATCTCCCC CATCAAGCTA CCANYGACTT  
251 TCTTCACAGA ATTGGAAAAA ACTACTTTAA AGTTCATATG GAACCAAAAA  
301 AGAGCCCA CA TTGCCAAGTC AATCCTAAGC CAAAGAACA AGCTGGAGS  
351 CATCACACTA CCGTACCTCA AACTATCCTA CAAGGCTGCA GTCACCAAAA  
401 CAGCATGGTA CTGTGTACCA AACAGAGATA TAGACCAATG GAACAGAACA  
451 GAGCCCTCAG AAATAATGCC GCATATCTAC AGCTATCTGA TCTTTGACAA  
501 ACCTGACAAA AACAAGCAAT GGGGAAGGA TTCCTTATTT AATAATGGT  
551 GCTGGGAAA CTGGGTAGCC ATATGTAGAA AGCTGAACT GGATCCCTTC  
601 CTTACACTTT ATACAAAAT TAATTCAGA TGGATTAAAG ACTTAAATGT  
651 TAGACCTAAA ACCGTAAAAA CCTAGAGA AAACCTAGGC AATACCATTTC  
701 AGGACACAGG CATGGGCAAG GACTTTCATGT CTAAACACC AAAACAATG

751 GCACAAAAG CCAAACTGA TAAAGGGAT CTAATTAAAC TAAAGAGCTT  
801 CTGCACAGCA AAGAAGACTA TCATCAGAAAT GAACAGAAAA CCTACAGAAAT  
851 GGGAGAAAAT GTTTCGAATC TACTCACTCG ACAAGGGCT AATACTAGA  
901 ATCTACAAAG AACTCAAACA AATTACAAAG AAAAAACAA CCCCATCAAC  
951 AAGTGGGTGA

!!AA SEQUENCE 1.0  
ID ADP31559 standard; protein; 755 AA.  
XX AC  
XX ADP31559;  
DT 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #2326.  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
PN  
XX

29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
PF  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406648P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410945P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.

18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467206P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3557; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 755 AA;

ADP31559 Length: 755 February 22, 2005 12:25 Type: P Check: 9950 ..

1 GTGATCTGA GTGCCTTCCT GTTCCGGTG ACTGTGCTCT TGTGCCACAT  
51 CCTGTACTG TACGTGGGG TCTGTGCTGT GCTGCACGCC TGGCGCTTGC  
101 CCCCTGCACC GCCATCTCA GGGCCGGGCG CCAGTCTGCA TTCGTCCCT  
151 GGCTGTGTC TGGCGCAGCA CTTCTACCG TACTGCGTGC TGCCACTCAC  
201 CTTGGCAAG TACTTCGCAT CCTGTGCACT GCACGTCAGC TTCTGGAAGG  
251 TGCCCATGTC CTATGCACAC ACCATTAAGG CCACCATGCC CATTGGGTG  
301 GTCCTCTGT CCCAGATCAT TATAAGAAG CAGAGCAACA AGGTGTACTT  
351 GTCACATATC CCCATCATCA GGGCGTCTCT GATGCCACG GTCACCAAGT  
401 TGTCTTTGA CATGTGGGA GGGCCGACG CTGTGCTTCT TGTTCAGAA  
451 CATTTCTCC AAAAAGATCT TGAGAGATTT GCGGATCCAC CATCTCCGCG

501 TGCTACACAT CTTGGGCTGC CACGCTGTTT TTTTATGATC CCACCTGGG  
551 TTCTGGTGGG CCTCTCAGT TTTCTGAATG TCATTGCTT CAGCATCTTC  
601 AACCTCGTCA GTCTCTGAG TATTTCAGTT GTCAATGCCA CCAAGAGAAT  
651 CATGGTCATC ACAGTGTCCC TGATCATGCT GCCCAACCCA GTCAACGACA  
701 CCAATGTCCT GGGCATAATG ACTGCCATCC TCGGGGTCTT CCTCTACAAG  
751 ACCAA

!IAA SEQUENCE 1.0  
ID\_ADP31569 standard; protein; 828 AA.

XX ADP31569;  
XX AC  
XX DT 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #2336.

DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.  
XX OS  
XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406555P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411041P.

XX PR 17-SEP-2002; 2002US-0411045P.

XX PR 17-SEP-2002; 2002US-0411046P.

XX PR 17-SEP-2002; 2002US-0411048P.

XX PR 17-SEP-2002; 2002US-0411052P.

XX PR 17-SEP-2002; 2002US-0411055P.

XX PR 17-SEP-2002; 2002US-0411073P.

XX PR 17-SEP-2002; 2002US-0411082P.

XX PR 17-SEP-2002; 2002US-0411101P.

17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463718P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471308P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases

such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3567; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPOWEB and is not in the specification.

Sequence 828 AA;

ADP31569 Length: 828 February 22, 2005 12:25 Type: P Check: 8440 ..

1 ATGGTGGGTG CCAAGGCCGG CCCACGCCCC GGCACCTCCC TGGGCGCTGGC

51 ACAGCAGCAC AGCGGAGGCA GCAGTGTCTT AGTGAAAAGT CCCTTCTGTC

101 AGGTGGCCCT CTCTCACCGC ATCCACTTGC AGCCGCCTGT TCTACATCCT

151 CCTCCATGTG GGGGCTCTCAG CAATCTGCTG CCTCCTGCTG TCAAGGACAG

201 TAGTGGAAAG GGTGTGGGGC AAGACACACA GGTGCTCAGT GGCTTGGGG

251 CTGTGTACCG AGTATGTGCA GGAACCGCCA CTTTCCACCT GCTGCAGGT

301 GTGTTGCTG3 TCCACCTCCA CTCCCCCACC AGCCCGCGGG CACAGTGCA

351 TTATAGCTTC TGGTCTCTCA AGCTGCTGTT CTGTGTAGGT CTCTGTGCTA

401 TTGCTTCTG3 CATTCCTGAT GAGCATCTCT TCCAGCATG GCATTACATT

451 GGCATCTGTG GAGGCTTTGG ATTCACTCTTA CTCAGTTGG TGCATTATTAC  
501 AGCTTTTGGC CATTCCTGGA ACAAGAACTG CAATGAGGCC TCCTACCTGG  
551 CTGAGGTATT TGGACCCCTG TGGATTGTCA AGGTTTACAG CTATGAGTTT  
601 CAGAAGCCCT CACTGTGTTT CTGCTGCCCT GAAACAGTGG AGGCAGACAA  
651 AGGGCAAAGG GGTGGGGCTG CGAGGCCAGC TGACCAAGAA ACCCTCCAG  
701 CTCCTCCAGT CCAAGTCCAG CATCTTTCTT ACAACTATTG TGCCTTCCAC  
751 TTGCTTTCTT TCCTTGCTTC ACTCTATGTC ATGGTTACCC TTACCAACTG  
801 GTTCAGAAAC CCCAGCCCTT TATCTTGA  
11AA SEQUENCE 1.0  
ID\_ADP31595 standard; protein; 3036 AA.  
XX  
AC ADP31595;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2362.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PP 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406648P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.

17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3593; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 3036 AA;  
ADP31595 Length: 3036 February 22, 2005 12:25 Type: P Check: 9916 ..  
1 AGTATTCTAC CTGTGTAATA CTGTTATTGT TATATACTGT AAATGATGAC  
51 ATCGTGCGC ACTAACCGAG CCGGGGAAA CTGGGAACAA CCTCAAAACC  
101 AAAACACAGC ACAGCACAG CAGCGGCCAC AGGCCACTGC AGACAAATT  
151 AGACTTGCAC AGATGATTTT GCACCATATAT GATGCTGACT TTGAGGAGAA  
201 GGTGAACAA TTGATTGATA TTACAGGCAA GAACCAAGAT GAATGTGTGA  
251 TTGCTTTGCA TGACTGCAAT GGAGATGTCA ACAGAGCTAT CAATGTTCTT  
301 CTGGAAGGAA ACCCAGACAC GCATTCTCTGG GAGATGGTCG GGAAGAAGAA

351 GGGAGTCTCA GGCAGAGG ATGTGGCCA GACGGAATCC AATGAGGAAG  
401 GCAAGAAAA TCGAGACCG GACAGAGACT ATAGTCGGG ACGTGTGGG  
451 CCACCAAGAC GGGGGAGAG TGCCAGCCGT GGACGAGAGT GTATGCATGG  
501 GGCTTTATCA AAACCAAGCTG TGGTTGAGG TCAGGAAAAT GGATTGGATG  
551 GCACCAAGAG TGGAGGGCCT TCTGGAAGAG GAACAGAAAG AGGCAGAAAG  
601 GGGCGTGGCC GAGGCAGAGG TGGCTCTGGT AGGCGAGGAG GAAGTPTTTC  
651 TGCTCAAGGA ATGGGAACCT TTAACCCAGC TGATTATGCA GAGCCAGCCA  
701 ATACTGATGA TAACTATGSC RATAGCAGG GCAATAGCTG GAACACACT  
751 GGCACATTTG AACCAGATGA TGGGACGAGA CTTGATTTCA TTGGGGTTGA  
801 GGGGTCAAAT TATCCCCCAA AATTATCCCC CAGACTGCTC CTGGTGCA TG  
851 GAGGACTGCA ACAGAGGAGT GGGGAGCTGA AGATTGGAAT GAAGATCTTT  
901 CTGAGACCAA GATCTTCACT GCGCTTAATG TGTCTTCAGT GCGTCTGCGT  
951 GCGGAGAATG TGACAAATCAC TGCTGGTCAG AGAATTGACC TTGCTGTTC  
1001 GCTGGGGAAG ACACCATCTA CAATGGAGAA TGATTCACT ATCTGGATC  
1051 CGTCTCAGG TCCTTCTCTG GCGGAGCCTC TGGTGTTCAG TAATTCGAAG  
1101 CAGACTGCCA TATCACAGCC TGCTTCAGG AACACATTTT CTCATCACAG  
1151 TGAGCATGTT AGGGAAGGA TTGGTGATG TCGGTGAAGC TAAAGCGCG  
1201 AGTACTACAG GCTCCAGTT CTTGAGAGAA TTCAAGACTG CCCAAGCCCT  
1251 GGCTCAGTTG CGAGCTCAGC ATTCTCAGTC TGGAAGCACC ACCACCTCCT  
1301 CTTGGGACAT GGGCTCGAG ACACAAATCCC CATCACTGGT GCGATATGGT  
1351 GAGAAGATGG AAATGATTCa CGAGTGCACA GCGCTTTTAC AAAGCGCCAG  
1401 GCCTTTTACCC CATCTTCAAC CATGATGAG GTGTTCTCTTC AGGAGAAGTC  
1451 ACCTGCAGTG GCTACTCCA CAGCTGCACC TCCACCTCCG TCTTCTCCTC  
1501 TGCCAAGCAA ATCCACATCG GCTCCACAGA TGTGCGCTCG ATCTTCAGAC  
1551 AACCAGTCTT CTAGCCCTCA GCGGCTCAG CAGAAACTGA AACAGCAGAA  
1601 GAAAAAAGCC TCGTTGACTT CTAAGATTCC TGCTCTGGCT GTGGAGATGC  
1651 CTGGCTCAGC AGATATCTCA GGGCTAAACC TGCAGTTTGG GGCATTTGCAG  
1701 TTTGGGTCAG AGCCTGCTCT TTCTGATTAT GAGTCCACCC CCACCAAGAG  
1751 GCGCTCTTCA AGCCAGGCTC CAAGTAGCCT GTATACCAGC ACGGCCAGTG  
1801 AATCATCTTC TACAATTTCA TCTAACCCAGA GTCAGGAGTC TGGTTATCAG  
1851 AGCGGCCCAA TTCAGTCGAC AACCTATACC TCCCAAAATA ATGCTCAGG  
1901 CCTCTTTTAT GAACAGAGAT CCACACAGAC TCGCGCGGTAC CCAGTCTCA  
1951 TCTCTTCATC ACCCCAAAAG GACCTGACTC AGGCAAAAGAA TGGCTTTCACT  
2001 TCTGTGCAGG CCAGCGAGTT ACAGACCACA CAATCTGTG AAGGTGCTAC  
2051 AGGCTCTGCA GTGAATCTG ATTCACTTC CACTTCTAGC ATCCCCCTTC  
2101 TCAATGAAC GGTATCTGCA GCTTCCTTAC TGACGACAAC CAATCAGCAT  
2151 TCATCCTCTT TGGGTGGCTT GAGCCACAGT GAGGAGATTC CAAATACTAC

2201 CACCACAAA CACAGACGA CGTTATCTAC GCAGCAGAAT ACCCTTTTCAT  
2251 CATCAACATC TTCTGGGGC ACTTCGACAT CCACTCTTTT GCACACAAGT  
2301 GTGAGAGTG AGGCGAATCT CCAATTCTTC TCCAGCACTT TTTCACCAC  
2351 ATCCAGCACA GTCTCTGCAC CTCGCCCACT GGTCACTGTC TCCTCCAGTC  
2401 TCAATAGTGG CAGTAGCCTG GGCCTCAGCC TAGGCAGCAA CTCCACTGTC  
2451 ACAGCCTCGA CTCGAAGCTC AGTTGCTACG ACTTCAGGAA AAGCTCCTCC  
2501 CAACTCTCCT CCTGGGTCC GCGGTTGTT GCCTAATCCG TATATTATGG  
2551 CTCAGGGCT GTTACATGCC TACCCGCCAC AAGTATATGG TTATGATGAC  
2601 TTCCAGATGC TTCAGACAAG ATTTCCATTG GATTACTACA GCATCCCAT  
2651 TCCCAACCC ACTACTCCG TGA CTGGGAG GGATGGTAGC CTGGCCAGCA  
2701 ACCTTATTC TGGTGACCTC ACAAGTTTCG GCGTGGGA TGCCTCCTCC  
2751 CCAGCCCCGG CCACAACCTT GGCCCAACCC CAACAGAAC AGACGCAGAC  
2801 TCACCATACC ACGCAGAGA CATTCTCTGAA CCGGCGCTG CCTCCTGGCT  
2851 ACAGTTACAC CAGCCTGCCA TACTATACAG GGTCCCGGG CCTCCCGAGC  
2901 ACCTTCCAGT ATGGGCTGCG TGTGTTCCCT GTGGCTCCTA CCTCTTCCAA  
2951 GCAGCATGGT GTGAATGCA GTGTGAATGC ATCGGCCACC CCTTTCCAAC  
3001 AGCCGAGTGG ATATGGTCT CATGGATACA ACACTG  
!!AA SEQUENCE 1.0  
ID ADP31600 standard; protein; 6729 AA.  
XX  
AC ADP31600;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2367.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; Immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406668P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.



PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3598; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX Sequence 6729 AA;  
SQ  
ADP31600 Length: 6729 February 22, 2005 12:25 Type: P Check: 1550 ..

1 GCAGCGGGTT GTTATGACAA TGGAAAACAC TATCAGATAA ATCAACACTG  
51 GGAGCGGACC TACCTAGGCA ATCGTTGGT TTGTACTTGT TATGGAGGAA  
101 GCCGAGGTTT TAACCTGCGAG AGTAAACCTG AAGCTGAAGA GACTTGCTTT  
151 GCAAGATCA CTGGGAACAC TTACCGAGTG GGTGACACTT ATGACGCTCC  
201 TAAAGACTCC ATGATCTGGG ACTGTACCTG CATCGGGGCT GGGCAGGGA  
251 GAATAAGCTG TACCATCGCA AACCGCTGCC ATGAAGGGGG TCAGTCTTAC  
301 AAGATTGGTG ACACCTGGAG GAGACCACAT GAGACTGGTG GTTACATGTT  
351 AGAGTGTGTG TGTCTTGGTA ATGGAAAAGG AGAATGGACC TCGAAGCCAT  
401 AGATGCAAG ATCAGGACAC AAGGACATCC TATAGNATTG GAGACACCTG  
451 GAGCAAGAAG GATATCGAG GAAACCTGCT CCAGTGCATC TGCACAGGCA  
501 ACGGCCGAGG AGAGTGGAAAG TGTGAGAGGC ACACCTCTGT GCAGACCACA  
551 TCGAGCGTTT ACCAACCGCA GCCTCACCCC CAGCCTCCTC CCTATGGCCA  
601 CTGTGTCACA GACAGTGGTG TGTCTTACTC TGTGGGGATG CAGTGGCTGA  
651 AGACACAAGG AAATAAGCAA ATGCTTTTGA CGTGCTCTGG CAACGGAGTC  
701 AGCTGCCAAG AGACAGCTGT AACCCAGACT TACGGTGCCA ACTCAATGG  
751 AGAGCCATGT GTCTTACCAT TCACCTACAA TGGCAGGAGC TTCTACTCCT  
801 GCACCACAGA AGGCGACAG GACGGACATC TTTGGTGCGAG CACAACCTCG  
851 AATTATGAGC AGGACCAGAA ATACTCTTTC TGCACAGACC ACACCTGTTT  
901 GGTTCAGACT CGAGGAGGAA ATTCCAATGG TGCCTTGTGC CACTTCCCTT  
951 TCCTATACAA CAACCACAAT TACACTGATT GCACCTTCTGA GGGCAGAAGA  
1001 GACAACATGA AGTGGTGTG GACCACACAG AACTATGATG CCGACCAGAA  
1051 GTTTGGGTTT TGCCCCCATG GTGCCCAACGA GGAATATCTGC ACAACCAATG  
1101 AAGGGGTCTT GTACCGCATT GGAGATCAGT GGGATAAGCA GCATGACATG  
1151 GGTACATGA TGAGGTGCAC GTGTGTTGGG ATGCTGCTG GGGATGAGC  
1201 ATGCATTGCC TACTCGCAGC TTGAGATCA GTGCATTGTT GATGACATCA  
1251 CTTACAATGT GAACGACACA TTCCACAAGC GTCATGAAGA GGGGCACATG  
1301 CTGAACGTA CATGCTTCGG TCAGGGTCCG GGCAGGTGGA AGTGTGATCC  
1351 CGTCGACCAA TGCAGGANTT CAGAGACTGG GACGTTTTAT CAAATGAGG  
1401 ATTCAATGGA GAAGTATGTG CATGGTGTC GATACCAGTG CTACTGTAT  
1451 GGCCGTGCA TTGGGGAGTG GCATTTGCCAA CCTTTACAGA CCTATCCNAG  
1501 CTCAGTGGT CTGTGGAAG TATTATAC TGAGACTCCG AGTCAGCCCA  
1551 ACTCCACCC CATCCAGTGG AATGCACCAC AGCCATCTCA CATTTCCAAG  
1601 TACATTCTCA GGTGGAGACC TAAATATTCT GTAGCCCGTT GGAAGGAGC  
1651 TACCATACCA GGCCACTTAA ACTCTTACAC CATCAAGGC CTGAAGCCTG

1701	GTGTGGTATA CGAGGGCCAG CTCATCAGCA TCACAGAGTA CGGCCACCAA	3551	TATCCCTATT TTTGAAGATT TTGTGGACTC CTCAGTAGGA TACTACACAG
1751	GAAGTGACTC GCTTTGACTT CACCACCACC AGCACACGCA CACCTGTGAC	3601	TCACAGGGCT GGAGCCGGGC ATTGACTATG ATATCAGCGT TATCACTCTC
1801	CAGCAACACC GTGACAGSAG AGAGACTTCC CTTTTCCTCT CTTGTGGCCA	3651	ATTAATGGCG GCGAGAGTGC CCTTACTTACA CTGACACAAC AAACGGCTGT
1851	CTTCTGAATC TGTGACCGAA ATCAGAGCA GTAGCTTTGT GGTCTCCTGG	3701	TCCTCTCCC ACTGACCTGC GATTACCAA CATTGGTCCA GACACCATGC
1901	GTCTCAGCTT CCGACACCTG GTCGGGATTC CGGTGGAAT ATGAGCTGAG	3751	GTGTACCTG GGTCCACCC CCATCCATTG ATTTAACCAG CTTCCTGGTG
1951	TGAGGAGGGA GATGAGCCAC AGTACTTGA TCTTCCAAGC ACAGCCACTT	3801	CGTTACTCAC CTGTGAAAAA TGAGGAGAT GTTGACAGAGT TGTCAATTTC
2001	CTGTGAACAT CCTGACCTG CTTCTGGCC GAAAAATACAT TGTAAATGTC	3851	TCCTTCAGAC AATGACGTGG TCTTAACAAA TCTCTGCTCT GGTACAGAAT
2051	TATCAGATAT CTGAGGATGG GGAGCAGAGT TTGATCTCTGT CTACTTCACA	3901	ATGTAGTGAG TGTCTCCAGT GTCTACGAAC AACATGAGAG CACACCTCTT
2101	AACACACAGG CCTGATGCC CTCCTGACAC GACTGTGGAC CAAGTTGATG	3951	AGAGGAAGAC AGAAAAAGGT CTTGATTTCCC CAACTGGCAT TGACTTTTTCT
2151	ACACCTCAAT TGTGTGTGCG TGGAGCAGAC CCCAGGCTCC CATCACAGGG	4001	GATATTACTG CCAACTCTTT TACTGTGCAC TGGATTGCTC CTCGAGCCAC
2201	TACAGAATAG TCTATTGCGC ATCAGTAGAA GGTAGCAGCA CAGAACTCAA	4051	CATCACTGGC TACAGGATCC GCCATCATCC CGAGCACTTC AGTGGGAGAC
2251	CCTTCTCGAA ACTGAAACT CCGTCACCTT CAGTGACTTG CAACTGGTG	4101	CTCGAGAAGA TCGGTGCC CACTCTCGGA ATTCCATCAC CCTCACCAAC
2301	TTCAGTATAA CATCACTATC TATGCTGTGG AAGAAAAATCA AGAAAGTACA	4151	CTCACTCCAG GCACAGAGTA TGTGGTCAGC ATCGTTGCTC TTAATGGCAG
2351	CCTGTTGTCA TTCAACAAGA AACCACTGGC ACCCAGCTT CAGGTAAGT	4201	AGAGGMAAGT CCCTTATTGA TTGCCCAACA ATCAACAGTT TCTGATGTTT
2401	GCCTCTTCCC AGGGACCTGC AGTTTGTGGA AGTGACAGAC GTGAAGGTCA	4251	CGAGGGACCT GGAAGTTGTT GCTGCGACCC CCACCAGCCT ACTGATCAGC
2451	CCATCATGTG GACACCGCTT GAGAGTGCG TGACCGGCTA CCGTGTGGAT	4301	TGGGATGCTC CTGCTGTCC AGTGAGATAT TACAGGATCA CTTACGGAGA
2501	GTGATCCCCG TCAACCTGCC TGGCAGACAC GGGCAGAGGC TGCCCATCAG	4351	GAACAGGGA AATGACCCCTG TCCAGGAGTT CACTGTGCTT GGGAGCAAGT
2551	CAGGAACACC TTTCAGAAAG TCACCGGCT GTCCCTTGGG GTCACCTATT	4401	CTACAGCTAC CATCAGCGC CTTAAACCTG GAGTTGATTA TACCATCACT
2601	ACTTCAAAGT CTTTGCAGTG AGCCATGGGA GGGAGAGCAA GCCTCTGACT	4451	GTGTATGCTG TCACTGGCCG TGGAGACAGC CCGCAAGCA GCAAGCCAAAT
2651	GCTCAACAGA CAACCAACT GGATGCTCCC ACTAACCTCC AGTTTGTCAA	4501	TTCCATTAAAT TACCGAACAG AAATTGCAAA ACCATCCCAG ATGCAAGTGA
2701	TGAACCTGAT TCTACTGTCC TGGTGAGATG GACTTCCACT CGGGCCCAGA	4551	CCGATGTTCA GGACAACAGC ATTAGTGTCA AGTGGCTGCC TTCAAAGTTCC
2751	TAACAGGATA CCGACTGACC GTGGSCCTTA CCGAAGAGG ACAGCCCAGG	4601	CCTGTTACTG GTTACAGAGT AACCACCACT CCCAAAAATG GACCAGGACC
2801	CAGTACAAATG TGGTCCCTTC TGTCTCCAAG TACCACCTGA GGAATCTGCA	4651	AACAAAAACT AAAACTGCAG GTCAGATCA AACAGAAATG ACTATTGAAG
2851	GCCTGCATCT GAGTACACCG TATCCTCTGT GGCCATAAAG GGCACCAAG	4701	GCTTGCAGCC CACAGTGGAG TATGTGGTTA GTGTCTATGC TCAGAAATCCA
2901	AGAGCCCCAA AGCCACTGGA GTCTTTIACCA CACTGCAGCC TGGGAGCTCT	4751	AGCGGAGAGA GTCAGCCTCT GGTTCAGACT GCAGTAACCA ACATTGATCG
2951	ATTCCACCTT ACACACCGA GGTGACTGAG ACCACCATTG TGATCAGATG	4801	CCCTAAAGGA CTGGCATTCA CTGATGTGGA TGTGATTTCC ATCAAAATTG
3001	GACGCCTGCT CCAAGAAATTG TCCTTCTCTT AGTGGGTGT ACGACCAAGC	4851	CTTGGGAAAG CCCACAGGGG CAAAGTTTCCA GGTACAGGGT GACCTACTCG
3051	CAGGGAGGAG AGSCACCAG AGAAGTGACT TCAGACTCAG GAAGCATCGT	4901	AGCCCTGAGG ATGGAATCCA TGAGCTATTC CCTGCACCTG ATGGTGAAGA
3101	TGTGTCCGGC TTGACTCCAG GAGTAGAATA CGTCTACACC ATCCAAAGTCC	4951	AGACACTGCA GAGCTGCAAG GCCTCAGACC GGGTTCTGAG TACACAGTCA
3151	TGAGAGATGG ACAGGAAAGA GATGCGCCA TTGTAAAAA AGTGTGACA	5001	GTGTGGTTGC CTTGCACCAT GATATGGAGA GCCAGCCCCCT GATTGGAAAC
3201	CCATTGTCTC CACCAACAA CTTGCATCTG GAGCAAAACC CTGACACTGG	5051	CAGTCCACAG CTATTCTGCG ACCAACTGAC CTGAAGTTCA CTCAGGTCA
3251	AGTGCTCACA GTCTCTGGG AGAGAGGAC CACCCAGTG GAAGAAGTGG	5101	ACCCACAAGC CTGAGCGCCC AGTGGACACC ACCCAATGTT CAGTCACTG
3301	TCCATGCTGA TCAGAGCTCC TGCACTTTTG ATAACCTGAG TCCCGGCTTG	5151	GATATCGAGT GCGGTGACC CCCAAGGAGA AGACCGGACC AATGAAAGAA
3351	GAGTACAATG TCAGTGTTTA CACTGTCAAG GATGACAAGG AAAGTGTCCC	5201	ATCAACCTTG CTCCTGACAG CTCATCCGTG GTTGTATCAG GACTTATGCT
3401	TATCTCTGAT ACCATCATCC CAGAGGTGCC CCAACTCACT GACCTAAGCT	5251	GGCCACCAAA TATGAAATGA GTGTCTATGC TCTTAAGGAC ACTTTGACAA
3451	TTGTTGATAT AACCAGATTA AGCATCGGCC TGAGGTGGAC CCGCTTAAAC	5301	GCAGACCAGC TCAGGGAGTT GTCAACCACTC TGGAGAATGT CAGCCCCACA

5351	AGAGGGCTC	GTGTGACAGA	TGCTACTGAG	ACCACCATCA	CCATTAGTCT
5401	GAGAACCAAG	ACTGAGACGA	TCACTGGGCTT	CCAAGTTGAT	GCGGTTCCAG
5451	CCAAATGGCCA	GACTCCAATC	CAGAGAACCA	TCAAGCCAGA	TGTCAGAAAGC
5501	TACACCATCA	CAGGTTTACA	ACCAGCACT	GACTACNAGA	TCTACTCTGA
5551	CACCTTGAAT	GACAATTGCTC	GGAGCTCCCC	TGTGGTCATC	GACGCTCCCA
5601	CTGGCAATTGA	TGCACCATCC	AACTGCGCTT	TCCTGGCCAC	CACACCCAAT
5651	TCCTTGCTGG	TATCATGGCA	GCCGCCAGT	GCAGAGTTA	CGGCTACAT
5701	CATCAAGTAT	GAGAAAGCTTG	GGTCTCTCC	CAGAGAAGTG	GTCCCTCGGC
5751	CCCGCCCTGG	TGTCACAGAG	GCTACTATTA	CTGGCCTGGA	ACCGGGAACC
5801	GAATATACAA	TTTATGTCTAT	TGCCCTGAAG	AATAATCAGA	AGAGCGAGCC
5851	CCTGATTGGA	AGGAAAAGA	CAGTCCGGGA	CTCAAATCCAA	ATGCTCTTAC
5901	AGGACAAGAA	GCTCTCTCTC	AGACAACCAT	CTCATGGGCC	CCATTCCAGG
5951	ACACTTCTGA	GTACATCAAT	TCATGTCAIC	CTGTTGGCAC	TCATGAAGAA
6001	CCCTTACAGT	TCAGGTTTCC	TGGAACTTCT	ACCAGTGCCA	CTCTGACAGG
6051	CCTCACCAGA	GGTGCCACCT	ACAACGTCTAT	AGTGGAGGCA	CTGAAAGACC
6101	AGCAGAGGCA	TAAGGTTTCGG	GAAGAGTTTG	TTACCCGTGG	CAACTCTGTC
6151	AACGAAGGCT	TGAAACCAAC	TACGATGAC	TCGTGCTTTTG	ACCCCTACAC
6201	AGTTTCCCAT	TATGCGCTTG	GAGATGAGTG	GGAAACGAATG	TCTGAATCAG
6251	GCTTTAAACT	GTGTGCCAAG	TGCTTAGGCT	TTGGAAAGTG	TCATTTCCAGA
6301	TGTAATTCTAT	CTATAGTGGTG	CCATGACNAAT	GGTGTGAATC	ACAAGATTGG
6351	AGAGAAGTGG	GACCGTCAGG	GAGAAAATGG	CCAGATGATG	AGCTGCACAT
6401	GTCTTTGGAA	CGGAAAAGGA	GAATTTCAAGT	GTGACCCCTCA	TGAGGCAACG
6451	TGTTATCATG	ATGGGAAGAC	ATACCACGTA	GGAGAACACT	GGCAGAGGGA
6501	ATATCTCGGT	GCAATTGTCT	CCTGCACATG	CTTTGGAGGC	CAGCGGGGCT
6551	GGCGCTGTGA	CAACTGCCGC	AGACTGGGG	GTGAACCCAG	TCCCGAAGGC
6601	ACTACTGGCC	AGTCTCTACAA	CCAGTATTCT	CAGAGATACC	ATCAGAGAAC
6651	AAACACTTAAT	GTTAATTGCC	CAATTGAGTG	CTTCAATGCT	TTAGATGTAC
6701	AGGCTGACAG	AGAAGATTCC	CGAGAGTAA		

28-AUG-2003;	2003WO-US026780;	2002US-0406576P;	2002US-0406576P;
29-AUG-2002;	2002US-0406576P;	2002US-0406576P;	2002US-0406576P;
29-AUG-2002;	2002US-0406588P;	2002US-0406588P;	2002US-0406588P;
29-AUG-2002;	2002US-0406588P;	2002US-0406588P;	2002US-0406588P;
29-AUG-2002;	2002US-0406608P;	2002US-0406608P;	2002US-0406608P;
29-AUG-2002;	2002US-0406611P;	2002US-0406611P;	2002US-0406611P;
29-AUG-2002;	2002US-0406612P;	2002US-0406612P;	2002US-0406612P;
29-AUG-2002;	2002US-0406616P;	2002US-0406616P;	2002US-0406616P;
29-AUG-2002;	2002US-0406640P;	2002US-0406640P;	2002US-0406640P;
29-AUG-2002;	2002US-0406642P;	2002US-0406642P;	2002US-0406642P;
29-AUG-2002;	2002US-0406653P;	2002US-0406653P;	2002US-0406653P;
29-AUG-2002;	2002US-0406655P;	2002US-0406655P;	2002US-0406655P;
29-AUG-2002;	2002US-0406666P;	2002US-0406666P;	2002US-0406666P;
17-SEP-2002;	2002US-0410947P;	2002US-0410947P;	2002US-0410947P;
17-SEP-2002;	2002US-0410947P;	2002US-0410947P;	2002US-0410947P;
17-SEP-2002;	2002US-0410948P;	2002US-0410948P;	2002US-0410948P;
17-SEP-2002;	2002US-0410949P;	2002US-0410949P;	2002US-0410949P;
17-SEP-2002;	2002US-0410953P;	2002US-0410953P;	2002US-0410953P;
17-SEP-2002;	2002US-0410957P;	2002US-0410957P;	2002US-0410957P;
17-SEP-2002;	2002US-0410958P;	2002US-0410958P;	2002US-0410958P;
17-SEP-2002;	2002US-0410959P;	2002US-0410959P;	2002US-0410959P;
17-SEP-2002;	2002US-0410960P;	2002US-0410960P;	2002US-0410960P;
17-SEP-2002;	2002US-0410961P;	2002US-0410961P;	2002US-0410961P;
17-SEP-2002;	2002US-0410962P;	2002US-0410962P;	2002US-0410962P;
17-SEP-2002;	2002US-041019P;	2002US-041019P;	2002US-041019P;
17-SEP-2002;	2002US-0411022P;	2002US-0411022P;	2002US-0411022P;
17-SEP-2002;	2002US-0411023P;	2002US-0411023P;	2002US-0411023P;
17-SEP-2002;	2002US-0411024P;	2002US-0411024P;	2002US-0411024P;
17-SEP-2002;	2002US-0411032P;	2002US-0411032P;	2002US-0411032P;
17-SEP-2002;	2002US-0411035P;	2002US-0411035P;	2002US-0411035P;
17-SEP-2002;	2002US-0411037P;	2002US-0411037P;	2002US-0411037P;
17-SEP-2002;	2002US-0411041P;	2002US-0411041P;	2002US-0411041P;
17-SEP-2002;	2002US-0411045P;	2002US-0411045P;	2002US-0411045P;
17-SEP-2002;	2002US-0411046P;	2002US-0411046P;	2002US-0411046P;
17-SEP-2002;	2002US-0411048P;	2002US-0411048P;	2002US-0411048P;
17-SEP-2002;	2002US-0411052P;	2002US-0411052P;	2002US-0411052P;
17-SEP-2002;	2002US-0411055P;	2002US-0411055P;	2002US-0411055P;
17-SEP-2002;	2002US-0411073P;	2002US-0411073P;	2002US-0411073P;
17-SEP-2002;	2002US-0411082P;	2002US-0411082P;	2002US-0411082P;
17-SEP-2002;	2002US-0411111P;	2002US-0411111P;	2002US-0411111P;
17-SEP-2002;	2002US-0411112P;	2002US-0411112P;	2002US-0411112P;
18-APR-2003;	2003US-0463700P;	2003US-0463700P;	2003US-0463700P;
18-APR-2003;	2003US-0463708P;	2003US-0463708P;	2003US-0463708P;
18-APR-2003;	2003US-0463716P;	2003US-0463716P;	2003US-0463716P;
18-APR-2003;	2003US-0463732P;	2003US-0463732P;	2003US-0463732P;
02-MAY-2003;	2003US-0467199P;	2003US-0467199P;	2003US-0467199P;
02-MAY-2003;	2003US-0467201P;	2003US-0467201P;	2003US-0467201P;
02-MAY-2003;	2003US-0467203P;	2003US-0467203P;	2003US-0467203P;
02-MAY-2003;	2003US-0467230P;	2003US-0467230P;	2003US-0467230P;
19-MAY-2003;	2003US-0471306P;	2003US-0471306P;	2003US-0471306P;
19-MAY-2003;	2003US-0471336P;	2003US-0471336P;	2003US-0471336P;
22-MAY-2003;	2003US-0472420P;	2003US-0472420P;	2003US-0472420P;
22-MAY-2003;	2003US-0472430P;	2003US-0472430P;	2003US-0472430P;
09-JUN-			

PA XX

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3617; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX SQ Sequence 588 AA;  
ADP31619 Length: 588 February 22, 2005 12:25 Type: P Check: 5648 ..  
1 ATGGCTCTCTG TGAAGATCAG CCAATGTGGTA TCATTTCTT CTGAGGATCC  
51 CAAGATATCTT GTAGAGAATC TGCTAAACCC AGATAGTCCA AGGAGACCTT  
101 GGCTCGGCTG CCTCAGGAC AAGATGGGC AATTGAAAGT AGAATACAG  
151 CTGAGAGGG CAGTGCCAC TGGCTACATT GATGTGGGTA ACTGTGGCTG  
201 TGGCTTCTTG CAAATTGATG TGGGCCATTG TTCTGGCCC CTGGACAGAC  
251 CTTTCATAAC CTTGCTCCCT GCAACCACGC TAATGTCTCT AACTGATTCA  
301 AAGCAGGGGA AGAACCGCTC CGGGTCCGC ATGTTTAAAG ATGGTAAAGA  
351 GGGCAAAAGC AGAAAAGATG GGGGTGTGCT TTATGAGAAA CAGAGATGCA  
401 GTACTAAGA GGACTCCTCA GGAGAGTTAT GGGATGCACT TCGCCTGACC  
451 TGCTCCCGAC CCTTCAGGG TCATCAGTCC TTGGCCCTGG CCTTCTACG  
501 GGTGTGTTCT TCTCTGGAAT CTTAGATGA CTCTGTGGTG GGTCCCTCAG  
551 CCCTTCTGAG CTCTGTGCTG AACAAAGTTT CTGTTTAA  
IIIA SEQUENCE 1.0  
ID\_ADP30475 standard; protein; 669 AA.  
XX AC ADP30475;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1242.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.

29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486466P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2473; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antitumour, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 669 AA;  
ADP30475 Length: 669 February 22, 2005 12:25 Type: P Check: 9707 ..  
1 ATGGAGAGCA AAGCCCTGCT CGTCTGACT CTGGCCGTGT GGCTCCAGAG  
51 TCTGACCGCC TCCCGCGAG GGTGGCGCG CGCCGACCCC CGGAACGGT  
101 CCCCAGAGTG GGATCCAGGA GGGGCCGGGA GGGAACTCTC TCCCGATCGT  
151 GAAGCGCGCG CGCCAGTTC CCGCTTTTC TCTCTCCCG GTTCCCGCGC  
201 TATCCCTTCC ACTCTGGCTG GGACCGGTT CCGGGCTCG CAGGCTCCGC  
251 CGGGAGGTT CCGGGGTGT GGGGCCGGGA CGCGGAGGC GGGGAGTAAG  
301 GCGCCGGCTG CCGGTGACT GCAGTCACT CTCTGCCGA GGGGCCCTGG  
351 AATGAAGGC GCGCGGCCA AGTGACCTC GCCTGGTTG GCACGTCCGC  
401 TCAGCCCCCG CCCGGGACT CCGGGGCCGA CTGTGGCCCC TTCTGGGAA  
451 GCGGGGCGC GGGGAGCGT TCCGGGCATC TCAGCGGCAC GGGGTACGCT  
501 CGCCCTCGC GGGGCCCTC GTCCCGTGT GGGAGTGGA GTGGGTGTCG  
551 GGGTGAGAA AGTACGGTG CGCGGAGTC CTGGGAGCC GCGCTCCAC  
601 CCGCTCTGG GAGCCCCGA CTCTCTCAG CTTCCAGGCT CGCATGCCCC  
651 TCTTTCTTA GTGCCCTGA  
IIAA SEQUENCE 1.0  
ID ADP30525 standard; protein; 4360 AA.  
XX  
AC ADP30525;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1292.  
XX  
XX Cytostatic; Antitumour; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX  
XX 29-AUG-2002; 2002US-0406579P.  
XX  
XX 29-AUG-2002; 2002US-0406585P.  
XX  
XX 29-AUG-2002; 2002US-0406588P.  
XX  
XX 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-040946P.  
PR 17-SEP-2002; 2002US-040947P.  
PR 17-SEP-2002; 2002US-040948P.  
PR 17-SEP-2002; 2002US-040949P.  
PR 17-SEP-2002; 2002US-040953P.  
PR 17-SEP-2002; 2002US-040957P.  
PR 17-SEP-2002; 2002US-040958P.  
PR 17-SEP-2002; 2002US-040959P.  
PR 17-SEP-2002; 2002US-040960P.  
PR 17-SEP-2002; 2002US-040961P.  
PR 17-SEP-2002; 2002US-040962P.  
PR 17-SEP-2002; 2002US-041019P.  
PR 17-SEP-2002; 2002US-041023P.  
PR 17-SEP-2002; 2002US-041024P.  
PR 17-SEP-2002; 2002US-041032P.  
PR 17-SEP-2002; 2002US-041035P.  
PR 17-SEP-2002; 2002US-041037P.  
PR 17-SEP-2002; 2002US-041041P.  
PR 17-SEP-2002; 2002US-041045P.  
PR 17-SEP-2002; 2002US-041046P.  
PR 17-SEP-2002; 2002US-041048P.  
PR 17-SEP-2002; 2002US-041052P.  
PR 17-SEP-2002; 2002US-041055P.  
PR 17-SEP-2002; 2002US-041073P.  
PR 17-SEP-2002; 2002US-041082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 17-SEP-2002; 2002US-041111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT

PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.

PS Claim 1; SEQ ID NO 2523; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

XX Sequence 4360 AA;

ADP30525 Length: 4360 February 22, 2005 12:25 Type: P Check: 7074 ..

1 GCGCTGCAGC CATGGCGGC GCGGTGCGC TGCTCTGGT GTCGCTATTG  
51 GTGCTGCTGG CGCAGTAGG GCGCAGCCT GGACTGGGCC GGCTCGAGA  
101 GCGTCTCCG GTGCGTTCA CCCCGGTGCT GTGCGGCTG CGTGTGCTC  
151 ATGGGCGGAC CGGCTCCGC TGTACCCCGA CTTGCGGCC CGCAACGCC  
201 ACCAGCGTGG ACAGCGGCG TCCGGCGGG GCGGCCCGG GGGGACCCGG  
251 CTTCCGCGCC TTCTGTGTC CTTTGAATCT TCACAAATGG GGTGTGTGG  
301 TGAAGCCTGA CGCTGCCTC TGTCCCCCG ACTTCGCTGG CAAGTTCTGC  
351 CAGTTGCACT CTTGCGGCG CCGGCCCGG GCGGCCGCTG TACCAGCCT  
401 CACCGCTCC GTGTACACTA TGCCACTGGC CAACACCCG GACGACGAGC  
451 ACGGCGTGG ATCTATGGTG AGCGTCCACG TGGAGCACCC GCAGGAGGG  
501 TCGGTGTGG TGCACAGGT GGAGCGTGTG TCTGGCCCTT GGGAGAGGC  
551 GGACGCTGAG CGGTTGGCG GGGCGGAAGC GCGCGCGCG GCGAGGCGG  
601 CAGCGCCTA CACGGTGTG GCACAGAGCG CGCGCGGGA GGACGCTAC  
651 TCAGATGCTT CCGGCTTGG TTACTGCTTT CCGGAGTGC GCGGAGCGA  
701 ATGCGCGTCC CGCTGCCCG GCTCCGGAC GCAGGAGTTC TGCTGCCGAG  
751 GGGCGGCTT GGCCTGGGC GTTACGACT GTCAGTGTG CTCGAGCGC  
801 CTGGATGGAC CTTGTCCAAC CGGCTTTGAA AGATTAAATG GGTCTTGGGA  
851 AGATGTGGAT GAGTGGCGA GTGGCGGCG CTGCCAGCAC GCGAGTGTG  
901 CAAACACGCG CGGCGGGTAC AGTGTGTGT GCCCGGACGG CTTTCTGCTC  
951 GACTCTGCC CGACGAGCTG CATCTCCCA CAGTGATCT CAGAGGCCAA  
1001 AGGCGCCTGC TTCCGCGTGC TCCGCGACGG CGGCTGTTCG CTGCCAATTC  
1051 TGCGGAACAT CACTAAACAG ATCTCTGCT GACGCGCGT AGGCAAGGC  
1101 TGGGGCCGGG GCTGCCAGT CTGCCACCC TTCCGCTCAG AGGTTTCCG  
1151 GGAGATCTGC CCGGCTGGTC CTGGTTACCA CTACTCGGC TCGACCTCC  
1201 GCTACAACAC CAGACCCCTG GSCCAGGAGC CACCCGAGT GTCACTCAGC  
1251 CAGCCTCGTA CCTTGCACG CACCTCTCG CCATCTCAG TGGCCAGCAT  
1301 CCCTGCTGG ACTGTCTCG AGATTCTGA ATCAGGTCCC TCCTCGGCA  
1351 TGTGTACGCG CAACCCCGAG GTCTCGGCC CAGGACGCTG CATTTCCCG

3201 CAGGGCCCTG TGGGNGTGG GGGCCGGAG TGCTACTTTG ACACAGCGG  
3251 CCCGGATGCA TGTGCAACA TCCTGGCTCG GAATGTGACA TGGCAGGAGT  
3301 GCTGCTGTAC TGTGGGTGAG GCGTGGGCA GCGCTGCGG CATCCAGCAG  
3351 TGCCCGGGCA CCGAGACAG TGAGTACCAG TCATTGTGCC CTCACGGCGG  
3401 GGCTTACCTG GCGCCAGTG GAGACCTGAG CCTCCGGAGA GAGTGGAGCG  
3451 AATGTGAGCT CTTCCGAGAC CAGGTGTGCA AGAGTGGCGT GTGTGTGAAC  
3501 ACGGCCCCGG GCTACTCATG CTATTGCAGC ACGGCTACT ACTACACAC  
3551 ACAGCGGCTG GAGTGATCG GCGCGCTGTG TCAACACTGT GGGCTCTTAT  
3601 CACTGTACCT GCGAGCCCC ACTGGTGTG GATGGCTCGC AGCGCGCTG  
3651 CGTCTCCAAC GAGAGGCAGA GCCTGATGA CAATCTGGGA GTGTGCTGGC  
3701 AGGAAGTGGG GGCTGACCTC GTGTGCAGCC ACCCTCGGCT GGACCGTCAAG  
3751 GCCACCTACA CAGAGTGTG CTGCTGTAT GGAGAGSCCT GGGGCATGGA  
3801 CTGCGGCTTC TGCCCTGGCC AGGACTCAGA TGACTTCGAG GCCCTGTGCA  
3851 ATGTGCTACG CCCCCCGCA TATAGCCCC CGGACCAGG TGGCTTTTGA  
3901 CTCCCCTACG AGTACGGCCC AGACTTAGT CCACCTTACC AGGGCTCCC  
3951 ATATGGGCTT GAGTTGTAGC CACCACCTGC GTTACCCTAC GACCCTTACC  
4001 CACCGCCACC TGGGCGCTTC GCCCGCCGG AGGCTCCTTA TGGGGCACCC  
4051 CGCTTCGACA TGCCAGACTT TGAGGACGAT GGTGGCCCT ATGGCGAATC  
4101 TGAGGCTCCT GCGCCACCTG GCCCGGGCAG CCGCTGGCCC TATCGGTCCC  
4151 GGGACACCCG CGCTCTCTTC CCAGAGCCCG AGGAGCTCC TGAAGGTGGA  
4201 AGCTATGGTT CCTGGCTGA GCCCTACGAG GAGCTGGAGG CGGAGGAGTG  
4251 CGGATCCTTG GACGGCTGCA CCAACGGCCG CTCGGTGGCG GTCCCGGAAG  
4301 GCTTACCTG CGTGTGCTTC GACGGCTACC GCCTGGACAT GACCGGCATG  
4351 GCCTGGTTG

!!AA\_SEQUENCE 1.0  
ID ADP30558 standard; protein; 1299 AA.  
AC  
ADP30558;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1325.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-040585P.  
PR 29-AUG-2002; 2002US-040658P.  
PR 29-AUG-2002; 2002US-0406608P.

29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411053P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411010P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
15-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Hallenbeck RF, Huang MM, Kothakota S, Haisan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases





PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX

DR New nucleic acid molecule for diagnosing, preventing or treating diseases

PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2565; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 1550 AA;

ADP30567 Length: 1550 February 22, 2005 12:25 Type: P Check: 7235 ..  
1 CTCCTAGTGTT GTTATATACA GTACTGGTAG TGGAGGGAT TGCCCTGGCC  
51 CAAATAAACCC AAGATGGACA AATATTGGA ATCAAGCAT TCCCTGGCAAC  
101 CCAGTGTGGC APTTGGGTTT GAACCAGCAA TGGAGGTCTAT TTGCTTGGC  
151 CAAATTATCC TGACTCATAT CCACCAACA AGGAGTGTAT CTACATTTTG  
201 GAAGCTGCTC CACGTCAAAG AATAGATTG ACCTTTGATG AACATTATTA  
251 TATAGAACCA TCATTTGAGT GTCGGTTGA TCACCTTGGAA GTTCGAGATG  
301 GGCCATTGG TTTCTCTCTT CTATAGATC GTTACTGTGG CGTGAAGAAGC  
351 CTTCCATTAA TTAGATCAAC AGGAGATTG ATGTGGATTA AGTTTGTTC  
401 TGATGAAGAG CTTGAAGGAC TGGGATTTG AGCAAAATAT TCAATTTATTC  
451 CAGATCCAGA CTTTACTTAC CTAGGAGTA TTTTAATCC CATTCAGAT  
501 TGTGAGTTC AGCTCTGGG AGCTGATGGA ATAGTCGGCT CPAGTCAGGT  
551 AGAACAAGAG GAGAAACAA AACCAGGCCA AGCCGTTGAT TGCACTCTGA  
601 CCATTAAAGC CACTCCAAA GCTAAGATTT ATTGAGGTT CTAATATTAT  
651 CAAATGGAGC ACTCAATGA ATGCAAGAGA AACTTCGTTG CAGTCTATGA  
701 TGGAGCAGT TCTATTGAAA ACCTGAAGGC CAAATTTTGC AGCACTGTGG  
751 CCAATGATGT AATGCTTAAA ACAGGAATTG GAGTGATTCG AATGTGGGCA  
801 GATGAAGGTA GTCGGCTTAG CAGGTTTCGA ATGCTCTTTA CTTCTCTTGT

851 GGAGCCTCCC TGCACAAGCA GCACTTTCTT TTGCCATAGC AACATGTGCA  
901 TCAATAAATTC TTTAGTCTGT AATGGTGTC AAAATTGTGC ATACCTTTGG  
951 GATGAAATC ATTGTAAAGA AAGAAAAA GCAGGAGTAT TTGAACAAT  
1001 CACTAAGACT CATGGAACAA TTATTGGCAT TACTTCAGGG ATTGCTTTGG  
1051 TCCTTCTCAT TATTCTATT TTAGTACAAG TGAACACAGC TGAATAAAG  
1101 GTCATGGCTT GCAAAACGC TTTTAATAA ACGGGTTCC AAGAAGTGT  
1151 TGATCCTCT CATTTATGAAC TGTTTTCACT AAGGGACAAA GAGATTTCTG  
1201 CAGACTGCG AGACTTGTG GAAGATTTG ACAACTTACCA GAAGATGCGG  
1251 CGCTCTCCA CGCTCTCCG CTGCATCCAC GACCACCACT GTGGGTCCGA  
1301 GGCCTCCAG GTCAAACAA GCAGGACCA CCTCAGTTCC ATGGAACCTC  
1351 CTTCCGAAA TGACTTTGCA CAACCACAG CAATGAAAC ATTTAATAGC  
1401 ACCTTCAAGA AAGTAGTTA CACTTTCAA CAGGGACATG AGTGCCCTGA  
1451 GCAGGCCCTG GAAGACCGAG TAATGGAGG GATTCCTCTG GAAATTTATG  
1501 TCAGGGGGCG AGAAGATTCT GCACAAGCAT CCATATCCAT TGACTTTCAA

!!AA\_SEQUENCE 1.0

ID ADP30575 standard; protein; 192 AA.

XX ADP30575;

XX

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1342.

DE Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

OS

XX WO2004035732-A2.

PN

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

PR 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 17-SEP-2002; 2002US-0410946P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.

PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 15-MAY-2003; 2003US-0471306P.  
PR 15-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

DR WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2573; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX Sequence 192 AA;

ADP30575 Length: 192 February 22, 2005 12:25 Type: P Check: 1699 ..

1 ATCGGGCGGC GCTCGGGGCT GCCCGCGCC GGGAACACAG CGGGGGCGAG

51 GCGAGGCGAG GCGGCGCGG GTGCTCCGG GACGCGGACC GCGAGGCAGC  
101 TTGCCAAGCT GGTGTCGTG GTTGTTCGTG TTATCATCAC CATCATCATC  
151 ATCTCTGTGT GTTTTCAGTC TGACACACAGC ACCACCATTT GA

IIAA SEQUENCE 1.0

ID ADP30603 standard; protein; 279 AA.

XX AC ADP30603;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1370.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411037P.

XX PR 17-SEP-2002; 2002US-0411041P.

XX PR 17-SEP-2002; 2002US-0411045P.

XX PR 17-SEP-2002; 2002US-0411046P.

XX PR 17-SEP-2002; 2002US-0411048P.

XX PR 17-SEP-2002; 2002US-0411052P.

XX PR 17-SEP-2002; 2002US-0411055P.

XX PR 17-SEP-2002; 2002US-0411073P.

XX PR 17-SEP-2002; 2002US-0411082P.

XX PR 17-SEP-2002; 2002US-0411010P.

XX PR 17-SEP-2002; 2002US-0411111P.

XX PR 18-APR-2003; 2003US-0463700P.

XX PR 18-APR-2003; 2003US-0463708P.

XX PR 18-APR-2003; 2003US-0463716P.

XX PR 18-APR-2003; 2003US-0463732P.

PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485446P.  
PR 14-JUL-2003; 2003US-0485448P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486896P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2601; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX Sequence 279 AA;  
SQ  
ADP30603 Length: 279 February 22, 2005 12:25 Type: P Check: 8325 ..  
1 ATGGCGAGCC TCCGGCTCG GCCACGCCA CGTCGCACGT GCTCTGGTG  
51 GACGGCTTCT CCAGCCCTA CTGCTCTCTC CCGGAGGGG CCGCGGCCCA  
101 GGCCGAGGCC GACTCGCTCA CTGCTACCT GGTGGTGGG TTGGCCTCAG  
151 TGTCTGCTGT CTCTCTCTC TCGGTGCTC TGTCTGTGC GGTGGGGCTG  
201 TGCAGGAGA GCAGGGGGC CCGGTGGGT CGCTGCTCG TGCCTGAGGG  
251 CCCCTTTCCA GGACATCTGG TGGACGTGA  
!!AA SEQUENCE 1.0  
ID \_ADP30633 standard; protein; 291 AA.  
XX AC ADP30633;  
XX  
XX 12-AUG-2004 (first entry)  
DT  
XX Human secreted protein SEQ ID #1400.  
DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX OS Homo sapiens.  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 02-MAY-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 22-MAY-2003; 2003US-0472430P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 09-JUN-2003; 2003US-0476641P.  
XX 08-JUL-2003; 2003US-0485218P.  
XX 08-JUL-2003; 2003US-0485223P.  
XX 08-JUL-2003; 2003US-0485224P.  
XX 14-JUL-2003; 2003US-0486891P.  
XX 15-JUL-2003; 2003US-0486896P.  
XX 15-JUL-2003; 2003US-0486960P.

PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2631; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 291 AA;  
ADP30633 Length: 291 February 22, 2005 12:25 Type: P Check: 1138 ..  
1 ATGACAACGC CCGCGCCTTC ACCNAACCT CCTACACCCT GTTCGTCCGC  
51 GAGAACAACA GCCCGCCCT GCACATCGGC AGCGTCAGCG CCACACACAG  
101 AGACTCGGC ACCNAGCCCC AGGTCACTTA CTCGCTGCTG CCGCCCCAGG  
151 ACCGCGACCT GCCCTCGGC TCCCTGGTCT CCATCAACGC GGACAACGGC  
201 CACCTGTTCG CTCCTCAGTC GCTGCACTAC GAGGCCCTGC AGCGGTTCGA  
251 GTTCCGGGTG GCGCGCGCAG ACCGCGGCTC CCGCGCGTTG A  
!!AA\_SEQUENCE 1.0  
ID ADP30653 standard; protein; 798 AA.  
XX  
AC ADP30653;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1420.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.

29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411011P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
02-MAY-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-048524P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-048646P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2651; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 798 AA;  
ADP30653 Length: 798 February 22, 2005 12:25 Type: P Check: 1735 ..  
1 CTGCTGCTGC CTGGCCCTCT CGCCACCCTG ACATCAACAA CCCTTTGGCA  
51 GTGCCACACCT GGGAGGAGC CCGACCTGCA GGGCACATTA TGCAGGCCCT  
101 GCGCCCGCAGG CACCTTCTCA GCTGCATGGG GTTCCAGCCC ATGCCAGCCC  
151 CATGCCCGTT GCAGCCTTTG GAGGAGGCTG GAGGCCCCAGG TGGGCATGCG  
201 AACTCGAGAT ACACCTCTGT GAGACTGAG GTGGTTTGGG CTGGGGGCGG  
251 CGGGCCCCGAC GTGGCGTGA GGTGGCAGCA GGGGCCAGCA GGGTGAGACA  
301 CGGACGCTTG GGAACGGCAC CCGGGCAGGT GGCCCGAGG AGACAGCCGC  
351 CCAGTAGCGG GTCATCGCA TCGTCCCTGT CTTCGCTCCT ATGGGGCTGT  
401 TGGGCATCCT GGTGTGCAAC CTCCTAAGC GGAAGGGGTA CCACCTGCAG  
451 GCGCACAGG AGGTGGGCCC CGGCCCTGGA GGTGGAGGCA GTGGACTGA  
501 GGATGCCAAT GAGGACACCA TTGGGTTCCT GGTGCGCTTG ATCAGAGAA  
551 AGAAGAGAA TGCTCGGCCC CTGAGGAGC TGCTGAAAGA GTACCACAGC  
601 AAACAGCTGG TGCAGACGAG CCACAGGCCT GTGTCCAAGC TGCCGCCAGC  
651 GCGCCCGAAC GTGCCACACA TCTGCCCGCA CGCCACCAT CTCACACGG  
701 TGCAGGCTCT GGCCTCGCTC TCTGGCCCTT GCTGTCCCG CTGTAGCCAG  
751 AAGAGTGGC CCGAGGTGCT GCTGTCCCT GAGGCTGTAG CGGCCACT  
IIAA SEQUENCE 1.0  
ID ADP30682 standard; protein; 1194 AA.  
XX  
AC ADP30682;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1449.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406613P.  
PR

PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-040946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Heetir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
PT

XX Claim 1; SEQ ID NO 2680; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1194 AA;  
ADP30682 Length: 1194 February 22, 2005 12:25 Type: P Check: 8061 ..  
1 ATGGGCAGCT GCCTCTTCGA AGGGCTGCCT AGCCTACCCC CTATGGCTGC  
51 TTTCTGCGGA AATATGTTTG TGGAGCCGG CGAGCAGTGT GACTGTGGCT  
101 TCCTGGATGA CTGGTGGAT CCTGTGTGT ATTCTTTGAC CTGCCAGCTG  
151 AGGCCAGGTG CACAGTGTGC ATTCGACGGA CCCTGTTTTC AAAATTGCCA  
201 GCTGCGCCCG TCTGGCTGGC AGTGTCTGCC TACCAGAGGG GATTGTGACT  
251 TGCCTGAATT CTGCCCAGGA GACAGTCCC AGTGTCCCC TGATGTCAGC  
301 CTAGGGGATG GCGAGCCCTG CGCTGGCGGG CAAGCTGTGT GCATGCACGG  
351 GCGTTGTGCC TCCTATGCC AGCAGTGCCA GTCACTTTGG GGACCTGGAG  
401 CCCAGCCCGG TGGCCACATT TGCTCCCAT CAGCTATAC TCGGGGAAT  
451 GGGGGGGGGA GCTGTGGGCG CAACCCCACT GGCAGTTATG TGTCTGTCAC  
501 CCCTAGAGAT GCCATTGTG GGCAGTCCA GTGCCAGACA GGTAGGACCC  
551 AGCTCTGTCT GGGCTGCATC CGGGATCTAC TCTGGGAGAC AATAGATGTG  
601 AATGGGACTG AGCTGAACTG CAGCTGGGTG CACCTGGACC TGGGCAGTGA  
651 TGTGCCCCAG CCCCTCTGA CTCTGCTGG CACAGCCTGT GGCCTTGGCC  
701 TGGTGTGTAT AGACCATGA TGCCAGCGTG TGGATCTCCT GGGGGACAG  
751 GAATGTGAA GCAATGCCA TGGACATGG GTCTGTGACA GCAACAGGCA  
801 CTGCTACTGT GAGGAGGCT GGGACCCGCC TGACTGCACC ACTCAGTCA  
851 AAGCAACGAG CTCCTGACC ACAGGCTGC TCCTCAGCCT CTGTGTTCTTA  
901 TTGTTCTCTG TGATGTTGG TGCCAGCTAC TGGTACCGTG CCGCCCTGCA  
951 CCAGGACTC TGCCAGTCA AGGACCCAC CTGCCAGTAC AGGCGAGCCC  
1001 AATCTGTGTC CTCTGAACG CCGAGACTTC GCGAGAGGGC CTGTGTTGGA  
1051 CGAGGCACTA AGCAGGCTAG TGCTCTCAG TTCCCGGGCC CCCCTTCCAG  
1101 GCCCTGCCG CTTGACCCCTG TGTCCAAGAG ACTCCAGCT GAGCTGGCTG  
1151 ACCGACCCAA TCCCTCTACC CGCCTCTGCG CCGTGCACCC GGTG  
!!AA SEQUENCE 1.0  
ID ADP30688 standard; protein; 976 AA.  
XX  
AC ADP30688;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1455.  
XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.

PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493373P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2686; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 976 AA;  
SQ  
ADP30688 Length: 976 February 22, 2005 12:25 Type: P Check: 5287 ..  
1 CAGTATCTTT CAGATATAAC AGCGAGACT TCTTGCTGGA AGCGCAAGTG  
51 AGGGATCAGC CACGCTGGCT CTGGTCTGC CATGAGGGCT GGAGCCCCGC  
101 CTGGGGCTG CAGATCTGCT GGAGCCTTGG GCATCTCAGA CTCACCTACC  
151 ACAAGGGAGT AAACCTCACT GACATCAAC TCAACAGTTC CCAGGAGTTT  
201 GCTCAGCTCT CTCCTAGACT GGGAGGCTTC CTGGAGGAGG CGTGGCAGCC  
251 CAGCTGTGGC TCCTGGGCGC TGGCCGTGGC AGGCCAGCGT GGCCTCTGGC  
301 TTCCGCGACA CGTGTGGGGG CTCTGTGCTA GCGCCACGCT GGGTGGTGAC  
351 TGCTGCACAT TGTATGCACA GCATGGCCCC TGTGTGCACT TTCAGGCTGG  
401 CCGCCTGTG CAGCTGGCGG GTTCATGCGG GGCTGTGTCAG CCACAGTGCC  
451 GTCAGGCCCC ACCAAGGGGC TCTGGTGGAG AGGATTATCC CACACCCCT  
501 CTACAGTGCC CAGAAATCAG ACTACGACGT GCGCCTCCTG AGGCTCCAGA  
551 CCGCTCTCAA CTTCTCAGCA GACACTGTGG GCGCTGTGTG CTGCGCGGCC  
601 AAGGAACAGC ATTTTCCGAA GGGCTCGCGG TGCTGGGTGT CTGGCTGGGG  
651 CCACACCCAC CTAAGCCATA TCTTCTCATG CTTACAGCTC GGATATGCTC  
701 CAGGACACGG TGGTGCCTTT GTTCAGCACT CAGCTCTGCA ACAGCTCTTG  
751 CGTGTACAGC GGAGCCCTCA CCCCCGCAT GCTTTGGGCT GGCTACCTGG  
801 ACGGAAGGGC TGATGCATGC CAGGAGATA GCGGGGGCCC CTAAGTGTGC  
851 CCAGATGGGG ACACATGGCG CTAAGTGGGG GTGGTCAGCT GGGGCGGTGG  
901 CTGGCGAGAG CCCAATCACC CAGGTGTCTA CGCCAAGGTA GCTGAGTTTC  
951 TGGACTGGAT CCATGACACT GCTCAG

!!AA\_SEQUENCE 1.0  
ID ADP30699 standard; protein; 659 AA.  
AC ADP30699;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1466.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.

PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Helsenbeck RE, Huang MW, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2697; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 659 AA;  
ADP30699 Length: 659 February 22, 2005 12:25 Type: P Check: 9178 ..  
1 TAATACCGCC ACGAGTCTCA AAGTCGCTGG ACTACGAGGC CTGCGAGGCT  
51 TTCGAGTTCC GCGTGGGGCGC CACAGACCGC GGCTTCCCGG CGTTGAGCAG  
101 CGAGGCGCTG GTGCGGCTGC TGGTGTCTGA CGCCAACGAC AACTCGCCCT  
151 TCGTGTGTGA CCGCTGTGCG AAGCGTCTCG GCGCCCTGCAC CGAGCTGGTG  
201 CCCCGGGCGG CCGAGCGGGG CTACCTGGTG ACCAAGGTGG TGGCGGTGGA  
251 CGGCGACTCG GCGCAGAACG CTTGGTCTGC GTACCAGCTG CTCAGGGCCA  
301 CGGAGCCCGG GCTGTTCGCG GTGTGGGGCG ACAATGGCGA GGTGGCGACC  
351 GCCAGGCTGC TGAGCGAGCG CGACGTGGCC AAGCACAGGC TAGTGTGTCT  
401 GGTCAAGGAC AATGGCGAGC CTCGCGCTC GGCCACCGCC ACGTCAAG  
451 TGCTCTCGGT GGAGCGCTTC TTTCAGCCCT ACCTGCCGCT CCAGAGAGCG  
501 GCCCGGCGCC AAGCCGAGGC CGACTCGCTC ACTGTCTACC TGGTGTGGC  
551 GTTGGCCTCG GTGTCTGTCG TCTTCTCTTT CTCGGTGTCT CTGTTCTGTG  
601 CGGTGCGGCC TTGTGAGGAG GAGCAGGGCG GCCCGGCTCG GTGCTGCTC  
651 GGTGCTTGA  
IIA\_SEQUENCE 1.0

ID  
XX  
AC ADP30701;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1468.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
OS  
XX Homo sapiens.  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.



PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2699; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
XX Sequence 659 AA;  
ADP30701 Length: 659 February 22, 2005 12:25 Type: P Check: 9178 ..  
1 TAAATACGGCC ACGAGTCTCA AAGTCGCTGG ACTACGAGGC CTGCAGGCT  
51 TTCGAGTTCC GCGTGGCGC CACAGACCGC GGCTTCCCGG CGTTGAGCAG  
101 CGAGGCGCTG GTGCCGCTGC TGGTCTGGA CGCCAACGAC AACTCGCCCT  
151 TCGTGCTGTA CCCGCTGCAG AACGGCTCCG CGCCCTGCAC CGAGCTGGTG  
201 CCCCAGGCGG CCGAGCCGGG CTACCTGGTG ACCAAGGTGG TGGCGGTGGA  
251 CGGCGACTCG GGCCAGACCG CTTGGCTGTC GTACCAAGCTG CTCAGGGCCA  
301 CGGAGCCCGG GCTGTTCCGC GTGTGGGCGC ACAATGGCGA GGTGGCGACC  
351 GCCAGGCTGC TGAGCGAGCG CGAGCTGGCC AAGCACAGGC TAGTGGTGCT  
401 GGTCAAGGAC AATGGCGAGC CTCGCGCTC GGCACCGGC AGCTGCGAAG  
451 TGCTCTGTGT GGACGGCTTC TCTCAGCCCT ACCTGCCGCT CCCAAGAGCG  
501 GCCCCGGCCC AAGCCAGGC CGACTCGCTC ACTGTCTACC TGGTGGTGGC  
551 GTTGGCTCG GTGCTGCGC TCTTCTCTTT CTGGTGCTC CTGTTGCTGG  
601 CGGTGCGGCC TTGTCAGGAG GAGCAGGGCG GCCCGGTCG GTCGCTGCTC  
651 GGTGCTTGA  
IIAA\_SEQUENCE 1.0  
ID ADP30706 standard; protein; 5304 AA.  
XX

AC ADP30706;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1473.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0467139P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.

PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2704; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 5304 AA;  
ADP30706 Length: 5304 February 22, 2005 12:25 Type: P Check: 7333 ..  
1 ATGGCTGGG CGCTGGGCT GCTCGTGTG CTGCTGTGC TCCGGCTGCC  
51 CTGGCGGGTG CCGGGCCAGC TGGACCCAG CACTGGCCG CGGTCTCGG  
101 AGCACAACT CTGGCGGAC GAGCAATGCA GCATGTTAAT GTACCGGGT  
151 GAGGCTCTTG AAGATTTCAC AGGCCCGGAT TGTCTTTTG TGAATTTAA  
201 AAAAGGTGAT CCGTATATG TTTACTATAA ACTGCAAGA GGATGGCCTG  
251 AAGTTTGGG TGAAGTGTG GGACGCACTT TTGATATTT TCCAAAGAT  
301 TTAATCCAGG TAGTTCATGA ATATACCAA GAAGAGCTAC AAGTTCCAAC  
351 AGATGAGACG GATTTTGTGTT GTTTTGATGG AGGAAGAGAT GATTTTCATA  
401 ATTATATGT AGAAGACTT TTAGGTTTT TGGAACTGTA CAATTTCTGA  
451 GCTACAGATT CTGAGAAAGC TGTAGAAAA ACTTTACAGG ATATGAAAA  
501 AAACCTGAA TTATCTAAGG AAAGGAACC TGAACCTGAA CCAGTAGNAG  
551 CCAACTAGA GGAAGTGAT AGTGATTTCT CAGAAACAC TGAGGATCTT  
601 CAGGAACAGT TTACAACCTA GAAGCACCAC TCCCATGCAA ACAGCCAAGC  
651 AAATCATGCT CAGGAGAGC AGGCTTCATT TGAATCTTTT GAAGAAATGC  
701 TGCAGATAA ACTAAAGTG CCAGAAAGTG AAAACAACAA AACCAAGAT  
751 AGTTCTCAGG TCTCAATGA ACAGGATAG ATTGATGCT ATAACTTTT  
801 GAAAAAGAA ATGACTCTAG ACTTGAACAC CAAATTTGGC TCAACAGCTG

851 ATGCACCTGT ATCTGATGAT GAGACAAACA GACTCGTTAC TTCAATTAGAA  
901 GATGATTTTG ATGAGGAATT GGATACTGAG TATTATGCAG TTGGAAGA  
951 AGATGAGGAG AACCAAGAAG ACTTTGATGA GTTGCCATTA CTTACCTTTA  
1001 CAGATGGGA AGATATGAA ACTCCAGCA AGTCTGCGT TGAGAAATAT  
1051 CCAACAGATA AAGACAGAA TTCAATGAA GAGGACAGG TTCAGCTAAC  
1101 TGTGCCCTT GGCATCAAAA ATGATGATAA AAATATACTA ACAACCTGGG  
1151 GGGACACTAT CTTCTCTATT GTCACAGAG GTCAAGAAAC AAGAGATACG  
1201 ATGATTTTAG AGAGCTCTAG TTCAGAGAA GAAAAAGAAG ATGATGATGA  
1251 TGCAATTAGT CCAGATAGCA AACAGGGGAA ACCACAGTCA GCAACAGATT  
1301 ATAGTGACCC TGACAATGTA GATGATGTC TTTTATTGT AGACATTCTT  
1351 AAACAATA ATGACAAAGA AGTAAACGCA GAACATCACA TTAAGGAAA  
1401 AGGAGGGGA GTTCAGGAAT CCAAGAGGGG CTTGGTACAA GATAAGACAG  
1451 AATTAGAGGA TGAATAACAA GAAGGCATGA CTGTGCACAG TTCTGTTTCA  
1501 AGCAATAACC TCACTCTAT GCCAGCTGCT GAAAAAGGTA AAGACACATT  
1551 AAATCAGCT TATGATGATA CAGAAAATGA CTTAAAGGA GCAGCTATTTC  
1601 ATATCTCAA AGGAATGCTC CACGAAGAAA AGCCTGGAGA GCAGATTTTG  
1651 GAAGTGGCT CAGAGAGTGA ATCTGCACAG AAAGCTGCAG GGAATCAAT  
1701 GAATGACAGA AAGATTCAAC AGGAATCCCT GGGTAGTGCA CCACCTCATG  
1751 GAGATGACCA CCTTAACGA TCCAGAGACA GTGTGGAGG AGACGCTTTG  
1801 GTAATGGGG CCAAACTGCA CACGCTTTCA GTGGAGCATC AACGTGAGGA  
1851 ATTTAAAGAG GAATTAGTTC TTAATACTCA AAACCAACCT AGATTCTCTT  
1901 CTCACAGTGA GATTGATTG CCCAGAGAAC TGAAGACGA GGTTCCTCAT  
1951 CTGGGAAGAA ATCTTCCCTG GCAACAAGAA AGAGATGTGG CTGCCACAGC  
2001 CAGTAAGCAA ATGAGTGAGA AGATAAGGCT CTCTGAGGGA GAAGCCAAAG  
2051 AGGACTCCTT GGATGAAGAG TTTTTCATC ACAAGGCAT GCAGGSCACA  
2101 GAGGTAGGAC AGACAGACCA AACTGACAGC ACAGGAGGAC CAGCTTCTCT  
2151 TTCTAAAGTA GAAGAGGATG ATTATCCCTC TGAAGAACTA CTAGAGGATG  
2201 AAAACGCTAT AAATGCAAAA CGGTCTAAAG AAAAAACCC TGGGAATCAG  
2251 GGACGCGAGT TTGATGTTAA TCTCAAGTC CTTGACAGAG CAGTTTTAGG  
2301 GACCATTCAT CCAGATCCAG AAATTGAAGA AAGCAAGCAA GAACTAGTA  
2351 TGATTTTGA TAGCGAAAA ACNAGTGA CTGCTGCCA AGGGGTCAAC  
2401 ACAGGAGGCA GGGAAACCAA TACANTGGT GAAAAAGAAC GCCCTCTGCG  
2451 AGATAAGAAA GCACAGAGAC CATTGAAACG AAGTGACTTT TCTGACAGCA  
2501 TAAATTTCA GACTCCAGAA TTAGGTGAAG TGTTTCAGAA TAAAGATTCT  
2551 GATTATCTGA AGAACGACAA CCCTGAGGAA CATCTGAAGA CCTCAGGCT  
2601 TGCAGGGGAG CCTGAGGAG AACTCTCAA AGAGGACCAT GAGAACACAG

2651 AGAAGTACAT GGGCACAGAA AGCCAGGGGT CTGCTGCTGC AGAACCTGAA  
2701 GATGACTCGT TCCACTGGAC TCCACATACA AGTGTAGAGC CAGGGCATAG  
2751 TGACAAGAGG GAGGACTTAC TTATCATAG CAGCTTCTTT AAGAACAAC  
2801 AGTCTTTGCA GGGTTTCAG AAGTACTTTA ATGTCCATGA GCTGGAAGCC  
2851 TTGCTACAAG AAATGTCATC AAAACTGAAG TCAGCGCAGC AGGAGAGCCT  
2901 GCCCTATAAT ATGGAAAAAG TCCTAGATAA GGTCTTCCGT GCTTCTGAGT  
2951 CACAAATCTT GAGCATAGCA GAAAAATGC TTGATACTCG TGTGCTGAA  
3001 AATAGAGATC TGGGAATGAA CGAAAAAATC ATATTTGAAG AGGCTGCAGT  
3051 GCTTGATGAC ATTCAAGACC TCATCTATTT TGTCAAGTAC AAGCACTCCA  
3101 CAGCAGAGGA GACAGCCACA CTGGTGATGG CACCACCTCT AGAGGAAGGC  
3151 TTGGGTGGAG CAATGGAAGA GATGCAACCA CTGCATGAAG ATAAATTTCTC  
3201 ACGAGAGAG ACAGCAGAAC TTAATGTGCA GGTTCCTGAA GAAACCCACC  
3251 ACTTGACCA ACGTGTGATT GGGGACACTC ATGCCCTCAGA AGTGTACAG  
3301 AAGCCAAATA CTGAGAAAGA CTTGGACCCA GGGCCAGTTA CAACAGAAGA  
3351 CACTCCTATG GATGCTATTG ATGCANACAA GCNACCAGAG ACAGCGCGG  
3401 AAGAGCCGC AAGTGTACA CTTTGGAAA AGCAATCCT TCTAATATAT  
3451 TCATTCATGT TTTATTTAAT TAAGTCAGT GTCGGCAAGA ATGTGAGACA  
3501 GCGAGCGCAA TGGAGTCTG GAGCGGAAC AGTAAGCAGA GCACTGAGTG  
3551 GCGAAGGAAG AAAGCCCGC CACTGCAATG GGGCCCATC TGAGCGGTGG  
3601 TCCTTCCAG CTGTGACAGG AAGGGCCAGC TCGGGCCGG CACGAGAGAC  
3651 CTGCTTTTCT CTTTTCCTCC AGTGCCTGCC CACATCCTC TCCAGCCCT  
3701 ATTGCTCTT CTCTCCGTC CCCTCGATAG TTGTTTCCT CGCTCTGGC  
3751 CCGCCCTCG CCGCCCGCT CTTTGTGTC CTTGAGGTG GCCAGGGCA  
3801 GTGGCTGATG ACGTGTTTTA TAGCGGCAT AAAGCGAAG TGCAGGCAGC  
3851 TGTGGAAGGC GAAGTTCAAT CCCAGAGTCC GCCCCCTGAA TTGGGGCCTT  
3901 TCCGGAGGAG GAAGCTCTGA AAAACAGGGG GCCCAGTGCC ATTCGCGAGG  
3951 GAATGTGCG TTGGTTTCAG CTGTTCTACA CAATGGAATC AGTACCTGCC  
4001 ACTGTGCTT CTATGCGCG TACCCCGGG GACCCGGAAC TTGTGGGACC  
4051 CTTGTCTGTG CTCTACGAG CTTTCTATG CAAGCTGCTG GAGGTGACAG  
4101 TCCCATTTCC CGGGAGGGA CCCAAGCTGT CACAGCGGG TGGATGAGTT  
4151 CTAAGCAGAG TGGGTGCACT GATTTGCTGT GCAAAAGGAGA AATGAGAGTGT  
4201 GTCAGATCCG AGGAAAGCAA GAGCTTTCTA TGTGTTTAG GGAGCAGCT  
4251 AGTTGCTACA TTGCTGATG ATGTTACGCC TGGGCTGAT TTTTATGGAC  
4301 TGCCATGGA ACCTGTATTT ATCACTGCCT TCTTGGGAAT TGCCTCGTTT  
4351 GCCATTTTCT TATGAGAAC TGTCTTGTG GTGAGGATA GAGTATATCA  
4401 AGTCACGGA CAGCAATTT CTGAGAGTT GAAGACTATC ATGAAGAAA  
4451 ATACAGACT TGTACAAAA TTGTCAAATT ATGAACAGAA GGATAAAATC

4501 AAGACACTTG AAAAAATCA GGAAATTTCTG GATGACACAG CTAAAAATCT  
4551 TCGTGTATG CTAGAATCTG AGAGAGNACA GAATGTCAG AATCAGGACT  
4601 TGATATCAGA AAACAAGAA TCTATAGAGA AGTTAAAGGA TGTATTTCA  
4651 ATGAATGCCT CAGAAATTTT AGAGGTTTCTG ATTGCACCTTA ATGAAGCTAA  
4701 GCTTAGTGAA GAGAAGGTGA AGTCTGAATG CCATCGGGTT CAAGAAGAAA  
4751 ATGCTAGGCT TAAGAAGAA AAGAGCAGT TGCAGCAGGA AATCGAAGAC  
4801 TGGAGTAAAT TACATGCTGA GCTCAGTGAG CAAATCAAT CATTGAGAA  
4851 GTCTCAGAAA GATTTGGAAG TAGCTCTTAC TCACAAGGAT GATAATATTA  
4901 ATGCTTTGAC TAACTGCATT ACACAGTTGA ATCTGTTAGA GTGTGAATCT  
4951 GAATCTGAGG GTCAAAATAA AGGTGAAAT GATTCAGATG AATTAGCAAA  
5001 TGGAGAAGTG GGAGGTGACC GGAATGAGAA GATGAAAAAT CAAATTAAGC  
5051 AGATGATGGA TGTCTCTCGG ACACAGACTG CAATATCGGT AGTTGAAGAG  
5101 GATCTAAAGC TTTTACAGCT TAAGCTAAGA GCCTCCGTGT CCACCTAAATG  
5151 TAACTGGAA GACCAGGTAA AGAAATTTGA AGATGACCGC AACTCACTAC  
5201 AAGCTGCCAA AGCTGGACTG GAAGATGAAT GCAAAACCTT GAGGAGAAA  
5251 GTGGAGATTG TGAATGAGCT CTATCAGCAG AAGGAGATGG CTTTGCRAAA  
5301 GTAA

## !!AA SEQUENCE 1.0

ID ADP30712 standard; protein; 659 AA.

XX ADP30712;

XX

XX

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1479.

DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX

XX Homo sapiens.

OS

XX WO2004035732-A2.

XX

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

XX 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 17-SEP-2002; 2002US-0406666P.

PR 17-SEP-2002; 2002US-0410946P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.

PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476841P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2710; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX  
SQ Sequence 659 AA;  
ADP30712 Length: 659 February 22, 2005 12:25 Type: P Check: 9178 ..  
1 TAATACCGCC ACGAGTCTCA AAGTCGCTGG ACTACGAGGC CCTGCAGGCT  
51 TTCGAGTTCC GGTGGGCGC CACAGACGC GGCCTTCCCGG CGTTGAGCAG  
101 CGAGGCGCTG GTGCGCGTGC TGFTGCTGGA CGCAAACGAC AACTCGCCCT  
151 TGGTGTCTGA CCGCGTCGAG AACGGCTCCG CGCCCTGCAC CGAGCTGSGT  
201 CCCCCGGCG CCGAGCCGGG CTACTCTGGT ACCAAGGTGG TGGCGGTGGA  
251 CGCGGACTCG GGCCAGAAGC CTGGGCTGTC GTACCAGCTG CTCGAAGGCCA  
301 CGGAGCCCGG GCTGTTCGGC GTGTGGGCGC ACAATGGCGA GGTGGCGCAC  
351 GCCAGGCTGC TGAGCGAGCG CGAGCTGGCC AAGCACAGGC TAGTGGTGCT  
401 GGTCAAGGAC AATGGCGAGC CTCGCGGCTC GGCCACGGCC ACGCTGCAAG  
451 TGCTCCTGGT GGACGGCTTC TCTCAGCCCT ACCTGCCGCT CCCAAGAGCG  
501 GCCCGGGCCC AAGCCAGGCG CGACTCGCTC ACTGTCTACC TGGTGGTGGC  
551 GTTGGCTCG GTGTGCTGCG TCTTCCTCTT CTCGGTGTCT CTGTTCTGGG  
601 CGGTGGGCGC TGTGCAGGAG GAGCAGGGCG GCCCGGCTCG GTGCTGTCTC  
651 GGTGCTTGA  
!!AA SEQUENCE 1.0  
ID ADP30726 standard; protein; 939 AA.  
XX  
AC ADP30726;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1493.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471308P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2724; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 939 AA;  
SQ

ADP30726 Length: 939 February 22, 2005 12:25 Type: P Check: 2752 ..  
1 ATGGCATGG AGAATCAGAC CTTCAACTCT GACTTCCTCC TCCTGGGAAT  
51 CTTCAATCAT AGCCCCACCC ACACCTTCCT CTTCTTTCTG GTCCTGGGCA  
101 TCTTTTCAGT GGCCTTCATG GAAACTCCA TCATGGTTCT COTCATCTAC  
151 CTGGATACCC AGCTCCACAC CCCCATGTAC TTCTCTCTCA GCCAACTGTC  
201 CCTCATGGAC CTCATGCTCA TCTGCACCAC TGTACCCCAAG ATGGCCTTCA  
251 ACTACTTTGTC TGGCAGCAAG TCCATTCTTA TGGCTGGCTG TGCCACACAA  
301 ATTTTCTTCT ATATATCATT GCTTGGCTCC GAATGCTTTC TGTGGCTGT  
351 TATGTCTTAT GACCGCTACA CTGCCATTG CCACCCCTCTA AGATACACA  
401 ATCTCATGAG ACCCAAATT TGTGACTTA TGAATGCCCTT CTCCTGGATC  
451 CTGGGCTCTA CAGATGGAAT CATTGATGCT GTAGGACAT TTTCCTTCTC  
501 CTACTGTGGG TCTCGGAAA TAGCCCACTT CTGCTGTGAC TTCCTTCCC  
551 TACTAATCCT CTCATGCAAT GACACATCAA TATTTGAAGA GGTATATTTT  
601 ATCTGCTGTA TAGTAATGCT TGTTTTCCCT GTTGAATCA TCATCATTTC  
651 CTATGCTCGA GTTATTTCTGG CTGTCAATCA CATGGATCT GGAGAGGAC  
701 GTGCAAAAGC TTTTACTACT TGTTCCTCTC ACCTCATGCT GGTGGGAATG  
751 TACTATGGAG CAGTTTGTGTT CATGTGCAAT CAGCCACAT CTCATCATTC  
801 TCCTATGCAG GACAAGATGG TGTCTGTATT CTACACCATC GTCACTCCCA  
851 TGCTGAATCC TCTCATTTAT AGCTCCGCA ACAAGGAAGT GACCAGAGCA  
901 TTAATGAAAA TCTTAGGAAA GGSCAAGTCT GGAGATTGA  
!!AA\_SEQUENCE 1.0  
ID ADP30740 standard; protein; 1878 AA.  
XX  
XX AC ADP30740;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #1507.  
XX  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR

PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2738; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC

CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1878 AA;

ADP30740 Length: 1878 February 22, 2005 12:25 Type: P Check: 112 ..

1 ATGGATGSCCT TCATCCCACT GCCGAATATT CAAGTGTGTTA ACGAAGGGGC  
51 GCTGCCCGAA GCCCACTGGA GCTGCAGAGC TGGAGAGGCC CCTAGAGTCC  
101 ACCCAACAAC AACAGTGGCA ATCATCATCA CCATCATCAT CATCATCACC  
151 ATCATCATCA TCATCATGAT GTACAGCCACA GACACGTGGA CATTAGCCTT  
201 TATGGAGCTC ACCACCTTCC AGCCCTTGCT GCTGCTGGCT GGGAAATGGTC  
251 AGTTCCCTGT GCCTCTGGTC ATCATCCTTC TGCTCTCTGT GTCCAGCGAT  
301 CAGGACGCCA CGSCTCCGCC TGAAGCGATG GCCAGGCCCT ACCCCCCCGC  
351 CCAGTACCCC CCTCGCCAC AGAAGGCAT CCCTGCCGAG TACGCCCCGC  
401 CCCACCGCA CCCACGGCAG GACTACTCCG GCACAGCCCC GGTCCCCACA  
451 GAGCATGGCA TGACCTGTGA CACACCAGCA CAGACCCACC CCGAGCAGCC  
501 AGGCTCCGAG GCCACACAC AGCCCATCGC CGGGACCCAG ACAGTGCCGC  
551 CCCCCCCCC CGGCCCGAG AGCTGTGTGC CAGGTTGGC ACCAGGTGAG  
601 GGCACACAAC CCCCCTGGAG CTCCTGGAC CCAGATGCCA CCCAGAGGCC  
651 ACTGGGGCTT CCGGCCCTCT CGCCCAAGGG GACTTCTTTC TGCTGGATCC  
701 TCAAGACAG CTTGGGCCCC AGTCCGGAA AGSCCTTCTT GGAATTTCTG  
751 GAACACAGAG GCCTTTCTCT GCTCTCTCTC CCCCAGGAG GGTTTCCAGC  
801 CAGCAATTGS TGGGAAGTCC GTGTTTATCC AACTCAGGGC CTTTCCCGAC  
851 ACCTCACCA CCCAGTGTGT GATGAGTTAA TGCCACCTC GGACAGTCA  
901 CCGTGCATCC ACCCGCCGA TGCTGATGAA GCACCTGCCA CATGCTGGA  
951 GTTCTCTGTC TGTGATACA GCCAGGACCA AGCCAGACTG AAGGCCAGCC  
1001 TTGCCCAGAC AGACAGGGG GCACAGAGG ACAGCCAGCC GCTCCACCCC  
1051 TCCGACCCTA CAGAGAAGA GCAGCCCAAG CGGCTACACG TCTCCAACAT  
1101 CCCCCTCCGS TTCAGGACC CCGACTTGGC GCAAATGTTT GGGCAATTGG  
1151 GAAATATTTT AGACGTGGAG ATCATTTTITA ACGAGCGGGG CTCCAAGGCT  
1201 TTTGGGTTTG TAACTTTTGA AACTAGTCTCA GATGCTGACC GAGCCCGGGA  
1251 GAAGCTGAAT GGGACGACG TAGAGGGACG GAAATATTGAG GTCAATAATG  
1301 CACGGCCCCG AGTGATGACC AACAGAAGA CGGGGAACCC CTACACCAAC  
1351 GAAGCCTCAG CGCTGCCCTT AGACGGGATG GATCTCCCTG TTGCCGTGGA  
1401 CTTTCAGACG GTGTCAACCC CAGCCTCTCA TGGCCCCCCA TGTGATCGGC  
1451 CATACGTGGA GTCAGGCTGG AAGTCAATC CAGTGTGGC GCGAGTCTAC  
1501 GGGCCTGAAT TCTATGCAGT GACGGGGTTC CCCTACCCCA CCACCGGCAC

1551 AGCGGTGGCC TACCGGGGGG CACATCTTTCG GGGCCGGGGC CGGGCGGTGT  
1601 ATAATACATT TCGGGCTGGG CCACCCCCAC CCCCCATCCC GACTTACGGA  
1651 GCGGTGCTGT ATCAGGATGG ATTTTATGGT GCTGAGATTT ATGGAGGCTA  
1701 CGCAGCTAC AGATAGGCTC AGCCGGCTGC AGCGGGGGCA GCTACAGGG  
1751 ACAGTTACGG CAGAGTCTAC GCAGCTGCCG ACCCGTACCA TCACACCATC  
1801 GGGCCCGCGG CGACCTACAG CATTGGAACC ATGGCTAGCC TCTGCCGAGG  
1851 AGGTTACAGC CGCTTCACCC CTRACTAG  
!!AA\_SEQUENCE 1.0  
ID ADP30895 standard; protein; 594 AA.  
XX  
AC ADP30895;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1662.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406613P.  
PR 29-AUG-2002; 2002US-0406618P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406668P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2893; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPOMEB and is not in the specification.  
XX  
XX SQ Sequence 594 AA;  
ADP30895 Length: 594 February 22, 2005 12:25 Type: P Check: 8205 ..  
1 ATGTCATCAG TTAAGGCAGG AACAGCCAC CTGGATGTGT ACGTGCAGGT  
51 CACAGATGAA TTAATAAACA AAACCGTGTG TGAAGACAAG GAGCTGAAC  
101 TGCACCTGCCA TGAATCCAAG TTCCTCAACA TCTACTCTGT GACATATGGC  
151 AGGAGGACCC AGGNAAGGGA CATCTGCTCC TCCAAGCCAG AGCGGCTCCC  
201 CCCTTTTCGG CAAGAAGTGT CCAATCTCTA CAGACCCACA GAATCTAATG  
251 GATGTCTCTA TATTCTCTCT CCTAGAACCA CAGAGGATCC AGAACGGCAG  
301 CCGGTCTCTCA CTGGGCTGTT CCTGTCCATG TGCCTGGTCA CAGTGCTGGG  
351 GAAGTGCTC ATCATGTGTG CCTTCAGCCC TGACTCCACC CTCACACCC





XX DE Human secreted protein SEQ ID #1706.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410945P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411043P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.

PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX PS Claim 1; SEQ ID NO 2937; 428pp; English.  
XX CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytosstatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX SQ Sequence 1133 AA;  
ADP30939 Length: 1133 February 22, 2005 12:25 Type: P Check: 237 ..  
1 TCTGATCGTG AAGTAGAAG AGTCTCACA AACAGCCATT TGGAAAAA  
51 GAAGTGTGAT GAGTATATTC CAGGTACAAC CTCCTTAGGC ATGCTCTGTTT  
101 TTAACCTAAG CAACGCCATT ATGGGCAGTG GGATTTTGGG ACTGCGCTTT  
151 GCCCTGGCAA ACACCTGGAAT CCTACTTTTT CTGGTACTTT TGACTTCAGT  
201 GACATTGCTG TCTATATATT CAATAAACCT CCTATTGATC TGTTCAAAG  
251 AACAGGCTG CATGGTGTAT GAAAAGCTGG GGGAAACAACT CTTTGGCACC  
301 ACAGGGAAGT TCGTAATCTT TGGAGCCACC TCTCTACAGA ACACCTGGAGC  
351 AATGCTGAGC TACCTCTTCA TCGTAATAAAA TGAACACTACC TCTGCCATAA  
401 AGTTTCTAAT GGGAAAGGAA GAGATGCATT TTCCCCAGAC CTGTACGTTG  
451 GATGGCCGCG TTCTGGTGGT GATAGTTACC TTGGCATAA TTCTCCCTCT  
501 GTGTCTCTTG AAGNACTTAG GGTATCTTGG CTATACTAGT GGATTTTCCT  
551 TGAGCTGTAT GGTTTTTTTC CTAATTGTGG TGTATGCTTTT ACCCACCATT  
601 GCATTTGCAAT TTGTTTGGCA CCGTCAAGTC CTGCCAATTT ACAGTGAGCT  
651 TAAAGACCGA TCACAGAAAA AAATGCAGAT GGTTCACAA ATCTCCCTTTT  
701 TCGCCANGTT TGTATGTATC TTCTTGACTG CCAATTTTGG CTACTTGACA  
751 TTCTATGACA ACGTGCAATC CGACCTCCTT CACAAATATC AGAGTAAAGA  
801 TGACATTCTC ATCTGACAG TCGGGCTGGC TGTCAATGTT GCTGTGATCC  
851 TCACAGTGCC GGTGTTATTT TTCAGTTTAT CAACTTGTG GTGATCTTCA

901 TACCTCCAT GAAGGATATT TTGGAGTCG TAGGAGTTAC ATCTGCTAAC  
951 ATGCTTATT TCATCTTCC TCACTCTTT TATTAAAA TCACAGCCA  
1001 GGATGGAGAT AAGGAACATC AAGAATTG GGTGCCCTT TTCTGGGCC  
1051 TGGGGTGT GTTCTCCTTG GTCAGATTC CTTGGTCACT CTATGACTGG  
1101 GCCTGCTCAT CGAGTAGTGA CGAAGGCCAC TGA

!!AA SEQUENCE 1.0  
ID ADP30950 standard; protein; 367 AA.  
XX  
AC ADP30950;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1717.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX

28-AUG-2003; 2003WO-US026780.  
XX  
29-AUG-2002; 2002US-0406576P.  
PR  
29-AUG-2002; 2002US-0406579P.  
PR  
29-AUG-2002; 2002US-0406585P.  
PR  
29-AUG-2002; 2002US-0406588P.  
PR  
29-AUG-2002; 2002US-0406608P.  
PR  
29-AUG-2002; 2002US-0406611P.  
PR  
29-AUG-2002; 2002US-0406612P.  
PR  
29-AUG-2002; 2002US-0406616P.  
PR  
29-AUG-2002; 2002US-0406640P.  
PR  
29-AUG-2002; 2002US-0406842P.  
PR  
29-AUG-2002; 2002US-0406646P.  
PR  
29-AUG-2002; 2002US-0406653P.  
PR  
29-AUG-2002; 2002US-0406655P.  
PR  
29-AUG-2002; 2002US-0406666P.  
PR  
17-SEP-2002; 2002US-0410946P.  
PR  
17-SEP-2002; 2002US-0410947P.  
PR  
17-SEP-2002; 2002US-0410948P.  
PR  
17-SEP-2002; 2002US-0410949P.  
PR  
17-SEP-2002; 2002US-0410953P.  
PR  
17-SEP-2002; 2002US-0410957P.  
PR  
17-SEP-2002; 2002US-0410958P.  
PR  
17-SEP-2002; 2002US-0410959P.  
PR  
17-SEP-2002; 2002US-0410960P.  
PR  
17-SEP-2002; 2002US-0410961P.  
PR  
17-SEP-2002; 2002US-0410962P.  
PR  
17-SEP-2002; 2002US-0411019P.  
PR  
17-SEP-2002; 2002US-0411022P.  
PR  
17-SEP-2002; 2002US-0411023P.  
PR  
17-SEP-2002; 2002US-0411024P.  
PR  
17-SEP-2002; 2002US-0411032P.  
PR  
17-SEP-2002; 2002US-0411035P.  
PR  
17-SEP-2002; 2002US-0411037P.  
PR  
17-SEP-2002; 2002US-0411041P.  
PR  
17-SEP-2002; 2002US-0411045P.  
PR  
17-SEP-2002; 2002US-0411046P.  
PR  
17-SEP-2002; 2002US-0411048P.  
PR  
17-SEP-2002; 2002US-0411052P.  
PR  
17-SEP-2002; 2002US-0411055P.  
PR  
17-SEP-2002; 2002US-0411073P.  
PR  
17-SEP-2002; 2002US-0411082P.  
PR  
17-SEP-2002; 2002US-0411101P.  
PR  
17-SEP-2002; 2002US-0411111P.  
PR  
18-APR-2003; 2003US-0463700P.

18-APR-2003; 2003US-0463708P.  
PR  
18-APR-2003; 2003US-0463716P.  
PR  
18-APR-2003; 2003US-0463732P.  
PR  
02-MAY-2003; 2003US-0467199P.  
PR  
02-MAY-2003; 2003US-0467201P.  
PR  
02-MAY-2003; 2003US-0467203P.  
PR  
02-MAY-2003; 2003US-0467230P.  
PR  
19-MAY-2003; 2003US-0471306P.  
PR  
19-MAY-2003; 2003US-0471336P.  
PR  
22-MAY-2003; 2003US-0472420P.  
PR  
22-MAY-2003; 2003US-0472430P.  
PR  
09-JUN-2003; 2003US-0476609P.  
PR  
09-JUN-2003; 2003US-0476641P.  
PR  
08-JUL-2003; 2003US-0485218P.  
PR  
08-JUL-2003; 2003US-0485223P.  
PR  
08-JUL-2003; 2003US-0485224P.  
PR  
08-JUL-2003; 2003US-0485325P.  
PR  
14-JUL-2003; 2003US-0486446P.  
PR  
14-JUL-2003; 2003US-0486480P.  
PR  
15-JUL-2003; 2003US-0486891P.  
PR  
15-JUL-2003; 2003US-0486960P.  
PR  
08-AUG-2003; 2003US-0493341P.  
PR  
08-AUG-2003; 2003US-0493370P.  
PR  
08-AUG-2003; 2003US-0493573P.  
PR  
08-AUG-2003; 2003US-0493577P.  
XX

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2948; 428pp; English.  
XX

The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer) inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX

SQ Sequence 367 AA;

ADP30950 Length: 367 February 22, 2005 12:25 Type: P Check: 5321 ..

1 ATGCCCCACT CCCACTCAT CTTAGGCTGC TTTGTGGTAA AGAAGCAAG  
51 AGTGTTCCT CTGACTCCT GGTGGCAGT GGTCTGTGAT GGAAGCTTC  
101 CATTCTCTT CCAGATCCTC TGGACCTTCT CCATCTACCT GGAGTCCGTG  
151 GCTATCCTTC CGCAGCTATT TATGATCAGC AAGACTGGGG AGGCCGAGAC  
201 CATCACACC CACTACCTGT TCTTCCTGGG CCTCTATCGT GCTTTGTATC  
251 TTGTCAACTG GATCTGGGCG TTCTACTTTG AGGGCTTCTT TGACCTCAT  
301 GCTGTGGTGG CGGGGTAGT CCAGACCATC CTATACTGTG ACTTCTTCTA  
351 CTTGTACATT ACAAAA

!!AA SEQUENCE 1.0  
ID ADP30952 standard; protein; 1132 AA.  
XX  
AC ADP30952;

XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1719.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
OS WO2004035732-A2..  
XX 29-APR-2004.  
PD 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406618P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406668P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 18-APR-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 02-MAY-2003; 2003US-0467230P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 22-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 09-JUN-2003; 2003US-0472430P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 08-JUL-2003; 2003US-0485218P.

PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Halshan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2950; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 1132 AA;  
SQ  
ADP30952 Length: 1132 February 22, 2005 12:25 Type: P Check: 736 ..  
1 GTACCGTACA GAGTGGATTG GCAGGGCAGT GGCATGGAGC CCCTCTTCCC  
51 CGCGCCGTTT TGGAGAGTTA TCTACGGCAG CCACCTTCAG GGCAACCTGT  
101 CCCTCCTGAG CCCCAACCAC AGTCTGCTGC CCCCGCATCT GCTGCTCAAT  
151 GCCAGCCACG GCGCTTTCCT GCCCTTCGGG CTCAGAGTCA CCATCGTGGG  
201 GCTTACCTG GCGGTGTGTG TCGGAGGGCT CTTGGGGAAC TGCCTTGTCA  
251 TGTAGTCTAT CCTCAGGCAG GCACACCAAA ATGAAGACAG CCACCAATAT  
301 TTACATCTTT AACCTGCCCC TGGCCGACAC TCTGTCCTG CTGACGCTGC  
351 CTTTCCAGGG CACGGACATC CTCCTGGGCT TCTGGCCGTT TGGGAATGCG  
401 CTGTGCAAGA CAGTCATTGC CATTGACTAC TACAACATGT TCACCAGCAC  
451 CTTACCCCTA ACTGCCATGA GTGTGATCG CTATGTAGCC ATCTGCCACC  
501 CCATCCGTCG CCTCGAGTTC CGCAGGTCCA GCAAAGCCCA GGCTGTCAAT  
551 GTGGCCATCT GGGCCCTGGC CTCTGTTGTC GGTGTTCCCG TTGCCATCAT  
601 GGGCTCGGCA CAGGTCGAGG ATGAAGAGAT CGAGTGCCTG GTGGAGATCC  
651 CTACCCCTCA GGATTACTGG GGGCCGGTGT TTGCCATCTG CATCTTCCTC  
701 TTCTCCTTCA TCGTCCCGGT GCTCGTCATC TCTGTCTGCT ACAGCCTCAT  
751 GATCCGGGGG CTCGCTGGAG TCGGCTGCTC CTCGGGCTCC CGAGAGAAGG  
801 ACCGGAACCT GCGGCGCATC ACTCGGCTGG TGCTGGTGGT AGTGGCTGTG

851 TTCGTGGGCT GCTGGAGGCC TGTCAGGTC TTCGTGCTGG CCCAAGGGCT  
901 GGGGGTTTCA GCGAGCAGCG AGACTGCCGT GGCCATTCTG CGGTTCTGCA  
951 CGGCCCTGGG CTACGTCAAC AGTGCCTCA ACCCATCTCT CTACGGCTTC  
1001 CTGATGAGA ACTTCAAGC CTGCTCCGC AAGTTCTGCT GTGCATCTGC  
1051 CTTGCCCGG GAGGTGACG TGTCGACG CGTGGCAGC ATTGCCAAGG  
1101 ACGTGGCCCT GGCCTGCAAG ACCTCTGAGA CG

!!AA SEQUENCE 1.0

ID\_ADP30997 standard; protein; 1654 AA.

XX ADP30997;

XX DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1764.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 29-AUG-2002; 2002US-0406666P.

XX 17-SEP-2002; 2002US-0410946P.

XX 17-SEP-2002; 2002US-0410947P.

XX 17-SEP-2002; 2002US-0410948P.

XX 17-SEP-2002; 2002US-0410949P.

XX 17-SEP-2002; 2002US-0410953P.

XX 17-SEP-2002; 2002US-0410957P.

XX 17-SEP-2002; 2002US-0410958P.

XX 17-SEP-2002; 2002US-0410959P.

XX 17-SEP-2002; 2002US-0410960P.

XX 17-SEP-2002; 2002US-0410961P.

XX 17-SEP-2002; 2002US-0410962P.

XX 17-SEP-2002; 2002US-0411019P.

XX 17-SEP-2002; 2002US-0411022P.

XX 17-SEP-2002; 2002US-0411023P.

XX 17-SEP-2002; 2002US-0411024P.

XX 17-SEP-2002; 2002US-0411032P.

XX 17-SEP-2002; 2002US-0411035P.

XX 17-SEP-2002; 2002US-0411037P.

XX 17-SEP-2002; 2002US-0411041P.

XX 17-SEP-2002; 2002US-0411045P.

XX 17-SEP-2002; 2002US-0411046P.

XX 17-SEP-2002; 2002US-0411048P.

XX 17-SEP-2002; 2002US-0411052P.

XX 17-SEP-2002; 2002US-0411055P.

XX 17-SEP-2002; 2002US-0411073P.

XX 17-SEP-2002; 2002US-0411082P.

XX 17-SEP-2002; 2002US-0411101P.

17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471308P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2995; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX Sequence 1654 AA;

ADP30997 Length: 1654 February 22, 2005 12:25 Type: P Check: 5840 ..

1 GCCACGGGG TGAGTACCC CAGTACCAG ACAAGGAAC CAAAGCCACA

51 ATGGGCACAG AAACACACC TGGAGGCAA GGCAGCCCG ACCCTCAGGA

101 CGTGGCGCCA AGTGTTGTTCC ATACATCAA GCTGTTGCTT CTGTGCCACA

151 GCTGCTGCA GCTGGCGCAG CTCATGATCT CCGGCTACCT AAAGAGCTCC

201 ATCTCCACAG TGGAGAAGG CTTGGGCTC TCAGGCCAGA CGTCGGGGCT

251 GCTGGGCTCC TTCACGAGG TGGGGAACAC AGCCTTGATT GTGTTGTGA

301 GCTATTTTGG CAGCGGGGTG CACGACCCC GAATGATGG CTATGGGGCT

351 ATCCTTGTGG CCCTGGCGGG CTGCTCATG ACTCTCCCG ACTTCATCTC

401 GGAGCCATAC CGTACGACA ACACGACCC TGTGTGGGG ATCATGTTGG

451 TGGCAGACG CCTGCTGGGC GTGGGCGGGG TGCCCAATTC A GCCCTTTGGC  
501 ATCTCTACA TCGATGACTT TGCCCAAC AGCAACTCGC CCTCTACCT  
551 CGGGATCCTG TTTCAGTGA CCATGATGGG GCCAGGCTTG GCTTTGGGC  
601 TGGGAGCCTT CATGTGGGC CTTTATGTGG ACATTAACCA GATGCAGAA  
651 GGTGTATATCA GCTGACCAT AAAGGACCCC CGATGGGTGG GTGCCCTGGT  
701 GCTGGGTTTC CTCATCGCTG CCGGTGCAGT GGCCTGGCT GCCATCCCT  
751 ACTTCTCTT CCCCAAGAA ATGCCCAAGG AAAACGTGA GCTTCAGTTT  
801 CGGCGAAAGG TCTTAGCAGT CACAGACTCA CCGCCAGGA AGTCTTCCC  
851 AGGTGCTGC TGCAGACCT AGCCACCCC ATCTTCTGCG TGGTGGTCT  
901 GTCCCAAGTA TGCTTGTCAT CCATGGCTGC GGGCATGGCC ATCTTCTGCG  
951 CCAAGTTCTT GGAGCGCCAG TTTTCCATCA CAGCCTCCTA CGCCAACCTG  
1001 CTCATCGGCT GCCTCTCCTT CCCTTCGGTC ATCGTGGGA TCGTGGTGG  
1051 TGGCGTCTG GTCAAGCGGC TCCACCTGGG CCTGTGGGA TGGGTGGCC  
1101 TTTGCTGCT GGGATGCTG CTGTGCTCT TCTTCAGCCT GCGGCTCTTC  
1151 TTTATCGGCT GCTCAGCCA CCAGATTGG GGCATCACAC ACCAGACCAG  
1201 CTGGTGGTGC CTTCTCTGCT CTTGGTCAGC CTGGGCTCGG CCTTGGCCTG  
1251 TCTCACCCAC ACACCCTCCT TCATGCTCAT CCTAAGAGGA GTGAAGAAAG  
1301 AAGACAGAC TTTGCTGTG GGCATCAGT TCATGTTCTT GAGGATTTTG  
1351 GGCCTGGATG CCCAGCCCG TGATCCACGG CAGCGCCATC GACACCACCT  
1401 GTGTGCACTG GSCCCTGAGC TGTGGCGTC GAGCTGTCTG TCGCTACTAC  
1451 AATATGACC TGCTCCGAAA CCGTTTCATC GGCCTCAGT TCTTCTTCAA  
1501 AACAGTTCT GTGATCTGCT TCGCCTTAGT TTTGGCTGTG CTGAGGCAGC  
1551 AGGACAAAGA GGCAAGGACC AAAGAGAGCA GATCCAGCCC TGCCGTAGAG  
1601 CAGCAATTGC TAGTGTGGG GCCAGGAAG AAGCCAGAGG ATTCCGGAGT  
1651 GTGA

!!AA SEQUENCE 1.0  
ID \_ADP31017 standard; protein; 363 AA.

XX ADP31017;

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1784.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO20004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406578P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-048646P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Heatir K, Beaurang PA, Behrens D;

Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3015; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 363 AA;  
ADP31017 Length: 363 February 22, 2005 12:25 Type: P Check: 1833 ..  
1 ATGCCCTGGC AGCCCGCCCC TTCCACAC CGCTCCCG GCACACGCCG  
51 CACCTGFCAG CCTCTGAGC TCCGAGGTGC GGTGACGGCT GAGCCACTGC  
101 CTGAGCCGCT GCTCCACGTC CTGGGCCCTTA GCTTCCCGCT GCAGACCTGC  
151 CGGCCGATTC TTGCTGCCCC TCCGGTCTC ATGAGCGGC TGGTCTGTGT  
201 TGTCACAGGC GGTCCCGCGC CGCTGGCATC CTTGAGAAAG ATGGCTACAC  
251 ACACCTTTCT CGAGGAGAGT TACTTTCATGA TGAAGGAAG AGCCAGATT  
301 CACAGTATGG TGAACCTACT GAAATTACA TTAAGAGAGG AAACATGGGA  
351 CCAGTGGAGA TAA  
!!AA SEQUENCE 1.0  
ID ADP31026 standard; protein; 2201 AA.  
XX  
AC ADP31026;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1793.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.

17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471308P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3024; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is

CC available on WIPWEB and is not in the specification.

XX SQ Sequence 2201 AA; ADP31026 Length: 2201 February 22, 2005 12:25 Type: P Check: 8557 ..  
1 CCTCTGACCA GTTGCTGAC ATGAGAGAGC TGACCATCTG GGAACAGCAC  
51 ACGGCCACAC TGTCCAAGGA CCCCGCGCG GGTCTTGGCA TTGCGATCTC  
101 TGGAGGCCGA GACCGGCCCG GTGGATCCAT GGTGTATCT GAGCTGGTAC  
151 CTGGAGGGCC GCGGAGGGC AGGCTACAGA CCACATCGTC ATGGTGAACG  
201 GGGTTTCCAT GGAGAATGCC ACCTCCGCGT TTGCCATTCA GATACTCAAG  
251 ACTGACCA CAATGAGCCCA CATCACAGTG AAACGTCCCC GGAGGATCCA  
301 CTGCCCCGCC ACCAAGCCA GCCCTTCAG CCCAGGGCGC CAGGACTCGG  
351 ATGAAGACGA TGGGCCCCAG CCGGTGGAGG AGGTGGACCA GGGCCGGGCG  
401 TATGAGGGG ACTCATCCAG TGGCTCCGGC CGCTCTCTGG ACGAGGGCTC  
451 CCGCCGGCCG AGGCTGTGTC GCGGGGGCCG GCGCGGAGC CATGGGCGTA  
501 GGAGCCGAGG TGGTGGCTCT GAGGCCAAG GGTGGCCCT GGTGTCCGCG  
551 TTTAGCGGC TGCCACGGCA GGAGCTGCAG ATGAAGCCTG TGAAGTCAGT  
601 GTGTGTGAAG AGGAGAGACA GCGAAGAGTT TGGCGTCAAG CTGGGCAATC  
651 AGATCTTCAT CAAGCACATT ACAGATTCGG GCCTGGCTGC CCGGCACCGT  
701 GGGCTGACG AAGGAGATCT CATCTACAG ATCAACGGGG TGCTAGCCA  
751 GAACCTGTCA CTGAACGACA CCGGGCGACT GATTGAGAAG TCAGAAGGGA  
801 AGCTAAGCCT GCTGTGTGCT AGAGATCGTG GGCAGTTTCT GGTGAACATT  
851 CCGCTGCTG TCAGTGACAG CGACAGCTCG CCATTGGAGG TCGGCTGGC  
901 AGGGGGCAAT GACGTGGGCA TCTTCGTGTC CGGGGTGCAG GCGGGCAGCC  
951 CCGCCGACGG GCAGGGCATC CAGGAGGAG ATCAGATTGT GAATGACGTG  
1001 CCATTCCAGA ACCTGACAG GGAGGAGGCA GTGCAGTTCC TGCTGGGGCT  
1051 GCCACCAGC GAGGAGATGG AGCTGGTGAC GCAGAGGAAG CAGGACATTT  
1101 TCTGGAAT GGTGAGTCC CGGTGGGTG ACTCCTTTCTA CATCCGCACT  
1151 CACTTTGAGC TGGAGCCAG TCACCGTCT GGCCTGGGCT TCACCGGTGG  
1201 CGACGTCTTC CACGTGTGG ACACGTGCA CCCCGGCCCC GGGCAGAGCC  
1251 ACGCAGAGG AGGCCACTGG CTGSCGTGC GCATGGGTG TGACCTGCGG  
1301 GAGCAAGAC GGGGATCAT TCCCAACAG AGCAGGGCGG AGCAGCTGGC  
1351 CAGCTTGAH GCTGCCAGA GGGCGGTGG AGTCGGGCCC GGCCTCTCGG  
1401 CGGGTCCAA TGCTCGGCC GAGTTCTGGC GGTGCGGGG TCTTGTGCA  
1451 GGAGCCAAGA AGACACTCA GCGAGCGGT GAGGACCTCT CAGCTCTGAC  
1501 CCGACAGGGC CGTACCGCG CCTACGAAC AGTGTGTGTT GCGAAGGAC  
1551 AGCCCTCCA AGATCATCA ACTAGACAC GTGCGGGTGA TTGCAGAAA  
1601 AGACAAGCAT GCGTCTCTGG ATGTGACCC CTCGCGCATC GAGCGCCTCA  
1651 ACTATGTGCA GTACTACCCC ATTGTGTGCT TCTTCATCCC CGAGAGCCGG

1701 CCGGCCCTCA AGGCACCTGC CCAGTGGCTG GCGCTTGCCT CCGCGCGCAG  
1751 CACCCGTGCG CTCTACGCAC AAGCCAGAA GCTGCGAAAA CACAGCAGCC  
1801 ACTCTTAC AGCCACCATC CTCTGATG GCACGAGTGA CACTTGGTAC  
1851 CAGGAGCTCA AGGCATCAT TCGAGAGCAG CAGACGCGGC CCATCTGGAC  
1901 GCGGAAGAT CAGCTGGATG GCTCTTTGGA GGACAACTTA GACCTCCCTC  
1951 ACCAGGGCT GCGCAGAGC TCGCTGACC TCAGCTGCGA CAGCCGCGTT  
2001 AACAGCGACT ACAGAGCGGA CCGCGAGGGC GCGCGGTACA CGGATGGCGA  
2051 GGGCTACACA GACGCGAGG GGGGGCCCTA CACGGATGTG GATGATGAGC  
2101 CCGCGCTCC AGCCTGGCC CGTCTCTCGG AGCCCGTGCA GGCAGATGAG  
2151 TCCAGAGCC CGAGGATCG TGGGAGATC TCGGCTCATC AGGGGGCCCA  
2201 G  
!!AA SEQUENCE 1.0  
ID ADP31035 standard; protein; 1365 AA.  
XX AC ADP31035;  
XX AC  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1802.  
DE  
XX  
XX Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.

PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H,  
XX WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3033; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1365 AA;  
ADP31035 Length: 1365 February 22, 2005 12:25 Type: P Check: 3732 ..  
1 ATGTGTTTCAG CTGGAGTGGG AAGGACAAGG ACTATTTTGA AGCCCAGGAC  
51 ACCACAGAAG AGACGAGAAC AAGGTGGAGT TTTTGACAAA GGAGAGTGG  
101 CTGGAGCCAA GGCTTTCTTG GGGATCAGGA AAGGAGAAAA CCAAAATGAG  
151 CGAAAGGGA GGCTGCTAAA AAATCAGAA AATGAAGCTT ATTTTAAAG

201 CTGGTATCAG AAGCTACTAG CTGCTCTCCA ATTCTGTGCA GGTAAAGCCT  
251 TGAATCATGA GTTTTCCCAAG GAGCAGAAAC TTATCAAAAT TCTGGGAGAT  
301 ATTGGGGAAG GAGTCAAGTC TGCCAGTGAC CATCAAGAC AGGAGGTACT  
351 GAAGAAAGAA ATTGCAGAC TAGAAGAGTT CTTTCAAGAT GTAAATACTT  
401 GTCATCTTCC TGTGAACCTT GCCCTATGTA TAAAAGGGAT TGATCAGAT  
451 GCATGTTTCAT ATTTTACATC TAATGCTTTG CCATTGAAGA TTACTTTTCAT  
501 CAATGCTAAT CCGATGGGCA AAAACATCAG CATTATTTT AAGGCTGGAG  
551 ATGATCTTCG TCAGGATATG CTTGTTCTGC AGCTTATTCA AGTGATGGAC  
601 AATATTTTGGC TGCAGGAAGG CTTGGATATG CAAATGATCA TTTATAGATG  
651 TCTATCCACA GGAAGAGACC AAGCTCTCCC TACGAGCGCG GCCCCTGCT  
701 CCAGGGGGCC CAGTCCCATC GACCACCTAA GGGCTGAGGA GTGTGGGCGC  
751 ACGGCGCAGG ACTGCGAGGC AGTCCACCT GCAGCCCCAA TCGGAGATCC  
801 ACTGGGTGAC GCCAGCTGGG CTCCTGAGTC TGGTAGGGAC GTGAACCTTT  
851 ACCTCTACCT CAGGAGTTGT AATGCAACCA ATCAGCGCGG TGTCAAAACA  
901 GACCACTCGG CTCTACCAAT CAGCAGGATG TCCGCACTT CACTCCTGAG  
951 CCAGCGAGAC CACGAACCCA CCAGAAGGAA GAAACTCCGA ACACATCCGA  
1001 ACATCAGAA GAACAACTC CAGACGGGCC ACCTTAAGAG CTGTAACACT  
1051 CACCGCGAAG GATTTGGTGA GATGTTACCT GATGCTGTGA CCCTAGCAAA  
1101 GATTTCATCG CATTCTGGAC TGATAGGACC ATTGAAAGAA AATACAATTA  
1151 AAGAGTGGTT CAGTCAGCAC AACCACTTA AGCAGATTA TGAAGAAGTG  
1201 TCCTGAACA ATTCCTCTGA ATTCAGTTCT CCAGGAATCT GGAATTTCTA  
1251 TTTTCGACACT CAGACCAACT CTGAGGCTCC CATAAACTTT CAAACTTCTA  
1301 AGAGAGAAA ATTAATCTT AGTTATGATT ATGAAGGATT TCACATCCTG  
1351 CATATAAACA AATGA  
!!AA SEQUENCE 1.0  
ID ADP31048 standard; protein; 2104 AA.  
XX  
AC ADP31048;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1815.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR



PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471338P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
PS Claim 1; SEQ ID NO 3046; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.

SQ Sequence 2104 AA;

ADP31048 Length: 2104 February 22, 2005 12:25 Type: P Check: 5063 ..

1 CTCCTCTCAGG ATGAGCACAA GCCTGGGAGA TGGCAGTGAT GGAATATGCC  
51 TGCCCCAGGTG CCCCTGGCTC AGCAGTGGGG CAGCAGAAGG AACTCCCCAA  
101 AGCCAAGGAG AAGACGCCGC CACTGGGGAA GAAACAGAGC TCCGTCTACA  
151 AGCTTTAGGC CGTGGAGAAG AGCCCTGTGT TCTGGCGAAA GTGGGAGATC  
201 CTGAATGACG TGATTACCAA GGGCACAGCC AAGGAAGGCT CCGAGGCAGG  
251 GCCAGCTGCC ATCTCTATCA TGCCCCAGGC TGAGTGTGAG AATAGCCNAG  
301 AGTTCAGCCC CACCTTTTCA GAACGCATTT TCATCGCTGG GTCCAAAACAG  
351 TACAGCCAGT CCGAGAGTCT TGNATCAGTC CCNACNATG TGGCCCATGC  
401 TACAGAGGCG AATATGCCCC GTGTGTGTTG GAAAGGAAAG CGTCGCAGCA  
451 AAGCCCGGAA GAAACGGAAG AAGAAGAGCT CAAAGTCCCT GGCTCATGCA  
501 GGAGTGGGCT TGGCCARACC CCTCCCCAGG ACCCTCTGAGC AGGAGAGCTG  
551 CACCATCCCA GTGCAGTGC CTGGCCCCACA COTGGAGCCC AGCTGCCTGT  
601 CTCGTGGTGC CCATGAGAAG TTTTCTGTGG AGGAATACCT AGTCATGCT  
651 CTGCAAGGCA CGGTGAGCTC AGGCCAGGCC CACAGCCTGA CCAGCCTGGC  
701 CAAGACCTGG GCAGCAAGGG GTTCCAGATC CCGGGAGCCC AGCCCCAAAA  
751 CTGAGGACAA CGAGGGTGTG CTGCTCCTG AGMAACTCAA GCCAGTGGAT  
801 TATGAGTACC GAGNAGNAGT CCNCTGGGCC AGCACCACAG TCCGCTTGGG  
851 CAGAGGCTCC TTCGGAGAGG TGCACAGGAT GGAGGACAAG CAGACTGGCT  
901 TCCAGTGGCG TGTCMAAAG TATGGAGCTG TGAGAGAAGG GCCTTGGGTC  
951 AACATCTTCA TGGAGCTGCT GGNAGTGGC TCCCTGGGCC AGCTGGTCAA  
1001 GGAGCAGGGC TGTCTCCAG AGGACGGGC CTTGTACTAC CTGGGCCAGG  
1051 CCCTGGAGGG TCTGGAATAC CTCCACTCAC GAAGGATTCT GCATGGGGAC  
1101 GTCAAAGCTG ACAACGTGCT CCTGTCCAGC GATGGAGGCC ACGCAGCCCT  
1151 CTGTGACTTT GGCCATGCTG TGTGTCTTCA ACCTGATGGC CTGGGAAAGT  
1201 CTTTGTCTAC AGGGAGCTAC ATCCCTTGGA CAGAGACCCA CATGGCTCCG  
1251 GAGTGTGTGC TGGGCAGGAG CTGGCAGGCC AAGTGGATG TCTGGAGCAG  
1301 CTGCTGTATG ATGCTGCACA TGCTCAACGG CTGCCACCCC TGGACTCAGT



ADP31051 Length: 1431 February 22, 2005 12:25 Type: P Check: 8408

1 GAGATCCCC GAGACCTCAC GCTGGATGCC CTGCTGGAGA TGAATGAGGC  
51 CAAGGTGAAG GAGACGCTGC GGCCTGTGG GGCACGGGG GATGAGTGTG  
101 GCGGTCTGCA GTATGCCCTC ACTGCTCTGC GGAAGTGAC AGGCCTGGGA  
151 GGGGAGCACA AGGAGACTC CAGTTGGAGT TCATTGGATG CGCGGGGGGA  
201 AAGTGSCTCA GGGCCTTCCA CGGACACCTC CTCAGCAGCC AGCCTGCCCT  
251 GGGCCCCAGG GAGTCTCCAG CTGGGAGAG CAGGCAACAG CGCCAGGGGC  
301 CCACGCTCCA TCTCGTGTCT AGCTCTTCCC GCCTCAGACT CCCCCACCCC  
351 CAGCTTCAGT GAGGCGCTCT CAGACACCTG TATTCCCTCG CAGGCCAGGG  
401 GCGGGTGAC CCCCCTGTC CTGCACAGCT TCATCACCCC GCCACACACA  
451 CCCCAGCTGC GACGGCACAC CAAGCTGAAG CCACCACGGA CGCCCCCCCC  
501 ACCCAGCCG AAGTCTTCCC AGTGTCTGCC CAGTTCCCC ACACTCACCC  
551 GGAGCAAGTC CATTGAGTCT CAGTGGGGA ACCGATTGA TGACGCTCTC  
601 TCGATGAGCA TGGATCCCCA CAGATGTATC GGAGGATAT CGGGCTGTGG  
651 GTGACGCACA GCTGGTGCAA GCATGTGCTT GTGTCCGCC TCTGAGGTT  
701 CTCACCAAG TCCTGGGTGT GCGAGGTCTG CCACGTGTGC CAGAAGACA  
751 TGATATTTGG AGTGAAGTGC AAGCATTTGCA GGGCTTTCGGA GGACAGAATC  
801 TGTCCCTCTG GACATCAACA ACCGGTGA CAGAGCAGCC GNAACCCATT  
851 TTGGAAACCT CCCCAAGCA CTGACAAGA AGGAGCACCC TCCGGCCATG  
901 AATCACCTGG ACTCCAGCAG CAACCCCTTCC TCCACCACTC COTCCACACC  
951 CTCCTCACCG GCGCCCTTCC CGACATCATC CAACCATCC AGCGCACCA  
1001 CGCCCCCAA CCCCTCACT GGCAGCGGG ACAGCAGGTT CAATTCCTCA  
1051 GCGTGAAGAG CCAGAGGCTG GCAAGTCAGA GGCAGAAGAC GATGAGGACG  
1101 AGGTGGACA CTTCGGAGC TCTCGCGGC CCTGGCGGG CCCCATCTCT  
1151 CGCAAGGCA GCCAGACAG CGTGTACTG CAGGAGTGGG ACATCCCTCT  
1201 CGAGCAGGTA GAGCTGGGCG AGCCCATCGG GCAGGSCCGG TGGGSCCGG  
1251 TGCACGGGG CCGTGGCAT GGGGAGGTGG CCAATGCGCT GCTGGAGATG  
1301 GACGGCCACA ACCAGGACCA CTTGAAGCTC TTCAAGAAAG AGGTGATGAA  
1351 CTACCGGAG ACGGGCATG AGAAGTGGT GCTCTTTCATG GGGGCTGCA  
1401 TGAACCCGCC CCACCTGGCC ATTATACCA G

!!AA SEQUENCE 1.0  
ID ADP31073 standard; protein; 1083 AA.

XX AC ADP31073;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1840.

XX DE Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX WO2004035732-A2.  
PN 29-APR-2004.  
XX  
PD  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.

PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H,  
XX  
XX WPI; 2004-348438/32.  
DR  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3071; 428pp; English.  
PS  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic.  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 1083 AA;  
SQ  
ADP31073 Length: 1083 February 22, 2005 12:25 Type: P Check: 4797 ..  
1 GACCAACAGC TCTGATGAGC TCCACAGTGG CTGCAGCTGC GCCTCGAGCT  
51 GGGGCTGCCT CCAGGAAGGA GTCTCCAGGC AGATGGGGCC TGGGGGAGGA  
101 TCCACAGGC GTGAGCCCTT CGCTCCAGTG CCGCGTGTGC GGAGACAGCA  
151 GCAGCGGAA GCACATATGC ATCATGCTT GCAACGGCTG CAGCGGCTTC  
201 TTCAGAGGA GGTACGGCG GAGGCTCATC TACAGGTGCC AGTGGGGGCG  
251 AGGATGTGC CCGTGGACA AGGCCACCG CAACCACTGC CAGGCCTGCC  
301 GGCTGAAGAA GTGCCTGCAG GCAGGGATGA ACCAGGACGC GGGGCCCCAC  
351 ACCATGTCT GCAGCCAGAG CCTGGGCCA CCATTCTATG CCAGCCTTTA  
401 TAACAGCTGA AACCTGTGCT AAGCTGGAGC CAGAGGATGC TGATGAGAAT  
451 ATTGATGCA CCAGCAATGA CCTGAGTTC CTTTCTCTCC CCTGGGCGCT  
501 GGACAGCATC CATGAGACCT CGGCTGGCTT ACTTCTCATG CGGTCGAAGT  
551 GGGCCAAAGAA CCTGCCTGTG TTCTCCAGCC TGCCCTTTCC GGATCAGGTG  
601 ATCTGTCTGG AAGAGCGGTG GAGTGAACCT TTTCTCTCTG GGGCCATCCA  
651 GTGGTCTCTG CCTCTGGACA GCTGTCTCTT GCTGGACCG CCGAGGCGCT  
701 CTGTGCGCGG TGGTGGCCAG GGGCCGGTCA CGTGGCCAG CATGGAGAGC  
751 CGTGTCTCTG AGGAACATAT CTCTCGGTTT CGGSCATTGG CGGTGGACCC  
801 CAGGAGTTT GCCTGATGA AGGCCTTGGT CCTCTTCAAG CCAGAGACGC  
851 GGGGCGCTGAA GGATCTCTGAG CAGCTAGAGG CTTTGCAGGA CCAGTCCCAA  
901 GTGATGCTGA GCCAGCACAG CAAGSCCCAC CACCCGACGC AGCCCGTGAG  
951 GTTTGGAAA TTGCTCTGCG TCCTCCCGTC TTTGAGGTTT ATCACTGGCG  
1001 AACGCATCGA GCTCCTCTTT TTCCGCAAGA CCATAGGGAA TACTCCAATG  
1051 GAGAAGCTCC TTTGTGATAT GTTCAAAAC TAG

!!AA SEQUENCE 1.0  
ID ADP31111 standard; protein; 429 AA.  
XX  
XX ADP31111;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1878.  
DE  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411011P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.

PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3109; 428pp; English.  
PS  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 429 AA;  
ADP31111 Length: 429 February 22, 2005 12:25 Type: P Check: 2413 ..  
1 ATGCTAGGA GGGCGGGAG CGGTACGCTG CCGTCCCC GGGCTGGGA  
51 GGAGGCCAGG GACTACGACG GCAGGTCTT CTACATTGAC CACACACCA  
101 GGAGGACCAG CTGGATGAC CCGCGGACA GTGGGCGCC GCGCGCGGG  
151 GCGCGGGCCC GTTCGGACAC GGGCGGTGTT GTCCCGGAGA CCGGCGCGG  
201 CGGGGGGCTG GGGCGGCGCC GGCGCGGGT GCCCGAGGG GTCCCGGGAG  
251 GGATGTGGG CTGCTGCTC CGCGGGGCGC GAGGAGCGC CCGTACCGGG  
301 GCTCTCCGC CCACCGGCTT CCGACGCC CTTCCGGGAC CCGGCCCGGA  
351 GGCAAGGCTG GAGTCGTGC CCGGGCGGA CCGCGGGGC CAGGCTAAG  
401 GACCCGAGG GCCACCTGAG CCCTGTTAG  
11AA SEQUENCE 1.0  
ID \_ADP311146 standard; protein; 2535 AA.  
XX  
AC ADP311146;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1913.  
DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX  
OS Homo sapiens.  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 02-MAY-2003; 2003US-0467230P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 22-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 09-JUN-2003; 2003US-0476641P.  
XX 08-JUL-2003; 2003US-0485218P.  
XX 08-JUL-2003; 2003US-0485223P.  
XX 08-JUL-2003; 2003US-0485224P.  
XX 14-JUL-2003; 2003US-0485325P.  
XX 14-JUL-2003; 2003US-0486446P.  
XX 15-JUL-2003; 2003US-0486891P.  
XX 15-JUL-2003; 2003US-0486960P.  
XX 15-JUL-2003; 2003US-0486961P.  
XX 15-JUL-2003; 2003US-0486966P.

PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493373P.  
PR 08-AUG-2003; 2003US-0493377P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PA  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3144; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 2535 AA;  
SD  
ADP31146 Length: 2535 February 22, 2005 12:25 Type: P Check: 2736 ..  
1 ATGGGATTT CAGCTGGTGC AATATTTCTC ACTCATTTACT TTAAACACCA  
51 AAACCTAAGT GACCTGCGCA TGCCCCAFTT CACCTACGAC AGCTCAGTGG  
101 TTGAGGAGCT AAAGCACCGC GCCCCCTTCA GTCTTACCAA CTTCGGGCTG  
151 GCCCCTGTGT CCGAGAGG GGACTTCCCA GGTCCGCGAG TCCTTGATCC  
201 TAGTGGGCGT TTGGGAAC TGGAAATCTT TGAGCGGTCA AGGGAAGAC  
251 AAGCCGACTC TTCCAGATCC TGTGACACA CTGCTGCTC TTCCATAGTC  
301 CGCTAAAGC CCTGCTGTGT GGCCAGGTG GATAGTGCC TCTACCCTGG  
351 GCTCATCTGG CTACACAGG ACTCTAAAG CTTCAGATT CCTGGAAC  
401 ATGCCACCCG GCATAGCCCT CAACAAGAAG AGGAATAATC CATTTTAAAG  
451 GCCTGGGCTG TAGAGACAGG GAAGTACCAG GAAGGGGTGG ATGACCCTGA  
501 CCCAGCTAAA TGGAAAGGCC AGTSGCGTG TGCTTCTCAAT AAGAGCAGAG  
551 AATTCAACCT GATGTATGAT GGCACCAAGG AGGTGCCCAT GAACCCAGTG  
601 AAGATATATC AAGTGTGTGA CATCCCTCAG CCCAGGGCT CGATCATTTAA  
651 CCCAGGATCC ACAGGGTCTG CTCCTGGGA TGAGAAGGAT AATGATGTGG  
701 ATGAAGAAGA TGAGGAAGAT GAGCTGGATC AGTGGCAGCA CCATGTTCC  
751 ATCCAGACA CTTTCCCTT CTTGNACATC AATGGTTCTC CCATGGCGCC  
801 AGCCAGTGTG GGCATTTGCA GTGTGGCAA CTGCAGCCCG GAGGCAGTGT  
851 GGCCCCAAAC TGAACCCCTG GAGATGGAAG TACCCAGGC ACCTATACAG  
901 CCCTTCTATA GCTCTCCAGA ACTGTGGATC AGCTCTCTCC CAATGACTGA  
951 CTGGACATC AAGTTTCACT ACCGTGGAA GGAGTACGG CAGACATGA  
1001 CCGTGAGCAA CCTCAGGCG TGCCGACTCT TCTATGGGGA CTGCGTCCC

1051 ATGCTGTACC AGGAGGAGCT CTTTGGTCCC GTGAGCTGG AGCAGGTCAA  
1101 ATTCCAGGT CTTGAGCATA TTACCAATGA GAAGCAGAAG CTGTTCACTA  
1151 GCAAGCTGCT GAGCTCATG GACAGAGGAC TGATCCTGGA GGTACGCGT  
1201 CATGCCATTT ATGCCATCAG GCTGTGCCAG TGCAAGGTGT ACTGGTCTGG  
1251 GCCATGTGCC CCATCAGTTG TTGCTCCCAA CTTGATTGAG AGACAAAAGA  
1301 AGGTCAAGCT ATTTTGTCTG GAAACATTC TTAGCGATCT CATGCCAC  
1351 CAGAAAGGAG AGATAGAA GCAGCCACCG TTTGAGATCT ACTTATGCTT  
1401 TGGGGHAGAA TGGCCAGATG GGAACCAATT GGAAGGAAA CTCATCTTGG  
1451 TTCAGGTCTAT TCCAGTAGTG GCTCGGATGA TCTACGAGAT GTTTTCTGCT  
1501 GATTTCCACAC GATCCTTTGA TAGTGGCAGT GTCCGCTGC AGATCTCAAC  
1551 CCCAGACATC AAGGATAACA TCGTTGCTCA GCTGAAGCAG CTGTACCGCA  
1601 TCCTTCAAAAC CCAGGAGAGC TGGCAGGCCA TGCAGCCAC CCCAGCATG  
1651 CAACTGCCCC CTGCCCTGCC TCCCCAAATA ATCATTTCCC TTGTAATGCT  
1701 CAGCATCCGC ATCTGTCTTG ACTGCAAACT TGCTGAAGAT CTCATGTCTAT  
1751 CACCGAGCCC TCAGCTGCTG GTGGCAGTG CTCAGCAGAC CCTTGGCATG  
1801 GGAAGAGAGC GGAGTCCACC CCAAGCCATC TGCCCTTCACT TAGCTGGAGA  
1851 GGTGCTGGCT GTGGCCCGGG GACTGAAGCC AGCTGTGCTC TATGATTGCA  
1901 ACTGTGAGG GGCATCAGAG CTCAGAGACT ATCTGGAGGA GCTGAAGGGG  
1951 CTTGGCTTCC TGACTTTTGG ACTTCACATC CTTGAGATTG GAGAAAACAG  
2001 CTTGATTGTC AGTCTGAGC ATGTATGTCA GCATTGGAG CAGGTGCTGC  
2051 TTGTTACCAT AGCCTTTGTG GATGTTTTCA GCTGCCAGCG TCACCCCTTCT  
2101 GTCTGTCCC TGGACCACTG TCAGGACTTG AAGGCCCTCG TGGCTGAGAT  
2151 CATCACACAT TTGAGGGGC TGCAGAGGGA CTTATCTCTA GCAGTCTCTT  
2201 ACAGCAGGCT CCAATCTCA GACTGGAATC TGTGTACTGT ATTTGGGATC  
2251 CTCTGGGCT ATCTGTCTCC CTATACCTTT CACCTGAACC AGGGAGATGA  
2301 CAACTGCTTA GCTCTGACTC CACTACGAGT ATTCAGTGC CGATCTCAT  
2351 GGTGTGAGG TCAACCCCA ATCTGTCTCT ATTTCTTTAG TGTCCCAGAG  
2401 AGTTTGTTC CAGGCTGAG GGACATTTCTA AACACCTGGG AGAAGGACCT  
2451 CAGAACCCGA TTTAGGACTC AGAATGACTT TGCTGATCTC AGCATCTCTT  
2501 CTGAGATAGT CACTGTCCG GCTGTGGCCC TCTGA

!!AA SEQUENCE 1.0

ID ADP31167 standard; protein; 950 AA.

XX

AC ADP31167;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1934.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

XX cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.  
XX WO2004035732-A2.  
XX PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463718P.  
XX 18-APR-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 02-MAY-2003; 2003US-0467230P.  
XX 19-MAY-2003; 2003US-0471308P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 22-MAY-2003; 2003US-0472430P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 09-JUN-2003; 2003US-0476641P.  
XX 08-JUL-2003; 2003US-0485218P.  
XX 08-JUL-2003; 2003US-0485223P.  
XX 08-JUL-2003; 2003US-0485224P.  
XX 14-JUL-2003; 2003US-0486462P.  
XX 14-JUL-2003; 2003US-0486480P.  
XX 15-JUL-2003; 2003US-0486891P.  
XX 15-JUL-2003; 2003US-0486960P.  
XX 08-AUG-2003; 2003US-0493341P.

PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Heatir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3165; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 950 AA;

ADP31167 Length: 950 February 22, 2005 12:25 Type: P Check: 8125 ..

1 GACTGTTCGA GGACAGTAAC CACCTCCCGA TGGTTTCTGT GGCTGGATCA  
51 GGCACCAGAA GAGGCTCCCC AGCTGTAACCT CTAGTGCAGT TACCTTCGGG  
101 CCAAACTATA CATGTCGAGG GAGTAATTCGA GACACCACAG CCATGGGGTTA  
151 TTCAGTCATC AGAATAACAC ACCGTTTCAGG TAGCAGCAAT TGCAGAGACA  
201 GATGAATCTG CAGAAATCAGA AGCTGTAATTT GATTCTCATA AACGTAGAGA  
251 AATCCTTTCA CGAAGACCCCT CTTATAGGAA AATCTGAAT GAACGTCTCT  
301 CTGATGTGCC TGGTGTTCCTCC AGATTGGAAG AAGAGAGATC AGAGGAAGAA  
351 GGAACACCAC CTAGTATTGC TACCATTGGCA GTACCAACTA GCATATATCA  
401 GACTAGCAGG GGGCAATACA TTGCTATAGC CCAAGGTGGA ACAATCCAGA  
451 TTTCTAACCC AGGATCTGAT GGTGTTTCAGG GACTGCAGGC ATTAACAATG  
501 ACAAAATTCAG GAGCTCCTCC ACCAGGTGCT ACNATTGTAC AGTAGGCAGC  
551 ACAATCAGCT GATGGCACAC AGCAGTTCTTT TGTCCCAGGC AGCCAGGTTG  
601 TTGTTCAAGA TGAGGAAACT GAACTTGCCC CAAATGCACAT GGCTGCTGCC  
651 ACTGCTGACA TGCCAACTTA CCAGATCCGA GCTCCTACTG CTGCTTTGCC  
701 ACAGGAGTG GTGATGGCTG CATCGCCCGG AAGTTTGCAC AGTCCCCAGC  
751 AGCTGGCAGA AGAAGCAACA CGCAACGAG AGCTGAGGCT AATGAAAAAC  
801 AGGGAGCTG CCAAGAATG TCGACGTCCA AAGAAGAAT ATGTAAATG  
851 TCTGGAGAGC CGAGTTGCAG TGTGGAAAT CCAGAACCAAG AAGCTTATAG  
901 AGGAACCTGA AACCTTGAAA GACATTGTTT CTCCCCAAAAC AGATTACTAG

!!AA SEQUENCE 1.0  
ID\_ADP31212 standard; protein; 474 AA.  
XX  
AC ADP31212;

XX 12-AUG-2004 (first entry)  
DT Human secreted protein SEQ ID #1979.  
XX  
DE  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
PN  
XX  
XX 29-APR-2004.  
PD  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
PF  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR

PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0484448P.  
PR 14-JUL-2003; 2003US-0484800P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3210; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 474 AA;  
ADP31212 Length: 474 February 22, 2005 12:25 Type: P Check: 543 ..  
1 ATGGCATCTG TAGCAGAGAG AGTTGGNAAT CGAATTCACC GGGCAAAAGC  
51 CATTCAGGT CAAGGAAATG GTGGAGCCA AGCCCTGGCA GTAGAAGAGC  
101 CCAAGTCCTG TGGGCCCTTT GTGGTTATTC AGATGAAGAA AGATCAGGAG  
151 GTCTCAGAT GCAGAAACA AGATATTAGG GGAGTAGAAA GGGAGCCAAG  
201 GCCCGCAACT CTTCCCGCT ACAACCGGT GATTCATGC AAGACTGTGG  
251 GCGTGGAGCC GGCAGCCCAT GGCAGAGGTG TCCTGGTGGT CACGAAGCGG  
301 AGATCCGGCC AGCGAGCGCC TGCCATCTCC TACGTGGGA CCATCATCAA  
351 CRAAGACGCT GGAGCCAAC TCAGCAGCAT CAGATACATG ATCCGCAAGA  
401 ACAAGTACCG CCTCACCTG CCATGGCTGC CATCAGCAAG GCCAGGGCCA  
451 TCCTGGCAG CCAGAGTGCT GTGA  
!!AA SEQUENCE 1.0  
ID ADP31220 standard; protein; 876 AA.  
XX  
XX ADP31220;  
AC  
XX  
XX 12-AUG-2004 (first entry)  
DT  
XX  
XX Human secreted protein SEQ ID #1987.  
DE  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS  
XX





XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW Cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 18-APR-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0463719P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 02-MAY-2003; 2003US-0467230P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 22-MAY-2003; 2003US-0472430P.  
XX 09-JUN-2003; 2003US-0476509P.  
XX 08-JUL-2003; 2003US-0476541P.  
XX 08-JUL-2003; 2003US-0485218P.  
XX 08-JUL-2003; 2003US-0485223P.  
XX 08-JUL-2003; 2003US-0485224P.  
XX 14-JUL-2003; 2003US-0485325P.  
XX 14-JUL-2003; 2003US-0486446P.

PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3276; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 702 AA;

ADP31278 Length: 702 February 22, 2005 12:25 Type: P Check: 430 ..

1 ATGGAGAGCG AGCGGACAT GTACCGCCAG TTCACGAGCT GTGCTCTAG  
51 GACTTACGGS GACTCAGCA AGACCAAGAC GGTGACCCGT AAAAAATACG  
101 AACGGATCGT CCAGTCTCTC AATGGCTCCG AGTCGAGCTC CAGGNCAC  
151 GCCAAATTTA AATTCTGGGT CAAATCGAAG GGCTTCCAGC TGGGCCAGCC  
201 GGACGAGGTC CGCGGGGAG CGCGGGCGC CAAGCAAGTG CTCTACGTGC  
251 CTGTCAAGAC CAGGTGAGT GACTCGCCTT CTCTGTATT TTGTCTGCCG  
301 GAGCAGCCCG CGCGGGAGG AGGAAGGAGA GAGCGGGAG AGAGGGGAG  
351 CGGTGAGCG CGTTTGGCTC GTGTGCCCC TACCTTCTC AACCCCTCC  
401 CCAAGTCGTC CCCACTCGA TTAGCCAGGC GCGTTTCCC CACTGTACAG  
451 TCTTTGTGGT CTTTATTTT AAAGCGGAG CGCACCTCCA GAGCTGGCCT  
501 CCCTCCCGC CTCGGTTC CGGACCGGCT GCAGGAGCTT CCTTCCCGG  
551 GTCGGGGCGG GCGGTCTGGC GTCTCGGGC TGGGCCATTG TCCATGTCC  
601 TTCTCTGGG GCGTGGCGG TGTCCACCG CGGCCACCG GCCTAAGGC  
651 CAGGCTGGA GCCCGCGCG ACCTCTGAG AGCAGGAG TCTGATCGAT  
701 AG

!!AA SEQUENCE 1.0  
ID ADP31304 standard; protein; 900 AA.  
XX  
XX ADP31304;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2071.  
DE

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
PN  
XX  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406658P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.

PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3302; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 900 AA;  
ADP31304 Length: 900 February 22, 2005 12:25 Type: P Check: 3085 ..  
1 ATGGGGGTCC GGCACATGCA CACAGCCAGG CTTGTCTGGCT GTGCAGAGC  
51 AGGCGCGCCC CAGGTGCCAG CAAGGTGTCT GTCTCCCTGC AAGGTGCGAG  
101 CTGGACCAGG CTTACCACAA GCAGCTTCCA TGACTGGCAC CAGGACACAC  
151 AGTGTATCCC AGAACTTGG AACACCAGG CAGAGCCCTA AAGAGGTCTT  
201 CAGCAGAGAG GGTGACTCCT CTCTGCAGCT GGTATCCCA TTATCTCTTT  
251 GGGTCCGGCT GAGTATGGGG CTTTATGGG CATTAGAGGG GAGGAGTTTC  
301 ATGCCAACTG GTCCACGGG AGCCATTGGC AGGCCTGGAA AAGCACAAG  
351 TTCCCACTCT GGTCCACAGG ATCAGCAGCT CGGCCCCAG GCTCCAGGCC  
401 TTCCCTGGCT TGAAGAAGGA GCNAGGCTCC CACTTGTCCA TGGCTCCAC  
451 TGGTCCATG GAGTGACAG CCTTGGCCAC ATTTTCCCA CAGCAACAGC  
501 AGGTGAGGTG CAGGTATGC CACACCCTGG CCAACCGCAC ACAACAAT  
551 TCGATGCTCT CAGGCTGGC TCCCNACTCC TGCTGCCACC ACCTGCACCT  
601 CCCCACTGGG GCCAGCATGA CGGCAGTGGC TGCTCCAGAT GGCCCACTGC  
651 TGCCATCAAT AGCGCGCGCC GCCAGCACCG GACCCGGAGC CGCCATGCC  
701 AAGTGCCCCA AGTGCGACAA GGAAGTTTAC TTCGCCGAGA GGGTGACCTC  
751 TCTGGCAAG GACTTGCCTC GGCCCTGCCT GAAGTGCAG AATGTGGAA  
801 GACGCTGACC TCCGAGGGCC ACGCTGAGCA CGAAGCAAG CCTTACTGCA  
851 ACCACTTGCT ATGCCGCCAT GTTTGGGCAA AAGGCTCTG GCCGGGTGA  
IIAA SEQUENCE 1.0  
ID ADP31406 standard; protein; 1194 AA.

XX ADP311406;  
AC  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2173.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 18-APR-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 02-MAY-2003; 2003US-0467230P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 22-MAY-2003; 2003US-0472430P.  
XX 09-JUN-2003; 2003US-0476609P.

PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3404; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 1194 AA;

ADP311406 Length: 1194 February 22, 2005 12:25 Type: P Check: 2221 ..

1 ATGCTGTGTG CCTGCTCTCT CTGCCCCAGC CTCCTGGGGG CCACCCAGGC  
51 CAGCCCCACC TCAGGCCCCC AGGAGTGTGC AAAGGGCTCC ACGGTGTGT  
101 GTCAGGATCT GCAGACAGCT GCCAGGTGCG GGGCTGTGGG GTACTGCCAA  
151 GGGGCGGTAT GGAACAAACC CACGCGAAG TCTCTGCCCT GCGACGTATG  
201 CCAGGACATA GCAGCGCGCG CTGGCAATGG GCTGAACCTT GACGCCACGG  
251 AGTCTGACAT CCTTGCTTTG GTGATGAAGA CTTGTGAGTG GCTCCCGAGC  
301 CAGGAGTCTT CAGCCGGATG CAAGTGGATG GTGGATGCCC ACAGTTGCGC  
351 CATCTTGAGC ATGCTCCGTG GGGCCCCGGA CAGTGCCCGG GCACAGGTCT  
401 GCACAGGCTT CAGCTCTGTG GAGCCGCTGC AGAGGCACCT GGCCACCTTG  
451 AGGCCACTCT CCAAGAGAGA CACCTTTTGA GCTGTGGCTC CGTTTCATGC  
501 CAATGGGCCC CTTACTTCC ACCCCGCCA GGGCGCTGAA GGAGCTCTCT  
551 GCCAAGACTG TGTACGGCAG GTCTCCGAC TCACGAGGC TGTCCGGTCC  
601 AACTTGACCT TGGCCGACTT GAACATCCAG GAGCAGTGTG AGTCTTTGGG  
651 GCCTGGCCTG GCCGTCTCT GCAAGAACTA CCTCTTCCAG TTTTGTGTC  
701 CTGCTGACCA AGCACTGAGG CTTCTCCCCC CGCAGGAGCT CTGCGAGGAG  
751 GGGGGATTCT GTGAGGAGCT AGGGGCACCT GCCCGTTTGA CTCAGTAGT

801 GGCATGGAC GGGTCCCT CCCTGGAGCT GGGTTGCCA AGGAACAGA  
851 GCGAGATGCA GATGAAGCC GGTGTGACCT GTGAGGTGTG CATGAACGTG  
901 GTGCAGAAC TGGACCACTG GCTCATGTCC AACAGCTCTG AGCTCATGAT  
951 CACCCATGCC CTGAGCGCG TGTGCTCGGT AATGCTTGCC TCTATCAGA  
1001 AGGAGTGCAT CATCTTGGTG GACACCTACA GCCCTTCTT GGTGAGCTT  
1051 GTGGCCAAA TCACCCAGAG GAAGGTGTGC AAGTTTCATCC GTCTGTGTGG  
1101 CAACCGGAG CGGGCCCGG CAGTCCATGA TGCTATGCC ATCGTCCGT  
1151 CCCAGAGTG GGACGCGGAG AACCAGGCA GCTTCTGCAA TGGN  
!!AA SEQUENCE 1.0  
ID \_ADP31427 standard; protein; 264 AA.  
XX  
AC ADP31427;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2194.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406645P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406665P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.

PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3425; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 264 AA;  
SQ  
ADP31427 Length: 264 February 22, 2005 12:25 Type: P Check: 3586 ..

1 ATGCCTAGTG TTTTGTACGT TGTATATTGC ATTGAGAATA TTTTTCCTCT  
51 TCTCACCTAT CCACAAATGCA ATGCCGTTCC CATGATGCAC CTCTGCTTGC  
101 TGTTTACCTG TATGTTAATT CGCTTGAATC CCATTGGCCC ACTGCCATCA  
151 TGTGCTCGCT GCCTGTATT AAAAGACTCA GTCGACTGCC AAAGCAATGA  
201 AGCGACCTCT CGAAGCAACT GTAGACCTGG TACTTTGACC TTTCACCTTT  
251 CGCTTTGCAT GTAG

!!AA SEQUENCE 1.0  
ID \_ADP31564 standard; protein; 270 AA.



PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406658P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485221P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Halenbeck RF, Linnemann T;  
PI

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3643; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 603 AA;  
ADP31645 Length: 603 February 22, 2005 12:25 Type: P Check: 5851 ..  
1 ATGTCAACTC AAACGTAGGC CAAGGGCAGG CACAGCCTGA ACTTAAACTA  
51 TGGAAACTGC ACCTTGGGCC TGCACACAGA GAGGCTGAGG TCCCTGGCAG  
101 GCAAGCAGCA TGGGCAGAA GCTATGGGA ATGCAGTCTG CTCAGTCTAT  
151 TTTTACAGAA AACCAAGT AGATATTGCC AGCAATGCAAT TATCAACGGT  
201 GTTGCTGCCA GAAAGACAAC GAGAGCTCTT TTCTGAAAAA TGGACCCATC  
251 ATCAGTCACC AAGACCTGAG AACAGAGAT GGCAGCCCTC TCACACAGGC  
301 GGCAGAGCAA GGAAGCTGTC AGCCGGCGAG CCTCTCTGAG TATACCTGAG  
351 ATGGGCAGAA CTGGGACAT CAGTTCTCTA CAGCAGCCCT GCAATGAGGG  
401 GCTGGAGTGG TATAGAAAAA ATTTCAACGC TTTTGTCTGT GCTTTGGAAA  
451 TTTCTGAATA CATCCAACAA CAGTCTGACT TCAGGCTATG AACAAATGG  
501 CATACCAGGA AAGTGCAGAA CACATCTGT CTGGAGGAGT GATACCACCTG  
551 GCAGCCATCA CAGCGACAAG CTGTCTACTC CCACTCTCTCC TCTGCAGGCT  
601 TAA  
!!AA SEQUENCE 1.0  
ID \_ADP30469 standard; protein; 2454 AA.  
XX  
AC ADP30469;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1236.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.

PR	29-AUG-2002	2002US-0406508.P
PR	29-AUG-2002	2002US-0406511.P
PR	29-AUG-2002	2002US-0406512.P
PR	29-AUG-2002	2002US-0406516.P
PR	29-AUG-2002	2002US-0406540.P
PR	29-AUG-2002	2002US-0406542.P
PR	29-AUG-2002	2002US-0406546.P
PR	29-AUG-2002	2002US-0406553.P
PR	29-AUG-2002	2002US-0406556.P
PR	29-AUG-2002	2002US-0406565.P
PR	17-SEP-2002	2002US-0410946.P
PR	17-SEP-2002	2002US-0410947.P
PR	17-SEP-2002	2002US-0410948.P
PR	17-SEP-2002	2002US-0410949.P
PR	17-SEP-2002	2002US-0410953.P
PR	17-SEP-2002	2002US-0410957.P
PR	17-SEP-2002	2002US-0410962.P
PR	17-SEP-2002	2002US-0411022.P
PR	17-SEP-2002	2002US-0411023.P
PR	17-SEP-2002	2002US-0411024.P
PR	17-SEP-2002	2002US-0410961.P
PR	17-SEP-2002	2002US-0411032.P
PR	17-SEP-2002	2002US-0411035.P
PR	17-SEP-2002	2002US-0411037.P
PR	17-SEP-2002	2002US-0411041.P
PR	17-SEP-2002	2002US-0411045.P
PR	17-SEP-2002	2002US-0411046.P
PR	17-SEP-2002	2002US-0411048.P
PR	17-SEP-2002	2002US-0411101.P
PR	17-SEP-2002	2002US-0411111.P
PR	18-SEP-2002	2003US-0463700.P
PR	18-SEP-2002	2003US-0463708.P
PR	18-SEP-2002	2003US-0463712.P
PR	18-SEP-2002	2003US-0463732.P
PR	17-SEP-2002	2002US-0411082.P
PR	02-MAY-2003	2003US-0467199.P
PR	02-MAY-2003	2003US-0467201.P
PR	02-MAY-2003	2003US-0467203.P
PR	02-MAY-2003	2003US-0467230.P
PR	13-MAY-2003	2003US-0471306.P
PR	13-MAY-2003	2003US-0471336.P
PR	22-MAY-2003	2003US-0472420.P
PR	22-MAY-2003	2003US-0472430.P
PR	09-JUN-2003	2003US-0476609.P
PR	09-JUN-2003	2003US-0476641.P
PR	08-JUL-2003	2003US-0485218.P
PR	08-JUL-2003	2003US-0485223.P
PR	08-JUL-2003	2003US-0485224.P
PR	14-JUL-2003	2003US-0486325.P
PR	14-JUL-2003	2003US-0486446.P
PR	14-JUL-2003	2003US-0486480.P
PR	15-JUL-2003	2003US-0486891.P
PR	15-JUL-2003	2003US-0486902.P
PR	08-AUG-2003	2003US-0493341.P
PR	08-AUG-2003	2003US-0493370.P
PR	08-AUG-2003	2003US-0493573.P
PR	08-AUG-2003	2003US-0493577.P

New nucleic acid molecule for diagnosing, preventing or treating diseases such as proliferative (e.g. cancer), inflammatory, immune, metabolic, genetic, bacterial and viral diseases.

1	ATGTGCCAA	CTCTCAACA	TATTGTGCT	TCCTCGAGA	GAATGGAAAT
51	ATTATCAAT	TCTTTAAATG	CAGCCTTGAC	TATTGGTGG	CAACAACCTCT
101	TCTCCTCTC	TACATTCAGC	TGTCCTTGTC	AGGTTGGAAA	AAATTTCTAT
151	TATGGTTCTG	CTTTTCTTGT	CATTCTGCC	TTGATCCTTC	TGCTTGCTGG
201	CTTTGTCTG	AGAAGCCAAA	TGTGACAAT	TACCGGTGAA	TACTGCTGCA
251	GCTGTGCCC	TCCATACAGG	AGAAATGACC	CCCTAGAGTG	CAAGCTGGCT
301	TGCTTTAGGT	TCTTCAGCAT	CACCTGGGAG	GCAGTTATTG	CTCCTTTTAACT
351	TTGGCTGGCG	GTGACCTTGC	TGACAGGCAC	GTATTATGAA	TGTGCAGCAA
401	GTGAATTTGC	ATCTGTGGAC	CATTACCCTAA	TGTTTGATAA	TGTCAGTGCC
451	AGCAACGAG	AAGATGCTCT	GGCTGGGTTT	CCATGTTGCA	GATCAGCTCC
501	TTCTGACGTG	ATCTAGTAA	GAGATGAAAT	AGCTCTTCTG	CACAGATACC
551	AGTCACAGAA	TGAGAGAGAA	CTCTTTGAAC	AAGCAGCAGA	GCAGCACTCT
601	CGGCTCCTCA	TGATGCATCG	CATAAAGAG	CTATTGGGCT	TCATTTCCGG
651	GAGTGAAGAC	GTCAACACA	TCGCATTCCT	TTCTTGTGAC	GACTGGAAAG
701	ATATTTTCAGT	ACCCACTCTT	TTATGCATGG	GTGATGACTT	GCAAGTCCAC
751	TATAGCTTCC	TTGGAATAAG	GGTGATGAG	GATAATGAGG	AAGACAGATC
801	AAGAGGAAAT	TGCTGGGGC	TCAITGGCAT	GGGGTGCCCT	GAGCCAGACC
851	AGACTGGGG	GACCGTTTC	TTCCCTTCCC	CACATCCCTA	CACTCTTGA
901	CCCTCTTCCC	ACAGCATGCG	ATGCCGGGGT	GTTCATAGTG	GAAGTGCCAG
951	CTCCACCTG	CAGCCCTGGA	GCGGCGGAG	TGSGTGACG	AGCAGGTCT
1001	TTCTTGGTG	TGCCCTGGA	CTGGGCCAG	GGTGCTCC	ACTGTGTGCC
1051	GCGGATCAGG	CTGTCTCTG	GGGTGCTGGA	AACCTCTGTG	GCCAGTGGA
1101	CCCTACTTG	AGTTTGTCTT	GTTCCTGCTG	GACTCGTTCA	GCCCACCTGG
1151	CCCAGCAGGC	CGTGCTCGCT	TGTGCTACCG	GCCAGATCC	TATGCTCTGG
1201	GAGAGTGAAC	CAGGCGCGGA	CGGCAAGGC	GTGTGTGAGC	GAGCAAGTAC
1251	GGGGTCCGC	CACTGTACAC	AGCAAGCATG	CCGGCTGCTG	CAGCGGAAA
1301	GAATGAGGTT	ATGCAGAAA	CTGGAAGGTA	AGCAAGGCGAG	AGAAGAGCTT







PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
PS Claim 1; SEQ ID NO 2517; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 339 AA;  
ADP30519 Length: 339 February 22, 2005 12:25 Type: P Check: 2331 ..  
1' ATGCGCTGCT CGCGGGAGG CGTCTGGCTG GCGCTGGCG CGTGGCTGCT  
51 GCACGTGTCC CTGCAAGCG AGTTCCAGAG GAAGCTTTTAC AAGGAGCTGG  
101 TCAAGAACTA CAATCCCTTG GAGAGGCCG TGGCCAATCA CTCGCAACCA  
151 CTCACGGTCT ACTTCTCCCT GAGCTCCTG CAGATCATGG ACGTGTCGCC  
201 AACCTTTTGG ACACCAAGGA CTTGTTTGT GGAAGACAACT TTTTCCATAG  
251 ACTGTGCGGG GCCATGTTT TGGATGAAA CTGTTCCACC TCAGATTGTC  
301 AGGCAATCAT TAGATTCTCA TAAGGAGCGT GCAACCTAG  
!!AA SEQUENCE 1.0  
ID ADP30555 standard; protein; 864 AA.  
XX  
AC ADP30555;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1322.  
XX  
XX Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX  
XX 29-AUG-2002; 2002US-0406579P.  
XX  
XX 29-AUG-2002; 2002US-0406585P.  
XX  
XX 29-AUG-2002; 2002US-0406588P.  
XX  
XX 29-AUG-2002; 2002US-0406608P.  
XX  
XX 29-AUG-2002; 2002US-0406611P.  
XX  
XX 29-AUG-2002; 2002US-0406612P.  
XX  
XX 29-AUG-2002; 2002US-0406616P.  
XX  
XX 29-AUG-2002; 2002US-0406640P.  
XX  
XX 29-AUG-2002; 2002US-0406642P.  
XX  
XX 29-AUG-2002; 2002US-0406646P.  
XX  
XX 29-AUG-2002; 2002US-0406653P.  
XX  
XX 29-AUG-2002; 2002US-0406655P.  
XX  
XX 17-SEP-2002; 2002US-0410946P.  
XX  
XX 17-SEP-2002; 2002US-0410947P.  
XX  
XX 17-SEP-2002; 2002US-0410948P.  
XX  
XX 17-SEP-2002; 2002US-0410949P.  
XX  
XX 17-SEP-2002; 2002US-0410953P.  
XX  
XX 17-SEP-2002; 2002US-0410957P.  
XX  
XX 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2553; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 864 AA;

ADP30555 Length: 864 February 22, 2005 12:25 Type: P Check: 8722 ..

1 CGCTGCTCTG CCGGCTGTGC TGGGCCTCC TGGCCCCGC TGCCCCGCC

51 GGCTACTCCG AGGAGCGGTG CAGCTGGAGG GGCAGCGGCC TCACCCAGGA

101 GCCCGGCAGC GTGGGCAGC TGGCCCTGGC CTGTGGGAG GCGCGGTTG

151 AGTGGCTGTA CCGGCTGGG GCGTGGCC TGACCTGGG CGGCCCGAT

201 CCCAGAGCGC GGCCTGTCTG CGGCCGTGC GGCCTTCGC

251 GGGCGCCAG GTCCTGGG AGCGCAGG GGGCGCCTG GAGCTGCTC

301 TGCCGAGGG CCGGGCCCG CGAGGGGCC GTTGGTGG CTGGGTCCC

351 CGGAGCGCC GGGCCCTCTT CTGCAGGCC ACGCCGACC AGGACATCAG

401 CCGCGCGTG CGCGCTTCC GCTTTAGCT GCGGAGGAC GGGCGCCCG

451 AGTGGCCCC CGAGGCCAC GGTCTGGCG TAGACGGTG CTGCGAGGC

501 CTCAGCGAC GCTGAGTGC TCCTGGCGC ATGCACGAC GACTTCGTA

551 TTCACGGAT CATCCATGG GTCACCCATG ACGTGGAGCT GCAGGAGTCT

601 GTCATCACTG TGGTGGCCG CCGTGTCTC GGCAGACAC CGCGCTGTT

651 CCAGCGGGG CGATCGGGG ACCAGGGGCT GACCTCCATT CGTACCCAC

701 TGGCTGTGG CGTCCACCG GSCCAGGCA CCTTCCTCTT CATGGGCTG

751 AGCGCTTTG GGGAGCCCG GCTGGGCTGT GCGCCAGAT TCAGGAGTT

801 CCGCGCTGCC TAGAGGCTG CCGGTGCTG CCACCTCCAC CCCTGCGAGG

851 TGGCGTGCA CTGA

!!AA SEQUENCE 1.0

ID ADP30600 standard; protein; 879 AA.

AC ADP30600;

XX

XX

DT 12-AUG-2004 (first entry)

XX

XX

DE Human secreted protein SEQ ID #1367.

XX

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

PN WO2004035732-A2.

XX

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

XX 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 29-AUG-2002; 2002US-0406656P.

PR 17-SEP-2002; 2002US-0410946P.

17-SEP-2002; 2002US-0410947P.

17-SEP-2002; 2002US-0410948P.

17-SEP-2002; 2002US-0410949P.

17-SEP-2002; 2002US-0410953P.

17-SEP-2002; 2002US-0410957P.

17-SEP-2002; 2002US-0410958P.

17-SEP-2002; 2002US-0410959P.

17-SEP-2002; 2002US-0410960P.

17-SEP-2002; 2002US-0410961P.

17-SEP-2002; 2002US-0410962P.

17-SEP-2002; 2002US-0411019P.

17-SEP-2002; 2002US-0411022P.

17-SEP-2002; 2002US-0411023P.

17-SEP-2002; 2002US-0411024P.

17-SEP-2002; 2002US-0411032P.

17-SEP-2002; 2002US-0411035P.

17-SEP-2002; 2002US-0411037P.

17-SEP-2002; 2002US-0411041P.

17-SEP-2002; 2002US-0411045P.

17-SEP-2002; 2002US-0411046P.

17-SEP-2002; 2002US-0411048P.

17-SEP-2002; 2002US-0411052P.

17-SEP-2002; 2002US-0411055P.

17-SEP-2002; 2002US-0411073P.

17-SEP-2002; 2002US-0411082P.

17-SEP-2002; 2002US-0411101P.

17-SEP-2002; 2002US-0411111P.

18-APR-2003; 2003US-0463700P.

18-APR-2003; 2003US-0463708P.

18-APR-2003; 2003US-0463716P.

18-APR-2003; 2003US-0463732P.

02-MAY-2003; 2003US-0467199P.

02-MAY-2003; 2003US-0467201P.

02-MAY-2003; 2003US-0467203P.

02-MAY-2003; 2003US-0467230P.

19-MAY-2003; 2003US-0471306P.

22-MAY-2003; 2003US-0471336P.

22-MAY-2003; 2003US-0472420P.

22-MAY-2003; 2003US-0472430P.

09-JUN-2003; 2003US-0476609P.

09-JUN-2003; 2003US-0476641P.

08-JUL-2003; 2003US-0485218P.

08-JUL-2003; 2003US-0485223P.

08-JUL-2003; 2003US-0485224P.

08-JUL-2003; 2003US-0485325P.

14-JUL-2003; 2003US-0486446P.

14-JUL-2003; 2003US-0486480P.

15-JUL-2003; 2003US-0486891P.

08-AUG-2003; 2003US-0486960P.

08-AUG-2003; 2003US-0493341P.

08-AUG-2003; 2003US-0493370P.

08-AUG-2003; 2003US-0493573P.

08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

PT New nucleic acid molecule for diagnosing, preventing or treating diseases

PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

XX genetic, bacterial and viral diseases.

PS Claim 1; SEQ ID NO 2598; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule

CC encoding a polypeptide which is believed to be cytostatic,

CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The

CC composition and methods are useful for diagnosing, preventing and

CC treating diseases such as proliferative (e.g. cancer), inflammatory,

CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.  
SQ Sequence 879 AA;

ADP30600 Length: 879 February 22, 2005 12:25 Type: P Check: 8766 ..

1 ATGCAGAGGA GACACAGAGC CGCGGGGCCA AGAGGACGAT CGGCGCGCTG  
51 CACGCAGGCG GGGAGCGCAT GGAGCTGCCC CGCGCCTTGC GCCTCTCTCT  
101 CGTGTGTGCG GGCTCCCTCG CGTCCCGGCC GGTGCCGAGC CGGTGTGCCC  
151 GGAGCGCTGC GACTGCCAGC ATCCCCAGCA TCTCTGTGTC ACCAACAGGG  
201 GGCTCGCGCT AGTGCCCAAG ACCAGCTCGC TGCCGAGCCC CCACGACGTG  
251 CTCACGTACA GCCTGGGGCG CACTTCATTA ACCAATCATC CGGCTTTCGA  
301 CTTCCACCGT CTGGGGCAGC TCAGACGGCT GGACCTGTCAG TACAACACAGA  
351 TCCGCTCTCT GCACCCCAAG ACCTTCAGA AGCTCTCGCG GCTGGAAGAG  
401 CTGTACTTGG GGAACAACCT CTTGCAGGCG CTCGCCCGCG GCACGCTGGC  
451 CCGCTGCGC AAGCTCGCCA TCCTCTACGC CAACGGGAAC GAGATCAGCC  
501 GCCTAAGCG CGGCTCCTTC GAGGCGCTGG AGAGTCTAGT CAAGCTCTCT  
551 CTGGACGGGA ACGCCCTGGG GCGCGTGGCG GACGCGGTCT TGGTCCCTTT  
601 GGGCAACCTG CTCTACCTAC ATCTGGAGTC CAACCGGATC CGCTTTCTGG  
651 GCAAGNACCG CTTGCCCGAG CTAGGCAAGC TGGGCTTCTT CAACCTCTCT  
701 GCCAAGGAGC TACAGCCCTC CTGCGGCCAC GGGGCCACCT TCGCACCGCT  
751 GGGCTCCCTC TCCTCCCTCA TCCTCTCGGC CAACAACCTG CAGCACCTCG  
801 GGCGCGGATC CTTCCAGCAC CTGCCAGTCT TCGGCTGTCT CTGCTCAGG  
851 GGCACACGAG TCACGCACTT CGGCGCTGA

!!AA SEQUENCE 1.0  
ID -ADP30606 standard; protein; 375 AA.

XX AC ADP30606;

XX XX 12-AUG-2004 (first entry)

XX XX Human secreted protein SEQ ID #1373.

XX Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406656P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 2604; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 375 AA;  
ADP30606 Length: 375 February 22, 2005 12:25 Type: P Check: 1879 ..  
1 ATGGGATCCC TGGGGCTCCC CGCTGCCAGT GCCAGCGGG CGCGGCGCTTG  
51 CAGGCAGAGC GGGGCTCTCTG CACCGCATCC GCGACGCGAGT CTTGCAACGA  
101 CCTCTGGCAG CACTTCTGGG TTCCCAACCC CGACCAAGCCG GGCTCCTACT  
151 CGTGCATGTG CGAGACCGGC TACCGGCTGG CGGCCGACCA ACACCGGTGC  
201 GAGGACGTGG ATGACTGCAT ACTGAGAGCC AGTCCGTGTC CGCAGCGCTG  
251 TGTCAACACA CAGGGTGGCT TCGAGTGCCA CTGCTACCCCT AACTACGACC  
301 TGGTGGACGG CGAGTGTGTG GAGCCGCTGG ACCGTGCTT CAGAGCCAAC  
351 TGGCAGTACC AGTGCCAGCC CTTGA  
II/AA SEQUENCE 1.0  
ID ADP30622 standard; protein; 492 AA.  
XX  
AC ADP30622;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1389.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406555P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 18-APR-2003; 2002US-041111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471308P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-047240P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linneemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2620; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 492 AA;  
ADP30622 Length: 492 February 22, 2005 12:25 Type: P Check: 5164 ..

1 ATGGGACAG CGCTGATCG TCATCATCGT GCTGGCGGG AGCTGACGC  
51 TGCTGTGGC GCCATCATC GCCATGCCA CCACCTGCCA CGCGCCGAG  
101 AAGGAGTGC GCAAAGGGG GGCCTCCGG GAAGAGGGC CGGGGGCGC  
151 GGGCGGGGA GCTCGGCTC CGGCTCCCG GGAGGAGGCC GCCCGGGAG  
201 CGGGGCCCCA GCCAACATG TTGACGTGC TCACCTTCCC TGCCACCGGC  
251 AAAGCGCCCT TTGGCAGCC CGCGCGGAC GCGCTCCGC CTGCGGTCC  
301 CGGGCGGAA GTGCCGGCT CAGAGGGGG CAGCGCACT GGGGAAAGG  
351 CTGTCACTT CGAGGGGCG CAGCGGTCC CGGCGCGCA CGCCGAGGTG  
401 AGGCTTCCT TCGGTGGGC GCCCCCTCC GAGCTCCGG GACAGGCTGG  
451 GGAAGGGAG ACTGGAGGG TAGGTGGGT GCATTCAGGT AG

!!AA SEQUENCE 1.0  
ID ADP30671 standard; protein; 908 AA.

XX ADP30671;

AC DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1438.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

PN 29-APR-2004.

PD 28-AUG-2003; 2003WO-US026780.

PF 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 29-AUG-2002; 2002US-0406668P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.

PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.

PR 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411022P.

PR 17-SEP-2002; 2002US-0411023P.

PR 17-SEP-2002; 2002US-0411024P.

PR 17-SEP-2002; 2002US-0411032P.

PR 17-SEP-2002; 2002US-0411035P.

PR 17-SEP-2002; 2002US-0411037P.

PR 17-SEP-2002; 2002US-0411041P.

PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2669; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytosstatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 908 AA;

ADP30671 Length: 908 February 22, 2005 12:25 Type: P Check: 4718 ..

1 GCTGGGGCT TCTGGATTAT AGACGGAGA AGTATGTGAT GACCAGGAC

51 TGGCGGGTGG CGGCCCTGCA GAGGCTGTG CAGTTTGGGA TCGTGGTCTA

101 TGTGTTAGGG TGGGCTCTCC TCGCCAAAAA AGGCTACCAG GAGCGGGACC

151 TGGAAACCCA GTTTTCCATC ATCACCNAAC TCAAGGGGGT TTCCGTCACT

201 CAGATCAAGG AGTTTGAAA CCGGCTGTGG GATGTGGCCG ACTTCGTGAA

251 GCCACCTCAG GGAGAGAAG TGTTCTTCTT GGTGACCAAC TTCTTTGTGA  
301 CGCCAGCCCA AGTTACGGC AGATGCCAC AGCACCCGTC CGTCCCACTG  
351 GCTAACTGCT GGGTCAGCA GGAATGCCCC GAAGGGGAGG GAGGCACACA  
401 CAGCCACGGT GTAAAAACAG GCCAGTGTGT GGTGTTCAAT GGGACCCACA  
451 GGACCTGTGA GATCTGGAGT TGGTGCCCGG TGGAGAGTGG CGTTGTGCCC  
501 TCGTAAGCCC CTGCTGGCCC AGGCCAGAA CTTACACACTG TTTCATCAAAA  
551 ACACAGTCAC CTTTCAGCAAG TTCAAGTGT CCGCATTTGGG GACCTCGTGG  
601 CCAAGGCTGG AGGACCTTC GAGGACCTGG CGTTGCTGGG TGGCTCTGTA  
651 GGCATCAGAG TTCACTGGGA TTGTGACCTG GACACCGGG ACTCTGGCTG  
701 CTGGCCTCAC TACTCTTCC AGCTGCAGGA GAAGAGCTAC AACTTCAGGA  
751 CAGCACTCA CTGGTGGGAG CAACCGGCTG TGGAGGGCCG CACCTGTCTC  
801 AAGCTCTATG GAATCCGCTT CGACATCTC GTACACCGGC AGCAGGGAA  
851 GTTCGGGCTC ATCCCCACGG CCGTCACACT GGGCACCGGG GCAGCTTGGC  
901 TGGCGCTG

!!AA SEQUENCE 1.0

ID\_ADP30680 standard; protein; 821 AA.

XX AC ADP30680;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1447.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476509P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2678; 428pp; English.

PS The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.

XX Sequence 821 AA;

ADP30680 Length: 821 February 22, 2005 12:25 Type: P Check: 9429 ..

1 TGACCCCGG CATGAAGATC TACATCGATC CTTTCACCTA CGAGGACCCC



51 AACGAGGCAG TCGGGAGTT TGCCAAGGAA ATTGACATCT CTGTGTCTCAA  
101 AATTGAGCAG GTGATCGGAG CAGGCCACCC TGAAGCTGCC AGGCAAGAGA  
151 GAGATCTTTG TGGCCATCA GACGCTCAAG TCGGGCTACA CGGAGAGCA  
201 GCGCCGGGAC TTCCTGAGCG AAGCCTCCAT CATGGGCCAG TTCGACCATC  
251 CCAACGTCAAT CCACCTGGAG GGTGCTGTGA CCAAGAGCAC ACCTGTGATG  
301 ATCATCACCG AGTTCAATGA GAATGGCTCC CTGACTCTCT TTCTCCGGCA  
351 AAACGATGGG CAGTTCACAG TCATCCAGCT GGTGGGCATG CTTCCGGGGA  
401 TCGCAGCTGG CATGAAGTAC CTGGCAGACA TGAATATGT TCACCGCTGAC  
451 CTGGCTGCCC GCAACATCCT CGTCAACAGC AACCTGGTCT GCAAGGTGTC  
501 GGACTTTGGG CTCTCAGCT TTCTAGAGGA CGATACCTCA GACCCACCT  
551 ACACCACTGC CCTGATTGTC ATGTGGGAGG TGATGTCCTA TGGGGAGCGG  
601 CCTACTGGG ACATGACCAA CCAGGATGTA ATCAATGCCA TTGAGCAGGA  
651 CTATCGGCTG CCACGCCCA TGGACTGCC GAGCGCCCTG CACCAACTCA  
701 TGTGACTGT TTGGCAGAAG GACCGCAACC ACCGGCCCAA GTTCGGCCAA  
751 ATTGTCAACA CGCTAGACAA GATGATCGC AATCCCAACA GCCTCAAGC  
801 ATGGCGCCC CTCTCCTCTG G

!!IAA SEQUENCE 1.0  
ID ADP30722 standard; protein; 659 AA.  
XX  
AC ADP30722;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1489.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406578P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 18-APR-2003; 2003US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Heatir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2720; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIFOWEB and is not in the specification.  
XX  
XX Sequence 659 AA;  
SQ

```
ADP30722 Length: 659 February 22, 2005 12:25 Type: P Check: 9178 ..
1  TNATACGCC ACCAGTCTCA AGTGCCTGG ACTAGAGGC CTGCGAGCT
51  TTCAGATTCC GGTGGGCGC CACAGACGC GGCTTCCCG CGTTAGCAG
101 CGAGGCGCTG GTGCGGCTG TGGTCTGGA CGCCAACGAC AACTGCCCT
151 TCGTCTGTA CCGCTGCAG AACGCTCG CGCCCTGCAC CGAGCTGGTG
201 CCCGGGCGG CCGAGCGGG CTACCTGGT ACCAAGTGG TGGCGTGGA
251 CGGCACTCG GGCAGAACG CTTGCTGTC GTACCACTG CTCAAGGCCA
301 CGGAGCCCG GCTGTTGCG GTGTGGGCG ACAATGGGA GGTGGCACC
351 GCCAGGCTG TGAGCGAGG CGAGCTGGC AAGCACAGG TAGTGGTGT
401 GGTCAAGGAC AATGGGAGC CTCGCGCTC GGCCACCGCC ACGCTGCAAG
451 TGCTCTGGT GGAGGCTTC TCTAGCCCT ACCTGCCGCT CCCAAGAGG
501 GCCCGGCCC AAGCCAGGC CGACTCGTC ACTGTCTACC TGGTGGTGGC
551 GTTGGCCTG GTGTGCTGC TCTTCTCTT CTCGGTCTC CTGTTGCTG
601 CGGTGGCGC TTGTGAGGAG GAGCAGGCG GCCCGGCTG GTGCTGCTC
651 GGTGCTTGA

!IAA SEQUENCE 1.0
ID_ADP30843 standard; protein; 975 AA.
XX AC ADP30843;
XX DT 12-AUG-2004 (first entry)
XX DE Human secreted protein SEQ ID #1610.
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
XX KW cancer; inflammatory; immune; human secreted protein.
XX OS Homo sapiens.
XX PN WO2004035732-A2.
XX PD 29-APR-2004.
XX PF 28-AUG-2003; 2003WO-US026780.
XX PR 29-AUG-2002; 2002US-0406576P.
XX PR 29-AUG-2002; 2002US-0406579P.
XX PR 29-AUG-2002; 2002US-0406585P.
XX PR 29-AUG-2002; 2002US-0406588P.
XX PR 29-AUG-2002; 2002US-0406608P.
XX PR 29-AUG-2002; 2002US-0406611P.
XX PR 29-AUG-2002; 2002US-0406612P.
XX PR 29-AUG-2002; 2002US-0406616P.
XX PR 29-AUG-2002; 2002US-0406640P.
XX PR 29-AUG-2002; 2002US-0406642P.
XX PR 29-AUG-2002; 2002US-0406646P.
XX PR 29-AUG-2002; 2002US-0406653P.
XX PR 29-AUG-2002; 2002US-0406655P.
XX PR 29-AUG-2002; 2002US-0406666P.
XX PR 17-SEP-2002; 2002US-0410946P.
XX PR 17-SEP-2002; 2002US-0410947P.
XX PR 17-SEP-2002; 2002US-0410948P.
XX PR 17-SEP-2002; 2002US-0410949P.
XX PR 17-SEP-2002; 2002US-0410953P.
XX PR 17-SEP-2002; 2002US-0410957P.
XX PR 17-SEP-2002; 2002US-0410958P.
XX PR 17-SEP-2002; 2002US-0410959P.
XX PR 17-SEP-2002; 2002US-0410960P.
```

```
17-SEP-2002; 2002US-0410961P.
17-SEP-2002; 2002US-0410962P.
17-SEP-2002; 2002US-0411019P.
17-SEP-2002; 2002US-0411022P.
17-SEP-2002; 2002US-0411023P.
17-SEP-2002; 2002US-0411024P.
17-SEP-2002; 2002US-0411032P.
17-SEP-2002; 2002US-0411035P.
17-SEP-2002; 2002US-0411037P.
17-SEP-2002; 2002US-0411041P.
17-SEP-2002; 2002US-0411045P.
17-SEP-2002; 2002US-0411046P.
17-SEP-2002; 2002US-0411048P.
17-SEP-2002; 2002US-0411052P.
17-SEP-2002; 2002US-0411055P.
17-SEP-2002; 2002US-0411073P.
17-SEP-2002; 2002US-0411082P.
17-SEP-2002; 2002US-041101P.
17-SEP-2002; 2002US-041111P.
18-APR-2003; 2003US-0463700P.
18-APR-2003; 2003US-0463708P.
18-APR-2003; 2003US-0463716P.
18-APR-2003; 2003US-0463732P.
02-MAY-2003; 2003US-0467199P.
02-MAY-2003; 2003US-0467201P.
02-MAY-2003; 2003US-0467203P.
02-MAY-2003; 2003US-0467230P.
19-MAY-2003; 2003US-0471306P.
19-MAY-2003; 2003US-0471336P.
22-MAY-2003; 2003US-0472420P.
22-MAY-2003; 2003US-0472430P.
09-JUN-2003; 2003US-0476609P.
09-JUN-2003; 2003US-0476641P.
08-JUL-2003; 2003US-0485218P.
08-JUL-2003; 2003US-0485223P.
08-JUL-2003; 2003US-0485224P.
08-JUL-2003; 2003US-0485325P.
14-JUL-2003; 2003US-048646P.
14-JUL-2003; 2003US-0486480P.
15-JUL-2003; 2003US-0486891P.
15-JUL-2003; 2003US-0486960P.
08-AUG-2003; 2003US-0493341P.
08-AUG-2003; 2003US-0493370P.
08-AUG-2003; 2003US-0493573P.
08-AUG-2003; 2003US-0493577P.
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX WPI; 2004-348438/32.
XX New nucleic acid molecule for diagnosing, preventing or treating diseases
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PT genetic, bacterial and viral diseases.
XX Claim 1; SEQ ID NO 2841; 428pp; English.
XX The present invention relates to an isolated nucleic acid molecule
CC encoding a polypeptide which is believed to be cytostatic,
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
CC composition and methods are useful for diagnosing, preventing and
CC treating diseases such as proliferative (e.g. cancer), inflammatory,
CC immune, metabolic, genetic, bacterial and viral diseases. The present
CC sequence represents a human secreted protein. The present sequence is
CC available on WIPOWEB and is not in the specification.
XX Sequence 975 AA;
SQ ADP30843 Length: 975 February 22, 2005 12:25 Type: P Check: 1960 ..
```

1 ATGGTAGTGC GGAAGCGGNA GAGCTGCAG GCGCGGGAAG CCTCTGTTTG  
51 GTCCGCCAG GTCCCGGGAT CCGGCGCGCC AGCTGCGATG CCAAGTCCCC  
101 GGAGGAGCAT GGAGGACGG CCGCTGGGCG TCTCCGCTTC GAGCAGCAGC  
151 AGCAGCCCCG GCAGCCGAGC CCATGGCGGC GGTGGCGGCG GCAGCAGGTT  
201 TGAGTTCCAG TCCCTGTCTCA GCAGCCGCGC CACGGCCGTG GACCCACACT  
251 GCGCCCGGCT CCGTGCATCG GAGAGCCAG TTCACCGCCG CGGCTCCCTTC  
301 CCCTGGCCG CCGCGGGGCC CTCGAGTGC CCGCGGCTC CGCTGCCGA  
351 GGAGGACCGC ATGAGCTTGA ACCCGTCTT CTGGGCGATC GCGCTGCGCT  
401 CCTGCTGCG CATCGACCTG TGGCTGTCCA AGAAGCTGGG GGTGTGCGCG  
451 GGAGAGAGCT GGTGTGGGG CAGCGTGGGA CCCCTTATGA AGCTGCTGGA  
501 GATCTCGGA CACGGCATCC CCTGGCTGCT GGGCACCCCT TACTGCTGT  
551 GCAGGAGCGA CAGCTGGGCC GGGCGCGAGG TGTGTATGAA CCTGCTCTTC  
601 GCGCTGCTGT TGGACCTGCT GCTGGTGGCC TTGATCAAG GCGTGGTCCG  
651 CAGGCGCCGC CCGGCCACCA ACCAGATGGA CATGTTTGTC ACTCTCTCGG  
701 TGGACAAGTA CTCCTTCCCC TCGGGCCATG CCACAAGGGC CGCCCTGATG  
751 TCGAGGTTCA TCGTAAGCA CTGGTGCTG GCCATTCCAC TGAGGGTGTCT  
801 GGTGGTTCTG TGGGCTTTCG TCTTGGGCTC ATCCAGGCTC ATGCTGGGGC  
851 GGCACAACTC CACCGACGTA GCTTTGGCT TTTTCTGGG CTACATGCAG  
901 TACAGCATCG TGGACTATTG CTGGCTCTCA CCCATAATG CTCGCGTCT  
951 CTTTTTACTG TGGAGTCAAC GATGA

!!AA\_SEQUENCE 1.0  
ID\_ADP30869 standard; protein; 507 AA.

AC ADP30869;

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1636.

DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Hallenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases

such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 2867; 428pp; English.

The present invention relates to an isolated nucleic acid molecule

encoding a polypeptide which is believed to be cytostatic,

antiinflammatory, immunosuppressive, antibacterial and virucidal. The

CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 507 AA;

ADP30869 Length: 507 February 22, 2005 12:25 Type: P Check: 8958 ..

1 CTGTGGCTCA GCTTTCACG TGTGGCTGAC GTCATTCGTG AGGACTTGGT  
51 CCTGTCCATG GAGCAGATCA ACTGCTCTGC ACTGGTCTAC CTCGTGGTAT  
101 CCACCCCAAT TGGCGTGGCG GCCATCTGGA TCTTGGACTC CGTGGGGCTC  
151 CGTGGCGCGA CCATCTCTGG TGCCTGGCTG AACTTTCCCG GGAGTGTGCT  
201 ACGCATGGTG CCTGTCATGG TTGTTGGGAC CCAAAACCCA TTTCCTCTCC  
251 TCATGGGTGG CCAGAGCCTC TGTGCCCTTG CCNAGAGCCT GGTCACTCTC  
301 TCTCCAGCCA AGCTGGCTGC CTGTGTGTTT CCAGAGCACC AGCGAGCCAC  
351 GGCAACATG CTCGCCACCA TGGGTGTCTA TACCATCCCT GCTGGGGTGG  
401 TCTGCTCTGCT GTCCACCATC TGCCTGTGGG AGAGTGTGCC CCCCACCCCG  
451 CCCTCTGCCG GGGCTGCCAG CTCACCTCA GAGAAAGTTC TGGATGGGCT  
501 CAAGCTG

!!AA SEQUENCE 1.0  
ID ADP30911 standard; protein; 2700 AA.

XX AC ADP30911;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1678.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.

17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

PS Claim 1; SEQ ID NO 2909; 428pp; English.

CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

XX Sequence 2700 AA;

SQ

ADP30911 Length: 2700 February 22, 2005 12:25 Type: P Check: 8754 ..

1 ATGGCCAGGC ATGGCTGTCT AGGCTGGGA CTGTCTGTCT GCGTCTGT  
51 TGCTGTACT GTGGGCCCC AGCCACCCC CTCATCCCA GGTGCCCCTG  
101 CCACCACTTT GACCCCGTA CTTCAAAGTG AGGCTCTAT GTGTCTCTC  
151 AACCTGGAC TTAACCTCAA ATTCCATCTT CCGGGACCTG GTGCTGTCTG  
201 GGGAGCCCA GTACAGAGA CCCAGCCACT CTCTCTTGG CCAGGCCAGG  
251 AGCCAGGGA AGAGTGGCC AGTGGGCTGA GGAAGTACC CTTTGGGAA  
301 TTGCTGGTG GCTCTCAGG GAACTCTCTC ACTAGTGGG GTCCACCGA  
351 AGGTGCTCA AAGCCCGGG CTTCTCCCT GCTTCCGGAG TCCATATCCC  
401 GGGCTCTGG GCCAGGAT GGGCCCACTG CCCCCTATCA GCCAGGAGG  
451 AGCACTGTA CTTGGACAC TGCTCTGATG GTACAGACAC TTCCATCCAG  
501 TGCTCCCAG CCCACACGA GCGAGCTGA GCTGAAGTTT GACATGGCAC  
551 TGAGAGCAGG TGCAGCCCC AGCTTGGGC ATGAAAGCT GCCCTGCTG  
601 CCCAGCTGC GGGCAGCCT GGCAGAGATT GCTGGCGGC TGGGACCCCT  
651 TGGATTCTTT GGCATATCT TGTCCCCACT CCGAACTTC TCCGGCTGA  
701 GCCCCCAGG TGAACATA TCCAAAGCT CTGCTCTGG AGTTTCGGGT  
751 TCTCTGGGT TCTTGGTAC CACTCTGTCC CTGCCCCCAT ACTCCCTGA  
801 GAGGAGCTC TCCAGCCAA GTCTCTGGA CCCAGTGTCT TCCTAAGTT  
851 TTGCTCTGAT TGCAACAACA TCATTAGACC CCACAGTCCC CATCTCTGGC  
901 CCAGATGACC TCTCTCTCC CGCAGCCTC GGAACCCCTT GGGGCGACC  
951 AGAGTGGG CCAGGTCTT GCAGCTGGG AGAATTGCTT GNAACGAGG  
1001 GGCAGCTCC CGAGCGCGG AGGCCCCCTT TTTTCTGAC CTTGAGGCC  
1051 GACTGGCAG AGGCCAGGC TCGCTGGGG CTGGCTGGG AGGCCACGT  
1101 GTACGGGTA GCGGCTCT TCGGCTGGT TGCTTGCTG GCGCTGCTG  
1151 CTCTGGCCCT CTGCTCTGG CGTGGCCCG CCGGCGCCC CTGCTGGCG  
1201 CTGCTGGACC TGCTGTGCT GTGCGCGGG ACCACGCGG CTTCCCGCT  
1251 CTTCTAGAC GCCTATGGC ACAGGATCG ACTGCCCGG CTGCTGGC  
1301 TGCTGTGCA GGACTTCCG CTGCTCTGCT TGCTTGCAG CTTGGGGCTG  
1351 GCCTGCTGC TGCTGGCCG GCGCGGCCG CCGGCTGCC CCACCGGCT  
1401 GCGTGGCTG CTGCTCTGG GCGTGGGGT GGGGGCGGC CCGCCCTCG  
1451 GGAGCGCGC GCATCGCCG CTGCGGCCG TGCGGCTGC CTGCGCGGG  
1501 CTGACGCTT TTCTCGCGG TTTCTTTCC GGGTGTCTG TGGGCTCTC  
1551 CTGCTGGGC GGGGGCGGC GGGGGCGCG GGGGCCCTG GGAGGCTCG  
1601 GCTTCAAGG GCACACACC CTGCGCAGG GCGCAGCCC CTTGCCCTT  
1651 CCGGAGTCT GCGGCGGCG GCGCGCACG GCCCGGTG GCGGACCTT  
1701 CCGGCTGCTG AGCGAGCCC TGCAGGCTA TGAGGTGCTG CACGCTCG  
1751 GCTACGGCG CCAATCCGC CTGGAAGGC CTGCGCCTG GTGGGCTTC

1801 CAGCTAGGC TGCCTGGG CGAGTGGG GTGCGCTCC GGTGGCGCT  
1851 GCTGGGCTC TACCGGCG TCTGAGTCC TCGGTGGC CCGGCTGCT  
1901 GGGCAAGCT CTTCCGTTG TCCCGGGC AGCGGCTCC GCTGTGCGG  
1951 GGAGCTGGG TCACTGGCC CCAGACAAAG GAGCCCCCTG GGAGGCCAT  
2001 CGCTCGGG GACGCGAG TGCTGAGCT GTGCGGCTG CAGGGCCAG  
2051 GCCAGACT CTTACTCAG GCGGAGGTT GCCGGGCTT CAAAGGCGG  
2101 GCGGCAACC CGGCCCGTC CCGGCTTCC TCTCCCTGCA GCGATTACAC  
2151 CGTGAATTC CGCCGCCCT CCCCAATCA CCTGCGAGC AGCATCGAGG  
2201 AGGCCCTCT CAGCGAGGC CTGCTTGGC GTGGCTCTT CAGGGCCCT  
2251 GCCTTCGAG ACCTCTGCC TGGGCTCGA CTCTACCGA CCGCTCGCT  
2301 GGGGACCGG GGCAGGCCA GTGAGAGATC AGGGGAGGC TCTGGCCCCG  
2351 CTGCCCCC GAGCTCCCC TCCCCTGGG CTTGGCCCGC AGGAGCAGC  
2401 GTCTCATCT GCTGTTCTG CGGACTCTG CGGACAGCT CGTCCATGCT  
2451 GCTGTGTTCC AGCCCCGACA GGGCCCCGG CTGCCCCCTG GTCTGGCTC  
2501 TCAGTCCCC GCGGCCCTG GGAAGCAGC CCAGCTCCC GGCCTCAGGA  
2551 TCCTACCAG CCCTGTCCC ACCCTCTCG GACTCCCG AGCCTGCTTC  
2601 TGAGTGCAG GCCGAGGAG CTTGTGTGA GGAGCAGTC CTGACGCTT  
2651 GCCGACAGT CGAGAGCTG AGGTTGGGA GCGACACCAT AGACTGTGA

## !!AA SEQUENCE 1.0

ID ADP30927 standard; protein; 1670 AA.

XX ADP30927;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1694.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410947P.



1651 ACATCACTGA TCAAGCTAA  
!IAA SEQUENCE 1.0  
ID ADP30938 standard; protein; 2828 AA.  
XX ADP30938;  
AC  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1705.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW Cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411053P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.

PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2936; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 2828 AA;  
ADP30938 Length: 2828 February 22, 2005 12:25 Type: P Check: 6333 ..  
1 ATGGAGCAAT CCCGTCACA GCAGCTGGG GGTGAACAA GCTGGTGGG  
51 TAGTGACCCC CAGTACCAGT ATATGCCCTT TGAACACTGC ACCAGCTACG  
101 GACTGCCCTC TGAGATGGG GGCCTCCAGC ACAGGCTCCG GAAGGATGCA  
151 GGCCCCCGCC ACAACGTCCA CCCACACAG TATGGCCATC ACAAGAACA  
201 ATTCTCAGAC AGGAGCAGG ACATAGGGAT GCCCAAGAAG ACAGGCTCCA  
251 GTTCTACCGT GGACAGCAAG GATGAGGATC ACTATTCTAA ATGTCAAGAT  
301 TGTATCCACC GCCTGGGACA GGTGGTGACA AGAAAATTAG GGAAGACGG  
351 GATCTTTCTG GTGCTTCTGG GACTGCTGAT GGCTCTGGTC AGCTGGAGCA  
401 TGGACTAGT CAGTGCANAA AGCCTTCAGG CCTACAAGT GTCCTAGCG  
451 CAGATGCAGC CCAGCCTTCC TCTGCAGTTC CTGGTCTGGG TCACCTTCCC  
501 ACTAGTCTCT ATCTCTTCA GGGCCCTCTT CTGCCACCTC ATCTCTCCC  
551 AGGCTGTTGG CTCTGGAATC CCGAAATGA AGACAATACT TCGTGGGGTT  
601 GTCCTGAAGG AATACCTCAC AATGAAGCC TTTGTGGCCA AGTTTGTGCG  
651 CCTGACTCG GGCCTGGGCA GTGGCATCCC CGTGGGAAA GAGGGCCCCC

701 TCGTCCACAT TGCAGCATC TGTGCTGCTG TCCTCAGCAA ATTCATGTCT  
751 GTGTTCTGGG GGGTATATGA CGAGCCATAC TACTACTCTG ATATCTGTAC  
801 GGTGGGCTGT GCTGTGGGAG TCGGCTGTGG TTTTGGGACA CCACITGGAG  
851 GCAATGCTAT TTAGCATCGA GGTCACTCC ACCTACTTTG CTGTTGGAA  
901 CTACTGGAGA GGATTTCTTG CAGCACAGTT CAGCGCCTTT GTGTTTCGAG  
951 TGCTGGCAGT GTGGAACAAG GATGCTGTCA CCATCACTGC TCTGTTTCAGA  
1001 ACCAATTTCC GAATGGATTT CCCCTTTGAC CTGAAGGAAC TACCAGCTTT  
1051 TGCTGCCATC GGGATTTGCT GTGGGCTCCT GGGAGCTGTA TTTGTGTATC  
1101 TGCATGCCA AGTCATGCTC GGTGTCCGAA AGCACAAGC CUTCAGCCAG  
1151 TTTCTTGCTA AGCACCGCCT GCTGTATCCT GGAATTTGTA CCTTTGTCA  
1201 TGCCTCATTC ACCTTCCAC CAGGAATGGG TCAATTCATG GCTGGAGAT  
1251 TGATGCCCG CGAAGCCATC AGTACTTTGT TTGACAACA TACATGGGTG  
1301 AAACACGGG GTGATCCTGA GAGCCTGGGC CAGTCAGCTG TGTGGATTCA  
1351 CCCC GGTC AAGTTGTCA TCATCATCTT TCTCTTCTTC GTCATGAAGT  
1401 TCTGGATGTC CATCTGTGCC ACCACTATGC CCATACCCTG CGGAGCTTC  
1451 ATGCTCTGT TGTGTGTAGG AGCTGCAATT GGAAGGCTGG TAGGAGAAAT  
1501 CATGGCCATG CTCTTTCCTG ATGGTATTTT GTTTGATGAC ATCATCTACA  
1551 AGATCTTACC TGGGGGCTAT CGAGTAATTT GAGCAGCAGC GCTGACTGGT  
1601 GCCGTTTTCC ACACAGTCTC CACAGCTGAG ATTGCTTTCG AATTAACGGG  
1651 TCAGATTGCT CACATCTGTC CCATGATGTT GGCTGTTATC TTGGCCAACA  
1701 TGTGTGGCCA GAGCCTGCAG CCCTCTCTCT ATGACAGCAT CATCCAGGTC  
1751 AAGAAGCTAC CCTACTTGCC TGACCTTGGC TGGAAACCAGC TCAGCAAATA  
1801 TACCATCTTT GTTGAGGACA TCATGTTAGG TGATGTGAAG TTTGTTTCAG  
1851 CTCTTTACAC ATATGGGGAG TTGGAACCC TGCTCCAGAC CACCACAGTC  
1901 AAGACTTTAC CACTGTGTTGA CTCAAAAGAT TCAATGATCC TGCTGGGCTC  
1951 GGTGGAGCGG TCGGAAGTGC AGGCCCTCCT GCAGGGCCAC CTGTGTCTTG  
2001 AGCGCAGGCT GCGCCAGCC CAAGAGATGG CGCGAAGTT GTCGAGCTG  
2051 CCTTACGACG GGAAGGCGG GCTGCTGGG GAGGGGCTCC CCGCGCGCC  
2101 TCCAGGCGGG CCGAGTCTT TCGCCTTTGT GGATGAGAT GAGGACGAAG  
2151 ACCTCTCTGG CAAGACGAG CCTGTTTCAC TGCTTGTGG GCAGAGCTCG  
2201 CCCACACAAG AAAAAACAA CCCAGGATTC CACAGATTTA GTGGATAACA  
2251 TGTCACTGTA AGAGATTGAG GCCTGGGAGC AGGAGAGCT GAGCCAGCCT  
2301 GTCTGTTTTG ATTCCTGCTG TATTGACCAG TCTCCCTTCC AGCTGGTGA  
2351 GCAGACAACC CTCACAAGA CTCATACCCT GTTTTCACTC CTTGGCCTCC  
2401 ACCTCGCTTA CGTGACCAGC ATGGGGAAGC TCAGGGCGGT CTTGGGCCCTG  
2451 GAGGAGTAC AGAAGGCCAT TGAGGGGCAC ACCAAGTCTG GGGTGAGCT  
2501 CCGCCCTCCC CTTGCCAGCT TCCGGAACAC GACTTCAACT CGAAAGAGTA

2551 CCGGGSCACC TCCATCTTCT GCAGAGAACT GGAACCTGCC TGAGGACAGG  
2601 CTTGGGGCCA CTGGAACAGG GGATGTGATT GCTGCCTCCC CAGAGACCCC  
2651 TGTGCCATCT CTTTCCCAG AGCCCCCTCT CTCCTTGGCC CCAGGCAAGG  
2701 TAGAGGGCGA GTTGAGGAG CTGGAGCTGG TGGAGAGTCC AGGGCTGGAA  
2751 GAGGAGCTGG CCGACATCTT GCAGGGCCCC AGCCTGGCAT CCACAGACGA  
2801 GGAGGATGAG GATGAACCTGA TCCTTTGA

!!AA SEQUENCE 1.0

ID ADP30967 standard; protein; 1616 AA.

XX

AC ADP30967;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1734.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

PN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

PR 29-AUG-2002; 2002US-0406576P.

PR

PR 29-AUG-2002; 2002US-0406579P.

PR

PR 29-AUG-2002; 2002US-0406585P.

PR

PR 29-AUG-2002; 2002US-0406588P.

PR

PR 29-AUG-2002; 2002US-0406608P.

PR

PR 29-AUG-2002; 2002US-0406611P.

PR

PR 29-AUG-2002; 2002US-0406612P.

PR

PR 29-AUG-2002; 2002US-0406616P.

PR

PR 29-AUG-2002; 2002US-0406640P.

PR

PR 29-AUG-2002; 2002US-0406642P.

PR

PR 29-AUG-2002; 2002US-0406646P.

PR

PR 29-AUG-2002; 2002US-0406653P.

PR

PR 29-AUG-2002; 2002US-0406655P.

PR

PR 29-AUG-2002; 2002US-0406666P.

PR

PR 17-SEP-2002; 2002US-0410946P.

PR

PR 17-SEP-2002; 2002US-0410947P.

PR

PR 17-SEP-2002; 2002US-0410948P.

PR

PR 17-SEP-2002; 2002US-0410949P.

PR

PR 17-SEP-2002; 2002US-0410953P.

PR

PR 17-SEP-2002; 2002US-0410957P.

PR

PR 17-SEP-2002; 2002US-0410958P.

PR

PR 17-SEP-2002; 2002US-0410959P.

PR

PR 17-SEP-2002; 2002US-0410960P.

PR

PR 17-SEP-2002; 2002US-0410961P.

PR

PR 17-SEP-2002; 2002US-0410962P.

PR

PR 17-SEP-2002; 2002US-0411019P.

PR

PR 17-SEP-2002; 2002US-0411022P.

PR

PR 17-SEP-2002; 2002US-0411023P.

PR

PR 17-SEP-2002; 2002US-0411024P.

PR

PR 17-SEP-2002; 2002US-0411032P.

PR

PR 17-SEP-2002; 2002US-0411035P.

PR

PR 17-SEP-2002; 2002US-0411037P.

PR

PR 17-SEP-2002; 2002US-0411041P.

PR

PR 17-SEP-2002; 2002US-0411045P.

PR

PR 17-SEP-2002; 2002US-0411046P.

PR

PR 17-SEP-2002; 2002US-0411048P.

PR

PR 17-SEP-2002; 2002US-0411052P.

PR

PR 17-SEP-2002; 2002US-0411055P.

PR

PR 17-SEP-2002; 2002US-0411073P.

PR

PR 17-SEP-2002; 2002US-0411082P.

PR



PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467206P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linneemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2965; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1616 AA;

ADP30967 Length: 1616 February 22, 2005 12:25 Type: P Check: 7290 ..

1 ATTGGAGCAT CTCTGATGTC CAGCAATGTG GGCAGTGGCT TGTTCATCGG  
51 CTGGCTGGG ACAGGGGTG CCGAGGSCCT TGGCGTAGT GGTTCGAGT  
101 GGAACGCAAC CTGGCTGTCTC CTGGCCCTTG GCTGGGTCTT CGTCCCTGTG  
151 TACATCGCAG CAGGTGTGGT CACAATGCCG CAGTATCTGA AGAAGCGATT  
201 TGGGGGCCAG AGGATCCAGG TGTACATGTC TGTCTGTCTT CTCATCTCTT  
251 ACATCTTCAAC CAAGATCTCG ACTGACATCT TCTCTGGAGC CTTCTTCATC  
301 CAGATGGCAT TGGGTGGAA CCTGTACCTC TCCACAGGGA TCCTGCTGGT  
351 GTGACTGCC GTCTACACCA TTGCAAGTGG CCTCATGGCC GTGATCTACA  
401 CAGATGCTCT GCAGACGGTG ATCATGGTAG GGGGAGCCCT GGTCTCTCATG

451 TTTCTGGGT TTCAGGAGT GGGCTGGTAC CCAGGCTTGG AGCAGCGGTA  
501 CAGGCAGGCC ATCCCTAATG TCACAGTCCC CAACACCACC TGTCACTCC  
551 CAGGCCCGA TGCTTTCAC ATTCTTCGGG ACCCTGTGAG CGGGACATC  
601 CTTGGCCAG GTCTCATTTT CGGGCTACA GTGCTGGCA CCTGGTGTG  
651 GTGCACAGC CAGTCAATTG TGCAGCGGTC TCTCTCGGC AAGATCTGT  
701 CTCATGCCAA GGGAGGTCC GTGCTGGGG GCTACTGAA GATCCTCCCC  
751 ATGTTCTTCA TCGTCATGCC TGGCATGATC AGCCGGGCC TGTTCACAGA  
801 CGAGGTGGGC TGCCTGGACC CTGATGCTG CCAAGAATC TGTGGGGCC  
851 GAGTGGGATG TTCAACATTT GCCTACCCTA AGTTGGTCAAT GGCCTCATG  
901 CCTGTTGGTC TCGGGGGCT GATGATTGCC GTGATCATGG CCGTCTCAT  
951 GAGTCACTC ACCTCCATCT TCAACAGCAG CAGCACCTG TTCACCATG  
1001 ATGTGTGGA GCGTTCCGC AGGAAGTCAA CAGAGCAGGA GCTGATGGT  
1051 GTGGCAGAG TGTGTTGGT GTTCCTGGT GTCATCAGCA TCCTCTGAT  
1101 CCCCATCATC CAAAGTCCA ACAGTGGGA GCTCTTCGAC TACATCCAGG  
1151 CTGTACACAG TTACTGGCC CCACCATCA CCGCTCTCTT CTGCTGGCC  
1201 ATCTTCTGCA AGAGGTAC AGAGCCCGGA GCTTCTTGG GCCTCGTGT  
1251 TGGCTGGGA GTGGGGCTT TCGGTATGAT CCGTGGATTC TCATACCCAG  
1301 GGCAGCCTG TGGGGAGGTG GACCGAGGC CAGCAGTGT GAAGACTTC  
1351 CACTACCTGT ACTTTGCAAT CCTCTCTGC GGGCTCACTG CCATCGTCAT  
1401 TGTCAATCCC CAAGCAGGTC CTGGGGAAG TTGCTCTGGA GCTGTTCTG  
1451 TGGGCTCTCT GGAACACCGG AGCAGGCCCT GAGCCACGA GAGAAGGCTG  
1501 CGCTAGAAC GAAGCTGACA AGCATTTAGG AGGAGCCACT CTGGAGACAT  
1551 GTCTGCAACA TCAATGCTGT CCTTTGCTG GCCATCAACA TCTTCTCTG  
1601 GGGCTATTTT GCGTGA

!!AA SEQUENCE 1.0

ID \_ADP30988 standard; protein; 753 AA.

XX AC ADP30988;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1755.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

PR	29-AUG-2002;	2002US-0406608P.	PT	New nucleic acid molecule for diagnosing, preventing or treating diseases
PR	29-AUG-2002;	2002US-0406611P.	PT	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PR	29-AUG-2002;	2002US-0406612P.	PT	genetic, bacterial and viral diseases.
PR	29-AUG-2002;	2002US-0406616P.	XX	
PR	29-AUG-2002;	2002US-0406640P.	PS	Claim 1; SEQ ID NO 2986; 428pp; English.
PR	29-AUG-2002;	2002US-0406642P.	XX	
PR	29-AUG-2002;	2002US-0406646P.	CC	The present invention relates to an isolated nucleic acid molecule
PR	29-AUG-2002;	2002US-0406653P.	CC	encoding a polypeptide which is believed to be cytostatic,
PR	29-AUG-2002;	2002US-0406655P.	CC	antitumour, immunosuppressive, antibacterial and virucidal. The
PR	29-AUG-2002;	2002US-0406666P.	CC	composition and methods are useful for diagnosing, preventing and
PR	17-SEP-2002;	2002US-0410946P.	CC	treating diseases such as proliferative (e.g. cancer), inflammatory,
PR	17-SEP-2002;	2002US-0410947P.	CC	immune, metabolic, genetic, bacterial and viral diseases. The present
PR	17-SEP-2002;	2002US-0410948P.	CC	sequence represents a human secreted protein. The present sequence is
PR	17-SEP-2002;	2002US-0410949P.	CC	available on WIPOWEB and is not in the specification.
PR	17-SEP-2002;	2002US-0410953P.	XX	
PR	17-SEP-2002;	2002US-0410957P.	SQ	Sequence 753 AA;
PR	17-SEP-2002;	2002US-0410958P.	ADP30988	Length: 753 February 22, 2005 12:25 Type: P Check: 5081 ..
PR	17-SEP-2002;	2002US-0410959P.		
PR	17-SEP-2002;	2002US-0410960P.	1	ATGCCGCCCC ACTTGCTGCA GGACGATATC TCTAGCTCCT ATACCACCAC
PR	17-SEP-2002;	2002US-0410961P.	51	CACCACCACC ATTACAGCGC CTCCTTCCAG GGTCCCGCAG AATGGAGGAG
PR	17-SEP-2002;	2002US-0410962P.	101	ATAAGTTGGA GACGAGGCC CTCTACTTGG AAGAAGACAT TCGCCCTGAT
PR	17-SEP-2002;	2002US-0410963P.	151	ATAAAGATG ATATATATAA CCTCACCTAC AAGGATAAGG AAGGCCCAAG
PR	17-SEP-2002;	2002US-0410964P.	201	CCCCAAGTT GAATATGTCT GGAGAAACAT CATCCTTATG TCTCTGCTAC
PR	17-SEP-2002;	2002US-0410965P.	251	ACTTGGGCGC CCGTATATGG ATCATTTTGA TTCTTACCTG CAACTTATAC
PR	17-SEP-2002;	2002US-0410966P.	301	ACCTGGCTTT GGGGAGGAG GTACTACAAA CCGGGCTTGC TGTTCATGTG
PR	17-SEP-2002;	2002US-0410967P.	351	CTTCATCTCG CCCAGCTTG TGCCCTGGTG TTCTGGGGT GAACTTTTC
PR	17-SEP-2002;	2002US-0410968P.	401	AAACAGCGT GTTCTGTGCC ACTTCTTTCG GATATGCTGT GGTGCTTAAT
PR	17-SEP-2002;	2002US-0410969P.	451	GCCAGTGGC TGGTGAACAG TGCTGCCAC CTCTTCAGAT ATCGTCCTTA
PR	18-APR-2003;	2003US-0463700P.	501	TGACAAGAAC ATTAGCTTCC GGGAGAATAT CTGGGTTTCA CCGGAGCTG
PR	18-APR-2003;	2003US-0463716P.	551	TGGGTGAGGG CTTTCACAAC TACCACCAC CTTTCCCTTA TGACTACTCT
PR	02-MAY-2003;	2003US-0467199P.	601	GCCAGTGAGT ACCGCTGGCA CATCAACTTC ACCACATTCT TCATTGATTG
PR	02-MAY-2003;	2003US-0467203P.	651	CATGGCGCC TTGGTCTGG CCTACGACCA GAAGAAGTC TCCAAGGCGG
PR	19-MAY-2003;	2003US-0467230P.	701	CCATCTTGGC CAGGATTAAG AGAACCGGAG AGGGAAACTA CAAGAGTGGC
PR	19-MAY-2003;	2003US-0471306P.	751	TGA
PR	09-JUN-2003;	2003US-0476609P.	!!AA_SEQUENCE 1.0	
PR	09-JUN-2003;	2003US-0476641P.	ID	ADP30995 standard; protein; 1358 AA.
PR	08-JUL-2003;	2003US-0485218P.	XX	
PR	08-JUL-2003;	2003US-0485223P.	AC	ADP30995;
PR	08-JUL-2003;	2003US-0485224P.	XX	
PR	08-JUL-2003;	2003US-0485325P.	DT	12-AUG-2004 (first entry)
PR	14-JUL-2003;	2003US-0486446P.	XX	
PR	14-JUL-2003;	2003US-0486480P.	DE	Human secreted protein SEQ ID #1762.
PR	15-JUL-2003;	2003US-0486891P.	XX	
PR	15-JUL-2003;	2003US-0486960P.	XX	
PR	08-AUG-2003;	2003US-0493341P.	KW	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
PR	08-AUG-2003;	2003US-0493370P.	KW	cancer; inflammatory; immune; human secreted protein.
PR	08-AUG-2003;	2003US-0493573P.	XX	
PR	08-AUG-2003;	2003US-0493577P.	OS	Homo sapiens.
XX			XX	
PA	(FIVE-) FIVE PRIME THERAPEUTICS INC.		PN	WO2004035732-A2.
XX			XX	
PI	Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;		PD	29-APR-2004.
PI	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnenmann T;		XX	
PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;		PF	28-AUG-2003; 2003WO-US026780.
XX			XX	
DR	WPI; 2004-348438/32.		PR	29-AUG-2002; 2002US-0406576P.
XX			PR	29-AUG-2002; 2002US-0406579P.

PR	29-AUG-2002;	2002US-04065855.P
PR	29-AUG-2002;	2002US-04065888.P
PR	29-AUG-2002;	2002US-04065908.P
PR	29-AUG-2002;	2002US-0406608P.
PR	29-AUG-2002;	2002US-0406611P.
PR	29-AUG-2002;	2002US-0406612P.
PR	29-AUG-2002;	2002US-0406616P.
PR	29-AUG-2002;	2002US-0406640P.
PR	29-AUG-2002;	2002US-0406642P.
PR	29-AUG-2002;	2002US-0406646P.
PR	29-AUG-2002;	2002US-0406653P.
PR	29-AUG-2002;	2002US-0406655P.
PR	29-AUG-2002;	2002US-0406666P.
PR	17-SEP-2002;	2002US-0410946P.
PR	17-SEP-2002;	2002US-0410947P.
PR	17-SEP-2002;	2002US-0410948P.
PR	17-SEP-2002;	2002US-0410949P.
PR	17-SEP-2002;	2002US-0410953P.
PR	17-SEP-2002;	2002US-0411019P.
PR	17-SEP-2002;	2002US-0411022P.
PR	17-SEP-2002;	2002US-0411023P.
PR	17-SEP-2002;	2002US-0411024P.
PR	17-SEP-2002;	2002US-0411032P.
PR	17-SEP-2002;	2002US-0411035P.
PR	17-SEP-2002;	2002US-0411037P.
PR	17-SEP-2002;	2002US-0411041P.
PR	17-SEP-2002;	2002US-0411045P.
PR	17-SEP-2002;	2002US-0411046P.
PR	17-SEP-2002;	2002US-0411048P.
PR	17-SEP-2002;	2002US-0411052P.
PR	17-SEP-2002;	2002US-0411055P.
PR	17-SEP-2002;	2002US-0411073P.
PR	17-SEP-2002;	2002US-0411082P.
PR	17-SEP-2002;	2002US-0411011P.
PR	17-SEP-2002;	2002US-0411111P.
PR	18-APR-2003;	2003US-0463700P.
PR	18-APR-2003;	2003US-0463708P.
PR	18-APR-2003;	2003US-0463716P.
PR	18-APR-2003;	2003US-0463732P.
PR	02-MAY-2003;	2003US-0467199P.
PR	02-MAY-2003;	2003US-0467201P.
PR	02-MAY-2003;	2003US-0467203P.
PR	02-MAY-2003;	2003US-0467230P.
PR	19-MAY-2003;	2003US-0471336P.
PR	22-MAY-2003;	2003US-0472420P.
PR	22-MAY-2003;	2003US-0472430P.
PR	09-JUN-2003;	2003US-0476609P.
PR	09-JUN-2003;	2003US-0476641P.
PR	08-JUL-2003;	2003US-0485219P.
PR	08-JUL-2003;	2003US-0485223P.
PR	08-JUL-2003;	2003US-0485224P.
PR	08-JUL-2003;	2003US-0485325P.
PR	14-JUL-2003;	2003US-0486446P.
PR	14-JUL-2003;	2003US-0486480P.
PR	15-JUL-2003;	2003US-0486891P.
PR	15-JUL-2003;	2003US-0486960P.
PR	08-AUG-2003;	2003US-0493341P.
PR	08-AUG-2003;	2003US-0493347P.
PR	08-AUG-2003;	2003US-0493573P.
PR	08-AUG-2003;	2003US-0493577P.

WPI; 2004-348438/32.  
 New nucleic acid molecule for diagnosing, preventing or treating a disease, such as proliferative (e.g. cancer), inflammatory, immune, genetic, bacterial and viral diseases.  
 Claim 1; SEQ ID NO 2993; 428pp; English.  
 The present invention relates to an isolated nucleic acid molecule encoding a polypeptide which is believed to be cytostatic, anti-inflammatory, immunosuppressive, antibacterial and virus composition and methods are useful for diagnosing, preventing or treating diseases such as proliferative (e.g. cancer), immune, metabolic, genetic, bacterial and viral diseases. The sequence represents a human secreted protein. The present invention is available on WIPWEB and is not in the specification.  
 Sequence 1358 AA;  
 ADP30995 Length: 1358 February 22, 2005 12:25 Type: P Check:  
 1 ACAAGGCTTT TTCACGCTT ACTGGAATGC TTGGCAATG TCCTTTGTGG  
 51 CTACATAGCA GGAAGGCCA ATGTCAATAC ATCAACCCAG GCCAAGAGCA  
 101 TAGGAATATT TGTCTCAGA TTGCACTTC CAGCTTTATT ATTCAAAAAC  
 151 ATGCTTGTAC TTAATTTTTC CAATGTGGAC TGGTCTCTCC TATATAGTAT  
 201 CTTAATTGCC AAAGCTTCG TATTTTCAT TGTATGTGA TTAACCTTAT  
 251 TGGTTGCCAG TCTGTATAGT CGATTAGCA AAGCTGGACT ATTCCTTATT  
 301 TTTGCTACAC AAAGTAATGA CTTTGCATTG GGATACCCCTA TAGTCTGGAT  
 351 CAGCCCTATT TTATCTTGGT CTCACATGG TGGGAAAAAT AAGAGAGCTG  
 401 AAGAAGTCGG CATTGTAGT ACTAATCTT CTCATCACAG CTAACCTTCT  
 451 GGTGCTGCCA CTTTCTGCGA GAGAAATGTT GGAATCTTTG GACAAGGGCG  
 501 ACAGTGTGGT GAACCATACA AGTTTATCAA ATTATGCATT TCTGTATGGT  
 551 GTATTTCTGT TAGCACAGG AGTGGCTATC TTGCAACAC AATTCACAT  
 601 GGAAGTAGAA ATTATAACCT CAGGGATGGT GATAAGCACA TTTGTGTCTG  
 651 CTCCTCATAT GTACGTTTCT GCCTGGTTAC TGACCTTTCC CACTATGGAC  
 701 CCTAAGGCAT TGGCATATGC CATCCAGAT GTTAGTTTTG ATATAGTAT  
 751 TGTGAGCCTG ATCTCCTTGA TCTGGTCTCT GGCTATTCTT CTTTGTAGTA  
 801 AGAAATATAA ACAGCTTCTT CATATGCTTA CAACTAATTT ACTCATTGCT  
 851 CAGTCTAATT TCTGTCTCGG AATGATGATA TGGAAATTTG TTAAGAAAAA  
 901 AAATTTTGGT GGACAAATTT TGGTGTTTGT TCTATTGPAC AGCTCCCTCT  
 951 ATAGCACCTA CTTGTGGACA GGCCTTCTAG CAATTTCTTT GTTTCTTTTG  
 1001 AAAAAGCGAG AGAGGTACA AATTCCTGTT GGAATATCA TAATATCTGG  
 1051 CTGGGGAATT CTGCTCTCC TTGTTGGTGT TCTTTTGATA ACTGGAAAAAC  
 1101 ACAATGGAGA TAGCAATTGAC TCAGCCTTCT TTTATGGAAA AGAACAGATG  
 1151 ATCACCACAG CAGTCACCCT GTTCTGCAGC ATCCTGATAG CTGGCATATC  
 1201 CCTCATGTGC ATGAACGAGA CTGCCCAAGC AGGAAGCTAT GAAGGTTTTCG  
 1251 ATCAGTCTCA GAGCCACAAA GTGGTGGAGC CTGGAAATAC TGCTTTTGTGAG

1301 GAGAGTCCAG CACCAGTAA TGAACGAA CTTTTTACAA GCTCTATTCC  
1351 AGAACAA

!!AA\_SEQUENCE 1.0  
ID\_ADP31010 standard; protein; 735 AA.

AC ADP31010;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1777.  
XX DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.

XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.

02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471365P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3008; 428pp; English.  
PS The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
SQ Sequence 735 AA;

ADP31010 Length: 735 February 22, 2005 12:25 Type: P Check: 6262 ..

1 ATGCTTCTCA GCAGCCAGC GACATGCACA GTAGGTCTGG ACTGTCAGGG  
51 GCAGGCAGGC CCCCACTCCC GGCCCCCATC CATGGAGCAT AGAGAAACAG  
101 GTGGTGAGCA TCCTCACTGG CAGATGCAGC AGCGGCTCAC AGCAGAGGCA  
151 AGCTCACTTT CTTTGCAATT GTATTCCCTC CAGCCCAAGT TCAGCCACAA  
201 AGGAATGTC CTTAATACC AAGACTCAGA CAGCCACAGA GTCAATTGCT  
251 TTGGATGCTT TTCCATCCTT GAGATGTTGG ATTCAAGGGA GGTGCGCTTC  
301 GACGAGCGGC TAGGTGCACT GCGGCGGCAG CACTTTCCAC GCGAGGAGCT  
351 GGAGCTGGGC TCTGGCAGC CCTTCGGCTC TCTGGTGGG GAGCTGAGTC  
401 CCGGGTTGTT GAGGCGGGGG TCCCTTAAGA CCGCTACCGG CCCCTCGGGG  
451 CTGACGGGCC GCGAGGGGCG TCACCTCTCCG AAGGCAGCCT GCGCGAAGGC  
501 AGACGCGGAC CGGACTTGCT CTTGCACAGC AGCGCGGAG CAGCGCAGCG  
551 GGAGGACGGG AGAGGTGCTG CCCTCCCCC GGAGTTGGAA GGCCTTAGT  
601 CGGGTCCAAA ATGCCCAAGA AGACGCGGAC GCCCATCCAG CTGACCCACG

651 CCCCCGACGG CTCACGCCGT GGTAAACGGG ACCAGCTCTG CGGAAACCAA  
701 CTTGGAGGCC TTGCAGAAGA AGCTGGAAGA GCTAG

!!AA SEQUENCE 1.0  
ID ADP31013 standard; protein; 579 AA.

AC ADP31013;

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1780.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

PN WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

PR 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406645P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 17-SEP-2002; 2002US-0410946P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.

PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.

PR 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411022P.

PR 17-SEP-2002; 2002US-0411023P.

PR 02-MAY-2003; 2003US-0467230P.

PR 19-MAY-2003; 2003US-0471306P.

PR 19-MAY-2003; 2003US-0471336P.

PR 22-MAY-2003; 2003US-0472420P.

PR 22-MAY-2003; 2003US-0472430P.

PR 09-JUN-2003; 2003US-0476609P.

PR 09-JUN-2003; 2003US-0476641P.

PR 08-JUL-2003; 2003US-0485218P.

PR 08-JUL-2003; 2003US-0485223P.

PR 08-JUL-2003; 2003US-0485224P.

PR 08-JUL-2003; 2003US-0485325P.

PR 14-JUL-2003; 2003US-0486446P.

PR 14-JUL-2003; 2003US-0486480P.

PR 15-JUL-2003; 2003US-0486891P.

PR 15-JUL-2003; 2003US-0486960P.

PR 08-AUG-2003; 2003US-0493341P.

PR 08-AUG-2003; 2003US-0493370P.

PR 08-AUG-2003; 2003US-0493573P.

PR 08-AUG-2003; 2003US-0493577P.

XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MW, Kochakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases

PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 3011; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule

CC encoding a polypeptide which is believed to be cytostatic,

CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The

CC composition and methods are useful for diagnosing, preventing and

CC treating diseases such as proliferative (e.g. cancer), inflammatory,

CC immune, metabolic, genetic, bacterial and viral diseases. The present

CC sequence represents a human secreted protein. The present sequence is

CC available on WIPWEB and is not in the specification.

XX Sequence 579 AA;

ADP31013 Length: 579 February 22, 2005 12:25 Type: P Check: 8091 ..

1 ATGTTCTGCG AGGCTGTACA GGAAGCACAG TGCTGCACAT CTGCTCAGCT

51 TCTGGGAAGG CTCAGGGAGC TTTTACTCAT GGCAGAGGT GAAGCAAGAG

101 CAGGCACATC ACATGGCAG AGCAAGAGCA AGAAGGGTGC CTTGACAGAG

151 CGGTAGGTG CACTGGCGGG GCAGCAGCTTT CCACGGCAGG AGTGGAGCT

201 GGGCTCTGGG CAGCCCTTCG GCTCTCTGCG TGGGAGCTG AGTCCCGGT

251 TGTGAGCGG GGGGTCCCTT AGACCGGTA CCGGCCCCCT GGCCTCAGC

301 GGCCCGGAG GGGCTACCC TCCGAAGGCA GCCTGCGCGA AGGCAGAGC

351 GGACCGGACT TGGTCTGTCA CAGCAGGCGC GGAGCAGGCG AGCGGGAGGA

401 CGCAGAGGT GCTGCCCTCC CCCCAGATT GGAAGCGCT TAGTCGGGT

451 CAAAATGCC AGAAGACGC GCAGCCCCAT CCAGCTGACC CCAGCCCCCG

501 ACGGCTCAG CCGTGTGTTA CGGGACCAGC TCTCGGAAA CCAACTTGA

551 GGCCTTCAG AGAAGCTGG AAGAGCTAG

!!AA SEQUENCE 1.0

ID ADP31071 standard; protein; 1122 AA.

XX AC ADP31071;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1838.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.

PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haisan L, Linnenann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX PS Claim 1; SEQ ID NO 3069; 428pp; English.  
XX CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX SQ Sequence 1122 AA;  
ADP31071 Length: 1122 February 22, 2005 12:25 Type: P Check: 1610 ..  
1 ATGTCCAGCC AGGTGGTGGG CAGTGAGCCT CTCTACATCA TGGCAGAGCC  
51 GCCCAGGCCT GACAGTCCAA AGGCTCCTC GGAGACGGAG ACCCGAGCCT  
101 CCTGTGGCCC TGGCCCTGGG TCAGCTCCC ACCCACTGCC TCCCAGGCCA  
151 CAAGGAAGAG GAGGATGGGA AGGGGCTGGG CCTGGCGAGC TGGGCGGTGG  
201 GAAGCTGGTG CTCAGCTTCC TGTCCAAGAG CCTCTGCCTG GTCTGTGGGG  
251 AGTGGCCTC CGGTACCAC TACGGTGTGT CATCCTGTGA GGACTGCAAA  
301 GCCTTTTCCA AGAGACCAT CCAGGGGAGC ATCAAGTACA GCTGTCCGGC  
351 CTCCAACAAG TGTGAGATCA TCAAGCGGAG ACGCAAGGCC TGTCAAGGCT  
401 GCGGCTTAC CAAGTGCTCG CCGGAGTGGC CTGGATCGC GTCCGGGGTG  
451 GCGGAAGAA GTACAAGCGG TGCACAGAGT GGACCCGCTG CCTTCCCGG  
501 GCGCCTTCCC TGCTGGGCC CTGCGAGTGG CTGGAGGCC CCAGAAGACA  
551 CCCAGTGAA TGGCTGGTG TCTCATCTGC TGGTGTGTA GCCTAGAGAG  
601 CTCTATGCCA TGCCCGACCC CATGTCACTA CTGCAGAGCG TGTGGATGGA  
651 GGTGCTGGTG CCCGCTGGG CCCAGCGCTC ACTGCCACTG CAGGATGAGC  
701 TGGCCTTAC TGAGACAGA GTCTGTGATG AAGAGGGGC ACGGCAGCT  
751 GGCCTGGGG AACTGGGAC TGCCCTGCTG CAACTGGTGC GCGCGCTGCA



!!AA SEQUENCE 1.0  
ID \_ADP31110 standard; protein; 806 AA.  
XX  
AC ADP31110;  
DT  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1877.  
DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406855P.  
PR 29-AUG-2002; 2002US-0406866P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR

22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486466P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3108; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 806 AA;  
ADP31110 Length: 806 February 22, 2005 12:25 Type: P Check: 5502 ..  
1 GAAATCCCTT CCCTGCGACA TATGCAAGA CGTTGTCACC GCAGCTGGTG  
51 ATATGCTGAA GGACAAATGCC ACTGAGCCTG TCATCCTGGA CATCATTA  
101 GGAGAAATGA GCCGTCTCTGG GGAGGTGTGC TCTGCTCTCA ACCTCTGCGA  
151 GTCTCTCCAG AAGCACCTAG CAGAGCTGAA TCACCAGAG CAGCTGGAGT  
201 CCAATAAGAT CCCAGAGCTG GACATGACTG AGTGTGTGGC CCCCTTCTATG  
251 GCCAACATCC CTCTCTCTCT CTACCCCTCAG GACGGCCCCC GCAGCAAGCC  
301 CCAGCCAAAG AAAGAAATAC TCGACGCTTT TGACAAAATG TGCTCGAAGC  
351 TGCCGAAGTC CTTGTGCGAA GAGTGCCAGG AGTGTGTGGA CACGTACGGC  
401 AGCTCCATCC TGTCCATCCT GCTGGAGGAG GTCAGCCCTG AGCTGGTGTG  
451 CAGCATGCTG CACCTCTGCT CTGGCAGCGG GCTGCGCTGCA CTGACCGGTG  
501 TGCAGAAGC TGGTGGGTTA TTTGGATCGC AACCTGGAGA AAAACAGCAC  
551 CAAGCAGGAG ATCCTGGCTG CTCTTGAGAA AGGCTGCAGC TTCCTGCCAG  
601 ACCCTTACCA GAAGCAGTGT GATCAGTTTG TGSCAGAGTA CGAGCCCGTG  
651 CTGATCGAGA TCCTGGTGGG GGTGATGGAT CCTTCCTCTG TGTGCTTGA  
701 AATTGGAGCC TGCCCCCTCG CCCATAAGCC CTTGTTGGGA ACTGAGAAAT



751 GTATATGGGG CCCAAGCTAC TGGTGCCAGA ACACAGAGAC AGCAGCCGAC  
801 TGC AAT  
!!AA SEQUENCE 1.0  
ID ADP31112 standard; protein; 3447 AA.  
XX  
AC ADP31112;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1879.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406658P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Heatir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3110; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytosolic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIFOWEB and is not in the specification.  
XX  
XX Sequence 3447 AA;  
ADP31112 Length: 3447 February 22, 2005 12:25 Type: P Check: 1469 ..  
1 ATGAAGGCAG AATAAAGAT GTTCTTTGAA ACCAAGGAGA ACAAGACAC  
51 AACATACCAG AATCTCTGGG ACACATTCAA AGCAGTGTGT AGAGGGAAT  
101 TTATAGCACT ACATGCCAC AGAGAAAGC AGGAAGATC CAAAATTGAC  
151 ACCCTAATAT CACAATTAAA AGAAGTAGAG AGCAAGAGC AAACACATTC  
201 AAAAGCTAGC AGAAGGCAAG AATAACTAA AATCAGACCA GGAAGTGAAG  
251 AAATAGAGAC ACAAAAACC CTTCAAAAA TTAATGAATC TAGGAGCTGG  
301 TTTTGTGAAA GGATCAACAA AATTGATAGA CCGTAGCAA GACTAATAAA  
351 GAAAGAAAGA GAGAAGAAATC AATAGACGC AATAAAAAAT GATTAAGGGG  
401 ATATCACCAC CAATCCACA AAAATACAAA CTACCATCAG AGAATACTAC  
451 AAACACCTCT ACGCAATAA ACTAGAAAT CTAGAGAAA TGGATAAATT  
501 CTTTGACACA TACACTCTCC CAAGACTAAA CCAGGAAGAA GTTGAATCTC  
551 TGAATAGACC AATAACAGGA GCTGAAATTG TGGCAATAAT CAATAGCTTA  
601 CCAACAAAA AGAGTCCAGG ACCAGATGGA TTCACAGCCG AATTCTACCA

651 GAGGCAAG GAGGAAGTGG TACCATTCTT TCTGAAACTA TTCCAATCAA  
701 TAGAAAAGA GGAATCCTC CCGACTCAT TTTATGAGGC CAGCATCAIT  
751 CTGNATCCAA AGCCGGGAG AGACAACACC AAAAAAGAGA ATTTAGACC  
801 AATATCCTTG ATGAACATCG ATGCAAAAAT CCTCAATAAA ATACTGGCAA  
851 ACCAAATCCA CGAGCACATC AAAAGCTTAA TCCGCCATGA TCNAGTGGGC  
901 TTCAATCCTG GGAATCAAGG CTGGTTCAAT ATACGCAAAAT CAATAAATGT  
951 AATCCAGCAT ATAAACAGAG CCAAGACAAA AAACCGCATG GTTATCTCAA  
1001 TAGATGAGA AAGGGCTTT GCAAAAATTC AACAAACCCCTT CATGCTAAAA  
1051 ACTCTCAATA AATTAGGTAT TGATGGGACA TATTTCAAAA TAATAAGAGC  
1101 TATCTATGAC AAACCCACAG CCAATATCAT ACTGAATGGG CAACAACCTGG  
1151 AAGCATTTCCC TTGAAAACCT GGCATAAGAC AAGGATGCCC TCTCTACCA  
1201 CTCCTATTCA ACATAGTGT TGAAGTTCTA GCCAGGGCAA TCAGGCAGGA  
1251 GAAGGAAATA AAGGGTATTC AATTAGGAAA AGAGGAAATC AATTGTCCC  
1301 TGTTTGAGA TGACATGANT GTATATCTAG AAACCCCAT TATCTCAGCC  
1351 CAAAATCTCC TTAAGCTGAT AAGCAACTTC AGCAAACTCT CAGGATACAA  
1401 AATCAATGTG CAAAATCTAC AAGCATTTCT ATACACCAAC AGACAACAG  
1451 AGAGCCAAAG CATGAGTGAA CTCCCATTTCA CAATTGCTTC AAAGAAATA  
1501 AAATACCTAG GAATCCAAT TACAAGGGAT GTGAAGGACC TCTTCAAGGA  
1551 GAACACAAA CCACTGCTCA AGGAAATAAA AGAGGATACA AACAAATGGA  
1601 AGAACATTCC ATGCTTATGG GTAGGAAGAA TCAATATCGT GAAATGGTC  
1651 ATACTGCCCA AGGTAATTTA CAGATTCAAT GCCATCCCGG TCAAGCTACC  
1701 AATGACTTTC TTCACAGAAT TGGAAAAAAC TACTTTAAAG TTCATATGGA  
1751 ACCAAAAAG AGCCCGCATC ACCAAGTCAA TCCTAAGCCA AAAGAACAAA  
1801 GCTGGAGGCA TCACGTACC TGACTTCAAA CTATACTACA AGSCTACAGT  
1851 AACCAAAACA GCATGTACT GTACCAAAA CAGAGATATA GATCAATGGA  
1901 ACAGAACAGA GCCTCAGAA ATACGCCGC ATATCTACAA GTATCTGATC  
1951 TTTGACAAAC CTGAGAAAAA CAAGCAATGG GGAAGGATT CCTATTTAA  
2001 TAAATGTGC TGGGAAACT GSGTAGCCAT ATGTAGAAAG CTGAAACTGG  
2051 ATCCCTTCTT TACACCTTGT ACAAANAATCA ATTCAAGATG GATTAAAGAC  
2101 TTAACGTTA GACCCAAAAC CATAAAAACC CTAGAAGAAA ACCTAGGCAT  
2151 TACCATTCAG GACATAGGCA TGGGCAAGGA CTTCATGTCT AAAACACCAA  
2201 AAGCAATGGC AACAAAGCC AAATTTGACA AATGGGATCT AATTAACHTA  
2251 AAGAGCTTCT GCACAGCAA AGAAACTACC ATCAGAGTGA ACAGGCAACC  
2301 TACAABATGG GAGAAATTT TCGCAACCTA CTCACTGAC AAAGGCTTAA  
2351 TATCCAGAT CTCAATGAA CTCAAACAAA TTACAAGAA AAAACAAAC  
2401 AACCCCATCA AAAAGTGGC AAAGGACATG AACAGACACT TCTCAAAAGA  
2451 AGACATTTAT GCAGCCAAA AACACATGAA AAAATGTCTA CCATCACTGG

2501 CCATCAGAGA AATGCAAAATC AAAACCACAA TGAGATACCA TCTCACACA  
2551 GTTAGAATGG CAATCATGAA AAGTACAGGA AACACAGCC CTGGCGTCAA  
2601 AGCCAGTTCC CGGCCAGTC TCGTCTTGA GCAGCCTGCC GCCTGCCTCC  
2651 TCTTTCCTTT CAACATGACA GATGCGCTG TGTCTTTCAC CAAGGACTTC  
2701 CTGGCAGGTG GAGTGGCAGC AGCATCTCC AAGATGGGG TAGCGCCAT  
2751 CGAGAGGCTC AAGCTGTGTC TGGAGGTACA GCATGCCAGC AAGCAGATCA  
2801 CCGCAGATAT GCAATACAA GGCATTATAG ACTGCGTGT CCATATTCTC  
2851 AAGAGCAGG GAGTCTGTC CTCTGGCAC CGTAACCTGG TCAATGTCTT  
2901 CAGATATTC CCCACCCAGG CTCTCAACTT GGCCTTTCAAA GATAAACACA  
2951 AGCAGATCTT CCTGGTGGT GTGACAAGA GGACCCAGTT TGGGAGCTAC  
3001 TTTGAGGGA ATCCGGCATC AGTGGTGCC GCTGGGGCCA CATCCTTGTG  
3051 TTTTGTGTAC CCTCTTGATT TTGCCCATAC CTGTCTAGCA GCTGACGGTA  
3101 TTATCATCTA CCGAGCTGCC TACTTTGGTA TCTATGACAC TGCAAAAGGA  
3151 ATGCTTCGG ATCCAGGAA CACTCACATC ATCATCAGCT GGATGATCAC  
3201 TCAGACTGTC ACTGCCATTG CTGGGTTGAC TTCCCATCCA TTTGACACCG  
3251 TTCGATGCCG CATGATGATG CAGTCAGGC GCAAAGGAAT TGACGTGATG  
3301 TCACACAGGA CGTTTGACTG CTGGAGGAAG ATTGTTGGTG ATGAAGGAGG  
3351 CAAAGATTTT TTCAAGGCTG CATGGTCCAG TGTCTCTAGA GGCATGGATG  
3401 GTGCTTTTGT GCTTGTCTTG TATGGTGAAA TCAAGAAGTA CACATAA

!!AA\_SEQUENCE 1.0

ID ADP31117 standard; protein; 3585 AA.

XX ADP31117;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1884.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

PN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

PR 29-AUG-2002; 2002US-0406576P.

PR

PR 29-AUG-2002; 2002US-0406579P.

PR

PR 29-AUG-2002; 2002US-0406585P.

PR

PR 29-AUG-2002; 2002US-0406588P.

PR

PR 29-AUG-2002; 2002US-0406608P.

PR

PR 29-AUG-2002; 2002US-0406611P.

PR

PR 29-AUG-2002; 2002US-0406612P.

PR

PR 29-AUG-2002; 2002US-0406616P.

PR

PR 29-AUG-2002; 2002US-0406640P.

PR

PR 29-AUG-2002; 2002US-0406642P.

PR

PR 29-AUG-2002; 2002US-0406646P.

PR

PR 29-AUG-2002; 2002US-0406653P.

PR

PR 29-AUG-2002; 2002US-0406655P.

PR

PR 29-AUG-2002; 2002US-0406666P.

PR

PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

DR WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.

PS Claim 1; SEQ ID NO 3115; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and

CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.

SQ Sequence 3585 AA;

ADP31117 Length: 3585 February 22, 2005 12:25 Type: P Check: 9880 ..

1 ATGGGCTCTGA CTGACATAGA CTGCGAGCTG CAGTTCTCCA TGTCCCAACC  
51 CGAAGCCCTC CTTCTCTGG CAGCAGGCC AGCTGACCAC CTCTGTGTGC  
101 AGCTCTACTC TGGACACCTG CAGGTGAGGC TTGTCTCTGG CCAGAGGAG  
151 CTGAGGCTGC AGACCCCGAG AGAATTCTA CTGAGTGGCT CCGTCCCCCA  
201 CACCACAGTT CTGACTGTCT CAGAGGACTG GCCACATTG TCAGTCAATG  
251 GGTTCCTGAA TGCCTCCTCT GTAGTCTTGG GAGCCCCCTT AGAAGTCCCC  
301 TATGGGCTCT TTGTTGGGAG CACTGGGAGA CTTGGCCTGC CTTACCTGAG  
351 GGGAAACCAG CATCCCTCTA GGGGTTGCCT CCATGGAGCC GCTCTCAATG  
401 GCCGCAGACT CCTCCAGCCT CTGACCCCCA ATAAGCATGA GGGCTGTGCT  
451 GAAGAGTTT CTGCCAATGA TGATGTGGCC CTGGGCTTCT CTGGGTCCCA  
501 CTCTCTGGCT GCCTTGCTG CTGCGGCGAC TCAGGATGAA GGAACCTTGG  
551 AGTTTACACT CACCACACAG AGCTGCAGG CACCCTTGCC CTTCCAGGCA  
601 GCAGGCTGGC ATGGGGACTT CATCCATGTG GACATATTG AGGCCACCT  
651 GTGGTCCATG GTTGAGAAGG GCCAGGGTAC TGTATTGTCT CTCAACAGTG  
701 TGCTGTGTAC TGACGCACAG CCCACAAGS TCAGCATCCA CATCAACATT  
751 CACCAGTAG AATCTCCAT GGACCATGAC CCCACACGAA CTGAGGAGTC  
801 CTCAGCTACC TGGAGCCAG AACACCGCTC AGGCCTGACA CCAGGGGCTG  
851 CCAATGCTCT CTTGCTGGG TGCTGTCATG GAAGACCTCA GTGTCAATGG  
901 CTAGAGGCG GGGCTGTGGG AGCCTTGCT GACGCACAAC ATGGTGGCTG  
951 GCTGCAGACT GGAGGAGCTG CTATCAGCG AGTGGTGGTG ACCGAGGCTG  
1001 GCACAGCCTG GCTTGTAGTG TGCCATGTGC AGCCCATGCT GGCACTGATG  
1051 GAGGTGAAC TGGCTAAATC CCAGGCCCCG TTCATCCAG ATGGCCCTGA  
1101 GGACACCTCT GACCACTGG TGCTGGAGGT GTCAGTGATG GCTTGGTGTG  
1151 CCATGCCCTC ATGCTGCGG AGGGGCCAAA CAGACCTCCT GCCATCCAG  
1201 GTCACCCCTG TCAATGACCC ACCCCACATC ATCTTCCAC ATGGCAGCCT  
1251 TATGGTGAAT CTGGAACACA CACAGAAGCC TCTGGGGCCT GAGGTCTTCC  
1301 AGGCTATGA CTTGGACTCT GCCTGTGAGG GCCTCACCTT CCAGCTCCTT  
1351 GGCACCCCTT CTGGCTCCC CGTGGAGCAC CGAGACCAGC CTGGGGAGCC  
1401 GGTGACTGAG TTCTCTGTCT GGGAGTTGGA GGGCGGCAGC CTAGTCTATG  
1451 TCCACTGTGG TGCCCCATCA CAGGACTTGA CATTCCGGGT CAGCAATGGA  
1501 CTGAGGCGCA GCGCCCCGGC CATGCTGAAG GTGGTGGCTG TCCAGCTGGC  
1551 CATAAAATC CACCGCAGCA CAGGGCTGCA TCTGGCCGAG GGCTCTCCCA

1601 TGCCATCTTT GCCTACCAAC CTGTGGTGG AGACCAGCGC CGTGGGGCAG  
1651 GATGTGACCG TGCTGTTCCG TGTACCCGGA GGCTGCGGT TCAGGGAGCT  
1701 GCAGAGCAG GGGGCTGGTG GGGTGGAGGA TGCTGAGTGG TGGGTACAC  
1751 AGGCGTTCCA CCAGCAGGAT GTGGAGCAGG GCCACGTGAG GTACCTGAGC  
1801 ACTGACCCAC AGCACTACAC CGAGGACACC GTGGAGNACC TGGATCTGCA  
1851 GGTGCAAGTG AGCTGGGAAA TCCTGAGCAA TCTGTCTTTC CTAGTGACCA  
1901 TCCAGAGAGC CACTGTGTGG ATGTGTCAGC TGGAGCCACT GCACACTCAG  
1951 AACACCCAGC AGAGGCCCT CACNACGCC CACCTGAGG CCACCTGGA  
2001 GGAGGCAGGC CCAAGCCCC CAACCTTCCA CTGTGAGGTG GTTCAGGCTC  
2051 CCAGGAAAGG CAACTTTCAA CTACAGGGCA CGATGCTGTC AGACGGTCAG  
2101 GGCTTCACCC AGATGACGT ACAGCTGCA GAGGTGACCT ATGGGGCCAT  
2151 GGCACATGCC TCAGTGGCAG TGGAGGACAC CTTCTGT TTC CATGTCACAG  
2201 CTCACCATTA TTTCTCCCA CTCTGTACCT TCTCCATCCA TATTGGCGGT  
2251 GACCCAGACA TGCTGTCTCT CGTGTGCCC GAGGTGGTG GGTGTGCTCT  
2301 CTCTGCTGAC CAGCTTTTCA TCNAGAGTCT CAACAGTGCC AGGTACCTCT  
2351 ATGAGGTGAT GGAGCAGCCC GCCATGGGA GGTGACTTG GCGTGGACA  
2401 CAGGACAGA TCACTATGTT GACATCTTTC ACCNATGGAG ACCTGATGCA  
2451 TGSCCAGCTG ACCATCAGCT CGCTTTTCCA CGTGGCCTGG GGTAGGTGCC  
2501 GGCTGCTGAC TACAGACAAC ATGGCCTTCA GCAATGCTGA TTCGGGCTTT  
2551 GCTGAGGCC AGCTGTGTGT GACCACACAG GACCTCTCTCT CTGGCAGTAT  
2601 CATGGCCACG GATGAGCCCA TGCAGCCCAT CTGCCGCTTC ATCCAGGAGG  
2651 GGCTCAGGA AGAGGGGAGT CCGTGTGTCG ATGGGCAGCA CCAGGCCATC  
2701 ACGGTGCTGG AGGTGAGGC CTTGAGGCT TACCTCTGTG TGGCCNATGG  
2751 CTCGGCCTC ATGTTTCTTC AAGGAGGCCA GGGTACCATC AACATGGCCG  
2801 AGCTCCACCT GGGCACCAAC CTCNACATCT GCAGTAGGGA TGAGGGCCAC  
2851 TACCACGTCA CAGACAGCCC TCACGTGGGA CAGTTGTCTCC AGCCNACTCA  
2901 GCCAGCCACA GCTTCTCTC AGCAGGACCT GCTGGTTGGG GCTGTTTTCT  
2951 ATGGCCACAA TGGCAGCCTC AGCTCCCGCA ACACCCTGGC CTTCTCAATG  
3001 GATGTGGAC CAGTGACAC AGATGCCACC CTACAAGTGA CCATTGCCCT  
3051 AGAGGGCCCA GTAGCCCCAC TGAAGCTGGC CCAGCACAA GAGATCTACA  
3101 TCTTCCAGGG AGAGGCAGCT GAGATCAGAA GGGACCAGCT GGAGGTAGCC  
3151 CAGGAGCAG TGGCGCCAGC AGACATCGTT TTCTCAGTGA AGAGCCACC  
3201 GAGTGGCGGC TACCTGGTGA TGGTGTCTCG TGGCATCTTG GCAGATGAGC  
3251 CACCCAGCCT GGACCCCGTG CAGAGCTTCT CCCAAGAGGC AGTGGACACA  
3301 GGAGAGATCC TCTACTGCA CTCGGCCCT GAGGCATGCC TTCTCGCTGG  
3351 ATGTGGCCTC GGCCTGGGTG CTCGCCCTTGA GAGCTCACG TGGAGTGA  
3401 GGTCTGCTT CCCCCTCTC CGGGCCCTTG GCCTGCAGGT GCTGGAGCCA

3451 CCCCGCATG GGGCCTGCA GAAGAGGAT GGGCCTCAAG CCAGGACCCCT  
3501 CAGCACCTTC TGCTGGAG AGTGGAGA GCATCTGATC CAGTACCTGC  
3551 ACGATGGAG CAAGACACTG ACGTTTTGT CCTGA  
!!AA SEQUENCE 1.0  
ID\_ADP31126 standard; protein; 768 AA.  
XX  
AC ADP31126;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1893.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.

PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3124; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 768 AA;

ADP31126 Length: 768 February 22, 2005 12:25 Type: P Check: 4411 ..  
1 ATGGTTAGG GTGAGMAAGG CCCAAGGC AGAAGATCA CCTCAAGGT  
51 GGCCAGGAAT TGCATCAAA TCACTTTGA TGGGAAAGG CGCCTTGACT  
101 TGAGCAAGAT GGAATTACC ACCTTCCCA AGTGATTCT GGCCTTAGT  
151 GACATGGAGC AGCTGGACCT TAGCCGAAT CTTATCAGGA AGATCCCTGA  
201 CTCCATCTCC AAGTTCNAGA ACTCCGGTG GCTGGACCTG CACAGCAACT  
251 ACATAGACAA GCTGCCTGAG TCCATTGGCC AGATGACCAG CTTGCTCTAC  
301 CTCACGTCA GCAACAACCG GCTGACCAGC AAGGGCTGC CGTGGAGCT  
351 GNAGCACTC AAGACATCC GCCTGTGAA CTTAGGCTTG AACCACTGG  
401 ACAGCGTGC CACCACACTG GGGGCCCTGA AGGAGCTCA CGAGTAGGG  
451 CTCCATGACA ACCTACTGAA CAACATCCC GTGAGCATCT CCAAGCTCCC  
501 CNAAGTGAA AAGCTCAACA TAAAGGGAA CCCCTTTCA AAGCAGGTG  
551 AGTCGGAAT ATTCATAGAC TCCATCAGGA GGCTGGAGAA CTTGTATGTT

601 GTGGAGGAGA AGGATCTCTG TGGGGTTGC CTGAGAAAT GCCAAAGCG  
651 CCGGACACAC CTGATAGAA TCAAGACAT GCCCAGCAG ACACCGAGAA  
701 AGACCATCTT TCCCAATCTG ATCTCACCA ATTCCATGGC CAAGGACTCC  
751 TGGGAAGACT GGAGGTGA  
!!AA SEQUENCE 1.0  
ID ADP31144 standard; protein; 510 AA.  
XX  
AC ADP31144;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1911.  
XX  
KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.

PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3142; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 510 AA;  
ADP31144 Length: 510 February 22, 2005 12:25 Type: P Check: 9342 ..  
1 GCCCTACATG TCTGTGGGTT CTTGTGTGA CCAGTGTATC TACCCGGACT  
51 CAGTGGAGGG CATGCGAAGG AAGGCTACC CGGAGCAGGA CTTGGAAGCC  
101 ATCTGTGACA TGTGTGACCT GCACACATC CTGCAGTGGG AGGAGCCCC  
151 AGGCCCAAGT AGCCCTCCTT GGATGAATGC ACCAGTCTGT TGAGCATCGA  
201 CGTGGGAAGG AGATCTTCC AGGGGCCAA GGACGCAGGC ATTGCCCTGC  
251 TCTCATCAC CCACAGCCC TCCTGTGGGA GTACCACACA CACTTGCTAC  
301 AGTTTCATGG GGAGGGTGGC TGGAGTTTCG AGAAGCTAGG CTCGGCTGCC  
351 CGCCTGAGCC TGACAGAGGA GAAGCAGCGG CTGGAGCAGC AGCTGCGCGG  
401 CATTCCCAAG ATGCAGCGGC ACCTCCAGGA GCTCTGCCAA ATCCTGGCGG  
451 AGGCCGTGGC CCCAGGCAC GTGCCGGCAC CTAGCCCCGA AGGCCCTGCT  
501 GGCTCCAGG

!!AA SEQUENCE 1.0  
ID ADP31199 standard; protein; 366 AA.  
XX  
AC ADP31199;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1966.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX WO2004035732-A2.  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406578P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.

PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485323P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linneemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3197; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 366 AA;  
SQ  
ADP31199 Length: 366 February 22, 2005 12:25 Type: P Check: 6637 ..  
1 ATGGCGCTGC AGAAGTACGA CAACAAGCTG GTCAATGCA TAGAGGAGCT  
51 ATGCCAGAAG CAGGAGGAGC TGTGCTGGCA GATCCAGCAG GAGGAGGACA  
101 AGAAACAGG GCTGCAGAT GAGGTGAGGC AGCTGACAGA GAAGCTGGCC  
151 TCGGTCAACG AGAAGCTGGC CCGGTCAAC GAGAACCCTGG CACGCAAGAT  
201 TGCCTCTTGC AGTAAGTTCT ACCAGACCAT CGCGGAGAGC GAGGCCACCT  
251 ACCTCAAGAT GCTGGAGAGC TCCAGACTT TGCTCAGTGT CCTGAAGAGG  
301 GAAAGTGGGA ACCTGACCAA GGCTACAGCC TCACACCAGA AAAGTAGTGG  
351 TGGCAGGAGC AGCTGA  
!!AA SEQUENCE 1.0  
ID ADP31200 standard; protein; 1539 AA.  
XX  
XX  
AC ADP31200;  
XX  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1967.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.

XX WO2004035732-A2.  
PN 29-APR-2004.  
XX  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471356P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.

PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3198; 429pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1539 AA;  
ADP31200 Length: 1539 February 22, 2005 12:25 Type: P Check: 5431 ..  
1 ATGCTCATGA AAAATGACCA GAAACACATT ACMAATTACA ATGTTGGCAA  
51 CGATGATGCT GAGGAGGAG AGCAGGGGCC CATGGAGAAG GACAGGGTCC  
101 ATACCACCAG CCTTACAGGA TGGACATCGC TATTCAATCC CATTTACAG  
151 ATGCAGAAAC TGAGCTTTCAG GGAAGCTGAG GAGCTCAACC TGGGTCAATAC  
201 GGCCAGCAAG TGGCAGAGTC AAGATCCGAA CCCAGGGGGAT GCTGCTGAGC  
251 TGCTTGGAGC CTTTCAATGCG GACATCCAGA CATGCCGCAG CAGCAGTGGC  
301 AAACCTTCTGC TTGCCCCCAAG AAGCCAGCTG AGTCTTCCAG GTCAAGTCCC  
351 TCTCCTGCTC CCCACAGTCC TGTACACCC CTGGCTGCTC CCCAGGACTC  
401 TTTCTGGGGG GAGCCTGGGC CACATGGAGT TCCTGGCAGC TGTGAAGAAG  
451 GAGGACTTCA CCAGGCTGGC TCTGTGCCCT GCAAGAACCA TCTGCTGGAG  
501 CCAGCAGCAG GCTGCTCTCT TTGAACGGGA CTTGTACCCT CCACTCCCTT  
551 ACCGCTGCAC CACACCAATC CATCATCA CA TTAATGAT CATCTTCTCA  
601 GAGGTGGGGA AGCTGAGGCC CAGAGAGGTG AGTGGCATAT CCGAAGCAGC  
651 CCAGCGCAGG GTCCGAGATT CTTTAAGCCG GTTTACATCA GGAATCCCTT  
701 TACTTTGACC CGAAGACATC CTTAATGAT CCTCTGGTTA TTTTGTCTTT  
751 TGTGAGCCGT GTCTGCTGTA CTGTGCCAGG ATAAATGCCA GTGTTATTCC  
801 CATTTTTCAG CTGCGACGGA AGAGCTCAAG AAGTGAAGTG GCTCCCATTTG  
851 GCACGGCAGA AGGAGCCGTG GTAAGGCCCTG ATCCTGGGCC AGATGCCAGA  
901 GGGCCCTTCC TGTGTCATC TCTGCAAGC CTCATGTGTT GTCTGATGGC  
951 AACATCGTAC TGGGAGAGCC CTGAGGCCCT GGACAGGAC CAAAGGACAG  
1001 TCAAGTGGAC AAAGGCCCTTT CTGAGGAGGA AGCAGACTCC AGTTACCCAG  
1051 GACTCTGGGT TCTCCTCTTT TGACTTGGAC TATGACTTTC AACGGATTAT

1101 TGATAGGATG TACAGTTACC CAGCACGTGT ACCTCCTCCT CCTCCTATTG  
1151 CTCGGGCTGT AGTGCCCTTG AACATCAGC GTGTATCAGG AACACCTCA  
1201 CAAAGGGGCA AAGTGGGCTT CAATTCTAAG AGTGGACAGC GGGGATCTTC  
1251 CAACTCTGGA AAGTTGAAGG GAGATGACCT TCAGGCCATT AAGCAGGAGT  
1301 TGACCCAGAT AAACAAAAA GTGGATTCTC TCCTGGAAGA CCGGGAANA  
1351 ATGGAAGAAGA AACAGAGCAA ACAAGCAGTA GAGATGAAGA ATGGTAAGTC  
1401 AGAAGAGAAG CAGAGCAGCA GCTCAGCTGA GACTCATGTG AAGATAGAGT  
1451 CTGAAGGTGG TGCAGATGAC TCTGCTGAGG AGAGGGACCT ACTGGATGAT  
1501 GAGGATAATG AAGATTGGGG GATGACCAGC TGGAGTTTGA  
IIAA SEQUENCE 1.0  
ID ADP31208 standard; protein; 934 AA.  
XX  
AC ADP31208;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1975.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.



PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486896P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3206; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 934 AA;  
ADP31208 Length: 934 February 22, 2005 12:25 Type: P Check: 2398 ..  
1 AGAGGTTGAG GCGCCCGGCC CAGTCAGCAA GGTGGCGCT GCCCTGTGAG  
51 ACCGCCAAGA TGGTGGTGGG CCGGTTCCCT ATGGCGNAGC TGCTATACTT  
101 GGGCATCCGG CAGGTCAGCA AGCGGTTGC CAACCGTATT AAGGAGGCCG  
151 CCGGCCGAAG CGAGTTCTTC AAGACCTATA TCTGCTCC CC CGCGCTCAA  
201 CTGTATCACT GGGTGGAGAT GCGGACCAAG ATGGCATCA TGGGTTCCG  
251 GGGCAGGTC ATCAAGCCGC TGAACGAGGA GCGGCGAGCT GAGCTGGCG

301 CAGAGCTGCT GGGCGAAGCC ACCATCTTCA TCGTGGGCGG CGGCTGCCTA  
351 GTGCTGGAGT ACTGGCGCCA CCAGGCGCAG CAGCGCCACA AGGAGGAGGA  
401 GCAGCGTGCT CCCTGGAAACG CGCTGGGGGA CGAGGTGGGC CACCTGGGCG  
451 TGGCGCTGGA AGCGCTGCAG GCCAGGTGC AGGCGCGGCC GCCACAGGGC  
501 GCGCTGGAGG AACTGCGCAC AGAGCTGCAA GAGTGTACCA CTGGCTGGAG  
551 ATGCGGACCA AATGCGCAT CATGGGTTTC AATGCGCTG CCATCAAGCC  
601 GCTGAACGAG GGTCCAGCCG CCGAGCTGGG CCGGAGCTG CTGGGCGAGG  
651 GCATCATCTT CATCACCGCC TGCAGCTGCC TGATGCTGGA GTATTGGCGC  
701 CACCAGTTGC AGCAGCGCG CAAGGAAAG GAGCGACGTG TTGCCAGGGA  
751 GCGCTGCGG GCGAGGTGG GCCACTTGGG GCTGGCGCTC GAGGAGTTGC  
801 AGGCGCAGT GCAGGCGACG TCGACGCAGC TCGCCCTGGA GGAGCTGCGC  
851 GCTCAGTGC AGGAGGTGCG AGCCACCTC TGCCTCCGAG ACCCGCCGCC  
901 TGCACCCCA GTTGGCGCG CGTCCGAGAA ATAG  
!!AA SEQUENCE 1.0  
ID\_ADP31232 standard; protein; 2790 AA.  
XX  
AC ADF31232;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1999.  
XX  
KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.



1901 CAAATGCTGG GGAAGAATCT GTCACGAATG TTGACAAATT GAGATTTGCT  
1951 GATGGAAGAA GCATAAGAAC ATCGGAATG CGACTCAGCA TGCAGAAGGG  
2001 CTGCTGGCTC GTGTACAGTT CACCACAGCA CCCACATCA GGAGTCCCGC  
2051 CAGGGGTGTG GGGAGGCAGC GTCGCCCTGGT TGGCCGTGGA GCCGTATGGA  
2101 ACATGCTGCC TCACAGGCAG TCTGCTTGGC GTCCCTGGATC CTGGCTGTAT  
2151 CCGCTGGAA AGGATGTGTT CAACGCCAAA TCATGCTGCC GTGTTCCGTG  
2201 TGGGAAGCTT GTTGCAAGAA GGTTGTGGGA AAATCAGCAA GCTCTATGGA  
2251 GACCTGAAGC ATCTGAAGAC GTTTGACCGG GGTGAGCAGA CAGTGGGCTC  
2301 TGTGCACACT GTTGGGCCCT GCCTTCTGCA GGGAAATGGTC TGGACACGG  
2351 ACCTGTTGGA GACCTTGAG CTGCAGAAC TGATGCTATG TGCCTGTCAG  
2401 ACCGTCAATG GAGCAGAGC GGGGAAGGAG TCACGGGGGGG CGCAGCCGG  
2451 GGAAGACTAC AAGGTGCCGA TTGATGAGTA CGATCACTCC AAGCCCATCC  
2501 AGGGGCAACA GAAGAAGCCC TTTGAGGAGC ACTGGAGGAA GCACACCCTG  
2551 TCCTATGTGG ACGTCAGCAC TGGGAAGGGA CCTACCCCCA GATCTTCCGA  
2601 TTCAGTCTCG GGGNACCCCA CCCAGATCT TTCTATTAG TCCTGGGTGG  
2651 ACGCTACCCC AGATCTTCCG ATTCACTCTT GGGGGGACCC TACCCAGAT  
2701 CTTCGGATTC AGTCTGGGG GGACCCCTACC CCAGATCTTC CGATTCACTC  
2751 CTGGGGGGAT GCTACCCCGAG ATCTTCCGAT TCAGTCCCTGA

!!AA\_SEQUENCE 1.0  
ID ADP31244 standard; protein; 771 AA.  
XX  
AC ADP31244;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2011.  
XX  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR  
XX 29-AUG-2002; 2002US-0406579P.  
PR  
XX 29-AUG-2002; 2002US-0406585P.  
PR  
XX 29-AUG-2002; 2002US-0406588P.  
PR  
XX 29-AUG-2002; 2002US-0406608P.  
PR  
XX 29-AUG-2002; 2002US-0406611P.  
PR  
XX 29-AUG-2002; 2002US-0406612P.  
PR  
XX 29-AUG-2002; 2002US-0406616P.  
PR  
XX 29-AUG-2002; 2002US-0406640P.  
PR  
XX 29-AUG-2002; 2002US-0406642P.  
PR  
XX 29-AUG-2002; 2002US-0406646P.  
PR  
XX 29-AUG-2002; 2002US-0406653P.  
PR  
XX 29-AUG-2002; 2002US-0406655P.  
PR  
XX 29-AUG-2002; 2002US-0406656P.  
PR  
XX 17-SEP-2002; 2002US-0410946P.  
PR  
XX 17-SEP-2002; 2002US-0410947P.  
PR  
XX 17-SEP-2002; 2002US-0410948P.  
PR

17-SEP-2002; 2002US-0410949P.  
PR  
17-SEP-2002; 2002US-0410953P.  
PR  
17-SEP-2002; 2002US-0410957P.  
PR  
17-SEP-2002; 2002US-0410958P.  
PR  
17-SEP-2002; 2002US-0410959P.  
PR  
17-SEP-2002; 2002US-0410960P.  
PR  
17-SEP-2002; 2002US-0410961P.  
PR  
17-SEP-2002; 2002US-0410962P.  
PR  
17-SEP-2002; 2002US-0411019P.  
PR  
17-SEP-2002; 2002US-0411022P.  
PR  
17-SEP-2002; 2002US-0411023P.  
PR  
17-SEP-2002; 2002US-0411024P.  
PR  
17-SEP-2002; 2002US-0411032P.  
PR  
17-SEP-2002; 2002US-0411035P.  
PR  
17-SEP-2002; 2002US-0411037P.  
PR  
17-SEP-2002; 2002US-0411041P.  
PR  
17-SEP-2002; 2002US-0411045P.  
PR  
17-SEP-2002; 2002US-0411046P.  
PR  
17-SEP-2002; 2002US-0411048P.  
PR  
17-SEP-2002; 2002US-0411052P.  
PR  
17-SEP-2002; 2002US-0411055P.  
PR  
17-SEP-2002; 2002US-0411073P.  
PR  
17-SEP-2002; 2002US-0411082P.  
PR  
17-SEP-2002; 2002US-0411101P.  
PR  
17-SEP-2002; 2002US-0411111P.  
PR  
18-APR-2003; 2003US-0463700P.  
PR  
18-APR-2003; 2003US-0463708P.  
PR  
18-APR-2003; 2003US-0463716P.  
PR  
18-APR-2003; 2003US-0463732P.  
PR  
02-MAY-2003; 2003US-0467199P.  
PR  
02-MAY-2003; 2003US-0467201P.  
PR  
02-MAY-2003; 2003US-0467203P.  
PR  
02-MAY-2003; 2003US-0467204P.  
PR  
19-MAY-2003; 2003US-0471306P.  
PR  
19-MAY-2003; 2003US-0471336P.  
PR  
22-MAY-2003; 2003US-0472420P.  
PR  
22-MAY-2003; 2003US-0472430P.  
PR  
09-JUN-2003; 2003US-0476609P.  
PR  
09-JUN-2003; 2003US-0476641P.  
PR  
08-JUL-2003; 2003US-0485218P.  
PR  
08-JUL-2003; 2003US-0485223P.  
PR  
08-JUL-2003; 2003US-0485224P.  
PR  
14-JUL-2003; 2003US-0485325P.  
PR  
14-JUL-2003; 2003US-0486446P.  
PR  
15-JUL-2003; 2003US-0486480P.  
PR  
15-JUL-2003; 2003US-0486891P.  
PR  
15-JUL-2003; 2003US-0486960P.  
PR  
08-AUG-2003; 2003US-0493341P.  
PR  
08-AUG-2003; 2003US-0493370P.  
PR  
08-AUG-2003; 2003US-0493573P.  
PR  
08-AUG-2003; 2003US-0493577P.  
PR  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX Williams IT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3242; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is

CC available on WIPWEB and is not in the specification.

XX Sequence 771 AA;

ADP31244 Length: 771 February 22, 2005 12:25 Type: P Check: 3622 ..

1 ATGAGGACACA GAAGAGGGCC CCTGGCACC TGCTGGSCAC AAGTGCAATG

51 GGGCGGAGGA GGTGACTCGG ACAAACTGTC ATACAGCCTT AAGCAAGAA

101 TGCCGATGGA GGGCCCTTGG CTTGCAGATG CACCCTCCTG GATGAATAAG

151 CTTGGCGCTG ATGGAATTC AGATGCTGTT GAAGCTCTGG GCGGCGACTG

201 GCTGGGAGGA GGGCCGAGG CCACCACGG CCACAGAGGA CAGTGCCCCA

251 AAGGAGAGCC TCAGGTGTCA GCACTGCCAT GCCATCAAAA ACTGCCGGAA

301 ATGGGAAGTT TTCAGGATCA CCCACCAAGT GCTTTTCCCA AGGCTCTGG

351 CTCTGAGTTG GAACCTCTTT GCTTGCAATC CATCCTGTCT GCAACACTGC

401 AGGCGTGTCC CGAAGAGCTC CTGAATGACG AGACAAAACG CATTTTCCTT

451 GACCGTTTAA ACCCATGTT TTCAAAGCAA ACAATAGAAT TCAAAAAAAT

501 GCTTAAACT TGTCTGATCA CCCAAGGAA GTGGATCTTT GTAAGTCTTA

551 CACCGCTGTA CTTGGCGTTA AATCTTGCTG AATTGTGGA ACTAGAGATC

601 CTTAGAGAAA TGGTTGGTTC TCTATCTGGG GCAGGAAATG TACCAGATCA

651 GCTGTGAGCA TCTTATTATA AACGATGCC AAGAGGCAT CAAAGGACTAC

701 TGGGACATG TCTAAAGGTT CCAGACCA ACGTGAAGAG GCTCTCACTG

751 GCCAGATATG GGTAAATTG A

IIAA\_SEQUENCE 1.0

ID\_ADP31251 standard; protein; 390 AA.

AC ADP31251;

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2018.

DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.

17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MM, Kothakota S, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3249; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,

CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPoWEB and is not in the specification.  
XX  
SQ Sequence 390 AA;  
ADP31251 Length: 390 February 22, 2005 12:25 Type: P Check: 4640 ..  
ID 1 ATGCTGTGCA GTCATTCGGT CCCGCTCTCT CGGACCCGCC CGGGCCGGCG  
51 GCGGATCC GAGRACCAGC CGGCCCGGC ACTCACTGGT GTCATGCGC  
101 TGCTGTGAT GAAGTGGCC ACACCTTCCA TGGGGTGCGG GTCCTGGGAG  
151 TCGTGGCTGG ACCTCATTTGG CTTGTGGCGC CTTCACTCGG AGAGACGGCG  
201 CTCACCCCGG AAGTGTGCGA GCGAATCT GCCTAGCAAC CGGGGAAGCC  
251 GGGCTGTGAA GGGGGCAATT TCAGTCGGCC GCGCGGGCGG CCACCTGAGG  
301 GAGTCGCCTC CGCGGGAGCC CACAAGACCT GACCGGACTG CGCCGCCCGA  
351 GCGCGTCGCG CGCCTCAGC GAGGGCGCG AGCAACTTCG  
!!AA\_SEQUENCE 1.0  
ID ADP31252 standard; protein; 2304 AA.  
XX  
AC ADP31252;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2019.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406662P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.

PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Hallenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3250; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPoWEB and is not in the specification.  
XX  
SQ Sequence 2304 AA;  
ADP31252 Length: 2304 February 22, 2005 12:25 Type: P Check: 6912 ..  
1 ATGGCGGATG CCCCTCCCC CACCAAGCTC AAGTGTCCTCA GGTGACCTC  
51 AGACTGCTGT GCTGGGAGTG AGAATTCAA GTCCATGGAT CTTAGCTTGG  
101 TGGGCTCGT GGGGGTGGGA CCCCCCAAGC CAGACCACTT GGCTCCCTGG

151 CTTTCAGCCC CTTTCAGGG GAGTGAACAG TTCGGTCTTA CGGGTGTTC  
201 AGATGTCTCT CTACACATA TGATCAAGGA ATTACCACCA AAAGAAACA  
251 ATAGCAGAG AAAAGPATTC CAAGCAGTGA TGTGGAAG ACATGAAATC  
301 CATGACATCC AAGATTTTTA CTTACAGAA ATGCAGCAA ATATTATGA  
351 CTTTGAGTGT CAGTGTACA ATGATGAG AGATTACAGA GAATACCTG  
401 CAATTAAAT TAAAAATC ACTGGAAGAA GAGATCAAGG TGATGGAAG  
451 AATGCAGAA ATAAGCCAGT TGAATCAG CTTGAACTAA GCTTTTGGTT  
501 GCATCTGGCT GAACTGCAG GATTTCAAAT TGAAGGAAA ATTTATGAAT  
551 GTAATCAAT TGAGAAGTCT GTCAACCCGT GGTCTCTCAGT TTCATTACTT  
601 CAAACAATC TTCCTTGTGT CAACACCAGC ATTTCTAATA TATACAGAA  
651 TGATTTTATG CATCTTTCAT TACTCACACA AGACCAGAAA GCATACATTA  
701 GGGAAAAACC TTACAAATGT AGTGATTGT GCAAGGCCCTT TAATCAGAG  
751 TCCAACCTTA CTACACATCA GAGAATCCAT ACTGGACAGA AACCATATA  
801 ATGTGACATA TGTGGCAAG GTTTCAGGG AATTGCAAC CTAGCNAATC  
851 ATCATAGAAT TCATCTGGA GAGAAACCTT ACAGANGTAA TGAGTGTGC  
901 AAGACCTTCA ATCAGACGTT CAACCTTACT ACACATCAGA GAATCCATAC  
951 TGGACAGAA CATATAAAT GTGATAGATG TGGCAAAGGT TTCAGGCAAA  
1001 TTGAAAACCT AGCAAGTCAAT CATAGAATTC ATACTGGAGA GAAACCTTAC  
1051 AGATGTAACG AGTGTGGCAA GACCTTTAAC AGGATGTTC ACCTTACTAG  
1101 ACATCAGAGA ATCCATACTG GACAGAAACC ATATAATGT GATATATGTG  
1151 GCAAAGGTTT CAGGCAAAAT GCNAACCTAG CAAGTCAATCA TAGAATTCAT  
1201 ACTGGAGAGA AACCTTACAA ATGTAGTGT TGTGGCAAGA CTTTTAATTA  
1251 CAGTCCCAAC CTTACAGAC ATCAGAGAT CCATCTGGA CAGAAACCGT  
1301 ATAAATGTGA TACATGTGC AAAGATTTCA GTCAAAATTC ATACCTTGAA  
1351 AATCATCAGA GAATTCACAC TAGAGAGAA TCTTACAGAT GTAATGAGTG  
1401 TGGCAAGACC TTATAAGA TGACCAACCT TACTACACAT CAGAGNATCC  
1451 ATACTGGACA GAAACATAT AAATGTGATA TATGTGGCAA AGGTTTTCAGG  
1501 CAAATTGGAA ACTAGCAAG TCATCATAGA ATTCATACTG GAGAGAAACC  
1551 TTACAGATGT AATGAGTGTG GCAAGACCTT CAATAGATG TTCCACCTTA  
1601 CTAGACATCA GAGAAATCCAT ACTGGACAGA AACCATATAA ATGTGATATA  
1651 TGTGGCAAAA AGTTCAAAAT TGTAAACAT CACAGGATTC ATTCTGGAGA  
1701 GAAACAAAAC AAAAGTAATG AATGTAGTAA GGCATTTATT CAAATTCNA  
1751 GTCTGTGGA CCATCAGAGA ACTCACACTG GAGAGAAACC TTACAAGTGT  
1801 AATGAGTGTG GTAAAACCTT TATTGGCAT TCAAGCCTAA CTAACCATCA  
1851 GGTAAATTCAT ACTGGAGAGA AACCTTACA ATGTAATGAG TGTGGNAAGG  
1901 CTTATGTGAA GTGGTCCCAC CTTAGACATC ATGAGAGTAT TCAAACTGGA  
1951 GAGAAGCCAT ACAATGTAC CAATGCAGC AAGGCCTTTA GACAATGGGC

2001 GGACATCAGG ATTCACCAA AATCTATGC TGGAGAGAAA CCTCACAAGT  
2051 ATGATGAGTG TGGAAAACC TTACCACAGG CCTCTCACCT CACTATACAT  
2101 CAGATTATCC ATACTGGAGA GAAACCATAT GAATATGACA TATATGGCAA  
2151 AGCTTTCAGT CAAATTCAC ATTTCAAAG TTATCATAGG ATTTGTAATG  
2201 AAGAGAAGCC TTACAAATGT GTGTGGCAAG GTCTCAGTC AAATTCACA  
2251 CCTGTAAAT CATCAGAA TTCTACTGG AGAGAAATCC TACAGATGTC  
2301 ATGA

!!AA\_SEQUENCE 1.0  
ID ADP31268 standard; protein; 1017 AA.

XX ADP31268;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2035.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.

PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471308P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3266; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX  
SQ Sequence 1017 AA;  
ADP31268 Length: 1017 February 22, 2005 12:25 Type: P Check: 4241 ..  
1 ATGGGGAAAA AACAGACAG AAAAATCGGA AACTCTAATA CGCAGAGCGC  
51 CTCCTCCTCT CCAAAGGAAC GCAGTTCTCTC ACCAGCAACA GAACAAAGCT  
101 GGATGGAGAA TGATTTTGAC GAGCTGAGAG AAGAAGGCTT CAGACAATCA  
151 AATTACTCTG AGCTACGGGA GGACATTCAA ACCAAGGCA AAGAATTGGA  
201 AAATCTTGAA AAAAATTAG AGAATGTAT AACTAGAATA ACCAATACAG  
251 AGAAGTGCTT AAAGGAGCTG ATGAGCTGA AAACCAAGGC TCGAGAACTA  
301 CGTGAAGAAAT GCAGAAGCCT CAGAGCCGA TCGGATCAAC TGGAGAAAG  
351 GGTATCAGCA ATGGAAGATG AAATGAATGA AATGAAGCGA GAAGGGAAGT

401 TTAGAGAAAA AAGAATAAAA AGAATGAGC AAAGCCTCCA AGAAATATGG  
451 GACTATGTGA AAAGACCANA TCTACGCTGT ATTGGTGTAC CTGAAAGTGA  
501 TGTGGAGAAT GGAACCAAGT TGGAAAAACAC TCTGCAGGAT ATTATCCAGG  
551 AGAACTTCCC CAATCTAGCA AGGCAGGCCA ACGTTTCAGAT TCAGGAAATA  
601 CAGAGAAGCG CACAAAGATA CTCCTCGAGA AGAGCAACTC CAAGACACAT  
651 AATTGTGAGA TTACCAAG TTGAATGAA GGAAAAAATG TTAAGGGCAG  
701 CCAGAGAGAA AGTTCGGGTT ACCTCAAAG GGAAGCCCAT CAGACTAACA  
751 GTGGATCTCT CGGCAGAAAC CCTACAAGCC AGAAGAGAGT GGGGGCCAAAT  
801 ATTCACAAAT CTTAAAGAAA AGAATTTTCA ACCCAGAATT TCATATCCAG  
851 CCAAACTAAG CTTCTAAGT GAAGGAGAAA TAAAAATCCTT TACAGACAAG  
901 CAAATGCTGA GAGATTTTGT CACCACCAGG CCTGCCCTAA AAGAGCTCCT  
951 GAAGGAAGCG CTAACATGG AAAGGAACAA CCGGTACCAG CCGTGCMAA  
1001 ATCATGCCAA AATGTAA  
IIAA SEQUENCE 1.0  
ID ADP31292 standard; protein; 1737 AA.  
XX  
XX AC ADEP31292;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2059.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3290; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1737 AA;  
ADP31292 Length: 1737 February 22, 2005 12:25 Type: P Check: 2305 ..  
1 ATGCCAGCCC ACAGCAAAAC CCGGCAGATA ATCAGCACAT CCCACTGTGTTT  
51 AGTCATATTT GACAACTGGG TTAACCTGGT ATCTAAGCGC TGCGGAAACC

101 GTACAAAGGG TGCCCTCAAT TACCACCAGA AGCCTCTAGC GCTGAGTTTA  
151 GCGGGCGGGA GCCTGGAGTC GCCTGGGCAC GAGCGCGGGG AGCGGGGAGC  
201 CGCGCGGGAC CCAAGCAGTT TTTCCGAGCA GCGGCCAGGC TCAGCCCCGC  
251 TCCAGCCTC GCTGGCAGC CAGAGACCTG CTATGGCCAC GTCTATATCT  
301 GGGGAAGAGC CGCGTTTCGG AACGACCCCG TTGGCCATGC TGGCGGCGAC  
351 CTGCAACAAG ATCGGCAACA CGAGCCCGCT GACGACGCTG CCAGAGTGGA  
401 GCGCCTTCGC CAAAGCGGC TTTACACCCCT GGAAGCGCTC CTCGTCCAGC  
451 TGCAACCTCG GCTCAGCCT CTCGGGCTTC GCGGTGGCCA CCGGGGGCGG  
501 TGGCTCGGGC GGCCTGGCGG GCGGCTCGGG CGCGGCCAAC AGCGCCTTCT  
551 GCTGGCCTC CAGCTCGGCC AGTTCGTCCG CTTTCAGCAG CGACTACGGC  
601 GGCCTTTCT CAACTCGGC GGTGCGCGG GCGGCAGCGG CCGGGGTGTC  
651 CCGCAGGAG GCGGTGGCC AGTCGGCCTT CATTTCCAAG GTGCACAGGA  
701 GCGCAGCCGA CGGCTGTAC CCGCGCGTGG GCATGGCGCA CCCGTACGAG  
751 TCTGTGTACA AGTCGGGCTT CCATTGCAAG CTGGCGGCGG GCGAGGTGAC  
801 CAACGGCGCG GCGTCGTCTG GTTGGGACGT GCACAGCAGC CCGGGCTCCT  
851 GGTGGAAGT GCAGAACCCC GCTGGGGGGC TCCAGAGCTC GCTGCACCTG  
901 GCGCCCCCCC AGGCTCTGCT GCACTGCGAG CTGGGCACCT ACAACCCCGA  
951 CTTCACTCG CTCAGCACT CCGCCTTCAG CTCACGGGC CTCGGCTCCT  
1001 CCGCGCGCGC CGCTCCACC CTGCTCTCCA CCAGCCAGCA CTTGCTGGCC  
1051 CAGGACGGT TCAAGCCGGT GTTGCCCTCC TATTGGAAT CCAGCGCGCG  
1101 CGTGGCAGCC GCGCGCGCA GCGCCATGAT ATCGGGCGCC GCGGCTGCGG  
1151 CCGCGGGGG GAGCTCGGCA CGCTCTGCCC GCGCTACTC GGGCGCGCGC  
1201 ACTTGGGACT GCGCCAACTG CAGGAGGGG GAGCGGCTGG GCCCGGCGG  
1251 GCGCAGCCTG CCGGCGCAAG GCTTGACAG CTGCCACATT CCGGGCTGCG  
1301 GCAAGGTGTA CCGGAGAGC TCGCACCTGA AGGCGCACCT GCGCTGGCAC  
1351 AGCGGGGAGC GGCCCTTCGT GTGCAACTGG CTCCTTTCGG GCAAGCGCTT  
1401 CACGCGCTCG GACGAGTGC AGCGGCATCT GCGGACTCAC ACGGGCGAGA  
1451 AGCGCTTCGC CTGTCGGTG TGCAACAAGC GCTTCATGCG CAGCGACAC  
1501 CTGAGCAAC ACATTAGAC GCACAACGG GCGGGCGGGG GCAAAAAGGG  
1551 CAGCGACACT GACACGGACG CCAGCAACCT GGAGACGCCC GGTTCGGAAT  
1601 CCCCCGACT CATCTGCAT GACTCCGGCG TCAGTGCCTG CCGGGGGCGG  
1651 GAGCGGGCG GCGGGGACG GCGGGCGGCG GCGGGCGCGG CTTCCGCGGG  
1701 AGGCAAGGAA GCAGCTCTG GCCCAACGA CTCCTTAG  
IIAA SEQUENCE 1.0  
ID ADP31328 standard; protein; 1282 AA.  
XX  
AC ADP31328;  
XX  
DT 12-AUG-2004 (first entry)



XX DE Human secreted protein SEQ ID #2095.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.

PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PA Williams LT, Chu K, Lee E, Heatir K, Beaurang PA, Behrens D;  
XX PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX DR WPI; 2004-348438/32.  
XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX PT genetic, bacterial and viral diseases.  
XX PS Claim 1; SEQ ID NO 3326; 428pp; English.  
XX CC The present invention relates to an isolated nucleic acid molecule  
XX CC encoding a polypeptide which is believed to be cytostatic,  
XX CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX CC composition and methods are useful for diagnosing, preventing and  
XX CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX CC immune, metabolic, genetic, bacterial and viral diseases. The present  
XX CC sequence represents a human secreted protein. The present sequence is  
XX CC available on WIPWEB and is not in the specification.  
XX SQ Sequence 1282 AA;  
ADP31328 Length: 1282 February 22, 2005 12:25 Type: P Check: 7113 ..  
1 GCACCTAAGAG GGAGCTGGAT GAGCTGAAC CATAGCAACT TCCAATTGGC  
51 CACACTATTTC AGCCCTCCCA GGGTGCCTT TCTATGATG ATGCCATTGA  
101 GAAGGCAAGG AAAACAGCTG AACTACAAGC TCGAATCCAA GCCGGGCTGG  
151 CACTGAAGCC AGGACTCATC AGCAATGCCA ACATGGAGGG AACCATTCAA  
201 GCAACAGCTA AAGAAAGC CATCAGAAGA CATGGAGTCC AATACCTTTT  
251 TTGACCCCGA GTCTCCACTG TCGCTTCCCA GCGCCAGAAA CGCCTTTTAA  
301 AATTCCATGA CAAGGGCAAA TTTGAGAAGA CTGCTCAGCG ATTAAGGACA  
351 AAGGCTCAAC TGGAGAAGCT TCAGGCAGAG ATTTCAACAAG CAGCTCAAAA  
401 AACAGACATC CATACTTTGA CTAGGCTTGC CTTATTGCT CTTAGGAAGG  
451 AGCTAAAGGA AGGAGATATC CCTGAAATTG AGTGTGGGA CTCTTACATA  
501 ATCCCCAATG GCTTTAACTT TAGAGAGGAA ATCCCAAGA GAGNAGATTA  
551 TTTTGGAAATC ACAATCTTGT TTGAACATCC AGCCGAGCTC AATGCTCCAG  
601 TTGACAAATGA CACACCAAGTT ACTTTGGGAG TGTATCTTAC CAAGAAGGAA  
651 CAGAAAAAATC TTCAAGAGCA GACAAGGAGG GAAGCACAGA AGGAACTACT  
701 AGAAAAAGTC AGGCTGGGCC TGATGCTTCC TCCAGAACCC AAAGTGAAGAA  
751 TTTCTAATTT GATGCGAGTA TTAGGAACAG AAGCTGTTCA AGACCCCAAG  
801 AAGGTAGAGG CCCATGTCAC AGCTCAGATG GCAAAAAGAC AGAATTTGCA  
851 TGAAGAGGCC AACTCTGCCT GAAAACTCAC AGCAAAACAC AGAAAGGTCA

901 AGAAATTTA AAGCTTAAG ACATTTACA GGGGTACAC GTATCTGTAT  
951 ATGAGTTAG AATTGTAGC ACCCAGGTG TCAAGTGGT AGTAGTGGAA  
1001 GGGGGCCCCA AGACCAGAA GAAATTGAAG CATCTTAGC TGCATCGGAT  
1051 AAGTGGGAT GAACAGACAT CTAACACAA GGGAGATGAT CATGAGGAAC  
1101 CTGATGAGGA AGCTGTGAAG AAACCAACA AATGTGTAAT ATTCTGGGAG  
1151 GGTACAGCCA AAGACCGGAG CTTTGGAGAG ATGAAGTTTA AACAGTGTCC  
1201 TATAGAGAAC ATAGTCTCATG AGCATTTTCAG AAGCATGGG GCTGAACATT  
1251 ACTGGGACCT TGGCTGAGT GNACTGTGT AG

!!AA\_SEQUENCE 1.0  
ID\_ADP31342 standard; protein; 1197 AA.

AC ADP31342;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #2109.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411037P.

XX PR 17-SEP-2002; 2002US-0411041P.

XX PR 17-SEP-2002; 2002US-0411045P.

XX PR 17-SEP-2002; 2002US-0411046P.

XX PR 17-SEP-2002; 2002US-0411048P.

XX PR 17-SEP-2002; 2002US-0411052P.

17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases

XX Claim 1; SEQ ID NO 3340; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPOWEB and is not in the specification.

SQ Sequence 1197 AA;

ADP31342 Length: 1197 February 22, 2005 12:25 Type: P Check: 8179 ..

1 ATGAAGACGG CAGCGGAGCA ACAGAAGACG CTGAGAGAGT TCGTGGTGGT

51 GATGGGCACT GAGCAGGACC GGGCCTGCTT CTTCTCGAG TCGGCTACCT

101 GGGACTTGCA GATTGGCGTA GCGAGCTTTT ATGAGGACAG AGGGGAAGAA

151 GACATCATAA CCATTTCACA GGCAACCCCC AGTTTCAGTG CCAGAGGCAC

201 AGCCCTAGT GATAATAGAG TGACATCCTT TAGAGATCTC ACTCATGACC

251 AAGATGAGGA TGAGAAGAG GAGGAAGGCC AGAGGTTTTA TGCCGGGGCC

301 TCAGAGAGAA GTGGACAGCA GATTGTGGC CCTCCAGAA AGAAAGTTC

351 CAATGAGCTG GTGGATGATC TCITTAAGG TGCCAAAGAG CATGGAGCTG  
401 TAGCTGTGGA GCGAGTGACC AACAGACCTG GAGAGACCCAG TACACCAAGA  
451 CCATTTCGCG GAGATGGCTA TGGCCTTGGG GCAGCACCAG AGGAAGAGTC  
501 TGTATTATGT GCAGAGAGAA AGAGACATCA TTCCAACCAA GATGTTCTATG  
551 TAGTGTGTAG TACCATTCTCT CCAGTCCAAAC TGGCAGAAAA TGAAGCCAAA  
601 GCCAGCTCTT CCATCTTAAT CGTCGAATCA GAGACTACCA CAAACATCCA  
651 AATTGGCTTT GCAGACGGTG GGAGGCTGGT GCAGAAATTT AACCAAGCC  
701 ACAGGATCAG CAACATCCAA CTCTTCATTG TGGATGCCCG GCCAGCCATG  
751 GCTGCCACCA GCTTTATCCT CATGACTACT TTCCCAACA AAGAGCTGGC  
801 TGACGAGAGC TGGACCCTGA AGGAGCCAA CTGTCTCAAT GTGCGCATCA  
851 TGCAGTGGCC TGTGCAAGG ACATATAGT CTTTGAGAAAT GACAGTGGAT  
901 TATACCAAC TTATCAAGG AGAACTCCA GTTAATCAA CTCATATAT  
951 CAAGTCAATG CATTCCTTTA TCTGGTGTGC AGTACTTGAT ATGACAAAAG  
1001 TGCCCCCACC CAGGCTCAT GGGAAAGTCT GCATGACCAG CTGTCTGAGG  
1051 AGCTCGTATC CAGATGGAGC AACAGATAT GAGCAGCTGA RATCGGCTGT  
1101 TACAGCTTTG CAGCTTCCTT CACAGAAAGC CTGACAGAG GAGCAGACT  
1151 TCCCATGGCA TGTCTTGGT CCAGTCTGCC CAGAAGAGAT GGCATGA

!!AA SEQUENCE 1.0  
ID\_ADP31362 standard; protein; 768 AA.

XX AC ADF31362;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2129.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406656P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.

17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472430P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348436/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases such as proliferative (e.g. cancer), inflammatory, immune, metabolic, genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3360; 428pp; English.

The present invention relates to an isolated nucleic acid molecule encoding a polypeptide which is believed to be cytostatic, antiinflammatory, immunosuppressive, antibacterial and virucidal. The composition and methods are useful for diagnosing, preventing and treating diseases such as proliferative (e.g. cancer), inflammatory, immune, metabolic, genetic, bacterial and viral diseases. The present sequence represents a human secreted protein. The present sequence is available on WIPOWEB and is not in the specification.

XX

SQ	Sequence 768 AA;	
ADP31362	Length: 768 February 22, 2005 12:25 Type: P Check: 5767 ..	
1	ATGGTCACCG AGCGCGCTAG CGCGGTGGG AGGCAGAAGA CAGAGAACCG	PR 17-SEP-2002; 2002US-0410949P.
51	AACGCGCTGGG ACCAGGGGCA TCCGTGTAAA CCGAAGAGGC GCTCAGACTC	PR 17-SEP-2002; 2002US-0410953P.
101	GGAGGGCAAG GCCCGGGGCC CCTCTCGCTG CCTCCTTTGC CTTCCCTTCC	PR 17-SEP-2002; 2002US-0410957P.
151	CCCATGCTGG AGAAGCAGGG CCCGGGCCG GTGCGGGAAC GGGAGGAGT	PR 17-SEP-2002; 2002US-0410958P.
201	GGTTGGTGCC TTAGCAACTA AAGCTGGCAA CTGGGACATC GTCCGGTGCT	PR 17-SEP-2002; 2002US-0410959P.
251	GCAGGTCTCA GCGGAAGGCG GTCGAAACT CGGCTCGCAT CGAGCAGTTT	PR 17-SEP-2002; 2002US-0410961P.
301	CCAGCCTCTCT GGGTAAAGGA CAGGTCCTCT CCTTTGCTTG GGACTCTGGA	PR 17-SEP-2002; 2002US-0410962P.
351	CGCATCTCAT TCCGGTGAAG GAGATGGGG CTGGGGTGAC TCGCGGGATC	PR 17-SEP-2002; 2002US-0411019P.
401	AGGAATTTC AAGAAACCGA GCGGAAGGG AATCCGCAA CATGAAGCCC	PR 17-SEP-2002; 2002US-0411022P.
451	TCTCTCGCTC CCAGGCACCC CTCTACCAGC AGCCTCCTGC CAGAGCAGAT	PR 17-SEP-2002; 2002US-0411023P.
501	TAGTCTCTAT CCAGAAATTA AGGGAGAGAT TGCTCGTAAA GATGACAAGC	PR 17-SEP-2002; 2002US-0411024P.
551	TGCTGTCAAT TCTAAATAT GTGTGTGTTG ATTCCAAGA TCCTGTGTCT	PR 17-SEP-2002; 2002US-0411032P.
601	TCCGTGCAGC TGAAGCTGC TGAACACGT CAGGAGCCAA AGAAATTCAG	PR 17-SEP-2002; 2002US-0411035P.
651	ATTGCCGAAA GGCCATCACT TTGATATGAT AATATTTAAG AGCATTCCCA	PR 17-SEP-2002; 2002US-0411037P.
701	AAGCAAAAT TTCCACTGTA GAAGCAITGA CACTTTTCAA TAATCATAAA	PR 17-SEP-2002; 2002US-0411041P.
751	CTTTATCCAG AAACATGA	PR 17-SEP-2002; 2002US-0411045P.
!IAA	SEQUENCE 1.0	PR 17-SEP-2002; 2002US-0411046P.
ID	ADP31365 standard; protein; 432 AA.	PR 17-SEP-2002; 2002US-0411048P.
XX		PR 17-SEP-2002; 2002US-0411052P.
AC	ADP31365;	PR 17-SEP-2002; 2002US-0411055P.
XX		PR 17-SEP-2002; 2002US-0411073P.
DT	12-AUG-2004 (first entry)	PR 17-SEP-2002; 2002US-0411082P.
XX		PR 17-SEP-2002; 2002US-0411101P.
DE	Human secreted protein SEQ ID #2132.	PR 17-SEP-2002; 2002US-041111P.
XX		PR 18-APR-2003; 2003US-0463700P.
XX		PR 18-APR-2003; 2003US-0463708P.
XW	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;	PR 18-APR-2003; 2003US-0463716P.
KW	cancer; inflammatory; immune; human secreted protein.	PR 18-APR-2003; 2003US-0463732P.
XX		PR 02-MAY-2003; 2003US-0467199P.
OS	Homo sapiens.	PR 02-MAY-2003; 2003US-0467201P.
XX		PR 02-MAY-2003; 2003US-0467203P.
PN	WO2004035732-A2.	PR 02-MAY-2003; 2003US-0467230P.
PD	29-APR-2004.	PR 19-MAY-2003; 2003US-0471308P.
XX		PR 19-MAY-2003; 2003US-0471336P.
PF	28-AUG-2003; 2003WO-US026780.	PR 22-MAY-2003; 2003US-0472420P.
XX		PR 22-MAY-2003; 2003US-0472430P.
XX		PR 09-JUN-2003; 2003US-0476609P.
PR	29-AUG-2002; 2002US-0406576P.	PR 09-JUN-2003; 2003US-0476641P.
PR	29-AUG-2002; 2002US-0406579P.	PR 08-JUL-2003; 2003US-0485218P.
PR	29-AUG-2002; 2002US-0406585P.	PR 08-JUL-2003; 2003US-0485223P.
PR	29-AUG-2002; 2002US-0406588P.	PR 08-JUL-2003; 2003US-0485224P.
PR	29-AUG-2002; 2002US-0406608P.	PR 08-JUL-2003; 2003US-0485325P.
PR	29-AUG-2002; 2002US-0406611P.	PR 14-JUL-2003; 2003US-0486466P.
PR	29-AUG-2002; 2002US-0406612P.	PR 14-JUL-2003; 2003US-0486480P.
PR	29-AUG-2002; 2002US-0406616P.	PR 15-JUL-2003; 2003US-0486891P.
PR	29-AUG-2002; 2002US-0406640P.	PR 15-JUL-2003; 2003US-0486960P.
PR	29-AUG-2002; 2002US-0406642P.	PR 08-AUG-2003; 2003US-0493341P.
PR	29-AUG-2002; 2002US-0406646P.	PR 08-AUG-2003; 2003US-0493370P.
PR	29-AUG-2002; 2002US-0406653P.	PR 08-AUG-2003; 2003US-0493573P.
PR	29-AUG-2002; 2002US-0406655P.	PR 08-AUG-2003; 2003US-0493577P.
PR	29-AUG-2002; 2002US-0406666P.	XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
PR	17-SEP-2002; 2002US-0410946P.	XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PR	17-SEP-2002; 2002US-0410947P.	XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PR	17-SEP-2002; 2002US-0410948P.	XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
		XX WPI; 2004-348438/32.
		XX New nucleic acid molecule for diagnosing, preventing or treating diseases
		XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
		XX genetic, bacterial and viral diseases.
		XX Claim 1; SEQ ID NO 3363; 428pp; English.
		XX The present invention relates to an isolated nucleic acid molecule
		XX encoding a polypeptide which is believed to be cytostatic,
		XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The
		XX composition and methods are useful for diagnosing, preventing and
		XX treating diseases such as proliferative (e.g. cancer), inflammatory,
		XX immune, metabolic, genetic, bacterial and viral diseases. The present
		XX sequence represents a human secreted protein. The present sequence is

101 ATGTCTCCTT CAAGCTATTT GCAGACAAGG TTCCAAGAC AGCAGAAAAC

CC available on WIPoWEB and is not in the specification.  
XX  
SQ Sequence 432 AA;  
ADP31365 Length: 432 February 22, 2005 12:25 Type: P Check: 1739 ..

1 ATGCGGGACC TCACCAAGGG GTACTCTGAG TGGGTAACCA CCCCTACACA  
51 TACAAGCCCG TGGCCCCCTG AGGTGATCGA GAAGAAACCA GAGGTGTTCA  
101 AGGTGCGCTG CCTGAGTGAC ATCCAGCAGC TGTTTCTGCC CCACGGACAG  
151 CCCTTCTATG CTGCGCTTTGG GAATAGGCCC AATGATGTCT TTGCTATCCG  
201 GCAGGTGGGC CTGCGCTGAGT CACGCATCTT CACAGTCAAC CCCCGGGGAG  
251 AGCTCATCCA GGAGCTCAT AAGAACCA CAATCCAGTA TGAGGGGCTT  
301 GGTGAAGTGG TCGAGTCTCT CTTCCACCT GTGGCCCCGTG GCCCCAGCAC  
351 AGACCTGGCC AACCCCTGAAT ACAGTAACTT CTGCTACTGG CGGAGGCCAC  
401 TGCTGTCTGT GGACCTTGAT ACCCTGGACT GA

!!!AA SEQUENCE 1.0  
ID ADP31395 standard; protein; 567 AA.  
XX  
AC ADP31395;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2162.  
XX  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PF 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411024P.

151 TTTCTGCTC TGAGCACTGG AGAGAAAGGA TTTGGTTATA AGGGTTCTCTG  
201 CTTTCACAGA ATTATTCCAG GGTTTATGTG TCAGGGTGGT GACTTCACAC  
251 ACCATAATGG CACTAGCAGC AAGTCCATCT ACGGGGAGAA ATTGTATGAT  
301 GAGAACTTCA TCTTAAAGCA TACAGGTCCCT GGCATCTTGT CCATGGCAAA  
351 TGCTGGACCC ACACAAACA GTTCCAGTT TTTCACTGCG ACTGCCAAGA  
401 CTGAGTGGTT GGATGGCAAG CATGTGGTCT TTGGCAAGGC GAAAGNAGGC  
451 ATGAATATTG TGGAGGCCAT AGAGCACTTT GGGTCCAGGA ATGGCAAGAC  
501 CAGCAGAAG ATCACCACCTG CTGACTGTGG ACAACTCTTA ATAAGTTTGA  
551 CTTGTGTTTT ATCTTAG

!!AA SEQUENCE 1.0  
ID ADP31487 standard; protein; 252 AA.  
XX  
AC ADP31487;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2254.  
XX  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
KW  
XX Homo sapiens.  
OS  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.

XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.

17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-041101P.  
17-SEP-2002; 2002US-041111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463718P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471308P.  
19-MAY-2003; 2003US-0471336P.  
19-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.

XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX  
PS Claim 1; SEQ ID NO 3485; 428pp; English.

XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX  
SQ Sequence 252 AA;

ADP31487 Length: 252 February 22, 2005 12:25 Type: P Check: 2222 ..

1 ATGCCCAAGGA CAGAGGAGGT CATCCCTGAC GGAACCTGTGA TCAGCGTCTC  
51 TCAGCCTCAG TCCCTGTGTA CATATCTCA GAACCTTGCT ATACTGGACC  
101 TCACAATGAA TAATCAGCGG ATGAATAATC AGACCTCTTC TCGCCATGGC  
151 CAGAGCCTAA CTGGGAGAC AGGATTTGTG TGCAGGGCAG GACCATCTTG  
201 CCGAAGCGT GCTGTTACCA TGGCACCAA CACGGCATCT GGTGTTACGT  
251 GA

```
!!AA_SEQUENCE 1.0
ID ADP31594 standard; protein; 2542 AA.
XX AC
XX ADP31594;
XX DT
XX DE 12-AUG-2004 (first entry)
XX DE Human secreted protein SEQ ID #2361.
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
XX KW cancer; inflammatory; immune; human secreted protein.
XX OS Homo sapiens.
XX PN WO2004035732-A2.
XX PD
XX PD 29-APR-2004.
XX PF
XX PF 28-AUG-2003; 2003WO-US026780.
XX PR
XX PR 29-AUG-2002; 2002US-0406576P.
XX PR 29-AUG-2002; 2002US-0406579P.
XX PR 29-AUG-2002; 2002US-0406585P.
XX PR 29-AUG-2002; 2002US-0406588P.
XX PR 29-AUG-2002; 2002US-0406608P.
XX PR 29-AUG-2002; 2002US-0406611P.
XX PR 29-AUG-2002; 2002US-0406612P.
XX PR 29-AUG-2002; 2002US-0406616P.
XX PR 29-AUG-2002; 2002US-0406640P.
XX PR 29-AUG-2002; 2002US-0406642P.
XX PR 29-AUG-2002; 2002US-0406646P.
XX PR 29-AUG-2002; 2002US-0406653P.
XX PR 29-AUG-2002; 2002US-0406655P.
XX PR 29-AUG-2002; 2002US-0406666P.
XX PR 17-SEP-2002; 2002US-0410945P.
XX PR 17-SEP-2002; 2002US-0410947P.
XX PR 17-SEP-2002; 2002US-0410948P.
XX PR 17-SEP-2002; 2002US-0410949P.
XX PR 17-SEP-2002; 2002US-0410953P.
XX PR 17-SEP-2002; 2002US-0410957P.
XX PR 17-SEP-2002; 2002US-0410958P.
XX PR 17-SEP-2002; 2002US-0410959P.
XX PR 17-SEP-2002; 2002US-0410960P.
XX PR 17-SEP-2002; 2002US-0410961P.
XX PR 17-SEP-2002; 2002US-0410962P.
XX PR 17-SEP-2002; 2002US-0411019P.
XX PR 17-SEP-2002; 2002US-0411022P.
XX PR 17-SEP-2002; 2002US-0411023P.
XX PR 17-SEP-2002; 2002US-0411024P.
XX PR 17-SEP-2002; 2002US-0411032P.
XX PR 17-SEP-2002; 2002US-0411035P.
XX PR 17-SEP-2002; 2002US-0411041P.
XX PR 17-SEP-2002; 2002US-0411045P.
XX PR 17-SEP-2002; 2002US-0411046P.
XX PR 17-SEP-2002; 2002US-0411052P.
XX PR 17-SEP-2002; 2002US-0411055P.
XX PR 17-SEP-2002; 2002US-0411073P.
XX PR 17-SEP-2002; 2002US-0411082P.
XX PR 17-SEP-2002; 2002US-0411101P.
XX PR 17-SEP-2002; 2002US-0411111P.
XX PR 18-APR-2003; 2003US-0463700P.
XX PR 18-APR-2003; 2003US-0463708P.
XX PR 18-APR-2003; 2003US-0463716P.
XX PR 18-APR-2003; 2003US-0463732P.
XX PR 02-MAY-2003; 2003US-0467199P.
XX PR 02-MAY-2003; 2003US-0467201P.
XX PR 02-MAY-2003; 2003US-0467203P.
XX PR 02-MAY-2003; 2003US-0467230P.
XX PR 19-MAY-2003; 2003US-0471306P.
XX PR 22-MAY-2003; 2003US-0471336P.
XX PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486446P.
PR 15-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
XX Williams LT, Chu K, Lee E, Heatir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX
XX WPI; 2004-348438/32.
XX
XX New nucleic acid molecule for diagnosing, preventing or treating diseases
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PT genetic, bacterial and viral diseases.
XX
XX Claim 1; SEQ ID NO 3592; 428pp; English.
XX
XX The present invention relates to an isolated nucleic acid molecule
CC encoding a polypeptide which is believed to be cytostatic,
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
CC composition and methods are useful for diagnosing, preventing and
CC treating diseases such as proliferative (e.g. cancer), inflammatory,
CC immune, metabolic, genetic, bacterial and viral diseases. The present
CC sequence represents a human secreted protein. The present sequence is
XX available on WIPWEB and is not in the specification.
XX
XX Sequence 2542 AA;
ADP31594 Length: 2542 February 22, 2005 12:25 Type: P Check: 1592 ..
1 GTATTCTACC TTGTAAATAC TGTATTGT ATATACTGTA AATGATGACA
51 TCGGTGGCA CTAACCGAGC CCGGGGAAC TGGGAACAAC CTCAAACCA
101 AAACAGACA CAGACAAGC AGCGGCCACA GGCCACTGCA GAACAAATTA
151 GACTTGACA GATGATTTCG GACCATAATG ATGCTGACTT TGAGGAGAAG
201 GTGAACAAT TGATTGATAT TACAGGCAAG ACCAGGATG AATGTGTGAT
251 TGCTTTGCAT GACTGCAATG GAGATGTCAA CAGAGCTATC AATGTTCTTC
301 TGAAGGAAA CCCAGACACG CATTCTGGG AGATGTCGG GAAGAAGAAG
351 GGAGTCTCAG GCCAGAGGA TGGTGCCAG ACGGNATCCA ATGAGGAAGG
401 CAAAGAAAAT CGAGACCGGG ACAGAGACTA TAGTCGGCGA CGTGGTGGCC
451 CACCAAGACG GGGGAGAGGT GCCAGCCGTG GACGAGAGTT TCGAGGTCAG
501 GAAATGGAT TGGATGGCAC CAAGAGTGA GGGCCCTCTG GAACAGGNAAC
551 AGAAGAGGC AGAAGGGGCC GTGGCCGAGG CAGAGGTGGC TCTGGTAGGC
601 GAGGAGGAAG GTTTCTGCT CAAGGAATGG GAACCTTAA CCCAGCTGAT
651 TATGAGAGC CAGCCATATC TGATGTAAC TATGCAATA GCAGCGGCA
701 TACGTGAAC AACACTGGCC ACTTTGAACC AGATGATGGG ACGAGACTTG
```





PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486448P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Halshan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3594; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1359 AA;  
ADP31596 Length: 1359 February 22, 2005 12:25 Type: P Check: 6852 ..  
1 CAGGAAGCTC CGTGTGCCA GTGGGGCAC AGCCCCAGCT GATGCCCCAG  
51 AGGGGCCACC CATGCAAGA GGGGCTTTGG GCTCTGCCCT CCCTCCCCAT  
101 GCGCATGGG CCAAGCCTG AGACTGNAG ACTGTGGAC CTCAGCTTC  
151 TGACAGAGGA GGAGCAGGAG GCCATTGCTG GCGTCTCTCA ACAGATGCC  
201 CGCCTGGCC AGCTGGAGGA GGGGCGGGTC AGCAAGCTCC GGGCCTCAGT  
251 GGCAGACCT GGGCAGCTGA AGATCTTGAC AGGGNACTGG TTCAGGGAAG  
301 CACGTCTCCA GCGGCACCAC AATGCCCACT TCGGCTCTGA CTTGTCCGA  
351 GCGTCTATGC GCAGGAGAA GAGCACCAGG GAGATCCTGG AGAATGGGGA  
401 GGAGGCCCCG GGGCCCCGACC CTTCTCTCGA CCGCATGCTC AGCAGCAGCT  
451 CCTCGGTGTC CAGCCTTAAC TCCTCCACGC TGAGCGGCAG CCAGATGAGC  
501 CTGTCAAGCG ACGCGGAGGC GGTGCAGGTC CGCGGCTCGG TGCACTTCGC  
551 GCTGCACCTAC GAGCGGGGCG CCGCCGAGCT GCGCGTGAC GTGATCCAGT  
601 GCCAGGCGCT GCGCGCGCGC CCGCGCGGCC GCTCGGACCC CTACGTCAAA  
651 AGCTACCTCC TCCCGGATAA GCAGAGCAAG CGCAAGACGG CGGTGAAGAA  
701 ACGGATCTG AATCCGGTTT TCAACGAGAC TCTCCGGGCC GAGCTTCAGG  
751 GCGCGTGTCT GAGCCTGTCT GTGTGGCACC GCGAAGAGCCT GGGTCGCAAC

801 ATCTTTCTGG GCGAAGTTGA AGTGCCCTTG GACACGTGGG ACTGGGGCTC  
851 TGAGCCCAACC TGGCTCCCCC TGCAGCCCCG GCTGTCCCTC AAGTACGTCC  
901 CGCCCGGCTC CGAGGGTGAG ACTGCCCCCG AGCGGGGAGC TGCATTTCTG  
951 GGTGAAGGAG GCTCGGACC TCCTGCCGCT GCGGGCAGGA TCCCTGGACA  
1001 CTTACGTACA ATGCTTCGTG CTCCTGATG ACAGCCAGGC CAGCGGCCAG  
1051 CGTACAAGG TTGTGCGAG CAGCCTCAGC CTTGTGTTCA ATCACAACAT  
1101 GGTGTACGAT GGCTTTGGGC CTGCTGACCT GCGCCAGGCT TGTGCCGAGC  
1151 TCTCCCTCTG GGACCATGGG GCGCTGGCCA ACCGCCAGCT GGGGGGCACA  
1201 GCGCTCAGCC TGGGCACGG CAGCAGCTAT GGGCTGCAGG TGCCCTGGAT  
1251 GGATTCACA CTGAGGAGA AGCAGCTGTG GCAAGCCCTC CTGGAGCAGC  
1301 CGTGGGAATG GGTGGATGGC CTTCTACCCC TCAGAACCACAA CTTGSCCCCC  
1351 AGGACGTAG  
!!AA SEQUENCE 1.0  
ID ADF31633 standard; protein; 462 AA.  
XX  
XX ADF31633;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #2400.  
XX  
XX KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.  
XX PR 17-SEP-2002; 2002US-0411023P.

PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493373P.  
PR 08-AUG-2003; 2003US-0493377P.  
XX  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnenann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3631; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPONEB and is not in the specification.  
XX  
SQ Sequence 462 AA;  
ADP31633 Length: 462 February 22, 2005 12:25 Type: P Check: 1437 ..  
1 GGCGTGGCCA TGTCGCCCTT CGAGAGCCTG TTCCCTTACC CCTACACGTA  
51 CATGGCGGCA GCGGGGCGG CCTCTCTGCG GGCAGCCTCC AGTCGGTGCG  
101 ACCGCCACCC CTTCTCTCAAT CTGAACACCA TGGCGCCGGG GCTGGCGCTAC

151 AGCCCTACT CCATCCCGGT GCGGTCCCG GACGGCAGCA GTCTGCTCAC  
201 CACCGCCCTG CCCTCCATGG CGGGGGCGCG GGGGGCCCTG GACGGCAAG  
251 TCGCGCCCTT GCGGCCAGC CCGGCCTCGG TGGCAGTGA CTCGGGCTCT  
301 GAACTCAACA GCGGCTCTC CAGCTCTCC TCCAGCTCCA TGTCTCTGTC  
351 GCCCAACTC TCGCGGAGA AAGAGGGCG CACCAGCGAA CTGCAGACA  
401 TCCAGCGGT GTTAGCGGCT TGGGAAGCA AGCCGACAG GTCCCGCAGC  
451 GCGTCCCGT AG  
!!AA SEQUENCE 1.0  
ID ADP31634 standard; protein; 461 AA.  
XX  
AC ADP31634;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2401.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.



PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-048218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3645; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 129 AA;  
SQ  
ADP31647 Length: 129 February 22, 2005 12:25 Type: P Check: 1854 ..  
1 CTCGGGAAG GCCCACCAGT CCCTCGGCT CCCAAGACA CCCCGTCCAA  
51 GGAGTCAG CAGGACGAGA TCCTAGCCT GTTGGAGGAC ACGTTGTGCC  
101 CTGAGATCAG CGTGACCACC CCCTCCACG  
!!AA SEQUENCE 1.0  
ID ADP31677 standard; protein; 660 AA.  
XX  
AC ADP31677;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2444.  
DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS  
XX WO2004035732-A2.  
PN  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
PF

XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406618P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406668P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3675; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antineoplastic, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 660 AA;  
ADP31677 Length: 660 February 22, 2005 12:25 Type: P Check: 800 ..  
1 ATGCAGGATA CCAGTGGGTT CCTACTCTG GTTTACATTG ACTCTGAGCT  
51 GAGACAGCTG AGTCTGTGG CCACAGGCAT CCTGCACCTT CCTAGGAGTC  
101 CCCGACAGAGA CCAGAGTGGG GCTACCATGG GCAGCTCTAC TTCAGAGGGG  
151 CAGATATCTG ATTTTGCAAA AAGGCACACA CCTATCTGCA GCAAAGAAGA  
201 CACTGACCAG ATTGCGAGCG GTGCTTTTGG ATGCTCTGTA GCCACCCCGG  
251 GCCCAGGAGG ACTGACTCGG CAGCAGATT CTGTCATGGG AATCGGAGAC  
301 CATGCCAGTG CAGCTGGTGC CCGACTCAGC TCTGGCCCTG CTGATGGTGA  
351 GTGTTTCAGAC AGGAGGCTCT TTGGAATGC TTTCTTGGGT CAGAGTATCA  
401 GCATGACAAA GCATTTCGAG GGAAGAGAG CTGTAGATTT GCCATTTTCAG  
451 AAACCTTGTG CTGAATGCTA TTTTGAGAGC TGTGCTTGCA AACAGTTCCA  
501 CTGGACAGAG AAATCCAAGA TCGAGGAATG GGCATCTGGG GAGGCCCTTC  
551 TTGCTACATC ATCCACAGC AAGGCAGAG GGCACAGAA GAGCAAGAGG  
601 GGGCTGAACCT CACCTTTTA TAACAGACA ATTCCACCA TGAAGGTGGA  
651 ATCTTTATGA  
IIAA SEQUENCE 1.0  
ID -ADP31685 standard; protein; 315 AA.  
XX  
XX ADP31685;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2452.  
XX  
XX Cytostatic; Antineoplastic; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR

29-AUG-2002; 2002US-0406579P.  
29-AUG-2002; 2002US-0406585P.  
29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-041101P.  
17-SEP-2002; 2002US-041111P.  
17-SEP-2002; 2002US-041111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493373P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.  
DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
PT  
XX  
PS Claim 1; SEQ ID NO 3683; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 315 AA;  
ADP31685 Length: 315 February 22, 2005 12:25 Type: P Check: 8232 ..  
1 AATGTTGAAG GTATCCACCT TTCTGGGAA CCTCCACCT CACCTTCTGG  
51 AAATAATTTTG GAATATTCAG CTAATTGGC TATCCGCACA GCACAGATAC  
101 AAGATAATCC AAGTCACCTT GTGTTTCATGA GGATTTATTG TGGTCTTAAG  
151 ACATCATGTA TAGTAACCTG TGGGCAACTT GCAAAATGCAC ATATTGATTA  
201 TACATCCAGG CCTGCCATTG TGTTCCAGAT ATCAGCAAG AATGAAAGG  
251 GATATGACC ACTACACAA GTTCGGTGGC TTCAAGGTAA CAATAGAAA  
301 GCACCTTTAA ATTGA  
! /AA SEQUENCE 1.0  
ID ADP30559 standard; protein; 878 AA.  
XX  
AC ADP30559;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1326.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406555P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471308P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
PT  
XX  
PS Claim 1; SEQ ID NO 2557; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is

CC available on WIPWEB and is not in the specification.

XX Sequence 878 AA;  
ADP30559 Length: 878 February 22, 2005 12:25 Type: P Check: 6700 ..  
1 GGCCCCGCTG GGCTCTCATY GCGGCGGCC TTCCCGGGGG CGTCTCTCTC  
51 GTCTCTGCG TCCTTGTC TGCTGTGTC TGCTGCGGC GCCACAGGAA  
101 GAAGCCGAGG GACAGGAGT CCGTGGGTCT GGCAGTGCC CGCGCACCA  
151 CCACACACCA CCTGATCAGG GTGGGCTGA GGCAGCAGC GCACCTGAGG  
201 CTGGGGGCA CGTGGACCC CTATGCCGG GTGAGCTCT CCACCCAGGC  
251 CGGACACAGA CATGAGACAA AAGTGCACCG AGGCACGCTC TGCCCCGCTGT  
301 TTGACGAGAC CTGTGCTTC CACATCCGC AGGCGGAGCT GCCAGGGGCC  
351 ACCCTGCAGG TGCAGCTTTT CACTTCAAG CGCTTCTCGG GGCATGAGCC  
401 CTTGGGTGAG CTCGCTGTC CACTGGGCAC CGTGGATCTG CAGCATGTTT  
451 TGGAGCACTG GTACTGTCTG GGGCGGCGG GTGCCACTCA GGGGAGCTG  
501 TGCTTTCTCT TCCGTGACTG GCCAGTCA GGCCTGCTGA CCGTGGTGGT  
551 GCTGGAGGCT CGAGGCTGTC GTCCAGGACT TGCAGCCCCC TACTTCAATG  
601 AGGCTTCAAC CTCTCTGCTG CCCTTACAG AGTTCAGAA TGTGACCTG  
651 GTGCTGGCTG TCTGGACCG CAGCCTGCG CTCCGAAGCTG AGCCCGTAGG  
701 CAAGTGTGAC CTGGTGCGC GGGCTCGGG CGAGCCCCCTG CAGCACTGGG  
751 CAGACATGCT GGCCACGCC GGGGGGCCA TTGCCAGCG GACCCCCCTG  
801 CGGCCAGCCA GGGAGTGGA CCGCATGCTG GGCCTGCAGC CCGGCTTTCG  
851 CTGCGGCTG CCCTTGCCCC ACTCCTGA  
!!AA\_SEQUENCE 1.0  
ID ADP30564 standard; protein; 2123 AA.  
XX  
XX ADP30564;  
XX  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1331.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.

29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-041101P.  
17-SEP-2002; 2002US-041111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
08-JUL-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 2562; 428pp; English.

The present invention relates to an isolated nucleic acid molecule

CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ

Sequence 2123 AA;

ADP30564 Length: 2123 February 22, 2005 12:25 Type: P Check: 9708 ..

1 CCAATATCTG TCCTGAAAA TGGCAAGGT CCCTTCCCCC AGAGACTGAA  
51 TCAGCTCAAG TCTAATAAG ATAGAGACAC CAAGATTTTC TACAGATCA  
101 CGGGGCCGGG GGCAGACAGC CCCCCTGAGG GTGTCTTTCG TGTAGAGAAG  
151 GAGACAGGCT GGTGTGTGTT GAATAAGCCA CTGGACCGGG AGGAGATTGC  
201 CAAGATGAG CTCCTTGGCC AGCGTGTGTC AGAAGTGGT GCCTCAGTGG  
251 AGGACCCCAT GAACATCTCC ATCATCGTGA CCGACCAGAA TGACCAACAAG  
301 CCCAAGTTTA CCCAGGACAC CTTCGGAGGG AGTGTCTTAG AGGGAGTCTT  
351 ACCAGGTACT TCTGTGATGC AGGTGACAGC CACGGATGAG GATGATGCCA  
401 TCTACACCTA CAATGGGGTG GTTGCTTACT CCATCCATAG CCAAGAACCA  
451 AAGGACCCAC AGCACTCAT GTTCACCATT CACCGGAGCA CAGGCACCAT  
501 CAGGTCATC TCCAGTGGCC TGGACCGGGA AAAGTCCCT GAGTACACAC  
551 TGACCATCCA GGCACACAGC ATGGATGGG ACGCTCCAC CACCACGGCA  
601 GTGGCAGTAG TGGAGATCCT TGATGCCAAT GACAATGCTC CCATGTTTGA  
651 CCCCCAGAAG GTGCCTGAGA ATGCAGTGGG CCATGAGGTG CAGAGGCTGA  
701 CGGTCACTGA TCTGGACGCC CCCAACTCAC CAGCGTGGCG TGCCACCTAC  
751 CTTATCATGG CGGGTGACGA CGGGGACCAT TTTACCATCA CCACCCACCC  
801 TGAGAGCAAC CAGGGATCC TGACAACAG GAGGGTTTG GATTTTGAGG  
851 CCAAAAACCA GCACACCTTG TACGTTGAAG TGACCAACGA GGCCTCTTTT  
901 GTGCTGAAGC TCCCAACCTC CACAGCCACC ATAGTGTGCC ACGTGGAGGA  
951 TGTGAATGAG GCACCTGTGT TTGTCCTACC CTCCAAAGTC GTTGAGGTCC  
1001 AGGAGGSCAT CCCCACCTGG GAGCCTGTGT GTGTCTACAC TGCAGAAGAC  
1051 CCTGACAAGG AGAATCAAAA GATCAGTGA CCCAGACAGT GGSCAGGTCA  
1101 CAGCTGTGGG CACCCTCGAC CGTAGGATG AGCAGTTTGT GAGGAACAAC  
1151 ATCTATGAAG TCATGTCTTT GGCCATGGAC AATGGAAGCC CTCGCCACAC  
1201 TGGCACGGGA ACCCTTCTGC TAACACTGAT TGATGTCAAT GACCATGGCC  
1251 CAGTCCCTGA GCCCGCTCAG ATCACCATCT ATCAACCAAG CCTGTGCGC  
1301 CAGGTGCTGA ACATCAACGA CAAGGACCTG TCTCCCAACA CTCTCCCTTT  
1351 CCAGGCCCCG CTCACAGATG ACTCAGACAT CTACTGGACG GCAGAGGTCA  
1401 ACAGAGGAAG TGACACAGTG GTCTGTGCCC TGAAGAAGTT CTGGAAGCAG  
1451 GATACATATG ACGTGCACCT TTCTGTGCTT GACCATGGCA ACAAGAGCA  
1501 GCTGACGGTG ATCAGGGCCA CTGTGTGCGA CTGCCATGGC CATGTGAAAA

1551 CCTGCCCTGG ACCCTGGAAG GGAGTTTCA TCCTCCTCTG GCTGGGGGCT  
1601 GTCTGGGCTC TGCTGTTCTT CCTGTGGTG CTGCTTTTGT TGGTGAGAAA  
1651 GAAGCGGAAG ATCAAGGAGC CCCTCCTACT CCAGAAGAT GACACCCGTG  
1701 ACAACGTCTT CTACTATGGC GAAGAGGGGG GTGGCGAAGA GGACCAAGAC  
1751 TATGACATCA CCGAGTCCA CCGAGGTCTG GAGGCCAGGC CGGAGGTGGT  
1801 TCTCCGCAAT GACGTGGCAC CAACCATCAT CCGACACACC ATGTACCGTC  
1851 CTCGGCCAGC CAACCCAGAT GAAATCGCA ACTTTATAAT TGAGAAACCTG  
1901 AGGGGGGCTA ACACAGACC CACAGCCCCG CCTACGACA CCCTCTTGGT  
1951 GTTCGACTAT GAGGCGAGC GCTCCGACGC CGCGTCCCTG AGTCCCTCA  
2001 CCTCCTCGC CTCCGACCAA GACCAAGATT ACGATTATCT GAACGAGTGG  
2051 GCGAGCCGT TCAAGAGCT GGCAGACATG TAGGTGGCG GGGAGGACGA  
2101 CTAGTTTTTT TTTTAATGC TAT

!!AA SEQUENCE 1.0

ID ADP30579 standard; protein; 1587 AA.

XX AC ADP30579;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1346.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.



PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471338P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2577; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1587 AA;  
XX  
ADP30579 Length: 1587 February 22, 2005 12:25 Type: P Check: 9526 ..  
1 ATGGTGGGTG TGCCTGCTGT TTTTGACATG ATGCTGACTA GTAGAAACAT  
51 TCATCCAGAT AGCCCAAGA AATGGGACT GGTGACCAA TTGGTAGAAC  
101 CCTGGGACC GGGNATAAAA CCTCCAGAGG AATGGACAAAT CGAATACCTG

151 GAAGCAGTTG CAATTACTTT TGCCAAAGGA CTAGCTGATA AGAAGATCTC  
201 TCCAAAGAGA GACAAGGAT TGGTGGNAAA ATTGACAGCG TACACCATGA  
251 CTATTCATTT TGTCAAGCAA CAGGTTTACA AAAAAGTGA AGAAAAAGTG  
301 CAAAAGGAGA CTAAAGGCTT TTATCCTGCA CCTCTGAAAA TAATTTGACGT  
351 GGTCTTGTGC AAGAAGAATA AATTTGGAGC ACCACAGAAG GATGTTAAGC  
401 GTCTGGCTAT TCTTGGTGAA GGGCTGAAGG GAGCAGGCAT CACCAAAGTC  
451 TCTGTGGATA AGAGGCTAAA GACTATACTT AAAGATGCCA CACTCACTAG  
501 GCTAGGCCAA GGACAGCAAC AAGTGTTCAA AGGATTGAAT GATAAAGTGA  
551 ATAAGAAAGC TCTAACATCA TTTTCTCTCG TCCCACCCGA CGAGAAACAC  
601 CCACAGATGT GGAGGGGCAG GCCACCCCTT CAACTGGGCA CTTTGATTAG  
651 CAACGTTTTA AAGTCCACA TGGTGATTGA AGCTGTGTTT GAGGACCTTA  
701 GTCTTAAGCA CAGAGTGCTA AAGGAAAGTAG AAGCGGTGAT TCCAGATCAC  
751 TGTGCTTTTG CCAGTAACAC ATCTGCTTTC CCAATCAGTG AAATCGCTGC  
801 TGTACAGCAA AGACCTCAGA AGGTGATTGG CATGCACCTAC TTCTCTCCCA  
851 TGGACAAGAT GCAGCTGCTG GAGATGATCA CAAACGAGAA AACTTCCAAA  
901 GACACTCAGT GCTTCAGCTG TGGCATCAGT CTCACAGCAGG GGAAGGTTCAT  
951 CATTTGGGTT ATGGATGGAC CTGGCTTCTA TACCACACAG TGCTCTGCAC  
1001 CCATGATGTC TGAAGTCATC CGAATCCTCC AGGAAGGAGT TGACCTGGAG  
1051 AAGCTGGATT CCCTGACCAC AAGCTTTGGC TTTCCTGTGG GTGCCGCCAC  
1101 ACTGTTGGAT GAAGTTGGCG TGGATGTAGC GAAACATATG GCGGAAGATC  
1151 TGCCGAAAGC CTTTGGGGAG CGGTTTGGAG GTGGAAACCC AGAATGCTGT  
1201 ACACAGATGG TGTCCAAGGG CTTTCTTAGT GCCAAGTTTG GGAAGGGCTT  
1251 TTACATCTAT CAGGAGGGTG TGAAGAGTAA GAAATTTGAAT TCTGATGTGG  
1301 ATAGTATCTT AGTGAGTCTA AAGATGCCTC CTAAGTCTGA AGTCTCCCCA  
1351 GGTGAAGACA TCCAGTTCCG CCTGGTGACA AGATTTGTGA ATGAGGCAGT  
1401 CATGTGCTG CGAGAGGGGA TCTTGGCCAC ACCTGCAGAG GGAGACATCG  
1451 CAGCTGTCTT TGGGCTTGGC TTCCCGCCTT GTTTTGGAGG GCCTTTCTGC  
1501 TTTGTGGCTC TGTATGCCCC CCAGAAGATA GTGGCCCGGC TCAAGAAGTA  
1551 TGAGGCTGCC TATGGAAAC AGTTCACTCC ATGCTAG

!!AA SEQUENCE 1.0

ID ADP30620 standard; protein; 2064 AA.

XX

AC ADP30620;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1387.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

PN	WO2004035732-A2.	PR	08-AUG-2003; 2003US-0493577P.	XX	
XX		XX	(FIVE-) FIVE PRIME THERAPEUTICS INC.	XX	
PD	29-APR-2004.	XX	Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;	XX	
XX		PI	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;	XX	
PF	28-AUG-2003; 2003WO-US026780.	PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;	XX	
XX		PI	WPI; 2004-348438/32.	XX	
XX	29-AUG-2002; 2002US-0406576P.	DR		XX	
XX	29-AUG-2002; 2002US-0406579P.	XX	New nucleic acid molecule for diagnosing, preventing or treating diseases	XX	
PR	29-AUG-2002; 2002US-0406585P.	PT	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,	XX	
PR	29-AUG-2002; 2002US-0406588P.	PT	genetic, bacterial and viral diseases.	XX	
PR	29-AUG-2002; 2002US-0406608P.	PS	Claim 1; SEQ ID NO 2618; 428pp; English.	XX	
PR	29-AUG-2002; 2002US-0406611P.	XX	The present invention relates to an isolated nucleic acid molecule	XX	
PR	29-AUG-2002; 2002US-0406612P.	CC	encoding a polypeptide which is believed to be cytostatic,	XX	
PR	29-AUG-2002; 2002US-0406616P.	CC	antiinflammatory, immunosuppressive, antibacterial and virucidal. The	XX	
PR	29-AUG-2002; 2002US-0406640P.	CC	composition and methods are useful for diagnosing, preventing and	XX	
PR	29-AUG-2002; 2002US-0406642P.	CC	treating diseases such as proliferative (e.g. cancer), inflammatory,	XX	
PR	29-AUG-2002; 2002US-0406646P.	CC	immune, metabolic, genetic, bacterial and viral diseases. The present	XX	
PR	29-AUG-2002; 2002US-0406653P.	CC	sequence represents a human secreted protein. The present sequence is	XX	
PR	29-AUG-2002; 2002US-0406655P.	CC	available on WIPOWEB and is not in the specification.	XX	
PR	29-AUG-2002; 2002US-0410947P.	XX	Sequence 2064 AA;	XX	
PR	29-AUG-2002; 2002US-0410948P.	ADP30620	Length: 2064 February 22, 2005 12:25 Type: P Check: 7451 ..	XX	
PR	29-AUG-2002; 2002US-0410949P.	1	ATGGCCGGGC GTGGGTGGG CGCGCTGTGG GTGTGCTGG CGGCCGCCAC	XX	
PR	29-AUG-2002; 2002US-0410953P.	51	CCTGCTGCAC GCTGGCGGC TGGCCCGCG AGACTGCTGS CTGATCGAGG	XX	
PR	29-AUG-2002; 2002US-0410957P.	101	GGCACAAGGG CTTGCTGTGG CTGGCCATCT GCAGCCAGAA CCAACCCGCC	XX	
PR	29-AUG-2002; 2002US-0410958P.	151	TACGAGGCCA TCCCACAGCA GATCAACAGC ACCATCGTGG ACCTCGCGCT	XX	
PR	29-AUG-2002; 2002US-0410959P.	201	CAACGAGAAC CGTATCCGCA GCGTGCACTA CGCCTCGCTC AGCCGCTTTG	XX	
PR	29-AUG-2002; 2002US-0410961P.	251	GCAACCTCAC GTACTCNAAC CTACCAAGA ACGAGATCGG CTACATCGAG	XX	
PR	29-AUG-2002; 2002US-0410962P.	301	GACGGCGCCT TCTCGGCCA GTTCAACCTG CAGGTGCTGC AGCTGGGCTA	XX	
PR	29-AUG-2002; 2002US-0410963P.	351	CAACCGGCTG CGCAACCTCA CGGAGGGCAT GCTGGCGGC CTGGGCAAGC	XX	
PR	29-AUG-2002; 2002US-0410964P.	401	TGAGGTACCT GTACTGCAG GCCAACCTCA TCGAGGTGGT CATGCCACGC	XX	
PR	29-AUG-2002; 2002US-0410965P.	451	AGCTTCTGGG AGTGTCCAA CATCGTCAAC ATCGACCTGT CCATGAACCG	XX	
PR	29-AUG-2002; 2002US-0410966P.	501	CATCCAGCAG CTCACACGG GCACCTTCGC CGGCCTGGCC AAGCTGTGG	XX	
PR	29-AUG-2002; 2002US-0410967P.	551	TGTGGAGCT CTACAGCAAC CCCTTCTACT GCTCTTGGCA GCTGTGGGC	XX	
PR	29-AUG-2002; 2002US-0410968P.	601	TTCTGCGCT GCGTGGCGC CTTACCCAAC GCCACACAGA CGTACGACCG	XX	
PR	29-AUG-2002; 2002US-0410969P.	651	CATGCAGTGC GAGTGGCGC CCGTCTACTC CGGCTACTAC CTCCTGGGCC	XX	
PR	29-AUG-2002; 2002US-0410970P.	701	AGGGCGCGC CGGCACCGC AGCATCTCTCA GCNAACTGCA GTCAGTCTGC	XX	
PR	29-AUG-2002; 2002US-0410971P.	751	ACCGAGGACT CGTACGCGC TGAGGTGGTC GGGCCCCCACC GTCCAGCATC	XX	
PR	29-AUG-2002; 2002US-0410972P.	801	CGGGCGCTCA CAGCGGGCC GCTCCCCGCC GCCCCCGCT CGCGCGGAGC	XX	
PR	29-AUG-2002; 2002US-0410973P.	851	CCAGTGACAT GCCCTGTGCC GATGATGAGT GCTTCTCCGG GGACGGGACC	XX	
PR	29-AUG-2002; 2002US-0410974P.	901	ACGCCACTGG TGGCCCTGCC CACGCTGGCC ACGCAGGCGC AGGCCCGGCC	XX	
PR	29-AUG-2002; 2002US-0410975P.	951	CCTCATCAAG GTCAGCAGC TCACTCAGAA CTCGGCCACC ATCACCCTCC	XX	
PR	29-AUG-2002; 2002US-0410976P.	1001	AGCTGCCCCC CCGTTCAC CCGATGTACA CCTTGGAGCA TTTCACCAAC	XX	
PR	29-AUG-2002; 2002US-0410977P.	1051	AGCAAGGCCT CCACCGTGTG CAGGCTGACC AAGGCCCCAGG AGGAGATCCG	XX	

1101 TCTGACCAAC CTGTTTCAGC TCACCAACTA CACCTACTGC GTGGTGTCCA  
1151 CCAGCGCCGG GCTGCGCCAC AACACACCT GCCTACCAT CTGCTTGCCC  
1201 CGGCTGCCCA GCCCGCTGG TCGGTGCC AGCCCTCCA CGGCACCCA  
1251 CTACATCATG ACCATCTGG GTCGCTCTTT CGGCATGGTG CTGGTGTGG  
1301 GCGCCGTCTA CTACTGCTG CGCAGCGGC GCGCCAGGA GGAGAAGCAC  
1351 AAGAAGCCG CCTCGGACG CGCAGCTGG AGCTCAAG AGACCATCAT  
1401 CGAGCTCAAG TACGGGCCAG AGCTGGAGG GCCCGCCTTG GCCCGCTGT  
1451 CCCAGGCCG GCTGTGGC CCCAGGCC TGACGGCCGAT CCTTTACCTG  
1501 CTTGCGCCG CGAGGTGA GCAGTCAAG CTGGTGGAG GCGCGACAC  
1551 CCCAAGGCC AGCAAGGCA GTTACATGGA GGTTCGAAC GGGGACCTC  
1601 CGAAGCGCAG GCACTGTGAG CTGGGCCGGC CGGGCCCCGA CAGCCAGAGT  
1651 TCGGTGGCG AGATCTCAC CATCGCAAG GAGTGGACA AGGTCAACA  
1701 GATCATCAAC AACTGCATCG ACGCGTCAA GTCCGAGTCC ACCTCTTCC  
1751 AGGGGTCAA GTCCGGGCC GTGTCCGTCG CGGAGCCGCC GCTGTGTGTG  
1801 CTGTCCGAG CGTGGCCGC CAAGCAGGC TTCTGGGCG CGGGTACAA  
1851 GGAGCGCTTC GGCCACAGCC TGCAGCGGCA CCACAGCGTG GAGGCGCCG  
1901 GSCCCCTCG TGCCAGCACC TCGTCCAGCG GCTCCGTGG CAGCCCCCGC  
1951 GCCTTCCGAG CCGAGCGGT CGGGGTGCAC AAGGCGCGC CGCGGAGGC  
2001 CAAGTACATC GAGAAGGCT CCCCCCGGC CGAGGCCATC CTCATGTGA  
2051 CACCCGCGC CGCC

## 11AA SEQUENCE 1.0

ID\_ADP30637 standard; protein; 189 AA.

XX AC ADP30637;

XX XX XX

DT 12-AUG-2004 (first entry)

DE Human secreted protein SEQ ID #1404.

XX Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX XX XX

XX PD 29-APR-2004.

XX XX XX

XX PF 28-AUG-2003; 2003WO-US026780.

XX XX 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406657P.

XX PR 29-AUG-2002; 2002US-0406659P.

XX PR 29-AUG-2002; 2002US-0406661P.

XX PR 29-AUG-2002; 2002US-0406663P.

XX PR 29-AUG-2002; 2002US-0406665P.

XX PR 29-AUG-2002; 2002US-0406667P.

XX PR 29-AUG-2002; 2002US-0406669P.

XX PR 29-AUG-2002; 2002US-0406671P.

XX PR 29-AUG-2002; 2002US-0406673P.

XX PR 29-AUG-2002; 2002US-0406675P.

XX PR 29-AUG-2002; 2002US-0406677P.

XX PR 29-AUG-2002; 2002US-0406679P.

XX PR 29-AUG-2002; 2002US-0406681P.

XX PR 29-AUG-2002; 2002US-0406683P.

XX PR 29-AUG-2002; 2002US-0406685P.

XX PR 29-AUG-2002; 2002US-0406687P.

XX PR 29-AUG-2002; 2002US-0406689P.

XX PR 29-AUG-2002; 2002US-0406691P.

XX PR 29-AUG-2002; 2002US-0406693P.

XX PR 29-AUG-2002; 2002US-0406695P.

XX PR 29-AUG-2002; 2002US-0406697P.

XX PR 29-AUG-2002; 2002US-0406699P.

XX PR 29-AUG-2002; 2002US-0406701P.

XX PR 29-AUG-2002; 2002US-0406703P.

XX PR 29-AUG-2002; 2002US-0406705P.

XX PR 29-AUG-2002; 2002US-0406707P.

XX PR 29-AUG-2002; 2002US-0406709P.

XX PR 29-AUG-2002; 2002US-0406711P.

XX PR 29-AUG-2002; 2002US-0406713P.

XX PR 29-AUG-2002; 2002US-0406715P.

XX PR 29-AUG-2002; 2002US-0406717P.

XX PR 29-AUG-2002; 2002US-0406719P.

XX PR 29-AUG-2002; 2002US-0406721P.

XX PR 29-AUG-2002; 2002US-0406723P.

XX PR 29-AUG-2002; 2002US-0406725P.

XX PR 29-AUG-2002; 2002US-0406727P.

XX PR 29-AUG-2002; 2002US-0406729P.

XX PR 29-AUG-2002; 2002US-0406731P.

XX PR 29-AUG-2002; 2002US-0406733P.

XX PR 29-AUG-2002; 2002US-0406735P.

XX PR 29-AUG-2002; 2002US-0406737P.

XX PR 29-AUG-2002; 2002US-0406739P.

XX PR 29-AUG-2002; 2002US-0406741P.

XX PR 29-AUG-2002; 2002US-0406743P.

XX PR 29-AUG-2002; 2002US-0406745P.

XX PR 29-AUG-2002; 2002US-0406747P.

XX PR 29-AUG-2002; 2002US-0406749P.

XX PR 29-AUG-2002; 2002US-0406751P.

XX PR 29-AUG-2002; 2002US-0406753P.

XX PR 29-AUG-2002; 2002US-0406755P.

XX PR 29-AUG-2002; 2002US-0406757P.

XX PR 29-AUG-2002; 2002US-0406759P.

XX PR 29-AUG-2002; 2002US-0406761P.

XX PR 29-AUG-2002; 2002US-0406763P.

XX PR 29-AUG-2002; 2002US-0406765P.

XX PR 29-AUG-2002; 2002US-0406767P.

XX PR 29-AUG-2002; 2002US-0406769P.

XX PR 29-AUG-2002; 2002US-0406771P.

XX PR 29-AUG-2002; 2002US-0406773P.

XX PR 29-AUG-2002; 2002US-0406775P.

XX PR 29-AUG-2002; 2002US-0406777P.

XX PR 29-AUG-2002; 2002US-0406779P.

XX PR 29-AUG-2002; 2002US-0406781P.

XX PR 29-AUG-2002; 2002US-0406783P.

XX PR 29-AUG-2002; 2002US-0406785P.

XX PR 29-AUG-2002; 2002US-0406787P.

XX PR 29-AUG-2002; 2002US-0406789P.

XX PR 29-AUG-2002; 2002US-0406791P.

XX PR 29-AUG-2002; 2002US-0406793P.

XX PR 29-AUG-2002; 2002US-0406795P.

XX PR 29-AUG-2002; 2002US-0406797P.

XX PR 29-AUG-2002; 2002US-0406799P.

XX PR 29-AUG-2002; 2002US-0406801P.

XX PR 29-AUG-2002; 2002US-0406803P.

XX PR 29-AUG-2002; 2002US-0406805P.

XX PR 29-AUG-2002; 2002US-0406807P.

XX PR 29-AUG-2002; 2002US-0406809P.

XX PR 29-AUG-2002; 2002US-0406811P.

XX PR 29-AUG-2002; 2002US-0406813P.

XX PR 29-AUG-2002; 2002US-0406815P.

XX PR 29-AUG-2002; 2002US-0406817P.

XX PR 29-AUG-2002; 2002US-0406819P.

XX PR 29-AUG-2002; 2002US-0406821P.

XX PR 29-AUG-2002; 2002US-0406823P.

XX PR 29-AUG-2002; 2002US-0406825P.

XX PR 29-AUG-2002; 2002US-0406827P.

XX PR 29-AUG-2002; 2002US-0406829P.

XX PR 29-AUG-2002; 2002US-0406831P.

XX PR 29-AUG-2002; 2002US-0406833P.

XX PR 29-AUG-2002; 2002US-0406835P.

XX PR 29-AUG-2002; 2002US-0406837P.

XX PR 29-AUG-2002; 2002US-0406839P.

XX PR 29-AUG-2002; 2002US-0406841P.

XX PR 29-AUG-2002; 2002US-0406843P.

XX PR 29-AUG-2002; 2002US-0406845P.

XX PR 29-AUG-2002; 2002US-0406847P.

XX PR 29-AUG-2002; 2002US-0406849P.

XX PR 29-AUG-2002; 2002US-0406851P.

XX PR 29-AUG-2002; 2002US-0406853P.

XX PR 29-AUG-2002; 2002US-0406855P.

XX PR 29-AUG-2002; 2002US-0406857P.

XX PR 29-AUG-2002; 2002US-0406859P.

XX PR 29-AUG-2002; 2002US-0406861P.

XX PR 29-AUG-2002; 2002US-0406863P.

XX PR 29-AUG-2002; 2002US-0406865P.

XX PR 29-AUG-2002; 2002US-0406867P.

XX PR 29-AUG-2002; 2002US-0406869P.

XX PR 29-AUG-2002; 2002US-0406871P.

XX PR 29-AUG-2002; 2002US-0406873P.

XX PR 29-AUG-2002; 2002US-0406875P.

XX PR 29-AUG-2002; 2002US-0406877P.

XX PR 29-AUG-2002; 2002US-0406879P.

XX PR 29-AUG-2002; 2002US-0406881P.

XX PR 29-AUG-2002; 2002US-0406883P.

XX PR 29-AUG-2002; 2002US-0406885P.

XX PR 29-AUG-2002; 2002US-0406887P.

XX PR 29-AUG-2002; 2002US-0406889P.

XX PR 29-AUG-2002; 2002US-0406891P.

XX PR 29-AUG-2002; 2002US-0406893P.

XX PR 29-AUG-2002; 2002US-0406895P.

XX PR 29-AUG-2002; 2002US-0406897P.

XX PR 29-AUG-2002; 2002US-0406899P.

XX PR 29-AUG-2002; 2002US-0406901P.

XX PR 29-AUG-2002; 2002US-0406903P.

XX PR 29-AUG-2002; 2002US-0406905P.

XX PR 29-AUG-2002; 2002US-0406907P.

XX PR 29-AUG-2002; 2002US-0406909P.

XX PR 29-AUG-2002; 2002US-0406911P.

XX PR 29-AUG-2002; 2002US-0406913P.

XX PR 29-AUG-2002; 2002US-0406915P.

XX PR 29-AUG-2002; 2002US-0406917P.

XX PR 29-AUG-2002; 2002US-0406919P.

XX PR 29-AUG-2002; 2002US-0406921P.

XX PR 29-AUG-2002; 2002US-0406923P.

XX PR 29-AUG-2002; 2002US-0406925P.

XX PR 29-AUG-2002; 2002US-0406927P.

XX PR 29-AUG-2002; 2002US-0406929P.

XX PR 29-AUG-2002; 2002US-0406931P.

XX PR 29-AUG-2002; 2002US-0406933P.

XX PR 29-AUG-2002; 2002US-0406935P.

XX PR 29-AUG-2002; 2002US-0406937P.

XX PR 29-AUG-2002; 2002US-0406939P.

XX PR 29-AUG-2002; 2002US-0406941P.

XX PR 29-AUG-2002; 2002US-0406943P.

XX PR 29-AUG-2002; 2002US-0406945P.

XX PR 29-AUG-2002; 2002US-0406947P.

XX PR 29-AUG-2002; 2002US-0406949P.

XX PR 29-AUG-2002; 2002US-0406951P.

XX PR 29-AUG-2002; 2002US-0406953P.

XX PR 29-AUG-2002; 2002US-0406955P.

XX PR 29-AUG-2002; 2002US-0406957P.

XX PR 29-AUG-2002; 2002US-0406959P.

XX PR 29-AUG-2002; 2002US-0406961P.

XX PR 29-AUG-2002; 2002US-0406963P.

XX PR 29-AUG-2002; 2002US-0406965P.

XX PR 29-AUG-2002; 2002US-0406967P.

XX PR 29-AUG-2002; 2002US-0406969P.

XX PR 29-AUG-2002; 2002US-0406971P.

XX PR 29-AUG-2002; 2002US-0406973P.

XX PR 29-AUG-2002; 2002US-0406975P.

XX PR 29-AUG-2002; 2002US-0406977P.

XX PR 29-AUG-2002; 2002US-0406979P.

XX PR 29-AUG-2002; 2002US-0406981P.

XX PR 29-AUG-2002; 2002US-0406983P.

XX PR 29-AUG-2002; 2002US-0406985P.

XX PR 29-AUG-2002; 2002US-0406987P.

XX PR 29-AUG-2002; 2002US-0406989P.

XX PR 29-AUG-2002; 2002US-0406991P.

XX PR 29-AUG-2002; 2002US-0406993P.

XX PR 29-AUG-2002; 2002US-0406995P.

XX PR 29-AUG-2002; 2002US-0406997P.

XX PR 29-AUG-2002; 2002US-0406999P.

XX PR 29-AUG-2002; 2002US-0407001P.

XX PR 29-AUG-2002; 2002US-0407003P.

XX PR 29-AUG-2002; 2002US-0407005P.

XX PR 29-AUG-2002; 2002US-0407007P.

XX PR 29-AUG-2002; 2002US-0407009P.

XX PR 29-AUG-2002; 2002US-0407011P.

XX PR 29-AUG-2002;

CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 189 AA;  
  
ADP30637 Length: 189 February 22, 2005 12:25 Type: P Check: 776 ..  
  
1 ATGTGTTACG GGTCTGAGC TGGGGAAGGA CGGCCGCTCT TGTGTGACCA  
  
51 GTGGGGAAGG ACAGCGGACC CTTGGGGGGA CCGGGGTGCC CACCAAGGCGC  
  
101 CCGCGGGCCA CTGCAACGAG CCCGTGGCG CAGAGACAT GGCATATCAG  
  
151 GGTGACGAG AAGTGGGAG AGACACCACT TGTCCCTGA  
  
11AA SEQUENCE 1.0  
ID ADP30685 standard; protein; 1264 AA.  
XX  
AC ADP30685;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1452.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406659P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.

17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-041101P.  
17-SEP-2002; 2002US-041111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471308P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-048646P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2683; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1264 AA;  
  
ADP30685 Length: 1264 February 22, 2005 12:25 Type: P Check: 6811 ..  
  
1 TGCTGTGCG GCCCTGTCC TGCTGTGCC CTGGCCTCTC GCCACCCTGA  
  
51 CATCAACAAC CTTTGGCAG TGCCACCTG GGGAGGAGCC CGACCTGCAG  
  
101 GGCACATTAT GCAGGCCCTG CCCCCAGGC ACCTTCTCAG CTGCATGGGG  
  
151 CTCAGCCCA TGCCAGCCCC ATGCCCGTTG CAGCCTTTGG AGGAGGCTGG  
  
201 AGGCCCAGGT GGGCATGGCA ACTCGAGATA CACTCTGTGG AGACTGCTCG  
  
251 CAGGTGGTTT GGGTGGGGG CGCGGGGCC GACGTGGCGT GGAGGTGGCA

301 GCAGGGGCA GCAGGGTGG TGAGACAGG CAGCCTGGGA AGGGCACCGG  
351 GGCAGGTGG CCAGAGGAGA CAGCGGCCA GTACGGCGTC ATCGCATCG  
401 TCCCTGCTT CTGCTCATG GGGCTGTTG GCATCTGTT GTGCAACCTC  
451 CTCACGGA AGGGTACCA CTGACGGCG CACAAGAGG TGGGGCCGG  
501 CCTGGAGT GGAGCAGTG GGACTAGGA TGCCAATGAG GACACATTG  
551 GGGTCTGCT GGGCTTGATC ACAGAGAAGA AAGAGAATGC TGGGGCCCTG  
601 GAGGAGTGC TGAAGAGTA CCACAGAAA CAGCTGGTGC AGACAGCA  
651 CAGGCTGTG TCCAAGTGC CGCAGCGCC CCGAACGTG CCACACATCT  
701 GCCGCGACG CCACCATCTC CACACCGTGC AGGGCCTGGC CTCGCTCTCT  
751 GGGCCTGCT GCTCCGCTG TAGCCAGAG AGTGGCCCG AGGTGCTGCT  
801 GTCCCTGAG GCTGTAGCG CCACTACTCC TGTTCCTCAGC TTCTGCTCTA  
851 ACCCGACCA GGTTCCTCA GCGGGGCCA AGCAGGGCG TCAGGGCGAG  
901 ATCACCATCT TGTCTGTGG CAGGTTCCG GTGGCTCGAA TTCCTGAGCA  
951 GCGGACAACT TCAATGGTGT CTGAGGTGAA GACCATCAG GAGGCTGGC  
1001 CCTCTGGGG TGATCTCCT GACTCCCCAC AGCCTGGCT CCCCCCTGAG  
1051 CAGCAGGCC TGCTAGGAG TGGCGGAGC CGTACAAAGT GGCTGAAGCC  
1101 CCCAGCAGG AACAAGGCG AGGAGAACC CTATGTGGTC CGGCTAAGTG  
1151 AGAGCAACT GGTATCTGA GGGCGGTCT AGTCTAAGA CACTCGGCC  
1201 CTGCCCCTGG AGGTTCCGAA GGTTCTCTG AGGAGGTGA GCTGAGCTG  
1251 GGACTGTGAG GACC

IIAA SEQUENCE 1.0  
ID \_ADP30733 standard; protein; 1434 AA.

XX AC ADP30733;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1500.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX FN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348436/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 2731; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The

CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
SQ Sequence 1434 AA;

ADP30733 Length: 1434 February 22, 2005 12:25 Type: P Check: 8711 ..

1 ATGTCCATGG CCAGAGAGT GATCAGCTC CTAGAAGATG AGGAGAGACC  
51 GAAGCCAGAC ACAGCCGCTG TCGTGCAT CTGGCGGCC GCAGACTCCC  
101 GAGACAGCC CTGGCTGTCA GGGGCACCA GCCGCTTCCT GTGCCCATCG  
151 CGTAGACTGG AGGGGGGCAC CAGGCGCAC GAGCCAGAGG CGCTTCAGGA  
201 AGCAAGAGAA GTCCCCGCGC GTCCGGGAC CCGCGCAGC TCATGGAGCA  
251 ACGACACCG GTACCCGGGG CAGTTAGCGC TATACCAGCA GCTGGCGCAG  
301 GGGAAATCCG TGGGGGGCTC GGGGGGGCA CCGCACTGG GGGCCGTGCA  
351 GGTGGTCACC GCGTGCTGCG TGACCCTACT CGTCATCTGG ACCTTGCTGG  
401 GCAACGTGCT GGTGTCCGCA GCCATCGTGT GGAGCCGCCA CTGCGCGGCC  
451 AAGATGACCA ACGTCTTCAT CGTGCTCTTA CTGTGTFCAG ACGCTTCGTT  
501 GGGCGTCTG GTCATCTCCT GGAAGGCAGT CGCGAGGTG GCGGTTACTT  
551 GGCCCTTTGA AGGTTCTGCG GACGCTCTGG TGGCTTCGA CATCATGTGC  
601 TCCACCGCCT CCATCTGTAA CTTGTGCTGC ATCAGCGTGG CCGCTACTTG  
651 GGCCATCTCC AGGCCCTTCC GTCACGAGCG CAAGATGACC CAGCGCATGG  
701 CTTTGTTCAT GGAGCCGTT TGGAGCCCG ACGTGAGGCG AGNAACTGT  
751 GATTCAGCC TGAATGAAAC CTAGCCATC CTTCTCTCGC TCATCAGCTT  
801 CTACATCCCC ATGGCCATCA TGATCGTGAC CTACACGCGC ATCTACCGCA  
851 TCGCCCAAGT GCAGATCCGC AGGATTTCTT CCTTGGAGAG GCGCGCAGAG  
901 CAGGTGCAGA GTGCGCGAG CAGCGCAGG TGCACGCGCG ACACAGCCT  
951 GCGGTTTTCC ATCAAGAGG AGACCGAGT TCTCAAGACC CTGTCGGTGA  
1001 TCATGGGGGT CTTCTGTGTG TGCTGGCTGC CTTCTTTCAT CCTTAACTGC  
1051 ATGGTTCCTT TGTGAGTGG ACACCCCAA GGCCCTCCGG CCGGCTTCCC  
1101 CTGCGTCAGT GAGACCACAT TCGATGTCTT CATCTGTFCAC TATGCTTCA  
1151 ACGCCGACTT CCGGAGGTG TTTGCCCAGC TGCTGGGGTG CAGCCACGTC  
1201 TGCTCCCGCA CGCCGTGGA GACGCTGAAC ATCAGCAATG AGCTCATCTC  
1251 CTACAACCAA GACACGGTCT TCCACAAGGA AATCGCAGCT GCGTACATCC  
1301 ACATGATGCC CAAAGCCATT CCCCCGGGG ACCGGGAGGT GGACACAGAT  
1351 GAGGAGGAGG AGAGTCTTTT CGATGCGATG TCCAGATATC ATCAGACATC  
1401 CCCAGATGGT GACCATGTTG CAGAGTCTGT CTGA

!!AA SEQUENCE 1.0  
ID ADP30884 standard; protein; 1221 AA.  
XX  
AC ADP30884;  
XX

DT 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1651.  
DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX WO2004035732-A2.  
PN 29-APR-2004.  
XX  
PD 28-AUG-2003; 2003WO-US026780.  
XX  
PF 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471366P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476611P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.



PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RE, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2973; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1087 AA;  
ADP30975 Length: 1087 February 22, 2005 12:25 Type: P Check: 7535 ..  
1 GCCCAGAAGG ATGTGCGTCT GCTACCGTCC CCCAGGGAAC GAGACACTGC  
51 TGAGCTGGAA GACTTCGCGG GCCACAGCA CAGCCTTCTT GCTGTGGGG  
101 GCGTGTCTGG GCGTGTCTGG CACCGCTTC GTGTGTGGGA GCTTGGCGGG  
151 CTGCGCGCCT GCACGGGGGC GACCGCTGGC GGCCACGCTT GTGCTGCACC  
201 TGGCGCTGGC CGACGGCGCG GTGCTGTCTG TCACGCCGCT CTTTGTGGCC  
251 TTCCTGACCC GGCAGGCGCTG GCGGTGGGGC CAGCGGGGCT GCNAGCGGCT  
301 GTACTACGTG TGGCGGCTCA GCATGTACGC CAGCGTGTCT CTACCGGGCC  
351 TGCTCASCCT GCAGCGCTGC CTCGAGTCA CCGCCCCCTT CTTGGCGCCT

401 CGGCTGCGCA GCCCGGCCT GGCCCGCCG CTGCTGCTGG CGGTCTGGCT  
451 GGCGGCGCTG TTGCTGCGCG TCCGGGCGC CGTCTACCGC CACCTGTGGA  
501 GGGACGCGCT ATGCCAGCTG TGCACCCCGT CGCCGGTCCA CGCCGCCGCC  
551 CACCTGAGCC TGGAGACTCT GACCGCTTTC GTGCTTCTTT TCGGGCTGAT  
601 GCTCGGCTGC TACAGCGTGA CGTGGCACG GCTGCGGGGC GCCCGCTGGG  
651 GTTCGCGGCG GCACGGGCGC CGGTGGGCGC GGCTGTGTAG GCCCATCTGTG  
701 CTTGCTTTCG GCTTGCTCTG GGCCCCCTAC CACGCAGTCA ACCTTCTGCA  
751 GCGGCTGCGA GCGCTGGCTC CACCGGAAGG GGCTTTGGCG AGCTGGGGCG  
801 GAGCCGGCCA GCGGCGCGGA GCGGGAACCTA CGGCCTTGGC CTTCTTCACT  
851 TCTAGCGTCA ACCCGGTGCT CTACGTCTTC ACCGCTGGAG ATCTGCTGCC  
901 CCGGGCAGGT CCCCCTTTC TCACGCGGCT CTTCGAAGGC TCTGGGGAGG  
951 CCCGAGGGGG CGCGCGCTCT AGGGAAGGGA CATTGGAGCT CCGAACTACC  
1001 CCTCAGCTGA AAGTGTGGG GCAGGGCGCG GGCATGGAG ACCCGGGGGG  
1051 TGGATGGAG AAGGACGGTC CGGNAATGGGA CCTTTGA  
!!AA SEQUENCE 1.0  
ID ADP30991 standard; protein; 253 AA.  
XX  
XX ADP30991;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1758.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406583P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.





PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PT  
XX  
PS Claim 1; SEQ ID NO 3006; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1626 AA;  
ADP31008 Length: 1626 February 22, 2005 12:25 Type: P Check: 1233 ..  
1 CTCCTCAGCA TCGTCGAGTG CCAGGGCCTC CCCATCGTGA ATGGGCAATG  
51 TGACCCCTAC GCCACGCTGA CGCTGGCAGG ACCCTTCAGG CAAACCAAA  
101 GAAGACGAAA GTGAAGAGGA AGACCAACAA TCCCCAGTTC GATGAAGTGT  
151 TTTATTTTGA GGTGACCCGG CCTGTAGCT ACAGCAAGAA GTCCCACTTT  
201 GACTTTGAGG AGGAGACGCT GGACAGCTC GAAATCAGAG TTGACCTCTG  
251 GAATGCCAGT AACCTGAAGT TTGGAGATGA ATTCTGGGA GAACTAAGGA  
301 TCCCGTTGAA AGTCCTGCGG CAGTCCAGCT CCTACGAGGC GTGTGAAGTC  
351 TGCGGATGTG GAGGTGTGTC TCAGCTCTGC GGCCCAATC CTGGGGCAGG  
401 TTTCGCCGGA GAAGCAGGAG GCGGCCGTCC CGTGTGTGCG GCTCTTCCTA  
451 CACTATGGCA GGGTGTGTGC ATTATCAGT GCCATGCCA GCGCGGAGGT

501 GAAGCGGACC CAGGACCCCA ACACCATCTT CCGAGGAAAC TCACCTGGCGT  
551 CCAAGTGCAAT CGACGAGACC ATGAAGCTGG CCGGGATGCA TTACCTGCAT  
601 GTACCCCTGA AGCCCGCCAT CGAGGAGATA TGCCAGAGCC ACAAACCCCTG  
651 TGAATTCGAC CCGTGAAGT TGAAGACGG AGAAAACCTT GAAAACAACA  
701 TGGTAGAACC TAGGCAGTA TGTGGACCGC GTCTTCCAGC CCATCAGTGA  
751 GTCTGGGGTG AGCTGCCCGA CCGTCATGTG TGACATCTTC TTCTCCCTCC  
801 GCGAGGCGGC GGCACGAGC TTCAGGATG ACCCGGACGT CAGGTACACT  
851 CGAGTGAGCA GCTTCATCTT CCGTGAAGTTC TTTCGCCCGG CCAATCTCTC  
901 CCCCACCTC TTCCAGTCTA CCGCGCACCA CAGCAGAGCC CTCGGCAGCC  
951 TGTCCAAGTC CAAATCTCGG AGTTTTAAGG AGTCCTACAT GGCTACATTT  
1001 TATGAATTCT TCAATGAGCA GAAATATGCT GATGCGGTGA AGAACGTAAT  
1051 TCTTGGATCT GATTTCTGTC TCGGGGAGAA GAGACCCCAA GAGTGTGAG  
1101 CAGCCCATCG TGCTTAAAGA AGGTTTCATG ATCAAGAGGG CCCAAGGAGG  
1151 GAAGCGCTTT GGGATGAAGA ATTTTAAGAA GAGATGGTTT CGCTTGACCA  
1201 ACCATGAATT TACCTACCAAC AAAAGCAAAAG GGGACCAGCC TCTCTACAGC  
1251 ATTCCCATCG AGAACATCCT GGCAGTGGAG AAGCTGGAGG AGGAGTCTTT  
1301 CAAATGAAA AACATGTTCC AGTCAATCCA GCCAGAGCGT GGCCTGTACA  
1351 TCCAGGCCAA CAACTGCGTG GAGGCCAAGG ACTGGATCGA CATTTCTACC  
1401 AAGTGAGGC AGTCAACCA GAAGCGCCTC ACCGTCTACC ACCCGTCCGC  
1451 CTACCTGAGC GGCACCTGGC TGTGCTGTAG GGGGCCATCC GACTCGGCTC  
1501 CGGGCTGCTC GCCCTGCACT GCGGGCCTCC CAGCCAAACAT CCAGCTGGAC  
1551 ATTGATGGG ACCGTGAGAC GGAGCGTATC TACTCCCTCT TCAACTTGTA  
1601 CATGAGCAAG CTGGAGAAGA TGCAGG  
!!AA\_SEQUENCE 1.0  
ID ADP31043 standard; protein; 1189 AA.  
XX  
AC ADP31043;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1810.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.

PR	29-AUG-2002;	2002US-0406612P.	PT	genetic, bacterial and viral diseases.
PR	29-AUG-2002;	2002US-0406616P.	XX	
PR	29-AUG-2002;	2002US-0406640P.	PS	Claim 1; SEQ ID NO 3041; 428pp; English.
PR	29-AUG-2002;	2002US-0406642P.	XX	
PR	29-AUG-2002;	2002US-0406646P.	XX	
PR	29-AUG-2002;	2002US-0406653P.	CC	The present invention relates to an isolated nucleic acid molecule
PR	29-AUG-2002;	2002US-0406655P.	CC	encoding a polypeptide which is believed to be cytostatic,
PR	29-AUG-2002;	2002US-0406666P.	CC	antiinflammatory, immunosuppressive, antibacterial and virucidal. The
PR	17-SEP-2002;	2002US-0410946P.	CC	composition and methods are useful for diagnosing, preventing and
PR	17-SEP-2002;	2002US-0410947P.	CC	treating diseases such as proliferative (e.g. cancer), inflammatory,
PR	17-SEP-2002;	2002US-0410948P.	CC	immune, metabolic, genetic, bacterial and viral diseases. The present
PR	17-SEP-2002;	2002US-0410949P.	CC	sequence represents a human secreted protein. The present sequence is
PR	17-SEP-2002;	2002US-0410953P.	XX	available on WIPWEB and is not in the specification.
PR	17-SEP-2002;	2002US-0410957P.	SQ	Sequence 1189 AA;
PR	17-SEP-2002;	2002US-0410958P.	ADP31043	Length: 1189 February 22, 2005 12:25 Type: P Check: 7714 ..
PR	17-SEP-2002;	2002US-0410959P.	1	ATTCAGCTTT TGCAGAAATT GAAGCACCCCT AATGTGATG CATTGCAGAA
PR	17-SEP-2002;	2002US-0410960P.	51	GGTGTTCCTT TCTCACAGTG ACAGGAAGGT ATGGCTGCTG TTTGATTATG
PR	17-SEP-2002;	2002US-0411022P.	101	CAGAGCATGA CTTGTGGCAT ATTATTAAGT TTCACCGTGC ATCAAAAGCA
PR	17-SEP-2002;	2002US-0411024P.	151	AATAAAAAGC CCATGCAGTT GCCAAGATCT ATGTTAAAT CCTTACTTTA
PR	17-SEP-2002;	2002US-0411032P.	201	CCAGATTCTT GATGGTATCC ATTACCTCCA TGCAAAATTGG GTGCTTCACA
PR	17-SEP-2002;	2002US-0411041P.	251	GAGACTTGCT GACATGGGTT TTGCCAGATT ATTCAATTCT CCTCTAAAGC
PR	17-SEP-2002;	2002US-0411045P.	301	CACATAGCAGA TTTGGATCCA GTAGTTGTGA CATTTTGGTA TCGGGCTCCA
PR	17-SEP-2002;	2002US-0411052P.	351	GAACTTTTGC TTGGTGCAAG GCATTATACA AAGGCCATTG ATATATGGGC
PR	17-SEP-2002;	2002US-0411073P.	401	AATAGTTGT ATATTGCTG AATTGTTGAC TTCGGAACCT ATTTTCACT
PR	17-SEP-2002;	2002US-0411011P.	451	GTGTCAGGA AGATATAAAA ACAGCAATC CCTTTCATCA TGATCAACTG
PR	18-APR-2003;	2003US-0463700P.	501	GATCGGATAT TTAGTGTGTCAT GGGGTTTCCT GCAGATAAAG ACTGGGAAGA
PR	18-APR-2003;	2003US-0463708P.	551	TATTAGAAAG ATGCCAGAT ATCCACACT TCAAAAAGAC TTTAGAAGAA
PR	18-APR-2003;	2003US-0463716P.	601	CAACGTATGC CAACAGTAGC CTCATAAAGT ACATGGAGAA ACACAAGTGC
PR	02-MAY-2003;	2003US-0467199P.	651	AAGCCTGACA GCAAAGTGTT CCTCTTGCTT CAGAAACTCC TGACCATGGA
PR	02-MAY-2003;	2003US-0467203P.	701	TCCAACCAAG AGAATTACCT CGGAGCAAGC TCTGCAGGAT CCCTATTTTC
PR	19-MAY-2003;	2003US-0471336P.	751	AGGAGGACCC TTGCGCAACA TTAGATGTAT TTGCCGGCTG CCAGATTCCA
PR	22-MAY-2003;	2003US-0472420P.	801	TACCCCAAC GAGAAITTCCT TAATGAAGAT GATCCTGAAG AAAAAGGTGA
PR	09-JUN-2003;	2003US-0476609P.	851	CAAGTGCAGC ACAGCCAGGA CTCACGCTG AACCAGGTGC CTCCAAACAA
PR	08-JUL-2003;	2003US-0476641P.	901	GAAGCCACGG CTAGGGCCTT CAGGGGCAAA CTCAGGTGGA CCTGTGATGC
PR	08-JUL-2003;	2003US-0485218P.	951	CCTCGGATTA TCAGCACTCC AGTTCGCGC TGAATTACCA AAGCAGCGTT
PR	08-JUL-2003;	2003US-0485223P.	1001	CAGGATCCT CTCAGTCCCA GAGCACACTT GGCTACTCTT CCTCGTCTCA
PR	08-JUL-2003;	2003US-0485325P.	1051	GCAGAGTCA CAGTACCAAC CATCTCACCA GGCCACCGG TACTGACCCA
PR	14-JUL-2003;	2003US-0486446P.	1101	GCATCTCTGT AACCTTCAGC ATTCTTTGA AGGATTTCTT GGTGCACCTT
PR	15-JUL-2003;	2003US-0486891P.	1151	TCTCATGCTG TAGCAATCAC TATGTTTAT CTTTTCAAA
PR	08-AUG-2003;	2003US-0486960P.	IIAA	SEQUENCE 1.0
PR	08-AUG-2003;	2003US-0493370P.	ID	ADP31062 standard; protein; 3407 AA.
PR	08-AUG-2003;	2003US-0493573P.	XX	
XX	08-AUG-2003;	2003US-0493577P.	XX	ADP31062;
PA	(FIVE-) FIVE PRIME THERAPEUTICS INC.		XX	
PI	Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;		XX	
PI	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;		XX	
PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;		XX	
DR	WPI; 2004-348438/32.		XX	
XX	New nucleic acid molecule for diagnosing, preventing or treating diseases		XX	
PT	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,		XX	
PT			DE	Human secreted protein SEQ ID #1829.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
PN  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.

PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
PT  
XX Claim 1; SEQ ID NO 3060; 428pp; English.  
PS  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 3407 AA;  
ADP31062 Length: 3407 February 22, 2005 12:25 Type: P Check: 5784 ..  
1 TGAGCCCGAG AGTGCTTTT CCTCAGCCCA CAGACACCTG AGCAGAAGGA  
51 ATGGGCTTTC CAGACTGTC CAGAGCAGGA CAGCGCTCTC TGAAGACAGA  
101 TGGAGCTCT ATTGTCTATC ATCACTGGCT GCCAGAATA TTGTACAAG  
151 TAAACTGCAC TGCCCTGCTG CCCCTGAGCA CACGGACCCG TCCGAACCGC  
201 GGGGAGTGT GTCTGTGTC TCCTGTGTC GGGGACTGTC CTCAGGGTGG  
251 TCCTCACCTC TGCTTCGGC CCTGTGTGC AACCTTAACA AGGCCATCTT  
301 CACGGTGGAT GCCAAGACCA CAGAGATCCT GGTGTGCTAAC GACAAAGCTT  
351 GCGGGCTCCT GGGGTACAGC AGCCAGGACC TGATTGGCCA GAAGCTCAGG  
401 CAGTTCTTTC TGAGTCTAGA TTCTGATGT GTGGAGGCCC TCAGCGAGGA  
451 GCACATGGAG GCCGAGGCC ACGTGGCGT GGTGTTTGGC ACGGTGGTGG  
501 ACATCATCAG CCGTAGTGGG GAGAAATTC CAGTGTCTGT GTGGATGAAG  
551 AGGATCGGCG AGGAGCGCCG CCTATGCTGC GTGGTGGTCC TGGAGCCCGT  
601 GGAGAGGGTC TCGACCTGGG TCGCTTTCCA GAGCGATTGC AGTCCCTCC  
651 TTCTGGCCAG CACATCCCAA AGAATCTCAA GATTACAGG TCTGTTGNA  
701 GAGCCAGGGA CGGTACCACC TTCCTCTGA GCTTAAAGCT GAAATCCCAA  
751 CCAGCAGCG AGGAGGCAC CACCGGTGAG GCGGCCCTG TGAGCGGCTA  
801 CCGGCATCT GTCTGGTGT TCTGCACCAT CAGTGGCCTC ATCACCCTCC  
851 TGCCGGATGG GACCATCCAC GGCATCAACC ACAGCTTCCG GCTGACACTG  
901 TTTTGGTTAG GAAAGACGGA GCTCCTGGC AGAATATCA CTTTCTCTAG

951 TCCTGGTTTC TACAGTACA TGGACCTTGC GTACAAAGC TCATTACAGC  
1001 TCCAGACCTT GGCACGCTGC CTGGACGTCG GCAATGAGAG TGGGTGTGGG  
1051 GAGAGAACTT TGGACCCGTG GCAGGGCCAG GACCCAGCTG AGGGGGGCCA  
1101 GGGGTGACA ATGTCCGAGA AGAAGCCTG CCAGTGCAAG GTGAACAGGC  
1151 GTGCCCCAAG GACCAGCAA TCACTGCCCTT GGGGAGAGAG GAACTGTGTG  
1201 CAATAGAGAG CCCCGACAG GATCTTCTGG GAGAAGCAG GTCTGAACCA  
1251 GTGGATGTGA ACCCATTTGC TTCTTGCGAA GATTCTGAAG CTCCAGTCCC  
1301 AGCTGAGGAT GGGGCGAGTG ATGCTGCGAT GTGTGGCCTG TGTGAGAAGG  
1351 CCCAGCTAGA GGGGATGGA GTCACTGGTC CCAGCGGTTT ACACCTTTGG  
1401 GCTGGGGCTG CCGTGGCCAA GCCCAGGCC AAGGGTCAGC TGGCGGGGGG  
1451 CAGCCTCTCTG ATGCACTGCC CTTCCTATGG GAGTGAATGG GCTTTGTGTT  
1501 GCGGAGCCA GGACTTGGCC CCCAGCCCCC CTGGGATGGC AGGCCCTCTG  
1551 TTTGGACAC CTACTCTAGA TGAGCCGTGG CTGGGAGTGG AAAACGACCG  
1601 AGAAGAGCTG CAGACCTGCT TGATTAAGGA GCAGCTGTCC CAGTTGAGCC  
1651 TTGCAGGAC CTGTGATGTC CCCACGCGG AACTCGTTCC GACAGAGTGC  
1701 CAGGCTGTCA CCGCTCTGTT GTGCTCTGTC GATCTGGGAG CGAGAGACCT  
1751 GTGCGGTGTC TGCACGGCA GCTCCTCAGC CTGCTATGCC TTGGCCACGG  
1801 ACTCCCTCG GGGCTTGAA GCAGTGAGG CCCAGGAGT GTATGTGAAT  
1851 TCGTTTCTCT GGAACCTCAA GGAACCTTTT TTCAGTGACC AGACAGACCA  
1901 AACGTCATCA AATTGTTCTT GTGCTACGTC TGAACCTCAGA GAGACACCT  
1951 CTTCTTGGC AGTGGCTCC GATCCAGATG TAGGCAGTCT CCAGGAACAG  
2001 GGGTGTGTGT TCCTGGATGA CAGGGAGCTG TTACTACTGA CCGGCACCTG  
2051 TGTGTACCTT GGCACAGGCC GACGTTTCCG GGAGAGCTGT GTGGACATG  
2101 ATCCAAACAG ACCGCTTGA GTTTGTGTTG TGTCTCTCTGA GCATTATGCA  
2151 GCAAGCGACA GAGAAAGCCC AGGACACGTT CCTTCCACGT TGGATGCTGG  
2201 CCTGAGGAC ACGTGCCCAT CAGCAGAGGA GCCAAGGCTG AACGTCCAGG  
2251 TCACCTCCAC GCCGTGATC GTGATGGCG GGGCTGCTGG CTTGACGGG  
2301 GAGATCCAGG AGGTGCTTA CTCGGGAGC TGCTACCATC GAGATGGCTT  
2351 ACGGCTGAGT ATACAGTTTG AGGTGAGCG GGTGGAGCTC CAGGSCCCCA  
2401 CACCTCTGTT CTGCTGTGG CTGGTGAAG ACTCTCTCA CAGCCAAAGC  
2451 GACTCAGCG CCAGGACCCG CCTGTTCTTT GCCAGCTCG CCGGCTCCAC  
2501 CCACCTACC GCTGCTGAGC TCACCGGACC CAGCCTGGTG GAAAGGTGCT  
2551 CAGAGCCAGA CCTGTGTTG AGAGCCCCC CAAAGCTGTG GAACGTGAGG  
2601 GGTGGCGGC CTGTGAGGC GAGTACTCCC AAAAGTACAG TACCATGAGC  
2651 CCGCTGGCA GTGGGCTT CGGCTTCGTG TGGACTGCTG TGGACAAGGA  
2701 AAAAAACAG GAGGTGGTG TGAAGTTTAT TAAAGAGGAG AAGTCTTGG  
2751 AGGATTGTTG GATTGAGGAT CCCAAACTTG GGAAGTTTAC TTTAGAGATC

2801 GCAATTCTAT CCAGGTGGA GCAGCCAAT ATCATCAAGG TATTGGATAT  
2851 ATTTGAAAC CAAGGTTCT TCAGCTTGT GATGGAGAAG CACGGCTCGG  
2901 GCCTAGACCT CTTGCTTTC ATCGACGCC ACCCCAGGCT GGATGAGCCC  
2951 CTGGCGAGCT ACATCTTCCG ACAAGACATC AAGGATGAGA ACATCGTGAT  
3001 CCGCGAGGAC TTCACATCA AGCTGATAGA CTTTGGCTCG GCCGCTACT  
3051 TGGAAAGGGG AAAATTATTT TATACTTTTT GTGGGACCAT CGAGTACTGT  
3101 GCACCGAAG TTCTCATGGG GAATCCCTAC AGAGGGCCGG AGCTGGAGAT  
3151 GTGGTCTCTG GGAGTCACTC TGTACAGCT GGTCTTTGAG GAGAACCCTT  
3201 TCTGTAGCT GGAGGAGACC GTGGAGGCTG CCATACACCC GCCATACCTG  
3251 GTGTCCAAAG AACTCATGAG CTTTGTCTCT GGGCTGCTGC AGCCAGTCCC  
3301 TGAGAGACGC ACCACCTGG AGAAGCTGGT GACAGACCCG TGGGTAAACAC  
3351 AGCCTGTGAA TCTTGTGAC TATACATGGG AAGAGGTGTT TCGAGTAAAC  
3401 AAGCCAG

!!AA\_SEQUENCE 1.0

ID\_ADP31065 standard; protein; 345 AA.

XX AC ADP31065;  
XXXX DT 12-AUG-2004 (first entry)  
XXXX DE Human secreted protein SEQ ID #1832.  
XXXX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XXXX OS Homo sapiens.  
XXXX PN WO2004035732-A2.  
XXXX PD 29-APR-2004.  
XXXX PF 28-AUG-2003; 2003WO-US026780.  
XXXX PR 29-AUG-2002; 2002US-0406576P.  
XXXX PR 29-AUG-2002; 2002US-0406579P.  
XXXX PR 29-AUG-2002; 2002US-0406585P.  
XXXX PR 29-AUG-2002; 2002US-0406588P.  
XXXX PR 29-AUG-2002; 2002US-0406608P.  
XXXX PR 29-AUG-2002; 2002US-0406611P.  
XXXX PR 29-AUG-2002; 2002US-0406616P.  
XXXX PR 29-AUG-2002; 2002US-0406640P.  
XXXX PR 29-AUG-2002; 2002US-0406642P.  
XXXX PR 29-AUG-2002; 2002US-0406653P.  
XXXX PR 29-AUG-2002; 2002US-0406666P.  
XXXX PR 17-SEP-2002; 2002US-0410946P.  
XXXX PR 17-SEP-2002; 2002US-0410948P.  
XXXX PR 17-SEP-2002; 2002US-0410953P.  
XXXX PR 17-SEP-2002; 2002US-0410957P.  
XXXX PR 17-SEP-2002; 2002US-0410958P.  
XXXX PR 17-SEP-2002; 2002US-0410959P.  
XXXX PR 17-SEP-2002; 2002US-0410960P.  
XXXX PR 17-SEP-2002; 2002US-0410961P.  
XXXX PR 17-SEP-2002; 2002US-0410962P.  
XX

XX PR 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411102P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486991P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3063; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX Sequence 345 AA;  
ADP31065 Length: 345 February 22, 2005 12:25 Type: P Check: 5718 ..  
1 ATGGCTGCTT TCCTTTGTGT TGGTGCATCT GCTCTGCTG GACTTTACCG  
51 TGGCCGAGAA GGAGGAATGG TACACCGCCT TCGTGAACAT CACCTACGCC

101 GAGCCGCGC CGACCCCGG GGCCGGGGCG GCGGGCGCG GCGGCGCGGA  
151 GCTGCACAG GAGAAGACGG AGTCCGGGCG CTACGGAGAG CACTGCCCCA  
201 AGCAGGACGC CCGCGGGGAG GTGGTCAATG CCAGCTCGGC CCACGACCGC  
251 CTGGCCTGGC ACCCAACAC CAAGTTTCGCC GCGCCGACCC GCGGCAAGAA  
301 CTGGATAGCC CTCATCCCA AGGCAACTG CACGTACAGG GATAA  
!!AA SEQUENCE 1.0  
ID ADP31075 standard; protein; 366 AA.  
XX ADP31075;  
AC  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1842.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; Immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 17-SEP-2002; 2002US-0411111P.

PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3073; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 366 AA;  
ADP31075 Length: 366 February 22, 2005 12:25 Type: P Check: 8413 ..  
1 CCGCGCGCGG GTCGCGGGCA ACGAGCTGAG GCGCGCGCGG CAGGAATGT  
51 GAGCGAGGAG CCACCGCGG AGCGCAACG GGGTCGGTGC CGATTGATG  
101 GGACGGGCC GCGGGGAGG ATCGTGAGG CGCGCGGCC ACCGGAACG  
151 TGAGTTGCG GTCGCGCGGT GAGCGCTAGA GCGTCGCGG CCGCGGAAC  
201 GGAGGACCC CGTACCGGAC AGCGTCGCC CCAGGCTCCC CGCACTGCC  
251 CGGACTCCC CTGCACGTC CCGTCCCGC CGCCGCCGCC CGTCGCGCC  
301 ACCTCGCGG TCTCCCGCCC CTCGAAGCCA CAGATCATCT TTGGATTCTT  
351 CCCCAGAGC TTCAAG  
IIAA\_SEQUENCE 1.0  
ID ADF31140 standard; protein; 933 AA.  
XX

AC ADF31140;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1907.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.

PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3138; 429pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 933 AA;  
SD  
ADP31140 Length: 933 February 22, 2005 12:25 Type: P Check: 2605 ..  
1 ATGTGGAGT GCGCAAGA GGGCGAGGCC CTCCTCATCC TCAACCTGGT  
51 GACAGACTTG AAGCCCCAGA TGCTGTTGGA CACAGTCCCG TGTCCTCCG  
101 CCTACATCCT CTACATGTGC ATTGCGCTCG CGGACCAAC CACAGATGAT  
151 CTCAGGTGTC ACTCCCTGAT GACCTCCACC ACCAACGGCA TTAAGAAAGT  
201 CCTGAAGAAG CACAGTGATG ACTTTGAGAT GACGTCATTC CTGTTATCCA  
251 ACACCTGCCA CTTTCTTAC TGCTTGAAGC GGTACACGGG GGTAGAGGGC  
301 TTCATGACTC AGAATACAGC AAGACACAAC GAACACTGCC TTAAGAACTT  
351 TGACCTCACC GAATACCGTC AGGTACTGAG CGACCTTTCC ATTCAGATCT  
401 ACCAGCAGCT CTTTAAATTT GCCGAGGGTG TGTTACAGCC GATGATAGTT  
451 TCTGCCATGT TGGAAATGA CAGCAATTCAG GGTCTATCTG GTGTGAAGCC  
501 CACTGGCTCC CAGAACCACT CCTCCAGCAT GGCAGATGGG GATACTCAT  
551 ACGCCTGGA AGCTATCATC CGCCAGATGA ATGCCCTTCA TACAGTCATG  
601 TGTGACCAGG GCTTGGACCC TGAGATCATC CTGCAGGTAT TCAACAGACT  
651 CTTCTACATG ATCAACGCAG TGACTCTTAA TGACCTGCTC CTGCGGAAGG  
701 ACGTCTGCTC TTGGAGACA GGCATGCAAC TCAGGTACAA TATAAGTCAG  
751 CTTGAGGAGT GGCTTTGGGG AAGAAACCTT CACCAGAGTG GAGTAGTTCA  
801 GACCATGAA CCTCTGATCC AAGCAGCCA GCTCCTGCAA TTAAGAAAGA

851 AAACCCAGGA GATGCAGAG GGCATCTGCT CCCTGTGTGC CTCCTCTCAGC  
901 ACCAGCAGA TTGTCAAAAT TTAAACCTT TAG  
!!AA SEQUENCE 1.0  
ID ADP31153 standard; protein; 1092 AA.  
XX  
AC ADP31153;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1920.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406618P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406668P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.



PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486448P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3151; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1092 AA;  
ADP31153 Length: 1092, February 22, 2005 12:25 Type: P Check: 7545 ..  
1 ATGTACTGTG ATNAGGTGTT TCACCGCAAG GATCATCTGC GGAACCAATCT  
51 GCAGACCCAT GACCCTAACA AAGAGGCCCT CCGCTGCTCT GAGTGGGTA  
101 AGAATTACNA TACNAGCTG GGCACCGGC GCCACCTGSC CATGATGCT  
151 GCCACAGCG GTGACCTCAG CTGCAAGGTG TGCCTGSCAG CTTTGTAGAG  
201 TACCCAGGCC CTGCTAGAGC ACCTGAAGGG CCACTCAACG CGGGTAGCAG  
251 GCAGTGCCNA GGAGAGNAG CACCCCTGTG ACCACTGCGA CCGGGGTTTC  
301 TATACTCGTA AGGATGTACA GCGGCACCTA GTGCTGCACA CAGGCCGTGA  
351 GGACTTCTCT GTGCAGTACT GTGCCCCGCG GTTTGSCCGA CCACCTGATG  
401 CGTATGTCA AGAAGAGCCA CTTGCAGGAG GAGCTCAAGA TCAGACAGA  
451 GCCCGTGGG ACATGTTAGG CTTACTTAGC TGCAGCTCCA CAGTCAGTGT  
501 GAAGGAAGAG CTGAGCCCTG TGCTGTGTCAT GGCCTCTCGG GAAGTAATGG  
551 GNACCAAGC CTTCCCTGGC ATGTTGCCCA TGGGCATGTA TGGTGCCCAAC  
601 ATCCCTACCA TGCCCAAGCAG GGGCGTGCAA CACTCTCTGA TGCACAACAC

651 GCTGCCCATG GGTATGAGCT GGCCTCTGGA ATCCTCACCT ATCTCTTCCC  
701 CAGCTCAGCT CCCTCCAAA TACCAGCTTG GATCTACCTC ATACTTGCCC  
751 GACAAATTGC CCAAGTGGG GGTGGATAGT TTTCTGGCGG AGCTTCTCTGG  
801 AAGCCTGTCT CTCTCAGCG CTGAACCCCA GCGCCGCTCA CCTCAGCGGG  
851 CGGCAGCTGC GGCCTCCTA GATGAAGCAC TGTTTGCCA GAGCCCGGCC  
901 AACCTCTCTG AGGCCCTCTG CGCTGCTAAC GTGGACTTCT CCCACCTACT  
951 GGGCTTTTCTT CCACCTAAC TCGCCCGCTG TAACCCACCT GGGCCACGG  
1001 GAGGCTGGT CATGGGCTAC TCCAGGCAG AGGCACAGCC CCTGCTCACC  
1051 ACTTTGCAAG CTCAGCCTCA AGATTCCCA GGAGCGGGGT GA  
!!AA SEQUENCE 1.0  
ID ADP31156 standard; protein; 1104 AA.  
XX  
XX ADP31156;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1923.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.



PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467139P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3222; 428pp; English.  
  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIFOWEB and is not in the specification.

XX Sequence 456 AA;  
SQ  
ADP31224 Length: 456 February 22, 2005 12:25 Type: P Check: 5149  
1 ATGTGTCAG TCGGGTTGCA GTCACCACTC ACAGCTCAAG ATGCTCACCT  
51 GCCCAACTT CCTGTGGCAG TAGTAGAGAC TGTGCTTCCA GTGGAGCAGC  
101 ACTCTGTAAG GGCACAACTT CTGGGGAAC TGGTCATTCC TGGGTCCAGC  
151 CAGCTCTGTG CCACTGCAGC CCTCCAAGCT GGCACCTGGCC AATGTCAGCG  
201 GCAGCTCCTG AGATGCAGAG ATAGGGGAAC TGAAGTTTAC AGGCTGGAG  
251 TCAGTCCCTT GATACCTGCA TTTTCCAGT GGCATCCTGA CACAACCACT  
301 TGCATCTTGG TGGAAATTGCT CTACTATGAA ATTCTTAAGT CCCGTGACCA  
351 TGCCTGCAGG TTGGCAAAAG CAGCTTTTGA TGATGCAATT GCAGAACTGG  
401 ATACGCTGAG TGAAGGAGC TATAATGACA CTATGGACTT CAGGCATGCA  
451 GGGTGA  
  
!!AA SEQUENCE 1.0  
ID \_ADP31246 standard; protein; 176 AA.  
XX  
AC ADP31246;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2013.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.

PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3244; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPONEB and is not in the specification.  
XX  
SQ Sequence 176 AA;  
ADP31246 Length: 176 February 22, 2005 12:25 Type: P Check: 5234 ..  
1 CCAGGCTTCG TGAGCTTCCA CAACCCGCC AGCGCGAGA CGCCCATCCA  
51 GGCCATGAAC GGGTCTCCAGA TCGGCATGAA GAGGCTCAAG GTGCAGCTGA  
101 AGCGGCCCAA AGACGCCAAT CGCCGTACT GAGCGCGGC GGGAGCGTCC

151 CCCGGGGGAG ACCAGGACTC GCACAG  
!!AA\_SEQUENCE 1.0  
ID ADP31340 standard; protein; 861 AA.  
XX  
AC ADP31340;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2107.  
DE  
DE  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406633P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.

PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3338; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 861 AA;  
ADP31340 Length: 861 February 22, 2005 12:25 Type: P Check: 4250 ..  
1 ATGAGACGG CAGCGGACCA ACAGAGACG CTGAGAGAGT TCGTGGTGGT  
51 GATGGGCACT GAGCAGGACC GGGCGCTGCTT CTTCCTCGAG TCGGCTACCT  
101 GGGACTTGCA GATTGCGCTA GCGAGCTTTT ATGAGGACAG AGGGGAAGAA  
151 GACATCATAA CCATTTCACA GGCACCCCTC AGTTGAGTGT CCAGAGGCAC  
201 AGCCCCTAGT GATAATAGAG TGACATCCTT TAGAGATCTC ACTCATGACC  
251 AAGATGAGGA TGAGGAAGAG GAGGAAGGCC AGAGGTTTAA TGCCGGGGCC  
301 TCAGAGAGAA GTGACACAGCA GATTGTGGC CTCCACAGAA AGAAAAGTTC  
351 CAATGAGCTG GTGGATGATC TCTTTAAAGG TGCCAAAGAG CATGGAGCTG  
401 TAGCTGTGGA GCGAGTGACC AACAGACCTG GAGAGACACG TACACCAAGA  
451 CCATTGGCGG GAGATGGCTA TGGCCTTGGG GCAGACACCG AGGAGAGTCT  
501 TGCTTATGTG GCAGGAGAAA AGAGACATCA TTCCAACCAA GATGTTTCATG  
551 TAGTGTGGAG TACCATCTCT CCAGTCCAAC TGGCAGAAAA TGAAGCCAAA  
601 GCCAGCTCTT CCATCTTAAT GTCTGAATCA GAGACTACCA CAACATCCA  
651 AATTCGGCTT GCAGACGGTG GGAGGCTGGT GCAGAAATTT AACCAAGCC

701 ACAGGATCAG CAACATCCAA CTCTTCATTG TGGATGCCCG GCCAGCCATG  
751 GCTGCCACCA GCITTTATCTT CATGACTACT TTCCCCAACA AAGAGCTGGC  
801 TGACGAGAGC TGGACCTCTGA AGGAAGCCAA CCTGTCTCAAT GCTGCCATCA  
851 TCCAGTGGTG A  
!!AA SEQUENCE 1.0  
ID ADP31360 standard; protein; 615 AA.  
XX  
AC ADP31360;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2127.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.

PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT Genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3358; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 615 AA;  
ADP31360 Length: 615 February 22, 2005 12:25 Type: P Check: 6006 ..  
1 ATGCTGGAGA AGCAGGGCCC GGGCCCGGTG CGGGAACGGG GAGGAGTGGT  
51 TGGTGCCTTA GCAACTAAG CTGGCAACTG GGACATCGTC CGGTGCTGCA  
101 GGTCACGCC GAAGGCGCTC GGAACCTCG CTGCGATCGA GCAGTTTCCA  
151 GCCTCTGGG TAAAGGAGCA GTCTCTCTCC TTGCTTGGGA CTCTGGACGC  
201 ATCTCATTC GGTGAAAGAG ATGGGGGTG CGGTGACTCG CGGGATCAGG  
251 AATTTCAGA GAACCGAGG GAAAGGNAA TC CGCAACAT GAAGCCCTCT  
301 CTCGCTTCCA GGCACCCCTTC TACCAGCAGC CTCTCTGCCAG AGCAGATTAG  
351 TCTCTATCCA GAAATTAAGG GAGAGATTGC TCGTAAGAT GACAAGCTGC  
401 TGTCTATTCT AAAATATGTG TGTGTGATT CCAAGATCC TGTGTCTTCC  
451 GTCAGCTGA AAGCTGCTGA AACACGTCAG GAGCCAAAGA AATTCAGATT  
501 GCCGAAAGGC CATCACTTGT ATATGATAAA TATTAAGAGC ATTCCCAAG

551 GCAAAATTTT CACTGTAGAA GCATTGACAC TTTTCAATAA TCATAAAGCTT  
601 TATCCAGAAA CATGA  
!!AA SEQUENCE 1.0  
ID ADP31363 standard; protein; 768 AA.  
XX  
AC ADP31363;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2130.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 18-APR-2003; 2002US-041111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.

PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485219P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3361; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX  
SQ Sequence 768 AA;  
ADP31363 Length: 768 February 22, 2005 12:25 Type: P Check: 5767 ..  
1 ATGGTCACCG AGCGGCTAG CGCGGTGGG AGGCAGAAGA CAGAGAACCG  
51 AACGCCTGG ACCAGGGCA TCCGTGTAA CCGAAGAGCG GTCAGACTC  
101 GGAGGGCAAG GCCCGGGCC CCTTCGCTG CTCCTTTGC CTCCTCTCC  
151 CCCATGCTGG AGAAGCAGG CCCGGGCCG GTCCGGGAC GGGGAGGAGT  
201 GGTGGTGCC TTAGCAACTA AAGCTGCAA CTGGGACATC GTCCGGTGCT  
251 GCAGTCTCA GCCAAGGCG GTCCGAAC TGGCTGCTCT GCGCTCGCAT  
301 CCAGCCTCT GGGTAAAGGA GCAGTCTCT CCTTTGCTTG GGACTCTGGA  
351 CGCATCTCAT TCCGGTAAA GAGATGGGG CTGCGGTGAC TCGCGGGATC  
401 AGGAATTCA AGAAGACCGA GCGGAAGGG AAATCCGCA CATGAAGCCC  
451 TCTCTCGCTC CCAGGCACCC CTCTACCAGC AGCCTCTCTC CAGAGCAGAT  
501 TAGTCTCTAT CCAGAAATTA AGGAGAGAT TCGTCGTAAA GATCACAAGC  
551 TGCTGTGCTT TCTAAATAT GTGTGTGTTG ATTCCAAAGA TCCTGTGTCT  
601 TCCGTGCAGC TGAAGCTGC TGAACACG T CAGGAGCCAA AGAAATTTCAG

651 ATTGCCGAAA GGCCATCACT TTGATATGAT AATATTAAAG AGCATTCCCA  
701 AAGGCAAAAT TTCCACTGTA GAAGCATTGA CACTTTTCAA TAATCATAAA  
751 CTTTATCCAG AAACATGA  
!!AA SEQUENCE 1.0  
ID \_ADP31372 standard; protein; 1848 AA.  
XX  
AC ADP31372;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2139.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.

PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476841P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnenmann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3370; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1848 AA;  
ADP31372 Length: 1848 February 22, 2005 12:25 Type: P Check: 2021 ..  
1 ATGGTGCAG CATCTGTGTC TGGTGAGGCT CTCAGGAAGC TTATAGTCAT  
51 GATGGAAGGC AGAGGAGGAG CAGGAGAGTGC GTATAGTCAG AATGAGAGGT  
101 CTGACTGAA TCTGGAGGAA TTCAACAAT TAGGGGTGAA AGAGAGAAGG  
151 AGAGGGAGC AACATTCAGT AGGAATGGAC AGAGAGGGAG GAGGAAGTCA  
201 GGAGAGCAGC GTGTCTCGGA AGCCAAGTGA AGACAATGTT TCAGGAGGA  
251 GAGTGGAAAC GCTGCTGCCA GGTCACTCTA TTATTGATGG GCATTGGGGT  
301 TGGTTCCAAG TCTTTTCTAT TGTGAAATAGT GCTGCAATAA ACATCTATC  
351 CAGAATCTAC AAAGAATTTA AGCAATATCA AGAGAAAAAC AACCCCATCA  
401 AAAAGTGGC AAAGGATATG AACACACACT TCTCAAAAGA AGACAGTAGA  
451 GCGACCTAA ACATGGAGAC AGCGGGCTCT GGTACTGGGC AGCGGCTTC  
501 TCTGCTGGAG GCTCCGGGT CCACGGATGA CCGGCTTTTC CTGGTTAAAG  
551 GTGGAATTTT CCTTGTAAT GTTGCTGCAG CAGGAACGCT AGCTGGATTT

601 ATTACAACAT TATCATTGGC TAAAAAGAAA AGCCCTGAAT GGTTCATATA  
651 GGAAGATATG GTCAGGACTG CATTACCGGA AGCGGGTCT TCCTTTGGCT  
701 TCGAGCTCT GGGTGGCGC TCACTGTATG CATGGTGTGG GGTGGGTG  
751 ATTAGCTTCT CAGTCTGAA AGCTTTAGGG GTTCACAGTG ACATGCTACA  
801 TCACCAACTT TCTACCCGAG AAGTCGTTTT TCTTCGGGAC CCACAATCA  
851 AGGCTTTTCT CCGGCATGAG AAAGGAGTAA CATTCGCCGC TGCGTGCTAG  
901 CCACTCATG GACACTGGCT CTTCACCTCC GTGAGCAAGA TGGCGACTGT  
951 GAAGAGTGAG CTTATTAGT GCTTCACCTC CGAGGAGGCC TTTCATCACA  
1001 GAAAGGTCTC CATCACAGA ACTGGATCAG TGGGCATGGC CTGCGCTACC  
1051 AGCATCTTAT TAAAGGCTT GAGTGATGAA CTTGCGCTTTG TGGATCTTGA  
1101 TGAAGGCAAA CTGAAAGGTG AGACAATGGA TCTTCAACAT GACAGCCCTT  
1151 TCATGAAAAA GTCAAATATT GTTTGTAGCA AAGATTACCT TGTACAGCA  
1201 AACCCCATC TAGTGATTAT CACAGCAGGT GCACGCCGAG AAAAGGGAGA  
1251 AATGCGCTTT AATTTAGTCC GGCAAAATGT GGCCATCTTC AAGTTAATGA  
1301 TTTCCAGTAT TGTCCAGCAG AGCCCCCTCT GCAAACTAAT TATTGTTTTCC  
1351 AATCCAGTAG ATATCTTAAC TTACGTAGCC TGGAAAGTTGA GTGCATTTCC  
1401 CAAAACCCGT GTTATTGAA CCGCTGTAA TCTGGATACT GTTCGTTTTTC  
1451 AATTCTTCAT TGGACAAAAG CTTGGTATCC ACTCTGAAAG CTGCCGTGGA  
1501 TGGATCCTCG GAGAGCATGG AGACTCAAGT GTTCCTGTGT GGAGTGAAT  
1551 GAACATAGT GGTGTCCTTT TGAAGGATCT GAATCTGTAT ATAGGAAGTG  
1601 ATAAAGATCC TGAGAAATGG AAAAATGTCC ACAAGAAGT GATTGCTAGT  
1651 GCCTATGAGA TTATTGAAT GAAAAGTTCT ACTTCGTGGG CCATTGGCCT  
1701 ATCTGGAGCT GATTAAACAG AAGTATTTT GAAGAATCTT AGGAGAAAAC  
1751 ATCCAGTTTC CACCATAATT AAGGGCCTCT ACGGAATAAA TGAAGAAGTC  
1801 TTCTCAGTA TTCTTCTTTT GGAGAGAAGG GTATTACCAA CCTTATAA  
!!AA\_SEQUENCE 1.0  
ID ADP31409 standard; protein; 906 AA.  
XX  
AC ADP31409;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2176.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR



PR 29-AUG-2002; 2002US-0405585P.  
PR 29-AUG-2002; 2002US-0405588P.  
PR 29-AUG-2002; 2002US-0406080P.  
PR 29-AUG-2002; 2002US-0406111P.  
PR 29-AUG-2002; 2002US-040612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0410966P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411057P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476646P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Halsham L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX

DR WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3407; 428pp; English.  
PS The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
SQ Sequence 906 AA;  
ADP31409 Length: 906 February 22, 2005 12:25 Type: P Check: 4479 ..  
1 ATGGCCGAGA TCCGAGGCG CAGCCAGAG CCGAGGCGG CGGCTGCGG  
51 GCGCGCGCG GCGCGAGAGG TGATCTCTGGT GCTCAGCGCG CCCTTCCTGC  
101 GTTGCCTCC CGCGCCGGCG GCTGGGGCCT CGGGGGGCAC TAGTCCGTCG  
151 GCCACGCAGC CCAACCGCG GGTATTTCATC TTCGAGCACA AGGCGCAGCA  
201 TATCTCGCG TTCATCACA ACAGCCACGA CCTCACCTAC TTTCGCTACC  
251 TGATCAAGGC GCAGCCCGAC GACCCCGAGT CGCAGATGGC CTGCCACGTT  
301 TTCCGCGCA CAGACCCAG CAGGCAAGA CAGGGGCTCG GAGGCGCGG  
351 GCGCGGCTCG GCCTTGGGG ATCGGGGAGC AGGGCGGGAG GGGCGGGGAC  
401 CCCACTTTAA GGACCGACTG AGGTTTGGCT GCAGGCGCGC CGCTTCCACG  
451 TGGCGCGCTC AAGCGCGCG TGGCCCTTC CCTGACCTT GGGAGTGGGA  
501 GAGAAGCGT TCGGGGCTG GCGAGCGGC GGGAGCGGC GCCCGGTAC  
551 AGCAGGGACC CGGAGGAAA AGGACAACG TCCCGGATG GAGGGGAGC  
601 TGGCGCGTCC AAGGACAGC CGTGGAGGAG CGCCCGTCCC GGGAGGACGG  
651 CGGTGCTGCG GGTGTGACCG GAGATGGCTT GCTTGCCTCA GTAGGCTACA  
701 GGAAAGATT GCCCAGGAAT CCAGGCCCAA GCAGTTTAT AATTACTTCA  
751 CTCCTCCGTA TCACTCATAT ATCAGGGATT GAAGCCTTTT ATGATTTAAT  
801 ACCGTATAGT TCAACTTTCA CCAGTTTCTT TGTGAAAA CACTTACGGC  
851 AATTGTAAA AACTTCTGTG GAATGTTAT GCAATGGAAT GTGGGTTAAT  
901 GTTTAG  
!!AA SEQUENCE 1.0  
ID ADP31417 standard; protein; 555 AA.  
XX  
XX ADP31417;  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #2184.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX

WO2004035732-A2.  
 29-APR-2004.  
 28-AUG-2003; 2003WO-US026780.  
 29-AUG-2002; 2002US-0406576P.  
 29-AUG-2002; 2002US-0406579P.  
 29-AUG-2002; 2002US-0406585P.  
 29-AUG-2002; 2002US-0406588P.  
 29-AUG-2002; 2002US-0406608P.  
 29-AUG-2002; 2002US-0406611P.  
 29-AUG-2002; 2002US-0406612P.  
 29-AUG-2002; 2002US-0406616P.  
 29-AUG-2002; 2002US-0406640P.  
 29-AUG-2002; 2002US-0406642P.  
 29-AUG-2002; 2002US-0406646P.  
 29-AUG-2002; 2002US-0406653P.  
 29-AUG-2002; 2002US-0406655P.  
 29-AUG-2002; 2002US-0406666P.  
 17-SEP-2002; 2002US-0410946P.  
 17-SEP-2002; 2002US-0410947P.  
 17-SEP-2002; 2002US-0410948P.  
 17-SEP-2002; 2002US-0410949P.  
 17-SEP-2002; 2002US-0410953P.  
 17-SEP-2002; 2002US-0410957P.  
 17-SEP-2002; 2002US-0410958P.  
 17-SEP-2002; 2002US-0410959P.  
 17-SEP-2002; 2002US-0410960P.  
 17-SEP-2002; 2002US-0410961P.  
 17-SEP-2002; 2002US-0410962P.  
 17-SEP-2002; 2002US-0411019P.  
 17-SEP-2002; 2002US-0411022P.  
 17-SEP-2002; 2002US-0411023P.  
 17-SEP-2002; 2002US-0411024P.  
 17-SEP-2002; 2002US-0411032P.  
 17-SEP-2002; 2002US-0411035P.  
 17-SEP-2002; 2002US-0411037P.  
 17-SEP-2002; 2002US-0411041P.  
 17-SEP-2002; 2002US-0411045P.  
 17-SEP-2002; 2002US-0411046P.  
 17-SEP-2002; 2002US-0411048P.  
 17-SEP-2002; 2002US-0411052P.  
 17-SEP-2002; 2002US-0411055P.  
 17-SEP-2002; 2002US-0411073P.  
 17-SEP-2002; 2002US-0411082P.  
 17-SEP-2002; 2002US-0411101P.  
 17-SEP-2002; 2002US-0411111P.  
 18-APR-2003; 2003US-0463700P.  
 18-APR-2003; 2003US-0463708P.  
 18-APR-2003; 2003US-0463716P.  
 18-APR-2003; 2003US-0463732P.  
 02-MAY-2003; 2003US-0467199P.  
 02-MAY-2003; 2003US-0467201P.  
 02-MAY-2003; 2003US-0467203P.  
 02-MAY-2003; 2003US-0467209P.  
 19-MAY-2003; 2003US-0471306P.  
 19-MAY-2003; 2003US-0471336P.  
 22-MAY-2003; 2003US-0472420P.  
 22-MAY-2003; 2003US-0472430P.  
 09-JUN-2003; 2003US-0476609P.  
 08-JUL-2003; 2003US-0476641P.  
 08-JUL-2003; 2003US-0485218P.  
 08-JUL-2003; 2003US-0485223P.  
 08-JUL-2003; 2003US-0485224P.  
 08-JUL-2003; 2003US-0485325P.  
 14-JUL-2003; 2003US-0486446P.  
 14-JUL-2003; 2003US-0486480P.  
 15-JUL-2003; 2003US-0486891P.  
 15-JUL-2003; 2003US-0486960P.  
 08-AUG-2003; 2003US-0493341P.  
 08-AUG-2003; 2003US-0493370P.  
 08-AUG-2003; 2003US-0493573P.  
 08-AUG-2003; 2003US-0493577P.  
 (FIVE-) FIVE PRIME THERAPEUTICS INC.  
 Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
 Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
 Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
 WPI; 2004-348438/32.  
 New nucleic acid molecule for diagnosing, preventing or treating diseases  
 such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
 genetic, bacterial and viral diseases.  
 Claim 1; SEQ ID NO 3415; 428pp; English.  
 The present invention relates to an isolated nucleic acid molecule  
 encoding a polypeptide which is believed to be cytostatic,  
 antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
 composition and methods are useful for diagnosing, preventing and  
 treating diseases such as proliferative (e.g. cancer), inflammatory,  
 immune, metabolic, genetic, bacterial and viral diseases. The present  
 sequence represents a human secreted protein. The present sequence is  
 available on WIPWEB and is not in the specification.  
 SQ Sequence 555 AA;  
 ADP31417 Length: 555 February 22, 2005 12:25 Type: P Check: 6553 ..  
 1 ATGAATAGGC AGATTCTTAA GGCAGTGGAA CTACAGTATG TAGAGAACAT  
 51 ACACTATGAT GCTGTCATGG TGGATGATGC CATTATAGGC CTGTGAGAAC  
 101 CCATAGAGG CACACCACCA AGAGTGAATG CTGATAAACT GTGGACTTTG  
 151 GTGATGATGA TGTGTCAATT CACAGTCGAC ACTTACATGA ATGCCTGGCT  
 201 ACTGATAAAA CTTTATTTAC AAAAACAGGG TCATCTGCAA ACCCCTGTCT  
 251 TAGAGTCAG ATTTTCTCA GTGATCTACT CAATACCCCT CCGTGGGTTT  
 301 CGTCCCACGC AGAGAAGCGG CATACAAAGA AGGCAACAG GGGTCTGGGC  
 351 CCCACTGCCC CCACTCACTC AGGAGGTCTC CCTCTCACTT GCTGCTCCAG  
 401 TGTCCGTCCT GCTGACCCAA GCATCCAGGC TCCATCCTGC TCGGGCCTGT  
 451 GTTCTCATCG TCCCACCACC CGGCAGTCAT GCAGCCCAACC CCGACCACAC  
 501 ATGCAGAGTC GCTGTCCCCA CCTGCACAAG CTGCCCCCCA CTTCTTCCGG  
 551 TTTAG  
 !!AA SEQUENCE 1.0  
 ID ADP31513 standard; protein; 1662 AA.  
 AC ADP31513;  
 XX 12-AUG-2004 (first entry)  
 DT Human secreted protein SEQ ID #2280.  
 XX  
 DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
 cancer; inflammatory; immune; human secreted protein.  
 KW Homo sapiens.  
 OS  
 PN WO2004035732-A2.  
 XX 29-APR-2004.  
 XX 28-AUG-2003; 2003WO-US026780.  
 XX 29-AUG-2002; 2002US-0406576P.  
 XX 29-AUG-2002; 2002US-0406579P.  
 XX 29-AUG-2002; 2002US-0406585P.  
 XX 29-AUG-2002; 2002US-0406588P.  
 XX 29-AUG-2002; 2002US-0406608P.  
 XX 29-AUG-2002; 2002US-0406611P.  
 XX 29-AUG-2002; 2002US-0406612P.  
 XX 29-AUG-2002; 2002US-0406616P.  
 XX 29-AUG-2002; 2002US-0406640P.  
 XX 29-AUG-2002; 2002US-0406642P.  
 XX 29-AUG-2002; 2002US-0406646P.  
 XX 29-AUG-2002; 2002US-0406653P.  
 XX 29-AUG-2002; 2002US-0406655P.  
 XX 29-AUG-2002; 2002US-0406666P.  
 XX 17-SEP-2002; 2002US-0410946P.  
 XX 17-SEP-2002; 2002US-0410947P.  
 XX 17-SEP-2002; 2002US-0410948P.  
 XX 17-SEP-2002; 2002US-0410949P.  
 XX 17-SEP-2002; 2002US-0410953P.  
 XX 17-SEP-2002; 2002US-0410957P.  
 XX 17-SEP-2002; 2002US-0410958P.  
 XX 17-SEP-2002; 2002US-0410959P.  
 XX 17-SEP-2002; 2002US-0410960P.  
 XX 17-SEP-2002; 2002US-0410961P.  
 XX 17-SEP-2002; 2002US-0410962P.  
 XX 17-SEP-2002; 2002US-0411019P.  
 XX 17-SEP-2002; 2002US-0411022P.  
 XX 17-SEP-2002; 2002US-0411023P.  
 XX 17-SEP-2002; 2002US-0

PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486911P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PR (FIVE-) FIVE PRIME THERAPEUTICS INC.

PA Williams LT, Chu K, Lee E, Heetir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI  
PI

PI  
XX  
DR  
XX  
XX  
PT  
PT  
XX  
XX  
PS  
XX  
CC  
CC  
CC  
CC  
CC  
CC  
CC  
XX  
SQ

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases such as proliferative (e.g. cancer), inflammatory, immune, metabolic, genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3511; 428bp; English.

The present invention relates to an isolated nucleic acid molecule encoding a polypeptide which is believed to be cytostatic, antiinflammatory, immunosuppressive, antibacterial and virucidal. The composition and methods are useful for diagnosing, preventing and treating diseases such as proliferative (e.g. cancer), inflammatory, immune, metabolic, genetic, bacterial and viral diseases. The present sequence represents a human secreted protein. The present sequence is available on WIPWEB and is not in the specification.

Sequence 1662 AA;

ADP31513 Length: 1662 February 22, 2005 12:25 Type: P Check: 3662 ..

1 ATGCAGCACA AGACAGTCAC CCCCAATAGA GGGAAAGTTC CTGATGAAGC

51 CACATCCATA GGAAAGGGG GAGAGTACTA CATCAAGAGA ACACCCTGCA

101 GGACAAAGA ATCTGAACA CAGCCTTCAG CCTAGACCT TCCCTCTGAC

151 AGAGCCTACC CAATGAGAA GGAATCAGAA AACCAACTCT GTCTTCACAA

201 GTTGAGAGAG TGTCTCCCC TCATCATTTT CCTAAGGAAC AGACTTAAGT

251 ATGCCCTGAC AGGAGATGAA GTAAAGATT GCATGCAGG GTTCATTAA

301 GTTGATGGCA AGTACGAAC TGAATAACC TACCCTGCTG GATTCATGGA

351 TGTTCATCAG ATTGACAAGA CGGGAGATAA TTTCATCTGT ATCTATGACA

401 CCNAGGTCG CTTTGTGTA CATCGTATTA CACCCGAGGA GGCTAAGTAC

451 AATTGGGTA AAGTGAAA AATCTTTGTG GGCACAAAAG GAATCCCTCA

501 TCTGTGACT CATGATGCTC ACAGCATCGG CTACCTTGAT CCCCTCATCA

551 AGGAGCAGC CCCAGGCCC GCTCGCACT GGGGCAATGC CAGCAGCTTT

601 CCTGATCAG ATGGGAAGCC CACAGTCCTC TCTCTCAGAG CAGCCACCAC

651 AGGGAGCACA GGACTGGACT TACTCTGCCT CAACAAATTA ATGCTAAAG

701 AAGGAGAAGA CCCTAAAGG GTTGCAACCG GATCTGGGG CCTGCTGCT

751 CCAGGAACAG TGGGATTAGT CCTAGGGTGG TCTAGCCTAT CTAGTAAAGG

801 AATTAATGTG CTCACCTGG TAATTGATAG TGATTATCAC AGAGAGATAT

851 TGGTTATGAT GGACTGAAA GGTCTGCATA TTCTTCCCC TGGATCAAG

901 ATAGCTCAGT TACTGATTTT ATCATACTGG GTCCCCAGTC TCTATGAAA

951 GGAAAGGGG AAGGGAAGTT TTGGGAGCAC AGGAGCCACA GGAGTATATT

1001 GGAATCAATT ATCACTGAT CAAGGACCCA TGAAGAAAT GGAATAAGA

1051 ATTTTACTGG CTTACTGGG ACAGGGGCG AGATTCAAT CATTAGTGA

1101 CAAAACCTGC CAGAACTTG GCTTTGGATA TTTAACCCCT GCAGCAAAA

1151 GGGAAATGA GGAATAGAA CAAGCGTCT CTCAGGGGCA GCTAGATCGC

1201 ATTGATCCAC GTTATTCAAT CCAATTGTTT TATCTTTCTC ACCAAACACT

1251 CCCTACAGG GTTAATPAGGA CAGATGGCCC CCGGCTATG CTTCTPAGAA  
1301 TGGGTTTTT GCCACATACC GGGACTAAA CACTATCTCC CTATAGTCAG  
1351 TTACTTACTA AGTCACTTA TTCAGGCCAC AAACAATGCA ATCAGTCACT  
1401 AGGTTATGAC CCTGATGTCA TCAGGATTCC TTTAAGTAAA AAGCAATTCA  
1451 AAGCAGTATT GCCAGTATCT ATTAATCTGC AAATAGCTTT CTCTGATTAC  
1501 ACAGGACAAA TAGAGCAAT ACTTCTCTGCT GATAACTCC TTTATTTCTTT  
1551 ATCTCATACC CTGTAATCT TACCACACAA AATAGTTTCA TCCTCCATAC  
1601 CTAATGCTTT AACACTGTTT ACTGATGTT CTGCTAACA TGGAAAAGCA  
1651 GCAGTCTGGT AG

!!AA SEQUENCE 1.0  
ID ADP31524 standard; protein; 552 AA.  
AC ADP31524;  
XX  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2291.  
XX  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.

XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.

17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471308P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3522; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 552 AA;

ADP31524 Length: 552 February 22, 2005 12:25 Type: P Check: 7764 ..  
1 ATGCATCTGT GGCAGCAGTT GGACTGGCAA GTGGATGATC TAGGATCCAG  
51 GATGGTTTCA TTATGTGTCT GGCTGTTGGC AAGTTATCAG CCAAGTTGTT  
101 CCTGGCCTT TCTATTCCC CAGTTATTTT CTATGCTTAC TCCCTGCTCT  
151 AAATCCACT GGCTGCTCTT ATTGCTTGCA TGGACTTCAA TATCGCAGTA  
201 CATCACCGGT TCTCTCTTAG AAGCAACCAC GTCTTTGGGA GCAAGAAGTG  
251 GCCTTCTCAG TACTTTTGGG GGATCCACTG GACGAATGAT GCTGAAAGCC

301 AGTGCTGAGG AGATGACCAA GTACCACAGT GATGACTACA TTAATCTCTT  
351 GCACTCCATT CATCTGTGATA ACATGTCTTGA GTACAGCCAG CAGGCACAGA  
401 GATTCAACAT TGGTGAGGAC TGTCAGTAT TTCATGSCCT CTTTGAGTTT  
451 CGTCAGTTGT CTGTGGCGG CTCTGTGGCA AGTTCTGTGA AACTTAATGA  
501 GTGGCAGACA GACATCACCA TGAACACAGC TGCACCATGC AAAGAAGTCT  
551 GA

IIAA SEQUENCE 1.0  
ID ADP31525 standard; protein; 528 AA.

AC ADP31525;

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2292.

DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 29-AUG-2002; 2002US-0406666P.

XX 17-SEP-2002; 2002US-0410948P.

XX 17-SEP-2002; 2002US-0410947P.

XX 17-SEP-2002; 2002US-0410949P.

XX 17-SEP-2002; 2002US-0410953P.

XX 17-SEP-2002; 2002US-0410957P.

XX 17-SEP-2002; 2002US-0410958P.

XX 17-SEP-2002; 2002US-0410959P.

XX 17-SEP-2002; 2002US-0410960P.

XX 17-SEP-2002; 2002US-0410961P.

XX 17-SEP-2002; 2002US-0410962P.

17-SEP-2002; 2002US-041111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
19-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
15-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493373P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3523; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPOWEB and is not in the specification.

SQ Sequence 528 AA;

ADP31525 Length: 528 February 22, 2005 12:25 Type: P Check: 9909 ..

1 ATGACCAAGG CCCTGGGAGC CATGAAGATA GAGGCCACAC TGGACATTTT

51 CAGCTGGGCA GAGAGAGGAA GTTGTTCCTT GGCCTTTCTC ATTCCCAGT

101 TATTTCTTAT GCTTACTCCC TGCTCTAAAC TCCACTGGCT GTCTTTATTG

151 CTTGCATGGA CTTCAATATC GCAGTACATC ACCGGTTCTC TCCTAGAAGC

201 AACCACGTCT TTGGAGGCAA GAAGTGGCCT TCTCAGTACT TTTGGAGGAT

251 CCACTGGACG AATGATGCTG AAAGCCAGTG CTGAGGAGAT GACCAAGTAC

301 CACAGTGATG ACTACATTAA ATCCTTGCAC TCCATTATC CTGTATAACAT

351 GTCTGAGTAC AGCCAGCAGG CACAGAGATT CAACATTTGGT GAGGACTGTCT

401 CAGTATTTC A TGGCCTCTTT GAGTTTCGTC AGTTGCTGT GGGCGGCTCT

451 GTGCAAGTT CTGTGAACT TAATGAGTGG CAGACAGACA TCACCATGAA  
501 CCAGACTGCA CAGTGAAG AAGTCTGA

!!AA SEQUENCE 1.0  
ID ADP31544 standard; protein; 3144 AA.  
XX  
AC ADP31544;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2311.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.

XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.

02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471338P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3542; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 3144 AA;

ADP31544 Length: 3144 February 22, 2005 12:25 Type: P Check: 2234 ..

1 ATGTTTGTGA TTTCTAGGCT GACGCCAGCC CTGCTCTGTT CCACCAAGCCC  
51 TTCCTCTCCC TTCAGGCATG ACATCTCACT TCGCTACAGT GCACGTGTTT  
101 ACCTGAGCCT TGCACCTGCA GATTTCTTAC ATAGGAGATT TGCCTGGCGT  
151 GATCCTGAGT TGCCTGAGGT CATTCACATG CTTTCAGCACC AGTTCCCATC  
201 TGTTTCAGGCA AATGCAGCG CTTACCTGCA GCACCTGTGC TTTGGTGACA  
251 ACAAGTGAA GATGAGGTG TGTAGGTTAG GGGGAATCAA GCATCTGGTT  
301 GACCTTCTGG ACCACAGAGT TTTGGAAGTT CAGAAGAATG CTTGTGGTGC  
351 CCTTCGAAAC CTCGTTTGTG GCAAGTCTAC AGATGAAAT AAAATAGCAA  
401 TGAAGAATGT TGGTGGGATA CTGCCTTGT TGGACTGTT GAGAAATCT  
451 ATTGATGCAG AACTCCCTCC TAGGAAGCAT CTTGCCCTCA GACCACCTGA  
501 GCACCCACIT CCCACTGCGC TGAAGCTGA GATGGTGTG TTCGAGACAC  
551 AGCTGGACCT GAGAGTTCTT TGGAAATTTAT CCTCATGTGA TCGTGTAAAA  
601 ATGACAATCA TTCGAGATGC TCTCTCAACC TTAACAAACA CTGTGATTGT

651 TCCACATTCT GGATCGAATA ACTCTTCTTT TGATGATGAT CATAAAAATTA  
701 AATTTCCAGAC TTCACTAGTT CTGCGTAACA CGACAGGTTG CCTAAGAATA  
751 GGGATGATAA TACCACCTCA GAGCTGTGAG GGGTCAGCAG GTACTTGTGG  
801 AAGGTGCTTA GCACAGTGTG ATCCATGAG CACTCAGAAC CTCAGTCCG  
851 CGGGGAAGA AGCTCGAAG CAATGCGGT CTGCGAGGG GCTGTAGAC  
901 TCACTTTGT ATGTGATCCA CACGTGTGTG AACACATCCG ATTACGACAG  
951 CAAGCATGAG CCCCTTACC TCTCCCTCT GTGCCCGAGT ACAGGCAAT  
1001 CTGCTCATCA TTGTTCAGCT GTGACGACCA TCCAGGATCC TCCTGGGGC  
1051 CGAGGAAGT GMAAGAACA GGAAGAGGG ACTGAAAGTG TCAGGACTTC  
1101 CAAGCGGC CAGTTACTTG GTGTCAAGAT GGACTGGACT AGGAGAGGC  
1151 ATTGGAAGT GTTGATTGT AAGGTTGAGC CTGAGAGAAA AAAGGATGAA  
1201 GAGTGCTCG GAGAGAGAG AGGAATCAA GGGAAACAGC AGTTTTTGAG  
1251 CCTATTGAA CCAGGAGATC TGCAGATGAA ATTGAGAGGA GTTTCAGTAC  
1301 AGAAGTGT TTGCTTAATG TGCCGAGTTG TTTTAAATTA TACGCCATGC  
1351 TGGGTTTCAG ACGGTGGAGA ACTGCGTGTG CACCCTGAGG AACCTGTCTA  
1401 TCGGCTGGAG CTGAGGTGC CCCAGGCCG GTTACTGGGA CTGAACGAAT  
1451 TGGATGACTT ACTAGAAAA GAGTCTCCCA GCAAAAGACTC TGAGCCAAGT  
1501 TCCTGGGA AGAAGAAGA AAGAAAAAG AGGACTCCG AGAAGATCA  
1551 ATGGGATGA GTTGTCTTA TCCAGAGCT GTGGAAGTCC CCCAAGGGG  
1601 TTGAGATGT GTGGACCCA TCGGTGGTAA AACCATATCT GACTCTTCTA  
1651 GCAGAAAGT CCAACCCAGC CACCTTGGAA GGCTCTGCAG GGTCTCTCCA  
1701 GAACCTCTCT GCTGGCACT GGAAGTTTGC AGCATATATC CGGGCGGCCG  
1751 TCCGAAAAGA AAAGGGGCTC CCCATCCTTG TGGAGCTTCT GAGAATGGAT  
1801 AACGATAGG TTGTTCTTC CGTGGCAACA GCCTTGAGGA ATATGGCACT  
1851 AGATGTTGC AACAGGAGC TCATAGGCAA ATACGCCATG CGAGACCTGG  
1901 TCAACCGGCT CCCCGCGGC AATGGCCCCA GTGTCTTGTG TGATGAGACC  
1951 ATGGCAGCA TCTGCTGTC TCTGCAGAG GTCAACAGCA AAACATGGA  
2001 GAACGAAAA GCCCTGGCCG ACTCAGAGG CATAGAGAG CTGGAACGTC  
2051 TTCTTGAATC CCCAGTTCTG GAATTGAGTT TTCTGCCACA TACCAGAAA  
2101 GTATTAAAT TACTGCTCG CAGCAGGGCT GCTGTGTGCG CTCAGGATGT  
2151 GCCCAGGCT TGGATGGCG ATTTCCCTTT GCTTCTGCAT GACACCTCAC  
2201 TGATTAAGCA GGAAGGAGG ACTAGAGAT CAGTGTGTA AATTGAAGGC  
2251 TGCTTGTCTAT GGAGCTGTAG CAGTGACTAT AGTTTGCTT TAGTATCAGA  
2301 TCAGAGAAAT GAGATTCGGA AAGTCTCTGA CCAAAATCAA TTGTCCTCTA  
2351 GCTCCACACA CTAACTTCT TTCAACAAGTA CTTACTGCCT GCCTGCTGTG  
2401 TGCCAGAGC TCTTCTCTAT CTGGGGGTTG CAGCAGCAGA CAGGTGCGAT  
2451 GACAGCCCCA CCCGAGGTAG CTTACGTTCC ATGGGTGAGA TCATCTCTGA

2501 AAGTGGTGAA GGCAGCAGCC CAGGTCTTGA ATACATTATG GCAATATCGG  
2551 GACCTCCGA CAATTATAA AAAGGATGGG TGAATCAGA ACCATTTTAT  
2601 TACACTGTG TCGACATGG AGCGAGCCG ATTCAATCA CATCCTTCT  
2651 TGCTTACCAC CAACCAACAG ATGTCACCA TCATTCAATC AGTCGGCAGC  
2701 ACCTCTTCT CACCAGCACT GTTAGGAATC AGAGACCCCTC GCTCTGAATA  
2751 CGATAGGACC CAGCCACCTA TGCAGTATTA CAATAGCCAA GGGATGCA  
2801 CACATAAAGG CCTGTACCCT GGCTCCAGCA AACCTTCACC AATTACATC  
2851 AGTTCCTATT CCTCACCAGC AAGAGAACA AATAGACGC TACGATCA  
2901 ACAGCTGTAT TATAGTCAAG ATGACTCCAA CAGAAAGAAC TTGATGCAT  
2951 ACAGATTGTA TTGCACTCT CCTCATAGCT ATGAAGATCC TTATTTGAT  
3001 GACCGAGTTC ACTTCCAGC TTCTACTGAT TACTCAACAC AGTATGGACT  
3051 GAAATCGACC ACAATTATG TAGACTTTTA TTCCACTAAA CGACCTTCTT  
3101 ATAGAGCAGA ACAGTACCCA GGTCCCCAG ACTCATGGGT GTAG

## !!AA SEQUENCE 1.0

ID\_ADP31546 standard; protein; 2664 AA.

XX

AC ADP31546;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #2313.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

FN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

PR 29-AUG-2002; 2002US-0406576P.

PR

PR 29-AUG-2002; 2002US-0406579P.

PR

PR 29-AUG-2002; 2002US-0406585P.

PR

PR 29-AUG-2002; 2002US-0406588P.

PR

PR 29-AUG-2002; 2002US-0406608P.

PR

PR 29-AUG-2002; 2002US-0406611P.

PR

PR 29-AUG-2002; 2002US-0406616P.

PR

PR 29-AUG-2002; 2002US-0406640P.

PR

PR 29-AUG-2002; 2002US-0406642P.

PR

PR 29-AUG-2002; 2002US-0406646P.

PR

PR 29-AUG-2002; 2002US-0406653P.

PR

PR 29-AUG-2002; 2002US-0406656P.

PR

PR 17-SEP-2002; 2002US-0410947P.

PR

PR 17-SEP-2002; 2002US-0410948P.

PR

PR 17-SEP-2002; 2002US-0410953P.

PR

PR 17-SEP-2002; 2002US-0410957P.

PR

PR 17-SEP-2002; 2002US-0410958P.

PR

PR 17-SEP-2002; 2002US-0410959P.

PR

PR 17-SEP-2002; 2002US-0410960P.

PR

PR 17-SEP-2002; 2002US-0410961P.

PR

PR 17-SEP-2002; 2002US-0410962P.

PR

PR 17-SEP-2002; 2002US-0411019P.

PR

```
PR 17-SEP-2002; 2002US-0411022P.
PR 17-SEP-2002; 2002US-0411023P.
PR 17-SEP-2002; 2002US-0411024P.
PR 17-SEP-2002; 2002US-0411032P.
PR 17-SEP-2002; 2002US-0411035P.
PR 17-SEP-2002; 2002US-0411037P.
PR 17-SEP-2002; 2002US-0411041P.
PR 17-SEP-2002; 2002US-0411045P.
PR 17-SEP-2002; 2002US-0411046P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411052P.
PR 17-SEP-2002; 2002US-0411055P.
PR 17-SEP-2002; 2002US-0411073P.
PR 17-SEP-2002; 2002US-0411082P.
PR 17-SEP-2002; 2002US-0411101P.
PR 17-SEP-2002; 2002US-0411111P.
PR 18-APR-2003; 2003US-0463700P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 18-APR-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467230P.
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX
XX WPI; 2004-348438/32.
XX
XX New nucleic acid molecule for diagnosing, preventing or treating diseases
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
PT genetic, bacterial and viral diseases.
XX
XX Claim 1; SEQ ID NO 3544; 428pp; English.
XX
XX The present invention relates to an isolated nucleic acid molecule
CC encoding a polypeptide which is believed to be cytostatic,
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The
CC composition and methods are useful for diagnosing, preventing and
CC treating diseases such as proliferative (e.g. cancer), inflammatory,
CC immune, metabolic, genetic, bacterial and viral diseases. The present
CC sequence represents a human secreted protein. The present sequence is
XX available on WIPOWEB and is not in the specification.
XX
XX Sequence 2664 AA;
SQ
ADP31546 Length: 2664 February 22, 2005 12:25 Type: P Check: 2853 ..
1 ATGTTTGTGA TTTCTAGGCT GACGCCAGCC CTGTCGTGTC CCACCAAGCCC
51 TTCCTCTCCC TTCAGGCATG ACATCTCACT TCGCTACAGT GCACGTGTTT
```

```
101 ACCTGAGCCT TGCACCTGCA GATTTCCTAC ATAGGGAGTT TGCCTGGCGT
151 GATCCTGAGT TGCCTGAGGT CAITTCACATG CITTACAGACC AGTTCCCATC
201 TGTTCAGGCA AATGACAGGG CTTACCTGCA GCACCTGTGC TTTGGTGACA
251 ACAAAAGTAA GATGAGGTTG TGTAGGTTAG GGGGAATCAA GCATCTGGTT
301 GACCTTCTGG ACCACAGAGT TTTGGAAGTT CAGAAGNATG CTTGTGGTGC
351 CTTTCGAAAC CTCGTTTTTG GCAAGTCTAC AGATGAAAT AAAATAGCAA
401 TGAAGAATGT TGGTGGGATA CCTGCCTTGT TGCAGACTGT GAGAAAATCT
451 ATTGATGTCAG TACTCCCTCC TAGGAAGCAT CTTGCCCTCA GACCACCTGA
501 GCACCCACTT CCCACTGCGC TGAAGGTGA GATGGTGGTG TTCCGAGCAC
551 AGCTGGACCT GAGAGTTCTT TGGAAATTTAT CCTCATGTGA TGCCTGTAAA
601 ATGACAATCA TTCGAGATGC TCTCTCAACC TTAACAAACA CTGTGATTGT
651 TCCACATTCT GGATGGAATA ACTCTTCTTT TGAATGATG CATAAAATTA
701 AATTTCAGAC TTCACTAGTT CTGCGTAACA CGACAGGTTG CCTAAGAATA
751 GGGATGATTA TACCACCTCA GAGCTGTGAG GGGTCAGCAG GTACTTGTGG
801 AAGGTGCTTA GCACAGTGTG ATCGCATGAG CACTCAGAAC CTCAGTCCG
851 CGGGGGAAGA AGCTCGGAAG CAAATGCGGT CCTGCGAGGG GCTGGTAGAC
901 TCACTGTTGT ATGTGATCCA CAGTGTGTG AACACATCCG ATTACGACAG
951 CAAGCATGAG CCCCTTACCC TCTCCCTCCT GTGCCGAGT ACAGGSCATT
1001 CTGCTCATCA TTTGTCACT GTGACGACCA TCCAGGATCC TCTGGGGGCG
1051 CGAGGAAAGT GGAAGAACA GGAAGAGGG ACTGAAAGTG TCAGGACTTC
1101 CAAAGCGGGC CAGTTACTTG GTGTCAGAT GGAATGGAAT AGGAGAGGCC
1151 ATTGGAAGGT GTTGATTGT AAGGTGAGC CTGAGAGAAA AAAGGATGAA
1201 GAGTGCCTGG GAGAAGAGG AGGAATGCAA GGAACAGGCC AGTTTTTGAG
1251 CCTTATTGAA CCAGGAGATC TGCAGATGAA ATTGAGAGGA TGTTCAGTAC
1301 AGAAGTGTTT TGCTCTAATG TGCCGAGTTG TTTTAAATTA TACGCCATGC
1351 TGGGTTTCAG ACGGTGGAGA ACTGGGTGTG CACCTGAGG AACCTGTCTA
1401 TCGGCTGGAG CTGAGGTGTC CCCAGGCCCG GTTACTGGGA CTGAACGAAT
1451 TGAATGACTT ACTAGGAAA GAGTCTCCA GCAAGACTC TGAGCCAAGT
1501 TGTGCGGGA AGAAGAAGAA AAAGAAAAG AGGACTCCGC AAGAAGATCA
1551 ATGGGATGGA GTTGTGCTTA TCCAGGACT GTCGAAGTCC CCCAAAGGGG
1601 TTGAGATGCT GTGGCACCCA TCGGTGGTAA AACCATATCT GACTCTTCTA
1651 GCAGAAAGTT CCAACCCAGC CACCTTGAAA GGCTTCGAG GGTCTCTCCA
1701 GAACCTCTCT GCTGCAACT GGAAGTTTGC AGCATATATC CGGGCGGCCG
1751 TCCGAAAGA AAAGGGGCTC CCCATCCTTG TGGAGCTTCT GAGATGGAT
1801 AACGATAGAG TTGTTTCTTC GTGGCAACA GCCTTGAGGA ATATGGCACT
1851 AGATGTTGCG AACAAGGAGC TCATAGGCAA ATACGCCATG CGAGACCTCG
```



1901 TCACCGGCT CCCGGGCGC AATGGCCCCA GTGTCTTGTC TGATGAGACC  
1951 ATGGCAGCCA TCTGCTGTGC TCTGCACGAG GTCACCAGCA AAAACATGGA  
2001 GAACGCAAAA GCCCTGGCG ACTCAGGAGG CATAGAGAAG CTGGAACGTC  
2051 TTCTTGAATC CCCAGTTCTG GAATGAGTTT TTTGCGCACA TACCCAGAAA  
2101 GTATTAATAA TACTGCTCTG CAGCAGGGCT GCTGTGTGGC CTCAGGATGT  
2151 GCCCAGGCT TGGATGGCG ATTTCCTTTT GCTTCTGCAT GACACCTCAC  
2201 TGATTAAGCA GGAAGGAGG ACTAGAGAA CTAGGTGAAA AATTAAGGCG  
2251 TGCTTGTCTA GGAGCTGTAG CAGTGACTAT AAGTTTGCCT TAGTATCAGA  
2301 TCAGAGAAAT GAGATTGGA AAGTCTTGA CCAATCAAA TTGTCTCCTA  
2351 GCTCCACACA CTTAACTTCT TTCACAAGTA CTTACTGCCT GCTGTGTG  
2401 TGCCAGACGC TCTTCTCTAT GCTGGGCTTG CAGCAGCAGA CAGGTGCGAT  
2451 GACAGCCCCA CCCGAGTAG CTTACGTTCC ATGGGTGAGA TCATCTCTGA  
2501 AGTGTGTGAA GGCAGCAGCC CAGGTCTTGA ATACATTATG GCAATATCGG  
2551 GACCTCCGGA GCATTATATAA AAGAACAATT GTTCCCCAGC CAGAGAAGAT  
2601 CAAACATAG CTGGTTAAGC CTGTCACTTC CAACACTACC CATGCGAGCG  
2651 AGAACCTTCT GTAG

!!IAA SEQUENCE 1.0  
ID ADP31551 standard; protein; 1476 AA.

XX AC ADP31551;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #2318.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406578P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406609P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0410946P.

PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Heatir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases such as proliferative (e.g. cancer), inflammatory, immune, metabolic, genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3549; 428pp; English.

The present invention relates to an isolated nucleic acid molecule encoding a polypeptide which is believed to be cytostatic, antiinflammatory, immunosuppressive, antibacterial and virucidal. The composition and methods are useful for diagnosing, preventing and treating diseases such as proliferative (e.g. cancer), inflammatory, immune, metabolic, genetic, bacterial and viral diseases. The present sequence represents a human secreted protein. The present sequence is available on WIPWEB and is not in the specification.

Sequence 1476 AA;

ADP31551	Length: 1476	February 22, 2005 12:25	Type: P	Check: 373	..
1	TTTGGCCGAA	GTGGCGGCCA	CAGCTGTAGC	CCCGAAGAGA	ACGAATTTCG
51	GGAGGAGGAG	CGGTTGCTGG	TACTGAGCCC	TGAGGAGCCC	GGGCTTGGCC
101	CAGCGCGGTT	CAGCTGCCCC	CGAGACTGTG	CCTGTTCCCA	GGAGGGCGTC
151	GTGACTGTG	GGGTAATTGA	CCTGGGTGAG	TTCCCGGGGG	ACGTGCTGA
201	GCACACCAAC	CACCTATCTC	TGCAGAACAA	CCAGCTGGAA	AAGATCTACC
251	CTGAGGAGCT	CTCCGGGCTG	CACCGGCTGG	AGACGCTGAA	CCTGCAAAAC
301	AACGGCTCTG	CTTCCGAGG	GCTCCACAG	AAGCGTTTGG	AGCATCTGAC
351	CAACCTCAAT	TACCTGTACT	TGGCCAATAA	CAAGCTGACC	TTGGCACCCC
401	GCTTCCTGCC	AAAGGCCCTG	ATCAGTGTGG	ACTTTGCTGC	CAACTATCTC
451	ACMAGATCT	ATGGGCTCAC	CTTTGGCCAG	AAGCCAAACT	TGAGGGTAGC
501	TTATGGGACC	ACCTCCCAGG	TGGGTGAGGA	CCTGTGCCCT	CCCAGTCTTG
551	TGTACCTGCA	CAACAACAAG	CTGGCAGAGC	CCGGGCTGCC	GGACAACATG
601	TTMACGGCT	CNAGAACGT	CGAGTCTCTC	ATCCTGTCCA	GCAACTTCCT
651	GGCCACAGTG	CCCAAGCACC	TGCGCCCTGC	CCTGTACAAG	CTGCACCTCA
701	AGAACACAA	GCTGGAGAAG	ATCCCCCGGG	GGGCTTTCAG	CGAGCTGAGC
751	AGCTGGCGG	AGCTATACCT	CGAGAACAC	TACCTGACTG	ACGAGGCGCT
801	GGACAACGAG	ACCTTCTGGA	AGCTCTCCAG	CCTGGAGTAC	CTGGATCTGT
851	CCAGCACAA	CCTGTCTCGG	GTCCACAGTG	GGCTGCCCGG	CAGCCTGGTG
901	CTGCTGCACT	TGGAGAAGAA	CGCCATCCGG	AGCGTGGAGC	CGAATGTGCT
951	GACCCCATC	CGCAGCTGG	AGTACCTGCT	GCTGCACAGC	AACCAAGCTG
1001	GGGAGCAGGG	CATCCACCCA	CTGGCCTTCC	AGGCGCTCAA	GCGTTTGAC
1051	ACGGTGCACC	TGTACACAA	CGCGTGGAG	CGGTGCCCA	GTGGCTTGCC
1101	TGCGCGGGTG	CGCACCCCTCA	TGATCTCTCA	CAACCAATC	ACAGGCAATTG
1151	GCCCGGAAGA	CTTTGCCACC	ACCTACTTCC	TGGAGGAGCT	CAACCTCAGC
1201	TACAACCGCA	TCACCAAGCC	GCAGTGCAC	CGGACGCGCT	TCGCGAAGCT
1251	GCGCCTGTGT	CGCTCGTGTG	ACCTGTCCGG	CAACCGGGTG	CACACGCTGC
1301	CACCTGGGCT	GCCTCGAAT	GTCCATGTGC	TGAAGTCAA	GCGCAATGAG
1351	CTGGCTGCGT	TGGCAGAGG	GGCGTGGTG	GGCATGGCTC	AGCTGGCTGA
1401	GCTGTACCTC	ACCAGCAACC	GACTGCGCAG	CCGAGCCCTG	GGCCCCCGTG
1451	CCTGGGTGGA	CCTCGCCCAT	CTGCAG		
!!AA SEQUENCE 1.0					
ID	ADP31620 standard; protein; 588 AA.				
XX	AC	ADP31620;			
XX	AC				
XX	DE				
XX	KW	Human secreted protein SEQ ID #2387.			
XX	DE				
XX	KW	Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;			
XX	KW	cancer; inflammatory; immune; human secreted protein.			

XX	Homo sapiens.
OS	WO2004035732-A2.
XX	
PN	29-APR-2004.
XX	
PD	
XX	28-AUG-2003; 2003WO-US026780.
XX	
PF	
XX	29-AUG-2002; 2002US-0406576P.
PR	29-AUG-2002; 2002US-0406579P.
XX	29-AUG-2002; 2002US-0406585P.
PR	29-AUG-2002; 2002US-0406588P.
XX	29-AUG-2002; 2002US-0406608P.
PR	29-AUG-2002; 2002US-0406611P.
XX	29-AUG-2002; 2002US-0406612P.
PR	29-AUG-2002; 2002US-0406616P.
XX	29-AUG-2002; 2002US-0406640P.
PR	29-AUG-2002; 2002US-0406642P.
XX	29-AUG-2002; 2002US-0406653P.
PR	29-AUG-2002; 2002US-0406655P.
XX	29-AUG-2002; 2002US-0406666P.
PR	17-SEP-2002; 2002US-0410947P.
XX	17-SEP-2002; 2002US-0410948P.
PR	17-SEP-2002; 2002US-0410949P.
XX	17-SEP-2002; 2002US-0410953P.
PR	17-SEP-2002; 2002US-0410957P.
XX	17-SEP-2002; 2002US-0410958P.
PR	17-SEP-2002; 2002US-0410959P.
XX	17-SEP-2002; 2002US-0410960P.
PR	17-SEP-2002; 2002US-0410961P.
XX	17-SEP-2002; 2002US-0410962P.
PR	17-SEP-2002; 2002US-0411019P.
XX	17-SEP-2002; 2002US-0411022P.
PR	17-SEP-2002; 2002US-0411023P.
XX	17-SEP-2002; 2002US-0411024P.
PR	17-SEP-2002; 2002US-0411032P.
XX	17-SEP-2002; 2002US-0411035P.
PR	17-SEP-2002; 2002US-0411037P.
XX	17-SEP-2002; 2002US-0411041P.
PR	17-SEP-2002; 2002US-0411045P.
XX	17-SEP-2002; 2002US-0411046P.
PR	17-SEP-2002; 2002US-0411048P.
XX	17-SEP-2002; 2002US-0411052P.
PR	17-SEP-2002; 2002US-0411055P.
XX	17-SEP-2002; 2002US-0411073P.
PR	17-SEP-2002; 2002US-0411082P.
XX	17-SEP-2002; 2002US-0411101P.
PR	17-SEP-2002; 2002US-0411111P.
XX	18-APR-2003; 2003US-0463700P.
PR	18-APR-2003; 2003US-0463708P.
XX	18-APR-2003; 2003US-0463716P.
PR	18-APR-2003; 2003US-0463732P.
XX	02-MAY-2003; 2003US-0467201P.
PR	02-MAY-2003; 2003US-0467203P.
XX	02-MAY-2003; 2003US-0467230P.
PR	19-MAY-2003; 2003US-0471306P.
XX	19-MAY-2003; 2003US-0471336P.
PR	22-MAY-2003; 2003US-0472420P.
XX	22-MAY-2003; 2003US-0472430P.
PR	09-JUN-2003; 2003US-0476609P.
XX	09-JUN-2003; 2003US-0476641P.
PR	08-JUL-2003; 2003US-0485218P.
XX	08-JUL-2003; 2003US-0485223P.
PR	08-JUL-2003; 2003US-0485224P.
XX	08-JUL-2003; 2003US-0485325P.
PR	14-JUL-2003; 2003US-0486446P.
XX	14-JUL-2003; 2003US-0486480P.
PR	15-JUL-2003; 2003US-0486891P.
XX	15-JUL-2003; 2003US-0486960P.

PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3618; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antitumour, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 588 AA;  
ADP31620 Length: 588 February 22, 2005 12:25 Type: P Check: 5648 ..  
1 ATGGCTCTCTG TGAAGATCAG CCATGTGGTA TCATTTTCTT CTCAGGATCC  
51 CAAGTATCTT GTAGAACT TGCTAAACC AGTAGTCCA AGGACACTT  
101 GGCTCGGCTG CCCTCAGGAC AAGAGTGGC AATTGAAAGT AGAATACAG  
151 CTGGAGAGGG CAGTCCCCAC TGGCTACATT GATGTGGGTA ACTGTGGCTG  
201 TCGGTTCTCTG CAATTTGATG TGGCCATTG TTCTGGCCCC CTGGACAGAC  
251 CTTTCATTAAC CTGCTCCCTT GCAACACGC TAATGTCTCT AACTGATTCA  
301 AAGCAGGGGA AGAACCGCTC CGGGGTCCGC ATGTTTAAAG ATGGTAAAGA  
351 GGGCAAAAGC AGAAAGATG GGGGTGCTCT TTATGAGAAA CAGAGATGCA  
401 GTACTAAAGA GGACTCTCTCA GGAGAGTTAT GGGATCGACT TCGCCTGACC  
451 TGCTCCCGAC CTTTACGCG TCATCAGTCC TTGGGCTGG CCTTTCTACG  
501 GGTGTGTTCT TCTCTGACT CTTAGATGA CTCTGTGGTG GGTCCCTCAG  
551 CCCTTCTGAG CTCTGTGCTG AACAAAGTTT CTGTTTAA  
11AA SEQUENCE 1.0  
ID ADP66690 Standard; protein; 2484 AA.  
XX ADP66690;  
XX 26-AUG-2004 (first entry)  
XX Human mismatch repair protein MLH1.  
XX PMS1; PMS2; PMSR3; PMSR2; PMSR6; MLH1; GTBP; MSH3; MSH1; PMSR;  
KW immunoglobulin; mismatch repair protein; human.  
XX Homo sapiens.  
XX WO2004046330-A2.  
XX 03-JUN-2004.  
PD

XX 14-NOV-2003; 2003WO-US036702.  
XX 15-NOV-2003; 2002US-0427165P.  
PR 10-SEP-2003; 2003US-0501650P.  
XX (MORP-) MORPHOTEK INC.  
XX Graasso L, Liang S, Nicolaides NE, Sass PM;  
XX WPI; 2004-440979/41.  
XX Producing mammalian expression cells producing high-affinity antibodies  
PT from immunized immunoglobulin-producing cells, by combining cells with  
PT antigen, forming parental hybridoma cells and hypermutated hybridoma  
PT cells, using myeloma cells.  
XX Claim 135; SEQ ID NO 12; 213pp; English.  
XX The invention relates to producing mammalian expression cells e.g.,  
CC hybridoma cells producing high-affinity and high titer antibodies from in  
CC vitro immunized immunoglobulin-producing cells. The method involves:  
CC combining donor cells comprising immunoglobulin (Ig)-producing cells with  
CC an immunogenic antigen in vitro, fusing the Ig-producing cells with  
CC myeloma cells to form parental hybridoma cells, where the hybridoma cells  
CC express a dominant negative allele of a mismatch repair gene, incubating  
CC the parental hybridoma cells to allow for mutagenesis, thus forming  
CC hypermutated hybridoma cells, performing a screen for binding of  
CC antibodies to antigen for antibodies produced from the hypermutated  
CC hybridoma cells, and selecting hypermutated hybridoma cells that produce  
CC antibodies with greater affinity for the antigen than antibodies produced  
CC by the parental hybridoma cells, thus producing hybridoma cells producing  
CC high-affinity antibodies. In the method, the dominant negative allele of  
CC a mismatch repair gene comprises a dominant negative allele of a gene  
CC chosen from PMS2, PMS1, PMSR3, PMSR2, PMSR6, MLH1, GTBP, MSH3, or  
CC MSH1, and homologues of PMSR genes. The method is useful for producing  
CC mammalian expression cells e.g., hybridoma cells producing high-affinity  
CC and high titer antibodies from in vitro immunized immunoglobulin-  
CC producing cells. The present sequence represents a human mismatch repair  
CC protein MLH1.  
XX Sequence 2484 AA;  
ADP66690 Length: 2484 February 22, 2005 12:25 Type: P Check: 9406 ..  
1 CTGTGCTCTT CTGGCGCAA AATGTCGTTT GTGGCAGGGG TTATTCGGCG  
51 GCTGGACGAG ACAGTGGTGA ACGCATCGC GCGCGGGGAA GTTATCCAGC  
101 GCGCAGCTAA TGCTATCAA GAGATGATTG AGAACTGTTT AGATGCRAAA  
151 TCCACAAGTA TTCAGTGAT TGTAAAGAG GGAGGCTTGA AGTTGATTCA  
201 GATCCAAGAC AATGGCACC GGATCAGGAA AGAAGATCTG GATATTGTAT  
251 GTGAAAGGTT CACTACTAGT AAATGCACT CTTTGGAGGA TTTAGCCAGT  
301 ATTTCTACCT ATGCTTTTCG AGGTGAGGCT TTGGCCAGCA TAAGCCATGT  
351 GGCTCATGTT ACTATTACAA CGAAACACAGC TGATGGAAG TGTCATACA  
401 GAGCAAGTTA CTCAGATGGA AAATGGAAG CCCCTCCTAA ACCATGTGCT  
451 GGCAATCAAG GGACCCAGAT CAGGTGGGAG GACCTTTTTC ACAACATAGC  
501 CACGAGGAGA AAGACTTTAA AAAATCCAAAG TGAAGAATAT GGGAAAAATTT  
551 TGGAAAGTTG TGGCAGGTAT TCAGTACACA ATGCAGGCAT TAGTTTCTCA  
601 GTTAAAAAAC AAGGAGAGAC AGTAGCTGAT GTTAGGACAC TACCAATGC  
651 CTCACCCGTG GACAATATTC GCTCCATCTT TGGAAATGCT GTTAGTCGAG

701 AACTGATAGA AATTGGATGT GAGGATAAAA CCTAGCCTT CAAAATGAAT  
751 GGTACATAT CCAATCGAAA CTACTCAGTG AAGAAGTGCA TCTTCTTACT  
801 CTTTCATCAAC CATCGTCTGG TAGAATCAAC TTCTTTGAGA AAAGCCATAG  
851 AAACAGTGTA TGCAGCCTAT TTGCCCAAAA ACACACACCC ATTCTGTATC  
901 CTCAGTTTAG AAATCAGTCC CCAGAAATGTG GATGTTAATG TGCACCCAC  
951 AAAGCATGAA GTTCACTTCC TGCACGAGGA GAGCATCCTG GAGCGGGTGC  
1001 AGCAGCATAT CGAGAGCAAG CTCCTGGGCT CCAATTCTCT CAGGATGTAC  
1051 TTCAACCAGA CTTTGTCTAC AGGACTTGGT GGCCCTCTCT GGGAGATGGT  
1101 TAAATCCACA ACAAGTCTGA COTCGTCTTC TACTTCTGGA AGTAGTGATA  
1151 AGGTCTATGC CCACCAGATG GTTCGTACAG ATTCCCGGGA ACAGAAGCTT  
1201 GATGCATTTT TGCAGCCTCT GAGCAAAACC CTGTCCAGTC AGCCCCAGGC  
1251 CATTTGCACA GAGGATAAGA CAGATATTTC TAGTGGCAGG GCTAGGCAGC  
1301 AAGATGAGGA GATGCTTGAA CTCCAGGCC CTGCTGAAGT GGCTGCCAAA  
1351 AATCAGAGCT TGGAGGGGA TACAACAAG GGGACTTCAG AAATGTCAGA  
1401 GAAGAGAGGA CTTACTTCCA GCAACCCCGAG AAAGAGACAT CGGGAAGATT  
1451 CTGATGTGGA AATGTTGGAA GATGATTCCC GAAAGGAAT GACTGCAGCT  
1501 TGTACCCCC GGAAGAGGAT CATTAACCTC ACTAGTGTTC TGAGTCTCCA  
1551 GGAAGAAATT AATGAGCAGG GACATGAGGT TCTCCGGGAG ATGTTGCATA  
1601 ACCACTCCTT CGTGGGCTGT GTGAATCCTC AGTGGGCTT GGCACAGCAT  
1651 CAACCAAGT TATACCTTCT CACACACCAC AAGCTTAGTG AAGACTGTT  
1701 CTACAGATA CTCATTATG ATTTTGCCAA TTTTGGTGT CTCAGGTTAT  
1751 CGGAGCCAGC ACGCTCTTT GACCTTGCCA TGCTTGCTT AGATAGTCCA  
1801 GAGAGTGGCT GGACAGAGGA AGATGGTCCC AAAGAAGGAC TTGCTGAATA  
1851 CATTTGTTAG TTTCTGAAGA AGAAGGCTGA GATGCTTTGA GACTATTTCT  
1901 CTTTGGAAAT TGATGAGGAA GGGAACTTGA TTGGATTACC CCTTCTGATT  
1951 GACAACTATG TGGCCCTTTT GGAGGGACTG CTTATCTTCA TTCTTCGACT  
2001 AGCCACTGAG GTGAATTGGG ACGAAGAAAA GGAATGTTTT GAAAGCCTCA  
2051 GTAAGAATG CGCTATGTTT TATTTCCATCC GGAAGCAGTA CATATCTGAG  
2101 GAGTCGACCC TCTCAGGCA CCAGAGTGAA GTGCTCTGGT CCAATTCAAA  
2151 CTCCTGGAAG TGGACTGTGG AACACATTTGT CTATAAAGCC TTGCGCTCAC  
2201 ACATTCCTGC TCTTAAACAT TTCACAGAAG ATGGAATAT CTTGCAGCTT  
2251 GCTAACCTGC CTGATCTATA CAAGTCTTTT GAGAGGTGTT AAATATGGTT  
2301 ATTTATGCAC TGTGGGATGT GTTCTTCTTT CTCTGTATTC CGATACAAAG  
2351 TGTGTTATCA AAGTGTGATA TACAAGGT ACCAACATAA GTGTTGGTAG  
2401 CACTTAAGAC TTATACTTGC CTTCTGATAG TATTCCTTTA TACACAGTGG  
2451 ATTGATTATA AATAAATAGA TGTGTCTTAA CATA

!!AA\_SEQUENCE 1.0

ID ADQ76348 standard; protein; 1036 AA.  
XX ADQ76348;  
AC  
XX  
DT 09-SEP-2004 (first entry)  
XX  
DE Bovine recessive oncogene bgl-1-related protein.  
XX  
KW bovine; cow; recessive oncogene; bgl-1.  
XX  
OS Bos taurus.  
XX  
PN KR2003088682-A.  
XX  
PD 20-NOV-2003.  
XX  
PF 14-MAY-2002; 2002KR-00026510.  
XX  
PR 14-MAY-2002; 2002KR-00026510.  
XX  
PA (BAEK/) BAEK K H.  
PA (CHAB-) CHABIOTECH CO LTD.  
XX  
PI Baek KH, Jung HM, Kim YS;  
XX WPI; 2004-255638/24.  
DR  
XX Recessive oncogene of bovine bgl-1 cdna and protein encoded thereby.  
PT Disclosure; SEQ ID NO 3; 24pp; Korean.  
PS  
XX  
CC The invention comprises the amino acid and coding sequence of a bovine  
CC recessive oncogene - bgl-1. The present sequence is shown in the  
CC specification as a 3-letter protein, however once it is changed to 1-  
CC letter code it matches exactly to the first 1036 bases of ADQ76346.  
XX  
SQ Sequence 1036 AA;  
ADQ76348 Length: 1036 February 22, 2005 12:25 Type: P Check: 1208 ..

1 ATGATGAAGT TTGGTTCCG GCGCAGGGC GCAGACCCGC AGCGCGAGAA  
51 GCTCAAGCAG GAGCTCTTCG CTTCCACAA GACTGTGGAG CATGCTTCC  
101 CCAACAGCC CAGCGCTTG GCCTTCACC CGGAGCTTCG CATCATGGCC  
151 ATCGGCACCA GATCTGGGC TGTCAGATC TATGGGGCAC CCGAGTGGA  
201 ATTTACAGC CTACACCGG ATGCGGCCAC TGTCACCCAG ATGCATTTCC  
251 TGCCTGGTCA GGGCCGACTT CTGACCTGT TAGACGACAG CAGCTTACAT  
301 CTGTGGGAAA TCATCCAGC TAATGGCTGT GCCATCTGG AGGAAGGGCT  
351 CAGCTTCCAC CCACCCAGCC GGCCAGTTT TGACAATGCC AGTTTCCCTG  
401 CCGCTTAAC CCGAGTCACT GTGTCTCTGC TGGCAGCTGG CGATACCGTG  
451 GTTCTGGGA CCGAGAGTGG TAGCATATTC TTCTTGGATG TCGCCACCCCT  
501 GGCACTGCTG GAGGGGCAGA CTCTCAGCCC AGATGAGGTC CTGCGCAGCG  
551 TGGCAGATGA CTACCGGTGT GGAAGGCCT TGGGCCCTGT GGAGTCACATC  
601 CAGGGACATC TGCAAGACCC CAGCAAGATC CTTATAGGCT ATAGTCGGGG  
651 CTTACTGGTC ATCTGGAGCC AGGCCACACA GTCTGTGGAG CACGTTTTCC  
701 TGGGTAACCA GCAGCTGGAG AGCTGTGTT GGGGGCGTGG TGGCAGCAAC  
751 ATTATCAGCT CACATAGTGA TGGCAGCTAT GCCATCTGTT CCACAGACAC  
801 TGGCAGCCCC CCAAGCTTC AGCCCACTGT AGTGACCACA CCTTATGGCC

851 CCTTCCCTG CAAGGCCATC AACAGATTG TGTGGCGGAG CTGTGAGTCA  
901 GGAGACCACT TTATCATCTT CAGTGGTGGC ATGCCTCGAG CCAGCTATGG  
951 TGACCCGCCAC TGTGTGTGTG TACTGGGGG AGAGACACTG GTGACCCCTGG  
1001 ACTTCACTC TCGTGTCACT GACTTCTTCA CGGTGC

!!AA SEQUENCE 1.0  
ID ADQ10419 standard; protein; 3046 AA.  
AC ADQ10419;  
XX  
XX 09-SEP-2004 (first entry)  
XX Human polypeptide #233.  
XX  
XX Human; cancer; obesity; gastritis; diarrhea; haemorrhoid; asthma;  
KW anaemia; graft-versus-host reaction; allergic reaction; cystic fibrosis;  
KW hypogonadism; cardiovascular disorder; arthritis; osteoarthritis;  
KW arteriosclerosis; hypertension; bacterial infection; psoriasis;  
KW diabetes mellitus; hepatitis; Alzheimer's disease; Huntington's disease;  
KW Parkinson's disease; AIDS; tuberculosis; viral infection; malaria;  
KW goiter; infertility; endometriosis; muscular disorder.  
XX  
OS Homo sapiens.  
XX  
XX US2004121396-A1.  
XX  
XX 24-JUN-2004.  
XX  
XX 19-DEC-2003; 2003US-00741790.  
XX  
XX 14-JUN-1999; 99US-00333159.  
XX 29-JUN-1999; 99US-00342364.  
XX 10-SEP-1999; 99US-00393996.  
XX 19-OCT-1999; 99US-00420707.  
XX 07-JAN-2000; 2000US-00479249.  
XX 27-APR-2000; 2000US-00559497.  
XX 24-MAY-2000; 2000US-00578063.  
XX 16-JUN-2000; 2000US-00596194.  
XX 23-JUN-2000; 2000US-00602871.  
XX 30-JUN-2000; 2000US-00608452.  
XX 12-JAN-2001; 2001US-00759130.  
XX (MILL-) MILLENNIUM PHARM INC.  
XX  
XX Fraser CC, Barnes TM, Sharp JD, Kirst SJ, Myers PS, Leiby KR;  
PI Holtzman DA, McCarthy SA, Wrighton N, Mackay CR, Goodearl ADJ;  
XX  
XX WPI; 2004-479675/45.  
XX  
XX New TANGO, INTERCEPT, and MANGO, useful in diagnosing, preventing, and  
PT treating cancer, constipation, hemorrhoids, cystic fibrosis,  
PT hypogonadism, psoriasis, hepatitis, Alzheimer's disease, AIDS,  
PT tuberculosis, malaria, goiter, infertility.  
XX  
XX Disclosure; SEQ ID NO 441; 483pp; English.  
XX  
XX The invention relates to human polynucleotides and the polypeptides they  
CC encode. The invention also relates to a host cell containing a  
CC polynucleotide of the invention, an antibody which selectively binds with  
CC a polypeptide of the invention, a method of detecting the presence of a  
CC polypeptide in a sample, a method of identifying a compound which binds  
CC with a polypeptide, and a method of modulating the activity of a  
CC polypeptide. The polynucleotides, polypeptides and compositions are  
CC useful for diagnosing, preventing and/or treating cancer, obesity,  
CC gastritis, diarrhea, haemorrhoids, asthma, anaemia, graft-versus-host  
CC reactions, allergic reactions, cystic fibrosis, hypogonadism,  
CC cardiovascular disorders, arthritis, osteoarthritis, arteriosclerosis,  
CC hypertension, bacterial infections, psoriasis, diabetes mellitus,  
CC hepatitis, Alzheimer's disease, Huntington's disease, Parkinson's

CC disease, AIDS, tuberculosis, viral infections, malaria, goiter,  
CC infertility, endometriosis, wounds and muscular disorders. This sequence  
CC represents a human polypeptide of the invention. Note: The sequence data  
CC for this patent did not form part of the printed specification but was  
CC obtained in electronic format from USPTO at  
CC seqdata.uspto.gov/sequence.html.  
XX  
XX Sequence 3046 AA;

ADQ10419 Length: 3046 February 22, 2005 12:25 Type: P Check: 8145 ..  
1 CTCGGAGGCC TGGGTTAGGG GTCTGTACTG CTGGGGNAAC ATCTGGTGAC  
51 CATCTCAGGC TGACCATGGC CCTACCATCC CTGGGCCAGG ACTCATGGAG  
101 TCTCTGTGGT GTTTTTTTCT TCCAACTCTT CCTGTGTCCA TCACGTGCCAC  
151 CTGCTTCTGG GACTGTGGGT CAGGGGCCCA TGCCCNAGAT CAATATACAT  
201 GCTGGAGAGC GGCACAGGGC CCTCAGCTTC TTCCAACAAA AAGGCCTCGG  
251 AGACTTTGAC ACGCTGTCTC TGAGTGACGA TGCAACACT CTCTATGTGG  
301 GGGCTCGAGA GACGTCTCTG GCCTTGAATA TCCAGAACCC AGGAATCCCA  
351 AGGCTAAAGA ACATGATACC CTGGCCAGCC AGTGAGAGAA AAAAGACCGA  
401 ATGTGCTTTT AAGAAGAAGA GCAATGAGAC ACAGTGTTC AACTTCATTC  
451 GAGTCTGTGT CTCTTACAAT GCTACTCACC TCTATGCCCTG TGGGACCTTT  
501 GCCTTCAGCC CTGCTGTGTAC CTTCATTGAA CTCCAAGATT CCTCTCTGTT  
551 GCCCATCTTG ATAGACAAGG TCATGGACGG GAAGGCCCAA AGCCCTTTGA  
601 CCTGTCTCAC AAGCACAAA GCTGTCTTGG TCGATGGGAT GCTTTATTCC  
651 GGCACCATGA ACAACTTCTT GGGCAGCGAG CCATCTCTGA TCGGACACT  
701 GGGATCCCAT CCTGTTCTCA AGACTGNACAT CTCTTACGC TGGCTGCACG  
751 CGGATGCCTC CTTCGTGGCA GCCATTCCAT CCACCCAGGT CGTCTATTTC  
801 TTCTTTGAGG AGACAGCCAG CGAGTTTGAC TTCTTTGAG AGCTGTATAT  
851 ATCCAGGTG GCTCAAGTCT GCAAGAACGA CGTGGGGGT GAAAAGCTGC  
901 TGCAGAAGAA GTGACCACC TTCTCAAAG CCCAGTTGCT CTGGCTCAG  
951 CCAGGCAGC TGCCATTCAA CATCATCCG CACGGGTCC TGCTGCCCGC  
1001 CGATTCTCCC TCTGTTTCCC GCATCTACGC AGTCTTTACC TCCCAGTGGC  
1051 AGTTTGGCGG GACCAGAGC TCAGCAGTCT GTGCCTTCTC TCTCAGGAC  
1101 ATTGAGCAG TCCTTAAAGG GAAGTACAAG GAGCTGAACA AGGAGACCTC  
1151 CGCTGGACC ACTTACCGG GCTCAGAGT CAGCCCGAGG CCAGGCAGTT  
1201 GCTCCATGG CCCCTCTCT GACAAAGCCT TGACCTTTCAT GAAGACCAT  
1251 TTTCTGATGG ATGAGCAGT GGTAGGAACA CCCCTGCTGG TGAAGTCTGG  
1301 TGTGAGTAC ACACGGCTTG CTGTGAGTC AGCTCGGGC CTTGATGGA  
1351 GCAGCATGT GGTATGTAT CTGGGTACCT CCACGGGTCC CCGCACAAAG  
1401 GCTGTGGTC CTCAGGACAG CAGTGTCTAT CTCTGGAGG AGATTACGT  
1451 GAGCCTGAC TCTGAGCTG TTCGAAACCT GCAGCTGGCC CCGCCCCAGG  
1501 GTGCAGTGT TGCAGGCTTC TCTGGAGGCA TCTGGAGAGT TCCCAGGGCC

1551 AATTGCAGTG TCTACAGAG CTGTGTGAC TGTGTGCTTG CCAGGACCC  
1601 TCACTGTGCC TGGGACCTCG AATCAAGACT CTGCAGCCTT CTGTCTGGCT  
1651 CTACCAAGCC TTGGAAGCAG GACATGGAAC CGGCAACCC GGAGTGGTA  
1701 TGCACCCGTG GCCCATGGC CAGGAGCCCC CGGCGTCAGA GCCCCCTCA  
1751 ACTAATTAAA GAAGTCCTGA CAGTCCCCAA CTCATCTCTG GAGCTGGCT  
1801 GCCCCCACT GTACGACTG GCCTCTTACC ACTGGATCA TGGCCAGCC  
1851 AAAATCTCAG AAGCCTCTGC TACCCTTAC AATGCTCCC TCTTGTGCT  
1901 GCCCAGGAT GGTGTGGGG GCCTCTACCA GTGTGTGGG ACTGAGAAG  
1951 GCTACTCATA CCTGTGGTC TCCTATTGGG TAGACAGCA GACACAGCC  
2001 CTGGCGCTGG ACCCTGAGCT GCGGGCGTTC CCCGTTGAGC GTGTGAGGT  
2051 CCCGCTGACC AGGGTCGGAG GCGGAGCTTC CATGGCTGCC CAGCGTCTCT  
2101 ACTGGCCCCA TTTTCTATC GTTACCGTTC TCCTGGCCAT CGTGTCTCTG  
2151 GGAAGTGCTCA CTCTCCTCT CGCTTCCCCA CTGGGGGCGC TGGGGGCTCG  
2201 GGGTAAGGTT CAGGGCTGTG GGAATCTGCC CCCCAGGGA AAGGCTCCAC  
2251 TGAGCAGGGA CAGACCTTC CAGCCCTCA AGGACACAG GACCTTGCC  
2301 AGTGAAGTAG ATGCCGACAA CAACCATCTG GCGCCGGAAG TGGCTTAAAC  
2351 AGGACACAG ATCCGAGCT GAGCAGAGCA AGCCACTGGC CTTGTTGGCT  
2401 ATGCCAGGCA CAGTGCACCT CTGACACAGG TAGGAGGCTC TCTGTGTAAC  
2451 GTGTGTCAAC TACAGCACCC AGTAGGTCCT CCCCTGTGGG ACTCTCTTCT  
2501 GCAAGCACAT TGGGCTGTCT CCATACCTGT ACTTGTGCTG TGACAGGAAG  
2551 AGCAGACAG GTTCTTTGA TTTTGATTGA CCCAAGAGCC CTGCCGTGTA  
2601 CAAACGTGCT CCAGGAGACC ATGAAGGTG TGGCTGTCTG GGAATCTGTG  
2651 GTGACARACC TAAGCATCCG ACRAAGCTGG GGCTATTCTT GCAAACTCCA  
2701 TCTGGAAGCC TGTCACTCTA GAAGCAGCTG CTGCTTTGAA CACAGGCCA  
2751 CCCTCCTTCC CAAGAGTCTC TATGGAGTTG GCCCCTTGTG TTTCTTTTAC  
2801 CAGTCGGGCC ATACTGTTG GGAAGTCATC TCTGAAGTCT AACCACTTC  
2851 CTTCTTGGTT CAGTTTGGAC AGATTGTTAT TATGTCTCT GCCTGGCTA  
2901 GAATGGGGGC ATAATCTGAG CCTTGTCTCC TTGTCCAGTG TGGCTGACCC  
2951 TTGACCTCTT CCTTCTCTCT CCCTTGTGTT TGGGATTCAG AAACTGCTT  
3001 GTCACAGACA ATTTATTTTT TATTAATAAA GATATAAGCT TTAAG

!1AA SEQUENCE 1.0  
ID ADQ10186 standard; protein; 678 AA.  
AC ADQ10186;  
XX  
XX  
DT 09-SEP-2004 (first entry)  
XX  
XX Human polypeptide #55.  
XX  
XX Human; cancer; obesity; gastritis; diarrhoea; haemorrhoid; asthma;  
KW anaemia; graft-versus-host reaction; allergic reaction; cystic fibrosis;  
KW hypogonadism; cardiovascular disorder; arthritis; osteoarthritis;  
KW arteriosclerosis; hypertension; bacterial infection; psoriasis;

diabetes mellitus; hepatitis; Alzheimer's disease; Huntington's disease;  
KW Parkinson's disease; AIDS; tuberculosis; viral infection; malaria;  
KW goiter; infertility; endometriosis; muscular disorder.  
XX  
OS Homo sapiens.  
XX  
PN US2004121396-A1.  
XX  
XX 24-JUN-2004.  
XX  
PF 19-DEC-2003; 2003US-00741790.  
XX  
XX 14-JUN-1999; 99US-00333159.  
PR 29-JUN-1999; 99US-00342364.  
PR 10-SEP-1999; 99US-00393996.  
PR 19-OCT-1999; 99US-00420707.  
PR 07-JAN-2000; 2000US-00479249.  
PR 27-APR-2000; 2000US-00559497.  
PR 24-MAY-2000; 2000US-00578063.  
PR 16-JUN-2000; 2000US-00596194.  
PR 23-JUN-2000; 2000US-00602871.  
PR 10-JUN-2000; 2000US-00608452.  
PR 12-JAN-2001; 2001US-00759130.  
XX  
(MILL-) MILLENNIUM PHARM INC.  
XX  
PI Fraser CC, Barnes TM, Sharp JD, Kirst SJ, Myers PS, Leiby KR;  
PI Holzman DA, McCarthy SA, Wrighton N, Mackay CR, Goodearl ADJ;  
XX  
XX WPI; 2004-479675/45.  
XX  
XX New TANGO, INTERCEPT, and MANGO, useful in diagnosing, preventing, and  
PT treating cancer, constipation, hemorrhoids, cystic fibrosis, and  
PT hypogonadism, psoriasis, hepatitis, Alzheimer's disease, AIDS,  
PT tuberculosis, malaria, goiter, infertility.  
XX  
XX Disclosure; SEQ ID NO 133; 483pp; English.  
XX  
XX The invention relates to human polynucleotides and the polypeptides they  
CC encode. The invention also relates to a host cell containing a  
CC polynucleotide of the invention, an antibody which selectively binds with  
CC a polypeptide of the invention, a method of detecting the presence of a  
CC polypeptide in a sample, a method of identifying a compound which binds  
CC with a polypeptide, and a method of modulating the activity of a  
CC polypeptide. The polynucleotides, polypeptides and compositions are  
CC useful for diagnosing, preventing and/or treating cancer, obesity, host  
CC gastritis, diarrhoea, haemorrhoids, asthma, anaemia, graft-versus-host  
CC reactions, allergic reactions, cystic fibrosis, hypogonadism,  
CC cardiovascular disorders, arthritis, osteoarthritis, arteriosclerosis,  
CC hypertension, bacterial infections, psoriasis, diabetes mellitus,  
CC hepatitis, Alzheimer's disease, Huntington's disease, Parkinson's  
CC disease, AIDS, tuberculosis, viral infections, malaria, goiter,  
CC infertility, endometriosis, wounds and muscular disorders. This sequence  
CC represents a human polypeptide of the invention. Note: The sequence data  
CC for this patent did not form part of the printed specification but was  
CC obtained in electronic format from USPTO at  
CC seqdata.uspto.gov/sequence.html.  
XX  
XX Sequence 678 AA;

ADQ10186 Length: 678 February 22, 2005 12:25 Type: P Check: 2811 ..

1 ATGGCAACCT ACGCTCTTCA AATGGCTGCA CTGGTGTCTG GTGGTGTGG  
51 CATGTGGGC ACGTGGCTG TGACTATCAT GCCTCAGTGG AGAGTGTCTG  
101 CCTTCATCGA AAGTAACATT GTGGTGTGTT AGAACCGCTG GGAAGGCTTG  
151 TGGATGAATT GTATGAGGCA TGCCAACATC AGAATGCAGT GCAAGGTCTA  
201 CGACTCCCTG CTGGCTCTTA GTCCAGACCT CCAGGCATCC CGAGGACTGA  
251 TGTGTGCTGC GTCCGTCTTG GCTTTCTTGG CTTTCATGAC AGCCATCCTC

301 GGAATGAAGT GCACGAGATG CACGGGGGAC GATGAGAAGC TGAAGAGCCG  
 351 CATCTTGCTG ACAGCGGGAA TCATCTTCTT CATCACGGC TTGTTGTGTC  
 401 TCATCCCTGT CAGCTGGGTT GCCAATTCCA TCATCAGAGA CTTCTACAAC  
 451 CCACTGGTGG ATGTGGCCCT AAAGCGGAG CTGGGAGAAG CCTCTTACAT  
 501 AGGCTGGACC ACAGCGCTGG TGCTGATCGC TGGAGGAGCA CTGTTCTGTT  
 551 GTGTGTTTGG TTGTACTGAA AGGAGCAACA GTTACAGGTA CTCGGTACCA  
 601 TCCATCGCA CCACTCAAGC GAGTTTCAC GCCGAAAGA GATCTCCGAG  
 651 CATATACTCC AAAAGTCAGT ATGTGTAG

!!AA\_SEQUENCE 1.0  
 ID ADQ35137 standard; protein; 101 AA.

XX AC ADQ35137;

XX DT 23-SEP-2004 (first entry)

XX DE Mutant cyanovirin-N protein SEQ ID NO:2.

XX KW antiviral; cyanovirin-N; CV-N; anti-HIV; virucide; infection;  
 KW high mannose envelope virus; immunodeficiency virus; influenza virus;  
 KW measles virus; herpes virus 6; marburg virus; ebola virus;  
 KW HIV-inactivating protein; cyanobacterium; Nostoc ellipsoforum; mutant.

XX OS Nostoc ellipsoforum.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Misc-difference 48

XX FT /label= Cys, Arg

XX FT Misc-difference 84

XX FT /label= Cys, Arg

XX FT Misc-difference 99

XX FT /label= Cys, Arg

XX PN WO2004056852-A2.

XX PD 08-JUL-2004.

XX PF 18-DEC-2003; 2003WO-US040585.

XX PR 19-DEC-2002; 2002US-0435950P.

XX PR 09-APR-2003; 2003US-0461731P.

XX PA (NEKT-) NEKTAR THERAPEUTICS AL CORP.  
 XX (USSH ) US DEPT HEALTH & HUMAN SERVICES.

XX PI Snell ME, Roberts MJ, Mori T, O'keefe BR, Boyd MR;

XX DR WPI; 2004-525422/50.

XX PT Novel antiviral polypeptide having sequence identity to native cyanovirin  
 PT -N and having cysteine substitution or insertion or arginine  
 PT substitution, useful for treating or preventing infection of influenza  
 PT virus or measles virus.

XX PS Disclosure; SEQ ID NO 2; 75pp; English.

XX CC The present invention describes an antiviral polypeptide (I) having at  
 CC least 70% sequence identity to native cyanovirin-N (CV-N) having the 101  
 CC amino acid sequence of SEQ ID NO:1 (S1, ADQ35136), and having a cysteine  
 CC substitution or insertion at one or more positions chosen from 5, 9-21,  
 CC 25, 29-40, 45-49, 52, 57, 59-72, 79-91, 96-101, the C-terminus, and the N  
 CC -terminus, or an arginine substitution at at least four residues chosen  
 CC from 3, 48, 74, 84 and 99. Also described: (i) an antiviral polypeptide  
 CC fragment (ii) comprising at least twenty contiguous amino acids and

CC spanning one or more of the substitutions or insertions of (I); (2) a  
 CC polynucleotide (III) encoding (I); (3) a vector (IV) comprising (III);  
 CC (4) a host cell comprising (IV); (5) an antiviral polypeptide-polymer  
 CC conjugate (V), comprising (I) or its fragment comprising at least 9 amino  
 CC acids and including one or more substitution or insertion as mentioned in  
 CC (I), and a water-soluble polymer covalently attached to (I) or its  
 CC fragment at one or more site of the substitution or insertion; (6) a  
 CC pharmaceutical composition (C1) comprising (V) and a carrier; (7) a  
 CC composition (C2) comprising no more than one species of (V); and (8)  
 CC preparing (V), which involves providing (I), covalently attaching to (I)  
 CC a water-soluble polymer at an insertion or substitution site, where (V)  
 CC has an antiviral activity. (I) has anti-HIV and virucide activities. (I)  
 CC is useful for preparing an antiviral polypeptide-polymer conjugate.  
 CC useful in treating infection caused by high mannose envelope virus. C1 is  
 CC useful for treating, preventing or mitigating infection by one or more  
 CC high mannose envelope virus, which involves administering C1 to a patient  
 CC who is in need of the treatment, where the envelope virus is chosen from  
 CC immunodeficiency virus, influenza virus, measles virus, herpes virus 6,  
 CC marburg virus and ebola virus. C1 is useful for treating, preventing or  
 CC mitigating infection caused by HIV. CV-N is a potent HIV-inactivating  
 CC protein that was originally isolated from aqueous extracts of the  
 CC cyanobacterium Nostoc ellipsoforum. The present sequence represents a  
 CC mutant CV-N, which is used in the exemplification of the present  
 CC invention.

XX SQ Sequence 101 AA;

ADQ35137 Length: 101 February 22, 2005 12:25 Type: P Check: 7705 ..

1 LGRFSQTGCC CCCCCCCCCC CBERTNGGCC CCCCCCCCCC ENVDCCXCQ

51 PSNFIECCCC CCCCCCCCCC CCCTRAQCC CCKXCCCCC CANIDCCXCK

101 C

!!AA\_SEQUENCE 1.0

ID ADQ35148 standard; protein; 101 AA.

XX AC ADQ35148;

XX DT 23-SEP-2004 (first entry)

XX DE Mutant cyanovirin-N protein SEQ ID NO:4.

XX KW antiviral; cyanovirin-N; CV-N; anti-HIV; virucide; infection;  
 KW high mannose envelope virus; immunodeficiency virus; influenza virus;  
 KW measles virus; herpes virus 6; marburg virus; ebola virus;  
 KW HIV-inactivating protein; cyanobacterium; Nostoc ellipsoforum; mutant.

XX OS Nostoc ellipsoforum.

XX OS Synthetic.

XX PN WO2004056852-A2.

XX PD 08-JUL-2004.

XX PF 18-DEC-2003; 2003WO-US040585.

XX PR 19-DEC-2002; 2002US-0435950P.

XX PR 09-APR-2003; 2003US-0461731P.

XX PA (NEKT-) NEKTAR THERAPEUTICS AL CORP.

XX (USSH ) US DEPT HEALTH & HUMAN SERVICES.

XX PI Snell ME, Roberts MJ, Mori T, O'keefe BR, Boyd MR;

XX DR WPI; 2004-525422/50.

XX PT Novel antiviral polypeptide having sequence identity to native cyanovirin  
 PT -N and having cysteine substitution or insertion or arginine  
 PT substitution, useful for treating or preventing infection of influenza  
 PT virus or measles virus.

PS Disclosure; SEQ ID NO 4; 75pp; English.

XX The present invention describes an antiviral polypeptide (I) having at

CC least 70% sequence identity to native cyanovirin-N (CV-N) having the 101

CC amino acid sequence of SEQ ID NO:1 (S1, ADQ35136), and having a cysteine

CC substitution or insertion at one or more positions chosen from 5, 9-21,

CC 25, 29-40, 45-49, 52, 57, 59-72, 79-91, 96-101, the C-terminus, and the N

CC terminus, or an arginine substitution at at least four residues chosen

CC from 3, 48, 74, 84 and 99. Also described: (1) an antiviral polypeptide

CC fragment (II) comprising at least twenty contiguous amino acids and

CC spanning one or more of the substitutions or insertions of (I); (2) a

CC polynucleotide (III) encoding (I); (3) a vector (IV) comprising (III);

CC (4) a host cell comprising (IV); (5) an antiviral polypeptide-polymer

CC conjugate (V), comprising (I) or its fragment comprising at least 9 amino

CC acids and including one or more substitution or insertion as mentioned in

CC pharmaceutical composition (C1) comprising (V) and a carrier; (7) a

CC composition (C2) comprising no more than one species of (V); and (8)

CC preparing (V), which involves providing (I), covalently attaching to (I)

CC a water-soluble polymer at an insertion or substitution site, where (I)

CC has an antiviral activity. (I) has anti-HIV and virucide activities. (I)

CC is useful for preparing an antiviral polypeptide-polymer conjugate. C1 is

CC useful in treating infection caused by high mannose envelope virus. C1 is

CC high mannose envelope virus, which involves administering C1 to a patient

CC who is in need of the treatment, where the envelope virus is chosen from

CC immunodeficiency virus, influenza virus, measles virus, herpes virus 6,

CC marburg virus and ebola virus. C1 is useful for treating, preventing or

CC mitigating infection caused by HIV. CV-N is a potent HIV-inactivating

CC protein that was originally isolated from aqueous extracts of the

CC cyanobacterium Nostoc ellipsosporum. The present sequence represents a

CC mutant CV-N, which is used in the exemplification of the present

CC invention.

XX

SQ Sequence 101 AA;

ADQ35148 Length: 101 February 22, 2005 12:25 Type: P Check: 9816 ..

1 LGKFSQTCYC CCCCCCCCCC TCERTNGGVN CCCCCCCCCC ENVDGCCCWQ

51 PSNFIETCRC CCCCCCCCCC CEKTRAQQC CCCCCCCCCC IANIDGCCCC

101 E

!!AA SEQUENCE 1.0

ID ADQ35147 standard; protein; 101 AA.

AC ADQ35147;

DT 23-SEP-2004 (first entry)

XX Mutant cyanovirin-N protein SEQ ID NO:3.

DE

XX antiviral; cyanovirin-N; CV-N; anti-HIV; virucide; infection;

KW high mannose envelope virus; immunodeficiency virus; influenza virus;

KW measles virus; herpes virus 6; marburg virus; ebola virus;

KW HIV-inactivating protein; cyanobacterium; Nostoc ellipsosporum; mutant.

XX

OS Nostoc ellipsosporum.

OS Synthetic.

XX

XX WO2004056852-A2.

PN

XX

XX 08-JUL-2004.

XX

XX 18-DEC-2003; 2003WO-US040585.

PF

XX

XX 19-DEC-2002; 2002US-0435950P.

PR

XX

XX 09-APR-2003; 2003US-0461731P.

XX

XX (NEKT-) NEKTAR THERAPEUTICS AL CORP.

PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.

PI Snell ME, Roberts MJ, Mori T, O'keefe BR, Boyd MR;

XX WPI; 2004-525422/50.

DR

XX Novel antiviral polypeptide having sequence identity to native cyanovirin

PT -N and having cysteine substitution or insertion or arginine

PT substitution, useful for treating or preventing infection of influenza

PT virus or measles virus.

XX

XX Disclosure; SEQ ID NO 3; 75pp; English.

XX The present invention describes an antiviral polypeptide (I) having at

CC least 70% sequence identity to native cyanovirin-N (CV-N) having the 101

CC amino acid sequence of SEQ ID NO:1 (S1, ADQ35136), and having a cysteine

CC substitution or insertion at one or more positions chosen from 5, 9-21,

CC 25, 29-40, 45-49, 52, 57, 59-72, 79-91, 96-101, the C-terminus, and the N

CC terminus, or an arginine substitution at at least four residues chosen

CC from 3, 48, 74, 84 and 99. Also described: (1) an antiviral polypeptide

CC fragment (II) comprising at least twenty contiguous amino acids and

CC spanning one or more of the substitutions or insertions of (I); (2) a

CC polynucleotide (III) encoding (I); (3) a vector (IV) comprising (III);

CC (4) a host cell comprising (IV); (5) an antiviral polypeptide-polymer

CC conjugate (V), comprising (I) or its fragment comprising at least 9 amino

CC acids and including one or more substitution or insertion as mentioned in

CC pharmaceutical composition (C1) comprising (V) and a carrier; (7) a

CC composition (C2) comprising no more than one species of (V); and (8)

CC preparing (V), which involves providing (I), covalently attaching to (I)

CC a water-soluble polymer at an insertion or substitution site, where (I)

CC has an antiviral activity. (I) has anti-HIV and virucide activities. (I)

CC is useful for preparing an antiviral polypeptide-polymer conjugate. C1 is

CC useful in treating infection caused by high mannose envelope virus. C1 is

CC high mannose envelope virus, which involves administering C1 to a patient

CC who is in need of the treatment, where the envelope virus is chosen from

CC immunodeficiency virus, influenza virus, measles virus, herpes virus 6,

CC marburg virus and ebola virus. C1 is useful for treating, preventing or

CC mitigating infection caused by HIV. CV-N is a potent HIV-inactivating

CC protein that was originally isolated from aqueous extracts of the

CC cyanobacterium Nostoc ellipsosporum. The present sequence represents a

CC mutant CV-N, which is used in the exemplification of the present

CC invention.

XX

SQ Sequence 101 AA;

ADQ35147 Length: 101 February 22, 2005 12:25 Type: P Check: 5108 ..

1 LGKFSQTCYC CCCCCCCCCC CCERTNGGCC CCCCCCCCCC ENVDCCCCCQ

51 PSNFIETCRC CCCCCCCCCC CEKTRAQQC CCCCCCCCCC CANIDCCCCC

101 C

!!AA SEQUENCE 1.0

ID ADQ35147 standard; protein; 201 AA.

XX

AC ADQ35147;

DT 04-NOV-2004 (first entry)

XX

XX Human protein useful for treating neurological disease Seq 2793.

DE

XX human; oligo-capping method; diagnostic marker; gene therapy;

KW osteoporosis; neurological disease; Alzheimer's disease;

KW Parkinson's disease; dementia; short memory; cancer;

KW sense or motor function; emotional reaction; fear response; panic;

KW osteopathic; neuroprotective; nootropic; antiparkinsonian; cytostatic;

XX tranquiliser.

XX

XX Homo sapiens.



PN EP1447413-A2.  
 XX  
 PD 18-AUG-2004.  
 XX  
 PF 12-FEB-2004; 2004EP-00003145.  
 XX  
 PR 14-FEB-2003; 2003JP-00102207.  
 PR 09-MAY-2003; 2003JP-00131452.  
 XX  
 PA (REAS-) RES ASSOC BIOTECHNOLOGY.  
 XX  
 PI Isogai T, Yamamoto J, Nishikawa T, Isono Y, Sugiyama T, Otsuki T;  
 PI Wakamatsu A, Ishii S, Nagai K, Irie R;  
 XX  
 DR WPI; 2004-583265/57.  
 DR N-PSDB; ADR07331.  
 XX  
 PT New 1995 cDNA, useful for treating osteoporosis, neurological diseases,  
 PT Alzheimer's diseases, Parkinson's diseases, dementia and various cancers.  
 XX  
 PS Claim 1; SEQ ID NO 2793; 2686pp; English.  
 XX  
 CC This invention relates to novel, isolated full length human cDNA  
 CC molecules and the encoded proteins thereof. Specifically, it refers to  
 CC cDNA clones obtained by an oligo-capping method, where none of these  
 CC clones are identical to any known human mRNAs. The present invention  
 CC describes an immunoassay to identify agonists and antagonists, as well as  
 CC antibodies, antisense molecules and siRNAs that can all be used to bind  
 CC to and modulate expression of the cDNA molecules. As such, these  
 CC molecules are useful for diagnostic markers or therapeutic targets for  
 CC the various diseases or morbid states. In particular, they are useful in  
 CC gene therapy for treating osteoporosis, neurological disease, Alzheimer's  
 CC disease, Parkinson's disease, dementia, short memory and various cancers,  
 CC as well as for maintaining equilibrium of sense or motor function, and  
 CC for treating emotional reaction, fear response and panic. Accordingly,  
 CC they exhibit osteoprotective, neuroprotective, nootropic, antiparkinsonian,  
 CC cytosstatic and tranquiliser activities. This polypeptide is a protein  
 CC encoded by a full length human cDNA sequence of the invention. NOTE: This  
 CC sequence is not given in the sequence listing of the specification but  
 CC can be obtained on CD-ROM from the European Patent Office, Vienna Sub-  
 CC office.  
 XX  
 SQ Sequence 201'AA;  
 ADR09287 Length: 201 February 22, 2005 12:25 Type: P Check: 571 ..  
 PS 1 MRAQEGCEG CVCVCVCVCV LCVSVCVCVC LCVCVCVCVC LCLCVLSVSV  
 51 CLCVCVSVCL CVCVSVCLC VCLCVCVSV CVCVSVCLC VCGFVCLCLC  
 101 VCVCLCVCVC LHLVCVCVGLC VSVCFVCVSV VCLCVCVCVC VFCVWVCVC  
 151 LCVCVCVCVC LCLCVFLCVC VFVSVVCVSV VCVCMCIGRT VVPAPQHQHA  
 201 L  
 OS Homo sapiens.  
 XX  
 !!AA SEQUENCE 1.0  
 ID \_ADS10978 standard; protein; 105 AA.  
 XX  
 AC ADS10978;  
 XX  
 DT 16-DEC-2004 (first entry)  
 XX  
 DE Human therapeutic protein - SEQ ID 1215.  
 XX  
 KW antiinflammatory; neuroprotective; antianaemic; cytostatic; vulnerary;  
 KW inflammatory; haematopoiesis; immunity; neurodegenerative; stem cell;  
 KW aplastic anaemia; cancer; wound healing; gene therapy.  
 OS Homo sapiens.  
 XX  
 PN WO2004080148-A2.  
 XX

PD 23-SEP-2004.  
 XX  
 PF 30-SEP-2003; 2003WO-US030720.  
 XX  
 PR 02-OCT-2002; 2002US-0416186P.  
 XX  
 PA (NUVE-) NUVELO INC.  
 XX  
 PI Tang YT, Asundi V, Ren F, Zhang J, Wehrman T, Wang Z, Ma Y;  
 PI Wang D, Chen R, Zhao QA, Wang J, Ghosh M, Xue AJ, Weng G, Zhou P;  
 XX  
 DR WPI; 2004-668857/65.  
 DR N-PSDB; ADS10294.  
 XX  
 PT New polynucleotide, useful in preparing a composition for diagnosing or  
 PT treating inflammatory, neurodegenerative or stem cell disorders, e.g.,  
 PT aplastic anaemia or cancer for promoting wound healing.  
 XX  
 PS Claim 20; SEQ ID NO 1215; 718pp; English.  
 XX  
 CC The invention relates to a novel isolated polynucleotide and the encoded  
 CC polypeptide. The molecules of the invention demonstrate antiinflammatory,  
 CC neuroprotective, antianaemic, cytostatic and vulnerary activities and may  
 CC be useful in preparing a composition for diagnosing or treating  
 CC inflammatory, haematopoietic, immune, neurodegenerative or stem cell  
 CC disorders, such as aplastic anaemia or cancer, as well as for promoting  
 CC wound healing. The molecules may also be utilised during gene therapy  
 CC procedures. The current sequence is that of a human therapeutic protein  
 CC of the invention. The current sequence is not shown explicitly within the  
 CC specification but can be accessed from the WIPO web-site.  
 XX  
 SQ Sequence 105 AA;  
 ADS10978 Length: 105 February 22, 2005 12:25 Type: P Check: 7493 ..  
 PS 1 MCCGCGGCGC GCGRCGCGC GGGCGGCGG GCGGCGGCGC GSCCTTCRCYR  
 51 VGCSSSCCPC CRGCGGCGCS TPVICCCRRRT CGSCGCGYK GCCQKCCQCCQ  
 101 KQCCC  
 OS Homo sapiens.  
 XX  
 !!AA SEQUENCE 1.0  
 ID \_ADS12210 standard; protein; 102 AA.  
 XX  
 AC ADS12210;  
 XX  
 DT 16-DEC-2004 (first entry)  
 XX  
 DE Human therapeutic contig protein - SEQ ID 2447.  
 XX  
 KW antiinflammatory; neuroprotective; antianaemic; cytostatic; vulnerary;  
 KW inflammatory; haematopoiesis; immunity; neurodegenerative; stem cell;  
 KW aplastic anaemia; cancer; wound healing; gene therapy.  
 OS Homo sapiens.  
 XX  
 Key Location/Qualifiers  
 FH Misc-difference 1..102  
 FT /label= Unknown, OTHER  
 FT /note= "OTHER = In-frame STOP codon"  
 XX  
 PN WO2004080148-A2.  
 XX  
 PD 23-SEP-2004.  
 XX  
 PF 30-SEP-2003; 2003WO-US030720.  
 XX  
 PR 02-OCT-2002; 2002US-0416186P.  
 XX  
 PA (NUVE-) NUVELO INC.  
 XX  
 PI Tang YT, Asundi V, Ren F, Zhang J, Wehrman T, Wang Z, Ma Y;  
 PI Wang D, Chen R, Zhao QA, Wang J, Ghosh M, Xue AJ, Weng G, Zhou P;  
 XX

XX WPI: 2004-668857/65.  
DR N-PSDB; ADS11612.  
XX  
PT New polynucleotide, useful in preparing a composition for diagnosing or  
PT treating inflammatory, neurodegenerative or stem cell disorders, e.g.,  
PT aplastic anemia or cancer for promoting wound healing.  
XX  
PS Example 2; SEQ ID NO 2447; 718pp; English.  
XX  
CC The invention relates to a novel isolated polynucleotide and the encoded  
CC polypeptide. The molecules of the invention demonstrate antiinflammatory,  
CC neuroprotective, antianaemic, cytostatic and vulnerary activities and may  
CC be useful in preparing a composition for diagnosing or treating  
CC inflammatory, haematopoietic, immune, neurodegenerative or stem cell  
CC disorders, such as aplastic anaemia or cancer, as well as for promoting  
CC wound healing. The molecules may also be utilised during gene therapy  
CC procedures. The current sequence is that of a human therapeutic contig  
CC protein of the invention.  
XX  
SQ Sequence 102 AA;  
ADS12210 Length: 102 February 22, 2005 12:25 Type: P Check: 6981 ..  
1 CGCGSGCGG GRCGGGCGGG CSGGGGGGGG GCGGGGGGSC TTCRCYRVGC  
51 CSSCCPCRCG CCGGCCSTPV ICCRRTGGS CGGCGKGCC QKCCCKQC  
101 CC

351 CCTGATATGG TCCCCACAG GCCTTGGCAG CCACATCCTC ATGGCTTTAC  
401 TGGGTGTAGC CCATGTGGCT GCTCATATGG GTTGGAGTTT TGTGCTTGAA  
451 GCTTTCCAG GCAGCCTGG AGCCTGGACA GTTCAAGGTC AAGGACAAC  
501 AAGTGGTGAA AACCTTGCTG GTGAGGACTC TCTGAAGAGT CTTGGGGCTG  
551 TGCAGGGCAT CTCATGCAAG TGTGTTGCTG CATCCAGCGC CCAGCGCTTA  
601 TGTCCCACCA CCATGTCFAA CAACACCGTG CCCAAGAGAA AGGTGAAGG  
651 GGATGCTAAA GGAGATAAAG CCAAGGTGAA GGATGAACCA CAGAGAGAT  
701 CCATGAGGTT TTCTGTCTAA CTTGCTCCTC CAAAGCCAGA GCCAAGCCT  
751 AAAAGGCCC CTCGAAGAA GGGAGAGAAG ATACCCAAAG GGAAGAAGG  
801 AAAAGCTGAT GCTGGCGAGG AGGGGAATAA CCTGTCAGAA AACGGAGATG  
851 CCAAAACAGA CCAGGCACAG AAAGCTGAAG GTGCTGGAGG TGCCAGTGA

!!AA SEQUENCE 1.0

ID ADP31344 standard; protein; 906 AA.

XX AC ADP31344;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #2111.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471336P.  
19-MAY-2003; 2003US-0471306P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
15-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RE, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX PT genetic, bacterial and viral diseases.

XX PS Claim 1; SEQ ID NO 3342; 428pp; English.

XX CC The present invention relates to an isolated nucleic acid molecule

XX CC encoding a polypeptide which is believed to be cytostatic,  
XX CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX CC composition and methods are useful for diagnosing, preventing and  
XX CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX CC immune, metabolic, genetic, bacterial and viral diseases. The present  
XX CC sequence represents a human secreted protein. The present sequence is  
XX CC available on WIPWEB and is not in the specification.

XX SQ Sequence 906 AA;

ADP31344 Length: 906 February 22, 2005 12:25 Type: P Check: 9535 ..

1 ATGTTCCCG AGCCCGCGGC CGGCCCGGG GGGCCCGGG CTGCGCCCGC

51 GAGCCGAGCC GGGGGCGGG GCCGGCGCC TGCCAGGGGC GCCTGCGAGG

101 TCTCGCCGCC GAGCGCGGC GGGGATCAAT GCACAGCTT CCGTGAGGAT

151 GCCCGCGGC CCCAGTGGC AGGGGAAGAA GGGGAGACCC CACCGTGCTCA

551 AGCCACTGGA TGTCCAAGTT TGCATCTATG TCATGGGCTT GGTCTCTGGAG  
601 TGGATTAAAA ACAATGGAGG TGCGCGGCC ATGAGAGC TTAGCTCCAT  
651 CAAATCTCAA ATGATTTATG AGATTATGGA TAATTCTCAA GGATTTCTAGG  
701 TATGTCGGGT GGAGGCCCAA AATAGAAGCA AGATGAATAT TCCATTTCTGC  
751 ATTGCAATG CCAAGGAGA TGATGCTTTA GAAAAAGAC TTTTGTATAA  
801 AGCTCTTGAA CTTAATATGT TGCCCTTTGAA AGGTTATAGG TCTGTGGGAG  
851 GCATCGGGC CTCCTGTAT AATGCTGTCA CTATTGAAGA TGTTCAGAAG  
901 CTGGCGGCTT TCATGAAAAA TTTTTGGAG ATGCATCAGC TATGA

!!AA SEQUENCE 1.0  
ID ADP31337 standard; protein; 900 AA.  
XX  
XX  
AC ADP31337;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX  
DE Human secreted protein SEQ ID #2104.  
XX  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
XX  
PD 29-APR-2004.

XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.

PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471338P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
DR  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3335; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOMED and is not in the specification.  
SQ  
SQ Sequence 900 AA;  
ADP31337 Length: 900 February 22, 2005 12:25 Type: P Check: 9791 ..  
1 ATGAGGCATC AATTCCATCA TGGAACTTCT TCAGGGGTTT GGACTCTCC  
51 CTTTATCTTT CTTTCTATGG AGGAGCCAGT TGTACCAGT ATTCAATTA  
101 AAGGACCCAT CAATCAGGTT TTTGAGAAAC AGGTGGTGT TCGTTACANT  
151 AAATGTACAA CACCACAGT GAATCCTAAT GAAAACATG GACTTTGGGA  
201 GATAATAAGG TGTAAGGTA GATTCATCA CTGTAACAA TGTACCACATG  
251 TGGTGCAGGA TGTTGAGAGT GGGGGAGGCT GTGCATGTGT GGGGACAGAA  
301 GTATATGGGA ACGCTCTTCT CTTATCTATG AGTGTGGAAG TCCAGAGGGC

101 TCCCGGGGAG GAGCACTGAG GATGCGCTCA AGCAAGGAGG CTTGGGCTAC  
151 AGCCAGCTGG GTGACGACCA CGTGAAGGAG ACTGCTTCC ACTTCACCAT  
201 CACGAACGAG GGGCGCTCGG TTGCGGGGCC GGCTTCAGCC TCAAGTTCTG  
251 GCAAG

! IAA SEQUENCE 1.0  
ID\_ADP31238 standard; protein; 945 AA.  
XX  
AC ADP31238;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2005.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406555P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.

18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
03-JUN-2003; 2003US-0476609P.  
03-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PA  
XX PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3236; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 945 AA;  
XX  
ADP31238 Length: 945 February 22, 2005 12:25 Type: P Check: 5429 ..  
1 ATGGAGCGCC CGAGGCACTT GGTCAACTTC GGGCCTGGTC CGGCCAAGCT  
51 GCCTCACTCA GTGTGTTTAG AGATAAAAAA GGAATTATTA GACTACAAG  
101 GAGTTGGCAT TAGTGTCTTT GAAATGAGTC ACAGGCCATC AGATTTTGCC  
151 AAGATTATTA ACGATACACA GAATCTTGTG CGGGAATTGC TAGCCGTTCC  
201 AGACAGCTGT AAGTGATTTT TTGTCAAGG AAGTGGTCTT GGCAGTTCG  
251 GTGCTGTCCC CTTAAACCTT ATTGCTTTGA AAGCAGGAAG ATGTGCGGAC  
301 TATGTGTGTA CAGGACTTTC GTCAGCTAAG GCCGCAGAAG AAGCCAAGAA  
351 GTTTGGGACT ATAAATATCA TTCACCCCTAA ACTTGGGAGT TATACAAAAA  
401 TTCAGATCC AAGCACCTGG AACCTCAACC CGGATGCCCT CTATGTGTAT  
451 TATTGCGCAA ATGAGGTGCT GCATGGTGTG GAGTTTGACT TTATACCCCTA  
501 TGTCAAGGGA GCAGTACTGG TTTGTGACAT GTCCTCAAC TTCTGTGTCCA

1101 CAGCACTTAC AACGCCGAG TCAAAGCTTT CAACTCTTCT GGTGCGGC  
1151 CTTACAGTAA AACTGTCGTC CTGCAGACAT CCGATGTGGC CTGGTTACA  
1201 TTGACCCCA ACTGTGGCA TCGGACATC ATTTTATCCA ATGACAACCA  
1251 GACAGCCACC TGCAGCAGT ATGACGACCG GGTGGTGTCTG GGCACAGCTG  
1301 CGTTCCTCAA GGGCGTGAC TACTGGAGC TGCACGTGGA CCGGTACGAC  
1351 AACCACCCAG ACCCGCCTT CGGGTGGCC AGGCCAGCG TGGTCAAGGA  
1401 CATGATGCTG GCAAGGATG ARAAGGCTG GGCCATGTAT GTGGACAACA  
1451 ACGGAGCTG GTTATGCAC TGCAACTCCC ACACCAACAG GACGGAAGT  
1501 GCGGTGTGCA AGGGGGCCAC CGTGGGCGTG CTGCTGGACC TGAATAAGCA  
1551 CACTCTCACC TTCTTCATCA ACGGGCAGCA GCAGGGCCCC ACAGCCTTCA  
1601 GCCACGTGA CGGGTCTTC ATGCCAGCCC TCAGCCTCAA CCGCAACGTG  
1651 CAGGTCACC TGCACACAGG ATTGGAAGTG CCGACTTAAC TGGGCGGCGC  
1701 AAAGCTGTCA GGCAATTAG  
!!AA\_SEQUENCE 1.0  
ID ADP31172 standard; protein; 255 AA.  
XX AC  
XX ADP31172;  
XX DT  
XX 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1939.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD  
XX 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.

PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PA Williams LT, Chu K, Lee B, Heatir K, Beaurang PA, Behrens D;  
XX PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX DR WPI; 2004-348438/32.  
XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX PT genetic, bacterial and viral diseases.  
XX PS Claim 1; SEQ ID NO 3170; 428pp; English.  
XX CC The present invention relates to an isolated nucleic acid molecule  
XX CC encoding a polypeptide which is believed to be cytostatic,  
XX CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX CC composition and methods are useful for diagnosing, preventing and  
XX CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX CC immune, metabolic, genetic, bacterial and viral diseases. The present  
XX CC sequence represents a human secreted protein. The present sequence is  
XX CC available on WIPWEB and is not in the specification.  
XX SQ Sequence 255 AA;  
ADP31172 Length: 255 February 22, 2005 12:25 Type: P Check: 5721 ..  
1 ATGACCTTCA GCCAGTACCC CTATAGCAAC CTCTGCAAGG GCTTGGGGGC  
51 CTTGCTCTCA GAACAGGGCT TTCATCTTAC GAACAAAGTTC CTGACCTACT

PN WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 18-APR-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 02-MAY-2003; 2003US-0467230P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 22-MAY-2003; 2003US-0472430P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 09-JUN-2003; 2003US-0476641P.  
XX 08-JUL-2003; 2003US-0485218P.  
XX 08-JUL-2003; 2003US-0485223P.  
XX 08-JUL-2003; 2003US-0485224P.  
XX 08-JUL-2003; 2003US-0485325P.  
XX 14-JUL-2003; 2003US-0486446P.  
XX 14-JUL-2003; 2003US-0486480P.  
XX 15-JUL-2003; 2003US-0486891P.  
XX 15-JUL-2003; 2003US-0486960P.  
XX 08-AUG-2003; 2003US-0493341P.  
XX 08-AUG-2003; 2003US-0493370P.  
XX 08-AUG-2003; 2003US-0493573P.

PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3135; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX Sequence 1719 AA;  
ADP31137 Length: 1719 February 22, 2005 12:25 Type: P Check: 7329 ..  
1 ATGGCCTCCA AGGACGACAT CATATCTTTT ATTCTTGAA CCATCCAGG  
51 CATTAGCCTG CGGTACGCGG TCTCTTCAA AACCACTCTG TTTTGGGCT  
101 TCTTGCCAAG CTCCTTGGTC TTTTGCCAA GCAGGAAGAA GGCACAACTA  
151 TCTCAGGCCT TAAATGGAGT TTCAGATAAG GCAAAGGAAG CAAAGGAGTT  
201 TCTGGTTTCTAG CTAAGAACA TATTGCAGCA GATCCAGCAC TCACCAGATT  
251 TTAGCATCTT CCCCCTAAAA CTCCTTGGCTT CTTCCTCAACC AACCCCAAC  
301 CTCTGCCAGG AAAACGGACT GGACTACGAA GCCTGCCCTCG TTGCTCAGTG  
351 TGATGCCCTT GTGGATGCTT TAACTCGTCA GAAAGCCAAAG CTGCTACCA  
401 AGGTGACTAA AGAGAGGGAA CACAAGTTGA AGATGGTTTG GGACCAGATC  
451 ATCACTGCA CATTGAAGCT CGGTACGTCC ACCGACTGA TGGAGTACTG  
501 CCTGGAGGTG ATCAGGAGA ACGACCCCTC CGGGTTCTTA CAGATCTCAG  
551 ATGCTCTGAT CAAGCCGCTC CAGGTGTCTC AGGAGCAGTG GGTCAAAGGC  
601 GCCCTGGAGC CGAAGTGTG TCGGAGGTTT GATCTGACTT TGGACACCGA  
651 GCCGCTGCTG CAGGCCATCC ACCAGCTGGA CTTCATTTCAG ATGANAATGA  
701 GGGGTGAGGA GGAGGAAGTG GTGGCAGAGG AGGAGGAGGT GGAGGAGGTA  
751 GTCATGGAGG AGGAGATGGA GGAGGAGGAG GTGGTGGCTA AGATAATGGA  
801 GGAGGAGGAG GAGGTAATGG TGGAGGAGGA GATGGAGGAG GAGGAAGAGG  
851 TAGCGGAGGA GGAGGTAGTG GAGGAGGAGG TGGAAAGAGGA GGAGGTGGTG  
901 GCTGAGATAG TGGAGGAGGA GGAGCTGGAG AATGCTGCA CCCTTAACAA  
951 CAGCGTCACG CTGGCCTGGA GGATGCCACC CTTCACCCAC AGCCCGCTGG  
1001 ACGGCTACAT CTTGGAGCTG GACGACGCTG CCGGGGGACA GTTCCGGGAA  
1051 GTGTACCTCG GTAAAGAGAC TTTGTGTACC ATCGACGGTC TTCACTTCAA

KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
PN  
PD 29-APR-2004.  
XX  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
PF  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411049P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3122; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 645 AA;  
SQ  
ADP31124 Length: 645 February 22, 2005 12:25 Type: P Check: 2732 ..  
XX  
XX 1 ATGGGCCAAA TCAGCGTGCC TTCTGTGTCAG CCAGGGGNTT ATAGAAGAAC  
51 ACGCTCCCTT GATTCCAACA GAACCTTGCTG CCACTCTGAT GTCTTCATGC  
101 CTCCTCAAGGA AAAACAGATG CAAAGCCCTT TATCAATTGC AAACAGTAT  
151 ACAATGTGTG TTATTACTCA CAGTTGTCTT ACTGTGACCA AACACTTTAT  
201 AAGCCTGGGG CAAGTCAGCC TTACTCTCAG GAAGTGGACA ATATTGGGG  
251 AAGGAGAGC AGCAGGATAT TTCAGACAG TAGCCTTGGG CCAGGCGCAGC  
301 TACCGGCCCA ACTTCATCCG GAGCGGCGTG TCGTCCGTCG GCCTCGCGGA  
351 CGTCAAGGCG CGCACCACGG GGGCGGGCAG CGACGGCAGG TTCTTCGGCA  
401 GGACGGCCGT CGAGTGTGTT GGGCCGATGG CGCGGCCCAA CGGGGGGAGT  
451 GTCCGGATGC CCTTCGCTTC CGCGCGCGCC GCGCGCGCGC CCTCTCCTGG  
501 CCCTTGTCCG CCGTGTGCTT CCGGGGCCAG CTGGGAGGCC CCGTCCCGGC  
551 TTTGCTCCGG CACTCCCGCG TCCTCACCTT CCAGCGCCCC ACTCCCGCGG  
601 CGCTCGCAGC CTCGCCGCGC CACCCCGGAC ACTGGGTTCT ATTAG  
!!AA SEQUENCE 1.0  
ID \_ADP31137 standard; protein; 1719 AA.  
XX  
XX ADF31137;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1904.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
OS



PN WO2004035732-A2.  
XX 29-APR-2004.  
PF 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406577P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.

PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3034; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 807 AA;  
ADP31036 Length: 807 February 22, 2005 12:25 Type: P Check: 6448 ..  
1 ATGCAGGCTC TGAAGCAATT CCCAGAAAGG AATCCCAAGA TAAGTTCTGA  
51 AGAGGAGAAA ATTACTCTTT TGGATTTATG TTTTGATGGG ACCGTCGGT  
101 TTCAGGAAA CAAGCTTAGG GCTCTACTG ATTCTATATT ATGGCTATCA  
151 TTTATGCCAA GACTATATCC ACAGACTCCT AGAAGACTTC TCTCACACTC  
201 CAAAGTCATCC CCATATCTCG TGGTGGAGGA AGCACTCAAA AAACCTGGCT  
251 GCGACCGAGT TTCTCTGGGA AATGTCATCA TTGACAATAG CTATTTCTTC  
301 ATCCAGAAC TGGGGGAGAG TGGGTTTCAGC CATGTGGACC TAGTGGAGGG  
351 GTTACAGGAT GGACACTTCT AGCCCTGAA GCGAATCCTG TGTACGAGC  
401 AGCAGGACTG GGAGGAGGCC CAGCCAAGAA GCAAACATGC ATCACCTCTT  
451 CAATCACCCC AACATCCTTT ACCTCAGGC TTACTGTCTG AGGGAAGCTC  
501 TTCCTTGAGC AGTCACTGTG TCATTGATGA ACAGACTGAT GTCTGGTCCC  
551 TGGGCTGTGT GATATATGCC ACAAATGTTT GGAAGAGCCC TTACGAAATG  
601 GTGTTCAAGA AAGGTGACAG TGTGGCCCTT GCTGTGCAGA ACCAATCTAG  
651 CATCCCACAA AGCCCCAGCG ATTCTTCAGG AGTGTGGCAG CTCCTGGCCT  
701 CAATGATGAC TGTGGACCTG CAGCAGCACC CTCACAATGC TTGCCTCCTC  
751 AGTCAGCTGG AGGTACTGCA GCCCCAGCT CTGGGCCAGC AACTGGCCCA  
801 AATCTGA  
11AA SEQUENCE 1.0  
ID ADP31124 standard; protein; 645 AA.  
XX ADP31124;  
XX  
DT 12-AUG-2004 (first entry)  
DE Human secreted protein SEQ ID #1891.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA  
PI Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3029; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 2469 AA;  
ADP31031 Length: 2469 February 22, 2005 12:25 Type: P Check: 4845 ..  
1 CCCTTTCAGA TCATCACTCC ATTCAGAAGG CTAATGCTGT GTGCTGAGAA  
51 CAGAAAGGAG ATGGAGGATT GGATCAGCTC ACTGAAGTCT GTACAGACCA  
101 GAGAACCCCTA CGAGGTGGCC CAGTTTAAATG TGGAAACATTT CTCAGGGATG  
151 CACAACCTGT AGCCTGTCTC CCAGGCCGA CCCACCTTCT GTAACGTGTG  
201 CAGAGAGAGT CTTTCTGGAG TCACCTCCCA TGGCCTGTCC TGCGAAGTGT  
251 GTAATTCAA GGCTCACAAA AGATGTGCAG TGAGAGCAAC AAATAACTGT  
301 AAATGACTA CCCTGGCCTC CATCGGGAAG GACATTATAG AGATGAAGA  
351 TGGCCTGCGG ATGCCTCACC AGTGGCTTGA GGGCAACCTG COTGPAAGTG  
401 CCAAGTGTGC TGTCTGCGAC AANAACATGTG GCAGTGTCTT CCGTCTACAG  
451 GATTGGAANT GCCTTTGGTG TAAGACAATG GTACACACTG CCTGCAAGA  
501 TTTATACCAT CCAATANGTC CACTTGGTCA ATGTAAAGTA TCTATCATAC  
551 CTCCAATTGC ACTAAACAGC ACCGATTCCG ATGGTTTCTG TAGAGCAACA  
601 TTTTCGTCTT GTGTAGTCC TCTATTGGTT TTTGTCAATT CTAAGAGTGG  
651 AGATAATCAG GGAGTAAAGT TCCTCCGTCG CTTTAAACAG TTGCTAAATC  
701 CGGCTCAGT GTTTGATTTA ATGAATGGAG GTCTCATTTT AGGTTTAAGA  
751 TTATTTTCAGA AGTTTGACAA TTTCCGGATT CTTGTTTGTG GAGGCGATGG  
801 AAGTGTAGGT TGGGTTTGTG CAGAAATCGA TAAGCTCAAC TTGAATAAAC  
851 AGTGTCACT GGGAGTGTG CTTTGGGTA CAGGAAATGA CCTTGCCCGA  
901 GTTCTTGGCT GGGAGGTTT ATATGAGAT GACACCAAC TTCCTCAGAT  
951 CCTAGAGAAA CTGAACAGAG CCAGTACCAA AATGTTGGAC AGGTGGAGTA  
1001 TAATGACATA TGAATCAA TTGCCACCA AAGCTTCCCT ACTTCCAGGA

1051 CCTCCAGAG CATCTGAAGA ATTTTATATG ACGATTTATG AAGACTCAGT  
1101 TGAACGGAT CTTACAAAA TCCTCAATTC TGATGAACAT GCAGTGGTCA  
1151 TATCTTCTGC CAAGACGCTA TGTGAAACTG TAAAGGACTT CGTTGCCAAA  
1201 GTAGAAAAA CGTATGACAA AACCTTGGAA AATGCCGTTG TAGCTGATGC  
1251 COTGGCCAGT AAACAGTGA AGAGTCCCTG GGTGAAAGCA AAGAGCAGCT  
1301 TGGGGATGAC GTTACAAAAC CTTCTCTCCA GAAAGCCGTC AAACCAAGGG  
1351 AATCATGTT GCGGCAAT AGTTTAAAGA AAGCACTGAG GCAAGTCATT  
1401 GAGGAAGCG GAAAGTTAT GATGACCCG ACAGTTCAAC COTGTGAACC  
1451 AGCTAATCAG TCCTCTGATT ATGACAGCAC AGAAACAGAT GAATCTAAGG  
1501 AGGAAGCTAA AGATGATGGT GCCAAGAAT CAATRACTGS TGAGGAAACT  
1551 GGGAAAAAAT TATTTGGAA TTAACAAAGA AAACCTCCCT GTGCTCAATA  
1601 CCAGAATAAT CTGCCAGGT TTAAGAGCAG GACTGGCTGC CTCAAATTGCT  
1651 GGGAGTTCGA TTATCAACAA AATGTTACTG GCAAAACATTG ATCCTTTTGG  
1701 TGCCACGCCG TTTATTGACC CGGATCTAGA TTCCGTAGAT GGATATTGAG  
1751 AAAAAATGTT CATGAACAAAT TACTTTGGGA TTGGATTAGA TGCAAAAAAT  
1801 TCATTAGAT TTAATATAA AAGAGAGGAG CACCCTGAAA RATGCAGGAG  
1851 CCGAACTAAA AACTTGATGT GGTATGGAGT CTTTGGAAAC CGGAGATTAT  
1901 TACAGAGATC GTACAAGAA TTAGAACAAA GGGTTCAACT TGAGTGTGAT  
1951 GGGCAGTATA TTCCTCTTCC CAGCTTGCAA GGCATAGCCG TGTGAAACAT  
2001 TCCCAGCTAT GCTGGAGGCA CTAACCTTTTG GGTGGAACAT AAAGAGGATG  
2051 ATATATTTGC TGCACCATCC TTTGATGACA AGATCCTGGA AGTTGTAGCA  
2101 ATATTTGATA GCATGCAAAAT GGCAGTTTCA AGGGTCATTA AACTGCAGCA  
2151 TCATCGAATA GCCCAGTGCC GTACAGTGAA AATCACTATA TTTGTTGACG  
2201 AAGGAGTCCC AGTGCAAGTG GATGGTGAAG CGTGGGTTCA GCCTCCAGGG  
2251 ATTATCAAAA TTGTGCACAA AAACAGAGCA CAAATGCTAA CAAGGACAG  
2301 AGCCTTTGAG AGCACTCTGA AATCTTGGGA AGATAAGCAG AAGTGTGATT  
2351 CTGGTAAACC AGTTCTCCGA ACCCATTTGT ACATCCATCA GCCCATTCAC  
2401 TTGGCAACAG AAGAGGTGTC GCAGATGCAG CTATGCTCCC AGGCTGCAGA  
2451 GGAGCTCAT ACTAGGTAG  
!!AA SEQUENCE 1.0  
ID \_ADP31036 standard; protein; 807 AA.  
XX  
AC ADP31036;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1803.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX

101	GGAAAGCAAC	CTGGCTGTCTC	CTGGGCCCTTG	GCTGGGGTCTT	CGTCCCTGCTT
151	TACATCGCAG	CAGGTGTGGT	CACAATGCCG	CAGTATCTGA	AGAAGCGATT
201	TGGGGGCCAG	AGGATCCAGG	TGTACATGTC	TGTCTGTCT	CTCATCCTCT
251	ACATCTTCAC	CAAGATCTCG	ACTGACATCT	TCTCTGGAGC	CCTCTTTCATC
301	CAGATGGCAT	TGGGCTGGAA	CCTGTACCTC	TCCACAGGGA	TCCTGTCTGGT
351	GGTGACTGCC	GTCTACACCA	TTGCAGGTGG	CCTCATGGCC	GTGATCTACA
401	CAGATGTCTT	GCAGACGGTG	ATCATGTGTAG	GGGAGGCCCT	GGTCTCTCATG
451	TTTCTGGGCT	TTCAGGACGT	GGGCTGTGTAC	CCAGGCCCTGG	AGCAGCGGTA
501	CAGCAGGCC	ATCCCTAATG	TCACAGTCCC	CAACACCACC	TGTCACCTCC
551	CACGGCCCGA	TGCTTTTCCAC	ATTCTTCGGG	ACCTGTGTAG	CGGGAGACATC
601	CCTTTGGCCAG	GTCTCATTTT	CGGGCTCACA	GTGCTGGCCA	CCTGGTGTGTG
651	GTGCACAGAC	CAGGTCAATG	TGCAGGGTCT	TCTCTGGCC	AGAGTCTGTGT
701	CTCATGCCAA	GGGAGGCTCC	GTGCTGGGGG	GCTACCTGAA	GAATCTTCCCC
751	ATGTTCTTCA	TCGTCATGCC	TGGCATGATC	AGCGGGSCC	TGTTCCACAGA
801	CGAGTGGGC	TGCGTGGACC	CTGATGTCTG	CCTAAGNATC	TGTTGGGGCCC
851	GAGTGGGATG	TTCCAACATT	GCCTACCCCTA	AGTTGTTCAT	GGCCCTCATAG
901	CCTGTTGGTC	TGGCGGGGCT	GATGATTGCC	GTGATCATGG	CGGCTCTCAT
951	GAGCTCACTC	ACCTCATCT	TCAACAGCAG	CAGCACCCCTG	TTACACCATTG
1001	ATGTGTGGCA	GCGCTTCCGC	AGGAAGTCAA	CAGAGCAGGA	GCTGATGGTG
1051	GTGGGCAGAG	TGTTTGTGTT	GTTCCTGGTT	GTCACTAGCA	TCTCTCTGGAT
1101	CCCCATCATC	CAAAAGTCCA	ACAGTGGGCA	GCTCTTGCAC	TACATCCAGG
1151	CTGTCACCAG	TTACCTTGGCC	CCACCATCA	CCGCTCTCTT	CCTGCTGGCC
1201	ATCTTCTGCA	AGAGGCTCAC	AGAGCCCGGA	GC'TTTCTGGG	GCCTCGTGT
1251	TGGCCTGGGA	GTGGGGCTTC	TGCGTATGAT	CCTGGAGTTC	TGATACCCAG
1301	CGCCAGCCTG	TGGGGAGGTG	GACCCGAGGC	CAGCAGTGCT	GAAGGACTTC
1351	CAC'TACCTGT	ACTTTGCAAT	CCTCTCTCTG	GGGCTCAC'TG	CCATCGTCAT
1401	TGTCATTCCC	CAAGCAGGTC	CTGGGGAAAG	TTGCTCTGGA	GCTGTGTTCTG
1451	TGGGCTCTCT	GGAAACCCGG	AGCAGGCCCT	GAGCCCAGCA	GAGAAAGGCTG
1501	CGCTAGAAC	GAAGCTGACA	AGCATTGAGG	AGGAGCCACT	CTGGAGACAT
1551	GTCTGCAACA	TCAATGCTGT	CGTTTGTGTC	GCCATCAACA	TCTTCTCTCTG
1601	GGGCTATTTT	GCGTGA			

!!AA SEQUENCE 1.0

ADP31031 standard; protein; 2469 AA.

ADP31031:  
AC  
XX  
ADP31031:

DT 12-AUG-2004 (first entry)

Human secreted protein SEO ID #1798.

human secreted protein 504 ID #1730.

XX  
CY  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

301 CTGCGCTTCT TCTGTACAT CGTGGGCTG AGTCTCTCTGG CGGCGCTCAG  
351 CFTGGAGCAG TGCCTGGCG CCCTCTTCCC AGCCTGTAT TCGTGCCGCC  
401 GCCCAGCCA CTTGACACC TGTGTGTGG CCTCACCTG GGCCTCTGTC  
451 CTGCTCTGCT ACCTGCTGCT CAGCAGGCC TGCACCCAGT TCTTCGGGGA  
501 GCCCAGCCG CACTTGTGCC GGACGCTGT GCTGTGTGGCA GCGGTGCTGC  
551 TGGCTCTGCT GTGTGTGACC ATGTGTGGG CCAGCCTTAT GCTGTGTGTG  
601 CCGGTGGAGC GAGGCCCCCA CGGCCCCCA CCCCGGGCT TCCCTGGGCT  
651 CATCTCTCTC ACCGTCCTCC TCTTCTCTTT CTGCGGCTG CCGTTGGGCA  
701 TCTACTGGCT GTCCCGAAC CTGCTCTGCT ACATCCCCCA CTACTTCTAC  
751 CACTTCAGCT TCCTCATGCC CGCGTGCAC TGGCGGGCCA AGCCCGTCTG  
801 CTACTTCTGC CTGGCAGTG CCCAGGGCG CAGGCTGCCC CTCGCGCTGG  
851 TCCTCAGCG AGCGTGGGA GACGAGCTG AGCTGGGGGC CGTCAGGAG  
901 ACCTCCCGCC GGGGCTGCT GGACATAGCA GCCTGA

!!AA SEQUENCE 1.0

ID ADP30987 standard; protein; 1616 AA.

XX AC

XX ADP30987;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1754.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.

XX XX

XX PN WO2004035732-A2.

XX PD

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PF 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 17-SEP-2002; 2002US-041111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PA Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

DR New nucleic acid molecule for diagnosing, preventing or treating diseases

XX PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX PT genetic, bacterial and viral diseases.  
XX PS Claim 1; SEQ ID NO 2985; 428pp; English.

XX CC The present invention relates to an isolated nucleic acid molecule

XX CC encoding a polypeptide which is believed to be cytostatic,  
XX CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX CC composition and methods are useful for diagnosing, preventing and  
XX CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX CC immune, metabolic, genetic, bacterial and viral diseases. The present  
XX CC sequence represents a human secreted protein. The present sequence is  
XX CC available on WIPWEB and is not in the specification.

SQ Sequence 1616 AA;

ADP30987 Length: 1616 February 22, 2005 12:25 Type: P Check: 7290 ..

1 ATTGGAGCAT CTCTGATGTC CAGCAATGTG GGCAGTGGCT TGTTCATCGG

51 CCTGGCTGGG ACAGGGGCTG CCGAGGCGCT TGCCGTAGGT GGCTTCGAGT

851 AGCACAGCAC GTATATCTCTG TTGCGGGAGG CCGAGGGCCG CCAGGTGCCCC  
901 GACAGCTGCT GCAAGACAGT GGTGTGTGCG TGCGGCCAGC GGGCCACACC  
951 CTCACATC TATAAGTGG AGGAGGCTG CCTCACACAG CTGGAGCAGT  
1001 TCCTGGCCGA CCACCTGCTG CTTATGGGGG CAGTGGGCAT CGGGTGGCC  
1051 TGCCTGCAGG CGAGGCCCTC TGTCTGTGT GCTGAACCCC AGAGGAGTAG  
1101 TCAGTGGGAA CAGGAGAGT CATGAACAG CACACCAGAG GCAGTTTCAG  
1151 ACTTGGACAG GATCATCACA GTGTGAGGT ACCACCCGAT CAGACTCTTC  
1201 CACCTGAAA GGCCTTACAG ACTACTGGA CCAGAGCCAC CGGCCCTGGC  
1251 TGCATGCTAG

## !!AA SEQUENCE 1.0

ID ADP30908 standard; protein; 936 AA.

AC ADP30908;

XX

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1675.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

PN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

XX

PR 29-AUG-2002; 2002US-0406576P.

PR

PR 29-AUG-2002; 2002US-0406579P.

PR

PR 29-AUG-2002; 2002US-0406585P.

PR

PR 29-AUG-2002; 2002US-0406608P.

PR

PR 29-AUG-2002; 2002US-0406611P.

PR

PR 29-AUG-2002; 2002US-0406612P.

PR

PR 29-AUG-2002; 2002US-0406616P.

PR

PR 29-AUG-2002; 2002US-0406640P.

PR

PR 29-AUG-2002; 2002US-0406642P.

PR

PR 29-AUG-2002; 2002US-0406646P.

PR

PR 29-AUG-2002; 2002US-0406653P.

PR

PR 29-AUG-2002; 2002US-0406655P.

PR

PR 29-AUG-2002; 2002US-0406666P.

PR

PR 17-SEP-2002; 2002US-0410946P.

PR

PR 17-SEP-2002; 2002US-0410947P.

PR

PR 17-SEP-2002; 2002US-0410948P.

PR

PR 17-SEP-2002; 2002US-0410949P.

PR

PR 17-SEP-2002; 2002US-0410953P.

PR

PR 17-SEP-2002; 2002US-0410957P.

PR

PR 17-SEP-2002; 2002US-0410958P.

PR

PR 17-SEP-2002; 2002US-0410959P.

PR

PR 17-SEP-2002; 2002US-0410960P.

PR

PR 17-SEP-2002; 2002US-0410961P.

PR

PR 17-SEP-2002; 2002US-0410962P.

PR

PR 17-SEP-2002; 2002US-0411019P.

PR

PR 17-SEP-2002; 2002US-0411022P.

PR

PR 17-SEP-2002; 2002US-0411023P.

PR

PR 17-SEP-2002; 2002US-0411032P.

PR

PR 17-SEP-2002; 2002US-0411033P.

PR

PR 17-SEP-2002; 2002US-0411035P.

PR

PR 17-SEP-2002; 2002US-0411037P.

PR

PR 17-SEP-2002; 2002US-0411041P.

PR

PR 17-SEP-2002; 2002US-0411045P.

PR

PR 17-SEP-2002; 2002US-0411046P.

PR

17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 2906; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPWEB and is not in the specification.

Sequence 936 AA;

ADP30908 Length: 936 February 22, 2005 12:25 Type: P Check: 9801 ..

1 ATGGAGGCCCA GAGAGCTGG ACAGCACGTG GGGGCCGCCA ACAGCGCCCA

51 GGAGGATGTG GCCTTCAACC TCATCATCT GTCCCTCACC GAGGGGCTCG

101 GCTTCGGTGG GCTGTGGGG AATGGGGCAG TCCTCTGGCT GCTCAGCTCC

151 AATGCTCTACA GAAACCCCTT CGCCATCTAC CTCCTGGACG TGGCCTCGCG

201 GGATCTCATC TTCCTTGGCT GCCACATGT GGCCATCGTC CCCGACTTGC

251 TGCAAGGCCG GCTGGACTTC CGGGCTCTCG TGCAGACGAG CTTGGGCAACG

XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1650.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411010P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 18-APR-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 02-MAY-2003; 2003US-0467230P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.  
XX 22-MAY-2003; 2003US-0472430P.  
XX 09-JUN-2003; 2003US-0476609P.  
XX 09-JUN-2003; 2003US-0476641P.  
XX 08-JUL-2003; 2003US-0485218P.

PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2881; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 1260 AA;

ADP30883 Length: 1260 February 22, 2005 12:25 Type: P Check: 9154 ..

1 ATGGTCTTCT GCCCTCTGT GTCGCCAGGA TGTGTGGGA GACAGGTCA  
51 CAGTCGAGGG GGATATGCAT TTGCTCTGCA CAGTGCCGTG GCAGAGCTGT  
101 TGCARAGCTC AGAAGAGAA ATGGTAAATA CATGTTCTGT TGCTCAACGG  
151 ATGCTCTGGA CTGCCAGAA CAGAGAAGTG GGAATGACA GGGTCGGGG  
201 AGCAGCCGTC CTGGCTGTGG GCATCTGGAC CTTGGTGGAG AAGAGTGGCT  
251 ACCTCAGCGT CTGGCCCTCC AGCACCTTTG CCGCCTCCGC CTACATCCTC  
301 ATCTTTGGGG GCGTACTTGT CATGGTGACC GGTTCCTTGG GCTTCGGTGC  
351 CATCTCTGG GAGCGAAGG GCTGCCTCTC CACGACCACA GGGATCGAT  
401 TTTGGAAGA CCGCAGCCCC TGGACCTGCA GGGGCAGACC AGTCACAGNA  
451 ACCAGAGTGG AGCTGGAGGT CAGTGGGATA GGTTCAGGTC ACACAAAGG  
501 CACAGGACC ATGAAGGCAG AACCAAGTAA TGGGGCAGTG GCTTCCCCCG  
551 AGAAGTGGGG TGACACTGCC AGCTATCCAG GAGTATCCTA CGGGCCTGAC  
601 TCACAGCTCA CAGTGGTGGT GGAGAGAAGG AAGTATTTCT GCCTTTGCT  
651 CGTCATCTTC CTGTTTGAGC TGGTGGCGGG AGTCTGTGGC CATGTGTATT  
701 ACCAGAGGCT GAGTGATGAA CTGAAGCAGC ACTTGAACCG GACTCTGGCT  
751 GAGAACTACG GGCAGCCCGG AGCCAGCAG ATCACGCTT CAGTGGACCG  
801 ACTCCAGCAG GATTTCAAGT GCTGTGGAAG CAACAGCTCA GCCGACTGCG

51 CCATCTGCCT GCTGCTGGCG TCCTACCAGG GCATCTCTGG CGCGCTGCGC  
101 CGGAGCCACG GCACCCAGAA GAGCGCGAAG GACCAGATCC AGCGGCTGGT  
151 GTCAGCACC GTGGTCACTT TCTTGGCTTG CTTCTGCTCC TACCAGTGT  
201 TGCTGTGGT GCGCAGCGTC TGGGAGGCCA GCTGCGACTT CGCCAAGGGC  
251 GTTTTCAACG CCTACCACAT CTCCCTCTCTG CTCACGAGCT TCAACTGCGT  
301 CGCGACCCC GTGCTTACT GTTTCGTCTAG CGAGACCAAC CACGGGAGCC  
351 TGGCCCGCCT CGCGGGGCC TGCCTGGCCT TCCTCACCTG CTCACGAGCC  
401 GGCCGGGCCA GGGAGGCCA CCGCTGGT GCGCCCGAGG CTTCCGGGAA  
451 AAGCGGGGCC CAGGGTGA

!!AA\_SEQUENCE 1.0  
ID\_ADP30808 standard; protein; 156 AA.  
AC  
XX  
AC  
XX  
DT  
XX  
12-AUG-2004 (first entry)  
XX  
Human secreted protein SEQ ID #1575.  
DE  
XX  
Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW  
cancer; inflammatory; immune; human secreted protein.  
KW  
XX  
OS  
Homo sapiens.  
XX  
PN  
WO2004035732-A2.  
XX  
PD  
29-APR-2004.  
XX

28-AUG-2003; 2003WO-US026780.  
XX  
PF  
XX  
29-AUG-2002; 2002US-0406576P.  
PR  
29-AUG-2002; 2002US-0406579P.  
PR  
29-AUG-2002; 2002US-0406585P.  
PR  
29-AUG-2002; 2002US-0406588P.  
PR  
29-AUG-2002; 2002US-0406608P.  
PR  
29-AUG-2002; 2002US-0406611P.  
PR  
29-AUG-2002; 2002US-0406612P.  
PR  
29-AUG-2002; 2002US-0406616P.  
PR  
29-AUG-2002; 2002US-0406640P.  
PR  
29-AUG-2002; 2002US-0406642P.  
PR  
29-AUG-2002; 2002US-0406646P.  
PR  
29-AUG-2002; 2002US-0406653P.  
PR  
29-AUG-2002; 2002US-0406655P.  
PR  
29-AUG-2002; 2002US-0406666P.  
PR  
17-SEP-2002; 2002US-0410946P.  
PR  
17-SEP-2002; 2002US-0410947P.  
PR  
17-SEP-2002; 2002US-0410948P.  
PR  
17-SEP-2002; 2002US-0410949P.  
PR  
17-SEP-2002; 2002US-0410953P.  
PR  
17-SEP-2002; 2002US-0410957P.  
PR  
17-SEP-2002; 2002US-0410958P.  
PR  
17-SEP-2002; 2002US-0410959P.  
PR  
17-SEP-2002; 2002US-0410960P.  
PR  
17-SEP-2002; 2002US-0410961P.  
PR  
17-SEP-2002; 2002US-0410962P.  
PR  
17-SEP-2002; 2002US-0411019P.  
PR  
17-SEP-2002; 2002US-0411022P.  
PR  
17-SEP-2002; 2002US-0411023P.  
PR  
17-SEP-2002; 2002US-0411024P.  
PR  
17-SEP-2002; 2002US-0411032P.  
PR  
17-SEP-2002; 2002US-0411035P.  
PR  
17-SEP-2002; 2002US-0411037P.  
PR  
17-SEP-2002; 2002US-0411041P.  
PR  
17-SEP-2002; 2002US-0411045P.  
PR  
17-SEP-2002; 2002US-0411046P.  
PR

17-SEP-2002; 2002US-0411048P.  
PR  
17-SEP-2002; 2002US-0411052P.  
PR  
17-SEP-2002; 2002US-0411055P.  
PR  
17-SEP-2002; 2002US-0411073P.  
PR  
17-SEP-2002; 2002US-0411082P.  
PR  
17-SEP-2002; 2002US-0411101P.  
PR  
17-SEP-2002; 2002US-0411111P.  
PR  
18-APR-2003; 2003US-0463700P.  
PR  
18-APR-2003; 2003US-0463708P.  
PR  
18-APR-2003; 2003US-0463716P.  
PR  
18-APR-2003; 2003US-0463732P.  
PR  
02-MAY-2003; 2003US-0467199P.  
PR  
02-MAY-2003; 2003US-0467201P.  
PR  
02-MAY-2003; 2003US-0467203P.  
PR  
02-MAY-2003; 2003US-0467230P.  
PR  
19-MAY-2003; 2003US-0471306P.  
PR  
19-MAY-2003; 2003US-0471336P.  
PR  
22-MAY-2003; 2003US-0472420P.  
PR  
22-MAY-2003; 2003US-0472430P.  
PR  
09-JUN-2003; 2003US-0476609P.  
PR  
09-JUN-2003; 2003US-0476641P.  
PR  
08-JUL-2003; 2003US-0485218P.  
PR  
08-JUL-2003; 2003US-0485223P.  
PR  
08-JUL-2003; 2003US-0485224P.  
PR  
08-JUL-2003; 2003US-0485325P.  
PR  
14-JUL-2003; 2003US-0486446P.  
PR  
14-JUL-2003; 2003US-0486480P.  
PR  
15-JUL-2003; 2003US-0486891P.  
PR  
15-JUL-2003; 2003US-0486960P.  
PR  
08-AUG-2003; 2003US-0493341P.  
PR  
08-AUG-2003; 2003US-0493370P.  
PR  
08-AUG-2003; 2003US-0493573P.  
PR  
08-AUG-2003; 2003US-0493577P.  
XX  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX  
DR WPI; 2004-348438/32.  
XX  
DR  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX  
PS Claim 1; SEQ ID NO 2806; 428pp; English.  
XX  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 156 AA;

ADP30808 Length: 156 February 22, 2005 12:25 Type: P Check: 9566 ..  
1 ATGGAGACCC GGGGGGTGGG ATGGAGAAG ACGGTCCGGA ATGGGACCTT  
51 TGACAGCAGA CCTACAACC TGCTGCCCTT CCTGTCCCT TTCCACCCCC  
101 CACCCACCT CCAGAGGTCA GTGTTCTGGG ACATTGGGG ACCTTCTTT  
151 GACTAG

!!AA\_SEQUENCE 1.0  
ID\_ADP30883 standard; protein; 1260 AA.  
XX  
AC ADP30883;

701 TGCTGCCAG CCTGGCGCAG CGCGCGCTGG CGGTGCTGCT GTACCGCGCG  
751 GCGGCGCAG GTGCGGTGCC CGCGTGTG GGCAGCGCGG GCTCGTGT  
801 CTGTGTGGA GAGTGTGTG CGCGCGCGT GAGCGGCGC TGGACGCTGG  
851 CGTGGCGCC GCGAGCGTC GGCCTCAGCC GCCTGGCGGT CCGTCTCACT  
901 CTGCCCGTC CGTGCCTCGT GGGCGACTG CTGAGCTGG CGGCGCGGCC  
951 CGGCGGCTG CGGAGCGGG TGCTGAGCT GCGCGCGGC GCGCGCGACC  
1001 CCTACAGCGA TCTCAGCAAG GCGTGTCTG GCTGCCGGAC CGTGGAGGAC  
1051 GTGCTCACG CCTCGAAGA CTGCTTCATG CTGGAGGCCA GCACGCTGCT  
1101 GGACTTCGGC GTCTGGCCA GCATCATGCA GAGCGGCCAC ACGCGCATCC  
1151 CGGTGTACGA GGAGGAGCGC TCCAACATCG TGGACATGCT CTACCTCAAG  
1201 GACTTGGCT TCGTGATCC CGRAGACTGC ACGCGCTCA GCACCATCAC  
1251 TCGTTTCTAC AACCATCGC TCACATTGCT CTTCAACGAC ACCAAGCTGG  
1301 ACGTGTCTCT GGAGGAATC AAGCGAGGTA ACGGCCCGG CATGGTGCAG  
1351 GGGACGCCG TCGAGTGCC CTCTCCCTGA  
!! AA SEQUENCE 1.0  
ID ADP30774 standard; protein; 468 AA.  
XX  
AC ADP30774;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1541.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
XX  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406613P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410945P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.

17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-041101P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
08-JUL-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
15-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2772; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC anti-inflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 468 AA;  
SQ

ADP30774 Length: 468 February 22, 2005 12:25 Type: P Check: 6317 ..

1 ATGGCAGCGC GCCATCAACT ACTACCGCTT CTGGTGGGC TTCTCTTCC



1101	GAGGAGGTGG	AGTGCAGCT	GGGACTGTGA	GGACC	
11AA	SEQUENCE 1.0				
ID	ADP30731	standard; protein; 1380 AA.			
AC	ADP30731;				
XX	AC				
DT	12-AUG-2004	(first entry)			
XX	Human secreted protein SEQ ID #1498.				
DE					
XX	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;				
KW	cancer; inflammatory; immune; human secreted protein.				
XX					
OS	Homo sapiens.				
XX					
PN	WO2004035732-A2.				
XX					
PD	29-APR-2004.				
XX					
PF	28-AUG-2003;	2003WO-US026780.			
XX					
PR	29-AUG-2002;	2002US-0406576P.			
PR	29-AUG-2002;	2002US-0406579P.			
PR	29-AUG-2002;	2002US-0406585P.			
PR	29-AUG-2002;	2002US-0406588P.			
PR	29-AUG-2002;	2002US-0406608P.			
PR	29-AUG-2002;	2002US-0406611P.			
PR	29-AUG-2002;	2002US-0406612P.			
PR	29-AUG-2002;	2002US-0406616P.			
PR	29-AUG-2002;	2002US-0406640P.			
PR	29-AUG-2002;	2002US-0406642P.			
PR	29-AUG-2002;	2002US-0406646P.			
PR	29-AUG-2002;	2002US-0406653P.			
PR	29-AUG-2002;	2002US-0406655P.			
PR	29-AUG-2002;	2002US-0406666P.			
PR	17-SEP-2002;	2002US-0410947P.			
PR	17-SEP-2002;	2002US-0410948P.			
PR	17-SEP-2002;	2002US-0410949P.			
PR	17-SEP-2002;	2002US-0410953P.			
PR	17-SEP-2002;	2002US-0410957P.			
PR	17-SEP-2002;	2002US-0410958P.			
PR	17-SEP-2002;	2002US-0410959P.			
PR	17-SEP-2002;	2002US-0410960P.			
PR	17-SEP-2002;	2002US-0410961P.			
PR	17-SEP-2002;	2002US-0410962P.			
PR	17-SEP-2002;	2002US-0411019P.			
PR	17-SEP-2002;	2002US-0411022P.			
PR	17-SEP-2002;	2002US-0411023P.			
PR	17-SEP-2002;	2002US-0411024P.			
PR	17-SEP-2002;	2002US-0411032P.			
PR	17-SEP-2002;	2002US-0411035P.			
PR	17-SEP-2002;	2002US-0411037P.			
PR	17-SEP-2002;	2002US-0411041P.			
PR	17-SEP-2002;	2002US-0411045P.			
PR	17-SEP-2002;	2002US-0411046P.			
PR	17-SEP-2002;	2002US-0411048P.			
PR	17-SEP-2002;	2002US-0411052P.			
PR	17-SEP-2002;	2002US-0411055P.			
PR	17-SEP-2002;	2002US-0411073P.			
PR	17-SEP-2002;	2002US-0411082P.			
PR	17-SEP-2002;	2002US-0411101P.			
PR	17-SEP-2002;	2002US-0411111P.			
PR	18-APR-2003;	2003US-0463700P.			
PR	18-APR-2003;	2003US-0463708P.			
PR	18-APR-2003;	2003US-0463716P.			
PR	18-APR-2003;	2003US-0463732P.			
PR	02-MAY-2003;	2003US-0467199P.			
PR	02-MAY-2003;	2003US-0467201P.			
PR	02-MAY-2003;	2003US-0467203P.			
PR	19-MAY-2003;	2003US-0467230P.			
PR	19-MAY-2003;	2003US-0471306P.			
PR	19-MAY-2003;	2003US-0471336P.			
PR	22-MAY-2003;	2003US-0472420P.			
PR	22-MAY-2003;	2003US-0472430P.			
PR	09-JUN-2003;	2003US-0476609P.			
PR	09-JUN-2003;	2003US-0476641P.			
PR	08-JUL-2003;	2003US-0485218P.			
PR	08-JUL-2003;	2003US-0485223P.			
PR	08-JUL-2003;	2003US-0485224P.			
PR	08-JUL-2003;	2003US-0485325P.			
PR	14-JUL-2003;	2003US-0486446P.			
PR	14-JUL-2003;	2003US-0486480P.			
PR	15-JUL-2003;	2003US-0486891P.			
PR	15-JUL-2003;	2003US-0486960P.			
PR	08-AUG-2003;	2003US-0493341P.			
PR	08-AUG-2003;	2003US-0493370P.			
PR	08-AUG-2003;	2003US-0493573P.			
PR	08-AUG-2003;	2003US-0493577P.			
XX					
PA	(FIVE-) FIVE PRIME THERAPEUTICS INC.				
XX					
PI	Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;				
PI	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;				
PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;				
XX					
XX	WPI; 2004-348438/32.				
XX					
PT	New nucleic acid molecule for diagnosing, preventing or treating diseases				
PT	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,				
PT	genetic, bacterial and viral diseases.				
XX					
PS	Claim 1; SEQ ID NO 2729; 428pp; English.				
XX					
CC	The present invention relates to an isolated nucleic acid molecule				
CC	encoding a polypeptide which is believed to be cytostatic.				
CC	antiinflammatory, immunosuppressive, antibacterial and virucidal. The				
CC	composition and methods are useful for diagnosing, preventing and				
CC	treating diseases such as proliferative (e.g. cancer), inflammatory,				
CC	immune, metabolic, genetic, bacterial and viral diseases. The present				
CC	sequence represents a human secreted protein. The present sequence is				
CC	available on WIPOWEB and is not in the specification.				
XX					
SQ	Sequence 1380 AA;				
ADP30731	Length: 1380	February 22, 2005 12:25	Type: P	Check: 406	
1	GGACTGCTTC	ATGATCCGCA	CGGATGCCAT	CCTGGACTTC	AACACCATGT
51	CGGAGATAAT	GGAAAGCGGC	TATACTGCA	TCCGGGTGTT	CGAAGACGAG
101	CAATGCGGC	GGCGGTAGCT	CGCGGGGTC	GGTTAGGCTG	GTGTTTCGCC
151	CGCTCTGCC	TGGGCACGC	CGCGGGGAG	GCCGCGCCG	GCCCGCGAGT
201	GCTGGGCTTC	TGCTGGAGG	AGGATGAGC	GGCGGGGCG	GGTTGGGTAC
251	GCGAGGGGC	GGCGGGGAC	ACGCCGACG	CCACCTTCCT	CCTGCGCTC
301	TTCGGCCCG	GCTTCGCCA	CAGCTCTGG	TCCTGGGTG	CCCCGGAGG
351	GCGGGGCTG	CGGAGGAGG	CGGCTTCCT	CGCGGGGCG	TGGCGGCGC
401	TGCTGCGCTT	GCGCCTCGG	GCCGAGGCG	TGCGCCGCA	CTCGGCGCTG
451	CTGGCGGTG	CGGTGGAGC	GGGTGGCGG	GCGGTGAGG	AGGCGGCGC
501	GCCCTGGCT	CTGGGCTGG	GGCGGGCGG	GCTGTGGCG	CTGGAGAGCG
551	TGGCGGAGG	CCTGCAGCTG	AGCGGCTGG	CGCTGGGCG	TGCCGAGGTG
601	CAGGTGCTG	CGGAGGCGG	CTCGAGGCG	GAGGTCGG	CGGCGGCGG
651	TTTGGAGCC	GCGCGGCGCT	GGCGGCGCTG	CGCTTGGGC	GGCTGCTGCTG

PN WO2004035732-A2.  
XX  
PD  
XX  
PF 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR

PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2693; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1135 AA;  
ADP30695 Length: 1135 February 22, 2005 12:25 Type: P Check: 31 ..  
1 TGCTGTGCG GCCCTGTCC TGCTGTGCC CTGGCTCTC GCCACCTGA  
51 CATCAACAAC CCTTGGCAG TGCCACCTG GGGAGGAGCC CGACCTGGAC  
101 CCAGGGCAGG GCACATTATG CAGGCCCTGC CCCCAGGCA CTTTCTCAGC  
151 TGCATGGGCG TCCAGCCCAT GCCAGCCCCA TGCCCGTTGC AGCCTTTGGA  
201 GGAGGCTGGA GGCCAGTGG GGGCGGGGG CCGGAGTGG CGTGGAGGTG  
251 GCAGCAGGG CCAGCAGCG TGGTGAGACA CGGCAGCCTG GGAACGGCAC  
301 CCGGCAGGT GGCCAGAGG AGACAGCGC CCAATAGCGG GTCATCGCCA  
351 TCGTCCCTGT CTTCTGCCTC ATGGGCTGT TGGGCATCCT GGTGTGCAC  
401 CTCCTCAAGC GGAAGGGCTA CCACTGCAG CGGCACAAG AGTCTGGGCC  
451 CGGCCCTGGA GGTGGAGGCA GTGGGACTGA GGATGCCAAT GAGGACACCA  
501 TTGGGGTCTT GGTGGGCTTG ATCAGAGAGA AGAAGGGCTG CCGCCAGGCG  
551 CCCCAGAGT GCCACATC TGCCCGCACC GCCACATCT CCACACCTG  
601 CAGGCGCTGG CCTCGCTC TGCCCGCTGC TGCTCCCGCT GTAGCGAAG  
651 GAAGTGGCCC GAGGTGCTG TGTCCCTGA GGCTGTAGCC CCCTACTC  
701 CTGTTCCAG CTTTCTCCT AACCCGACCA GGGTTCCCAA GGCCTGGGCC  
751 AAGGCAGGC GTCAGGCGA GATCACCATC TTGTCTGTGG GCAGTTCCG  
801 CGTGGCTGA ATTCTGAGC AGCGGACAAG TTCATGGTG TCTGAGGTGA  
851 AGACCATCAC GGAGGTGGG CCTCTGTGG GTGATCTCCC TGACTCCCA  
901 CAGCCTGGCC TCCCCCTGA GCAGCAGGCC CTGCTAGGAA GTGGCGAAG  
951 CCGTACAAAG TGGCTGAAG CCCAGCAGA GAAAGAGCC GAGGAGAACC  
1001 GCTATGTGGT CCGGCTAAGT GAGAGCAACC TGGTCACTG AGGGCGGTG  
1051 TAGTCTAAG ACCTGGGC CCGGCTGGG GAGGTTCCA AGGTTCTCTG

PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0410963P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX  
PS Claim 1; SEQ ID NO 2681; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present

CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX  
SQ Sequence 1264 AA;

ADP30683 Length: 1264 February 22, 2005 12:25 Type: P Check: 6811 ..

1 TGCTGTGCCG GCCCTGTGCC TGCTGTGCC CTGGCCTCTC GCCACCTGA  
51 CATCAACAAC CCTTTGGCAG TGCCACCTG GGGAGGAGCC CGACCTGCAG  
101 GGCACATTAT GCAGGCCCTG CCCCCAGGC ACCTTCTCAG CTGCATGGGG  
151 CTCACGCCCA TGCCAGCCCC ATGCCCGTTG CAGCCTTTGG AGGAGGCTGG  
201 AGGCCCCAGT GGGCATGGCA ACTCGAGATA CACTCTGTGG AGACTGCTCG  
251 CAGGTGTTTT GGGCTGGGGG CGGCGGGCCC GACGTGGCGT GGAGGTGGCA  
301 GCAGGGGCCA GCAGCGGTGG TGAGACACGG CAGCCTGGGA ACGGCACCCG  
351 GGCAGGTGGC CCAGAGGAGA CAGCCGCCCA GTACGGGTC ATGCCCATCG  
401 TCCCTGTCTT CTGCCCTCATG GGGCTGTGG GCATCCTGGT GTGCAACCTC  
451 CTCAAGCGGA AGGGCTATCCA CTGCACGGCG CACAAGGAGG TCGGGGCCCG  
501 CCCTGGAGGT GGAGGCAGTG GGACTGAGGA TGCCAATGAG GACACCATTT  
551 GGGTCTCTGT GGGCTTGATC ACAGAGAAGA AAGAGATGC TGGGGCCCTG  
601 GAGGAGCTGC TGAAGAAGTA CCACAGCAAA CAGCTGGTGC AGACGAGCCA  
651 CAGGCTGTG TCCAAGTGC CGCCAGCGCC CCGAACGTG CCACACATCT  
701 GCCCGCACCG CCACATCTC CACACCGTGC AGGCGCTGGC CTCGCTCTCT  
751 GGCCCTCTGT GCTCCCGCTG TAGCCAGAAG AAGTGGCCCG AGGTGCTGCT  
801 GTCCCTGTAG GCTGTAGCG CCACTACTCC TGTTCACAGC CTTCTGCCTA  
851 ACCGACACAG GGTTCACAG GCCGGGGCCA AGGAGGGGGC TCAGGGGGAG  
901 ATCACCATCT TGTCTGTGGG CAGGTTCCGC GTGGCTCGAA TTCCTGAGCA  
951 GCGGACAAGT TCAATGGTGT CTGAGGTGAA GACCATCAG GAGGCTGGGC  
1001 CCTGTGGGG TGATCTCCCT GACTCCCCAC AGCTGGCCT CCCCCCTGAG  
1051 CAGCAGGCCC TGCTAGGAAG TGGCGGAAGC CGTACAAAGT GGTGGAAGCC  
1101 CCCAGCAGAG AACAAGGCG AGGAGAACCG CTATGTGGTC CGGCTAAGTG  
1151 AGAGCAACCT GGTATCTGA GGGGGGTCT AGTCTAAGGA CACTGGGGCC  
1201 CTGCCCTGGG AGGTTCCGAA GGTTCTCTGG AGGAGGTGGA GCTGCAGCTG  
1251 GGACTGTGAG GACC

!!AA SEQUENCE 1.0

ID\_ADP30695 standard; protein; 1135 AA.

XX

AC ADP30695;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1462.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX



!!AA SEQUENCE 1.0  
ID ADP30627 standard; protein; 156 AA.  
AC ADP30627;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1394.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR  
XX 29-AUG-2002; 2002US-0406579P.  
PR  
XX 29-AUG-2002; 2002US-0406585P.  
PR  
XX 29-AUG-2002; 2002US-0406588P.  
PR  
XX 29-AUG-2002; 2002US-0406608P.  
PR  
XX 29-AUG-2002; 2002US-0406611P.  
PR  
XX 29-AUG-2002; 2002US-0406612P.  
PR  
XX 29-AUG-2002; 2002US-0406616P.  
PR  
XX 29-AUG-2002; 2002US-0406640P.  
PR  
XX 29-AUG-2002; 2002US-0406642P.  
PR  
XX 29-AUG-2002; 2002US-0406646P.  
PR  
XX 29-AUG-2002; 2002US-0406653P.  
PR  
XX 29-AUG-2002; 2002US-0406655P.  
PR  
XX 29-AUG-2002; 2002US-0406656P.  
PR  
XX 17-SEP-2002; 2002US-0410946P.  
PR  
XX 17-SEP-2002; 2002US-0410947P.  
PR  
XX 17-SEP-2002; 2002US-0410948P.  
PR  
XX 17-SEP-2002; 2002US-0410949P.  
PR  
XX 17-SEP-2002; 2002US-0410953P.  
PR  
XX 17-SEP-2002; 2002US-0410957P.  
PR  
XX 17-SEP-2002; 2002US-0410958P.  
PR  
XX 17-SEP-2002; 2002US-0410959P.  
PR  
XX 17-SEP-2002; 2002US-0410960P.  
PR  
XX 17-SEP-2002; 2002US-0410961P.  
PR  
XX 17-SEP-2002; 2002US-0410962P.  
PR  
XX 17-SEP-2002; 2002US-0411019P.  
PR  
XX 17-SEP-2002; 2002US-0411022P.  
PR  
XX 17-SEP-2002; 2002US-0411023P.  
PR  
XX 17-SEP-2002; 2002US-0411024P.  
PR  
XX 17-SEP-2002; 2002US-0411032P.  
PR  
XX 17-SEP-2002; 2002US-0411035P.  
PR  
XX 17-SEP-2002; 2002US-0411037P.  
PR  
XX 17-SEP-2002; 2002US-0411041P.  
PR  
XX 17-SEP-2002; 2002US-0411045P.  
PR  
XX 17-SEP-2002; 2002US-0411046P.  
PR  
XX 17-SEP-2002; 2002US-0411048P.  
PR  
XX 17-SEP-2002; 2002US-0411052P.  
PR  
XX 17-SEP-2002; 2002US-0411055P.  
PR  
XX 17-SEP-2002; 2002US-0411073P.  
PR  
XX 17-SEP-2002; 2002US-0411082P.  
PR  
XX 17-SEP-2002; 2002US-0411101P.  
PR  
XX 17-SEP-2002; 2002US-0411111P.  
PR  
XX 18-APR-2003; 2003US-0463700P.  
PR  
XX 18-APR-2003; 2003US-0463708P.  
PR  
XX 18-APR-2003; 2003US-0463716P.  
PR  
XX 18-APR-2003; 2003US-0463732P.  
PR  
XX 02-MAY-2003; 2003US-0467199P.  
PR  
XX 02-MAY-2003; 2003US-0467201P.  
PR  
XX 02-MAY-2003; 2003US-0467203P.  
PR  
XX 02-MAY-2003; 2003US-0467230P.  
PR  
XX 19-MAY-2003; 2003US-0471306P.  
PR  
XX 19-MAY-2003; 2003US-0471336P.  
PR  
XX 22-MAY-2003; 2003US-0472420P.  
PR

PR 22-MAY-2003; 2003US-0472430P.  
PR  
PR 09-JUN-2003; 2003US-0476609P.  
PR  
PR 09-JUN-2003; 2003US-0476641P.  
PR  
PR 08-JUL-2003; 2003US-0485218P.  
PR  
PR 08-JUL-2003; 2003US-0485223P.  
PR  
PR 08-JUL-2003; 2003US-0485224P.  
PR  
PR 08-JUL-2003; 2003US-0485325P.  
PR  
PR 14-JUL-2003; 2003US-0486446P.  
PR  
PR 15-JUL-2003; 2003US-0486891P.  
PR  
PR 15-JUL-2003; 2003US-0486960P.  
PR  
PR 08-AUG-2003; 2003US-0493341P.  
PR  
PR 08-AUG-2003; 2003US-0493370P.  
PR  
PR 08-AUG-2003; 2003US-0493573P.  
PR  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2625; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.  
XX  
XX Sequence 156 AA;  
ADP30627 Length: 156 February 22, 2005 12:25 Type: P Check: 9331 ..  
1 ATGCACCTGT GTTGAGAAA AGCAGGTATG AAGTCTCCAC GCGGGAAAAC  
51 AACTTACCCT CTCTCACCT CATTACCATC AAGGCTCATG ATGCAGACTT  
101 GGGCATTAT GGAAGAAGTCT CATACCGCAT CCAGGACTCC CCAGTTGCTC  
151 ACTTAG  
!!AA SEQUENCE 1.0  
ID ADP30659 standard; protein; 363 AA.  
XX  
AC ADP30659;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1426.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR  
XX 29-AUG-2002; 2002US-0406579P.  
PR

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.  
XX PR 17-SEP-2002; 2002US-0411023P.  
XX PR 17-SEP-2002; 2002US-0411024P.  
XX PR 17-SEP-2002; 2002US-0411032P.  
XX PR 17-SEP-2002; 2002US-0411035P.  
XX PR 17-SEP-2002; 2002US-0411037P.  
XX PR 17-SEP-2002; 2002US-0411041P.  
XX PR 17-SEP-2002; 2002US-0411045P.  
XX PR 17-SEP-2002; 2002US-0411046P.  
XX PR 17-SEP-2002; 2002US-0411048P.  
XX PR 17-SEP-2002; 2002US-0411052P.  
XX PR 17-SEP-2002; 2002US-0411055P.  
XX PR 17-SEP-2002; 2002US-0411073P.  
XX PR 17-SEP-2002; 2002US-0411082P.  
XX PR 17-SEP-2002; 2002US-0411101P.  
XX PR 17-SEP-2002; 2002US-0411111P.  
XX PR 18-APR-2003; 2003US-0463700P.  
XX PR 18-APR-2003; 2003US-0463708P.  
XX PR 18-APR-2003; 2003US-0463716P.  
XX PR 18-APR-2003; 2003US-0463732P.  
XX PR 02-MAY-2003; 2003US-0463719P.  
XX PR 02-MAY-2003; 2003US-0467201P.  
XX PR 02-MAY-2003; 2003US-0467203P.  
XX PR 02-MAY-2003; 2003US-0467230P.  
XX PR 19-MAY-2003; 2003US-0471306P.  
XX PR 19-MAY-2003; 2003US-0471336P.  
XX PR 22-MAY-2003; 2003US-0472420P.  
XX PR 22-MAY-2003; 2003US-0472430P.  
XX PR 09-JUN-2003; 2003US-0476609P.  
XX PR 09-JUN-2003; 2003US-0476641P.  
XX PR 08-JUL-2003; 2003US-0485218P.  
XX PR 08-JUL-2003; 2003US-0485223P.  
XX PR 08-JUL-2003; 2003US-0485224P.  
XX PR 08-JUL-2003; 2003US-0485325P.  
XX PR 14-JUL-2003; 2003US-0486446P.

PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX PA Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
XX PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX PT genetic, bacterial and viral diseases.  
XX XX Claim 1; SEQ ID NO 2584; 428pp; English.  
XX PS The present invention relates to an isolated nucleic acid molecule  
XX CC encoding a polypeptide which is believed to be cytostatic,  
XX CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX CC composition and methods are useful for diagnosing, preventing and  
XX CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX CC immune, metabolic, genetic, bacterial and viral diseases. The present  
XX CC sequence represents a human secreted protein. The present sequence is  
XX CC available on WIPOWEB and is not in the specification.  
XX SQ Sequence 948 AA;

ADP30586 Length: 948 February 22, 2005 12:25 Type: P Check: 9580 ..

1 ATGAGCGGCG CGAGCCTCCG TGGCGCGGCC GGGGGTTGG GGCTGCTGCT  
51 GTGCGCGGTG CTGGGCGCGC GTGGCGGTC AGACAGCGGC GTTCGGGGG  
101 AACTCGGGCA GCCCTCTGGG GTAGCGCGCG AGCGCCCATG CCCCACTACC  
151 TGGCGCTGCC TCGGGGACCT GCTGGACTGC AGTCGTAAGC GGCTAGCGCG  
201 TCTTCCCGAG CCATCCCGT CTTGGGTGCG TCGGCTGGAC TTAAGTCACA  
251 ACAGATTATC TTTCATCAAG GCAAGTTCCA TGAGCCACCT TCAAAGCCTT  
301 CGAGAAGTGG CTGGAACAG GATTGTTGAA ATACTCCCTG AACATCTGAA  
351 AGAGTTTCAG TCCTTTGAAA CTTTGGACCT TAGCAGCAAC AATATTCAG  
401 AGCTCCAAAC TGCATTCCA GCCCTACAGC TCAAATATCT CGAATTGAAC  
451 CGAAACAAGA TTAAAAATGT AGATGGACTG ACATTTCCAG GCCTTGGTGC  
501 TCTGAAGTCT CTGAAATGC AAAGAAATGG AGTAACGAAA CTTATGGATG  
551 GAGCTTTTTG GGGGCTGAGC AACATGGAAA TTTTSCAGCT GGACCATAAC  
601 AACCTAACAG AGATTACCMA AGGCTGGCTT TAGGCTTGC TGATGCTGCA  
651 GGAACCTCAT CTCAGCCAAA ATGCCATCAA CAGGATCAGC CTTGATGCTT  
701 GGGAGTTCTG CCAGAAAGCTC AGTGAGCTGG ACCTAACTTT CAATCACTTA  
751 TCAAGGTTAG ATGATTTCAAG CTTCTCTGGC CTAAGCTTAC TAAATACACT  
801 GCACATTGGG AACAACAGAG TCAGTACAT TGCTGATTGT GCCTTCGGGG  
851 GGCTTTCCAG TTTAAAGACT TTGATACTCC AAGGAAATCG GATCCGTTCT  
901 ATTACTAAAA AAGCCTTTCAC TGGTTTGGAT GCATTGGAGC ATCTGTCA

1451 CACATCTATG GTAGTCACCA AACCCGATGA CCAAGAGCAG TCTCAAGTTG

1501 CTGAGAGCC CATGGAGGC G

IIAA SEQUENCE 1.0

ID \_ADP30549 standard; protein; 425 AA.

XX AC ADP30549;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1316.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

XX KM cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411037P.

XX PR 17-SEP-2002; 2002US-0411041P.

XX PR 17-SEP-2002; 2002US-0411045P.

XX PR 17-SEP-2002; 2002US-0411046P.

XX PR 17-SEP-2002; 2002US-0411048P.

XX PR 17-SEP-2002; 2002US-0411052P.

XX PR 17-SEP-2002; 2002US-0411055P.

XX PR 17-SEP-2002; 2002US-0411073P.

XX PR 17-SEP-2002; 2002US-0411082P.

XX PR 17-SEP-2002; 2002US-0411101P.

XX PR 17-SEP-2002; 2002US-0411111P.

XX PR 18-APR-2003; 2003US-0463700P.

XX PR 18-APR-2003; 2003US-0463708P.

XX PR 18-APR-2003; 2003US-0463716P.

XX PR 18-APR-2003; 2003US-0463732P.

XX PR 02-MAY-2003; 2003US-0467199P.

XX PR 02-MAY-2003; 2003US-0467201P.

XX PR 02-MAY-2003; 2003US-0467203P.

02-MAY-2003; 2003US-0467230P.

PR 19-MAY-2003; 2003US-0471306P.

PR 19-MAY-2003; 2003US-0471336P.

PR 22-MAY-2003; 2003US-0472420P.

PR 22-MAY-2003; 2003US-0472430P.

PR 09-JUN-2003; 2003US-0476609P.

PR 09-JUN-2003; 2003US-0476641P.

PR 08-JUL-2003; 2003US-0485218P.

PR 08-JUL-2003; 2003US-0485223P.

PR 08-JUL-2003; 2003US-0485224P.

PR 08-JUL-2003; 2003US-0485325P.

PR 14-JUL-2003; 2003US-0486446P.

PR 14-JUL-2003; 2003US-0486480P.

PR 15-JUL-2003; 2003US-0486891P.

PR 15-JUL-2003; 2003US-0486960P.

PR 08-AUG-2003; 2003US-0493341P.

PR 08-AUG-2003; 2003US-0493370P.

PR 08-AUG-2003; 2003US-0493573P.

PR 08-AUG-2003; 2003US-0493577P.

XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

XX PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX DR WPI; 2004-348438/32.

XX PT New nucleic acid molecule for diagnosing, preventing or treating diseases

PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

PT genetic, bacterial and viral diseases.

XX PS Claim 1; SEQ ID NO 2547; 428pp; English.

XX CC The present invention relates to an isolated nucleic acid molecule

CC encoding a polypeptide which is believed to be cytostatic,

CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The

CC composition and methods are useful for diagnosing, preventing and

CC treating diseases such as proliferative (e.g. cancer), inflammatory,

CC immune, metabolic, genetic, bacterial and viral diseases. The present

CC sequence represents a human secreted protein. The present sequence is

CC available on WIPWEB and is not in the specification.

XX SQ Sequence 425 AA;

ADP30549 Length: 425 February 22, 2005 12:25 Type: P Check: 8184 ..

1 ACTGGACTGA AGACACTCAA TTGGGAAGC TGTGTGATCG CCACAAACCT

51 TCAGGAATA CGAAATGGAT TTCTGAGAT ACGGGGCACT GTGCAAGCCA

101 AGATGGAAA CATTGACATC AGAATCTTAA GGAGGACTGA GTCTTTGCAA

151 GACACAAAGT CTATCTGAC AGGTATTTA AAAACTACCA GACCCCTGAC

201 CATTATCTC TCGGAAGAT CAGCAGCCTC GCCAATTCCT TTCTTACCAT

251 CAAGAAGGAC CTCGGCTCT GTCATGCCCA CATGACATGC CATTGTGGGG

301 AGGAAGCAAT GAAGAAATAC AGCCAGATTC TGAGTCACCT TGAAGAAGTGG

351 GAACTCAGG CAGCAGTTGT GAAGGCTTTG GGGGAACTAG ACATTTCTCT

401 GCAATGGATG GAGGAGACAG AATAG

IIAA SEQUENCE 1.0

ID ADP30586 standard; protein; 948 AA.

XX AC ADP30586;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1353.

PR	29-AUG-2002;	2002US-0406640P.	PS	Claim 1; SEQ ID NO 2540; 428pp; English.
PR	29-AUG-2002;	2002US-0406642P.	XX	
PR	29-AUG-2002;	2002US-0406646P.	CC	The present invention relates to an isolated nucleic acid molecule
PR	29-AUG-2002;	2002US-0406648P.	CC	encoding a polypeptide which is believed to be cytostatic,
PR	29-AUG-2002;	2002US-0406653P.	CC	antiinflammatory, immunosuppressive, antibacterial and virucidal. The
PR	29-AUG-2002;	2002US-0406655P.	CC	composition and methods are useful for diagnosing, preventing and
PR	29-AUG-2002;	2002US-0406666P.	CC	treating diseases such as proliferative (e.g. cancer), inflammatory,
PR	17-SEP-2002;	2002US-0410946P.	CC	immune, metabolic, genetic, bacterial and viral diseases. The present
PR	17-SEP-2002;	2002US-0410947P.	CC	sequence represents a human secreted protein. The present sequence is
PR	17-SEP-2002;	2002US-0410948P.	CC	available on WIPOWEB and is not in the specification.
PR	17-SEP-2002;	2002US-0410949P.	XX	
PR	17-SEP-2002;	2002US-0410953P.	SQ	Sequence 1521 AA;
PR	17-SEP-2002;	2002US-0410957P.	ADP30542	Length: 1521 February 22, 2005 12:25 Type: P Check: 8168 ..
PR	17-SEP-2002;	2002US-0410958P.		
PR	17-SEP-2002;	2002US-0410959P.		
PR	17-SEP-2002;	2002US-0410960P.		
PR	17-SEP-2002;	2002US-0410961P.		
PR	17-SEP-2002;	2002US-0410962P.		
PR	17-SEP-2002;	2002US-0411019P.		
PR	17-SEP-2002;	2002US-0411022P.		
PR	17-SEP-2002;	2002US-0411023P.		
PR	17-SEP-2002;	2002US-0411024P.		
PR	17-SEP-2002;	2002US-0411032P.		
PR	17-SEP-2002;	2002US-0411035P.		
PR	17-SEP-2002;	2002US-0411037P.		
PR	17-SEP-2002;	2002US-0411041P.		
PR	17-SEP-2002;	2002US-0411045P.		
PR	17-SEP-2002;	2002US-0411048P.		
PR	17-SEP-2002;	2002US-0411049P.		
PR	17-SEP-2002;	2002US-0411052P.		
PR	17-SEP-2002;	2002US-0411055P.		
PR	17-SEP-2002;	2002US-0411073P.		
PR	17-SEP-2002;	2002US-0411082P.		
PR	17-SEP-2002;	2002US-0411101P.		
PR	17-SEP-2002;	2002US-0411111P.		
PR	18-APR-2003;	2003US-0463700P.		
PR	18-APR-2003;	2003US-0463708P.		
PR	18-APR-2003;	2003US-0463716P.		
PR	18-APR-2003;	2003US-0463732P.		
PR	02-MAY-2003;	2003US-0467199P.		
PR	02-MAY-2003;	2003US-0467201P.		
PR	02-MAY-2003;	2003US-0467203P.		
PR	02-MAY-2003;	2003US-0467230P.		
PR	19-MAY-2003;	2003US-0471306P.		
PR	19-MAY-2003;	2003US-0471336P.		
PR	22-MAY-2003;	2003US-0472420P.		
PR	22-MAY-2003;	2003US-0472430P.		
PR	09-JUN-2003;	2003US-0476609P.		
PR	09-JUN-2003;	2003US-0476641P.		
PR	08-JUL-2003;	2003US-0485218P.		
PR	08-JUL-2003;	2003US-0485223P.		
PR	08-JUL-2003;	2003US-0485224P.		
PR	08-JUL-2003;	2003US-0485232P.		
PR	14-JUL-2003;	2003US-0486446P.		
PR	14-JUL-2003;	2003US-0486480P.		
PR	15-JUL-2003;	2003US-0486891P.		
PR	15-JUL-2003;	2003US-0486896P.		
PR	08-AUG-2003;	2003US-0493341P.		
PR	08-AUG-2003;	2003US-0493370P.		
PR	08-AUG-2003;	2003US-0493573P.		
PR	08-AUG-2003;	2003US-0493577P.		
XX				
PA	(FIVE-) FIVE PRIME THERAPEUTICS INC.			
XX				
PI	Williams LT, Chu K, Lee B, Heatir K, Beaurang PA, Behrens D;			
PI	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;			
PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;			
XX				
XX				
DR	WPI; 2004-348438/32.			
XX				
PT	New nucleic acid molecule for diagnosing, preventing or treating diseases			
PT	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,			
PT	genetic, bacterial and viral diseases.			
XX				



PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX

DR WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2520; 428pp; English.  
PS The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX SQ Sequence 576 AA;  
ADP30522 Length: 576 February 22, 2005 12:25 Type: P Check: 291 ..  
1 CCACAACGAC CTGCCCCCTGG TCCTAAGGCA GGTTACCAG AAAGGGCTAC  
51 AGGATGTTAA CCTGGCGCAAT TTCAGCTACG GCCAGACCAG CTTGGACAGG  
101 CTTAGAGATG GCCTCGTGGG CGCCGAGTTC TGCTCAGCCT ATGTGCCATG  
151 CCAGACCCAG GACCGGGATG CCCTGGGCT CACCCTGGAG CAGATTGACC  
201 TCATACGCCG CANGTGTGGC TCCTATTCTG AGCTGGAGCT TGTGACCTCG  
251 GCTAAAGCTC TGAACGACAC TCAGAAATTG GCCTGCCTCA TCGGTGTAGA  
301 GGGTGGCCAC TCGCTGGACA ATAGCTCTC CATCTTAGT ACCTTCTACA  
351 TGCTGGAGT GCGTACCTG AGGCTCACC ACACCTGCAA CACACCTGA  
401 AGGTGGTGGC AGAAATGAAC CGCCTGGGCA TGATGGTGA CTTATCCCAT  
451 GTCTCAGATG CTGTGGCAG CCGGGCCCTG GAAGTGTGAC AGSCACCTGT  
501 GATCTTCTCC CACTCGGCTG CCGGGGTGT GTGCAACAGT GCTCGGAATG  
551 TTCCTGATGA CATCCTGCA CTTCTG  
!1AA SEQUENCE 1.0  
ID ADP30542 standard; protein; 1521 AA.  
XX AC ADP30542;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1309.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX

PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 02-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2497; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1578 AA;  
ADP30499 Length: 1578 February 22, 2005 12:25 Type: P Check: 4585 ..  
1 ATGGTCTTCT GCCCTCTGT GCTGCCAGGA TCTGCTGGGA GACAGGGTCA  
51 CAGTCGAGG GGNATGCGT TTGGTCTGCA CAGTGCCTGG GCAGAGCTGT  
101 TGCAAAAGCTC AGAAGAGAAA ATGGTAATA CATGTTCTGT TGCTCAACGG  
151 ATGTCTGTGA CTGCCAGAA CAGAGACTG GGAATGACA GGTTCGGGGG  
201 AGCAGCGTC CTGGCTGGG GCATCTGGAC CTTGGTGGAG AAGAGTGGCT  
251 ACCTCAGCGT CTGGCCTCC AGCACCTTTG CGCCTCTCCG CTACATCCTC  
301 ATCTTTGGG CGTACTTGT CATGGTGACC GCCTTCTTGG CTTTCGGTGC

351 CATCTCTGG GAGCGAAGG GCTGCCTCTC CAGACCACA GGGGATCGAT  
401 TTTGGAAGA CCGCAGGCC TGGACCTGCA GGGGAGACC AGTCACAGAA  
451 ACCAGAGTGG AGCTGGAGGT CAGTGGGATA GGTTCAGGTC ACACCAAGGG  
501 CACAGGACC ATGAAGGCAG AACCACTAAC TGGGGCAGTG GCTTCCCCCG  
551 AGAAGTGGG TGACACTGCC AGCTATCCAG GAGTATCCTA CGGGCTGAC  
601 TCACAGCTCA CAGTGGTGGT GGAGAGAAGG AAGTATTTCT GCCTGTGCT  
651 CGTCATCTTC CTGGTTGAGC TGGTGGGGG AGTCTGGCC CATGTGTATT  
701 ACCAGAGGCT GAGTGATGAA CTGAAGCAGC ACTTGAACCG GACTCTGGCT  
751 GAGAACTACG GGCAGCCCG AGCCAGCAG ATCACCGCCT CAGTGGACCG  
801 ACTCCAGCAG GATTTCAAGT GCTGTGAAG CAACAGCTCA GCCGACTGGC  
851 AGCAGAGCAC GTACATCTCTG TTGCGGAGG CCGAGGGCCG CCAGGTGCC  
901 GACAGCTGCT GCAAGACAGT GGTGGTCCG TGCGGCCAGC GGGCCCAACC  
951 CTCCAACATC TATAAGGTGG AGGAGGCTG CCTCACCAG CTGAGACAGT  
1001 TCCTGGCCGA CCACCTGCTG CTTATGGGG CAGTGGGCAT CGGGGTGGCC  
1051 TGCTTCAGG GCAGGCCCTTC TGTCTGTGT GCTGAACCCC AGAGGAGTAG  
1101 TCAGTGGGAA CAGGAGAAGT CATGGAACAG CACACCAGAG GCAGTTTCAG  
1151 ACCTGGACAG GATCATACA GTGCTGAGG AGTGTGTTA CTGGCTTACA  
1201 ACTGTGCTT ACACAGCCC AACAGCCAAC AAGAGCCTTG TCAGCCAGGC  
1251 AGGCAGCATG ATGCCATTGC TGAAGCTGTG CCTTTGGTGG CTGCTGGCTG  
1301 GCCTGCCAGC TGCCACTACT TCCAGCAAG TCGTGTATGCC TCATGTACAG  
1351 CCCAAAGACC AAGTTGTGAT TGCTGCTCTT GGGCTCCTGT CTGCAGATGC  
1401 CAGGACTGGC AGGACCCCTG TGTCTCTTCC ACGCATTTCT AGCGNAGSCT  
1451 GGTCCAGGAT GAGGAGACAC AGCAACGTCC CTGTCAACCAC AGTTATTGAG  
1501 TGCTTGCCCC GTGCCTTCAA CAAGCCAGGG AAACAGACAC ATAAACAGAT  
1551 GATGCGAGTG CGATGCGTGT TTCGATAG

!!AA SEQUENCE 1.0

ID ADP30522 standard; protein; 576 AA.

XX

AC ADP30522;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1289.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

FN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

28-AUG-2003; 2003WO-US026780.

XX

29-AUG-2002; 2002US-0406576P.

XX

29-AUG-2002; 2002US-0406579P.

PR

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3651; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1623 AA;  
ADP31653 Length: 1623 February 22, 2005 12:25 Type: P Check: 88 ..  
1 ATGCCACGCG TGTCACACAC AGGGAAGGCT CTCGCCATGA CGCTGGGCCT  
51 GGCCCTGACC ACCGGCAGGA GCTGTGTCAA CTGGCAAGCT CCAGGTGGCA  
101 GTTACTTGGT GGTGGGTGAC GAGGGCTGC CAGCAGGAGC AGCTGTGAGC  
151 GCGCTCACTC TCAGGCACCC AGGGCTGGCC GGGCCCCGGA GCTTAGTGCA  
201 CTGTGAGACA AGCTCTCTGC AGCCTACCT TCTTTGGACC GGGTCACTCA  
251 TTCCCATGGG GCAGGTGGAC GGGACTGGC CAAAGATGAC CTGTCTGTGC  
301 TGCCACAGGG GTCTGCACCC TGTTTGTGGG CACCAGTGC TGCTCTGCCA  
351 ACTTGCCCAT CTTACACACG GCTAGCAGA CTCTCTCTGG TCCTTTAAGA  
401 GCCTGTCAAA TGCACCCCTC CCATTCTCG CCAGTGGTAC CCATGAGCTG  
451 CCAGCTCGCC TCCTTGGCAC CCAGCACGTA ACTGATCCCT ACTGGGAAGG  
501 GGAGCTGGG AGTGGGCTGG GAGCGCCCA CTCCTCATCC GCCTGAGGG  
551 ACAGGACAG CACAACGGAG GCCCTGCACC TTGCGCAGA GTGTCAACTT  
601 CATTATCACA GGGATGGAAT CCTGGCCAGC CCCACGGCCC ACAGGAATGG  
651 GGTGCTCCAG GCTCAGAGAC CCCACTCGC CCAGAGCAGC CTTGCTATGG  
701 AAGTCGAGCC TGTAGACCCT GAGGTCAAGC CCAAGGGGTG GGGCAGGCAC  
751 GAGGGGCCAG AAATACAAGT CCCCAGGCC AGGCCTGGAA AATACGGTGA  
801 CCAGGCAGCG TGTTGGGTGC AGGAGAAAGG CCCGAGGTG ACGCTCTGA  
851 GGAGGGCATG GTCTTGGGAC CCACCTCAGC CATCTGCACC GGGCCCCCTCA  
901 TGCTCCTTGG TTCCGGGTGA TGTCAGTGCT GGCTTCAACC AGCTGGAAGC  
951 TGTGGAGTGT GGCTTCTTTT CTTCTGAGTT TAATTGTCTG CCCCCCACA  
1001 CAGTCTACGA GCCCCAGCA AAGCGAGCTT TTACAGGCT ACTGTGCCCT  
1051 CTGCAGAGGC CCATTGAGAA GGAAAAAGCC AAGATGGCAC AAGGAAGGCC  
1101 CGCAGACATC CCAGACCAA CGTCCAAACA GGCAGCCCTG TGGTGCCACA  
1151 GGCACCTAGG CACCGTGCTC AGCGTGGCG GTCTGCCCTC GGGGCTCCAC  
1201 CAACAGCAGG GACACAGGTG CTGGCAGGTC ACCCAAGTGG CAAAGGGAGC

1251 CACAGGAAGA GCGGGCTCCA GGCCTGGGA GGGCCAGAA GGCCTGTGAG  
1301 AGGCCCATGA CAGGGAGAT GAGCTGTGG GGGTTGGAGG GCAGAGCATA  
1351 AAGGAAGCTG GGGATGGTGG AGGTTTGGG CACAAGAAAGC CAGGCAACCA  
1401 GGCAAGGCMA TGCTCCCTCT CCAACAAGGA GACTCGTGA GAGCTTCTGTG  
1451 TTTTATATCA CTTTGTGAAA ACAACAGAA AGGAGCTCA AAGCTACGG  
1501 AAGCAGCAAA ACAATGCCCC CGGCACCTC ACAAGGCAC AGGGAAGTG  
1551 GGGTCACTTA AAGCAAGCA GGAAGTTTC ACAGTTGAGT CCAATGAAAA  
1601 TCAAGAAGAA TAGAGGAGAG TAA  
!!AA\_SEQUENCE 1.0  
ID\_ADP30499 standard; protein; 1578 AA.  
XX  
XX AC ADP30499;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1266.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.  
XX PR 17-SEP-2002; 2002US-0411023P.  
XX PR 17-SEP-2002; 2002US-0411024P.  
XX PR 17-SEP-2002; 2002US-0411032P.  
XX PR 17-SEP-2002; 2002US-0411035P.  
XX PR 17-SEP-2002; 2002US-0411037P.  
XX PR 17-SEP-2002; 2002US-0411041P.  
XX PR 17-SEP-2002; 2002US-0411045P.  
XX PR 17-SEP-2002; 2002US-0411046P.  
XX PR 17-SEP-2002; 2002US-0411048P.

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3650; 429pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 711 AA;  
ADP31652 Length: 711 February 22, 2005 12:25 Type: P Check: 5638 ..  
1 ATGGTGCACT GCACCTCACTC CCCTCATCGC CTTACTAAGA TTTTGCAAAAC  
51 TTCAGGCAGC CGCTTGGGCA GAACGGTTGT GCACCTCCCTC TTCCTCTCTCC  
101 AGACCATATAA CTTGAATAAG CCTCTCGCA TCTTCAAAGC AFTTGCTCGC  
151 GCGTCTGGCG CGCACTCTCC AGGCGCACAC TTGAGCGGGG CGCGAAGGAG  
201 TGGGCGGCTT TTCCTCAGG CGCTGCACAT TTCTTCCGG ATGACTAGGG  
251 AGTTGCAGC CGTCTTCAC AGTGGAGTGG TTTCTCTTT GCGAGCGGGA  
301 GGAAGTCTCC AGCCGCGCCT CCTCACTCTC ATTCTTACCA ACTTCGCGGC  
351 GGAGCCAAGC CAGGTGGGA ANTGGTCCG AGTGTGCTG CATGGAGAAC  
401 AGCGAGGACA GACTGCGGGG GCCAAGAAGC CTGCTGGCTT TGCTCCACCC  
451 CCCATCAGTC CCAGSCTCG ACCTTTCTGC CAGAGCAGCA AAGAAACCCG  
501 AGGCTGCATT TATCTACTCA ACTGAGAGG AAGGGTTCA GAAGGAATG  
551 GGATCGAAAG TGTAACGCC TGCAATAAAT TAAAGAGCCT GCTGCTGCTG  
601 CTGCTGCTGC TGCTGCTGCT GCTGCTTTGG CGGCCAGAAC TGGAGAGAGA  
651 AAATGAGATC AGTGCCTTAA AGCTTGATC GATCAGAGTG ATTAGACGTC  
701 ATFCGATGTA G  
!!AA SEQUENCE 1.0  
ID ADP31653 standard; protein; 1623 AA.  
XX  
AC ADP31653;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2420.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI

1 GCACTCATTTG CACCTTCTCTG CCACCCCCAGG CAGTGTCTGG GCCTCAGCT  
51 CCCCTCCCT CCACCTACCC CCTCACACC ACCACTAGA CCCACGGGA  
101 TACCCAGCCC AGACGGAGGA AACCCGAGC CTAGAGACAT GAGAGTTGGA  
151 GGAGCATTTCC ACCTTCTACT CGTGTGCTTG AGCCGAGCAC TGCTGTCTGC  
201 TGTGCGGATC AACGGGGATG GACAGGAGT CCTGTACCTG GCAGAAGGTG  
251 ATAATGTGAG GCTGGGGTGC CCTAGGTCC TGGACCCCTGA GGAATATGTT  
301 CCCAATGGC TGGACATCGA GTGGATGCG GTCAACTCAG ACCCCGCCCA  
351 CCACCGAGAG AACGTGAGCA AGAGGATCAA CCATGGCAGC CTTCCCCATC  
401 TGCAGCAGAG GGTCCGGTTT GCAGCCTCAG ACCAAGCCA GTAGGATGCC  
451 TCCATCAACC TCATGAACCT GCAGGTATCT GATACAGCCA CTTATGAGTG  
501 CCGGTGAAG AAGACCACCA TGGCCACCAG GAAGTCAAT GTCACTGTCC  
551 AAGCACACC TGCAGTGCCC ATGTGCTGGA CAGAGGGCCA CATGACATAT  
601 GGCAACGATG TGGTGTGTGA GTGCTATGCC AGTGGGGCT CCCAGCCCTT  
651 CTCCTACAAG TGGGCCAAGA TCAGTGGGCA CCATTACCCC TATCGAGCTG  
701 GGTCTTACAC CTCACAGCAC AGCTACCACT CAGAGCTGTC CTACAGGAG  
751 TCCTTCCACA GCTCCATAA CCAAGGATGG CTTGTATCAG TGCACAGTGG  
801 CCAACAAGT GGGCTACAGT GTTTGTGTGG TGGAGGTGAA GGTCTCAGAC  
851 TCCCGGGTA TAGCGGTGAT CATCGGCATC GTCCTGGGCT CTCTGCTCGC  
901 GCTGGGCTGC CTGGCCGTAG GCATCTGGGG GCTGCTGTC TGCTGTGGG  
951 GGGGCTCGG GGCTGGGGC GCCCGGGTG CTTCCGGCTA CGCAACGGC  
1001 GCGGGGGTGC GCGAGGGGC CTGGCGGCAC TTGGGTAGTG AGATCAGAGA  
1051 GGAGCCCGTG GCSCCCGGGT GCAAGGCCAG CGGCGCGGC AGCGGCTCA  
1101 CCCACCTCT GGGGTACCG ACACAGAAC TCAGCGCTC CTTGGCGGC  
1151 AAGTACGGC CTCCCGCTG CCGCGCCCTG GAGGACGTGG CCTGGCGCC  
1201 CTGACCCGCC GCGCGCCCT GCGAAGCGGG CCCCTCCCG GTCTACGTCA  
1251 AGGTCAAGAG CCGGAGCCG GCTGACTGCG CCGAGGGGCC GTGCACTGC  
1301 AAGAACGCC TCTTGTGTG A

!!AA SEQUENCE 1.0  
ID ADP31652 standard; protein; 711 AA.

XX AC  
XX AC  
XX ADP31652;  
XX DT 12-AUG-2004 (first entry)  
XX XX  
XX Human secreted protein SEQ ID #2419.  
XX DE  
XX DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX KW  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX XX  
XX 29-APR-2004.  
XX PD  
XX XX  
XX PF 28-AUG-2003; 2003WO-US026780.

29-AUG-2002; 2002US-0406576P.  
29-AUG-2002; 2002US-0406579P.  
29-AUG-2002; 2002US-0406585P.  
29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410949P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411010P.  
17-SEP-2002; 2002US-0411101P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486891P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX XX  
XX PA  
XX PI

1251	TTATCAGCAC	AAAGAGCATC	CAGAGTGACG	AGCGGGATGA	CATCAGACAG	PR	17-SEP-2002; 2002US-0410961P.
						PR	17-SEP-2002; 2002US-0410962P.
1301	AACTACAAGT	ATGAGNAGC	ACCTTCCTTT	CGACCCAGTG	ATGTGGTGCA	PR	17-SEP-2002; 2002US-0411019P.
						PR	17-SEP-2002; 2002US-0411022P.
1351	AGTCTCCCTG	AAATTCAGC	TGCTCGACCC	GCCCAACATG	GGCCAGGATA	PR	17-SEP-2002; 2002US-0411023P.
						PR	17-SEP-2002; 2002US-0411024P.
1401	TATGCTTTGT	CCTGCTGGCC	CTCAACATGT	CCTCCAGTT	CAAGGACCTC	PR	17-SEP-2002; 2002US-0411032P.
						PR	17-SEP-2002; 2002US-0411035P.
1451	AAAGTGAACC	TGAGTGCCCA	GTCTCTGCTG	CACGATGGCA	GCCCCCTGTC	PR	17-SEP-2002; 2002US-0411037P.
						PR	17-SEP-2002; 2002US-0411041P.
1501	CCATTCTCG	CAGGACACAG	CGTTTCATC	ACTCTCTCCT	AAAGAAGCAA	PR	17-SEP-2002; 2002US-0411045P.
						PR	17-SEP-2002; 2002US-0411046P.
1551	AGACCTACCC	CTGCAAAATC	TCCTATTCCC	AGTACAGCCA	GTACCTGTCA	PR	17-SEP-2002; 2002US-0411048P.
						PR	17-SEP-2002; 2002US-0411052P.
1601	ACAGACAAAC	TCATCCGAT	CAGTGCCTG	GGTGAAGAGA	AAAGCAGTCC	PR	17-SEP-2002; 2002US-0411055P.
						PR	17-SEP-2002; 2002US-0411073P.
1651	TGAGAAAATC	CTGTGTGAACA	AGATCATCAC	CTTATCTTAT	CCAAGCATCA	PR	17-SEP-2002; 2002US-0411082P.
						PR	17-SEP-2002; 2002US-0411082P.
1701	CGATTAATGT	TCTAGGAGCA	GCCGTTGTGA	ACCAGCCACT	CTCCATACAG	PR	17-SEP-2002; 2002US-0411111P.
						PR	18-APR-2003; 2003US-0463700P.
1751	GTGATATTTT	CAAAACCCCT	CTCGGAGCAG	GTTGAGGACT	GTGTGCTGAC	PR	18-APR-2003; 2003US-0463708P.
						PR	18-APR-2003; 2003US-0463716P.
1801	TGTGGAAGGA	AGTGCCTCT	TCAAGAAACA	GCAGAAAGTC	TTCTTTGGAG	PR	18-APR-2003; 2003US-0463732P.
						PR	02-MAY-2003; 2003US-0467199P.
1851	TCCTCAAACC	CCAACACCAA	GCAAGCATCA	TTCTGGAGAC	CGTCCCTTTC	PR	02-MAY-2003; 2003US-0467201P.
						PR	02-MAY-2003; 2003US-0467203P.
1901	AAAGTGGGAC	AAAGGCAGAT	CCAAGCTAAT	ATGAGAAGCA	ACAGTTTAA	PR	02-MAY-2003; 2003US-0467230P.
						PR	19-MAY-2003; 2003US-0471308P.
1951	GGACATTAAG	GGTTCACAGG	ATGTTTATGT	AGACTTTGCA	TTATAA	PR	19-MAY-2003; 2003US-0471336P.
						PR	22-MAY-2003; 2003US-0472420P.
!!IAA	SEQUENCE 1.0					PR	09-JUN-2003; 2003US-0476609P.
ID	ADP31608	standard; protein; 1321 AA.				PR	08-JUL-2003; 2003US-0476641P.
XX						PR	08-JUL-2003; 2003US-0485218P.
AC	ADP31608;					PR	08-JUL-2003; 2003US-0485224P.
XX						PR	08-JUL-2003; 2003US-0485224P.
DT	12-AUG-2004	(first entry)				PR	14-JUL-2003; 2003US-0486446P.
XX						PR	14-JUL-2003; 2003US-0486480P.
DE	Human secreted protein	SEQ ID #2375.				PR	15-JUL-2003; 2003US-0486891P.
XX						PR	15-JUL-2003; 2003US-0486960P.
KW	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;					PR	08-AUG-2003; 2003US-0493341P.
KW	cancer; inflammatory; immune; human secreted protein.					PR	08-AUG-2003; 2003US-0493370P.
XX						PR	08-AUG-2003; 2003US-0493573P.
OS	Homo sapiens.					PR	08-AUG-2003; 2003US-0493577P.
XX						XX	
FN	WO2004035732-A2.					XX	
XX						XX	
PD	29-APR-2004.					PA	(FIVE-) FIVE PRIME THERAPEUTICS INC.
XX						XX	
PF	28-AUG-2003; 2003WO-US026780.					PI	Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
XX						PI	Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
XX						PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
PR	29-AUG-2002; 2002US-0406576P.					DR	WPI; 2004-348438/32.
PR	29-AUG-2002; 2002US-0406579P.					XX	
PR	29-AUG-2002; 2002US-0406585P.					XX	
PR	29-AUG-2002; 2002US-0406588P.					XX	
PR	29-AUG-2002; 2002US-0406608P.					XX	
PR	29-AUG-2002; 2002US-0406611P.					XX	
PR	29-AUG-2002; 2002US-0406612P.					XX	
PR	29-AUG-2002; 2002US-0406616P.					XX	
PR	29-AUG-2002; 2002US-0406640P.					XX	
PR	29-AUG-2002; 2002US-0406642P.					XX	
PR	29-AUG-2002; 2002US-0406646P.					XX	
PR	29-AUG-2002; 2002US-0406651P.					XX	
PR	29-AUG-2002; 2002US-0406655P.					XX	
PR	29-AUG-2002; 2002US-0406663P.					XX	
PR	17-SEP-2002; 2002US-0410946P.					XX	
PR	17-SEP-2002; 2002US-0410947P.					XX	
PR	17-SEP-2002; 2002US-0410948P.					XX	
PR	17-SEP-2002; 2002US-0410949P.					XX	
PR	17-SEP-2002; 2002US-0410953P.					XX	
PR	17-SEP-2002; 2002US-0410957P.					XX	
PR	17-SEP-2002; 2002US-0410958P.					XX	
PR	17-SEP-2002; 2002US-0410959P.					XX	
PR	17-SEP-2002; 2002US-0410960P.					XX	
						SQ	Sequence 1321 AA;
						ADP31608	Length: 1321 February 22, 2005 12:25 Type: P Check: 5984 ..

PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 3597; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

XX Sequence 1996 AA;

ADP31599 Length: 1996 February 22, 2005 12:25 Type: P Check: 4778

1 GGCTAGAAGT GGCCTTCACA GACCTCCAGA GTCCAGAAA TAATGTGCGG  
51 CACCACACGG AGGAGATCAC TGTGACCAC CTGCTTGTTT GCCGGGGCCA  
101 GGCCTTCAAC CTCACCTGT ACTTCAGGAA CCGGAGCTTC CAGCCAGGCC  
151 TGGACAACAT CATCTTCGTG GTTGAACTG GGGACTCGG CTGTGTTTCTAG  
201 CCTGGCAGCG CATCACAGCC CCAGCCCTG GATTGCCCTG CTGGAGACCA  
251 ATGGGGCCAC CTCACAGAG GTGAGCTTGT GCGTCTCTCC CACGGCGGCC  
301 GTGGGTGCGT ACCTTTTGAA AATCCACAT GACTCTCTCC AGGGGTCTGT  
351 GACGGCCTAC CAGCTAGGGG AGTTTCATCT GCTTTTCAAT CCCTGGTGCC  
401 CAGAGGATGC TGTCTACTTG GACAGTGAAC CCCAGAGGCA GGAGTATGTC  
451 ATGAATGATT ATGGCTTCAAT CTACAAGGC AGCAAGAACT GGATCCGCCC  
501 ATGTCCCTGG AACTATGGAC AGTTTGAAGA CAAAATCATA GACATCTGCC  
551 TGAAGCTGCT AGACAAGAGC CTGCACCTCC AGACTGACCC AGCCACAGAC  
601 TGTGCTCTGC GGGGAAGCCC CGTCTACGTC AGCAGAGTGG TGTGTGCCAT  
651 GATCAACAGC AATGATGATA ATGGGGTGCT CAATGGAAC TGGAGTGAAG  
701 ATTACACAGA CGCGCCCAAC CCTGGGAGT GGACGGGCG CGTGGCCATC  
751 CTGAAGCAGT GGAAGCCAC AGGCTGCCAG CCCGTGCGCT ACGGGCAATG  
801 CTGGGTCTTT GCTGCGGTCA TGTGCACAGG TAGGAGTGAT GAGGTGCTG  
851 GGGATCCCTA CCCGTGTGAT CACCACTTC GACTCTGCC ACGATACAGA  
901 TGGAAACCTG ATCATAGATG AGTATTATGA CAACACAGGC AGGATTTTGG  
951 GGAATAAGAA GAAGGATACT ATCTGGAAC TCCATGTCTG GAATGAGTGC  
1001 TGGATGCCC GGAAGGATCT GCGCCCTGCA TATGGAGGCT GGCAGGTGCT  
1051 GGACGCCACA CCTCAGGAGA TGAGCAAGG CGTCTACTGC TGTGGCCCTG  
1101 CCTCTGTGAG AGCCATCAA GAAGGAGAAG TGGACCTGAA CTATGACAGC  
1151 CCCTTTGTGT TTTCGATGCT GAATGCTGAC TGCATGCTCT GGCCTGCTCCA  
1201 GGGAGGGAAG GAGCAGAAGC TTCACCAGGA CAGAGTCTCT GTTGGCAATT

PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams JT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3534; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1530 AA;  
ADP31536 Length: 1530 February 22, 2005 12:25 Type: P Check: 401 ..  
1 ATGGCAGAGA TAAATTCAGGA ACACAAAGAA GATCAGCTCC CTGAATTGGA  
51 ACAGCTAGAG CACATTGGAC TGTTCACTCA TGCAGAGATT AACGCTATCA  
101 TTAAGAAGGC TTCTGATCTA CAGTACAGAA TCCAGGAAG AGCCCTTTTC  
151 AAGGACGACT TTATCAATTA TGTTCAACAT GAAATTAATC TTTTCGAACA  
201 GATCCAGAGA AGNACACGA TTGGATATTC ATTTAAGAAG GATGAGATTG

251 AGAATTTCTAT TGTACACCAG GTACAAGGTG TTTTCCGAAG TGCCTCAGCA  
301 AAGAGAAAG ACGATGTTCA ACTTTGGCTC TCTATCCAG CTTTGTGGAT  
351 TATGGCAGCC AAATGGGAAA TGAAGACTG CTTGTCTTCA GAAAGTGCAA  
401 GGCAACTATT TCTTTGGGCA CTCACATTTC ATCCAGAGGG CCCAAACTTT  
451 TATCAAGACT ACTTTAGAT GGAGCTGATG CATGCTGAAA AACTGAGAA  
501 GGAAAAGCAA GAAATTTCAA AAGCCAACAT GGATGTGGAG AATCTGATT  
551 ATTCTGAAGA AATCCTTAAG GGCAAAATTGG CACGGATCAT CTATGAAAAT  
601 TCTGGACCAG TTCAAGTAAC ATTTCTGCAG AGGCTCCCTT TGTGTGCTAT  
651 ACCAGATTCA GGCAGTGGGA GAAGAAAAGA GGAAACAGTT TCTTCTGAGA  
701 GCAGACAGAT CAAACCGGTG AATGCAAGGG CAGCCACATT TCAATCACAA  
751 AAAGGGTGTG CCTTAAGTTT TGGCTCCCC ACTCGCCGC CCACCTTTCA  
801 ACAAGCCGAA GCCTTTGAAG GAGGCTCGGT GCCATCTCGG TGTGATCGCG  
851 TCCCGCGGAC GCTGGCCACC ATGGCCGGTG CGACTCCCTA CCCGCGCCCG  
901 CAGACGGACT TCCTGGAAG CACCGGGCTG GGCCTTACCTG ACTGGCGCCC  
951 GCAGGGGCGG CCGACCTCTT CACAGACCCA CGGAAACTGC CGGCGGCAAG  
1001 CCGAGGCTCG GTTCCAGCA CCGCGCGGTA TCGGTTTCGG GGATGATGTA  
1051 GCTATTGCAG GGCAGTTTCT GCCATCCTTA TCTTCCTTTT CCATCTTCAA  
1101 GCTCTACACC AGGCGCACCT ACTATGTACA AGGCACCTTA CAAGATGATA  
1151 CTGAAGATAC AAAGATGGAT GAGACACAGT CCTGCCTCCA AGGGCTTATG  
1201 AAAGTCATTG GAGGCCATGC TTCAAAACCT TTCTTAGCAG AAATATTACT  
1251 GACCAGGGCT AAGGTTGCTG GTGATAACAA GGCAGCTGCT GCCCTGGAGA  
1301 GCTATTTCGA GGACATTGGT TTCCCTAATG CTGGTGCCCT GTCAGGGGCC  
1351 ATGTTTCTGT TGAAGAGAA GCACCTGCTC TTTGGGCTGT TGGGTACTCG  
1401 AGTGTTAGAA CTTTCGAATT TCTATGGGAT AGAAATTCCA GAAGAGACCC  
1451 GTGAACAGT GCACCTTTGAC TATTTTCATG GCCGTTTATC CACGGCACTT  
1501 GCAATTCGT CACCAACTGG CTTTAACTAA  
!!AA SEQUENCE 1.0  
ID \_ADP31599 standard; protein; 1996 AA.  
XX  
AC ADP31599;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2366.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX



401 GCATCATGGG CCTAGACCGA TCATGTGGGA CCAGGGAGAT TGGATCTGCT  
451 CTCACAGGA TGTGCATGAG GCACAGAAGC ATTGAAGCCA AGCTGAGGCA  
501 GTTTTCGAGC GCITTAATTG ATTGTCTGAT AAACCCACTT CAAGAACAGA  
551 TGGAGAGATG GAGAAAGTG GCCAACCCAGC TGGATAAAGA CCAGGCCAAA  
601 GAATATAAGA AAGCCCGCCA AGAGATAAAA AAGAAGTCTT CGGATACGCT  
651 GAAACTGCAG AAGAAAGCAA AAAAAGGGAG AGGTGATATC CAGCCTCAGT  
701 TGGACAGTGC TCTCCAGAT GTCAATGATA AGTATCTCTT ATTGGAAGAA  
751 ACAGAAAAGC AGGCTGTCCG GAAGGCTTTG ATTGAAGAAC GTGGCCGATT  
801 CTGTACCTTC ATCTCTATGC TGGGCCCACT GATTGAAGAA GAAATCTCAA  
851 TGCTAGGGGA AATAACCCAC CTTTCAGACCA TCTCGGAAGA TCTAAAAGC  
901 CTGACCATGG ACCCTCACAA ACTGCCCTCC TCAAGTGAAC AGGTGATTCT  
951 GGACTTGAAA GGTTCGTGAT ACAGCTGGTC GTATCAGAGC CCACCTCTTT  
1001 CCCCAGAC CACATGTCC AGAAAGTCCA GTGTCTGCAG CAGCCTGAAC  
1051 AGTGTCAACA GCAGTGAATC CCGGTCCAGC GGTCTCCACT CGCATTCGCC  
1101 CAGCTCACAT TACCGTACC GCAGCTCCA CTTGGCCAG CAGGCTCCTG  
1151 TGAGGCTGTC CAGGCTGTC TCCATGACT CAGGATTCAT ATCCAGGAT  
1201 GCCTTCCAGT CCAAGTCACC ATCCCCCATG CCGCCAGAGG CCCCCAACCA  
1251 GAACCTCGTC AGCTCGGCT CTTCCGAGC CTCGGAACC TGCAGTCAG  
1301 TGAGCGAGTG CAGTCCCCC ACCTCTGTCA GTCGGGGTC CACATGGGT  
1351 GCCTGGGTGT CCACAGAGAA GGTGACCGCC CCGGTGGCAG CCACAGCGGC  
1401 CCCACTCTCC CTGGTCCCC TCCTTGCTGC TCAGACAGCC CTCACAGCG  
1451 CGGCAACCTG GAAGCTGAGA ATGCACACCA AGAGTGGGGC TCCTCTTGGG  
1501 GACAGAGGTT TATCAAGTGA GTCCACAGTG GGGCCACCG GTGCAGSCCT  
1551 TTTCCCTCAT TGCTGGCTG CTCCGGCT GCTCCCTCG GTCACTCTG  
1601 TCCACCTTCC AGACTAGCT CATTAATTACA CCATTTGGCC CGGATGTTT  
1651 CCGTCATCTC AGATCCCTAG CTGGAAGGAC TGGGCTAAGC CTGGGCCCTA  
1701 TGACACGCT CTGCTGACA CCTGACAGG CCGCAAGAG AAGGAGAAC  
1751 CGGACCCCAA CCGGGAGGA CCCACTACG CCAGCGGCC ACCTGACGA  
1801 GCTCAGGAGG CTCAGAGACC ACGGAGCATG ACTGTATCG CTGCCACAG  
1851 GCCTGGTGAG GAGATGGAG CTTGTGAGGA GCTGGCCCTG GCCCTGTCTC  
1901 GGGGCTTCCA GCTGGACACC CAGAGGAGCA GCCGGGACTC GCTTCAGTGC  
1951 TCCAGCGGCT ACAGCACCCA GACAACCC CCCTGCTGCT CTGAGGACAC  
2001 CATCCCTTCC CAGATTATG ATATTCTTC TGTAAAGTGT GACCAGGAG  
2051 CAGATCAGCA GAGTTGGAC AAGTCTTCCA CCATTTCCAA AATACGGAC  
2101 ATCAGCCAGT CCTACCGAG GATGTTCCAA GCCAAGCTC CAGCCTCAAC  
2151 TGCTGGGCTC CCACACACC TGGGACCTGC TATGTCNCT CAGGGGTTG  
2201 CAACTATCG ACGGACCCCT TCCACCAAGC CTTCTGTCCG CCGGGGAAC

2251 ATTGGAGCTG GTCCATCCC CATCAAGACA CCCGTGATCC CTGTCAAGAC  
2301 CCCAACCGTC CCAGACCTCC CAGGGTGTG GCCAGCCCTT CCAGATGGGC  
2351 CAGAGAGCG GGGGAGCAC AGCCTGAGT CGCATCTGT GGTGAGGGC  
2401 CCCAAGGTG TCACCAGCAT GCCCTCTCA ATGTGGAGC GCCAAGCTTC  
2451 CGTTAACCTT CCACCTCCAG GCCGAGCC CAGTATCCT GAGGAGCACA  
2501 GACAGGCAAT TCCAGAACT GAAGCTGAAG ACCAGGAAG GGAACCCCA  
2551 AGTGCCACTG TCTCCCCAG CCAGATTCCA GAGAGTGACC CTGCAGACTT  
2601 GAGCCCAAG GATACTCCAC AAGGAGAAGA CATGCTGAAC GCCATCGAA  
2651 GGGGCGTGA ACTGAAGAAG ACCAGGACA ACGATCGCT AGCCCTCGC  
2701 TTTCTTAG

!IAA SEQUENCE 1.0  
ID ADP31536 standard; protein; 1530 AA.  
XX AC  
XX ADP31536;  
XX DT  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #2303.  
DE  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN  
XX PD  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.

101 CGGACCCCG CCTAACACC AGTCACATTCT TGTGGGATGC TCCTCATTC  
151 ATTCTGTGCC ACGCAGACGC GAGTTTCTGT AGAGTTGTAA CCACCATATA  
201 CATGCAGGCC CAAGGTACCA GGAGGCAGAT GCTGACAGAT GCATCTCAGT  
251 ATGCCCGGCA CCTCCACCAC ACAAGGCTG TGCTGTTGCT TGTGGGAATG  
301 CTGCAGGCA CAAACCGAT AATCTGGAG GAGAGACCA GCAACACAA  
351 GGCTCAAGAA ACTCAGTAT GTAAGAAGAG GACATGACA ATGGAAGAGG  
401 GAAGCCACCA TGCAGATGT CGGGTGCAC TTTTAAATGG GACAGTCAAG

!!AA\_SEQUENCE 1.0  
ID\_ADP31526 standard; protein; 2709 AA.  
XX AC  
XX ADP31526;  
XX  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2293.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX

XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406613P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406648P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.

PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485234P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Halshan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3524; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 2709 AA;

ADP31526 Length: 2709 February 22, 2005 12:25 Type: P Check: 683 ..

1 ATGACATGTG GTTCTGTCAT CAGGCCACAG CTGCTTCGCT GGCAGGAGCT  
51 GGCCTCATCG AGTCGCTCAG ACCTGGCTTC AGCAGGAGCA TCTTCTGTG  
101 CCCATGCAGC AGAGGCAGAC CATGGCAATG GGGGGTTTCAT GGTGGCAGAT  
151 GTCGGGGAGA CAGCTGGCAT TTCCAGGCT GCGTGGAGTG TGCTGCCAT  
201 CCAAGTGTGT GGGAAAGAGG AGACAGATGG GAATACAGCT GCCAAGGAGC  
251 CCCAAGCCG TTTTGGAGGT CATTTGGGG AGGAGGGGT CACTTACCTC  
301 AATAGATCAG GAAACAATTC CCAGAGGCC TCCCAGCAG CCTCTCTCC  
351 ATGTCTTTGT CCCATCCTCTG AAGCAGCCAC TGCCAAAGGG GATGGAGTTA

651 GCTCACACTC CTTCCACAAA CCTGCCGGAG TCTCCACTCG CCGCCCAACT  
701 GTAGCTTCCA TCTGGGCCCC AGCCCCCGC ACAAGCCCCC TCCGTGCGGG  
751 GTCTCTTACC TTGTGGCCTT TCCCGGGGG ATACTGAGC CTATTGGAGA  
801 CTCCTGGCGT TTGATTCATG TCCAGAGGAA GTTGAGGGGC CCAGATTCTC  
851 TACCTTCAAA ACTTCTTAGG CGCTGGAGG GTGGCGACAG AGCCGAGTCT  
901 GGGCGAGGC GAGGGAGCC TCCAGCTGC AGGCTTCTGT GCAGGGGCGG  
951 TAAATCCG AGCCAGAGC TGGAGAAGGA GAAGCAGCTG CTGGACCCC  
1001 GGAGGAAGC CGGGCCGGC CGAGCGGCTC CGAGGGGCT CTGCCAGTG  
1051 CTGCTCCCC GGAACAGT TCAGACGCT CAAGACCAGA AGCGGAGCA  
1101 AACCCTAAG GAGCTCCAAG GAGGCGAGG CCACCGCTGC AAGGAGCCCA  
1151 CGGTGCGCG CTCCTGCTCA GGGCGATCT TTCCACACCC CCCTCAGCCT  
1201 CAAAGCTCA GGTGTGAGC GTCATCAGTG CGACTCGG CACCCACCC  
1251 ACCAGCAGG GGTAA

!!AA SEQUENCE 1.0  
ID\_ADP31451 standard; protein; 450 AA.  
XX AC ADP31451;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2218.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406577P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.

17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 3449; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPOWEB and is not in the specification.  
SQ Sequence 450 AA;  
ADP31451 Length: 450 February 22, 2005 12:25 Type: P Check: 8464 ..  
1 ATGGGCCAGG AGTGGNATCA AGGAAGGTGC TGGGAGGAAT TTGAGATGTC  
51 CCAGATCTCA GCCCTACCCA GCCTTCTGAA AGAGGAAAAA GAATTCTCCC

751 AGTTGTAGG CTCCTCTCTA TGATGTGGCT GCTCATGAAG AGAAAGTTCT  
801 GAGACGAC TAG  
!!AA SEQUENCE 1.0  
ID ADP31450 standard; protein; 1266 AA.  
AC  
AC ADP31450;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2217.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411059P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.

PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3448; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC anti-inflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1266 AA;  
SQ

ADP31450 Length: 1266 February 22, 2005 12:25 Type: P Check: 7076 ..

1 ATGGGGGAAT CCCAAGAGCC ATTTTGTAG GAACTCCACC CAATAGAGCC  
51 AAGGACCAG AAGGGGTAA AGACAGGAAG TGTGAGGATG TGTGAAGCCA  
101 TCACAGTGAG AGAAAGGCT AAAAGCCATC TTCCAACATT CTATGTGAGG  
151 GTCTCCAAAG AAGCTCTCCA AAAGCTCCCC ATGAGAAAAA ATGGTGGTTC  
201 TGAAGCCAAG TGTGTGAGAA AGAAAGGCG GCAGGAAAAA GACCTGCTGT  
251 TATGGCAGCA ACTGTGTAAA CGCCGTAAGC CTTGCATGAG TTTCCTCATGT  
301 CCCGTAGCCT GCACGCATCG CTCATTAAA GTTAATGAAG CACGTGTCGG  
351 TGACAGCAGC CAGGCCAGC GCCCGGGGA GAGCCCCGGG CGCGTTCGCC  
401 GGGAAAGAGC TCCTCTGCAA GTCTGTGCCC AGGGGGCCTC GCATCATATGG  
451 GAACACAGCTG CACCTGCCAG CCCAGCCGCA AAGCAGGGTA GGATCTCCAG  
501 CCCCAGGGTG GCCCGGGGA GCGGATGCAC GGGCAGAGCC CTGCTGTCTGG  
551 CCGCGGGTCT ACAAAACAGC ATACGTTCTC TCAACCCCTG CGATCCGCCA  
601 ACCATCTCTCA GTCACCGACC CCTGCAAGGG ATGCAGAGCC ACCAGCGGCT

!!AA SEQUENCE 1.0  
ID -ADP31282 standard; protein; 813 AA.  
AC ADP31282;  
DT 12-AUG-2004 (first entry)  
DE Human secreted protein SEQ ID #2049.  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406656P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.  
XX 17-SEP-2002; 2002US-0411041P.  
XX 17-SEP-2002; 2002US-0411045P.  
XX 17-SEP-2002; 2002US-0411046P.  
XX 17-SEP-2002; 2002US-0411048P.  
XX 17-SEP-2002; 2002US-0411052P.  
XX 17-SEP-2002; 2002US-0411055P.  
XX 17-SEP-2002; 2002US-0411073P.  
XX 17-SEP-2002; 2002US-0411082P.  
XX 17-SEP-2002; 2002US-0411101P.  
XX 17-SEP-2002; 2002US-0411111P.  
XX 18-APR-2003; 2003US-0463700P.  
XX 18-APR-2003; 2003US-0463708P.  
XX 18-APR-2003; 2003US-0463716P.  
XX 18-APR-2003; 2003US-0463732P.  
XX 02-MAY-2003; 2003US-0467199P.  
XX 02-MAY-2003; 2003US-0467201P.  
XX 02-MAY-2003; 2003US-0467203P.  
XX 02-MAY-2003; 2003US-0467230P.  
XX 19-MAY-2003; 2003US-0471306P.  
XX 19-MAY-2003; 2003US-0471336P.  
XX 22-MAY-2003; 2003US-0472420P.

PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486896P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
DR New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3280; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX Sequence 813 AA;  
ADP31282 Length: 813 February 22, 2005 12:25 Type: P Check: 8432 ..  
1 ATGGCGTACG TTTTGAATCT GGAAAGTAGA AGTCCCGCGC TCGCACAGC  
51 CCCAGCCCTG ATCTCCACCC AGCCCAATCT TCCGCTGCCA GCCCTGCTTC  
101 TGTCTCTCTCG CCCACCATCT GGGCTCCAC GCGGGCTCTCT TCCAAGTGCT  
151 GGCACAAATC TGGTCTCTTCA GCATAGGTGC TCAAAAAGCA CAAAGCTGTC  
201 CAGNAGTGCA TGGCAGGAGG ACTTCAACAC CTGGAGGCCA GCCCGGCTCA  
251 CGGATGAGGC AGCAACCGNA CTCAGGTGCC GGCATCCCCA CCCTGCCCGG  
301 CCACCAATCA CTCGAGGGCC TGGCATCGGT TACATAGTGG CTCTCTCTGG  
351 GGTGGGGGCT CCTTCCAGGC AGAAGCGCTG TGGTCTAAAC CTTGTCTGTA  
401 GTCAAGGTGT GGCAGCAGC GGGCAGGTGG CGATTACGGC CCNAGAGGC  
451 CCAGTGTCTGG GTGCATACAC TCAACACTGT GATCATCTTT TGTGGACAC  
501 TGGAGCCCGG ACACCCACCA CGGTCTCTGT GGAGCTTTCC AAACAAGCTT  
551 TCCAGATCTG CTCACCTGTT TCCGTGATT CTGAACACAG CAGAACCTTG  
601 GTTGTAAAGC TGACAGTTGA GGAGTGCAGC AGAAGGGGGT GTGAAAAGC  
651 GCCTCAAGT TGGGAGACAT CAGTAAACG GTCTCTCTACC CATGAACAC  
701 AGCAGATTTC AGGATCTTTA TATAACACCG TCAAGCTGTG GGATTCAAGA

551 AGAGTGATGA CATGACCGTC TCTCTCATTC ACCACGAGG AATTCTGTTT  
601 TGCAGGAAC AAGACCTGTC TGACCACCGA GCGTTTCATAC CCAAGGATGT  
651 CTGTGCTTCC AATGAGCTTC CTGGAGGAAC CCCCCAGGAG TCATCAGTAC  
701 CCCTGGGCCA TGCTAACAG GACCTGATTA ACAAGGAGCC CTGTGCCCCC  
751 CTGCTCCAGC CACATCTGGA CCNATCAGTG ACTGCCTGCC ACAGACTGGG  
801 AGTGCTTGTG GGAGATCTTG CAGAGTGGG GACAATTGTT CTTCTAGTT  
851 TTCCAGGGAC TCTTGGGCTT AGAACTCAT CGCACACTTG A

IIAA\_SEQUENCE 1.0  
ID ADP31247 standard; protein; 390 AA.  
XX AC  
XX ADP31247;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2014.  
DE  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX  
XX 29-APR-2004.  
XX  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406645P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.

17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3245; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 390 AA;

ADP31247 Length: 390 February 22, 2005 12:25 Type: P Check: 4640 ..

1 ATGCCTGTCA GTCAATCCGT CCGCCTCCT CGGACCCGCC CCGGCCGGCG  
51 CGCGGATCCC GAGAACCCAGC CGGCCCGCGC ACTCACTGCT CGTCATGGCG  
101 TGCTGTGTCAT GAAGCTGGCC ACACCTTCCA TGGGGTGGCG GTCTCTGGAG  
151 TCCTGGGTGG ACCTCAATGG CTTTGGCGCG CTTCACTCGG AGAGACGGCG  
201 CTCAACCCGG AAGTGTGCGA GCGGAATCT GCCTAGCAAC CGGGGAAGCC  
251 GGGCTGTGAA CGGGGCAATT TCAGTCGGCC GCCGCGGGGG CCACCTGAGG  
301 GAGTCGCCTC CGCGGGAGCG CACAAGACCT GACCGGACTG CGCCGCCCGA  
351 GGCGCTCGCG CGCCGTGAGC GAGGGCGCGG AGCAACTTTC

201 TTGTTGAAA GACTGTGCTCA AATTTCTTGA CAACACAGCA TTACTCTCCAG  
251 AAACGTGGGT CCACCATTC ACTGCTTCT CAGGCTGCC AGGATGCTTC  
301 TCAGGAGAGC TCGTGGAGTG CACTCAGGAG CTGACGATTG ATGTCACCAA  
351 GAGCTATTAT CAGAAGTTTT TGCCCTCTGAC ACAAGTCTAG

11AA SEQUENCE 1.0  
ID\_ADP31230 standard; protein; 891 AA.  
XX AC ADP31230;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #1997.  
XX DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406577P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406555P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.

18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3228; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 891 AA;  
SQ

ADP31230 Length: 891 February 22, 2005 12:25 Type: P Check: 7422 ..

1 ATGGGGGCGT CTGTGGCGG GAAATCTCTA CAGCACCAGG AGCAGCTGGA  
51 GGGCAGCAAG GAGCTGCAGC CTTTGGCCAG CCATCAGGAG ACCTCTGCCG  
101 GGGCCCTTGAG TTCCCTAAGC AGACAGCTCC AAAGAGGCT GCCCTTGAGA  
151 GCTGTCAACC TCAGCTCCA GGCAGGCCCC TCCTGGAAC GCCTGGAAC  
201 ACCAGAGCCA GAGCCACAGG CCTCCAGGC TCAGCTCCC TCAGCTAAGA  
251 GTGCTTTGGG TGCCAAGTCC CAGAGATCC AGGAGTCTTA CCAAGCGGC  
301 ACCAAATGGC TGGTGGAGAC CCAGCCGAG ACCCCTGGA GAAGGAGCAT  
351 CACGGCTCT CTGCCCCATA GGCTCACCTG CCACCCAGT AGGTTGTCTG  
401 AGGGGGGAGG CTGCTTCCG GAGCCCTTAC TCCTCAACAG AGCCCTCTTG  
451 CTCTCCCATG AGTCTGACAG TGACCGAGG ACCTCGGGG CGGGAATCA  
501 GCATCTCCAG AAGCTCTCCC AAGAGCTGGA CGAAGCTATT ATGGCGGAG

1901 TTGCCTCTCT CAAGTGCAC TACAGTGACC GAGGTTCCCA GTCCTTCTTC  
1951 TGGTACAGAC AATATCTGG GAAAGCCCT GAGTTGATTA TGTTCATATA  
2001 CTCCAATGTT GACAAAGAAG ATGGAAGGTT TACAGCACAG CTCATAAAG  
2051 CCAGCCACAT TGGTGTGCA GGAGGAACCA GAGCCCAAGTC GGTGACCCAG  
2101 CTTGGCAGCC ACGTCTCTGT CTCTGAAGGA GCCTGGTTC TGCTGAGGTG  
2151 CAACTACTCA TCGTCTGTTT CACATATCT CTTCTGGTAT GTGCAATACC  
2201 CCAACCAAGG ACTCCAGCTT CTCCTGAAGT ACACATCAGC GGCCACCCCTG  
2251 GTTAAAGGCA TCAACGGTTT TGAGGCTGAA TTTAAGAAGA GTGAACCTC  
2301 CTTCCACCTG ACGAAACCTT CAGCCCATAT GAGCGACGG GCTGAGTACT  
2351 TCTGTGCTGT GAGTGACACA GTGCTTGAGA CTCGAGGAGA GGTGAACATA  
2401 AACCTCCTGA GATGCTGA

!!AA SEQUENCE 1.0  
ID ADP31218 standard; protein; 390 AA.

XX ADP31218;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1985.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3216; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 390 AA;

ADP31218 Length: 390 February 22, 2005 12:25 Type: P Check: 6303 ..

1 ATGGAGTTAG GTGAGCTGCT CTCACACAG TCTGAGTATA TCAGACGGC.

51 ATCTGGGAAC AAAAAATCA GCAAAGGTGT TGAATTCCTT CTTTACATA

101 TTGGGGACCA TGTCTTTATT GAGGAAGAGT GTGTGTCAC CGCAGCTCAG

151 ATTGTTCTT GCATTCATGT TGGCAAGAC TGCCTGATTG GGTGCCGGTG





XX	Sequence 522 AA;	
SQ	ADP31070 Length: 522 February 22, 2005 12:25 Type: P Check: 5595 ..	
1	ATGGCAATGT CTCTCATCCA AGCGTGTGCG AGTCTGGCTC TCTCAACATG	
51	GCTGCTTTCC TTTTGTTCG TGCATCTGCT CTGCGCTGGAC TTTACCGTGG	
101	CCGAGAAGGA GGAATGGTAC ACCGCTTCG TGAACATCAC CTACGCCGAG	
151	CCCGCGCCGG ACCCGGGGCG GGGGGCGGCG GGGGGCGGCG GCGCGGAGCT	
201	GCACACGGAG AAGACGGAGT GCGGGCGGCTA CGGAGAGCAC TCGCCCAAGC	
251	AGGACGCCCG CGGGGAGGTG GTCATGGCCA GCTCGGCCCA CGACCGCCTG	
301	GCCTGCGACC CCAACACCAA GTTCGCCGCC CCGACCCGCG GCAAGAACTG	
351	GATAGCCCTC ATCCCCAAGG GCAACTGCAC GTACAGGGAT AAGATCCGGA	
401	ACGCGTTTCT GCAGAACGCC TCAGCCGTGG TCATCTTCAA CGTGGGCTCC	
451	AACACCAACG AGACCATCAC CATGCCCCAC GCGGTGGATC AATTAATGGC	
501	TTGCTTATTT TTAAGAAAA CA	
!!AA SEQUENCE 1.0		
ID	ADP31105 standard; protein; 2418 AA.	
XX	AC ADP311105;	
XX	DT 12-AUG-2004 (first entry)	
XX	Human secreted protein SEQ ID #1872.	
DE	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;	
KW	cancer; inflammatory; immune; human secreted protein.	
XX	Homo sapiens.	
XX	W02004035732-A2.	
XX	29-APR-2004.	
XX	28-AUG-2003; 2003WO-US026780.	
PR	29-AUG-2002;	2002US-0406576P.
PR	29-AUG-2002;	2002US-0406579P.
PR	29-AUG-2002;	2002US-0406585P.
PR	29-AUG-2002;	2002US-0406588P.
PR	29-AUG-2002;	2002US-0406608P.
PR	29-AUG-2002;	2002US-0406611P.
PR	29-AUG-2002;	2002US-0406612P.
PR	29-AUG-2002;	2002US-0406616P.
PR	29-AUG-2002;	2002US-0406640P.
PR	29-AUG-2002;	2002US-0406642P.
PR	29-AUG-2002;	2002US-0406646P.
PR	29-AUG-2002;	2002US-0406653P.
PR	29-AUG-2002;	2002US-0406655P.
PR	29-AUG-2002;	2002US-0406666P.
PR	17-SEP-2002;	2002US-0410946P.
PR	17-SEP-2002;	2002US-0410947P.
PR	17-SEP-2002;	2002US-0410948P.
PR	17-SEP-2002;	2002US-0410949P.
PR	17-SEP-2002;	2002US-0410953P.
PR	17-SEP-2002;	2002US-0410957P.
PR	17-SEP-2002;	2002US-0410958P.
PR	17-SEP-2002;	2002US-0410959P.
PR	17-SEP-2002;	2002US-0410960P.
PR	17-SEP-2002;	2002US-0410961P.
PR	17-SEP-2002;	2002US-0410962P.
PR	17-SEP-2002;	2002US-0411019P.

PR	17-SEP-2002;	2002US-0410953P.
PR	17-SEP-2002;	2002US-0410957P.
PR	17-SEP-2002;	2002US-0410958P.
PR	17-SEP-2002;	2002US-0410959P.
PR	17-SEP-2002;	2002US-0410960P.
PR	17-SEP-2002;	2002US-0410961P.
PR	17-SEP-2002;	2002US-0410962P.
PR	17-SEP-2002;	2002US-0411019P.
PR	17-SEP-2002;	2002US-0411022P.
PR	17-SEP-2002;	2002US-0411023P.
PR	17-SEP-2002;	2002US-0411024P.
PR	17-SEP-2002;	2002US-0411032P.
PR	17-SEP-2002;	2002US-0411035P.
PR	17-SEP-2002;	2002US-0411037P.
PR	17-SEP-2002;	2002US-0411041P.
PR	17-SEP-2002;	2002US-0411045P.
PR	17-SEP-2002;	2002US-0411046P.
PR	17-SEP-2002;	2002US-0411048P.
PR	17-SEP-2002;	2002US-0411052P.
PR	17-SEP-2002;	2002US-0411055P.
PR	17-SEP-2002;	2002US-0411073P.
PR	17-SEP-2002;	2002US-0411082P.
PR	17-SEP-2002;	2002US-0411101P.
PR	17-SEP-2002;	2002US-0411111P.
PR	18-APR-2003;	2003US-0463700P.
PR	18-APR-2003;	2003US-0463708P.
PR	18-APR-2003;	2003US-0463716P.
PR	18-APR-2003;	2003US-0463732P.
PR	02-MAY-2003;	2003US-0467199P.
PR	02-MAY-2003;	2003US-0467201P.
PR	02-MAY-2003;	2003US-0467203P.
PR	19-MAY-2003;	2003US-0471306P.
PR	19-MAY-2003;	2003US-0471336P.
PR	22-MAY-2003;	2003US-0472420P.
PR	22-MAY-2003;	2003US-0472430P.
PR	09-JUN-2003;	2003US-0476609P.
PR	09-JUN-2003;	2003US-0476641P.
PR	08-JUL-2003;	2003US-0485218P.
PR	08-JUL-2003;	2003US-0485223P.
PR	08-JUL-2003;	2003US-0485224P.
PR	08-JUL-2003;	2003US-0485325P.
PR	14-JUL-2003;	2003US-0486446P.
PR	14-JUL-2003;	2003US-0486480P.
PR	15-JUL-2003;	2003US-0486891P.
PR	15-JUL-2003;	2003US-0486960P.
PR	08-AUG-2003;	2003US-0493341P.
PR	08-AUG-2003;	2003US-0493370P.
PR	08-AUG-2003;	2003US-0493573P.
PR	08-AUG-2003;	2003US-0493577P.
XX	(FIVE-) FIVE PRIME THERAPEUTICS INC.	
XX	Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;	
PI	Hallenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;	
PI	Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;	
XX	WPI; 2004-348438/32.	
XX	New nucleic acid molecule for diagnosing, preventing or treating diseases	
PT	such as proliferative (e.g. cancer), inflammatory, immune, metabolic,	
PT	genetic, bacterial and viral diseases.	
XX	Claim 1; SEQ ID NO 3068; 428pp; English.	
XX	The present invention relates to an isolated nucleic acid molecule	
CC	encoding a polypeptide which is believed to be cytostatic,	
CC	antiinflammatory, immunosuppressive, antibacterial and virucidal. The	
CC	composition and methods are useful for diagnosing, preventing and	
CC	treating diseases such as proliferative (e.g. cancer), inflammatory,	
CC	immune, metabolic, genetic, bacterial and viral diseases. The present	
CC	sequence represents a human secreted protein. The present sequence is	
CC	available on WIPWEB and is not in the specification.	

PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H,  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3031; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 831 AA;

1 ATGAGCTGGG ACCACTCAAT GGGAACTGAA ACCACTAAGG GAAGGACCAC  
51 CCGTGGAAG CAAGATAAGG AGGAAGAGAC TCTGATGTTT TCTGTTTCGTG  
101 CTAACTTCAA TTGAAATTT CTCTCTCCCA GGAAGTCTAT TTCCACTCCC  
151 ATTTTAGCCT TTTTGTGCA TAATCTGGAC CAGGGGTCCC TAACCCCTGG  
201 ACCACTTGGT ACCGCTCTGC AGCCGTTAG GAACCAAGCT GCATGGCAGA  
251 AGGACCCCT ACCACTGCTG TCATGTGAAG AGTCCAAAT CTTTGAAGAC  
301 ACCGATCGAC TCGAACTCAT TTTTGGTCC CCAGCACTGA GCTTGGCCCCA  
351 GCAGTTTCAT GAATGATGA ATGAAAGATT CAATGGGAGT CCGCAGCCGC  
401 TGACGGGGG CCGAGAGGCC CGCTCGCTTC TGGTCTCTCG ACTGCGGGCC  
451 AGGGCCACGG GCGGGTCTCT TGCAGCCGTT CGTGGCGCG TCGCGGGGAG  
501 GCGGCGCGG GCGGAGGTG GCGGCGGGC TCCGATATG AAGCGGAGCC  
551 GCTGCGCGGA CCGACCGCAG CCGCGGGCCG CCAGCCGCCG GGAGGATGGA  
601 GTTCAGCGGG CAGCGGAGCT GTCTCAGTCT TTGCCGCCGC GCGGGCGAGC  
651 GCGGCGGGG AGGCAGCGC TGGAGGAGCG GACGGGGCCC GCGGGGCCCG  
701 AGGGCAAGGA CGAGAGATG ACAGTCCAT GTCACTTCCA TTATTGCTCC  
751 ATTATTGCC CTGAATACCT TCCATGGAA CAAGATGTGG AGGTGGAAGA  
801 CAGTGATATT GATGATCTCG ACCCTGTGTA G  
IIAA SEQUENCE 1.0  
ID\_ADP31070 standard; protein; 522 AA.  
XX  
XX ADP31070;  
XX  
XX 12-AUG-2004 (first entry)  
XX Human secreted protein SEQ ID #1837.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406666P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.

PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PI Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3001; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1419 AA;  
ADP31003 Length: 1419 February 22, 2005 12:25 Type: P Check: 5508 ..  
1 CTGGTGGTGT GCCCTGAGCC ATGGAGCGGC CTTTGCAGAC AGAGATGGTG  
51 GAGCTGGTGC CCAATGGCAA ACACCTCAGAG GGGCTGCTCC TGACCTGTGC  
101 CTACAGGTGC AGGACCTTGC ACGGACTGT ATGGAGGGCA AGAGTTTCCT  
151 ACAGAAAAGT CCCAGCAAGG AGCCACACTT CACTGACTTC GAGGGGAAGA  
201 CATCATTCGG GATCTCAGTG TTCAACCTCA GCAATGCCAT CATGGGCAGC  
251 GGCATCCTGG GACTCGGCCTA TGGCATGGCC AATACGGGCA TTATCCTTTT  
301 CTTGTTCTCTG TTGACAGTGT TCGCCTTGCT TCCAGCTAC TCCATCCACC  
351 TGCTACTCAA GTCCTCAGGG GTCGTGGCA TCCGTGCCTA TGACGAGTGT  
401 GGCTACCGTG CTTTGGGAC CCACAGAAAG CTGGCAGCAG CCCTGGCCAT  
451 CACGCTCCAG AACATCCGAG CCATGTCCAG CTACCTGTAC ATCATCAAGT  
501 CTGAGCTGCC ACTTGTGATA CAGACCTTCC TGAACCTGGA GGAGAAACC  
551 TCTCTGTAC CATCATCTGT CCCTGGCAC TGAATGGGCA GCTTGGCTAC  
601 CTGGGCTACT CCAGCGGCTT CTCTCTTAGC TGCAATGGGT TCTTCCTAAT  
651 TGCAGGCAAC TTCAGCCACG TGGAGATCGT GAAGGAGAAG GTGCAGCTGC

701 AGGTGAGCC TGAGGCTTCA GCCTTCTGCA CTTCCAGCTA CTTACAGGCTC  
751 AACTCACAGA CAGCATACAC CATCCCCATC ATGGCCTTCG CTTTGGTCTG  
801 CCACCCCGAG GTGTGTGCCA TCTATACTGA GCTCAAGGAC CCCTCCAAGA  
851 AGAAGATGCA GCACATCTCC AACCTGTCCA TCGCTGTCAAT GTACATCATG  
901 TACTTCTCTGG CTGCCCTCTT CGGCTACCTC ACCTTCTACA ACGGGGTGGA  
951 GTCGGAGCTG CTGCACACCT ACAGCAAGGT GGACCCGTTT GACGTCCTGA  
1001 TCCTGTGTGT GCGGTGGCC GTGCTGACAG CAGTCAAGCT CACATGCCCC  
1051 ATCGTTCGTG TCCCGTGGC CCGCGCATC CAGCAGATGC TGTTCCTAAA  
1101 CCAGGAGTTC AGCTGGGTGC GGCATGTGCT TATTGCCGTT GGCCTGTCTCA  
1151 CTTGTATCAA CTTGCTGGTC ATCTTTGCC CCAACATCCT GGGCATCTTT  
1201 GGGGTCAATG GTGCCACATC TGCCCCATTC CTCATCTTCA TCTTCCCTGC  
1251 CATCTTCTAC TTCCGAATCA TGCCCCACGGA GAAGGAGCCT GCAAGATCCA  
1301 CCCCCAAAT CCTGGCCCTG TGTTTTGCTA TGCCTGGCTT CTTGCTGATG  
1351 ACCATGAGCT TGAGCTTCAT CATCATTGAC TGGGCTCTAG GGACAGCCG  
1401 GCATGGAGGA AACCACTAG  
IIAA SEQUENCE 1.0  
ID ADF1033 standard; protein; 831 AA.  
XX  
AC ADP31033;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1800.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 08-JUN-2003; 2003US-0476609P.  
PR 08-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kochakota S, Halshan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2994; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX  
SQ Sequence 268 AA;  
ADP30996 Length: 268 February 22, 2005 12:25 Type: P Check: 761 ...  
1 ATGTGGGCCC TGTTAGCGG GGTGTGCTG GGCTCGGCGT GTCGCGTGA  
51 GTGGCTCCTC GCTCCAGCC CTGCGGCTGC TGTGCTTCG CCCCCGCGG  
101 CGTGTGGCT GCGCCCCAGC CAGCCCGGG GTGCGCTGAA GAGGTGGCC  
151 GGGCGGCAGA ACATCGGGC CTTGAGCGCC CGAAGTCAG ACTGGGAGG  
201 GCCCCACGGG GAATCGGGG CCCCCCTTCT TCCTCCCTTC CTTTCCCTGG

251 TCGTCTTCTT CCCCCCTG  
11AA SEQUENCE 1.0  
ID ADP31003 standard; protein; 1419 AA.  
XX  
XX ADP31003;  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1770.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.

PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486448P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2976; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1087 AA;  
ADP30978 Length: 1087 February 22, 2005 12:25 Type: P Check: 3777 ..  
1 GAGCCCATCG AAGACCTCAG CCAGACCCGG GTGCTGGACC TCCAGGCTGA  
51 TTCCCGGCTG CACGTCATCT TCGGGGGGCAC CAAGGTGGTG CAGCACATCC  
101 CCCCACAGAA AGCCACCACG GGCTGAAGC GGCAAGCTGC TGGCACCAT  
151 CCTCTTCGGG GTCAGAGGG TGACTGGGAA CAACTGGAG ACCTTCATCT  
201 TCATCCTCTT CCTCCTGGTG TTTGCCATCG CTCAGCTCG CTATGTATGG  
251 ATTGAAGGTA CCAAGGACCC CAGCCGGAAC CGCTACAAGC TGTTCCTGGA  
301 GTGCACCTTG ATCCTCACCT CGGTGCTGCC TCTGAGCTG CCCATCGAGC  
351 TGTCCCTGGC CGTCAACACC TCCTTCATCG CCTTGGCCAA GCTCTACATG  
401 TACTGCACAG AGCCCTTCGG GATCCCTTTT GCTGGCAAGG TCGAGGTGTG  
451 CTGCTTTGAC AAGACGGGGA CGTTGACCAG TCACAGCCTG GTGGTGGCGG  
501 GTGTGGCCGG GCTGAGAGAC GGGAGAGGAG TGACCCCACT GTCCAGCATC  
551 CCTGTAGAAA CACACCGGGC CTTGGCCTCG TGCCACTCGC TCATGCAGCT

601 GGACGACGCG ACCCTCGTGG GTGACCCCTCT AGAGAAGGCC ATGCTGACGG  
651 CCGTGGACTG GACGCTGACC AAGATGAGA AAGTATTCCC CGAAGTATT  
701 AAAACTCAGG GGCTGAAAAT TCACCAGCGC TTTCAATTTG CCAGTGCCTT  
751 GAAGCGAATG TCCGTGCTTG CCTCGTATGA GAAGCTGGGC TCCACCGACC  
801 TCTGCTACAT CGCGGCCGTG AAGGGGGCCC CCGAAACTCT GCATCTCCATG  
851 TTCTCCCACT GCCCGCCCGA CTACCACCAC ATCCACACCG AGATCTCCCG  
901 GGAAGGAGCC CGCTCTCTGG CGCTGGGGA CAAGGAGCTG GGACACCTCA  
951 CTCACCAGCA GGCCCGGGAG GTCAAGCGGG AGGCCCTGGA GTGCAGCCTC  
1001 AAGTTCGTGC GCTTCAATGT GGTCTCTGCG CCGCTCAAGG CTGACTCCAA  
1051 GGCCGTGATC CGGAGATCC AGAATGGTGC CCACCGG  
!!AA SEQUENCE 1.0  
ID ADF30996 standard; protein; 268 AA.  
XX  
XX ADF30996;  
AC  
XX  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX  
DE Human secreted protein SEQ ID #1763.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
XX 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
XX 29-AUG-2002; 2002US-0406608P.  
XX 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
XX 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
XX 29-AUG-2002; 2002US-0406646P.  
XX 29-AUG-2002; 2002US-0406653P.  
XX 29-AUG-2002; 2002US-0406655P.  
XX 29-AUG-2002; 2002US-0406656P.  
XX 17-SEP-2002; 2002US-0410946P.  
XX 17-SEP-2002; 2002US-0410947P.  
XX 17-SEP-2002; 2002US-0410948P.  
XX 17-SEP-2002; 2002US-0410949P.  
XX 17-SEP-2002; 2002US-0410953P.  
XX 17-SEP-2002; 2002US-0410957P.  
XX 17-SEP-2002; 2002US-0410958P.  
XX 17-SEP-2002; 2002US-0410959P.  
XX 17-SEP-2002; 2002US-0410960P.  
XX 17-SEP-2002; 2002US-0410961P.  
XX 17-SEP-2002; 2002US-0410962P.  
XX 17-SEP-2002; 2002US-0411019P.  
XX 17-SEP-2002; 2002US-0411022P.  
XX 17-SEP-2002; 2002US-0411023P.  
XX 17-SEP-2002; 2002US-0411024P.  
XX 17-SEP-2002; 2002US-0411032P.  
XX 17-SEP-2002; 2002US-0411035P.  
XX 17-SEP-2002; 2002US-0411037P.

501 GATTGGCGAG AAGCTGAAGA ACAAGACGCG GATCTTGGTC ACGCAGACGA  
551 TGAGCTACTT GCGCAGGTG GAGCTCATCA TCGTCATGAG TGGCGGCAAG  
601 ATCTCTGAGA TGGGCTCCTA CCAGAGAGCTG CTGGCTCGAG ACGGCGCTT  
651 CGCTGAGTTC CTGCGTACCT ATGCAGACAC AGACAGGAG CAGGATGCAG  
701 AGGAGAACGA AGGAGGAGAC CTGGAAGCTG ATGGAGGCTG ACAAGGCGCA  
751 GACAGGCGAG GTCAAGCTTT CCGTGTACTG GGACTACATG AAGGCCATCG  
801 GACTCTTCAT CTCTTCTCCT AGCATCTTCC TTTTCATGTG TAACCATGTG  
851 TCCGCGCTGG CTTCACACTA TTGGCTCAGC CTCTGGAGTG ATGACCCCAT  
901 CGTCAACGGG ACTCAGAGC ACACAAAGT CCGGCTGAGC GTCTATGGAG  
951 CCCTGGGCAT TTCACAAGTT TGGCTACTCC ATGGCCGTGT CCATCGGGGG  
1001 GATCTTGGCT TCCCGCTGTC TGCAGGTGGA CTTGCTGCAC AGCATCCTGC  
1051 GGTCAACCAT GAGCTTCTTT GAGCGGACCC CCAGTGGGAA CTTGGTGAAC  
1101 CGTTTCTCCA AGGAGCTGGA CACAGTGGAC TCCATGATCC CGGAGGTCA  
1151 CAAGATGTTT ATGGGTCTCC TGTTCAAGCT CATTGGTGCC TGCATCGTTA  
1201 TCCTGCTGGC CAGGCCATC GCGGCATCA TCATCCGCC CCTTGGCCTC  
1251 ATCTACTTCT TCGTCCAGAG GTTCTACGTG GCTTCTCTCC GGAGCTGAA  
1301 GCGGCTCGAG TCGGTCAGCC GCTCCCGGT CTATTCCCAT TTCAACGAGA  
1351 CTTTGTGGG GTTCAGGCTC ATTCAGGCT TCGAGGAGCA GGAGCGCTTC  
1401 ATCCACCAGA GTGACCTGAA GGTGGACGAG AACCAGAAG CCTATTACCC  
1451 CAGCATGCTG GCCAACAGGT GCGTGGCGGT CCGGCTGGAG TGTGTGGCA  
1501 ACTGCATCGT TCTGTTTGCT GCGCTGTTTG CGTGATCTC CAGGCACAGC  
1551 CTCAGTCTG GCTTGTGGG CTTCTCAGTG TCTTACTCAT TGCAGTFCAC  
1601 CAGTACTTG AACTGCTG TTCGATGTC ATCTGAATG GAAACCAACA  
1651 TCGTGGCGGT GAGAGGCTC AAGGAGTATT CAGAGACTGA GAAGGAGCGG  
1701 CCCTGGCAAA TCCAGGAGAC AGCTCCGCC AGCAGTGGC CCAGGTGGG  
1751 CCGAGTGGAA TTCCGGAAT ACTGCTGCG CTACCGAGAG GACCTGGACT  
1801 TCGTTCTCAG GCATCATAT GTACAGTCA ATGGGGAGA AAGGTGGGC  
1851 ATCGTGGGC GGACGGGAGC TGGGAAGTGG TCCCTGACCC TGGGCTTATT  
1901 TCGGATCAAC GAGTCTGCC AGGAGAGAT CATCATCAT GGCATCAACA  
1951 TCGCCAAGAT CGGCTGAC GACCTCCGT TCAAGATCAC CATCATCCCC  
2001 CAGGACCCCTG TTTTGTTC GGGTTCCCT CGAATGAACC TGGACCCATT  
2051 CAGCCAGTAC TCGGATGAG AAGTCTGGAC GTCCCTGGAG CTGGCCCAAC  
2101 TGAAGGACTT CGTGTACGCC CTTCCTGACA AGCTAGACCA TGAATGTGA  
2151 GAAGGCGGG AGAACCTCAG TGTGCGGAG CGCCAGCTTG TGTGCTTAGC  
2201 CCGGCGCCCTG CTCGAGGA GAAGATCTCT TGTGTGGAT GAGGCCACGG  
2251 CAGCCGTGGA CTTGGAAAG GAGGACCTCA TCCAGTCCAC CATCCGGACA  
2301 CAGTTCGAGG ACTGCACCGT CCTCACCATC GCCCACCGG TCAACACCAT

2351 CATGGACTAC ACAAGGTGA TCGTCTTGA CAAAGGAGAA ATCCAGGACT  
2401 ACGGCGCCCC ATCGGACCTC CTGCAGCAGA GAGGTCTTTT CTACAGCATG  
2451 GCCAAAGACG CCGGCTTG  
!!AA\_SEQUENCE 1.0  
ID ADP30978 standard; protein; 1087 AA.  
XX  
AC ADP30978;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1745.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-041101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.





XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
OS WO2004035732-A2.  
PN XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.

PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnenann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2917; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 1170 AA;  
ADP30919 Length: 1170 February 22, 2005 12:25 Type: P Check: 9820 ..  
1 CAGTGTCTTAA GTTCTGGAGA CCTCTTCACT GCCACAAT TCAGCAGCA  
51 GTCGCGGATT GGGAGCAGG AGCTCCAGGA GTTCTGCCCC ACCATCCTCC  
101 AGCAGCTGGA TTCCCGGGCC TGCACCTCGG AGAACCCAGGA AAACGAGGAG  
151 AATGAGCAGA CGGAGGAGGG GCGGCCAAGC GCTGTTGAAG TGTGGGGCTT  
201 TGGTTTTTCT AGTGCTCTAC TGATTAACCT GGCCTCTCTC CTGGGAGTCC  
251 TCGTCTCTGC CTGCACAGAG AAAGCGTTT TCAGCCGTGT GCTCACTTAC  
301 TTCAATGCCC TGTCCATGG AACGTGCTG TCTAACGGC TATTCAGCT  
351 CATCCACAG GCATTGTTGTT TCAACCCCTCT GGAAGATTAT TATGTTCCA  
401 AGTCTGCAGT GGTGTTTGGG GGCTTTTATC TTTTCTTTT CACAGAGNAG  
451 ATCTTGAGA TTCTTCTTAA CGAGAAAAT GAGTCCAAGA AGGACCAGGA  
501 GGAGGGGGTG ATGGAGAAGC TGCAGAACGG GGACCTGGAC CACATGATTC  
551 CTCAGCACTG CAGCAGTGAG CTGGACGGCA AGGCGCCCAT GGTGGACGAG  
601 AAGGTCAATG TGGGCTCGCT CTCTGTGAG GACCTGCAGG CTTCCACAGAG  
651 TGCTTGCTAC TGGCTGAAGG GTGTCCGCTA CTCTGATATC GGCACCTCTGG  
701 CCTGGATGAT CACTCTGAGC GACGSCCTCC ATAATTTTCA CGATGSCCTG  
751 GCCATCGGTG CTTCTCTTAC TGTGTCAATT TTCCAAGGCA TCAGCACCTC  
801 GGTGGCCATC CTCTGTGAGG AGTTCCCAAC TGAGCTAGGA GACTTTGTCA  
851 TCCTGCTCAA CGCTGGGATG AGCATCCAAC AAGCTCTCTT CTTCAACTTC  
901 CTTTCTGCCT GCTGCTGCTA CTTGGGTCTG GCCTTTGGCA TCCTGCGCGG

PR 29-AUG-2002; 2002US-0406555P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411043P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463718P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471308P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-048680P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX  
PS Claim 1; SEQ ID NO 2886; 428pp; English.  
XX  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,

CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1341 AA;

ADP30888 Length: 1341 February 22, 2005 12:25 Type: P Check: 873 ..

1 AGGCTTGAAG AAGACCAAGG GCATAACGTG ATGTTCCAGG COTTGATTCA  
51 CTGTGTGAAA GGCACATGG GCACAGGGAT CTTGGGACTA CCCCTCGGTG  
101 TGAAGAAGCG GGGCATCTCTG ATGGGGCCAC TCAGTCTGCT GGTGATGGGC  
151 TTCAATTGGCT GCCACTGTAT GCACATCCTG GTCAAGTGTG CCCAGCGCTT  
201 CTTCGTGAGC TTCTTCCTTA TTATCACCCA ACTTGGCTTC TGCTGTGTGT  
251 ACATTGTGTT TTTGGCTGAT AATTAAAC AGGTAGTGA AGCTGTTAAT  
301 AGCACAAACA ACAACTGCTA TTCCAATGAG ACGGTGATTG TGACCCCCAC  
351 CATGGACTCG CGACTCTACA TGCTCTCCTT CCGTCCCTTC CTGTGTGTGC  
401 TGGTCTTCAT CCGGAACCTC AGGATCTTGA CCATCTTCTC CATGCTGCCC  
451 AACATCAGCA TGCTGGTCAG CTTGGTTCATC ATCATACAGT ACATTACCCA  
501 GGAATCCCA GACCCAGCC GGTGGCACT GGTAGCAAGC TGGAGAGCCT  
551 ACCCTCTCTT CTTCGGAACA GCCATTTTTT CTTTGAAG CATTTGTGTG  
601 GTTCGCTCTC TGGAAACAA GATGAAGAT GCCGCCACT TCCCAGCCAT  
651 CTGTCTTTG GGAATGTCCA TGCTCACTTC CCTATACATT GGCATGGCGG  
701 CTCTGGGCTA CTTGCGGTTT GGAGATGACA TCAAGGCCAG CATAAGCCTT  
751 AACCTGCCCTA ACTGCTGAAG GTCCCTCTCA GTCAATTTCA GAAAGGGAAA  
801 CAAAGCCCCA AGTCATTGTC CCAAGGTCAG AGGTTAATGT TCCAAGGAGG  
851 CCAGTGTGAG AACACAGTGG CCGTGGAGAG CAGCTCTGTG GTTTGTCTTG  
901 CAGGCTGTAC CAGTCTGTCA AGCTTCTCTA CATTGCCGCG ATCCTGTGCA  
951 CCTATGCCCT GCAGTTCTAC GTCCCTGCGAG AATCATCAT CCCTTTTGCC  
1001 ATCTCCCGGG TGTCAACAG CTGGGCACTG COTCTGGATC TGTCCATTGG  
1051 CTTGCTCATG GTCTGCGCTGA CATGCCCTCT GSCCATCCTC ATCCCCCGCC  
1101 TGGACCTGGT CATCTCCCTG GTGGGCTCCG TGAGTGGCAC GGCCTGTGCC  
1151 CTCATCATCC CACCGCTCCT GGAGGTCAAC AGTTTCTACT CAGAGGGCAT  
1201 GAGCCCCCTC ACCATCTTCA AGGACGCCCT GATCAGCATC CTGGGCTTGG  
1251 TGGGCTTTGT GGTGGGGACC TACCAGGCC TGGACGAGCT GCTCAAGTCA  
1301 GAAGACTCTC ACCCTTTTTC CAACTCCACC ACTTTGTTC G

!!AA SEQUENCE 1.0

ID \_ADP30919 standard; protein; 1170 AA.

XX ADP30919;

AC

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1686.

PR 17-SEP-2002; 2002US-0410962P.  
 PR 17-SEP-2002; 2002US-0411019P.  
 PR 17-SEP-2002; 2002US-0411022P.  
 PR 17-SEP-2002; 2002US-0411023P.  
 PR 17-SEP-2002; 2002US-0411024P.  
 PR 17-SEP-2002; 2002US-0411032P.  
 PR 17-SEP-2002; 2002US-0411035P.  
 PR 17-SEP-2002; 2002US-0411037P.  
 PR 17-SEP-2002; 2002US-0411041P.  
 PR 17-SEP-2002; 2002US-0411045P.  
 PR 17-SEP-2002; 2002US-0411046P.  
 PR 17-SEP-2002; 2002US-0411048P.  
 PR 17-SEP-2002; 2002US-0411052P.  
 PR 17-SEP-2002; 2002US-0411055P.  
 PR 17-SEP-2002; 2002US-0411073P.  
 PR 17-SEP-2002; 2002US-0411082P.  
 PR 17-SEP-2002; 2002US-0411101P.  
 PR 17-SEP-2002; 2002US-0411111P.  
 PR 18-APR-2003; 2003US-0463700P.  
 PR 18-APR-2003; 2003US-0463708P.  
 PR 18-APR-2003; 2003US-0463716P.  
 PR 18-APR-2003; 2003US-0463732P.  
 PR 02-MAY-2003; 2003US-0467199P.  
 PR 02-MAY-2003; 2003US-0467201P.  
 PR 02-MAY-2003; 2003US-0467203P.  
 PR 02-MAY-2003; 2003US-0467230P.  
 PR 19-MAY-2003; 2003US-0471306P.  
 PR 19-MAY-2003; 2003US-0471336P.  
 PR 22-MAY-2003; 2003US-0472420P.  
 PR 22-MAY-2003; 2003US-0472430P.  
 PR 09-JUN-2003; 2003US-0476609P.  
 PR 09-JUN-2003; 2003US-0476641P.  
 PR 08-JUL-2003; 2003US-0485218P.  
 PR 08-JUL-2003; 2003US-0485223P.  
 PR 08-JUL-2003; 2003US-0485224P.  
 PR 08-JUL-2003; 2003US-0485325P.  
 PR 14-JUL-2003; 2003US-0486446P.  
 PR 15-JUL-2003; 2003US-0486480P.  
 PR 15-JUL-2003; 2003US-0486891P.  
 PR 15-JUL-2003; 2003US-0486960P.  
 PR 08-AUG-2003; 2003US-0493341P.  
 PR 08-AUG-2003; 2003US-0493370P.  
 PR 08-AUG-2003; 2003US-0493573P.  
 PR 08-AUG-2003; 2003US-0493577P.  
 XX  
 PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
 XX  
 PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
 PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
 PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
 XX  
 DR WPI; 2004-348438/32.  
 XX  
 XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
 PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
 PT genetic, bacterial and viral diseases.  
 XX  
 XX Claim 1; SEQ ID NO 2872; 428bp; English.  
 XX  
 CC The present invention relates to an isolated nucleic acid molecule  
 CC encoding a polypeptide which is believed to be cytostatic,  
 CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
 CC composition and methods are useful for diagnosing, preventing and  
 CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
 CC immune, metabolic, genetic, bacterial and viral diseases. The present  
 CC sequence represents a human secreted protein. The present sequence is  
 CC available on WIPWEB and is not in the specification.  
 XX  
 SQ Sequence 1032 AA;

ADP30874 Length: 1032 February 22, 2005 12:25 Type: P Check: 5112 ..

1 TTCCAGGCGCT TGATTCACCT GGTGAAGGC AACATGGGCA CAGGGATCCT

51 GGGACTACCC CTCGCTGTGA AGAAGCGGG CATCCTGATG GGGCCCACTCA  
 101 GTCCTGTGGT GATGGCTTC ATTGCTGCC ACTGTATGCA CATCCTGGTC  
 151 AAGTGTGCC AGCGTCTCTT CGTAGCTTC TTCTTTATTA TCACCAACT  
 201 TGGCTTCTGC TGTGTGTACA TTGTGTTTTT GGCTGATAAT TTAACAACAGG  
 251 TAGTGAAGC TGTTAATAGC ACAACCAACA ACTGCTATTG CAATGAGAGC  
 301 GTGATTCTGA CCCCACCANT GGACTGGGGA CTCTACATGC TCTCCTTCCT  
 351 GCCCTTCTCG GTGCTGCTGG TCCTCATCCG GAACCTCAGG ATCTTGACCA  
 401 TCTTCTCCAT GCTGGCCRAA ATCAGCATGC TGGTCAGCTT GGTCAATCATC  
 451 ATACAGTACA TTACCAGGA AATCCAGAC CCAGCCGGT TGGCACTGGT  
 501 AGCAAGCTGG AAGACCTACC CTCTCTTCTT CGGAACAGCC ATTTTTTCTT  
 551 TTGAAAGCAT TGGTGTGGTT CTGCTCTGG AAAACAAGAT GAAGAATGCC  
 601 CGCACTTCC CAGCCATCCT GTCTTTGGGA ATGTCCATCG TCACCTCCCT  
 651 ATACATTGGC ATGGCGGCTC TGGCTACCT GCGGTTTGGG GATGACATCA  
 701 AGGCCAGCAT AAGCCTTAAC CTGCTTAAC TCAAGGTCCC TCTCAGTCAT  
 751 TTTCAGAAAG GGAACAAMA GCCCAAGTCA TTGTCCCAAG GTCAGAGGTG  
 801 TTCCAAGGAG GCCAGTGTCA GAACACAGTG GCCGTGGAGA GCAGCTCTGT  
 851 GGTCTTGCAG GCTGTACCAG TCTGTCAAGC TTCTCTACAT TGCCGGCATC  
 901 CTGTGACCT ATGCCCTGCA GTTCTACGTC CTTGCAGAAA TCATCATCCC  
 951 CTTTGGCCAT TCCCGGTGT CAACACGCTG GGCACATGCT CTGGATCTGT  
 1001 CCATTGCGCT CGTCATGGTC TGCTGACAT GC

IIIA SEQUENCE 1.0

ID\_ADP30888 standard; protein; 1341 AA.

XX

AC ADP30888;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1655.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

PN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US025780.

XX

PR 29-AUG-2002; 2002US-0406576P.

PR

PR 29-AUG-2002; 2002US-0406579P.

PR

PR 29-AUG-2002; 2002US-0406585P.

PR

PR 29-AUG-2002; 2002US-0406588P.

PR

PR 29-AUG-2002; 2002US-0406608P.

PR

PR 29-AUG-2002; 2002US-0406611P.

PR

PR 29-AUG-2002; 2002US-0406616P.

PR

PR 29-AUG-2002; 2002US-0406640P.

PR

PR 29-AUG-2002; 2002US-0406642P.

PR

PR 29-AUG-2002; 2002US-0406646P.

PR

PR 29-AUG-2002; 2002US-0406653P.

PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Halshan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2847; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present

CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 534 AA;  
ADP30849 Length: 534 February 22, 2005 12:25 Type: P Check: 642 ..  
1 TGCCGCAAGG TGCTGGCCT GAATGTCTCT GACCGCTGTG ACTTCATCGG  
51 GACCAACCT GACTGCCACA GTGATGGGGG GTACCTGGAC TACCTGGAG  
101 GCATCTTCTG CCACTTCCTT CCACAGCTCC TCCCTCTGGC TGTCACTCTC  
151 TAGGTTTCTT GGCTGTCTTA CCGTGTTCG ATTCTGGGAG TCACCGCAGC  
201 CAAGTTTTTC TGCCCCAACT TGTGGGCCAT TTCTACCACA CTGAAGCTCT  
251 CCCACAAGT GGCAATCGTC ACCTTCTTGG CATTTGGGAA TGGTGCACCT  
301 GACATCTTCA GTGCCCTGGT GGCCTTCTCT GACCCGCACA CAGCGGGCCT  
351 GGCCCTTGGG GCACTGTGGC GCTGGCGTGC TGGTTACCAC AGTGGTGGCC  
401 GGAGGCATTA CCATCCTACA CCCTTTCATG GCTGCTTCCA GGCCTTCTT  
451 CAGGGACATC GTTTTCTACA TGGTGGCTGT GTTCTGTGACC TTCCTCATGC  
501 TCTTCCGTGG CAGGTCACC CTGGCATGGG CTCT  
!!!AA SEQUENCE 1.0  
ID \_ADP30874 standard; protein; 1032 AA.  
XX  
AC ADP30874;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1641.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.

PI 29-AUG-2002; 2002US-0406576P.  
XX 29-AUG-2002; 2002US-0406579P.  
DR 29-AUG-2002; 2002US-0406585P.  
XX 29-AUG-2002; 2002US-0406588P.  
PT 29-AUG-2002; 2002US-0406608P.  
PT 29-AUG-2002; 2002US-0406611P.  
XX 29-AUG-2002; 2002US-0406612P.  
XX 29-AUG-2002; 2002US-0406616P.  
PS 29-AUG-2002; 2002US-0406640P.  
XX 29-AUG-2002; 2002US-0406642P.  
CC 29-AUG-2002; 2002US-0406646P.  
CC 29-AUG-2002; 2002US-0406653P.  
CC 29-AUG-2002; 2002US-0406655P.  
CC 29-AUG-2002; 2002US-0406666P.  
CC 17-SEP-2002; 2002US-0410946P.  
CC 17-SEP-2002; 2002US-0410947P.  
CC 17-SEP-2002; 2002US-0410948P.  
CC 17-SEP-2002; 2002US-0410949P.  
CC 17-SEP-2002; 2002US-0410953P.  
CC 17-SEP-2002; 2002US-0410957P.  
CC 17-SEP-2002; 2002US-0410958P.  
CC 17-SEP-2002; 2002US-0410959P.  
CC 17-SEP-2002; 2002US-0410960P.  
CC 17-SEP-2002; 2002US-0410961P.  
CC 17-SEP-2002; 2002US-0410962P.  
CC 17-SEP-2002; 2002US-0411019P.  
CC 17-SEP-2002; 2002US-0411022P.  
CC 17-SEP-2002; 2002US-0411023P.  
CC 17-SEP-2002; 2002US-0411024P.  
CC 17-SEP-2002; 2002US-0411032P.  
CC 17-SEP-2002; 2002US-0411035P.  
CC 17-SEP-2002; 2002US-0411037P.  
CC 17-SEP-2002; 2002US-0411041P.  
CC 17-SEP-2002; 2002US-0411045P.  
CC 17-SEP-2002; 2002US-0411046P.  
CC 17-SEP-2002; 2002US-0411048P.  
CC 17-SEP-2002; 2002US-0411052P.  
CC 17-SEP-2002; 2002US-0411055P.  
CC 17-SEP-2002; 2002US-0411073P.  
CC 17-SEP-2002; 2002US-0411082P.  
CC 17-SEP-2002; 2002US-0411101P.  
CC 17-SEP-2002; 2002US-0411111P.  
CC 18-APR-2003; 2003US-0463700P.  
CC 18-APR-2003; 2003US-0463708P.  
CC 18-APR-2003; 2003US-0463716P.  
CC 18-APR-2003; 2003US-0463732P.  
CC 02-MAY-2003; 2003US-0467199P.  
CC 02-MAY-2003; 2003US-0467201P.  
CC 02-MAY-2003; 2003US-0467203P.  
CC 02-MAY-2003; 2003US-0467230P.  
CC 19-MAY-2003; 2003US-0471306P.  
CC 19-MAY-2003; 2003US-0471356P.  
CC 22-MAY-2003; 2003US-0472420P.  
CC 22-MAY-2003; 2003US-0472430P.  
CC 09-JUN-2003; 2003US-0476609P.  
CC 08-JUL-2003; 2003US-0485218P.  
CC 08-JUL-2003; 2003US-0485223P.  
CC 08-JUL-2003; 2003US-0485224P.  
CC 08-JUL-2003; 2003US-0485325P.  
CC 14-JUL-2003; 2003US-0486446P.  
CC 14-JUL-2003; 2003US-0486480P.  
CC 15-JUL-2003; 2003US-0486891P.  
CC 15-JUL-2003; 2003US-0486960P.  
CC 08-AUG-2003; 2003US-0493341P.  
CC 08-AUG-2003; 2003US-0493370P.  
CC 08-AUG-2003; 2003US-0493573P.  
CC 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 2836; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX Sequence 321 AA;  
ADP30838 Length: 321 February 22, 2005 12:25 Type: P Check: 9460 ..  
1 ATGGATCAGG CTAGCTGTCT ACATCGTGCC GGTCACTGTG CTCGCTGCCT  
51 GCTACGGCCT TATCAGCTTC AAGATCTGGC AGAACTTTCG GCTCAAGACC  
101 GCTGCAGCGG CGCGCGCGGA GCGCCAGAG GCGCGCGCGG CTGGCGATGG  
151 GGGCGCGGTG GCCCTGGCGC GTGTCAGCAG CGTCAAGCTC ATCTCAAGG  
201 CCAAGATCCG CACGCTCAAG ATGACTTTCA TCATCGTGCT GGCCTTTCATC  
251 GTGTGCTGGA CGCCTTTCTT CTTCTGTCAG ATGTGGAGCG TCTGGGATGC  
301 CAACGGCGCC AAGGAAGGTA G  
!!AA SEQUENCE 1.0  
ID ADP30849 standard; protein; 534 AA.  
XX  
AC ADP30849;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1616.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 29-AUG-2002; 2002US-0410946P.  
PR 29-AUG-2002; 2002US-0410947P.  
PR 29-AUG-2002; 2002US-0410948P.  
PR 29-AUG-2002; 2002US-0410949P.  
PR 29-AUG-2002; 2002US-0410953P.  
PR 29-AUG-2002; 2002US-0410957P.  
PR 29-AUG-2002; 2002US-0410958P.  
PR 29-AUG-2002; 2002US-0410959P.  
PR 29-AUG-2002; 2002US-0410960P.  
PR 29-AUG-2002; 2002US-0410961P.  
PR 29-AUG-2002; 2002US-0410962P.  
PR 29-AUG-2002; 2002US-0411019P.  
PR 29-AUG-2002; 2002US-0411022P.  
PR 29-AUG-2002; 2002US-0411023P.  
PR 29-AUG-2002; 2002US-0411024P.  
PR 29-AUG-2002; 2002US-0411032P.  
PR 29-AUG-2002; 2002US-0411035P.  
PR 29-AUG-2002; 2002US-0411037P.  
PR 29-AUG-2002; 2002US-0411041P.  
PR 29-AUG-2002; 2002US-0411045P.  
PR 29-AUG-2002; 2002US-0411046P.  
PR 29-AUG-2002; 2002US-0411048P.  
PR 29-AUG-2002; 2002US-0411052P.  
PR 29-AUG-2002; 2002US-0411055P.  
PR 29-AUG-2002; 2002US-0411073P.  
PR 29-AUG-2002; 2002US-0411082P.  
PR 29-AUG-2002; 2002US-0411101P.  
PR 29-AUG-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471356P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

```

08-AUG-2003; 2003US-0493341P.
08-AUG-2003; 2003US-0493370P.
08-AUG-2003; 2003US-0493573P.
08-AUG-2003; 2003US-0493577P.
(FIVE-) FIVE PRIME THERAPEUTICS INC.
Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
WPI: 2004-348438/32.
New nucleic acid molecule for diagnosing, preventing or treating diseases
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
genetic, bacterial and viral diseases.
Claim 1; SEQ ID NO 2711; 428pp; English.
The present invention relates to an isolated nucleic acid molecule
encoding a polypeptide which is believed to be cytosolic,
antiinflammatory, immunosuppressive, antibacterial and virucidal. The
composition and methods are useful for diagnosing, preventing and
treating diseases such as proliferative (e.g. cancer), inflammatory,
immune, metabolic, genetic, bacterial and viral diseases. The present
sequence represents a human secreted protein. The present sequence is
available on WIPWEB and is not in the specification.
Sequence 2322 AA;
ADP30713 Length: 2322 February 22, 2005 12:25 Type: P Check: 9426 ..
1 CTCGTAGGTG TGGTGTGAGC ACAGCGCAG GTCACGGTTC AGGAAGGACC
51 CTGTGTACCG ATGGAGGGCT CCACATCAC TATCTGGTGC AATGTGAGTG
101 GCTCCACGGG ACCTCCTGAG CAGAAATTCC AGTGGTCCAT TTACTCGCCT
151 TCGTGGCCAG AGCGAGAGT GCAGATCGTC AGCACCATTG ACCCTTCCTT
201 CCCATATGCC ATCTACACC AGCGGTCCG CGGAGGGAGG ATCTTCATAG
251 AAAGAGTCCA GGGGAACCCA ACCCTAFTGC ACATCACAGA TCTTCAGGCC
301 CGGATGCCG GAGAAATAGA ATGCCACA CCCAGCACGG ATAAGCAATA
351 CTTTGGGAGT TACAGTGCA AGATGAACCT AGTGGTGATC CCAGACTCCC
401 TGCAGACCAC TGCCATGCC CAGACTTGC ACAGAGTGGG GCAGGACCCA
451 CTGGAGTCA CTTGTGAGT GGCTCGGAG ACCGTTTCAG ACAGCCACCT
501 GTCTGTGGCC TGGCTCTGGC AGAAGTTGG CGAGAAGCCC GTGAGGTCA
551 TCTCCCTGAG CCGAGATTTC ATGCTTCACT CTGGCAGCGA ATATGCCAG
601 AGCAGAGCC TGGGGGAGT GCGCTGGAC AAGCTGGGGA GGACCACCTT
651 CTGCTTACC ATCTTCCACC TGCAGCTTC TGACAGGGC GAGTCTACT
701 GCAGAGCCCG TGAGTGGATC CAGGATCCGG ATGGGTCTGT GTATGCTATG
751 ACCGAAAGC GTTCCGAGG AGCAGTGGTC AAGCTCCAGC CAACTGAGAA
801 AGAATTCACT GTTGGGTGG AAACAGAGAA GCGGTCTGAC ATGGTGGGG
851 AGCCGGTGA GTTCAGATGC ATCCCGGAGG CTCAGATGT TCCCGACCGT
901 TACTTTGCTG TCTCTGGGC CTTCAACAGC TCGTCTATCG CCACATGGG
951 CCCTAAGCT GTGCTGTGCC TCAACAGCGA ATTTGCTCAC CGGGAAGCCA
1001 GGGGACAGCT TAACGTGGCC AAAGAGAGCG ACAGTGTCTT TGTGCTCAAG

```

1551	GGAGCCAGTC	CCAGAGCAG	CAGCCAGCCA	GACCACGGCC	GCCTCTCCCC
1601	CCCAGAAGCT	CCGACACGGC	CCACCATCTC	CACGGCCTCC	GAGACCTCAG
1651	TGTACGTGAC	CTGGATTCCC	CGTGGGAATG	GTGGGTTCCC	AATCCAGTCC
1701	TTCCGTGTGG	AGTACAAGAA	GCTAAAGAAA	GTGGGAGACT	GGATTCCTGGC
1751	CACCAGCGCC	ATCCCCCCAT	CGCGCTGTCT	CGTGAGATC	ACGGGCCTAGAG
1801	AGAAAGGCAC	CTCTCTAAG	TTTCAGTGCC	GGGCTCTGAA	CATGCTGGGG
1851	GAGAGCGAGC	CCAGCGCCCC	CTCTCGGCC	TACGTGTGT	CGGGCTACAG
1901	CGGTGCGGTG	TACGAGAGGC	CGGTGGCAGG	TCCTTATATC	ACCTTTCACGG
1951	ATCGGTTCAA	TGAGACCACC	ATCATGCTCA	AGTGGATGTA	CATCCACGA
2001	AGTAAACAACA	ACACCCCAAT	CCATGGCTTTT	TATATCTATT	ATCGACCCAC
2051	AGACAGTGAC	AATGATAGTG	ACTACAAGAA	GGATATGGTG	GAAGGGACACA
2101	AGTACTGGCA	CTCCATCAGC	CACCTGCAGC	CAGAGACCTC	CTACGACATT
2151	AAGATGTCAGT	GCTTCAATGA	AGGAGGGAG	AGCGAGTTCA	GCAACGTGAT
2201	GATCTGTGAG	ACCAAAGCGG	CCGGTGGGCA	CTGGGGCCAT	GGTGGCTCGC
2251	TCCAGCGACC	TGCCCTATCT	GATTGTCGGG	GTGTCCTG	GCTCCATCGT
2301	TCTCATCATC	GTCACTTCA	TCCCCCTCTG	CTTGTGGAGG	GCCTGGTCTA
2351	AGCAAAAACA	TACAACAGAC	CTGGGTTTTT	CTCGAAGTGC	CCTTCCACCC
2401	TCCTGCCCGT	ATACTATGTT	GCCATTGGGA	GGACTCCAG	GCCACCGAGC
2451	CAGTGGACAG	CCCTACCTCA	GTGGCATCAG	TGGACGGGCC	TGTGCTAATG
2501	GGATCCACAT	GAATAGGGGC	TGCCCCCTCG	CTGCAGTGGG	CTACCCGGGC
2551	ATGAAGCCCC	AGCAGCACTG	CCAGGCCAG	CTTCAGCAGG	TAGCGCATTC
2601	TTGGGTGTGG	CGGCACGGGT	CTCAGGCTGG	GCTGCTGGGC	CAGGCTTTCT
2651	TTAGTCAGGA	GCAGATGCTC	CTGTTGTTGA	GTGAAGACTG	GAAAGTTACC
2701	TGGACTCCCC	GGCGTGGCG	TCTCATTA	CTTCTCTTTG	ACGACGAGAG
2751	TGACACCAGC	AGCCTGCTGA	GGCAGACCCA	TCTTGGCAAT	GGATATGACC
2801	CCCAAAAGTCA	CCAGATCACG	AGTGGGACCC	TCCATTTTAC	TCAGGGCCCC
2851	CATGCTGTTT	GGGCCTTTGG	CCAGTTGAAG	AGGTGGACAG	TCCGTGACTCC
2901	TGCCAAAGTGA	GTGGAGGAGA	CTGTGTCTCC	CAGCACCCCG	TAGGGGGCTA
2951	CGTAGGACAG	GAACCTGGAA	TGCAGTCTC	CCCGGGCCA	CTGGTGGCTG
3001	TGCTCTTTTGA	AACACACCT	CTCACAATTT	AGGCGAAGC	TGATATCCCA
3051	GAAGAGACTAT	ATATTTGTTT			

!!AA SEQUENCE 1.0

ID	NAME_SEQUENCE	TYPE	STATUS
ADP30713	standard; protein;	2322 AA.	

XX  
AC ADP30713;

DT 12-AUG-2004 (first entry)

Human secreted protein SEQ ID #1480.

AA Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW

PR 29-AUG-2002; 2002US-0406655P.  
 PR 29-AUG-2002; 2002US-0406666P.  
 PR 17-SEP-2002; 2002US-0410948P.  
 PR 17-SEP-2002; 2002US-0410949P.  
 PR 17-SEP-2002; 2002US-0410949P.  
 PR 17-SEP-2002; 2002US-0410949P.  
 PR 17-SEP-2002; 2002US-0410953P.  
 PR 17-SEP-2002; 2002US-0410957P.  
 PR 17-SEP-2002; 2002US-0410958P.  
 PR 17-SEP-2002; 2002US-0410959P.  
 PR 17-SEP-2002; 2002US-0410960P.  
 PR 17-SEP-2002; 2002US-0410961P.  
 PR 17-SEP-2002; 2002US-0410962P.  
 PR 17-SEP-2002; 2002US-0411019P.  
 PR 17-SEP-2002; 2002US-0411022P.  
 PR 17-SEP-2002; 2002US-0411023P.  
 PR 17-SEP-2002; 2002US-0411024P.  
 PR 17-SEP-2002; 2002US-0411032P.  
 PR 17-SEP-2002; 2002US-0411035P.  
 PR 17-SEP-2002; 2002US-0411037P.  
 PR 17-SEP-2002; 2002US-0411041P.  
 PR 17-SEP-2002; 2002US-0411045P.  
 PR 17-SEP-2002; 2002US-0411046P.  
 PR 17-SEP-2002; 2002US-0411048P.  
 PR 17-SEP-2002; 2002US-0411052P.  
 PR 17-SEP-2002; 2002US-0411055P.  
 PR 17-SEP-2002; 2002US-0411073P.  
 PR 17-SEP-2002; 2002US-0411082P.  
 PR 17-SEP-2002; 2002US-0411101P.  
 PR 17-SEP-2002; 2002US-0411111P.  
 PR 18-APR-2003; 2003US-0463700P.  
 PR 18-APR-2003; 2003US-0463708P.  
 PR 18-APR-2003; 2003US-0463718P.  
 PR 18-APR-2003; 2003US-0463732P.  
 PR 02-MAY-2003; 2003US-0467199P.  
 PR 02-MAY-2003; 2003US-0467201P.  
 PR 02-MAY-2003; 2003US-0467203P.  
 PR 02-MAY-2003; 2003US-0467230P.  
 PR 19-MAY-2003; 2003US-0471308P.  
 PR 22-MAY-2003; 2003US-0472420P.  
 PR 22-MAY-2003; 2003US-0472430P.  
 PR 09-JUN-2003; 2003US-0476609P.  
 PR 09-JUN-2003; 2003US-0476641P.  
 PR 08-JUL-2003; 2003US-0485218P.  
 PR 08-JUL-2003; 2003US-0485223P.  
 PR 08-JUL-2003; 2003US-0485224P.  
 PR 14-JUL-2003; 2003US-0485325P.  
 PR 14-JUL-2003; 2003US-0486446P.  
 PR 15-JUL-2003; 2003US-0486480P.  
 PR 15-JUL-2003; 2003US-0486891P.  
 PR 15-JUL-2003; 2003US-0486960P.  
 PR 08-AUG-2003; 2003US-0493341P.  
 PR 08-AUG-2003; 2003US-0493370P.  
 PR 08-AUG-2003; 2003US-0493573P.  
 PR 08-AUG-2003; 2003US-0493577P.  
 XX  
 PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
 XX  
 PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
 PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
 PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
 XX  
 DR WPI; 2004-348438/32.  
 XX  
 PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
 PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
 PT genetic, bacterial and viral diseases.  
 XX  
 XX Claim 1; SEQ ID NO 2708; 428pp; English.  
 PS The present invention relates to an isolated nucleic acid molecule  
 XX encoding a polypeptide which is believed to be cytostatic,  
 CC

CC antinflammatory, immunosuppressive, antibacterial and virucidal. The  
 CC composition and methods are useful for diagnosing, preventing and  
 CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
 CC immune, metabolic, genetic, bacterial and viral diseases. The present  
 CC sequence represents a human secreted protein. The present sequence is  
 CC available on WIPOWEB and is not in the specification.  
 XX  
 SQ Sequence 3070 AA;  
 ADP30710 Length: 3070 February 22, 2005 12:25 Type: P Check: 6107 ..  
 1 TTGCCTCCTC CTAGCCACAG CAGGCTGCTT TGTGACTTGG AACGAGGTCC  
 51 CTCAGGTAC CGTCCAGCCT GCGTCCACCG TCCAGNAGCC CGGAGGCACT  
 101 GTGATCTTGG GCTGCGTGGT GGAACCTCCA AGGATGAATG TAACTGGCG  
 151 CCTGAATGGA AAGGAGCTGA ATGGCTCGGA TGATGCTCTG GGTGTCTCTA  
 201 TCACCCACGG GACCTCGTC ATCACTGCCC TTAACAACCA CACTGTGGGA  
 251 CGGTACCAGT GTGTGGCCCG GATGCTGGG GGGGCTGTGG CCAGCGTGCC  
 301 AGCCACTGTG ACACTAGCCA ATCTCCAGGA CTTCAGATTA GATGTGCAGC  
 351 ACGTGATTGA AGTGGATGAG GGAACACAG CAGTCATTGC CTGCCACCTG  
 401 CCTGAGAGCC ACCCAAGC CCAGGTCCCG TACAGGTCA AACAGAGTG  
 451 GCTGGAGGCC TCCAGAGGTA ACTACCTGAT CATGCCCTCA GGGAACCTCC  
 501 AGATTGTGAA TGCAGGCCAG GAGGACGAG GCATGTACNA GTGTGCAGCC  
 551 TACAACCCAG TGACCCAGGA AGTGAANAAC TCCGGCTCCA GCGACAGGCT  
 601 ACGTGTGGCG CGTCCACCG CTGAGGCTGC CGCATCATC TACCCCCAG  
 651 AGGCCCCAAC CATCATCGTC ACCAAGGCC AGAGTCTCAT TCTGGAGTGT  
 701 GTGGCCAGTG GAATCCACC CCACCGGTC ACCTGGGCCA AGGATGGGTC  
 751 CAGTGTCAAC GGCTACAACA AGACGGCTT CCGTGTGAGC AACCTCCTCA  
 801 TCGACACCAC CAGGAGGAG GACTAGGCA CCTACGGCTG CATGGCCGAC  
 851 AATGGGGTTG GGCAGCCCG GGCAGCGGTC ATCTCTTACA ATGTCCAGGT  
 901 GTTTGAACCC CCGAGGTCA CCATGGAGCT ATCCCAGCTG GTCATCCCTT  
 951 GGGGCCAGAG TGCCNAGCTT ACCTGTGAGG TCGTGGGNA CCCCCGGCCC  
 1001 TCCGTGCTGT GGTGAGGAA TGTGTGCCC CTCACTTCCA GCCAGCGCTT  
 1051 CCGGCTCTCC CGCAGGGCCC TGGCGTGTCT CAGCATGGGG CCTGAGGACG  
 1101 AAGGGTCTA CCACTGCATG GCGGAGAACG AGGTTGGGAG CGCCCATGCC  
 1151 GTAGTCCAGC TGCAGACCTC CAGGCCAATG TCCAGGAGAG AAGGGCAGG  
 1201 GGGCTCCCGC CGAGGCTCCC ATCATCTCA GCTCGCCCCG CACCTCCAAG  
 1251 ACAGACTCAT ATGNACTGGT GTGGGGGCTT CGGCATGAGG GCAGTGGCCG  
 1301 GCGCCCAATC CTCTACTATG TGGTGAACA CCGCAAGTCC TCTGACGATT  
 1351 GGACCATCTC TGGCATTTCCA GCCAACACG ACCGCTGAC CCTCACCAGA  
 1401 CTTGACCCCG GGAGCTTGTA TGAAGTGGAG ATGGCAGCTT ACAACTGTGC  
 1451 GGGAGAGGGC CAGACAGCCA TGGTCACTTT CCGAACTGGA CGGCGGCCCA  
 1501 AACCCGAGAT CATGGGCCAG AAGAGCAGC AGATCCAGAG AGACGACCTT



XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RE, Huang MM, Kohakota S, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2655; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 2123 AA;  
ADP30657 Length: 2123 February 22, 2005 12:25 Type: P Check: 9708 ..  
1 CCAATATCTG TCCTGAAAT TGGCAAGGT CCCTTCCCC AGAGCTGAA  
51 TCAGCTCAAG TCTAATAAG ATAGAGACAC CAAGATTTC TACAGCATCA  
101 CGGGCGCGG GGCAGACAG CCCCCTGAG GTGCTTCG TGTAGAGAAG  
151 GAGACAGCT GGTGTGTTT GAATAGCCA CTGGACCGG AGGAGATTG  
201 CAAGTATGAG CTCTTTGGC AGCTGTGTC AGAAGTGGT GCCTCAGTGG  
251 AGGACCCCAT GAACATCTC ATCATCTGA CCGACCAGAA TGACCACAAG  
301 CCCAAGTTTA CCAGAGACAC CTTCCGAGGG AGTGTCTTAG AGGAGTCTT  
351 ACCAGGTACT TCTGTGATG AGGTGACAGC CACGGATGAG GATGATGCCA  
401 TCTACACCTA CAATGGGGT GTTGCTTACT CCATCCATAG CCAAGAACCA  
451 AAGGACCCAC AGACCTCAT GTTCACCAT CACGGAGCA CAGGCACCAT  
501 CAGCGTCATC TCCAGTGGCC TGGACCGGA AAAAGTCCCT GAGTACACAC  
551 TGACCATCCA GGCACACAGC ATGGATGGG ACGGTCCAC CACCAAGGCA  
601 GTGGCAGTAG TGGAGATCCT TGATGCCAAT GACAATGCTC CCATGTTTGA  
651 CCCCAGAGA GTCCCTGAGA ATGCAGTGG CCATGAGGTG CAGAGGCTGA  
701 CGGTCACTGA TCTGGAGCC CCCAATCAC CAGCGTGGC TGCCACCTAC  
751 CTTATCATGG GCGGTAGCA CGGGAGACCAT TTTACCATCA CCACCCACCC  
801 TGAGAGCAAC CAGGGCATCC TGACAACCCAG GAAAGGTTTG GATTTTGAGG  
851 CCAAAACCA GCACCCCTG TAGTTGAG TGACCAACGA GGCCCTTTT  
901 GTGCTGAAGC TCCCAACCTC CACAGCCACC ATAGTGTGCC ACGTGGAGGA  
951 TGTGAATGAG GCACCTGTGT TTGTCCACC CTCCAAAGTC GTTGAGGTCC  
1001 AGGAGGGCAT CCCACTGGG GAGCCTGTGT GTGTCTACAC TGCAGAAGAC  
1051 CCTGACAGG AGAATCAAAA GATCAGTGA CCGACAGAGT GGGCAGGTCA  
1101 CAGCTGTGGG CACCTCGAC CGTGAGGATG AGCAGTTTGT GAGGAACAAC

1151 ATCTATGAAG TCATGGTCTT GCCCATGGAC AATGGAAGCC CTCCCACCAC  
1201 TGGCACGGGA ACCCTTCTGC TAACACTGAT TGATGTCAAT GACCATGGCC  
1251 CAGTCCCTGA GCCCGTTCAG ATCCACTATC GCAACCAAG CCCTGTGGCC  
1301 CAGGTGCTGA ACATCACGGA CAAGGACCTG TCTCCCCACA CTCCCTTTT  
1351 CCAGGCCAG CTCACAGATG ACTCAGACAT CTACTGGACG GCAGAGGTCA  
1401 ACAGAGAGG TCACACAGTG GTCTTGTCCC TGAAGAAGTT CTGAAGCAG  
1451 GATACATATG ACGTGCACCT TTCTGTGTCT GACCATGGCA ACAAGAGCA  
1501 GCTGACGGTG ATCAGGGCCA CTGTGTGGA CTGCCATGGC CATGTCGAAA  
1551 CTGCGCCCTGG ACCCTGGAGG GGAGTTTCCA TCCTCCCTGT GCTGGGGCT  
1601 GTCTGTGCTC TGCTGTTCCT CCTGTGCTG CTGCTTTTGT TGGTGAGAAA  
1651 GAAGCGAAG ATCAGGAGC CCCTCTACT CCCAGAAGAT GACACCCGTG  
1701 ACAAGTCTT CTACTATGSC GAAGAGGGG GTGCCGAAGA GGACCAAGAC  
1751 TATGACATCA CCGAGCTCCA CCGAGGTCTG GAGGCCAGGC CGGAGGTGT  
1801 TCTCCGCAAT GACGTGGCAC CAACCATCAT CCGACACACC ATGTACCGTC  
1851 CTGCGCCAGC CAACCCAGAT GAATCGGCA ACTTTATAAT TGAGAACCTG  
1901 AAGCGCGCTA ACACAGACCC CACAGCCCCG CCTTACGACA CCTCTTGGT  
1951 GTTCGACTAT GAGGCGAGC GCTCCGAGC CGGTCCCTG AGCTCCCTCA  
2001 CTCCTCTCCG CTCGAGACCA GACCAAGATT ACGATTATCT GAACGAGTGG  
2051 GGCAGCGCT TCAAGAAAGT GGCAGACATG TACGGTGGCG GGGAGGACGA  
2101 CTAGTTTTTT TTTTAATGC TAT  
!AA SEQUENCE 1.0  
ID ADP30710 standard; protein; 3070 AA.  
XX  
AC ADP30710;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1477.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406653P.

```
3351 CCAAGTAGAA ATAAGCCACC CCTCTGTCCA TGCCCTTAT GCCAAGGAA
3401 TCACTGGAAG GCCACTGAC CCAGGGGATG AAGCTGTACC TAACCTTAC
3451 ACTCTGCTTT CCCAATACC AGAAGAGCA GAGTGTGTTA TACTCTGGA
3501 CCTTAAGGAT GCCCTTTTCT TCATCCCTGT ACATCTGTAC TCTCAATTCT
3551 TGTTTGCTTT TGAAGATCCT TCAAACTCAA CATCTCACT CACCTGGACT
3601 GTTTTACCCC TAGCGTTCAG GAATGGCCCC CATCTATTTG GCCAGGCATC
3651 AACCCAAGAC TTGAGCCAGC TCTCATACCT GGACACTCTT GTCCCTTTGCG
3701 ATGTGGATGA TTTACTTTTA GCTGCCTGTT CAGAAACCTT GTGCCATCAA
3751 GCCACCCAAG CACTCTTAAA TTTCTCTCACT ACCTGTGGTT ACAAGTTTTC
3801 CAAACCAAAG GCTCAACTCT GCTCACAGCA GGTAAATATC TTAGGGCTAA
3851 AATTACCCAA AGGCACCAGG GCCCCCAGTG AGGAATGTAT CCAGCTATA
3901 CTGGCTTATC CTCATCCCAA AACCTTAAG CAACTAAGAG CGTTCCTTTGG
3951 CATAACAGGT TTCTGCCGAA TATGGATTCC CAGCATACTC ACTGCTAAAG
4001 GAGACTTGTG GCTGTCAGAT AACCATTTAC TTAATATATCA GGTCTTATTA
4051 CTTGAAGGCG CAGTGTGCA ACTGCGCACT TGTGCAACTC TTAACCCAGC
4101 CACATTTCTT CCAGACAATG AAGAAAGAT AGAACATAAC TGTCAACAAG
4151 TAAATTGCTCA AACCTAGGCC ACTCGAGGGG ACCTTTTAGA GGTCCCTTGG
4201 ACTGATCCCG ACCTCAACTT GTATACTGAT GGAAGTTCTT TTGTACAAA
4251 AGGACTTCAA AAAGCGGGAT ATGCAGTGGT CAGTGATAAT GGAATACTTG
4301 AAAGTAATCC CTTCACTCCA GGAAGTAGCA CTCAGCTGCG AGAAGTGGTA
4351 GCCCTCACTT GGGCACTAGA ATTCCGAGAA GGAAGAAAGG TAAATATAAA
4401 TACAGGCTCT AAGTATGCTT ACCTAGTCTT CCATGCCCAT GCATCAATAT
4451 GGAGAGAAAG GGAATTCCTA ACTTCGAGG GAACACCTAT CAACATCAG
4501 GAAGCCATTA GGAGATTATT ATTGGTTGTA CAGAAACCTG AAGAGTGGC
4551 AGTCTTACAC TGCTGGGGTC ATCCGAAAGG AAAGGAAAGG GAAATAGAAG
4601 GGAAGTGGCA AGCGATATT GAAGCCAAA GAGCCTCAAG GCAGGACCCT
4651 CCATTAGAAA TGCTTATAGA AAGACACCTA GTATGGGGTA ATCCCTCTGT
4701 GGAACCAAC CCACAGTACT CAGCAGAGA AATAGATGG GGAACCTCAT
4751 GA

!!AA SEQUENCE 1.0
ID ADP30657 standard; protein; 2123 AA.
XX
AC ADP30657;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #1424.
XX
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW cancer; inflammatory; immune; human secreted protein.
XX
OS Homo sapiens.
XX
PN WO2004035732-A2.
```

```
XX
PD
XX
PF 29-APR-2004.
XX
28-AUG-2003; 2003WO-US026780.
29-AUG-2002; 2002US-0406576P.
29-AUG-2002; 2002US-0406579P.
29-AUG-2002; 2002US-0406585P.
29-AUG-2002; 2002US-0406588P.
29-AUG-2002; 2002US-0406608P.
29-AUG-2002; 2002US-0406611P.
29-AUG-2002; 2002US-0406612P.
29-AUG-2002; 2002US-0406616P.
29-AUG-2002; 2002US-0406640P.
29-AUG-2002; 2002US-0406642P.
29-AUG-2002; 2002US-0406646P.
29-AUG-2002; 2002US-0406653P.
29-AUG-2002; 2002US-0406655P.
29-AUG-2002; 2002US-0406666P.
17-SEP-2002; 2002US-0410946P.
17-SEP-2002; 2002US-0410947P.
17-SEP-2002; 2002US-0410948P.
17-SEP-2002; 2002US-0410949P.
17-SEP-2002; 2002US-0410953P.
17-SEP-2002; 2002US-0410957P.
17-SEP-2002; 2002US-0410958P.
17-SEP-2002; 2002US-0410959P.
17-SEP-2002; 2002US-0410960P.
17-SEP-2002; 2002US-0410961P.
17-SEP-2002; 2002US-0410962P.
17-SEP-2002; 2002US-0411019P.
17-SEP-2002; 2002US-0411023P.
17-SEP-2002; 2002US-0411024P.
17-SEP-2002; 2002US-0411032P.
17-SEP-2002; 2002US-0411035P.
17-SEP-2002; 2002US-0411037P.
17-SEP-2002; 2002US-0411041P.
17-SEP-2002; 2002US-0411045P.
17-SEP-2002; 2002US-0411046P.
17-SEP-2002; 2002US-0411048P.
17-SEP-2002; 2002US-0411052P.
17-SEP-2002; 2002US-0411055P.
17-SEP-2002; 2002US-0411073P.
17-SEP-2002; 2002US-0411082P.
17-SEP-2002; 2002US-0411011P.
17-SEP-2002; 2002US-0411111P.
18-APR-2003; 2003US-0463700P.
18-APR-2003; 2003US-0463708P.
18-APR-2003; 2003US-0463716P.
18-APR-2003; 2003US-0463732P.
02-MAY-2003; 2003US-0467199P.
02-MAY-2003; 2003US-0467201P.
02-MAY-2003; 2003US-0467203P.
02-MAY-2003; 2003US-0467230P.
19-MAY-2003; 2003US-0471306P.
19-MAY-2003; 2003US-0471336P.
22-MAY-2003; 2003US-0472420P.
09-JUN-2003; 2003US-0476609P.
09-JUN-2003; 2003US-0476641P.
08-JUL-2003; 2003US-0485218P.
08-JUL-2003; 2003US-0485223P.
08-JUL-2003; 2003US-0485224P.
14-JUL-2003; 2003US-0485325P.
14-JUL-2003; 2003US-0486446P.
15-JUL-2003; 2003US-0486480P.
15-JUL-2003; 2003US-0486891P.
08-AUG-2003; 2003US-0493341P.
08-AUG-2003; 2003US-0493370P.
08-AUG-2003; 2003US-0493573P.
08-AUG-2003; 2003US-0493577P.
```

CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ

Sequence 4752 AA;

ADP30651 Length: 4752 February 22, 2005 12:25 Type: P Check: 2463 ..

1 ATGAGCGCGC CGAGCTTCG TCGCGCGGCC CGGGGTTGG GGCTGTGCT  
51 GTGCGCGGTG CTGGGCGCG CTGGCGGTC AGACAGCGC GGTGCGGGG  
101 AACTCGGGCA GCCCTTGGG GTAGCGCGC AGCGCCATG CCCCACTACC  
151 TGCGCTGCC TCGGGGACCT GCTGGACTGC AGTCGTAAGC GGCTAGCGCG  
201 TCTTCCCGAG CCACCTCCGT CTGGGTGCG TCGGCTGGAC TTAAGTCACA  
251 ACAGATTATC TTTTCATCAAG GCAAGTTCCA TGAGCCACCT TCAAGGCTT  
301 CGAGAAGTGG CTGGAACACAG GATTGTTGAA ATACTCCCTG AACATCTGAA  
351 AGAGTTTCAG TCCCTTGAA CTTTGGACCT TAGCAGCAAC AATATTTTCAG  
401 AGCTCCAAAC TGCATTCCA GCCCTACAGC TCAATATCT CGAATTGAAC  
451 CGAAACAAGA TTAATAATGT AGATGGACTG ACATTCCAAG GCCTTGGTGC  
501 TCTGAAGTCT CTGAAATGC AAGAATAAG AGTAACGAA CTTATGGATG  
551 GAGCTTTTGG GGGGCTGAGC ACATGGGAAA TTTTGCAGCT GGACCATAAC  
601 AACCTAACAG AGATTACCAA AGGCTGGCTT TACGGCTTGC TGATGTGCA  
651 GGAATTTTCAT CTCAGCAAA ATGCCATCAA CAGGATCAGC CTTGATGCCCT  
701 GGGAGTTCTG CAGAGCTC AGTGAGCTGG ACCTAACCTT CAATCACTTA  
751 TCAAGGTTAG ATGATTCAAG CTTCTTGGC CTAAGCTTAC TAAATACACT  
801 GCACATTGGG AACACACAG TCACTATCAT TGCTGATTGT GCCTTCGGG  
851 GGCTTTCAG TTTAAAGACT TTGATACTCC AAGGAAATCG GATCCGTTCT  
901 ATTACTAAA AAGCCTTTCAC TGGTTTGGAT GCATTGGAGC ATCTGCATTT  
951 AATACATCA AGCCTTTTGT GCGATTGCCA GCTAAATGG CTCCACAGT  
1001 GGGTGGCGGA AAACAACCTT CAGAGCTTGG TAAATGCCAG TTGTGCCCAT  
1051 CCTCAGCTGC TAAAGGAAG AAGCATTTTT GCTGTTAGCC CAGATGGCTT  
1101 TGTGTGTGAT GATTTTCCA AACCOCAGAT CACGTTTCAG CCAGAAACAC  
1151 AGTCGGCAAT AAAAGGTTCC AATTTGAGTT TCATCTGTC AGCTGCCAGC  
1201 AGCAGTGATT CCCCAATGAC TTTTGTGGG AAAAAGACA ATGAATCTACT  
1251 GCATGATGCT GAAATGAAA ATTATGCACA CTTCCGGGCC CAAGGTGGCG  
1301 AGGTGATGGA GTATACACC ATCTTCGGC TGCGGAGGT GGAATTTGCC  
1351 AGTGAGGGA AATATCAGT GTGTCATCTCC AATCACTTTG GTTCATCCTA  
1401 CTCTGTCAA GCCAAGCTTA CAGTAATAT GCTTCCCTCA TTCACCAAGA  
1451 CCCCCATGGA TCTCACATC CGAGCTGGGG CCATGGCAGC CTTGGAGTGT  
1501 GCTGCTGTGG GGCACCCAGC CCCCCAGATA GCCTGGCAGA AGGATGGGG

1551 CACAGACTTC CCAGCTGCAC GGGAGAGAGC CATGCATGTG ATGCCCGAGG  
1601 ATGACGTGTT CTTTATCGTG GATGTGAAGA TAGAGGACAT TGGGGTATAC  
1651 AGCTGCACAG CTCAGNACAG TGCAGGAAGT ATTTACAGAA ATGCAACTCT  
1701 GACTGTCTTA GAAACACCAT CATTTTTCGG GCCACTGTGT GACCGAACTG  
1751 TAACCAAGGG AGAAACAGCC GTCCTACAGT GCATTGTCTG AGGAAGCCCT  
1801 CCCCCTAAC TGAACCTGGAC CAAAGATGAT AGCCCATTTG TGTAAACCGA  
1851 GAGGCACTTT TTTGCAGCAG CCAATCAGCT TCTGATTATT GTGGACTCAG  
1901 ATGTCACTGA TGTGGGAAA TACACATGTG AGATGTCTAA CACCCTTGGC  
1951 ACTGAGAGAG GAAACGTGCG CTCAGTGTG ATCCCCACTC CAACCTGGCA  
2001 CTCCTCTCAG ATGACAGCCC CATCGTTAGA CGATGACGGA TGGGCCACTG  
2051 TGGGTGCTG GATCATAGCC GTGGTTTGT GTGTGGTGG CAGCTCACTC  
2101 GTGTGGGTG TCAATCATATA CCACACAAGG CGGAGGAATG AGATTGCGAG  
2151 CATTACCAAC ACAGATGAGA CCAACTTGCC AGCAGATATT CTTAGTTATT  
2201 TGTCACTCA GGGACGTTA GCTGACAGCC AGGATGGTA CGTGTCTTCA  
2251 GAAAGTGGAA GCCACCACA GTTGTGACA TCTTCAGGTG CTGGATTTT  
2301 CTTACCACAA CATGACAGTA GTGGACCTG CCATATTGAC AATAGCAGTG  
2351 AAGCTGATG GGAAGCTGCC ACAGATCTGT TCCTTTGTCC GTTTTGGGA  
2401 TCCACAGGCC CTATGTATT GTAGGGAAT GTGTATGCT CAGATCCTTT  
2451 TGAACATAT CATACAGGTA CTTTGGAAA AGCTCTCAGG AGACCTCACC  
2501 TAGATGCCTA TTCAAGCTTT GGACAGCCAT CAGATTGTCA GCCAAGAGCC  
2551 TTTTATTGGA AAGCTCATTC TTCCCCAGC TTGGACTCTG GTGGTTTTAT  
2601 GATTGCCCTG TGGTACCAG GACTCTTTAG TCCAGAAACCA GCTTTTGTAT  
2651 TAAAGCTAG GGATGATGA GGTACTCTC ATAGTCATAG AGCTGGCCAG  
2701 CATGGCTCA AGTACTACT CTTTCAAGCA CTTGCAGAAG GAAATGTGTT  
2751 GCGGAGGCC CCACACAGAG TTCCCCCTGG GGCACCACCT ACTGGAGCTG  
2801 CGAGNAGAGA GCTACTGTCC TCCATCTCTC AGAATGGTAG ATCCACTGAC  
2851 AGCTTGGCT CTGTGCTGC AAAAGCCGA GACACTCAAT GCCAATCTGT  
2901 GAAAGCAGCC AGGAGGGAG CTGTACCCTG CAAAGTCACA GGGCCGGAGC  
2951 TGCCCAAGC CACAGGAGC TATCTCTTGC ATCAGTGTGA CTTGGATATG  
3001 AGCATGGAG TCAAAACAGA TCATTCTGGA CTTTAAAGAA TTGGAGGAAA  
3051 ATACCGAGCA CTTGTGGCC AGTTAAAAAC GATTAGTGTG GCCACCGGAC  
3101 TTAAGACTCA GCTTTCCTAT CAAAACCCCT TCATTAAACC TGTAAACCCG  
3151 CGATGCATTC AATCTGTAGC GGCAACTGCT TTGCTAACAG AAGAAAGTAG  
3201 AAAAGAACT TTTAGAGGAA ACCTCATTTGT GAGGAAACCT CATTGCAAGC  
3251 GGACTTTGGA GCCTCTGGAA AAGGAAAAG CTGGGAAAAT TGAATGCCTA  
3301 ATAGGGCTTG CTTCCAGTGT GGTCTACAAG GACACTTTAA AAAAGATTGT

351 TGACTCCATC TCGGAGAGTG GGGGCCTCAA CTGGAAGATG ACCCTGTGCC  
401 TCCTCGTGCC CTGGAGCATC GTGGGGATGG CTGTGCTTAA GGGCATCCAG  
451 TCCTCGGGGA AGGTGATGTA TTTGAGCTCC CTCTTCCCTT ACGTGGTGCT  
501 GGCCTGCTTC CTGCTCCGGG GGCTGTTGCT GCGAGGGGCA GTTGATGGCA  
551 TCCTACACAT GTTCACTCCC AAGCTGGACA AGATGCTGGA CCCCCAGGTG  
601 TGGCGGGGAG CAGCTACCCA GGTCTTCTTT GCTTGGGCC TGGGCTTTGG  
651 TGGTGTGCTT GCTTCTCCA GCTACAATAA GCAGGACAACT AACTGCCACT  
701 TCGATGCCGC CTTGCTGTC TTCACTCACT TCTTCACTGTC AGTGTGGCC  
751 ACCTCGTGG TGTGTTGCTGT GCTGGGCTTC AAGGCCAACA TCATGAATGA  
801 GAAGTGTGTC GTGGAAGATG CTGAGAAAAA CCTAGGGTAC CTTAACACCA  
851 ACGTCTCTGAG CCGGACCTC ATCCCACCCC ACGTCAACTT CTCCCACCTG  
901 ACACAAAGG ACTACATGGA GATGTACAAT GTCATCATGA CCGTGAAGGA  
951 GGACCAAGTTC TCAGCCCTGG GCCTTGACCC CTGCTTCTG GAGGACGAGC  
1001 TGGACAAGTC CGTGCAGGC ACAGGCCTGG CCTTCATGCG CTTCACTGAG  
1051 GCGATGACGC ACTTCCCGCG CTCGCCGTTT TGGTCCGTC A TGTTCTTCTT  
1101 GATGCTTATC AACCTGGGCC TGGGACGAT GATCGGGACC ATGGCAGGCA  
1151 TCACCAGGCC CATCATGAC ACCTTCAAGG TGCCCAAGGA GATGTTACA  
1201 GCTGCTGTGT CTTTGCAATC CTCGTGGGGC TGTTGTTGCT CCAGCGCTCC  
1251 GGAAACTACT TTGTCAACCAT GTTCGATGAC TACTCGGCCA CCGTCCCACT  
1301 CACTCTCATC GTCATCCTTG AGACATGCG TGTGGGCTGG ATTTATGGNA  
1351 CCAGAAAGTT CATGC

!!AA SEQUENCE 1.0  
ID ADP30651 standard; protein; 4752 AA.

XX ADP30651;

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1418.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410951P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486468P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases

such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 2649; 428pp; English.

The present invention relates to an isolated nucleic acid molecule

1	ATGACAAAGC	CCCGCGCTTC	ACCCAAACTT	CCTAGGCCCT	GTTCGTCCGC
51	GAGAACACA	GCCCGCCCT	GCACATCGG	AGCATCAGG	CCACAGACAG
101	AGACTCGGC	ACCAACGCC	AGGTCAACTA	CTCGTGCTG	CCGTCCACAGG
151	ACCGCACCT	GCCCTCGGC	TCCCTGTCT	CCATCAAGC	GGACAAAGGC
201	CACCTGTTG	CCCTAGGTC	GCTGACTAC	GAGGCCCTGC	AGGGTTCCA
251	GTTCGCGTG	GGCGCCACAG	ACCACGGTC	CCCGGTTTG	A
11AA SEQUENCE 1.0					
ID	ADP30648 standard; protein; 1365 AA.				
AC	ADP30648;				
XX					
DT	12-AUG-2004 (first entry)				
XX					
DE	Human secreted protein SEQ ID #1415.				
XX					
XX	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;				
KW	cancer; inflammatory; immune; human secreted protein.				
XX					
OS	Homo sapiens.				
XX					
PN	WO2004035732-A2.				
XX					
PD	29-APR-2004.				
XX					
PF	28-AUG-2003; 2003WO-US026780.				
XX					
XX	29-AUG-2002; 2002US-0406576P.				
PR	29-AUG-2002; 2002US-0406579P.				
PR	29-AUG-2002; 2002US-0406585P.				
PR	29-AUG-2002; 2002US-0406588P.				
PR	29-AUG-2002; 2002US-0406608P.				
PR	29-AUG-2002; 2002US-0406611P.				
PR	29-AUG-2002; 2002US-0406612P.				
PR	29-AUG-2002; 2002US-0406616P.				
PR	29-AUG-2002; 2002US-0406640P.				
PR	29-AUG-2002; 2002US-0406642P.				
PR	29-AUG-2002; 2002US-0406646P.				
PR	29-AUG-2002; 2002US-0406653P.				
PR	29-AUG-2002; 2002US-0406655P.				
PR	29-AUG-2002; 2002US-0406666P.				
PR	17-SEP-2002; 2002US-0410946P.				
PR	17-SEP-2002; 2002US-0410947P.				
PR	17-SEP-2002; 2002US-0410948P.				
PR	17-SEP-2002; 2002US-0410949P.				
PR	17-SEP-2002; 2002US-0410953P.				
PR	17-SEP-2002; 2002US-0410957P.				
PR	17-SEP-2002; 2002US-0410958P.				
PR	17-SEP-2002; 2002US-0410959P.				
PR	17-SEP-2002; 2002US-0410960P.				
PR	17-SEP-2002; 2002US-0410961P.				
PR	17-SEP-2002; 2002US-0410962P.				
PR	17-SEP-2002; 2002US-0411019P.				
PR	17-SEP-2002; 2002US-0411022P.				
PR	17-SEP-2002; 2002US-0411023P.				
PR	17-SEP-2002; 2002US-0411024P.				
PR	17-SEP-2002; 2002US-0411032P.				
PR	17-SEP-2002; 2002US-0411035P.				
PR	17-SEP-2002; 2002US-0411037P.				
PR	17-SEP-2002; 2002US-0411041P.				
PR	17-SEP-2002; 2002US-0411045P.				
PR	17-SEP-2002; 2002US-0411046P.				
PR	17-SEP-2002; 2002US-0411048P.				
PR	17-SEP-2002; 2002US-0411052P.				

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2633; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX Sequence 189 AA;  
SQ  
ADP30635 Length: 189 February 22, 2005 12:25 Type: P Check: 776 ..  
1 ATGTGCTACG GGCITCGAGC TGGGGAAGGA CGGCCGCTCT TGTGTGACCA  
51 GTGGGAAGG ACAGCCGACC CTTGGGGGGA CCGGGGTGCC CACCAAGGCGC  
101 CGCCCGGCCA CTGCAACCAACG CCCCGTGCCG CAGAGAACAAT GGCCAATCAG  
151 GGTGACGAG AAGCTGGGAG AGACACCACT TGTCCCTGA  
!!AA\_SEQUENCE 1.0  
ID ADP30640 standard; protein; 291 AA.  
XX  
XX ADP30640;  
XX  
XX 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #1407.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX  
XX 29-AUG-2002; 2002US-0406579P.  
XX  
XX 29-AUG-2002; 2002US-0406585P.  
XX  
XX 29-AUG-2002; 2002US-0406588P.  
XX  
XX 29-AUG-2002; 2002US-0406608P.  
XX  
XX 29-AUG-2002; 2002US-0406611P.  
XX  
XX 29-AUG-2002; 2002US-0406612P.  
XX  
XX 29-AUG-2002; 2002US-0406616P.  
XX  
XX 29-AUG-2002; 2002US-0406640P.  
XX  
XX 29-AUG-2002; 2002US-0406642P.  
XX  
XX 29-AUG-2002; 2002US-0406646P.  
XX  
XX 29-AUG-2002; 2002US-0406653P.  
XX  
XX 29-AUG-2002; 2002US-0406655P.  
XX  
XX 29-AUG-2002; 2002US-0406666P.  
XX  
XX 17-SEP-2002; 2002US-0410946P.  
XX  
XX 17-SEP-2002; 2002US-0410947P.  
XX  
XX 17-SEP-2002; 2002US-0410948P.  
XX  
XX 17-SEP-2002; 2002US-0410949P.  
XX  
XX 17-SEP-2002; 2002US-0410953P.

17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 2638; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPWEB and is not in the specification.



2901	GAAGCAGCC	AGGAGGAGG	CTGTACCCCTG	CAAAGTCACA	GGGCCGGAGC	4751	GA
2951	TGCCCAAGC	CACAGGACC	TATCTCTTG	ATCAGTGTGA	CCTGGATATG	!!AA_SEQUENCE 1.0	
3001	AGACATGGAG	TCAAAACAGA	TCATTCCTGGA	GCTTTAAGAA	TTGGAGGAAA	ID ADP30628 standard; protein; 234 AA.	
3051	ATACCAGCA	CCTGTGCGCC	AGTTAAAAAC	GATTAGTGTG	GCCACCGGAC	XX AC ADP30628;	
3101	TTAAGACTCA	GCTTTCCTAT	CAAAAAACCT	TCATTAAACC	TGTAACCCGC	XX DT 12-AUG-2004 (first entry)	
3151	CGATGCATTC	AATCTGTAGC	GGCAACTGCT	TTGCTAACAG	AAGAAAGTAG	XX DE Human secreted protein SEQ ID #1395.	
3201	AAAAGAAACT	TTTAGAGGAA	ACCTCAITGT	GAGGAAACCT	CATTGCAAGC	XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;	
3251	GGACTTTTGA	GCCTCTGGA	AAGGAAAAG	CTGGGAAAT	TGAATGCCTA	XX KW cancer; inflammatory; immune; human secreted protein.	
3301	ATAGGGCTTG	CTTCAGTGT	GGTCTACAAG	GACACTTTAA	AAAGATTGT	XX OS Homo sapiens.	
3351	CCAAGTAGAA	ATAAGCCACC	CCCTCGTCCA	TGCCCCCTTAT	GCCAAGGGA	XX PN WO2004035732-A2.	
3401	TCACTGGAG	GCCNACTGAC	CCAGGGGATG	AAGCTGTACC	TAAACCTTAC	XX PD 29-APR-2004.	
3451	ACTCTGCTTT	CCCAANTACC	AGAGAAAGCA	GAGTGGTTTTA	TACTCCTGGA	XX PF 28-AUG-2003; 2003WO-US026780.	
3501	CCTTAAGGAT	GCCCTTTTCT	TCATCCCTGT	ACATCCTGAC	TCTCAATTCT	XX PR 29-AUG-2002; 2002US-0406576P.	
3551	TGTTTGCCTT	TGAAGATCCT	TCAACTCAA	CATCTCAACT	CACCTGGACT	XX PR 29-AUG-2002; 2002US-0406579P.	
3601	GTTTTACCCC	TAGCGTTCCAG	GAATGGCCCC	CATCTATTTG	GCCAGGCATC	XX PR 29-AUG-2002; 2002US-0406585P.	
3651	AACCCAAAG	TTGAGCCAGC	TCTCATACCT	GGACACTCTT	GTCCCTTTGGC	XX PR 29-AUG-2002; 2002US-0406588P.	
3701	ATGTGGATCA	TTTACTTTTA	CTGCGCTGTT	CAGAAACCTT	GTGCCATCAA	XX PR 29-AUG-2002; 2002US-0406611P.	
3751	GCCACCCAA	CACCTCTTAA	TTTCTCTCACT	ACCTGTGGTT	ACAAGGTTTC	XX PR 29-AUG-2002; 2002US-0406612P.	
3801	CAAACCAA	GCTCAACTCT	GCTCACAGCA	GGTTAAATAC	TTAGGGCTAA	XX PR 29-AUG-2002; 2002US-0406616P.	
3851	ANTTACCNA	AGGCACCAAG	GCCCCCAGTG	AGGAATGTAT	CCAGCCTATA	XX PR 29-AUG-2002; 2002US-0406640P.	
3901	CTGGCTTATC	CTCATCCCAA	AACCCTAAAG	CAACTAAGAG	CGTTCCTTTGG	XX PR 29-AUG-2002; 2002US-0406642P.	
3951	CATAACAGT	TTCTGCCGAA	TATGGATTCC	CAGCATACTC	ACTGCTAAAG	XX PR 29-AUG-2002; 2002US-0406645P.	
4001	GAGACTTGTG	GCTGTCAGAT	AACCATTTAC	TTAAATATCA	GGTTCATATTA	XX PR 29-AUG-2002; 2002US-0406653P.	
4051	CTTGAAGGC	CAGTGTGSCA	ACTGCGCACT	TGTGCAACTC	TTAACCCAGC	XX PR 29-AUG-2002; 2002US-0406655P.	
4101	CACATTTCTT	CCAGACAATG	AAGAAAAAGT	AGAACATAAC	TGTCACAAG	XX PR 17-SEP-2002; 2002US-0410945P.	
4151	TAATTGCTCA	AACCTACGCC	ACTGAGGGG	ACCTTTTAGA	GGTTCCTTTG	XX PR 17-SEP-2002; 2002US-0410947P.	
4201	ACTGATCCG	ACCTCAACTT	GTATACTGAT	GGAAGTTTCT	TTGTACAAA	XX PR 17-SEP-2002; 2002US-0410948P.	
4251	AGGACTTCAA	AAAGCGGAT	ATGCAGTGGT	CAGTGATAT	GGAATACTTG	XX PR 17-SEP-2002; 2002US-0410949P.	
4301	AAAGTAATCC	CTTCACTCCA	GGAACCTAGCA	CTCAGCTGCG	AGAATGGTA	XX PR 17-SEP-2002; 2002US-0410953P.	
4351	GCCCTCACTT	GGGCACCTAGA	ATTCCGGAGAA	GGAAAAAGGG	TAAATATAAA	XX PR 17-SEP-2002; 2002US-0410957P.	
4401	TACAGGCTCT	AAGTATGCTT	ACCTAGTCTT	CCATGCCCAT	GCATCAATAT	XX PR 17-SEP-2002; 2002US-0410958P.	
4451	GGAGAGAAAG	GGAATTCCTA	ACTTCCGAGG	GAACACCTAT	CAACATCAG	XX PR 17-SEP-2002; 2002US-0410959P.	
4501	GAAGCCATTA	GGAGATTATT	ATTGGTTGTA	CAGAAACCTG	AAGAGGTGGC	XX PR 17-SEP-2002; 2002US-0410960P.	
4551	AGTCTTTAC	TGCTGGGGTC	ATCCGAAAGG	AAAGGAAAGG	GAAATAGAAG	XX PR 17-SEP-2002; 2002US-0410961P.	
4601	GGAACCTGCA	AGCCGATATT	GAAGCCMAA	GAGCCTCAAG	GCAGACCCCT	XX PR 17-SEP-2002; 2002US-0410962P.	
4651	CCATTAGAAA	TGCTTATAGA	AAGACACCTA	GTATGGGGTA	ATCCCTCTG	XX PR 17-SEP-2002; 2002US-0410966P.	
4701	GGAAACCAAC	CCCCAGTACT	CAGCAGAAGA	AATAGAATGG	GGAACCTCAT	XX PR 17-SEP-2002; 2002US-0411019P.	
						XX PR 17-SEP-2002; 2002US-0411022P.	
						XX PR 17-SEP-2002; 2002US-0411023P.	
						XX PR 17-SEP-2002; 2002US-0411024P.	
						XX PR 17-SEP-2002; 2002US-0411032P.	
						XX PR 17-SEP-2002; 2002US-0411033P.	
						XX PR 17-SEP-2002; 2002US-0411037P.	
						XX PR 17-SEP-2002; 2002US-0411041P.	
						XX PR 17-SEP-2002; 2002US-0411045P.	
						XX PR 17-SEP-2002; 2002US-0411046P.	
						XX PR 17-SEP-2002; 2002US-0411052P.	
						XX PR 17-SEP-2002; 2002US-0411055P.	
						XX PR 17-SEP-2002; 2002US-0411073P.	
						XX PR 17-SEP-2002; 2002US-0411082P.	
						XX PR 17-SEP-2002; 2002US-0411010P.	
						XX PR 18-APR-2003; 2003US-0463700P.	
						XX PR 18-APR-2003; 2003US-0463708P.	
						XX PR 18-APR-2003; 2003US-0463716P.	
						XX PR 18-APR-2003; 2003US-0463732P.	
						XX PR 02-MAY-2003; 2003US-0467199P.	
						XX PR 02-MAY-2003; 2003US-0467201P.	
						XX PR 02-MAY-2003; 2003US-0467203P.	



PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2583; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytosolic,  
CC anti-inflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX Sequence 4752 AA;  
ADP30585 Length: 4752 February 22, 2005 12:25 Type: P Check: 2463 ..  
1 ATGAGCGCGC CGAGCTTCOG TCGCGCGGCC CGGGGTTTGG GGCTGTGCT  
51 GTGCGCGGTG CTGGGCGCG CTGGCGCGTC AGACAGCGGC GGTGCGGGG  
101 AACTCGGGCA GCCCTCTGGG GTAGCGCGCG AGCGCCCATG CCCCACTACC  
151 TGCGGCTGCC TCGGGGACCT GCTGGACTGC AGTCGTAAGC GGCTAGCGCG  
201 TCTTCCCGAG CCACCTCCCGT CTTGGGTGCG TCGGCTGGAC TTAAGTCACA  
251 ACAGATTATC TTTCATCAAG GCNAGTTCCA TGAGCCACTC TCAAGGCCTT  
301 CGAGAAGTGG CTGGAACACG GATTGTTGAA ATACTCCCTG AACATCTGAA  
351 AGAGTTTCAG TCCTCTGAAA CTTTGGACCT TAGCAGCAAC AATATTTTCAG  
401 AGCTCCAAAC TGCAATTCCA GCCTACAGC TCAATATCTC GGAATTGAAC  
451 CGAAACAAGA TTAAAAATGT AGATGGACTG ACATTCCAAG GCCTTGCTGC  
501 TCTGAAGTCT CTGAAATGC AAAGAAATGG AGTAACGAAA CTTATGGATG  
551 GAGCTTTTTG GGGGCTGAGC AACATGGAAA TTTTGCAGCT GGACCATAAC  
601 AACCTAACAG AGATTACCAA AGGCTGGCTT TACGGCTTGC TGATGCTGCA  
651 GGAACCTTCAT CTCAGCCAAA ATGCCATCAA CAGGATCAGC CTTGATGCCT  
701 GGGAGTTCTG CCAGAGCTC AGTGGCTGG ACCTAACCTTT CAATCACTTA  
751 TCAAGGTTAG ATGATTCAAG CTTCTTTGGC CTAAGCTTAC TAAATACACT  
801 GCACATTGGG AACACACAG TCAGCTACAT TGCTGATTGT GCCTTCCGGG  
851 GGCTTTCCAG TTTAAGACT TTGATACTCC AAGGAATCG GATCCGTTCT  
901 ATTACTAAA AAGCCTTTCAC TGGTTTGGAT GCATTGGAGC ATCTGCATTT  
951 AATATACATCA AGCCTTTTGT GCGATTGCCA GCTAAATGG CTCCACAGT  
1001 GGGTGGCGGA AAACAACCTT CAGAGCTTTG TAAATGCCAG TTGTGCCCAT  
1051 CCTCAGCTGC TAAAGGAAG AAGCAATTTT GCTGTTAGCC CAGATGCTT

1101 TGTGTGTGAT GATTTTCCA AACCCAGAT CACGGTTTCAG CCAGAAACAC  
1151 AGTCGGCAAT AAAAGGTTCC AATTGAGTT TCATCTGCTC AGCTGCCAGC  
1201 AGCAGTGATT CCCCAATGAC TTTTCTTGG AAAAAGACA ATGAATCTACT  
1251 GCATGATGCT GAAATGAAA ATTATGCACA CTTCCGGGCC CAAGGTGGCG  
1301 AGGTGATGGA GTATACCACC ATCTTTCGCG TGCGCGAGGT GGAATTTGCC  
1351 AGTGAGGGGA AATATCAGTG TGTATCTCC AATCATTCTT GTTCATCTTA  
1401 CTCTGTCAAA GCCAAGCTTA CAGTAAATAT GCTTCCCTCA TTCACCAAGA  
1451 CCCCCATGGA TCTCACCATC CGAGCTGGG CCATGGCAGC CTTGGAGTGT  
1501 GCTGCTGTGG GGCACCCAGC CCCCAGATA GCCTGGCAGA AGGATGGGGG  
1551 CACAGACTTC CCAGCTGCAC GGGAGAGAGC CATGCATGTG ATGCCCGAGG  
1601 ATGACGTGTT CTTTATCGTG GATGTGAAGA TAGAGGACAT TGGGGTATAC  
1651 AGCTGCACAG CTCAGAACAG TGCAGGAAGT ATTTCAGCAA ATGCAACTCT  
1701 GACTGTCTTA GAAACACCAT CATTTTTCGG GCCACTGTTG GACCGAACTG  
1751 TAACCAAGGG AGAAACAGCC GTCTACAGT GCATTGCTGG AGGAAGCCCT  
1801 CCCCCTAAC TGAACCTGGAC CAAGATGAT AGCCCATTGG TGGTAACCGA  
1851 GAGGCACTTT TTTGACGACG GCAATCAGCT TCTGATTATT GTGCACTCAG  
1901 ATGTCAGTGA TGCTGGGAAA TACACATGTG AGATGTCTAA CACCTTGGC  
1951 ACTGAGAGAG GAAACGTGGC CCTAGTGTG ATCCCCACTC CAACCTGCGA  
2001 CTCCTCTCAG ATGACAGCCC CATCGTTAGA CGATGACGGA TGGGCCACTG  
2051 TGGGTGCTGT GATCATAGCC GTGGTTTGT GTGTGGTGGG CAGCTCACTC  
2101 GTGTGGGTGG TCATCATATA CCACACAAGG CGGAGGAATG AAGATTGCGA  
2151 CATTTACCAAC ACAGATGAGA CCAACTTGGC AGCAGATATT CCTAGTTATT  
2201 TGTCACTCA GGGAACTTA GCTGACAGCG AGGATGGGA CGTGTCTTCA  
2251 GAAAGTGGAA GCCACCACA GTTTGTACA TCTTCAGGTG CTGGATTTTT  
2301 CTTACCACAA CATGACAGTA GTGGGACCTG CCATATTGAC AATAGCAGTG  
2351 AAGCTGATGT GGAAGCTGCC ACAGATCTGT TCCTTTGTCC GTTTTGGGA  
2401 TCCACAGGCC CTATGTATTT GAAGGGAAT GTGTATGGCT CAGATCTTTT  
2451 TGAACATAT CATACAGGTA CCTTTGGAAA AGCTCTCAGG AGACCTCACC  
2501 TAGATGCTTA TTCAAGCTTT GGACAGCCAT CAGATTGTCA GCCAAGAGCC  
2551 TTTTATTTGA AAGCTCATTC TTCCCCAGAC TTGGACTCTG GTGGTTTTAT  
2601 GATTGCTTGT TGGTACCAGG GGAATCTTTAG TCCAGAAACCA GCTTTTGTAT  
2651 TAAAGCTAG GGATGATGTA GGTACTCTGC ATAGTCATAG AGCTGGCCAG  
2701 CATTTGGCTCA AGTACTACCT CTTTCAAGCA CTTGCAGAA GAAATGTGGT  
2751 GCGGAGGCC CCACACAGAG TTCCCCCTGG GGCACCACCT ACTGGAGCTG  
2801 CGAGAAGAG GCTACTGTCC TCCAATCTC AGAATGGTAG ATCCACTGAC  
2851 AGCTTGCCT CTGTGCTGC AAAAGCCGA GACACTCAAT GCCAATCTGT

CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1183 AA;

ADP30536 Length: 1183 February 22, 2005 12:25 Type: P Check: 7217 ..

1 GAGCTCCATT GAATCGCGCG GCGCGCGCG GCGAGCGCG GGGCTGCGGC  
51 GGGATCGCTG CGCCCTCGCG CGCTGGGCTC TGGCAGCGCG GCGCTGCGGC  
101 CGAGCACACC GCGCGCGCG CGGTCTCGC CCGCGCGCTG CCCCCAGGAT  
151 GGTCCGCGCG AGGCACACG CCGGTGGGCT TTGCCTCCTG CTGCTGCTGC  
201 TCTGCAGATT CATGGAGAC GCGAGTCCC AGGCTGGGAA CTGCTGGCTC  
251 CGTCAAGCGA AGAAGCGCG CTGCCAGTC CTGTACAAGA CCGAACTGAG  
301 CAAGGAGGAG TGCTGCAGCA CCGCGCGGCT GAGCACCTCG TGGACCGAGG  
351 AGGACGTGAA TGACNACACA CTCTCAAGT GGNATGATTTT CNAAGGGGCG  
401 GCGCCCAACT GCATCCCCCTG TAAAGAAACG TGTGAGAACG TGGACTGTGG  
451 ACCTGGGAAA AAATGCCGAA TGAACAAGAA GAACAAACCC CGCTGCGTCT  
501 GCGCCCCGGA TTGTTCCAACT ATCACTGGA AGGTCAGT CTGCGGGCTG  
551 GATGGGAAA CCTACCGCAA TGAATGTGCA CTCCTAAAGG CAAGATGTAA  
601 AGAGCAGCCA GAACGTGGAAG TCCAGTACCA AGGCAGATGT AAAAGACTT  
651 GTCGGGATGT TTTCTGTCCA GGCAGCTCCA CATGTGTGGT GGACGAGCC  
701 AATAATGCTT ACTGTGTGAC CTGTAAATCGG ATTTGCCCAG AGCCTGTCTT  
751 CTCTGAGCAA TATCTCTGTG GGAATGATGG AGTCACCTAC TCCAGTGCCT  
801 GCCACTGAG AAAGGCTACC TGCTGTCTGG CGAGATCTAT TGGATTAGCC  
851 TATGAGGAAA AGTGTATCAA AGCAAAGTCC TGTGAAGATA TCCAGTGCAC  
901 TGGTGGGAAA AAATGTTTAT GGGATTTCAA GGTTCGGAGA GCGCGGTGTT  
951 CCCTCTGTGA TGAGTGTGCG CTTGACAGTA AGTCGGATGA GCCTGTCTGT  
1001 GCCAGTGA CAATGCCACTTA TGCAGCGAG TGTGCCATGA AGGAAGCTGC  
1051 CTGCTCTCA GGTGTGCTAC TGGAGTAAA GCATCCGGA TCTTGCAACT  
1101 CCATTTCGA AGACACGAG GAGAGAGG AGATGAAGA CCAGACTAC  
1151 AGCTTTCCTA TATCTTCTAT TCTAGATGG TAA

!!AA SEQUENCE 1.0  
ID\_ADP30585 standard; protein; 4752 AA.  
XX  
AC ADP30585;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1352.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.

XX WO2004035732-A2.  
PN  
XX 29-APR-2004.  
PD  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.



XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1176 AA;  
ADP30495 Length: 1176 February 22, 2005 12:25 Type: P Check: 403 ..  
1 TGCCTCCGG GGAAGGGTGA GGGCTACCGG GGCACAGCCA ATACCACCA  
51 CGCGGGCGTA CTTGCCAGC GTTGGGAGCG GAAATCCCG CATCAGCACC  
101 GATTTACGCC AGAAAAATAC CGGTGCAAG ACCTTCGGGA GAACCTTCTGC  
151 CGGAACCCCG ACGGCTCAGA GCGCCCTCG TGCCTCACAC TCGGCCCCGG  
201 CATGCGGTG GCGTTTGCT ACCAGATCCG GCGTTGTACA GACGACGTGC  
251 GCGCCACAGA CTGCTACCAC GCGCGGGGG AGCAGTACCG CGGCACGGTC  
301 AGCAAGACC GCAAGGTGT CAGTGCCAG CGCGGATGG GGATAGCCAT  
351 GGGCCCTGGT GCTACAGAT GGAACCCMAG ACCCATTCG ACTACTGTGC  
401 CCTGCGAGCG TGCCTGATG ACCAGCGCC ATCAATCTCTG GACCCCCCA  
451 GACCAAGTGC AGTTTGAGAA GTGTGGCAAG AGGTGGATC GGCTGGATCA  
501 GCGTTGTTC AAGTGCGCG TGSGTGGGG CCATCGGGG AACTCACCCCT  
551 GGACAGTCAG CTTGGGGAAT CAGGGCCAGC ATTTCGCGG GGGGTCTCTA  
601 GTGAAGGAGC AGTGATACT GACTGCCCGG CAGTGTCTCT CTTCTGCCA  
651 TATGCTCTC ACGGGTATG AGTATGGTT GGGCACCCCTG TTCCAGAAAC  
701 CACAACATGG AGAGCCAGG CTACAGCGG TCCAGTAGC CAAGATGCTG  
751 TGTGGGCCCT CAGGCTCTCA GCTTGCTCTG CTCAGCTGG AGAGATCTGT  
801 GACCTGAAC CAGCGTGTG CCTGTATCTG CTGCGCGCT GAATATGTGG  
851 TGCCTCCAGG GACCAAGTGT GAGATTGCAG GCGGGGGTGA GACCAAAAGT  
901 AAGAGCAACA CAGTCCTAAA TGTGGCCTTG CTGAATGTCA TCTCAACCA  
951 GGAGTGTAA ATCAAGCACC GAGGACATGT GCGGGAGAGC GAGATGTGCA  
1001 CTGAGGGACT GTTGCCCTCT GTGGGGCCT GTGAGACTAC GGGGGCCAC  
1051 TTGCTGTCTT TACCACAC TGTGGGTCC AAGGAATTAG AATCCCCAAC  
1101 CGAGTATGCG CAAGGTGCG CTGGCCAGCC GTCTTCACGC GTGTCTCTGT  
1151 GTTTGTGGAC TGGATTACA AGGTCA  
IIAA\_SEQUENCE 1.0  
ID ADP30530 standard; protein; 207 AA.  
XX  
AC ADP30530;  
XX  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1297.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX  
OS Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.

PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2482; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
XX Sequence 234 AA;  
SQ  
ADP30484 Length: 234 February 22, 2005 12:25 Type: P Check: 4048 ..  
1 ATGAAGTCCT TCATCAGCT CCAAACCTTT TCAAGCTGCG TGCAAGCTGC  
51 CATCCTGGAG CTTTCCTTCA TCATTATCCT GAGAAATTCT ATGCCTAATG  
101 ATATTACCAC AAATATATC CGTGAATAAA TAGAAACAAA GGGCAGTCAG  
151 TATCTCGCTG GCAGGGTGC TGGCAAGAGT GAAGAAAGG AGACCCAGG  
201 AAAACTGTCT CCTACAAGTG GATACGTCTC CTTAA  
!!AA-SEQUENCE 1.0  
ID ADP30495 standard; protein; 1176 AA.  
XX  
AC ADP30495;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1262.  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
XX WO2004035732-A2.  
PN  
XX  
XX 29-APR-2004.  
PD  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
PF  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR

PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2493; 428pp; English.

151 CCGGCGCTTG GCAGGAGGAT GTGCAGATG CTGAAGAGTG TGCTGGTGGC  
201 TGTGGCCCT TAATGGACTG CCGCTCTTC AGGAGAAAGG TACATGCCCA  
251 CGCTCGGNA TGGCTGGAA GAGACTTCT GCGGTAACCC TGATGGCGAC  
301 CCCGAGGTC CTTGGTGCCA CACAACAGAC CTTGCCGTGC GCTTCCAGAG  
351 CTGGGCGATC AAATCCTGCC GGGTGGGTTT CTCGACCAAG GTCTGGACGA  
401 CAACTATTGC CGGAATCCTG ACGGCTCCGA GCGGCCATGG TGCTACACTA  
451 CGGATCCGCA GATCGAGCGA GAATTCTGTG ACCTCCCCCG CTGCGGGTCC  
501 GAGGCACAGC CCCGCCAAGA GGGCACAGT GTCAGTGTCT TCCGCGGAA  
551 GGGTAGGGC TACCGGGGCA CAGCCAATAC CACCACCGG GCGGTACCTT  
601 GCCAGCGTTG GGACCGCGCA ATCCCGCATC AGCACCGATT TACGCCAGAA  
651 AAATACGCGT GCAAGACCT TCGGAGAAC TTCTGCCGA ACCCGACGG  
701 CTCAGAGGG CCCTGGTGCT TCACACTGCG GCGCGGCATG CCGTGGGCT  
751 TTTGCTACCA GATCCGGCGT TGTACAGACG ACGTGGCGCC CCAGGACTGC  
801 TACCACGGG CGGGGGAGCA GTACCGCGGC ACGGTCAGCA AGACCGCAA  
851 GGGTGTCCAG TGCAGGCGG GGAATGGGAT AGCCATGGGC CTTGGTGCTA  
901 CACGATGGAC CCAAGGACCC CATTTCGACTA CTGTGCCCTG CGACGCTGCG  
951 CTGATGACCA GCCGCCATCA ATCCTGGACC CCCCCGACC AGGTGCAGTT  
1001 TGAGAAGTGT GGCAGAAGGG TGGATCGGCT GGATCAGGCT TGTTCGAAGC  
1051 TCGCGTGGC TGGGGGCCAT CCGGGCAACT CACCCTGGAC AGTCAGCTTG  
1101 CGGAATTGA GGGCCAGCAT TTCTGGGGG GGTCTCTAGT GAAGGAGCAG  
1151 TGGATACTGA CTGCCCCGCA GTGCTTCTCC TCCTGCCATA TGCCTCTCAC  
1201 GGGCTATGAG GTATGTTGG GCACCCTGTT CCAGAACCACA CAACATGGAG  
1251 AGCCAGGCT ACACGGGTC CCAGTAGCCA AGATGCTGTG TGGCCCTCA  
1301 GGCTCTCAGC TTGTCTGTCT CAAGCTGGAG AGATCTGTGA CCCTGAACCA  
1351 GCGTGTGCC CTGATCTGCC TGCCGCTGA ATGATATGTG GTGCCCTCAG  
1401 GGACCAAGTG TGAGATTGCA GCGCGGGTG AGACCAAGG TAAGAGCATA  
1451 ACACAGTCTT AAATGTGGCC TTGCTGAATG TCATCTCAA CCAGAGTGT  
1501 AACATCAAGC ACCAGGACA TGTGCGGGAG AGCGAGATGT GCACTGAGGG  
1551 ACTGTTGCC CCTGTGGGG CTTGTAGGG TGACTACGGG GGGCCACTTG  
1601 CTGCTTTAC CCAACAATGC TGGGTCTTGA AAGGAATTAG AATCCCCAAC  
1651 CGAGTATGCG CAAGGTGCG CTGGCCAGCC GTCTTCAAGC GTGTCTGT  
1701 GTTGTGGAC TGGATTACA AGGTCAATGAG ACTGGGTTAG

!!AA SEQUENCE 1.0  
ID ADP30484 standard; protein; 234 AA.  
XX  
AC ADP30484;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1251.  
XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX Homo sapiens.  
XX WO2004035732-A2.  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485252P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.

101 ACACCGCTG GTCCACCTC ACCCACCAG GGAACAAGAT CAACCTCCTC  
151 GGCTTCTTGG GCTTGTCCA CTGCTTCCC TGCAAGATT CGTGCAGCG  
201 CGTGGAGTGC GGCCCGGGCA AGGCGTGCGG CATCTGGGG GCGCGCCCGC  
251 GCTCGAGTG CGCGCCCGAC TGCTCGGGC TCCCGGCGG GCTGCAGGTC  
301 TCGCGCTCAG ACGGCGCCAC CTACCGCGC GAGTGCAGC TGGCGCGCGC  
351 GCGTGGCGG GGGCACCAGG ACCTGAGGT CATGTACGG GCGCGTGGC  
401 GCAAGTCTTG TGAGCAGTG GTGTGCCCG GGCACAGTC GTGCGTGTG  
451 GACCAGCGG CGACGCCCA CTGCGTGTG TGTGAGCGG CGCCCTGCC  
501 TGTGCCCTCC AGCCCGCGG AGGAGCTTG CGGCAACAAC AAGTCACCT  
551 ACATCTCTC GTGCCACATG CGCCAGGCA CCTGCTTCTT GCGCCGCTCC  
601 ATCGCGGTGC GCCACGCGG CAGCTGCGCA GGCACCCCTG AGGAGCGGC  
651 AGTGGTGAG TCTGCAGAAG AGGAAGAA CTTGCTGTGA

## !AA SEQUENCE 1.0

ID ADP30472 standard; protein; 1740 AA.

AC ADP30472;

XX DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1239.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
02-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 2470; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytosolic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

XX Sequence 1740 AA;

ADP30472 Length: 1740 February 22, 2005 12:25 Type: P Check: 4200 ..

1 ACAGTGCGC CTCAGCCAG AAGGATGGG TGGCTCCAC TCTGTGCT

51 TCTGACTCAA TCGTTAGGG TCCCTGGGCA GCGCTGCCA TTGAATGACT

101 TCTAGGTGCT CCGGGGCGACA GAGTACAGC GCGCTACAA GCGGTGTGTC

2401 GCCTGGCGC TCGCCAGAG GACACATGCG CCAGCGTGGC GAGGCTGGT  
2451 CTCGGCGGC TGGCAACCT GGCTCCGGC TGCCCTGACA AGCCATCGC  
2501 ATCCGGCTTT TCTTGCACG TGAGAAGATG GAGTTCGGA CGGCATCTAT  
2551 CGCCTCTTT GGGCACCTTA ACAAGTCTG CCACGGAGAC TGTGAGGACG  
2601 TCTTCTTGA CCAGTGTGT GCGGGGTGG CGCCCTGTCT GCTGCACCTG  
2651 CAGGACCTTC AGGCCACGT GGCAGGCGC TGCAGTTTG CCCTGGCAT  
2701 GTGTGCCCC AATCTGGCAT GTGAGGAGCT CTCAGTGTCT TTCCAGAAAC  
2751 ACCTCAGGA GGGCCGAGCC CTGCACTTCG GGGAGTTCCT CAACACCACC  
2801 TGCAAGCAC TGATGCACCA TTTCGCCAGC CTGCTGGGCC GTCTCCTGAC  
2851 CACCTGCTTG TTACTTCA AGAGCAGCTG GGAGAACGTC CGAGGGTTCC  
2901 TGGTCTGCA CTCGGAGCCC AGCAGCAGC CGCAGGTGGA CTTGACCAGG  
2951 CTCATTGGG CGCTCCAGAT CTGTCTGAAG GACCCGGCCC CGAGGTGCG  
3001 GACGAGGGCT GCTGAGGCC TGGGCCGCCCT GGTGAAGCTC GCCTAA  
!!AA SEQUENCE 1.0  
ID \_ADP31686 standard; protein; 690 AA.  
XX AC ADP31686;  
XX DT  
XX DE  
XX DE Human secreted protein SEQ ID #2453.  
XX KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
XX PR 29-AUG-2002; 2002US-0406588P.  
XX PR 29-AUG-2002; 2002US-0406608P.  
XX PR 29-AUG-2002; 2002US-0406611P.  
XX PR 29-AUG-2002; 2002US-0406612P.  
XX PR 29-AUG-2002; 2002US-0406616P.  
XX PR 29-AUG-2002; 2002US-0406640P.  
XX PR 29-AUG-2002; 2002US-0406642P.  
XX PR 29-AUG-2002; 2002US-0406646P.  
XX PR 29-AUG-2002; 2002US-0406653P.  
XX PR 29-AUG-2002; 2002US-0406655P.  
XX PR 29-AUG-2002; 2002US-0406666P.  
XX PR 17-SEP-2002; 2002US-0410946P.  
XX PR 17-SEP-2002; 2002US-0410947P.  
XX PR 17-SEP-2002; 2002US-0410948P.  
XX PR 17-SEP-2002; 2002US-0410949P.  
XX PR 17-SEP-2002; 2002US-0410953P.  
XX PR 17-SEP-2002; 2002US-0410957P.  
XX PR 17-SEP-2002; 2002US-0410958P.  
XX PR 17-SEP-2002; 2002US-0410959P.  
XX PR 17-SEP-2002; 2002US-0410960P.  
XX PR 17-SEP-2002; 2002US-0410961P.  
XX PR 17-SEP-2002; 2002US-0410962P.  
XX PR 17-SEP-2002; 2002US-0411019P.  
XX PR 17-SEP-2002; 2002US-0411022P.

17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-048690P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Heatir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 3684; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPWEB and is not in the specification.  
Sequence 690 AA;  
ADP31686 Length: 690 February 22, 2005 12:25 Type: P Check: 6057 ..

1 GGTGTGTTT CTGGCTCCA GAGGCCAG GAGGCCACT GCAGCTGGT

51 GCTCCAGACT GATGTACACC GGGCCGAGTG CTGTGCCTCC GGCAACATTG



PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 08-JUN-2003; 2003US-0476609P.  
PR 08-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485232P.  
PR 14-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 3682; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 3046 AA;  
ADP31684 Length: 3046 February 22, 2005 12:25 Type: P Check: 4855 ..  
1 AGCGTGGGG CCATCAGCGT GCGCACCCCTC TACCTGGTCA GCACCACCGT  
51 GGACAGGATG AGTCACGTGA GTCCCTCTGGC CATACCTGCT CCAGTTCCCTC  
101 ACCCCTGTGC GCTTCACTGG GCGCCTGACT CCGCTCTGCA GGAGCCCTCGT  
151 GCATCTGGCG CAGAAGAGGC AGGAGGCCGG GCGCGACGCC TTCTCATCC  
201 AGTACGACGC CCATGCGAGC CTCGCCGTCTC CTTATGTGTG AACGGGAAGA  
251 CTGTGTGGTTG TGTCTTCCAG CCGCTACCTA GGGGACGGAC GTGGGGCAGC  
301 GGCCTGGGC CTCTCAGTG TTCTGCACCC AACATTAC CCITTGTGG  
351 GTCAGCATTG GGAACGACT GTCCCGCTGC TGCTGGGGTA CTTGGATGTT  
401 CCTCGGAGAC ACCCTGGCCA TCATTCTGA CAACGCGTGG ATCTGCCAGC  
451 TGAGCCTGGA GCTGTGAGG CAGCTGCCCT GCTACGATGA GGACCCCGAG  
501 GAGAAGCTCA GGAGTCAGAA CTTCTGTATC AAATGATATG GCACCACTCT  
551 GGGTGTCTCT TCAAGTAAGG AGTGTGTGAG GAAGCACCTT CAAGAGCTGC

601 TGGAGAGCGC CAGATACCAG GAGGAGGAG AACGCGAGGG CCTCGCCTGC  
651 TGCTTCGGGA TCTGTGCCAT CTCCACCTC GAGGACACGC TGGCCACGCT  
701 GGAGGACTTC GTGAGGTGAG AGGTCTTCAG AAATCCATT GGCATTCTCA  
751 ACATTTTAA GGTGGAAGT GAGAACGAAG TGGAGAAAGT GAAGAGTGCT  
801 CTGATCCTGT GCTATGGGCA CGTGGCGGCC CGGCCCCCCC GGGAGCTGGT  
851 GCTGGGCAAG GTAGAGTCAAG ACATCTCCG GAACATCTGC CAGCATTCA  
901 GCACCAAGGT TCTAGGAATA AAGGTAGAAA CCAAGGACCC AGCCCTGAAG  
951 CTGTGCTTG TCCAGAGTGT GTGCATGCT AGCGCGCCA TCTGCAGCAG  
1001 CACCCAGGCT GGTCTCTTCC ACTTACCCG GAAAGCAGAG CTGGTGGCAC  
1051 AGATGATGGA GTTCATCAGG GCAGAGCCCC CGGACTCTTT GAGGACACCT  
1101 ATTGGAAGA AAGCCATGCT CACCTGCACT TACTTGTCT CCGTGGAGCC  
1151 AGCGTGGAC GAGCAGGCC GGGCGGATGT GATCCATGGC TGCCTGCACA  
1201 GCATCATGGC CCTGTCTGCT GAGCCCAAGG AGGAGGACGG AGGCTGCCAG  
1251 AAGCTGTATC TGGAGACACT GCACGCCCTT GAGGATCTGC TGACGAGCCT  
1301 CTTGAGCGG AACATGACCC CCAAGGCCCT GCAGATCATG ATTGAGCACC  
1351 TGAGCCCATG GATCAAGTCC CCAAGAGGTC ACAGAGCGGC GCGGGCCCTG  
1401 GCGCTGAGCG CCTCTCTGCT GCGTACTTTC CTGGAGCACC TGGTGTGTCAG  
1451 CCCTTTCAC AACCTGGGCC TTCTCATCGG CCTCTTCTCC CACGGGTGTG  
1501 CGGACCTGTG GCGTGCACC GCGCAGGAGG CCGTGGACTG TGTCTACTCC  
1551 CTGCTGTACC TCCAGTCTGG CTAAGAGGTC TTCTCCCGG ACTACCGGA  
1601 TGAGTGGGG GAGCGGCTCC TCAGCCTCAA GGAGCGGCTC GTGACACCTG  
1651 ACCCGGCAAT TCTCTTCCAC ACCTGCCACA GTGTAGGCCA GATTATTGCC  
1701 AAGGCGCTCC CCCCAGACCA GCTCATCAGC CTCTTGCTAA CCATGTTGA  
1751 GGCCTTGGGA GACCCGAAA AGAATGTCTC CCGAGCAGCT ACCGTATGA  
1801 TCAACTGCTT GCTGCAGGAG CCGGCGGCTG TGCTCCAGGA GAAGCCACAC  
1851 CTGCATGCTG TGGCGGGCGC TGGCGGTGGA GCCTCGCCTA GCTGCCCAGG  
1901 TCCTGGGGCT GCTGTGGAG AAGATGAGTA GGGACGTCCC TTTCAGGAG  
1951 AGCGGGGCT TCTGTGGG CCGCACCCCA GACCGCGTGG CCACGCTGCT  
2001 GCCTCTCTCG GCTACCTGTG CACTGTTTGA GGTCACTGCC ACSCCTGCAG  
2051 CCGGGCCCCG GGTGTGAG CTCTACCCCC AGTGTGTTGT GGTGCTTCTG  
2101 CTGCGCTCA GCTGCACCGT GGGTGTCCAG CTGCCCGGA ACCTGCAGGC  
2151 CCAGGAAGG AGGGGTGCCA GTCCAGCCCT AGCCACCAGG AACCTGGAAC  
2201 CTTGAGCTC TGCAGTGGAC ACCCTGCGGT CCATGCTACT CCGAGCGGGC  
2251 AGCGAGGATG TGTACAGCG CATGGACCTG GAGGAGGCT GGGAACTGCT  
2301 CAGGACCTCG GCGGGCATG AGGAGGGGC CACCAAGTTG GCCAGCTGCT  
2351 GAACAGCAAC GTGGCCAACG ACCTCATGCT CTTGGACTCG CTGCTGGAGA

PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3649; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPONEB and is not in the specification.  
XX  
SQ Sequence 555 AA;

ADP31651 Length: 555 February 22, 2005 12:25 Type: P Check: 9556 ..  
1 ATGGGGCTGG TACAAGCACC CTCCTCGCTC AGGACTCTGG CCTCATCCCC  
51 AGGGCACCAG GGCTCACAGG GGGATGGGCC CGGGTTTAGC CCCACGAAGA  
101 TGAAGTGGGC ACCCGCAACG TGCTGGGCTC TGCTACTGSC GGCCGCCTTC  
151 CTCTGCGACA CGCGCGCAGC CAAAGGGGGC CGCGAGGTG CGCGGGGCG  
201 TGCCCCGGGA GGGGTCCGCG GGGGTGCGCG CGGGGCCTCG AGGGTGGCGG  
251 TGAGSCGGC GCACGCTAC GGTGCCCCGG GTCTCTCCCT CGCGGTGSGCT  
301 GCCGCCGGGG CGGCAGCCGG GCGCGCGGGG GGAGCGGGCG CGGGCCTTGGC  
351 GCGGGGCTCG GGCTGGAGAA GGGCCGCGGG ACCCGGGGAA CGCGGCCTGG  
401 AGGACGAGGA GGACGGGGTG CCGGAGGCA ACGGGACAGG CCCCGGCATC

451 TACAGTACC GGGCGTGGAC TTCGGGGGCT GGACCCACGC GGGGCCCCGG  
501 TCTCTGTCTC GTGCTGGGCG GGGCCCTCGG AGCCCTGGGG CTGCTGGCGC  
551 CCTAG  
!!AA\_SEQUENCE 1.0  
ID\_ADP31684 standard; protein; 3046 AA.  
XX  
AC ADF31684;  
DT  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2451.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.

PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3587; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1358 AA;  
ADP31589 Length: 1358 February 22, 2005 12:25 Type: P Check: 1874 ..  
1 AGGTGGGGGG CTCTGGGACC CTGCGAGGCA GCGCGGCTCA ACCTTGGCGA  
51 CCCAGCCTGG GATCCCTTAC CGTACTCACC GAGAGCTTGA GGAGACCTCC  
101 AGCCCCCAT CCTTGGCTCC CGGTAACTGC TGTTCCTTTT TGCCTTTGCA  
151 GATGGACGGG ACAGAAGGCA GTGCGGGGCA GCGCGGCCCC GCTGAGCGAT  
201 CCCACCGAAG CASCCTGTCC TCGGTGGGAG CCCGAGTCAG TGCCCATGAG  
251 CTGACACCGG CTGTGCGGGA GGTCTCTGAG CTTCAGNACA TCGCCCTGGA  
301 TGTCTTCGCG CTCTGCTGCG TCTCCCTCTT GAGAGGTGCA GCTGAACCC  
351 AAGCACACAGC CCTACAAGCT GGGACGCCAG TGGCGGAGCG TGCTGTCTGG  
401 CTTACACAGT GCCCAGATG ATGAGTGGC CATGATGAG CTTTCTCTGC  
451 AGTTCCGAAG GAACGTGTTT TTCCCAAAGC GCGGGGAGCT CCAGATCCAT  
501 GACGAGGAGG TCCTGCGGCT GCTCTATGAG GAGGCCAAGG GCAACGTGCT  
551 GGCTGACAGG TACCCTGTGG AGCTGGAGGA CTGCGAGGCT CTGGGGGCCC  
601 TGTGTGTCCG CGTGCAGCTT GGGCCCTTACC AGCCCGGCGG GCGGGCAGCC  
651 TGCACACCTGA GGGAGAGCT GGAATCCTTC CTCCCTGCC ACCTCTGTAA  
701 GCGGGGGCAG AGTCTCTTTG CTGCGCTCTCG GGGCGGTGGG GCCAGGGCCG  
751 GCGCGGGCGA GCAGGGGCTG CTGAAGCGCT ACCGCCAGGT GCAGGAGTTC  
801 AGCAGCGACG GCGGGTGCGA GSCCGCCCTG GGCACCCACT ACCGGGCTTA  
851 TCTCTCAAG TGCCACAGC TCGCGTTTAA TGGGTGTGCC TTCTTCAAG  
901 GTGAGGTGA CAAGCCGGCC CAAGGCTTTT TGCACCGGGG TGGGCGCAAG  
951 CCAGTTTCTG TGCCCATCAG TCTGGAAGG GTGCACGTCA TCGATAGCAG  
1001 AGAAGACAT GTCTGTCTGG GCTTCGGCTT CCAGAGCTG TCGTGGGACC  
1051 ACACCTCCCC CGAGGAGGAG GAGCCCATCT TGTGCTGGA GTTCAGCGG

1101 GACAGCGAGG GCACACCTGT CAACAAGCTC CTCAAGATCT ACTCAAGCA  
1151 GGTAGCGCAG CCGCCCAAGC TGCGGAGGCA GGGCAGTGTG GTGTCCAGCC  
1201 GGATCCAGCA TTTCTCCACC ATCGACTACG TGGAGGACGG CAAGGGGATC  
1251 AGCGGAGTGA AGCCGAAGCG CACCACATCC TTCTTCAGCC GGCAGCTGTC  
1301 CTTGGGCCAG GGGAGCTACA CCGTGGTGCA GCCCGGGGAC AGCCTGGAGC  
1351 AGGCTGTA  
! /AA SEQUENCE 1.0  
ID ADP31651 standard; protein; 555 AA.  
XX  
XX ADP31651;  
AC  
XX  
XX 12-AUG-2004 (first entry)  
DT  
XX  
XX Human secreted protein SEQ ID #2418.  
DE  
XX  
XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.

351 CAGCGACTCG GGCCTCATCC AGTGGTGGAT GCTGCTGTGC CTGGCCTGGC  
401 CATGGAGCGT CCGTACATG TGCACCATCC GCGGCATCGA GACCACCGGG  
451 AAGGCCGTGT ACATCACCTC CACGCTGCC TATGTCGTCC TGACCATCTT  
501 CCTCATCCGA GGCCTGAGCG TGAAGGCGC CACCAATGGC ATCGTCTTCC  
551 TCTTCAGCC CAACGTCAG GAGCTGGCCC AGCGGACAC CTGGCTGGAC  
601 GGGGGGCAC AGGTTCTTCTT CTCCTTCTCC CTGGCCTTGC GGGGCTCAT  
651 CTCCTTCTCC AGCTACAACT CTGTGCATGG CTCAGCCTCT CACTCCTGGG  
701 GCTGGCGCTC TGGGGGGAT GCGATGCTG CCTTGGGCTG TGTCTCTGACC  
751 TGGGACCTCA TGGCCAGCGG CCATGACACT GGTCTCGTCT GCAGCAACAA  
801 CTCGGAAGAG GACTCGTGA TTGTGTCCAT CATCAACGGC TTACATCGG  
851 TGTATGTGCG CATCGTGCTC TACTCCGTCA TTGGGTTCGG CGCCACACAG  
901 CGCTAGGAG ACTGTTTCAG CACGAACATC CTGACCTCTA TCAACGGGTT  
951 CGACCTGCCT GAAGCGAACG TGACCCAGGA GAACTTTGTG GACATGCAGC  
1001 AGCGGTGCAA CGCCTCCGAC CCGCGGCCT ACGGCAGCT GGTGTTCAG  
1051 ACCTGGACA TCAAGCGCTT CCTCTCAGAG GCGTGGAGG GCACAGGCT  
1101 GGCCTTCATC GTCTTCACCG AGGCCATCAC CAAGATGCCG TTGTCCCCAC  
1151 TGTGTCTGT GCTCTTCTTC ATTATGCTCT TCTGCCTGGG GGTGTCTCT  
1201 ATGTTTGGGA ACATGGAGGG CGTGTGTGT CCCCTGCAGG ACCTCAGAGT  
1251 CATCCCCCG AAGTGGCCCA AGGAGGTGCT CACAGGCCCTC ATCTGCCTGG  
1301 GGACATTCCT CATTTGGCTTC ATCTTCACGC TGNACTCCGG CAGTACTGG  
1351 CTCTCCCTGC TGGACAGCTA TGCCGGCTCC ATTCCCCTGC TCATCATCGC  
1401 CTTCTGCGAG ATGTTCTCTG TGGTCTACGT GTACGGTGTG GACAGTTCA  
1451 ATAAGGACAT CGAGTTCATG ATCGGCCACA AGCCCAACAT CTTCGGCAA  
1501 GTCACGTGGC GCGTGGTCAG CCCCCTGCTC ATGCTGATCA TCTTCTCTT  
1551 CTTCTTCGTG GTAGAGGTCA GTCAGGAGCT GACCTACAGC ATCTGGGACC  
1601 CTGGCTACGA GGATTTCCC AATCCAGGA AGATCTCTTA CCGNACTGG  
1651 GTGTATGTGG TGGTGGTGA TGTGGCTGGA GTGCCCTCCC TCACCATCCC  
1701 TGGCTATGCC ATCTACAAGC TCATCAGGAA CCACTGCCAG AAGCAGGGG  
1751 ACCATCAGGG GCTGGTGAGC ACATGTCCA GAGCCTCAT GAACGGGAGC  
1801 CTGAAGTACT GA

!!AA SEQUENCE 1.0  
ID \_ADP31589 standard; protein; 1358 AA.

XX  
AC ADP31589;

XX  
DT 12-AUG-2004 (first entry)

XX  
DE Human secreted protein SEQ ID #2356.

XX  
KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.

XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.

301 GACCTTCTGG ACCACAGAGT TTTGGAAGTT CAGAAGAATG CTTGTGGTGC  
351 CTTTCGAAC CTCGTTTTTG GCAAGTCTAC AGATGAAAT AAAATAGCAA  
401 TGAAGATGT TGTGGGATA CCTGCTTGT TGCAGTGT GAGAAATCT  
451 ATTGATCAG AAGTAAGGA GCTTGTACA GCGCCAGGG ATAGAAAGAT  
501 GAATAAACT CAGTGCTGC GCTTAAGTCA CCTCAGATT GGTGAGGAAC  
551 ACAGTGTGTT TTTGTAGCGT CAGGGAATG TGGCAAGTCT CACTACACAG  
601 AGTTGCATT GGCACACAG GATGGTAAC GAAGTTCCTT GGTGACATG  
651 A

## !1AA SEQUENCE 1.0

ID\_ADP31556 standard; protein; 1812 AA.

XX AC ADP31556;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #2323.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411037P.

XX PR 17-SEP-2002; 2002US-0411041P.

XX PR 17-SEP-2002; 2002US-0411045P.

XX PR 17-SEP-2002; 2002US-0411046P.

XX PR 17-SEP-2002; 2002US-0411048P.

XX PR 17-SEP-2002; 2002US-0411052P.

17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 3554; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
XX encoding a polypeptide which is believed to be cytostatic,  
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
XX composition and methods are useful for diagnosing, preventing and  
XX treating diseases such as proliferative (e.g. cancer), inflammatory,  
XX immune, metabolic, genetic, bacterial and viral diseases. The present  
XX sequence represents a human secreted protein. The present sequence is  
XX available on WIPOWEB and is not in the specification.

XX Sequence 1812 AA;

ADP31556 Length: 1812 February 22, 2005 12:25 Type: P Check: 5715 ..

1 ATGATCCCGT TCCTCATCCT GCTGGTCTGT GAGGGCATCC CCTGTGTGTA

51 CCTGGAGTTC GCCATCGGCG AGCGCTGCG GCGGGGCGAGC CTGGGCGGTGT

101 GGAGCTCCAT CCACCGGCGC CTGAAGGCGC TAGGCTTGGC CTCCATGCTC

151 ACGTCCTTCA TGGTGGGACT GTATTACAAC ACCATCATCT CTGTGATCAT

201 GTGGTACTTA TTCAACTCCT TCCAGGAGCC TCTGCCCTGG AGCGACTGCC

251 CGCTCAACGA GAACCAGACA GGTATGTGG ACCAGTGGCG CAGGAGCTCC

301 CCTGTGGACT ACTTCTGGTA CCGAGAGACG CTCAACATCT CCACGTCCAT

CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 225 AA;

ADP31501 Length: 225 February 22, 2005 12:25 Type: P Check: 9247 ..

1 ATGCGCCACC TGTGCGTGCT CTATGCGGAG GAGGTGGGAG AGGGTCATGA  
51 TACAGTCATC AGTAATGAAA TGGGCATTGT CCTCATCTCT CTTGTGCACA  
101 CTGTGGGGAG GGAAAAGGA CCCAGGACGT TCTTAAGTGC CAGATTGGAA  
151 GCAGCAGACA TCACTCTCAC CGGCATTCCA GACCTCAGTC ATGTACACAG  
201 GAGGCCAGAA ATGCTGTCCA GCTAG

!!AA SEQUENCE 1.0  
ID ADP31543 standard; protein; 651 AA.  
XX  
AC ADP31543;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2310.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR

451	CTGAGACTTA GAGGGGACGA ACATCCGACC CACGTCAGGG ACTCCCTTGG	PR	17-SEP-2002; 2002US-0410947P.
501	AGATGAGGGC AGACAGTGG ATGGCACCTT CTGCTCCAAG GCTCCGGGGC	PR	17-SEP-2002; 2002US-0410948P.
551	CTCATGAAGC AGCGTTCTT ATTGAACAGC TCCAGCAGCT GCAGTGTTC	PR	17-SEP-2002; 2002US-0410949P.
601	TTCTGTATT CTTCAGAAC TGTGTCTCTG AAGCTCCAGC GCCAGCCTCT	PR	17-SEP-2002; 2002US-0410953P.
651	CTTCTATAAG CTGGATGCC CGGGCCCAAC ACCCCACAGA GAAAAGCCT	PR	17-SEP-2002; 2002US-0410957P.
701	CCAATGCTC CCTGCGATC AGCGTTCTC TGCAAAAG CATCTGTAAT	PR	17-SEP-2002; 2002US-0410958P.
751	GCCACGCCA GCCACAGAG CGCCCTCTCC ACCCTCTGGC AGCTGAGGC	PR	17-SEP-2002; 2002US-0410959P.
801	ATTTGGAAA GTCAAGGAAC AGAATGATGA GGAACGATCT GAGCAAGTT	PR	17-SEP-2002; 2002US-0410960P.
851	CTTTTGAAA ATTCCAGTGC AGCTCAGCTG TACTGAGAAC ACGGGAAGGA	PR	17-SEP-2002; 2002US-0410961P.
901	TCAGAGGCAA ACGTTGAAAC AGTACTCTGT ACTCAGAGCG CTGTGTTCTG	PR	17-SEP-2002; 2002US-0410962P.
951	GGGAGAGCG GACCCCGCTG ACCCCAGCAT CTGTGGGCCC AGCAGCAGCC	PR	17-SEP-2002; 2002US-0411019P.
1001	TTCTCTGGGT GCTGAGTCC AACCTGTCTG CTAGACAGG GCACCTGGCA	PR	17-SEP-2002; 2002US-0411022P.
1051	GCTCAGGAAC AACAGACATG GACTTCTCAG GGTTCGTAAG GCTGGAAGCT	PR	17-SEP-2002; 2002US-0411023P.
1101	CAAGATCCAG GCCTCAGCAG ATTGCGCACC CAGGGAAGG CTTCTCTGTT	PR	17-SEP-2002; 2002US-0411024P.
1151	CACAGCTGGG GGTTCCTGGT GCTCCAGGG ACTTAGAATT CAAGGCCCCA	PR	17-SEP-2002; 2002US-0411032P.
1201	GATCAAGTTC CTTCTGGGAA TCAGCAAGGC CACAAACAGA AAGAGAACAT	PR	17-SEP-2002; 2002US-0411035P.
1251	GAGAACCCAGA AATTCACCT CTTACATGT GGGAGGAAT CAGACCCCTTG	PR	17-SEP-2002; 2002US-0411037P.
1301	ATAAGGTGG AATACACCG TTCACCCACG AATTGGCCAA AGAACAACT	PR	17-SEP-2002; 2002US-0411041P.
1351	CTAGAGCCAG CCGTCTGGG TTTCACCCCT GGCTCTGTC CTGACCAG	PR	17-SEP-2002; 2002US-0411045P.
IIAA SEQUENCE 1.0			PR 17-SEP-2002; 2002US-0411046P.
ID	ADP31501 standard; protein; 225 AA.	PR	17-SEP-2002; 2002US-0411048P.
XX	AC	PR	17-SEP-2002; 2002US-0411052P.
XX	ADP31501;	PR	17-SEP-2002; 2002US-0411055P.
XX	AC	PR	17-SEP-2002; 2002US-0411073P.
XX	DT	PR	17-SEP-2002; 2002US-0411082P.
XX	12-AUG-2004 (first entry)	PR	17-SEP-2002; 2002US-0411111P.
DE	Human secreted protein SEQ ID #2268.	PR	17-SEP-2002; 2002US-0411112P.
XX	Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;	PR	17-SEP-2002; 2002US-0411052P.
KW	cancer; inflammatory; immune; human secreted protein.	PR	17-SEP-2002; 2002US-0411055P.
XX	OS	PR	17-SEP-2002; 2002US-0411055P.
XX	Homo sapiens.	PR	17-SEP-2002; 2002US-0411055P.
XX	WO2004035732-A2.	PR	17-SEP-2002; 2002US-0411055P.
XX	XX	PR	17-SEP-2002; 2002US-0411055P.
XX	29-APR-2004.	PR	17-SEP-2002; 2002US-0411055P.
XX	29-AUG-2003; 2003WO-US026780.	PR	17-SEP-2002; 2002US-0411055P.
XX	29-AUG-2002; 2002US-0406576P.	PR	17-SEP-2002; 2002US-0411055P.
PR	29-AUG-2002; 2002US-0406579P.	PR	17-SEP-2002; 2002US-0411055P.
PR	29-AUG-2002; 2002US-0406585P.	PR	17-SEP-2002; 2002US-0411055P.
PR	29-AUG-2002; 2002US-0406588P.	PR	17-SEP-2002; 2002US-0411055P.
PR	29-AUG-2002; 2002US-0406608P.	PR	17-SEP-2002; 2002US-0411055P.
PR	29-AUG-2002; 2002US-0406611P.	PR	17-SEP-2002; 2002US-0411055P.
PR	29-AUG-2002; 2002US-0406612P.	PR	17-SEP-2002; 2002US-0411055P.
PR	29-AUG-2002; 2002US-0406616P.	PR	17-SEP-2002; 2002US-0411055P.
PR	29-AUG-2002; 2002US-0406642P.	PR	17-SEP-2002; 2002US-0411055P.
PR	29-AUG-2002; 2002US-0406646P.	PR	17-SEP-2002; 2002US-0411055P.
PR	29-AUG-2002; 2002US-0406653P.	PR	17-SEP-2002; 2002US-0411055P.
PR	29-AUG-2002; 2002US-0406655P.	PR	17-SEP-2002; 2002US-0411055P.
PR	29-AUG-2002; 2002US-0406656P.	PR	17-SEP-2002; 2002US-0411055P.
PR	17-SEP-2002; 2002US-0410946P.	PR	17-SEP-2002; 2002US-0411055P.
(FIVE-) FIVE PRIME THERAPEUTICS INC.			PR 17-SEP-2002; 2002US-0411055P.
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;			PR 17-SEP-2002; 2002US-0411055P.
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;			PR 17-SEP-2002; 2002US-0411055P.
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;			PR 17-SEP-2002; 2002US-0411055P.
WPI; 2004-348438/32.			PR 17-SEP-2002; 2002US-0411055P.
New nucleic acid molecule for diagnosing, preventing or treating diseases			PR 17-SEP-2002; 2002US-0411055P.
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,			PR 17-SEP-2002; 2002US-0411055P.
genetic, bacterial and viral diseases.			PR 17-SEP-2002; 2002US-0411055P.
Claim 1; SEQ ID NO 3499; 428pp; English.			PR 17-SEP-2002; 2002US-0411055P.
The present invention relates to an isolated nucleic acid molecule			PR 17-SEP-2002; 2002US-0411055P.
encoding a polypeptide which is believed to be cytostatic,			PR 17-SEP-2002; 2002US-0411055P.
antiinflammatory, immunosuppressive, antibacterial and virucidal. The			PR 17-SEP-2002; 2002US-0411055P.
composition and methods are useful for diagnosing, preventing and			PR 17-SEP-2002; 2002US-0411055P.
treating diseases such as proliferative (e.g. cancer), inflammatory,			PR 17-SEP-2002; 2002US-0411055P.

1401 AGGTTATGAC CCTGATGTCA TCAGGATTCC TTTAAGTAAA AAGCAATTCA  
1451 AAGCAGTATT GCCAGTATCT ATTAATCTGC AAATAGCTTT CTCGTATTAC  
1501 ACAGGACAAA TAGAGCATAT ACTTCCTGCT GATAAACTCC TTTATTTCTT  
1551 ATCTCATACC CTGGTAATCT TACCACAAA AATAGTTTAC TCCCCATAC  
1601 CTAATGCTTT AACACTGTTT ACTGATGTT CTGGTAAACA TGGAAAAGCA  
1651 GCAGTCTGGT AG

!!IAA SEQUENCE 1.0  
ID ADP31488 standard; protein; 1398 AA.

AC ADP31488;

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #2255.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

OS WO2004035732-A2.

PN 29-APR-2004.

PD 28-AUG-2003; 2003WO-US026780.

PF 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406646P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406655P.

PR 17-SEP-2002; 2002US-0406666P.

PR 17-SEP-2002; 2002US-0410946P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.

PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410961P.

PR 17-SEP-2002; 2002US-0410962P.

PR 17-SEP-2002; 2002US-0410966P.

PR 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411022P.

PR 17-SEP-2002; 2002US-0411023P.

PR 17-SEP-2002; 2002US-0411024P.

PR 17-SEP-2002; 2002US-0411032P.

PR 17-SEP-2002; 2002US-0411035P.

PR 17-SEP-2002; 2002US-0411037P.

PR 17-SEP-2002; 2002US-0411041P.

PR 17-SEP-2002; 2002US-0411045P.

PR 17-SEP-2002; 2002US-0411046P.

PR 17-SEP-2002; 2002US-0411048P.

PR 17-SEP-2002; 2002US-0411052P.

PR 17-SEP-2002; 2002US-0411055P.

PR 17-SEP-2002; 2002US-0411073P.

PR 17-SEP-2002; 2002US-0411082P.

PR 17-SEP-2002; 2002US-0411101P.

17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3486; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytosstatic, the  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPWEB and is not in the specification.

XX Sequence 1398 AA;

ADP31488 Length: 1398 February 22, 2005 12:25 Type: P Check: 2208 ..

1 ATGGTCCTTG CTTCCTCTTT GCCTTCTGCC ATGATTACAA AGAAGCAGTT

51 CCAGCCAACT CCAGCCAAAG AGGGACCAGA GCAGCCCAAC AGCCAGCCGA

101 CCCATGGTCT CGAAACAGCA GGAACACCT GTGGGTTTAA GGCCTGTACA

151 CCAATAGCAG GTGCAGTCAA TCATCAACA GCATTCATT TGACCAGTGA

201 TGCCCTGAGC GAAGTCAAG GCAGCCACA GTCCGGTGAG AAGTGGACCC

251 CTTTGTATGA GGACAGTGAC AAAGAAGCTG TGGCCGTGTT CATTTGTTCT

301 AGCGTTGATC CTGGCTTGCT GGGTATATT CCATCGTCTG GAGGTGTGCG

351 AGTTTACTCA TCCATTACC TGCTAGGGG CATCTGTTT GCTTCCACGG

401 TTGTGGATAA AGTGCGATC GACATGCAG TGCAGGAGTC ACATTTCAAC



PR	29-AUG-2002;	2002US-0406612P.	PT	genetic, bacterial and viral diseases.
PR	29-AUG-2002;	2002US-0406616P.	XX	
PR	29-AUG-2002;	2002US-0406640P.	PS	Claim 1; SEQ ID NO 3417; 428pp; English.
PR	29-AUG-2002;	2002US-0406642P.	XX	
PR	29-AUG-2002;	2002US-0406646P.	CC	The present invention relates to an isolated nucleic acid molecule
PR	29-AUG-2002;	2002US-0406653P.	CC	encoding a polypeptide which is believed to be cytostatic,
PR	29-AUG-2002;	2002US-0406655P.	CC	antiinflammatory, immunosuppressive, antibacterial and virucidal. The
PR	29-AUG-2002;	2002US-0406666P.	CC	composition and methods are useful for diagnosing, preventing and
PR	17-SEP-2002;	2002US-0410946P.	CC	treating diseases such as proliferative (e.g. cancer), inflammatory,
PR	17-SEP-2002;	2002US-0410947P.	CC	immune, metabolic, genetic, bacterial and viral diseases. The present
PR	17-SEP-2002;	2002US-0410948P.	CC	sequence represents a human secreted protein. The present sequence is
PR	17-SEP-2002;	2002US-0410949P.	CC	available on WIPWEB and is not in the specification.
PR	17-SEP-2002;	2002US-0410953P.	XX	
PR	17-SEP-2002;	2002US-0410957P.	SQ	Sequence 1662 AA;
PR	17-SEP-2002;	2002US-0410958P.	ADP31419	Length: 1662 February 22, 2005 12:25 Type: P Check: 3662 ..
PR	17-SEP-2002;	2002US-0410959P.	1	ATGCAGCACA AGACAGTCAC CCCCAATAGA GGGAAAGTTC CTGATGAGC
PR	17-SEP-2002;	2002US-0410960P.	51	CACATCCATA GGAAAGGGG GAGAGTACTA CATCAAGAGA ACACCTGCA
PR	17-SEP-2002;	2002US-0411019P.	101	GGACAAAAGA ATCTGAACAA CAGCCTTCAG CCCTAGACCT TCCCTCTGAC
PR	17-SEP-2002;	2002US-0411023P.	151	AGAGCCTACC CAAATGAGAA GGAATCAGAA ACCCACTCT GTCTCACA
PR	17-SEP-2002;	2002US-0411024P.	201	GTTCAGAGAG TGTCTCCCCC TCATCATTTT CTTAAGGAAC AGACTTAAAGT
PR	17-SEP-2002;	2002US-0411032P.	251	ATGCCCTGAC AGGAGATGAA GTAAAGATTT GCATGCAGGG GTTCATTAAAG
PR	17-SEP-2002;	2002US-0411033P.	301	GTTCATGGCA AGGTAGGAAC TGATATAACC TACCCTGCTG GATTCATGGA
PR	17-SEP-2002;	2002US-0411035P.	351	TGTCATCAGC ATTGACAAGA CGGGAGATAA TTTCCATCTG ATCTATGACA
PR	17-SEP-2002;	2002US-0411037P.	401	CCAAGGCTCG CTTTGTCTGTA CATCGTATTA CACCCGAGGA GGCTAAGTAC
PR	17-SEP-2002;	2002US-0411041P.	451	AAATTGGGTA AAGTGAGAA AATCTTTGTG GGCACAAAAG GAATCCTCA
PR	17-SEP-2002;	2002US-0411044P.	501	TCTGGTGAAT CATGATGCTC ACAGCATCCG CTACCTTTGAT CCCCTCATCA
PR	17-SEP-2002;	2002US-0411045P.	551	AGGAGCAAGC CCCAGCCCC GCTCGCACT GGGCAATGC CAGCAGCTTT
PR	17-SEP-2002;	2002US-0411046P.	601	CCTCGATCAG ATGGGAGGCC CACAGTCCTC TCTCTCAGAG CAGCCACCAC
PR	17-SEP-2002;	2002US-0411048P.	651	AGGGAGCACA GGACTGGACT TACTTGCCT CAACAAATTA ATGCTAAAAG
PR	17-SEP-2002;	2002US-0411052P.	701	AAGGAGAAGA CCTAAAAGG GTTGCAACCG GGATCTGGG CCTGCTGCCT
PR	17-SEP-2002;	2002US-0411055P.	751	CCAGGAACAG TGGGATTAGT CCTAGGGTGG TCTAGCCTAT CTAGTAAAGG
PR	17-SEP-2002;	2002US-0411073P.	801	AATTAATGTG CTCACCGTGG TAATTGATAG TGATTATCAC AGAGAGATAT
PR	17-SEP-2002;	2002US-0411073P.	851	TGGTTATGAT GGACTGTAAA GGTCTGCATA TTCTTCCCC TGGATCAAAG
PR	17-SEP-2002;	2002US-0411082P.	901	ATAGCTCAGT TACTGATTTT ATCATACTGG GTCCCCAGTC TCTATGAAA
PR	17-SEP-2002;	2002US-0411082P.	951	GGAAAGGGGG AAGGGAAGTT TTGGAGCAC AGGAGCCACA GGAGTATATT
PR	17-SEP-2002;	2002US-0411082P.	1001	GGAATCAATT AATCACTGAT CAAGGACCCA TGAAGAAATT GGAATAAGA
PR	17-SEP-2002;	2002US-0411082P.	1051	ATTTTACTGG CTTACTGGGC ACAGGGGAG ACATTTCAAT CATTATGAT
PR	17-SEP-2002;	2002US-0411082P.	1101	CAAAACTGGC CAGAAACTTG GCTTTGGATA TTTAAACCCCT GCAGCAAAA
PR	17-SEP-2002;	2002US-0411082P.	1151	GGGAAATTGA GGAATAGAA CAAGCGTCT CTCAGGGGCA GCTAGATCGC
PR	17-SEP-2002;	2002US-0411082P.	1201	ATTGATCCAC GTTATTCAT CCAATTGTTT TATCTTTCTC ACCAAACACT
PR	17-SEP-2002;	2002US-0411082P.	1251	CCCTACAGG GTTAATAGGA CAGATGGGCC CCGGGCTATG CTTCTAGAA
PR	17-SEP-2002;	2002US-0411082P.	1301	TGGGTTTTTT GCCACATACC GGGACTAAA CACTATCTCC CTATAGTCAG
PR	17-SEP-2002;	2002US-0411082P.	1351	TTACTTACTA AAGTCATCTA TTCAGGCCAC AAACAATGCA ATCAGTCACT

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471338P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3390; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOMEB and is not in the specification.  
XX Sequence 585 AA;  
ADP31392 Length: 585 February 22, 2005 12:25 Type: P Check: 4716 ..  
1 ATGTGGTCCG CAGTCAGCAC CACAGCACCT GGCCTCTCTGC ACACCTGAA  
51 GGTAGCACCC CTGCCTTTGG CTCAGAGTAT GCTGGTGCCG GTGCCAGCTC  
101 CCAGAAAGGA ATATGAGTCT AGTTTTTCCA ATGAGGAAGC ACAGAGGCA  
151 CAGGCCCTTC AACTGGGCTC TTACCTCAAC CTGGCCATGT GTCATCTGAA  
201 ACTACAGGCC TTCTCTGCTG CCACTGAAG CTGTAACAG GCCCTGGAAC  
251 TGGGCAGCAA CAACGAGAAG GGCCTCTTCC ATTGGGGAGA GGCACACCTG  
301 GCTGTGAATG ACTTTGAAC TGCACAGGCT GACTTCCAGA AGGTCTTGA  
351 GCTCTACCCC AACAAACGAG CCGCCAAGGC CCAGCTGGCT GTGTGCCAGC  
401 AGCAGATCTG CAGGCAGCTT GCCTGGGAGA AGACGCTCTA CGCCAACACG  
451 TTTGAGAGGC TGGCTGAGGA AGAGAACAAAG GCCAAGGCCAG AGGTTCTCTC  
501 AGGAGACAAAT CTCACCTGCA CAGAGATGGA GGAGCAGAGAG AGCAACACCA  
551 CAGAGAGCCA GTCTCAAGTG GAGACAGAAG CATAG  
!!AA SEQUENCE 1.0  
ID \_ADP31419 standard; protein; 1662 AA.  
XX  
AC ADP31419;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2186.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471338P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3369; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1386 AA;  
ADP31371 Length: 1386 February 22, 2005 12:25 Type: P Check: 8173 ..  
1 ATGGAGACAG CGGGCTGTGG TACTGGGCAG CCGGCCTCTC TGCTGGAGGC  
51 TCCCGGGTCC ACGGATGACC GGCCTTCTCT GGTAAAGGT GGAATTTTCC

101 TTGTACTGT TGTGTCAGCA GGAACGCTAG CTGGATTAT TACAACATTA  
151 TCATTGGCTA AAAAGAAAG CCCTGAATGG TTCAATAAGG GAAGTATGGT  
201 CACGACTGCA TTACCGGAAA GCGGTCCTTC CCTTGCCTTG CGAGCTCTGG  
251 GCTGCGGCTC ACTGTATGCA TGGTGTGGGG TTGGTGTGAT TAGCTTTCTCA  
301 GTCTGGAAG CTTTAGGGGT TCACAGTGAC ATGCTACATC ACCAATCTTC  
351 TACCCGAGAA GTCGTTTTC TTCCGGACCC ACAATCAAAG GCTTTCCTCC  
401 GGCATGAGAA AGGAGTAACA TTCCCGCCTG CGTGCATGCC ACTCATGGGC  
451 ACTTGGCTCT TCACCTCCGT GAGCAAGATG GCGACTGTGA AGAGTGAGCT  
501 TATTGAGTGC TTCACTTCGG AGGAGCCCTT TCATCACAGA AAGGTCTCCA  
551 TCACAGGAAC TGGATCAGTG GGCATGGCCT GCGCTACCAG CATCTTTATTA  
601 AAAGGCTTGA GTGATGAAC TGCCTTTGTG GATCTTGATG AAGGCAAACT  
651 GAAAGGTGAG ACAATGGATC TTCAACATGA CAGCCCTTTC ATGAAAATGT  
701 CAAATATTGT TTGTAGCAA GATTACCTTG TCACAGCAA CCCCCATCTA  
751 GTGATTATCA CAGCAGGTGC ACGCGAGAA AAGGAGAAA TGGCGCTTAA  
801 TTTAGTCCGG CAAAATGTGG CCATCTTCAA GTTAATGATT TCCAGTATTG  
851 TCCAGCAGAG CCCCCTCTGC AAACATAATTA TTGTTTCCAA TCCAGTAGAT  
901 ATCTTAACIT ACGTAGCCTG GAAGTTGAGT GCATTTCCCA AAAACGCTGT  
951 TATTGGAAGC GGCTGTAATC TGGATACTGT TCGTTTTCAA TTCTTCATTG  
1001 GACAAAAGCT TGGTATCCAC TCTGAAAGCT GCGTGGATG GATCCTCGGA  
1051 GAGCATGGAG ACTCAAGTGT TCCTGTGTGG AGTGGAAATGA ACATAGCTGG  
1101 TGTCTTTTGG AAGGATCTGA ACTCTGATAT AGGAACTGAT AAAGATCCTG  
1151 AGAAATGGAA AAATGTCCAC AAAGAAGTGA TTGCTAGTGC CTATGAGATT  
1201 ATTGAATGA AAGTTCTTAC TTCTGGGCC ATTGGCCTAT CTGGAGCTGA  
1251 TTTAACAGAA AGTATTTTGA AGAATCTTTAG GAGAAAAACAT CCAGTTTCCA  
1301 CCATAATTA GGGCCTCTAC GGAATAAATG AAGAAGTCTT CCTCAGTATT  
1351 CCTTCTTTGG AGAGAAGGT ATTACCAACC TTATAA  
!!AA SEQUENCE 1.0  
ID ADP31392 standard; protein; 585 AA.  
XX  
AC ADP31392;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2159.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX

PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463715P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471308P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3362; 428bp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytosstatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 687 AA;  
ADP31364 Length: 687 February 22, 2005 12:25 Type: P Check: 5032 ..  
1 ATGAGGAGAG AACCTATCT TGCAGCCAA AGGTGGAGAG TTTTCAGGA

51 GGC AAAA C C T TCA A C T G A G G A C T T G G G G A T A A G A A G G A A G G T G A A T A T A  
101 T T A A A C T C A A A G T C A T T G G A C A G A T A G C A G T G A T T C A C T T C A A A G T G  
151 A A A T G A C A A C A C A T C T C A A G A A A C T C A A G A A T C A T C T G C A A A G A C A  
201 G G G T G T T C C A A T G A A T T C A C T C A G G T T T C T C T T T G A G G G T C A G A G A A T T G  
251 C T G A T A T C A T A C T C C A A A G A G C T C T A C C C T A T A C T G A T G T C C G A C T  
301 G C T A C T C A G A G T C T A T C A T C C A A G C T T T G T C A C C C C A G G G G T G C C A  
351 C A G T C C C C A C A T G T C G G C C G C T T T C C T G A G C C T C T C T G T A T C T T C C C A  
401 T G G C C C A G T C T G T G G C T G T T G G T C T T T A G G T T C C A C A A T C C C A T G G C T  
451 T A T T A T C C A G T T G T G C C C A T C T A T C C A C C T G G C T C C A C A G T G C T G T G G A  
501 A G G G G G T A T G A T C A G G T G C C A G A T T G A G C T G G G G C T A C T G T G G C A  
551 A C A T T C T T C C T C C A C C T C C T C G T A A C T C A G T G G A A G G G A A C T T C T T  
601 G T C A T G C A G G C A G C A A T G T C C T C G T A A C T C A G T G G A A G G G A A C T T C T T  
651 C A T G G G T G A A T C A G A T G G T G C T A C A C C A T C T G T G A  
!! AA SEQUENCE 1.0  
ID ADP31371 standard; protein; 1386 AA.  
XX  
AC ADP31371;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2138.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.

XX  
PS  
XX  
CC  
CC  
CC  
CC  
CC  
CC  
CC  
CC  
CC  
CC  
SQ

Claim 1; SEQ ID NO 3325; 428pp; English.

The present invention relates to an isolated nucleic acid molecule encoding a polypeptide which is believed to be cytostatic, antinflammatory, immunosuppressive, antibacterial and virucidal. The composition and methods are useful for diagnosing, preventing and treating diseases such as proliferative (e.g. cancer), inflammatory, immune, metabolic, genetic, bacterial and viral diseases. The present sequence represents a human secreted protein. The present sequence is available on WIPWEB and is not in the specification.

Sequence 2127 AA;

ADP31327 Length: 2127 February 22, 2005 12:25 Type: P Check: 1885 ..

1 ATGGCTTGCA GAGTCGTAA CAAGAAGA CACATGGAC TTCACAACT  
51 TTCATCATTC GCGGAACAG GAAGAACTTT CCTAGGCCCA CTAAATCAT  
101 CCAAAATTTAT TATAGATGAA GAATGTCATG AAGTGTAATT AATCAGTTCA  
151 ACAGTAAGGC TTCTTGAAAG TTGGATTTA ACCAGTCAG TGGGACAACT  
201 TCTCAATGAA GCAGTTCAAG CACAAAACAA CACATATAGA ACTGGAATCA  
251 GTACTCTTTT GTTCTTGT GTGCTTGGG GCAGTGCAGT TGAAGAATGT  
301 CTTCACTCTG GTGTCCCAT TTCCNATAA GTATCAGTAA TGTCAAGAGG  
351 CTTAAACTTT TGTAGTGAAG AGGTAGTTTC TCTTCATGTA CTTGTTTACA  
401 ATATATTGA CTGTATGGC AGCAGAAAA CATTTTCTCA ACTTGAACA  
451 TTTAGTGTA GTTTGTGTC TTTTCTACAG GTCCCTTCAG ATACTGATTT  
501 GATAGAGGAA TTGCATGTC TCAAAGATGT TGCCTCTCAA ACACAGACCA  
551 TTTTCAACCT TTCTGGGAGA CCTCTTAAT CATATGAATT ATTAAACCT  
601 CAGACAAAGG TTGAAGCAGA TAACACACA TCAGAACTC TGAANAACAG  
651 CTTGCTTGCA GATACCTGCT GCAGACAGTC AATACTAATC CACAGTAGGC  
701 ATTTTAATAG GACAGATAAT ACTGAAGGG TAAGCAAAAC AGATGGAATT  
751 CAAGAACATG TTACAGCTAC TCACAAAAC TACAGATGTA ATGATTTGGT  
801 AGAGTTGGCA GTAGGCTTGA GTCATGGAGA TCACAGCAGC ATGAAGTTAG  
851 TAGAAGAAGC AGTACAGCTG CAATATCAGA ATGCTTGTGT GCAACAAGGC  
901 AACTGTACAA AACATTTAT GTTGACATTT TCAAGAAATT TCACCTTGCTG  
951 TCTACCAGGC TTACTCTGAA CTCTTCTTGT TGTTTGTCCA GGATATATCA  
1001 CTGTGTGTC AGTATCTAAT AATCCTGTGA TCAAGGAATT GCAGAACTAG  
1051 CTTGTGGGAA TAGTTCTCAT TGAGGGTGAC CTCACAGAGA ATTACCGCCA  
1101 CTTGGGATTT AATAAGTCTG CAAATATTTAA AACAGTATTA GATAGCATGC  
1151 GGCTTCAAGA AGACAGCTCA GAAGAAGTGT GGGCAATCA CGTGTTCACAG  
1201 GTGTTAATCC AGTTCAAGTT GAACCTTGTG CTGTACAAG GAAATGTGTC  
1251 CGAACGCTTA ATTGAATAAT GTATAAACAG TAAGCGGTGT GTAATCGGCT  
1301 CAGTGAATGG CAGTGTGATG CAGGCTTTTG CAGAGGCTGC AGGAGCAGTA  
1351 CAGGTGSCCT ACATACACA AGTGAATGAA GATTGTGTGG GCACGGGGT  
1401 CTGCGTGACC TTCTGGAGAA GCAGCCCTTT GGATGTTGTA GATAGGAACA

1451 ACAGAAATCG AATCTTATTA AAAACAGAAG GAATTAATTT GGTACGGCC  
1501 GTGCTCACTA ACCAGTTTAC TGCACAGATG CAAATCAAAG AAGATAGGTT  
1551 CTGGACATGT GCCTATCGTT TGTATTATGC TCTAAAAGAG GAAAAGGTCT  
1601 TCCTTGAGG TGCTGCAGTT GAATTTTTGT GTCTTAGCTG TCTTCATATT  
1651 CTTGCAGAGC AATCTCTGAA AAAAGAAAAC CATGCCCTGCT CAGGGTGGCT  
1701 GCATAATACT TCCTCTTGGC TGGCTTCATC TCTGGCAATA TACAGACCAA  
1751 CTGTGCTTAA ATTCTCTGCA AATGGATGGC AGAAATACCT TTCAACTCTC  
1801 CTATATAACA CTGCCAATTA CTCATCAGAA TTTGAAGCCA GCACATACAT  
1851 TCACATCAT CTGCAAAATG CCACAGACTC TGGCTCTCCT TCATCTTACA  
1901 TCTTGAATGA ATATAGTAAA CTAAATAGTA GAATTTTTAA TTCAGACATT  
1951 TCAAAATAAC TGGAGCAGAT TCCGAGAGTT TATGACGTTG TTACACCAAA  
2001 GATTGAGGCG TGGCCCGCAG CATTGGATTT AGTATTGTTA GTACTTCAGA  
2051 CAGACAGTGA AATAATTACT GGACATGGAC ACACACAGAT AAATTCACAG  
2101 GAATTAACGG GCTTTCTATT TTTGTAG

!!AA\_SEQUENCE 1.0

ID ADP31364 standard; protein; 687 AA.

XX

AC ADP31364;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #2131.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

PN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

29-AUG-2002; 2002US-0406576P.

PR

29-AUG-2002; 2002US-0406579P.

PR

29-AUG-2002; 2002US-0406585P.

PR

29-AUG-2002; 2002US-0406588P.

PR

29-AUG-2002; 2002US-0406608P.

PR

29-AUG-2002; 2002US-0406611P.

PR

29-AUG-2002; 2002US-0406616P.

PR

29-AUG-2002; 2002US-0406640P.

PR

29-AUG-2002; 2002US-0406642P.

PR

29-AUG-2002; 2002US-0406646P.

PR

29-AUG-2002; 2002US-0406653P.

PR

29-AUG-2002; 2002US-0406666P.

PR

17-SEP-2002; 2002US-0410946P.

PR

17-SEP-2002; 2002US-0410947P.

PR

17-SEP-2002; 2002US-0410948P.

PR

17-SEP-2002; 2002US-0410949P.

PR

17-SEP-2002; 2002US-0410953P.

PR

17-SEP-2002; 2002US-0410957P.

PR

17-SEP-2002; 2002US-0410958P.

PR

17-SEP-2002; 2002US-0410959P.

PR

17-SEP-2002; 2002US-0410960P.

PR

17-SEP-2002; 2002US-0410961P.

PR

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
PS Claim 1; SEQ ID NO 323; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 624 AA;  
ADP31325 Length: 624 February 22, 2005 12:25 Type: P Check: 4933 ..  
1 ATGATCCAGG AATCTTGG CTTTGATCAA GCTCAGCAGA TAAATGCTT  
51 TAAATAGTAAT TTGTTCTGT GCAATATCTG TTTCTGTAG AAGCTGGGTA  
101 GTGAATGCAT GTACTTCTTG GAGTGCAGGC ATGTGTACTG CAAAGACTGT  
151 CTGAAGGACT ACTTTGAAAT CCAGATCAGA GATGCCAGG TTCAATGCCT  
201 CAACTGCCA GAACCAAAGT GCCCTTCAGT GCCCACTACT GGTCAAGTCA  
251 AAGAGCTAGT GGAAGCAGAG TTATTTGCCCT ATTATGACTG CTTTCTCTC  
301 CAGTCCACCT TGGACCTGAT GGCAGATGTG GTGTACTGCC CCCAGGCATG  
351 CTGCCAGCTG CCTGTGATGC AGGAGCCTGG TPACATCATG GGTATCTGCT  
401 CCAGCTGCAA TTTTGCCTTC TGTACCTTGT GCAGGTTGAC CTACCATGGG  
451 GTCTCTCCAT GTAGGTGAC TGCAGAGAA TTAATAGACT TACTAAATGA  
501 ATACTTGCAA GCAGATAAGG CCAATAAAG ACTTTTGGAA CAAAGGTATG  
551 ATAAGAGGCT GATTCAAGAG GCACTGGNAG AGATGGAAAG TAAGGAGTGG  
601 CTAGAGAAA ACTTCAGAA CTGA  
!!AA SEQUENCE 1.0  
ID ADP31327 standard; protein; 2127 AA.  
XX  
AC ADP31327;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
XX Human secreted protein SEQ ID #2094.  
XX  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
PR  
XX 29-AUG-2002; 2002US-0406579P.  
PR  
XX 29-AUG-2002; 2002US-0406585P.  
PR  
XX 29-AUG-2002; 2002US-0406588P.  
PR  
XX 29-AUG-2002; 2002US-0406608P.  
PR  
XX 29-AUG-2002; 2002US-0406611P.  
PR  
XX 29-AUG-2002; 2002US-0406612P.  
PR

PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411010P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 3322; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 624 AA;  
SQ  
ADP31324 Length: 624 February 22, 2005 12:25 Type: P Check: 4933 ..  
1 ATGATCCAGG AATCTTGG CTTTGATCAA GCTCAGCAGA TAAATGCTT  
51 TAATAGTAAT TTGTTCTCTG GCAATATCTG TTTCTGTAAAG AAGCTGGTA  
101 GTGAATGCAT GTACTTCTTG GAGTCAGGC ATGTGTACTG CAAAGACTGT  
151 CTGAAGGACT ACTTTGAAAT CCAGATCAGA GATGCCCAGG TTCAATGCCT  
201 CAATGCCCA GAACCAAGT GCCCTTCAGT GGCCACTACT GGTCAGTCA  
251 AAGAGCTAGT GGNAGCAGAG TTATTGGCT ATATGACTG CTTCTCCTC  
301 CAGTCCACCT TGGACCTGAT GGCAGATGTG GTGTACTGCC CCCACGATG  
351 CTGCCAGCTG CCTGTGATGC AGGACCTGG CTACATCATG GGTATCTGCT  
401 CCAGCTGCAA TTTTGCTTC TGTACTTGT GCAGTTGAC CTACCATGGG  
451 GTCTCTCCAT GTAAGGTGAC TGCAGAGAAA TTAATAGACT TACTAAATGA  
501 ATACCTGCAA GCAGATAAGG CCAATAAAG ACTTTTGAA CAAAGGTATG  
551 ATAAGAGGT GATTAGAAG GCACCTGGAAG AGATGGAAG TAAGGAGTGG  
601 CTAGAGAAAA ACTTCAAGAA CTGA  
!!AA SEQUENCE 1.0  
ID ADP31325 standard; protein; 624 AA.  
XX AC ADP31325;  
XX DT 12-AUG-2004 (first entry)  
XX DE Human secreted protein SEQ ID #2092.  
XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
XX OS Homo sapiens.  
XX PN WO2004035732-A2.  
XX PD 29-APR-2004.  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX PR 29-AUG-2002; 2002US-0406576P.  
XX PR 29-AUG-2002; 2002US-0406579P.  
XX PR 29-AUG-2002; 2002US-0406585P.  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
XX Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

2151 TAGCAACTCC AGTAATGAAA ATTCAACCTC CATAAAGTGT GAGGACATTA  
2201 ATGCTGAAGA GTATAGTAAA GACACCTCAA AGGCATGGG AGGGCTAGGG  
2251 AGGGCGTGG CACTTACAAA GAGGATATCC AGTCGTTCGG TGCACTGCCG  
2301 CTCTGCAAAAC AGTGACCTTG GAGCAGTTCA CCTTGGGCTT AGTTCGGTTT  
2351 ATTTGGCCCA CGCTCCACGG GAAGACGAAG GACAGCCCAT CCCCTGGCTG  
2401 AACCTTGGGA GGTCCAAAGA GTGGGTGGA GGTCCCTCTT TGTCCCCCA  
2451 GCCAGACGTC CCGCCAGGCT TATCTGCAGA CGCTTTCAGG CCCAGATTGC  
2501 AAACCTTTCC AGCCCCCTCC TGGACCTCC CGGGGGGCC CGAATTTCAC  
2551 CGGGAGGCCA AGGACAAAG CGTTGAAGAT GTGCTTTTAA AGATATATGT  
2601 ACTGTGGATG ACTGATTTAG ATTCCGGAAG GGAGACTCAT AGCCCCCTA  
2651 TCCTGGTCAG CGCCTTCCCC ACACCCCCAA GAGCCCCCTT ACATCTGCAT  
2701 COAACCCAG AATATGGGA GATGCGATGG AATTTCGAAA ACAGTGCTCT  
2751 CCTATTTCTG CCCTCTAGAA AGCCCCAAAG TGCTAATCAC TGCCGGGATA  
2801 TAGCAGATTC TGGCCCTAGT CTATTTGGGG TCCTGTATGT TTTTGCATCG  
2851 TACAGTAAAA AAGAACCTGG TACTTTGGAA AAGTCCCTCA CAGTGTTTAA  
2901 TAGMAACGGC TTCGGCGCG CGGAACCCGA CCTGGGCTGG ATTTTCTTCC  
2951 GGGCCGACGA GCTAAGCAT ATCTTGGACA GTCTGAAGTT ACAGGCACCT  
3001 TTTTCTTCTC CCCCTCTCC CCCAACAGA CGATGGGACT CCAGCCTTGC  
3051 TGGTCATCGA ATTTCTCCTT ATTACGACTT AAATGAAAA CTAAAGTGA  
3101 ATACTATTTA TTGTCTACAT AGACGCAGAA AAGTATTGGG ACAAGACGTG  
3151 CGGCAGCCG AGCCAGCATT CCTGGCTCGC TTCAAGGAGT GGGTTGGCTA  
3201 TAGGGAGGAG CCCACCGTAG AGACCAAGAG AATCCAGCCT CATCTCCAG  
3251 ACGAAAATGG GGATCAGT GACAAAGATG AAGACCTCA AGTGATGTTT  
3301 TTTAAAAAGG GAGACCTGTC AGTTGAAGAA GTCATGAAAA TTAAGCAGA  
3351 AGTAAAGGCT GCCAAGCAG ATAAAGAAC AGCTCCAGCT GAGGGAAGAA  
3401 TCATGTATCA AAAACCAAGTA AAGCACCAGT CAACTGCCCC TCAGATGAAA  
3451 AATATTCAGG TTTAA

IIIA SEQUENCE 1.0  
ID \_ADP31324 standard; protein; 624 AA.  
XX  
AC ADP31324;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #2091.  
XX  
KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.

29-AUG-2002; 2002US-0406576P.  
29-AUG-2002; 2002US-0406579P.  
29-AUG-2002; 2002US-0406585P.  
29-AUG-2002; 2002US-0406588P.  
29-AUG-2002; 2002US-0406608P.  
29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410946P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;



PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

XX (FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 3232; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX Sequence 3465 AA;

ADP31234 Length: 3465 February 22, 2005 12:25 Type: P Check: 1398 ..

1 ATGGTGGTGA AGGGACGGAA TCCGGGATCA GGAAACTGA GCAGAAAGGA  
51 TTTTAAATTG TGGGGATAA AAGTGACTGT CTCGCCGAAA GCAGTTGTGT  
101 TGGCGCCACC GGAGGAGAGG AAGCAGCCAG CTGGCGTCTG CGCTTTGCAA  
151 AGCATGCAGT TAGGGGAGCA GCTCTTGGTG AGCTCAGTGA ACCTGCCTGG  
201 CGCGCACTTC TACCGCTGG AGAGTGGCGG AGGGCGCAGC GCGGGAGCG  
251 CTGGCCACCT CCCGAGCGG GCGCCCTCTC CTCAGAGTT GGACTTAGAC  
301 AAAGCGTCCA AGAAGTTTTC CGGCAGTCTC TCCTCGCAGG CGGTGAGCGG

351 GGAGCCCGCA GCCGCCAGG CAGGGGCCCC CGCGGCCATG CTTAGTGACA  
401 CCGACGCCGG GGAGCAATTT GCCAGCGCTG CGGCAGTGGC CAAGCCGGGG  
451 CCCCCGAGC GCGCAAGGG CTCGCCCTGC GGGGAGGAGG AGCTGCCCTC  
501 CGCCGCTGCA GCGCGCGCGG CCGCGCGCGC CGCGGCTGCG GCACATGCGC  
551 GCTACTCCAT GGACAGCCTG AGCTCCGAGC GGTACTACCT CCAGTCCCCC  
601 GGTCTCAGG GGTGCGAGT GGCTGCGCCC TGCTCACTCT TCCCGTACCA  
651 GCGCGCGGCT GGGGCGCCCC ACGACCTGT GTACCCGGCT CTTAACGGGG  
701 CCGGCTACCC CTACGGCTC ATGCTGCCCC CCGCGGGCTT CCGCGGGCT  
751 GTGTGCCCC CCGGGAGGGC GAGTTGCGC CAGGAGCCG GTGCGGGCAG  
801 TGCGCGCGGC GGTAGCAGG GCGGGGGCGG CGGCCCGGGC ACCTATCAGT  
851 ACAGCCAGGG GGTCCGCTC TACGGGCGT ACCCTGGAGC CGCAGCGGGC  
901 GATCTTGGG GAGGACTGGG GGGCTGGGG GTTCCAGTT CTGGCTTCGG  
951 TGCCACAGTC TACCTGTGCA ACCGGCTCT GTGGCTCAAA TTCCACCGCC  
1001 ACCAACTGA GATGATCAT AGGAAACAGG GCAGGGCAT GTTTCCTTTC  
1051 TTGAGCTTCA ACATAAACG ACTCAATCCC ACTGCCACT ACNATGTGT  
1101 CGTAGAGGTG GTGCTGGCG ACCCAACCA CTGGCGCTTC CAGGGGGGCA  
1151 AATGGGTGAC CTGTGCAAA GCCGACAATA ACATGCAGG CAACAAATG  
1201 TATGTTCAAC CAGAGTCTCC TAATCTGGT TCCACTGGA TGAGACAGGA  
1251 GATTTCAATC GGGAAATTA AACTCACC AAACAAAGGC GCAATTAACA  
1301 ACAACACCCA GATGATAGT TTACAATCT TACACAAATA CCAACCCCGA  
1351 CTCGATATTG TTGAAGTTAC AGAGATGGC GTGGAGGACT TGAATGAGCC  
1401 CTCAAAGACC CAGACTTTTA CTTCTCAGA AACGCAATC ATTGCAGTGA  
1451 CTGCTACCA AACACCCGAT ATTACTAAC TAAAGATTGA TCATACCCCC  
1501 TTTGCAAAAG GCTTCAGAGA CACTATGAT TCCATGTACA CGCTTCAGA  
1551 AAATGACAGG TTAACCTCCAT CTCACACGGA TTCTCTTAGA TCCCATCAGA  
1601 TTGTCCTCG AGGTGGTAC GCGGTTCAAT CTTCTTCCC GGAGCCCTTT  
1651 GTCAACACTT TACCTCAAGC CGGTATTAT AATGGGAGGA GAACCGTGCC  
1701 ACAGACCAAC GGCCTCCTTT CACCCCAACA GAGCGAAGAG GTGGCCCAAC  
1751 CTCGCCAGG GTGGCTTGTG ACGCTGTCC AGCAACCTGG GACCAACAAA  
1801 CTAGACATCA GTTCTATAGA ATCTGAATAT ACTTCTAGCA CATGTCTCCC  
1851 ATATGGCAAT AAATCCTTGC CCTTTCAGAC ATCCCATGCC CTGGGGTATT  
1901 ACCCAGACCC NACCTTCTC GCAATGGCAG GGTGGGGAGG TCGAGGTCT  
1951 TACAGAGGA AGATGGCAGC TGGACTACCA TGGACCTTCCA GAACAAGCCC  
2001 CACTGTGTTT TCTGAAGATC AGCTCTCCAA GGAGAAAGTG AAAGAGGAAA  
2051 TTGGCTCTTC TTGGATAGAG ACACCCCTT CCATCAATC TCTAGATTCC  
2101 AATGATTCAG GAGTATACAC CAGTGTCTGT AAGCGAAGGC GGCTGTCTCC

51 ATGAAGTCCG GCAGGAGATT GAAGCAGAGA CCGACAGGGT CACGGGGACC  
101 AACAAAGGCA TCTCCCAAGT GCCATCAAC CTTTCGAGTCT ACTCGCCACA  
151 CGTGTGTAAC TTGACCCTCA TCGACCTCCC GGGTATCACC AAGTGCCTG  
201 TGGGGACCA GCCTCCAGAC ATCGAGTACC AGATCAAGGA CATGATCCTG  
251 CAGTTTCATCA GCGGGAGAG CAGCCTCATT CTGGCTGTCA CGCCGCCAA  
301 CATGACCTG GCCAACTCCG AGCCCTCAA GCTGGCCAAAG GAATCGATC  
351 CCCAAGGCT ACGGACCATC GGTGTCTACA CCAAGCTTGA COTGATGGAC  
401 GAGGGACCG ACGCAGGGA CGTCTTGAG AACAAATTGC TCCCGTTGAG  
451 AAGAGGCTAC ATTGGCGTGG TGAACCGCAG CCAGAAGGAT ATTGAGGCA  
501 AGAAGGACAT CCGTGCAGCA CTGGCAGCTG AGAGGAAGTT TTCTCTCTCC  
551 CACCCGGCT ACCGCACAT GCGCGACCG ATGGGCACGC CACATCTGCA  
601 GAAGAGCTG AATCAGCAAC TGACCAACCA CCCACCCGCA AAACCAAGC  
651 CCTACGTAG CAAACTACAG AGCCAGCTGC TGTCCCTGGA GAAAGAGGTG  
701 GAGGAGTACA AGAATTTTCG GCCCGAGCAG CCCACCCGCA AAACCAAGC  
751 CTGCTGCGAG ATGCTCCAGC AGTTTGGGT GGAATTTGAG AAGAGGATCG  
801 AGGGCTCAGG AGATCAGGTG GACACTCTGG AGCTCTCCGG GGGCGCCGGA  
851 ATCAATCGA TCTTCCAGGA CGGTTCCCA TTTCAGCTGG TGAAGGAGAT  
901 CAGCTATGCC ATTAAGAACA TCCATGGAGT CAGGCAAGAC CGGGCTTTTC  
951 ACCCGGACT TGGCATTGGA GGCATTGTG AAAAAGCAGG TCGTCAAGCT  
1001 GAAAGAGCCC TGTCTGAAT GTGTGCACCT GGTATCCAG GAGCTAATCA  
1051 ATACAGTTAG CGAGTGTACC AGTAAGCTCA GTTCTTACCC CGGTTGCGA  
1101 GAGGAGACAG AGCGAATCGT CACCACCTAC ATCCCGGGAAC GGGAGGGAG  
1151 AACGAAGAC CAGATTCTTC TGCTGATCGA CATTGAGCAG TCCTACATCA  
1201 ACACGAACA TGAGGACTTC ATCGGGTTTG CCAATGCCCA GCAGAGGAGC  
1251 ACGCAGCTGA ACAAGAGAG AGCCATCCCC AATCAGGTGA TCCGCAGGGG  
1301 CTGGCTGACC ATCAACAACA TCAGCCTGAT GAAAGCGCG TCCAAGGAGT  
1351 ACTGGTTTGT GCTGACTGCC GAGTCACTGT CCTGGTACAA GGATGAGGAG  
1401 GAGAAAGAGA AGAAGTACAT GCTGCCTCTG GACAACCTCA AGATCCGTGA  
1451 TGTGAGAGAG GGCTTCATGT CCACAAAGCA CGTCTTCGCC ATCTTCAACA  
1501 CGGAGCAGAG AAACGTCTAC AAGGACCTGC GGCAGATCGA GCTGGCCTGT  
1551 GACTCCAGG AAGACGTGGA CAGCTGGAAG GCCTCGTTCC TCCGAGCTGG  
1601 CGTCTACCCC GAGAAGGACC AGGCAGAAA CGAGATGGG GCCCAGGAGA  
1651 ACACCTTCTC CATGGACCCC CAACCTGGAGC GGCAGGTGGA GACCATTCGC  
1701 AACCTGGTGG ACTCATAGT GGCCATCATC AACAAGTCA TCCGGGACCT  
1751 CATGCCAAG ACCATCATGC ACCTCATGAT CAACAATAGC AAGGCTTCA  
1801 TCCACCAGGA GCTGCTGGCC TACCTATACT CCTCGGCAGA CCAGAGCAGC  
1851 CTCATGGAG AGTCGGCTGA CCAGGCACAG CGGCGGGAGC ACATGCTCG

1901 CATGTACCAT GCCCTCAAGG AGGCGCTCAA CATCATCGGT GACATCAGCA  
1951 CCAGCACTGT GTCCACGCCT GTACCCCGCG CTGTGATGA CACCTGGCTC  
2001 CAGAGCGCCA GCAGCCACAG CCCACTTCCA CAGCGCCGAC CGGTGTCCAG  
2051 CATACACCC CCTGGCGGC CCCAGCAGT GAGGGGCCCC ACTCCAGGGC  
2101 CCCCCTGAT TCCTGTTCCC GTGGGGCAG CAGCCTCCTT CTCGGCGCCC  
2151 CCAATCCCAT CCGGCTCTGG ACCCCAGAGC GTGTTTGCCA ACAGTGACCT  
2201 CTTCCAGCC CCGCTCAGA TCCCATCTCG GCCAGTTGG ATCCCCCAG  
2251 GGATTCCCC AGGAGTGCCC AG

!!AA SEQUENCE 1.0

ID ADP31234 standard; protein; 3465 AA.

XX ADP31234;

AC

XX 12-AUG-2004 (first entry)

DT Human secreted protein SEQ ID #2001.

DE

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
cancer; inflammatory; immune; human secreted protein.

Homo sapiens.

WO2004035732-A2.

29-APR-2004.

28-AUG-2003; 2003WO-US026780.

29-AUG-2002; 2002US-0406576P.

29-AUG-2002; 2002US-0406579P.

29-AUG-2002; 2002US-0406585P.

29-AUG-2002; 2002US-0406588P.

29-AUG-2002; 2002US-0406608P.

29-AUG-2002; 2002US-0406611P.

29-AUG-2002; 2002US-0406612P.

29-AUG-2002; 2002US-0406616P.

29-AUG-2002; 2002US-0406640P.

29-AUG-2002; 2002US-0406642P.

29-AUG-2002; 2002US-0406653P.

29-AUG-2002; 2002US-0406655P.

29-AUG-2002; 2002US-0406666P.

17-SEP-2002; 2002US-0410946P.

17-SEP-2002; 2002US-0410947P.

17-SEP-2002; 2002US-0410948P.

17-SEP-2002; 2002US-0410949P.

17-SEP-2002; 2002US-0410953P.

17-SEP-2002; 2002US-0410957P.

17-SEP-2002; 2002US-0410958P.

17-SEP-2002; 2002US-0410959P.

17-SEP-2002; 2002US-0410960P.

17-SEP-2002; 2002US-0410961P.

17-SEP-2002; 2002US-0410962P.

17-SEP-2002; 2002US-0411019P.

17-SEP-2002; 2002US-0411022P.

17-SEP-2002; 2002US-0411023P.

17-SEP-2002; 2002US-0411024P.

17-SEP-2002; 2002US-0411032P.

17-SEP-2002; 2002US-0411035P.

17-SEP-2002; 2002US-0411037P.

17-SEP-2002; 2002US-0411041P.

17-SEP-2002; 2002US-0411045P.

17-SEP-2002; 2002US-0411046P.

17-SEP-2002; 2002US-0411048P.

17-SEP-2002; 2002US-0411048P.

17-SEP-2002; 2002US-0411048P.

17-SEP-2002; 2002US-0411048P.

17-SEP-2002; 2002US-0411048P.

17-SEP-2002; 2002US-0411048P.

17-SEP-2002; 2002US-0411048P.

17-SEP-2002; 2002US-0411048P.

17-SEP-2002; 2002US-0411048P.

2651 AGGACCTGCT GGTGGGGCT GTTCCCTATG GCCAATATGG CAGCCTCAGC  
2701 TCCGCAACA CCTTGGCTT CTAATGGAT GTGGACACAG TGACACACAGA  
2751 TGCACCCCTA CAGTAGCA TTGCCCTAGA GGGCCACAGTA GCCCACTGA  
2801 AGCTGGCCCA GCACAGAAG ATCTACATCT TCCAGGGAGA GGCAGCTGAG  
2851 ATCAGAAGG ACCAGCTGGA GGATGTGGC TCGCCTGGG TGCTCCCTT  
2901 GAGACGTCA CGTGGAGCTG GAGGTGCTGC CTGCTGTCTAT CCCACTGGG  
2951 GGCACAAAC TTCAGCAGTA GAGGGGGCAC AGTCGACGT GCACCTTGGC  
3001 CCCTCCACTG CTCGGGTTG CCAGGTGCTTA CTTCGCCACT CTCGCGGCC  
3051 TTGGCCTGCA GGTGCTGGAG CCACCCCGC ATGGGGCCCT GCAGAAGGAG  
3101 GATGGGCTC AAGCCAGGAC CCTCAGACC TTCTGCTGGA GAGAGGTGGA  
3151 AGAGCATCTG ATCCAGTACC TGCACGATGG GAGCAAGACA CTGACGGTTT  
3201 TGTCTGATG GCTAATGCTT CTGAGATGGA CGGCAGAGC CATCCTGTGG  
3251 CTTTCACTGT CACCATCTG CCTGTCAATG GCCAACCCCC GACCTCATAC  
3301 AAACCTCAGC CTGCAG

!!AA SEQUENCE 1.0  
ID\_ADP31136 standard; protein; 2272 AA.

XX ADP31136;

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1903.

DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

OS WO2004035732-A2.

PN 29-APR-2004.

PD 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 29-AUG-2002; 2002US-0406666P.

XX 17-SEP-2002; 2002US-0410946P.

XX 17-SEP-2002; 2002US-0410947P.

17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411033P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;

Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases

Genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3134; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPOWEB and is not in the specification.

Sequence 2272 AA;

ADP31136 Length: 2272 February 22, 2005 12:25 Type: P Check: 1875 ..

1 AGAACATGCC GAGTTTGTTC ACTCAAGTC CAAAAAGTTT ACAGACTTTG

PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486448P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX  
XX Claim 1; SEQ ID NO 3114; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 3316 AA;  
ADP31116 Length: 3316 February 22, 2005 12:25 Type: P Check: 1816 ..  
1 AACCACCCGG AGGTGACTGT GGCCATGGCT CTGACTGACA TAGACCTGCA  
51 GCTGCAGTTC TCCATGTCCC AACCGAAGC CCTCCTTCTC TTGGCAGCAG  
101 GCCCAGCTGA CCACCTCTCTG CTGCAGTCT ACTCTGGACA CTGCAGCTC  
151 AGGCTTGTCC TGGGCCAGGA GAGCTGAGG CTCAGACCC CAGCAGAAAT  
201 TCTACTGAGT GACTCCGTCC CCCACACCAC AGTTCTGACT GTCTCAGAGG  
251 ACTGGCCNAC ATTGTCAGTC AATGGGTTTC TGAATGCCTC CTCTGTAGTC  
301 CTGGGAGCCC CCTAGAAGT CCCTATGGG CTCTTTTGTG GGAGCACTGG  
351 GAGACTTGGC CTGCCCTACC TGAGGGGAAC CAGCCATCCC CTGAGGGGTT  
401 GCCTCCATGC AGCCGCTCTC AATGGCCGCA GACTCTCTCA GCCTCTGACC  
451 CCCAATAAGC ATGAGGGCTG TGCTGAAGAG TTTTCTGCCA ATGACGATGT  
501 GGCCCTGGGC TTCTCTGGGT CCCACTCTCT GGCTGCCTTG CCTGCCTGGG  
551 GCACCTCAGGA TGAAGGAACC CTGAGTTTA CACTCACAC ACAGACTGG  
601 CAGGCACCTT TGGCCTTTCCA GGCAGCAGGC TGGCATGGGG ACTTCATCCA  
651 TGTGGACATA TTTGAGGGCC ACCTGTGGTC CATGGTTGAG AAGGCCCAGG  
701 GTACTGTATT GCTCCTCMAC AGTGTGCTGT TGACTGATGC ACAGCCCCAC  
751 AAGGTCAGCA TCCACATCAA CATTCACCAG CTAGAAATCT CCATGGACCA  
801 GTACCCACCA TGTACTTTGA ACCGAGGAGT CCTCAGCTAC CTGGAGCCAC

851 GTGACAGTCT CCTTCTTTGGG GAGCTGGTGC AGAGGCCTCT CGTCACCTCC  
901 AGGAACACCG CTCAGGCCTG AATGTTTACC CTTCGTGAGG TGGTGAACGT  
951 CAAGGCCCGC TTCAATCAAG ATGGCCCTGA GGACACCTCT GACCAGCTGG  
1001 TGCTGGAGGT GTCACTGATG GCTTGGGTGC CTATGCCCTC ATGCTCTGGG  
1051 AGGGGCCAAA CAGACCTCCT GCCCATCCAG GTCAACCCCTG TCAATGACCC  
1101 ACCCCACATC ATCTTCCAC ATGGCAGCCT TATGTGTATC CTGGAACACA  
1151 CACACAAGCC TCTGGGGCCT GAGGTTTCTCC AGGCCATATGA CCTGACTCT  
1201 ACCTGTGAGG GCCTCACCTT CNAGCTCCTT GGCACCCCTT CTGGCCTCCC  
1251 CGTGGAGCAC CGAGACAGC CTGGGAGCC GGTGACTGAG TTCTCTGTCT  
1301 GGGAGTTGGA GGC CGGCAGC CTAGTCTATG TCCACTGCGG TGGCCTTACA  
1351 CAGGACTTGA CATTCGGGT CAGCAATGGA CTGCAGGCA GCCCCCCGGC  
1401 CATGCTGAAG GTGGTGGCTG TCCAGCTGGC CATACAAATC CACCGCAGCA  
1451 CAGGCTGCA TCTGGGCCAG GGCTCTGCCA TGCCCCATCTT GCCTACCAAC  
1501 CTGTTGTGGG AGACCAGCG CGTGGGGCAG GATGTGACGG TGCTGTTCCA  
1551 TGTCACTGGA GGCTGTCCGT TCAGGGAGCT GCAGAAAGCAG GGGCTGGTG  
1601 GGGTGGAGGA TGCTGAGTGG TGGGTACAC AGGCTTTCCA CCAGCAGGAT  
1651 GTGAGCAGG GCCACGTGAG ATACCTGAGC ACTGACCCAC AGCACTACAC  
1701 CGAGGACACC GTGGAGAACC TGGATCTGCA GGTGCAGGTG AGTGGGAAA  
1751 TCCTGAGCAA TCTGTCTTTC CTAGTGACCA TCCAGAGAGC CACTGTGTGG  
1801 ATGTGTCAGC TGAGGCCACT GCACACTCAG AACCCACAG AGGAGGCCCT  
1851 CACCACAGCC CACCTGGAGG CCACCTTGA GGAGSCAGGC CCAAGCCCCC  
1901 CAACCTTCCA CTGTGAGGTG GTTCAGGCTC CCAGGAAAG CAACCTTTCAA  
1951 CTACAGGGCA CGATGATGTC AGACGTGAG GGTTCACCC AGGATGAGGT  
2001 ACAGGCTGCA GAGGTGACCT ATGGGGCCAT GGCACGTGCC TCAGTGGCAG  
2051 TGGAGGACAC CTTCGTGTTTC CATGTACAG CTCACACATA TTTCTCCCCA  
2101 CTCTGTACCT TCTCCATCCA TATTTGGCGT GACCACAGCA TGCTGTCTCT  
2151 CGTGTGCCC GAGGTTGGTG AGTGTGTCTT CTCTGTGAC CAGCTCTTCA  
2201 TCAAGAGTCT CAACAGTGCC AGGTGGCGG TGCTGACTAC AGACAACATG  
2251 GCCTTCAGCA ATGCTGATTC GGGCTTTGCT GAGGCCACAG TGGTGTGTAC  
2301 CCACAGGAC CTCCTCTCTG GCAGTATCAT GGCACAGGAT GAGCCCATGC  
2351 AGCCCATCTG CCGTTCATC CAGGAGGGG CTCAGGAAGA GGCAGTCTCT  
2401 GTGTCCGATG GGCAGCACCA GGCATCACG GTGTGGAGG TGCAGGCCCT  
2451 GGAGCCTTAC CTCTGTGTGG CCAATGGCTC CGGCCTCATG GTTCTCAAG  
2501 GAGGCCAGG TACCATCAAC ATGGCCGAGC TCCACCTGGG CACCAACCTC  
2551 AACATCTGCA GTAGGGATGA GGCACACTAC CAGTTCACAG ACAGCCCTCA  
2601 CTGGGGACAG TTGCTCCAAG CCACTCAGCC AGCCACAGCC TTCTCTCAGC



PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471338P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnewann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 3095; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC anti-inflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 681 AA;  
ADP31097 Length: 681 February 22, 2005 12:25 Type: P Check: 7643 ..  
1 ATGCCTGACC TGAAGATGCA GGAGGTGAAG AAGATCTGCT ATGAGTTGGC  
51 CCTGCCTTAC TTCACACAG GGACAGGTGA GATTGAGGCC CTGGCCACCC  
101 TCAAGGTGTG GGAGTTGTGT CACACCTATG GCAAGCCAGA GGGCCCCAGA  
151 GATGCCTGGA GGGCTGTGGC CCGGGATTC TGGGACACCG TGGCGGAGGA  
201 GGAAGGAGGT GGAGCTGGCA GTGGTGTGG CAGCGAGGAG GGAACCCGAG  
251 GGGTGGAGGT GGAGGACCTC CAGGCCACCA TCTGCAAGCT CATGGGGATT  
301 CTGCAGCAGG TGAAGCTGCA GAACAGCAGC AAGGACTGGG AGCTGCAGGC  
351 GCTGCAGGAC CGCATGTCT GCATGAGAG GATCATCCCC CTGGCCCNAG  
401 ATCATGAGGA TGAGAATGAA GAAGGTGGCC TCCAAGTCCC CGAAGGTCCC  
451 ACCATCTCCG CAGGAATCC CTGAGGAGAG GGGGCCAATC CTGGGGAGCG

501 GGTTCGTGAC AGCCTGRACC CCAGCACTTC TAGGCCAAA AGCACAACCTT  
551 ACATTCAGCA GCCCAACTG TACCAGCCC AGGGCCCCC AGAGCCCCGC  
601 TACTCCCCAT ACATCTACTCC CCCACAAATG AGATGGCAGC GCTCTGCCCC  
651 TGACCTCAAG GAGAGTGGG CGGCTGTGTG A  
!!AA\_SEQUENCE 1.0  
ID ADF31100 standard; protein; 429 AA.  
XX  
AC ADP31100;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1867.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.

PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
XX genetic, bacterial and viral diseases.  
PS Claim 1; SEQ ID NO 3091; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.

XX Sequence 1640 AA;

ADP31093 Length: 1640 February 22, 2005 12:25 Type: P Check: 7563 ..

1 ATGGGGGGCT GGGCTTGGGT CCCAGCCCC TGGCCCCCAC CGGGGTGGG  
51 CCCCTTCTC CTCTCTCTC TGCTGCTGT GCTGCTGCC CGGGGTTC  
101 AGCCCCAGCC TGGCGGAAC CGTACGGAGT CCCAGAAC TAATGCCACA  
151 GCGACCCCTG CGATCCCCAC TATCTTGGT ACCTCTGTGA CTCTGAGAC  
201 CCCAGCAACA AGTGCTCCAG AGGCAGAGG ACCCAAAGT GGGGGGCTCC  
251 CGCCCCCGCC CAGGGCAGTT CCCTGAGCA GTAGCCCCCA GGGCCAGGG  
301 GAGGCCCTGC AGGTTCCCTT TCCGTACGG GGGCCGCATG CTGCATGCCT  
351 GCATCTCGGA GGGCAGTGCA CACAGAGT GGTGTGCCAC AACTCACAAC  
401 TAGACCGGG ACAGGGCTG GGGTACTGT GTGAGGCCA CCGCGCTCC  
451 AGGGGGCCCA GGGCTTTCAC GGGCAAGGAC TGGCGCACAG AGAATGCTT  
501 TGATGAGACC CGTACGAGT ACCTGGAGG GGGCGACCG TGGGCGCGG  
551 TGGCCACAGG CCACGTGGAA CAGTGGAGT GCTTGGGGG CCGGACCTGG  
601 TGGCAAGGCA CCGACATAC AGCTTGTCTG AGCAGCCCTT GCCTGAACGG  
651 GGGCACCTGC CACCTGATG TGGCCACCG GACCACCGT TGTGCTGTC  
701 CACAGGCTT CGTGTGACG CTCTGACCA TCGTACCGT GGGTGGCCA  
751 GCACCTCAGC CTCGGGCTC AGCTGCTTG CCTGGAATC CGATCTGCTC  
801 TACCAGAGC TGCACGTGA CTCCGTGGC CCGCGGGCC TGCTGGGCTT  
851 GGGCCCCCAT GCTACTGCC GGAATCCGA CAATGACAG AGGCCCTGTT  
901 GCTACGTGGT GAAGACAGC GCGCTCTCT GGGAGTACT CCGCTGGAG  
951 GCCTGCGGAG GCACAAGAG AGGACGTTCC TGGCGCCAC TATCATCGGC  
1001 GGCTCTCTCT CGTGTGCGG CTGCGACCCC TGGTGGCGG CCATCTACAT  
1051 CGGGACAGC TTCTGCGCG GAGGCTGTGT CCACACCTGC TGGGTGGTGT  
1101 CGGCGGCCCA CTGCTTCTC CACAGCCCC CAGGGACAG CGTCTCGTG  
1151 GTGCTGGGCC AGCACTTCTT CAACGCGAG CCGGACGTGA CGCAGACCTT  
1201 CGGCATCGAG AAGTACATCC CGTACACCTT GTACTCGGTG TTCAACCCCA  
1251 GCGACCAGCA CCTCGGACA CAAGTGCCAG ATTGCGGCT GGGGCCACTT  
1301 GGATGAGAAC GTAGCGGCT ACTCAGCTC CTTGGGGAG GCGCTGGTCC  
1351 CCCTGTGTCG CGACCACAAG TGCAGCAGC CTGAGGTCTA CGGCGCGCAG

1401 ATCAGCCCCA ACATGCTCTG TCGCGGTAC TTGCACTGCA AGTCCGACGC  
1451 CTGCCAGGG GACTCAGGG GGGCCCTGGC CTGGAGAAG AACGGCGTGG  
1501 CTTACTCTTA CGGATCATC AGCTGGGGT ACGGCTGGG GGGGCTCCAC  
1551 AAGCCGGGG TCTACACCG CGTGGCCAAC TATGTGACT GGATCAACGA  
1601 CCAGATACGG CTTCCAGGC GGCCTGTGGC TCCTCTCTGA

!!AA SEQUENCE 1.0

ID ADP31097 standard; protein; 681 AA.

XX AC ADP31097;

XX XX

DT 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1864.

XX Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 29-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 17-SEP-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

XX PR 17-SEP-2002; 2002US-0410959P.

XX PR 17-SEP-2002; 2002US-0410960P.

XX PR 17-SEP-2002; 2002US-0410961P.

XX PR 17-SEP-2002; 2002US-0410962P.

XX PR 17-SEP-2002; 2002US-0411019P.

XX PR 17-SEP-2002; 2002US-0411022P.

XX PR 17-SEP-2002; 2002US-0411023P.

XX PR 17-SEP-2002; 2002US-0411024P.

XX PR 17-SEP-2002; 2002US-0411032P.

XX PR 17-SEP-2002; 2002US-0411035P.

XX PR 17-SEP-2002; 2002US-0411037P.

XX PR 17-SEP-2002; 2002US-0411041P.

XX PR 17-SEP-2002; 2002US-0411045P.

XX PR 17-SEP-2002; 2002US-0411046P.

XX PR 17-SEP-2002; 2002US-0411048P.

XX PR 17-SEP-2002; 2002US-0411052P.

XX PR 17-SEP-2002; 2002US-0411055P.

XX PR 17-SEP-2002; 2002US-0411073P.

XX PR 17-SEP-2002; 2002US-0411082P.

XX PR 17-SEP-2002; 2002US-0411101P.

XX PR 17-SEP-2002; 2002US-0411111P.

ADP31074 Length: 1122 February 22, 2005 12:25 Type: P Check: 1610 ..

1 ATGTCAGCC AGGTGGTGGG CAGTGAGCCT CTCTACATCA TGGCAGAGCC  
51 GGCCAGGCGT GACAGTCAA AGGGCTCCTC GGAGACGGAG ACCGAGGCTT  
101 CTTGTGGCCC TGGCCCTCTG TCCAGCTCCC ACCCACTGCC TCCAGGGCCA  
151 CAAGGAAGAG GAGGATGGA AGGGCTGGG CCTGGCGAGC TGGGCGGTGG  
201 GAAGCTGGTG CTCAGCTTCC TGTCGAAGAG CCTTCCCTCG GTCTGTGGGG  
251 ACGTGGCCTC CGGCTACCAC TAGCGTGTGT CATCTCTGTA GGAATGCAAA  
301 GCCTTCTTCA AGAGGACCAT CCAGGGGAGC ATCAAGTACA GCTGTCCGGC  
351 CTCGAACAAAG TGTGAGATCA TCAAGCGGAG AGCAAGAGCC TGTCAAGCCT  
401 GCCGCTTCAAC CAAGTGCCCTG CGGAGTGGC CCTGGATCGC GTCCGGGGTG  
451 GGCGGNAGAA GTACNAGCGG TGCAGAGGT GGACCCGCTG CCCTTCCCGG  
501 GGCCTTCCCT TGCTGGGCCC CTGGCAGTGC CTGGAGGCC CCAGAAGACA  
551 CCCCAGTGAA TGCCTGGTG TCTCATCTGC TGGTGGTTGA GCCTGAGAAG  
601 CTCTATGCCA TGCCCGACCC CATGTCAGTA CTGCAGAGCG TGTGATGGA  
651 GGTGCTGGTG CCCGGTGTGG CCCAGCGCTC ACTGCCACTG CAGGATGAGC  
701 TGGCCTTCAAC TGAGGACAGA GTCTCTGTG CCCATCGAAG ATGCCGAGGC TGTGAGCAG  
751 GGCCTGGGGG AACTGGGGAC TGGCCTGCTG CAACTGTGTC GCGGCTGCA  
801 GTCCCTGCGG CTGAGGCGAG GGGAGTACGT TCTACTGAAG GCCCTGGCCC  
851 TTGCCAATTC AGACTCTGTG CCCATCGAAG ATGCCGAGGC TGTGAGCAG  
901 CTGCCAGAAG CTCGCGACGA GGCCTTGCTG GAGTATGAAG CCGGCGGGC  
951 TGGCACCGGA GGGGGTGTGT AGCGGGGGCG GCCAGGCGAG CTGCTGTTCA  
1001 CGCTACCGCT CCTCCACCAG ACAGCGGGCA AAGTGTCTGC CCATTTCAT  
1051 GGGGTGAAGC TGGAGGGCAA GGTGCCCATG CACAAGCTGT TCTTGGAGAT  
1101 GCTCGAGGCC ATGATGGACT GA

!!AA SEQUENCE 1.0

ID\_ADP31093 standard; protein; 1640 AA.

XX

AC ADP31093;

XX

DT 12-AUG-2004 (first entry)

XX

DE Human secreted protein SEQ ID #1860.

XX

KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;

KW cancer; inflammatory; immune; human secreted protein.

XX

OS Homo sapiens.

XX

FN WO2004035732-A2.

XX

PD 29-APR-2004.

XX

PF 28-AUG-2003; 2003WO-US026780.

XX

PR 29-AUG-2002; 2002US-0406576P.

PR

PR 29-AUG-2002; 2002US-0406579P.

PR

PR 29-AUG-2002; 2002US-0406585P.

PR

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2002US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

Halenbeck RF, Huang MW, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases



401 GTCATCTTCC TCTGAACCCCT GCCTATATGA TAAAAAGGAT TGATCAGCAT  
451 GCATGTTTCAT ATTTTACATC TAATGCTTGG CCAITGAAGA TTACTTTTCAT  
501 CAATGCTTAAT CCGATGGGCA AAAACATCAG CATTAATTTTT AAGCTGGAG  
551 ATGATCTTTCG TCAGGATATG CTTGTCTTGC AGCTTATTTCA AGTGATGGAC  
601 AATATTGGC TGCAGGAAGG CTTGGATATG CAATGATCA TTTATAGATG  
651 TCTATCCACA GGAAGAGACC AAGCTCCCC TACGAGCGCG GCCCCCTGCT  
701 CCACGGCGCC CAGTCCCATC GACCACCTAA GGGCTGAGGA GTGTGGCGCG  
751 ACGGCGCAGG ACTGGCAGGC AGCTCCACCT GCAGCCCCAA TGCAGATCC  
801 ACTGGGTGAC GCAGCTGGG CTCCTGAGTC TGGTAGGAC GTGAACCTTT  
851 ACCTCTACCT CAGGGATTGT AAATGCACCA ATCAGCGCGG TGTCAAAACA  
901 GACCACTCGG CTCTACCAAT CAGCAGGATG TCCGAGCTT CACTCCTGAG  
951 CCACGAGAC CAGAACCCCA CAGAGAGGAA GAACTCCGA ACACATCCGA  
1001 ACATCAGAAA GAACAAACTC CAGACGCGCC ACCTTAAGAG CTGTAACACT  
1051 CACGCGAAG GATTGGTGCA GATGTTACCT GATGCTGGA CCTAGCAAA  
1101 GATTTCATCGC CATTCTGGAC TGATAGGACC ATTGAAGAA AATACAATTA  
1151 AAAAGTGTT CAGTCAGCAC AACCACTTAA AGGCAGATTA TGAAGAAG

I/AA SEQUENCE 1.0

ID \_ADP31074 standard; protein; 1122 AA.

XX AC ADP31074;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1841.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

XX PR 29-AUG-2002; 2002US-0406608P.

XX PR 29-AUG-2002; 2002US-0406611P.

XX PR 29-AUG-2002; 2002US-0406612P.

XX PR 29-AUG-2002; 2002US-0406616P.

XX PR 29-AUG-2002; 2002US-0406640P.

XX PR 29-AUG-2002; 2002US-0406642P.

XX PR 29-AUG-2002; 2002US-0406646P.

XX PR 28-AUG-2002; 2002US-0406653P.

XX PR 29-AUG-2002; 2002US-0406655P.

XX PR 29-AUG-2002; 2002US-0406666P.

XX PR 17-SEP-2002; 2002US-0410946P.

XX PR 17-SEP-2002; 2002US-0410947P.

XX PR 17-SEP-2002; 2002US-0410948P.

XX PR 17-SEP-2002; 2002US-0410949P.

XX PR 17-SEP-2002; 2002US-0410953P.

XX PR 17-SEP-2002; 2002US-0410957P.

XX PR 17-SEP-2002; 2002US-0410958P.

17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
08-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

Claim 1; SEQ ID NO 3072; 428pp; English.

The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPONEB and is not in the specification.

Sequence 1122 AA;

1301 CGCCAGCCTG TGGGGAGGTG GACCGGAGGC CAGCAGTGCT GAAGGACTTC  
1351 CACTACCTGT ACTTTGCAAT CCTCTCTGC GGGCTCACTG CCATCGTCAT  
1401 TGTCAATCCC CAGCAGGTC CTGGGGAAG TTGCTCTGGA GCTGGTTCTG  
1451 TGGGCTCTCT GGAACACCGG AGCAGGCCCT GAGCCCGAGCA GAGAAGGCTG  
1501 CGCTAGAACA GAAGCTGACA AGCATTGAGG AGGAGCCACT CTGGAGACAT  
1551 GTCGTGAACA TCAATGCTGT CCTTTGCTG GCCATCAACA TCTTCTCTG  
1601 GGGCTATTTT GCGTGA

!!AA SEQUENCE 1.0  
ID ADP31034 standard; protein; 1197 AA.

XX AC ADP31034;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1801.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

PR 29-AUG-2002; 2002US-0406579P.

PR 29-AUG-2002; 2002US-0406585P.

PR 29-AUG-2002; 2002US-0406588P.

PR 29-AUG-2002; 2002US-0406608P.

PR 29-AUG-2002; 2002US-0406611P.

PR 29-AUG-2002; 2002US-0406613P.

PR 29-AUG-2002; 2002US-0406640P.

PR 29-AUG-2002; 2002US-0406642P.

PR 29-AUG-2002; 2002US-0406645P.

PR 29-AUG-2002; 2002US-0406653P.

PR 29-AUG-2002; 2002US-0406666P.

PR 17-SEP-2002; 2002US-0410946P.

PR 17-SEP-2002; 2002US-0410947P.

PR 17-SEP-2002; 2002US-0410948P.

PR 17-SEP-2002; 2002US-0410949P.

PR 17-SEP-2002; 2002US-0410953P.

PR 17-SEP-2002; 2002US-0410957P.

PR 17-SEP-2002; 2002US-0410958P.

PR 17-SEP-2002; 2002US-0410959P.

PR 17-SEP-2002; 2002US-0410960P.

PR 17-SEP-2002; 2002US-0410962P.

PR 17-SEP-2002; 2002US-0411019P.

PR 17-SEP-2002; 2002US-0411022P.

PR 17-SEP-2002; 2002US-0411023P.

PR 17-SEP-2002; 2002US-0411032P.

PR 17-SEP-2002; 2002US-0411035P.

PR 17-SEP-2002; 2002US-0411037P.

PR 17-SEP-2002; 2002US-0411041P.

PR 17-SEP-2002; 2002US-0411045P.

PR 17-SEP-2002; 2002US-0411048P.

PR 17-SEP-2002; 2002US-0411052P.

PR 17-SEP-2002; 2002US-0411055P.

PR 17-SEP-2002; 2002US-0411073P.

PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486466P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;

PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;

PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

XX WPI; 2004-348438/32.

XX New nucleic acid molecule for diagnosing, preventing or treating diseases

XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,

XX genetic, bacterial and viral diseases.

XX Claim 1; SEQ ID NO 3032; 428bp; English.

XX The present invention relates to an isolated nucleic acid molecule

XX encoding a polypeptide which is believed to be cytostatic,

XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The

XX composition and methods are useful for diagnosing, preventing and

XX treating diseases such as proliferative (e.g. cancer), inflammatory,

XX immune, metabolic, genetic, bacterial and viral diseases. The present

XX sequence represents a human secreted protein. The present sequence is

XX available on WIPWEB and is not in the specification.

XX SQ Sequence 1197 AA;

ADP31034 Length: 1197 February 22, 2005 12:25 Type: P Check: 403 ..

1 ATGTGTTTCAG CTGGAGTGGG AAGGACAAGG ACTATTGTGA AGCCGAGGAC

51 ACCACAGAAG AGACGACAAC AAGGTGGAGT TTTTGACAAA GGAGAAGTGG

101 CTGGAGCCAA GGCTTTCTTG GGGATCAGGA AAGGAGAAAA CCAAAATGAG

151 CGAAAAGGGA GGCTGTGTA AATGCAGAA AATGAAGCTT ATTTTAAAG

201 CTGGTATCAG AAGCTACTAG CTGCTCTCCA ATTCTGTGCA GGTAAGCCT

251 TGAATGATGA GTTTTCCAAG GAGCAGAAC TTATCAAAAT TCTGGGAGAT

301 ATTGGGGAAA GAGTCAAGTC TGCCAGTGAC CATCAAGAGC AGGAGGTACT

351 GAAGAAAGAA ATTGGCAGAC TAGAAGAGTT CTTTCAAGAT GTAAATACTT

PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467159P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 19-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX

(FIVE-) FIVE PRIME THERAPEUTICS INC.

PA Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX

DR  
XX  
PT  
PT  
XX  
PS  
XX  
CC  
CC  
CC  
CC  
CC  
CC  
CC  
XX  
SQ  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases such as proliferative (e.g. cancer), inflammatory, immune, metabolic, genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 3002; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule encoding a polypeptide which is believed to be cytostatic, antiinflammatory, immunosuppressive, antibacterial and virucidal. The composition and methods are useful for diagnosing, preventing and treating diseases such as proliferative (e.g. cancer), inflammatory, immune, metabolic, genetic, bacterial and viral diseases. The present sequence represents a human secreted protein. The present sequence is available on WIPOWEB and is not in the specification.

Sequence 1616 AA;

ADP31004 Length: 1616 February 22, 2005 12:25 Type: P Check: 7290 ..

1 ATTGGAGCAT CTCGTATGTC CAGCAATGTG GGCAGTGGCT TGTTCATCGG  
51 CTGTGGCTGGG ACAGGGGCTG CCGGAGGCCT TGCGTAGGT GGGTTGAGT  
101 GGAACGCCAAC CTGGCTGTCT CTGGCCCTTG GCTGGGTCTT CGTCCCTGTG  
151 TACATCCGAG CAGGTGTGGT CACAATGCCG CAGTATCTGA AGAAGCGATT  
201 TGGGGGCCAG AGGATCCAGG TGTACATGTC TGTCTGTGCT CTGATCCTCT  
251 ACATCTTCAC CAAGATCTCG ACTGACATCT TCTCTGGAGC CCTCTTCATC  
301 CAGATGGCAT TGGGCTGGAA CCTGTACCTC TCCACAGGGA TCCTGCTGGT  
351 GGTGACTGCC GTCTACACCA TTGCAGTGGG CTCATGAGCC GTGATCTACA  
401 CAGATGCTCT GCAGACGGTG ATCATGGTAG GGGGAGCCCT GGTCTCATG  
451 TTCTGGGCT TTCAGGACGT GGGCTGGTAC CCAGGCCCTG AGCAGCGGTA  
501 CAGGACGGCC ATCCCTAATG TCACAGTCCC CAACACCACC TGTACCTCC  
551 CAGGCCCCGA TGCTTTCCAC ATTCTTCGGG ACCCTGTGAG CCGGGACATC  
601 CCTTGGCCAG GTCTCATTTT CGGCTCACA GTGCTGSCCA CTGTGTGTTG  
651 GTGCACAGAC CAGGTCAATTG TGCAGCGGTC TCTCTCGGCC AAGAGTCTGT  
701 CTCATGCCAA GGGAGGCTCC GTGCTGGGGG GCTACCTGAA GATCCTCCCC  
751 ATGTTCTTCA TCGTCATGCC TGGCATGATC AGCGGGGCC TGTTCACAGA  
801 CGAGGTGGGC TGGCTGGACC CTGATGTCG CCAAGAATC TGTGGGGCCC  
851 GAGTGGGATG TTCAACAATT GCCTACCCTA AGTTGGTCAAT GGCCTCATG  
901 CCTGTTGGTC TGGGGGGCT GATGATTGCC GTGATCATGG CCGCTCTCAT  
951 GAGTCACTC ACCTCCATCT TCAACAGCAG CAGCACCCCTG TTCACCATGG  
1001 ATGTGTGGCA GCGCTTCCCG AGGAAGTCAA CAGAGCAGGA GCTGTGGTG  
1051 GTGGGCAGAG TGTCTGTGGT GTTCTGGTGT GTCATCAGCA TCCTCTGGAT  
1101 CCCCATCATC CAAAGTCCA ACAGTGGGCA GCTCTTCGAC TACATCAGG  
1151 CTGTCAACAG TTACCTGGCC CCACCCATCA CCGCTCTCTT CTGTGCGCC  
1201 ATCTTCTGCA AGAGGGTCAAC AGAGCCCGGA GCTTCTCTGG GCCTCGTGT  
1251 TGGCCTGGGA GTGGGGCTTC TGCATATGAT CTGGAGTTC TCATACCCAG

PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406656P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
PR (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PR Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
PR Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PR Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
PR WPI; 2004-348438/32.  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX

PS Claim 1; SEQ ID NO 2967; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 852 AA;  
ADP30969 Length: 852 February 22, 2005 12:25 Type: P Check: 7752 ..  
1 ATGGGGACTG CAGCTGCGGC AGCGGGCGGC GCGGGCGCG GCGGGCGCGG  
51 GGAGGGGGCG CGTAGCCCGA GCCCCGCCGC CGTGTGCTC GGCCTGGGCG  
101 TGGCCGTCGT GTCGAGCCTG GTGAACGGGT CCACGTTCT GCTACAGAAG  
151 AAGGCATCG TGCGTGCCAA GCGGCGAGGG TCCATTTTAG CTTCTATCT  
201 CCTGAAGGAA AAGCTCAACA TCTTGGGCAA GTTGGGGTGC CTGCTAAGCT  
251 GTGCAGGCTC CGTCGTGCTG ATTATCCACT CCCCAAGTC TGAGAGTGTG  
301 ACAACTCAGG CTGAGCTGGA GMAAAGCTG ACCAATCCAG TGTTCGTGGG  
351 CTACCTGTGC ATCGTGTGTC TCATGTGCTT GCTGTCTATC TTCTGGATCG  
401 CGCGGGCCCA TGGGCCCAAC AACATCATGG TCTACATCAG CATCTGCTCC  
451 TTGCTGGGCA GTTTCACCGT GCCTCCACC AAGGGCATCG GGCTGGCGGC  
501 CCAAGACATC TTGCATAACA ACCCGTCCAG TCAGAGAGCC CTCTGCCTGT  
551 GCCTGGTACT CCTGGCCGTG CTCGGCTGCA GCATCATCGT CCAGTTCAGG  
601 TACATCAACA AGCGCTGGA GTGCTTCGAC TCCTCGGTGT TCGGGGCCAT  
651 CTACTACGTC GTGTTTACCA CGCTGTCTCT GCTGGCCTCA GCCATCCTCT  
701 TCCGGGAGTG GAGCAACGTG GGCCTGTGCG ACTTCTTGGG GATGGCCTGT  
751 GGATTCACGA CGTCTCCGT GGGGATTGTC CTTATACAGG TGTTCAAAGA  
801 GTTCAATTTC AACCTTGGGG AGATGAACAA ATCTAATATG AAAACAGACT  
851 AG  
!!AA SEQUENCE 1.0  
ID ADP31004 standard; protein; 1616 AA.  
XX  
AC ADP31004;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1771.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.

PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 14-JUL-2003; 2003US-0486425P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348439/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2929; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX SQ Sequence 1133 AA;  
ADP30931 Length: 1133 February 22, 2005 12:25 Type: P Check: 237 ..  
1 TCTGATGCTG AAGTAGAAG AAGTCTCACA AACGCCATT TGGAAAAA

51 GAAGTGTGAT GAGTATATTC CAGGTACAAAC CTCCTTAGGC ATGCTCTGTTT  
101 TTAACCTAAG CAACGCCATT ATGGCGAGTG GGATTTTGGG ACTCGCCTTT  
151 GCCCTGGCAA ACACGGAACT CCTACTTTTTT CTGGTACTTTT TGACTTTCAGT  
201 GACATTGCTG TCTATATATT CAATAAACCT CTTATTGATC TGTTCAAAAG  
251 AACAGGCTG CATGGTGTAT GAAAAGCTGG GGGAACAAAGT CTTTGGCACC  
301 ACAGGGAAGT TCGTAATCTT TGGAGCCACC TCTCTACAGA AACTGGAGC  
351 AATGCTGAGC TACCTCTTCA TCGTAAAAA TGAATACCC TCTGCCATAA  
401 AGTTTCTAAT GGGAAAGGAA GAGATGCATT TTCCCCAGAC CTGGTACGTG  
451 GATGGCCGGG TTCTGGTGTG GATAGTTACC TTTGGGCATAA TTCTCCCTCT  
501 GTGTCTCTTG AAGAAGCTTAG GGTATCTTGG CTATACTAGT GGATTTTCCT  
551 TGAGCTGTAT GGTTTTTTTC CTAATTGGG TGTATGCTTT ACCCACCATT  
601 GCATTTGCAT TTGTTTGCCA CCGTCAAGTC CTGCCAATTT AAGTGAAGCT  
651 TAAAGACCGA TCACAGAAAA AAATGCAGAT GGTTCCAAAC ATCTCCTTTT  
701 TCGCCATGTT TGTATGTATC TTCTTGACTG CCATTTTGG CTACTTGACA  
751 TTCTATGACA ACGTGCAGTC CGACTCTCTT CACAAATATC AGAGTAAAGA  
801 TGACATTCTC ATCTGCACAG TCGCGCTGGC TGTCAATTGT GCTGTGATCC  
851 TCACAGTGCC GGTGTTATTT TTCAGGTTAT CAACTTGTG GTGATCTTCA  
901 TACCCTCCAT GAAGATATTT TTTGGAGTCG TAGGAGTTAC ATCTGTAAAC  
951 ATGCTTATTT TCATCTCTTC TTCTCTCTT TATTTAAAAA TCACAGACCA  
1001 GGATGGAGAT AAGGAACATC AAGAATTTG GCGTGCCTTT TTCTTGGGCC  
1051 TGGGGGTGTT GTTCTCCTTG GTCAGCATTC CCTTGGTCAAT CTATGACTGG  
1101 GCCTGTCTCAT CGAGTAGTGA CGAAGGCCAC TGA  
11AA SEQUENCE 1.0  
ID ADP30969 standard; protein; 852 AA.  
XX  
XX AC ADP30969;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #1736.  
XX  
XX DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.

PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
PI Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
PR New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
PS Claim 1; SEQ ID NO 2904; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.  
XX  
SQ Sequence 1171 AA;  
ADP30906 Length: 1171 February 22, 2005 12:25 Type: P Check: 3887 ..  
1 ATGGCCTCCA GCCCATGGG CTGTGTATGT GGCCTTCTGC TGTGCTGCT  
51 GCCACTCTCTG GGGACTGGCC CTGCGCTGGG GAGGGGCTTT CCCAGGCCAC  
101 TTGAATACTC CGAATACCTT ATGATCCCTG GAGCCCCACCC CAAGGGCTCT  
151 GTGGGCTCAG AGCCCCAGGC CTTTGAGGTG TTCCCGGAGA ACCCCAGAGC  
201 TGACAGTCAC AGGAACCTCTG ATGTCCGCCA CGCCCTCTGT GAAGAGATGC  
251 CTGAGAAGCC TGTAGCTCTT CCCTTTGGCC CAGCCCTGTGA CGGGCCCAAA  
301 GCAGCACAA GAGCTCAGAG AGAACGACTC CCAGTAACTG ATGACCTCCA  
351 GATGGCTCAA GGACCAAGCT CCCACGGCTG GACAGGACCT CTGGACTCAC  
401 AAGAGCTTCT GCAGCAAGAA GCAGTGGCTC CCCACCCAGT GGGCCACCTT  
451 CATCTCACTT TCATCCCCAC AACTCCACA CGTCAACTCA GGGTAGCCAC

501 AGTTCTCTCC TCCCTGCAGC ATGAGGCCA AGAGGGACAG TGGCCACCTA  
551 GAGATGAGGG TCTGAAGGCC AAAACTAAGA GCAGGGTCCC ACCCACTTCT  
601 CCCTCAGACC ACCAGGGCCC ACCCCACACC CTTGTTTCCC ACTCAGGTAC  
651 TGTCAAGAGG CCACTGTCTGG AAGACAGGG TGGGTTTGAG GAACACTTGC  
701 AGGAGGCAGC TCAAGGTCCC CACTTCACCC AGCAGGATCC AGCAGCCCTT  
751 GATGTTGGCT CAGTACCCCC AGTTGAGGTG GTGTACTCTC AGGAGCCAGG  
801 GGCCACAGCA GACTTGCCAT TGCCCAAGAG CTTTCTCTCT GCTGAGGAGC  
851 TGCCGGTTGA GACCCCCAAG AGGGCTGGCG CTGAGGTGTC CTGGAAGTTC  
901 AGTCCCCCAG GTCCCCCGCC CAAGCAGGCT GACCTTCTCTG ACGCTAAGGA  
951 TTCACCAGGA CCCCAGGCCA CGGATCCACC CGCCTCAGAG GCTCCTGATC  
1001 GGCCGTCTAA GCCAGAGAGA GCAGCAATGA ATGGAGCAGA CCCATCTTCC  
1051 CCCCAGCGGG TGAGAGGAGC TGTGGAGGCC CCAGGCACCC CCAAGTCTCT  
1101 CATCCCTGGT CCCTCAGACC CTGGCCCCAG TGTAAACCGA ACAGAGAGCC  
1151 CCATGGGGGC CTGCAAGCCA G  
!!AA SEQUENCE 1.0  
ID \_ADP30931 standard; protein; 1133 AA.  
XX  
AC ADP30931;  
XX  
DT 12-AUG-2004 (first entry)  
DE Human secreted protein SEQ ID #1698.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
PF  
PF 28-AUG-2003; 2003WO-US026780.  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.

PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2888; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 917 AA;  
ADP30890 Length: 917 February 22, 2005 12:25 Type: P Check: 6967 ..  
1 CCCCTGCTTT GGCACAGC TTTGTGTGGG TAAGCCTGG CCTCGACCC  
51 CTGTGGAGGG CACTGACCTG CGGTTTGTCT CCCTGCAGTC TTACCTGCTG  
101 ATGCTGACTG TCATCTCTCT CCCCTATGTC AGCAAGGTCA CCGGCTGGTG  
151 CAGAGACAGG CTCTGGCTC AGCAAGGAGC GCGTGGAGC CTTCAGGCAC  
201 GGAGCTACG CCATCTGGC CAGGCTTCTC ATCTGGACA TCTGCCAAGA  
251 CAACGTCGG GACCCCAAGG ATGTGAAGG GAGGTTACG GGCAGCCTCG  
301 TGGCCGGCCT GAGTGGACC GGGCCGGCT TCCTGGCGTA CTTGGGCTCC  
351 TTGCCACAG TGGGACTGCT GTGGTTGCGC CACCACTCAC TCTTCCTGCA  
401 TGTGGCAAG GCCACGCGG CCATGGGCT GCTGAACACG CTCTCGCTGG  
451 CTTCTGTGGG TGGCCTCCCA CTAGCCTACC AGCAGCCTC GGCCTTGGCC  
501 CGGCAGCCCC GCGATGAGCT GGAGCGCGTG CGTGTGAGCT GCACCATCAT  
551 CTTCTGTGCC AGCATCTTCC AGCTGSCCAT GTGGACCACG GCGTGTGTCG  
601 ACCAGGCGGA GAGCTGACG CCTCTGGTGT GGTTCGGGG CCGGAGCAT  
651 GTGCTCATGT TCGCCAAGCT GCGCTGTGAC CCTGTGCA GCCTGTGTCG

701 CTTGCGCTCC ACCTGCCTGC TGAGCAGGTT CAGTGTGGGC ATCTTCCACC  
751 TCATGCAGAT CGCGCTGCC TGCGCCTTCC TGTGTCTGGC CTTGCTCGTG  
801 GGCTGTGGCC TGGCACCCT GCGGTCTCTG CCGGGCCTCG CCGGGCCCGA  
851 ACACCCCGCG CCAGCCCCCA CCGGCCAGGA CGACCCACAG TCCCAGCTCC  
901 TCCCTGCCCC CTGCTAG  
!!AA SEQUENCE 1.0  
ID ADP30906 standard; protein; 1171 AA.  
XX  
AC ADP30906;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1673.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.

PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2863; 428pp; English.  
XX  
CC The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytosstatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 600 AA;  
ADP30865 Length: 600 February 22, 2005 12:25 Type: P Check: 7393 ..  
1 TCTGTCCAGG GTGCTTTGAT CTTGCGAGAG CTGCTTTTCAG CAGTGAACG  
51 CTCACCTGGCT CGAACCTGG TCATCATAGT CAGTCGTGGGA TATGCGATCG  
101 TCAAGCCAGC CTTGGAGTC ACTCTTCATA AGTTGTAGT AGCAGGAGCC  
151 CTCATATCTTT TGTTCCTGCG CATGGAAGGG GTCCTCAGAG TTACTGGGTA  
201 TTTTCTTTAT CCGTGGACTC TGATAGTAAA CCTGGGCCCTC TCAGCAATTG  
251 AGCCTGTGT TATTTATGG ATATTTATTA GCCTGACTCA AACATGAAG  
301 CTATTAATAAC TTCGAGGAA CATTGTAAAA CTCCTCTTGT ATCGGCATTT  
351 CACCAACAGC CTTATTTGG CAGTGGCAGC ATCCATTGCG TTTATCATCT  
401 GGACAAACCAT GAAGTTCAGA ATAGTACAT GTCAGTCGGA CTGGCGGGAG  
451 CTGCGGTAG ACGATGCCAT CTGGCGCTTG CTGTTCTCCA TGATCCTCTT  
501 TGTATCATCG GTTCTCTGGC GACCATCTGC AAACACGAA GGAATGAAA

551 TGAGGAAGTAC CAAACAAGAA CCAATGGAA ATAGTAAAGT TAACAAAGCA  
IIAA SEQUENCE 1.0  
ID ADF30890 standard; protein; 917 AA.  
XX  
AC ADF30890;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1657.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
FN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 17-SEP-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.



PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 02-MAY-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halebek R, Huang MM, Kochakota S, Haisan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2812; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX  
SQ Sequence 426 AA;

ADP30814 Length: 426 February 22, 2005 12:25 Type: P Check: 8035 ..

1 ATGAGGCTT CGGCGCCCTG TGCAGTGC GTTCTGGGT CTTCAGATT

51 GTGGTCATCT CCACGCCCTC GGTATGTAC CTGGGCTACG CCGTGCACCG

101 CCTGGCCCGT GCCTCTGAGC AGGAGCGCG CGCGGCCCTC CGCGCGCGCC

151 CGGGGCGCAG CCGGGGGCCC CGAGCGCAC TCCGCCCCCC GCAGCGCGGC

201 TGGCCTGAGC CCGCCGACCT GGGCGAGGAG GAGCCCATGC TGGGCTTGGG

251 CGAGGAGGAG GAGGAGGAGG AGACGGGGG AGCCGAGGGC GCCGGCGAGG  
301 AAGCGGAGGA GCGAGGCGG GAGGAGCGT GCACTAAGGC GGTGGCGGCT  
351 GACGGCAAGG CGGAGGAGC CCGGGGGCCG ACCGGGCAAC ACGATGGGCG  
401 GAGGCGCATC CAGCGGAGG GCCTGA

IIAA SEQUENCE 1.0  
ID ADP30865 standard; protein; 600 AA.  
XX  
AC ADP30865;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1632.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-040576P.  
PR 29-AUG-2002; 2002US-040579P.  
PR 29-AUG-2002; 2002US-040585P.  
PR 29-AUG-2002; 2002US-040588P.  
PR 29-AUG-2002; 2002US-040608P.  
PR 29-AUG-2002; 2002US-040611P.  
PR 29-AUG-2002; 2002US-040612P.  
PR 29-AUG-2002; 2002US-040616P.  
PR 29-AUG-2002; 2002US-040640P.  
PR 29-AUG-2002; 2002US-040642P.  
PR 29-AUG-2002; 2002US-040646P.  
PR 29-AUG-2002; 2002US-040653P.  
PR 29-AUG-2002; 2002US-040655P.  
PR 29-AUG-2002; 2002US-040666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411053P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.

PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee B, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGF, Wu G, Zhang H;  
XX  
DR WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2659; 428bp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
SQ Sequence 1065 AA;  
ADP30661 Length: 1065 February 22, 2005 12:25 Type: P Check: 8727 ..  
1 ATGAGGAAGA CCAGGCTCTG GGGGCTGCTG TGGATGCTCT TTGTCTCAGA  
51 ACTCCGAGCT GCACTAAAT TAACTGAGGA AAGATATGAA CTGAAAGAGG  
101 GGCAGACCCT GGATGTGAAA TGTGACTACA CGCTAGAGAA GTTTGCCAGC  
151 AGCCGAAAG CTGGGAGAT ATAAAGGAC GGAGAGATGC CCAAGACCCT  
201 GGCATGCACA GAGAGGCTTT CRAAGAATTG CCATCCAGTC CAAGTGGGGA  
251 GGATCATACT AGAAGACTAC CATGATCATG GTTTACTGGG CGTCCGAATG  
301 GTCACCTTC AAGTGAAGA TTCTGACTG TATCAGTGTG TGATCTACCA  
351 GCCTCCCAAG GAGCCTCACA TGCTGTTGGA TGGCATCCGC TTGGTGGTGA  
401 CCAAGGGTTT TTCAGGACC CCTGGCTCCA ATGAGAATTG TACCCAGAAT  
451 GTGTATAAGA TTCCTCTTAC CACCCTAAG GCCTTGTGCC CACTCTATAC  
501 CAGCCCCAGA ACTGTGACC NAGCTCCACC CAAGTCAACT GCCGATGCT  
551 CCACTCCTGA CTCTGAATC AACCTTACAA ATGTGACAGA TATCATCAGG

601 GTTCGGTGT TCAACATTGT CATTCCTCTG GCTGGTGGAT TCCTGAGTAA  
651 GAGCCTGGTC TTCTCTGTCC TGTTCGTGTG CACGCTGAGA TTCCAAGCTG  
701 TAGGTGACAT GGAGGACAA ATGTGCTCTG TAGAAGGACA GAATCTGACC  
751 ATGGCCTGTT CTTACAACAT CATGAATAT GCCTCCAGCC TGAAGGCCCTG  
801 GCAGTGGGGT TGGAGCCAGG GTCCCCCAGA GACTCTGGTG CTCATGGAGA  
851 CTAGAAACAA AGACCTAAAC TGGGCTGTGG CTGGGAGGTC CCCTTTGTCC  
901 TGCACCATCG GATTGGCTG GTATTGGTGC AAAGGTGAGC AGCTGCAGGA  
951 TTCAGGTCAAT GGAAGGTCTC CTTAGGCAC AGCCAATGAG CTGGACCCCA  
1001 TCTGCCCATT CATGAGGGG TGTTCGGAGG GCAGCACAGA GCAATGGGAA  
1051 AAGTTGCAGG CCTGA  
!!AA SEQUENCE 1.0  
ID ADP30814 standard; protein; 426 AA.  
XX  
XX AC ADP30814;  
XX  
XX DT 12-AUG-2004 (first entry)  
XX  
XX DE Human secreted protein SEQ ID #1581.  
XX  
XX KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KM cancer; inflammatory; immune; human secreted protein.  
XX  
XX OS Homo sapiens.  
XX  
XX PN WO2004035732-A2.  
XX  
XX PD 29-APR-2004.  
XX  
XX PF 28-AUG-2003; 2003WO-US026780.  
XX  
XX PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406608P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.

PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411025P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485232P.  
PR 08-JUL-2003; 2003US-0485234P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX

## (FIVE-) FIVE PRIME THERAPEUTICS INC.

PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
PI Halenbeck RF, Huang MW, Kochakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

PT New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.

PS Claim 1; SEQ ID NO 2643; 428pp; English.

XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPWEB and is not in the specification.

XX Sequence 249 AA;

ADP30645 Length: 249 February 22, 2005 12:25 Type: P Check: 8744 ..

1 CCTGCAGATC TTCTCTGTT CGGTTTCGTG TTGCGCTCTCT ACGTGAGCAA

51 AGTGTTCCTG GAGGAGGAGG ACAGCTGGTG GGAGTCTCTGC CCTCAGATTC

101 TTCCCTTCA GGACCAAGTC TCCCTCTCTT CGCCCCGGCC GCGATCCCT  
151 AACATCGGCC GCCCTCTTTC GCAGTTTGAC TTCATCGGCG GCTTTGACTC  
201 CTACGGATAC CAGGCGCCCC AGAAGACGTC GCATTTACAG CTGCAGCCT

## !!AA\_SEQUENCE 1.0

ID ADP30661 standard; protein; 1065 AA.

XX AC ADP30661;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1428.

XX KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0408585P.

XX 29-AUG-2002; 2002US-0408588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 29-AUG-2002; 2002US-0406666P.

XX 17-SEP-2002; 2002US-0410946P.

XX 17-SEP-2002; 2002US-0410947P.

XX 17-SEP-2002; 2002US-0410948P.

XX 17-SEP-2002; 2002US-0410949P.

XX 17-SEP-2002; 2002US-0410953P.

XX 17-SEP-2002; 2002US-0410957P.

XX 17-SEP-2002; 2002US-0410958P.

XX 17-SEP-2002; 2002US-0410959P.

XX 17-SEP-2002; 2002US-0410960P.

XX 17-SEP-2002; 2002US-0410961P.

XX 17-SEP-2002; 2002US-0410962P.

XX 17-SEP-2002; 2002US-0411019P.

XX 17-SEP-2002; 2002US-0411022P.

XX 17-SEP-2002; 2002US-0411023P.

XX 17-SEP-2002; 2002US-0411024P.

XX 17-SEP-2002; 2002US-0411032P.

XX 17-SEP-2002; 2002US-0411035P.

XX 17-SEP-2002; 2002US-0411037P.

XX 17-SEP-2002; 2002US-0411041P.

XX 17-SEP-2002; 2002US-0411045P.

XX 17-SEP-2002; 2002US-0411046P.

XX 17-SEP-2002; 2002US-0411048P.

XX 17-SEP-2002; 2002US-0411052P.

XX 17-SEP-2002; 2002US-0411055P.

XX 17-SEP-2002; 2002US-0411073P.

XX 17-SEP-2002; 2002US-0411082P.

XX 17-SEP-2002; 2002US-0411101P.

XX 18-APR-2003; 2003US-0463700P.

XX 18-APR-2003; 2003US-0463708P.

XX 18-APR-2003; 2003US-0463716P.

XX 18-APR-2003; 2003US-0463732P.

1 ATGGCGGGC GTGGTGGG CGGCTGTG GTGTGGTGG CGGCGGCAC  
51 CTGTCTGAC GCTGGCGCC TGGCCCGGC AGACTGCTGG CTGATCGAGG  
101 GCGACAAGG CTTGTGTGG CTGGCCATCT GCAGCCAGAA CCAACCCCC  
151 TACGAGGCCA TCCACAGCA GATCAACAGC ACCATGTTGG ACCTCGGCT  
201 CAACGAGAAC CGTATCCGA CGGTGCAGTA CGCCTCGTC AGCCCTTTG  
251 GCAACTCAC GTACCTCAAC CTCACCAAGA ACGAGATCGG CTATATCGAG  
301 GACGGCGCT TCTGGGCCA GTTCAACCTG CAGGTGCTGC AGCTGGGCTA  
351 CAACCGGCTG CGCAACCTCA CGGAGGCGAT GCTGCGCGG CTGGCAAGC  
401 TGGAGTACCT GTACCTGCAG GCCAACCTCA TCGAGGTGGT CATGGCCAGC  
451 AGTTTCTGG AGTGTCCAA CATGCTCAAC ATCGACCTGT CCATGAACCG  
501 CATCCAGCAG CTCACAGCG GCACCTTCGC CGGCTTGGCC AAGTGTGCG  
551 TGTGCGAGCT CTACAGCAAC CCTTCTACT GCTCTTGGGA GCTGCTGGC  
601 TTCCTGCGT GGCTGGCGC CTTTACCAC GGCACACAGA CGTAGCACG  
651 CATGCAGTGC GAGTCGCGG CCGTCTACT CCGCTACTAC CTCTGGGCC  
701 AGGGCCGCG CGGCCACCG AGCATCTCA GCAAACTGCA GTCAGTCTGC  
751 ACCGAGGACT CGTACGGCG TGAGGTGGTC GGGCCCCCAG GTCCAGCATC  
801 CGGGCGCTCA CAGCGGGCC GCTCCCGCC GCCCGCGCT CGCGGGAGC  
851 CCAGTGACAT GCCCTGTGCC GATGATGAGT GCTTCTCCG GAGCGCAC  
901 AGCCACTGG TGGCCCTGCC CACGCTGGC ACGCAGGCG AGGCCGGCC  
951 CCTATCAAG GTCAGCAGC TCACCTAGAA CTCGGCCACC ATCACGTC  
1001 AGTCCCCAG CCCGTTCCAC CGGATGTACA CCTCGAGCA TTCAACAAC  
1051 AGCAGGCGT CCACGCTGC CAGGCTGACC AAGGCCCAG AGGATCCG  
1101 TCTGACCAAC CTGTTACGC TCACCAACTA CACCTACTGC GTGGTGTCA  
1151 CCAGCGCGG GCTGCGCAC AACACACCT GCCTCACCAT CTGCTTGCC  
1201 CGGCTGCCA GCCCGCTGG TCCGTTGCC AGCCCTCCA CGGCCACCA  
1251 CTACATCATG ACCATCTGG GTCGCTCTT CGGCATGGTG CTGTTGTGG  
1301 GCGCGTCTA CTACTGCTG CGCAGCGGC GCGCCAGGA GGAGAAGCAC  
1351 AAGAAGCGC CCTCGGAGC CGCAGTGGC AGCTCAAGA AGACCATCAT  
1401 CGAGTCAAG TACGGGCCAG AGCTGAGGC GCCCGGCTGT GCCCGCTGT  
1451 CCCAGGCGC GCTGCTGGC CCGAGGCGG TGACGCGCAT CCTTTACTG  
1501 CCTGGGCGG CGCAGGTGGA CAGTACAAG CTGGTGGAGA GCGCGGACAC  
1551 CCCAAGGCC AGCAAGGCA GTTACATGGA GGTTCGAACC GGGGACCTC  
1601 CGGAACGAG GGACTGTGAG CTGGGCGGC CGGGCCCCGA CAGCAGAGT  
1651 TCGTGGCGG AGATCTCCAC CATCGCCAAG GAGGTGGACA AGTCAACCA  
1701 GATCATCAAC AACTGCATCG ACGCGTCAA GTCCGAGTCC ACTTCCTTC  
1751 AGGGCGTCAA GTCGGGGCC GTGTGGTGG CCGAGCCGCC GCTGGTGTG  
1801 CTGTCCGAGC CGTGGGCGC CAAGCAGGC TTCCTGGCGC CCGGGTACAA

1851 GGACGCTTC GGCACAGCC TGCAGCGGA CCACAGCGTG GAGGCGCGG  
1901 GGCCCCCTCG TGCAGCACC TCGTCCAGCG GCTCCGTGCG CAGCCCCCGC  
1951 GCTTCCGAG CCGAGGCGT CGGGGTGCAC AAGGCGCGG CCGCGAGGC  
2001 CAAGTACATC GAGAAGGGCT CCCCCGGGC CGACGCCATC CTCACTGTA  
2051 CACCCGCGC CGCGTGTCTG CCGGCCGAGG CCGAGAAAGG TCGCCAGTAC  
2101 GCGCAGCACC GGCACCTGTA CCCCCTCTCC CACCGCGCG AGCCACCTGC  
2151 GCCCCCCGG CCACCGCGC CGCCTCGGA CGAGGCGCTG GGGCGCAAGG  
2201 CGTCCATCT GGAGCCATC ACCCGCGCG GCCCGCGGA CCTGCTTAC  
2251 TCGCAGCTGT CCGCGCAGTA CCACAGCTG AGTACTCTT CCAGCCCCGA  
2301 GTACACCTGC CGGCTTCCC AGAGCATCTG GGAGCGCTTC AGACTGAGCC  
2351 GCCGCGGCA CAAGGAGGAA GAGGAGTTCA TGGCCGCGG CCATGCCCCG  
2401 CGAAGAAGG TTCAGTTGCG CAAAGACGAG GATCTGCAG CATCTCTGA  
2451 CTACTGGAAG GCGGTGTCG CCCAGCACAA GTCCTGA

## !!AA SEQUENCE 1.0

ID ADP30645 standard; protein; 249 AA.

XX AC ADP30645;  
XX DT XX

XX 12-AUG-2004 (first entry)

XX Human secreted protein SEQ ID #1412.

XX Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
XX cancer; inflammatory; immune; human secreted protein.

XX Homo sapiens.

XX WO2004035732-A2.

XX 29-APR-2004.

XX 28-AUG-2003; 2003WO-US026780.

XX 29-AUG-2002; 2002US-0406576P.

XX 29-AUG-2002; 2002US-0406579P.

XX 29-AUG-2002; 2002US-0406585P.

XX 29-AUG-2002; 2002US-0406588P.

XX 29-AUG-2002; 2002US-0406608P.

XX 29-AUG-2002; 2002US-0406611P.

XX 29-AUG-2002; 2002US-0406612P.

XX 29-AUG-2002; 2002US-0406616P.

XX 29-AUG-2002; 2002US-0406640P.

XX 29-AUG-2002; 2002US-0406642P.

XX 29-AUG-2002; 2002US-0406646P.

XX 29-AUG-2002; 2002US-0406653P.

XX 29-AUG-2002; 2002US-0406655P.

XX 17-SEP-2002; 2002US-0410946P.

XX 17-SEP-2002; 2002US-0410947P.

XX 17-SEP-2002; 2002US-0410948P.

XX 17-SEP-2002; 2002US-0410949P.

XX 17-SEP-2002; 2002US-0410953P.

XX 17-SEP-2002; 2002US-0410957P.

XX 17-SEP-2002; 2002US-0410958P.

XX 17-SEP-2002; 2002US-0410959P.

XX 17-SEP-2002; 2002US-0410960P.

XX 17-SEP-2002; 2002US-0410961P.

XX 17-SEP-2002; 2002US-0410962P.

XX 17-SEP-2002; 2002US-0411019P.

PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX Claim 1; SEQ ID NO 2607; 428pp; English.  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX Sequence 279 AA;  
SQ  
ADP30609 Length: 279 February 22, 2005 12:25 Type: P Check: 269 ..  
1 ATGCGAGACC TCGCGCTCG GCACCGCCA CGTGCAAGT GTCCTGGTG  
51 GACGGCTTCT CCCAGCCCTA CTTGCGGCTC CTTGAGGGG CACCGGCCA  
101 GCGCCAGGCC GACTCGCTCA CCGTCTACTT GGTGGTGGG TTGGCTCGG  
151 TGTCTTCGCT CTTCCTCTTC TCGTGCTCC TGTTCGTGGC GTGCGGCTG  
201 TGCAGGAGGA GCAGGGCGGC CTCGGTGGGA AGCTGCTCGG TGCCTAAGG  
251 CCCCTTTCCA GGGCATCTGG TGGACGTGA  
!!AA SEQUENCE 1.0  
ID ADP30621 standard; protein; 2487 AA.  
XX  
AC ADP30621;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1388.  
XX  
DE Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
KW  
XX Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX  
XX 29-AUG-2002; 2002US-0406579P.  
XX  
XX 29-AUG-2002; 2002US-0406585P.  
XX  
XX 29-AUG-2002; 2002US-0406588P.  
XX  
XX 29-AUG-2002; 2002US-0406608P.  
XX  
XX 29-AUG-2002; 2002US-0406611P.  
XX  
XX 29-AUG-2002; 2002US-0406612P.  
XX  
XX 29-AUG-2002; 2002US-0406616P.  
XX  
XX 29-AUG-2002; 2002US-0406640P.  
XX  
XX 29-AUG-2002; 2002US-0406642P.  
XX  
XX 29-AUG-2002; 2002US-0406646P.  
XX  
XX 29-AUG-2002; 2002US-0406653P.  
XX  
XX 29-AUG-2002; 2002US-0406655P.  
XX  
XX 29-AUG-2002; 2002US-0406666P.  
XX  
XX 17-SEP-2002; 2002US-0410946P.  
XX  
XX 17-SEP-2002; 2002US-0410947P.  
XX  
XX 17-SEP-2002; 2002US-0410948P.  
XX  
XX 17-SEP-2002; 2002US-0410949P.  
XX  
XX 17-SEP-2002; 2002US-0410953P.  
XX  
XX 17-SEP-2002; 2002US-0410957P.  
XX  
XX 17-SEP-2002; 2002US-0410958P.  
XX  
XX 17-SEP-2002; 2002US-0410959P.  
XX  
XX 17-SEP-2002; 2002US-0410960P.

17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411025P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411046P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411010P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
18-APR-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
02-MAY-2003; 2003US-0467230P.  
19-MAY-2003; 2003US-0471306P.  
19-MAY-2003; 2003US-0471336P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493573P.  
08-AUG-2003; 2003US-0493577P.  
(FIVE-) FIVE PRIME THERAPEUTICS INC.  
Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang MM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
WPI; 2004-348438/32.  
New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.  
Claim 1; SEQ ID NO 2619; 428pp; English.  
The present invention relates to an isolated nucleic acid molecule  
encoding a polypeptide which is believed to be cytostatic,  
antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
composition and methods are useful for diagnosing, preventing and  
treating diseases such as proliferative (e.g. cancer), inflammatory,  
immune, metabolic, genetic, bacterial and viral diseases. The present  
sequence represents a human secreted protein. The present sequence is  
available on WIPOWEB and is not in the specification.  
Sequence 2487 AA;  
SQ

ADP30621 Length: 2487 February 22, 2005 12:25 Type: P Check: 6670 ..

351 CTTTTCTTTG TTTATTAGTG CTTTGCCTGC CTTCCCAATT AGAGTAGAGA  
401 ATCCCAAAGG CTTCAAGGAA GGGGCATTGG AACTGGGCTT GGACAGCACA  
451 CACAGACATG CTTGTTCCCT GCTAGATAAA CTCACAGAGAC ACATGGAGGA  
501 GCAAGGAGAG GGCCCAACGC AGCTCAGGGG CAGCTGGCAG CTTACATGGG  
551 GTCTCTGGGA CAGCAGCCAC TCTCTTGAC AGTGTCGCAC AGATTTGAAA  
601 ATCCAGTGTC TGCCAGCAGG AGAGCTGACT GGATTTTTTCT CTCCTCCTGC  
651 CTCCTGTATC TCCTACCAGG AGGTGCCAGG GCTGGATTCC CCTGGTCTTA  
701 ACTGCTCTC AGGAGCCCTC ACTGGTGCAAT TTCTCTGGTT TCCGTTCCCC  
751 GTTTTAGCCT CTGCTCAGCA GGCCACTGGG CTTGTCACTG GCCATCTTGG  
801 CAGTCATCCT TGTGACTTTT CTTCCCCAGA CCCCCTAAGA TCTGCCCTGA  
851 TTCAACCACT TCCTTCTCTG ATTTCTGTCT CAGTGAAGAG CATCACCAAG  
901 GACCCAGTGG TGGCCAAGCA AAGCCTCCAA GAAATATGGG ACTATGTGAA  
951 AAGACCAAT CTACGCTCTGA TTGCTGTATC TGAAGTGTAT GGGGAGATG  
1001 GAACCAAGTT GGAAGACT CTGCAGGATA TTATCCAGGA GAATTCCTCC  
1051 AATCTAGCAA GGCAGGCCAA CGTTTCAGATT CAGGAAATAC AGAGAACGCC  
1101 ACAAGAGATC TCCTCGAGAA GAGCAACTCC AAGACACATA ATTGTCAAGT  
1151 TCACCAAGT TGAATGNAAC GAAAAATGT TAAGGCAGC CAGAGAGAAA  
1201 GGTGGGGTTA CCTCAAAGG GAAGCCCATC AGACTAACAG CAGATCTCTC  
1251 GGCAGAAACC CTACAAGCCA GAAGAGAGTG GGGGCCAATA TTCAACATTC  
1301 TTAAGAGAAA GAATTTTCAA CCAGAAATTT CATATCCAGC CAAACTAAGC  
1351 TTCATAAGTG AAGGAGAAAT AAAATACTTT ACAGACAAGC AAATGCTGAG  
1401 AGATTTTCTC ACCACCAGC CTCCTTTACA AGAGCTCCTG AAGGAAGCAC  
1451 TAAACATGGA AAGAACNAAC CGGTACCAGC CACTGCMAAA TCATGCCMAA  
1501 ATGTAA

!!AA SEQUENCE 1.0  
ID \_ADP30609 standard; protein; 279 AA.

AC ADP30609;

XX DT 12-AUG-2004 (first entry)

XX DE Human secreted protein SEQ ID #1376.

XX KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.

XX OS Homo sapiens.

XX PN WO2004035732-A2.

XX PD 29-APR-2004.

XX PF 28-AUG-2003; 2003WO-US026780.

XX PR 29-AUG-2002; 2002US-0406576P.

XX PR 29-AUG-2002; 2002US-0406579P.

XX PR 29-AUG-2002; 2002US-0406585P.

XX PR 29-AUG-2002; 2002US-0406588P.

29-AUG-2002; 2002US-0406611P.  
29-AUG-2002; 2002US-0406612P.  
29-AUG-2002; 2002US-0406616P.  
29-AUG-2002; 2002US-0406640P.  
29-AUG-2002; 2002US-0406642P.  
29-AUG-2002; 2002US-0406646P.  
29-AUG-2002; 2002US-0406653P.  
29-AUG-2002; 2002US-0406655P.  
29-AUG-2002; 2002US-0406666P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410947P.  
17-SEP-2002; 2002US-0410948P.  
17-SEP-2002; 2002US-0410953P.  
17-SEP-2002; 2002US-0410957P.  
17-SEP-2002; 2002US-0410958P.  
17-SEP-2002; 2002US-0410959P.  
17-SEP-2002; 2002US-0410960P.  
17-SEP-2002; 2002US-0410961P.  
17-SEP-2002; 2002US-0410962P.  
17-SEP-2002; 2002US-0411019P.  
17-SEP-2002; 2002US-0411022P.  
17-SEP-2002; 2002US-0411023P.  
17-SEP-2002; 2002US-0411024P.  
17-SEP-2002; 2002US-0411032P.  
17-SEP-2002; 2002US-0411035P.  
17-SEP-2002; 2002US-0411037P.  
17-SEP-2002; 2002US-0411041P.  
17-SEP-2002; 2002US-0411045P.  
17-SEP-2002; 2002US-0411048P.  
17-SEP-2002; 2002US-0411052P.  
17-SEP-2002; 2002US-0411055P.  
17-SEP-2002; 2002US-0411073P.  
17-SEP-2002; 2002US-0411082P.  
17-SEP-2002; 2002US-0411101P.  
17-SEP-2002; 2002US-0411111P.  
18-APR-2003; 2003US-0463700P.  
18-APR-2003; 2003US-0463708P.  
18-APR-2003; 2003US-0463716P.  
02-MAY-2003; 2003US-0463732P.  
02-MAY-2003; 2003US-0467199P.  
02-MAY-2003; 2003US-0467201P.  
02-MAY-2003; 2003US-0467203P.  
19-MAY-2003; 2003US-0471306P.  
22-MAY-2003; 2003US-0472420P.  
22-MAY-2003; 2003US-0472430P.  
09-JUN-2003; 2003US-0476609P.  
09-JUN-2003; 2003US-0476641P.  
08-JUL-2003; 2003US-0485218P.  
08-JUL-2003; 2003US-0485223P.  
08-JUL-2003; 2003US-0485224P.  
14-JUL-2003; 2003US-0485325P.  
14-JUL-2003; 2003US-0486446P.  
14-JUL-2003; 2003US-0486480P.  
15-JUL-2003; 2003US-0486891P.  
15-JUL-2003; 2003US-0486960P.  
08-AUG-2003; 2003US-0493341P.  
08-AUG-2003; 2003US-0493370P.  
08-AUG-2003; 2003US-0493373P.  
08-AUG-2003; 2003US-0493377P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Heestir K, Beaurang PA, Behrens D;

Halenbeck RE, Huang MM, Kothakota S, Haishan L, Linnemann T;

Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases

351 GGTGCTGGAG AGCGTGCCCC GTATCGTGAA GGTGACGCTC CTGCGATATC  
401 TGAAGCGGCT CCCAGTCCCT GAAGCAATTA CCGGGTTTCG TAGGCTCACA  
451 GAATGGCTTC GGTATATGCC TTTCCTTGGT GTACTCGAC TTCTTGGCTA  
501 CTTTGCAGTT CGTCCATCC TCCCGAAGAA GAAACAACAG AAGGATAGCT  
551 TGATTAATCT TAAATACAA AAGGAAATC CGAAGTAGT GAATGAAATA  
601 AACATTGAAG ATTGTGTCT TACTAAAGCA GCTTATTGTA GGTGTTGGCG  
651 TTCTAAACG TTTCCTGCTT CGGATGGTTC ACATAATAAA CACAATGAAT  
701 TGACAGGAGA TAATGTGGT CCACATAATC TGAAGAAGAA AGAAGTATTA  
!!AA SEQUENCE 1.0  
ID\_\_ADP30596 standard; protein; 1506 AA.  
XX  
AC ADP30596;  
DT  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1363.  
XX  
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035732-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 28-AUG-2003; 2003WO-US026780.  
XX  
PR 29-AUG-2002; 2002US-0406576P.  
PR 29-AUG-2002; 2002US-0406579P.  
PR 29-AUG-2002; 2002US-0406585P.  
PR 29-AUG-2002; 2002US-0406588P.  
PR 29-AUG-2002; 2002US-0406589P.  
PR 29-AUG-2002; 2002US-0406611P.  
PR 29-AUG-2002; 2002US-0406612P.  
PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411022P.  
PR 17-SEP-2002; 2002US-0411023P.  
PR 17-SEP-2002; 2002US-0411024P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.

PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0467199P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476099P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.  
XX  
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.  
XX  
XX Williams LT, Chu K, Lee E, Hestir K, Beurang PA, Behrens D;  
PI Halenbeck RP, Huang MM, Kothakota S, Haishan L, Linnemann T;  
PI Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;  
XX  
XX WPI; 2004-348438/32.  
XX  
XX New nucleic acid molecule for diagnosing, preventing or treating diseases  
PT such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
PT genetic, bacterial and viral diseases.  
XX  
XX Claim 1; SEQ ID NO 2594; 428pp; English.  
XX  
XX The present invention relates to an isolated nucleic acid molecule  
CC encoding a polypeptide which is believed to be cytostatic,  
CC antiinflammatory, immunosuppressive, antibacterial and virucidal. The  
CC composition and methods are useful for diagnosing, preventing and  
CC treating diseases such as proliferative (e.g. cancer), inflammatory,  
CC immune, metabolic, genetic, bacterial and viral diseases. The present  
CC sequence represents a human secreted protein. The present sequence is  
CC available on WIPOWEB and is not in the specification.  
XX  
XX Sequence 1506 AA;  
ADP30596 Length: 1506 February 22, 2005 12:25 Type: P Check: 4549 ..  
1 ATGGCTCGCG CTTTAAATCC CAGCGCTTTG GGAGGTGCGAG GCGGGCGGTC  
51 ACGAGTCTCT CGTCCACCA GACGAGAAAC ACCACAGCT AGGCCCTTCT  
101 GCTTCTGCTC TGGGGGAGTC TGCAGGGGTA GAAAGAGGCA GAATCTCTCC  
151 CTCTGGGGGA AGGTTACAG AGAGAAGCT TTGAGAAATC AGAACCCTGAA  
201 AATCAAGTTC AAGAATTCCT TGGCTCTGCT CAAACGCCTC CTTTGGGGAG  
251 AGGCTTCTG GCTGGCTAC CTGAAGGTGT ACCCTGCCTC CATGATTATG  
301 CTGTGTACA TCATCATGAC TATTTCTTTC CTCACACTTA TCGTGTCTGTA

```
CC available on WIPoWEB and is not in the specification.
XX
SQ Sequence 207 AA;
ADP30551 Length: 207 February 22, 2005 12:25 Type: P Check: 2445 ..
1 CGGCGAAGTG CGAGCATGAT CGTCATTACC TCCATCCTCT CTTCCTCTGGC
51 CGGCTCCTCTA CTCTGGGCT TCTTGGCAGC CTTTACCATG CGCTTCTCCA
101 GCGTGTGGTG GCCGGAGGAG GCCCGGAGC AGCTGGGGAT CGGCTCTCTTC
151 ATGGGCAAGC GCTACATGAC CCACCACATC CCACCCAGAG AGGCGGCCAC
201 ACTGGCG

!!AA SEQUENCE 1.0
ID ADP30576 standard; protein; 750 AA.
XX
AC ADP30576;
XX
DT 12-AUG-2004 (first entry)
XX
DE Human secreted protein SEQ ID #1343.
XX
KW Cytostatic; Antiinflammatory; Immunosuppressive; Antibacterial; Virucide;
KW cancer; inflammatory; immune; human secreted protein.
XX
OS Homo sapiens.
XX
PN WO2004035732-A2.
XX
PD 29-APR-2004.
XX
PF 28-AUG-2003; 2003WO-US026780.
XX
PR 29-AUG-2002; 2002US-0406576P.
PR 29-AUG-2002; 2002US-0406579P.
PR 29-AUG-2002; 2002US-0406585P.
PR 29-AUG-2002; 2002US-0406588P.
PR 29-AUG-2002; 2002US-0406608P.
PR 29-AUG-2002; 2002US-0406611P.
PR 29-AUG-2002; 2002US-0406612P.
PR 29-AUG-2002; 2002US-0406616P.
PR 29-AUG-2002; 2002US-0406640P.
PR 29-AUG-2002; 2002US-0406642P.
PR 29-AUG-2002; 2002US-0406646P.
PR 29-AUG-2002; 2002US-0406653P.
PR 29-AUG-2002; 2002US-0406655P.
PR 29-AUG-2002; 2002US-0406666P.
PR 17-SEP-2002; 2002US-0410946P.
PR 17-SEP-2002; 2002US-0410947P.
PR 17-SEP-2002; 2002US-0410948P.
PR 17-SEP-2002; 2002US-0410949P.
PR 17-SEP-2002; 2002US-0410953P.
PR 17-SEP-2002; 2002US-0410957P.
PR 17-SEP-2002; 2002US-0410958P.
PR 17-SEP-2002; 2002US-0410959P.
PR 17-SEP-2002; 2002US-0410960P.
PR 17-SEP-2002; 2002US-0410961P.
PR 17-SEP-2002; 2002US-0410962P.
PR 17-SEP-2002; 2002US-0411019P.
PR 17-SEP-2002; 2002US-0411022P.
PR 17-SEP-2002; 2002US-0411023P.
PR 17-SEP-2002; 2002US-0411024P.
PR 17-SEP-2002; 2002US-0411032P.
PR 17-SEP-2002; 2002US-0411035P.
PR 17-SEP-2002; 2002US-0411037P.
PR 17-SEP-2002; 2002US-0411041P.
PR 17-SEP-2002; 2002US-0411045P.
PR 17-SEP-2002; 2002US-0411046P.
PR 17-SEP-2002; 2002US-0411048P.
PR 17-SEP-2002; 2002US-0411052P.

PR 17-SEP-2002; 2002US-0411055P.
PR 17-SEP-2002; 2002US-0411073P.
PR 17-SEP-2002; 2002US-0411082P.
PR 17-SEP-2002; 2002US-0411101P.
PR 17-SEP-2002; 2002US-0411111P.
PR 18-APR-2003; 2003US-0463700P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 18-APR-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467230P.
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 08-JUL-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 14-JUL-2003; 2003US-0486446P.
PR 15-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
XX (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
XX Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
XX Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;
XX Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;
XX WPI; 2004-348438/32.
XX
XX New nucleic acid molecule for diagnosing, preventing or treating diseases
XX such as proliferative (e.g. cancer), inflammatory, immune, metabolic,
XX genetic, bacterial and viral diseases.
XX
XX Claim 1; SEQ ID NO 2574; 428pp; English.
XX
XX The present invention relates to an isolated nucleic acid molecule
XX encoding a polypeptide which is believed to be cytostatic,
XX antiinflammatory, immunosuppressive, antibacterial and virucidal. The
XX composition and methods are useful for diagnosing, preventing and
XX treating diseases such as proliferative (e.g. cancer), inflammatory,
XX immune, metabolic, genetic, bacterial and viral diseases. The present
XX sequence represents a human secreted protein. The present sequence is
XX available on WIPoWEB and is not in the specification.
XX
SQ Sequence 750 AA;
ADP30576 Length: 750 February 22, 2005 12:25 Type: P Check: 1842 ..
1 ATGTCCGCTC TGACGGNACT ACTGCCAGCT GCCAGCTCC GCCCTCCCC
51 CTCCTCTCTGC CTCTTCACCG CCGCGGATCA GTCCGCCAAC GCCGCCGTCC
101 CGAGCACAGG ACCGATTATC CTTTCTGCTG GTCTCCAGCA TCTACAGACG
151 TTAAAGGCC AACAGGAGGG CCACCTTCAC ACGAGATTCC GAGGAGGGCC
201 TCGTATACCG CAGATTCCCG CGCCTCGGCA GTCCGCCCGC AGCCCGCAGG
251 CCGCCAGTGC CCGCCGCGCG CTTCCGCTCC CGGCGCAGGC GCTGCAGCTT
301 GGCCAGAGCG GAGGGGGCTC GGGAGAGGAG TGGACGCCGC TGGCCAGGAT
```





PT surveying tissues.  
XX Claim 45; SEQ ID NO 33022; 80pp; English.  
XX  
CC The invention relates to a nucleic acid probe for measuring human gene  
CC expression, comprising any of the 27,400 fully defined nucleotide  
CC sequences in the specification, or their complements or fragments, and  
CC encoding at least 8 amino acids of any of the 6888 amino acid sequences  
CC fully defined in the specification. The probe is a single exon probe that  
CC hybridises under high stringency conditions to a nucleic acid molecule  
CC expressed in human cells or tissues. Also included are a spatially-  
CC addressable set of single exon nucleic acid probes for measuring human  
CC gene expression (comprising a plurality of single exon nucleic acid  
CC probes cited above, where each of the plurality of probes is separately  
CC and addressable or amplifiable from the plurality), a single  
CC exon microarray for measuring human gene expression, a method of  
CC measuring human gene expression, a vector comprising the single exon  
CC probe cited above, an ORF-encoded peptide comprising at least 8  
CC contiguous amino acids of any of the above-mentioned amino acid  
CC sequences (optionally with conservative amino acid substitutions), an  
CC isolated antibody that binds specifically to a peptide cited above,  
CC methods of selling and/or licensing single exon probes or microarrays to  
CC a customer desiring to measure gene expression, a method of providing  
CC human gene expression data by subsequence, and a computer-readable  
CC storage medium which contains a database having a plurality of records  
CC (each record including data on the expression of a single exon probe  
CC cited above. The probe, methods and apparatus are useful in gene  
CC expression analysis. The probes may be used as tools for surveying  
CC tissues to detect the presence of expressed messages that contain their  
CC specific exon, or in constructing genome-derived single exon microarrays.  
CC In addition, the probes are used in identifying and characterising  
CC alternative splicing events, in detecting and characterising gross  
CC alterations in the genomic locus that includes their exon, in assessing  
CC smaller genomic alterations, in priming the synthesis of nucleic acids,  
CC or in expressing the ORF-encoded peptide. The present sequence is a human  
CC single exon probe protein of the invention. Note: The sequence data for  
CC this patent did not form part of the invention. Note: The sequence data for  
CC obtained in electronic format directly from USPTO at  
CC seqdata.uspto.gov/sequence.html?docID=20030194704  
XX  
SQ Sequence 47 AA;  
ABO59388 Length: 47 February 22, 2005 12:25 Type: P Check: 7388 ..  
1 ALKNWYCC CCCYCCYCC CCCCCCCC CCCCCCCCCC CCCCCC  
!!AA SEQUENCE 1.0  
ID ADP30550 standard; protein; 483 AA.  
XX  
AC ADP30550;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Human secreted protein SEQ ID #1317.  
XX  
KW Cytostatic; Antinflammatory; Immunosuppressive; Antibacterial; Virucide;  
KW cancer; inflammatory; immune; human secreted protein.  
XX  
OS Homo sapiens.  
XX  
XX WO2004035732-A2.  
XX  
XX 29-APR-2004.  
XX  
XX 28-AUG-2003; 2003WO-US026780.  
XX  
XX 29-AUG-2002; 2002US-0406576P.  
XX  
XX 29-AUG-2002; 2002US-0406579P.  
XX  
XX 29-AUG-2002; 2002US-0406585P.  
XX  
XX 29-AUG-2002; 2002US-0406588P.  
XX  
XX 29-AUG-2002; 2002US-0406608P.  
XX  
XX 29-AUG-2002; 2002US-0406611P.  
XX  
XX 29-AUG-2002; 2002US-0406612P.

PR 29-AUG-2002; 2002US-0406616P.  
PR 29-AUG-2002; 2002US-0406640P.  
PR 29-AUG-2002; 2002US-0406642P.  
PR 29-AUG-2002; 2002US-0406646P.  
PR 29-AUG-2002; 2002US-0406653P.  
PR 29-AUG-2002; 2002US-0406655P.  
PR 29-AUG-2002; 2002US-0406666P.  
PR 17-SEP-2002; 2002US-0410946P.  
PR 17-SEP-2002; 2002US-0410947P.  
PR 17-SEP-2002; 2002US-0410948P.  
PR 17-SEP-2002; 2002US-0410949P.  
PR 17-SEP-2002; 2002US-0410953P.  
PR 17-SEP-2002; 2002US-0410957P.  
PR 17-SEP-2002; 2002US-0410958P.  
PR 17-SEP-2002; 2002US-0410959P.  
PR 17-SEP-2002; 2002US-0410960P.  
PR 17-SEP-2002; 2002US-0410961P.  
PR 17-SEP-2002; 2002US-0410962P.  
PR 17-SEP-2002; 2002US-0411019P.  
PR 17-SEP-2002; 2002US-0411032P.  
PR 17-SEP-2002; 2002US-0411033P.  
PR 17-SEP-2002; 2002US-0411035P.  
PR 17-SEP-2002; 2002US-0411037P.  
PR 17-SEP-2002; 2002US-0411041P.  
PR 17-SEP-2002; 2002US-0411045P.  
PR 17-SEP-2002; 2002US-0411046P.  
PR 17-SEP-2002; 2002US-0411048P.  
PR 17-SEP-2002; 2002US-0411052P.  
PR 17-SEP-2002; 2002US-0411055P.  
PR 17-SEP-2002; 2002US-0411073P.  
PR 17-SEP-2002; 2002US-0411082P.  
PR 17-SEP-2002; 2002US-0411101P.  
PR 17-SEP-2002; 2002US-0411111P.  
PR 18-APR-2003; 2003US-0463700P.  
PR 18-APR-2003; 2003US-0463708P.  
PR 18-APR-2003; 2003US-0463716P.  
PR 18-APR-2003; 2003US-0463732P.  
PR 02-MAY-2003; 2003US-0463719P.  
PR 02-MAY-2003; 2003US-0467201P.  
PR 02-MAY-2003; 2003US-0467203P.  
PR 02-MAY-2003; 2003US-0467230P.  
PR 19-MAY-2003; 2003US-0471306P.  
PR 19-MAY-2003; 2003US-0471336P.  
PR 22-MAY-2003; 2003US-0472420P.  
PR 22-MAY-2003; 2003US-0472430P.  
PR 09-JUN-2003; 2003US-0476609P.  
PR 09-JUN-2003; 2003US-0476641P.  
PR 08-JUL-2003; 2003US-0485218P.  
PR 08-JUL-2003; 2003US-0485223P.  
PR 08-JUL-2003; 2003US-0485224P.  
PR 08-JUL-2003; 2003US-0485325P.  
PR 14-JUL-2003; 2003US-0486446P.  
PR 14-JUL-2003; 2003US-0486480P.  
PR 15-JUL-2003; 2003US-0486891P.  
PR 15-JUL-2003; 2003US-0486960P.  
PR 08-AUG-2003; 2003US-0493341P.  
PR 08-AUG-2003; 2003US-0493370P.  
PR 08-AUG-2003; 2003US-0493573P.  
PR 08-AUG-2003; 2003US-0493577P.

(FIVE-) FIVE PRIME THERAPEUTICS INC.

Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;  
Halenbeck RF, Huang WM, Kothakota S, Haishan L, Linnemann T;  
Pierce K, Wang Y, Wong JGP, Wu G, Zhang H;

WPI; 2004-348438/32.

New nucleic acid molecule for diagnosing, preventing or treating diseases  
such as proliferative (e.g. cancer), inflammatory, immune, metabolic,  
genetic, bacterial and viral diseases.

```
XX
SQ      Sequence 2688 AA;
ADN11593 Length: 2688   February 22, 2005 12:25   Type: P   Check: 9787   ..
1  ATGCTGACCC CGCGGTGCT CCGTGTGTC CCCCTGTCTT CAGCTTGCT
51  CGCGCGGCT ATCGAGCCC CTAAGACTTG CAGCCCCAAG CAGTTTGCCT
101 GCAGAGATCA AATAACTGT ATCTCAAGG GCTGGCGTG CGACGGTGAG
151 AGGACTGCC CAGACGGATC TGACGAGCC CCTGAGATT GTCCACAGAG
201 TAAGCCQAG CGATGCCAGC CAAACGAGCA TAACTGCTG GGTACTGAGC
251 TGTGTGTCC CATGTCCCG CTCTGCAATG GGGTCCAGGA CTGCATGGAC
301 GGTTCAGATG AGGGGCCCCA CTGCGAGAG CTCCAAGGCA ACTGTCTCTG
351 CTTGGGCTGC CAGCACCAAT GTGTCCCCAC ACTCGATGGG CCCACCTGCT
401 ACTGCAACAG CAGCTTTCAG CTTTCAGCAG ATGCCAAGAC CTGCAAGAT
451 TTTGATGAGT GCTCAGTGA CCGCACCTGC AGCCAGCTAT GCACCAACAC
501 AGACGGCTCC TTCATATGTG GCTGTGTTGA AGGATACCTC CTGCAGCCGG
551 ATAACCGCTC CTGCAAGGCC AGAAGCAGC CAGTAGACCG GCCCCTGTG
601 CTGTTGATAG CCAACTTCCA GAACATCTTG GCCACGTACC TGAGTGGGGC
651 CCAGGTGTCT ACCATCACAC CTACGAGCAC CGCGCAGACC ACAGCCATGG
701 ACTTCAGCTA TGCCACAGAG ACCGTATGCT GGGTGCATGT TGGGGACAGT
751 GCTGCTCAGA CGCAGCTCAA GTGTGCCCGC ATGCTCTGCC TAAAGGCTT
801 CGTGGATGAG CACACCATCA ACATCTCCTC CAGTCTGCAC CAGCTGGAAC
851 AGATGGCCAT CGACTGGCTG ACAGGCAACT TCTACTTTGT GGTATGATC
901 GATGATAGGA TCTTTGTCTG CAACAGAAAT GGGGACACAT GTGTCAATT
951 GCTAGACCTG GAACTCTACA ACCCCAAAGG CATTGCCCTG GACCTGCCA
1001 TGGGAAGGT GTTTTCACT GACTATGGC AGATCCCAA GGTGGAAGC
1051 TGTGACATGG ATGGGCAGAA CCGCACCAAG CTCGTGCACA GCAAGATTGT
1101 GTTTCCTCAT GGCATCAGC TGGACCTGCT CAGCCGCTT GTCTACTGGG
1151 CAGATGCCTA TCTGGACTAT ATTGAAGTGG TGGACTATGA GGGCAAGGGC
1201 CGCCAGACCA TCATCCAGGG CATCTGTGAT GAGCACTGT ACGGCTGTAC
1251 TGTGTTTGGG AATTATCTCT ATGCCACCAA CTCGGACAAT GCCAATGCCC
1301 AGCAGAGAC GAGTGTGATC CGTGTGAACC GCTTTACAG CACCGAGTAC
1351 CAGGTTTCCA CCGGGTGA CAAGGGTGGT GCCCTCCACA TCTACCACCA
1401 GAGCGCTCAG CCCCAGTGA GGAGCCATGC CTGTGAAAC GACCAGTATG
1451 GGAAGCCGGG TGGCTCTCT GACATCTGCC TGCTGGCCAA CAGCCACAAG
1501 CGCGGACCT CGCGTGCAG TTCCGGCTTC AGCTGGGCA GTACCGGAA
1551 GTCATGCAAG AAGCCGAGC ATGAGTGT CTCTGTGTAT GGCAAGGGCC
1601 GGCAGGCAT CATCCGGGC ATGGATATGG GGGCCAAGGT CCCGGATGAG
1651 CACATGATCC CCATTGAAA CCTCATGAAC CCCCAGGCC TGGACTTCCA
```

```
1701 CGCTGAGACC GGCCTTCTCT ACTTTGCCGA CACCACCAGC TACCTCATTTG
1751 GCCGCCAGAA GATTGATGCG ACTGAGCGGG AGACCATCTT GAAGGACGGC
1801 ATCCACAATG TGGAGGTGT GGCCTGTGAC TGGATGGGAG ACATCTGTA
1851 CTGAGCGGAC GATGGGCCCA AAAAGACAAT CAGCGTGGCC AGGCTGGAGA
1901 AAGCTCTCA GACCCGCAAG ACTTTAATCG AGGGCAAAAT GACACACCCC
1951 AGGGCTATTG TGGTGGATCC ACTCAATGGG TGGATGTACT GGACAGACTG
2001 GGAGGAGGAC CCCAAGSACA GTGGCGCTGG GCGGCTGGAG AGGGCGTGA
2051 TGGATGGCTC ACACCGGAGC ATCTTTGTCA CTTCCAAGAC AGTGTCTTGG
2101 CCCAATGGGC TAAGCTTGA CATCCCGCTT GGGGGCTCT ACTGGGTGA
2151 TGCCTTCTAC GACCGCATCG AGACGATACT GCTCAATGGC ACAGACCGGA
2201 AGATTGTGTA TGAAGGTCTT GAGCTGAACC ACGCCTTTGG CCTGTGTCAC
2251 CATGGCAACT ACCTCTTCTG GACTGAGTAT CGGAGTGGCA GTGTCTACCG
2301 CTTGGAACGG GGTGAGGAG GCGCACCCCC CACTGTGACC CTTCTGCGCA
2351 GTGAGCGGCC CCCCATCTTT GAGATCCGAA TGTATGATGC CCAGCAGCAG
2401 CAAGTTGGCA CCAACAATG CCGGCTGAC ATGGCGGCT GCAGCAGCCT
2451 GTGCTTGGCC ACCCTTGGGA GCCGCCAGTG CGCCTGTGCT GAGGACCAAG
2501 TGTGTCAGCG AGACGGCTC ACTTGCTTGG CGAACCCATC CTACGTGCTT
2551 CCACCCAGT GCCAGCCAGG CGAGTTTGGC TGTGCCAACA GCGGCTGCAT
2601 CCAGGAGCGC TGGAAAGTGT ACGGAGACAA CGATTGCCTG GACACAGTG
2651 ATGAGGCCCC AGCCCTCTGC CATCAGCACA CCTGCCCC

!!AA_SEQUENCE 1.0
ID_ABO59388 standard; protein; 47 AA.
XX
AC ABO59388;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human genome derived single exon protein #5622.
XX
KW Human; gene expression; single exon probe; microarray;
KW alternative splicing event; genomic alteration.
XX
OS Homo sapiens.
XX
PN US2003194704-A1.
XX
PD 16-OCT-2003.
XX
PF 03-APR-2002; 2002US-00029386.
XX
PR 03-APR-2002; 2002US-00029386.
XX
PA (PENN/) PENN S G.
PA (RANK/) RANK D R.
PA (HANZ/) HANZEL D K.
XX
PI Penn SG, Rank DR, Hanzel DK;
XX
WPI; 2004-119264/12.
XX
New human genome-derived single exon nucleic acid probes useful for human
PT gene expression analysis, for identifying or characterizing alternative
PT splicing events, for assessing genomic alterations or as tools for
```

201 KI

!!AA\_SEQUENCE 1.0

ID ADN89765 standard; peptide; 1218 AA.

XX AC ADN89765;

XX DT 01-JUL-2004 (first entry)

XX DE Human 202P5A5v.1 protein epitope #1.

XX KW 202P5A5; human; cancer; tumour; epitope.

XX OS Homo sapiens.

XX PN WO2004016736-A2.

XX PD 26-FEB-2004.

XX PF 16-JUN-2003; 2003WO-US018906.

XX PR 16-AUG-2002; 2002US-0404306P.

XX PR 01-NOV-2002; 2002US-0423290P.

XX PA (AGEN-) AGENSYS INC.

XX PI Raitano AB, Paris M, Challita-Eid PM, Jakobovits A, Ge W;

XX DR WPI; 2004-203774/19.

XX PT New compositions having the 202P5A5 gene and encoded protein, useful for

XX PT diagnosing, preventing, prognosticating or treating cancer of the

XX PT prostate, bladder, colon, lung, ovary, breast, stomach, cervix, lymphoma,

XX PT bone and/or skin.

XX PS Claim 1; Fig 2A; 266pp; English.

XX OS The invention relates to a composition comprising 202P5A5 proteins. The

XX CC composition and proteins are useful for detecting and treating cancer by

XX CC inhibiting the growth or viability of cancer cells. The present sequence

XX CC represents the amino acid sequence of a human 202P5A5v.1 protein epitope.

XX CC Note the epitope sequences are displayed in tables VIII-XLIX.

XX SQ Sequence 1218 AA;

ADN89765 Length: 1218 February 22, 2005 12:25 Type: P Check: 9819 ..

1 MPSPDPFNTR RAYTSEDEAW KSYLENPLTA ATKAMMSING DEDSAAALGL

51 LYDYKVRPD KRLLSVSKAS CCCCCCCCCC CCCCCCHHH HHHHHHHH

101 HHHHHHCCC CHHHHHHHH HHHHHCCCC CBEEBECCC DSQBDQEKRN

151 CLGTSEAQSN LSGGENRVQV LKTVPVNLSL NQDHLENSKR EQYSISPPES

201 SAITPVSGIT CCCCCHHHH CCCCCCCCCC CCCCCCBE EEECCCCCEC

251 CCHHCCCCC CBEEBECCC CBEEBECCC VVKAEFTFPV FMAPPVHYPR

301 GDGEQRVVI FEQTQYDVPS LATHSAYLKD DQRSTPDSTY SESPKDAATE

351 EEECCCCCE ECCCCCCCC CCCCCBEE EEECCCCC CCCCCBEE

401 CCCCCCCCC CHHHHHHHH KFRASVGA EYMYDQTSSG TFQYTLBATK

451 SLRQKQSGP MTVLNKQGFY AITLSETGDN KCFRHPISKV HHHHHCCC

501 HHHHHCCCC CBEHHHHH HHHHHCCCC EEECCCCBEE EEECCCCC

551 CCCCCCCCC RSVMVMVFE DKNRDLQKY WKYHSRQHT AKQRLVDIAD

601 YKESPTIGN IEEIAYNAV FTDVNVNEAK EEEEBECCC CCCCCHHH

651 HHHCCCCCHC HHHHHHHH HHHHHCCCC HHHHHHHH CCCCCCCCC

701 IFITVNCIST DFSSQGVKG LPLMIQIDTY SYNNSNKPI HRAYCQIKVF

751 CDKGAERKIR DEERKQNRKK EEEEBECCC CCCCCCCCC CEEEBECCC

801 CCCCCCHHH HHHHHBEE HCCCCHHHH HHHHHHHHC GKQASQTQC

851 NSSDGLAA IPLOKSDIT YFTMPDLHS QPVLFPDVH FANLQRTQV

901 YYNTDDEREG CCCCCCCCC CCCCCCCEE CCCCCCCEE EEECCCCC

951 CCHHECCHH HCHHCCCEE EEECCCCCCC GSVLVKRMFR PMEEFPGVP

1001 SKQKKEGTK RVLLYRKET DDVFDALMLK SPTVKGLEMA ISEKYGLPVE

1051 CCHHHHHHC CCHHCCCC CHCHCCCC CHCHCCCC EEEEBECCC HHHHHHHHC

1101 CCHHHHHHH HHHCCCCCH KIADLYKSK KGILVNMDDN IIEHYSNEDT

1151 FILNMESMVE GFKVTLMBIH HHHHHHHCCC EEEEBCCCC EEECCCCCH

1201 BEHHHHHCC CEEEBECC

!!AA\_SEQUENCE 1.0

ID ADN11593 standard; protein; 2688 AA.

XX AC ADN11593;

XX DT 15-JUL-2004 (first entry)

XX DE Human CD91 protein fragment SEQ ID NO: 14.

XX KW antidiabetic; neuroprotective; antiinflammatory; dermatological;

XX KW immunosuppressive; anabolic; hypertensive; antibacterial; antiarthritic;

XX KW hepatotropic; cytostatic; nootropic; osteopathic; CD91; human.

XX OS Homo sapiens.

XX PN WO2004033657-A2.

XX PD 22-APR-2004.

XX PF 07-OCT-2003; 2003WO-US032167.

XX PR 07-OCT-2002; 2002US-0416821P.

XX PA (ANTI-) ANTIGENICS INC

XX PA (UYCO-) UNIV CONNECTICUT HEALTH CENT.

XX PI Leclair K, Srivastava PK;

XX DR WPI; 2004-340920/31.

XX PT New nucleic acids encoding CD91 polypeptides, useful for diagnosing or

XX PT treating diabetes mellitus, multiple sclerosis, scleroderma, myasthenia

XX PT gravis, rheumatoid arthritis, cirrhosis or cancer.

XX PS Claim 4; Page 224-236; 253pp; English.

XX CC The present invention provides the human CD91 protein and coding

XX CC sequences. The nucleic acids and polypeptides are useful for diagnosing

XX CC and treating HSP-CD91-related disorders and conditions, including

XX CC autoimmune diseases, cancer, and infectious diseases. Autoimmune

XX CC disorders or diseases include insulin dependent diabetes mellitus,

XX CC autoimmune diabetes, multiple sclerosis, systemic lupus erythematosus,

XX CC scleroderma, Addison's disease, Grave's disease, myasthenia gravis,

XX CC rheumatoid arthritis or cirrhosis. Infectious diseases include those

XX CC caused by intracellular pathogens, including viruses, bacteria,

XX CC protozoans and intracellular parasites. It can also be used for treating

XX CC hypercholesterolemia, Alzheimer's disease, diabetes, or osteoporosis. The

XX CC present sequence is a fragment of the human CD91 protein.

11AA SEQUENCE 1.0  
ID -ADN42248 standard; protein; 202 AA.  
XX  
AC ADN42248;  
XX  
DT 17-JUN-2004 (first entry)  
XX  
DE Human novel proteinNOV 31.  
XX  
KW Human; NOVX; cancer; diabetes; cardiomyopathy; atherosclerosis.  
XX  
OS Homo sapiens.  
XX  
PN US2004033493-A1.  
XX  
PD 19-FEB-2004.  
XX  
PF 31-JAN-2002; 2002US-00072012.  
XX  
PR 31-JAN-2001; 2001US-0265395P.  
PR 31-JAN-2001; 2001US-0265412P.  
PR 31-JAN-2001; 2001US-0265514P.  
PR 31-JAN-2001; 2001US-0265517P.  
PR 02-FEB-2001; 2001US-0266406P.  
PR 05-FEB-2001; 2001US-0266767P.  
PR 07-FEB-2001; 2001US-0266975P.  
PR 07-FEB-2001; 2001US-0267057P.  
PR 08-FEB-2001; 2001US-0267459P.  
PR 09-FEB-2001; 2001US-0267823P.  
PR 15-FEB-2001; 2001US-0268974P.  
PR 26-FEB-2001; 2001US-0271664P.  
PR 27-FEB-2001; 2001US-0271839P.  
PR 27-FEB-2001; 2001US-0271855P.  
PR 02-MAR-2001; 2001US-0272788P.  
PR 02-MAR-2001; 2001US-0273046P.  
PR 14-MAR-2001; 2001US-0275925P.  
PR 14-MAR-2001; 2001US-0275947P.  
PR 14-MAR-2001; 2001US-0275950P.  
PR 15-MAR-2001; 2001US-0275989P.  
PR 15-MAR-2001; 2001US-0276448P.  
PR 15-MAR-2001; 2001US-0276450P.  
PR 16-MAR-2001; 2001US-0276397P.  
PR 16-MAR-2001; 2001US-0276768P.  
PR 20-MAR-2001; 2001US-0278652P.  
PR 26-MAR-2001; 2001US-0278775P.  
PR 26-MAR-2001; 2001US-0278778P.  
PR 29-MAR-2001; 2001US-0279882P.  
PR 29-MAR-2001; 2001US-0279884P.  
PR 30-MAR-2001; 2001US-0280147P.  
PR 11-APR-2001; 2001US-0282992P.  
PR 11-APR-2001; 2001US-0283083P.  
PR 20-APR-2001; 2001US-0285133P.  
PR 23-APR-2001; 2001US-0285749P.  
PR 03-MAY-2001; 2001US-0288327P.  
PR 03-MAY-2001; 2001US-0288504P.  
PR 29-MAY-2001; 2001US-0294047P.  
PR 30-MAY-2001; 2001US-0294473P.  
PR 08-JUN-2001; 2001US-0296964P.  
PR 18-JUN-2001; 2001US-0298959P.  
PR 19-JUN-2001; 2001US-0299324P.  
PR 13-AUG-2001; 2001US-0312020P.  
PR 16-AUG-2001; 2001US-0312889P.  
PR 16-AUG-2001; 2001US-0312908P.  
PR 21-AUG-2001; 2001US-0313930P.  
PR 28-AUG-2001; 2001US-0315470P.  
PR 31-AUG-2001; 2001US-0316447P.  
PR 07-SEP-2001; 2001US-0318115P.  
PR 07-SEP-2001; 2001US-0318118P.  
PR 12-SEP-2001; 2001US-0318740P.  
PR 19-SEP-2001; 2001US-0323379P.  
PR 18-OCT-2001; 2001US-0330245P.  
PR 18-OCT-2001; 2001US-0330308P.

14-NOV-2001; 2001US-0332701P.  
(TCHE/) TCHERNEV V T.  
(SPYT/) SPYTEK K A.  
(ZERH/) ZERHUSEN B D.  
(PATT/) PATTURAJAN M.  
(SHIM/) SHIMKETS R A.  
(LILL/) LI L.  
(GANG/) GANGOLLI E A.  
(PADI/) PADIGARU M.  
(ANDE/) ANDERSON D W.  
(RAST/) RASTELLI L.  
(MILL/) MILLER C E.  
(GERL/) GERLACH V.  
(TAUP/) TAUPIER R J.  
(GUSE/) GUSEV V Y.  
(COLM/) COLMAN S D.  
(WOLE/) WOLENC A R.  
(PENA/) PENA C E A.  
(FURT/) FURTAK K.  
(GROS/) GROSSE W M.  
(ALSO/) ALSOBROOK J P.  
(LEPL/) LEPLEY D M.  
(RIEG/) RIEGER D K.  
(BURG/) BURGESS C E.  
Tchernev VT, Spytek KA, Zerhusen BD, Patturajan M, Shimkets RA;  
Li L, Gangolli EA, Padigaru M, Anderson DW, Rastelli L, Miller CE;  
Gerlach V, Taupier RJ, Gusev VY, Colman SD, Wolenc AR, Pena CEA;  
Furtak K, Grosse WM, Alsobrook JP, Lepley DM, Rieger DK, Burgess CE;  
WPI; 2004-180039/17.  
N-PSDB; ADN42247.  
Isolated NOVX polypeptides and polynucleotides, useful for preventing  
diagnosing and/or treating cancer, diabetes, cardiomyopathy and  
atherosclerosis.  
Claim 1; SEQ ID NO 130; 1309pp; English.  
The invention relates isolated 162 NOVX polypeptides (NOV1-NOV99,  
including splice variants) and the nucleic acids (NA) that encode them.  
Also included are the mature NOVX proteins (and their encoding  
polynucleotides), a vector comprising NOVX NA, a cell comprising the  
vector, an antibody that binds immunospecifically to NOVX, determining  
the presence or amount of NOVX in a sample, determining the presence or  
amount of NOVX NA in a sample, identifying an agent that binds to NOVX,  
modulating the activity of NOVX, treating or preventing a NOVX-associated  
disorder, determining the presence of or predisposition to a disease  
associated with altered levels of NOVX and treating a pathological state  
in a mammal comprising administering a polypeptide which is at least 95%  
identical to NOVX (or fragment). NOVX and NA may be used in the  
prevention, treatment and diagnosis of diseases associated with  
inappropriate expression and activity of NOVX (e.g. cancer, diabetes,  
cardiomyopathy and/or atherosclerosis). The anti-NOVX antibodies and  
antagonists may also be used to down regulate expression and activity of  
NOVX. The anti-NOVX antibodies may also be used as diagnostic agents for  
detecting the presence of NOVX in samples (e.g. by enzyme linked  
immunosorbant assay (ELISA). The agents and methods may be used in this  
way to prevent, diagnose and treat cancer, diabetes, cardiomyopathy  
and/or atherosclerosis. The present sequence represents a NOVX protein.  
Sequence 202 AA;

ADN42248 Length: 202 February 22, 2005 12:25 Type: P Check: 6390 ..  
1 MWDIKSRGSG GSTPAPPSHL LLYLLHPOST RTMCCCGCSG GCGSSCGGCD  
51 SSCGSCGSGC RCGPSPCCAP VYCKPVCCC VPACSCSSCG KRGCSCGGS  
101 KGGCGSGCS QCSCKPCCS SSGCGSSCCQ CSCKKPYCSQ SSCCKPCCCS  
151 SGCSSGCCQS SCKPCCCSQ SCCVPVCCQS SCKPCCCSQ NCCVPVCCQC

PS Disclosure; SEQ ID NO 3; 25pp; English.  
XX  
CC The present invention relates to a vector suitable for use in a human  
CC comprising a polynucleotide which encodes a calbindin-D28K polypeptide.  
CC Also disclosed is a pharmaceutical composition suitable for use in a  
CC human comprising a calbindin-D28K polynucleotide or polypeptide and a  
CC carrier, a method for treating a disease associated with abnormal  
CC glucocorticoid induced cell death, and a vector for the delivery of a  
CC calbindin-D28K therapeutic element to a human. Compositions comprising a  
CC calbindin-D28K polynucleotide or polypeptide are useful for treating  
CC glucocorticoid induced cell death, particularly glucocorticoid-induced  
CC osteoporosis. Compositions comprising an antisense polynucleotide to the  
CC sequence encoding calbindin-D28K is useful for treating a disease  
CC associated with a lack of normal cell death or apoptosis, including  
CC osteoblastic cancer, osteocytic cancer, prostrate cancer, lymphocytic  
CC cancer, leukaemia and lymphoma. The present protein sequence of unknown  
CC function is given in the Sequence listing as SEQ ID No:3 but is not  
CC mentioned elsewhere in the specification.  
XX  
SQ Sequence 1440 AA;

ADG34533 Length: 1440 February 22, 2005 12:25 Type: P Check: 9646 ..

1 TGCTGGTGGG ATCAAAGCGC AGTGCTCTGC GCGGGGGAGC TTGGAACGCT  
51 AAGAAAAGTG ACCATGGAGA ACAACAAAC CTCAGTGGAT TCMAAATCCA  
101 TTAATAATTT TGAAGTAAAG ACCATACATG GGAGCAAGTC AGTGACTCT  
151 GGGATCTATC TGGACAGTAG TTACAAAATG GATTATCCTG AAATGGGCAT  
201 ATGCATAATA ATTAATAATA AGAATTCCA TAAGAGCACT GGAATGTGAT  
251 CTCGCTCTGG TACGGATGTG GAGCGAGCCA ACCTCAGAGA GACATTCATG  
301 GGCCTGAAAT ACCAAGTCAG GAATAAAAAT GATCTTACTC GTGAAGACAT  
351 TTTGGAATTA ATGCATAGTG TTTCTAAGGA AGATCATAGC AAAGGAGCA  
401 GCTTTGTGTG TGTGATTTCTA AGCCATGGTG ATGAAGGGGT CATTTATGGG  
451 ACAATGGGC CTGTTGAAC TGAAGAGTTG ACTAGTCTCT TCAGAGGCGA  
501 CTACTGCCGG AGTCTGACTG GAAAGCGGAA ACTCTTCATC ATTCAGGCT  
551 GCGGGGTAC GGACTGGAC TGTGGCATTG AGACAGACAG TGGAGCTGAT  
601 GAGGAGATGG CTTGCCAGAA GATACCGGTG GAGGCTGACT TCCTGTATGC  
651 TTACTCTACA GCACCTGGTT ACTATTCTCTG GAGAAATCCA AAGGACGGGT  
701 CGTGGTTTCAT CCAGTCCCTT TGCAGCATGC TGAAGCTGTA GCGCACAAAG  
751 CTAGAATTTA TGCACATCTC CACTCGGTT AACAGGAAGG TGGCAACGGA  
801 ATTCGAGTCC TTCTCCCTGG ACTCCACTTT CCACGCAAG AAACAGATCC  
851 CGTGTATTGT GTCCATGCTC ACAGAAAGAC TGATCTTTTA TCATAGAGG  
901 AATGATTGGG GGTGGGGGGG GCGGTGTTTC TGTTTGTGTA TGCCAAATGA  
951 GAAAGCTGTC AGGAGACTC TCATTAAAT TCAATCTGAC GGTCTCTCTG  
1001 GTCTTTGTAC GTTACCACTG CCTAGCAATG CAGCCAGCCA CAGTGCAGCT  
1051 ACCTCAACTT CGACATCAGG TAGTTGAAAT GAAATTTAAT TTAATAAGGA  
1101 GCAAGTAACT GTCAATGATG GTACTATCAT CCTAGATGAA ATTACAAGT  
1151 TGCCCTTTTA TAATTAGCAA GAATTTGGCGA TACTATGAAT TTTGAAGTCA  
1201 TTTTGAAGCA GTACAGCTTT TCCACTGATG ATTTTATACT CCCCACTCAT

1251 GTTAAGAATG TTGTTCTAGT TTTTCGTTTAAA CGTAGAACA ATAATGTCAA  
1301 ATGATAATGT CTTAGAATCTT GAATCCATGA GCAGAGTCNA AGGATGGAAC  
1351 CTTGTTTTTG GACCTGATTT ATGGAAGTGA AGAGTTGGAC CACCATAGCA  
1401 TGCATTATAG CTACTGCTTT TGTGACAGTT GTCCACAACA  
!!AA\_SEQUENCE 1.0  
ID ADG47243 standard; protein; 162 AA.  
XX  
AC ADG47243;  
XX  
DT 11-MAR-2004 (first entry)  
XX  
DE Human TNF-Rdelta163 truncated protein.  
XX  
KW Tumour necrosis factor; TNF; tumour necrosis factor receptor; TNFR;  
KW interleukin-1 receptor; IL-1R; therapy; cachexia; rheumatoid arthritis;  
KW diabetes; multiple sclerosis; pulmonary fibrosis; silicosis;  
KW cerebral malaria; allograft rejection; xenograft rejection;  
KW graft versus host disease; immunomodulator; neuroprotective;  
KW immunosuppressive; human; mutant; mutein.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
FN US6541610-B1.  
XX  
PD 01-APR-2003.  
XX  
PF 20-MAR-1995; 95US-00406824.  
XX  
PR 05-SEP-1989; 89US-00403241.  
PR 11-SEP-1989; 89US-00405370.  
PR 13-OCT-1989; 89US-00421417.  
PR 10-MAY-1990; 90US-00523635.  
PR 08-JUN-1994; 94US-00255849.  
XX  
PA (IMMV ) IMMUNEX CORP.  
XX  
PI Smith CA;  
XX  
XX WPI; 2004-040377/04.  
XX  
PT New fusion protein, useful for treating e.g. cachexia, rheumatoid  
PT arthritis or diabetes, comprising two human TNF receptor polypeptides and  
PT a human interleukin-1 receptor.  
XX  
PS Example 6; Col; 4pp; English.  
XX  
CC The present invention relates to a fusion protein comprising two human  
CC tumour necrosis factor (TNF) receptor (TNFR) polypeptides and a human  
CC interleukin-1 receptor (IL-1R). The present invention is useful for  
CC treating diseases such as cachexia, rheumatoid arthritis, diabetes,  
CC multiple sclerosis, pulmonary fibrosis, silicosis, cerebral malaria,  
CC allograft rejection and xenograft rejection in graft versus host disease.  
CC The present sequence is human TNF-R truncated protein. Note: This  
CC sequence is not shown in the specification, but is derived from human  
CC wild type TNF-R protein shown as SEQ ID NO: 2 in column 41-44 of the  
CC specification.  
XX  
SQ Sequence 162 AA;  
ADG47243 Length: 162 February 22, 2005 12:25 Type: P Check: 4982 ..  
1 GCGAGGCGAG CAGCTGGAG AGAAGCGCT GGGCTGGAG GCGCGGAGG  
51 GCGAGGGCA GGGGGCAACC GGACCCCGCC CGCATCCATG GCGCCCGTCG  
101 CCGTCTGGC CGCGTGGCC GTCGGAAGTGG AGCTCTGGG TGCGGCGCAC  
151 GCCTTGCCCG CC

PR 31-JAN-2001; 2001US-0265412P.  
 PR 31-JAN-2001; 2001US-0265514P.  
 PR 31-JAN-2001; 2001US-0265517P.  
 PR 02-FEB-2001; 2001US-0266406P.  
 PR 02-FEB-2001; 2001US-0266767P.  
 PR 07-FEB-2001; 2001US-0266975P.  
 PR 07-FEB-2001; 2001US-0267057P.  
 PR 08-FEB-2001; 2001US-0267459P.  
 PR 09-FEB-2001; 2001US-0267823P.  
 PR 15-FEB-2001; 2001US-0268974P.  
 PR 26-FEB-2001; 2001US-0271664P.  
 PR 27-FEB-2001; 2001US-0271839P.  
 PR 27-FEB-2001; 2001US-0271855P.  
 PR 02-MAR-2001; 2001US-0272704P.  
 PR 02-MAR-2001; 2001US-0273046P.  
 PR 14-MAR-2001; 2001US-0275925P.  
 PR 14-MAR-2001; 2001US-0275947P.  
 PR 14-MAR-2001; 2001US-0275950P.  
 PR 14-MAR-2001; 2001US-0275989P.  
 PR 15-MAR-2001; 2001US-0276448P.  
 PR 15-MAR-2001; 2001US-0276450P.  
 PR 16-MAR-2001; 2001US-0276397P.  
 PR 16-MAR-2001; 2001US-0276768P.  
 PR 20-MAR-2001; 2001US-0278652P.  
 PR 26-MAR-2001; 2001US-0278775P.  
 PR 26-MAR-2001; 2001US-0278778P.  
 PR 29-MAR-2001; 2001US-0279882P.  
 PR 29-MAR-2001; 2001US-0279884P.  
 PR 30-MAR-2001; 2001US-0280147P.  
 PR 11-APR-2001; 2001US-02822992P.  
 PR 11-APR-2001; 2001US-0283083P.  
 PR 20-APR-2001; 2001US-0285133P.  
 PR 23-APR-2001; 2001US-0285749P.  
 PR 03-MAY-2001; 2001US-0288327P.  
 PR 03-MAY-2001; 2001US-0288504P.  
 PR 30-MAY-2001; 2001US-0294473P.  
 PR 30-MAY-2001; 2001US-0294473P.  
 PR 08-JUN-2001; 2001US-0296964P.  
 PR 19-JUN-2001; 2001US-0299324P.  
 PR 13-AUG-2001; 2001US-0310209P.  
 PR 16-AUG-2001; 2001US-0312889P.  
 PR 21-AUG-2001; 2001US-0312908P.  
 PR 28-AUG-2001; 2001US-0313390P.  
 PR 31-AUG-2001; 2001US-0315470P.  
 PR 07-SEP-2001; 2001US-0316447P.  
 PR 07-SEP-2001; 2001US-0318115P.  
 PR 07-SEP-2001; 2001US-0318118P.  
 PR 12-SEP-2001; 2001US-0318740P.  
 PR 19-SEP-2001; 2001US-0323379P.  
 PR 18-OCT-2001; 2001US-0330245P.  
 PR 19-OCT-2001; 2001US-0330308P.  
 PR 14-NOV-2001; 2001US-0332701P.  
 (CURA-) CURAGEN CORP.  
 PA Tchernev VT, Spytsek KA, Zerhusen BD, Patturajan M, Shinkets RA;  
 PI Li L, Gangolli EA, Padigar M, Anderson DW, Rastelli L, Miller CE;  
 PI Gerlach VL, Taupier RJ, Gusev VY, Colman SD, Wolenc AR, Pena CE;  
 PI Furtak K, Grosse WM, Alsobrook JP, Lepley DM, Rieger DK, Burgess CE;  
 XX WPI; 2002-706998/76.  
 DR N-PSDB; ADI16593.  
 DR  
 XX New NOVX polypeptides and nucleic acids, useful for preventing or  
 PT treating NOVX-associated disorders, e.g. cancer, cardiomyopathy,  
 PT atherosclerosis, or diabetes, and in chromosome mapping, tissue typing or  
 PT pharmacogenomics.  
 XX  
 PS Claim 1; SEQ ID NO 130; 1498pp; English.  
 XX  
 XX This invention relates to a novel nucleic acids, and encoded polypeptides  
 CC thereof, which have properties related to the stimulation of biochemical

CC or physiological responses in a cell, tissue, organ or organism.  
 CC Specifically, it refers to the use of biologically active fragments for  
 CC diagnostic and prognostic assays and furthermore in the treatment of  
 CC diverse pathological conditions. The present invention describes novel  
 CC human and murine NOVX proteins, as well as methods to modulate their  
 CC expression using antisense oligos, ribozymes and peptide nucleic acids.  
 CC The NOVX polypeptides, polynucleotides and antibodies are useful in  
 CC treating or preventing NOVX-associated disorders, e.g. cardiomyopathy,  
 CC atherosclerosis, cancer and diabetes. Furthermore, they may be used in  
 CC treating or preventing diseases such as inflammation, autoimmune  
 CC disorders, allergies, blood disorders, acquired immunodeficiency syndrome  
 CC (AIDS), obesity, asthma, immunoglobulin (IgA) nephropathy, cirrhosis,  
 CC arthritis, Alzheimer's disease, infections, stroke, muscular dystrophy  
 CC and epilepsy. Accordingly, these molecules have many activities including  
 CC cytostatic, cardiant, antiinflammatory, immunosuppressive, antiallergic,  
 CC haemostatic, anti-HIV, antidiabetic, antiarteriosclerotic, anorectic,  
 CC antiasthmatic, nephrotropic, antiarthritic, hepatotropic,  
 CC neuroprotective, nootropic, antibacterial, virucide, antiparasitic,  
 CC relaxant and anticonvulsant. In addition, they are useful in screening  
 CC assays to identify small molecules that modulate or inhibit, for example,  
 CC neurogenesis, wound healing and angiogenesis. The nucleic acids are also  
 CC used as in chromosome mapping, tissue typing, preventive medicine and  
 CC pharmacogenomics. This polypeptide is a human NOVX protein of the  
 CC invention.  
 XX  
 XX Sequence 202 AA;  
 SQ  
 ADI16594 Length: 202 February 22, 2005 12:25 Type: P Check: 6526 ..  
 1 MWDIKSRGSG GSTAPPSSL LLYLLHPQST RTMGCGCGSG GCGSSCGGGCD  
 51 SSCGSGSGSG RGCGPSCCAP VYCKPVCCC VPACSCSSCG KRGCGSGCGS  
 101 KGGCGSGGCS QCSCKPCCC SSGCGSSCCQ CSCKKPYCSQ SSCCKPCCCS  
 151 SGGSSGCCQS SCKKPCCCQS SCCVPVCCQS SCKKPCCCQS NCCVPVCCQC  
 201 KI  
 IIAA\_SEQUENCE 1.0  
 ID\_ADG34533 standard; protein; 1440 AA.  
 XX  
 AC ADG34533;  
 XX  
 DT 26-FEB-2004 (first entry)  
 XX  
 DE Glucocorticoid induced cell death associated rat protein.  
 XX  
 KW Calbindin-D28K; Glucocorticoid induced cell death;  
 KW glucocorticoid-induced osteoporosis; apoptosis; osteoblastic cancer;  
 KW osteocytic cancer; prostate cancer; lymphocytic cancer; leukaemia;  
 KW lymphoma; osteopathic; cytostatic; rat.  
 XX  
 OS Rattus norvegicus.  
 XX  
 PN US2003219421-A1.  
 XX  
 PD 27-NOV-2003.  
 XX  
 PF 23-MAY-2002; 2002US-00155567.  
 XX  
 PR 23-MAY-2002; 2002US-00155567.  
 XX  
 PR (UYNE-) UNIV NEW JERSEY MEDICINE & DENTISTRY.  
 PA  
 PI Christakos S;  
 XX  
 DR WPI; 2004-021929/02.  
 XX  
 PT New vector comprising a polynucleotide encoding a calbindin-D28k  
 PT polypeptide, useful for treating glucocorticoid induced cell death,  
 PT particularly glucocorticoid-induced osteoporosis.  
 XX





```
1201 CTCTATCCTG CACAAGGCTG GCGAGGTGGT GGTAGCCTTC CCAGCGCCCC
1251 GGCTGAGCAC GGGGCCAGCC CTGGTGGCAG CAGGCGCTGC TCACAGCTGAG
1301 GTGGTGGTGG CCACGGTGGC CAGCAGTGGG GTGTGAAGT TTGGCAGCAC
1351 GGGCTCCACG CCCCCCGTGT TCCCACCCCC CTCGGAGGCG TCACTGTCTCA
1401 GCACGGGCGA TGAAACTCC ACCCCGGGGG ACACCTTTGG TGAGATGGTG
1451 ACATCACCTC TGAGGCGAGT GACCCTGGAG GCCTCGCCAC TGCAGATCCT
1501 CGTGAAGGAG GAGGGCCCCC GGGCCGGGTC CTGTTGCCGT AGCCCTGGGG
1551 GCGGGGCGA GCTAGAGGGG GCGACAAGG ACCAGATGCT GCAGGAGAAA
1601 GACAAGCAGA TCGAGGCGCT GAGCGCATG CTCGGGCAGA AGCAGAGCT
1651 GGTGAGCGG CTCAGCTGC AGCTGGAGCA GGAGAAGCGA GCCCAGCAGC
1701 CCGCCCCCGC CCGCGCCCCC CTCGGCACCC CCGTGAAGCA GGAGAACAGC
1751 TTCTCCAGCT GCGAGCTGAG CCAGCAGCCC CTGGGCCCGG CTCACCCATT
1801 CAACCCACAG CTCGGCGGCC CAGCCACCAA CCACATAGAC CTTTGTGCTG
1851 TGGCCCCGGG GCCCCCGTCC GTGGTGGTGA AGCAGGAGC CTTGCAGCCT
1901 GAGCCCGAGC CGGTCCCCCG CCCCCAGTTG TTTCTGGGGC CTCAGGGCCC
1951 CAGCCTCATC AAGGGGGTTG CACCTCCAC CTTATCACC GACTCCACAG
2001 GGACCCACCT TGTCTTACC GTGACCAATA AGAATGCAGA CAGCCCTGGC
2051 CTGTCCAGTG GAGGCCCCCA CGAGCCCTCG TCCCAGCCTG GCTCTCCAGC
2101 GCCTGCCCCC TCTGCCAGA TGGACCTGGA GCACCCACTG CAGCCCCCTCT
2151 TTGGGACCCC CACTTCTCTG CTGAGAAGG AACCACTTGG CTATAGGAA
2201 GCCATGAGCC AGCAGCCCAA ACAGCAGGAA AATGTTCTCT CAAGCCAGCA
2251 GATGGACGAC CTGTTTGACA TTCTCATTTCA GAGCGGAAA ATTTACGACG
2301 ATTTCAAGGA GCGCCCATCC CTGCCAGGA AGGAGAGCC ATCCCCGAG
2351 ACAGTCTGTG GGTCCCCCCT GGCAGCACAG CCATCACCTT CTGCTGAGCT
2401 CCCCAGGCT GCGCCACCTC CTCCAGGCTC ACCCTCCCTC CTGGAGCGCC
2451 TGGAGGACTT CTTGGAGAGC AGCAGCGGGC TGCCCTGCT GACCAGTGGG
2501 CATGACGGGC CAGAGCCCCCT TTCCCTCATT GACGACCTCC ATAGCCAGAT
2551 GCTGAGCAGC ACTGCCATCC TGGACCAACC CCGCTCACCC ATGGACACCT
2601 CGGAATTGCA CTTTGTTCCT GAGCCACGCA GCACCATGGG CTGGACCTG
2651 GCTGATGGCC ACCTGGACAG CATGGACTGG CTGGAGCTGT CGTCAGGTGG
2701 TCCCGTGTCT AGCCTAGCCC CCTCAGCAC CACAGCCCCC AGCCTCTTCT
2751 CCACAGACTT CTTGATGGC CATGATTTGC AGCTGCATG GATTTCTGTC
2801 TTGTAGTCTT CTGGCTCAAG ACGGGGTGGG GAAAGGGCTG GGAGCCAGGG
2851 TACTCCAAATG CGTGGCTCTC CTGCGTGAAT CGGCGCTCC ACATGGTTGT
2901 GAGTCTTGAC AATCAGAGCC CTGCTCTTTT CCCTTCCCTG GGAGGCTAGA
2951 ACAGAGAAGC CCTTACTCCT GTTTCAGTGC CACGACGGGC AGAGGAGAGC

3001 AGCTGTCAAG AAGCAGCCCT GGCTCTCAG CTGGGGTTTT GGACACACGG
3051 TCAGGGTCAG GGCCATTCA GCTTGACCTC CTTTTTTGAG GTCAGGGGGC
3101 ACTGTCTGTC TGGCTACAAT TTGGCTAAGG TAGTGAAGC CTGGCCAGGC
3151 GGGAGGCTTC TCTTTGACC CAGGCTGAG ACAGTTTAAG GGTGAATCT
3201 CCTTCCTTTC TCTCCCTGCT TTGCTGTGAA GGGAGAAAAT AGCCTGGGCC
3251 TCTACCCCTT ATTCCCTGTG TCTGCCAACC CCAGGATCCC AGGCTCCCT
3301 GCCATTTTAG TGTCTGGTG TAGTGAACC ATTTAGTGGT TGGTGGAAAC
3351 AATTTTATGT ACAGGTGTAT ATACCTCTAT ATTATATATC GACATACATA
3401 TATATTTTTG GGGGGGGGCG GACAGGAGAT GGGTGCAACT CCCTCCCATC
3451 CTACTCTCAC AGAAGGCGCT GGATGCAAGG TTACCCTTGA GCTGTGTGCC
3501 ACAGTCTGGT GCCCAGTCTG GCATGCAGCT ACCCAGGCCC ACCATCAACG
3551 TGTGATTGAC ATGTAGGTAC CTTGCCACGG CCTATGCCCC ACCTGCCCTG
3601 CTTCTCTGGT CTTTATCAGT GCCATGAGGG CAGAGGTGCT ACCTGGCCTT
3651 CTTGCCAGGA GCTCTCCACC CACTCACATT CCGTCCCCCG CGCTCACTG
3701 CAGCCAGCGT GGTCTTAGGA CAGGAGGAGC TTCGGGGCCA GCTTCAACCT
3751 GCGGTGGGGC TGAGGGGTGG CCATCTCCTG CCTTGGGGCC ACTGGCTTCA
3801 CATTTCTGGC TGACTCATAG GGGAGTAGGG GTGGAGTCAC CAAAACCACT
3851 CTTGGGACAA AGATGGGAA GGTGTGTGAA CTTTTTAAAA TAAACACAAA
3901 AACACAG

!!AA SEQUENCE 1.0
ID_AAU91279 standard; protein; 1329 AA.
XX
AC AAU91279;
XX
DT 18-JUN-2002 (first entry)
XX
DE Human NOV3a protein.
XX
KW Human; NOV3; gene therapy; cardiomyopathy; atherosclerosis; diabetes;
cell signal processing; metabolic pathway modulation; inflammation;
KW autoimmune disorder; scleroderma; transplantation; allergy;
KW systemic lupus erythematosus; haemophilia; Alzheimer's disease;
KW graft versus host disease; Lesch-Nyhan syndrome; periodontitis;
KW pancreatitis; musculoskeletal disorder; Parkinson's disease;
KW Huntington's disease; behavioural disorder; pain; obesity; wound healing;
KW neurodegenerative disorder; neuropsychiatric disorder; hypertension;
growth disorder; reproductive disorder; lung disease.
XX
OS Homo sapiens.
XX
PN WO200216600-A2.
XX
PD 28-FEB-2002.
XX
PF 27-AUG-2001; 2001WO-US026518.
XX
PR 25-AUG-2000; 2000US-0227800P.
PR 25-AUG-2000; 2000US-0228205P.
PR 25-AUG-2000; 2000US-0228324P.
PR 30-AUG-2000; 2000US-0228997P.
PR 30-AUG-2000; 2000US-0229185P.
PR 01-SEP-2000; 2000US-0229780P.
PR 01-SEP-2000; 2000US-0229848P.
PR 01-SEP-2000; 2000US-0229850P.
```

CC growth, tissue repair, healing of burns, incisions, ulcers, treatment of  
CC osteoporosis, osteoarthritis, bone degenerative disorders and periodontal  
CC disease. The sequences of the invention are also useful for gut  
CC protection or regeneration and treatment of lung or liver fibrosis,  
CC reperfusion injury in various tissues, immune deficiencies and disorders  
CC including severe combined immunodeficiency (SCID), bacterial or fungal  
CC infections, autoimmune disorders e.g. multiple sclerosis and myasthenia  
CC gravis, allergic conditions such as asthma, thrombolysis or thrombosis  
CC and coagulation disorders. Sequences ABG66666-ABG66758 represent human  
CC novel polypeptides of the invention  
XX  
SQ Sequence 207 AA;

ABG66758 Length: 207 February 22, 2005 12:25 Type: P Check: 95 ..

- 1 MYVLEMSVCA VCACVCCVVFV CAVPMCAVHA CVLCAVCVCCV LCSCVCCVCM
- 51 CCVHVCAVVF CVLCLVLCSCV LCSRCAVCA CVCCVFCVCL CASVLCVHVC
- 101 ACAVRLCAVC SCVCCVCVCA VRLCVRVRLR VCCVCMCVRFV CAVRLCAVCA
- 151 CVCVCVLCVC VCAVSSVCC VCAFCVCLY ARVCAVLVCV LCSCVCCVLC
- 201 VCSGDA

!!AA SEQUENCE 1.0  
ID ABG70822 standard; protein; 3907 AA.  
XX  
AC ABG70822;  
XX  
DT 16-DEC-2002 (first entry)  
XX  
DE Mouse myocardin associated protein #1.  
XX  
KW Mouse; myocardin; myocardial infarction; cardiomyocyte;  
KW post-mitotic cell; differentiation; therapeutic; gene therapy;  
KW heart disease; cardiomyopathy; mortality; heart failure; hypertension.  
XX  
OS Mus sp.  
XX  
PN WO200260946-A2.  
XX  
PD 08-AUG-2002.  
XX  
PF 21-DEC-2001; 2001WO-US050606.  
XX  
PR 21-DEC-2000; 2000US-0257716P.  
XX  
PA (TEXA ) UNIV TEXAS SYSTEM.  
XX  
PI Olson EN, Wang D;  
XX  
DR WPI; 2002-732693/79.  
XX  
PT New myocardin polypeptides and polynucleotides, useful for respecifying  
PT non-cardiac cells, stimulating cardiac tissue regeneration, and for  
PT treating cardiovascular disorders, such as myocardial infarction and  
PT hypertension.  
XX  
PS Disclosure; Page 146-159; 175pp; English.

XX  
XX  
CC The invention discloses an isolated polynucleotide encoding a myocardin  
CC polypeptide. Myocardial infarction results in the loss of cardiomyocytes,  
CC which are post-mitotic cells and generally do not regenerate after birth.  
CC Transplanting foetal cardiomyocytes has limitations so identifying new  
CC regulators of cardiomyocyte growth and differentiation is an important  
CC goal in the search for therapeutics to treat myocardial tissue damage.  
CC The polynucleotides, polypeptides and methods of the invention can be  
CC used to modulate the phenotype of a non-cardiomyocyte cell to include one  
CC or more phenotypic functions of a cardiomyocyte cell, to generate a  
CC cardiomyocyte, which comprises introducing into a cardiac fibroblast the  
CC myocardin polynucleotide and a promoter which is active in the  
CC fibroblast, stimulate cardiac tissue regeneration which comprises

CC inhibiting the function of myocardin in a post-mitotic cardiomyocyte and  
CC for screening for a modulator of myocardin expression. The nucleic acid  
CC can also be used in gene therapy to treat a heart disease, including a  
CC cardiomyopathy, comprising administering a polynucleotide encoding a  
CC myocardin peptide or protein or an antisense nucleic acid. The  
CC polynucleotide and polypeptide can also be used for decreasing mortality  
CC in a subject with heart failure, comprising inhibiting the function of  
CC myocardin in post-mitotic cardiomyocytes, increasing the level of  
CC myocardin in fibroblasts to generate cardiomyocytes, inhibiting the  
CC function of myocardin in post-mitotic cardiomyocytes or increasing the  
CC level of myocardin in fibroblasts to generate cardiomyocytes in the  
CC subject. The compositions and methods of the present invention are useful  
CC for respecifying non-cardiac cells, stimulating cardiac tissue  
CC regeneration, for treating cardiovascular disorders, such as myocardial  
CC infarction and hypertension, and for screening compounds for various  
CC abilities to interact and/or affect myocardin expression or function. The  
CC sequence presented is the mouse myocardin associated protein, #1. Note:  
CC This sequence is presented as a 3-letter coded protein sequence in the  
CC specification, but when changed into the single letter code, forms a DNA  
CC sequence identical to that given in ABS5224. It, therefore, appears to  
CC be the DNA sequence encoding human myocardin 2  
XX  
SQ Sequence 3907 AA;

ABG70822 Length: 3907 February 22, 2005 12:25 Type: P Check: 8356 ..

- 1 CCAAGGATC ATGCCGCTT TGAAGAAGTCC AGCCGATTT CATGAGCAGA
- 51 GAAGGAGCTT GGAGCGGGCC AGGACAGAGG ACTATCTCAA ACGGAAGATT
- 101 CGTTCCCGC CGGAGAGATC GGAGCTGGTC AGGATGCCA TTTTGAAGA
- 151 GACCTGGCT GAGCCATCCC TCCAGGCCAA GCAGCTGAAG CTGAAGAGAG
- 201 CCAGACTAGC CGATGACCTC AATGAGAAGA TTGCACAGAG GCCTGGCCCC
- 251 ATGGAGCTGG TGGAGAAGAA CATCCTTCCT GTTGAGTCCA GCCTGAAGGA
- 301 AGCCATCATT GTGGGCCAGG TGAATATATC CAAAGTAGCA GACAGCTCTT
- 351 CTTTCGATGA GGACAGCAGC GATGCCCTAT CCCCAGGCA GCCTGCCAGC
- 401 CATGAGTCCC AGGTTCTGT GCGTCACCC CTGGAGGCCC GAGTCAGCA
- 451 ACCACTGCTC AGTGCCACCT CTGCATCCC CACCAGGTT GTGTCTAAC
- 501 TTCCGATGGG CCGGATTC AGAGAAATGC TTTTCTGGC AGAGCAGCCT
- 551 CCTCTGCCCT CCCACCTCT GCTGCCCTCC AGCCTCACC ATGGNACCAC
- 601 TATCCCCACT GCCAAGTCCA CCCCCACACT CATTAAAGCAA AGCCAACCCA
- 651 AGTCTGCCAG TGAAGATCA CAGCGCAGCA AGAAGGCCAA GGAGCTGAAG
- 701 CCAAGGTGA AGAAGCTCAA GTACACCACAG TACATCCCCC CGGACCAGAA
- 751 GCAGACAGG GGGGCACCCC CCATGGACTC ATCTTACGCC AAGATCTTCG
- 801 AGCAGCAGCA GCTCTTCTC CAGCTGCAGA TCCTCAACCA GCAGCAGCAG
- 851 CAGCACCACT ACTACAGGC CATCTGCTT CCCCCGCCA AGTCAGCAGG
- 901 CGAGGCCCTG GGAAGCAGCG GGACCCCCCC AGTAGCAGC CTCTCCACTA
- 951 CCAATAGCAG CTCAGCTCG GGGCGCCCTG GGGCCCTGTGG GCTGGCAGCT
- 1001 CAGAACAGCA CCTCACTGAC TGGCAAGCCG GGAGCCCTGC CGGCCAACCT
- 1051 GGACGACATG AAGGTGCGAG AGCTGAAGCA GAGCTGAAG TTGCGATCAC
- 1101 TGCCTGTCTC GGGCACCAAA ACTGAGCTGA TTGAGCGCTT TCGAGCCTAT
- 1151 CAAGACCAA TCAGCCCTGT GCCAGGAGCC CCCAAGGCC CTGCCGCCAC

1 HMYVCGGIC VCMXACVMCV CAWCMCICVX VCPQWXCVC GVCICVCMVA  
51 CVLYVWGVGM CGAWGACVWG VCVQCCMCVC VSRVVVVVCVY LCARGLCVGH

!!AA SEQUENCE 1.0  
ID \_AAO14246 standard; protein; 925 AA.

AC AAO14246;

DT 10-MAY-2002 (first entry)

XX Human presenilin enhancer protein pen-1B derived protein SEQ ID NO: 25.

DE Human; fruit fly; mouse; rat; cow; presenilin enhancer protein; pen;

XX Alzheimer's disease; pen-1; pen-1B; pen-2; Aph-2; amyloid beta.

XX Homo sapiens.

OS Synthetic.

XX WO200185912-A2.

XX 15-NOV-2001.

XX 03-MAY-2001; 2001WO-US014648.

XX 05-MAY-2000; 2000US-00568942.

XX (EXEL-) EXELIXIS INC.

XX Curtis DT, Francis GR, Ellis MC, Ruddy DA, Nicoll SM, McGrath GU;

PI WPI; 2002-062245/08.

XX Presenilin enhancer proteins and polynucleotides useful for modulating

PT presenilin function and screening for an agent that modulates the

PT interaction of the protein to a binding target.

XX Disclosure; Page 67-70; 78pp; English.

XX The present invention relates to a method of detecting compounds capable  
CC of altering the interaction between a presenilin enhancer protein (such  
CC as pen-1, pen-1B, pen-2 and Aph-2) and presenilin. The inhibition of  
CC presenilin activity causes the production of amyloid beta to be reduced  
CC and thus be used in the treatment of Alzheimer's disease. The present  
CC sequence is a presenilin enhancer protein described in the  
CC exemplification of the invention

XX Sequence 925 AA;

AAO14246 Length: 925 February 22, 2005 12:25 Type: P Check: 8867 ..

1 GATGACTGCG GCGGTGTTCT TCGGTGCGC CTTCAATGCC TTCGGGCGTG

51 CGCTCGCCCT TTATGCTTTC ACCATCGCCA CCGAGCCGTT GCGTATCATC

101 TTCCTCATCG CCGAGCTTT CTTCTGGTTG GTGCTCTAC TGATTTGCTC

151 CTTTGTGTTGG TTCATGGCAA GAGTCATTTAT TGACAACAAA GATGGACCAA

201 CACAGAAAATA TCTGCTGATC TTTGGAGCGT TTGCTCTGT CTATATCCAA

251 GAATGTTTCC GATTTGCATA TTATAAATC TTAATAAAG CCACTGAAGG

301 TTTGAAGAGT ATAAACCCAG GTGAGACAGC ACCCTCTATG CGACTGCTGG

351 CCTATGTTTC TGGCTTGGGC TTTGGAATCA TGAATGAGT ATTTTCTTTT

401 GTGAATACCC TATCTGACTC CTTGGGCCA GGCACAGTG GCATTCATGG

451 AGATTCCTCT CAATTCCTCC TTTATTTCAGC TTTCAATGACG CTGCTCATTA

501 TCTTGCTGCA TGTATTCTGG GGCATTGTAT TTTTGTATGG CTGTGAGAAG

551 AAAAAGTGGG GCATCCTCCT TATGTTTCTC CTGACCCACC TGCTGGTGTC  
601 AGCCGAGACC TTCATAAGTT CTTATTATGG AATAAACCTG GCGTCAGCAT  
651 TTATAATCCT GGTGCTCATG GGCACCTGGG CATTCITAGC TGGGGGAGGC  
701 AGCTGCCGAA GCGTGAACCT CTGCTGCTGC TGCCAAGACA AGAACTTTCT  
751 TCTTTACAAC CAGCGCTCCA GATAACCTCA GGAACCCAGC ACTTCCCAAA  
801 CCGCAGACTA CATCTTTAGA GGAAGCACAA CTGTGCCCTT TCTGAAAT  
851 CCCTTTTCTT GGTGGAATTG AGAAAGRAAT AAAACTATGC AGATATGCGT  
901 TCCAAAAAAA AAAAAAAA AAAA

!!AA SEQUENCE 1.0  
ID \_ABG66758 standard; protein; 207 AA.

XX ABG66758;

DT 30-AUG-2002 (first entry)

XX Human novel polypeptide #93.

XX Human; inflammatory condition; shock; sepsis; immune response; cancer;  
XX wound healing; central nervous system disease; haematopoiesis;  
XX peripheral nervous system disease; amyotrophic lateral sclerosis; tendon;  
XX myeloid cell disorder; lymphoid cell disorder; platelet disorder; bone;  
XX cartilage; ligament; nerve tissue; ulcer; osteoporosis; osteoarthritis;  
XX bone degenerative disorder; periodontal disease; reperfusion injury;  
XX lung fibrosis; liver fibrosis; autoimmune disorder; bacterial infection;  
XX allergic condition; thrombolysis; thrombosis; coagulation disorder;  
XX fungal infection.

XX Homo sapiens.

XX WO200244340-A2.

XX 06-JUN-2002.

XX 30-NOV-2001; 2001WO-US047004.

XX 30-NOV-2000; 2000US-00728952.

XX (HYSE-) HYSEQ INC.

XX Tang YT, Goodrich RW, Liu C, Zhou P, Asundi V, Wang J, Wang D;  
PI Yamazaki V, Ujwal ML, Drmanac RT;

DR WPI; 2002-508509/54.

DR N-PSDB; ABK94982.

XX Novel nucleic acids and polypeptides for diagnosis, treatment of  
PT inflammatory, autoimmune, nervous system, myeloid or lymphoid cell  
PT disorders, cancer and promoting wound healing.

PS Claim 10; Page 672; 672pp; English.

XX The invention relates to human novel polynucleotides and associated  
CC polypeptides. The polynucleotides and polypeptides are useful for  
CC treating inflammatory conditions such as arthritis, nephritis, Crohn's  
CC disease, ischaemia-reperfusion injury, shock, sepsis, immune responses  
CC and cancer and for promoting wound healing. The sequences are used to  
CC induce the proliferation of neural cells and regeneration of nerve and  
CC brain tissue, and are useful for the treatment of central and peripheral  
CC nervous system diseases and neuropathies, such as Alzheimer's disease,  
CC Parkinson's disease, Huntington's disease and amyotrophic lateral  
CC sclerosis. The sequences are involved in chemotactic or chemokinetic  
CC activity, regulation of haematopoiesis, treatment of myeloid or lymphoid  
CC cell disorders and platelet disorders such as thrombocytopenia,  
CC regeneration of bone, cartilage, tendon, ligament and/or nerve tissue

!!IAA\_SEQUENCE 1.0  
ID \_ABP00320 standard; protein; 75 AA.  
XX AC ABP00320;  
XX DT 25-JUN-2002 (first entry)  
XX XX  
XX DE Human ORFX protein sequence SEQ ID NO:622.  
XX XX  
XX KW Human; open reading frame; ORFX; gene therapy; cancer; cirrhosis;  
KW hyperproliferative disorder; psoriasis; benign tumour; haemorrhage;  
KW degenerative disorder; osteoarthritis; neurodegenerative disorder;  
KW cardiovascular disease; diabetes mellitus; systemic lupus erythematosus;  
KW hypertension; hypothyroidism; cholesterol ester storage disease;  
KW immune deficiency; immune disorder; infectious disease;  
KW autoimmune disorder; rheumatoid arthritis; autoimmune thyroiditis;  
KW myasthenia gravis.  
XX OS Homo sapiens.  
XX XX  
XX PN WO200192523-A2.  
XX PD 06-DEC-2001.  
XX XX  
XX PF 29-MAY-2001; 2001WO-US010836.  
XX XX  
XX PR 30-MAY-2000; 2000US-0206132P.  
XX PR 29-AUG-2000; 2000US-0228716P.  
XX XX  
XX PA (CURA-) CURAGEN CORP.  
XX XX  
XX PI Shimkets RA, Leach MD;  
XX DR WPI; 2002-106308/14.  
XX DR N-PSDB; ABN16072.  
XX XX  
XX PT Novel human polypeptides and polynucleotides useful for diagnosing,  
PT preventing and treating cardiovascular disease, neurodegenerative,  
PT hyperproliferative disorders and autoimmune disorders.  
XX XX  
XX PS Disclosure; SEQ ID NO 622; 1037pp; English.  
XX XX  
XX CC The present invention describes substantially purified human proteins  
CC (referred to as open reading frame, ORFX, where X is 1-11491 (see Table 1  
CC in the specification). ABN15762 to ABN27252 encode the human ORFX  
CC proteins given in ABP00010 to ABP11500. ORFX proteins are useful for  
CC treating or preventing a pathology associated with an ORFX-associated  
CC syndrome associated with ORFX-associated disorder. ORFX polynucleotide  
CC sequences can be used in gene therapy. ORFX sequences can be used in the  
CC treatment of cancer, hyperproliferative disorders, disorders related to organ  
CC transplantation, neurodegenerative disorders, diabetes mellitus, systemic  
CC psoriasis, benign tumours, keloid, degenerative disorders, haemorrhage,  
CC osteoarthritis, neurodegenerative diseases, disorders related to organ  
CC storage disease, various immune deficiencies and disorders, infectious  
CC diseases, autoimmune disorders such as multiple sclerosis, rheumatoid  
CC arthritis, autoimmune thyroiditis, myasthenia gravis, graft-versus-host  
CC disease and autoimmune inflammatory eye disease. ORFX proteins are also  
CC useful for treating burns, incisions, ulcers, for treating osteoporosis,  
CC bone degenerative disorders, or periodontal disease, and for gut  
CC protection or regeneration and treatment of lung or liver fibrosis,  
CC reperfusion injury in various tissues and conditions resulting from  
CC systemic cytokine damage. N.B. The sequence data for this patent did not  
CC form part of the printed specification, but was obtained in electronic  
CC format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
XX XX  
SQ Sequence 75 AA;  
ABP00320 Length: 75 February 22, 2005 12:25 Type: P Check: 5712 ..  
1 CGDCVCVCAH MHMCACTCTC VCVCMVCVH VSACLWGMG ACVCTCVHVC  
ABP05967 Length: 100 February 22, 2005 12:25 Type: P Check: 9068 ..



CC electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 122 AA;

ABG27074 Length: 122 February 22, 2005 12:25 Type: P Check: 9200 ..  
1 HRCSTGAFST AASNSNADRP PPARRRGLPR PGLPPEVAAT TTEGAVAE  
51 ETEDEDEGEG AAGDARRPL PPGJRTLAAA GGGCCCCCCCC CCCCCCCCCC  
101 CCCCCCCCCC CCGFSDMR EF

!!AA SEQUENCE 1.0  
ID \_ABG08983 standard; protein; 87 AA.  
XX  
AC ABG08983;  
XX  
DT 13-FEB-2002 (first entry)  
XX  
DE Novel human diagnostic protein #8974.  
XX  
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
KW food supplement; medical imaging; diagnostic; genetic disorder.  
XX  
OS Homo sapiens.  
XX  
FN WO200175067-A2.  
XX  
PD 11-OCT-2001.  
XX  
PF 30-MAR-2001; 2001WO-US008631.  
XX  
PR 31-MAR-2000; 2000US-00540217.  
PR 23-AUG-2000; 2000US-00649167.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Drmanac RT, Liu C, Tang YT;  
XX  
DR WPI; 2001-639362/73.  
DR N-PSDB; AAS73170.  
XX  
PT New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity.  
XX  
PS Claim 20; SEQ ID NO 39342; 103pp; English.  
XX  
CC The invention relates to isolated polynucleotide (I) and polypeptide (II)  
CC sequences. (I) is useful as hybridisation probes, polymerase chain  
CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
CC and in recombinant production of (II). The polynucleotides are also used  
CC in diagnostics as expressed sequence tags for identifying expressed  
CC genes. (I) is useful in gene therapy techniques to restore normal  
CC activity of (II) or to treat disease states involving (II). (II) is  
CC useful for generating antibodies against it, detecting or quantitating a  
CC polypeptide in tissue, as molecular weight markers and as a food  
CC supplement. (II) and its binding partners are useful in medical imaging  
CC of sites expressing (II). (I) and (II) are useful for treating disorders  
CC involving aberrant protein expression or biological activity. The  
CC polypeptide and polynucleotide sequences have applications in  
CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
CC amino acid sequences of the invention. Note: The sequence data for this  
CC patent did not appear in the printed specification, but was obtained in  
CC electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 87 AA;

ABG27078 Length: 186 February 22, 2005 12:25 Type: P Check: 1603 ..  
1 ESTAAEADTR FGCSSWAVAV EAEGEDCCCC CCCCCCCCCC CCCCCCCCCC  
51 CCCCLPPSAG GRGPGSGARY PALIDAAQRE DGGDAYRVGL AAALVNAAE

ABG08983 Length: 87 February 22, 2005 12:25 Type: P Check: 1329 ..  
1 NHPQLKXAGL KNGCCVCMCV CVCVCVVRVW IWCVCVCVCV CVCVCVCVCV  
51 CCVCICVCIX VWCVCVCCLC LSLPKCWDYR HEPORPA

!!AA SEQUENCE 1.0  
ID \_ABG27787 standard; protein; 186 AA.  
XX  
AC ABG27787;  
XX  
DT 18-FEB-2002 (first entry)  
XX  
DE Novel human diagnostic protein #27778.  
XX  
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
KW food supplement; medical imaging; diagnostic; genetic disorder.  
XX  
OS Homo sapiens.  
XX  
FN WO200175067-A2.  
XX  
PD 11-OCT-2001.  
XX  
PF 30-MAR-2001; 2001WO-US008631.  
XX  
PR 31-MAR-2000; 2000US-00540217.  
PR 23-AUG-2000; 2000US-00649167.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Drmanac RT, Liu C, Tang YT;  
XX  
DR WPI; 2001-639362/73.  
DR N-PSDB; AAS91974.  
XX  
PT New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity.  
XX  
PS Claim 20; SEQ ID NO 58146; 103pp; English.  
XX  
CC The invention relates to isolated polynucleotide (I) and polypeptide (II)  
CC sequences. (I) is useful as hybridisation probes, polymerase chain  
CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
CC and in recombinant production of (II). The polynucleotides are also used  
CC in diagnostics as expressed sequence tags for identifying expressed  
CC genes. (I) is useful in gene therapy techniques to restore normal  
CC activity of (II) or to treat disease states involving (II). (II) is  
CC useful for generating antibodies against it, detecting or quantitating a  
CC polypeptide in tissue, as molecular weight markers and as a food  
CC supplement. (II) and its binding partners are useful in medical imaging  
CC of sites expressing (II). (I) and (II) are useful for treating disorders  
CC involving aberrant protein expression or biological activity. The  
CC polypeptide and polynucleotide sequences have applications in  
CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
CC amino acid sequences of the invention. Note: The sequence data for this  
CC patent did not appear in the printed specification, but was obtained in  
CC electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 186 AA;

CC useful for generating antibodies against it, detecting or quantitating a  
CC polypeptide in tissue, as molecular weight markers and as a food  
CC supplement. (II) and its binding partners are useful in medical imaging  
CC of sites expressing (II). (I) and (II) are useful for treating disorders  
CC involving aberrant protein expression or biological activity. The  
CC polypeptide and polynucleotide sequences have applications in  
CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
CC amino acid sequences of the invention. Note: The sequence data for this  
CC patent did not appear in the printed specification, but was obtained in  
CC electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 74 AA;

ABG23597 Length: 74 February 22, 2005 12:25 Type: P Check: 9127 ..

1 FRDAICLIMR AAFWRCCCCC CCCCCCCCCC CCCCCCCCCC CCRDWMWSGA

51 GCCRGPEGK LSGTGVNSP GRPG

!!AA SEQUENCE 1.0  
ID ABG23599 standard; protein; 61 AA.  
AC ABG23599;  
XX  
XX  
DT 18-FEB-2002 (first entry)  
XX  
DE Novel human diagnostic protein #23590.  
XX  
XX Human; chromosome mapping; gene mapping; gene therapy; forensic;  
KW food supplement; medical imaging; diagnostic; genetic disorder.  
KW  
XX  
OS Homo sapiens.  
XX  
XX WO200175067-A2.  
PN  
XX 11-OCT-2001.  
PD  
XX  
XX 30-MAR-2001; 2001WO-US008631.  
PF  
XX  
XX 31-MAR-2000; 2000US-00540217.  
PR  
XX 23-AUG-2000; 2000US-00649167.  
PR  
XX (HYSE-) HYSEQ INC.  
PA  
XX Drmanac RT, Liu C, Tang YT;  
PI  
XX WPI; 2001-639362/73.  
DR  
XX N-PSDB; AAS87786.  
DR  
XX  
XX New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity.  
XX  
PS Claim 20; SEQ ID NO 53958; 103pp; English.

CC The invention relates to isolated polynucleotide (I) and polypeptide (II)  
CC sequences. (II) is useful as hybridisation probes, polymerase chain  
CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
CC and in recombinant production of (II). The polynucleotides are also used  
CC in diagnostics as expressed sequence tags for identifying expressed  
CC genes. (I) is useful in gene therapy techniques to restore normal  
CC activity of (II) or to treat disease states involving (II). (II) is  
CC useful for generating antibodies against it, detecting or quantitating a  
CC polypeptide in tissue, as molecular weight markers and as a food  
CC supplement. (II) and its binding partners are useful in medical imaging  
CC of sites expressing (II). (I) and (II) are useful for treating disorders  
CC involving aberrant protein expression or biological activity. The  
CC polypeptide and polynucleotide sequences have applications in

CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
CC amino acid sequences of the invention. Note: The sequence data for this  
CC patent did not appear in the printed specification, but was obtained in  
CC electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 61 AA;

ABG23599 Length: 61 February 22, 2005 12:25 Type: P Check: 2373 ..

1 SKWWWWWWC CCCCCCCCCC CCCCCCCCCC CCCCCCCCCC CCCCCCCCCC

51 CCCCCCCCCC W

!!AA SEQUENCE 1.0  
ID ABG27074 standard; protein; 122 AA.  
XX  
AC ABG27074;  
XX  
XX  
DT 18-FEB-2002 (first entry)  
XX  
DE Novel human diagnostic protein #27065.  
XX  
XX Human; chromosome mapping; gene mapping; gene therapy; forensic;  
KW food supplement; medical imaging; diagnostic; genetic disorder.  
KW  
XX  
OS Homo sapiens.  
XX  
XX WO200175067-A2.  
PN  
XX 11-OCT-2001.  
PD  
XX  
XX 30-MAR-2001; 2001WO-US008631.  
PF  
XX  
XX 31-MAR-2000; 2000US-00540217.  
PR  
XX 23-AUG-2000; 2000US-00649167.  
PR  
XX (HYSE-) HYSEQ INC.  
PA  
XX Drmanac RT, Liu C, Tang YT;  
PI  
XX WPI; 2001-639362/73.  
DR  
XX N-PSDB; AAS91261.  
DR  
XX  
XX New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity.  
XX  
PS Claim 20; SEQ ID NO 57433; 103pp; English.

CC The invention relates to isolated polynucleotide (I) and polypeptide (II)  
CC sequences. (I) is useful as hybridisation probes, polymerase chain  
CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
CC and in recombinant production of (II). The polynucleotides are also used  
CC in diagnostics as expressed sequence tags for identifying expressed  
CC genes. (I) is useful in gene therapy techniques to restore normal  
CC activity of (II) or to treat disease states involving (II). (II) is  
CC useful for generating antibodies against it, detecting or quantitating a  
CC polypeptide in tissue, as molecular weight markers and as a food  
CC supplement. (II) and its binding partners are useful in medical imaging  
CC of sites expressing (II). (I) and (II) are useful for treating disorders  
CC involving aberrant protein expression or biological activity. The  
CC polypeptide and polynucleotide sequences have applications in  
CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
CC amino acid sequences of the invention. Note: The sequence data for this  
CC patent did not appear in the printed specification, but was obtained in

XX PS Claim 20; SEQ ID NO 53959; 103pp; English.

XX CC The invention relates to isolated polynucleotide (I) and polypeptide (II) sequences. (I) is useful as hybridisation probes, polymerase chain reaction (PCR) primers, oligomers, and for chromosome and gene mapping.

XX CC and in recombinant production of (II). The polynucleotides are also used in diagnostics as expressed sequence tags for identifying expressed genes. (II) is useful in gene therapy techniques to restore normal activity of (II) or to treat disease states involving (II). (II) is useful for generating antibodies against it, detecting or quantitating a polypeptide in tissue, as molecular weight markers and as a food supplement. (II) and its binding partners are useful in medical imaging of sites expressing (II). (I) and (II) are useful for treating disorders involving aberrant protein expression or biological activity. The polypeptide and polynucleotide sequences have applications in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits to assess biodiversity and to produce other types of data and products dependent on DNA and amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic amino acid sequences of the invention. Note: The sequence data for this patent did not appear in the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

XX SQ Sequence 87 AA;

ABG23600 Length: 87 February 22, 2005 12:25 Type: P Check: 8132 ..

1 SMSSSLIASP RSLPSAPELV AGLSHGCELC PDRSPCCCC CCCCCCCCCC

51 CCCCCCCCCC CCCCCCCCCC CCCCCCCCCC FCCCFSK

!!AA\_SEQUENCE 1.0

ID \_ABG23598 standard; protein; 130 AA.

XX AC ABG23598;

XX DT 18-FEB-2002 (first entry)

XX DE Novel human diagnostic protein #23589.

XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic; food supplement; medical imaging; diagnostic; genetic disorder.

XX OS Homo sapiens.

XX PN WO200175067-A2.

XX PD 11-OCT-2001.

XX PF 30-MAR-2001; 2001WO-US008631.

XX PR 31-MAR-2000; 2000US-00540217.

XX PR 23-AUG-2000; 2000US-00649167.

XX PA (HYSE-) HYSEQ INC.

XX PI Drmanac RT, Liu C, Tang YT;

XX DR WPI; 2001-639362/73.

XX DR N-PSDB; AAS87785.

XX PT New isolated polynucleotide and encoded polypeptides, useful in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits and to assess biodiversity.

XX PS Claim 20; SEQ ID NO 53957; 103pp; English.

XX CC The invention relates to isolated polynucleotide (I) and polypeptide (II) sequences. (I) is useful as hybridisation probes, polymerase chain reaction (PCR) primers, oligomers, and for chromosome and gene mapping,

CC and in recombinant production of (II). The polynucleotides are also used in diagnostics as expressed sequence tags for identifying expressed genes. (I) is useful in gene therapy techniques to restore normal activity of (II) or to treat disease states involving (II). (II) is useful for generating antibodies against it, detecting or quantitating a polypeptide in tissue, as molecular weight markers and as a food supplement. (II) and its binding partners are useful in medical imaging of sites expressing (II). (I) and (II) are useful for treating disorders involving aberrant protein expression or biological activity. The polypeptide and polynucleotide sequences have applications in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits to assess biodiversity and to produce other types of data and products dependent on DNA and amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic amino acid sequences of the invention. Note: The sequence data for this patent did not appear in the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

XX SQ Sequence 130 AA;

ABG23598 Length: 130 February 22, 2005 12:25 Type: P Check: 8816 ..

1 QTLMRVKHHR CSTGAFSTAA SNSNADRPAP ARRRLPLPP LPPPEVAATT

51 BEGAVAEDEE TEDEDEGEGAA AGDARRPLPP GLRTLAAGG CCCCCCCCCC

101 CCCCCCCCCC CCCCCCCCCC WGFSDMVRFF

!!AA\_SEQUENCE 1.0

ID \_ABG23597 standard; protein; 74 AA.

XX AC ABG23597;

XX DT 18-FEB-2002 (first entry)

XX DE Novel human diagnostic protein #23588.

XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic; food supplement; medical imaging; diagnostic; genetic disorder.

XX OS Homo sapiens.

XX PN WO200175067-A2.

XX PD 11-OCT-2001.

XX PF 30-MAR-2001; 2001WO-US008631.

XX PR 31-MAR-2000; 2000US-00540217.

XX PR 23-AUG-2000; 2000US-00649167.

XX PA (HYSE-) HYSEQ INC.

XX PI Drmanac RT, Liu C, Tang YT;

XX DR WPI; 2001-639362/73.

XX DR N-PSDB; AAS87784.

XX PT New isolated polynucleotide and encoded polypeptides, useful in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits and to assess biodiversity.

XX PS Claim 20; SEQ ID NO 53956; 103pp; English.

XX CC The invention relates to isolated polynucleotide (I) and polypeptide (II) sequences. (I) is useful as hybridisation probes, polymerase chain reaction (PCR) primers, oligomers, and for chromosome and gene mapping, and in recombinant production of (II). The polynucleotides are also used in diagnostics as expressed sequence tags for identifying expressed genes. (I) is useful in gene therapy techniques to restore normal activity of (II) or to treat disease states involving (II). (II) is



XX Claim 20; SEQ ID NO 57805; 103pp; English.  
PS  
CC The invention relates to isolated polynucleotide (I) and polypeptide (II)  
CC sequences. (I) is useful as hybridisation probes, polymerase chain  
CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
CC and in recombinant production of (II). The polynucleotides are also used  
CC in diagnostics as expressed sequence tags for identifying expressed  
CC genes. (I) is useful in gene therapy techniques to restore normal  
CC activity of (II) or to treat disease states involving (II). (II) is  
CC useful for generating antibodies against it, detecting or quantitating a  
CC polypeptide in tissue, as molecular weight markers and as a food  
CC supplement. (II) and its binding partners are useful in medical imaging  
CC of sites expressing (II). (I) and (II) are useful for treating disorders  
CC involving aberrant protein expression or biological activity. The  
CC polypeptide and polynucleotide sequences have applications in  
CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
CC amino acid sequences of the invention. Note: The sequence data for this  
CC patent did not appear in the printed specification, but was obtained in  
CC electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 89 AA;  
ABG27446 Length: 89 February 22, 2005 12:25 Type: P Check: 4889 ..  
1 YLRVFKWV NVLITVAEVG EFGGCSVAAP AAAATCCCCC CCCCCCCCCC  
51 CCCCCCCCCC CCCCCCCCCC CCWLRLRAVD SSAARSRV  
!!AA SEQUENCE 1.0  
ID ABG19008 standard; protein; 398 AA.  
XX  
AC ABG19008;  
DT 18-FEB-2002 (first entry)  
XX  
DE Novel human diagnostic protein #18999.  
XX  
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
KW food supplement; medical imaging; diagnostic; genetic disorder.  
XX  
OS Homo sapiens.  
XX  
FN WO200175067-A2.  
PD 11-OCT-2001.  
XX  
PF 30-MAR-2001; 2001WO-US008631.  
XX  
PR 31-MAR-2000; 2000US-00540217.  
PR 23-AUG-2000; 2000US-00649167.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Drmanac RT, Liu C, Tang YT;  
XX  
DR WPI; 2001-639362/73.  
DR N-PSDB; AAS83195.  
XX  
PT New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity.  
XX  
PS Claim 20; SEQ ID NO 49367; 103pp; English.  
XX  
CC The invention relates to isolated polynucleotide (I) and polypeptide (II)  
CC sequences. (I) is useful as hybridisation probes, polymerase chain  
CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,

CC and in recombinant production of (II). The polynucleotides are also used  
CC in diagnostics as expressed sequence tags for identifying expressed  
CC genes. (I) is useful in gene therapy techniques to restore normal  
CC activity of (II) or to treat disease states involving (II). (II) is  
CC useful for generating antibodies against it, detecting or quantitating a  
CC polypeptide in tissue, as molecular weight markers and as a food  
CC supplement. (II) and its binding partners are useful in medical imaging  
CC of sites expressing (II). (I) and (II) are useful for treating disorders  
CC involving aberrant protein expression or biological activity. The  
CC polypeptide and polynucleotide sequences have applications in  
CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
CC amino acid sequences of the invention. Note: The sequence data for this  
CC patent did not appear in the printed specification, but was obtained in  
CC electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 398 AA;  
ABG19008 Length: 398 February 22, 2005 12:25 Type: P Check: 1993 ..  
1 GRRRRFWRK RIGGGGGGMA MPAEAPWNAS SFNGFLSLPP GWLLLPSPSD  
51 RNPPLOPSSR PPLCVRMWN APTPLISLFF WASLVSSGAR RLHPIQPQC  
101 REQAPWAPG AARSAVAASM SDCTVAGPCT GSHTPCHSTS DSQSPCGGVG  
151 SSLVVAERS CAQCRMSPRK GHCCCCCCCC CCCCSCCCYC HYCCCYCCCC  
201 CCCCCCCCCC CCCCCCCCCC CCCCCCCCCC CYCCCCCCCC CCCCCCRCCC  
251 CCCCRCOCXH YCCCCCCCCG CCCCRCYCCC RYRCYCFCC CCCCCCYCCC  
301 CXRTAHWPS MNKSQCVLPC ICKVPLGRLA VTTGCPGFGX GGCWEDCMFP  
351 AKGPSIRLEQ WFSTTAILLP SGPGDFWQYL GTLLAVTTRE EVLLESGG  
!!AA SEQUENCE 1.0  
ID ABG23600 standard; protein; 87 AA.  
XX  
AC ABG23600;  
DT 18-FEB-2002 (first entry)  
XX  
DE Novel human diagnostic protein #23591.  
XX  
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
KW food supplement; medical imaging; diagnostic; genetic disorder.  
XX  
OS Homo sapiens.  
XX  
PN WO200175067-A2.  
XX  
PD 11-OCT-2001.  
XX  
PF 30-MAR-2001; 2001WO-US008631.  
XX  
PR 31-MAR-2000; 2000US-00540217.  
PR 23-AUG-2000; 2000US-00649167.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Drmanac RT, Liu C, Tang YT;  
XX  
DR WPI; 2001-639362/73.  
DR N-PSDB; AAS87787.  
XX  
PT New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity.

XX WPI; 2001-639362/73.  
 DR N-PSDB; AAS87788.  
 XX  
 XX New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, forensics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity.  
 XX  
 PS Claim 20; SEQ ID NO 53960; 103pp; English.  
 XX  
 CC The invention relates to isolated polynucleotide (I) and polypeptide (II)  
 CC sequences. (I) is useful as hybridisation probes, polymerase chain  
 CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
 CC and in recombinant production of (II). The polynucleotides are also used  
 CC in diagnostics as expressed sequence tags for identifying expressed  
 CC genes. (I) is useful in gene therapy techniques to restore normal  
 CC activity of (II) or to treat disease states involving (II). (II) is  
 CC useful for generating antibodies against it, detecting or quantitating a  
 CC polypeptide in tissue, as molecular weight markers and as a food  
 CC supplement. (II) and its binding partners are useful in medical imaging  
 CC of sites expressing (II). (I) and (II) are useful for treating disorders  
 CC involving aberrant protein expression or biological activity. The  
 CC polypeptide and polynucleotide sequences have applications in  
 CC diagnostics, forensics, gene mapping, identification of mutations  
 CC responsible for genetic disorders or other traits to assess biodiversity  
 CC and to produce other types of data and products dependent on DNA and  
 CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
 CC amino acid sequences of the invention. Note: The sequence data for this  
 CC patent did not appear in the printed specification, but was obtained in  
 CC electronic format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 74 AA;  
 ABG23601 Length: 74 February 22, 2005 12:25 Type: P Check: 9127 ..  
 1 FRDAICLIMR AAFWRCCCC CCCCCCCCC CCCCCCCCC CCRDWSGA  
 51 GCCRGPEK LSGTGVNSP GRPG  
 !!AA\_SEQUENCE 1.0  
 ID ABG08984 standard; protein; 166 AA.  
 XX  
 AC ABG08984;  
 XX  
 DT 13-FEB-2002 (first entry)  
 XX  
 DE Novel human diagnostic protein #8975.  
 XX  
 KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
 KW food supplement; medical imaging; diagnostic; genetic disorder.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200175067-A2.  
 XX  
 PD 11-OCT-2001.  
 XX  
 XX 30-MAR-2001; 2001WO-US008631.  
 XX  
 XX 31-MAR-2000; 2000US-00540217.  
 XX  
 PR 23-AUG-2000; 2000US-00649167.  
 XX  
 XX (HYSE-) HYSEQ INC.  
 XX  
 XX Drmanac RT, Liu C, Tang YT;  
 XX  
 XX WPI; 2001-639362/73.  
 XX  
 DR N-PSDB; AAS73171.  
 XX  
 XX New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, forensics, gene mapping, identification of mutations

PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity.  
 XX  
 PS Claim 20; SEQ ID NO 39343; 103pp; English.  
 XX  
 CC The invention relates to isolated polynucleotide (I) and polypeptide (II)  
 CC sequences. (I) is useful as hybridisation probes, polymerase chain  
 CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
 CC and in recombinant production of (II). The polynucleotides are also used  
 CC in diagnostics as expressed sequence tags for identifying expressed  
 CC genes. (I) is useful in gene therapy techniques to restore normal  
 CC activity of (II) or to treat disease states involving (II). (II) is  
 CC useful for generating antibodies against it, detecting or quantitating a  
 CC polypeptide in tissue, as molecular weight markers and as a food  
 CC supplement. (II) and its binding partners are useful in medical imaging  
 CC of sites expressing (II). (I) and (II) are useful for treating disorders  
 CC involving aberrant protein expression or biological activity. The  
 CC polypeptide and polynucleotide sequences have applications in  
 CC diagnostics, forensics, gene mapping, identification of mutations  
 CC responsible for genetic disorders or other traits to assess biodiversity  
 CC and to produce other types of data and products dependent on DNA and  
 CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic  
 CC amino acid sequences of the invention. Note: The sequence data for this  
 CC patent did not appear in the printed specification, but was obtained in  
 CC electronic format directly from WIPO at  
 CC ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 166 AA;  
 ABG08984 Length: 166 February 22, 2005 12:25 Type: P Check: 5869 ..  
 1 YLSGNGGEGK FCHALPDHRL RVLQHPPHA CVETDTVDLG ITSISLADVR  
 51 VCVCMCVVCV CVCVRVMIWV CVCVCVCVCV CVCVCVCVCV CVCVCVCVCV CVCVCVCVCV  
 101 CVCVCVCVCV VCICCVCCVCV CVCVCVCVCV IXVCVCVVCV VCVCLCTVLG  
 151 IHSFLTARNA HQPIGH  
 !!AA\_SEQUENCE 1.0  
 ID ABG27446 standard; protein; 89 AA.  
 XX  
 AC ABG27446;  
 XX  
 DT 18-FEB-2002 (first entry)  
 XX  
 DE Novel human diagnostic protein #27437.  
 XX  
 KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
 KW food supplement; medical imaging; diagnostic; genetic disorder.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200175067-A2.  
 XX  
 PD 11-OCT-2001.  
 XX  
 XX 30-MAR-2001; 2001WO-US008631.  
 XX  
 XX 31-MAR-2000; 2000US-00540217.  
 XX  
 PR 23-AUG-2000; 2000US-00649167.  
 XX  
 XX (HYSE-) HYSEQ INC.  
 XX  
 XX Drmanac RT, Liu C, Tang YT;  
 XX  
 XX WPI; 2001-639362/73.  
 XX  
 DR N-PSDB; AAS91633.  
 XX  
 XX New isolated polynucleotide and encoded polypeptides, useful in  
 PT diagnostics, forensics, gene mapping, identification of mutations  
 PT responsible for genetic disorders or other traits and to assess  
 PT biodiversity.

XX PA (HYSE-) HYSEQ INC.  
XX DR Drmanac RT, Liu C, Tang YT;  
XX PI  
XX DR WPI; 2001-639362/73.  
XX DR N-PSDB; AAS91972.  
XX PT New isolated polynucleotide and encoded polypeptides, useful in  
XX PT diagnostics, forensics, gene mapping, identification of mutations  
XX PT responsible for genetic disorders or other traits and to assess  
XX PT biodiversity.  
XX PS Claim 20; SEQ ID NO 58144; 103pp; English.  
XX PS  
XX CC The invention relates to isolated polynucleotide (I) and polypeptide (II)  
XX CC sequences. (I) is useful as hybridisation probes, polymerase chain  
XX CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
XX CC and in recombinant production of (II). The polynucleotides are also used  
XX CC in diagnostics as expressed sequence tags for identifying expressed  
XX CC genes. (I) is useful in gene therapy techniques to restore normal  
XX CC activity of (II) or to treat disease states involving (II). (II) is  
XX CC useful for generating antibodies against it, detecting or quantitating a  
XX CC polypeptide in tissue, as molecular weight markers and as a food  
XX CC supplement. (II) and its binding partners are useful for treating disorders  
XX CC of sites expressing (II). (I) and (II) are useful for biological activity. The  
XX CC polypeptide and polynucleotide sequences have applications in  
XX CC diagnostics, forensics, gene mapping, identification of mutations  
XX CC responsible for genetic disorders or other traits to assess biodiversity  
XX CC and to produce other types of data and products dependent on DNA and  
XX CC amino acid sequences. ABG0010-ABG30377 represent novel human diagnostic  
XX CC amino acid sequences of the invention. Note: The sequence data for this  
XX CC patent did not appear in the printed specification, but was obtained in  
XX CC electronic format directly from WIPO at  
XX CC ftp.wipo.int/pub/published\_pct\_sequences  
XX SQ Sequence 130 AA;  
ABG27785 Length: 130 February 22, 2005 12:25 Type: P Check: 8816 ..  
1 QTLMRVKHHR CSTGAFSTAA SNSNADRPFP ARRGLPRPG LPPPEVAATT  
51 EEGAVAEDEE TEDEDEGGAA AGDARRPLPP GLRTLAAAGG GCCCCCCCCC  
101 CCCCCCCCCC CCCCCCCCCC WGFSDWREF  
!!AA SEQUENCE 1.0  
ID ABG08986 standard; protein; 239 AA.  
XX AC ABG08986;  
XX AC  
XX DT 13-FEB-2002 (first entry)  
XX DE  
XX DE Novel human diagnostic protein #8977.  
XX DE  
XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
XX KW food supplement; medical imaging; diagnostic; genetic disorder.  
XX OS Homo sapiens.  
XX OS  
XX PN WO200175067-A2.  
XX PN  
XX PD 11-OCT-2001.  
XX PD  
XX PF 30-MAR-2001; 2001WO-US008631.  
XX PF  
XX PR 31-MAR-2000; 2000US-00540217.  
XX PR 23-AUG-2000; 2000US-00649167.  
XX PR  
XX PA (HYSE-) HYSEQ INC.  
XX PA  
XX PI Drmanac RT, Liu C, Tang YT;

XX WPI; 2001-639362/73.  
XX DR N-PSDB; AAS73173.  
XX PT New isolated polynucleotide and encoded polypeptides, useful in  
XX PT diagnostics, forensics, gene mapping, identification of mutations  
XX PT responsible for genetic disorders or other traits and to assess  
XX PT biodiversity.  
XX PS Claim 20; SEQ ID NO 39345; 103pp; English.  
XX PS  
XX CC The invention relates to isolated polynucleotide (I) and polypeptide (II)  
XX CC sequences. (I) is useful as hybridisation probes, polymerase chain  
XX CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,  
XX CC and in recombinant production of (II). The polynucleotides are also used  
XX CC in diagnostics as expressed sequence tags for identifying expressed  
XX CC genes. (I) is useful in gene therapy techniques to restore normal  
XX CC activity of (II) or to treat disease states involving (II). (II) is  
XX CC useful for generating antibodies against it, detecting or quantitating a  
XX CC polypeptide in tissue, as molecular weight markers and as a food  
XX CC supplement. (II) and its binding partners are useful for treating disorders  
XX CC of sites expressing (II). (I) and (II) are useful for biological activity. The  
XX CC involving aberrant protein expression or biological activity. The  
XX CC polypeptide and polynucleotide sequences have applications in  
XX CC diagnostics, forensics, gene mapping, identification of mutations  
XX CC responsible for genetic disorders or other traits to assess biodiversity  
XX CC and to produce other types of data and products dependent on DNA and  
XX CC amino acid sequences. ABG0010-ABG30377 represent novel human diagnostic  
XX CC amino acid sequences of the invention. Note: The sequence data for this  
XX CC patent did not appear in the printed specification, but was obtained in  
XX CC electronic format directly from WIPO at  
XX CC ftp.wipo.int/pub/published\_pct\_sequences  
XX SQ Sequence 239 AA;  
ABG08986 Length: 239 February 22, 2005 12:25 Type: P Check: 2423 ..  
1 RVPHRHGMKR VRQRHGMKRV PHRHEMKRVP HRHGMKRVPH RHGRKRVPHR  
51 HGRKRVPHRH GRKRVPAQVQ DEEGHCQKPG RCVMCMVCVCV CVCVRVWIW  
101 CVCVCVCVCV CVCVCVCVCV CVCVCIXWV CVCVCVCVCV VCICCCVCVCV  
151 CVCVCICVC IXVCVCVVC VCVCLCLFYL VLQCFICSCI ISGGQRWCXR  
201 KTWCSLPPAH SHHSFPGHFF LIFQSRSPQV SFHPHCTFW  
!!AA SEQUENCE 1.0  
ID ABG23601 standard; protein; 74 AA.  
XX AC ABG23601;  
XX AC  
XX DT 18-FEB-2002 (first entry)  
XX DE  
XX DE Novel human diagnostic protein #23592.  
XX DE  
XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
XX KW food supplement; medical imaging; diagnostic; genetic disorder.  
XX OS Homo sapiens.  
XX OS  
XX PN WO200175067-A2.  
XX PN  
XX PD 11-OCT-2001.  
XX PD  
XX PF 30-MAR-2001; 2001WO-US008631.  
XX PF  
XX PR 31-MAR-2000; 2000US-00540217.  
XX PR 23-AUG-2000; 2000US-00649167.  
XX PR  
XX PA (HYSE-) HYSEQ INC.  
XX PA  
XX PI Drmanac RT, Liu C, Tang YT;

```

XX DE Human polypeptide SEQ ID NO 16176.
XX DE
XX KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
XX KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
XX KW tissue growth factor; immunomodulatory; cancer; leukaemia;
XX KW nervous system disorders; arthritis; inflammation.
XX OS
XX OS Homo sapiens.
XX PN WO200164835-A2.
XX PD
XX PD 07-SEP-2001.
XX PF
XX PF 26-FEB-2001; 2001WO-US004927.
XX PR
XX PR 28-FEB-2000; 2000US-00515136.
XX PR 18-MAY-2000; 2000US-00577409.
XX PA
XX PA (HYSE-) HYSEQ INC.
XX PI
XX PI Tang YT, Liu C, Drmanac RT;
XX DR
XX DR WPI; 2001-514838/56.
XX DR N-PSDB; AAI82215.
XX PT
XX PT Isolated nucleic acids and polypeptides, useful for preventing diagnosing
XX PT and treating e.g. leukemia, inflammation and immune disorders.
XX PS
XX PS Claim 20; SEQ ID NO 16176; 1399pp + Sequence Listing; English.
XX CC
XX CC The invention relates to human polynucleotides (AAI79941-AAI93841) and
XX CC the encoded proteins (AAO00010-AAO13910) that exhibit activity elating to
XX CC cytokine, cell proliferation or cell differentiation or which may induce
XX CC production of other cytokines in other cell populations. The
XX CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
XX CC peptide therapy. The polypeptides have various cytokine-like activities,
XX CC e.g. stem cell growth factor activity, haematopoiesis regulating
XX CC activity, tissue growth factor activity, immunomodulatory activity and
XX CC activin/inhibin activity and may be useful in the diagnosis and/or
XX CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
XX CC inflammation. Note: The sequence data for this patent did not form part
XX CC of the printed specification, but was obtained in electronic format
XX CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX SQ Sequence 155 AA;
AAO02284 Length: 155 February 22, 2005 12:25 Type: P Check: 6785 ..
1 SLTHRVAGGA AVTEPLAHAGA RQIFFLGDPH PTSSLLGWGP AWDPCAFQVS
51 DHPASSRVGK TLLSCPGGGR LPWVTCPPGG QLSCLTQMHL TPAGMCSPCV
101 CVCVCVCVCV PNGMCPRCMC VCVPCRDVY ICVCVCVCVCV VCMCLCPQWD
151 VFTEL
!!AA SEQUENCE 1.0
ID ABG27784 standard; protein; 90 AA.
XX AC
XX AC ABG27784;
XX DT
XX DT 18-FEB-2002 (first entry)
XX DE
XX DE Novel human diagnostic protein #27775.
XX KW
XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
XX KW food supplement; medical imaging; diagnostic; genetic disorder.
XX OS
XX OS Homo sapiens.
XX PN
XX PN WO200175067-A2.

```

```

PD 11-OCT-2001.
XX 30-MAR-2001; 2001WO-US008631.
XX 31-MAR-2000; 2000US-00540217.
XX 23-AUG-2000; 2000US-00649167.
XX (HYSE-) HYSEQ INC.
XX Drmanac RT, Liu C, Tang YT;
XX WPI; 2001-639362/73.
XX N-PSDB; AAS91971.
XX PT
XX PT New isolated polynucleotide and encoded polypeptides, useful in
XX PT diagnostics, forensics, gene mapping, identification of mutations
XX PT responsible for genetic disorders or other traits and to assess
XX PT biodiversity.
XX PS
XX PS Claim 20; SEQ ID NO 58143; 103pp; English.
XX CC
XX CC The invention relates to isolated polynucleotide (I) and polypeptide (II)
XX CC sequences. (I) is useful as hybridisation probes, polymerase chain
XX CC reaction (PCR) primers, oligomers, and for chromosome and gene mapping,
XX CC and in recombinant production of (II). The polynucleotides are also used
XX CC in diagnostics as expressed sequence tags for identifying expressed
XX CC genes. (II) is useful in gene therapy techniques to restore normal
XX CC activity of (II) or to treat disease states involving (II). (II) is
XX CC useful for generating antibodies against it, detecting or quantitating a
XX CC polypeptide in tissue, as molecular weight markers and as a food
XX CC supplement. (II) and its binding partners are useful in medical imaging
XX CC of sites expressing (II). (I) and (II) are useful for treating disorders
XX CC involving aberrant protein expression or biological activity. The
XX CC polypeptide and polynucleotide sequences have applications in
XX CC diagnostics, forensics, gene mapping, identification of mutations
XX CC responsible for genetic disorders or other traits to assess biodiversity
XX CC and to produce other types of data and products dependent on DNA and
XX CC amino acid sequences. ABG00010-ABG30377 represent novel human diagnostic
XX CC patent did not appear in the printed specification, but was obtained in
XX CC electronic format directly from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX SQ Sequence 90 AA;
ABG27784 Length: 90 February 22, 2005 12:25 Type: P Check: 676 ..
1 GGGGGGGGGG GGGGGGGGGG CCCCCCCCCC CCCCCCCCCC CCCCCCCCCC WKDLRDSKAF
51 ISFSRVANAV SRPARQSPGA SGRLAAPLST GAMNGALGRR
!!AA SEQUENCE 1.0
ID ABG27785 standard; protein; 130 AA.
XX AC
XX AC ABG27785;
XX DT
XX DT 18-FEB-2002 (first entry)
XX DE
XX DE Novel human diagnostic protein #27776.
XX KW
XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
XX KW food supplement; medical imaging; diagnostic; genetic disorder.
XX OS
XX OS Homo sapiens.
XX PN
XX PN WO200175067-A2.
XX PD
XX PD 11-OCT-2001.
XX 30-MAR-2001; 2001WO-US008631.
XX 31-MAR-2000; 2000US-00540217.
XX 23-AUG-2000; 2000US-00649167.

```

1151 TGGTCCAGTA CCAGATGGCA CAGCTGCTCC GGGACCGTGA CTGGATCAAC  
 1201 CAGGTGTACC TGCCGGANAA CATGCCCGG CTCAGGCTG CCACACCTA  
 1251 TGTCTAGAA GAGCTTAGG CATTGGGAT CCCTTCTTG AGTCGTGGG  
 1301 CTGGCTTCTT CATCTGGTT GACTTGAGAA AGTAATGCT GGTGGAGTG  
 1351 CGGCTGAGA GGGAGTTTCA GGTCTCCCTC CAGCAGTACC TGCCCRAGG  
 1401 CACCTTTGAG GAGGAATGC TGCTCTGGG CCGCTTTTGG GACAAACAGG  
 1451 TGCTGTCTC CTTTGGCAAG GCGTTGCGT GTAAAGAGCC TGGTTGGTTT  
 1501 CGCTTTGTCT TCTCAGACCA GGTCCACCGG CTTTGCCTGG GGATGCAGAG  
 1551 GGTCCAGCAG GTCTTGGCAG GCAATGCCA AGTGGCAGAA GACCCCGTC  
 1601 CCTCTCAGC CCAGGAGCCA AGTGACCAAC GCAGGTGAGC TGGTCATTGT  
 1651 CTCGTGGCCA GAGGGCCCGC CAGGCCACTG

!!AA SEQUENCE 1.0  
 ID\_\_AAO01712 standard; protein; 55 AA.

XX AC AAO01712;  
 XX DT 06-NOV-2001 (first entry)  
 XX DE Human polypeptide SEQ ID NO 15604.  
 XX KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
 KW nervous system disorders; arthritis; inflammation.

XX OS Homo sapiens.

XX PN WO200164835-A2.

XX PD 07-SEP-2001.

XX PF 26-FEB-2001; 2001WO-US004927.

XX PR 28-FEB-2000; 2000US-00515126.

XX PR 18-MAY-2000; 2000US-00577409.

XX PA (HYSE-) HYSEQ INC.

XX PI Tang YT, Liu C, Drmanac RT;

XX DR WPI; 2001-514838/56.

XX DR N-PSDB; AAI81643.

XX PT Isolated nucleic acids and polypeptides, useful for preventing diagnosing  
 PT and treating e.g. leukemia, inflammation and immune disorders.

XX PS Claim 20; SEQ ID NO 15604; 1399pp + Sequence Listing; English.

XX CC The invention relates to human polynucleotides (AAI79941-AAI93841) and  
 CC the encoded proteins (AAO00010-AAO13910) that exhibit activity elating to  
 CC cytokine, cell proliferation or cell differentiation or which may induce  
 CC production of other cytokines in other cell populations. The  
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
 CC peptide therapy. The polypeptides have various cytokine-like activities,  
 CC e.g. stem cell growth factor activity, haematopoiesis regulating  
 CC activity, tissue growth factor activity, immunomodulatory activity and  
 CC activin/inhibin activity and may be useful in the diagnosis and/or  
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
 CC inflammation. Note: The sequence data for this patent did not form part  
 CC of the printed specification, but was obtained in electronic format  
 CC directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

XX

SQ Sequence 55 AA;

AAO01712 Length: 55 February 22, 2005 12:25 Type: P Check: 8832 ..

1 YTCVFVCLCL CDCMCCVCAC MYICVVCCTR VCMXVCVCMC VRVCVQLTV

51 LCKSV

!!AA SEQUENCE 1.0  
 ID\_\_AAO02062 standard; protein; 73 AA.

XX AC AAO02062;

XX DT 06-NOV-2001 (first entry)

XX DE Human polypeptide SEQ ID NO 15954.

XX KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
 KW nervous system disorders; arthritis; inflammation.

XX OS Homo sapiens.

XX PN WO200164835-A2.

XX PD 07-SEP-2001.

XX PF 26-FEB-2001; 2001WO-US004927.

XX PR 28-FEB-2000; 2000US-00515126.

XX PR 18-MAY-2000; 2000US-00577409.

XX PA (HYSE-) HYSEQ INC.

XX PI Tang YT, Liu C, Drmanac RT;

XX DR WPI; 2001-514838/56.

XX DR N-PSDB; AAI81993.

XX PT Isolated nucleic acids and polypeptides, useful for preventing diagnosing  
 PT and treating e.g. leukemia, inflammation and immune disorders.

XX PS Claim 20; SEQ ID NO 15954; 1399pp + Sequence Listing; English.

XX CC The invention relates to human polynucleotides (AAI79941-AAI93841) and  
 CC the encoded proteins (AAO00010-AAO13910) that exhibit activity elating to  
 CC cytokine, cell proliferation or cell differentiation or which may induce  
 CC production of other cytokines in other cell populations. The  
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
 CC peptide therapy. The polypeptides have various cytokine-like activities,  
 CC e.g. stem cell growth factor activity, haematopoiesis regulating  
 CC activity, tissue growth factor activity, immunomodulatory activity and  
 CC activin/inhibin activity and may be useful in the diagnosis and/or  
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
 CC inflammation. Note: The sequence data for this patent did not form part  
 CC of the printed specification, but was obtained in electronic format  
 CC directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

XX SQ Sequence 73 AA;

AAO02062 Length: 73 February 22, 2005 12:25 Type: P Check: 6071 ..

1 ELKVILHLR DRLQSSIMK VILKILILS VCCVCVCVCV CAVCSCVCVC

51 SCVCVCSCVC LCVLCVCVCV LSC

!!AA SEQUENCE 1.0

ID\_\_AAO02284 standard; protein; 155 AA.

XX AC AAO02284;

XX DT 06-NOV-2001 (first entry)

PF 23-MAR-2001; 2001WO-US009231.  
XX  
XX  
PR 23-MAR-2000; 2000US-0191637P.  
PR 11-JUL-2000; 2000US-00614150.  
XX  
XX (PEKE ) PE CORP NY.  
XX  
XX  
PI Venter JC, Adams M, Li PWD, Myers EW;  
XX  
XX WPI; 2001-656860/75.  
DR N-FSDB; ABL10487.  
XX  
XX New isolated nucleic acid detection reagent for detecting 1000 or more  
PT genes from Drosophila and for elucidating cell signaling and cell-cell  
PT interactions.  
XX  
XX  
XX Disclosure; SEQ ID NO 25944; 2lpp + Sequence Listing; English.  
XX  
XX The invention relates to an isolated nucleic acid detection reagent  
CC capable of detecting 1000 or more genes from Drosophila. The invention is  
CC useful in developmental biology and in elucidating cell signalling and  
CC cell-cell interactions in higher eukaryotes for the development of  
CC insecticides, therapeutics and pharmaceutical drugs. The invention  
CC discloses genomic DNA sequences (ABL16175) and the encoded proteins (ABBS57737-  
CC ABB72072). The sequence data for this patent did not form part of the  
CC printed specification, but was obtained in electronic format directly  
CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
XX Sequence 271 AA;  
ABBS6384 Length: 271 February 22, 2005 12:25 Type: P Check: 6468 ..  
1 MPKDKDKSKK QAKPSAKNKK KSGSKVKKK MSEHSNEIE GTVASPQETP  
51 EDEDAHPCPN CKKPCPTPPT KEMRTCCGSA NLPEENEDPP PAPSPPPPAP  
101 SNPPVPVPCNH APAPVNTCCM PCSNQCPWSW YYNPCTGCVY YCANCCNSCR  
151 NCCNYCCSPC GCCCSNPAA QLEKIPPKPK QKQRDRSN STRNSGGTAV  
201 SLGSCAPST FAPWKCPQRE VSTMPGYSPT ASPHFSSPYS GRWKAGCVDS  
251 HRNYQRNNQG PPFNIGRVHH V  
!!AA\_SEQUENCE 1.0  
ID\_AA007343 standard; protein; 1679 AA.  
XX  
XX AA007343;  
XX  
XX  
XX 04-DEC-2001 (first entry)  
XX  
XX 1-aminocyclopropane carboxylate (ACPC) synthase #12.  
DE  
XX 1-aminocyclopropane carboxylate synthase; ACPC synthase; brain trauma;  
KW excitatory neurotransmission; neurodegeneration; stroke; nerve damage;  
KW neurodegenerative disease; Alzheimer's disease; depression; epilepsy;  
KW alcohol abuse; cognitive function; memory; learning impairment; human.  
XX  
XX Homo sapiens.  
XX  
XX WO200168879-A2.  
XX  
XX 20-SEP-2001.  
XX  
XX 14-MAR-2001; 2001WO-EP002857.  
XX  
XX 14-MAR-2000; 2000US-0189086P.  
PR 05-APR-2000; 2000US-0194702P.  
XX  
XX (FARB ) BAYER AG.  
XX  
XX Ramakrishnan S;

XX WPI; 2001-550286/61.  
XX  
XX Isolated polynucleotide encoding a human 1-aminocyclopropane-carboxylate  
PT (ACPC) synthase, useful for treating brain trauma and neurodegenerative  
PT disease (e.g. Alzheimer's disease, depression, epilepsy).  
XX  
XX Claim 1; Page 231-237; 242pp; English.  
XX  
XX The invention relates to reagents and methods for regulating excitatory  
CC neurotransmission, and to prevent neurodegeneration. The method involves  
CC the use of an expression vector or a reagent that modulates the activity  
CC of a 1-aminocyclopropane-carboxylate (ACPC) synthase polypeptide. The  
CC reagent is useful for modulating the activity of an ACPC synthase in a  
CC disease such as stroke, a nerve damage or a neurodegenerative disease.  
CC The ACPC synthase polypeptide, polynucleotides and modulators are also  
CC useful for treating brain trauma and neurodegenerative disease (e.g.  
CC Alzheimer's disease, depression, epilepsy). The ACPC synthase modulators  
CC are also useful for treating alcohol abuse and improve cognitive function  
CC and memory of patients with learning impairment. The present sequence  
CC represents the amino acid sequence of human 1-aminocyclopropane-  
CC carboxylate (ACPC) synthase #12, used in the method of the invention  
XX  
XX Sequence 1679 AA;  
AAU07343 Length: 1679 February 22, 2005 12:25 Type: P Check: 200 ..  
1 ATCGAGTGGG GGTATCTGGC TGTGGATTGC CCGCCGTCCT GCTGGACGCC  
51 TGGAGGCTCG AACCCCGCCG CCCCCCTACC CCAGGCTTTA CTCCACACCC  
101 GCGTTCCGCC CACTGTGCTG CCCTTCTCTG GACCTGGGCT GTCGGGAGAG  
151 CTGGAGATGT TCACCCCTTC TCAAAAGGAC TTCAGGGGCTC CCACCACCTG  
201 TCTGGGCCCC ACCTGCATGC AGGACCTGGG CAGTAGCCAT GGGGAAGATC  
251 TGGAAGGAGA ATGCTCCAGA AACTGGACC AGAAGCTGCC AGAGCTCCGT  
301 GGAGTGGGTG ATCCTGCCAT GATCTCTCTT GATACCTCTT ACCTGTCTCT  
351 TAGAGGAAGA ATGATTAAAT GGTTCGGGA TTCAGCTGAG GAGGGCTACA  
401 GGACCTACCA CATGGATGAG TATGATGAG ACAAGAACCC CAGTGGCATC  
451 ATTAACCTGG GCACCACTGA GAACAAACTC TGCTTTGACC TGCTGTCTCTG  
501 GCGGCTGAGT CAGCGCGACA TGCAGAGGGT GGAGCCATCC CTGCTGCAGT  
551 ATGCTGACTG GAGGGGACAT CTGTTCTCTC GGGAGGAGT GCCCAAGTTC  
601 CTGCTTTTCT ACTGCAAGAG CCCAGTACCC CTCAGACACAG AGAATGTGGT  
651 TGTCCTGAAT GGTGTGCTCT CGCTCTTCTC TGCTCTGGCC ACGGTGCTGT  
701 GTGAGCCGGG GGAGGCTTTC CTGATCCCCA CCCCCTACTA TGGCGCTATC  
751 ACACAGCAGC TGTTCTCTTA TGGCAACATC CCGGTGGCCT ATGTCTACCT  
801 GGACAGTGAG GGTGTGAAGG TCAAAGGCCT CATCTCTCATC AGCCCCCAGA  
851 ACCCTCTGGG TGATGTATAC TCCCCCTGAAG AGCTACAGGA GTACTGTGTA  
901 TTGCGCAAGA GGCACAGGCT GCATGTGATT GTGGATGAGG TCTACATGCT  
951 GTCCGTGTTT GAGAAGTCTG TTGGGTACCG CAGTGTCTTA AGCCTGGA  
1001 GGCTCCCTGA CCCCACAGG ACCCATGTA TGTGGGCAAC CAGCAAGGAC  
1051 TTCGGGATGT CTGGGCTCCG CTTTGGACG CTGTACACAG AAACCCAGGA  
1101 TGTGGCCACT GCGTGGCTT CCCTCTGCCG CTACCACGGC CTCAGTGGCT

```

XX PS Disclosure; SEQ ID NO 26457; 2lpp + Sequence Listing; English.
XX CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
CC ABB72072). The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
XX from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 74 AA;

ABB66555 Length: 74 February 22, 2005 12:25 Type: P Check: 915 ..

1 MCCGPLGFCG PCSPGCGPCG PCGPGCGCGS CCSPGCGSCCA PCGPGCGPCGP
51 CCGCGCGPCGP CGPCCGPCRP YCGC

!!AA SEQUENCE 1.0
ID ABB70243 standard; protein; 47 AA.
XX AC ABB70243;
XX DT 26-MAR-2002 (first entry)
XX DE Drosophila melanogaster polypeptide SEQ ID NO 37521.
XX KW Drosophila; developmental biology; cell signalling; insecticide;
XX KW pharmaceutical.
XX OS Drosophila melanogaster.
XX PN WO200171042-A2.
XX PD 27-SEP-2001.
XX PF 23-MAR-2001; 2001WO-US009231.
XX PR 23-MAR-2000; 2000US-0191637P.
XX PR 11-JUL-2000; 2000US-00614150.
XX PA (PEKE ) PE CORP NY.
XX PI Venter JC, Adams M, Li PWD, Myers EW;
XX DR WPI; 2001-656860/75.
XX DR N-PSDB; ABL14346.
XX XX New isolated nucleic acid detection reagent for detecting 1000 or more
XX genes from Drosophila and for elucidating cell signalling and cell-cell
XX interactions.
XX PS Disclosure; SEQ ID NO 37521; 2lpp + Sequence Listing; English.
XX CC The invention relates to an isolated nucleic acid detection reagent
XX capable of detecting 1000 or more genes from Drosophila. The invention is
XX useful in developmental biology and in elucidating cell signalling and
XX cell-cell interactions in higher eukaryotes for the development of
XX insecticides, therapeutics and pharmaceutical drugs. The invention
XX discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
XX sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
XX ABB72072). The sequence data for this patent did not form part of the
XX printed specification, but was obtained in electronic format directly
XX from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 47 AA;

ABB70243 Length: 47 February 22, 2005 12:25 Type: P Check: 3853 ..

```

```

1 MCCGPGCPRC CDPGCGCYNC CVELCCVPCT PAYIQCSFMP CGPRGCC

!!AA SEQUENCE 1.0
ID ABB60549 standard; protein; 43 AA.
XX AC ABB60549;
XX DT 26-MAR-2002 (first entry)
XX DE Drosophila melanogaster polypeptide SEQ ID NO 8439.
XX KW Drosophila; developmental biology; cell signalling; insecticide;
XX KW pharmaceutical.
XX OS Drosophila melanogaster.
XX PN WO200171042-A2.
XX PD 27-SEP-2001.
XX PF 23-MAR-2001; 2001WO-US009231.
XX PR 23-MAR-2000; 2000US-0191637P.
XX PR 11-JUL-2000; 2000US-00614150.
XX PA (PEKE ) PE CORP NY.
XX PI Venter JC, Adams M, Li PWD, Myers EW;
XX DR WPI; 2001-656860/75.
XX DR N-PSDB; ABL04652.
XX XX New isolated nucleic acid detection reagent for detecting 1000 or more
XX genes from Drosophila and for elucidating cell signalling and cell-cell
XX interactions.
XX PS Disclosure; SEQ ID NO 8439; 2lpp + Sequence Listing; English.
XX CC The invention relates to an isolated nucleic acid detection reagent
XX capable of detecting 1000 or more genes from Drosophila. The invention is
XX useful in developmental biology and in elucidating cell signalling and
XX cell-cell interactions in higher eukaryotes for the development of
XX insecticides, therapeutics and pharmaceutical drugs. The invention
XX discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
XX sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
XX ABB72072). The sequence data for this patent did not form part of the
XX printed specification, but was obtained in electronic format directly
XX from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 43 AA;

ABB60549 Length: 43 February 22, 2005 12:25 Type: P Check: 9665 ..

1 MVCKGCGTNC QCSAQKCGDN CACNKDCQCV CKNGPKDQCC SNK

!!AA SEQUENCE 1.0
ID ABB66384 standard; protein; 271 AA.
XX AC ABB66384;
XX DT 26-MAR-2002 (first entry)
XX DE Drosophila melanogaster polypeptide SEQ ID NO 25944.
XX KW Drosophila; developmental biology; cell signalling; insecticide;
XX KW pharmaceutical.
XX OS Drosophila melanogaster.
XX PN WO200171042-A2.
XX PD 27-SEP-2001.
XX XX

```

```
XX PD 27-SEP-2001.
XX PF 23-MAR-2001; 2001WO-US009231.
XX PR 23-MAR-2000; 2000US-0191637P.
XX PR 11-JUL-2000; 2000US-00614150.
XX PA (PEKE ) PE CORP NY.
XX PI Venter JC, Adams M, Li PWD, Myers EW;
XX DR WPI; 2001-656860/75.
XX DR N-PSDB; ABL04820.
XX PT New isolated nucleic acid detection reagent for detecting 1000 or more
XX PT genes from Drosophila and for elucidating cell signaling and cell-cell
XX PS interactions.
XX PS Disclosure; SEQ ID NO 8943; 21pp + Sequence Listing; English.
XX CC The invention relates to an isolated nucleic acid detection reagent
XX CC capable of detecting 1000 or more genes from Drosophila. The invention is
XX CC useful in developmental biology and in elucidating cell signalling and
XX CC cell-cell interactions in higher eukaryotes for the development of
XX CC insecticides, therapeutics and pharmaceutical drugs. The invention
XX CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
XX CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
XX CC ABB72072). The sequence data for this patent did not form part of the
XX CC printed specification, but was obtained in electronic format directly
XX CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 580 AA;
ABB60717 Length: 580 February 22, 2005 12:25 Type: P Check: 9817 ..
1 MELALNKPSS CVDCKCKCTL LPPCSASACC DASCDAACGL IPPDPVRYEY
51 QEPENFISI DDVKKISFLW QIQQQOBEKE LEIKRIMEQE KREKREKERR
101 EAEKRDRQEV IELDEBEAQs PGLIISAAR SLAHWNSSIR RVTPDIELIP
151 RRVHRWAEBI ELSDSHDDED SEVDVDVSLP SNAVSCVLNE QRQDSQNPQ
201 ELVIIVPSDQ EDEQKTNVI KRKSSGSRL VGRPGANRR GRHMYECPDC
251 GKQVQSNYNL RRHMMIHTGE RPFPCDLCE RREFSFDLKK HRRHSHDPQ
301 FICMICHLGA PLEQDSTRCA DCESKNLMVK PQPEELGKGT TEHSDMEG
351 DDDEIEEAAL ENKQPQVAT QPSLMVTLIP PIQSPPEKVP SHTQPSRPPL
401 PRSCSSANSS SSSLNDGNIA GKSMSTRRS YPCPLCHRRP GTRHNLKRHY
451 MIHTGEKPPS CSKCRKPFRE CSTLKKHMTV HVRDRWYKCL RCPSKFRDYL
501 EYSDHKNHQ DQLSSRKSSI YESDDGDGSS VEDCLECEC QORFTELDAY
551 TAILKKHDLLE LYGMSIDDVA DEBQDDVDVA
!!AA SEQUENCE 1.0
ID _ABB61256 standard; protein; 43 AA.
XX AC ABB61256;
XX DT 26-MAR-2002 (first entry)
XX DE Drosophila melanogaster polypeptide SEQ ID NO 10560.
XX KW Drosophila; developmental biology; cell signalling; insecticide;
XX KW pharmaceutical.
XX PT Drosophila melanogaster.
XX OS Drosophila melanogaster.
```

```
XX PN WO200171042-A2.
XX PD 27-SEP-2001.
XX PF 23-MAR-2001; 2001WO-US009231.
XX PR 23-MAR-2000; 2000US-0191637P.
XX PR 11-JUL-2000; 2000US-00614150.
XX PA (PEKE ) PE CORP NY.
XX PI Venter JC, Adams M, Li PWD, Myers EW;
XX DR WPI; 2001-656860/75.
XX DR N-PSDB; ABL05359.
XX PT New isolated nucleic acid detection reagent for detecting 1000 or more
XX PT genes from Drosophila and for elucidating cell signaling and cell-cell
XX PT interactions.
XX PS Disclosure; SEQ ID NO 10560; 21pp + Sequence Listing; English.
XX CC The invention relates to an isolated nucleic acid detection reagent
XX CC capable of detecting 1000 or more genes from Drosophila. The invention is
XX CC useful in developmental biology and in elucidating cell signalling and
XX CC cell-cell interactions in higher eukaryotes for the development of
XX CC insecticides, therapeutics and pharmaceutical drugs. The invention
XX CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
XX CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
XX CC ABB72072). The sequence data for this patent did not form part of the
XX CC printed specification, but was obtained in electronic format directly
XX CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 43 AA;
ABB61256 Length: 43 February 22, 2005 12:25 Type: P Check: 9524 ..
1 MVCKGCGTNC KCQDTKCGDN CACNQDCKV CKNGPKDQCC KSK
!!AA SEQUENCE 1.0
ID _ABB66555 standard; protein; 74 AA.
XX AC ABB66555;
XX DT 26-MAR-2002 (first entry)
XX DE Drosophila melanogaster polypeptide SEQ ID NO 26457.
XX KW Drosophila; developmental biology; cell signalling; insecticide;
XX KW pharmaceutical.
XX OS Drosophila melanogaster.
XX PN WO200171042-A2.
XX PD 27-SEP-2001.
XX PF 23-MAR-2001; 2001WO-US009231.
XX PR 23-MAR-2000; 2000US-0191637P.
XX PR 11-JUL-2000; 2000US-00614150.
XX PA (PEKE ) PE CORP NY.
XX PI Venter JC, Adams M, Li PWD, Myers EW;
XX DR WPI; 2001-656860/75.
XX DR N-PSDB; ABL10658.
XX PT New isolated nucleic acid detection reagent for detecting 1000 or more
XX PT genes from Drosophila and for elucidating cell signaling and cell-cell
XX PT interactions.
```



FT /label= Unknown  
FT /note= "Xaa may be 9 amino acids in length; some amino  
FT acids may be absent"  
FT  
FT Misc-difference 4  
FT /label= Unknown  
FT /note= "Xaa may be 42 amino acids in length; some amino  
FT acids may be absent"  
FT  
FT Misc-difference 14  
FT /label= Unknown  
FT  
FT Misc-difference 15  
FT /label= Unknown  
FT  
FT Misc-difference 16  
FT /label= Unknown  
FT  
FT Misc-difference 17  
FT /label= Unknown  
FT  
FT Misc-difference 18  
FT /label= Unknown  
FT  
FT Misc-difference 19  
FT /label= Unknown  
FT  
FT Misc-difference 21  
FT /label= Unknown  
FT  
FT /note= "Xaa may be 10 amino acids in length; some amino  
FT acids may be absent"  
FT  
FT Misc-difference 23  
FT /label= Unknown  
FT  
FT Misc-difference 24  
FT /label= Unknown  
FT  
FT Misc-difference 25  
FT /label= Unknown  
FT  
FT Misc-difference 27  
FT /label= Unknown  
FT  
FT /note= "Xaa may be 7 amino acids in length; some amino  
FT acids may be absent"  
FT  
FT Misc-difference 29  
FT /label= Unknown  
FT  
FT /note= "Xaa may be 27 amino acids in length; some amino  
FT acids may be absent"  
FT  
FT Misc-difference 31  
FT /label= Unknown  
FT  
FT /note= "Xaa may be 13 amino acids in length; some amino  
FT acids may be absent"  
FT  
XX  
PN WO200021555-A1.  
XX  
PN 20-APR-2000.  
XX  
PF 13-OCT-1999; 99WO-US023640.  
XX  
PR 15-OCT-1998; 98US-0104355P.  
XX  
XX (HARD ) HARVARD COLLEGE.  
PA  
XX McMahon AP, Parr BA, Vaino S;  
XX  
XX WPI; 2000-317845/27.  
XX  
XX Contraceptive composition for inhibiting oocyte development in a female  
XX primate comprises a Wnt polypeptide antagonist.  
XX  
XX Claim 12; Page 44; 57pp; English.  
XX  
XX The patent discloses a method of female primate contraception comprising  
XX administering an antagonist of a Wnt polypeptide, inhibiting oocyte  
XX development. Wnt polypeptides are useful for promotive maturation of an  
XX immature oocyte. Wnt polypeptides are also useful for increasing the  
XX number of mature oocytes and to enhance oocyte viability. The present  
XX peptide is a consensus sequence of Wnt antagonist which inhibits the  
XX physiological activity of a Wnt polypeptide. Antagonistic polypeptides  
XX may contain a cysteine-rich domain  
XX  
SQ Sequence 31 AA;

AAV70731 Length: 31 February 22, 2005 12:25 Type: P Check: 9217 ..

1 CXKXCXCCCC CCCXXXXXXC XXXXXCXCX C  
!!AA SEQUENCE 1.0  
ID ABB66556 standard; protein; 72 AA.  
XX  
AC ABB66556;  
XX  
DT 26-MAR-2002 (first entry)  
XX  
XX Drosophila melanogaster polypeptide SEQ ID NO 26460.  
XX  
XX Drosophila; developmental biology; cell signalling; insecticide;  
XX pharmaceutical.  
XX  
XX Drosophila melanogaster.  
XX  
XX WO200171042-A2.  
XX  
XX 27-SEP-2001.  
XX  
XX 23-MAR-2001; 2001WO-US009231.  
XX  
XX 23-MAR-2000; 2000US-0191637P.  
XX  
XX 11-JUL-2000; 2000US-00614150.  
XX  
XX (PEKE ) PE CORP NY.  
XX  
XX Venter JC, Adams M, Li PWD, Myers EW;  
XX  
XX WPI; 2001-656860/75.  
XX  
XX N-PSDB; ABL10659.  
XX  
XX New isolated nucleic acid detection reagent for detecting 1000 or more  
XX genes from Drosophila and for elucidating cell signaling and cell-cell  
XX interactions.  
XX  
XX Disclosure; SEQ ID NO 26460; 21pp + Sequence Listing; English.  
XX  
XX The invention relates to an isolated nucleic acid detection reagent  
XX capable of detecting 1000 or more genes from Drosophila. The invention is  
XX useful in developmental biology and in elucidating cell signalling and  
XX cell-cell interactions in higher eukaryotes for the development of  
XX insecticides, therapeutics and pharmaceutical drugs. The invention  
XX discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA  
XX sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-  
XX ABB72072). The sequence data for this patent did not form part of the  
XX printed specification, but was obtained in electronic format directly  
XX from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 72 AA;  
  
ABB66556 Length: 72 February 22, 2005 12:25 Type: P Check: 8119 ..  
  
1 MGCAPGPGCC GPCGPGCGPC CGPCGPGCCG PCGPGPGCC GPCGPRGPGC  
51 GPCGPGCGTM EKRNGLQRCC PF  
!!AA SEQUENCE 1.0  
ID ABB60717 standard; protein; 580 AA.  
XX  
XX  
AC ABB60717;  
XX  
XX 26-MAR-2002 (first entry)  
XX  
XX Drosophila melanogaster polypeptide SEQ ID NO 8943.  
XX  
XX Drosophila; developmental biology; cell signalling; insecticide;  
XX pharmaceutical.  
XX  
XX Drosophila melanogaster.  
XX  
XX WO200171042-A2.  
XX  
PN

KW Neisseria meningitidis; Neisseria gonorrhoeae; antigen; vaccine;  
 KW antigenic; diagnosis; immunogenic; infection; meningitis; septicaemia;  
 KW antibacterial; gene therapy.  
 XX  
 OS Neisseria meningitidis.  
 XX  
 PN WO9957280-A2.  
 XX  
 PD 11-NOV-1999.  
 XX  
 PF 30-APR-1999; 99WO-US009346.  
 XX  
 PR 01-MAY-1998; 98US-0083758P.  
 PR 31-JUL-1998; 98US-0094869P.  
 PR 02-SEP-1998; 98US-0098994P.  
 PR 02-SEP-1998; 98US-0099062P.  
 PR 09-OCT-1998; 98US-0103749P.  
 PR 09-OCT-1998; 98US-0103794P.  
 PR 09-OCT-1998; 98US-0103796P.  
 PR 25-FEB-1999; 99US-0121528P.  
 XX  
 PA (CHIR ) CHIRON CORP.  
 PA (GENO-) INST GENOMIC RES.  
 XX  
 PI Fraser C, Galeotti C, Grandi G, Hickey E, Masignani V, Moxa M;  
 PI Petersen J, Pizza M, Rappuoli R, Ratti G, Scalato E, Scarselli M;  
 PI Tettelin H, Venter JC;  
 XX  
 DR WPI; 2000-062150/05.  
 DR N-PSDB; AA253553.  
 XX  
 PT Novel Neisserial polypeptides predicted to be useful antigens for  
 PT vaccines and diagnostics.  
 XX  
 PS Claim 2; Page 606; 1453pp; English.  
 XX  
 CC AA253015 to AA254536, AA254577 to AA254615, and AA274253 to AA275941  
 CC represent novel Neisseria meningitis and N. gonorrhoeae polynucleotides  
 CC and polypeptides. AA254537 to AA254576 and AA254616 to AA255473 represent  
 CC PCR primers used in the exemplification of the present invention. The  
 CC polypeptides, the polynucleotides, antibodies and compositions of the  
 CC invention can be used as vaccines, as diagnostic reagents, and as  
 CC immunogenic compositions. The polypeptides can be used in the manufacture  
 CC of medicaments for treating or preventing infection due to Neisserial  
 CC bacteria (e.g. meningitis and septicaemia), to detect the presence of  
 CC Neisseria bacteria, or to raise antibodies. They may also be used to  
 CC screen for agonists or antagonists, which may themselves have use as  
 CC antibacterial agents. The polynucleotides of the invention may also be  
 CC used in gene therapy protocols  
 XX  
 SQ Sequence 233 AA;  
 AAY74791 Length: 233 February 22, 2005 12:25 Type: P Check: 9481 ..  
 1 GCAGCAGGCG AATTGACGA TGCCAACTC GCGCGGCTCG CCGCCTTCAC  
 51 CCAAGCCGTA ATGCGGAAAA AGGCGGGGT ATCCGACGAG GAATCTAAAG  
 101 CATTTTTCGA TCGCGGGCTAC AACCAGCAGC AGGCAGTCCA AGTCGTGATG  
 151 GCGGTASVCT GGCAACCCCTG TGCAACTACG TCAACACACT CGGACAAACC  
 201 GAATCAACC CCGAATTGCA GGCTTACGCC TGA  
 !!AA SEQUENCE 1.0  
 ID \_AAY64780 standard; protein; 66 AA.  
 XX  
 AC AAY64780;  
 XX  
 DT 01-FEB-2000 (first entry)  
 XX  
 DE Human 5' EST related polypeptide SEQ ID NO:941.  
 XX

KW Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;  
 KW gene therapy; chromosome mapping; upstream regulatory sequence; forensic;  
 KW location; development; protein synthesis; stability; regulation;  
 KW identification.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO9953051-A2.  
 XX  
 PD 21-OCT-1999.  
 XX  
 PF 09-APR-1999; 99WO-IB000712.  
 XX  
 PR 09-APR-1998; 98US-00057719.  
 PR 28-APR-1998; 98US-00069047.  
 XX  
 PA (GEST ) GENSET.  
 XX  
 PI Dumas Milne Edwards J, Duclert A, Giordano J;  
 XX  
 DR WPI; 2000-038446/03.  
 DR N-PSDB; AA242394.  
 XX  
 PT Novel secreted protein 5' expressed sequence tag sequences used in  
 PT diagnostic, forensic, gene therapy, and chromosome mapping procedures.  
 XX  
 PS Claim 3; Page 640; 837pp; English.  
 XX  
 CC AA242265 to AA243075 represent novel 5' expressed sequence tag (EST)  
 CC sequences, corresponding to human secreted proteins. AAY64651 to AAY65438  
 CC represent the EST-related proteins corresponding to AA242265 to AA243052.  
 CC The 5' ESTs can be used for producing secreted human gene products. They  
 CC can be used to identify and isolate 5' untranslated regions (UTRs) and  
 CC upstream regulatory regions which control the location, development  
 CC stage, rate, and quantity of protein synthesis, as well as stability of  
 CC mRNA. The ESTs are also useful as probes for chromosome mapping, and to  
 CC obtain full length cDNA clones. The ESTs can also be used in forensic  
 CC procedures to identify individuals, or in diagnostic procedures to  
 CC identify individuals having genetic diseases resulting from abnormal gene  
 CC expression. The products may also be used in gene therapy protocols. The  
 CC nucleic acids encoding signal peptides can be used for directing  
 CC extracellular secretion of a polypeptide or the insertion of a  
 CC polypeptide into a membrane, or importing a polypeptide into a cell. The  
 CC proteins encoded by the EST sequences may be useful in treating a variety  
 CC of human conditions. Secreted proteins have therapeutic value, and the  
 CC identification of new secreted proteins is valuable. AA242249 to AA242264  
 CC and AAY64644 to AAY64650 represent sequences used in the exemplification  
 CC of the present invention  
 XX  
 SQ Sequence 66 AA;  
 AAY64780 Length: 66 February 22, 2005 12:25 Type: P Check: 971 ..  
 1 MCVVCSVHGV CCVVVCLVS CVLVCVCPVC WMCCVCVIC CVVWCVCMC  
 51 CVLSCVSHG LCGVSW  
 !!AA SEQUENCE 1.0  
 ID \_AAY70731 standard; protein; 31 AA.  
 XX  
 AC AAY70731;  
 XX  
 DT 24-JUL-2000 (first entry)  
 XX  
 DE Wnt antagonist protein consensus sequence-1.  
 XX  
 DE Wnt antagonist; contraceptive; contraceptive vaccine; oocyte development;  
 KW female primate contraception; oocyte viability.  
 XX  
 OS Synthetic.  
 XX  
 PH Key Location/Qualifiers  
 FT Misc-difference 2

```
!!AA SEQUENCE 1.0
ID _AAW62829 standard; protein; 666 AA.
XX
AC _AAW62829;
XX
DT 27-OCT-1998 (first entry)
XX
DE Macadamia integrifolia antimicrobial protein.
XX
DE Macadamia integrifolia.
XX
FH Key Location/Qualifiers
FT Peptide 1..28
FT Protein /note= "signal peptide"
FT /note= "mature protein"
XX
PN W09827805-A1.
XX
PD 02-JUL-1998.
XX
PF 22-DEC-1997; 97WO-AU000874.
XX
PR 20-DEC-1996; 96AU-00004275.
XX
PA (RETR-) COOP RES CENT TROPICAL PLANT PATHOLOGY.
XX
PI Manners JM, Marcus JP, Goulter KC, Green JL, Bower NI;
XX
DR WPI; 1998-377279/32.
DR N-PSDB; AAV42311.
XX
XX
PT Novel anti-microbial protein from e.g. Macadamia integrifolia - useful
PT for controlling microbial infestations of plants or mammals.
XX
PS Claim 1; Page 39-41; 96pp; English.
XX
CC The sequence is that of an antimicrobial protein which can be used to
CC control microbial infestations in plants and mammalian animals
XX
SQ Sequence 666 AA;
AAW62829 Length: 666 February 22, 2005 12:25 Type: P Check: 911 ..
1 MAINTSNLCS LFLFLSLFL STTVSLAESE FDRQYEYBECK RQCMQLETS
51 QMRRCVSQCD KRPEEDIDWS KYDNQDDPOT DCQCQRRRCR QESGPRQOQ
101 YCQRCKEIC EEEYNNRQ RQOQYEQOQ ERCQHEHETEP RHMQTCQORC
151 ERYEKEKRC QKRYEQQOR EDEEYKYEEM KEEDNKRDPQ QREYEDCRRR
201 CEQOEPQOY QCQRRCREQ RQHGRGGDLI NPQRGGSGRY EEGEEKQSDN
251 PYPFDESLR TRRTRECHI SVLENFYGRS KLLRALKNYR LVILLEAPNA
301 FVLPTHLAD AILLVTGGRG ALKMIHRDNR ESYNLECGDV IRIPAGTFFY
351 LINRDNNEHL HIAKFLQIS TPGQYKEFFP AGGQNPPEYL STFSKEILEA
401 ALNTOAERLR GVUGQREGV IISASQEQIR ELTRDDSESER RWHIRRGES
451 SRGPYNLFNK RPLYSNKYQ AYEVKPEDYR QLQDMDSVVF IANITQSGMM
501 GPPFTRSTK VVVVASGEAD VEMACHPLSG RHGGRGGRK HEEEDVHYE
551 QVKARLSKRE AIVVPVGHV VTFVSSGNEL LLFAPGINAQ NNHENFLAGR
601 ERNVLOQIEP QAMELAFAP RKEVEBELFNS QDESIFFPGP ROHQOQSSRS
651 TKOQQLVSI LDFVGF
```

---

```
!!AA SEQUENCE 1.0
ID _AAY60558 standard; protein; 169 AA.
XX
AC _AAY60558;
XX
DT 31-JAN-2000 (first entry)
XX
DE Human normal bladder tissue EST encoded protein 230.
XX
DE Human; bladder; treatment; EST; expressed sequence tag; cytostatic;
XX cancer; gene therapy.
XX
OS Homo sapiens.
PN DE19818620-A1.
XX
PD 28-OCT-1999.
XX
PF 21-APR-1998; 98DE-01018620.
XX
PR 21-APR-1998; 98DE-01018620.
XX
PA (META-) METAGEN GES GENOMFORSCHUNG MBH.
XX
PI Rosenthal A, Specht T, Hinzmann B, Schmitt A, Pilarsky C, Dahl E;
XX
DR WPI; 1999-602416/52.
DR N-PSDB; AAZ42235.
XX
XX
PT New polypeptides and their nucleic acids, useful for treatment of bladder
PT tumor and identification of therapeutic agents.
XX
PS Claim 23; Page 338; 366pp; German.
XX
CC This invention describes novel polypeptide fragment sequences (I) and
CC their encoding nucleic acids (II) which are highly expressed in normal
CC bladder tissue and have cytostatic activity. (II) are used for
CC recombinant expression of (I) and to isolate complete genes. (I) are used
CC to identify agents suitable for the treatment of bladder tumours, to
CC directly treat this form of cancer (including expression from gene
CC therapy vectors), or are used in a preparation for cancer treatment. (I)
CC is also used for the generation of specific antibodies. (II) are
CC identified by assembling ESTs (expressed sequence tags) from a particular
CC tissue type before comparison of expression patterns. This allows a
CC significantly longer fragment of the gene to be revealed, and therefore
CC reduces the number of failures because of ESTs from different libraries
CC representing different parts of the same unknown gene distorting the
CC estimated frequency of occurrence in a particular tissue. AAY60329-Y60591
CC represent protein fragments encoded by the human normal bladder tissue
CC cDNA library derived EST fragments represented in AAZ42122-242248
XX
SQ Sequence 169 AA;
AAY60558 Length: 169 February 22, 2005 12:25 Type: P Check: 6048 ..
1 PRLPSVAVG MVRPAVSVA GGIANWSSPC NCKSKALCR MEPLRREAE
51 VPMFRSRGCC GCCGGPPLTP WQRACGGDCW SSCWSCSNCC CNCCWCSCC
101 CNCWSCCCC CWSCCCCWL NWARLPARP QRSSRPHGWA GPAAPTPRPG
151 GSGFRAPGLP AATPGVGS
!!AA SEQUENCE 1.0
ID _AAY74791 standard; protein; 233 AA.
XX
AC _AAY74791;
XX
DT 21-MAR-2000 (first entry)
XX
DE Neisseria meningitidis ORF 263 protein sequence SEQ ID NO:1056.
XX
```

